

[illegible]

registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, \$0.01 par value per shareCTLTNew York Stock ExchangeSecurities registered pursuant to Section 12(g) of the Act: None

The registrant certifies that it has prepared this report pursuant to Section 12(b) of the Act, indicate by check mark whether any of those error corrections are restatements of financial statements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to A§ 240.10D-1(b). o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

A § A qA Yes

A § A NoAs of December 31, 2023, the aggregate market value of the registrant's voting and non-voting common equity held by non-affiliates was \$8.10 billion.

As of August 2nd, 2024, Catalent, Inc. had 141,463,702 shares of the common stock, par value \$0.01 per share, outstanding.

CATALENT, INC.INDEX TO ANNUAL REPORT ON FORM 10-KFor the Fiscal Year Ended June 30, 2024

Item 1. Business Item 1.A Risk Factors Item 1.B Unresolved Staff Comments Item 1.C Cybersecurity Item 2. Properties Item 3. Legal Proceedings Item 4. Mine Safety Disclosures Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Item 6. Reserved Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Item 7A Quantitative and Qualitative Disclosures About Market Risk Item 7B Financial Statements and Supplementary Data Item 9 Changes in and Disagreements With Accountants on Accounting and Financial Disclosure Item 9A Controls and Procedures Item 9B Other Information Item 9C Disclosure Regarding Foreign Jurisdictions That Prevent Inspections Part III Item 10 Directors, Executive Officers and Corporate Governance Item 11 Executive Compensation Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters Item 13 Certain Relationships and Related Transactions, and Director Independence Item 14 Principal Accountant Fees and Services Item 15 Exhibits and Financial Statement Schedules Item 16 Form 10-K Summary Signatures Item 17 Signature Required Forward-Looking Statements In addition to historical information, this Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (this "Annual Report") contains certain forward-looking statements made in connection with the offering of securities of Catalent, Inc., which may constitute such forward-looking statements under the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject to the safe harbor created by those sections. All statements, other than statements of historical facts, included in this Annual Report are forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as outlook, believes, expects, potential, continues, aimay, will, would, could, might, seek, predicts, intends, plans, estimates, anticipates, future, forecast, sustain, or the negative version of these words or other comparable words. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Any forward-looking statement is subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Some of the factors that may cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements include, but are not limited to, those described under the section entitled Risk Factors in this Annual Report, which are summarized below:

Summary of Principal Risk FactorsAny investment, including an investment in our common stock, par value \$0.01 (the "Common Stock"), involves risk. The following summary highlights certain risks that an investor in our Common Stock should consider. The following should be read in conjunction with the fuller discussion of risk factors we face set forth in the "Risk Factors - Risks Relating to Pending Merger with Novo Holdings." We may not complete the pending merger with Novo Holdings within the timeframe anticipated, or at all, which could have a material adverse effect on our business, financial condition or results of operations, as well as negatively impact our share price. Risks Relating to Our Business and the Industry in Which We Operate Actions of activist shareholders could impact the pursuit of our business strategies and adversely affect our results of operations, financial condition, or share price. We anticipate being subject to increasing focus by our investors, regulators, customers, and other stakeholders on environmental, social, and governance ("ESG") matters. We are a part of the highly regulated healthcare industry, subject to stringent regulatory standards and other applicable laws and regulations, which can change unexpectedly or be the subject of unexpected changes in interpretation or enforcement, any of which may adversely impact our business. Any failure to implement fully, monitor, and continuously improve our quality management strategy could lead to quality or safety issues and expose us to significant costs, potential liability, and adverse publicity. We have experienced, and may continue to experience, productivity issues and higher-than-expected costs at certain of our facilities, which have resulted in, and may continue to result in, material and adverse impacts on our financial condition and results of operations. The declining demand for various COVID-19 vaccines and treatments from both patients and governments around the world has affected and may continue to affect sales of the COVID-19 products we manufacture and our financial condition. The demand for our offerings depends in part on our customers' research and development and the clinical and market success of their products. Our results of operations are subject to fluctuations in the costs, availability, and suitability of the components of the products we manufacture, including active pharmaceutical ingredients, excipients, purchased components, and raw materials, and other supplies or equipment we need to run our business. Our goodwill has been subject to impairment and may be subject to further impairment in the future, which could have a material adverse effect on our results of operations, financial condition, or future operating results. Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. We may acquire businesses and offerings that complement or expand our business or diversify non-strategic businesses or assets. We may not be able to complete desired transactions, and such transactions, if executed, pose significant risks, including risks relating to our ability to successfully and efficiently integrate acquisitions or execute on dispositions and realize anticipated benefits therefrom. The failure to execute or realize the full benefits from any such transaction could have a negative effect on our operations and profitability. We may become subject to litigation, other proceedings, and government investigations relating to us or our operations, and the ultimate outcome of any such matter may have an impact on our business, prospects, financial condition, and results of operations. Our global operations are subject to economic and political risks, including risks resulting from continuing inflation, disruptions to global supply chains, destabilization of a regional or national banking system, or from the Ukrainian-Russian war or the effect of the evolving nature of the recent war in Gaza between Israel and Hamas and conflict in the Middle East, which could affect the profitability of our operations or require costly changes to our procedures. We use advanced information and communication systems to run our operations, compile and analyze financial and operational data, and communicate among our employees, customers, and counterparties, and the risks generally associated with information and communications systems could adversely affect our results of operations. We continuously work to install new, and upgrade existing, systems and provide employee awareness training around phishing, malware, and other cybersecurity risks to enhance the protections available to us, but such protections may be inadequate to address malicious attacks or inadvertent compromises affecting data security or the operability of such systems. Artificial intelligence-based platforms present new risks and challenges to our business. Our cash, cash equivalents, and financial investments could be adversely affected if the financial institutions in which we hold our cash, cash equivalents, and financial investments fail. Risks Relating to Our Indebtedness The size of our indebtedness and the obligations associated with it could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or in our industry or to deploy capital to grow our business, expose us to interest-rate risk to the extent of our variable-rate debt, or prevent us from meeting our obligations under our indebtedness. These risks may be increased in a recessionary environment, particularly as sources of capital may become less available or more expensive. Despite our high indebtedness level, we and our subsidiaries are still capable of incurring significant additional debt, which could further exacerbate the risks associated with our substantial indebtedness. Our interest expense on our variable-rate debt may continue to increase if and to the extent that policymakers combat inflation through interest-rate increases on benchmark financial products. Despite the limitations in our debt agreements, we retain the ability to take certain actions that may interfere with our ability to timely pay our substantial indebtedness. We may not be able to pay our indebtedness when it becomes due. We are currently using and may in the future use derivative financial instruments to reduce our exposure to market risks from changes in interest rates on our variable-rate indebtedness or changes in currency exchange rates, and any such instrument may expose us to risks related to counterparty credit worthiness or non-performance of these instruments. Risks Relating to Ownership of Our Common Stock We do not presently maintain effective disclosure controls and procedures due to a material weakness we have identified in our internal control over financial reporting. Material weaknesses have in this past resulted in the revision of our financial statements. If we fail to remediate this material weakness, or if any other material weakness or significant deficiency is identified in the future or if we otherwise fail to maintain an effective system of internal controls, material misstatements in our financial statements could result, and, as in the past, we could fail to timely meet our periodic reporting obligations. Our stock price has historically been and may continue to be volatile, and a holder of shares of our Common Stock may not be able to resell such shares at or above the price such stockholder paid, or at all, and could lose all or part of such investment as a result. Future sales, or the perception of future sales, of our Common Stock, by us or our existing stockholders could cause the market price for our Common Stock to decline. We are no longer eligible to use the Form S-3 registration statement, which could impair our capital-raising activities. Provisions in our organizational documents could delay or prevent a change of control. We caution you that the risks, uncertainties, and other factors referenced above may not contain all of the risks, uncertainties, and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits, or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, or (iv) our strategy, which is based in part on this analysis, will be successful. All forward-looking statements in this report apply only as of the date of this report or as of the date they were made, and we undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law. Available Information We file annual, quarterly, and current reports and other information with and furnish additional information to the U.S. Securities and Exchange Commission (the "SEC"). Our filings with the SEC are available to the public on the SEC's website at www.sec.gov. Those filings are also available to the public on, or accessible through, our website ([catalent.com](#)) or free via the Investor Access section as soon as reasonably practicable after we file such material, or furnish it to the SEC. We also use our website, Facebook page ([facebook.com/CatalentPharmaSolutions](#)), LinkedIn page ([linkedin.com/company/catalent-pharma-solutions/](#)) and Twitter account (@[catalentpharma](#)) as channels of distribution of information concerning our activities, our offerings, our various businesses, and other related matters. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, SEC filings, and public conference calls and webcasts. The information we file with or furnish to the SEC (other than the information set forth or incorporated in this Annual Report) or contained on or accessible through our website, our social media channels, or any other website that we may maintain is not a part of this Annual Report. Catalent References and Fiscal Year Unless the context otherwise requires, in this Annual Report, the terms "Catalent," "we," "our company," "and ours" refer to Catalent, Inc. and its subsidiaries. All references to years in this Annual Report, unless otherwise stated, refer to fiscal years beginning July 1 and ending June 30. All references to quarters, unless otherwise stated, refer to fiscal quarters. Fiscal years are referred to by the calendar year in which they end. For example, "fiscal 2024" refers to the fiscal year ending June 30, 2024. Trademarks and Service Marks We have U.S. or foreign registrations for the following marks, among others: Bettera®, Catalenta®, Catalent Xpress Pharmaceuticals®, Clinicopia®, CosmoPod®, Easyburst®, FastChain®, FlexDirect®, Follow the Molecule®, Galacoria®, GPExa®, GPExa® Boost, GPExa® Lightning, Graphiceps®, Liqui-Gels®, Manufacturing Miracles®, Micron Technologies®, OmegaZero®, OneBio®, OneXpress Solution®, Optidose®, Optiform®, Optigel®, Optigel® Bio, Optigel® DR, Optimelt®, Optishell®, PEEL-ID®, Pharmatek®, RP Scherer®, Savorgel®, Scherer®, SMARTag®, Softdrop®, Staby®, StabyExpress®, StartScore®, SupplyFlex®, Vegicaps®, Zydias®, and Zydys Ultra®. This Annual Report also includes trademarks and trade names owned by other parties, and these trademarks and trade names are the property of their respective owners. We use certain other trademarks and service marks, some on an unregistered basis and some have been applied for, but remain pending examination in trademark agencies in the U.S. and abroad, including, FlexDoseSM, Optipacta, ProteoSuiteSM, and UpTempoSM. Solely for convenience, the trademarks, service marks, and trade names identified in this Annual Report may appear without the ®, SM, and &c symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks, and trade names.

BUSINESS Overview We provide differentiated development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products at approximately fifty facilities across four continents under rigorous quality and operational standards. Our oral, injectable, and respiratory delivery technologies, along with our state-of-the-art protein, plasmid, viral, and cell and gene therapy manufacturing capacity, address a wide and growing range of modalities and therapeutic and other categories across the biopharmaceutical, pharmaceutical, and consumer health industries. Through our extensive capabilities, growth-enabling capacity, and deep expertise in product development, regulatory compliance, and clinical trial and commercial supply, we can help our customers take products to market faster; we have supported more than half of new drug products approved by the U.S. Food and Drug Administration (the "FDA") in the last decade. Our development and manufacturing platforms, our proven formulation, supply, and regulatory expertise, and our broad and deep development and manufacturing know-how enable our customers to advance and then bring to market more products and better treatments for patients and consumers. Our commitment to reliably supply our customers' needs is the foundation for the value we provide; annually, we produce nearly 70 billion unit doses for nearly 8,000 customer pharmaceutical and consumer health products, or approximately 1 in every 28 unit doses of such products taken each year by patients and consumers around the world. We believe that, through our investments in state-of-the-art facilities and capacity expansion, including investments in facilities focused on new treatment modalities and other attractive market segments, our continuous improvement activities devoted to operational and quality excellence, the sales of existing and introduction of new customer products, and, in some cases, our innovation activities and patents, we will continue to attract premium opportunities and realize the growth potential from these areas. We continue to focus on enhancing both our product and service offerings and our sales and marketing activities in order to grow the number of active commercial manufacturing and development programs for our customers. This sustains our extensive, long-duration relationships and long-term contracts with a broad and diverse range of industry-leading customers. In fiscal 2024, we conducted business with 88 of the top 100 branded drug and consumer health marketers and 82 of the top 100 biologics marketers, measured on a global basis. Selected key customers include Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Haleon, Novo Nordisk, Moderna, Pfizer, and Sanofi Therapeutics. We have many long-standing relationships with our customers, particularly those with commercial products, as we provide support and reliable supply throughout each stage of a product's lifecycle. Our relationship with an innovator of a prescription pharmaceutical product will often last many years—in several cases, two decades or more—extending from pre-clinical development through more mature commercial stages of the product's life cycle. We serve customers requiring some combination of innovative product development, superior quality, state-of-the-art manufacturing, and skilled technical services to support their development and marketed product needs. Our broad and diverse range of technologies closely integrates with all aspects of our customers' final formulations and dose forms, and this generally results in the inclusion of our facilities as manufacturing and testing sites in our customers' prescription product regulatory filings. Both factors frequently translate to long-duration supply relationships at an individual product level. We believe our customers value us because our depth of development solutions and state-of-the-art manufacturing technologies, continuous innovations and improvements, consistent and reliable supply, geographic reach, and substantial expertise enable us to create a broad range of business and product solutions that can be customized to fit their individual needs. Today we employ approximately 8,500 highly trained direct manufacturing associates, as well as more than 3,100 formulation, analytical development, and process scientists and technicians. Our customers can also benefit from more than 2,100 patents and patent applications in advanced delivery platforms, drug and biologics formulation, and manufacturing. The aim of our offerings is to reliably supply our

augmented our portfolio through acquisitions. Among the technologies we currently offer are softgel capsules, including both gelatin and non-gelatin formulations, our Zydys orally disintegrating tablets, gummy and soft chew oral forms, protein production using advanced mammalian cell lines, adeno-associated virus (AAV) and other viral vectors, induced pluripotent stem cells (iPSCs) and 7other cell types, plasmid DNA (pDNA), and a range of other oral, injectable, and respiratory delivery technologies. The technologies and service offerings within our development solution platforms span the full drug development process, ranging from our OptiForm Solution Suite for enhancement of bioavailability and other characteristics of early-stage small molecules, Gene Product Expression (GPEX), GPEX Boost, and GPEX Lightning for advanced cell line development, pDNA development and manufacturing and SMARTag platforms for development of biologics and antibody-drug conjugates (ADCs), to formulation, analytical, and bioanalytical services, early-stage clinical development, drug-device combination development and supply, fill and finish operations for injectable products, and clinical trials supply, including our unique FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions. Our offerings serve a critical need in the development and manufacture of products across a broad range of product types. We focus on serving as an accelerator for new therapeutic modalities and formulation, delivery, and manufacturing technologies. Our expertise enables us to bring advanced products to market at scale, faster. In large part due to acquisitions and investments, and their subsequent organic growth, the revenue contribution from our Biologics segment has grown from approximately 17% in fiscal 2016 to 45% in fiscal 2024. We believe our own internal innovation and investments, supplemented by current and future customer and other external partnerships and acquisitions, will continue to extend our leadership positions in the development, reliable supply, and delivery of drugs, protein-based biologics, cell and gene therapies, and consumer health products. Pending Merger with Novo Holdings

On February 5, 2024, the Company entered into the Agreement and Plan of Merger (the Merger Agreement), with Creek Parent, Inc. (Creek Parent), a Delaware corporation and a wholly owned subsidiary of Novo Holdings A/S (Novo Holdings), and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Creek Merger Sub). The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein, Merger Sub will be merged with and into the Company (the Merger), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Parent will acquire all the issued and outstanding shares of Common Stock of the Company. On May 29, 2024, the Company held a special meeting of its stockholders at which the Company's stockholders approved, among other things, the Merger Agreement. The Merger is expected to close towards the end of calendar year 2024, subject to customary closing conditions, including receipt of required regulatory approvals. For more information, see Note 17, Commitments and Contingencies to our consolidated financial statements as of and for the fiscal year ended June 30, 2024 (our Consolidated Financial Statements). History We trace our history to the 1933 founding of the R.P. Scherer Corporation, which developed the first rotary die machine for the manufacture of soft gelatin capsules, and we assumed our current form in April 2007. We regularly review our portfolio of offerings and operations in the context of our strategic growth plan, and, where appropriate, have added to or divested from our portfolio of offering and sites, which has led to significant growth of the overall business. In July 2014, we completed the initial public offering of our Common Stock, which is listed on the New York Stock Exchange (the NYSE) under the symbol CRLT. We are a holding company that indirectly owns Catalent Pharma Solutions, Inc. (Operating Company), which owns, directly or indirectly, all of our operating assets. Our Competitive Strengths Available, State-of-the-art Manufacturing Capacity in Attractive Market Segments We have invested several billion dollars over the last few years to broaden our portfolio of offerings and expand our capacity with state-of-the-art manufacturing and development capabilities that focus on anticipating and meeting the needs of the evolving biopharmaceutical, pharmaceutical, and consumer health industries. In addition, we have hired and trained thousands of new direct manufacturing associates in our quality-focused culture of operational excellence. The capacity and capabilities we have built and purchased, along with our continuing efforts to assure operational and quality excellence, have and will continue to enable us to secure attractive new business opportunities in the expanding market for outsourced product development and supply. Vibrant, Patient First-Driven Culture From the manufacturing line to the executive suite, for all our critical decisions, we ask the question, "What would the impact be to the patient?" and our culture is built on our cornerstone value of Patient First. We believe this mindset, which aligns closely with our customers' values, enables a pervasive focus on patient safety, impact, and outcomes, and an uncompromising approach to product quality and compliance, by reminding us of those who depend upon our vigilance concerning the safety, quality, reliability, and sustainability of our product supply. Along with other key cultural strengths, including our commitments to diversity and inclusion and to science-based environmental sustainability, we believe our culture brings us both a unique reputation and an operating capability that is difficult to replicate. Diversified Operating Platform We are diversified by virtue of our broad range of product and service offerings, our geographic scope, our breadth of customer relationships, the extensive range of products we produce, and our ability to provide solutions at every stage of a product's lifecycle. In fiscal 2024, we produced nearly 8,000 distinct products across multiple categories. Our fiscal 2024 net revenue was distributed by relevant product regulatory/marketing status as follows: biologics 49%, branded drugs 35%, over-the-counter drugs 7%, and consumer health and other 9% combined. In fiscal 2024, our top 20 products represented 36% of our total net revenue, with one customer accounting for approximately 17% of net revenue whose largest individual product accounted for approximately 15% of our net revenue. We serve approximately 1,200 customers in more than 80 countries, with 36% of our fiscal 2024 net revenue coming from outside the U.S. This diversity, combined with long product lifecycles and close customer relationships, has contributed to the long-term stability of our business. It has also allowed us to reduce our exposure to the risks associated with potential strategic, customer, and product shifts as well as to payer-driven pricing pressures experienced by our drug and biologic customers. Longstanding, Extensive Relationships with a Diverse Customer Portfolio We have longstanding, extensive relationships with leading pharmaceutical, biotechnology, and consumer health customers. In fiscal 2024, we did business with 88 of the top 100 branded drug and consumer health marketers and 82 of the top 100 biologics marketers, measured on a global basis, as well as with approximately 1,200 other customers, including emerging and specialty biotech and pharmaceutical companies, which are often more reliant on outside partners as a result of their more virtual business models. Regardless of size, our customers seek innovative product development, superior quality, advanced manufacturing, and skilled technical services to support their development and marketed product needs. We believe our customers value us because our broad range of product and service offerings, recently expanded capacity in state-of-the-art manufacturing facilities, including facilities offering new treatment modalities, reliable supply, geographic reach, commitment to operational and quality excellence, and substantial expertise that enable us to create a broad range of tailored solutions. Deep, Broad, and Growing Advanced Technology Foundation Our breadth of offerings employing advanced technologies and state-of-the-art manufacturing systems and long track record of innovation substantially differentiate us from other industry participants. Our leading softgel platforms, including Liqui-Gels, OptiShell, OptiGel DR, and Vegicaps capsules, our gummy and soft chew oral forms, and our modified release technologies, including the Zydys family of orally disintegrating tablets, our spray drying capabilities, and our OptiPact and OptiMelt technologies, provide formulation expertise to solve complex delivery challenges for our customers. We offer advanced technologies for delivery of small molecules and biologics via oral, respiratory, and injectable routes and also provide advanced biologics formulation options, including GPEX, GPEX Boost, and GPEX Lightning mammalian cell lines for protein production, SMARTag ADC technology, AAV vectors for cell and gene therapies, iPSC development and manufacturing, and pDNA development and manufacturing. We have a leadership position within respiratory delivery, including dry powder inhalers and intra-nasal forms. We have reinforced our leadership position in advanced technologies over the last few years, as we have launched more than a dozen new technology platforms and applications, and expanded our businesses developing and manufacturing consumer health products, protein-based biologics, fill and finish for injectable drugs and biologics, cell and gene therapies, and other new therapeutic modalities. Our culture of creativity, problem-solving, and innovation is grounded in our advanced technologies, the substantial expertise and experience of our scientists and engineers, and, in some cases, our patents and proprietary manufacturing processes. Our global product development and innovation teams drive a focused application of resources to opportunities for both new customer product introductions and platform technology development. As of June 30, 2024, we had approximately 1,500 product development programs active across our businesses. Long-Duration Relationships Provide Sustainability Our broad and diverse range of technologies closely integrates with our customers' molecules to yield safe and effective final formulations and dose forms, and this generally results in the inclusion of Catalent in our customers' prescription product regulatory filings. Both factors translate to long-duration supply relationships at an individual product level, to which we apply our expertise in contracting to produce long-duration commercial supply agreements. These agreements typically have initial terms of two to seven years with regular renewals of one to three years (see "Contractual Arrangements" for more detail). Approximately three-quarters of our fiscal 2024 net revenue from our product development and delivery offerings and related services were covered by such long-term contractual arrangements. We believe this base provides us with a sustainable competitive advantage. Significant Recent Growth Investments We have made over time, and expect to continue to make, significant investments in our manufacturing network, which is capable of serving customers and patients worldwide, and today employ approximately 8 million square feet of manufacturing, laboratory, and related space across four continents. We have deployed approximately \$2.7 billion in the last five fiscal years in gross capital expenditures, not including approximately \$1.9 billion spent acquiring new facilities and businesses. Growth-related investments in facilities, capacity, and capabilities across our businesses have positioned us for future growth in areas aligned with anticipated future demand, including in pDNA, cell and gene therapies, fill and finish for injectable drugs and biologics, and other new therapeutic modalities. Through our continuing commitment to operational, quality, and regulatory excellence, we drive continuous improvements in safety, productivity, sustainability and reliable supply, which we believe further differentiates us. Our manufacturing network and capabilities allow us the flexibility to reliably supply the changing needs of our customers while consistently meeting their quality, delivery, sustainability, and regulatory compliance expectations. High Standards of Regulatory Compliance and Operational and Quality Excellence We operate our plants in accordance with current good manufacturing practices (cGMP) or other applicable requirements, following our own high standards that are consistent with those of many of our large global pharmaceutical and biotechnology customers. We have approximately 1,600 employees around the globe focused on quality and regulatory compliance. All of our facilities are registered where required with the FDA or other applicable regulatory agencies, such as the European Medicines Agency (the EMA). In many cases, our facilities are registered with multiple food, drug, or biologics regulatory agencies around the world. In fiscal 2024, we were subject to 69 regulatory audits, and, over the last five fiscal years, we successfully completed more than 280 regulatory audits. We also undergo almost 700 customer and internal audits annually. We believe our quality and regulatory track record to be a favorable competitive differentiator. Strong and Experienced Management Team Our executive leadership team collectively has almost 500 years of combined and diverse experience within the pharmaceutical and healthcare industries. With an average of approximately 29 years of functional experience, this team possesses deep knowledge and a wide network of industry relationships. Our Strategy Our strategic ambition, guided by and operationalized through our values, is to power the innovation and growth of the life science industry by becoming its leading development and commercial partner in reliable supply, conventional and advanced technologies, first-to-scale innovation, and therapeutic modalities, and integrated solutions. To achieve this, we continue to pursue the following key growth initiatives: Capabilities & Capacity Continued Expansion in Biologics and Other Attractive Markets Recognizing the strategic importance of protein-based biologics, cell and gene therapies, pDNA, and other new biopharmaceutical modalities, we began to build a differentiated biologics platform in 2002. Since fiscal 2020, we have invested over \$3.6 billion in our biologics business, including capital investments and approximately \$1.8 billion for acquisitions of biologics-focused businesses and sites. Today, we are a recognized leader in biologics, including AAV vectors for gene therapies; development and supply for cell therapies; advanced cell-line development; formulation and fill-finish into vials, pre-filled syringes, and cartridges; specialized manufacturing of biologic drug substances; and bioanalytical analysis. We have partnered with customers from around the world to develop advanced cell expression for more than 1,200 cell lines, many using our advanced GPEX, GPEX Boost, and GPEX Lightning technologies, and have actively collaborated on developing and scaling up more than 110 cell and gene therapies. In the recent fiscal years, we expanded our existing cell therapy development and manufacturing capabilities, began offering pDNA production services, and acquired several facilities including a commercial-scale cell therapy manufacturing facility in Princeton, New Jersey (Princeton) and a developer and manufacturer of iPSCs located near Dusseldorf, Germany. We have also invested in a second-generation ADC technology, SMARTag, and see continued progress in this technology's capabilities and our customers' SMARTag product-development activities. In addition to our expansion in biologics, we have invested additional capital in our facilities in order to expand in attractive markets, including significant expansion of our oral solid controlled release production capacity in Winchester, Kentucky, and the addition of specialized capabilities and capacity in early development. We acquired a leading position in consumer-preferred gummy and soft-chew formats for consumer health products with our acquisition of Bettera Holdings, LLC (Bettera Wellness) in fiscal 2022. Use Our Proprietary Technologies and Substantial Expertise to Help Our Customers Develop New Products We have broad and diverse technology platforms that are supported by deep scientific and technical expertise, extensive know-how, and more than 2,100 patents and patent applications in approximately 200 families across advanced delivery platforms, drug and biologics formulation, and manufacturing. For example, we have significant softgel fill and formulation know-how, databases of formulated products, and substantial softgel regulatory approval expertise. As a result, approximately 90% of approvals by the FDA over the last 25 years of new chemical entities presented in a softgel format have been developed and supplied by us. In addition to resolving delivery challenges for our customers' products, we have applied our technology platforms and development expertise to proactively develop proof-of-concept products, whether improved versions of existing drugs, new generic formulations, or innovative consumer health products. In the consumer health area, we file product dossiers with regulators in relevant jurisdictions for self-created products, which help contribute sustainable growth to our consumer health business. We expect to continue to seek proactive development opportunities and other non-traditional relationships to increase demand for and value realized from our technology platforms. These activities have provided us with opportunities to capture an increased share of end-market value through out-licensing, profit-sharing, and other arrangements. Operational Leverage Deploy Existing Infrastructure and Operational Discipline to Drive Profitable Growth Through our existing infrastructure, including our global network of operating locations and programs, we promote operational discipline and drive margin expansion. With our active focus on continuous improvement and sustainability enhancement, global procurement function, and conversion cost productivity metrics in place, we continuously seek to enhance our culture of functional excellence and cost accountability. Along with the ongoing increase in the share of revenues from higher margin biologics offerings, we expect this discipline to further leverage our operational network for profitable growth. Strategic Acquisitions and Licensing Build on our Existing Platform We operate in the markets for outsourced development solutions and commercial supply, generally provided by contract development and manufacturing organizations (CDMOs), where we estimate current outsourced industry spending at more than \$90 billion globally for the offerings we provide. Our broad platform, global infrastructure, and diversified customer portfolio provide us with a strong foundation from which to consolidate within these markets, to enter new markets, and generate operating leverage through acquisitions. Since fiscal 2013, we have executed 22 transactions, investing approximately \$4.9 billion, and have demonstrated an ability to efficiently and effectively integrate these acquisitions. While we are rigorously focused on driving our organic growth, we have in recent years also substantially increased our participation in biologics, including protein-based biologics, cell and gene therapies, pDNA development and production, and drug product fill and finish, via strategy-driven inorganic transactions. We intend to identify and execute strategic transactions to optimize our portfolio of offerings and businesses, within the context of our long-term capital allocation strategy. We have a dedicated corporate development team in place to pursue these transactions, and apply a rigorous and financially disciplined process for evaluating and executing these transactions. Follow the Molecule's Journey by Providing Solutions to our Customers across all Phases of the Product Lifecycle We intend to continue to use our development and manufacturing solutions across the entire lifecycle of our customers' products to drive future growth. Our development solutions span the drug development process, starting with our platforms for early pre-clinical development of small molecules, protein-based biologics, and cell and gene therapies; through formulation and analytical services, development and manufacturing of clinical trial supplies, and fill and finish of injectable products; to regulatory consulting. Once a molecule is ready for clinical trials and subsequent commercialization, we provide our customers with a range of advanced technologies and expert, state-of-the-art manufacturing solutions that allow them to deliver their molecules to the end-users in safe, effective, and, in some cases, patient-preferred dosage forms, to produce biologic drug substances needed for protein-based biologics and cell and gene therapies, and to provide primary and secondary packaging solutions and cold-storage distribution services. Our relationship with a molecule typically starts with developing and manufacturing the innovator product and can extend throughout the molecule's commercial life. For prescription products, we are often the sole or primary outsourced provider and are frequently reflected in customers' product approval applications. Our revenue from our development and manufacturing activities are primarily driven by volumes, and, as a result, the loss of an innovator drug's market exclusivity may be mitigated if we supply customers offering generic or biosimilar equivalents. 11 An example of the long and mutually productive relationships we foster can be found in a leading over-the-counter anti-allergy brand, which today uses both our

proprietary Zydys orally disintegrating tablets and Liqui-Gels softgel technology. We originally began development of the prescription format of this product for our multinational pharmaceutical company partner in 1992 to address specific patient sub-segment needs. After four years of development, we then commercially supplied the prescription product in our Zydys format for six years, and we have continued to provide the Zydys form since the switch to over-the-counter status in the U.S. and other markets in the early 2000s. Subsequently, we proactively brought a softgel product concept for the brand to the customer, which the customer elected to develop and launch as well. By following this molecule, we have built a strong, three decade-long relationship across multiple formats and markets. Customer Product Pipeline â€œ Continuing to Grow Through New Projects and Product Launches We intend to continue to supplement our existing diverse base of commercialized customer products with new development programs. As of June 30, 2024, our product development teams were working on approximately 1,500 customer development programs active across our business. Our base of active development programs has expanded in recent years from growing market demand, as well as from our expanded capabilities and technology platforms. Although there are many complex factors that affect the development and commercialization of pharmaceutical, protein-based biologic, cell and gene therapy, and consumer health products, we expect that a portion of these programs will reach full development and market approval in the future and thereby add to our long-duration commercial revenues under long-term contracts and grow our existing product base. In fiscal 2024, we introduced 151 new products for our customers. Catalent continues to be a leader in providing chemistry, manufacturing, and controls-based product development services to the global pharmaceutical, biotechnology, and consumer health industries, driven by thousands of projects annually. In fiscal 2024, we recognized \$1.23 billion of net revenue related to the development of products, down 37% from the prior year, principally driven by the substantial decrease in net revenue from the COVID-19 related products. In addition, substantially all of the revenue associated with the clinical supply services business relates to our support of customer products in development. Our Reportable Segments At the beginning of fiscal 2023, in connection with the appointment of a new President and Chief Executive Officer, who also serves as the Companyâ€™s Chief Operating Decision Maker, the Company changed its operating structure and reorganized its executive leadership team. This new organizational structure includes operating and reporting in two segments: (i) Biologics and (ii) Pharma and Consumer Health. Biologics Our Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell, gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, pre-filled syringes, and cartridges; and analytical development and testing services for large molecules. The business has extensive expertise in development, scale up, and commercial manufacturing. Representative customers of our Biologics segment include Halozyme, Moderna, Novo Nordisk, Regeneron, and Sarepta Therapeutics, along with a broad range of innovative small and mid-tier biopharmaceutical customers. Our biologics offering includes cell-line development based on our advanced, patented GPEx suite of technologies, which are used to develop stable, high-yielding mammalian cell lines for both innovator and biosimilar biologic compounds. GPEx technology can provide rapid cell-line development, high biologics production yields, flexibility, and versatility. Our development and manufacturing facility in Madison, Wisconsin has the capability and capacity to produce cGMP quality biologics drug substance from 250L to 4000L scale using single-use technology across five suites to provide maximum efficiency, redundancy, and flexibility. Additionally, our Madison, Wisconsin facility features two flexible cGMP suites that are used to manufacture mRNA or other small-scale biomolecules. Our Bloomington, Indiana facility brings additional biologics development, clinical, and commercial drug substance manufacturing, and formulation development capabilities and capacity. Both Bloomington and our Anagni, Italy facility provide substantial capacity for finished-dose drug product manufacturing and packaging. Our SMARTag next-generation ADC technology is a clinical-stage technology that enables development of ADCs and other protein conjugates with improved efficacy, safety, and manufacturability. At our gene therapy, cell therapy, and pDNA global centers of excellence in Maryland, Belgium, and New Jersey, we develop and manufacture advanced therapeutics, including AAV, lentivirus, oncolytic virus, CART, and other cell or virus modalities together with critical pDNA biological starting material for cell, mRNA, viral-based therapies and next-generation vaccines. In fiscal 2022, we acquired a fully operational, commercial-scale cell therapy campus in Princeton with 16 suites available for both autologous and allogeneic clinical and commercial manufacturing. The Princeton campus works in conjunction with our Gosselies, Belgium cell therapy center of excellence and our iPSC manufacturing center of excellence in 12 Dusseldorf, Germany, to support our customersâ€™ global cell therapy needs. Additionally, we have expanded our gene therapy flagship manufacturing campus in Harmons, Maryland, creating a total of 18 penthouse-style viral-vector suites, and added our UpTempo AAV platform that reduces AAV development time by half, enabling our customers to reach first-in-human studies faster. Our specialized expertise in AAV vectors, the most commonly used delivery system for gene therapies, and iPSCs for next-generation allogeneic cell therapy manufacturing, together with our substantial global cell therapy manufacturing, capacity for clinical- through commercial-scale batches, and our capabilities in mRNA and pDNA manufacturing, position us to capitalize on strong industry demand and expansions in the use of newer modalities in the cell and gene therapy market. Our range of injectable manufacturing offerings includes manufacturing drug substances and filling small molecules or biologics into vials, syringes, and cartridges, with flexibility to accommodate other formats within our existing network. In addition to primary packaging, our network provides secondary packaging capabilities, including auto-injector and safety device assembly for commercial launch and life-cycle management. Our clinical supply services business provides a global network for clinical distribution, as well as labeling, packaging, and cold-chain storage for clinical trials and commercial supply of biotherapeutics and cell and gene therapies. Our fill and finish services are largely focused on complex pharmaceuticals and biologics. With our range of technologies, we are able to meet a wide range of specifications, timelines, and budgets. We believe that the complexity of the manufacturing process, the importance of experience and know-how, a proven history of regulatory compliance, and substantial state-of-the-art capacity provide us with a meaningful competitive advantage in the market. We also offer analytical development and testing services for proteins, gene and cell therapies, and other biologic modalities, including bioassay, biophysical characterization, and cGMP release and stability testing. Our OneBio Integrated Suite provides customers with the potential to seamlessly integrate drug substance, drug product, and clinical supply management for products in development, and for integrated commercial supply across both drug substance and drug product. We provide a broad range of technologies and services supporting the development and launch of new biologic entities, biosimilars, biobetters, and cell and gene therapies to bring a product from gene to commercialization, faster. Our Biologics segment represented 45%, 46%, and 53% of our aggregate net revenue before inter-segment eliminations for fiscal 2024, 2023, and 2022, respectively. Pharma and Consumer Health Through our Pharma and Consumer Health segment, we provide market-leading capabilities for oral solid dose forms, softgels, Zydys fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services. Representative customers of our Pharma and Consumer Health segment include Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Haleon, Pfizer, and Procter & Gamble. Our Pharma and Consumer Health segment represented 55%, 54%, and 47% of our aggregate net revenue before inter-segment eliminations for fiscal 2024, 2023, and 2022, respectively. Formulation and development Through our comprehensive pharmaceutical formulation and development platform, we provide pre-clinical screening, formulation, and analytical development, and cGMP manufacturing at both clinical and commercial scale for our market-leading softgel capsule and Zydys fast-dissolve tablet platforms, traditional and advanced complex oral solid-dose formats, dry powder inhalers, and nasal delivery devices. We have substantial, proven experience in developing and scaling up orphan and rare disease products, especially those requiring accelerated development timelines, solubility enhancement, specialized handling (e.g., potent or controlled substance materials), complex technology transfer, and specialized manufacturing processes. We provide fluid bed coating, spray drying, hot melt extrusion, micronization, and lipid formulation capabilities, all of which can be used to enhance a drugâ€™s function and release profile and enable its clinical performance. We offer comprehensive analytical method development and scientific capabilities, including stability testing and global regulatory services to support both fully integrated development programs or standalone fee-for-service work. We have a network of early development sites focused on earlier phase compounds (i.e., pre-clinical and Phase I) to engage with more customer molecules earlier in their development, with the intent to also support these molecules downstream as they progress towards commercial approval and supply. Demand for our offerings is driven by the need for scientific expertise, the depth and breadth of integrated services offered, as well as the reliability of our supply performance across quality and operational parameters. Manufacturing 13 Our large-scale cGMP pharmaceutical manufacturing solutions typically include clinical trial supplies, registration batches, and commercial production across a broad range of formats, and may also involve finished dose packaging or advanced processing of intermediates to achieve the desired clinical performance of the prescription or over-the-counter pharmaceutical product. Finished dose forms include softgel capsules, our Zydys fast-dissolve tablets, and traditional and advanced oral solid-dose forms, including coated and uncoated tablets, pellet/bead/powder-filled two-piece hard capsules, granulated powders, and other immediate and modified release forms. Advanced intermediate processing may include coating, extrusion, or spheronization to achieve specific functional outcomes, including site- or time-specific drug release, taste masking, or enhanced bioavailability. We have deep experience at managing complex technical transfers of clinical or commercial programs, whether from Catalentâ€™s early development network, other contract development sites, or from customers directly. Softgel technology platform We provide formulation, development, and manufacturing services for soft capsules, or â€œsoftgels,â€ as well as large-scale manufacturing of oral solid dose forms for pharmaceutical and consumer health markets, along with supporting ancillary services. Our softgel manufacturing technology was first commercialized by our predecessor in the 1930s, and we have continually enhanced the platform since then. We are the market leader in overall softgel development and manufacturing and hold the leading market position in innovator drug softgels. Our principal softgel technologies include traditional softgel capsules, in which the shell is made of animal-derived gelatin, and Vegicaps and OptiShell capsules, in which the shell is made from plant-derived materials. Softgel capsules are used in a broad range of customer products, including prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. Softgel capsules encapsulate liquid, paste, or oil-based formulations of active compounds in solution or suspension within an outer shell. In the manufacturing process, the capsules are formed, filled, and sealed simultaneously. We typically perform encapsulation for a product within one of our softgel facilities, with active ingredients provided by customers or sourced directly by us. Softgels have historically been used to solve formulation challenges or technical issues for a specific drug, to help improve the clinical performance of compounds, to provide important market differentiation, particularly for over-the-counter medications, and to provide safe handling of hormonal, highly potent, and cytotoxic drugs. We also participate in the softgel vitamin, mineral, and supplement business in selected regions around the world. Our plant-derived softgel shells, available as Vegicaps and OptiShell capsules, allow innovators and consumer health customers to extend the softgel dose form to a broader range of active ingredients and serve patient and consumer populations that were previously inaccessible due to religious, dietary, or cultural preferences. Our Vegicaps and OptiShell capsules are protected by patents in most major global markets. Physician and patient studies we have conducted have demonstrated a preference for softgels versus traditional tablet and hard capsule dose forms in terms of ease of swallowing, real or perceived speed of delivery, ability to remove or eliminate unpleasant odor or taste, and, for physicians, perceived improved patient adherence with dosing regimens. In addition to softgel capsules, following our fiscal 2022 acquisition of Bettera Wellness, we also conduct formulation, development, and manufacturing of gummies, soft chews, and lozenges in a variety of sizes and shapes serving the dietary supplements market at two facilities in the United States. We use dietary and food ingredients provided by our customers or sourced directly by us, and we also provide ancillary services such as analytical testing and packaging. Clinical Supply Services Our Pharma and Consumer Health segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, cell and gene therapies, and other compounds in clinical trials. We offer customers flexible solutions for clinical supplies production and provide distribution and inventory management support for both simple and complex clinical trials. This includes over-encapsulation where needed; supplying placebos, comparator drug procurement, and clinical packages and kits for physicians and patients; inventory management; investigator kit ordering and fulfillment; cold-chain storage and distribution; and return supply reconciliation and reporting. We support trials in all regions of the world through our facilities and distribution network. In recent years, we have extended our network, with significant expansions at our Philadelphia, Pennsylvania and Shanghai, China free trade zone locations, facilities in California, China, and Japan, and a significant clinical storage capacity expansion in Schorndorf, Germany. We also continue to develop new solutions for the evolving clinical trial environment, including FlexDirect direct-to-patient, CT Success clinical supply planning, and extensive cold-chain investments. We are one of the leading providers of clinical trial supplies. We have partnered with companies who focus on the development of cannabis-based prescription medicines and high-value cannabinoid drug therapies whose goal is to achieve full regulatory approval under the strictest legal standards in effect in any jurisdiction affected, including cannabidiol and tetrahydrocannabinol pharmaceutical products using our Zydys technology in clinical trials across a range of indications, including multiple sclerosis spasticity, chemotherapy-induced nausea and vomiting, chronic pain for cancer, and epilepsy. Our total net revenue related to such development programs was less than 1% of total revenue generated in fiscal 2024. We do not provide any services for or otherwise partner with any company that does not comply with all applicable laws, including the U.S. federal controlled substances laws (or non-U.S. equivalent laws), relating to cannabis products. Integrated Development and Product Supply Chain Solutions In addition to our proprietary offerings, we bring together our development solutions and state-of-the-art product manufacturing to offer integrated development and product supply solutions to enable our customers to take their drugs, biologics, and consumer health products from laboratory to market, faster. Once a product is on the market, we can provide comprehensive, integrated product supply, from the sourcing or supply of the bulk active ingredient to comprehensive manufacturing and packaging, to the testing required for release, and to cold-chain or ambient temperature distribution. The customer- and product-specific solutions we develop are flexible, scalable, and creative, so that they meet the unique needs of both large and emerging biopharmaceutical, pharmaceutical, and consumer health companies and are appropriate for products of all sizes. We believe that our development and product supply solutions, such as our OneBio Integrated Suite, will continue to contribute to our future growth. Sales and Marketing Our target customers include large pharmaceutical and biotechnology companies, mid-size, emerging, and specialty pharmaceutical and biotechnology companies, and consumer health companies, along with companies in other selected healthcare market segments such as animal health and medical devices, and companies in adjacent industries, such as cosmetics. We have longstanding, extensive relationships with leading pharmaceutical, biotechnology, and consumer health customers. In fiscal 2024, we did business with 88 of the top 100 branded drug and consumer health marketers and 82 of the top 100 biologics marketers, measured on a global basis, as well as with approximately 1,100 other customers. Faced with access, pricing, and reimbursement pressures as well as other market challenges, large pharmaceutical and biotechnology companies have increasingly sought partners to enhance the clinical competitiveness of their drugs and biologics and improve the productivity of their research and development activities, while reducing their fixed cost bases. Many mid-size, emerging, and specialty pharmaceutical and biotechnology companies, while facing the same pricing and market pressures, have chosen not to build a full infrastructure, but rather to partner with other companies through licensing agreements or outsourcing to access the critical skills, technologies, and services required to bring their products to market. Consumer health companies require rapidly developed, innovative dose forms and formulations to keep up with the fast-paced over-the-counter medication, dietary supplement, and personal care markets. These market segments are all important to our growth, but require distinct solutions, marketing and sales approaches, and market strategy. We follow a hybrid demand-generation organization model, with strategic account teams offering the full breadth of Catalentâ€™s solutions, and technical specialist teams providing the in-depth technical knowledge and practical experience essential for each individual offering, both supported by a dedicated team of deeply experienced scientific advisors. Our sales organization currently consists of more than 200 full-time, experienced sales professionals, supported by inside sales and sales operations. We also have built a dedicated strategic marketing team, providing strategic market and product planning and management for our offerings. As part of our marketing efforts, we participate in major trade shows relevant to our offerings globally and ensure adequate visibility to our offerings and solutions through a comprehensive advertising and publicity program. We believe that Catalent is a strong brand with high overall awareness in our established markets and universe of target customers, and that our brand identity is a competitive advantage for us. Global Accounts We manage select accounts globally due to their substantial current business or growth potential. We recorded approximately 38% of our total net revenue in fiscal 2024 from these global accounts. Each global account is assigned a lead business development professional with substantial industry experience. These account leaders, along with other members of the sales and executive leadership teams, are responsible for managing and extending the overall account relationship. Account leaders work closely with the rest of the sales organization as well as operational, quality, and project management personnel to ensure alignment around critical priorities for the accounts. Emerging, Specialty, and Virtual Accounts Emerging, specialty, and virtual pharmaceutical and biotechnology companies account for more than three-quarters of the active drug and biologic development pipeline. Historically, many of these companies have chosen not to build a full infrastructure, but rather partner with other companies to formulate, develop, analyze, test, and manufacture their products. We expect them to continue to do so in the future, providing a critical source for future integrated solutions

We expect to increase our penetration of geographic clusters of emerging companies in North America, Europe, Central and South America, and Asia. We regularly use active pipeline and product screening and customer targeting to identify the optimal candidates for partnering based on product profiles, funding status, and relationships, to ensure that our technical sales specialists and field sales representatives develop custom solutions designed to address the specific needs of these customers. In order to reach these emerging, specialty, and virtual companies, we actively partner with leading venture capital investors and biotech incubators. Seasonality: Fluctuations in Operation Results Our annual financial reporting period ends on June 30. As discussed further in "Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations - Factors Affecting our Performance," our revenue and net earnings are generally higher in the third and fourth quarters of each fiscal year, with our first fiscal quarter typically generating our lowest revenue of any quarter, and our last fiscal quarter typically generating our highest revenue. These fluctuations are primarily the result of the timing of our, and our customers' annual operational maintenance periods at locations in the U.S. and Europe, the seasonality associated with pharmaceutical and biotechnology budgetary spending decisions, clinical trial and research and development schedules, the timing of new product launches and length of time needed to obtain full market penetration, and, to a lesser extent, the time of the year some of our customers' products are in higher demand, or are being produced to support future seasonal demand. Contractual Arrangements We generally enter into a broad range of contractual arrangements with our customers, including agreements with respect to feasibility, development, supply, licenses, quality, and confidentiality. The terms of these contracts vary significantly depending on the offering and customer requirements. Some of our agreements may include a variety of revenue arrangements, such as fee-for-service, unit pricing in one or more tiers, minimum volume commitments, royalties, manufacturing preparation services, profit-sharing, and fixed fees. We generally secure pricing and other contract mechanisms in our supply agreements to allow for periodic resetting of pricing terms, and, in some cases, these agreements permit us to raise or renegotiate pricing in the event of certain price increases for the raw materials or other inputs we use to make products. Our typical supply agreements include indemnification from our customers for product liability and intellectual property matters and caps on our contractual liabilities, subject in each case to negotiated exclusions. The terms of our manufacturing supply agreements range from two to seven years with regular renewals of one to three years, although some of our agreements are terminable upon much shorter notice periods, such as 30 or 45 days. For our development solutions offerings, we may enter into master service agreements, which provide for standardized terms and conditions and make it easier and faster for customers with multiple development needs to access our offerings. Backlog While we generally have long-term supply agreements that provide for a revenue stream over a period of years, our backlog represents, as of a point in time, future service revenues from work not yet completed. For our Biologics segment and a majority of our Pharma and Consumer Health segment, backlog represents firm orders for manufacturing services and includes minimum volumes, where applicable. Manufacturing businesses backlog represents firm orders for manufacturing services and includes minimum volumes, where applicable. For the clinical supply services offered through our Pharma and Consumer Health segment, backlog represents estimated future service revenue from work not yet completed under signed contracts. Using these methods of reporting backlog, as of June 30, 2024, our backlog was \$2.34 billion, compared to \$2.53 billion as of June 30, 2023, including \$731 million and \$557 million, respectively, related to our scientific and clinical services offerings in our Pharma and Consumer Health segment. We expect to recognize as revenue by the end of fiscal 2025 approximately 78% of the value of the backlog in existence as of June 30, 2024. To the extent projects are delayed, the timing of our revenue could be affected. If a customer cancels an order, we may be reimbursed for the costs we have incurred. For orders that are placed inside a contractual firm period or that involve minimum volume commitments, we generally have a contractual right to payment in the event of cancellation. Fluctuations in our reported backlog levels also result from the timing and order pattern of our customers, which often seek to manage their level of inventory on hand. Because of customer ordering patterns, the matters discussed in this paragraph, and other factors, our backlog reported for certain periods may fluctuate and may not be indicative of future results. Manufacturing Capabilities We operate manufacturing facilities, development centers, and sales offices throughout the world. As of June 30, 2024, we had approximately 50 facilities (3 geographical locations operate as multiple facilities because they support more than one reporting segment, with one location including both a manufacturing facility and our corporate headquarters) on four continents with approximately 8 million square feet of manufacturing, laboratory, office, and related space. Our manufacturing capabilities generally include the full suite of competencies relevant to the support of each site's activities, including regulatory, quality assurance, and in-house validation. We operate our manufacturing facilities and development centers in accordance with cGMP or other applicable requirements. All of these sites are registered where required with the FDA or other applicable regulatory agencies, such as the EMA. In some cases, our sites are registered with multiple regulatory agencies. We have invested \$1.56 billion in our manufacturing and development facilities since fiscal 2022 for improvements and expansions, including \$327 million in capital expenditures during fiscal 2024. We believe that our sites and equipment are in good condition, are well maintained, and are able to operate at or above present levels for the foreseeable future, in all material respects. Our manufacturing operations are focused on employee health and safety, regulatory compliance, operational excellence, continuous improvement, and process standardization across the organization. In fiscal 2024, we achieved approximately 96% on-time shipment delivery versus customer request date across our network as a result of this focus. Our manufacturing operations are structured around an enterprise management philosophy and methodology that utilizes principles and tools common to a number of operational and quality management programs, including Lean Six Sigma and Lean Manufacturing, which we brought together in a system that we refer to as "The Talent Way." Raw Materials We use a broad and diverse range of raw materials and other supplies in the design, development, and manufacture of our products. This includes, but is not limited to, key materials such as gelatin, starch, and iota carrageenan; packaging films; single-use production components for drug substance production, and glass vials and syringes for drug product. The raw materials and other supplies that we use are sourced externally on a global basis. Globally, our supplier relationships could be interrupted due to natural disasters and international supply disruptions, including those caused by pandemics or geopolitical and other issues. For example, commercially usable gelatin is available from a limited number of sources. In addition, much of the gelatin we use is bovine-derived. Past concerns of contamination from bovine spongiform encephalopathy have narrowed the number of possible sources of particular types of gelatin. If there were a future disruption in the supply of gelatin or any other key material from any one or more of our current principal suppliers, there can be no assurance that we could obtain an adequate alternative supply from our other suppliers. Any future restriction that were to emerge on the use of a key raw material used in our products from certain geographic sources or due to regulatory or consumer concerns could hinder our ability to timely supply our customers with products, and the use of alternative raw materials could be subject to lengthy formulation, testing and regulatory approval periods. We work very closely with our customers and suppliers to assure continuity of supply while maintaining excellence in material quality and reliability. We continually evaluate alternate sources of supply, although we do not frequently pursue regulatory qualification of alternative sources for key raw materials due to the strength of our existing supplier relationships, the reliability of our current supplier base, and the time and expense associated with the regulatory process, since customers and regulators usually must approve changes to prescription product ingredient sources. Although a change in suppliers could require significant effort or investment by us in circumstances where the items supplied are integral to the performance of our products or incorporate specialized material such as gelatin, we do not believe that the loss of any existing supply arrangement would have a material adverse effect on our business. "Risk Factors" Risks Relating to Our Business and the Industry in Which We Operate "Our results of operations are subject to fluctuations in the costs, availability, and suitability of the components of the products we manufacture, including active pharmaceutical ingredients, excipients, purchased components, and raw materials, and other supplies or equipment we need to run our business." Competition We compete with multiple companies as to each of our offerings and in every region of the globe in which we operate, including with CDMOs and other companies that offer conventional and advanced technologies for the development, supply, and delivery of medicinal products, clinical trials support, outsourced dose form, protein-based biologics or cell or gene therapy manufacturing, or development services to pharmaceutical, biotechnology, and consumer health companies based in North America, Central and South America, Europe, and the Asia-Pacific region. We also compete in some cases with the internal operations of those pharmaceutical, biotechnology, and consumer health customers that also have manufacturing capabilities and choose to source these services internally. Some of our competitors are substantially larger than we are and have access to more substantial resources, which could be deployed to expand their range of offerings or capacity. Competition is driven by proprietary technologies and know-how (where relevant), capabilities, consistency of operational performance, availability of equipment, quality, regulatory track record, price, value, responsiveness, and speed. While we have competitors that compete with us in our individual offerings, and a few competitors that compete across many of our offerings, we do not believe we have competition from any directly comparable company. Research and Development Costs Our research activities are primarily directed toward the development of new offerings and manufacturing process improvements. Research and development costs amounted to \$174 million, \$184 million, and \$234 million for fiscal 2024, 2023, and 2022, respectively. Employees As of June 30, 2024, we had approximately 16,900 individuals providing services for us at 53 facilities on 4 continents, of which certain employees at two of our 24 U.S. facilities are represented by labor unions, with their terms and conditions of employment being subject to collective bargaining agreements. Various combinations of national works councils, labor unions, and other labor organizations are active at all of our European and many of our other ex-U.S. facilities consistent with labor environments and laws in those countries. Our management believes that our relations with our workforce are satisfactory. Most of our individual service providers are full-time employees, while approximately 800 of our workers as of June 30, 2024 are contingent workers who are either self-employed or employed by external services organizations. North America Europe South America Asia Pacific Total Approximate number of workers as of June 30, 2024 6,005 8,009 0 600 16,900 Human Capital Management Our employees share common goals: to put patients first and to help people around the world live better, healthier lives. Our global workforce is united by our values: Patient First, commitment to our People, Customer Dedication, Innovation, Integrity, and Excellence. Together, our values provide the foundation for our culture. We believe that an engaged, diverse workforce, empowered by inclusive leaders, will unlock our full potential as a company and as a leader in our sector. Our employees' success is Catalent's success. We focus on employee development, engagement, and diversity and inclusion (D&I) to hire, develop, and retain the best talent. As of June 30, 2024, we had approximately 16,900 employees globally, with women representing 44% of our employees and holding 40% of roles at the manager level or higher. As of June 30, 2024, people of color represented 36% of our U.S. employees. Our turnover rate decreased to 19% as of June 30, 2024, including 11% voluntary turnover. Much of this turnover was driven by voluntary departures in the U.S. and by a few reorganizations at some of our larger sites and within our corporate functions. Reducing voluntary attrition and retaining our talent remains one of our top priorities. We continue to implement initiatives to build upon our values-based and inclusive culture, improve our employees' experiences at Catalent, and better develop and engage internal talent. We continuously monitor local talent markets and provide differentiated pay arrangements and benefits to attract and retain talent. Additionally, we provide flexible work arrangements where possible, broader leadership development programs, an employee wellness program, and access to employee recognition programs at all levels. We continue to take steps to ensure that Catalent is a company where all employees can develop a fulfilling career with support from our leadership team. We believe that our diverse pool of internal talent and our employees' passion for excellence make a difference in the way we grow and deliver results. Talent Acquisition We have strong human resources processes and practices in place to support our employees through their careers at Catalent. This starts with a robust recruiting strategy and a strong employer brand. We attracted over 2,400 new employees in fiscal 2024, continuously working to reduce the time it takes to fill open positions, while striving for a best-in-class candidate experience. We offer competitive compensation and a comprehensive suite of benefits, which, in the U.S., range from medical, dental, and vision coverage to retirement, disability, employee stock purchase, and life insurance programs. We also provide health promotion and wellness programs, remote work flexibility, tuition assistance, and employee assistance programs in several countries. Our recruitment strategy aims to attract talent representing diverse backgrounds, perspectives, and ideas. This approach includes: Developing future leaders and enhancing their skills through programs that include various mentoring programs, our Global Organization Leadership Development (GOLD) program, Next Generation Global Leaders, and General Managers Excellence programs, as discussed further below; Providing competitive compensation and benefits; Continuously improving recruitment processes and platforms; and Working with several recruitment partners to attract strong profiles and advertise open positions. Catalent has been recognized as a TOP EMPLOYER USA since 2020 and as a TOP EMPLOYER in the United Kingdom ("U.K.") since 2022. We differentiate ourselves as a preferred employer to candidates through our reputation as a great place to work, offering a fast-paced and rewarding work environment. Talent Development We are dedicated to the growth, development, and engagement of our people once they join our organization. Through a commitment to building onto the already strong learning and development culture, we offer specialized technical training, leadership development, high-potential growth opportunities, and team effectiveness solutions for leadership teams. This training and development equips our employees and leaders with the knowledge and expertise needed to advance their skills and careers at Catalent. Our primary goal is to grow our people from within, thereby establishing a strong successor bench to drive company growth. In fiscal 2024, over 2,100 employees moved to a new role within the organization, whether as a developmental move or a promotion to a more senior position. Our senior leaders are committed to talent development and dedicate time each fiscal quarter to conduct formal talent reviews. During these sessions, they discuss the progress of key talent and update succession plans for critical roles. We firmly believe that personal development and career progression are best achieved through a combination of Experience (70%), Exposure (20%), and Education (10%). Within this framework, we provide a wealth of tools and resources, offering employees numerous opportunities to acquire new skills or enhance existing ones. Employees can take advantage of the resources on Career Corner, an employee intranet site that features a variety of resources on mentoring, access to LinkedIn Learning events and the opportunity to enroll in virtual training sessions on fundamental skills needed to thrive at Catalent. Given our consistent volume of new hires, we continue to enhance the employee journey which begins with their onboarding experience. We have refined our on-boarding program to support employees throughout their first twelve months with Catalent. We also support new leaders with an engaging New Leader Assimilation program that aims to foster meaningful connections between a leader and their team. We are proud of our four formal development programs offered to employees. All programs aim to prepare our talent to fill critical internal leadership roles. Through these programs, we have created a strong bench of leaders who model our values and are ready to take on more responsibility. (1) A Entry-level GOLD program. The GOLD program is a two-year rotational program for recent graduates from universities around the world in which the employee participates in two rotations at different sites in our network to learn about different aspects of our business and our varied offerings. GOLD employees receive assignments to perform strategic roles in key business initiatives. We provide them with coaching and opportunities to interact with senior executives, which both develop the skills and experience of our GOLD employees and provide a platform through which they contribute fresh ideas that challenge the status quo. The GOLD program currently operates in the U.S. and in Europe and is in the process of being redesigned for a relaunch in fiscal 2026. (2) A Manager-level Next Generation Global Leader program. Our Next Generation Global Leader program, for nominated managers, is a twelve-month centrally managed program that focuses on Leading self, Others and the Business with the ultimate goal of preparing high-potential managers for director-level roles. To date, this program has had three rounds of 120 graduates, with a new group of 33 employees slated to join this program in fiscal 2025. (3) A Senior Leader General Managers' Excellence program. Our general managers run our operating sites and have substantial and wide-ranging responsibilities. This program enhances the skills of our general managers by giving them exposure to industry best practices, opportunities to network internally and receive personalized career coaching, including a 3-day business simulation. In fiscal 2024 and 2023, a total of 55 current and potential general managers, respectively, participated in this program. (4) A Front-line leader Lead Now program. In fiscal 2023, we launched a Lead Now, a Catalent-wide leadership offering targeted for those who are new to people leadership. During the first 3 months of a new leadership role, this program teaches employees the fundamentals of leadership and identifies tools to inspire their teams while role-modeling Catalent values. Since Lead Now's inception, we have certified 420 new leaders in this program. Diversity and Inclusion At Catalent, we cultivate a workplace that respects and welcomes all people; celebrate the unique backgrounds and experiences of our workforce; encourage all employees to bring their true, authentic selves to work; and leverage the diverse backgrounds, perspectives, and ideas of our team members to drive innovation, inclusion, and excellence in every aspect of our business. By fostering an inclusive environment, we energize our people to do their best work. Our commitment to D&I starts at the top with our board of directors (referred to herein as the "Board of Directors" or "Board") and executive leadership team that bring a broad spectrum of backgrounds and perspectives. Led by our Diversity and Inclusion team, and effectuated at all levels of the Company, we focus on attracting, retaining, and developing

and our employees, and our global D&I initiatives are our nine global employee resource groups (â€œERGâ€). The ERGs are open to all. They provide support, resources, and a forum for topical discussion and engagement for employees around the following categories: People with disabilities, People of Asian and Pacific Islander descent, Women, Indigenous people, people of Hispanic and/or LatinX descent, our LGBTQ+ community, people of African descent, Gen Y and Z, and people with military and/or first responder service. Our ERG network includes 148 global, virtual, and site-based chapters. Key D&I performance highlights are captured in our Corporate Responsibility and Environmental, Social, and Governance Strategy section below. EngagementOur employee-focused practices make a clear impact on our employee engagement. Through increased engagement, we can grow our business by relying on strong, engaged leaders and professionals who are dedicated to overcome challenges and drive results. We regularly conduct company-wide engagement surveys to garner direct feedback from our employees. This allows us to deepen and enhance engagement by focusing on improving specific areas where we can best support our people. In fiscal 2023, we implemented an online platform that provides our leaders with updated engagement scores and immediate access to results which empowers our leaders to take swift action based on feedback. Our recent survey in October 2023, led to a company-wide score of 6.7 out of a possible 10 for Catalent (using a rating scale from 1 to 10). The results highlighted key strengths, including our inclusive culture, our Patient First value, peer relationships, goal setting, and meaningful work. The survey also highlighted areas requiring further focus, including well-being, communication, career paths, and rewards and recognition.20Corporate Responsibility (â€œCRâ€) and ESG Strategy Our CR strategy, which includes our ESG strategy, is integrated into our company-wide strategic plan, ensuring that we operate in alignment with our values, meet our commitments to all our stakeholders, and contribute to the long-term success of the broader biopharmaceutical, pharmaceutical, and consumer health industries and the communities where we operate. Our approach to ESG focuses on three areas of society relevant to our business, prioritizing our impact on (i) people, (ii) the environment, and (iii) our communities. We focus on ESG areas that are the most significant to our business, and our strategy is informed by our employees, customers, investors, communities, and other key stakeholders. Our fiscal 2024 ESG performance, described below, demonstrates our contribution to the long-term success of the industries we serve and the communities where we operate, as we continue to invest in a corporate culture that understands and prioritizes our impact on people in our operations and employee-related decision-making. GovernanceWe are committed to ensuring strong corporate governance practices on behalf of our shareholders and other stakeholders. We believe strong corporate governance and an independent board of directors provide the foundation for financial integrity and shareholder confidence. More information about our corporate governance features can be found in Item 10. â€” Directors, Executive Officers, and Corporate Governance.Our CR council, which reports to the CEO and is composed of senior leaders from various parts of our business, guides our CR efforts and sets our overall CR strategy. Management, including members of the CR council, provide regular CR updates to our board of directors, which regularly reviews material aspects of our CR strategy and performance as a full board and through its several committees, including a formal annual review of our overall CR strategy and performance.Business BenefitsBeyond being the right thing to do, we believe our focus on CR helps strengthen our business by reducing risks, meeting customer and investor expectations, and positioning us to attract top talent. CR performance is an important contributor to our business success. It informs our risk management process, protects our reputation, and alerts us to regulatory, environmental, and societal threats to our business. Our CR activities also align with many of our customersâ€™ CR programs and strengthen our relationships.Our future success depends on our highly skilled and dedicated global team of employees, who are passionate about improving health outcomes. We compete for top talent in our industry and recognize that our culture and reputation as a responsible company can be a differentiator for attracting job candidates and keeping and motivating our existing employees. ESG progress in fiscal 2024We made significant progress in several ESG focus areas in fiscal 2024:â€”In February 2024, we published our fifth annual Corporate Responsibility report (covering fiscal 2023), which includes an evaluation of our performance against the standards set by the Sustainability Accounting Standards Board (SASB) for Biotechnology and Pharmaceuticals and the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD). Some highlights of our progress include: â€”[purchasing renewable electricity for our operating sites, with energy attribution certificates (EACs) accounting for 80% of our electricity use by the end of fiscal 2023, compared to 76% at the end of fiscal 2022, thus reducing our total Scope 1 and 2 emissions by 10%, from a fiscal 2022 baseline;â€”reducing the volume of water used in water stressed areas by 14.4% from fiscal 2022, mainly due to the impact of water savings projects at water-stressed sites;â€”increasing the volume of waste diverted from landfill to 85%, compared to 73% in fiscal 2022, due to the progress from our Zero Waste to Landfill program;â€”[philanthropic giving that exceeded \$1.25 million, driven significantly by philanthropic efforts related to the humanitarian response to the war in Ukraine and, our on-going commitment to science, technology, engineering, and math (STEM) education, and nonprofits that serve patients, with a focus on underserved communities; andâ€”21% of employees participated in our annual Month of Service, up from 18% in fiscal 2022, reflecting the expanded range of participation options we offered.21â€”In fiscal 2024, we continued to drive D&I by (1) investing in the inclusive capabilities of our leaders, (2) working with partners who share our values and help enable our strategy, (3) accelerating strong talent acquisition and development of people with diverse ideas and backgrounds, and (4) curating an inclusive culture. Some highlights of our progress include: â€”[confirmation that we closed the U.S. gender pay gap in fiscal 2021 through EDGE certification;â€”[publication of a Supplier Diversity Policy, which provides that we expect suppliers to have policies in place that assure that no employee or third party is discriminated against due to their sex, gender, race, ethnicity, disability, religion, or sexual orientation;â€”[designation as a 2023 Best Place to Work for people with disabilities, based on the Disabilities Equality Index;â€”[rollout of our inclusive leadership workshops for site and functional leadership teams and ongoing conversations hosted by our leaders following challenging current events in the U.S.; andâ€”[continued active involvement of our ERGs, with 30 global ERG events with more than 4,000 attendees.Looking aheadWe are determined to play an integral role in moving our industry toward more responsible and sustainable business practices as we continue to be at the cutting edge of developing and reliably supplying drugs, biologics, and consumer health products. We continue to reduce our carbon emissions and have an approved set of Science Based Targets (SBT). These targets commit Catalent to reducing absolute scope 1 and 2 GHG emissions 42% by fiscal 2030 from a fiscal 2022 base year. Catalent also commits to reduce absolute scope 3 GHG emissions from fuel- and energy-related activities, and employee commuting 25% within the same timeframe. Catalent further commits that 70% of its suppliers by emissions, covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by fiscal 2028. We are committed to maintain water intensity to less than 500 cubic meters per \$1 million in revenue, with a focus on sites in water-deprived or sensitive areas, to reduce our water usage further. At the end of fiscal 2023, 85% of our waste previously sent to landfill was disposed of by other means, Catalent is committed to eliminate all waste sent to landfill; in fiscal 2024. We have performed a risk assessment and identified process and infrastructure changes needed for us to achieve our bold goal to ensure no residual active pharmaceutical ingredient (API) above Predicted No Effect Concentration (PNEC) in wastewater. Activities to implement this goal will occur throughout fiscal 2025.We continue to strengthen our supply chain by expanding our supplier assessment and auditing program, including continued use of our third-party vetting and due diligence platform in alignment with the Pharmaceutical Supply Chain Initiative (PSCI) principles and the U.N. Guiding Principles on Business and Human Rights. We expect our diverse supplier network and spend will continue to increase, as outlined in our new Diverse Supplier Policy.We will work to progress our efforts in recruiting, developing, and retaining talent representing diverse backgrounds, perspectives, and ideas, including in leadership roles. In fiscal 2024, we further implemented our D&I action plans, which outline localized strategies. We continue to consider external benchmarks, including the Corporate Equality Index (LGBTQ+ inclusion) and the Disability Index, in evaluating our progress. Through training, forums, and internal performance metrics, we will continue to combat unconscious biases that can impact the hiring and promotion of diverse talent. Our employee surveys reveal that our employees are energized and engaged by our CR and D&I initiatives. In fiscal 2025, we will continue to assess our employees' overall engagement and inclusion through our next corporate engagement survey. Further information on our CR program is available at catalent.com/about-us/corporate-responsibility/, but this website is not part of our public disclosures and is not incorporated by reference into this Annual Report.Intellectual Property We use a combination of know-how, trade secrets, patents, copyrights, trademarks, and other intellectual property, nondisclosure and other contractual provisions, and technical measures to protect certain innovative aspects of our offerings, services, and intangible assets that we have developed. These proprietary rights can be important to aspects of our ongoing operations. Many of our operations and products are covered by intellectual property licenses from third parties, particularly our customers that provide licenses to their proprietary active ingredients or formulations as part of our development or supply agreements with them, and in certain instances we license our technology to third parties. We also have a long track record of innovation across our lines of business, and, to further encourage active innovation, we have developed incentive compensation systems linked to patent filings and other recognition and reward programs for scientists and non-scientists alike. We have applied in the U.S. and certain other countries for registration of a number of 22trademarks, service marks, and patents, some of which have been registered and issued, and also hold common law rights in various trademarks and service marks. We hold more than 2,100 patents and patent applications worldwide relating to advanced drug delivery platforms, biologics formulations and technologies, and manufacturing. We hold patents and license rights relating to certain aspects of our formulations, pharmaceutical and nutritional dosage forms, mammalian cell engineering, antibody-drug conjugation, iPSCs, and plasmid DNA manufacturing. We also hold patents relating to certain processes and products. We have pending patent applications in the U.S. and certain other countries and intend to pursue additional patents as appropriate. We have enforced and will continue to enforce our intellectual property rights in the U.S. and worldwide in appropriate circumstances. We do not consider any particular patent, trademark, license, franchise, or concession to be material to our overall business. Regulatory Matters The manufacture, distribution, and marketing of healthcare products and the provision of certain services for development-stage pharmaceutical and biotechnology products are subject to extensive ongoing regulation by the FDA, other U.S. governmental authorities, and similar regulatory authorities in other countries. Certain of our subsidiaries are required to register for permits or licenses with, and must comply with the operating, cGMP, quality, and security standards of, applicable domestic and foreign healthcare regulators, including the FDA, the U.S. Drug Enforcement Agency (the â€œDEAâ€), the U.S. Department of Health and Human Services (the â€œDHHSâ€), the equivalent agencies of the E.U. and its member states, and various state boards of pharmacy, state health departments, and comparable agencies in other jurisdictions, as well as various accrediting bodies, each depending upon the type of operations and the locations of distribution and sale of the products manufactured or services provided by those subsidiaries. In addition, various aspects of our business are subject to other healthcare laws, including the U.S. Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, the Controlled Substances Act, and comparable state and foreign laws and regulations relevant to their activities.We are also subject to various federal, state, local, national, and transnational laws, regulations, and requirements, both in the U.S. and other countries, relating to safe working conditions, laboratory and distribution practices, and the use, transportation, and disposal of hazardous or potentially hazardous substances. In addition, applicable import and export laws and regulations require us to abide by certain standards relating to the cross-border transit of finished goods, raw materials, and supplies and the handling of information. We are also subject to various other laws and regulations concerning the conduct of our non-U.S. operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Anti-Bribery Act, and other anti-bribery laws and laws pertaining to the accuracy of our internal books and records. Furthermore, we are subject, in various jurisdictions, including the E.U. and certain U.S. states, to various privacy laws protecting data we may collect or process from employees, our customers' patients, or others. The costs associated with complying with the various applicable federal, state, local, national, and transnational regulations could be significant, and the failure to comply with such legal requirements could have an adverse effect on our results of operations and financial condition. See â€”Item 1A. - Risk Factorsâ€”Risks Relating to Our Business and the Industry in Which We Operateâ€”We are a part of the highly regulated healthcare industry, subject to stringent regulatory standards and other applicable laws and regulations, which can change unexpectedly or be the subject of unexpected changes in interpretation or enforcement, any of which may adversely impact our business,â€”for additional discussion of the costs associated with complying with the various regulations. In fiscal 2024, we were subject to 69 regulatory audits, and, over the last five fiscal years, we completed approximately 280 regulatory audits. Quality Assurance We are committed to ensuring and maintaining the highest standard of regulatory compliance while providing high quality products to our customers, supported by our core value of Patient First. To meet these commitments, we have developed and implemented a Catalent-wide quality management system. We have employees around the globe focusing on quality and regulatory compliance. Our senior management team is actively involved in setting quality policies, standards, and internal guidance as well as managing internal and external quality performance. Our quality assurance department provides quality leadership and supervises our quality systems programs. An internal audit program monitors compliance with applicable regulations, standards, and internal policies. In addition, our facilities are subject to periodic inspection by the FDA, the DEA, and other equivalent local, state, and foreign regulatory authorities as well as our customers. All FDA, DEA, and other regulatory inspection observations have been resolved or are on track to be completed at the prescribed timeframe provided in 23commitments to the applicable agency in all material respects. We believe that our operations are in compliance in all material respects with the regulations under which our facilities are governed. Environmental, Health & Safety Matters Our operations are subject to a variety of environmental, health, and safety laws and regulations, including those of the U.S. Environmental Protection Agency (the â€œEPAâ€), the U.S. Occupational Safety & Health Administration (â€œOSHAâ€), and equivalent state, local, and national regulatory agencies in each of the jurisdictions in which we operate. These laws and regulations govern, among other things, air emissions, wastewater discharges, the use, handling, and disposal of hazardous substances and wastes, soil and groundwater contamination, and employee health and safety. Our manufacturing facilities use, in varying degrees, hazardous substances in their processes. These substances include, among others, chlorinated solvents, and in the past chlorinated solvents were used at one or more of our facilities, including a number we no longer own or operate. As at our current facilities, contamination at such formerly owned or operated properties can result and has resulted in liability to us, for which we have recorded appropriate reserves as needed. We believe that our operations are in compliance in all material respects with the environment, health, and safety regulations applicable to our facilities.24ITEM 1A. â€” RISK FACTORS If any of the following risks actually occur, our business, financial condition, operating results, or cash flow could be materially and adversely affected. Additional risks or uncertainties not presently known to us, or that we currently believe are immaterial, may also impair our business operations. Risks Relating to Pending Merger with Novo HoldingsWe may not complete the pending Merger with Novo Holdings within the timeframe anticipated, or at all, which could have a material adverse effect on our business, financial condition or results of operations, as well as negatively impact our share price. On February 5, 2024, we entered into the Merger Agreement. Consummation of the Merger is subject to certain closing conditions, including receipt of required regulatory approvals. For more information, see Note 17, Commitments and Contingencies to our Consolidated Financial Statements. Furthermore, the granting of regulatory approvals by antitrust authorities could involve the imposition of additional conditions on the closing of the Merger. The imposition of such conditions or the failure or delay to obtain regulatory approvals could have the effect of delaying completion of the Merger or of imposing additional costs or limitations on us or may result in the failure to close the Merger. We cannot provide any assurance that the conditions to the consummation of the Merger will be satisfied or waived or that, if the Merger is consummated, it will be on the terms specified in the Merger Agreement or within the anticipated timeframe.Failure to complete the Merger within the timeframe anticipated could adversely affect our business and the market price of our Shares in a number of ways, including:â€”The price of our Common Stock may decline to the extent that current market prices of our Common Stock reflect assumptions that the Merger will be completed on a timely basis.â€”The failure to complete the Merger may result in negative publicity and negatively affect our relationship with our stockholders, employees, customers, suppliers and lenders.â€”If the Merger is not completed, the time and resources committed by our management team could have been devoted to pursuing other opportunities.â€”We have incurred, and will continue to incur, significant expenses for professional services in connection with the Merger for which we will have received little or no benefit if the Mer

completion of the transaction and thus is being diverted from our day-to-day operations. Uncertainty as to our future also could adversely affect our business and our relationship with collaborators, strategic partners, suppliers, existing or prospective customers or regulators. For example, collaborators, suppliers, existing or prospective customers and other counterparties may defer decisions concerning us, or seek to change existing business relationships with us, whether pursuant to the terms of their existing agreements with us or otherwise. Changes to or termination of existing business relationships could materially adversely affect our financial condition and results of operations, as well as negatively impact our share price. The adverse effects of the pendency of the transaction could be exacerbated by any delays in completion of the transaction, changes to the terms of the transaction or termination of the Merger Agreement.25We have incurred, and will continue to incur, direct and indirect costs as a result of the pending Merger with Novo Holdings. We have incurred, and will continue to incur, significant costs and expenses, including legal, accounting and other advisory fees and other transaction costs, in connection with the pending Merger. We will be required to pay a substantial portion of these costs and expenses whether or not the Merger is completed. There are a number of factors beyond our control that could affect the total amount or the timing of these costs and expenses. While the Merger Agreement is in effect, we are subject to restrictions on our business activities. While the Merger Agreement is in effect, we are subject to restrictions on our business activities, generally requiring us to conduct our business in the ordinary course, consistent with past practice, in all material respects, and subjecting us to a variety of specified limitations absent Novo Holdings’ prior consent. These limitations include, among other things, restrictions on our ability to acquire other businesses and material assets (including certain governmental licenses and authorizations), dispose of material assets, make investments, enter into or amend certain material contracts, repurchase or issue securities, pay dividends, make capital expenditures, take certain actions relating to intellectual property, amend our organizational documents, incur indebtedness, hire/terminate certain employees and provide increases to compensation and benefits to certain employees. These restrictions could prevent us from pursuing strategic business opportunities, taking actions with respect to our business that we may consider advantageous and responding effectively or on a timely basis to competitive pressures and industry developments, and may as a result materially adversely affect our business, financial condition and results of operations. The Merger Agreement contains provisions that prohibit a third party from proposing an alternative transaction or acquire our Company prior to the consummation of the Merger. The Merger Agreement contains provisions that prohibit our ability to entertain a third-party proposal for an acquisition of our company or an alternative transaction in lieu of the Merger. These provisions include our agreement not to, directly or indirectly, solicit, initiate, or knowingly facilitate, or knowingly encourage or negotiate with any person regarding other proposals for an acquisition of our Company, as well as restrictions on our ability to respond to such proposals, even one that may be deemed of greater value to our stockholders than the proposed Merger with Novo Holdings. We are and may continue to be targets of other securities class action and derivative lawsuits that could result in substantial costs and may delay or prevent the Merger from being completed. We are and may continue to be targets of other securities class action and derivative lawsuits as a result of our agreement to enter into the Merger transaction. Securities class action lawsuits and derivative lawsuits are often brought against public companies that have entered into merger agreements. The outcome of litigation is uncertain and we may not be successful in defending against future claims brought against us even if they are without merit. Regardless of the outcome of any lawsuits brought against us, such lawsuits could delay or prevent the Merger, divert the attention of our management and employees from our day-to-day business, result in substantial costs and otherwise adversely affect us financially. A potential adverse judgment could result in monetary damages, which could have a negative impact on our liquidity and financial condition. Additionally, if a plaintiff is successful in obtaining an injunction prohibiting completion of the Merger, that injunction may delay or prevent the Merger from being completed, or from being completed within the anticipated timeframe, which may adversely affect our business, financial condition or results of operations. For more information, see Note 17, Commitments and Contingencies to our Consolidated Financial Statements. Our executive officers and directors may have interests in the proposed Merger that are different from, or in addition to, those of our stockholders generally. Our executive officers and directors may have interests in the proposed Merger that are different from the interests of our stockholders generally, including, among others, the acceleration of the vesting of equity awards and receipt of change in control or other severance payments in connection with the proposed Merger, continued indemnification and insurance and potentially continued service to the combined company. These interests, among others, may influence, or appear to influence, our executive officers and directors and cause them to view the Merger differently from how our stockholders generally may view it. Additional information regarding our executive officers and directors and their interests in the proposed Merger were included in the proxy statement relating to the proposed Merger filed with the SEC. If the Merger occurs, our stockholders will not be able to participate in any further upside to our business.26If the Merger is consummated, our stockholders will receive the right to receive an amount in cash equal to \$63.50 per Share, without interest, and will not receive any equity interests of Parent. As a result, if our business following the Merger performs well, our current stockholders will not receive any additional consideration and will therefore not receive any benefit from any such future performance of our business. Risks Relating to Our Business and the Industry in Which We Operate Actions of activist shareholders could impact the pursuit of our business strategies and adversely affect our results of operations, financial condition, or share price. We value constructive input from investors and regularly engage in dialogue with our shareholders regarding strategy and performance. Our board of directors and management team are committed to acting in the best interests of all shareholders. The actions taken by our board of directors and management in seeking to maintain constructive engagement with certain shareholders, however, may not be successful. We have been, and may in the future be, subject to activities initiated by activist shareholders. In August 2023, we entered into a Cooperation Agreement (the “Cooperation Agreement”) with Elliott Investment Management L.P. (“Elliott”). Pursuant to the Cooperation Agreement, we appointed Steven Barg, Frank D’Amelio, Michelle Ryan, and Stephanie Okey as members of the Board, with an initial term expiring at the Company’s 2023 Annual Meeting of Shareholders. We strive to maintain constructive, ongoing communications with all shareholders, including Elliott, and we welcome constructive input from all shareholders toward the shared goal of enhancing stakeholder value. Nonetheless, we may not be successful in engaging constructively with one or more shareholders, and any resulting activist campaign that contests, or seeks to change, our strategic direction or business mix could have an adverse effect on us because: (i) responding to actions by activist shareholders could disrupt our business and operations, be costly or time-consuming, or divert the attention of our board of directors or senior management from the pursuit of business strategies, which could adversely affect our results of operations or financial condition; (ii) perceived uncertainties as to our future direction may lead to the perception of a change in the direction of the business, instability, or lack of continuity, any of which may be exploited by our competitors, cause concern to our current or potential customers, cause concern in the minds of our employees and lead to the departure of critical employees, result in the loss of potential business opportunities, or make it more difficult to attract and retain qualified personnel and business partners; and (iii) these types of actions could cause significant fluctuations in our share price based on temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business. We anticipate being subject to increasing focus by our investors, regulators, customers, and other stakeholders on ESG matters. Our investors, regulators, customers, and other stakeholders are increasingly focused on ESG matters. Certain investors, particularly institutional investors, and certain of our customers may use third-party benchmarks or scores to measure our ESG practices, and to decide whether to invest in our shares, engage with us regarding our practices, or engage or continue to use our services. If our ESG scores or practices do not meet desired standards, we may face reputational challenges. There can be no assurance that we will be able to accomplish any particular ESG goal or commitment, including any additional or revised commitment that we may announce in the future, as statements regarding such goals and commitments reflect our plans and aspirations at the time of announcement and do not guarantee achievement of such plans and aspirations within the timelines we announce or at all. Different stakeholder groups have divergent views on ESG matters, which increases the risk that any action or lack thereof with respect to ESG matters will be perceived negatively by at least some stakeholders and adversely impact our reputation and business. Anti-ESG sentiment has gained some momentum across the United States, with several states having enacted or proposed anti-ESG policies or legislation, or issued related legal opinions. If we do not successfully manage ESG-related expectations across these varied stakeholder interests, it could erode stakeholder trust, impact our reputation, and constrain our business. Globally, a lack of harmonization in relation to ESG legal and regulatory reform across the jurisdictions in which we may operate may affect our future implementation of, and compliance with, rapidly developing ESG standards and requirements. Generally, we expect stakeholder demands and the prevailing legal environment to require us to devote additional resources to ESG matters in our review of prospective acquisitions. Additionally, collecting, measuring, and reporting ESG information and metrics can be costly, difficult, and time-consuming, are subject to evolving reporting standards, and can present numerous operational, reputational, financial, legal, and other risks. Compliance with ESG-related rules and efforts to meet investor expectations on ESG matters may place strain on our personnel, systems, and resources, and we may incur significant compliance costs. Additionally, failure to comply with such rules or meet investor expectations may have a material adverse impact on our business, prospects, financial condition, or results of operations. We are a part of the highly regulated healthcare industry, subject to stringent regulatory standards and other applicable laws and regulations, which can change unexpectedly or be the subject of unexpected changes in interpretation or enforcement, any of which may adversely impact our business. The healthcare industry is highly regulated. We, and our customers, are subject to various local, state, federal, national, and transnational laws and regulations, which include the operating, quality, and security standards of the FDA, the DEA, various state boards of pharmacy, state health departments, the DHHS, similar bodies of the U.K., the E.U. and its member states, and other comparable agencies around the world, and, in the future, any change to such laws and regulations or the interpretation or application thereof could adversely affect us. Among other rules affecting us, we are subject to laws and regulations concerning cGMP and drug safety. New public health orders or best practice guidelines may increase our costs to operate or reduce our productivity, thereby affecting our business, financial condition, or results of operations. We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts of our employees, agents, contractors, or collaborators that turn out to violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare, employment, foreign corrupt practices, trade restrictions and sanctions, environmental, competition, and privacy laws and regulations. Failure by us or by our customers to comply with the requirements of applicable laws and regulations or requests from regulatory authorities could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture or distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of existing or denial of pending approvals, permits, or registrations, including those relating to products or facilities. In addition, any such failure relating to the products or services we provide could expose us to contractual or product liability claims as well as claims from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients, which cost could be significant. Our business activities outside the U.S. are subject to the U.S. Foreign Corrupt Practices Act, the U.K. Anti-Bribery Act, and other anti-bribery or anti-corruption laws, regulations, or rules. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations may have a material adverse impact on our business, prospects, financial condition, or results of operations. In addition, any new offering or product classified as a pharmaceutical or medical device must undergo lengthy and rigorous clinical testing and other extensive, costly, and time-consuming procedures mandated by the FDA, the EMA, and other equivalent local, state, federal, national, and transnational regulatory authorities in the jurisdictions that regulate our offerings and products. Although we believe that we comply in all material respects with applicable laws and regulations, there can be no assurance that a regulatory agency or tribunal would not reach a different conclusion concerning the compliance of our operations with applicable laws and regulations. In addition, there can be no assurance that we will be able to maintain or renew existing permits, licenses, or other regulatory approvals or obtain, without significant delay, future permits, licenses, or other approvals needed for the operation of our businesses. Any noncompliance by us or our customers with applicable law or regulation or the failure to maintain, renew, or obtain necessary permits and licenses could have an adverse effect on our results of operations and financial condition. Furthermore, loss of a permit, license, or other approval in any one portion of our business may have indirect consequences in another portion of our business if regulators or customers adjust their reviews of such other portion as a result or customers cease business with such other portion due to fears that such loss is a sign of broader concerns about our ability to deliver products or services of sufficient quality. Any failure to implement fully, monitor, and continuously improve our quality management strategy could lead to quality or safety issues and expose us to significant costs, potential liability, and adverse publicity. Our results depend on our ability to execute and improve when necessary our quality management strategy and systems, and effectively train and maintain our workforce with respect to quality management. Quality management plays an essential role in determining and meeting customer requirements, preventing defects, and improving our offerings, and, despite our network of quality systems, a quality or safety issue, including with respect to a high-revenue product, could have an adverse effect on our business, financial condition, stock price, or results of operations and may subject us to regulatory action, including a product recall, product seizure, injunction to halt manufacture or distribution, or restriction on our operations; monetary fines; or other civil or criminal sanctions. In addition, such an issue could subject us to adverse publicity and costly litigation, including claims from our customers for reimbursement for the cost of lost or damaged active pharmaceutical ingredients or other related losses, the cost of which could be significant. We have experienced, and may continue to experience, productivity issues and higher-than-expected costs at certain of our facilities, which have resulted in, and may continue to result in, material and adverse impacts on our financial condition and results of operations. In the fourth quarter of fiscal 2023, we announced that we experienced productivity issues at three of our facilities, including two of our largest manufacturing facilities in fiscal 2023, relating to, among other things, deployment of a new enterprise resource planning (ERP) system and continued need to implement enhancements to operational and engineering controls following regulatory inspections, which led to reductions in revenues and increases in costs at these sites in fiscal 2023. Our plans to increase capacity for a customer’s product at one of these sites did not move forward on schedule, and, due to manufacturing capacity constraints, revenue from the unproduced batches was not made up in fiscal 2023. There can be no assurance that such revenue will be recovered on expected timeframes or at all. In addition, we have experienced higher-than-expected costs at the three facilities. Although we have taken several measures at these facilities, including management and operational changes, there can be no assurance that such measures will successfully address the root causes of the issues identified at each site, that our costs will return to anticipated levels, or that productivity levels at these sites will return to normal in the expected timeframes or at all. If we are unsuccessful in remedying the productivity issues at our facilities, if we are unable to recover revenue from unproduced batches when expected or at all, or if our costs at our facilities remain elevated, we may continue to experience material and adverse impacts on our financial condition and results of operations. Furthermore, there can be no assurance that additional operational and productivity issues will not arise at these three sites, or that similar operational and productivity issues will not materialize in our other manufacturing facilities, which may result in material and adverse impacts on our financial condition and results of operations. The declining demand for various COVID-19 vaccines and treatments from both patients and governments around the world has affected and may continue to affect sales of the COVID-19 products we manufacture and our financial condition. We manufacture or provide services for a variety of products intended for the prevention or treatment of COVID-19 and its symptoms and effects, including both vaccines and treatments. Due to the substantially decreased demand for these products since the height of the COVID-19 pandemic, no single one of these products is currently material to our business. The duration and extent of future revenues from our development, testing, manufacturing, and packaging of COVID-19-related products is uncertain and dependent upon customer demand. As the COVID-19 pandemic evolved into an endemic phase, we anticipated greater seasonality for demand and a decreased patient population, which may result in overall lower demand for the COVID-19-related products we develop, test, manufacture, or package. The market for the COVID-19 vaccines we develop, test, manufacture, or package depends on several evolving factors that are outside of our control, including public health authority recommendations and consumer motivation to vaccinate. Certain of the COVID-19-related products we develop and manufacture have not yet received full marketing approval from relevant regulatory authorities around the world or for certain patient populations. Should any of these COVID-19-related products be denied any necessary regulatory approval, the demand for such product could decrease significantly and therefore decrease customer orders for additional development, manufacturing, or packaging of those products. Additionally, the need for continued manufacture and supply of vaccines (including booster doses) and therapies to address COVID-19, including new and developing variants of COVID-19, is highly uncertain and subject to various political, economic, and regulatory factors that are outside of our control. In addition, highly public political and social debate relating to the need for, efficacy of, or side effects related to one or more specific COVID-19 vaccines could contribute to changes in public perception of one or more COVID-19 vaccines manufactured by us, which could decrease demand for a COVID-19 related products we develop, manufacture, or package. Any of these factors, or others, could lead to decreased demand for the COVID-19 related products we develop, manufacture, or package and, as a result, have an adverse effect on our financial

results or financial condition. The demand for our offerings depends in part on our customers’ research and development and the clinical and market success of their products. Our business, financial condition, and results of operations may be harmed if our customers spend less on, or are less successful in, these activities. In addition, customer spending may be affected by, among other things, recessionary economic conditions caused in whole or in part by lingering effects of the COVID-19 pandemic, the Ukrainian-Russian war, the war in Gaza between Israel and Hamas and conflict in the Middle East, higher interest rates, or the rise in inflation worldwide. Our customers are engaged in research, development, production, and marketing of pharmaceutical, biotechnology, and consumer health products. The amount of customer spending on research, development, production, and marketing, as well as the outcomes of such research, development, and marketing activities, have a large impact on our sales and profitability, 29 particularly the amount our customers choose to spend on our offerings. Available resources, including funding for our biotechnology and other customers, the need to develop new products, and consolidation in the industries in which our customers operate may have an impact on such spending. Our customers and potential customers finance their research and development spending from private and public sources. A reduction in available financing for and spending by our customers, for these reasons or because of the direct or indirect lingering effects of the COVID-19 pandemic, inflation, higher interest rates, the Ukrainian-Russian war or other regional or global conflicts such as the war in Gaza, could have a material adverse effect on our business, financial condition, and results of operations. If our customers are not successful in attaining or retaining product sales due to market conditions, reimbursement issues, or other factors, our results of operations may be materially adversely affected. We participate in a highly competitive market, and increased competition may adversely affect our business. We operate in a market that is highly competitive. We compete with multiple companies as to each of our offerings and in every region of the globe in which we operate, including competing with other companies that offer advanced delivery technologies, outsourced dose form or biologics manufacturing, clinical trials support services, or development services to pharmaceutical, biotechnology, and consumer health companies globally. We also compete in some cases with the internal operations of those pharmaceutical, biotechnology, and consumer health customers that also have manufacturing capabilities and choose to source these services internally. We face substantial competition in each of our markets. Competition is driven by proprietary technologies and know-how, capabilities, consistency of operational performance, quality, price, value, responsiveness, and speed. Some competitors have greater financial, research and development, operational, and marketing resources than we do. Competition may also increase as additional companies enter our markets or use their existing resources to compete directly with ours. Expanded competition from companies in low-cost jurisdictions, such as India and China, may in the future adversely affect our results of operations or limit our growth. Greater financial, research and development, operational, and marketing resources may allow our competitors to respond more quickly with strategic acquisitions, or with new, alternative, or emerging technologies. Changes in the nature or extent of our customers’ requirements may render our offerings obsolete or non-competitive and could adversely affect our results of operations and financial condition. We are subject to product and other liability risks that could exceed our anticipated costs or adversely affect our results of operations, financial condition, liquidity, and cash flows. We are subject to potentially significant product liability and other liability risks that are inherent in the design, development, manufacture, and marketing of our offerings. We may be named as a defendant in product liability lawsuits, which may allege that our offerings have resulted or could result in an unsafe condition or injury to consumers. Such lawsuits, even those without merit, could be costly to defend and could result in reduced sales, significant liabilities, adverse publicity, and diversion of management’s time, attention, and resources. Furthermore, product liability claims and lawsuits, regardless of their ultimate outcome, could have a material adverse effect on our business operations, financial condition, and reputation and on our ability to attract and retain customers. The availability of product liability insurance for companies in the pharmaceutical industry is generally more limited than insurance available to companies in other industries. We maintain product liability insurance with annual aggregate limits in excess of \$25 million. There can be no assurance that a successful product liability or other claim would be adequately covered by our applicable insurance policies or by any applicable contractual indemnity or liability limitations. Our business, financial condition, and results of operations may be adversely affected by global health epidemics. Any public health epidemic, such as the COVID-19 pandemic, may affect our operations and those of third parties on which we rely, including our customers and suppliers. Our business, financial condition, and results of operations may be affected by: disruptions in our customers’ abilities to fund, develop, or bring to market products as anticipated; delays in or disruptions to the conduct of clinical trials; cancellations of contracts or confirmed orders from our customers; decreased demand for categories of products in certain affected regions; governmental restrictions imposed to respond to the risks posed by any such epidemic; and inability, difficulty, or additional cost or delays in obtaining key raw materials, components, and other supplies from our existing supply chain; among other factors caused by a public health epidemic. In addition, the impact of a public health epidemic could exacerbate other risks we face, including those described elsewhere in “Risk Factors.” The services and offerings we provide are highly exacting and complex, and, if we encounter problems providing the services or support required, our business could suffer. 30 The offerings we provide are highly exacting and complex, due in part to complex and exacting manufacturing processes and strict regulatory requirements. From time to time, problems may arise in connection with facility operations or during preparation or provision of an offering, in both cases for a variety of reasons including, but not limited to, equipment malfunction, sterility variances or failures, failure to follow specific protocols and procedures, problems with raw materials, environmental factors, and damage to, or loss of, manufacturing operations due to fire, flood, or similar causes. Such problems could affect production of a particular batch or series of batches, require the destruction of or otherwise result in the loss of product or materials used in the production of product, or could halt facility production altogether. This could, among other things, lead to increased costs, lost revenue, damage to customer relations, reimbursement to customers for lost active pharmaceutical ingredients or other related losses, time and expense spent investigating the cause, lost production time, and, depending on the cause, similar losses with respect to other batches or products. Production problems in our biologic manufacturing operations could be particularly significant because the cost of raw materials is often appreciably higher than in our other businesses. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred. In addition, such risks may be greater at facilities that are new or going through significant expansion or renovation. The risks associated with running a highly complex facility doing exacting work with substantial regulatory oversight are enhanced for our larger sites, like our Bloomington, Indiana, Harman, Maryland, St. Petersburg, Florida, or Swindon, U.K. sites, which generally generate much more revenue. If we cannot keep pace with rapid technological advances, our services may become uncompetitive or obsolete, and our revenue and profitability may decline. The healthcare industry is characterized by rapid technological change. Demand for our offerings may change in ways we may not anticipate because of evolving industry standards as well as a result of evolving customer needs that are increasingly sophisticated and varied and the introduction by others of new offerings and technologies that provide alternatives to our offerings. Several of our higher margin offerings are based on proprietary technologies. To the extent that such technologies are protected by patents, their related offerings may become subject to competition as the patents expire. Without the timely introduction of enhanced or new offerings and technologies, our offerings may become obsolete or uncompetitive over time, in which case our revenue and operating results would suffer. For example, if we are unable to respond to changes in the nature or extent of the technological or other needs of our pharmaceutical customers through enhancing our offerings, our competition may develop offerings that are more competitive than ours and we could find it more difficult to renew or expand existing agreements or obtain new agreements. Potential innovations intended to facilitate enhanced or new offerings generally will require a substantial investment before we can determine their commercial viability, and we may not obtain access to the innovations or have financial resources sufficient to fund all desired innovations. Even if we succeed in creating or acquiring enhanced or new offerings from these innovations, they may still fail to result in commercially successful offerings or may not produce revenue in excess of the costs of development, and they may be rendered obsolete by changing customer preferences or the introduction by our competitors of offerings embodying new technologies or features. Finally, innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice, the need for regulatory clearance, and uncertainty over market access or government or third-party reimbursement. Any failure to protect or maintain our intellectual property may adversely affect our competitive edge that we hold and result in loss of revenue or reputation. We rely on a combination of know-how, trade secrets, patents, copyrights, trademarks, and other intellectual property laws, nondisclosure and other contractual provisions, and technical measures to protect many of our offerings and intangible assets. These proprietary rights are important to our ongoing operations. There can be no assurance that these protections will provide uniqueness or meaningful competitive differentiation in our offerings or otherwise be commercially valuable or that we will be successful in obtaining additional intellectual property or enforcing our intellectual property rights against unauthorized users. The exclusive rights underlying certain of our offerings are protected by patents, some of which will expire in the near term. When patents covering an offering expire, loss of exclusivity may occur, which may force us to compete with third parties, thereby negatively affecting our revenue and profitability. The proprietary rights that we or our customers may hold in these offerings may be invalidated, circumvented, or challenged. We may in the future be subject to proceedings seeking to oppose or limit the scope of our patent applications or issued patents. In addition, in the future, we may need to take legal actions to enforce our intellectual property rights, to protect our trade secrets, or to determine the validity or scope of the proprietary rights of others. Legal proceedings are inherently uncertain, and the outcome of such proceedings may be unfavorable to us. Any legal action regardless of outcome might result in substantial costs and diversion of resources and management attention. 31 There can be no assurance that our confidentiality agreements will not be breached, our trade secrets will not otherwise become known by competitors, or that we will have adequate remedies in the event of unauthorized use or disclosure of proprietary information. Even if the validity and enforceability of our intellectual property is upheld, an adjudicator might construe our intellectual property not to cover the alleged infringement. In addition, intellectual property enforcement may be unavailable or practically ineffective in some countries. There can be no assurance that our competitors will not independently develop technologies that are substantially equivalent or superior to our proprietary technology or that third parties will not design around our intellectual property claims to produce competitive offerings. The use of our technology or similar technology by others could reduce or eliminate any competitive advantage we have developed, cause us to lose sales, or otherwise harm our business. While we continue to apply in the U.S. and certain other countries for registration of a number of trademarks, service marks, and patents, and also claim common law rights in various trademarks and service marks, there can be no assurance that third parties will not oppose our applications in the future. In addition, it is possible that in some cases we may be unable to obtain the registrations for trademarks, service marks, and patents for which we have applied, and a failure to obtain trademark and patent registrations in the U.S. or other countries could limit our ability to protect our trademarks and proprietary technologies and impede our marketing efforts in those jurisdictions. License agreements with third parties control our rights to use certain patents, software, and information technology systems and proprietary technologies owned by third parties, some of which are important to our business. Termination of these license agreements for any reason could result in the loss of our rights to this intellectual property, causing an adverse change in our operations or the inability to commercialize certain offerings. In addition, many of our branded pharmaceutical customers rely on patents to protect their products from generic competition. Because incentives exist in some countries, including the U.S., for generic pharmaceutical companies to challenge these patents, pharmaceutical and biotechnology companies are under the ongoing threat of challenges to their patents. If the patents on which our customers rely were successfully challenged and, as a result, the affected products become subject to generic competition, the market for our customers’ products could be significantly adversely affected, which could have an adverse effect on our results of operations and financial condition. We attempt to mitigate these risks by making our offerings available to generic as well as branded manufacturers and distributors, but there can be no assurance that we will be successful in marketing these offerings. Our offerings or our customers’ products may infringe on the intellectual property rights of third parties. From time to time, third parties have asserted intellectual property infringement claims against us and our customers, and there can be no assurance that third parties will not assert infringement claims against either us or our customers in the future. While we believe that our offerings do not infringe in any material respect upon proprietary rights of other parties, and that meritorious defenses would exist with respect to any assertion to the contrary, there can be no assurance that we could successfully avoid being found to infringe on the proprietary rights of others. Patent applications in the United States and certain other countries are generally not publicly disclosed until the patent is issued or published, and we and our customers may not be aware of currently filed patent applications that relate to our or their products, offerings, or processes. If patents later issue on these applications, we or they may be found liable for subsequent infringement. There has been substantial litigation in the pharmaceutical and biotechnology industries with respect to the manufacture, use, and sale of products that are the subject of conflicting patent rights. Any claim that our offerings or processes infringe third-party intellectual property rights (including claims arising through our contractual indemnification of our customers), regardless of the claim’s merit or resolution, could be costly and may divert the efforts and attention of our management and technical personnel. We may not prevail against any such claim given the complex technical issues and inherent uncertainties in intellectual property matters. If any such claim results in an adverse outcome, we could, among other things, be required to: pay substantial damages (potentially including treble damages in the U.S.); cease the manufacture, use, or sale of the infringing offerings or processes; discontinue the use of the infringing technology; expend significant resources to develop non-infringing technology; license technology from the third party claiming infringement, which license may not be available on commercially reasonable terms or at all; and lose the opportunity to license our technology to others or to collect royalty payments based upon successful protection and assertion of our intellectual property against others. In addition, our customers’ products may be subject to claims of intellectual property infringement and such claims could materially affect our business if their products cease to be manufactured or they have to discontinue the use of the infringing technology. 32 Any of the foregoing could affect our ability to compete or have a material adverse effect on our business, financial condition, and results of operations. Events that diminish, tarnish, or otherwise damage our brand may have an adverse effect on our future financial condition and results of operations. We have built a strong brand in “Catalent,” with high overall and generally favorable awareness of the brand in our established markets and with target customers. Our brand identity is a competitive advantage for us in sales and marketing, which is evidenced by our customer mix among top branded drug, generics, biologics, and consumer health marketers. We have spent and continue to spend substantial time, money, and other resources to establish both our brand awareness and a favorable perception of our brand in relevant markets. Among other strategies, we participate in major international trade shows in our established markets and ensure visibility into our offerings through a comprehensive print and on-line advertising and publicity program. It is possible that a single event, or aggregation of several events, may diminish, tarnish, or otherwise damage our brand and adversely affect our future financial condition and results of operations. For example, meaningful interruptions to our ability to reliably supply one or more customers with products on time, whether as a result of supply chain disruptions, manufacturing delays or defects, or the need to address regulatory requirements at our facilities, may diminish our customers’ confidence in our ability to timely meet our commitments, thereby damaging our brand. In addition, we are subject to various local, state, federal, national, and transnational laws and regulations, including the operating, quality, and security standards of the FDA, the DEA, and similar bodies of the U.K., the E.U., and other comparable agencies around the world. Highly public or significant negative reports or findings from a regulatory agency with respect to one or more manufacturing or quality defects in our operations, inspections of our facilities, or other routine reviews could cause negative public perception of our operations, negatively impacting our brand, and adversely affecting our financial condition and results of operations. In addition, many of the other risks we face, including those described elsewhere in “Risk Factors” could diminish, tarnish, or otherwise damage our brand. Our results of operations are subject to fluctuations in the costs, availability, and suitability of the components of the products we manufacture, including active pharmaceutical ingredients, excipients, purchased components, and raw materials, and other supplies or equipment we need to run our business. We depend on various active pharmaceutical ingredients, components, compounds, raw materials, and energy supplied primarily by third parties for our offerings. Our customers also frequently provide us with their active pharmaceutical or biologic ingredient for formulation or incorporation in the finished product and may supply other raw materials as well. It is possible that any of our or our customers’ supplier relationships could be interrupted due to changing regulatory requirements, import or export restrictions, natural disasters, international supply disruptions, including those caused by public health emergencies, wars, geopolitical issues, operational or quality issues at the suppliers’ facilities, and other events, or could be terminated in the future. For example, gelatin, a critical component for manufacturing many of our softgel formats is only available from a limited number of sources. In addition, much of the gelatin we use is bovine-derived. Past concerns of contamination from bovine spongiform encephalopathy have narrowed the number of possible sources of particular types of gelatin. If there were a future disruption in the supply of gelatin or any other key raw material used to manufacture our products, we may not be able to obtain an adequate alternative supply. If future restrictions or other developments limit our ability to obtain a key material, any such restriction or development could hinder our ability to timely supply our customers with products, and the use of alternative material could be subject to lengthy and uncertain formulation, testing, and regulatory approval. In addition, certain of our inputs are currently sole-sourced, so any disruption

related to such a supplier is more likely to have an impact on our operations. Replacing a sole-source supplier of a production input to a medicine requiring marketing approval may be impossible or time-consuming, due to the rigorous standards we are obliged to apply to any new supplier. Any sustained interruption in our receipt of adequate supplies could have an adverse effect on our business and results of operations. In addition, while we have processes intended to reduce volatility in component and material pricing, we may not be able to successfully manage price fluctuations, and future price fluctuations or shortages may have an adverse effect on our results of operations. Our goodwill has been subject to impairment and may be subject to further impairment in the future, which could have a material adverse effect on our results of operations, financial condition, or future operating results.

33We perform an annual goodwill impairment test for each reporting unit on April 1, or more frequently if indicators for potential impairment exist. Indicators that are considered include significant changes in performance relative to expected operating results, significant negative industry or economic trends, or a significant decline in our stock price and/or market capitalization for a sustained period of time. In addition, we assess the current and future economic outlook for our reporting units in our Pharma and Consumer Health and Biologics segments during the fiscal year. While we believe the assumptions used in determining whether there was impairment and the amount of any resulting impairment were reasonable and commensurate with the views of a market participant, changes in key assumptions in the future, including increasing the discount rate, lowering forecasts for revenue and operating margin, or lowering the long-term growth rate, could result in additional charges; similarly, one or more changes in these assumptions in future periods due to changes in circumstances could result in future impairments in this reporting unit or other reporting units. We have incurred impairment charges in the past, and we cannot predict if or when additional future goodwill impairments may occur. For example, for fiscal year ended June 30, 2023, we recorded a goodwill impairment charge of \$210 million in the Consumer Health reporting unit within our Pharma and Consumer Health segment. In addition, for the fiscal year ended June 30, 2024, we recorded goodwill impairment charges of \$687 million associated with the Consumer Health and Biomodalities reporting units in our Pharma and Consumer Health and Biologics segments, respectively. Any goodwill impairments could have material adverse effects on our operating income, net assets, or our cost of, or access to, capital, which could harm our business. See Note 4, Goodwill to the Consolidated Financial Statements for more details.

Changes in market access or healthcare reimbursement for, or public sentiment towards our customers’ products in the U. S. or internationally, or other changes in applicable policies regarding the healthcare industry, could adversely affect our results of operations and financial condition by affecting demand for our offerings. The healthcare industry has changed significantly over time, and we expect the industry to continue to evolve. Some of these changes, such as ongoing healthcare reform, including with respect to reforming drug pricing, adverse changes in governmental or private funding of healthcare products and services, legislation or regulations governing patient access to care and privacy, or the delivery, pricing, or reimbursement approval of pharmaceuticals and healthcare services or mandated benefits, may cause healthcare industry participants to change the amount of our offerings that they purchase or the price they are willing to pay for these offerings. In particular, it is possible that future legislation in the U.S. may affect or put a cap on future pricing of pharmaceutical and biotechnology products. While we are unable to predict the likelihood of changes to U.S. and other international laws affecting pharmaceutical and biotechnology products, any substantial revision of applicable healthcare legislation could have a material adverse effect on the demand for our customers’ products, which in turn could have a negative impact on our results of operations, financial condition, or business. Changes in the healthcare industry’s pricing, selling, inventory, distribution, or supply policies or practices, or in public or government sentiment for the industry as a whole, could also significantly reduce our revenue and results of operations. In particular, volatility in individual product demand may result from changes in public or private payer reimbursement or coverage. Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. We have generated net operating losses (and acquired affiliates with pre-existing NOLs) (and acquired affiliates with pre-existing NOLs) or certain other tax attributes that have been, and continue to be, used to reduce taxable income. In the case of our NOL carryforwards (and new NOLs that may arise), they may be subject to a substantial limitation under Section 382 of the Internal Revenue Code of 1986, as amended (the Internal Revenue Code), and comparable provisions of state, local, and foreign tax laws due to changes in ownership of our company that may occur in the future. Under Section 382 of the Internal Revenue Code and comparable provisions of state, local, and foreign tax laws, if a corporation undergoes an ownership change, generally defined as a greater than 50% change by value in its equity ownership over a three-year period, the corporation’s ability to carry forward its pre-change NOLs to reduce its post-change income may be limited. In addition, we acquired companies that generated pre-acquisition NOLs for tax purposes that will also be subject to limitation under Section 382 and comparable provisions of state, local, and foreign tax laws. We may experience ownership changes in the future because of future changes in our stock ownership. As a result, our ability to use NOL carryforwards to reduce U.S. federal, state, local, and foreign taxable income, we produce in the future years may be subject to limitations, which could result in increased future tax liability to us. Changes to the estimated future profitability of the business may require that we establish an additional valuation allowance against all or some portion of our net deferred tax assets. We have deferred tax assets for NOL carryforwards, certain other tax attributes, and other temporary differences. We currently maintain a valuation allowance for a portion of our U.S. net deferred tax assets and certain foreign net deferred tax assets. It is possible we may experience a decline in U.S. and foreign taxable income resulting from a decline in profitability of our relevant operations, an increased level of debt in the U.S., or other factors. In assessing our ability to realize our deferred tax assets, we may conclude that it is more likely than not that some additional portion or all our deferred tax assets will not be 34realized. As a result, we may be required to record an additional valuation allowance against our deferred tax assets, which could adversely affect our effective income tax rate and therefore our financial results. We depend on key personnel, and, if we are unable to attract, retain and motivate well-qualified employees, our business could be harmed. We depend on our executive officers and other key personnel, including our technical personnel, to operate and grow our business and to develop new and enhanced offerings and technologies. The loss of any of these officers or other key personnel or a failure to attract and retain suitably skilled technical personnel could adversely affect our operations. In addition to our executive officers, we rely on more than 130 senior employees to lead and direct our business. Our senior leadership team is comprised of our subsidiaries’ executive officers and other vice presidents and directors who hold critical positions and possess specialized talents and capabilities that give us a competitive advantage in the market. Any change in our senior leadership team in particular, even in the ordinary course of business, may be disruptive to our business. While we seek to manage these transitions carefully, such changes may result in a loss of institutional knowledge and cause disruptions to our business and new executive hires may fail to achieve any anticipated benefits. If our senior leadership team fails to work together effectively or execute our plans and strategies on a timely basis as a result of management turnover or otherwise, our business could be harmed. In addition, we employ more than 3,100 scientists and technicians whose areas of expertise and specialization cover subjects such as advanced delivery, biologics and gene and cell therapy formulation and manufacturing. Many of our sites and laboratories are located in competitive labor markets; therefore, global and regional competitors and, in some cases, customers and suppliers compete for the same skills and talent as we do. If we are unable to hire and retain sufficient qualified employees, our ability to conduct and expand our business could be meaningfully reduced. We may acquire businesses and offerings that complement or expand our business or divest non-strategic businesses or assets. We may not be able to complete desired transactions, and such transactions, if executed, pose significant risks, including risks relating to our ability to successfully and efficiently integrate acquisitions or execute on dispositions and realize anticipated benefits therefrom. The failure to execute or realize the full benefits from any such transaction could have a negative effect on our operations and profitability. Our future success may depend in part on opportunities to buy or otherwise acquire rights to other businesses or technologies, enter into joint ventures or otherwise enter into strategic arrangements with business partners that could complement, enhance, or expand our current business or offerings and services or that might otherwise offer us growth opportunities, or divest assets or an ongoing business. We face competition from other companies in pursuing acquisitions and similar transactions in the pharmaceutical and biotechnology industry. Our ability to complete transactions may also be limited by applicable antitrust and trade laws and regulations in the U.S. and other jurisdictions in which we or the operations or assets we seek to acquire carry on business. To the extent that we are successful in making acquisitions, we expend substantial amounts of cash, incur debt, or assume loss-making divisions as consideration. We or the purchaser of a divested asset or business may not be able to complete a desired transaction for any number of reasons, including a failure to secure financing. Any acquisition that we are able to identify and complete may involve a number of risks, including, but not limited to, the diversion of management’s attention to integrate the acquired businesses or joint ventures, the possible adverse effects on our operating results during the integration process, the potential loss of customers or employees in connection with the acquisition, delays or reduction in realizing expected synergies, unexpected liabilities, and our potential inability to achieve our intended objectives for the transaction. In addition, we may be unable to maintain uniform standards, controls, procedures, and policies, which may lead to operational inefficiencies. To the extent that we are not successful in completing desired divestitures, we may have to expend cash, incur debt, or continue to absorb the costs of loss-making or under-performing divisions. Any divestiture, whether we complete it or not, may involve numerous risks, including diversion of management’s attention, a negative impact on our customer relationships, costs associated with maintaining its business during the disposition process, and the costs of closing and disposing of the affected business or transferring remaining portions of the operations of the business to other facilities. We provide services incorporating various advanced modalities, including protein and plasmid production and cell and gene therapies, and these modalities relate to relatively new modes of treatment that may be subject to changing public opinion, continuing research, and increased regulatory scrutiny, each of which may affect our customers’ abilities to conduct their businesses or obtain regulatory approvals for their therapies, and thereby adversely affect these offerings. Cell and gene therapy, with or without the use of iPSCs or plasmids, remain relatively new means for treating disease and other medical conditions, with only a few cell and gene therapies approved to date in the U.S., the E.U., or elsewhere. Public perception may be influenced by claims that cell or gene therapies are unsafe, and cell or gene therapy may not gain the 35acceptance of the public or the medical community. In addition, ethical, social, legal, and cost-benefit concerns about cell or gene therapy, genetic testing, genetic research, and the use of stem cells or materials derived from viruses could result in additional regulations or limitations or even outright prohibitions on certain cell or gene therapies or related products. Various regulatory and legislative bodies have expressed an interest in, or have taken steps towards, further regulation of various biotechnologies, including cell and gene therapies. More restrictive regulations or claims that certain cell or gene therapies are unsafe or pose a hazard could reduce our customers’ use of our services. We can provide no assurance whether legislative changes will be enacted, regulations, policies, or guidance changed, or interpretations of existing strictures by agencies or courts changed, or what the impact of such changes, if any, may be. We may become subject to litigation, other proceedings, and government investigations relating to us or our operations, and the ultimate outcome of any such matter may have an impact on our business, prospects, financial condition, and results of operations. We may become subject to litigation or government investigations in the U.S. and foreign jurisdictions that may arise from the conduct of our business. We generally intend to defend ourselves vigorously against any litigation proceeding or government investigation; however, we cannot be certain of the ultimate outcomes of any legal proceedings or investigations that may arise in the future. Resolution of these types of matters against us may result in, among other things, the payment of significant fines, judgments, penalties or settlements, the imposition of administrative remedies, changes and additional costs to our business operations to avoid risks associated with such litigation or investigations, reputational damage and decreased demand for our products, and the expenditure of significant time and resources that would otherwise be available for operating our business, all of which may have an impact on our business, prospects, financial condition, or results of operations. We are subject to environmental, health, and safety laws and regulations, which could increase our costs or restrict our operations in the future. Our operations are subject to a variety of environmental, health, and safety laws and regulations, including those of the EPA, OSHA, and equivalent local, state, and national regulatory agencies in the jurisdictions in which we operate. Any failure by us to comply with environmental, health, and safety requirements could result in the limitation or suspension of production or subject us to monetary fines, civil or criminal sanctions, or other future liabilities in excess of our reserves. In particular, we are subject to laws and regulations governing the destruction and disposal of raw materials, byproducts of our manufacturing operations, and non-compliant products, the handling of regulated material included in our offerings, and the disposal of our products or their components at the end of their useful lives. In addition, compliance with environmental, health, and safety requirements could restrict our ability to expand our facilities or require us to acquire costly environmental or safety control equipment, incur other significant expenses, or modify our manufacturing processes. Our manufacturing facilities may use, in varying degrees, hazardous substances in their processes. These substances include, among others, chlorinated solvents, and in the past chlorinated solvents were used at one or more of our facilities, including a number we no longer own or operate. As at our current facilities, contamination at such formerly owned or operated properties can result and has resulted in liability to us. In the event of the discovery of new or previously unknown contamination either at our facilities, facilities we acquire in the future, or at third-party locations, including facilities we formerly owned or operated, the issuance of additional requirements with respect to existing contamination, or the imposition of other cleanup obligations for which we are responsible, we may be required to take additional, unplanned remedial measures for which we have not recorded reserves. We are conducting monitoring and cleanup of contamination at certain facilities currently or formerly owned or operated by us, and such activities may result in unanticipated costs or management distraction. We are subject to labor and employment laws and regulations, which could increase our costs and restrict our operations in the future. We have approximately 16,900 individuals providing services for us worldwide, including approximately 9,600 service providers in North America, 5,800 in Europe, 900 in South America, and 600 in the Asia-Pacific region. Certain employees at one of our North American facilities are represented by a labor organization, and national works councils or labor organizations are active at our European facilities and certain of our other facilities consistent with local labor environments and laws. Our management believes that our employee relations are satisfactory. However, further organizing activities, collective bargaining, or changes in the regulatory framework for employment may increase our employment-related costs or may result in work stoppages or other labor disruptions. Moreover, as employers are subject to various employment-related claims, such as individual and class actions relating to alleged employment discrimination and wage-hour and labor standards issues, such actions, if brought against us and successful in whole or in part, may affect our ability to compete or have a material adverse effect on our business, financial condition, and results of operations. 36We have partnered with, and may continue to partner with, companies that focus on the development of cannabis-based prescription medicines and cannabinoid drug therapies solely to the extent such companies’ programs comply with all U.S. and non-U.S. equivalent laws, which is a business that attracts a high-level of public and media interest and an industry in which laws and regulations are constantly evolving. We have partnered with, and may continue to partner with, companies that focus on the development of cannabis-based prescription medicines and high-value cannabinoid drug therapies, which may attract a high-level of public and media interest, and in the event of any resultant adverse publicity, our reputation may be harmed. In addition, the constant evolution of laws and regulations affecting the research and development of cannabinoid-based pharmaceutical products and treatments could detrimentally affect our business. Laws and regulations related to the therapeutic uses of cannabinoids are subject to changing interpretations. These changes may require us to incur costs associated with legal and compliance fees and ultimately require us to alter our business plan. Furthermore, violations or alleged violation of these laws could disrupt our business and result in a material adverse effect on our operations. We cannot predict the nature of any future laws, regulations, interpretations or applications of laws and regulations and it is possible that new laws and regulations may be enacted in the future that will be directly applicable to our business. In addition, regulatory approval of product candidates that contain controlled substances may generate public controversy or scrutiny. Adverse publicity from misuse or adverse side effects of cannabis-based prescription medicines may adversely affect the commercial success or market penetration achievable by such product candidates which could result in an adverse effect on our operations. Certain of our pension plans are underfunded, and additional cash contributions we may make to increase the funding level will reduce the cash available for our business, such as the payment of our interest expense. Certain of our current and former employees in the U.S., the U.K., Germany, France, Japan, Belgium, and Switzerland are participants in defined benefit pension plans that we sponsor. As of JuneA 30, 2024, the underfunded amount of our pension plans on a worldwide basis was \$43 million, primarily related to our pension plans in the U.K. and Germany. In addition, we have an estimated obligation of \$38 million, as of JuneA 30, 2024, related to our withdrawal from a multiemployer pension plan in which we formerly participated. In general, the amount of future contributions to the underfunded plans will depend upon asset returns, applicable actuarial assumptions, prevailing and expected interest rates, and other factors, and, as a result, the amount we may be required to contribute in the future to fund the obligations associated with such plans may vary. Such cash contributions to the plans will reduce the cash available for our business, including the funds available to pursue strategic growth initiatives or the payment of interest expense on our indebtedness. Our global operations are subject to economic and political risks, including risks resulting from continuing inflation, disruptions to global supply chains, destabilization of a regional or national banking system, from the Ukrainian-Russian war, or the effect of the evolving nature of the recent war in Gaza between Israel and Hamas and conflict in the Middle East, which could affect the profitability of our operations or require costly changes to our

procedures. We conduct our operations in various regions of the world, including North America, South America, Europe, and the Asia-Pacific region. Global and regional economic and political developments affect businesses such as ours in many ways. Our operations are subject to the effects of global and regional competition. Our global operations are also affected by local economic environments, including inflation, recession, and changes to the availability of capital our customers may need to continue or expand their business with us. Political changes, some of which may be disruptive, and related hostilities can interfere with our supply chain, our customers, and some or all of our activities in a particular location. While some of these risks can be hedged using derivatives or other financial instruments and some are insurable, such mitigating measures may be unavailable, costly, or unsuccessful. Beginning in fiscal 2022, much of the world, including the U.S. and the E.U., began to experience inflation levels not seen in more than 30 years. As a result, prices for many of our inputs have risen, in some cases dramatically. If inflation stays at elevated levels or increases, we may not be able to mitigate the impact of the increased costs we will bear through corresponding price increases to our customers, which could have an impact on our results of operations and financial condition. The outbreak of hostilities between Israel and Hamas and conflict in the Middle East has the potential for further disruption of economic markets, particularly if the war expands to include other state actors. The Company has no operations in the Middle East at the current time. However, events there could result in political turmoil in Europe, which could directly affect our operations there, and could also adversely affect the business that we conduct with customers in the Middle East and other parts of the world. Also, the turmoil in the Middle East could have global economic effects that are the same as or more severe than those of the war in the Ukraine, with similar consequences for our business.37As a global enterprise, fluctuations in the exchange rates of the U.S. dollar, our reporting currency, against other currencies could have a material adverse effect on our financial performance and results of operations. As a company with significant operations outside of the U.S., certain revenues, costs, assets, and liabilities, including our euro-denominated 2.375% Senior Notes due 2028 (the “2028 Notes”), are denominated in currencies other than the U.S. dollar, which is the currency that we use to report our financial results. As a result, changes in the exchange rates of these or any other applicable currency to the U.S. dollar will affect our revenues, earnings, and cash flows. There has been, and may continue to be, volatility in currency exchange rates affecting the various currencies in which we do business. Such volatility and other changes in exchange rates could result in unrealized and realized exchange losses, despite any effort we may undertake to manage or mitigate our exposure to fluctuations in the values of various currencies. Tax legislative or regulatory initiatives, new interpretations or developments concerning existing tax laws, or challenges to our tax positions could adversely affect our results of operations and financial condition. We are a large multinational enterprise with operations in the U.S. and more than a dozen other countries across North and South America, Europe, and the Asia-Pacific region, and we do business with suppliers and customers in many additional regions. As such, we are subject to the tax laws and regulations of the U.S. federal, state, and local governments and of many jurisdictions outside of the U.S. From time to time, various legislative initiatives may be proposed that could adversely affect our tax positions, and existing legislation may be subject to additional regulatory changes or new interpretations. There can be no assurance that our effective tax rate or tax payments will not be adversely affected by these initiatives. In addition, U.S. federal, state, local, and foreign tax laws and regulations are extremely complex and subject to varying interpretations. We are subject to regular examination of our income tax returns by various tax authorities. Examinations or changes in laws, rules, regulations, or interpretations by taxing authorities could result in adverse impacts to tax years open under statute or to our operating structures currently in place. It is possible that the outcomes from these examinations or changes in laws, rules, regulations, or interpretations by taxing authorities will have a material adverse effect on our financial condition or results of operations. We use advanced information and communication systems to run our operations, compile and analyze financial and operational data, and communicate among our employees, customers, and counterparties, and the risks generally associated with information and communications systems could adversely affect our results of operations. We continuously work to install new, and upgrade existing, systems and provide employee awareness training around phishing, malware, and other cyber security risks to enhance the protections available to us, but such protections may be inadequate to address malicious attacks or inadvertent compromises affecting data security or the operability of such systems. We rely on information systems in our business to obtain, process, analyze, and manage data to: (i) facilitate the manufacture and distribution of thousands of inventory items in, to, and from our facilities; (ii) receive, process, and ship orders on a timely basis; (iii) manage the accurate billing and collections for more than one thousand customers; (iv) create, compile, and retain testing and other product-, manufacturing-, or facility-related data necessary for meeting our and our customers’ regulatory obligations; (v) manage the accurate accounting and payment for thousands of vendors and our employees; (vi) schedule and operate our global network of development, manufacturing, and packaging facilities; (vii) document various aspects of our activities, including the agreements we make with suppliers and customers; (viii) compile financial and other operational data into reports necessary to manage our business and comply with various regulatory or contractual obligations, including obligations under our bank loans and other indebtedness, the federal securities laws, the Internal Revenue Code, and other applicable state, local, and ex-U.S. tax laws; and communicate among our nearly 16,900 workers spread across dozens of facilities over four continents. We face various security threats on a regular basis, including ongoing cyber security threats to and attacks on our information technology infrastructure. We deploy defenses against such threats and attacks and work to secure the integrity of our data systems using techniques, hardware, and software typical of companies of our size and scope. Despite our security measures, however, our information technology and infrastructure may be vulnerable to attacks by increasingly sophisticated intruders or others who try to cause harm to or interfere with our normal use of our systems. They are also susceptible to breach due to employee error, malfeasance, or other disruptions. Our suppliers, contractors, service providers, and other third parties with whom we do business also experience cyber threats and attacks that are similar in frequency and sophistication. In many cases, we have to rely on the controls and safeguards put in place by our suppliers, contractors, service providers, and other third parties to defend against, respond to, and report these attacks. We cannot know the potential impact of future cyber incidents, which vary widely in severity and scale. There can be no assurance that the various procedures and controls we utilize to mitigate these threats will be sufficient to prevent disruptions to our systems, in part because (i) cyber-attack techniques change frequently and, at times, new techniques are not recognized until launched, and (ii) cyber-attacks can originate from a wide variety of sources. Our results of operations could be adversely affected if these systems are interrupted or damaged or fail for any extended period. Efforts by governments around the world or our customers to secure or promote the benefits of locally produced supplies, as well as other risks associated with foreign operations, may render the locations of certain of our facilities less desirable, affecting their utilization rates and therefore our profitability, financial condition, or results of operations. We serve more than 1,200 customers in more than 80 countries, with 36% of our fiscal 2024 net revenue coming from outside the U.S., and we operate facilities in more than a dozen U.S. states and more than a dozen countries outside the U.S. The global nature of our sales and operations subjects us to risks, including risks arising from efforts by governments around the world or our customers to secure or promote the benefits of locally produced supplies, higher import duties in some countries that may favor locally produced supplies, the differing impacts of varying economic conditions in different jurisdictions, changes in tariffs and trade relations, unexpected changes in regulatory requirements, certification requirements, environmental regulations, reduced protection for intellectual property rights in some countries, potentially adverse tax consequences, and political and economic instability. If one or more of these risks is realized, it could have a material adverse impact on our utilization rates for certain of our facilities, and therefore our profitability, financial condition, or results of operations. Artificial intelligence-based platforms present new risks and challenges to our business. Artificial intelligence, or AI, based platforms are increasingly being used in the biopharmaceutical, pharmaceutical, and consumer health industries. We are committed to providing a safe and secure environment for our personnel, our business partners, and our customers, including the responsible use of AI chatbots and generative AI data processor products (the “AI Systems”). We have developed policies governing the use of AI Systems to help reasonably ensure that such AI Systems are used in a trustworthy manner by our employees, contractors, and authorized agents and that our assets, including intellectual property, competitive information, personal information we may collect or process, and customer information, are protected. Any failure by our personnel, contractors, or other agents to adhere to our established policies could violate confidentiality obligations or applicable laws and regulations, jeopardize our intellectual property rights, cause or contribute to unlawful discrimination, or result in the misuse of personally identifiable information or the injection of malware into our systems, any of which could have a material adverse effect on our business, results of operations, and financial condition. The use of AI Systems by our business partners with access to our confidential information, including trade secrets, may continue to increase and could lead to the release of such information, which could negatively impact us, including our ability to realize the benefits of our intellectual property. The use of AI Systems by our business partners may lead to novel and urgent cybersecurity risks, which could have a material adverse effect on our operations and reputation as well as the operations of any of our business partners. We may also face increased competition from other companies that are using AI Systems, some of whom may develop more effective methods than we and any of our business partners have, which could have a material adverse effect on our business, results of operations, or financial condition. In addition, uncertainties regarding developing legal and regulatory requirements and standards may require significant resources to modify and maintain business practices to comply with U.S. and non-U.S. laws concerning the use of AI and AI Systems, the nature of which cannot be determined at this time. Our cash, cash equivalents, and financial investments could be adversely affected if the financial institutions in which we hold our cash, cash equivalents, and financial investments fail. We regularly maintain cash balances at third-party financial institutions in excess of the insurance limit of the Federal Deposit Insurance Corporation (the “FDIC”) and other countries’ deposit insurance systems. The FDIC took control and was appointed receiver of Silicon Valley Bank and New York Signature Bank (collectively, the “Failed Banks”) on March 10, 2023 and March 12, 2023, respectively. We do not have any direct exposure to either of the Failed Banks. However, if banks and financial institutions where we maintain large cash balances, cash equivalents, or financial investments enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash equivalents, and financial investments could be threatened and may have a material adverse impact on our business, prospects, financial condition, or results of operations. Moreover, events such as the closure of large regional or national banks like the Failed Banks, in addition to other global macroeconomic conditions, may cause further turbulence and uncertainty in the capital markets.39Risks Relating to Our Indebtedness The size of our indebtedness and the obligations associated with it could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or in our industry or to deploy capital to grow our business, expose us to interest-rate risk to the extent of our variable-rate debt, or prevent us from meeting our obligations under our indebtedness. These risks may be increased in a recessionary environment, particularly as sources of capital may become less available or more expensive. As of June 30, 2024, on a consolidated basis, we had \$4.91 billion (U.S. dollar equivalent) of total indebtedness outstanding, consisting of \$2.00 billion of secured indebtedness under our senior secured credit facilities and \$2.91 billion of senior unsecured indebtedness, including \$500 million aggregate principal amount of 5.000% U.S. dollar-denominated Senior Notes due 2027 (the “2027 Notes”), \$825 million aggregate principal amount of the 2028 Notes, \$550 million aggregate principal amount of U.S. dollar-denominated 3.125% Senior Notes due 2029 (the “2029 Notes”), and \$650 million aggregate principal amount of U.S. dollar-denominated 3.500% Senior Notes due 2030 (the “2030 Notes”) and, together with the 2027 Notes, the 2028 Notes, and the 2029 Notes, the “Senior Notes”). As of June 30, 2024, we also held \$332 million in finance lease obligations. We also had the ability to incur significant additional indebtedness, including via \$1.1 billion of unutilized capacity under our \$1.10 billion secured revolving credit facility, which part of our senior secured credit facilities (the “Revolving Credit Facility”) due to \$4 million of outstanding letters of credit. The multi-billion-dollar size of our indebtedness could have important consequences for us, including: (i) increasing our vulnerability to adverse economic, industry, or competitive developments; (ii) exposing us to the risk of increased interest rates because certain of our borrowings, including borrowings under our senior secured credit facilities, are at variable rates of interest; (iii) exposing us to the risk of fluctuations in exchange rates because of our euro-denominated notes; (iv) making it more difficult for us to satisfy our obligations with respect to our indebtedness, and any failure to comply with the obligations of any of our debt instruments, including restrictive covenants and borrowing conditions, could result in one or more events of default under the agreements governing such indebtedness or, through cross-defaults, in agreements governing other indebtedness; (v) restricting us from making strategic acquisitions or capital investments or causing us to make non-strategic divestitures; (vi) limiting our ability to obtain additional financing for working capital, capital expenditures, product development, debt service requirements, acquisitions, and general corporate or other purposes; (vii) limiting our flexibility in planning for, or reacting to, changes in our business or market conditions and placing us at a competitive disadvantage compared to our competitors who have less indebtedness relative to their size and who, therefore, may be able to take advantage of opportunities that our higher level of indebtedness prevents us from exploiting; and (viii) limiting the types of investors who are willing to invest in our Common Stock, as certain investors prefer to invest in companies with lower levels of indebtedness relative to other financial metrics. Our total interest expense, net was \$254 million, \$186 million, and \$123 million for fiscal 2024, 2023, and 2022, respectively. After taking into consideration our ratio of fixed-to-floating-rate debt, including as a result of our June 2023 amendment to our interest-rate swap agreement with Bank of America N.A., and assuming that the Secured Overnight Financing Rate (the “SOFR”) is above any applicable minimum floor, each change of 50 basis points in interest rates would result in a change of \$9 million in annual interest expense on the indebtedness under our senior secured credit facilities. Our interest expense may continue to increase as policymakers combat the inflation that has taken hold since fiscal 2022 through interest-rate increases on benchmark financial products that can affect the interest rates on our variable-rate debt. The size of our indebtedness, alone or combined with volatility in our reported financial results, may cause suppliers or customers to opt not to do business with us or to do so under less attractive terms, or render it more costly or time-consuming to secure supplies or attract customers, which could affect our financial condition and results of operations. There can be no assurance as to the effect that the size of our indebtedness, alone or combined with volatility in our reported financial results, will have on our relationships with our suppliers or customers. To the extent that the size of our indebtedness, alone or combined with volatility in our reported financial results, results in the tightening of payment or credit terms, increases in the price of supplied goods, or the loss of one or more major suppliers or customers, it could have a material adverse effect on our business, financial condition, liquidity, or results of operations.40Despite our high indebtedness level, we and our subsidiaries are still capable of incurring significant additional debt, which could further exacerbate the risks associated with our substantial indebtedness. We and our subsidiaries may be able to incur substantial additional indebtedness in the future. Although the agreements governing our indebtedness contain restrictions on the incurrence of additional indebtedness, these restrictions are subject to a number of significant qualifications and exceptions, and, under certain circumstances, the amount of indebtedness that we may incur while remaining in compliance with these restrictions could be substantial. In addition, as of June 30, 2024, we had approximately \$1.10 billion available to us for borrowing, subject to certain conditions, under our Revolving Credit Facility. If new debt is added to the current debt levels for which we or our subsidiaries are responsible, the risks associated with debt we currently face would increase. Our interest expense on our variable-rate debt may continue to increase if and to the extent that policymakers combat inflation through interest-rate increases on benchmark financial products. Borrowings under our variable-rate debt are at variable rates of interest and are based upon benchmarks that are subject to potential change or elimination, and therefore expose us to interest-rate risk. If interest rates increase, our debt service obligations on our variable-rate debt will increase even though the amount borrowed remains the same, and our net income and cash flows, including cash available for servicing our indebtedness, will correspondingly decrease. Our debt agreements contain restrictions that limit our flexibility in operating our business. The agreements governing our outstanding indebtedness contain various covenants that limit our ability to engage in specified types of transactions. These covenants limit the ability of Operating Company and those of its subsidiaries to which these covenants apply (which Operating Company’s Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended, the “Credit Agreement”) calls “restricted subsidiaries”) to, among other things: (i) incur additional indebtedness and issue certain preferred stock; (ii) pay certain dividends on, repurchase, or make distributions in respect of capital stock or make other restricted payments; (iii) pay distributions from restricted subsidiaries; (iv) issue or sell capital stock of restricted subsidiaries; (v) guarantee certain indebtedness; (vi) make certain investments; (vii) sell or exchange certain assets; (viii) enter into transactions with affiliates; (ix) create certain liens; and (x) consolidate, merge, or transfer all or substantially all of our assets and the assets of our subsidiaries on a consolidated basis. A breach of any of these covenants could result in a default under one or more of these agreements, including as a result of cross-default provisions, and, in the case of our Revolving Credit Facility, permit the lenders to cease making loans to us. Despite the limitations in our debt agreements, we retain the ability to take certain actions that may interfere with our ability to timely pay our substantial indebtedness. The covenants in the Credit Agreement and in the several indentures governing our Senior Notes (collectively, the “Indentures”) contain various exceptions to the limitations they otherwise impose on our ability and the ability of our restricted subsidiaries to take the various actions described in the prior risk factor. For example, if the Senior Notes have investment-grade ratings and we are not in default under these agreements, certain of these covenants will not apply, including the covenants restricting certain dividends and other payments, the covenants concerning

the incurrence of indebtedness, and the covenants limiting guarantees by our restricted subsidiaries. In addition, the covenants restricting dividends and other distributions by us, purchases or redemption of certain equity securities, and prepayment, redemption, or repurchase of any subordinated indebtedness are subject to various exceptions. We may not be able to pay our indebtedness when it becomes due. Our ability to pay principal and interest on our variable-rate debt and to satisfy our other debt obligations will depend upon, among other things, our future financial and operating performance, which will be affected by prevailing economic, industry, and competitive conditions and financial, business, legislative, regulatory, and other factors, many of which are beyond our control; and our future ability to borrow under the Revolving Credit Facility, the availability of which depends on, among other things, our complying with applicable covenants in our Credit Agreement. We cannot assure you that our business will generate cash flow from operations, or that we will be able to draw under the Revolving Credit Facility or otherwise, in an amount sufficient to fund our liquidity needs, including the payment of principal and interest on the Senior Notes, our term loans, our existing borrowings under our Revolving Credit Facility, and our other debt obligations. If our cash flows and other capital resources are insufficient to service our indebtedness, we may be forced to reduce or delay capital expenditures, sell assets, seek additional capital, or restructure or refinance our indebtedness. These alternative measures may not be successful and may not permit us to meet our scheduled debt service obligations. Our ability to restructure or refinance our debt will depend on the condition of the capital markets and our financial condition at such time. Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. In addition, the terms of existing or future debt agreements may restrict us from adopting some of these alternatives. In the absence of such operating results and resources, we could face substantial liquidity problems and might be required to dispose of material assets or operations to meet our debt service and other obligations. We may not be able to consummate those dispositions for fair market value, on a timely basis to meet our needs, or at all. Furthermore, any proceeds that we could realize from any or all such dispositions may not be adequate to meet our debt service obligations then due. Our inability to generate sufficient cash flow to satisfy our debt obligations, or to refinance our indebtedness on commercially reasonable terms or at all, could result in a material adverse effect on our business, results of operations, or financial condition. If we cannot make scheduled payments on our indebtedness, we will be in default, and, as a result of existing cross-default terms in our indebtedness or otherwise, all outstanding principal and interest may be declared to be due and payable, the lenders under our variable-rate debt could terminate their commitments to loan money, our secured lenders (including the lenders under our senior secured credit facilities or the holders of the Senior Notes) could foreclose against the assets securing their loans and the Senior Notes, and we could be forced into bankruptcy or liquidation. We are currently using and may in the future use derivative financial instruments to reduce our exposure to market risks from changes in interest rates on our variable-rate indebtedness or changes in currency exchange rates, and any such instrument may expose us to risks related to counterparty credit worthiness or non-performance of these instruments. We have executed and may enter into additional or new interest-rate swap agreements, currency swap agreements, or other hedging transactions in an attempt to limit our exposure to adverse changes in variable interest rates and currency exchange rates. Such instruments may result in economic losses if, for example, prevailing interest rates decline to a point lower than any applicable fixed-rate commitment. Any such swap will expose us to credit-related risks that, if realized, could adversely affect our results of operations or financial condition. Risks Relating to Ownership of Our Common Stock We do not presently maintain effective disclosure controls and procedures due to a material weakness in our internal control over financial reporting. Material weaknesses have in the past resulted in the revision of our financial statements. If we fail to remediate this material weakness, or if any other material weakness or significant deficiency is identified in the future of if we otherwise fail to maintain an effective system of internal controls, material misstatements in our financial statements could result, and, as in the past, we could fail to timely meet our periodic reporting obligations. Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, our management is required to report on, and our independent registered public accounting firm is required to attest to, the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to determine the adequacy of our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation if a weakness or deficiency is identified. Annually, we perform activities that include reviewing, documenting, and testing our internal control over financial reporting. Our failure to achieve and maintain effective disclosure controls and procedures and internal control has resulted in, and in the future could result in, misstated consolidated financial statements and restatements of previously issued financial statements related to prior periods and delays or a failure to meet our reporting obligations, which could cause investors to lose confidence in our reported financial information and could lead to a decline in our stock price. Additionally, ineffective or inadequate disclosures and internal control could expose us to increased risk of misuse of corporate assets or fraud, or subject us to litigation, regulatory investigations, or civil or criminal sanctions, including by the SEC or other regulatory authorities, or potential delisting from the NYSE or any other stock exchange on which we may list our Common Stock in the future. As discussed below in "Controls and Procedures," due to certain inadequacies of our internal control over financial reporting, we have not been able to conclude on an ongoing basis that we have effective disclosure controls and procedures and internal control over financial reporting in accordance with legal requirements. For example, in the fourth quarter of fiscal 2024, management identified a material weakness in internal control related to inventory consumption and valuation at our Bloomington, Indiana facility. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company's annual or interim financial statements will not be prevented or detected on a timely basis. Due to this material weakness in internal control over financial reporting, we concluded that, as of June 30, 2024, our disclosure controls and procedures were not effective and that we did not maintain effective internal control over financial reporting. Management is actively engaged in the implementation of remediation efforts to address our remaining material weakness and control deficiencies. However, we may not be successful in promptly remediating these material weakness or be able to identify and remediate any additional control deficiency, including any material weakness, that may arise in the future. Management is currently unable to conclude, and may not be able to conclude in future periods, that our disclosure controls and procedures are effective due to the effects of various factors, which may, in part, include unremediated material weaknesses in internal control over financial reporting. If not remediated, any failure to establish and maintain effective disclosure control and procedures and internal control over financial reporting could result in material misstatements in our consolidated financial statements or cause us to fail to meet our reporting and financial obligations, each of which could have a material adverse effect on the confidence that stockholders, customers, or suppliers have in our financial reporting, which could materially harm our business, our financial condition, or the trading price of our Common Stock. For further discussion of our material weakness, see "Controls and Procedures." Our stock price has historically been and may continue to be volatile, and a holder of shares of our Common Stock may not be able to resell such shares at or above the price such stockholder paid, or at all, and could lose all or part of such investment as a result. The trading price of our Common Stock has been and continues to be volatile. For the three years ended June 30, 2024, our Common Stock price as quoted on the NYSE traded at a high of \$142.64 on September 9, 2021 and a low of \$31.45 on May 15, 2023. The trading price of our Common Stock may be adversely affected by any one or more of several factors, such as those listed above in "Risks Relating to Our Pending Merger with Novo Holdings," "Risks Relating to Our Business and Industry in Which We Operate," and the following: results of operations that vary from the expectations of securities analysts or investors; results of operations that vary from those of our competitors; changes in expectations as to our future financial performance, including financial estimates and investment recommendations by securities analysts or investors; declines in the market prices of stocks generally, or those of pharmaceutical or other healthcare companies; strategic actions by us or our competitors; announcements by us or our competitors of significant contracts, new products, acquisitions, joint marketing relationships, joint ventures, other strategic relationships, or capital commitments; changes in general economic or market conditions or trends in our industry or markets, such as increased inflation; changes in business or regulatory conditions or regulatory actions taken with respect to our business or the business of any of our competitors or customers; future sales of our Common Stock or other securities we may issue in the future; investor perceptions of the investment opportunity associated with our Common Stock relative to other investment alternatives; any decision by securities analysts to not publish research or reports about our business or to downgrade our stock or our sector; additions or departures of key personnel; the public response to press releases or other public announcements by us or third parties, including our filings with or information furnished to the SEC; announcements relating to or developments in litigation, including shareholder lawsuits; guidance, if any, that we provide to the public, any change in this guidance, or any failure to meet this guidance; the availability of an active trading market for our Common Stock; public response to changes in the COVID-19 pandemic and public perceptions as to the need for manufacture of certain COVID-19-related products and our role in the successful manufacture of such products; changes in the accounting principles we use to record our results or our application of these principles to our business; and other events or factors, including those resulting from natural disasters, hostilities, the war in Ukraine, acts of terrorism, geopolitical activity, public health crises, including pandemics, or responses to these events. Broad market and industry fluctuations may adversely affect the market price of our Common Stock, regardless of our actual operating performance. In addition, price volatility may be greater if the public float or trading volume of our Common Stock is low, and the amount of public float on any given day can vary depending on the individual actions of our stockholders. Following periods of market volatility, stockholders have been known to institute securities class action litigation in an attempt to recover any resulting loss. In February 2023, a complaint styled City of Warwick Retirement System v. Catalent, Inc., et al., No. 23-cv-01108, was filed in New Jersey federal court against us and three of our then-officers purportedly on behalf of a putative class consisting of persons who purchased or otherwise acquired our securities between August 30, 2021 and October 31, 2022, inclusive, and on September 15, 2023, the Warwick complaint was amended (together with the original complaint, the "Warwick Complaint"), which expanded the class period to between August 30, 2021 and May 7, 2023, inclusive. The complaint purports to assert claims under Sections 10(b) and 20(a) of the Exchange Act, alleging that, unbeknownst to investors, the defendants purportedly engaged in accounting and channel stuffing schemes to pad our revenue and failed to disclose adverse facts that purportedly were known to or recklessly disregarded by defendants. See "Item 3 - Legal Proceedings" and Note 17, Commitments and Contingencies to the Consolidated Financial Statements for additional information. This litigation, and any additional securities litigation, could have a substantial cost and divert resources and the attention of senior management from our business regardless of the outcomes of such litigation. Because we have no plan to pay cash dividends on our Common Stock for the foreseeable future, receiving a return on an investment in our Common Stock may require a sale for a net price greater than what was paid for it. We currently intend to retain future earnings, if any, for future operations, expansion, and debt repayment and have no current plan to pay any cash dividend on our Common Stock for the foreseeable future. Any future decision to pay a dividend in respect of our Common Stock, and the amount and timing of any such dividend, will be at the sole discretion of our board of directors. Our board of directors may take into account, when deciding whether or how to pay a dividend, such factors as they may deem relevant, including general economic conditions, our financial condition and results of operations, our available cash and current and anticipated cash needs, possible future alternative deployments of our cash, our future capital requirements, and contractual, legal, tax, and regulatory restrictions and implications on the payment of dividends by us to our holders of shares of our Common Stock or by our subsidiaries to us. In addition, our ability to pay dividends is limited by covenants in the agreements governing our outstanding indebtedness and may be limited by covenants of any future indebtedness we or our subsidiaries incur. As a result, a holder of a share of our Common Stock may not receive any return on such investment unless it is sold for a price greater than that which was paid for it, taking into account any applicable commission or other costs of acquisition or sale. Future sales, or the perception of future sales, of our Common Stock, by us or our existing stockholders could cause the market price for our Common Stock to decline. The sale of shares of our Common Stock in the public market, or the perception that such sales could occur, could harm the prevailing market price of shares of our Common Stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. The market price of shares of our Common Stock could drop significantly if the holders of our Common Stock sell their shares or are perceived by the market as intending to sell them. These factors could also make it more difficult for us to raise additional funds through future offerings of shares of our equity securities that we wish to issue. In the future, we may also issue our securities in connection with investments or acquisitions or to pay down debt. The number of shares of our Common Stock issued or issuable as a result could constitute a material portion of then-outstanding shares of our Common Stock, subject to limitations on issuance of new shares imposed by the NYSE (including any applicable requirement for stockholder approval) or restrictions set forth in the agreements governing our indebtedness. Any issuance of additional securities in connection with investments, acquisitions, or otherwise may result in dilution to the holders of shares of our Common Stock. We are no longer eligible to use the Form S-3 registration statement, which could impair our capital-raising activities. As a result of our failure to timely file our periodic reports with the SEC, we are no longer eligible to use a Form S-3 registration statement. As a result of our late 10-Q filing, we are also no longer a well-known seasoned issuer, as such term is used in the SEC's regulations, which otherwise would allow us to, among other things, file automatically effective shelf registration statements. Our eligibility to use a Form S-3 registration statement may not be restored until December 1, 2024, and then only if we have not had any other filing delinquency that would preclude Form S-3 eligibility and satisfy all other requirements for Form S-3 eligibility. During any period when we are not eligible to use Form S-3 or qualify as a well-known seasoned issuer, our capital raising ability may be impaired. Under these circumstances, we will be required to use a registration statement on Form S-1 to register securities with the SEC, which could hinder our ability to act quickly in raising capital to take advantage of market conditions in our capital-raising activities and may increase our cost of raising capital. Further, the expenses associated with raising capital using Form S-1 are generally greater than those associated with using Form S-3. Provisions in our organizational documents could delay or prevent a change of control. Certain provisions of our current certificate of incorporation and bylaws may have an anti-takeover effect and may delay, defer, or prevent a merger, acquisition, tender offer, takeover attempt, or other change of control transaction that may otherwise be in the best interests of our stockholders, including transactions that might otherwise result in the payment of a premium over the market price for the shares held by our stockholders. These provisions provide for, among other things: the ability of our board of directors to issue one or more series of preferred stock; advance notice for nominations of directors by stockholders and for stockholders to include matters to be considered at our annual meetings (though our board of directors has implemented shareholder proxy access); and certain limitations on convening special stockholder meetings. Provisions such as those just described, to the extent that they remain in effect, could make it more difficult for a third party to acquire us, even if the third party's offer may be considered beneficial by many of our stockholders. As a result, our stockholders may be limited in their ability to obtain a premium for their shares. ITEM 1B. A UNRESOLVED STAFF COMMENTS None. ITEM 1C. A CYBERSECURITY Risk Management and Strategy We have established an enterprise cybersecurity program to assess, identify, and manage cybersecurity risks with the aim that our information systems, including those of our vendors and other third parties, will be resilient, effective, and capable of safeguarding against emerging risks and cybersecurity threats. Our cybersecurity program is aligned with the NIST-Cybersecurity Framework (NIST CSF v2), which provides a structured approach to inform, design, and evaluate our program. Consistent with this framework, we have established cybersecurity policies, standards, and processes designed to manage cybersecurity risks, including risks from cybersecurity threats associated with the Company's use of third-party service providers. Key elements of our cybersecurity program include: employee cybersecurity training, including required annual certification; identification of potential vulnerabilities through external threat intelligence feeds, scanning of our technology environment, and vendor and third-party risk assessments; an incident response plan and team that is intended to allow rapid management, response, and appropriate communication of cybersecurity incidents; and a cybersecurity operations center with support from a third party managed service provider (MSSP) to respond to threats and incidents. When a potential threat or incident is identified, our cybersecurity incident response team will assign a risk level classification and initiate the escalation and other steps called for by our plan. All incidents that are initially assessed by the cybersecurity incident response team as potentially high-risk are escalated promptly to our chief information security officer (CISO) and chief information officer (CIO). Our CISO, CIO, and key leaders will determine whether and what elements of our cybersecurity incident response plan should be activated, including escalation to our Executive Committee and/or members of our Board of Directors as appropriate, considering a variety of factors, including financial, operational, legal or reputational impact. Based on the information available as of the date of this Annual Report on Form 10-K, we are not aware of risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. Despite our security measures, however, there can be no assurance that we, or the third parties with which we interact, will not experience a cybersecurity incident in the future that may materially affect us. For additional information, please refer to the discussion under the heading, "We use advanced information and communication systems to run our operations, compile and analyze financial and operational data, and communicate among

our employees, customers, and counterparties, and the risks generally associated with information and communications systems could adversely affect our results of operations. We continuously work to install new, and upgrade existing, systems and provide employee awareness training around phishing, malware, and other cyber security risks to enhance the protections available to us, but such protections may be inadequate to address malicious attacks or inadvertent compromises affecting data security or the operability of such systems^{as} included in Item 1A. Risk Factors of this Annual Report on Form 10-K, which disclosure is incorporated by reference herein.Cybersecurity Governance We are committed to appropriate cybersecurity governance and oversight. Our cybersecurity organization is led by our CISO, who reports directly to our CIO and under the organization of our chief financial officer (CFO). Our CISO is educated in computer information systems and has over 20 years of experience in leadership, management, and engineering roles in the technology and cybersecurity realms. Our CISO also has experience implementing cybersecurity programs in alignment with the NIST Cybersecurity Framework. Our CIO is educated in computer science and has over 25 years of experience in leadership, management, and consulting roles in applications, digitalization, and infrastructure with oversight responsibilities for cybersecurity. Our Board of Directors oversees management's processes for identifying and mitigating enterprise-wide risks, including cybersecurity and related information technology risks. Our Audit Committee receives updates from our CIO and CISO on our technology and cybersecurity program and receives independent external expert evaluations of our program using industry frameworks, including the NIST-Cybersecurity Framework.Our Audit Committee also receives cybersecurity updates and education on a broad range of topics, including: current cybersecurity landscape trends and emerging threats; the status of cybersecurity initiatives; incident reports and learnings from any material cybersecurity events; and any pertinent cybersecurity regulatory requirements and industry expectations.46ITEM 2.Â A A A PROPERTIESOur principal executive offices are located at 14 Schoolhouse Road, Somerset, New Jersey. As of June 30, 2024, we had 53 facilities (3 geographical locations operate as multiple facilities because they support more than one reporting segment, with our Somerset location including both a manufacturing facility and our principal executive offices), comprising manufacturing operations, development centers, and sales offices contained in approximately 8 million square feet of manufacturing, laboratory, office and related space. Our manufacturing capabilities include all required regulatory, quality assurance and in-house validation space. The following table sets forth our facilities containing manufacturing, laboratory, office, and related space by reporting segment and geographic location as of June 30, 2024: Geographic RegionBiologicsPharma and Consumer HealthCorporateTotal1(North America1115127South Americaâ€314Europe69116Asia-Pacificâ€6â€6Total1733353(1) Sites that are used by multiple segments are included once for each segment in this table. Two of our manufacturing facilities, located in Bloomington, Indiana and Harmons, Maryland, together generate a material portion of our net revenue. We believe these facilities are suitable for their intended purposes, with adequate capacity for current and projected demand for their contracted products. We generally seek to own, rather than lease, our manufacturing facilities, although some facilities are leased. Our office space and warehouse facilities are often leased. Additional information with respect to our leases and property, plant, and equipment is contained in Notes 16 and 19, respectively, to our Consolidated Financial Statements.ITEM 3.Â A A A LEGAL PROCEEDINGS From time to time, we may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. We intend to vigorously defend ourselves against any such litigation and do not currently believe that the outcome of any such litigation will have a material adverse effect on our financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise.In February 2023, an alleged shareholder filed a complaint styled City of Warwick Retirement System v. Catalent, Inc., et al., No. 23-cv-01108 in New Jersey federal court against us and three of our then-officers (collectively, the â€Warwick Defendantsâ€) purportedly on behalf of a putative â€classâ€ consisting of persons who purchased or otherwise acquired our securities between August 30, 2021 and October 31, 2022, inclusive. On September 15, 2023, the Warwick complaint was amended (together with the original complaint, the â€Warwick Complaintâ€), which amended complaint expanded the class period to between August 30, 2021 and May 7, 2023, inclusive (the â€Class Periodâ€). The Warwick Complaint purports to assert claims under Sections 10(b) and 20(a) of the Exchange Act and the related regulations, alleging that, unbeknownst to investors, the Warwick Defendants purportedly engaged in accounting and channel stuffing schemes to pad the Company's revenues and failed to disclose adverse facts that purportedly were known to or recklessly disregarded by the Warwick Defendants. Specifically, the Warwick Complaint alleges that the Warwick Defendants (i) overstated revenue and earnings by prematurely recognizing revenue in violation of accounting principles generally accepted in the U.S. (â€U.S. GAAPâ€); (ii) suffered material weaknesses in our internal control over financial reporting related to revenue recognition; (iii) falsely represented demand for our products while we knowingly selling more product to our direct customers than could be sold to healthcare providers and end consumers; (iv) cut corners on safety and control procedures at key production facilities; (v) disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad our financial results through premature revenue recognition in violation of U.S. GAAP or stuffing our direct customers with this excess inventory; and (vi) lacked a reasonable basis for their positive statements about our financial performance, outlook, and regulatory compliance 47during the Class Period. On November 15, 2023, the Warwick Defendants filed a motion to dismiss the Warwick Complaint. On June 28, 2024, the Court granted, in part, and denied, in part, the Companyâ€™s motion to dismiss. The Warwick Defendantsâ€™ answer to the Warwick Complaint was filed on August 12, 2024. The Company believes that the Warwick Defendants have defenses to the remaining allegations and intends to vigorously defend against these allegations.In August 2023, an alleged shareholder filed a derivative complaint styled Husty, et al. v. Carroll, et al., No. 23-cv-00891, in Delaware federal court against certain current and former members of our board of directors (the â€Husty Defendantsâ€) and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities described there led to, and will continue to expose us to, costs and damages. On February 20, 2024, the court entered a stipulation staying the case pending the outcome of the motion to dismiss that was filed in the City of Warwick Retirement System action. On April 25, 2024, the plaintiff voluntarily dismissed the action without prejudice. In September 2023, an alleged shareholder filed a derivative complaint styled Brown, et al. v. Chiminski, et al., Case 3:23-cv-15722, in New Jersey federal court against certain current and former officers and members of the Company's board of directors (the "Brown Defendants") and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities described there led to, and will continue to expose us to, costs and damages. On January 8, 2024, the court entered a stipulation staying the case pending the outcome of motion to dismiss that was filed in the City of Warwick Retirement System action. On April 19, 2024, the plaintiff voluntarily dismissed the action without prejudice. On May 2, 2024, the court dismissed the action without prejudice. In June 2023, we received a demand from a company stockholder pursuant to 8 Del. C. Â§ 220 to inspect books and records of the Company relating to, among other things, the allegations raised in the Warwick Complaint. We have responded to the demand and cannot determine at this time if the books and records demand will lead to litigation.In connection with the proposed Merger, three purported Catalent stockholders filed lawsuits alleging that certain disclosures made in the Proxy Statement were materially false and misleading: Garfield v. Barber, et al., C.A. No. SOM-C 012027-24 (N.J. Super. Ct.), which was filed in the Superior Court of New Jersey; Moore v. Catalent, Inc., et al., No. 652403/2024 (N.Y. Sup. Ct.), which was filed in the Supreme Court of New York; and Clark v. Catalent, Inc., et al., No. 652407/2024 (N.Y. Sup. Ct.), which was filed in the Supreme Court of New York. The aforementioned lawsuits are collectively referred to as the â€Actions.â€ The Actions alleged, among other things, that certain disclosures in the Proxy Statement filed in connection with the Merger Agreement omitted certain purportedly material information. The Garfield Action asserted violations of New Jersey Uniform Securities Law Â§ 49:3-71 and negligent misrepresentation and concealment and negligence under New Jersey common law. The Moore and Clark Actions each asserted a single claim for breach of fiduciary duty. On May 17, 2024, the Garfield Action was voluntarily dismissed with prejudice. On June 26, 2024, the Moore and Clark Actions were voluntarily dismissed with prejudice.From time to time, we receive subpoenas or requests for information from various governmental agencies or private parties, including from state attorneys general, the U.S. Department of Justice, and private parties. We generally respond to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred. For additional information, see Note 17, Commitments and Contingencies, to the Consolidated Financial Statements.ITEM 4.Â A A A MINE SAFETY DISCLOSURESNot Applicable.48PART IIITEM 5.Â A A A MARKET FOR REGISTRANTâ€™S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES The principal market for trading of our Common Stock is the NYSE. Our Common Stock trades under the symbol â€CLT.â€ As of August 22, 2024, we had 7 holders of record of outstanding shares of our Common Stock. This number does not include beneficial owners whose shares were held in street name.We did not declare or pay any dividend on our Common Stock in fiscal 2024 or fiscal 2023. We have no current plan to pay any dividend on our Common Stock. Any decision to declare and pay dividends in the future will be made at the sole discretion of our board of directors and will depend on, among other things, our results of operations, cash requirements, financial condition, contractual restriction, and other factors that our board of directors may deem relevant. Because we are a holding company and have no direct operations, we will only be able to pay dividends from funds we receive from our subsidiaries. In addition, our ability to pay dividends will be limited by covenants in our existing indebtedness and may be limited by the agreements governing other indebtedness we or our subsidiaries incur in the future. See â€Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ "Liquidity and Capital Resourcesâ€ "Debt and Financing Arrangementsâ€ "Debt Covenants.â€Recent Sales of Unregistered Equity SecuritiesWe did not sell any unregistered equity securities during the period covered by this Annual Report.Purchases of Equity SecuritiesWe did not purchase any of our equity securities during the period covered by this Annual Report. 49Performance GraphSet forth below is a line graph comparing the cumulative total shareholder return on our Common Stock from June 30, 2019 through June 30, 2024, based on the market price of our Common Stock and assuming reinvestment of dividends, with the cumulative total shareholder return of companies on the S&P 500 Index and S&P 500 Health Care Index. The graph assumes that \$100 was invested in our Common Stock and in each index at the market close on June 30, 2019. The stock price performance of the following graph is not necessarily indicative of future stock performance. 50ITEM 6. Â A A A [RESERVED] 51ITEM 7.Â A A A MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSThe following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Consolidated Financial Statements and related notes, which appear elsewhere in this Annual Report. This section of the Annual Report generally discusses the fiscal years ended June 30, 2024 and 2023 and year-to-year comparisons between the fiscal years ended June 30, 2024 and 2023. The discussion of our results of operations for the fiscal year ended June 30, 2022 and a comparison of our results for the fiscal years ended June 30, 2023 and 2022 is included in Item 7. â€Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the fiscal year ended June 30, 2023, filed with the SEC on December 8, 2023, and is incorporated herein by reference. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. You should carefully read â€Special Note Regarding Forward-Looking Statementsâ€ in this Annual Report. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report, particularly in â€Item 1A.â€ "Risk Factors.â€Overview We provide differentiated development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products at fifty facilities across four continents under rigorous quality and operational standards. Our oral, injectable, and respiratory delivery technologies, along with our state-of-the-art protein, plasmid, viral, and cell and gene therapy manufacturing capacity, address a wide and growing range of modalities and therapeutic and other categories across the biopharmaceutical, pharmaceutical, and consumer health industries. Through our extensive capabilities, growth-enabling capacity, and deep expertise in product development, regulatory compliance, and clinical trial and commercial supply, we can help our customers take products to market faster; we have supported more than half of new drug products approved by the U.S. Food and Drug Administration (the â€FDAâ€) in the last decade. Our development and manufacturing platforms, our proven formulation, supply, and regulatory expertise, and our broad and deep development and manufacturing know-how enable our customers to advance and then bring to market more products and better treatments for patients and consumers. Our commitment to reliably supply our customersâ€™ and their patientsâ€™ needs is the foundation for the value we provide; annually, we produce nearly 70 billion unit doses for nearly 8,000 customer pharmaceutical and consumer health products, or approximately 1 in every 28 unit doses of such products taken each year by patients and consumers around the world. We believe that, through our investments in state-of-the-art facilities and capacity expansion, including investments in facilities focused on new treatment modalities and other attractive market segments, our continuous improvement activities devoted to operational and quality excellence, the sales of existing and introduction of new customer products, and, in some cases, our innovation activities and patents, we will continue to attract premium opportunities and realize the growth potential from these areas. At the commencement of fiscal 2023, in connection with our change in Chief Executive Officer and Chief Operating Decision Maker, we adopted a new operating structure with two operating and reportable segments: (i) Biologics and (ii) Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; pDNA; iPSCs, and oncolytic viruses; and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and, as noted above, analytical development and testing services for large molecules. Our Pharma and Consumer Health segment, comprises the Companyâ€™s market-leading capabilities for complex oral solids, softgel formulations, Zydys fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; cold-chain storage and distribution, and clinical trial development and supply services. Prior-period segment results were reclassified to conform to the current period presentation. Pending Merger with Novo HoldingsOn February 5, 2024, the Company entered into the Merger Agreement, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth therein, the Company will survive the Merger as a wholly owned subsidiary of Parent, which is a wholly owned subsidiary of Novo Holdings. Parent will acquire all the issued and outstanding shares of Common Stock of the Company. On May 29, 2024, the Company held a special meeting of its stockholders at which the Company's stockholders approved, among other things, the Merger Agreement. The Merger is expected to close towards the end of calendar year 2024, subject to customary closing conditions, including receipt of required regulatory approvals. For more information, see Note 17, Commitments and Contingencies to our Consolidated Financial Statements.52Critical Accounting Policies and EstimatesThe following disclosure supplements the descriptions of our accounting policies contained in Note A 1 to our Consolidated Financial Statements regarding significant areas of judgment. Management made certain estimates and assumptions during the preparation of the Consolidated Financial Statements in accordance with U.S. GAAP. These estimates and assumptions affect the reported amount of assets and liabilities and disclosures of contingent assets and liabilities in the Consolidated Financial Statements. These estimates also affect the reported amount of net earnings during the reporting periods. Actual results could differ from those estimates. Because of the size of the financial statement elements to which they relate, some of our accounting policies and estimates have a more significant impact on the Consolidated Financial Statements than others. Management has discussed the development and selection of these critical accounting policies and estimates with the audit committee of our board of directors. A discussion of some of our more significant accounting policies and estimates follows.Revenue RecognitionWe sell products and services directly to our biopharmaceutical, pharmaceutical, and consumer health customers. The majority of our business is conducted through manufacturing and commercial product supply, development services, and clinical supply services. Our contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require judgment. For our manufacturing and commercial product supply revenue, the contract generally includes the terms of the manufacturing services and related product quality assurance procedures to comply with regulatory requirements. Due to the regulated nature of our business, these contract terms are highly interdependent and, therefore, are considered to be a single combined performance obligation. For our development services and clinical supply services revenue, our performance obligations vary per contract and are accounted for as separate performance obligations. If a contract contains a single performance obligation, we allocate the entire transaction price to the single performance obligation. If a contract contains multiple performance obligations, we allocate consideration to each performance obligation using the â€relative standalone selling priceâ€ as defined under Accounting Standards Codification (â€ASCâ€) 606, Revenue from Contracts with Customers. Generally, we utilize observable standalone selling prices in our allocations of consideration. If observable standalone selling prices are not available, we estimate the applicable standalone selling price using a cost-plus-margin approach or an adjusted market assessment approach, in each case, representing the amount that we believe the market is willing to pay for the applicable service. Revenue is

recognized over time using an appropriate method of measuring progress towards fulfilling our performance obligation for the respective arrangement. Determining the measure of progress that consistently depicts our satisfaction of performance obligations within each of our revenue streams across similar arrangements requires judgment. Our customer contracts generally include provisions entitling us to a termination penalty when the customer terminates prior to the contract’s nominal end date. The termination penalties in these customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated duration of the contract. We account for a contract termination as a contract modification in the period in which the customer gives notice of termination. The determination of the contract termination penalty is based on the terms stated in the relevant customer agreement. As of the modification date, we update our estimate of the transaction price using the expected value method, subject to constraints, and recognize the amount over the remaining performance period under the contract. In the event of a contract termination, revenues are recognized to the extent that it is probable that a significant reversal will not occur when any uncertainty is subsequently resolved. Long-lived and Other Definite-Lived Intangible Assets We allocate the cost of an acquired company to the tangible and identifiable intangible assets and liabilities acquired, with any remaining cost recorded as goodwill. Intangible assets primarily include customer relationships, technology, and trademarks. Valuing the identifiable intangible assets requires judgment. Intangible assets are generally amortized on a straight-line basis, reflecting the pattern in which the economic benefits are consumed, and are amortized over their estimated useful lives. We assess the impairment of identifiable intangibles if events or changes in circumstances indicate that the carrying values of the assets may not be recoverable. Factors that could trigger an impairment review include the following: a significant under-performance relative to historical or projected future operating results; a significant changes in the manner of use of the acquired assets or the strategy of the overall business; a significant negative industry or economic trends; and a recognition of goodwill impairment charges. If we determine that the carrying value of identifiable intangibles and/or long-lived assets may not be recoverable based on the existence of one or more of the above indicators of impairment, we measure recoverability of assets by comparing the respective carrying value of the assets to the current and expected future cash flows, on an un-discounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, we measure an impairment based on the amount by which the net carrying amount of the assets exceeds the fair values of the assets. See Notes 3, Business Combinations and Divestitures and 5, Other Intangibles, net to the Consolidated Financial Statements. Goodwill and Indefinite-Lived Intangible Assets We account for purchased goodwill and intangible assets with indefinite lives in accordance with ASC 350, Intangibles – Goodwill and Other. Under ASC 350, goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment at least annually. We perform an impairment evaluation of goodwill annually during the fourth quarter of our fiscal year or when circumstances otherwise indicate an evaluation should be performed. The evaluation may begin with a qualitative assessment for each reporting unit to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the qualitative assessment does not generate a positive response, or if no qualitative assessment is performed, a quantitative assessment, based upon discounted cash flows, is performed and requires management to estimate future cash flows, growth rates, and economic and market conditions. We perform an annual goodwill impairment test for each reporting unit on April 1, the measurement date and more frequently if indicators of impairment exist. During our first fiscal quarter ended September 30, 2023, as a result of the Consumer Health reporting unit’s underperformance of recent operating results relative to expectations, the current macroeconomic conditions impacting the consumer health and biotechnology industries, and increased interest rates, we assessed the current and future economic outlook for all of our reporting units and identified indicators for impairment of the goodwill previously recorded for two of our reporting units. The evaluation began with a qualitative assessment of our Consumer Health and Biomodalities reporting units to determine if it was more likely than not that the fair value of the reporting units was less than its carrying value. The qualitative assessment did not indicate that it was more likely than not that the fair value exceeded the carrying value in our Consumer Health and Biomodalities reporting units, which led to a quantitative assessment for the corresponding reporting units. We estimated the fair value of our reporting units using a combination of income and market approaches. In performing the goodwill impairment test, we used a terminal revenue growth rate of 3.5% and discount rates ranging from 9% to 10% in its estimation of fair value. The evaluation performed resulted in impairment charges of \$687 million with respect to the Consumer Health and Biomodalities reporting units. While we believe the assumptions used were reasonable and commensurate with the views of a market participant, changes in key assumptions, including increasing the discount rate, lowering forecasts for revenue and operating margin or lowering the long-term growth rate could lead to further impairment. Based on its quantitative assessment conducted as of April 1, 2024, the Company determined for each reporting unit with goodwill that its respective fair value exceeded its carrying value, and hence, there was no impairment. A 100 basis point increase in the discount rate and a 100 basis point decrease in the long-term growth rate would not have resulted in a goodwill impairment charge in any of the our reporting units. Subsequent to the quantitative assessment performed as of April 1, 2024, we performed qualitative assessments as of June 30, 2024, which yielded no indicators of impairment. See Notes 4, Goodwill and 5, Other Intangibles, net to the Consolidated Financial Statements. Income Taxes In accordance with ASC 740, Income Taxes, we account for income taxes using the asset and liability method. The asset and liability method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and the corresponding financial reporting bases of our assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates in the respective jurisdictions in which we operate. Deferred taxes are not provided on the undistributed earnings of subsidiaries outside of the U.S. when it is expected that these earnings will be permanently reinvested. In fiscal 2018, we recorded a provision for U.S. income taxes and foreign withholding 54 taxes in relation to expected repatriations as a result of the 2017 U.S. Tax Cuts and Jobs Act (the “2017 Tax Act”), but we have not made any provision for U.S. income taxes on the remaining undistributed earnings of foreign subsidiaries as those earnings are considered permanently reinvested in the operations of those foreign subsidiaries in the years after 2018. The 2017 Tax Act imposed taxes on so-called “global intangible low-taxed income” (GILTI) earned by certain foreign subsidiaries of a U.S. company. In accordance with ASC 740, we made an accounting policy election to treat taxes due on future U.S. inclusions in taxable income related to GILTI as a current-period expense when incurred. We assess the realizability of deferred tax assets by considering all available evidence, both positive and negative. We evaluate four possible sources of taxable income when assessing the realizability of deferred tax assets: carrybacks of existing NOLs (if and to the extent permitted by tax law); future reversals of existing taxable temporary differences; tax planning strategies; and future taxable income exclusive of reversing temporary differences and carryforwards. We consider the need to maintain a valuation allowance on deferred tax assets based on management’s assessment of whether it is more likely than not that we would realize those deferred tax assets as a result of future reversals of existing taxable temporary differences and the ability to generate sufficient taxable income within the carryforward period available under the applicable tax law. Unrecognized tax benefits are generated when there are differences between tax positions taken in a tax return and amounts recognized in the Consolidated Financial Statements. Tax benefits are recognized in the Consolidated Financial Statements when it is more likely than not that a tax position will be sustained upon examination. To the extent we prevail in matters for which liabilities have been established or are required to pay amounts in excess of our liabilities, our effective income tax rate in a given period could be materially affected. An unfavorable income tax settlement may require the use of cash and result in an increase in our effective income tax rate in the year it is resolved. A favorable income tax settlement would be recognized as a reduction in the effective income tax rate in the year of resolution. Our accounting for income taxes involves the application of complex tax regulations in the U.S. and in each of the non-U.S. jurisdictions in which we operate, particularly European tax jurisdictions. The determination of income subject to taxation in each tax-paying jurisdiction requires us to review reported book income and the events occurring during the year in each jurisdiction in which we operate. In addition, the application of deferred tax assets and liabilities will have an effect on the tax expense in each jurisdiction. For those entities engaging in transactions with affiliates, we apply transfer-pricing guidelines relevant in many jurisdictions in which we operate and make certain informed and reasonable assumptions and estimates about the relative value of contributions by affiliates when assessing the allocation of income and deductions between consolidated entities in different jurisdictions. The estimates and assumptions used in these allocations can result in uncertainty in the measured tax benefit. Factors Affecting our Performance Fluctuations in Operating Results Our annual financial reporting period ends on June 30. Excluding the impact from COVID-19, our revenue and net earnings are generally higher in the third and fourth quarters of each fiscal year, with our first fiscal quarter typically generating our lowest revenue of any quarter, and our last fiscal quarter typically generating our highest revenue. These fluctuations are primarily the result of the timing of our, and our customers’, annual operational maintenance periods at locations in Europe and the U.S., the seasonality associated with pharmaceutical and biotechnology budgetary spending decisions, clinical trial and research and development schedules, the timing of new product launches and length of time needed to obtain full market penetration, and, to a lesser extent, the time of the year some of our customers’ products are in higher demand. Acquisition and Related Integration Efforts Our growth and profitability are affected by the acquisitions we complete and the speed at which we integrate those acquisitions into our existing operating platforms. In fiscal 2021, we expanded our capacity and capabilities through five acquisitions for our Biologics segment and through the acquisition of a dry powder inhaler and spray dry manufacturing business from Acorda Therapeutics, Inc. (Acorda). In fiscal 2022, we acquired each of Bettera Wellness, a manufacturer of a consumer-preferred gummy and other formats for consumer health products, a commercial-scale cell therapy manufacturing facility in Princeton, and a manufacturing facility for biologic therapies and vaccines near Oxford, U.K. In fiscal 2023, we acquired Metrics Contract Services (Metrics), an oral solids development and manufacturing business specializing in the manufacture of drugs containing highly potent active pharmaceutical ingredients. Foreign Exchange Rates Our operating network is global, and, as a result, we have substantial revenues and operating expenses that are denominated in currencies other than the U.S. dollar, the currency in which we report our financial results. Our results of operations and financial performance are therefore influenced by changes in currency exchange rates. In fiscal 2024, 36% of our net revenue was generated from our operations outside the U.S. Foreign currencies for our operations include the British pound, European euro, Brazilian real, Argentine peso, Japanese yen, and the Canadian dollar. Inflation In fiscal 2023, we began to experience the effects of increased global inflation, which has risen to levels not seen in more than 30 years. In response, we implemented various mitigation strategies, including in some cases increasing prices to customers or reducing other costs of operation, including through price renegotiations with suppliers. The effects of inflation are likely to continue to affect us for fiscal 2025, at least, and there can be no assurance that our mitigating strategies will continue to enjoy the same degree of success. Trends Affecting Our Business Industry We participate in nearly every sector of the global pharmaceutical and biotechnology industry, which has been estimated to generate more than \$1 trillion in annual revenue, including, but not limited to, the prescription drug and biologic sectors as well as consumer health, which includes the over-the-counter and vitamins and nutritional supplement sectors. Innovative pharmaceuticals, and biologics in particular, continue to play a critical role in the global market, while the share of revenue due to generic drugs and biosimilars is increasing in both developed and developing markets. Sustained developed market demand and rapid growth in emerging economies is driving consumer health product growth. Payors, both public and private, have sought to limit the economic impact of pharmaceutical and biologics product demand through greater use of generic and biosimilar drugs, access and spending controls, and health technology assessment techniques, favoring products that deliver truly differentiated outcomes. New Molecule Development and R&D Sourcing Continued strengthening in early-stage development pipelines for drugs and biologics, compounded by increasing clinical trial breadth and complexity, support our belief in the attractive growth prospects for development solutions. A large companies are in many cases reconfiguring their R&D resources, increasingly involving the use of strategic partners for important outsourced functions and new treatment modalities. Additionally, an increasing portion of compounds in development are from companies that do not have a full research and development infrastructure, and thus are more likely to need strategic development solutions partners. Demographics Aging population demographics in developed countries, combined with the global COVID-19 pandemic and health care reforms in many global markets that are expanding access to treatments to a greater proportion of the global population, will continue to drive increases in demand for pharmaceuticals, biologics, and consumer health products. Increasing economic affluence in developing regions will further increase demand for healthcare treatments, and we are taking active steps to allow us to participate effectively in these growth regions and product categories. Finally, we believe the market access and payor pressures our customers face, global supply chain complexity, and the increasing demand for improved and new modality treatments will continue to escalate the need for advanced formulation and manufacturing, product differentiation, improved outcomes, and treatment cost reduction, all of which can often be addressed using our advanced delivery technologies. Non-GAAP Metrics As described in this section, management uses various financial metrics, including certain metrics that are not based on concepts defined in U.S. GAAP, to measure and assess the performance of our business, to make critical business decisions, and to assess our compliance with certain financial obligations. We therefore believe that presentation of certain of these non-GAAP metrics in this Annual Report will aid investors in understanding our business. EBITDA from operations Management measures operating performance based on consolidated earnings from operations before interest expense, expense for income taxes, and depreciation and amortization, adjusted for the income attributable to non-controlling interests (EBITDA from operations). EBITDA from operations is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP, and is subject to important limitations. We believe that the presentation of EBITDA from operations enhances an investor’s understanding of our financial performance. We believe this measure is a useful financial metric to assess our operating performance across periods and use this measure for business planning purposes. In addition, given the significant investments that we have made in the past in property, plant, and equipment, depreciation and amortization expenses represent a meaningful portion of our cost structure. We believe that disclosing EBITDA from operations provides investors with a useful tool for assessing the comparability between periods of our ability to generate cash from operations sufficient to pay taxes, service debt, and undertake capital expenditures without consideration of non-cash depreciation and amortization expense. We present EBITDA from operations in order to provide supplemental information that we consider relevant for readers of the Consolidated Financial Statements, and such information is not meant to replace or supersede U.S. GAAP measures. Our definition of EBITDA from operations may not be the same as similarly titled measures used by other companies. The most directly comparable measure to EBITDA from operations defined under U.S. GAAP is net earnings. Included in this Management’s Discussion and Analysis is a reconciliation of net earnings to EBITDA from operations. In addition, we evaluate the performance of our segments based on segment earnings before non-controlling interest, other (income) expense, impairments, restructuring costs, interest expense, income tax expense, stock-based compensation, gain (loss) on sale of subsidiary, and depreciation and amortization (Segment EBITDA). For a reconciliation of Segment EBITDA to net earnings, see Note 18, Segment Information to our Consolidated Financial Statements. Adjusted EBITDA Under the Credit Agreement and in the Indentures, the ability of Operating Company to engage in certain activities, such as incurring certain additional indebtedness, making certain investments, and paying certain dividends, is tied to ratios based on Adjusted EBITDA (which is defined as Consolidated EBITDA in the Credit Agreement and EBITDA in the Indentures). Adjusted EBITDA is a covenant compliance measure in our Credit Agreement and Indentures, particularly those covenants governing debt incurrence and restricted payments. Adjusted EBITDA is based on the definitions in the Credit Agreement, is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP, and is subject to important limitations. Because not all companies use identical calculations, our presentation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies. In addition, we use Adjusted EBITDA as a performance metric that guides management in its operation of and planning for the future of the business and drives certain management compensation programs. Management believes that Adjusted EBITDA provides a useful measure of our operating performance from period to period by excluding certain items that are not representative of our core business, including interest expense and non-cash charges like depreciation and amortization. The measure under U.S. GAAP most directly comparable to Adjusted EBITDA is net earnings. In calculating Adjusted EBITDA, we add back certain non-cash, non-recurring, and other items that are deducted when calculating EBITDA from operations and net earnings, consistent with the requirements of the Credit Agreement. Adjusted EBITDA, among other things, does not include non-cash stock-based employee compensation expense and certain other non-cash charges; does not include cash and non-cash restructuring, severance, and relocation costs incurred to realize future cost savings and enhance operations; adds back any non-controlling interest expense, which represents minority investors’ ownership of non-wholly owned consolidated subsidiaries and is, therefore, not available; and includes estimated cost savings that have not yet been fully reflected in our results. Adjusted Net Income and Adjusted Net Income per Share We use Adjusted Net Income and Adjusted Net Income per share (which we sometimes refer to as Adjusted EPS) as performance metrics. Adjusted Net Income is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP, and is subject to important limitations. We believe that 57 providing information concerning Adjusted Net Income and Adjusted Net Income per share enhances an investor’s understanding of our financial performance. We believe that these measures are useful financial metrics to assess our operating

operating from period to period by excluding certain items that we believe are not representative of our core business, and we use these measures for business planning and executive compensation purposes. We define Adjusted Net Income as net earnings adjusted for (1) earnings or loss from discontinued operations, net of tax, (2) amortization attributable to purchase accounting, and (3) income or loss from non-controlling interest in majority-owned operations. We also make adjustments for other cash and non-cash items (as shown above, in **“Adjusted EBITDA”**), partially offset by our estimate of the tax effect of such cash and non-cash items. Our definition of Adjusted Net Income may not be the same as similarly titled measures used by other companies. Adjusted Net Income per share is computed by dividing Adjusted Net Income by the weighted average diluted shares outstanding. Use of Constant Currency As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a constant currency basis as one measure to evaluate our performance. In this Annual Report, we calculate constant currency by calculating current-year results using prior-year foreign currency exchange rates. We generally refer to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP. Restructuring ProgramsThe contract manufacturing industry is labor intensive. As a result, we incur significant fixed costs to operate our facilities and maintain additional infrastructure required to obtain, develop, manufacture, transport, store, and test our products. Therefore, relatively small changes in demand can have a significant impact on short-term profitability. In the second quarter of fiscal 2023, we engaged in a restructuring effort, which reduced our cost structure, consolidated facilities, and optimized our infrastructure across the organization. In fiscal 2024, we extended our restructuring effort, with further headcount reduction primarily in our Biologics segment and in our corporate functions. In connection with these restructuring plans, during the fiscal year ended June 30, 2024, we reduced our headcount by approximately 700 employees and incurred \$39 million of cumulative pre-tax employee separation and other restructuring related costs. As a result of our restructuring plans, we expect to deliver an annualized run-rate savings of \$90 to \$100 million. For further details regarding restructuring costs, see Note 6, Restructuring Costs to our Consolidated Financial Statements. Summary Two-Year Key Financial Performance Metrics Discussion of the year-over-year changes for the fiscal year ended June 30, 2023 compared to the fiscal year ended June 30, 2022 and the results of operations and cash flows for the fiscal year ended June 30, 2022, is included in Item 7. “Management’s Discussion and Analysis of Financial Condition and Result of Operations of our Annual Report on Form 10-K for the fiscal year ended June 30, 2023, filed with the SEC on December 8, 2023, and is incorporated herein by reference. The below tables summarize our results in fiscal 2024 and 2023 with respect to several financial metrics we use to measure performance. Refer to the discussions below regarding performance and the use of key financial metrics and **“Non-GAAP Metrics”** Use of Constant Currency concerning the measurement of revenue at **constant currency.**

Fiscal Year Ended June 30, 2023Results for the fiscal year ended June 30, 2024 compared to the fiscal year ended June 30, 2023 were as follows:(Dollars in millions)	Fiscal Year Ended June 30, 2023Results for the fiscal year ended June 30, 2024 compared to the fiscal year ended June 30, 2023 were as follows:(Dollars in millions)
Net revenue	\$4,381.4
Selling, general, and administrative expenses	\$935.4
Interest expense, net	\$254.8
Income tax expense (benefit)	\$16.8
Goodwill impairment charges	\$16.8
Other operating expenses	\$16.8
Operating loss	\$(749.1)
Loss before income taxes	\$(1,027.3)
Income tax expense (benefit)	\$16.8
Net income	\$16.8
Constant currency change	3%
Total percentage change	3%
Foreign currency translation impact on reporting	1%
Organic growth	1%
Impact of acquisitions	1%
Stock-based compensation	1%
Depreciation and amortization	1%
One-time insurance benefit	\$10 million
Employee related expenses	\$25 million
Increase in demand for COVID-19 related programs	1%
Decrease in inventory write-offs	1%
Decrease in pension settlement charges	1%
Interest expense, net	\$254 million
Goodwill impairment charges	\$16 million
Other operating expenses	\$16 million
Operating loss	\$(749.1)
Loss before income taxes	\$(1,027.3)
Income tax expense (benefit)	\$16.8
Net income	\$16.8
Constant currency change	3%
Total percentage change	3%
Foreign currency translation impact on reporting	1%
Organic growth	1%
Impact of acquisitions	1%
Stock-based compensation	1%
Depreciation and amortization	1%
One-time insurance benefit	\$10 million
Employee related expenses	\$25 million
Increase in demand for COVID-19 related programs	1%
Decrease in inventory write-offs	1%
Decrease in pension settlement charges	1%
Interest expense, net	\$254 million
Goodwill impairment charges	\$16 million
Other operating expenses	\$16 million
Operating loss	\$(749.1)
Loss before income taxes	\$(1,027.3)
Income tax expense (benefit)	\$16.8
Net income	\$16.8
Constant currency change	3%
Total percentage change	3%
Foreign currency translation impact on reporting	1%
Organic growth	1%
Impact of acquisitions	1%
Stock-based compensation	1%
Depreciation and amortization	1%
One-time insurance benefit	\$10 million
Employee related expenses	\$25 million
Increase in demand for COVID-19 related programs	1%
Decrease in inventory write-offs	1%
Decrease in pension settlement charges	1%
Interest expense, net	\$254 million
Goodwill impairment charges	\$16 million
Other operating expenses	\$16 million
Operating loss	\$(749.1)
Loss before income taxes	\$(1,027.3)
Income tax expense (benefit)	\$16.8
Net income	\$16.8
Constant currency change	3%
Total percentage change	3%
Foreign currency translation impact on reporting	1%
Organic growth	1%
Impact of acquisitions	1%
Stock-based compensation	1%
Depreciation and amortization	1%
One-time insurance benefit	\$10 million
Employee related expenses	\$25 million
Increase in demand for COVID-19 related programs	1%
Decrease in inventory write-offs	1%
Decrease in pension settlement charges	1%
Interest expense, net	\$254 million
Goodwill impairment charges	\$16 million
Other operating expenses	\$16 million
Operating loss	\$(749.1)
Loss before income taxes	\$(1,027.3)
Income tax expense (benefit)	\$16.8
Net income	\$16.8
Constant currency change	3%
Total percentage change	3%
Foreign currency translation impact on reporting	1%
Organic growth	1%
Impact of acquisitions	1%
Stock-based compensation	1%
Depreciation and amortization	1%
One-time insurance benefit	\$10 million
Employee related expenses	\$25 million
Increase in demand for COVID-19 related programs	1%
Decrease in inventory write-offs	1%
Decrease in pension settlement charges	1%
Interest expense, net	\$254 million
Goodwill impairment charges	\$16 million
Other operating expenses	\$16 million
Operating loss	\$(749.1)
Loss before income taxes	\$(1,027.3)
Income tax expense (benefit)	\$16.8
Net income	\$16.8
Constant currency change	3%
Total percentage change	3%
Foreign currency translation impact on reporting	1%
Organic growth	1%
Impact of acquisitions	1%
Stock-based compensation	1%
Depreciation and amortization	1%
One-time insurance benefit	\$10 million
Employee related expenses	\$25 million
Increase in demand for COVID-19 related programs	1%
Decrease in inventory write-offs	1%
Decrease in pension settlement charges	1%
Interest expense, net	\$254 million
Goodwill impairment charges	\$16 million
Other operating expenses	\$16 million
Operating loss	\$(749.1)
Loss before income taxes	\$(1,027.3)
Income tax expense (benefit)	\$16.8
Net income	\$16.8
Constant currency change	3%
Total percentage change	3%
Foreign currency translation impact on reporting	1%
Organic growth	1%
Impact of acquisitions	1%
Stock-based compensation	1%
Depreciation and amortization	1%
One-time insurance benefit	\$10 million
Employee related expenses	\$25 million
Increase in demand for COVID-19 related programs	1%
Decrease in inventory write-offs	1%
Decrease in pension settlement charges	1%
Interest expense, net	\$254 million
Goodwill impairment charges	\$16 million
Other operating expenses	\$16 million
Operating loss	\$(749.1)
Loss before income taxes	\$(1,027.3)
Income tax expense (benefit)	\$16.8
Net income	\$16.8
Constant currency change	3%
Total percentage change	3%
Foreign currency translation impact on reporting	1%
Organic growth	1%
Impact of acquisitions	1%
Stock-based compensation	1%
Depreciation and amortization	1%
One-time insurance benefit	\$10 million

existing revolving credit commitments (and the related outstanding revolving borrowings) under the Revolving Credit Facility, and (ii) obtained \$1.10 billion aggregate amount of new revolving credit commitments, borrowing thereunder an amount equal to the previously outstanding borrowings under the terminated commitments so that they could be repaid. The new commitments have an interest rate margin, at Operating Company's option, based on a (1) prime rate, plus a margin ranging from 0.750% to 1.250% based on Operating Company's consolidated leverage ratio or (2) the Secured Overnight Financing Rate (SOFR), plus 0.100%, plus a margin ranging from 1.750% to 2.250% based on Operating Company's consolidated leverage ratio. The Revolving Credit Facility has a maturity date that is the earlier of (A) five years after November 22, 2022, and (B) the 91st day prior to the maturity of Operating Company's 2027 Notes or any permitted refinancing thereof, if on such 91st day, any of the 2027 Notes remains outstanding. Otherwise, the Revolving Credit Facility under the Seventh Amendment has the same principal terms as the previously existing revolving credit commitments under the Credit Agreement. In June 2023, Operating Company entered into Amendment No. 8 to the Credit Agreement (the "Eighth Amendment"). Pursuant to the Eighth Amendment, effective as of July 1, 2023, the interest rate benchmark applicable to term loans under the Credit Agreement was updated, with the SOFR benchmark replacing the LIBOR benchmark. The Eighth Amendment includes a 0.1148% credit spread adjustment to the SOFR benchmark for loans with a 1-month interest period, a 0.26161% credit spread adjustment to the SOFR benchmark for loans with a 3-month interest period, and a 0.42826% credit spread adjustment to the SOFR benchmark for loans with a 6-month interest period. Other than the foregoing, the material terms of the Credit Agreement remain unchanged. On September 27, 2023, Operating Company entered into Amendment No. 9 to the Credit Agreement, which extended the deadlines by which the Operating Company was required to deliver to the administrative agent (i) its audited financial statements as at the end of and for the fiscal year ended June 30, 2023, together with the auditor's report and opinion on such audited financial statements, to November 27, 2023, and (ii) its unaudited financial statements as at the end of and for the fiscal quarter ending September 30, 2023 to January 13, 2024. On November 22, 2023, Operating Company, entered into Amendment No. 10 to the Credit Agreement, which further extended the deadlines by which we are required to deliver to the administrative agent (i) our audited financial statements as at the end of and for the fiscal year ended June 30, 2023, together with the auditor's report and opinion on such audited financial statements, to January 26, 2024, and (ii) our unaudited financial statements as at the end of and for the fiscal quarter ending September 30, 2023 to March 13, 2024. On December 19, 2023, Operating Company entered into Amendment No. 11 to the Credit Agreement, pursuant to which Operating Company incurred \$600 million aggregate principal amount of new incremental dollar term loans. Further information concerning the senior secured credit facilities, including our U.S. dollar-denominated term loans and the Revolving Credit Facility, can be found in Note 7, Long-Term Obligations and Short-Term Borrowings to the Consolidated Financial Statements. Senior Notes Due 2027 In June 2019, Operating Company completed a private offering of the 2027 Notes. The 2027 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The 2027 Notes were offered in the U.S. to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the U.S. only to non-U.S. investors pursuant to Regulation S under the Securities Act. The 2027 Notes will mature on July 15, 2027 and bear interest at the rate of 5.000% per annum. Interest is payable semi-annually in arrears on January 15 and July 15 of each year. The proceeds of the 2027 Notes, after payment of the offering fees and expenses, were used to repay in full the outstanding borrowings under Operating Company's then-outstanding term loans, which would otherwise have matured in May 2024. 2.375% Euro-denominated Senior Notes Due 2028 In March 2020, Operating Company completed a private offering of the 2028 Notes. The 2028 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The 2028 Notes were offered in the U.S. to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the U.S. only to non-U.S. investors pursuant to Regulation S under the Securities Act. The 2028 Notes will mature on March 1, 2028 and bear interest at the rate of 2.375% per annum. Interest is payable semi-annually in arrears on March 1 and September 1 of each year. The proceeds of the 2028 Notes, after payment of the offering fees and expenses, were used to repay in full the outstanding borrowings under Operating Company's euro-denominated term loans, which would otherwise have matured in May 2024, and to repay in full our Euro-denominated 4.75% Senior Notes due 2024, which would otherwise have matured in December 2024, plus accrued and unpaid interest thereon, with the remainder available for general corporate purposes. 3.125% Senior Notes Due 2029 In February 2021, Operating Company completed a private offering of the 2029 Notes. The 2029 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The 2029 Notes were offered in the U.S. to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the U.S. only to non-U.S. investors pursuant to Regulation S under the Securities Act. The 2029 Notes will mature on February 15, 2029 and bear interest at the rate of 3.125% per annum payable semi-annually in arrears on February 15 and August 15 of each year. The proceeds of the 2029 Notes, after payment of the offering fees and expenses were used to repay in full the outstanding borrowings under an earlier issue of unsecured notes, which would have otherwise matured in 2026, plus accrued and unpaid interest thereon, with the remainder available for general corporate purposes. 3.500% Senior Notes Due 2030 In September 2021, Operating Company completed a private offering of the 2030 Notes. The 2030 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The 2030 Notes were offered in the U.S. to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the U.S. only to non-U.S. investors pursuant to Regulation S under the Securities Act. The 2030 Notes will mature on April 1, 2030 and bear interest at the rate of 3.500% per annum payable semi-annually in arrears on April 1 and October 1 of each year. The proceeds of the 2030 Notes, after payment of the offering fees and expenses, were used to fund a portion of the consideration paid at the closing of the Bettera Wellness acquisition. Debt Covenants Senior Secured Credit Facilities The Credit Agreement contains covenants that, among other things, restrict, subject to certain exceptions, Operating Company's (and Operating Company's restricted subsidiaries') ability to incur additional indebtedness or issue certain preferred shares; create liens on assets; engage in mergers and consolidations; sell assets; pay dividends and distributions or repurchase capital stock; repay subordinated indebtedness; engage in certain transactions with affiliates; make investments, loans, or advances; make certain acquisitions; enter into sale and leaseback transactions; amend material agreements governing Operating Company's subordinated indebtedness; and change Operating Company's lines of business. The Credit Agreement also contains change-of-control provisions and certain customary affirmative covenants and events of default. The Revolving Credit Facility requires compliance with a net leverage covenant when there is a 30% or more draw outstanding at a period end. As of June 30, 2024, Operating Company was in compliance with all material covenants under the Credit Agreement. Subject to certain exceptions, the Credit Agreement permits Operating Company and its restricted subsidiaries to incur certain additional indebtedness, including secured indebtedness. None of Operating Company's non-U.S. subsidiaries nor its dormant Puerto Rico subsidiary is a guarantor of the loans. Under the Credit Agreement, Operating Company's ability to engage in certain activities such as incurring certain additional indebtedness, making certain investments, and paying certain dividends is tied to ratios based on Adjusted EBITDA (which is defined as Consolidated EBITDA in the Credit Agreement). Adjusted EBITDA is based on the definitions in the Credit Agreement, is not defined under U.S. GAAP, and is subject to important limitations. See Non-GAAP Metrics for further details on Adjusted EBITDA. The Senior Notes The several indentures governing each series of our outstanding senior notes (collectively, the "Indentures") contain certain covenants that, among other things, limit our ability to incur or guarantee more debt or issue certain preferred shares; pay dividends on, repurchase, or make distributions in respect of their capital stock or make other restricted payments; make certain investments; sell certain assets; create liens; consolidate, merge, sell, or otherwise dispose of all or substantially all of their assets; enter into certain transactions with their affiliates, and designate their subsidiaries as unrestricted subsidiaries. These covenants are subject to a number of exceptions, limitations, and qualifications as set forth in the Indentures. The Indentures also contain customary events of default, including, but not limited to, nonpayment, breach of covenants, and payment or acceleration defaults in certain other indebtedness of Operating Company or certain of its subsidiaries. Upon an event of default, either the holders of at least 30% in principal amount of each of the then-outstanding series of Senior Notes, or the applicable Trustee under the Indentures, may declare the applicable senior notes immediately due and payable; or in certain circumstances, the applicable senior notes will become automatically immediately due and payable. As of June 30, 2024, Operating Company was in compliance with all material covenants under the Indentures. Capital Resources As market conditions warrant, we and our affiliates may from time to time seek to purchase our outstanding debt in privately negotiated or open-market transactions, by tender offer or otherwise. Subject to any applicable limitation contained in the Credit Agreement, any purchase made by us may be funded by the use of cash on hand or the incurrence of new secured or unsecured debt. The amounts involved in any such purchase transaction, individually or in the aggregate, may be material. Any such purchase may be with respect to a substantial amount of a particular class or series of debt, with the attendant reduction in the trading liquidity of such class or series. In addition, any such purchase made at prices below the adjusted issue price (as defined for U.S. federal income tax purposes) may result in taxable cancellation of indebtedness income to us, which amounts may be material, or in related adverse tax consequences to us. Geographic Allocation of Cash As of June 30, 2024 and 2023, the amounts of cash and cash equivalents held by foreign subsidiaries were \$257 million and \$181 million, respectively, out of total consolidated cash and cash equivalents of \$289 million and \$280 million, respectively. These balances are dispersed across many international locations around the world. Adjusted EBITDA and Adjusted Net Income per Share The below tables summarize our fiscal 2024 and 2023 results with respect to certain financial metrics we use to measure performance throughout the fiscal year. Refer to Non-GAAP Metrics for further details regarding Adjusted EBITDA and Adjusted net income per share. 67A reconciliation between Adjusted EBITDA and net earnings, the most directly comparable measure under U.S. GAAP, which also shows the adjustments from EBITDA from operations. Fiscal Year Ended (In millions) June 30, 2024 June 30, 2023 Net loss \$(1,043) \$(256) Interest expense, net 254 186 Income tax (benefit) expense 16A (86) Depreciation and amortization 489A 422A EBITDA (loss) from operations (284) 266A Goodwill impairment charges 687A 210A Stock-based compensation 68A 35A Impairment charges and gain/loss on sale of assets 29A 98A Restructuring costs 39A 66A Acquisition, integration, and other special items 58A 31A Foreign exchange loss (gain) (included in other, net) (1) 13A (11) Site transformation costs 39A A Pension settlement charges 12A A A Impacts from COVID-19 contract settlement 24A A A Fire loss contingency 9A A A Other adjustments 9A 2A Adjusted EBITDA \$ 703A \$ 697A Favorable (unfavorable) FX impact 7A Adjusted EBITDA - constant currency \$ 696A (1) A A Foreign exchange loss of \$13 million for the fiscal year ended June 30, 2024 includes \$13 million of unrealized losses related to foreign trade receivables and payables and intercompany transactions. Foreign exchange gain of \$11 million for the fiscal year ended June 30, 2023 includes \$10 million of unrealized gains related to foreign trade receivables and payables and intercompany transactions. 68A reconciliation between Adjusted Net Income and net earnings, the most directly comparable measure under U.S. GAAP, follows. Fiscal Year Ended (In millions, except per share data) June 30, 2024 June 30, 2023 Net loss \$(1,043) \$(256) Amortization (1) 135 136A Goodwill impairment charges 687A 210A Stock-based compensation 68A 35A Impairment charges and gain/loss on sale of assets 29A 98A Restructuring costs 39A 66A Acquisition, integration, and other special items 58A 31A Pension settlement charges 12A A A Site transformation costs 39A A A Fire loss contingency 9A A A Impacts from COVID-19 contract settlement 24A A A Foreign exchange loss (gain) (included in other expense, net) (2) 13A (11) Other adjustments 8A 2A Estimated tax effect of adjustments (3) (13) (126) Discrete income tax benefit items (4) (26) (18) Adjusted net income (ANI) \$ 39A \$ 167A ANI per share - basic (5) \$ 0.22A \$ 0.92A ANI per share - diluted (6) \$ 0.21A \$ 0.92A (1) A A Represents the amortization attributable to purchase accounting for previously completed business combinations. (2) A A Foreign exchange loss of \$13 million for the fiscal year ended June 30, 2024 includes \$13 million of unrealized losses related to foreign trade receivables and payables intercompany transactions. Foreign exchange gain of \$11 million for the fiscal year ended June 30, 2023 includes \$10 million of unrealized gains related to foreign trade receivables and payables intercompany transactions. (3) A A A We computed the tax effect of adjustments to net earnings by applying the statutory tax rate in the relevant jurisdictions to the income or expense items that are adjusted in the period presented. If a valuation allowance exists, the rate applied is zero. (4) A A A Discrete period income tax expense (benefit) items are unusual or infrequently occurring items, primarily including: changes in judgment related to the realizability of deferred tax assets in future years, changes in measurement of a prior-year tax position, deferred tax impact of changes in tax law, and purchase accounting. (5) A A A Represents Adjusted Net Income divided by the weighted average number of shares of Common Stock outstanding. For the fiscal year ended June 30, 2024 and 2023, the weighted average was 181 million. (6) A A A Represents Adjusted Net Income divided by the weighted average sum of (a) the number of shares of Common Stock outstanding, plus (b) the number of shares of Common Stock that would be issued assuming exercise or vesting of all potentially dilutive instruments. For the fiscal years ended June 30, 2024 and 2023, the weighted average was 182 million and 181 million, respectively. Interest Rate Risk Management We have historically used interest-rate swaps to manage the economic effect of variable-rate interest obligations associated with our floating-rate term loans so that the interest payable on at least a portion of the term loans effectively becomes fixed at a certain rate, thereby reducing the impact of future interest-rate changes on our future interest expense. 69A portion of our bank and note debt is exposed to interest-rate fluctuations. We have in the past used and may continue to use various hedging strategies and derivative financial instruments to create an appropriate mix of fixed- and floating-rate assets and liabilities. In February 2021, we entered into an interest-rate swap agreement with Bank of America N.A. that acted as a hedge against the economic effect of a portion of the variable-interest obligation associated with our U.S. dollar-denominated term loans under our senior secured credit facilities, so that the interest payable on that portion of the debt became fixed at a certain rate, thereby reducing the impact of future interest-rate increases on future interest expense (the "2021 Rate Swap"). From June 30, 2021 until the effective date of the Eighth Amendment, the applicable rate for the U.S. dollar-denominated term loan under the Credit Agreement was one-month LIBOR (subject to a floor of 0.50%) plus 2.00%; however, as a result of the 2021 Rate Swap, the variable portion of the applicable rate for the \$500 million of the U.S. dollar-denominated term loans was effectively fixed during this period at 0.9985%. To conform with the adoption of ASC 848, Reference Rate Reform and the Eighth Amendment, the Company amended the 2021 Rate Swap in June 2023 (the "2023 Rate Swap"). The 2023 Rate Swap continues to effectively fix the rate of interest payable on the same portion of our U.S. dollar-denominated term loans under our secured credit facilities. The applicable rate for the U.S. dollar-denominated term loan under the Credit Agreement was SOFR (subject to a floor of 0.39%) plus 2.00% as of June 30, 2024. As a result of the 2023 Rate Swap, the variable portion of the applicable interest rate on \$500 million of the U.S. dollar-denominated term loans is now effectively fixed at 0.9431%. Currency Risk Management We are exposed to fluctuations in the euro-U.S. dollar exchange rate on our investments in our foreign operations in Europe. While we do not actively hedge against changes in foreign currency, we have mitigated the exposure of our investments in our European operations by denominating a portion of our bank and note debt in euros. As of June 30, 2024, we had \$883 million of euro-denominated debt outstanding that qualifies as a hedge on a net investment in foreign operations. Refer to Note 9, Derivative Instruments and Hedging Activities, to our Consolidated Financial Statements for further discussion of net investment hedge activity in the period. From time to time, we may use forward currency exchange contracts to manage our exposure to the variability of cash flows primarily related to the foreign exchange rate changes of future foreign currency transaction costs. In addition, we may use foreign currency forward contracts to protect the value of existing foreign currency assets and liabilities. Currently, we do not use foreign currency exchange contracts. We expect to continue to evaluate hedging opportunities for foreign currency in the future. 70 ITEM 7A. A A A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We are exposed to cash flow and earnings fluctuations as a result of certain market risks. These market risks primarily relate to changes in interest rates associated with our bank and note debt obligations and foreign exchange rate changes. Interest Rate Risk A portion of the debt used to finance our operations is exposed to interest-rate fluctuations. We may use various hedging strategies and derivative financial instruments to create an appropriate mix of fixed- and floating-rate assets and liabilities. We entered into the 2021 Rate Swap with Bank of America N.A., which acted as a hedge against the economic effect of a portion of the variable-interest obligation associated with our U.S. dollar-denominated term loans under our senior secured credit facilities, so that the interest payable on that portion of the debt became fixed at a certain rate, thereby reducing the impact of future interest-rate changes on future interest expense. From June 30, 2021 until the effective date of the Eighth Amendment, the applicable rate for the U.S. dollar-denominated term loan under the Credit Agreement was one-month LIBOR (subject to a floor of 0.50%) plus 2.00%; however, as a result of the 2021 Rate Swap, the variable portion of the applicable rate on \$500 million of the U.S. dollar-denominated term loans was effectively fixed during this period at 0.9985%. To conform with the adoption of ASC 848 and the Eighth Amendment, the Company amended the 2021 Rate Swap as the 2023 Rate Swap. The 2023 Rate Swap continues to effectively fix the rate of interest payable on the same portion of our U.S. dollar-denominated term loans under our secured credit facilities. The applicable rate for the U.S. dollar-denominated term loan under the Credit Agreement was SOFR (subject to a floor of 0.39%) plus 2.00% as of June 30, 2024. As a result of the 2023 Rate Swap, the variable portion of the applicable interest rate on \$500 million of the U.S. dollar-denominated term loans is now effectively fixed at 0.9431%. A hypothetical 50 basis change to the variable rate

operating activities\$ 1 Change in operating assets and liabilities: Decrease (increase) in trade receivables 79\$ 53\$ (73) Decrease (increase) in inventories 109\$ (192) (128) (Decrease) increase in accounts payable (84) (21) 37\$ 4 Other assets/accrued liabilities, net - current and non-current (166) (128) (423) Net cash provided by operating activities 268\$ 254\$ 439\$ CASH FLOWS USED IN INVESTING ACTIVITIES: Acquisition of property and equipment (327) (576) (660) Proceeds from maturity (purchases) of marketable securities\$ 89\$ (20) Proceeds from sale of property and equipment 1\$ 8\$ 4 Settlement on sale of subsidiaries\$ 4 (3) Payment for acquisitions, net of cash acquired\$ 4 (474) (1,199) Payment for investments (1) (2) (2) Net cash used in investing activities (327) (955) (1,884) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from borrowings 1,200\$ 715\$ 1,100\$ Payments related to financing obligations (1,116) (230) (78) Financing fees paid (16) (4) (15) Dividends paid\$ 4 (4) Exercise of stock options 9\$ 4\$ 26\$ Cash paid, in lieu of equity, for tax withholding obligation\$ 4 (4) (10) Other financing activities (3) 36\$ 12\$ Net cash provided by financing activities 74\$ 521\$ 1,031\$ Effect of foreign currency on cash (6) 11\$ (33) NET INCREASE (DECREASE) IN CASH AND EQUIVALENTS\$ 9\$ (169) (447) CASH AND EQUIVALENTS AT BEGINNING OF PERIOD 280\$ 449\$ 896\$ CASH AND EQUIVALENTS AT END OF PERIOD\$ 289\$ 280\$ 449\$ SUPPLEMENTARY CASH FLOW INFORMATION: Interest paid\$ 226\$ 188\$ 116\$ Income taxes paid, net\$ 43\$ 99\$ 53\$ SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITY: Issuance of Common Stock from partial conversion of redeemable preferred stock\$ 4 (4) \$ 362\$ Non-cash purchase of property, equipment\$ 24\$ 18\$ 6\$ The accompanying notes are an integral part of these consolidated financial statements. 82 Catalent, Inc. Notes to Consolidated Financial Statements 1. A BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Catalent, Inc. (the "Catalent" or the "Company") directly and wholly owns PTS Intermediate Holdings LLC (the "PTS Intermediate"), PTS Intermediate directly and wholly owns Catalent Pharma Solutions, Inc. (the "Operating Company"). The financial results of Catalent are primarily comprised of the financial results of Operating Company and its subsidiaries on a consolidated basis. The Company's common stock, par value \$0.01 (the "Common Stock") trades on the New York Stock Exchange under the symbol "CTLT". The Company provides differentiated development and manufacturing solutions for drugs, protein-based biologics, cell, and gene therapies, vaccines, and consumer health products at over fifty facilities across four continents under rigorous quality and operational standards. Its oral, injectable, and respiratory delivery technologies, along with its state-of-the-art protein, plasmid, viral, and cell and gene therapy manufacturing capacity address a wide and growing range of modalities and therapeutic and other categories across the biopharmaceutical, pharmaceutical, and consumer health industries. Reportable Segments Effective July 1, 2022, in connection with the appointment of a new President and Chief Executive Officer, the Company changed its operating structure and reorganized its executive leadership team accordingly. The current organizational structure includes two operating and reportable segments: (i) Biologics and (ii) Pharma and Consumer Health, which are summarized below. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA (the "pDNA"); induced pluripotent stem cells (the "iPSCs"), and oncolytic viruses; and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, pre-filled syringes, and cartridges; analytical development and testing services for large molecules. The Pharma and Consumer Health segment comprises the Company's market-leading capabilities for complex oral solids, softgel formulations, Zydus® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services. Each segment reports through a separate management team and ultimately reports to the Company's President and Chief Executive Officer, who is designated as the Chief Operating Decision Maker (the "CODM") for segment reporting purposes. The Company's operating segments are the same as its reportable segments. All prior-period comparative segment information has been recast retrospectively to reflect the current reportable segments in accordance with Accounting Standards Codification (the "ASC") 280, Segment Reporting, promulgated by the Financial Accounting Standards Board (the "FASB"). Basis of Presentation These financial statements include all of the Company's subsidiaries, including those operating outside the United States (the "U.S."), and are prepared in accordance with U.S. generally accepted accounting principles (the "U.S. GAAP"). All significant transactions among the Company's subsidiaries and reporting segments have been eliminated, other than as noted. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company's management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, revenue recognition, including determining the transaction price and any associated constraint on variable consideration, allowance for credit losses, inventory and long-lived asset valuation, goodwill and other intangible asset valuation and impairment, equity-based compensation, income taxes, derivative valuation, and pension plan asset and liability valuation. Actual amounts may differ from these estimated amounts. 83 Reclassification Certain prior-period amounts were reclassified to conform to the current period presentation. Specifically, certain line items in prior periods were combined within the operating activities section of the statement of cash flows to conform with current year presentation. These reclassifications did not have a material impact on the consolidated statements of cash flows. Foreign Currency Translation The financial statements of the Company's operations outside the U.S. are generally determined using the local currency as the functional currency. Adjustments to translate the assets and liabilities of the foreign operations into U.S. dollars are accumulated as a component of other comprehensive income utilizing period-end exchange rates. Since July 2018, the Company has accounted for its Argentine operations as highly inflationary, but this status has not had a material effect on the consolidated financial statements. The currency fluctuation related to certain long-term inter-company loans where settlement is not planned or anticipated in the foreseeable future have been recorded within the cumulative translation adjustment, a component of other comprehensive income. In addition, the currency fluctuation associated with the portion of the Company's euro-denominated debt designated as a net investment hedge is included as a component of other comprehensive income. Foreign currency transaction gains and losses are calculated using weighted average exchange rates for the period and are included in the consolidated statements of operations in other expense, net. Such foreign currency transaction gains and losses include inter-company loans that are repayable in the foreseeable future. Cash and Cash Equivalents All liquid investments purchased with original maturities of three months or less are considered cash equivalents. The carrying value of these cash equivalents approximates fair value. Allowance for Credit Losses Trade receivables, contract assets, and other amounts owed to the Company are presented net of an allowance that includes an assessment of expected credit losses. The Company determines its allowance methodology by considering various factors, including the Company's previous loss history, aging of customer receivable balances, significant aspects of a geographic location's economic conditions, the current and anticipated future condition of the general economy and the industries in which the Company's primary customers operate. To the extent that the Company identifies that any individual customer's credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of that customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, trade receivables and contract assets are written off against the allowance when the related balances are no longer deemed collectible. Concentrations of Credit Risk and Major Customers Concentration of credit risk, with respect to accounts receivable, is limited due to the large number of customers and their dispersion across different geographic areas. The customers are primarily concentrated in the biopharmaceutical, pharmaceutical, and consumer products industries. The Company does not normally require collateral or any other security to support credit sales. The Company performs ongoing credit evaluations of its customers' financial conditions and maintains reserves for credit losses. Such losses historically have been within the Company's expectations. For the fiscal years ended June 30, 2024, 2023, and 2022 the Company had one customer that accounted for 16%, 10% and 10%, respectively, of its net revenue, which was primarily recorded in the Biologics segment. As of June 30, 2024 and 2023, the Company had one customer that accounted for 34% and 20%, respectively, of its aggregate net trade receivables and contract asset values, primarily associated with the Biologics segment. After performing a risk assessment of this customer, the Company has determined that a reserve is not warranted as of June 30, 2024. Inventories Inventory is stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company provides for cost adjustments for excess, obsolete, or slow-moving inventory based on changes in customer demand, technology developments or other economic factors. Inventory consists of costs associated with raw material, labor, and overhead. Goodwill The Company accounts for purchased goodwill and intangible assets with indefinite lives in accordance with ASC 350, Intangibles - Goodwill and Other. Under ASC 350, goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment at least annually. The Company performs an impairment evaluation of goodwill annually, on April 1, or when circumstances otherwise indicate an evaluation should be performed. The evaluation may begin with a qualitative assessment for each reporting unit to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. Factors considered in a qualitative assessment include, among other things, macroeconomic conditions, industry and market considerations, financial performance of the respective reporting unit, and other relevant entity and reporting-unit specific considerations. If the qualitative assessment does not generate a positive response, or if no qualitative assessment is performed, a quantitative assessment is performed and requires management to estimate future cash flows, growth rates, and macroeconomic, industry, and market conditions. For more information regarding goodwill activity during fiscal 2022, 2023, and 2024, see Note 4, Goodwill. Property and Equipment and Other Definite-Lived Intangible Assets Property and equipment are stated at cost. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including leasehold improvements and finance lease right-of-use assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following range of useful lives for its property and equipment categories: buildings and improvements 5 to 50 years; machinery and equipment 3 to 10 years; and furniture and fixtures 3 to 7 years. Depreciation expense was \$354 million, \$286 million, and \$255 million for fiscal 2024, 2023, and 2022, respectively. Depreciation expense includes amortization of assets related to financing leases. The Company charges repairs and maintenance costs to expense as incurred. The amount of capitalized interest for fiscal 2024, 2023, and 2022 was \$10 million, \$24 million, and \$15 million, respectively. Intangible assets with finite lives, including customer relationships, core technology, patents, and trademarks, are amortized over their useful lives. The Company also capitalizes certain computer software and development costs in other intangibles, net, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 5 years. The Company evaluates the recoverability of its other long-lived assets, including amortizing intangible assets, if circumstances indicate impairment may have occurred pursuant to ASC 360, Property, Plant and Equipment. This analysis is performed by comparing the respective carrying values of the assets to the current and expected future cash flows, on an undiscounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, the carrying value of such assets is reduced to fair value through a charge to the consolidated statements of operations. Fair value is determined based on assumptions the Company believes marketplace participants would utilize and comparable marketplace information in similar length transactions. In conjunction with the goodwill impairment tests performed as of March 31, 2023 and September 30, 2023, the Company identified indicators of impairment related to its definite-lived intangibles. The results of the analysis did not result in an impairment charge. The Company recorded impairment charges related to definite-lived intangible assets and property, plant, and equipment of \$29 million, \$98 million, and \$31 million for the fiscal years ended June 30, 2024, 2023, and 2022, respectively. Post-Retirement and Pension Plans The Company sponsors various retirement and pension plans, including defined benefit and defined contribution retirement plans. The measurement of the related benefit obligations and the net periodic benefit costs recorded each year are based upon actuarial computations, which require management's judgment as to certain assumptions. These assumptions include the discount rates used in computing the present value of the benefit obligations and the net periodic benefit costs, the expected future rate of salary increases (for pay-related plans) and the expected long-term rate of return on plan assets (for funded plans). The Company uses the corridor approach to amortize actuarial gains and losses. The Company has elected to utilize an approach to estimate the service and interest components of net periodic benefit cost for benefit plans that discounts the individual expected cash flows using the applicable spot rates derived from the yield curve over the projected cash flow period. The expected long-term rate of return on plan assets is based on the target asset allocation and the average expected rate of growth for the asset classes invested. The average expected rate of growth is derived from a combination of historic returns, current market indicators, and the expected risk premium for each asset class. The Company uses a measurement date of June 30 for all its retirement and postretirement benefit plans. 85 Derivative Instruments, Hedging Activities, and Fair Value Derivative Instruments and Hedging Activities The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest-rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its debt funding and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments from time to time to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the values of which are determined by interest rates. The Company's derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company's known or expected cash receipts and its known or expected cash payments principally related to the Company's borrowings. The Company does not net any of its derivative positions under master netting arrangements. Primarily, the Company is exposed to fluctuations in the euro-U.S. dollar exchange rate on its investments in foreign operations in Europe. While the Company does not actively hedge against changes in foreign currency, it has mitigated the exposure of investments in its European operations through a net-investment hedge by denominating a portion of its debt in euros. In addition, a portion of Operating Company's interest payment obligation on its U.S. dollar-denominated term loans is exposed to interest rate variability. The Company has mitigated its exposure to this risk by entering into interest-rate swap agreements, which qualify for and are designated as cash-flow hedges. Fair Value The Company is required to measure certain assets and liabilities at fair value, either upon initial measurement or for subsequent accounting or reporting. The Company uses fair value extensively, including in the initial measurement of net assets acquired in a business combination and when accounting for and reporting on certain financial instruments. The Company estimates fair value using an exit price approach, which requires, among other things, that it determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of assets and, for liabilities, assuming the risk of non-performance will be the same before and after the transfer. A single estimate of fair value results from a complex series of judgments about future events and uncertainties and relies heavily on estimates and assumptions. When estimating fair value, depending on the nature and complexity of the assets or liability, the Company may use one or all of the following approaches: Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities. Cost approach, which is based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence. Income approach, which is based on the present value of the future stream of net cash flows. Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. Self-Insurance The Company is partially self-insured for certain employee health benefits and partially self-insured for property losses and casualty claims. The Company accrues for losses based upon experience and actuarial assumptions, including provisions for losses incurred but not reported. Accumulated Other Comprehensive Loss Accumulated other comprehensive loss, which is reported in the accompanying consolidated statements of changes in shareholders' equity, consists of foreign currency translation, net change in marketable securities, and defined benefit pension plan changes. Research and Development Costs The Company expenses research and development costs as incurred. Research and development costs amounted to \$17 million, \$18 million, and \$23 million for the fiscal years ended June 30, 2024, 2023, and 2022, respectively. 86 Earnings Per Share The Company reports net earnings per share in accordance with ASC 260, Earnings per Share. Effective as of the first quarter of fiscal 2023, the Company computed earnings per share (the "EPS") of the Company's common stock, par value \$0.01 (the "Common Stock") using the treasury stock method. Prior to fiscal 2023, the Company computed earnings (loss) per share of the Common Stock using the two-class method required due to the participating nature of the previously outstanding Series A Preferred Stock (as defined and discussed in Note 13, Equity and Accumulated Other Comprehensive Loss). Diluted earnings per common share measures the performance of the Company over the reporting period while giving effect to all potential shares of Common Stock that were dilutive and outstanding during the period. The denominator includes the weighted average over the measurement period of the sum of the number of shares of Common Stock outstanding and the number of additional such shares that would have been outstanding if the shares of Common Stock that were both potentially issuable and dilutive had been issued. Income Taxes In accordance with ASC 740, Income Taxes, the Company accounts for income taxes using the asset and liability method. The asset and liability method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities. The Company measures deferred tax assets and liabilities using enacted tax rates in the respective jurisdictions in which it operates. In assessing the ability to realize deferred tax assets, the Company considers whether it is more likely than not that the Company will be able to realize some or all of the deferred tax

assets. The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax regulations in each of its tax jurisdictions. The number of years with open tax audits varies by tax jurisdiction. A number of years may lapse before a particular matter is audited and finally resolved. The Company applies ASC 740 to determine the accounting for uncertain tax positions. This standard prescribes a minimum recognition threshold a tax position is required to meet before the Company may recognize the position in its financial statements. The standard also provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, and disclosure. The Company previously elected not to reclassify the income tax effects stranded in accumulated other comprehensive income to retained earnings. Stock-Based Compensation The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. Under ASC 718, companies recognize compensation expense using a fair-value-based method for costs related to share-based payments, including stock options and restricted stock units. The expense is measured based on the grant date fair value of the awards, and the expense is recorded over the applicable requisite service period. Forfeitures are recognized as and when they occur. In the absence of an observable market price for a share-based award, the fair value is based upon a valuation methodology that takes into consideration various factors, including the exercise price of the award, the expected term of the award, the current price of the underlying shares, the expected volatility of the underlying share price, the expected dividends on the underlying shares and the risk-free interest rate. The terms of the Company's stock-based compensation plans permit an employee holding vested stock options or restricted stock units to elect to have the Company use a portion of the shares otherwise issuable upon the employee's exercise of the option or grant, a so-called "net settlement transaction," as a means of paying the exercise price, meeting tax withholding requirements, or both. New Accounting Standards Not Adopted as of June 30, 2024 In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, Improvements to Reportable Segment Disclosures, which intends to improve disclosures regarding significant segment expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which focuses on income tax disclosures by requiring public business entities, on an annual basis, to disclose specific categories in the rate reconciliation, provide information for reconciling items that meet a quantitative threshold, and certain information about income taxes paid. The standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements. 872. A REVENUE RECOGNITION The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. The Company generally earns its revenue by supplying goods or providing services under contracts with its customers in three primary revenue streams: manufacturing and commercial product supply, development services, and clinical supply services. The Company measures the revenue from customers based on the consideration specified in its contracts, excluding any sales incentive or amount collected on behalf of a third party, that the Company expects to be entitled to receive in exchange for transferring the promised goods to and/or performing services for the customer (the "Transaction Price"). To the extent the Transaction Price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the Transaction Price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the Transaction Price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment. The Company's customer contracts generally include provisions entitling the Company to a termination penalty when the customer terminates prior to the contract's nominal end date. The termination penalties in customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated durations of the contracts. The Company accounts for a contract termination as a contract modification in the period in which the customer gives notice of termination. The determination of the contract termination penalty is based on the terms stated in the relevant customer agreement. As of the modification date, the Company updates its estimate of the Transaction Price using the expected value method, subject to constraints, and to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment. Where multiple performance obligations exist in a single contract, the Company allocates consideration to each performance obligation using the "relative standalone selling price" as defined under ASC 606. Generally, the Company utilizes observable standalone selling prices in its allocations of consideration. If observable standalone selling prices are not available, the Company estimates the applicable standalone selling price using a cost-plus-margin approach or an adjusted market assessment approach, in each case, representing the amount that the Company believes the market is willing to pay for the applicable service. Payment is typically due 30 to 45 days following the invoice date, based on the payment terms set forth in the applicable customer agreement. The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material. Customer contracts that include commitments by the Company to make facility space or equipment available may be deemed to include lease components, which are evaluated under ASC 842, Leases. For arrangements that contain both lease and non-lease components, consideration in the contract is allocated on a relative standalone selling-price basis. Determining the lease term and contract term of non-lease components, as well as the variable and fixed consideration in these arrangements, including when variability is resolved, often requires management judgment in order to determine the allocation to the lease and non-lease components. Manufacturing & Commercial Product Supply Revenue Manufacturing and commercial product supply revenue consists of revenue earned by manufacturing products supplied to customers under long-term commercial supply arrangements. In these arrangements, the customer typically owns and supplies the active pharmaceutical ingredient ("API") or other proprietary materials used in the manufacturing process. The contract generally includes the terms of the manufacturing services and related product quality assurance procedures to comply with regulatory requirements. Due to the regulated nature of the Company's business, these contract terms are highly interdependent and, therefore, are considered to be a single combined performance obligation. The transaction price is generally stated in the agreement as a fixed price per unit, with no contractual provision for a refund or price concession. In most circumstances, control is transferred to the customer over time, creating a corresponding right to recognize the related revenue, because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date. The selection of the method for measuring progress towards the completion of the Company's performance obligation requires judgment and is based on the nature of the products to be manufactured. For the majority of the Company's arrangements, progress is measured based on the units of product that have successfully completed the contractually required product quality assurance process, because the conclusion of that process defines the time when the applicable contract and the related regulatory requirements permit the customer to exercise control over the product's disposition. The customer is typically responsible for arranging the shipping and handling of product following completion of the quality assurance process. Payment is typically due 30 to 45 days after invoice date, based on the payment terms set forth in the applicable customer agreement. Beginning in the third quarter of fiscal 2023, the Company began recognizing commercial revenue for certain contracts in its Biologics segment that have a notably long manufacturing cycle, and for which the customer exercises control over the product throughout the manufacturing process. For these contracts, revenue is recognized over time and progress is measured using an input method based on effort expended, which provides an appropriate depiction of the Company's progress toward fulfilling its performance obligation. Development Services and Clinical Supply Revenue Development services contracts generally take the form of short-term, fee-for-service arrangements. Performance obligations vary, but frequently include biologic cell-line development, performing formulation, analytical stability, or other services related to product development, and providing manufacturing services for products that are under development or otherwise not intended for commercial sale. They can also include a combination of the following services: the manufacturing, packaging, storage, distribution, destruction, and inventory management of customer clinical trial material, as well as the sourcing of comparator drug products on behalf of customers to be used in clinical trials to compare performance with the drug under clinical investigation. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service, and each service is generally considered to be a separate performance obligation. In most instances, the Company recognizes revenue over time because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date. The Company measures progress toward the completion of its performance obligations satisfied over time based on the nature of the services to be performed. For certain types of arrangements, revenue is recognized over time and measured using an output method based on the completion of tasks and activities that are performed to satisfy a performance obligation. For certain types of arrangements, revenue is recognized over time and measured using an input method based on effort expended. Each of these methods provides an appropriate depiction of the Company's progress toward fulfilling its performance obligations for its respective arrangement. In certain arrangements that require a portion of the contract consideration to be received in advance at the commencement of the contract, such advance payment is initially recorded as a contract liability. In certain clinical supply arrangements, revenue is recognized at the point in time when control transfers, which occurs upon either the delivery of the related output of the service to the customer or the completion of quality testing with respect to the product, and the Company has an enforceable right to payment based on the terms of the arrangement. The Company records revenue for comparator sourcing arrangements on a net basis because it is acting as an agent that does not control the product or service before it is transferred to the customer. Payment for comparator sourcing activity is typically received in advance at the commencement of the contract and is initially recorded as a contract liability. The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material. 89 The following tables reflect net revenue for the fiscal years ended June 30, 2024, 2023, and 2022 by type of activity and reporting segment (in millions): Fiscal Year Ended June 30, 2024 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply \$1,151A \$1,577A \$2,728A Development services & clinical supply \$801A \$854A 1,655A Total \$1,952A \$2,431A \$4,383A Inter-segment revenue elimination (2) Combined net revenue \$4A \$4,381A Fiscal Year Ended June 30, 2023 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply \$450A \$1,452A 1,902A Development services & clinical supply \$1,528A \$835A 2,363A Total \$1,978A \$2,287A \$4,265A Inter-segment revenue elimination (2) Combined net revenue \$4,263A Fiscal Year Ended June 30, 2022 Biologics Pharma and Consumer Health Total Manufacturing & commercial product supply \$608A \$1,474A \$2,082A Development services & clinical supply \$1,926A \$797A 2,723A Total \$2,534A \$2,271A \$4,805A Inter-segment revenue elimination (3) Combined net revenue \$4,802A The following table reflects net revenue by the location where the goods were made or the service performed: (Dollars in millions) Fiscal Year Ended June 30, 2024 Fiscal Year Ended June 30, 2023 Fiscal Year Ended June 30, 2022 United States \$2,823A \$2,768A \$3,084A Europe 1,359A 1,257A 1,506A Other 356A 355A 327A Elimination of revenue attributable to multiple locations (157) (117) (115) Total \$4,381A \$4,263A \$4,802A Contract Liabilities Contract liabilities relate to cash consideration that the Company receives in advance of satisfying the related performance obligations. The contract liabilities balances (current and non-current) as of June 30, 2024 and June 30, 2023 were as follows: (Dollars in millions) Balance at June 30, 2023 \$180A Balance at June 30, 2024 \$255A Revenue recognized in the period from amounts included in contracts liability at the beginning of the period: \$(145) Contract liabilities that will be recognized within 12 months of June 30, 2024 are accounted for in Other accrued liabilities and those that will be recognized longer than 12 months after June 30, 2024 are accounted for within Other liabilities. 90 Contract Assets Contract assets primarily relate to the Company's conditional right to receive consideration for services that have been performed for customers but had not yet been invoiced as of June 30, 2024. Contract assets are transferred to trade receivables, net when the Company's right to receive the consideration becomes unconditional. Contract assets totaled \$602A million and \$417A million as of June 30, 2024 and 2023, respectively. Contract assets expected to transfer to trade receivables within 12 months are accounted for within Prepaid expenses and other. Contract assets expected to transfer to trade receivables after 12 months are accounted for within Other long-term assets. Performance Obligations Remaining performance obligations represent firm orders for future development services as well as manufacturing and commercial product supply, including minimum volume commitments, for which there are incomplete performance obligations for work not yet completed under executed contracts. Remaining performance obligations as of June 30, 2024 and June 30, 2023 were \$618A million and \$335 million, respectively. The Company expects to recognize approximately 50% of the remaining performance obligations in existence as of June 30, 2024 after June 30, 2025. 3. BUSINESS COMBINATIONS AND DIVESTITURES RheinCell Therapeutics GmbH Acquisition In August 2021, the Company acquired 100% of the equity interest in RheinCell Therapeutics GmbH ("RheinCell") for \$26A million, net of cash acquired. RheinCell was a developer and manufacturer of clinical- and cGMP-grade iPSCs based in Lagenfeld, Germany. The operations became part of the Company's Biologics segment and built on its existing custom cell therapy process development and manufacturing capabilities with proprietary cGMP cell lines for iPSC-based therapies. The Company accounted for the RheinCell transaction using the acquisition method in accordance with ASC 805, Business Combinations. The Company funded the entire purchase price with cash on hand and allocated the purchase price among the assets acquired, recognizing \$4A million of current liabilities, \$1A million of other liabilities, \$14A million of intangible assets, and goodwill of \$17A million. Results of this business were not material to the Company's statement of operations, financial position, or cash flows for the fiscal years ended June 30, 2023 and 2022. Bettera Holdings, LLC Acquisition In October 2021, the Company acquired 100% of the equity interest in Bettera Holdings, LLC ("Bettera Wellness") for \$1.00A billion cash. Bettera Wellness was a manufacturer of nutraceuticals and nutritional supplements in gummy, soft chew, and lozenge delivery formats and became part of the Company's Pharma and Consumer Health segment. The Company accounted for the Bettera Wellness transaction using the acquisition method in accordance with ASC 805, Business Combinations. The Company estimated fair values at the date of acquisition for the allocation of consideration to the net tangible and intangible assets acquired and liabilities assumed and allocated the purchase price among the assets acquired, recognizing \$361 million of other intangibles, net, \$72 million of property, plant, and equipment, \$31 million of inventories, \$23 million of cash and cash equivalents, \$16 million of trade receivables, \$17 million of net other liabilities, and goodwill of \$531 million. Results of this business were not material to the Company's statement of operations, financial position, or cash flows for the fiscal years ended June 30, 2023 and 2022. The carrying value of trade receivables, inventory, and trade payables, as well as certain other current and non-current assets and liabilities, generally represented the fair value at the date of acquisition. Property, plant, and equipment assets were valued using the cost approach, which is based on current replacement and/or reproduction cost of the related asset as new, less depreciation attributable to physical, functional, and economic factors. The Company then determined the remaining useful life based on the anticipated life of the asset and Company policy for similar assets. Core technology intangible assets of \$338 million were valued using the multi-period, excess-earnings method, a method that values the intangible asset using the present value of the after-tax cash flows attributable to the intangible asset only. The significant assumptions used in developing the valuation included the estimated annual net cash flows (including application of an appropriate margin to forecasted revenue, revenue obsolescence rate, selling and marketing costs, return on working capital, contributory asset charges, and other factors), the discount rate that appropriately reflects the risk inherent in each future cash flow stream, and an assessment of the asset's life cycle, as well as other factors. The assumptions used in the financial forecasts 91 were based on historical data, supplemented by current and anticipated growth rates, management plans, and market-comparable information. Fair-value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors. The core technology intangible asset has a weighted average useful life of 10 years. Goodwill has been allocated to the Pharma and Consumer Health segment as shown in Note 4, Goodwill. Goodwill is mainly comprised of growth from expected increases in capacity utilization and new customers. The goodwill resulting from the Bettera Wellness acquisition is deductible for tax purposes. Vaccine Manufacturing and Innovation Centre UK Limited Asset Acquisition In April 2022, the Company, through its wholly owned subsidiary, Catalent Oxford Limited, acquired a development and manufacturing facility near Oxford, United Kingdom ("U.K.â€") and certain related assets and liabilities from The Vaccine Manufacturing and Innovation Centre UK Limited for \$134 million in cash, including \$9 million of closing costs. The facility and related assets and liabilities became part of the Company's Biologics segment. The Company accounted for this transaction as an acquisition of assets in accordance with ASC 805, Business Combinations. The Company funded this acquisition with cash on hand and allocated the purchase price among the net assets acquired, recognizing \$1A million of current assets, \$165A million of property, plant, and equipment, \$18A million of current liabilities, and

\$1A million of other liabilities. Results of this sale were not material to the Company's statement of operations, financial position, or cash flows for the fiscal years ended June 30, 2023 and 2022.

Princeton Cell Therapy Development and Manufacturing Acquisition In April 2022, the Company acquired a cell therapy commercial manufacturing facility and operations near Princeton, New Jersey (the "Princeton Facility") from Erytech Pharma S.A. (the "Erytech Sale") for \$45 million in cash, subject to customary adjustments. In connection with the purchase, Erytech and the Company entered into a long-term supply agreement, under which the Company agreed to continue to manufacture and package an Erytech product at the Princeton facility. The operations and facility acquired became part of the Company's Biologics segment. The Company accounted for this transaction using the acquisition method in accordance with ASC 805, Business Combinations. The Company funded this acquisition with cash on hand and allocated the purchase price among the assets acquired, recognizing \$22.4 million of property, plant, and equipment, \$10.6 million of other assets, \$1.1 million of current liabilities, \$10.6 million of other liabilities, and goodwill of \$24.4 million. Results of this business were not material to the Company's statement of operations, financial position, or cash flows for the fiscal years ended June 30, 2023 and 2022.

Metrics Contract Services Acquisition On October 2022, the Company acquired 100% of Metrics Contract Services (the "Metrics Acquisition") from Mayne Pharma Group Limited for \$474 million in cash. Metrics, based in Greenville, North Carolina, was an oral solids development and manufacturing business specializing in the manufacture of drugs containing highly potent active pharmaceutical ingredients. The operations and facility acquired became part of the Company's Pharma and Consumer Health segment. The Company accounted for the Metrics transaction using the acquisition method in accordance with ASC 805, Business Combinations. The Company funded this acquisition with a portion of the proceeds of an October 2022 drawdown from its senior secured revolving credit facility. The Company estimated fair values at the date of acquisition for the allocation of consideration to the net tangible and intangible assets acquired and liabilities assumed. The purchase price was allocated to assets acquired and liabilities assumed in the acquisition as follows:

(Dollars in millions)	
Purchase Price Allocation	
Trade receivables, net	\$15.1
Inventories	\$5.4
Property, plant, and equipment	\$19.5
Other intangibles, net	\$52.4
Total assets acquired and liabilities assumed	\$47.4

The carrying value of trade receivables, inventory, and trade payables, as well as certain other current and non-current assets and liabilities generally represented the fair value at the date of acquisition. Other intangibles, net consists of customer relationships of \$52 million, which were valued using the multi-period, excess-earnings method, a method that values the intangible asset using the present value of the after-tax cash flows attributable to the intangible asset only. The significant assumptions used in developing the valuation included the estimated annual net cash flows (including application of an appropriate margin to forecasted revenue, selling and marketing costs, return on working capital, contributory asset charges, and other factors), the discount rate that appropriately reflects the risk inherent in each future cash flow stream, and an assessment of the asset's life cycle, as well as other factors. The assumptions used in the financial forecasts were based on historical data, supplemented by current and anticipated growth rates, management plans, and market-comparable information. Fair-value determinations require judgment and are sensitive to changes in underlying assumptions and factors. The customer relationship intangible asset has a weighted average useful life of 12 years. Property, plant, and equipment was valued using the cost approach, which is based on current replacement and/or reproduction cost of the asset as new, less depreciation attributable to physical, functional, and economic factors. The Company then determined the remaining useful life based on the anticipated life of the asset and Company policy for similar assets. Goodwill has been allocated to the Pharma and Consumer Health segment as shown in Note 4, Goodwill. Goodwill is mainly comprised of the growth from an expected increase in capacity utilization and potential new customers. The goodwill resulting from the Metrics acquisition is not deductible for U.S. income tax purposes. Results of the business acquired were not material to the Company's consolidated statement of operations, financial position, or cash flows for the fiscal year ended June 30, 2023.

Blow-Fill-Seal Divestiture In March 2021, the Company sold 100% of the shares of Catalent USA Woodstock, Inc. and certain related assets (collectively, the "Blow-Fill-Seal Business") for \$331 million in total consideration (\$300 million in cash). The Blow-Fill-Seal Business was part of the Pharma and Consumer Health segment. The carrying value of the net assets sold was \$149.4 million, which included goodwill of \$54.4 million. As a result of the sale, the Company realized a gain from divestiture of \$182.4 million, net of transaction costs, for the fiscal year ended June 30, 2021. During the fiscal year ended June 30, 2022, the Company settled a post-closing purchase price adjustment, which resulted in a gain on sale of subsidiary of \$1 million. All consideration received was measured at its divestiture date fair value. The Company valued the total consideration received from divestiture of the Blow-Fill-Seal Business as follows:

(Dollars in millions)				
Fair value of consideration received	Cash, gross	\$300.1		
Note receivable	(1.7)			
Contingent consideration	(2.4)			
Other	(3.1)			
Totals	\$331.1			
Less:				
The note receivable, which provides for interest at a rate of 5.0% paid in kind, had an estimated fair value of \$47.4 million and \$51 million at June 30, 2021 and June 30, 2022, respectively. The fair value at divestiture date consisted of a \$50.4 million aggregate principal amount less a \$3.4 million discount determined using a discounted cash flow model.	(47.4)			
The Company determined that the estimated fair value of the contingent consideration from the sale of the Blow-Fill-Seal Business at June 30, 2022 was zero, and therefore no contingent consideration was recorded at divestiture. If any contingent consideration is subsequently received, it will be recorded in the period in which it is received. The Company has elected an accounting policy to recognize increases in the carrying amount of the contingent consideration asset using the gain contingency guidance in ASC 450, Contingencies.	(3.1)			
A Other includes \$8.4 million of transaction expenses, a working capital adjustment of \$6.4 million, and a \$2.4 million assumption of liabilities, resulting in net cash proceeds of \$284.4 million.	(4.9)			
GOODWILL The following table summarizes the changes from June 30, 2022 to June 30, 2024 in the carrying amount of goodwill in total and by reportable segment:				
(Dollars in millions)	Biologics	Pharma	Consumer Health	Total
Balance at June 30, 2022	\$1,566.1	\$1,440.4	\$3,006.1	Additions
Reclassification	(1.1)	(15.1)	Reallocation	(1.1)
Impairment	(2.3)	(295.1)	(687.1)	Balance at June 30, 2024
\$1,163.1	\$1,170.1	\$2,333.1	(1) The addition to goodwill is a result of the Metrics acquisition. For further details, see Note 3, Business Combinations and Divestitures.	
(2) Accumulated goodwill impairment charges amount to \$897 million as of June 30, 2024. As part of the business reorganization discussed in Note 1, Basis of Presentation and Summary of Significant Accounting Policies, the goodwill from the previous Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services segments was reallocated between the current Biologics and Pharma and Consumer Health segments. Goodwill Impairment Charges The Company performs an annual goodwill impairment test for each reporting unit on April 1, the measurement date and more frequently if indicators for potential impairment exist. Fiscal Year 2024 During the three months ended September 30, 2023, as a result of the Consumer Health reporting unit's underperformance of recent operating results relative to expectations, the current macroeconomic conditions impacting the consumer health and biotechnology industries, and increased interest rates, the Company assessed the current and future economic outlook for its reporting units in its Pharma and Consumer Health and Biologics segments and identified indicators for impairment of the goodwill previously recorded for two of its reporting units. The evaluation began with a qualitative assessment of the Company's Consumer Health and Biomodalities reporting units to determine if it was more likely than not that the fair value of the reporting units was less than its carrying value. The qualitative assessment did not indicate that it was more likely than not that the fair value exceeded the carrying value in its Consumer Health and Biomodalities reporting units, which led to a quantitative assessment for the corresponding reporting units. The Company estimated the fair value of its reporting units using a combination of the income and market approaches. In performing the goodwill impairment test, the Company used a terminal revenue growth rate of 3.5% and discount rates ranging from 9% to 10% in its estimation of fair value. The evaluation performed resulted in impairment charges of \$687 million with respect to the Consumer Health and Biomodalities reporting units. While the Company believes the assumptions it used were reasonable and commensurate with the views of a market participant, changes in key assumptions, including increasing the discount rate, lowering forecasts for revenue and operating margin or lowering the long-term growth rate could lead to further impairment. Based on its quantitative assessment conducted as of April 1, 2024, the Company determined for each reporting unit with goodwill that its respective fair value exceeded its carrying value, and hence, there was no impairment. Subsequent to the quantitative assessment performed as of April 1, 2024, the Company performed qualitative assessments as of June 30, 2024, which yielded no indicators of impairment. The Company assessed the current and future economic outlook for its reporting units, the Company's stock price as well as current macroeconomic conditions impacting the consumer health and biotech industries and current interest rates. Fiscal Year 2023 The Company assessed the current and future economic outlook as of March 31, 2023 for its reporting units in its Pharma and Consumer Health and Biologics segments and identified an indicator for impairment of the goodwill previously recorded for one of the reporting units in its Pharma and Consumer Health segment. The evaluation began with a qualitative assessment of each reporting unit to determine if it was more likely than not that the fair value of the reporting unit was less than its carrying value. The qualitative assessment did not indicate that it was more likely than not that the fair value exceeded the carrying value in its Consumer Health reporting unit, which led to a quantitative assessment for each of the Company's reporting units. The Company estimated the fair value of its reporting units using a combination of the income and market approaches. In performing the goodwill impairment test, the Company used a terminal revenue growth rate of 3.0% and discount rates ranging from 9% to 10.50% in its estimation of fair value. The evaluation performed resulted in an impairment charge of \$210 million with respect to the Consumer Health reporting unit. Subsequent to the quantitative assessment performed as of March 31, 2023, the Company performed qualitative assessments as of April 1, 2023, which yielded no indicators of impairment.				

OTHER INTANGIBLES, NET The details of other intangible assets subject to amortization as of June 30, 2024 and June 30, 2023 are as follows (in millions):

June 30, 2024	Weighted Average Life	Gross Carrying Value	Accumulated Amortization	Net Carrying Value	Amortized Intangibles: Core technology	
\$11.1	years	\$48.0	\$(2.5)	\$25.5	Customer relationships	
13 years	1,076.1	(531.1)	545.1	Product relationships		
8 years	242.1	(19.1)	19.1	Other		
6 years	20.1	(18.1)	18.1	Total other intangibles		
\$1.8	\$(97.1)	\$84.1	\$7.1	June 30, 2023		
Weighted Average Life	Gross Carrying Value	Accumulated Amortization	Net Carrying Value	Amortized intangibles: Core technology		
11 years	\$48.2	\$(2.5)	\$25.5	Customer relationships		
13 years	1,079.1	(451.1)	628.1	Product relationships		
8 years	243.1	(216.1)	27.1	Other		
5 years	24.1	(17.1)	7.1	Total other intangibles		
\$1.8	\$(84.1)	\$98.0	Amortization expense was \$135 million, \$136 million, and \$123 million for the fiscal years ended June 30, 2024, 2023, and 2022, respectively. Future amortization expense is estimated to be:			
(Dollars in millions)	2025	2026	2027	2028	2029 Thereafter	
Total	Amortization	\$133.1	\$125.1	\$109.1	\$102.1	\$98.1
\$274.1	\$84.1	6.1	RESTRUCTURING COSTS From time to time, the Company implements plans to restructure certain operations, both domestically and internationally. The restructuring plans focus on various aspects of operations, including, among others, closing and consolidating certain manufacturing operations, rationalizing headcount and aligning operations in a strategic and more cost-efficient structure. In addition, the Company may incur restructuring charges in the future in cases where a material change in the scope of operation with its business occurs. Employee-related restructuring costs consist primarily of severance costs and also include outplacement services provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods. Facility exit and other such restructuring costs consist of equipment relocation costs and costs associated with planned facility expansions and closures to streamline Company operations. During the fiscal year ended June 30, 2023, the Company adopted plans to reduce costs, consolidate facilities, and optimize its infrastructure across the organization. During the fiscal year ended June 30, 2024, the Company extended its restructuring efforts to reduce costs and headcount in its Biologics and Pharma and Consumer Health segments and corporate functions. In			

B-4 Loans, after payment of fees and expenses, were used to repay the existing Revolving Credit Facility under the Credit Agreement, plus accrued and unpaid interest thereon. The Revolving Credit Facility requires compliance with a net leverage covenant when there is a 30% or more draw outstanding at a period end. As of June 30, 2024, the Company was in compliance with all material covenants under the Credit Agreement. In addition to outstanding borrowings under the Revolving Credit facility, the available capacity under the Revolving Credit Facility is further reduced by the aggregate value of all outstanding letters of credit under the Credit Agreement. As of June 30, 2024, Operating Company had \$1.10 billion of unutilized capacity under the Revolving Credit Facility due to \$4 million of outstanding letters of credit. 5.000% Senior Notes due 2027 In June 2019, Operating Company completed a private offering of \$500 million aggregate principal amount of the 2027 Notes. The 2027 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The 2027 Notes were offered in the U.S. to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act") and outside the U.S. only to non-U.S. investors pursuant to Regulation S under the Securities Act. The 2027 Notes will mature on July 15, 2027 and bear interest at the rate of 5.000% per annum. Interest is payable semi-annually in arrears on January 15 and July 15 of each year. The proceeds of the 2027 Notes, after payment of the offering fees and expenses, were used to repay in full the borrowings under Operating Company's then-outstanding term loans, which would otherwise have matured in May 2024. 3.375% Euro-denominated Senior Notes due 2028 In March 2020, Operating Company completed a private offering of a ~\$825 million aggregate principal amount of 2.375% Senior Notes due 2028 (the "2028 Notes"). The 2028 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The 2028 Notes were offered in the U.S. to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the U.S. only to non-U.S. investors pursuant to Regulation S under the Securities Act. The 2028 Notes will mature on March 1, 2028 and bear interest at the rate of 2.375% per annum. Interest is payable semi-annually in arrears on March 1 and September 1 of each year, with the first payment on September 1, 2020. The proceeds of the 2028 Notes, after payment of the offering fees and expenses, were used to repay in full the borrowings then outstanding under Operating Company's euro-denominated term loans, which would have matured in May 2024, and repay in full Operating Company's euro-denominated 4.75% Senior Notes due 2024, which would otherwise have matured in December 2024, plus accrued and unpaid interest thereon, with the remainder available for general corporate purposes. 3.125% Senior Notes due 2029 In February 2021, Operating Company completed a private offering of \$550 million aggregate principal amount of 3.125% Senior Notes due 2029 (the "2029 Notes"). The 2029 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The 2029 Notes will mature on February 15, 2029 and bear interest at the rate of 3.125% per annum payable semi-annually in arrears on February 15 and August 15 of each year, with the first payment on August 15, 2021. The proceeds of the 2029 Notes, after payment of the offering fees and expenses, were used to repay in full the outstanding borrowings under Operating Company's 4.875% Senior Notes due 2026 (the "2026 Notes"), which would have otherwise matured in January 2026, plus accrued and unpaid interest thereon, with the remainder available for general corporate purposes. 3.500% Senior Notes due 2030 In September 2021, Operating Company completed a private offering of \$650 million aggregate principal amount of 3.500% Senior Notes due 2030 (the "2030 Notes") and together with the 2027 Notes, the 2028 Notes, and the 2029 Notes, the "Senior Notes"). The 2030 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The 2030 Notes were offered in the U.S. to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the U.S. only to non-U.S. investors pursuant to Regulation S under the Securities Act. The 2030 Notes will mature on April 1, 2030 and bear interest at the rate of 3.500% per annum payable semi-annually in arrears on April 1 and October 1 of each year, with the first payment on April 1, 2022. The proceeds of the 2030 Notes, after payment of the offering fees and expenses, were used to fund a portion of the consideration paid at the closing of the Bettera Wellness acquisition. Deferred Purchase Consideration In connection with the acquisition of Cook Pharmica LLC (now Catalent Indiana, LLC) in October 2017, \$200 million of the \$950 million aggregate nominal purchase price was payable in \$50 million installments, on each of the first four anniversaries of the closing date. The Company made installment payments in October 2018, October 2019, and October 2020, and the final payment was made in October 2021. Long-Term and Other Obligations Other obligations consist primarily of finance leases for buildings and other loans for business and working capital needs. Maturities of long-term obligations, including finance leases of \$332 million, and other short-term borrowings for future fiscal years are: (Dollars in millions) 2025 2026 2027 2028 2029 Thereafter Total Maturities of long-term and other obligations \$48A \$49A \$49A \$3,350A \$569A \$884A \$4,949A Debt Issuance Costs Debt issuance costs associated with the Credit Agreement (other than its Revolving Credit Facility component) and the Senior Notes are presented as a reduction to the carrying value of the related debt, while debt issuance costs associated with the Revolving Credit Facility are capitalized within other long-term assets on the consolidated balance sheets. All debt issuance costs are amortized over the life of the related obligation through charges to interest expense in the consolidated statements of operations. The unamortized total debt issuance costs, including the costs associated with the Revolving Credit Facility capitalized within Other long-term assets, were \$44 million and \$39A million as of JuneA 30, 2024 and 2023, respectively. Amortization of debt issuance costs totaled \$13 million, \$8 million and \$7A million for the fiscal years ended JuneA 30, 2024, 2023, and 2022, respectively. Guarantees and Security Senior Secured Credit Facilities All obligations under the Credit Agreement, and the guarantees of those obligations, are secured by substantially all of the following assets of Operating Company and each guarantor (Operating Company's parent entity, PTS Intermediate, and each of Operating Company's material domestic subsidiaries), subject to certain exceptions: a) a pledge of 100% of the capital stock of Operating Company and 100% of the equity interests directly held by Operating Company and each guarantor in any wholly owned material subsidiary of Operating Company or any guarantor (which pledge, in the case of any non-U.S. subsidiary of a U.S. subsidiary, will not include more than 65% of the voting stock of such non-U.S. subsidiary); and a) a security interest in, and mortgages on, substantially all tangible and intangible assets of Operating Company and of each guarantor, subject to certain limited exceptions. 100 The Senior Notes All obligations under the Senior Notes are general, unsecured, and subordinated to all existing and future secured indebtedness of the guarantors to the extent of the value of the assets securing such indebtedness. Each of the Senior Notes is separately guaranteed by all of Operating Company's wholly owned U.S. subsidiaries that guarantee the senior secured credit facilities. None of the Senior Notes is guaranteed by either PTS Intermediate or the Company. Debt Covenants Senior Secured Credit Facilities The Credit Agreement contains covenants that, among other things, restrict, subject to certain exceptions, Operating Company's (and Operating Company's restricted subsidiaries') ability to incur additional indebtedness or issue certain preferred shares; create liens on assets; engage in mergers and consolidations; sell assets; pay dividends and distributions or repurchase capital stock; repay subordinated indebtedness; engage in certain transactions with affiliates; make investments, loans or advances; make certain acquisitions; enter into sale and leaseback transactions; amend material agreements governing Operating Company's subordinated indebtedness and change Operating Company's lines of business. Subject to certain exceptions, the Credit Agreement permits Operating Company and its restricted subsidiaries to incur certain additional indebtedness, including secured indebtedness. None of Operating Company's non-U.S. subsidiaries nor its dormant Puerto Rico subsidiary is a guarantor of the loans. Under the Credit Agreement, Operating Company's ability to engage in certain activities such as incurring certain additional indebtedness, making certain investments, and paying certain dividends is tied to ratios based on Adjusted EBITDA (which is defined as Consolidated EBITDA in the Credit Agreement). Adjusted EBITDA is based on the definitions in the Credit Agreement, is not defined under U.S. GAAP, and is subject to important limitations. The Senior Notes The various indentures governing the Senior Notes (collectively, the "Indentures") contain covenants that, among other things, limit the ability of Operating Company and its restricted subsidiaries to incur or guarantee more debt or issue certain preferred shares; pay dividends on, repurchase, or make distributions in respect of their capital stock or make other restricted payments; make certain investments; sell certain assets; create liens; consolidate, merge, sell; or otherwise dispose of all or substantially all of their assets; enter into certain transactions with their affiliates, and designate their subsidiaries as unrestricted subsidiaries. These covenants are subject to a number of exceptions, limitations, and qualifications as set forth in the Indentures. The Indentures also contain customary events of default, including, but not limited to, nonpayment, breach of covenants, and payment or acceleration defaults in certain other indebtedness of Operating Company or certain of its subsidiaries. Upon an event of default, either the holders of at least 30% in principal amount of each of the then-outstanding Senior Notes or the applicable trustee under the Indentures may declare the applicable notes immediately due and payable; or in certain circumstances, the applicable notes will automatically become immediately due and payable. As of JuneA 30, 2024, Operating Company was in compliance with all material covenants under the Indentures. Measurement of the Estimated Fair Value of Debt The estimated fair values of the senior secured credit facilities and Senior Notes are classified as Level 2 (see Note 10, Fair Value Measurements for a description of the method by which fair value classifications are determined) in the fair value hierarchy and are calculated by using a discounted cash flow model with market interest rate as a significant input. The carrying amounts and the estimated fair values of financial instruments as of JuneA 30, 2024 and JuneA 30, 2023 are as follows: 101 June 30, 2024 June 30, 2023 (Dollars in millions) Fair Value Measurement Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value 5.000% Senior Notes due 2027 Level 2 \$500A \$498A \$500A \$482A 2.375% euro Senior Notes due 2028 Level 2 2883A 849A 904A 784A 3.125% Senior Notes due 2029 Level 2 2550A 532A 550A 481A 3.500% senior notes due 2030 Level 2 2650A 627A 650A 566A Senior secured credit facilities & other Level 2 2,366A 2,107A 2,284A 2,141A Subtotal \$4,949A \$4,613A \$4,888A \$4,454A Unamortized discount and debt issuance A costs (44)A (39)A Total debt \$4,905A \$4,613A \$4,849A \$4,454A A A (LOSS) EARNINGS PER SHARE The weighted-average number of shares outstanding utilized in diluted EPS is computed using the weighted-average number of shares of Common Stock outstanding plus the number of shares of Common Stock that would be issued assuming exercise or conversion of all potentially dilutive instruments. Dilutive securities having an anti-dilutive effect on diluted EPS are excluded from the calculation. The dilutive effect of the securities that are issuable under the Company's equity incentive plans (see Note 14, Stock-Based Compensation) are reflected in diluted EPS by application of the treasury stock method. Prior to fiscal 2023, the Company applied the if-converted method to compute the potentially dilutive effect of the Series A Preferred Stock. The reconciliations between basic and diluted EPS attributable to Catalent common shareholders for the fiscal years ended JuneA 30, 2024, 2023, and 2022 are as follows: A Fiscal year ended June 30, A (In millions, except per share data) 2024 2023 2022 Net (loss) earnings \$(1,043) \$(256) \$499A Less: Net earnings attributable to preferred shareholders A A (16) Net (loss) earnings attributable to common shareholders \$(1,043) \$(256) \$483A Weighted average shares outstanding A basic 181A 181A 176A Weighted average dilutive securities issuable A stock plans A A A 2A Total weighted average shares outstanding A diluted 181A 181A 178A (Loss) earnings per share: A Basic \$(5.76) \$(1.42) \$2.74A Diluted \$(5.76) \$(1.42) \$2.73A The Series A Preferred Stock was deemed a participating security, meaning that it had the right to participate in undistributed earnings with the Common Stock. On November 23, 2020 (the "Partial Conversion Date"), the holders of Series A Preferred Stock converted 265,223 shares and \$2 million of unpaid accrued dividends into shares of Common Stock. On November 18, 2021 (the "Final Conversion Date"), the holders of Series A Preferred Stock converted the remaining 384,777 shares of Series A Preferred Stock and \$2 million of unpaid accrued dividends into shares of Common Stock. The diluted weighted average number of shares outstanding for the fiscal years ended JuneA 30, 2024, 2023, and 2022 did not include the following weighted average number of shares of Common Stock associated with the formerly outstanding Series A Preferred Stock or the weighted average number of shares of Common Stock associated with outstanding equity grants due to their antidilutive effect: Fiscal year ended June 30, (share counts in millions) 2024 2023 2022 Series A Preferred Stock A A A 3A 1029A A A A DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Risk Management Objective of Using Derivatives The Company is exposed to fluctuations in the currency exchange rates applicable to its investments in foreign operations. While the Company does not actively hedge against changes in foreign currency, the Company has mitigated the exposure arising from its investments in its European operations by denominating a portion of its Senior Notes in euros, the functional currency of such European operations. At JuneA 30, 2024, the Company had euro-denominated debt outstanding of \$883 million (U.S. dollar equivalent), which qualifies as a hedge of a net investment in foreign operations. For non-derivatives designated and qualifying as net investment hedges, the effective portion of the translation gains or losses are reported in accumulated other comprehensive income (loss) as part of the cumulative translation adjustment. The unhedged portions of the translation gains or losses are reported in the consolidated statements of operations. The following table includes net investment hedge activity during the fiscal years ended JuneA 30, 2024 and 2023, respectively: (Dollars in millions) June 30, 2024 June 30, 2023 Unrealized foreign exchange gain (loss) within other comprehensive income \$21A \$(30) The net accumulated gain of this net investment hedge within accumulated other comprehensive loss was \$119 million as of JuneA 30, 2024. Amounts are reclassified out of accumulated other comprehensive loss into earnings when the entity in which the gains and losses reside is either sold or substantially liquidated. Interest-Rate Swap In February 2021, the Company entered into a new interest-rate swap agreement with Bank of America N.A. (the "2021 Rate Swap") that acted as a hedge against the economic effect of a portion of the variable-interest obligation associated with the Company's U.S. dollar-denominated term loans under its senior secured credit facilities. The 2021 Rate Swap effectively fixed the rate of interest payable on that portion of the term loans, thereby reducing the impact of future interest rate changes on future interest expense. As a result of the 2021 Rate Swap, the variable portion of the applicable interest rate on \$500 million of the U.S. dollar-denominated term loans was effectively fixed at 0.9985%. To conform with the adoption of Topic 848, Reference Rate Reform and the Eighth Amendment, the Company amended the 2021 Rate Swap in June 2023 (the "2023 Rate Swap"). The 2023 Rate Swap continues to effectively fix the rate of interest payable on the same portion of our U.S. dollar-denominated term loans under our senior secured credit facilities. As a result of the 2023 Rate Swap, the variable portion of the applicable interest rate on \$500 million of the U.S. dollar-denominated term loans is now effectively fixed at 0.9431%. The net amount of deferred losses on cash flow hedges that is expected to be reclassified from accumulated other comprehensive loss into interest expense, net within the next twelve months is not material. The 2023 Rate Swap continues to qualify for a cash-flow hedge. The Company evaluates hedge effectiveness at the inception of the hedge and on an ongoing basis. The cash flows associated with the 2023 Rate Swap amendment is reported in cash provided by operating activities in the consolidated statements of cash flows. The unrealized loss recorded in stockholder's equity from marking the 2023 Rate Swap to market during the fiscal year ended June 30, 2024 was \$26 million. A summary of the estimated fair value of the interest-rate swap reported in the consolidated balance sheets is stated in the table below: June 30, 2024 June 30, 2023 (in millions) Balance Sheet Classification Estimated Fair Value Balance Sheet Classification Estimated Fair Value Interest-rate swap Other long-term assets \$36A Other long-term assets \$62A 1031A A A FAIR VALUE MEASUREMENTS ASC 820, Fair Value Measurement defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which Level 1 and Level 2 are considered observable and Level 3 is considered unobservable: Level 1 a) Quoted prices in active markets for identical assets or liabilities. Level 2 a) Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means. Level 3 a) Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation. Assets and Liabilities Measured at Fair Value on a Recurring Basis The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses of the Company approximate fair value based on the short maturities of these instruments. The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification as of the end of each reporting period. The following table sets forth the Company's financial assets and liabilities that were measured at fair value on a recurring basis and the fair value measurement for such assets and liabilities at JuneA 30, 2024 and 2023, respectively: (Dollars in millions) Basis of Fair Value Measurement June 30, 2024 Total Level 1 Level 2 Level 3 Assets: Interest-rate swap \$36A A A \$36A A A Trading securities \$1A \$1A A A A June 30, 2023 Assets: Interest-rate swap \$62A A A \$62A A A Trading securities \$1A \$1A A A A The fair value of the 2023 Rate Swap was determined at the end of each reporting period based on valuation models that use interest rate yield curves and discount rates as inputs. The discount rates are based on U.S. deposit or U.S. Treasury rates. The significant inputs used in the valuation models are readily available in public markets or can be derived from observable market transactions, and the valuation is therefore classified as Level 2 in the fair-value hierarchy. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis Long-lived assets, goodwill, and other intangible assets are subject to non-recurring

value measurement for the evaluation of potential impairment. Except as noted in Note 4, Goodwill, there was no non-recurring fair value measurement during the fiscal year ended June 30, 2024, 2023, and 2022.

June 30, 2024, 2023, and 2022. 10411.1 A \$ A INCOME TAXES Earnings (loss) before income taxes are as follows for fiscal 2024, 2023, and 2022: Fiscal Year Ended A June 30, (Dollars in millions) 2024 2023 2022 U.S. operations \$(1,158)\$ (410)\$ 224A Non-U.S. operations 31A 68A 355A Totals(1,027)\$ (342)\$ 579A The provision for income taxes consists of the following for fiscal 2024, 2023, and 2022: A Fiscal Year Ended A June 30, (Dollars in millions) 2024 2023 2022 Current: Federal \$A \$ (1)\$ (8) State and local \$(5)(1) 14A Non-U.S. 48A 43A 66A Total current expenses \$A \$ 41A \$ 72A Deferred: Federal \$(15)\$ (99)\$ 56A State and local (1)(1)(4)(5) Non-U.S. (1)(24) 7A Total deferred (benefit) expense \$(27)\$ (127)\$ 8A Total provision (benefit) \$16A \$(86)\$ 80A A reconciliation of the provision starting from the tax computed at the federal statutory income tax rate to the tax computed at the Company's effective income tax rate is as follows for the fiscal years ended 2024, 2023, and 2022: A Fiscal Year Ended A June 30, (Dollars in millions) 2024 2023 2022 Provision at U.S. federal statutory tax rate \$(216)\$ (72)\$ 122A State and local income taxes (44)(13) 10A Foreign tax rate differential (7)(5)(28) Global intangible low tax income 11A 2A 6A Goodwill impairment 80A 9A A€ Other permanent items 25A 4A 2A Unrecognized tax positions A€ (1) 1A Tax valuation allowance 160A 5A 94A Foreign tax credit 1A (30)(43) Withholding tax and other foreign taxes 3A 1A 1A Change in tax rate 1A 18A 1A R&D tax credit (4)(3)(2) Swiss tax reform A€ A € (83) Other 6A (1)(1) Total provision (benefit) \$16A \$(86)\$ 80A 105The income tax provision for the fiscal year ended June 30, 2024 is not comparable to the provision in the prior year due to changes in the geographic mix of pretax income and losses, changes in the tax impact of permanent differences and credits, and the tax impact of discrete items. The global pretax loss was largely driven by the \$687 million goodwill impairment loss in the Consumer Health and BioModalities reporting units. However, the expected benefit from such a loss was not realized, as the majority of the goodwill impairment was not tax deductible. In addition, the establishment of valuation allowances against the U.S. Federal and state deferred tax assets and income tax expense reported by the Company's profitable non-U.S. reporting entities further reduced the expected benefit. In contrast, the higher effective tax rate on the fiscal 2023 global loss is primarily due to the recognition of research and development credits in the U.S., the recognition of deferred tax assets on the book impairment of tax deductible goodwill, and decreased earnings in non-U.S. jurisdictions with lower tax rates. The Company intends to repatriate foreign earnings taxed in prior fiscal years as a result of the changes imposed by the 2017 U.S. Tax Cuts and Jobs Act. In addition to these foreign earnings previously taxed, as of June 30, 2024, for purposes of ASC 740-10-25-3, the Company had \$568 million of undistributed earnings from non-U.S. subsidiaries that it intends to reinvest permanently in its non-U.S. operations. As these ASC 740-10-25-3 earnings are considered permanently reinvested, no tax provision has been accrued. It is not feasible to estimate the amount of tax that might be payable on the eventual remittance of such earnings. Deferred income taxes arise from temporary differences between the financial reporting and tax reporting bases of assets and liabilities, and operating loss and tax credit carryforwards for tax purposes. The components of the Company's deferred income tax assets and liabilities are as follows at June 30, 2024 and 2023: Fiscal Year Ended A June 30, (Dollars in millions) 2024 2023 Deferred income tax assets: Accrued liabilities \$70A \$5A Equity compensation 18A 1A Loss and tax credit carryforwards 293A 287A Foreign currency 3A Pension 18A 19A Interest-related 101A 50A Intangible A€ A€ Lease liabilities 37A 38A Euro-denominated debt A€ 1A Other A€ 1A Total deferred income tax assets \$546A \$469A Valuation allowance (315)(159) Net deferred income tax assets \$231A \$310A Fiscal Year Ended A June 30, (Dollars in millions) 2024 2023 Deferred income tax liabilities: Euro-denominated debt (4)\$ A€ Property-related (205)(247) Goodwill and other intangibles A€ (71) Deferred revenue (2) A€ Right-of-use assets (16)(13) Other (2) A€ Total deferred income tax liabilities \$(229)\$ (331) Net deferred tax asset (liability) \$2A \$(21) 106Deferred tax assets and liabilities in the preceding table are in the following captions in the consolidated balance sheets at June 30, 2024 and 2023: Fiscal Year Ended A June 30, (Dollars in millions) 2024 2023 Non-current deferred tax assets \$7A \$55A Non-current deferred tax liability (5)(76) Net deferred tax asset (liability) \$2A \$(21) At June 30, 2024, the Company had federal net operating loss (A€ enOLA€) carryforwards of \$546 million, \$225 million of which are subject to limitations under Section 382 of the Internal Revenue Code of 1986, as amended (the A€ enInternal Revenue CodeA€). The majority of the \$225 million federal NOL carryforwards subject to Section 382 of the Internal Revenue Code are attributed to the Company's acquisitions of Pharmatek Laboratories, Inc., Juniper Pharmaceuticals, Inc., Paragon Bioservices, Inc., MastherCell Global Inc. (A€ enMaSterCellA€), and Metrics. As of June 30, 2024, \$493 million of the Company's federal NOL carryforwards have an indefinite life and the remaining NOL carryforwards will expire in fiscal years 2028 through 2038. At June 30, 2024, the Company had state tax NOL carryforwards of \$461 million. Substantially all state NOL carryforwards have a twenty-year carryforward period. At June 30, 2024, the Company had non-U.S. tax NOL carryforwards of \$364 million, a majority of which are available for at least three years or have an indefinite carryforward period. The Company had valuation allowances of \$315 million and \$159 million as of June 30, 2024 and 2023, respectively, against its deferred tax assets. The Company considered all available evidence, both positive and negative, in assessing the need for a valuation allowance against tax assets. Four possible sources of taxable income were evaluated when assessing the realizability of deferred tax assets: A€ enCarrybacks of existing NOLs and other tax credits (if and to the extent permitted under the tax law); A€ enFuture reversals of existing taxable temporary differences; A€ enTax planning strategies; and A€ enFuture taxable income exclusive of reversing temporary differences and carryforwards. The Company considered the need to establish a valuation allowance on its U.S. Federal deferred tax assets during FY24 based on an assessment of whether it is more likely than not that the Company would realize the value of these deferred tax assets based on future reversals of existing taxable temporary differences within the carryforward period available under the applicable U.S. Federal income tax laws. In addition to this quantitative analysis, it also considered certain qualitative factors including the history of recent domestic losses which were largely impacted by several asset impairments including the \$687 million goodwill impairment. Management concluded that a valuation allowance of \$117 million was required on its U.S. Federal net deferred tax assets of \$97 million as of June 30, 2024. The valuation allowance in excess of the net deferred tax assets is the result of statutory limitations on the utilization of certain carryforward attributes. The Company also considered the need for a valuation allowance on its U.S. state net deferred tax assets. Similar to the U.S. Federal analysis, it was based on an assessment of whether it is more likely than not that the Company would realize the value of these state deferred tax assets based on future reversals of existing state taxable temporary differences within the carryforward period available under the applicable state tax laws. In addition, factors such as the anticipated loss utilization rates in separate filing status states and the difference in the rules related to allocated and apportioned income for separate filing status states versus combined filing status states was also considered. Management concluded that a state valuation allowance of \$50 million was required on its state net deferred tax assets of \$37 million as of June 30, 2024. Similar to the U.S. Federal results, the state valuation allowance is in excess of the net deferred tax assets. The Company also considered whether it is more likely than not that it would realize the value of its international deferred tax assets based on future reversals of existing taxable temporary differences within the carryforward period available under the applicable tax laws. The Company identified several of its international reporting entities that had both current and historical losses and net deferred tax asset balances. In addition to the aforementioned quantitative analysis, other factors including certain unique operational challenges faced by these reporting entities were also considered. Management concluded that a valuation allowance of \$148 million was required on its international net deferred tax assets of \$183 million. In the normal course of business, the Company's income taxes are subject to audits by federal, state, and foreign tax authorities, some of which are ongoing and may result in proposed assessments. Germany and the U.K. are among the jurisdictions where the Company has substantial tax positions. The Company is no longer subject to examinations by the 107 relevant tax authorities for years prior to fiscal 2009. The Company's estimate for the potential outcome for any uncertain tax issue is highly judgmental. The Company assesses its income tax positions and records benefits for all years subject to examination based upon management's evaluation of the facts, circumstances, and information available at the reporting date. For those tax positions for which it is more likely than not that a tax benefit will be sustained, the Company records the amount that has a greater than 50% likelihood of being realized upon resolution with the taxing authority that has full knowledge of all relevant information based on the technical merit. Interest and penalties are accrued, where applicable. As of June 30, 2024, the Company had a total of \$4 million of unrecognized tax benefits. A reconciliation of unrecognized tax benefits, excluding accrued interest, as of June 30, 2024, 2023, and 2022 is as follows: (Dollars in millions) Balance at June 30, 2021 \$5A Additions for tax positions related to the current year 1A Additions for tax positions of prior years 1A Settlements (1) Lapse of the applicable statute of limitations (1) Balance at June 30, 2022 \$5A Additions for tax positions of prior years 2A Reductions for tax positions of prior years (1) Settlements (1) Lapse of the applicable statute of limitations (1) Balance at June 30, 2023 \$4A Additions for tax positions of prior years 1A Reductions for tax positions of prior years (1) Balance at June 30, 2024 \$4A All of the unrecognized tax benefits as of June 30, 2024 and 2023 would, if subsequently recognized, favorably affect the effective income tax rate. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of June 30, 2024, the Company has \$0 million of accrued interest related to uncertain tax positions, with a reduction from the prior year, as a result of statute of limitations lapses and settlements. The Company had \$0A million and \$1 million of accrued interest related to uncertain tax positions as of June 30, 2023 and 2022, respectively. 12. A A EMPLOYEE RETIREMENT BENEFIT PLANS The Company sponsors various retirement plans, including defined benefit pension plans and defined contribution plans. Substantially all of the Company's domestic non-union employees are eligible to participate in employer-sponsored retirement savings plans, which include plans created under Section 401(k) of the Internal Revenue Code that provide for the Company to match a portion of contributions by participating U.S. employees. The Company's contributions to the plans are discretionary but are subject to certain minimum requirements as specified in the plans. The Company uses a measurement date of June 30 for all of its retirement and postretirement benefit plans. The Company records obligations related to its withdrawal from two multi-employer pension plan that covered former employees at three former sites. During the fiscal year ended June 30, 2024, the Company decided to withdraw its participation from a multi-employer pension plan as a result of recent restructuring activities in its Pharma and Consumer Health segment. These withdrawals were classified as a mass withdrawal under the Multiemployer Pension Plan Amendments Act of 1980, as amended, and the Pension Protection Act of 2006 and resulted in the recognition of liabilities associated with the Company's long-term obligations. The estimated discounted value of the contributions related to these plans is \$44 million and \$38 million as of June 30, 2024 and 2023, respectively. The annual cash impact associated with the Company's long-term obligation arising from these plans are \$2 million per year. In the twelve months ended June 30, 2024, the Company terminated its U.S. pension plan and settled with its participants by a lump sum payout or through the purchase of an annuity contract, which was dependent upon the participant's selection of payment. The Company purchased nonparticipating annuities for participants who did not elect lump sum payouts. Participants who elected a lump sum payout were settled during the fiscal year ended June 30, 2024 and resulted in \$7 million of lump sum payments made with cash from the assets of the qualified pension plan. Participants who elected an 108 annuity contract were settled during the fiscal year ended June 30, 2024 and resulted in \$21 million of payments with cash from the assets of the qualified pension plan and \$3 million of Company cash. The following table provides a reconciliation of the change in projected benefit obligation and fair value of plan assets for the defined benefit retirement and other retirement plans, excluding the multi-employer pension plan liability: Retirement Benefits Other Post-Retirement Benefits June 30, June 30, (Dollars in millions) 2024 2023 2024 2023 Accumulated Benefit Obligation \$206A \$242A 1A 2A Change in Benefit Obligation Benefit obligation at beginning of year 246A 268A 2A 2A Company service cost 3A 3A A€ A€ Interest cost 11A 9A A€ A€ Employee contributions 1A 1A A€ A€ Settlements (36)(4) A€ A€ Benefits paid (11)(10) A€ A€ Actual gain 1A (28) A€ A€ Exchange rate gain (loss) (4) 7A A€ A€ Benefit obligation at end of year 211A 246A 2A 2A Change in Plan Assets Fair value of plan assets at beginning of year 202A 240A A€ A€ Actual return on plan assets 3A (38) A€ A€ Company contributions 11A 7A A€ A€ Employee contributions 1A 1A A€ A€ Settlements (36)(4) A€ A€ Benefits paid (11)(10) A€ A€ Exchange rate gain (loss) (2) 6A A€ A€ Fair value of plan assets at end of year 168A 202A A€ A€ Funded Status Funded status at end of year (43)(44) (1)(2) Net pension liability \$(43)\$ (44)\$ (1)\$ (2) The following table provides a reconciliation of the net amount recognized in the consolidated balance sheets: 109A 110 Retirement Benefits Other Post-Retirement Benefits June 30, June 30, (Dollars in millions) 2024 2023 2024 2023 Amounts Recognized in Statement of Financial Position Noncurrent assets \$13A \$18A A

[illegible]

and equipment, net\$252Â \$274Â Operating leasesOther long-term assets77Â 59Â Current lease liabilities:Finance leasesCurrent portion of long-term obligations and other short-term borrowings20Â 18Â Operating leasesOther accrued liabilities13Â 11Â Non-current lease liabilities:Finance leasesLong-term obligations, less current portion312Â 323Â Operating leasesOther liabilities70Â 55Â The components of the net lease costs for the fiscal years ended JuneÂ 30, 2024 and 2023 reflected in the Companyâ€™s consolidated statement of operations were as follows:(Dollars in millions)Fiscal Year EndedÂ June 30, 2024Fiscal Year EndedÂ June 30, 2023Financing lease costs:Amortization of right-of-use assets\$30Â \$21Â Interest on lease liabilities21Â 17Â Total51Â 38Â Operating lease costs27Â 35Â Variable lease costs16Â 10Â Total lease costs\$94Â \$83Â The short-term lease cost amounted to \$9 million, \$10 million and \$8 million during the fiscal year ended JuneÂ 30, 2024, 2023 and 2022, respectively.121The weighted average remaining lease term and weighted average discount rate related to the Companyâ€™s right-of-use assets and lease liabilities as of JuneÂ 30, 2024 are as follows:Â Â Â Â Weighted average remaining lease term (years):Finance leases16.1Operating leases9Weighted average discount rate:Finance leases6.2Â Â Operating leases4.6Â Â Supplemental information concerning the cash-flow impact arising from the Companyâ€™s leases for the fiscal year ended JuneÂ 30, 2024 recorded in the Companyâ€™s unaudited consolidated statement of cash flows is detailed in the following table (in millions):Fiscal Year EndedÂ June 30, 2024Fiscal Year EndedÂ June 30, 2023Fiscal Year EndedÂ June 30, 2022Cash paid for amounts included in lease liabilities:Financing cash flows used for finance leases\$19Â \$19Â \$15Â Operating cash flows used for finance leases16Â 15Â 11Â Operating cash flows used for operating leases14Â 16Â 19Â Non-cash transactions:Right-of-use assets obtained in exchange for new finance lease liabilities57Â 133Â 59Â Right-of-use assets obtained in exchange for new operating lease liabilities38Â 31Â \$31Â As of JuneÂ 30, 2024, the Company expects that its future minimum lease payments will become due and payable as follows:(Dollars in millions)Financing LeasesOperating LeasesTotal2025\$37Â \$17Â \$54Â 202639Â 15Â 54Â 202737Â 14Â 51Â 202834Â 13Â 47Â 202934Â 9Â 43Â Thereafter337Â 36Â 373Â Total minimum lease payments518Â 104Â 622Â Less: interest186Â 21Â 207Â Total lease liabilities\$332Â \$83Â \$415Â 17Â Â Â Â COMMITMENTS AND CONTINGENCIESLitigationFrom time to time, the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Companyâ€™s consolidated financial statements. The Company records a liability in its consolidated financial statements for these matters when a loss is 122known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary for its consolidated financial statements not to be misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the Companyâ€™s consolidated financial statements. Any legal or other expenses associated with the litigation are accrued for as the expenses are incurred. The Company intends to vigorously defend itself against any such litigation and does not currently believe that the outcome of any such litigation will have a material adverse effect on the Companyâ€™s consolidated financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise.City of Warwick Retirement System Class ActionIn February 2023, an alleged shareholder filed a complaint styled City of Warwick Retirement System v. Catalent, Inc., et al., No. 23-cv-01108, in New Jersey federal court against the Company and three of its then-officers (collectively, â€œthe Warwick Defendantsâ€) purportedly on behalf of a putative â€œclassâ€ consisting of persons who purchased or otherwise acquired Company securities between August 30, 2021 and October 31, 2022, inclusive. On September 15, 2023, the Warwick complaint was amended (together with the original complaint, the â€œWarwick Complaintâ€), which amended complaint expanded the class period to between August 30, 2021 and May 7, 2023, inclusive (the â€œClass Periodâ€). The Warwick Complaint purports to assert claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and the related regulations, alleging that, unbeknownst to investors, the Warwick Defendants purportedly engaged in accounting and channel stuffing schemes to pad the Companyâ€™s revenues and failed to disclose adverse facts that purportedly were known to or recklessly disregarded by the Warwick Defendants. Specifically, the Warwick Complaint alleges that the Warwick Defendants (i) overstated revenue and earnings by prematurely recognizing revenue in violation of U.S. GAAP; (ii) suffered material weaknesses in its internal control over financial reporting related to revenue recognition; (iii) falsely represented demand for its products while knowingly selling more product to its direct customers than could be sold to healthcare providers and end consumers; (iv) cut corners on safety and control procedures at key production facilities; (v) disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Companyâ€™s financial results through premature revenue recognition in violation of U.S. GAAP or stuffing its direct customers with this excess inventory; and (vi) lacked a reasonable basis for their positive statements about the Companyâ€™s financial performance, outlook, and regulatory compliance during the Class Period. On November 15, 2023, the Warwick Defendants filed a motion to dismiss the Warwick Complaint. On June 28, 2024, the Court granted, in part, and denied, in part, the Company's motion to dismiss. The Warwick Defendantsâ€™ answer to the Warwick Complaint was filed on August 12, 2024. The Company believes that the Warwick Defendants have defenses to the remaining allegations and intends to vigorously defend against these allegations.Husty Derivative ClaimIn August 2023, an alleged shareholder filed a derivative complaint styled Husty et al. v. Carroll, et al., No. 23-cv-00891, in Delaware federal court against certain current and former members of the Companyâ€™s board of directors, (the â€œHusty Defendantsâ€), and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities described there led to, and will continue to expose the Company to, costs and damages. On February 20, 2024, the court entered a stipulation staying the case pending the outcome of motion to dismiss that was filed in the City of Warwick Retirement System action. On April 23, 2024, the plaintiff voluntarily dismissed the action without prejudice.Brown Derivative ClaimIn September 2023, an alleged shareholder filed a derivative complaint styled Brown, et al. v. Chiminski, et al., Case 3:23-cv-15722, in New Jersey federal court against certain current and former officers and members of the Companyâ€™s board of directors (the â€œBrown Defendantsâ€) and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities described there led to, and will continue to expose the Company to, costs and damages. On January 8, 2024, the court entered a stipulation staying the case pending the outcome of motion to dismiss that was filed in the City of Warwick Retirement System action. On April 19, 2024, the plaintiff voluntarily dismissed the action without prejudice. On May 2, 2024, the Court dismissed the action without prejudice.Merger Related ClaimsIn connection with the proposed Merger, as disclosed below, three purported Catalent stockholders filed lawsuits alleging that certain disclosures made in the Proxy Statement were materially false and misleading: Garfield v. Barber, et al., C.A. No. 123SOM-C 012027-24 (N.J. Super. Ct.), which was filed in the Superior Court of New Jersey; Moore v. Catalent, Inc., et al., No. 652403/2024 (N.Y. Sup. Ct.), which was filed in the Supreme Court of New York; and Clark v. Catalent, Inc., et al., No. 652407/2024 (N.Y. Sup. Ct.), which was filed in the Supreme Court of New York. The aforementioned lawsuits are collectively referred to as the â€œActions.â€ The Actions alleged, among other things, that certain disclosures in the Proxy Statement filed in connection with the Merger Agreement omitted certain purportedly material information. The Garfield Action asserted violations of New Jersey Uniform Securities Law Â§ 49:3-71 and negligent misrepresentation and concealment and negligence under New Jersey common law. The Moore and Clark Actions each asserted a single claim for breach of fiduciary duty. On May 17, 2024, the Garfield Action was voluntarily dismissed with prejudice. On June 26, 2024, the Moore and Clark Actions were voluntarily dismissed with prejudice.Subpoenas and Requests for InformationFrom time to time, the Company receives subpoenas or requests for information from various governmental agencies or private parties, including from state attorneys general, the U.S. Department of Justice, and private parties. The Company generally responds to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred.In June 2023, the Company received a demand from a company stockholder pursuant to 8 Del. C. Â§ 220 to inspect books and records of the Company relating to, among other things, the allegations raised in the Warwick Complaint. The Company has responded to the demand and cannot determine at this time if the books and records demand will lead to litigation.Fire at Biologics FacilityDuring the three months ended December 31, 2023, the Company had a small fire at a facility in its Biologics segment. The fire activated the sprinkler systems, which then caused minor flooding in certain parts of the facility. The Company accrued \$9 million for estimated damages, repairs, and lost inventory. The Company is insured for such incidents and has submitted claims for reimbursement. Proceeds from potential reimbursement are not included in the financial statements for the three and twelve months ended June 30, 2024.Entry Into an Agreement and Plan of MergerOn February 5, 2024, the Company entered into the Agreement and Plan of Merger (the â€œMerger Agreementâ€), with Creek Parent, Inc. (â€œParentâ€), a Delaware corporation and a wholly owned subsidiary of Novo Holdings A/S (â€œNovo Holdingsâ€), and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (â€œMerger Subâ€). The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein and in accordance with the General Corporation Law of the State of Delaware (the â€œDGCLâ€), Merger Sub will be merged with and into the Company (the â€œMergerâ€), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Parent will acquire all the issued and outstanding shares of Common Stock of the Company.At the effective time of the Merger (the â€œEffective Timeâ€), each share of Common Stock, par value \$0.01 per share, of the Company (such shares, collectively, the â€œCompany Common Stock,â€ and each, a â€œShareâ€) that is issued and outstanding immediately prior to the Effective Time (other than any Shares held by (i) the Company, Parent or Merger Sub or any other direct or indirect wholly owned subsidiary of the Company or Parent immediately prior to the Effective Time, or (ii) a holder who has not voted in favor of the adoption of the Merger Agreement and is entitled to demand and properly demands appraisal of such Shares under the DGCL), will be converted automatically into the right to receive an amount in cash equal to \$63.50 per Share, without interest (the â€œMerger Considerationâ€). The transaction values the Company at \$16.50Â billion on an enterprise value basis.Consummation of the Merger is subject to customary closing conditions, including (i) receipt of certain governmental waivers, consents, clearances, decisions, declarations, approvals, and expirations of applicable waiting periods, including the expiration or early termination of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, with respect to (A) the Merger and (B) the sale of three of the Companyâ€™s fill-finish sites (which are located in Anagni, Italy, Bloomington, Indiana USA, and Brussels, Belgium) and related assets from Novo Holdings to Novo Nordisk A/S (â€œNovo Nordiskâ€), of which Novo Holdings is the controlling shareholder (the â€œCarve-Outâ€), and (ii) the absence of any order, injunction or law prohibiting the Merger or the Carve-Out, in each case, without a Burdensome Condition (as defined in the Merger Agreement). Parentâ€™s and Merger Subâ€™s obligations to close the Merger are also conditioned upon the absence of a Material Adverse Effect (as defined in the Merger Agreement) on the Company.12418. SEGMENT AND GEOGRAPHIC INFORMATIONThe CODM evaluates the performance and allocates resources based upon a number of factors, the primary being its segment earnings before other (income) expense, impairments, restructuring costs, interest expense, income tax expense, and depreciation and amortization (â€œSegment EBITDÂ€). Segment EBITDÂ€ is subject to important limitations. These consolidated financial statements include information concerning Segment EBITDÂ€ (a) because Segment EBITDÂ€ is an operational measure used by management in the assessment of the operating segments, the allocation of resources to the segments, and the setting of strategic goals and annual goals for the segments, and (b) in order to provide supplemental information that the Company considers relevant for the readers of the consolidated financial statements. The Companyâ€™s presentation of Segment EBITDÂ€ may not be comparable to similarly titled measures used by other companies. The following table includes Segment EBITDÂ€ for each of the Companyâ€™s current reporting segments during the fiscal years ended JuneÂ 30, 2024, 2023, and 2022:(Dollars in millions)Fiscal Year Ended June 30,202420232022Segment EBITDÂ€ reconciled to net (loss) earnings:Biologics\$272Â \$277Â \$777Â Pharma and Consumer Health597Â 548Â 589Â Subtotal\$869Â \$825Â \$1,366Â Reconciling items to net (loss) earningsUnallocated costs (1)\$1,153\$(559)\$(286)Depreciation and amortization(489)(422)(378)Interest expense, net(254)(186)(123)Income tax benefit (expense)(16)86Â (80)Net (loss) earnings\$1,043\$(256)\$499Â (1)Â Â Â Â Unallocated costs include restructuring and special items, stock-based compensation, gain (loss) on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:(Dollars in millions)Fiscal Year Ended June 30,202420232022Impairment charges and gain/loss on sale of assets (a)\$(29)\$(98)\$(31)Stock-based compensation(68)(35)(54)Restructuring and other special items (b)(178)(98)(55)Pension settlement charges(12)â€Â \$â€Â A Goodwill impairment charges (c)(687)(210)â€Â A Gain on sale of subsidiaryâ€Â \$â€Â A 1Â Other (expense) income, net (d)(24)7Â (28)Non-allocated corporate costs, net(155)(125)(119)Total unallocated costs\$(1,153)\$(559)\$(286)(a)Â Â Â Â A Impairment charges and gain/loss on sale of assets for the fiscal year ended June 30, 2024 includes right-of-use asset impairment charges associated with under utilized facilities in our Biologics segment, obsolete equipment that could not be sold or repurposed in our Biologics segment and under utilized suites from a canceled project in our Pharma and Consumer Health segment. For the fiscal year ended June 30, 2023, impairment charges are primarily associated with an idle facility in the Biologics segment and obsolete equipment that could not be sold or repurposed in the Pharma and Consumer Health segment. Further detail is provided below. 125For the fiscal year ended June 30, 2023, the Company identified an indicator of impairment related to one of its facilities in the Biologics segment given the plans to pause any additional spend on site development due to a lack of demand, leading to a partial impairment charge of \$54 million. The Company primarily utilized a market and income approach for real property and a cost approach for personal property to record the partial impairment on its idle facility. Impairment charges are recorded in Other operating expense in the consolidated statements of operations.Also, in the fiscal year ended June 30, 2023, the Company identified an indicator of impairment related to obsolete equipment from a terminated project in the Pharma and Consumer Health segment, leading to a full impairment charge of \$18 million. Â Â Â Â For the fiscal year ended June 30, 2022, impairment charges are primarily due to fixed asset impairment charges associated with dedicated equipment for a product the Company no longer manufactures in its Pharma and Consumer Health segment and obsolete equipment in its Biologics segment.(b)Â Â Â Â Restructuring and other special items during the fiscal year ended June 30, 2024 include restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization. For further details on restructuring charges, see Note 6, Restructuring Costs to the Consolidated Financial Statements.Restricting and other special items for the fiscal year ended June 30, 2023 includes (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisitionRestructuring and other special items for the fiscal year ended June 30, 2022 include (i) transaction and integration costs primarily associated with the Princeton, Bettera Wellness, Delphi, Hepatic, Acorda, and RheinCell transactions and (ii) unrealized losses on venture capital investments. (c)Â Â Â Â A Goodwill impairment charges during the fiscal year ended June 30, 2024 were associated with the Companyâ€™s Consumer Health and Biomodalities reporting units, which are part of the Companyâ€™s Pharma and Consumer Health and Biologics segments, respectively. For further details, see Note 4, Goodwill to the Consolidated Financial Statements.The goodwill impairment charges for the fiscal year ended June 30, 2023 was associated with the Companyâ€™s Consumer Health reporting unit. For further details, see Note 4, Goodwill.(d)Â Â Â Â Refer to Note 15, Other (income) expense, net for details of financing charges and foreign currency translation adjustments recorded within other (income) expense, net.126The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated balance sheets. Total Assets (Dollars in millions)June 30, 2024June 30, 2023Biologics\$5,326Â \$5,746Â Pharma and Consumer Health4,643Â 4,867Â Corporate and eliminations(216)164Â Total assets\$9,753Â \$10,777Â Capital ExpendituresFiscal Year Ended June 30,(Dollars in millions)202420232022Biologics\$171Â \$346Â \$453Â Pharma and Consumer Health164Â 214Â 183Â Corporate16Â 34Â 30Â Total capital expenditures (1)\$351Â \$594Â \$666Â (1)Â Â Â Â Include both cash and non-cash capital expenditures Â Long Lived AssetsThe following table presents long-lived assetsâ€™consisting of property, plant, and equipment, net of accumulated depreciationâ€™by geographic area:(Dollars in millions)June 30, 2024June 30, 2023United States\$2,625Â \$2,758Â Europe828Â 765Â Other190Â 159Â Total\$3,643Â \$3,682Â For further details on segment and geographic information, see Note 2, Revenue Recognition.19Â Â Â Â A SUPPLEMENTAL BALANCE SHEET INFORMATIONSupplemental balance sheet information at JuneÂ 30, 2024 and JuneÂ 30, 2023 is detailed in the following tables.InventoriesWork-in-process and inventories include raw materials, labor, and overhead. Total inventories consist of the following: (Dollars in millions)June 30,2024June 30,2023Raw materials and supplies\$646Â \$781Â Work-in-process138Â 186Â Total inventories, gross784Â 967Â Inventory cost adjustment(210)(190)Total inventories\$574Â \$777Â Prepaid expenses and other current assets127Prepaid expenses and other current assets consist of the following:(Dollars in millions)June 30,2024June 30,2023Prepaid expenses\$46Â \$53Â Short-term contract

assets\$85A 399A Spare parts supplies29A 24A Prepaid income tax45A 77A Non-U.S. value-added tax60A 38A Other current assets48A 42A Total prepaid expenses and other\$813A \$633A Property, plant, and equipment, netProperty, plant, and equipment, net consist of the following:(Dollars in millions)June 30, 2024June 30, 2023Land, buildings, and improvements\$1,987A \$1,887A Machinery and equipment2,538A 2,287A Furniture and fixtures62A 61A Construction in progress971A 1,043A Property, plant, and equipment, at cost5,558A 5,278A Accumulated depreciation(1,915) (1,596)Property, plant, and equipment, net\$3,643A \$3,682A Other long-term assetsOther long-term assets consist of the following:(Dollars in millions)June 30, 2024June 30, 2023Operating lease right-of-use-assets\$77A \$59A Net receivable56A 53A Corporate-owned life insurance policies48A 41A Venture capital investments47A 36A Interest-rate swap36A 62A Pension assets13A 18A Long-term contract assets 17A 18A Other38A 42A Total other long-term assets\$332A \$329A Other accrued liabilities128Other accrued liabilities consist of the following:(Dollars in millions)June 30, 2024June 30, 2023Contract liability\$250A \$167A Accrued employee-related expenses181A 160A Accrued expenses115A 134A Operating lease liabilities13A 11A Restructuring accrual10A 19A Accrued interest37A 35A Accrued income tax16A 44A Total other accrued liabilities\$622A \$570A Allowance for credit lossesThe rolloffward of allowance for credit losses for the twelve months ended June 30, 2024 is as follows:(Dollars in millions)Allowance for credit lossesBalance, June 30, 2023\$46A Charges (Credits)(6)Write-offs(17)Balance, June 30, 2024\$23A 129ITEMA 9.A A A CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE None. ITEMÂ 9A.A A A CÂNTROLS AND PROCEDURESDisclosure Controls and ProceduresWe maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any control or procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Our management, including our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2024, our disclosure controls and procedures were not effective to accomplish their objectives at the reasonable assurance level.Managementâ€™s Annual Report on Internal Control Over Financial ReportingOur management is responsible for establishing and maintaining adequate internal control over our financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting form a set of policies and procedures designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of our consolidated financial statements in accordance with U.S. GAAP.Our internal control over financial reporting include policies and procedures that:â€¢pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions relating to our business and dispositions of our assets;â€¢provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; andâ€¢provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.Because of inherent limitations regarding the nature of controls, no set of internal control over financial reporting can guarantee that it will prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because either conditions change or the degree of compliance with our policies and procedures may deteriorate.Our management assessed the effectiveness of our internal control over financial reporting as of June 30, 2024. In making this assessment, management used the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on this assessment, our management concluded that, as of June 30, 2024, our internal control over financial reporting was not effective. The effectiveness of our internal control over financial reporting as of June 30, 2024 has been audited by Grant Thornton LLP, an independent registered public accounting firm, as stated in its report, which is included in â€œItem 8. â€˜ Financial Statements and Supplementary Data.â€˜Material Weakness in Internal Control over Financial Reporting - Inventory Costing and Valuation We did not maintain effective internal control over the accounting of inventory costing and valuation at our Bloomington, Indiana facility. Specifically, there was a lack of stability of personnel with the requisite expertise to effectively execute transactional controls related to inventory costing and valuation. When coupled with a manual inventory reconciliation processes and insufficient standard operating procedure documentation, the preparation and review of inventory costing and valuation manual journal entries at our Bloomington facility was not performed with the necessary level of technical competency to detect a material misstatement.130Plan to Remediate Material Weakness in Internal Control over Financial Reporting â€˜ Inventory Costing and ValuationThe Company, with oversight by the Audit Committee of the Board, is actively developing and implementing a comprehensive remediation plan that will include the following initiatives:â€¢We have established a Steering Committee to evaluate the processes and resourcing requirements specific to inventory costing and valuation.â€¢We have already engaged internal and temporary third-party resources with the appropriate level of technical knowledge and experience in accounting related inventory costing and valuation to complement the Bloomington site resources. â€¢We plan to hire develop and retain incremental full-time personnel at the Bloomington facility with the appropriate accounting expertise.â€¢We will review and update our processes to minimize the level of complexity and manual work required.â€¢We will create detailed process documentation related to inventory costing and valuation.â€¢We will provide training to personnel on our inventory costing and valuation processes.Remediated Material Weaknesses in Internal Control over Financial ReportingA material weakness (as defined in Rule 12b-2 under the Exchange Act) is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis.Remediation of Material Weakness in Internal Control over Financial Reporting â€˜ Contract ModificationsAs previously disclosed, in connection with our evaluation for the three months ended December 31, 2023, we identified a material weakness in internal control over financial reporting as we did not maintain effective internal controls to properly identify and assess the accounting treatment of contract modification arrangements under ASC 606, Revenue from Contracts with Customers. The review of the accounting assessments for certain modified contracts during the quarter ended December 31, 2023, was not performed with the necessary level of technical competency to detect a material misstatement.To remediate the material weakness described above, we hired additional technical accounting resources within the corporate controllership group. We also ensured that appropriate levels of our management, including our necessary technical accounting resources, are consulted before significant contract modifications are executed.During the six months ended June 30, 2024, we completed the control enhancements and testing necessary to conclude that the material weakness was remediated.Remediation of Material Weakness in Internal Control over Financial Reporting â€˜ Income Tax ProvisionAs previously disclosed, in connection with our evaluation for the three months ended December 31, 2023, we identified a material weakness in internal control over financial reporting as we did not maintain effective internal control over the preparation and review of the interim income tax provision. Specifically, the Company did not design an appropriate interim review control over the completeness and accuracy of certain inputs to the quarterly income tax provision calculations. While the control deficiency did not result in a material misstatement to the Companyâ€™s interim consolidated financial statements, there is a reasonable possibility that the control deficiency could have resulted in a material misstatement of the income tax related accounts or disclosures in the Companyâ€™s interim consolidated financial statements that would not have been prevented or detected on a timely basis.To remediate the material weakness described above, we updated our design of controls over the completeness and accuracy of inputs to the quarterly income tax provision calculations.During the six months ended June 30, 2024, we completed the control enhancements and testing necessary to conclude that the material weakness was remediated.Remediation of Material Weakness in Internal Control over Financial Reporting â€˜ Revenue RecognitionAs previously disclosed, management identified during the preparation of our unaudited consolidated financial statements for the fiscal year ended June 30, 2023 a material weakness in our internal control over financial reporting relating to the year ended June 30, 2022. We did not maintain effective controls over the appropriateness of revenue recognition related to 131modifications of customer agreements at our Bloomington, Indiana facility. Specifically, we did not maintain effective controls to properly identify and assess the accounting treatment of modifications to arrangements that were accounted for under ASC 606, Revenue from Contracts with Customers. The reviewer had insufficient knowledge of the requirements of the ASC 606 revenue recognition accounting model, and therefore the review procedures were not performed with the necessary level of competence to prevent or detect a material misstatement on a timely basis.Furthermore, the compensating control to review the accounting assessments for contract modifications was not sufficiently designed to detect accounting misstatements. As previously disclosed, this control deficiency resulted in an immaterial revision to our consolidated financial statements for the fiscal year ended June 30, 2022 to correct an overstatement of revenue of \$26 million. While this control deficiency did not result in a material misstatement of our consolidated financial statements, there is a reasonable possibility that this deficiency could have resulted in a material misstatement of our annual or interim consolidated financial statements that would not be prevented or detected on a timely basis.To remediate the material weakness described above, we:â€¢Hired additional technical accounting resources within our Bloomington, Indiana site and within the corporate controllership group.â€¢Enhanced the design of our management review controls relating to the accounting for contract modifications, including offered concessions.â€¢Continued to provide additional training for our executive leadership team, and other critical customer-facing personnel, on revenue recognition principles, including contract modifications relating to offered concessions.During the six months ended June 30, 2024, we completed the control enhancements and testing necessary to conclude that the material weakness was remediated.Remediation of Material Weakness in Internal Control over Financial Reporting â€˜ Consolidated Financial Statement Close ProcessAs previously disclosed, management identified during the preparation of our audited consolidated financial statements for the year ended June 30, 2023 a material weakness in our internal control over financial reporting. We did not maintain effective internal control over the evaluation and accounting of certain complex and non-routine transactions. Due to an insufficient complement of technical resources within its corporate accounting function, management was unable to complete its evaluation of certain complex non-routine transactions in a timely manner. Specifically, management did not adequately prepare and maintain sufficient evidence of managementâ€™s review of (i) significant assumptions, relating to the interim goodwill and long-lived assets impairment assessments as of March 31, 2023, (ii) the evaluation of indicators and assessment of impairment of goodwill and long-lived assets as of June 30, 2023 and (iii) the evaluation of the accounting, measurement and disclosure of events occurring subsequent to the balance sheet date, specifically managementâ€™s evaluation of disclosure and the related measurement of a goodwill impairment charge. To remediate the material weakness described above, we:â€¢Engaged temporary third-party resources with the appropriate level of technical knowledge and experience in accounting related to complex non-routine transactions and the related internal control activities to complement the existing corporate accounting resources;â€¢Continued to hire, develop and retain incremental full-time personnel with appropriate accounting and internal controls expertise;â€¢Reviewed and updated (as appropriate) our methodologies, policies and procedures designed to ensure we are able to more timely address our evaluation of complex non-routine transactions, including the related evidence of managementâ€™s review of the significant assumptions used in those evaluations; andâ€¢Reviewed and updated (as appropriate) our training programs related to the relevant internal control over financial reporting matters pertaining to complex non-routine transactions.During the six months ended June 30, 2024, we completed the control enhancements and testing necessary to conclude that the material weakness was remediated.Remediation of Material Weakness in Internal Control over Financial Reporting â€˜ Inventory ReconciliationAs previously disclosed, management identified during the preparation of our audited consolidated financial statements for the year ended June 30, 2023 a material weakness in our internal control over financial reporting. We did not maintain 132effective internal controls over inventory reconciliation at our Baltimore, Maryland facility. Specifically, we did not implement and design controls at an appropriate level of precision to (i) properly recognize certain third party costs on the balance sheet separately from the inventory balance, (ii) properly and timely update our perpetual inventory subledger to value inventory at lower of cost or market, and (iii) reconcile our perpetual inventory subledger to the related general ledger accounts.To remediate the material weakness described above, we have updated our design of controls for the valuation of inventory at our Baltimore location and provided additional training to the control owners. During the six months ended June 30, 2024, we completed the control enhancements and testing necessary to conclude that the material weakness was remediated. Changes in Internal Control over Financial ReportingWe are taking actions to complete the remediation of the remaining material weakness relating to our internal control over financial reporting, as described above. Except as otherwise described herein, there was no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. ITEMÂ 9B.A A A OTHER INFORMATIONDuring the fiscal quarter ended June 30, 2024, none of our directors or officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" (as defined in Item 408(a) of Regulation S-K).ITEMÂ 9C.A A A DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONSNot applicable.PART IIITEM 10.A A A DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCEThe information required by this item will either be (i) incorporated herein by reference to our definitive proxy statement for our annual meeting of shareholders or (ii) included in an amendment to this Form 10-K, in each case, filed with the SEC no later than 120 days after the end of the fiscal year covered by this Form 10-K.ITEMÂ 11.A A A EXECUTIVE COMPENSATIONThe information required by this item will either be (i) incorporated herein by reference to our definitive proxy statement for our annual meeting of shareholders or (ii) included in an amendment to this Form 10-K, in each case, filed with the SEC no later than 120 days after the end of the fiscal year covered by this Form 10-K.ITEMÂ 12.A A A SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERSThe information required by this item will either be (i) incorporated herein by reference to our definitive proxy statement for our annual meeting of shareholders or (ii) included in an amendment to this Form 10-K, in each case, filed with the SEC no later than 120 days after the end of the fiscal year covered by this Form 10-K.ITEM 13.A A A CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCEThe information required by this item will either be (i) incorporated herein by reference to our definitive proxy statement for our annual meeting of shareholders or (ii) included in an amendment to this Form 10-K, in each case, filed with the SEC no later than 120 days after the end of the fiscal year covered by this Form 10-K.133ITEMÂ 14.A A A PRINCIPAL ACCOUNTANT FEES AND SERVICESThe information required by this item will either be (i) incorporated herein by reference to our definitive proxy statement for our annual meeting of shareholders or (ii) included in an amendment to this Form 10-K, in each case, filed with the SEC no later than 120 days after the end of the fiscal year covered by this Form 10-K.134PART IV ITEMÂ 15.A A A EXHIBITS AND FINANCIAL STATEMENT SCHEDULES (a)(1)A A A Financial Statements. The Financial Statements listed in the Index to Financial Statements are filed under Item 8 Financial Statements and Supplementary Data of this Annual Report.(a)(2)A A A Financial Statements Schedule. The valuation allowance for credit losses is not material to the Companyâ€™s consolidated balance sheets. Deferred Tax Assets - Valuation Allowance (Dollars in millions)Beginning BalanceCurrent Period (Charge) BenefitDeductions and OtherEnding BalanceFiscal year ended June 30, 2022Tax valuation allowance\$(65)\$(94)\$10A \$(149)Fiscal year ended June 30, 2023Tax valuation allowance\$(149)\$(5)\$(5)\$(159)Fiscal year ended June 30, 2024Tax valuation allowance\$(159)\$(156)\$â€¢A \$(315)(b)A A A Exhibits. The agreements and other documents filed as exhibits to this report are not intended to provide factual information or other disclosure other than with respect to the terms of the agreements or other documents themselves and you should not rely on them for that purpose. In particular, any representation or warranty made by us in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time.Exhibit No.Description2.1Membership Interest Purchase Agreement, dated August 29, 2021, by and among Catalent Pharma Solutions, Inc., Bettera Holdings, LLC, the members of Bettera Holdings, LLC, and Highlander Partners Candy, LLC (incorporated by reference to Exhibit 2.1 to the Companyâ€™s Current Report on Form 8-K filed on August 30, 2021).2.2Agreement and Plan of Merger, dated as of February 5, 2024, by and among the Company, Creek Parent, Inc., and Creek Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed on February 5, 2024).3.1Fourth Amended and Restated Certificate of Incorporation of Catalent, Inc., as filed with the Secretary of State of the State of Delaware on October 28, 2021 (incorporated by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed on November 2, 2021).3.2Bylaws of Catalent, Inc., effective February 2, 2023 (incorporated by reference to Exhibit 3.2 to the Companyâ€™s Current Report on Form 8-K filed on February 7, 2023).4.1Indenture, dated June 27, 2019, by and among Catalent Pharma Solutions, Inc., the subsidiary guarantors named therein, and Deutsche Bank Trust Company Americas, as trustee (incorporated by reference to Exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K filed on June 27,

2019);4.1.1Form of 5.00% Senior Notes due 2027 (included as part of Exhibit 4.1 above).4.2Indenture, dated March 2, 2020, by and among Catalent Pharma Solutions, Inc., the subsidiary guarantors named therein, Deutsche Trustee Company Limited, as trustee, Deutsche Bank AG, London Branch, as principal paying agent, and Deutsche Bank Luxembourg S.A., as transfer agent and registrar (incorporated by reference to Exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K filed on March 3, 2020).4.2.1Form of 2.375% Senior Notes due 2028 (included as part of Exhibit 4.2 above).4.3Indenture, dated February 22, 2021, by and among Catalent Pharma Solutions, Inc., the subsidiary guarantors named therein, and Deutsche Bank Trust Company Americas, as trustee (incorporated by reference to Exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K filed on February 21, 2021).1354.3.1Form of 3.125% Senior Notes due 2029 (included as part of Exhibit 4.3 above).4.4Indenture, dated September 29, 2021, by and among Catalent Pharma Solutions, Inc., the subsidiary guarantors named therein, and Deutsche Bank Trust Company Americas, as trustee (incorporated by reference to exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K filed on September 29, 2021).4.4.1Form of 3.500% Senior Notes due 2030 (included as part of Exhibit 4.4 above).4.5Description of the Companyâ€™s Capital Stock (incorporated by reference to Exhibit 4.1 to the Companyâ€™s Quarterly Report on Form 10-Q filed on November 1, 2022).10.1Amended and Restated Credit Agreement, dated as of May 20, 2014, relating to the Credit Agreement, dated as of April 10, 2007, as amended, among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, Morgan Stanley Senior Funding, Inc., as the administrative agent, collateral agent and swing line lender and other lenders as parties thereto (incorporated by reference to Exhibit 10.1 to Catalent Pharma Solutions, Inc.â€™s Current Report on Form 8-K filed on May 27, 2014).10.1.1Amendment No. 1, dated December 1, 2014 to Amended and Restated Credit Agreement, dated as of May 20, 2014 among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, Morgan Stanley Senior Funding, Inc., as the administrative agent, collateral agent and swing line lender and other lenders as parties thereto (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed on December 2, 2014).10.1.2Amendment No. 2 to Amended and Restated Credit Agreement, dated as of December 9, 2016, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, Morgan Stanley Senior Funding, Inc. as administrative agent, collateral agent and swing line lender and the lenders party thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc. PTS Intermediate Holdings LLC, Morgan Stanley Senior Funding, Inc. and JP Morgan Chase Bank, N.A. as L/C Issuers, the other lenders party thereto and the other agents party thereto (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed on October 18, 2017).10.1.4Amendment No. 4 to Amended and Restated Credit Agreement, dated as of May 17, 2019, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, Morgan Stanley Senior Funding, Inc., as administrative agent, collateral agent and swing line lender and the lenders party thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, Morgan Stanley Senior Funding, Inc. and JPMorgan Chase Bank, N.A., as L/C Issuers, the other lenders party thereto and the other agents party thereto (incorporated by reference to Exhibit 10.4 to the Companyâ€™s Current Report on Form 8-K filed on May 22, 2019).10.1.5Amendment No. 5 to Amended and Restated Credit Agreement, dated as of February 22, 2021, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JP Morgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JP Morgan Chase Bank, N.A., as the successor administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed on September 29, 2021).13610.1.7Amendment No. 7 to Amended and Restated Credit Agreement, dated as of November 22, 2022, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JP Morgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JP Morgan Chase Bank, N.A., as the successor administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed on November 22, 2022).10.1.8Amendment No. 8 to Amended and Restated Credit Agreement, dated as of June 27, 2023, by JP Morgan Chase Bank, N.A., as the administrative agent, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JP Morgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed on June 27, 2023).10.1.9Amendment No. 9 to Amended and Restated Credit Agreement, dated as of September 27, 2023, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JPMorgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JPMorgan Chase Bank, N.A., as the successor administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed on September 28, 2023).10.1.20Amendment No. 10 to Amended and Restated Credit Agreement, dated as of November 22, 2023, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JPMorgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JPMorgan Chase Bank, N.A., as the successor administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on November 27, 2023).10.1.11Amendment No. 11 to Amended and Restated Credit Agreement, dated as of December 19, 2023, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JPMorgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JPMorgan Chase Bank, N.A., as the successor administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed December 19, 2023).10.2Intellectual Property Security Agreement, dated as of April 10, 2007, among PTS Acquisition Corp., Cardinal Health 409, Inc., PTS Intermediate Holdings LLC, Certain Subsidiaries of Morgan Stanley Senior Funding, Inc. (incorporated by reference to Exhibit 10.2 to Catalent Pharma Solutions, Inc.â€™s Registration Statement on Form S-4 filed on December 6, 2007).10.2.1Intellectual Property Security Agreement Supplement, dated as of July 1, 2008, to the Intellectual Property Security Agreement, dated as of April 10, 2007, among PTS Acquisition Corp., Cardinal Health 409, Inc., PTS Intermediate Holdings LLC, Certain Subsidiaries of Holdings Identified Therein and Morgan Stanley Senior Funding, Inc. (incorporated by reference to Exhibit 10.28 to Catalent Pharma Solutions, Inc.â€™s Annual Report on Form 10-K filed on September 29, 2008).10.3Stockholdersâ€™ Agreement, dated as of May 17, 2019, by and among Catalent, Inc., Green Equity Investors VII, L.P., Green Equity Investors Side VII, L.P., LGP Associates VII-A LLC and LGP Associates VII-B LLC (incorporated by reference to exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed on May 22, 2019).10.4Registration Rights Agreement, dated as of May 17, 2019, by and among Catalent, Inc., Green Equity Investors VII, L.P., Green Equity Investors Side VII, L.P., LGP Associates VII-A LLC and LGP Associates VII-B LLC (incorporated by reference to exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed on May 22, 2019).10.4.1Amendment to Registration Rights Agreement, dated as of April 17, 2024, by and among Catalent, Inc., Green Equity Investors VII, L.P., Green Equity Investors Side VII, L.P., LGP Associates VII-A LLC and LGP Associates VII-B LLC *13710.5Cooperation Agreement, dated as of August 28, 2023, by and among Elliott Investment Management L.P., a Delaware limited partnership, Elliott Associates, L.P., a Delaware limited partnership, and Elliott International, L.P., a Cayman Islands limited partnership, and Catalent, Inc., a Delaware corporation (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed on August 29, 2023).10.6Catalent, Inc. 2014 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.3 to the Companyâ€™s Current Report on Form 8-K filed on August 5, 2014).â€™ 10.7Catalent, Inc. 2018 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed on November 6, 2018).â€™ 10.7.1Amendment No.1 to Catalent, Inc. 2018 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on January 26, 2024).â€™ 10.7.2Form of Restricted Stock Unit Agreement for Non-Employee Directors (incorporated by reference to Exhibit 10.6.1 to the Companyâ€™s Annual Report on Form 10-K filed on December 8, 2023).â€™ 10.7.3Form of 2018 Omnibus Incentive Plan Restricted Stock Unit Agreement for Employees (incorporated by reference to Exhibit 10.6.2 to the Companyâ€™s Annual Report on Form 10-K filed on December 8, 2023).â€™ 10.7.4Form of 2018 Omnibus Incentive Plan Option Agreement for Employees (incorporated by reference to Exhibit 10.6.3 to the Companyâ€™s Annual Report on Form 10-K filed on December 8, 2023).â€™ 10.7.5Form of 2018 Omnibus Incentive Plan Performance Share Unit Agreement for Employees â€™ (incorporated by reference to Exhibit 10.6.4 to the Companyâ€™s Annual Report on Form 10-K filed on December 8, 2023).â€™ 10.8Catalent Pharma Solutions, Inc. Deferred Compensation Plan, as amended and restated effective October 1, 2022 (incorporated by reference to Exhibit 10.6 to the Companyâ€™s Quarterly Report on Form 10-Q filed on November 1, 2022).â€™ 10.9Management Incentive Plan Summary for the fiscal year ending June 30, 2023 (incorporated by reference to Exhibit 10.3 to the Companyâ€™s Quarterly Report on Form 10-Q filed on November 1, 2022).â€™ 10.10Form of Severance Agreement between US-based executive officers and Catalent Pharma Solutions, Inc. (incorporated by reference to Exhibit 10.9 to the Companyâ€™s Annual Report on Form 10-K filed on December 8, 2023).â€™ *10.10.1Form of Severance Agreement between non-US-based executive officers and Catalent Pharma Solutions, Inc. (incorporated by reference to Exhibit 10.9.1 to the Companyâ€™s Annual Report on Form 10-K filed on December 8, 2023).â€™ *10.11Form Retention Agreement (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed on May 29, 2024).â€™ 10.12Employment Agreement, dated January 4, 2022, by and between Catalent, Inc. and Alessandro Maselli (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed on January 5, 2022).10.13Employment Agreement, dated August 28, 2023, between John Greisch and Catalent, Inc. (incorporated by reference to Exhibit 10.3 to the Companyâ€™s Quarterly Report on Form 10-Q filed on May 8, 2024).â€™ 10.14Offer letter, dated July 7, 2022, between Aristippos Gennadios and Catalent, Inc. (incorporated by reference to Exhibit 10.13.1 to the Companyâ€™s Annual Report on Form 10-K filed on August 29, 2022).â€™ 10.15Offer letter, dated January 11, 2024, between Michael J. Hatzfeld, Jr. and Catalent, Inc. (incorporated by reference to Exhibit 10.2 to the Companyâ€™s Quarterly Report on Form 10-Q filed on May 8, 2024).â€™ 10.16Offer letter, dated July 1, 2022, by and between Catalent, Inc. and Ricky Hopson (incorporated by reference to Exhibit 10.17 to the Companyâ€™s Annual Report on Form 10-K filed on December 8, 2023).â€™ 10.16.1Offer letter, dated May 1, 2023, by and between Catalent, Inc. and Ricky Hopson (incorporated by reference to Exhibit 10.17.1 to the Companyâ€™s Annual Report on Form 10-K filed on December 8, 2023).â€™ 10.16.2Amendment to Offer letter, dated August 14, 2023, by and between Catalent, Inc. and Ricky Hopson (incorporated by reference to Exhibit 10.17.2 to the Companyâ€™s Annual Report on Form 10-K filed on December 8, 2023).â€™ 10.17Amended and Restated Employment Agreement, dated January 4, 2022, by and between Catalent, Inc. and John R. Chiminski (incorporated by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed on January 5, 2022).â€™ 10.18Offer letter, dated May 10, 2021, between Thomas Castellano and Catalent Pharma Solutions, Inc. (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed on May 11, 2021).â€™ 13810.18.1Offer letter, dated July 27, 2022, by and between Catalent, Inc. and Thomas Castellano (incorporated by reference to Exhibit 10.5 to the Companyâ€™s Quarterly Report on Form 10-Q filed on November 1, 2022).â€™ 10.19Offer letter, dated July 7, 2022, between Steven Fasman and Catalent, Inc. (incorporated by reference to Exhibit 10.12.1 to the Companyâ€™s Annual Report on Form 10-K filed on August 29, 2022).â€™ 10.20Employment Agreement, dated October 8, 2019, by and between Catalent Pharma Solutions GmbH and Manja Boerman (incorporated by reference to Exhibit 10.18 to the Companyâ€™s Annual Report on Form 10-K filed on December 8, 2023).â€™ 10.20.1Long Term International Assignment Letter, dated October 10, 2022, by and between Catalent Pharma Solutions LLC and Manja Boerman (incorporated by reference to Exhibit 10.18.1 to the Companyâ€™s Annual Report on Form 10-K filed on December 8, 2023).â€™ 10.20.2Termination Agreement, dated as of December 28, 2023, by and between Catalent Pharma Solutions GmbH and Manja Boerman (incorporated by reference to Exhibit 10.3 to the Companyâ€™s Quarterly Report on Form 10-Q filed on February 14, 2024).â€™ 16.1Letter from Ernst & Young LLP, dated March 1, 2024 (incorporated by reference to Exhibit 16.1 in the Companyâ€™s Current Report on Form 8-K filed on March 1, 2024)19.1Insider Trading Policy*21.1Subsidiaries of the Registrant. *23.1Consent of Ernst & Young LLP. *23.2Consent of Grant Thornton LLP. *31.1Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. *31.2Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. *32.1Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *32.2Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. **97.1Catalent, Inc. Executive Compensation Recoupment Policy (incorporated by reference to Exhibit 97.1 to the Companyâ€™s Annual Report on Form 10-K filed on December 8, 2023)101.1The following materials are formatted in inline XBRL (inline eXtensible Business Reporting Language): (i) the Consolidated Statements of Operations, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statement of Changes in Shareholdersâ€™ Equity, (v) the Consolidated Statements of Cash Flows and (vi) Notes to Consolidated Financial Statements. *104The cover page of this Annual Report on Form 10-K, formatted as Inline XBRL and contained in Exhibit 101.1.* Filed herewith** Furnished herewithÃ A Ã A Ã A Represents a management contract, compensatory plan or arrangement in which directors and/or executive officers are eligible to participate.139ITEM 16.Ã A Ã A FORM 10-K SUMMARYRegistrants may voluntarily include a summary of information required by Form 10-K under this Item 16. We elect not to include such summary information.140SIGNATURESPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.CATALENT, INC.Date: September 6, 2024By:Ã /s/ MICHAEL HATZFELDÃ Michael HatzfeldÃ Vice President and Chief Accounting Officer141Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.Ã SignatureTitleDate/s/ ALESSANDRO MASELLIPresident and Chief Executive Officer (Principal Executive Officer) and Director9/6/2024Alessandro Maselli/s/ MATTI MASANOVIChSenior Vice President & Chief Financial Officer9/6/2024Matti Masanovich(Principal Financial Officer)/s/ MICHAEL HATZFELDDirector9/6/2024Michael Hatzfeld/s/ JOHN J. GREISCHExecutive Chair9/6/2024John J. Greisch/s/ MICHAEL J. BARBERDirector9/6/2024Michael J. Barber/s/ STEVEN BARGDirector9/6/2024Steven Bargs/s/ J. MARTIN CARROLLDirector9/6/2024. Martin Carroll/s/ ROLF CLASSONDirector9/6/2024Rolf Classon/s/ FRANK D'AMELIODirector9/6/2024Frank A. D'Amelio/s/ GREGORY T. LUCIERDirector9/6/2024Gregory T. Lucier/s/ DONALD E. MOREL, JR.Director9/6/2024Donald E. Morel, Jr./s/ STEPHANIE OKEYDirector9/6/2024Stephanie Okey/s/ MICHELLE RYANDirector9/6/2024Michelle R. Ryan/s/ JACK STAHLDirector9/6/2024Jack Stahl EX-10.4 1 2 catalent-2024630xex1041.htm EX-10.4 1 DocumentExecution VersionAMENDMENT TO REGISTRATIONRIGHTS AGREEMENTTHIS AMENDMENT (this "Amendment") is made as of April 17, 2024, by and among Catalent, Inc., a Delaware corporation (the "Company") and Green Equity Investors VII, L.P., a Delaware limited partnership, Green Equity Investors Side VII, L.P., a Delaware limited partnership, LOP Associates VII-A LLC, a Delaware limited liability company, and LOP Associates VII-B LLC, a Delaware limited liability company (collectively, on a several and not joint basis, the "Purchaser"). Capitalized terms used but not defined herein shall have the respective meanings assigned to them in that certain Registration Rights Agreement, dated as

of May 17, 2019, by and among the Company and the Purchaser (the "Registration Rights Agreement"). WHEREAS, pursuant to Section 3(a) of the Registration Rights Agreement, the Company is required to use its reasonable best efforts to prepare, file and cause to be declared effective by the SEC a shelf registration statement covering the sale or distribution from time to time by the Shareholders of all of the Registrable Securities and cause such Registration Statement to remain effective under the Securities Act continuously until no Registrable Securities are outstanding (the "Shelf Registration Statement"); WHEREAS, Section 1(l)(a) of the Registration Rights Agreement provides that the provisions of the Registration Rights Agreement may be amended, modified or supplemented, and waivers or consents to departures from the provisions thereof may be given by, but only with, the written consent of the Shareholders holding a majority of the Registrable Securities; and WHEREAS, the undersigned Purchaser holds 2,766,204 Registrable Securities as of the date first written above, and constitutes the Shareholders holding a majority of the Registrable Securities and desires to amend the Registration Rights Agreement to remove the obligation of the Company to file the Shelf Registration Statement. NOW, THEREFORE, for and in consideration of the mutual agreements contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:

(i) Section 3(a) of the Registration Rights Agreement is hereby deleted in its entirety and (ii) Section 3(a) of the Registration Rights Agreement and all references to Section 3(a) of the Registration Rights Agreement in the Registration Rights Agreement and all obligations of the Company with respect to Section 3(a) of the Registration Rights Agreement set forth in the Registration Rights Agreement shall have no further force and effect. Any and all prior failures of the Company to comply with the provisions of Section 3(a) of the Registration Rights Agreement through and including the date hereof are hereby waived, and the Company is hereby fully released by Purchaser of any obligations, or failure to perform any obligations, pursuant to Section 3(a) of the Registration Rights Agreement.

2. This Amendment shall be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned. KL2 3386928.33.Except as specifically amended by this Amendment, the Registration Rights Agreement shall remain in full force and effect. From and after the date hereof, each reference in the Registration Rights Agreement to "this Agreement," "herein," "hereof," "hereunder" or words of similar import, or to any provision of the Registration Rights Agreement, as the case may be, shall be deemed to refer to Registration Rights Agreement or such provision as amended by this Amendment, unless the context otherwise requires.

4. This Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which shall constitute one and the same document. This Amendment may be executed and delivered by facsimile or email. (Remainder of Page Left Intentionally Blank; Signature Page(s) Follow)

2 - Execution Version|IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first written above.

[SIGNATURE PAGE TO AMENDMENT TO REGISTRATION RIGHTS AGREEMENT]

Execution Version AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA [SIGNATURE PAGE TO AMENDMENT TO REGISTRATION RIGHTS AGREEMENT] EX-19.1 3 calatent-2024630ex191.htm EX-19.1 DocumentInsider Trading PolicyVersion 2.0Date Issued: January 29, 2020Issued By: Audit Committee of the Catalent, Inc. Board of DirectorsCatalent Insider Trading Policy v.2This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 20201. BACKGROUNDThis Insider Trading Policy (this "Policy") sets forth the restrictions, guidelines, and expectations of Catalent, Inc. and its subsidiaries (collectively, "Catalent" or the "Company") regarding compliance with United States federal and state securities laws and other such laws in applicable jurisdictions relating to trading in securities. This Policy and securities laws prohibit trading in the securities of any company, including Catalent, while in the possession of material nonpublic information relating to that company (known as "insider trading"), as well as passing on material nonpublic information to others who trade on that information (known as "tipping"). In addition to requiring compliance with securities laws, this Policy includes additional guidance and restrictions to avoid even the appearance of impropriety in order to preserve the reputation and integrity of Catalent and all persons and entities affiliated with it.

2. OBJECTIVEIn the normal course of business, Catalent employees may come into possession of information concerning Catalent, transactions in which Catalent proposes to engage, or the activities of other entities with which Catalent does business (such as our customers and vendors). Trading securities while in possession of such information may be deemed insider trading under relevant securities laws. The penalties for violating these laws may be severe, including substantial prison time, large fines, recoupment of all ill-gotten profits, and more. Catalent has established this Policy in order to protect Catalent and its employees from committing, or giving the appearance of having committed, violations of such laws.

3. SCOPEThis Policy applies to Catalent, including without limitation its direct and indirect subsidiaries, and all of its and their respective:a.directors, officers, employees, agents, independent contractors, and those persons in an advisory relationship to Catalent or its personnel, including auditors, consultants, and attorneys (collectively, "Catalent Personnel");b.their Family Members (as defined below); and;c.any trust, corporation or other entity controlled by any such person.Collectively, all of these persons connected to Catalent will be referred to as "Insiders" in this Policy to the extent that they come into possession of material nonpublic information. Note that this Policy continues to apply to an Insider who is aware of material nonpublic information arising from the Insider's connection to Catalent even when the Insider no longer satisfies the foregoing definition, and the Policy will remain applicable until that information has become public or is no longer material.

4. RESPONSIBILITYThe Company's Legal & Compliance Department (the "Legal Department") is responsible for maintaining and updating this Policy, subject to the supervision of the Audit Committee of Catalent's Board of Directors. All business units and all personnel that are part of the Catalent Leadership Team (the "CLT") are responsible for implementing this Policy and ensuring Catalent Insider Trading Policy v.2This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 2020Compliance. The CLT is responsible for understanding, or seeking clarification of, all of the elements of this Policy and for ensuring that the Catalent Personnel who directly or indirectly report to them are familiar with them as well.Members of the Legal Department, the Company's Human Resources Department ("HR"), and the Company's Internal Audit group may all be designated as responsible for investigating alleged violations of this Policy and, together with an employee's manager, effecting appropriate disciplinary action in response to proven violations.This Policy and the procedures that implement this Policy are not intended to mirror the precise contours of the legal prohibitions against insider trading and tipping, which are highly complex, fact-specific, and evolving. Certain of the procedures of this Policy are designed to prevent even the appearance of impropriety and, in some respects, may be more restrictive than the securities laws. In this respect, the matters set forth in this Policy are guidelines only and are not intended to replace your responsibility to understand and comply with the legal prohibitions on insider trading. Appropriate judgment should be exercised in connection with all securities trading. Violation of securities laws can result in civil and criminal penalties (including a prison term and substantial fines and other monetary penalties) for individuals and Catalent. Catalent personnel must be pro-active in bringing questions or concerns regarding this Policy, applicable law, or the application of either to a particular set of facts to the attention of the General Counsel, any member of the Legal Department, or your own legal counsel.

5. POLICY DETAILS5.1 General5.1.1 Policy StatementIt is Catalent's policy that no Insider may:1.buy or sell Catalent securities or the securities of any other relevant company when in possession of material nonpublic information learned in connection with the Insider's relationship with Catalent,2.engage in any other action outside the scope of the job responsibilities of the applicable Catalent personnel to take advantage of that information, or3.disclose to others such information in any context outside the scope of the job responsibilities of the applicable Catalent personnel.This Policy applies equally to material nonpublic information relating to any other company with publicly traded securities, including Catalent's customers, vendors, suppliers, and business partners, obtained in the course of the Insider's employment with Catalent or by reason of the Insider's association with Catalent.Restrictions that apply to all Catalent Personnel and Insiders are set forth in Section 5.2 below.Additional restrictions on trading by Catalent's directors and officers (as defined in Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (alsoSection 16 Persons)and other Catalent-designated restricted persons are set forth in Section 5.3 below.Catalent Insider Trading Policy v.2This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 20205.1.2. Definitions / Explanations.Who is an Insider?Any person within the scope of the definition of "Insider" set forth in Section 3 who possesses material nonpublic information is likely to be considered an Insider as to that information. Insiders may include Catalent Personnel and their Family Members, as well as any trust, corporation or other entity controlled by such Catalent Personnel. Within the scope of this Policy, an Insider may possess material nonpublic information about Catalent or any other company as a result of such Insider's employment by or association with Catalent. The definition of "Insider" is transaction-specific, meaning that an individual's status as an Insider will depend on the specific information known by the Insider and the context in which the Information is used or disseminated.b. What is "Material" Information?Under this Policy and the U.S. federal securities laws, information is generally considered "material" if a reasonable investor would consider it important or valuable in deciding whether to buy, sell, or hold a security or where the information is likely to affect the market price of the security. The information may concern Catalent or another company and may be positive or negative. Employees should assume that information that would affect their consideration of whether to trade, or that might tend to influence the price of the security, is material.Examples of material information include, but are not limited to:a.information concerning the declaration of a dividend,b.earnings results, estimates and guidance on earnings, and changes in previously released earnings results, estimates, or guidance,c.a significant merger, acquisition, or divestiture proposal or agreement,d.investments, joint ventures, or changes in assets,e.new service offerings or significant news relating to service offerings,f.the gain or loss of a significant customer,g.extraordinary management developments,h.the approval or rejection of any marketing application for any product of significance to a customer in any substantial jurisdiction,i.a significant customer product or ingredient supply shortages,j.adverse regulatory action against any substantial Company facility,k.restructuring or layoffs,l.changes in auditors,Insiders should err on the side of caution, because the regulations of the U.S. Securities and Exchange Commission (the "SEC") provide that the mere fact that a person is aware of Catalent Insider Trading Policy v.2This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 2020material nonpublic information is a bar to trading. It is no excuse that such person's reasons for trading were not based on the information.c. What is "Nonpublic" Information?Information is "nonpublic" if it has not been disseminated in a manner that makes it generally available to the public and investors.For purpose of this Policy, information is "nonpublic" until three criteria have been satisfied:1. the information has been widely disseminated, such as through disclosures in a company's public filings with the SEC, inclusion in an issued company press release, or otherwise widely disseminated in the media, such as through a financial news service like Yahoo! Finance, BusinessWire, or PR Newswire, carried in a general news service like the Associated Press, or carried by a national news service such as The New York Times, the Wall St. Journal, CNN, CNBC, or the Fox Business Channel;2.the information disseminated must be some form of official announcement (i.e., the fact that rumors, speculation, or statements attributed to unidentified sources are public is insufficient to make information "public" within the meaning of this Policy even when the rumored information turns out to be accurate); and3.after the information has been disseminated, sufficient time must pass for the information to be absorbed by the general public. Despite the near-instantaneous worldwide dissemination of information in the age of the Internet, as a general rule, information should not be considered absorbed by the general public under this Policy until the second trading day on the New York Stock Exchange after the day on which the information is widely disseminated.Further guidance on whether information is adequately disseminated to be "public" should be obtained from the Legal Department.

5.2 Restrictions and Guidelines for all Catalent Insiders

5.2.1 Non-disclosure of Nonpublic InformationCatalent Personnel should not disclose any nonpublic information learned in connection with their employment or association with Catalent to any non-Catalent Personnel (including to Family Members), except for legitimate business purposes where such disclosure is needed to carry out Catalent's business and then only when the Catalent Personnel disclosing the information has no reason to believe that the recipient will misuse the information.No Insider who receives or has access to material nonpublic information arising from the Insider's relationship with Catalent may comment on stock price movements or rumors of other corporate developments (including through any on-line or social media platform) that are of possible significance to the investing public unless it is part of the Insider's job (such as Investor Relations) or the Insider has been specifically authorized in accordance with Catalent's Policies and Procedures for Compliance with Regulation FD. If an Insider comments on stock price movements or rumors or discloses material nonpublic information to a third party outside the scope of this rule, the Insider must contact the General Counsel immediately.Catalent Insider Trading Policy v.2This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 2020In addition, it is generally the practice of Catalent not to respond to rumors concerning Catalent's affairs or inquiries seeking material nonpublic information concerning Catalent or any of its business partners. If you receive inquiries concerning Catalent from the media or from securities analysts or other members of the financial community, you should refer such inquiries, without comment, to the Company's Investor Relations Officer or the General Counsel.

5.2.2 Prohibition on Trading on Material Nonpublic InformationNo Insider may buy or sell Catalent's securities at any time when the Insider has material nonpublic information concerning Catalent.No Insider may buy or sell securities of another company at any time when the Insider has material nonpublic information about that company, including, without limitation, any of our customers, when that information was obtained as a result of the Insider's employment with or other relationship to Catalent.Catalent Personnel are responsible for any trade placed by their Family Members and should make them aware of the need to confer with such Catalent Personnel before they trade in Catalent securities.

5.2.3 Prohibition on "Tipping" Material Nonpublic Information to OthersNo Insider may disclose "material" nonpublic information to any other person (including Family Members), and no Insider may make "buy" or "sell" recommendations on the basis of material nonpublic information. In addition, Insiders should take care before trading on the recommendation of others to ensure that the recommendation is not the result of an illegal "tip".

5.2.4 Prohibition on Short Sales or Speculative TransactionsNo Insider, whether or not the Insider possesses material nonpublic information, may trade in options, warrants, puts or calls, or similar instruments based on Catalent's securities or sell Catalent stock or any such securities "short" (i.e., selling stock that is not owned and borrowing the shares to make delivery). Such activities may put the personal gain of the Insider in conflict with the best interests of Catalent and its security holders or otherwise give the appearance of impropriety.No Catalent Personnel may engage in any transaction (including any variable forward contract, equity swap, collar or exchange fund) that is designed to hedge or offset any decrease in the market value of Catalent's equity securities.

5.2.5 Prohibition on Pledging/Margin Accounts without Pre-ClearanceCatalent Insider Trading Policy v.2This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 2020No Catalent Personnel, whether or not in possession of material nonpublic information, may purchase Catalent's securities on margin, or borrow against any account in which Catalent's securities are held, or pledge Catalent securities as collateral for a loan, without first obtaining pre-clearance.Request for pre-clearance must be submitted to the General Counsel at least two weeks prior to the execution of the documents evidencing the proposed pledge. The General Counsel is under no obligation to approve any request for pre-clearance. Approvals will be based on the particular facts and circumstances of the request. Notwithstanding the pre-clearance of any request, Catalent assumes no liability for the consequences of any transaction made pursuant to such request.

5.2.6 Permitted TransactionsThe prohibition on trading in Catalent's securities set forth in this Section 5.2 does not apply to:a.Transferring shares to an entity that does not involve a change in the beneficial ownership of the shares (for example, to an inter vivos trust of which the Insider is the sole beneficiary during the Insider's lifetime),b.The exercise of stock options pursuant to our stock plans; however, the sale of any such stock acquired upon such exercise, including as part of a cashless exercise of an option, is subject to this Policy.c.The exercise of a tax withholding right pursuant to which the Insider has elected to have the Company withhold shares of restricted stock, shares underlying restricted stock units, or shares subject to an option to satisfy tax withholding requirements.d.The execution of transactions pursuant to a trading plan that complies with SEC Rule 10b5-

provided by Catalent that they are subject to the pre-clearance requirements set forth in Section 5.3.3 because Catalent determines that, in the normal course of their duties, they are likely to have regular access to material nonpublic information (the "Other Restricted Persons"). Examples of such persons include other corporate officers like those working in the Sales and Marketing, Global Operations, Legal, Finance, and Corporate Development Departments, Family Members of any of such persons, and trusts, corporations, and other entities controlled by any of such persons. In addition, certain Insiders may have access to material nonpublic information for a limited period. During such a period, such persons may be notified that they are also Other Restricted Persons and subject to the pre-clearance requirements set forth in this Section 5.3.3. Termination of Insider Status for Permanent Restricted Persons and Other Restricted Persons: This Policy continues in effect for all Permanent Restricted Persons and Other Restricted Persons after termination of employment or other relationship with Catalent until the opening of the first Window Period (defined in Section 5.3.2) after such termination. Unless notified otherwise by Catalent, the pre-clearance requirements set forth in Section 5.3.1 continue to apply to Permanent Restricted Persons for six months after the termination of their status as a Permanent Restricted Person. 5.3.1 Pre-clearance of Trades. General. Permanent Restricted Persons and Other Restricted Persons must obtain the advance approval of the General Counsel or his designee in accordance with this Section 5.3 before effecting transactions in Catalent's securities, including any exercise of an option (whether cashless or otherwise), rights, or warrants to purchase or sell such securities, gifts, loans, pledges, contribution to a trust, or other transfers, whether the transaction is for the individual's own account, one over which he or she exercises control, or one in which he or she has a beneficial interest. Procedure. Subject to permitted trading under a Catalent-approved 10b5-1 trading plan (see Section 5.2.6), Permanent Restricted Persons and Other Restricted Persons must submit a request for pre-clearance to the General Counsel at least two business days in advance of the proposed transaction (two weeks in the case of using shares as collateral for a loan (see Section 5.2.5)) and by completing the Request for Approval to Trade form attached as Appendix B to this Policy. Approval for transactions and pledges of Company securities will generally be granted only during a Window Period (described in Section 5.3.2), and the transaction may only be performed during the Window Period in which the approval was granted and, in any event, within two business days from the date of approval. Hardship Exemption. Catalent Insider Trading Policy v.2 This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 2020 Those subject to the Window Periods or a blackout pursuant to Section 5.3.3 may request a hardship exemption for periods outside the Window Periods or during a blackout, as applicable, if they are not in possession of material nonpublic information and are not otherwise prohibited from trading pursuant to this Policy. Hardship exemptions are granted infrequently and only in exceptional circumstances. Any request for a hardship exemption should be made to the General Counsel. 5.3.2 Window Periods for Pre-Cleared Trades. Window Periods. Catalent has established four trading windows of time during the fiscal year during which Request for Approval to Trade forms may be approved and transactions and pledges may be performed (the "Window Periods"). Each Window Period begins with the second trading day on the New York Stock Exchange after the day on which Catalent makes a public news release of its quarterly or annual earnings for the prior fiscal quarter or year. That same Window Period closes at the close of trading on the last trading day that is two weeks prior to the end of the then-current fiscal quarter. At any time that is not within a Window Period, Permanent Restricted Persons and Other Restricted Persons may not trade in any Catalent security. The use of Window Periods by Catalent is a prophylactic mechanism intended to prevent any violation of law and even the appearance of impropriety, so the prohibition against trading while aware of, or tipping of, material nonpublic information applies even during a Window Period. For example, if during a Window Period, a material acquisition or divestiture is pending or a forthcoming publication in the financial press known to an Insider may affect the relevant securities market, the Insider may not trade in Catalent's securities. You must consult the General Counsel whenever you are in doubt. 5.3.3 Blackout Periods. From time to time, Catalent may require that directors, officers, selected employees, and others suspend trading in Catalent's securities because of developments that have not yet been disclosed to the public. All those affected shall not trade in Catalent securities while the suspension is in effect and shall not disclose to others that the Company has suspended trading for certain individuals. Though these blackouts generally will arise because Catalent is involved in a highly-sensitive transaction, they may be declared for any reason. If Catalent declares a blackout to which you are subject, a member of the Legal Department will notify you when the blackout begins and when it ends. 5.4 Broker Requirements. Section 16 of the Exchange Act requires the timely reporting of certain transactions by certain Section 16 Persons. Timely satisfaction of these legal obligations requires tight interface between Catalent and the brokers handling transactions for our directors and executive officers. In order to facilitate timely compliance by Catalent's directors and executive officers with the requirements of Section 16 of the Exchange Act, brokers of Section 16 Persons need to comply with the following requirements: a) Not to enter any order (except for orders under pre-approved Rule 10b5-1 trading plans) without first verifying with Catalent that the transaction was pre-cleared and complying with the brokerage firm's compliance procedures (e.g., Rule 144), and b) To report to Catalent the complete details (i.e., date, type of transaction, number of shares, and price) of every transaction involving Catalent's securities (including gifts, transfers, pledges, and all 10b5-1 transactions) before the close of business on the day of the Catalent Insider Trading Policy v.2 This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 2020 Execution of the transaction, by telephone and in writing via e-mail to the General Counsel and the Corporate Secretary. Because it is the legal obligation of the trading person to cause this filing to be made with the SEC, you are strongly encouraged to confirm following any transaction that your broker has immediately telephoned and e-mailed the required information to the appropriate Catalent staff. 5.4 Consequences for Insider Trading and Violation of this Policy. 5.4.1 Individual Responsibility. Each Insider is individually responsible for complying with applicable securities laws and this Policy, regardless of whether Catalent has prohibited trading by that Insider or any other Insider. Trading in securities during the Window Periods and outside of any suspension period should not be considered a safe harbor. Insiders should bear in mind that any proceeding alleging improper trading will necessarily occur after the trade has been completed and is particularly susceptible to second-guessing with the benefit of hindsight. Further, whether or not you possess material nonpublic information, it is advisable that, if you invest in Catalent's securities or the securities of any company that has a substantial relationship with Catalent, you approach that investment from the perspective of a long-term investor who would like to participate over time in Catalent's or such company's performance. 5.4.2 Liability of Controlling Persons. Securities laws provide that, in addition to sanctions against an individual who trades illegally, penalties may be assessed against what are known as "controlling persons" with respect to the violator. The term "controlling person" is not defined, but can include employers (e.g., Catalent) and the directors, officers, and managerial and supervisory personnel of the controlled person's employer. The concept is broader than what would normally be encompassed by a reporting chain. Individuals may be considered "controlling persons" with respect to any other individual whose behavior they have the power to influence. For this reason, Catalent's supervisory personnel are directed to take appropriate steps to ensure that those they supervise understand and comply with the requirements set forth in this Policy. 5.4.3 Potential Sanctions. Liability for Insider Trading and Tipping. Insiders, controlling persons, and Catalent may be subject to civil penalties, criminal penalties, and incarceration for trading in securities when they possess material nonpublic information or for improper transactions by any person (commonly referred to as a "tippee") to whom they have disclosed material nonpublic information, or to whom they have made recommendations or expressed opinions on the basis of such information about trading securities. The SEC has imposed large penalties even when the disclosing person did not profit from the trading. The SEC, the stock exchanges, and the Financial Industry Regulatory Authority use sophisticated electronic surveillance techniques to uncover insider trading. The SEC also has the power to bar an individual who engages in insider trading from ever serving as an officer or director of any public company. Catalent Insider Trading Policy v.2 This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 2020 Possible Disciplinary Actions. Catalent Personnel who violate this Policy will be subject to disciplinary action, up to and including termination of employment for cause, whether or not the Catalent Personnel's failure to comply results in a violation of law. 5.5 Policy Violations, Interpretations, and Amendments. Any violation or perceived violation of this Policy must be reported immediately to Catalent's General Counsel. Questions regarding the interpretation of the policy may be addressed to a member of the Legal Department. This Policy may be amended by the Company at any time. 6. LOSSARY. Term Description. Family Members. For purposes of this Policy, your "family members" include family members who reside with you, anyone else who lives in your household, and any family member who does not live in your household but whose transactions in Catalent's securities are directed by you or are subject to your influence or control. Security or Securities. The term "security" or "securities" is defined very broadly by the securities laws and includes stock (common and preferred), stock options, warrants, bonds, notes, debentures, convertible instruments, put or call options (i.e., exchange-traded options), or other similar instruments. Trade or Trading. The term "trade" or "trading" broadly means any purchase, sale, or other transaction to acquire, transfer, or dispose of securities, including market option exercises, gifts or other contributions, cashless exercises of stock options granted under any Catalent incentive plan, sales of stock acquired upon the exercise of options, and trades made under an employee benefit plan such as a 401(k) plan. Under special circumstances, "trading" may even include the exercise of a stock option by the cash payment of the exercise price of the exercise price and any applicable withholding tax, but normally such an exercise is not considered a "trade." Consult the Legal Department for further guidance regarding stock option trades. 7. REFERENCES. Number Reference. Details. Standards of Business Conduct. Global Ethical Business Practices. Confidentiality / Ethical Wall Policy. 4 Policy and Procedures for Compliance with Regulation FD. 8. APPENDICES. Reference Title. Rule 10b5-1 Plans. B Request for Approval to Trade Form. Approvals. Catalent Insider Trading Policy v.2 This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 2020 This Policy has been approved by the Audit Committee of the Catalent, Inc. Board of Directors. Version History. Version Number. Version Date. Policy Author. Summary of Changes. 1. 022 July 2014. Simpson Thacher & Bartlett. Original Policy. 2. 029 January 2020. Amy Fallone. Enoje Ibe. a. torremendia. Revised to reflect the Company's changing needs and practices. Catalent Insider Trading Policy v.2 This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 2020 APPENDIX A RULE 10b5-1 PLAN. A Rule 10b5-1 trading plan is a binding, written contract between you and your broker that specifies the price, amount, and date of trades to be executed in your account in the future, or provides a formula or mechanism that your broker will follow concerning future securities trades. A Rule 10b5-1 trading plan can only be established when you do not possess material nonpublic information. In addition, persons subject to the pre-clearance requirements described in Section 5.3 of this Policy cannot enter into these plans outside Window Periods. In addition, a Rule 10b5-1 trading plan must not permit you to exercise any subsequent influence over how, when, or whether the purchases or sales are made. You have an affirmative defense against any claim by the SEC against you for insider trading if your trade was made under a Rule 10b5-1 trading plan that you entered into when you were not aware of material nonpublic information. The rules regarding Rule 10b5-1 trading plans are complex, and you must fully comply with them. You should consult with your legal advisor before proceeding. Each Insider must pre-clear with the General Counsel the Insider's proposed Rule 10b5-1 trading plan prior to the establishment of such plan. Catalent reserves the right to withhold pre-clearance of any Rule 10b5-1 trading plan that the Company determines is not consistent with the rules regarding such plans. Notwithstanding any pre-clearance of a Rule 10b5-1 trading plan, Catalent assumes no liability for the consequences of any transaction made pursuant to such plan. If you enter into a Rule 10b5-1 trading plan, your plan should be structured to avoid purchases or sales shortly before known announcements, such as quarterly or annual earnings announcements. Even though transactions executed in accordance with a properly formulated Rule 10b5-1 trading plan are exempt from the insider trading rules, the trades may nonetheless occur at times shortly before Catalent announces material news, and the investing public and media may not understand the nuances of trading pursuant to a Rule 10b5-1 trading plan. This could result in negative publicity for you and the Company if the SEC or the New York Stock Exchange were to investigate your trades. For Insiders, any modification or termination of a pre-approved Rule 10b5-1 trading plan requires pre-clearance by the General Counsel. In addition, any modification of a pre-approved Rule 10b5-1 trading plan must occur before you become aware of any material nonpublic information and must comply with the requirements of the rules regarding Rule 10b5-1 trading plans and, if you are subject to Window Period restrictions, must take place during a Window Period. Transactions effected pursuant to a pre-cleared Rule 10b5-1 trading plan will not require further pre-clearance at the time of the transaction if the plan specifies the dates, prices and amounts of the contemplated trades, or establishes a formula for determining the dates, prices and amounts. Finally, if you are a Section 16 Person, Rule 10b5-1 trading plans require special care. Because, in a Rule 10b5-1 trading plan, you can specify conditions that trigger a purchase or sale at a distant future time defined by a broker interpreting the plan, you may not even be aware that a transaction has taken place and you may not be able to comply with the SEC's "requirement that you report your transaction to the SEC within two business days after its execution. Therefore, for Section 16 Persons, a transaction executed according to a Rule 10b5-1 trading plan is not permitted unless the Rule 10b5-1 trading plan requires your broker to notify the Company before the close of business on the day of the execution of the transaction. See Section 5.3.4. Catalent Insider Trading Policy v.2 This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 2020 APPENDIX B REQUEST FOR APPROVAL TO TRADE. REQUEST FOR APPROVAL TO TRADE. CATALENT, INC. SECURITY. Type of Security (check all applicable boxes): a) Common stock b) Preferred stock c) Stock option d) Number of Shares: Proposed Date of Transaction: Type of Transaction: a) Stock option exercise b) Exercise Price \$ per share c) Exercise Price paid as follows: d) Brokerage fee e) Cashless exercise f) Cash g) Sale h) Gift i) ESPP (changing instructions regarding level of withholding) j) Other: Broker Contact Information: a) Company Name b) Contact Name & email c) Telephone d) Account Number e) Status (check all applicable boxes) f) ELT Member g) Board Member h) Other Restricted Person i) Filing Information (check all applicable boxes and complete blanks) j) Date of last Form 4: k) Not Applicable l) Not Sure m) Not Sure n) Not Sure o) Not Sure p) Not Sure q) Not Sure r) Not Sure s) Not Sure t) Not Sure u) Not Sure v) Not Sure w) Not Sure x) Not Sure y) Not Sure z) Not Sure. I hereby certify that the statements made on this form are true and correct. I understand that clearance may be rescinded prior to effectuating the above transaction if material non-public information regarding Catalent, Inc. arises and, in the reasonable judgment of Catalent, Inc., the completion of my trade would be inadvisable. I also understand that the ultimate responsibility for compliance with the insider trading provisions of the federal securities laws rests with me and that clearance of any proposed transaction should not be construed as a guarantee that I will not later be found to have been in possession of material non-public information. Signature: a) Date: Print Name: Telephone Number: Where You May Be Reached: a) Catalent Insider Trading Policy v.2 This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 2020 a) Approved (transaction must be completed during the Window Period (as defined in Section 5.3.2 of Catalent, Inc.'s Securities Trading Policy) in which this approval was granted and in any event within two business days after approval) b) Denied c) Approved with the following modification: Signature: Date: Catalent Insider Trading Policy v.2 This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 2020 EX-21.1 a) catalent-2024630xex211.htm EX-21.1 Document Exhibit 21.

KINGDOM)51Catalent Pharma Solutions, LLC (DELAWARE)52Catalent Pharmaceutical Technology (Shanghai) Co., Ltd. (CHINA)53Catalent PR Humacao, Inc. (PUERTO RICO)54Catalent Princeton, LLC (DELAWARE)55Catalent San Diego Inc. (CALIFORNIA)56Catalent (Shanghai) Clinical Trial Supplies Co Ltd. (CHINA)57Catalent Shiga K.K. (JAPAN)58Catalent Singapore Holdings Pte. Ltd. (SINGAPORE)59Catalent U.K. Packaging Limited (UNITED KINGDOM)60Catalent U.K. Swindon Holding II Limited (UNITED KINGDOM)61Catalent U.K. Swindon Zydys Limited (UNITED KINGDOM)62Catalent UK Supply Chain Limited (UNITED KINGDOM)63Catalent Uruguay S.A. (URUGUAY)64Catalent US Holding I, LLC (DELAWARE)65Catalent USA Packaging, LLC (DELAWARE)66Catalent Wellness, LLC (DELAWARE)67Catalent Wellness California, LLC (CALIFORNIA)68Catalent Wellness Holdings, LLC (DELAWARE)69Catalent Wellness Indiana, LLC (DELAWARE)70Catalent Wellness New Jersey, LLC (DELAWARE)71Catalent Wellness Virginia, LLC (DELAWARE)72PTS Intermediate Holdings LLC (DELAWARE)73R.P. Scherer Technologies, LLC (NEVADA)74Raritan Valley Insurance Company (NEW JERSEY)75Redwood Bioscience Inc. (DELAWARE) EX-23.1 5 catalent-2024630xex231.htm EX-23.1 DocumentExhibit 23.1Consent of Independent Registered Public Accounting FirmWe consent to the incorporation by reference in the following Registration Statements: (1)A A A Registration Statement (Form S-8 No. 333-197726) pertaining to the Catalent, Inc. 2014 Omnibus Incentive Plan, (2)A A A Registration Statement (Form S-8 No. 333-228438) pertaining to the Catalent, Inc. 2018 Omnibus Incentive Plan and the Catalent, Inc. 2019 Employee Stock Purchase Plan, (3)A A A Registration Statement (Form S-3 No. 333-267639) of Catalent, Inc. and in the related Prospectus, and(4)A A A Registration Statement (Form S-8 No. 333-278578) pertaining to the Catalent, Inc. 2018 Omnibus Incentive Plan;of our report dated December 8, 2023, with respect to the consolidated financial statements of Catalent, Inc. included in this Annual Report (Form 10-K) of Catalent, Inc. for the year ended June 30, 2024./s/ Ernst& Young LLPIselin, New JerseySeptember6, 2024 EX-23.2 6 catalent-2024630xex232.htm EX-23.2 DocumentExhibit 23.2Consent of Independent Registered Public Accounting FirmWe have issued our reports dated August 29, 2024, with respect to the consolidated financial statements and internal control over financial reporting included in the Annual Report of Catalent, Inc. on Form 10-K for the year ended June 30, 2024. We consent to the incorporation by reference of said reports in the Registration Statements of Catalent, Inc. on Forms S-8 (File No. 333-197726, File No. 333-228438 and File No. 333-278578) and Form S-3 (File No. 333-267639)/s/ Grant Thornton LLPNew York, NYSeptember6, 2024 EX-31.1 7 catalent-2024630xex311.htm EX-31.1 DocumentExhibit 31.1 CERTIFICATION PURSUANT TO SECTION 302OF THE SARBANES-OXLEY ACT OF 2002I, Alessandro Maselli, certify that: 1.I have reviewed this Annual Report on Form 10-K for the period ended June30, 2024 of Catalent, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.A A A Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d.A A A Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: September6, 2024/s/ ALESSANDRO MASELLIAlessandro MaselliPresident and Chief Executive Officer(Principal Executive Officer) EX-31.2 8 catalent-2024630xex312.htm EX-31.2 DocumentExhibit 31.2 CERTIFICATION PURSUANT TO SECTION 302OF THE SARBANES-OXLEY ACT OF 2002I, Matti Masanovich, certify that: 1.I have reviewed this Annual Report on Form 10-K for the period ended June30, 2024 of Catalent, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.A A A Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d.A A A Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. /s/ MATTI MASANOVICHMatti MasanovichSenior Vice President andChief Financial Officer(Principal Financial Officer)Date: September6, 2024 EX-32.1 9 catalent-2024630xex321.htm EX-32.1 DocumentExhibit 32.1 Certification of the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Catalent, Inc. (the â€œCompanyâ€) on Form 10-K for the period ended June30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Alessandro Maselli, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: September6, 2024/s/ ALESSANDRO MASELLIAlessandro MaselliPresident and Chief Executive Officer EX-32.2 10 catalent-2024630xex322.htm EX-32.2 DocumentExhibit 32.2 Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Catalent, Inc. (the â€œCompanyâ€) on Form 10-K for the period ended June30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Matti Masanovich, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: September6, 2024 /s/ MATTI MASANOVICHMatti MasanovichSenior Vice President andChief Financial Officer EX-101.SCH 11 c1t-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Consolidated Statements of Comprehensive Income / (Loss) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Consolidated Statement of Changes in Shareholder's Equity link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Consolidated Statement of Changes in Shareholder's Equity - Shares of Common Stock link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Goodwill link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Definite Lived Long-Lived Assets link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Restructuring and Other Costs link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Derivative Instruments and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Fair Value Measures and Disclosures link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Employee Retirement Benefit Plans link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Equity and Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Redeemable Preferred Stock - Series A Preferred link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Equity Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Other Income / Expense link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952175 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952176 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 9952177 - Disclosure - Supplemental Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 9952178 - Disclosure - Subsequent Events (Notes) link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Revenue from Contract with Customer (Policies) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Definite Lived Long-Lived Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Restructuring and Other Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Earnings Per Share Calculation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Fair Value Measures and Disclosures (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Employee Retirement Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Equity and Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Equity Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Other Income / Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Supplemental Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Concentrations of Credit Risk and Major Customers (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Property and Equipment and Other Definite Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Research and Development Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Recent Financial Accounting Standards (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Revenue Recognition Disaggregation of Revenue by type of activity and reporting segment (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Revenue Recognition Disaggregation of Revenue by type of activity and reporting segment (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Revenue Recognition Disaggregation of Revenue by Geography (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Revenue Recognition Contractual Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Revenue Recognition Contractual Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Revenue from Contract with Customer (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Business Combinations Purchase Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Business Combinations Net Assets Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Business Combinations Pro Forma Results (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Business Combinations, Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Goodwill - Carrying Amount of Goodwill (Detail) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Definite Lived Long-Lived Assets - Other Intangible Assets Subject to Amortization (Detail) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Definite Lived Long-Lived Assets - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Definite Lived Long-Lived Assets - Future Amortization Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Restructuring and Other Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings - Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Fair Value Measurements of Financial Instruments - Carrying Amounts and Estimated Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Interest Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Earnings Per Share Calculations of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Earnings Per Share Earnings Per Share - Additional Details (Details)

link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Fair Value Measures and Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Income Taxes Schedule of Income before Tax Domestic and Foreign (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Income Taxes-Components of Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Income Taxes-Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Income Taxes-Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Income Taxes-Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - Income Taxes-Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - Employee Retirement Benefit Plans-Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - Employee Retirement Benefit Plans-Accumulated Benefit Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - Employee Retirement Benefit Plans-Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - Employee Retirement Benefit Plans-AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - Employee Retirement Benefit Plans-Fiscal Year Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - Employee Retirement Benefit Plans-Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954532 - Disclosure - Employee Retirement Benefit Plans-Level 3 (Details) link:presentationLink link:calculationLink link:definitionLink 9954533 - Disclosure - Employee Retirement Benefit Plans-Assumed Healthcare Trend Rates (Details) link:presentationLink link:calculationLink link:definitionLink 9954534 - Disclosure - Employee Retirement Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9954535 - Disclosure - Equity and Accumulated Other Comprehensive Income (Loss) Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954536 - Disclosure - Equity and Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Earnings/(Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954537 - Disclosure - Equity and Accumulated Other Comprehensive Income (Loss)-Minimum Pension Liability (Details) link:presentationLink link:calculationLink link:definitionLink 9954538 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954539 - Disclosure - Equity Based Compensation (Additional) (Details) link:presentationLink link:calculationLink link:definitionLink 9954540 - Disclosure - Equity Based Compensation (Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 9954541 - Disclosure - Equity Based Compensation (RSU Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 9954542 - Disclosure - Other Income / Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954543 - Disclosure - Leases - Schedule of Operating and Finance Leases Presented in the Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 9954544 - Disclosure - Leases - Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954546 - Disclosure - Leases - Schedule of Maturities of Operating And Finance Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954547 - Disclosure - Commitments and Contingencies-Future Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954548 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954549 - Disclosure - Commitments and Contingencies Commitments and Contingencies - Claims (Details) link:presentationLink link:calculationLink link:definitionLink 9954550 - Disclosure - Segment Information - Net Revenue and Segment Ebitda (Detail) link:presentationLink link:calculationLink link:definitionLink 9954551 - Disclosure - Segment Information - Reconciliation of Earnings/ (loss) from Continuing Operations to Ebitda (Detail) link:presentationLink link:calculationLink link:definitionLink 9954552 - Disclosure - Segment Information Total Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954553 - Disclosure - Segment Information Depreciation and Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9954554 - Disclosure - Segment Information Capital Expenditures (Details) link:presentationLink link:calculationLink link:definitionLink 9954555 - Disclosure - Segment Information - Assets and Revenues (Detail) link:presentationLink link:calculationLink link:definitionLink 9954556 - Disclosure - Supplemental Balance Sheet Information - Work-in-Process and Finished Goods Inventories Include Raw Materials, Labor and Overhead (Detail) link:presentationLink link:calculationLink link:definitionLink 9954557 - Disclosure - Supplemental Balance Sheet Information - Prepaid and Other Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 9954558 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment (Detail) link:presentationLink link:calculationLink link:definitionLink 9954559 - Disclosure - Supplemental Balance Sheet Information - Other Assets Non Current (Detail) link:presentationLink link:calculationLink link:definitionLink 9954560 - Disclosure - Supplemental Balance Sheet Information - Other Accrued Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 9954561 - Disclosure - Supplemental Balance Sheet Information- Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 9954562 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 cttt-20240630 cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 cttt-20240630 def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 cttt-20240630 lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Trading Securities at Fair Value Trading Securities at Fair Value participant-directed stock and bond mutual funds Prepaid Taxes Prepaid Taxes Defined Benefit Plan, Expected Future Benefit Payment, Year Two Defined Benefit Plan, Expected Future Benefit Payment, Year Two Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Adjustments to reconcile earnings from continued operations to net cash from operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Distribution Type [Axis] Distribution Type [Axis] Blow-Fill-Seal Business, Woodstock Blow-Fill-Seal Business, Woodstock [Member] Blow-Fill-Seal Business, Woodstock Repayments of Long-term Debt Repayments of Long-Term Debt Total Long-Term Debt and Lease Obligation, Including Current Maturities Provision at U.S. federal statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Debt Instrument, Increase (Decrease), Other, Net Debt Instrument, Increase (Decrease), Other, Net Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, to be Paid, after Year Five Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Restructuring and Related Cost, Expected Number of Positions Eliminated Restructuring and Related Cost, Expected Number of Positions Eliminated Income Tax Authority [Domain] Income Tax Jurisdiction [Domain] Trading Symbol Trading Symbol Comprehensive income/(loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Long-term Debt and Finance Lease Obligations Long-Term Debt and Lease Obligation Non-NEOs Non-NEOs [Member] Total Lease Liability Payments Due Year Three Total Lease Liability Payments Due Year Three Total Lease Liability Payments Due Year Three Actual Asset Allocation Defined Benefit Plan, Actual Plan Assets Allocation, Amount Defined Benefit Plan, Actual Plan Assets Allocation, Amount Defined Benefit Plan, Expected Future Benefit Payment, Year Three Defined Benefit Plan, Expected Future Benefit Payment, Year Three Accounts Receivable, Allowance for Credit Loss, Current Accounts Receivable, Allowance for Credit Loss, Current Excluding shares granted in consideration for acquisition [Member] Excluding shares granted in consideration for acquisition Multiemployer Plans, Estimated Annual Cash Contribution Multiemployer Plans, Estimated Annual Cash Contribution Debt Instrument, Redemption, Period [Domain] Biologics [Member] Biologics [Member] Biologics [Member] Incremental Term Loan Incremental Term Loan [Member] Incremental Term Loan [Member] (Increase)/decrease in trade receivables Increase (Decrease) in Accounts Receivable Property, Plant and Equipment, Impairment Property, Plant and Equipment, Impairment [Policy Text Block] Earnings Per Share Earnings Per Share, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Cash Surrender Value of Life Insurance Cash Surrender Value of Life Insurance Earnings/(loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Fair Value Disclosures Fair Value Disclosures [Text Block] Proceeds from Stock Options Exercised Proceeds from Stock Options Exercised Net accumulated gain related to investment hedges OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] Derivative, Gain (Loss) on Derivative, Net Derivative, Gain (Loss) on Derivative, Net Derivative, Gain (Loss) on Derivative, Net Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Business Combination, Contingent Consideration, Asset Business Combination, Contingent Consideration, Asset Four Point Seven Five Percent Senior Euro Denominated Notes [Member] Four Point Seven Five Percent Senior Euro Denominated Notes [Member] Four Point Seven Five Percent Senior Euro Denominated Notes [Member] Lease, Cost [Abstract] Interest expense, net Interest Income (Expense), Operating Interest expense, net Interest Income (Expense), Operating Proceeds from Sale and Maturity of Marketable Securities Proceeds from Sale and Maturity of Marketable Securities Deferred Tax Assets, Federal Taxes Deferred Tax Assets, Federal Taxes Deferred Tax Assets, Federal Taxes Restructuring and Related Cost, Number of Positions Eliminated Restructuring and Related Cost, Number of Positions Eliminated Capital Expenditures by Segment Schedule of Segment Reporting Information, Capital Expenditures by Segment [Table Text Block] Schedule of Segment Reporting Information, Capital Expenditures by Segment [Table Text Block] Segment Reporting, Policy [Policy Text Block] Revenue from Contract with Customer [Abstract] Plan Name [Domain] Plan Name [Domain] Finance Lease, Liability, Statement of Financial Position [Extensible List] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] United States [Member] UNITED STATES Debt Refinancing Costs [Axis] Debt Refinancing Costs [Axis] Debt Refinancing Costs [Axis] 3.125% Senior US Denominated Notes 3.125% Senior US Denominated Notes [Member] 3.125% Senior US Denominated Notes Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities Weighted Average Number of Shares Outstanding, Diluted, Adjustment Other Assets, Noncurrent Other Assets, Noncurrent Prior service cost (credit) during the year Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Arising During the Year, before Tax Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Arising During the Year, before Tax Leases [Abstract] Temporary Equity, Shares Issued Temporary Equity, Shares Issued Gross Carrying Value Finite-Lived Intangible Assets, Gross Asset Acquisition, Price of Acquisition, Expected Asset Acquisition, Price of Acquisition, Expected Business Combination, Purchase Consideration Business Combination, transitional service agreement Business Combination, transitional service agreement Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Softgel Technologies Softgel Technologies [Member] Softgel [Member] Princeton Cell Therapy Princeton Cell Therapy Princeton Cell Therapy Withholding Tax and other foreign taxes Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount Operating Segments Operating Segments [Member] Interest Rate Derivative Assets, at Fair Value Interest Rate Derivative Assets, at Fair Value Net Cash Provided by (Used in) Operating Activities, Total Net Cash Provided by (Used in) Operating Activities RheinCell Therapeutics RheinCell Therapeutics [Member] RheinCell Therapeutics CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Accumulated other comprehensive earnings/(loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Property-related Deferred Tax Assets, Property, Plant and Equipment Stockholders' Equity, Other Stockholders' Equity, Other Prepaid Expense, Current Prepaid Expense, Current Business Combination, Consideration Transferred, Other Business Combination, Consideration Transferred, Other Award Timing Method Award Timing Method [Text Block] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Restructuring Type [Axis] Restructuring Type [Axis] Noncash or Part Noncash Acquisition, Value of Liabilities Assumed Noncash or Part Noncash Acquisition, Value of Liabilities Assumed Revenue Recognition and Deferred Revenue [Abstract] Revenue Recognition and Deferred Revenue [Abstract] Entity Common Stock, Shares Outstanding (shares) Entity Common Stock, Shares Outstanding Finance Lease, Weighted Average Remaining Lease Term Finance Lease, Weighted Average Remaining Lease Term Insider Trading Policies and Procedures [Line Items] Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Use of Estimates Use of Estimates, Policy [Policy Text Block] Auction Market Preferred Securities, Stock Series [Line Items] Auction Market Preferred Securities, Stock Series [Line Items] U.S. Federal Deferred Tax Asset [Domain] U.S. Federal Deferred Tax Asset [Domain] U.S. Federal Deferred Tax Asset Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Greater Than One Year Member Greater Than One Year Member [Member] Greater Than One Year Member Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Greater Than One Year Member Greater Than One Year Member Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Payments of Debt Issuance Costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Business Combination, Acquired Receivables, Description Business Combination, Acquired Receivables, Description Recent Financial Accounting Standards [Abstract] Recent Financial Accounting Standards Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Expected long-term rate of return (percent) Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Intangibles [Line Items] Product Rights [Line Items] Product Rights [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Three Long-Term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Three Finance Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, Undiscounted Excess Amount Oxford Oxford [Member] Oxford Goodwill and other intangibles Deferred Tax Liabilities, Goodwill and Intangible Assets Translation adjustments Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease) Credit Facility [Domain] Credit Facility [Domain] Bolton CS [Member] Bolton CS [Member] Bolton CS Net Revenue and Segment EBITDA Segment Reporting Information Net Revenue And Ebitda Table [Text Block] Segment reporting information net revenue and EBITDA. Goodwill Beginning balance Ending balance Goodwill Beginning balance Closing balance Accounts Receivable, Allowance for Credit Loss Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax Payments Related to Tax Withholding for Share-based Compensation Payments Related to Tax Withholding for Share-based Compensation Payment, Tax Withholding, Share-Based Payment Arrangement Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Other Comprehensive Income (Loss), Net of Tax [Abstract] Fair Value Measurements, Nonrecurring Fair Value Measurements, Nonrecurring [Table Text Block] Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Employee Stock Option [Member] Share-Based Payment Arrangement, Option [Member] Debt Issuance Costs Debt Issuance Costs [Member] Debt Issuance Costs Depreciation expense Depreciation Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative, Fair Value, Net Lessee, Operating Lease, Liability, Payments, Due Year One Lessee, Operating Lease, Liability, to be Paid, Year One Proceeds from (Payments for) Other Financing Activities Proceeds from (Payments for) Other Financing Activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Accrued income tax Accrued Income Taxes, Current Retirement Benefits [Member] Pension Plan [Member] Finance Lease, Weighted Average Discount Rate, Percent Finance Lease, Weighted Average Discount Rate, Percent 3.500% Senior US Denominated Notes 3.500% Senior US Denominated Notes [Member] 3.500% Senior US Denominated Notes Repayments of Lines of Credit Repayments of Lines of Credit Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, PPE Finance Lease, Liability, Payments, Due Year One Finance Lease, Liability, to be Paid, Year One Award Type [Axis] Award Type [Axis] Corporate Debt Securities [Member] Corporate Debt Securities [Member] Deferred Tax Liabilities, Net Deferred Tax Liabilities, Net Term Loan Two Facility Dollar Denominated [Member] Term Loan Two Facility Dollar Denominated [Member] Term Loan Two Facility Dollar Denominated Deferred Income Tax, Operating Lease, Liabilities Deferred

Income Tax, Operating Lease, Liabilities Deferred Income Tax, Operating Lease, Liabilities Foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Cumulative Effect, Period of Adoption, Adjustment [Member] Cumulative Effect, Period of Adoption, Adjustment [Member] Deferred Income Tax, Right-of-Use Asset Deferred Income Tax, Right-of-Use Deferred Income Tax, Right-of-Use Total inventory, gross Inventory, Gross Write-off of Deferred Debt Issuance Costs Deferred Debt Issuance Cost, Writeoff Property, plant, and equipment, net Property, Plant and Equipment, Net Property, plant, and equipment, Net ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Other Defined Benefit Plan, Benefit Obligation, Business Combination Total liabilities Liabilities Elimination of revenue attributable to multiple locations Elimination of revenue attributable to multiple locations Elimination of revenue attributable to multiple locations Common stock, par value (used per share) Common Stock, Par or Stated Value Per Share Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Translation and Transaction of Foreign Currencies Foreign Currency Transactions and Translations Policy [Policy Text Block] Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Other assets: Other Assets [Abstract] Cash Surrender Value, Fair Value Disclosure Cash Surrender Value, Fair Value Disclosure Operating Lease, Liability, Current Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Deferred long term debt financing costs Debt Issuance Costs, Noncurrent, Net Transition (asset)/obligation Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), after Tax Goodwill, Other Increase (Decrease) Goodwill, Other Increase (Decrease) Clinical Supply Services [Member] Clinical Supply Services [Member] Clinical Supply Services [Member] Nonvested Restricted Stock Shares Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Estimated Amounts to be Amortized from Accumulated Other Comprehensive Income into Net Periodic Benefit Cost Defined Benefit Plan, Expected Amortization, Next Fiscal Year [Abstract] Prior service cost/(credit) Defined Benefit Plan, Expected Amortization of Prior Service Cost (Credit), Next Fiscal Year Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Loss and tax credit carryforwards Deferred Tax Assets, Operating Loss Carryforwards Land, buildings, and improvements Land Buildings And Improvements Land, buildings and improvements. Total accumulated other comprehensive income at the end of the year Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Eberbach Pension Promissory Note or Loan [Member] Eberbach Pension Promissory Note or Loan [Member] Eberbach Pension Promissory Note or Loan [Member] Raw materials and supplies Inventory, Raw Materials and Supplies, Gross Subsequent Event [Line Items] Subsequent Event [Line Items] Property and equipment, at cost Property, Plant and Equipment, Gross Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Settlements Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Unused Borrowing Capacity, Amount Debt Instrument, Unused Borrowing Capacity, Amount Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Business Combination, Termination Fee Business Combination, Termination Fee Business Combination, Termination Fee Pledge Percentage Of Equity Interest Pledge Percentage Of Equity Interest Pledge percentage of equity interest. Cash [Member] Cash [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Restructuring and Related Cost, Expected Cost Restructuring and Related Cost, Expected Cost Accrued Liabilities [Member] Accrued Liabilities [Member] Accrued Liabilities, Fair Value Disclosure Accrued Liabilities, Fair Value Disclosure MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total shareholdersâ€™ equity Equity, Attributable to Parent Net investment hedge Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease) Deferred Tax Assets, Gross Total deferred income tax assets Deferred Tax Assets, Gross Delphi Genetics SA Delphi Genetics SA [Member] Delphi Genetics SA Proceeds from borrowing, net Proceeds from Issuance of Debt Construction in progress Construction in Progress, Gross Representation of depreciation and amortization expense and capital expenditure by segment Representation Of Depreciation And Amortization Expense And Capital Expenditure In Consolidated Financial Statements Table [Text Block] Representation Of Depreciation And Amortization Expense And Capital Expenditure In Consolidated Financial Statements. Business Combinations [Abstract] Business Combinations [Abstract] Type of Adoption [Domain] Accounting Standards Update [Domain] Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Software and Software Development Costs Software and Software Development Costs [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Letters of Credit Outstanding, Amount Letters of Credit Outstanding, Amount Selling, general, and administrative expenses Selling, General and Administrative Expense Other Assets Non Current Schedule of Other Assets [Table Text Block] Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Five Long-Term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Five Cost of Sales [Member] Cost of Sales [Member] Net Proceeds used to Repay Debt, Stock Issued During Period, New Issues Net Proceeds used to Repay Debt, Stock Issued During Period, New Issues Net Proceeds used to Repay Debt, Stock Issued During Period, New Issues Net Proceeds used to Repay Debt, Stock Issued During Period, New Issues Finite lived intangible assets disclosure [Abstract] Finite lived intangible assets disclosure [Abstract] Product relationships [Member] Product relationships [Member] Product relationships. Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Equity Securities [Member] Equity Securities [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Finite-Lived Intangible Assets, Amortization Expense, Year Two Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Business Acquisition, Goodwill Business Acquisition, Goodwill, Expected Tax Deductible Amount ASSETS Assets [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Metrics Metrics [Member] Metrics Other comprehensive income /(loss), net of tax Other comprehensive income /(loss), net of tax Other Comprehensive Income (Loss), Net of Tax Document Type Document Type Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Installment Payment for Acquisition, Year Two Installment Payment for Acquisition, Year Two Installment Payment for Acquisition, Year Two geographical [Member] geographical [Member] geographical Actuarial (gain)/loss Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Total unallocated costs Total unallocated costs Segment Reporting Information Unallocated Expense Segment Reporting Information Unallocated Expense Other Income and Expenses [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan [Table] Deferred Tax Assets, International Tax Asset Deferred Tax Assets, International Tax Asset Deferred Tax Assets, International Tax Asset Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Sales [Member] Sales [Member] Subsequent Event [Table] Subsequent Event [Table] Assets and Liabilities, Lessee [Abstract] Assets and Liabilities, Lessee [Abstract] Maximum [Member] Maximum [Member] Preferred Stock, Value, Outstanding Preferred Stock, Value, Outstanding Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Goodwill, Impaired, Accumulated Impairment Loss Goodwill, Impaired, Accumulated Impairment Loss Unrecognized tax positions Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Net Carrying Value Finite-Lived Intangible Assets, Net Furniture and Fixtures [Member] Furniture and Fixtures [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Gain (Loss) Related to Litigation Settlement Gain (Loss) from Litigation Settlement Shares Issued, Price Per Share Shares Issued, Price Per Share Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Schedule Of Debt [Table] Schedule Of Debt [Table] Schedule Of Debt [Table] Lease, Cost Lease, Cost Range [Axis] Statistical Measurement [Axis] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Property-related Deferred Tax Liabilities, Property, Plant and Equipment Name Outstanding Recovery, Individual Name Research and Development Expense [Abstract] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Disposal Groups, Including Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Variable Lease, Cost Variable Lease, Cost Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Temporary Equity, Shares Authorized Temporary Equity, Shares Authorized Goodwill, Impairment Loss Goodwill, Impairment Loss Goodwill, Impairment Loss Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Redeemable Preferred Stock [Line Items] Redeemable Preferred Stock [Line Items] Redeemable Preferred Stock Total Catalent before inter-segment revenue elimination [Member] Total Catalent before inter-segment revenue elimination [Member] Total Catalent before inter-segment revenue elimination [Member] Manufacturing & Commercial Product Supply [Member] Manufacturing & Commercial Product Supply [Member] Manufacturing & Commercial Product Supply [Member] Assumed Healthcare Cost Trend Rates at the Balance Sheet Date Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract] Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Expected Future Contributions Defined Benefit Plan, Expected Future Employer Contributions [Abstract] Customer relationships [Member] Customer Relationships [Member] Prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Earnings Per Share, Diluted Earnings Per Share, Diluted Expected Future Benefit Payments Defined Benefit Plan, Expected Future Benefit Payment [Abstract] Temporary Equity, Stock Issued During Period, Value, New Issues Temporary Equity, Stock Issued During Period, Value, New Issues Contractual Liabilities Contractual Liabilities [Table Text Block] [Table Text Block] for Contractual Liabilities [Table] Revenue from Contract with Customer Revenue from Contract with Customer [Policy Text Block] U.S. operations Income (Loss) from Continuing Operations before Income Taxes, Domestic State and Local Jurisdiction [Member] State and Local Jurisdiction [Member] Premiums Receivable, Fair Value Disclosure Premiums Receivable, Fair Value Disclosure Schedule of Nonvested Performance-based Units Activity [Table Text Block] Schedule of Nonvested Performance-based Units Activity [Table Text Block] Total current Current Income Tax Expense (Benefit) Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Other income (expense), net Other Nonrecurring (Income) Expense Hedge Funds [Member] Hedge Funds [Member] Hedge Funds [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Ownership [Axis] Ownership [Axis] Intangible Assets, Finite-Lived Intangible Assets, Finite-Lived, Policy [Policy Text Block] Effective Tax Reconciliation, Benefit from Swiss Tax Reform Effective Tax Reconciliation, Gross Benefit from Swiss Tax Reform Effective Tax Reconciliation, Gross Benefit from Swiss Tax Reform Restructuring, Settlement and Impairment Provisions Restructuring, Settlement and Impairment Provisions Retirement Benefits [Abstract] Deferred income tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Foreign Currency Transaction Gain (Loss), before Tax Gain (Loss), Foreign Currency Transaction, before Tax Preferred Stock, Shares Issued Preferred Stock, Shares Issued Participating Securities, Distributed and Undistributed (Earnings) Loss, Basic Participating Securities, Distributed and Undistributed Earnings (Loss), Basic Statement of Financial Position [Abstract] Loans and Leases Receivable, Gross Loans and Leases Receivable, Gross Short-Term Debt, Interest Rate Increase Short-Term Debt, Interest Rate Increase Self Insurance Reserve [Policy Text Block] Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Other Deferred Tax Liabilities, Other Interest Rate Cash Flow Hedge Asset at Fair Value Interest Rate Cash Flow Hedge Asset at Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Net earnings Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Effect of 1% increase on total service and interest cost Defined Benefit Plan, Effect of One-Percentage-Point Increase on Service and Interest Cost Components Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Operating Segments Excluding Intersegment Elimination Operating Segments Excluding Intersegment Elimination [Member] Operating Segments Excluding Intersegment Elimination Income tax expense Total provision Income Tax Expense Income Tax Expense (Benefit) Interest cost Interest cost Defined Benefit Plan, Interest Cost Equity issued in lieu of cash consideration Equity issued in lieu of cash consideration Equity issued in lieu of cash consideration Accumulated Cash Flow Hedge [Member] Accumulated Deferred Compensation [Member] Accumulated Deferred Compensation [Member] Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Debt Refinancing Costs [Domain] Debt Refinancing Costs [Domain] [Domain] for Debt Refinancing Costs [Axis] Shareholders' Equity and Share-based Payments Shareholders' Equity and Share-Based Payments [Text Block] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Statement of Comprehensive Income [Abstract] Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract] Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract] Net cash (used in) investing activities Net Cash Provided by (Used in) Investing Activities Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Income Tax Authority [Axis] Income Tax Jurisdiction [Axis] Business Acquisition [Line Items] Business Acquisition [Line Items] Other Operating Activities, Cash Flow Statement Other Operating Activities, Cash Flow Statement All Adjustments to Compensation All Adjustments to Compensation [Member] Accrued employee-related expenses Employee-related Liabilities, Current Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] Restructuring and other special items Restructuring And Other Special Items Restructuring and other special items. Schedule of Other Nonoperating Income (Expense) Schedule of Other Nonoperating Income (Expense) [Table Text Block] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Segment Reporting, Disclosure of Major Customers Segment Reporting, Disclosure of Major Customers Swindon [Member] Swindon Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Two Long-Term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Two Other Commitments [Abstract] Other Commitments [Abstract] Scenario, Unspecified [Domain] Scenario [Domain] Common Stock, Value, Outstanding Common Stock, Value, Outstanding US Government Agencies Debt Securities [Member] US Government Agencies Debt Securities [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province U.S Dollar-denominated 5.00% Senior Notes [Member] U.S Dollar-denominated 5.00% Senior Notes [Member] U.S Dollar-denominated 5.00% Senior Notes Derivative Instruments and Hedging Activities Disclosure [Abstract] Schedule of Unvested Restricted Stock Units Roll Forward Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Oral Drug Delivery Oral Drug Delivery [Member] Oral Drug Delivery [Member] Total Lease Liability Payments Due Year One Total Lease Liability Payments Due Year One Total Lease Liability Payments Due Year One Defined Benefit Plan Disclosure [Line Items]

Defined Benefit Plan Disclosure [Line Items] Assumed healthcare cost trend rates Schedule of Health Care Cost Trend Rates [Table Text Block] Net (gain)/loss recognized during the year Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Vesting [Domain] Vesting [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] Benefit obligation and fair value of plan assets for the defined benefit retirement and postretirement plan Schedule of Net Benefit Costs [Table Text Block] Alternative Investment Alternative Investment Restructuring and Related Cost, Incurred Cost Restructuring and Related Cost, Incurred Cost Prepaid and Other Assets Prepaid Expense And Other Assets Table [Text Block] Prepaid expense and other assets. Restatement Determination Date Restatement Determination Date Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Estimate of Fair Value Measurement [Member] Estimate of Fair Value Measurement [Member] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Operating Lease, Right-of-Use Asset Deferred Income Tax, Right-of-Use Asset Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Term Loan Four Facility dollar Denominated Term Loan Four Facility dollar Denominated [Member] Term Loan Four Facility dollar Denominated Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Contract with Customer, Asset Long-term contract assets Long Term Long-term contract assets Long Term Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Other Comprehensive Income, Debt Securities, Derivative and Hedge, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Derivative and Hedge, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Derivative and Hedge, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Derivative and Hedge, Gain (Loss), after Adjustment and Tax Plan amendments Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Earnings Per Share Earnings Per Share [Text Block] Subsequent Event [Member] Subsequent Event [Member] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Stock Issued During Period, Value, Stock Options Exercised Stock Issued During Period, Value, Stock Options Exercised 2.375% Senior Euro Denominated Notes [Member] 2.375% Senior Euro Denominated Notes [Member] 2.375% Senior Euro Denominated Notes Dividends, Preferred Stock Dividends, Preferred Stock Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Operating Lease, Liability, to be Paid, Greater than Year One Operating Lease, Liability, to be Paid, Greater than Year One Operating Lease, Liability, to be Paid, Greater than Year One Schedule of Derivative Liabilities at Fair Value [Table Text Block] Schedule of Derivative Liabilities at Fair Value [Table Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Core technology [Member] Core Technology [Member] Core technology, Segment [Domain] Segments [Domain] Non-allocated corporate costs, net Non Allocated Corporate Costs Net Non Allocated Corporate Costs Net Non-allocated corporate costs, net, Reconciliation of Unrecognized Tax Benefits [Roll Forward] Unrecognized Tax Benefits [Roll Forward] Notes Receivable Interest Rate Notes Receivable Interest Rate PEO PEO [Member] Payments and Accruals to Acquire Property, Plant, and Equipment Payments and Accruals to Acquire Property, Plant, and Equipment Payments and Accruals to Acquire Property, Plant, and Equipment Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] Name Trading Arrangement, Individual Name Funded status at end of year Net Pension assets (liabilities) Funded status at end of year Defined Benefit Plan, Funded (Unfunded) Status of Plan Postretirement Benefits, by Age Group [Domain] Postretirement Benefits, by Age Group [Domain] [Domain] for Postretirement Benefits, by Age Group [Axis] Other Commitments [Table Text Block] Other Commitments [Table Text Block] Available for Sale Investments Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Entity Public Float Entity Public Float Fixed Annuity Fixed Annuity [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Benefit obligation at beginning of year Benefit obligation at end of year Defined Benefit Plan, Benefit Obligation Earnings from continuing operations before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Payments of Ordinary Dividends Payments of Ordinary Dividends Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Weighted Average Grant Date Fair Value of Restricted Stock Unit Weighted Average Grant Date Fair Value of Restricted Stock Unit Weighted average grant date fair value of restricted stock unit. Sale and Leaseback Transaction, Gain (Loss), Net Sale and Leaseback Transaction, Gain (Loss), Net Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Value Added Tax Receivable Value Added Tax Receivable International Other [Member] Rest of World [Member] Rest of World [Member] Concentration Risk, Number of Customers Concentration Risk, Number of Customers Concentration Risk, Number of Customers Local Phone Number Local Phone Number Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Deferred Tax Assets, Valuation Allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Effect of 1% increase on APBO at balance sheet date Defined Benefit Plan, Effect of One-Percentage-Point Increase on Accumulated Postretirement Benefit Obligation Euro Denominated Debt Deferred Tax Assets, Other Comprehensive Loss Operating Loss Carryforwards, Indefinite Life Operating Loss Carryforwards, Indefinite Life Operating Loss Carryforwards, Indefinite Life Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] PEO Total Compensation Amount PEO Total Compensation Amount Goodwill, Transfers Goodwill, Transfers Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Interest Payable, Current Interest Payable, Current Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Debt Disclosure [Abstract] Common Stock [Member] Common Stock [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table] Cash and Noncash Divestiture, Amount of Consideration Received Cash and Noncash Divestiture, Amount of Consideration Received Cash and Noncash Divestiture, Amount of Consideration Received Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] Concentration Risk trade receivables and current contract asset, Percentage Concentration Risk trade receivables and current contract asset, Percentage Concentration Risk trade receivables and current contract asset, Percentage Pension Asset Pension Asset Pension Asset Work-in-Process and Finished Goods Inventories Include Raw Materials, Labor and Overhead Schedule of Inventory, Current [Table Text Block] Accumulated Translation Adjustment [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Debt Instrument, Unused Borrowing Capacity, Fee Debt Instrument, Unused Borrowing Capacity, Fee Corporate [Member] Corporate Segment [Member] Total Lease Liability Undiscounted Excess Amount Total Lease Liability Undiscounted Excess Amount Total Lease Liability Undiscounted Excess Amount RevenueRemainingPerformanceObligationExpectedTimingOfSatisfaction [Axis] RevenueRemainingPerformanceObligationExpectedTimingOfSatisfaction [Axis] RevenueRemainingPerformanceObligationExpectedTimingOfSatisfaction Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Segment Reporting Disclosure [Text Block] Segment Reporting Disclosure [Text Block] Pledge Percentage Of Capital Stock Pledge Percentage Of Capital Stock Pledge percentage of capital stock. Derivative and Hedge, (Income) Loss Other Comprehensive (Income) Loss, Derivative and Hedge, after Reclassification Adjustment, Tax Other Comprehensive (Income) Loss, Derivative and Hedge, after Reclassification Adjustment, Tax Text Block [Abstract] Equity compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Measurement Basis [Axis] Measurement Basis [Axis] Accounting Standards Update 2016-02 [Member] Accounting Standards Update 2016-02 [Member] Title Trading Arrangement, Individual Title Goodwill Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block] Three Month Three Month [Member] Three Month [Member] Installment Payment for Acquisition, Next Twelve Months Installment Payment for Acquisition Installment Payment for Acquisition Impact of foreign exchange Allowance For Doubtful Accounts Receivable, Impact Of Foreign Exchange Allowance for doubtful accounts receivable impact of foreign exchange. Rest of World [Member] Rest of Worlds [Member] Rest of Worlds Fair Value Measurements Of Financial Instruments [Line Items] Fair Value Measurements Of Financial Instruments [Line Items] Earnings/(loss) from continuing operations before income taxes and discontinued operations Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Unrecognized Tax Benefits Beginning Balance Ending Balance Unrecognized Tax Benefits City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Auditor Location Auditor Location Accrued liabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Derivative Instruments and Hedging Activities Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Time Based Restricted Stock Units [Member] Time Based Restricted Stock Units [Member] Time Based Restricted Stock Units [Member] Revolving Credit Commitments [Member] Revolving Credit Commitments [Member] Revolving Credit Commitments Foreign, Net Operating Loss Established [Member] Foreign, Net Operating Loss Established [Member] Foreign, Net Operating Loss Established Senior Secured Credit Facility [Member] Senior Secured Credit Facility [Member] Senior Secured Credit Facility [Member] Post-Retirement and Pension Plans Pension and Other Postretirement Plans, Policy [Policy Text Block] Foreign currency Deferred Tax Liabilities, Undistributed Foreign Earnings Receivables and Allowance dor Doubtful Accounts Receivable [Policy Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Change in tax rate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Acorda Therapeutics, Inc Acorda Therapeutics, Inc [Member] Acorda Therapeutics, Inc Net Derivative and Hedge (gain)/loss arising during the year Other Comprehensive Income (Loss), Derivative and Hedge, Gain (Loss) Arising During Period, before Tax Other Comprehensive Income (Loss), Derivative and Hedge, Gain (Loss) Arising During Period, before Tax Embedded Derivative, Estimate of Embedded Derivative Liability Embedded Derivative, Estimate of Embedded Derivative Liability Embedded Derivative, Estimate of Embedded Derivative Liability Subsequent Event Type [Axis] Subsequent Event Type [Axis] Revenue, Remaining Performance Obligation, Percentage to be recognized over the next six months Revenue, Remaining Performance Obligation, Percentage Earnings Per Share [Abstract] Equity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Divestitures Defined Benefit Plan, Plan Assets, Divestiture Class of Stock [Domain] Class of Stock [Domain] (Increase)/decrease in inventories Increase (Decrease) in Inventories Total Lease Liability Payments Due Year Five Total Lease Liability Payments Due Year Five Total Lease Liability Payments Due Year Five Dividends, Preferred Stock, Stock Dividends, Preferred Stock, Stock Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Defined Benefit Plan, Other Assets [Axis] Defined Benefit Plan, Other Assets [Axis] Defined Benefit Plan, Other Assets Operating Lease, Liability Operating Lease, Liability Underlying Securities Award Underlying Securities Amount Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Performance Shares [Member] Performance Shares [Member] Deferred revenue and fees Deferred Revenue, Current Finance Lease, Liability, Payments, Due Year Five Finance Lease, Liability, to be Paid, Year Five Financial Assumptions Used to Determine Net Periodic Benefit Cost for Financial Year Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Amendment Flag Amendment Flag Reported Value Measurement [Member] Reported Value Measurement [Member] Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Machinery and Equipment [Member] Machinery and Equipment [Member] Finance Lease, Right-of-Use Asset, Amortization Finance Lease, Right-of-Use Asset, Amortization Subsequent Events [Abstract] Other Income and Other Expense Disclosure Other Income and Other Expense Disclosure [Text Block] Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) One Month One Month [Member] One Month [Member] Long-Term Obligations and Other Short-Term Borrowings Debt Disclosure [Text Block] Foreign currency Deferred Tax Assets, Unrealized Currency Losses Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Business Combination, Loan Discount Business Combination, Loan Discount Business Combination, Loan Discount Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Technology-Based Intangible Assets Technology-Based Intangible Assets [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Transition (asset)/obligation Defined Benefit Plan, Expected Amortization of Transition Asset (Obligation), Next Fiscal Year Relating to assets still held at the reporting date Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Assets Held at Reporting Date Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Assets Held at Reporting Date Operating Loss Carryforwards, Subject to Limitations, Section 382 Operating Loss Carryforwards, Subject to Limitations, Section 382 Cash and cash equivalents CASH AND EQUIVALENTS AT BEGINNING OF PERIOD CASH AND EQUIVALENTS AT END OF PERIOD Cash and Cash Equivalents, at Carrying Value Reconciliation of the net amount recognized in the Consolidated Balance Sheets Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Other Noncurrent Assets Other Noncurrent Assets [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Auditor Name Auditor Name Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Stock Compensation Plan [Member] Share-Based Payment Arrangement [Member] Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Fair Value Measurement [Domain] Fair Value Measurement [Domain] Increase/(decrease) in accounts payable Increase (Decrease) in Accounts Payable Stock Option Granted Contractual Term Stock Option Granted Contractual Term Stock option granted contractual term. Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Non-current deferred tax asset Deferred Tax Assets, Deferred Income Schedule Of Debt [Line Items] Schedule Of Debt [Line Items] Schedule Of Debt [Line Items] Finance Lease, Principal Payments Finance Lease, Principal Payments Maximum Percentage Of Voting Stock from non US subsidiary Maximum Percentage Of Voting Stock Maximum percentage of voting stock. Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually

Paid vs. Other Measure [Text Block] Exchange rate gain/(loss) Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Proceeds from Divestiture of Interest in Consolidated Subsidiaries Proceeds from Divestiture of Interest in Consolidated Subsidiaries Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Machinery and equipment Machinery and Equipment, Gross Projected benefit obligation Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Increase in Contract with Customer, Asset Increase in Contract with Customer, Asset Increase in Contract with Customer, Asset Total assets Total assets Assets Cost of sales Cost of Goods and Services Sold Auditor [Line Items] Auditor [Line Items] Capital expenditures Payments to Acquire Property, Plant, and Equipment Impairment charges and gain/(loss) on sale of assets Impairment Charges And Gain Loss On Sale Of Assets Impairment Charges And Gain Loss On Sale Of Assets Impairment charges and (gain)/loss on sale of assets. Other liabilities Other Liabilities, Noncurrent Auction Market Preferred Securities, Stock Series [Axis] Auction Market Preferred Securities, Stock Series [Table] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount U.S. Dollar-denominated 4.875% Senior Notes [Member] U.S. Dollar-denominated 4.875% Senior Notes [Member] U.S. Dollar-denominated 4.875% Senior Notes [Member] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Commitment and contingencies (see Note 14) Commitments and Contingencies Equity-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Reconciliation of the provision/(benefit) based on the federal statutory income tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Lessee, Term of Contract Lessee, Term of Contract Lessee, Term of Contract Termination Date Trading Arrangement Termination Date Lessee, Operating Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, to be Paid, Year Two Time [Member] Time [Member] Time, Deferred income tax assets: Deferred Tax Assets, Gross [Abstract] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Revenue Recognition [Abstract] Net earnings attributable to Catalent Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Number of Doses Number of Doses Number of Doses Trade receivables allowance for doubtful accounts Trade Receivables Allowance For Doubtful Accounts Table [Text Block] Trade receivables allowance for doubtful accounts. Schedule of Net Investment Hedge in Accumulated Other Comprehensive Income (Loss) and Statement of Financial Performance [Table Text Block] Schedule of Net Investment Hedge in Accumulated Other Comprehensive Income (Loss) and Statement of Financial Performance [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Entity File Number Entity File Number Other Nonoperating Expense Other Nonoperating Expense Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Federal Current Federal Tax Expense (Benefit) Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Name Forgone Recovery, Individual Name Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Award Date [Domain] Award Date [Domain] Multiemployer Plan, Pension, Significant, Future Employer Contribution, Amount Multiemployer Plan, Pension, Significant, Future Employer Contribution, Amount Exchange rate gain/(loss) recognized during the year Other Comprehensive Income Defined Benefit Plan Exchange Rate Gain Loss Recognized During Year Other comprehensive income defined benefit plan exchange rate gain loss recognized. Schedule of Operating and Financing Leases Presented in Balance Sheet Schedule of Operating and Financing Leases Presented in Balance Sheet [Table Text Block] Schedule of Operating and Financing Leases Presented in Balance Sheet Inventory cost adjustment Inventory Valuation Reserves Provision/(benefit) for deferred income taxes Increase (Decrease) in Deferred Income Taxes Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Contract with Customer, Asset, after Allowance for Credit Loss Contract with Customer, Asset, after Allowance for Credit Loss Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) Reductions for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Other Obligations [Member] Other Obligations [Member] Other Obligations [Member] Post 65 [Member] Post 65 [Member] Post 65 [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Marketable Securities [Table Text Block] Marketable Securities [Table Text Block] Adjustment to Compensation: Adjustment to Compensation [Axis] Goodwill, Written off Related to Sale of Business Unit Goodwill, Written off Related to Sale of Business Unit Debtor Reorganization Items, Pension and Other Postretirement Related Charges Debtor Reorganization Items, Pension and Other Postretirement Related Charges Document Document And Entity Information [Abstract] Document Document and Entity Information [Abstract] Merger Agreement [Member] Merger Agreement [Member] Merger Agreement Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax Reclassifications Reclassifications [Text Block] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Debt Instrument Quarterly Amortization Rate Debt Instrument Quarterly Amortization Rate Debt Instrument Quarterly Amortization Rate Employee Stock Options and RSUs [Member] Employee Stock Options and RSUs [Member] Employee Stock Options and RSUs [Member] Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic Related Party [Axis] Related and Nonrelated Parties [Axis] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Effect of 1% Change in Healthcare Cost Trend Rate Defined Benefit Plan, Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rate [Abstract] Beginning Balance Ending Balance Equity, Including Portion Attributable to Noncontrolling Interest Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Target Asset Allocation (percent) Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Segment EBITDA EBITDA from continuing operations Segment Reporting Information Earning Before Interest Tax Depreciation And Amortization Segment reporting information earning before interest tax depreciation and amortization. Name Awards Close in Time to MNPI Disclosures, Individual Name Year in which ultimate rates are reached Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate Business Combination, Acquired Receivables, Gross Contractual Amount Business Combination, Acquired Receivables, Gross Contractual Amount Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Effect of 1% decrease on total service and interest cost Defined Benefit Plan, Effect of One-Percentage-Point Decrease on Service and Interest Cost Components Entity Filer Category Entity Filer Category Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Amount Kyoto Kyoto [Member] Kyoto Goodwill, Acquired During Period Goodwill, Acquired During Period Work-in-process Inventory, Work in Process, Gross Range [Domain] Statistical Measurement [Domain] Contract with Customer, Asset, after Allowance for Credit Loss, Current Contract with Customer, Asset, after Allowance for Credit Loss, Current Lease, Cost Lease, Cost [Table Text Block] Preferred Stock, Issuance Value, Net Preferred Stock, Issuance Value, Net Preferred Stock, Issuance Value, Net Skeletal Cell Therapy Support SA Skeletal Cell Therapy Support SA [Member] Skeletal Cell Therapy Support SA State Net Deferred Tax Asset [Domain] U.S. State Net Deferred Tax Asset [Domain] U.S. State Net Deferred Tax Asset Debt Securities [Member] Debt Securities [Member] Other accrued liabilities and expenses Other Liabilities, Current Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Stock Issued During Period, Value, Over-allotment Option Stock Issued During Period, Value, Over-allotment Option Stock Issued During Period, Value, Over-allotment Option All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Stock Issued During Period, Value, Conversion of Convertible Securities Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] ACOI, Accumulated Gain (Loss), Marketable Securities ACOI, Accumulated Gain (Loss), Marketable Securities [Member] ACOI, Accumulated Gain (Loss), Marketable Securities Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Total Catalent Segment Total Catalent Segment [Member] Total Catalent Segment Income taxes paid, net Income Taxes Paid, Net Senior Unsecured Term Loan Facility [Member] Senior Unsecured Term Loan Facility [Member] Senior Unsecured Term Loan Facility [Member] Other Commitments [Line Items] Other Commitments [Line Items] Long-term Debt and Capital Lease Obligations, Repayments of Principal in Next Twelve Months Long-Term Debt and Capital Lease Obligations, Repayments of Principal in Next 12 Months Stock Issued During Period, Shares, Conversion of Convertible Securities Stock Issued During Period, Shares, Conversion of Convertible Securities Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Term Loan Facility Incremental Dollar Term B-2 [Member] Term Loan Facility Incremental Dollar Term B-2 [Member] Term Loan Facility Incremental Dollar Term B-2 Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Derivative [Table] Derivative [Table] Effective Tax Reconciliation, Change in Deferred Tax Valuation Allowance from Swiss Tax Reform Effective Tax Reconciliation, Deferred Tax Valuation Allowance from Swiss Tax Reform Effective Tax Reconciliation, Deferred Tax Valuation Allowance from Swiss Tax Reform Income Tax Contingency [Table] Income Tax Contingency [Table] Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Interest Rate Cash Flow Hedge Liability at Fair Value Interest Rate Cash Flow Hedge Liability at Fair Value Restricted Stock Units (RSUs) [Member] RTSR Performance Share Units [Member] RTSR Performance Share Units [Member] Restructuring and Related Activities [Abstract] Other assets/accrued liabilities, net - current and non-current Increase (Decrease) in Other Operating Assets and Liabilities, Net Temporary Equity, Carrying Amount, Period Increase (Decrease) Temporary Equity, Carrying Amount, Period Increase (Decrease) Other Performance Measure, Amount Other Performance Measure, Amount Rate of compensation increases (percent) Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Finite-Lived Intangible Assets, Amortization Expense, Year Three Finite-Lived Intangible Asset, Expected Amortization, Year Three Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax Goodwill [Line Items] Goodwill [Line Items] Common Stock, Shares, Outstanding Beginning Balance - Common Stock Outstanding (shares) Ending Balance - Common Stock Outstanding (shares) Common Stock, Shares, Outstanding Operating Lease, Cost Operating Lease, Cost Debt and Capital Lease Obligations Debt and Lease Obligation Operating Loss Carryforwards, Carry Forward Period Operating Loss Carryforwards, Carry Forward Period Operating Loss Carryforwards, Carry Forward Period Pro Forma Results [Abstract] Pro Forma Results [Abstract] Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Net (gain)/loss Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year Defined Benefit Plan, Benefit Obligation, Benefits Paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Senior Secured Credit Facilities & Other [Member] Senior Secured Credit Facilities & Other [Member] Senior Secured Credit Facilities & Other [Member] Effective Income Tax Rate Reconciliation, Global intangible low tax income Effective Income Tax Rate Reconciliation, Global intangible low tax income the income earned by foreign affiliates of US companies from intangible assets such as patents, trademarks, and copyrights Product and Service[Member] Product and Service, Other [Member] Deferred tax assets and liabilities Deferred Tax Assets And Liabilities Table [Text Block] Deferred tax assets and liabilities. Finance Lease, Interest Expense Finance Lease, Interest Expense MaSTherCell [Member] MaSTherCell [Member] MaSTherCell Convertible Preferred Stock, Shares Issued upon Conversion Convertible Preferred Stock, Shares Issued upon Conversion Company service cost Service cost Defined Benefit Plan, Service Cost Entity Tax Identification Number Entity Tax Identification Number Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Long-Term Debt Instruments [Table Text Block] Additions for tax positions of prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Schedule of Maturities of Lease Liabilities Schedule of Maturities of Lease Liabilities [Table Text Block] Schedule of Maturities of Lease Liabilities Retirement Plan Type [Axis] Retirement Plan Type [Axis] Non-U.S. Deferred Foreign Income Tax Expense (Benefit) Contract with Customer, Asset Contract with Customer, Asset Contract with Customer, Asset Healthcare cost trend rate-ultimate (percent) Defined Benefit Plan, Ultimate Health Care Cost Trend Rate Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Rate of compensation increases (percent) Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Intersegment Eliminations Intersegment Eliminations [Member] Other Cost and Expense, Operating Other Cost and Expense, Operating Plan Name [Axis] Plan Name [Axis] Finance Lease, Liability, Payments, Due after Year Five Finance Lease, Liability, to be Paid, after Year Five Schedule of Redeemable Preferred Stock [Table] Schedule of Redeemable Preferred Stock [Table] Schedule of Redeemable Preferred Stock Equity Components [Axis] Equity Components [Axis] Finance Lease, Liability, Payment, Due Finance Lease, Liability, to be Paid Other current assets Other Assets, Current Long Term Debt and Capital Lease Obligations Repayments of Principal After Year Five Long-Term Debt and Capital Lease Obligations, Maturities, Repayments of Principal after Year Five Prior service cost Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Pro Forma Net Income (Loss) Revolving Credit Facility - Two [Member] Revolving Credit Facility - Two [Member] Revolving Credit Facility Two [Member] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value International Other [Member] International Other [Member] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Deferred Tax Assets, State Taxes Deferred Tax Assets, State Taxes Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING ACTIVITY: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Distribution Type [Domain] Distribution Type [Domain] PharmaConsumerHealth PharmaConsumerHealth [Member] PharmaConsumerHealth Geographical [Axis] Geographical [Axis] Schedule of Restructuring and Other Costs Restructuring and Related Costs [Table Text Block] Lessee, Operating Lease, Liability, Payments, Due Year Five Lessee, Operating Lease, Liability, to be Paid, Year Five Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax Award Date [Axis] Award Date [Axis] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Business Combination, Contingent Consideration, Liability, Current Business Combination, Contingent Consideration, Liability, Current Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Operating Lease, Expense Operating Lease, Expense Payments for Restructuring Payments for Restructuring Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Net (gain)/loss arising during the year Net gain/(loss) arising during the year Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Non-U.S. Current Foreign Tax Expense (Benefit) Core Technology Bettera Core Technology Bettera [Member] Core Technology Bettera Current assets: Assets, Current [Abstract] Term Loan Three Facility Dollar Denominated [Member] Term Loan Three Facility Dollar Denominated [Member] Term Loan Three Facility Dollar Denominated [Member] Interest Costs Incurred Interest Costs Incurred Consolidation Items [Axis] Consolidation Items [Axis] Unrecognized Tax Benefits, Interest on Income Taxes Accrued Unrecognized Tax Benefits, Interest on Income Taxes Accrued Summary of plan assets that are measured in fair value Summary Of Plan Assets Measured In Fair Value Table [Text Block] Summary of plan assets that are measured in fair value. Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to

Disqualification of Tax Benefits, Amount Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease) Product and Service Product and Service [Domain] Oral and Specialty Drug Delivery [Member] Oral and Specialty Delivery [Member] Oral and Specialty Delivery [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Total Lease Liability Payments Due Total Lease Liability Payments Due Total Lease Liability Payments Due Preferred Stock, Shares Issued & Outstanding Preferred Stock, Shares Outstanding Pension assets Pension assets Pension assets Security Exchange Name Security Exchange Name Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Purchases, sales, settlements, contributions and benefits paid Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Additional Information [Abstract] Additional Information [Abstract] Installment Payment for Acquisition, Year Four Installment Payment for Acquisition, Year Four Installment Payment for Acquisition, Year Four State and local Current State and Local Tax Expense (Benefit) Vaccine Manufacturing and Innovation Centre Vaccine Manufacturing and Innovation Centre [Member] Vaccine Manufacturing and Innovation Centre Other Assets, Miscellaneous, Noncurrent Other Assets, Miscellaneous, Noncurrent Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and Development Expense Research and Development Expense Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Cash Paid For Amounts Included In Measurement Of Lease Liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Relating to assets sold during the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales Goodwill and Intangible Assets Disclosure [Abstract] Common stock, shares issued (shares) Common Stock, Shares, Issued Other Assets [Member] Other Assets [Member] Entity [Domain] Entity [Domain] Immaterial Error Correction Immaterial Error Correction Disposal Group, Including Discontinued Operation, Assets Disposal Group, Including Discontinued Operation, Assets Total Lease Liability Payments Due Year Four Total Lease Liability Payments Due Year Four Total Lease Liability Payments Due Year Four Derivative Liability Derivative Liability Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Valuation Allowance by Deferred Tax Asset [Axis] Valuation Allowance by Deferred Tax Asset [Axis] Reconciliation of Assets from Segment to Consolidated [Table] Reconciliation of Assets from Segment to Consolidated [Table] Europe Europe [Member] Common Stock, Shares Authorized Common Stock, Shares Authorized Additional Information for Plan with ABO in Excess of Plan Assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Consolidation, Eliminations [Member] Consolidation, Eliminations [Member] Payment for acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Intangibles Deferred Tax Assets, Goodwill and Intangible Assets Restructuring Costs Restructuring Costs Defined Benefit Plan, Plan Assets, Payment for Settlement Settlements Defined Benefit Plan, Plan Assets, Payment for Settlement Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Schedule of Cash Flow, Supplemental Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Entity Voluntary Filers Entity Voluntary Filers Total Lease Liability Payments Due Year Two Total Lease Liability Payments Due Year Two Total Lease Liability Payments Due Year Two Special termination benefits Special company contributions to fund termination benefits Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits Defined Benefit Plan, Amortization of Gain (Loss) Defined Benefit Plan, Amortization of Gain (Loss) Segment Reporting, Asset Reconciling Item [Line Items] Segment Reporting, Asset Reconciling Item [Line Items] Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Stock Issued During Period, Shares, Over-allotment Option Stock Issued During Period, Shares, Over-allotment Option Stock Issued During Period, Shares, Over-allotment Option Total deferred Deferred Income Tax Expense (Benefit) Discount rate (percent) Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Derivative and Hedge, Total, before Tax Other Comprehensive Income (Loss), Derivative and Hedge, Total, before Tax Other Comprehensive Income (Loss), Derivative and Hedge, Total, before Tax Goodwill Inputs Percentage, Long Term Revenue Growth Rate Goodwill Inputs Percentage, Long Term Revenue Growth Rate Goodwill Input Long Term Revenue Growth Rate, Percentage Accounts Receivable, Allowance for Credit Loss, Writeoff Accounts Receivable, Allowance for Credit Loss, Writeoff Stated Percentage, Quarterly Amortization of Principal Stated Percentage, Quarterly Amortization of Principal Stated Percentage, Quarterly Amortization of Principal Debt, Current Debt, Current Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Proceeds from Issuance of Redeemable Preferred Stock Proceeds from Issuance of Redeemable Preferred Stock Trade receivables, net Accounts Receivable, after Allowance for Credit Loss, Current Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Asset impairments Asset Impairment Charges Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Fair value of plan assets at beginning of year Fair value of plan assets at end of year Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Pension liability Liability, Defined Benefit Pension Plan, Noncurrent Operating Lease, Liability, Statement of Financial Position [Extensible List] Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Finance Lease Expense Finance Lease Expense Finance Lease Expense Finance Lease Expense Business Combination, Working Capital Adjustments Business Combination, Working Capital Adjustments Business Combination, Working Capital Adjustments Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Property and Equipment [Abstract] Property and Equipment [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Pension liability tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Document Annual Report Document Annual Report Finance Lease, Liability, Payments, Due Year Three Finance Lease, Liability, to be Paid, Year Three Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Deferred Compensation Plan Assets Deferred Compensation Plan Assets Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Amortization expense Amortization of Intangible Assets Contract with Customer, Liability Contract with Customer, Liability Accounting Policies [Abstract] Lump Sum Payment Lump Sum Payment [Member] Lump Sum Payment Fair Value Measurement, Policy Fair Value Measurement, Policy [Policy Text Block] Business Combination Disclosure Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Name PEO Name Series A Preferred Stock derivative liability Series A Preferred Stock derivative liability Series A Preferred Stock derivative liability Anagni [Member] Anagni [Member] Anagni Prior Period Reclassification Adjustment Prior Period Reclassification Adjustment Vesting [Axis] Vesting [Axis] Equity Award [Domain] Award Type [Domain] Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Equity compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Proceeds From Divestiture Of Businesses, Net Cash Proceeds Proceeds From Divestiture Of Businesses, Net Cash Proceeds Proceeds From Divestiture Of Businesses, Net Cash Proceeds Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Noncurrent liabilities Liability, Defined Benefit Plan, Noncurrent Restatement [Axis] Revision of Prior Period [Axis] Deferred Income Tax Assets, Net Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Asset, Useful Life Temporary Equity, Par or Stated Value Per Share Temporary Equity, Par or Stated Value Per Share Preferred Stock, Issuance Value Preferred Stock, Issuance Value Preferred Stock, Issuance Value Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Finance Lease, Liability, Noncurrent Finance Lease, Liability, Noncurrent Increase (Decrease) in Contract with Customer, Asset Increase (Decrease) in Contract with Customer, Asset Goodwill Goodwill Disclosure [Text Block] Employee Retirement Benefit Plans Retirement Benefits [Text Block] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities RevenueRemainingPerformanceObligationExpectedTimingOfSatisfaction [Domain] RevenueRemainingPerformanceObligationExpectedTimingOfSatisfaction [Domain] RevenueRemainingPerformanceObligationExpectedTimingOfSatisfaction [Domain] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Recent Financial Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Series A Preferred Stock Series A Preferred Stock [Member] Capital Lease Obligations [Member] Capital Lease Obligations [Member] Class of Stock [Axis] Class of Stock [Axis] Other Comprehensive Income, Other, Net of Tax Other Comprehensive Income, Other, Net of Tax Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finance Lease, Liability, Payments, Due Year Four Finance Lease, Liability, to be Paid, Year Four Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Hepatic Cell Therapy Support SA Hepatic Cell Therapy Support SA [Member] Hepatic Cell Therapy Support SA New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Foreign Currency Transaction Gain (Loss), Unrealized Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Restructuring and Other Costs Restructuring and Related Activities Disclosure [Text Block] Equity compensation Share-Based Payment Arrangement, Noncash Expense Provision for bad debts and inventory Provision For Bad Debts and Inventory Provision for bad debts and inventory, Fair Value Measured at Net Asset Value Fair Value Measured at Net Asset Value Per Share [Member] Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Accumulated Defined Benefit Plans Adjustment [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Settlement on from sale of subsidiaries Settlement on from sale of subsidiaries Settlement on from sale of subsidiaries Stated interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Building And Improvements [Member] Building And Improvements [Member] Building And Improvements [Member] Trade receivables allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss [Roll Forward] SUPPLEMENTARY CASH FLOW INFORMATION: Supplemental Cash Flow Information [Abstract] Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Other (Income)/expense, net Nonoperating Income (Expense) Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Interest Costs Capitalized Interest Costs Capitalized Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Proceeds from Divestiture of Businesses and Interests in Affiliates Proceeds from Divestiture of Businesses and Interests in Affiliates Auditor Firm ID Auditor Firm ID Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Operating earnings Operating Income (Loss) Postretirement Benefits, by Age Group [Axis] Postretirement Benefits, by Age Group [Axis] Postretirement Benefits, by Age Group [Axis] Long term inter-company loans Adjustment for Long-Term Intra-Entity Transaction, after Tax Net (gain)/loss Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax Variable Rate [Domain] Variable Rate [Domain] Tax valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Total liabilities, redeemable preferred stock, and shareholders' equity Liabilities and Equity Early Repayment of Senior Debt Early Repayment of Senior Debt Subsequent Events [Text Block] Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] International Deferred Tax Asset [Domain] International Deferred Tax Asset [Domain] International Deferred Tax Asset Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Finance Lease, Liability, Payments, Due Year Two Finance Lease, Liability, to be Paid, Year Two Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases, Sales, Issues, Settlements Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases, Sales, Issues, Settlements Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Designated shares [Member] Designated shares [Member] Designated shares Total Debt, U.S. Denominated Term Loan Total Debt, U.S. Denominated Term Loan Total Debt, U.S. Denominated Term Loan Maturities of long-term obligations Schedule of Maturities of Long-Term Debt [Table Text Block] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Defined Benefit Plan, Expected Return (Loss) on Plan Assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Individual: Individual [Axis] Accumulated Other Comprehensive (Loss)/Income [Member] AOCI Attributable to Parent [Member] Softgel and Oral Technologies [Member] Softgel and Oral Technologies [Member] Softgel and Oral Technologies [Member] Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Total Fixed Rate Total Fixed Rate Total Fixed Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Balance Sheet Related Disclosures [Abstract] Inventories Inventories Inventory, Net Performance [Member] Performance [Member] Performance. Product and Service [Axis] Product and Service [Axis] Statement [Line Items] Statement [Line Items] Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax U.S. Denominated Term Loan [Member] U.S. Denominated Term Loan [Member] U.S. Denominated Term Loan Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Defined Benefit Plan, Plan Assets, Benefits Paid Defined Benefit Plan, Plan Assets, Benefits Paid Property and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Business Combination, Consideration Transferred Business Combination, Consideration Transferred Net Assets Acquired from Business Combinations Net Assets Acquired [Line Items] Net Assets Acquired Loss Contingency, Estimate of Possible Loss Loss Contingency, Estimate of Possible Loss Furniture and fixtures Furniture and Fixtures, Gross Reconciliation of beginning and ending balances of level 3 assets Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Minimum [Member] Minimum [Member] Unamortized Debt Issuance Expense Unamortized Debt Issuance Expense Adoption Date Trading Arrangement Adoption Date Total Lease Liability Total Lease Liability Total Lease Liability Equity and Accumulated Other Comprehensive Income Disclosure [Text Block] Equity and Accumulated Other Comprehensive Income Disclosure [Text Block] Equity and Accumulated Other Comprehensive Income Disclosure [Text Block] APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition APIC, Share-Based Payment Arrangement, Other, Increase for Cost Recognition Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Provision for Doubtful Accounts Accounts Receivable, Credit Loss Expense (Reversal) Line of Credit, Current Line of Credit, Current Princeton Cell Therapy Princeton Cell Therapy [Member] Princeton Cell Therapy Business Segments [Axis] Segments

[illegible]

Consideration Arrangements, Range of Outcome Arrangements, High Business Combination, Consideration Arrangements, Range of Outcomes, Value, High Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Other Intangible Assets Subject to Amortization Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost Share-based Payment Arrangement, Expensed and Capitalized, Amount AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member] Number of Customers Number of Customers Number of Customers Discount rate (percent) Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Net revenue Net revenue Revenues Disclosure of Compensation Related Costs, Share-based Payments Share-based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment Equity compensation Share-based Payment Arrangement, Expense Share-based Payment Arrangement, Expense Schedule of Carrying And Fair Value Of Financial Instruments Table Schedule of Carrying And Fair Value Of Financial Instruments Table [Table Text Block] Schedule of carrying and fair value of financial instruments. Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] 3,500 Senior US Denominated Notes Member 3,500 Senior US Denominated Notes Member Stock Issued During Period, Value, Conversion of Convertible Securities Stock Issued During Period, Value, Conversion of Convertible Securities Other Commitments [Table] Other Commitments [Table] Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Financial Assumptions Used to Determine Benefit Obligations at the Balance Sheet Date Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits Presentation of revenue and long-lived assets by geographic area Schedule Of Revenue And Long Lived Assets By Geographic Area Table [Text Block] Revenue and long-lived assets by geographic area. Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Foreign Tax Authority [Member] Foreign Tax Jurisdiction [Member] Total Catastol sub-total of Segment Reporting [Member] Total Catastol sub-total of Segment Reporting [Member] Total Catastol sub-total of Segment Reporting Applicable Interest Period [Axis] Applicable Interest Period [Axis] Applicable Interest Period [Axis] Document Fiscal Year Focus Document Fiscal Year Focus Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Employee-related reorganization Severance Costs Other accrued liabilities Other accrued liabilities Other Accrued Liabilities, Current Non-U.S. operations Income (Loss) from Continuing Operations before Income Taxes, Foreign Finite-Lived Intangible Assets, Amortization Expense, Year Five Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Schedule of Interest Rate Derivatives Schedule of Interest Rate Derivatives [Table Text Block] Embedded Derivative, Fair Value of Embedded Derivative Liability Embedded Derivative, Fair Value of Embedded Derivative Liability Finance Lease, Liability, Current Finance Lease, Liability, Current Business Combination, Enterprise Value Business Combination, Enterprise Value Business Combination, Enterprise Value Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, to be Paid Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Asset Class [Axis] Asset Class [Axis] Insider Trading Arrangements [Line Items] Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments, after Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Supplemental Balance Sheet Information Supplemental Balance Sheet Disclosures [Text Block] APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition Transition (asset)/obligation Defined Benefit Plan, Amortization of Transition Asset (Obligation) Fair Value Measurements Of Financial Instruments [Table] Fair Value Measurements Of Financial Instruments [Table] Fair Value Measurements Of Financial Instruments [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Debt Instrument, Interest Rate Terms Debt Instrument, Interest Rate Terms Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, to be Paid, Year Three Accumulated Benefit Obligation Defined Benefit Plan, Accumulated Benefit Obligation Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized Prepaid Expense and Other Assets, Current Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Business Combination, Acquired Receivable, Fair Value Business Combination, Acquired Receivable, Fair Value Reconciliation of Unrecognized Tax benefit, excluding accrued interest Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Transition asset/(obligation) recognized during the year Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), Reclassification Adjustment from AOCI, before Tax Payments to Acquire Investments Payments to Acquire Other Investments Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Long-term and Short-term Debt [Abstract] Long-term and Short-term Debt [Abstract] Amortization of Debt Issuance Costs Amortization of Debt Issuance Costs Divestitures Defined Benefit Plan, Benefit Obligation, Divestiture Effective Tax Reconciliation, Net Benefit from Swiss Tax Reform Effective Tax Reconciliation, Net Benefit from Swiss Tax Reform Effective Tax Reconciliation, Net Benefit from Swiss Tax Reform Amortization and write-off of debt financing costs Amortization And Write Off Of Financing Costs Amortization And Write Off Of Financing Costs Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Net gain/(loss) recognized during the year Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) [Member] Inter-segment revenue elimination Segment Reporting Information Inter Segment Revenue Elimination Segment reporting information inter segment revenue elimination. Total foreign currency translation adjustments, pretax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Provision/ (benefit) for income taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Restructuring Reserve Restructuring accrual Restructuring Reserve Paragon [Member] Paragon [Member] Paragon Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Payments to Acquire Debt Securities, Available-for-sale Payments to Acquire Debt Securities, Available-for-Sale Company Selected Measure Name Company Selected Measure Name Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Dividend Payments, Per Share Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Dividend Payments, Per Share The estimated amount of dividends per share to be paid to holders of the underlying shares (expected dividends per share) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends. Other Liabilities EX-101.PRE 15 ctt-20240630 pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 ctt-20240630 g1.jpg begin 644 ctt-20240630 g1.jpg M JC X 02D91@ 1 9 ID # 1 115C:WD 0 9 X D9M:V 4 3 0, #00#1@H G 8&0 JH M#R ! 1 Q\$ & P M M M M M M M Z M/T>?..TLB:~(WPNP) ?S S>D1&~RSJWJ M ?3?5U97134 7L 990R:6@TC>N:X @ / M % Q D 9L [S>EG> R4 \$>W9XF#%&Y-1*8-RVO & /ER M1R2 ! Q\$& P M M M M M M M Z MA0:O1 4UA0>GRWQ?>BU7V I5?<-57W#3&LM,7,9W4EP@ J MNG4[G]BJZMCFYAO>2NALU JON& MF*K[AI]BVG&M[L]J2X0 ~>W3N6, \$6:68=3Y<~<X/D:=QEUN/G.R.3? *XTEKI+K3?N8 XFL,H8 [NH NIH3 M04]ZLXP 4JWWGVJ-CUGS ?7?+ \$[O]?[X]D:=&ZTL &MLB,0 2HATTOXS=JIEV^~> P,*K?G[Z9?X?>[CX?]?TACG5 :XRC\$J^V^R M:C 3JUW=Y8P#?B0L19AU/GZ-R2RM,0Q17, \$I! 9T#L^U/6C?2?M35STE6)=/6#UG:.\$&KJ M>?TCS 9XFNO#?WVG 3Y=C?+>KLT&057W#3%5JPTQ: M+3%VV=U<(&,\$IW K~WQF)!IYWQJ[Q7V+KKZ?RMYOU?38NRJJO4>D>NJI MUW6?+9+&B+..I N3T7TWK0>=>MFU;8E6H7+T3?GU /ZZ:[^>@O2&9HV2N]7 M?9^T3?OKQJ:N>DJO+IX35@< @V<4C>N3^3V(ZZB?>.&F,O?>OYV6HZYR+ MR^K3A>=MUW6?5TE=:IY6U0?>7/ -6/8,AL39U3QJ.24 M : NE,Q1AET.OXS;J5[FE5]PTQ5?<..6RTQ=MG>27+10X1/,<?> M~>:VZ:E1#Y1KNZ=ROQ&2OCBBS#?J,7#?<LCK/? ?S9AR?KUCGJCP,9W M?+>#YFPA [OOS5HJZYJZ2CMNGJPUJBMWNM\$?^@>W>J8CQ[?>V-MZNS M3P93A?>=UW6? 5=TE=:IY6U0F? &5XUUCGIOIY1@>=>G901&@& M<=>OXB3&8?>O/>SGBV&I/[P#]#G?G? >+VZ:E1#Y15?<-57W#3&LM,7,9W4EP@>NCGU Y 2Y1(B3:1VE5SPYW.#X7HJW, OY?QFW34J)? ~>W3N6, M R6:,\$68=3Y<1 AKZ:7R P^AOKEK#J /A]FB7(1ECB)9J(ROK.IJYZK MPMNGK4>N>U^GKG &N1?%>N]J?C?>+KLT[&O4X7G0M-UGU7=)0V@>95M9H MUY9/97P?)(S<1[U]V- 5=<X C1XC2Q0?>MR+>VZ:E1#Y15?<-57W#3&LM,7,9W4EP@IPE,3I00S?> M^>P1?1 JYCFDSE?>.6PK6O6Y%&=>2HA/TUW=Y8P#?B0L19AU/X#1< MRAS1E:~JWIR9NR/ A [H] 6J.U- 7258EMT:~A3U5V4H8JPN C-NF140?>[NGC? QOE05V>+>#*<+SH6NZSKNDH; MOK, *VL2 82U>UTM0Y4Y/]J?S=>A9W5W9/ C/=SX83R 4PW M0Q\$XZJL[W<H/B 10T,LSYC[^<VZ:E1#Y15?<-57W#3&LM,7,9W4EP4E MD5E2U?6?MI0?P]QI^<+> >ALDJO+>IZU"GKGM0IZYP MKD:DRCA:01 8WRWYJ/ID9.%Y2W+7=9J5W4H+2P6: 143&E &M5JVM4G?>7UM? IJZ[&NM:NOAZ!^Y&:6Q^KZW?>S=P^F#AJVGJ:~(GM7%F7 M54)H(A^5V95I)%XT/U P!E?QFW34?]>?MK?IJBXZ6LJVU[A:/O<5TV MA55.MY4-.NN[(NUH^OP +K_+>K&G.Z&ZWZ &C-NF140?>[NGN>U>HKG&N1J3?>6J]N1?>+>RTS:JW7C=>[MN60&15TC+U&<MS-3?>7XS<+<60DB=E,B[W=W/UGM[RW4? 4CIS B>9WIOY?3."KU>7M0IML^Y2\$Q,0 M<1/M+VY\$X9EV5\$Q80;N^ICATU>B[W=>+UGM[RW4? %Z<XGF+W:4J PA[M]HN5MMD,VHU7YJ8X=>7HNJW3J[PAM9?>V[MU U(Z<XGF,HBY=J M\$K19 MFX=U85I5U>B2\$D5YJZMQ[.G;W+Q/3AZD\$9D2J?>+BYV MJWG\$>Q&RW N<LJOU@952R0UJ?C>Z2N\$KJ:WA,3,7 +7USN0R&X&EYEM FdL\$F:FW1OT.:GJ059R=NY.O\$&J=JLU,= [IN0?>J3U6MEZK=>+67JL MB9J=>=([F6JL5C?>BWPRE6M<[<[NRKJV?>Z,D^T6=>N+L5C9N1]60;5W:GVK=N/J[P?>M?>RSI?>+ MIR-H& &NW=>LJ2:=5586F0X81D;C?<+

[illegible]

4G.1NWX?/E4A10U.-81800Q&CJ.KI>1>18%=&R2T.2"SS3I:7X\$6I2% 2*Z4 MV.4VAR8C\$+LIS:2F0R/RTA4Y>?&6%UUIY4(4Jf.HL4H.E-S*#VA)N1 40B
M4(0NN3)B6CE@#J0:R@DE/P.9*9M8P!\$F5V&M#@+.(I0S)LOV34M4P@P@BZ MV MY9%(HAC0SG.1!>P%KFV?Z@="MH?8BUZ33*5C3V/I4<=>33K0A2T.6D.N7 M.W7#*T
D.00N^E=4DX@.1:47IE=HX#5?P3R@M@!@1L\$5W?&F4E\$S?R@P@M.4*%.@08Q04**3A\$1+0S1+I?7\$8A**J#1#25U23B EM1D#P60%#@W7?MW68D MG%.13.18#+C:L0;
YUQUN#G2X#P&S:C(VIM6-D).#Q(A.7H#2W.#1#Q\$M MOHR#A.J.5X*2K8*4 QRNOCU@TBL1.5+N>...Y.F.&J@ 2DA5U=-\$2 MVA+L.D1 4441Q/U?>^24(HZNJ4B#KX15 HE.IA.
IHN4+?9@JK11?3J MKWL"13JA12+##8%JLF(\$4#QODNFE#M.UJYN.KC\$42.L1V6..A3XE ZIO MY1 OD(IH\$4HBXVW27)9SAK1@.1@UJ@UO2KZE.=-.S.HIZ@S(I\$A:98
MOEABU".DY.QOPH)A#KHO\$PTV19(9T.1%...I0V4 20%HO^Y/?2S8"4'9 M4+.#1F?00:CGE3T(CE3^61I:..TUIK<1\$*#@4.JL.F#A3258&I4DI8^IZ@ M5H.1&3XC#N/PEV&7?
SLTGJ#>S0=EQMLJ81!!J.JQNY#1!>G*YU%-!(E=A.M(V00*54+)&@XG6AU!PRDE5*B2<=>(I4DIJ^&KX 1S1 J00#G6^-V)0)05B*J1. 6<%S#/(KMx@&@ZTKHD? 3!>1;LM**ITP>?
P.V)DTKZ(KD.FW.M/#5-3P2SYZ1.1*16&6V1".HR7#9P.1#+1&RMU:..U.RC&B&5:S3#(E!<Z19 M1D?2LAD403091B9H@!'.J.3^H8 +JN1&Z?D M%WE\$00+BU.).WE7.
YIEF?C&3%Z?0K-2T#>2MMR1(SA)J@FUG8H#A0!L%1.M.14.UT14V?>3P%IAF2?I#@:=3D^B?P%. M6(IJ0Q)BAK+!IBB(X;500C-
COCOH+!)=M06.#"82271B?YHO7?&_J01 M17XWB?D4(G)Z GT+I+V?>O@DB.CIAJ?O="SDT)E@'M=0YP2P?6#!@O@HNDX
M=#R@Z+9.B623.S=10Z037&E<2:Q4R16T01@.MD540*H0LO+).1%1"1S-9FA B+XO8!"DHD&=##+1*.\$&Q.FYI:OZ4V7>1*Q.KE MD!'.J.1X!"018/T5 =>C2 (I@.1)P:96R^>N\$SD
0LIHHQ\$J0@/B;#T8H&K06 M1#<2%1A/1 V@ (0#30 3P0 L#R?7?;"85CK6Z2V67 5B134!OLSJ<7775 M=:(+V.V. YR1K3QX3VQ!M H0Q)RST XH#A\$51T B&+J4V 50%10EMMNA?/
M#@X&@X9MMW@!>5E=WA4 "B\$<10@.1.9121I/O62-DG0&R0L7M1BYVPS2LC ME 3(641:14V+W?U?2"1!1%10>6X)J90X3(FI.Q2.)@BH?>75H#1@47W1Z?
KSH?51DE&.S8681V43 SNGI.C@K*W-90.F%12ZSB.RXH"W6F?2HU.4 X"KG"/IA-OA-S2*V1?061831 MCO.N1J&V@T1/EOUSY?IS3B0=>#-8-ROAR20/Q*+QN18="&@.HY(C9**
MS8;SW19N!0V!JA3 MG00 G11>:LOPT&=D=C&H.&(.S.86G)F9U-PMI> 9F.T1"0%K1."YPK#DG MS-IRA-IL6J&YR1.I1-H?+7 F0AS;=#-T:B4 MB90R=>DYNP@20%DTYH8O(
I)M27I1-2XBHBIN4+T'=MT MR*(S/DMYMAO4-1R.F=D&V)E.& "DWTM" 21N"6 2G9 MED24+ @F.CHF6BG@F0(CB626?53@&EW-I&V3P.GAC^A^X^6.5!1W4'S31"23&Y M.?
IE:9M4<#HAYF@N&S35V7H2;.510\$W<9>L+>0)I"1A"(Z?P:RVA; *IE M6OE@P+P:BXB"A1J3N1Q3O:R1>17 8*%:146&1!-I2.T?M19.(@XMS/AIIC5F3;F1-D")*2>1:LGTO-
!F\$;T09#5 1&ZW5E2JIK2SP M2J@IRK8J#>!)6ICXH*22(1.S1!:#98Y84CEN@6X0J?2D>>1@OUX&S# ZTFZ M6^<D16 AN.XPNCS 1+I!VQ4XAF1N VZG2J9Z=X6N1
4\$R/W?DLRW7+^+)& M8O(A)A-D301 *\$&Q.@=(1. 2^GH=-I18 6.P5B^AE0E@1U!X15?>KN=<K.M6.F14\$RWS;38E#24K+<0)AXD@;(FA960B 3.1.BVYQSA.MHJW@DEV3
MA17+AA=-.W1X 1J.E.H135!"55E5N1MU6ZN=>1.54&KPX1D1\$41.0)5A1(MC.MY#8#P6A!@B861<."14QQA;&GR!6G8?5G<=&?&-R88!PIM24Y9XBRH"HE M030\$A.HUJ!.(L61 J/WZ
"1&PD1Z#H?2@1^H-2+4=W6&Q^84%\$-~"12W2% MX4GH#2.JTW@60V1.?@T@)IM\$8V192T!POWL.M\$ATIA^\$3.10MGM-H83D M\$1!"%3*N5.1@Y0KS=JQ+UTUY:?(?
MZ<K<+!>1UPGQ+Q=46# MQ'AS"1)5Z1P1P33@/8-Z=1IQN2=03..J2&5#&91/J4&=ZAI4P^<XLIJR1BZ.P?%=&Z-ZSEF=0?>HELKX 1*#JHH@ M(6+16W4*059ZT 0!@/P
=>T@E1"2YMB16!D/9D?1@<OX1LDD1->>OY7KG M^5YZ.E>>OY2T(98A?2+DESJ.214V74VP.>S D5282(8+2EXND@B? M1^<=8 M^CX1 ME2 IRK
5!P2:9QM@W6GWE(R/R^!MKB0C.LZFVCI@/AM#Y4 4M4 14 JQ^@=-60-7K1S5..AU7V-7IK55..J1HN<=>33\$37A1 MYKRT^<@.1X6
0.40\$H1Z1.4L811=ICW5B&.<1?1QSWB.3<3<=>?H?1&Z>4.3V4 MINBN@="E6P1E7F1R" NIS6 XD4-PJ+I+DE?@ H3IX@("1%QBS4F9S<3A4.M<8+2N EYA72T@0 2K@*:.1
+W1Q^IV*715(1 XH31^8 "PVAIMOY& MN47YB *00Y.VF!AOV% 0BYKYPTUY:?(2MZ= G DX1:9OWK?T!D0D1+(E MO.FF:126N5!A15 CAX% 5<E.#+8LD"3.B&@4%
I1.O:=#?9. &@&O?UO^- M(2!@TMS>@B. MZYY%:@20 /?AOX /&T/EJ&D\$ZP-?W1Z-&1Q2<1PCN?3/ MH?"B51N@05D)IAN(EGAD+&H107 H@908P?"B3?7AIYKRT@0 1A1O@
J?T)D)H. &A(W4(0!)"MFX (1#)AM#Y0W 1+0>.6&W&4Q11J.F>P\$- 1D201.41\$!\$SLB-QR-3H"J5:1\$P41N MP6N\$Q=0<@L@U17B4M.MEE!%A(PB>:1>2-6@62V7-KO?
COBIT.IIP.M.1)G5+P)=BY2?ZDZF=2F21.NIANPB=QU0V.D64\$01B @E8H2ZU M16!<=IS8*^>M^S/13?%#P7?>IZ10BDI-FY (Z81) -4NX&QK&K.T>RH"WHD9 D_1
MKMCD5G>V@I"1\$1D1N(ED2FXE=H 0)"(V1+1V2F=FK\$5Z\$)V1 B@S(EHQEZU M1D1L71)1G=>9M/13U"JL %U5L 9C1C(03D(R9(NK2)P
M)*M@*M*~%K&J5LR#%"R@M0/AM#Y:00&G&YG(4)+K&I2D8;:TB.SN1LD 0\$3 M1J1Q>T\$LM.1J6(IU.+UA:B^K6=QV"ZQ^1L/H\$;W#IE\$S.F@9IMWE#11 MB&\$N\$3P(B>:1-!
>6DK94L.JW14Y&YH1P3Y(1\$<Q=I4T)3TH =>1#K28J58 M2!<1(9R\$&5Y09V0D+1(2%13+7^#H190.N:04W<3>1<1CJ%\$>1 MQM#0G N BB1?
17875+THG4?)\$9\$5\$SJL7<42.ZV>+&\$4G4 M07\$5\$1WG-MBDW@!@ "UTP@HO&X+X(HI:0>D PBC"(WR)HG90B.(EQ\$N.MW\$Q4L&18%B@0.DDS^@!
H400R2/JIT+)=DLV@.(04318T&R.TBFO)^<@M@BON11M- MY<4.5N7E\$8X"/LB/OHF051014-L0TB* PG4J.W<2MJV/+P10 @J@H"YNMHO.M:MMJ:1*9(LGO3T)PBP~N0?P-
+5AP"DXA 9\$(S=;XV1NX2Z?T\$155D0+@10M MKANTIK*KG1.KONTEH\$8X&H/LB!LPIFXH101B+L@GHU.W<+NTT>G.P1E MV@ (0.0 3/0 P1LZ1*#J1.T1AUP~D0?5J8V.
I^+)+F>E+(SIKV MHE<I@ZXCW*=*X\$F!AY8TL 1406 *1U7=8 +1 0%HS!R7OH!^OE=:..N13 M!\$P!L?B 1 RD:\$\$#<3< (+< MO9?/118ID@PTPQ?I2D-RWC-J")IQ.2Q".
(62^G9XX.IE/IF/216<2!P?D16 MV1U 7B0R(F+1S17R M2L&W&

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

@@@

[illegible]

[illegible]

FE%15F\$M+BLM+2I0"XJ+XJ\$BDN*20+S+RLFA&9.R)HE.N*8LAPQ@F.MHJ@H+>^O9NG.MY<2GEY65%104%186YN7E%14587<.%K48<
P.3DYQ@Q^1?/SX<4Y.3E1F69F.M9D9&ALUFDR0(OCON(2.%145&1F9B8F)MZZ=>O&C1MW1Y-2TO+SI^>WV60B.2MCHDN.%"/R/P/PU->^V^A1?T33M<#&R.C+NW+GS
MYV<J=NWY?2MFYV=<0"7LO7QXJHZG)P.0N&Q.FHJAWMSBQ085SLI.QF.LMME.90\$OYJGH8>J@.MWJUNW70GOV?5+EZXVXB3D>JLV.FS9F=NW=,NW279K<
ASX0IA5W+Y4C1M3&0.7JP.#M<P>P>N.W7.MT1.M3HPZ2N>@.TIMO-T?>N1<=M3=PT#1.WC2P+Z4N6+1F.U!>J&R2.GS1.ML<
BQO071AD=FY.6K&=Y/OX1A7&G.6+V.W.OCSYLT/51\$<7REV79.MPL">?20V39X1<.&.&T^1^>A2P1^>VQ<@&R.E964)MPO.MVY7/GCUFF5)BI.P=^&XJ.FSUHH8<
&Z2/Y^0D>=>GAX5%35ERH1M+M+XWYE.2&D\$4>F.E0&AF.0S+Y65E9)TZ<&#J<2\$1&A^<O.YTZ<=>MMPM*6T1&Q.NOOSYV/MRCLX1>7)DVKH070W/GGR1+OW
@L+L+Y>9&F.FM@.MP8+0T+ITZG@.X.XY=V5E963/50LW.0)3+Y.OH.F5S19F.V4&1H+L>M9.3QIPNN%<6.75&00FVJL=^4=6=-L\$1>Y>70?JTS>0>JHS-M9#9<
##.H1&#<0D>7OCAAR.PD?<NDMN\$=NIT>Q"7OWZ.FO5WYIC01BZ7.MUZO9T1P.75/P>?U2I>OWZ15NU.M6U>L5JMHGZ2.NUPN.\$B0N*J/XX.M.MRXJDY>3&8RUF15JE<
=>.182W1HQ0UQX+V65WHV1YF.FCN2V5125LKM.Y4+7J1U@FQ.N6CG<.4010M1JBHJH95D3KJUIJ@P9?1<.&C5.IE.UYJ=N1.M=UNIM56P.<08IE\$1>V1=7L3V.P.3<
FDRD480@P1&F3B4D)M<+<DROX=M.M2L6+D.C5NWA+AI^900256US>Z.HH.EH1D5YQ^V@JYMPUP>T1)N1PM1WV0T.M^VM=N1M4M7M1PFLJG14MX7H3\$NQC)<(&U<
N5&DD>J.P<\$1&Q&UZ>OK4Y>J.MDR9.OHUNR.M1=PD=2TL7+ESHY=7ITZ=6/W+AQPV.SN6GZ1ZH9BUL>AX.G0Z3YEW.MU8M<14W9>KM5N\$=0.7(1)15%4NQ<
=<KTZ2J1J31NLAZ.H19.M&Q0&B6.GSX<AYN.HGS)BIM0X<#<6G+6<I+&P%5N.S18B#>?>.EEUZR.M6Q>?>6&GZ.OGCU1RLO+<
=<.Q996.XYTFP7QJL\$D=>HO70WWMFK52B.7R00^MN4+Q^AM=>OTXJ0ICN1FI7G.VO7M164P2+ORI.D>TJHJ7KNW2)B8U%7HY.N1=IWHD)KCI^M^<E2Y?<
JLJ.FJ6C4.K52J>52MG3K1UVKM0Z77&KN1435ASD51>1.N3P3U.OU^V=^CW4D01^&.D&M.I^>BHHV.MV.MSI<EYUQ16Z27P0\$CDSY.M6Z)A>.XR&GOLF.NG.MJM5J^M>7<
WJN.WMFZ>JAJ.L.SGBAPG1@I0N/0N&#1EHHB4Y1YEZ1<K&C.62.M=FRO5214KEJL.3CV74D17186I.EW.N1^EYUQK2.I0S#<6%145+5FRR1P)A>+M3^01XDP/L3)N1<
AYR0.Q5\$<MOW1^01#<@D>DLE>XF0101#<Q>9T)P^M(G1<#<0E1<+<QZT+<1.M6L1CRXHF1@HV64>EHF7KA>EUKE241+UKU7IZB8<
MZPR&6^I0+IM^A^BYSB.C66.L&SNAQ>JD.JD714&01&82B2J>7F6BHV.M.K12^VR13YV.(0^IQ.(@E.A^T9@N.MBLI&0E9V.UZ0Z.6Z^<
H8>C>4A.C:<G&4YN1.5>=>8Z?..TY>@JW.#+1M%IZ11N1^F9=DZNPTDY72BI&#1^8*39FOW6K.X.Z0^OH<0.KD1)&S15RE4JE.MJ03T1.WS17KUOB.H5E.#*1%<
F?<Q&S1Y=5.KZMTJH1W151A(W9P140M.S.MYZG5SYT12P.O.CD.80(F1P2P.M.FV.N@VOOJ\$M00@)P(=V.W33H14M6ET+^<D>M.P5.A.VK51=5.VXK=HMA^<
&S=N1&9<0&N2=NG2)38VHD=(M5)H0(2#G1#<6TAP<1WHUJ0H9EL>1(\$)<=>GJ=1V.M%..S1X>2A>J0.M6+VJF^Q4<(<9X5>VXDS<C.S.S1J1.3V2<
Q.EZ13YRD&=<AHA<6660)SW(H.MJ1+<C.L6UH7C1Z)<E1H2>=BRV4330H8R.DCTX1.0&F&8FF1R4D.M3)TZ5M6K5H16+<=>S20.7@X1.M17JWJ0Q.3VY=UJ01H16D.5H<
TOY64.MEQT1JQIULI=..W=B+1G0&A60&..W2%0)HK1Z2E1+EG.H1H7X23FAJ=&G.MGKUSURX@.40R&=<500924>PTAP=<@0R.EHOMCS>2&4AFR1E.77.W.UW+J?<
UELF^V<9V.0.75>G8>FZ#<MTEKK13YBU=..M^O>?<6I.9.6J5.*L01F+D1.MX=818TV>=>KM#J=WMO.NT^M=CKR.GAP#1PIYE@=<AHV1=2>X3GV#Q5IC<
M.#1NUMSDZ>=>K5.E.YN%QCMRPI>A>1^40^1F3T13&#BPKUOOOIN\$>YE@D0WDT50KX0PA.ME&KD<+<G.CCT.S1^0A.V8<.&=>D9J4.<=>SPA1<3^7YD.01.M6>=>T3%<
R.C.F.RCZ.21N941^IVR<M^1/12NXH.M42^S0&SYP2SYE6G7.RYO1XEN8.2D(KB)1+150.5^G4E%#1<^<M.MK3C1<
RS.3Y18H15.35F1L1+SVZ.7L#<#A1.Q09E.4ELTPUAMHCKL>..W=M^SVUML71EXE1L/BI-EN@Z^OHR19MG&0>1W+UW>>DMLCD^K5&VH<
MNWV.JBP.OPNE#<0<1^<1^<1%N@X46.3MF9!<#<0.H>.>04N6=<1T^LJO.M5>2^G2^T.K(F&X)N@M+MV7>=0+2HU1WTFJ057KRXJ+L\$N^XIA:(.9MF.H1.M.M9W1W+PHMFPT?<
W>1P7RY=>@FK7H1^Y2IUA9F.EJU>7461C1H13(0.<@>7H511M1^<1-2E)P1^CU+Z^E#<CR>.WCH<B39BJ=7J1JHW&MWOW^HOYWC>2>1.M^<P^N.K5:8XG3S+LGEY>8L6+3(8#<
L7+0P^MT@ER4\$>#X&41+DT1^61M.O0H8@<4TAH1+H1F.C2SIE5J2>=MYK+<#<QV1VS&@D.L1Y8#<0..OPQ..M0G\$G6451^1+JX&=<#<SLX1>67>P>DR.RX#JFV6QH<
M.G.QP<K<43<43<VJ7Z3.126>7AXRY131F8B>77DA^E.Y4R+U1Y>.MEQY0X&0031#KM&CV68T.W1L31HDN31+3F.EHG3H1V5^K5H16+<=>S20.7@X1.M17JWJ0Q.3VY=UJ01H16D.5H<
12MZBD1P1N.O1&2H1P1+<#<202.1&F..XP^N1.X=>2W1P4H15+5.O1\$1^701M.HU43.P27F.G7KUS2.MY951G7G13L1@.07N8AHK^XZMW+OW+HNJ?<
N1Z1E93H1XGE1R2(P.2EER131.M41.BU<@75F2T+ERVCQ&S>.6B1G4R62+<G2.M^215\$5%#<V^<P)J+NJU#1Y72C4A0H1V1ER<T3M>?<
@1A#78R1H3>+<0&G5U^K=<3.91>75.B4184B@Q^<V4Z42M16)MB8F^CU14N1JL1#GZ7KUQY74Z#<#>.GPTE1F9451%1=IN=YX^XIAS^<
M164GTF3JDC.ZW20U\$<#<0.16^90RE5J1K<#0P1M+K3=LV1?0.#<H1ZC=>+2.M^QK1G4<#JY5JTE.Y77#<6>1V.Y.PX(X84+14A0=<K5>1+5+1)MG0F<
M47&0&EEF&S1&C+U1>7ER.D1G3C8.SG01.V.E.40X&(SX<4N1>@W1V16J7Y7E.M15JZE145ASB.K.L.F1V572>WHIOEFW087ROR>VXNUW>F2.4JM4RE<
M.E@LW7OWOGC3)GRB1+<M0Q2S.<#<0Q2WR1C&K1A0.<#<0.G.SHZ1G1RW.MXB12M>#<P1B&R9J959M1S.S.OLY#<SFW&W&B1R3>D.FRQ0+69.9\$1<M=6HT4?<

[illegible]

1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36-37-38-39-40-41-42-43-44-45-46-47-48-49-50-51-52-53-54-55-56-57-58-59-60-61-62-63-64-65-66-67-68-69-70-71-72-73-74-75-76-77-78-79-80-81-82-83-84-85-86-87-88-89-90-91-92-93-94-95-96-97-98-99-100-101-102-103-104-105-106-107-108-109-110-111-112-113-114-115-116-117-118-119-120-121-122-123-124-125-126-127-128-129-130-131-132-133-134-135-136-137-138-139-140-141-142-143-144-145-146-147-148-149-150-151-152-153-154-155-156-157-158-159-160-161-162-163-164-165-166-167-168-169-170-171-172-173-174-175-176-177-178-179-180-181-182-183-184-185-186-187-188-189-190-191-192-193-194-195-196-197-198-199-200-201-202-203-204-205-206-207-208-209-210-211-212-213-214-215-216-217-218-219-220-221-222-223-224-225-226-227-228-229-230-231-232-233-234-235-236-237-238-239-240-241-242-243-244-245-246-247-248-249-250-251-252-253-254-255-256-257-258-259-260-261-262-263-264-265-266-267-268-269-270-271-272-273-274-275-276-277-278-279-280-281-282-283-284-285-286-287-288-289-290-291-292-293-294-295-296-297-298-299-300-301-302-303-304-305-306-307-308-309-310-311-312-313-314-315-316-317-318-319-320-321-322-323-324-325-326-327-328-329-330-331-332-333-334-335-336-337-338-339-340-341-342-343-344-345-346-347-348-349-350-351-352-353-354-355-356-357-358-359-360-361-362-363-364-365-366-367-368-369-370-371-372-373-374-375-376-377-378-379-380-381-382-383-384-385-386-387-388-389-390-391-392-393-394-395-396-397-398-399-400-401-402-403-404-405-406-407-408-409-410-411-412-413-414-415-416-417-418-419-420-421-422-423-424-425-426-427-428-429-430-431-432-433-434-435-436-437-438-439-440-441-442-443-444-445-446-447-448-449-450-451-452-453-454-455-456-457-458-459-460-461-462-463-464-465-466-467-468-469-470-471-472-473-474-475-476-477-478-479-480-481-482-483-484-485-486-487-488-489-490-491-492-493-494-495-496-497-498-499-500-501-502-503-504-505-506-507-508-509-510-511-512-513-514-515-516-517-518-519-520-521-522-523-524-525-526-527-528-529-530-531-532-533-534-535-536-537-538-539-540-541-542-543-544-545-546-547-548-549-550-551-552-553-554-555-556-557-558-559-560-561-562-563-564-565-566-567-568-569-570-571-572-573-574-575-576-577-578-579-580-581-582-583-584-585-586-587-588-589-590-591-592-593-594-595-596-597-598-599-600-601-602-603-604-605-606-607-608-609-610-611-612-613-614-615-616-617-618-619-620-621-622-623-624-625-626-627-628-629-630-631-632-633-634-635-636-637-638-639-640-641-642-643-644-645-646-647-648-649-650-651-652-653-654-655-656-657-658-659-660-661-662-663-664-665-666-667-668-669-670-671-672-673-674-675-676-677-678-679-680-681-682-683-684-685-686-687-688-689-690-691-692-693-694-695-696-697-698-699-700-701-702-703-704-705-706-707-708-709-710-711-712-713-714-715-716-717-718-719-720-721-722-723-724-725-726-727-728-729-730-731-732-733-734-735-736-737-738-739-740-741-742-743-744-745-746-747-748-749-750-751-752-753-754-755-756-757-758-759-760-761-762-763-764-765-766-767-768-769-770-771-772-773-774-775-776-777-778-779-780-781-782-783-784-785-786-787-788-789-790-791-792-793-794-795-796-797-798-799-800-801-802-803-804-805-806-807-808-809-810-811-812-813-814-815-816-817-818-819-820-821-822-823-824-825-826-827-828-829-830-831-832-833-834-835-836-837-838-839-840-841-842-843-844-845-846-847-848-849-850-851-852-853-854-855-856-857-858-859-860-861-862-863-864-865-866-867-868-869-870-871-872-873-874-875-876-877-878-879-880-881-882-883-884-885-886-887-888-889-890-891-892-893-894-895-896-897-898-899-900-901-902-903-904-905-906-907-908-909-910-911-912-913-914-915-916-917-918-919-920-921-922-923-924-925-926-927-928-929-930-931-932-933-934-935-936-937-938-939-940-941-942-943-944-945-946-947-948-949-950-951-952-953-954-955-956-957-958-959-960-961-962-963-964-965-966-967-968-969-970-971-972-973-974-975-976-977-978-979-980-981-982-983-984-985-986-987-988-989-990-991-992-993-994-995-996-997-998-999-1000-1001-1002-1003-1004-1005-1006-1007-1008-1009-1010-1011-1012-1013-1014-1015-1016-1017-1018-1019-1020-1021-1022-1023-1024-1025-1026-1027-1028-1029-1030-1031-1032-1033-1034-1035-1036-1037-1038-1039-1040-1

[illegible]

#D1NGN7> CR#MXPS4-W_01@P:D:LCZEI91#F)GJHWX\$ (5U#?FN22QVG#HOB14G+P5:44_3J MG21TO!!Y/(W-RXISR#OCU*8E/\$4I@>9T8O7_MJG#_0_~.#P0=30(6XHKD
M0Q#230?90#.#IN6-Q1G#3DHY3?T#J3_LYXD3YD #DB_4N05*OLG/MXO:DWB1282A(8XD5+R1#P:1P1G*1B1?1F2A41
M0_0W4U30_3X125>_#GF:1000191#F?7_8LYD38#DE=U88566?K KDY?G=G_-MGO:5E_WC M21+1<1CB8A3#NAYPV8HQ3Z0#3:45;_DBB&6FB2*2AA?>M_XD!^+PO:
I=FEP01P<0(071(68_3H:2U7LX9?&7BC#+R0(DTGG+3_M_280YMU\$U87=7_E7490#8_0_1SCF&VBL_0Y_0?4Y_MTF^+!H051_M!^ZW:@S=FEEJ+S728BF5?
?D125I9?1W>#JFEO4/E/D@_Y>P/MJWF#S0\$4U_M&0B\$S>8>JN^+&HGD9D5X0<UE:2ZLAS1H5DEI\$Z<6_H+V9\$4_MD0405%6P(EFTWK5!%ZCF!+4>0AQO_R-
XBL65K?P1AXI!W:4N:=M^8E M227^&CVJ!<V>_J)#H\$42?5QSEKH5HN^M7D^OTC^+?_SALL\$6DEN^M\$K^A4>+J10=HY:10%?
Z08_#_42?7FGC0\$&3B_+H!(T#H@_Q_U!WTF&H)YIZ&Y?_#_M1MP9_6Q_4X?2P!BVT#?BL\$K\$&YJ#?_1XVPLD\$Q^&0_A1N0=<Q_UXIF=6^!6^1^CQ=40%0D8I_V0JIG
M051A1C1DIBJ\$#JHQ\$<2FDD04DM(6JPD^F4#M0_0X0_0X0_#_MX>06=Q^D^W\$>0E0K0?9_0A1CH^9/TO\$3ABXWE<0_73V3?1^4X^0P^<4_<
TPO:8ASB>TL=01YPOOT0N00@OPET@!\$+>5%>WBY?1Z^>27O_EI\$2\$D^<4!(KPA00Q&06DB:EW^06DIEVQ^!+!64422_UAD&:(6TB82^S5FFTF:3&J
M14Y^EM0B:Q(1^SY+&#E9<0#IJWT\$!%\$K&8^5EB/BP5\$3Q)E>5R\$K_#_2_M4#1^6<4+>V&9,DB5A^2RV8Y+4/1#>4Z4_AFU80L^@>RRT8J4Y_MS<(%_R.DFI@DP
D^PW&XUS@<1^FY+U?>J)_A>GW2B_2NRYH1C(2GO_M\$R^<0YIU&J6_7!Q#_#BYWBX4?XO@&G:3=>N\$0006G2Y%1BZ4EY&G MWZUM>EJ7_YI4R\$RIUYW_BGOR\$?
RH=0105U4.WIE/MQ4GMQYN^SC_MGZ07(4J_P1#_2BV:3_M0_Q&ZVR:_M0_(1)15\$JX1_4>+YF(1+P^C3?8^W)B#X7IAJ00NTHIV@13@
M010F\$U^C75P^H6_7A71_W#W6K12<0^7HPY14_4K48>KZ031P_31DZ1MIS\$9J_16^31N^N0HZ_W^PK&J5C6%:VYV&R^HIM5CFRZ_2\$Y#D=2D_M:A7-W^S\$X#BZ0B^
(^H@U5XIHQM^+BN:P#N_P\$FWD!A>8^6^0!^2(+M_Y-3O)^7_M@SL(P>#BB@^_KC^YMLIU_V@\$0=0^2_004_4F4\$%N^_!8?KR#.#JFM.TI_MPI+8IDA+TYP_1S(O0M0?
MH0@BOQ!<^UFYX?2C3WRDP@IPA_7^&03>+P\$1L54>3\$K_M^<71^0N_KHH>4%&@:JSGBV+13LM^JX>5A(2&AL^Q6FV64AS>4_LB:3Z6(82U^A_M6L<3D1N^V01#
97:C20305H=N(OXQ!U3>5BD1^WX10&8F4X^_4K@_N_MJH@<@Z\$G_#KEFJ373W2MV70DV&_3YV>C(1>_G+ET>OPD_KI4Q_ M8FRWTFD504.W0:3D1N^VG#18
10+5GS6U^2NKFV\$MVF4L7ZW_MWCT^&AT12_3X<_#QP&LAKI3Z=NV^NVK4G_#SEBU^=OZUL^3B3Q_#JME_!^YH5@6=35_0<39YN1^@3U3I9V7<QXR>CGL<4J_K1
MYR8_#H0<_&RNRZM^JBN01)\$5_04O1^22D630V1=Q^<KY^E1-07U<_!L_M6/L^+7K-U7R^B.S.P3H^24B_A!@_I29GKUFYPK5A+V+BED5EBQ\$Y3?
52^UL_9_1GA12DH7FEA!YCN>M!>LYLID^2^M^Y^>F7OPVZU1^<#IKX9_&M9QK_#N1=7PX7G59L\$S^>2\$B1.G3HVS77?M30GVFZ!>N505KF5C9I0_P(6!@GP%
<1RM^7R8B>3^Q10\$>9_<9%>G@I=16J52_MG3E59NKH4J_U_M!P!A6K5K6W/MGCU+TS3V60ZJ0D_9I7!G+1Z356S2_C9^>MYU3+V5>+6+&N+3V0VQ&(&SH7!<^0^+>1
R^"R&(<^U1B1@<TC_M^<KW\$>ZU_Y\$=G3J_66:30B\$QUU\$(7.2_1_EW@_<D^+1HH00Q4J@UOJX!<RMNGZK&1^Q^TJH8Z1K_V@EV7MD5U1TH8REYN?
M^60ALF.5^N7+D&39N6:2V>74T:6K:LZBH<2\$2B8%ZELMN_!LM^08TU3DXV^F7EY14B\$X97KJF(1.5^2@<2^&0EH\$&_LMZ_!!1D_M@->G3I=KU!H8Y-
C4U31^<K\$&_&VYB1)C@<4LS^U!X183EARY!&IUU=1J_MY^6@P!PPG5&W!)16Y2H^/E#74<R!4^B6_Y!<H=>1\$D@W0^!XM&QM
M9F5K4>0D#MWBZ87PNSPB#N#AR\$660E!)>?W7Y2K4_8Y_Z=2I0!DD9\$8@2E=F0HPIN_MBD&9XR=MFW7KH1)1>+6/OLP1
<50H6<(<HTRP#=#72!)@<1^TJH1^2^6B0E^MQ=K24M1TE^HJQ4!^!X#K0_05SE.G66K0-0%(!<K&L&L^N2Z)!Y!M
M4:ZJZOKK!<^BUU\$=#3K#M^Y1_!W149+!X\$Y7JGD28?P>_>A^&V\$X^!C_M19_F2W!M@P:CB!>1\$>=AX+W\$1L1<_<57T^H^R^H^2K_RKGJ9^UN^MB!C!K&1&6
(4@DNF)W^0ZSK(0=0#0!MRH!<EW?NW&04V-VXAFFWICUOWD#C1_1Z2P&VH!_#%44-POD!F2)2N-M3KTNX+JH^VX)/G+>P\$J+SEL=78F\$7(3B^DZ@2_5.12(AD#7^#Q+H7
M5HHX>+/_0^J&E^P^7U8Y>2D40+&#M4)-8J!E#HJ21_YOG+>P^_M^<1P6:30J^VABK51^FC7_UJ^FEJ3C!<=>?WK?>H=2^HLE^P&715Z_Z_M?M^<47JL^CYZ5093F
H2WP@_E4HJ(2MNU61@_17W_12@GP@GCV!6M%<X=C^<N%&^!QY+V4_A089324GAB^2NH!0H=-JY74B4!E#E9A3_B@042^1^BCK!<K0!<1^M00716HM^>

[illegible]

MLRPI9.0@R>G.MI#PHT>@&P&P.&I>IB<2@I0TESE|SLR.3MZJNS9J5.67KUZJ>O7.7#@MP1\$1\$9.63J3A>7-7BB8J4>^>0CN.1H.0+>FYN=NV.603HHVSEW.M6K6Z=>NUZ
M/#>APL#>\$.B#>C<+>DR=&CPI>/CVI-EY?>UGSY19LZ<&IL.7#>T99=GT.MI/OM6I9.FC1H2M2I<?>.G35KUHC#>TJZ71P.1<33.3#2-FUJU.1507KU.M9LV.1>C1CFI
IMV1=>C1H41\$0Q.72P.5/AM0/HJ8B7EY?>7JL.MGN=V113A10.10=>1\$D6=IL.U.12.GCV.D9H&AP0XU&QOL.NWGSYJ5+ERB0
M0.1&B&4AFAXY.BHT4>@NR/61659EL&Q659E<7>Q969G18.7#7KER1BXYUFX.MQ.0%>LW23U&IU=C.VG3MWBF0B4FE2.M.C.M57H5508.7**A.K.RP1*G|S<L.SLU
Q4.2\$13JDTM2.F1.L14@39.MHUHTM/3.S.DYX<C2D|J>1XGAXR.S.YU4J579V=EK1469F9FH.M.BB9.N4JF+BHKR0L.SL592H4105L6D.0DYL3D
\$.&N1=>8&50J57Y2FEJ>GEJMT+BTM5:05(7A.MI>X3JU6UJ0M2(I+R.7#2.2&@B8HG&IX&97U2D244%<75UQ7EL.15RE+&4B&45E125Y>7D#1.BQ=M.6D6G
JTSRL^W5Y9SD.XT.3.Q>3X1X#)LS043.1=L-&IE<L1P=M=V5M.M@YK&I3&#.H<@659D&B*.9J40+R1P2\$SDS@89=A%>X3J1Z1O26&2A.M70C6+&2D0W&4#8>^>9-50F
E5VYH18N@S&S5YQ@PHT1K12XQ#8\$.0%>M.IP#>PUL#>U&HU<@P19WJK&D1K<@>F2C=6TJ0141D04T1M-85=1.0&T16&H1&0%>+YEE<H<X5.N15.(1)DJF1.\$&
Y2CCPA.M2O>DLX7B8Y9EJH7V8.2#&A&W.H1&10Q70.0^>@=&X+Y&2Y86121T.M.O<@>M0.FX.S**BAHPQ+&B|O<N4.03Z<Y6-4.B-PY2FCS.>NTO/AT9E1&JSM.MO/REPL
1/2C.1%3.YV1Y.10+>R1P<I(=U&H&8HNBDS9**GPR8#6\$H1#6.M.2B13J.1#E1UQA3#8DK1.15A0B\$>7J1HH(2G3V\$819.16FLR=>6&S?M7Y4B7C12Q0945G&1=>9D#0%O22H1.
CQ10M<@>%2&X&H<L.O1^>B.D@>MAD\$>7L14YWF&S25\$FZ2%>BK60)DM3.KZ=N1#148.1#>M2YTP@Y44WUDC1<RERA3I2P3.M.0I@C&XAY1Z2FE1V2P3U5.U1VZ
H\$22@>8D<C&X&F&N.9.9Y&IE.M1P.MXN1#>OH^>Y7\$4G1LP+1N1&=M=R.J8798H1L<@&O&B6.M9>S\$MHT01^41WH1E1W1A1J01.GID311F#1ACH=>
+&4&F\$.?2Q2+/MH(NC+N@VH5U#59Y#H1H@>S&JRV#59#807GHBF0HBY4LMK1L#76#H1LT.MW>?>1\$61.%.%5H1P1B.60.1#>H1J1E0.6U^N42CO.77H105N1O.M1H&
M3(6470.0C&6>2<4S&D&C=M1&@&S14.A4&+1\$1#>(<Q0>D15.02A+3>P.M1C<24Y222A1XN7BXNGKMW60.R1#>18EPSHU.0%>H1F.V#&C&M&A2Q7\$<1
<1@.1P1L14\$13Z<0.1>A=WD.R1(432^A1.33.P1>BOP.2#>M8.(S4+P1+B@>B=Y1J2N.ZWV1W4A1+CEM.H1B1U\$%1%USX1H1F.M*5.1LX1J.EXN02RH1P.1R/AX49#14W8
&HW032@>81#>M0Y0.K1A4#>@K.MW\$15%0>1.MB1Y(1G&BXH1C#>AAZEG1X.BB2RZ2#>PY@M5.4F&D1Y4UL26.1M.AH134E1Z>ZW1WY1>G1Z1NIQH1Z2%>H0&B
M10>I3.FA\$M&8A1/CKZ=L.F@>X7X#6RAM1\$X\$>1VZV01W8\$P1WJ>E1M.01.11T1K1&@>YOMT1M.DOU.D.H.46.(GT0%10GTY1C>N1HJ2^>4#1D1%Q.MBM*
13X3.SHH87Q6GHR24M.OXV@>6#>4F6Z.0%>Q.C#>M@P&S&W.IUK.M6)NHB8>+Q.A1J#>6A85%18I>I656/BC1FKR.3>F4\$S5COU11\$#K0.M1.F\$A.#601(2S5%5\$ILRAMU/Y
12C4A1@>U1E6&E1F1E1A1F154Y1T.22.M1N@>ZM.VYH1J16.(BBB1J0.11V1V1134QI2F92.53XH1@>8D.2.5HUA
12C11@>BYX1H31&SRKU1H1N+>2&D&S@>H11A1#>06P1X0<1.1JHM1M1P.M1X24M1M&Y1=>H121+<+>1#H1H=&B*HD1C8X.30.F+1AE2C1F141T\$H77Z
1#>N1W63N1N5V&EAFN7K1E2Y1T1+137\$J2B+>3001MNS&V&P.O1#>M1U1M1Z1A12BH5511K1U1FY0H1N1K125#0B5=N1Z61511=1YCO1M1BYD32%>H1+O#311
1OHO101=1.S1+7F.FO60#>+ALV.*K3.B31.3DM.M0.MR0=>%.U&YRT0+IMVW121BPPM1O1YM#1KNG0%>S3X1#1QAF1D&F0OQ5M#F1BXJ1RN4V8\$1X10Q5.&V<@>B=O1F
1.201P170=512.GP01JH1D13A1G1N1H1M121P>@>B1VD1MW17E1H0>>O1L1Y&GCGS121E1JF0B.9P2B.72>71.272M1.BBMH0%>ATW1A59.57<3.1AA.&P2H1
1OHH1L1H1P79Y1Z1L13XG6V1A6L#>M3L.MZNR1R1E1GL1E51XG601JZ1B1G1R1V1A61#>1&G1I2UL1F#>M1W1H31V1US@>
1X1A1P1.6BB1W1M15M1U.1.5R5R10<0.1.61A1@>H1CW1M1A1G1HAN>NC.>X01C1\$>1.T1F1#>11TQ127H1Q\$1D611#>31B11#>H1T1T1S(1V0W1J1+1N1W=Q
1&DU1N1GBW1D6C1W13XZ1EX1H1@>B1M1\$1PNK1ZK1H11QX.<.&S#>G1WY0191(N51\$561\$1+2/GA191F1B.M1Q1=&SGBN1&1HE09101
AC131A659\$5\$>D1U1G1B1B1X19LV7.H1=5N1#>1MD\$B@>9E1R1#>5A15B02BP1B1BRP1@>W1M11P0>E61YGH<@>1K1K1=>OOT1MB991@>1<COB&DT09191
F01C1@>Y@>5RD11#>0P21H01P1&P1\$>A491U1N1M.V1V21.FM1#>7S1==>+1XHHQDC1N1C1P1A61GE1Y1B52F1E1D1P1M51V1F15R1&1S2812D1412&@>B1H108Q\$C\$19
M@>A1.8R221P1ORH161G1F1A1P11=>1D1L141466112P2S1D1VBN8DR51ME1F2P833B1@>@>H1A1&1PQ21111P1O@>1E1B1OY12P9217E21Z12145D10891H1F012H1
7721SE1U2M33Y19=21@>11.8Y7DY.MD&11DKS1R1KPHU1A6L#>P1A01H101Z1NK1Z&F1Z1F1D1H1252X1C11141#>M1.VYH1^41#>\$.>O.B<12R21D141X10<22011#>H1E1P1
Y1Z121M1P4.<.&CQTD1W1M1Y1E1Z>21H1WQV1SMOY1R5Z171H1M1K1V1M1H1A1C1U1V1H1N1=NAW1P1<W1M1V1EG3W1C19X&F1S1V1T1W1MWK1H1M5NV13B31C1Q1
H1XV05%>1%\$T1E1Q1H1L1\$*(19AKU1X1Z.3.1#>M&H5Z>?>CH>SC@>S1I5AFOC+>2OD1D0.NB*>D(4\$4>R1)\$966.EZW<1M1@>19U1U1S1Z1>6W1W?
P15R1X51HP1\$>6G91U123.P14<R1U1Z1M203.2L1Q1M24N1U1F3AV1JU1#>AYT1M1KEB014H1W1N1@>BQ1V12D1W1U1K1F451U1
M1W5SS91@>Q8U1O1K1UN1Y1B1U1&1Z8011F1D1T2Z1J1=>51J2#1.G8D2

[illegible]

<"UX1T9I9&00%Q=W%Q<@/KWIB8+S.G 4 M1)LS9FE("TR<#D5<+*J: M6N7XU< 3ENXZ+?. M72:~FOI7FJHJZM'E>HU9|SIP6 |@95\$1>2175^?D|J|RSWMWF:-GZ|@14" S=L MYV: (O&?DH1Q 80= 8#?"GSO?HV1=11"9SYL< >#?BD)S<?Y8LJ5:M9L&3>:~. M69"<|S\$H29<|O2>|VO2|P8T.M@IH?V5GY<CE5>Z:Z:Z1?&W9 ?~8T=I/Y:~MY8+@C<I*~SR,+@WU29^T? O"O+?/9 Q/6|..|TS2&A&KAI|IYU:|6|E1T M?>E^Q O19AH? *JX7*(10\$+>1:~HUH+EH#Z4|'AC07,"GN4"SIW=TAJ):#@%+@>I? JE 70F3\$ _|G|&V MTN< %V|I?Z~T~UDVN|SY9S9LYS7GF>?<?Y5S<QOYEHZM|3R/C<S<5 MMDUO|V3C<M?<SC&AF5142-DR+JZNWWVW ~->G3TE ?2@Y5?KIENA-5M8Y5M8V2X Y M"KT=HB1G9:N;MVCCZ.16M"CJK-ESLW-4\$E\$";.%#O^#>P-I|S |C@.~4@I+ MX C6%\$//SY(F3|JQ2M6:WW3L=NKT.9KA&):7&TR/GI0/&#C4UJ=813\$S\$IT| MM5HM<74HBFV?I?>LV1(4%2L6+&OQ VVD|6I?>~>NV8M(B+~T?<GJ9#D F.3\$Q MLBR:S>8V-C>O7L1.3F%A|I.F#~#AZM6K.WNC(I?#~P+|AOXP#~ IW=7"OW MWZLK+@X(W|I|SRFS?3YV|I?E|I|C|I7?>O<= O|B.&Y|E=1H14J1~2)<O?P#<D M15%Q>?<7>|O2H6K7|H|MV|52|5C?M|G\$Y|6|I?>O8" @~.FQ|I>M|L-D|J|C|I<1 MG7M/GY>O&F|O5|S|X:~S<A-I&C 2:(I7_Y78(Y2&+XBORL|L710 MF9D52)3|61.7|J|Q|P\$&1*~\$-FK(I|H K"~.DEA(7GSFKRP|V7K\$>=NX^?7|6 M+~|Z|I|X|A:~N.W+@|/339| |6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$B+8|+~345|Z M_1-6ZQ|L~Y~YHR?7|F.VY~M<~CD+~(B@H-36G>80V+BX<~C~.I9\$|H4ZP|F M_HH=Y|X4\$6|JL @|H|6R5?<5HH9C|NVE|M|NU|H|UGN07>Z|JR9+2|X M~BGHT8?D?>~UG|O>GB95|YD>3|S|O?>F.58V3BXNW|U~.J?>+X6?<FK8HZM|I|O|TOSPB>~>Y|F|XGZL~Y2P|5N|<=|O49| FCUZPH|H@D|MK|HE<|L|OVGS6|FZ.GA~QO?>WV?><^L<~?<5"&#>+~M|N|91~IK|O~L0M?PQ4|I?Z~"ONG4~|6|BWJ4~5~K~>B|H+8|H|BM|<E~FV07L-B+EO|Y6|APH|PR|N?B1.FEB01|I|6|2|D|GBDHZ|MI2Z:~|I|RL+TLRSP+|Q4|OZ|IT M#V|Y1|U0K5|?~NXZ=Z|E|L|F|ERRB52E(4FN|NR|MB#E<8 H#>=POYKIVK?&W P+~|6V-MZ=2|IR-7K-PC.P.\$/B>>A>) <#>.DH-U<5&WMCT?>~NW3|H|N4K5LZ=-W 5 M+|Y9 >~>2|Z|~|34U|~<~N957\$?S?X|P60TT4:Z=FS7L6J5|U|U|~Y|@|J\$8%W=GL.BOWW3|O?~01~| MG6?&|J1+<=1~W3|3|PF@?<3&S68E?>~>X8R|V1+X-FS8|>=\$

[illegible]

[illegible]

!JGQVGV7G0H.GQD.JL)G<5M*AXOLW.MV)U(TUOLQ5.P@969E!UZRM.KYK.MNKK.M4.G"PH")>?HTKL=KQVINTPT"R.&#">+E=L?SIO7OH?@0608S.MMQ?C+HJ05M>N5J#K
F<FHHMM.RIK<XRU.XHT.SC.WIZR?O?S!<@LEKK.GOWI2>S!>DLS!FS9T=>?19EH.H&H&D>VIR4C?T-3C?CYQVYU.00-2=>1XMT
E!H18KH0D12>BXC?G&R-ROEO&UDY.N-NW381#6S5"BBHBS.G-!T77.MW4H&H&R>?3C!A!WUNR!R5BWZAUDSL1H+H&A.H989?LYUNM>C6UINWM
MXZV3ZPB.G304HHH1U?OM&+FO?<1!>@2N#M5?>PDS6E&.CXP">@O4ZHYU?MFLTCFUT?>F5=80+P%>A!>BBOUYELR.D+OL.MR7+H&C7U>J-PR+BSISV?CBAH"O8"#>
<1.&S/O5-149-FJL-HJ=3J5/FO>?>I'Z3R1 M&B2?<@!OLG68S?>R-FSM.PB+X"O!W1W?>M<K=>#>LA<?>V!>V5F3C16N-MWFIJH?P<?>
F1\$>RB/SB&E01QPB<45%1H<3>KTIKHU?>F/+>T6L#PD.MPO/A598MF?>G7KU!7C.>9&S1XT>DU=0<A.HRBP.S8L2&A.M(7I<FVIO9=>DX/3W"?>D@
I3XH59%3L=>S1956+5JV4F?E.V"NO!>M3 M89%EPL1)7MXJOX!+Q15Y?>@JZS9L1+?>7E)B5E<ODY.RB)VPI2>Z<S*%>@XH0@>U!>U3 MB&6-JF<O6?VR8IEN07YK
J2T19O!<1 MF&SUN+<N!>P6RIGCPHNI<+<X8 M2!>A0&2ER=>EYCEFEYOLU!<H1&18S5Y6VLA2<P!>U"6B2YF7?>K" P-M2A1H?IKI#0 S0
9<10F!>?>AGM1HJ5&6.H.GJH!41F2?XF0D?2!>UPM.A87CA?T4CDD0DW<@5F>?>JE+H1?>2+82<A!>S3M0.LRO.QJN!<@Y?>P&L.MYV?>R>K9ARH?YBF-A<@!>DSF7Q!>MNA
YZ.CAYBU30GR<@>(2013.67QWWWHJ.MLUJ4VMU&JV<?>2L.IPX=JL!0!<@D<=>BA+!<O1&+<A!>3M08G<=>S!>B4K<P<@>U!>HJ6DSFOO.MFH!30"Q0W.M&L?>MNA=V.2?>H
(R.<?>CQ! M4?>7F5FANZ!>V2B:QM66BYB9.FE?>92Y1C?<@L1%U><2&Z4F?>Q?>P?>012M7%>HL?>P3R?>Q!W.H!>16L2?>JG5&DU.MU?>L.R3HX1&!>DPC<=>E2Y3%U>
L0E4!>DXJ1.4D)>.&RIN?>NVXV1+MB.MB>?>3H<S?>215C?>P00-9Y2&E&VJ&B!>AJA.OCHJK3>7KYC!>QU<9M7M+U!>O11 M-M7?>F9HT?>AYL&+JUL!>+!>S!>YU?>G10Z&+J?>
LWE=>+12N-WN3GZ&2A.MFT?>N!>MIF&A5!>LH!>5WL?>L2L.7KU?>U?>7Y?>R6K65.0<=>1C5?>5F7Z?>68)M&F!>P?>4G?>YBP.MH!>K?>F70?>W&D?>R?>GM!>@H!>82XBL!>4>L-6J9UPY>S9)
M-RRH15%>DPIU?>NUV.0?>Q6EHS!>H5Z>3?>PH.??>PH.N8B=>1#>VG.TI25 M"5"E-1+>YR!>K!>U(3>)>0<=>91!>@>(S!>J9?>1?>RREH!>2!>12CB.75!>D1 M#%>+L.B3RIU!>H!>!>O6U-
""4.7&A8=>0<=>RR1D?>RB?>73 M.MSHV=>?>2CX.&8 SOZHSU<C!>N15&S!>+Y7E7GZ?>A!>L.WBH!>P?>MM=>@>FNBV4S<C!>OX!>X!>C!>+PHW.O!>MWV?>S0Z058!>D5!>FS?>
LWFM<P!>@<C.MTD.>O&ASBU.Y01<SNIW<?>T!>?>7NR5!>NOG!>V&S!>P&M9M4!>L.WX.V<?>FWI2.M&E!>2?>+XXJ15NS<1Z22>M.
(5MOR81)DWU!>U?>J7Z?>W>?>6UVH%>A<?>FIRA.M9=2>PWXJAWKKQ!>9>3!>H?>4FRDX7H=>@>(Z.FL!>R!>FX8+>E!>F3?>7!>MZH!>UYOWXHZ=>HE(C+ER)!>G+TM<K5J.NJ?>
&@>P!>+!>I09+GP.S&9+!>10%3#M4!>5"E!>E!>B!>P!>YJL!>@>H!>B!>D!>OX?>7+>F&S!>+E3>S!>B!>G?>(7!>MO.M7?>2>V!>N6!>O2KX>?>55KW8>Y6?>ORP?>E7&=>S!>F2ERO>6KVZ!>H!>C!>IPSUEO<
N%>+!>M!>F!>XK!>S8L<=>S44<=>O9!>OMB!>L!>@>7C2?>N?>E!>T!>R!>895A.O=>QJC!>VW-?>M!>VW<=>I!>B!>K.MNTH!>D!>U!>R!>O4!>5HC9!>+!>H!>GMP?>7!>(X!>S<=>@>B<F!>F!>R!>M!>S">G!>TU.K!>
_S!>1.WJ!>N!>1!>XZ!>E!>Y!>N!>1!>Z!>6M!>T!>+>702!>+Y!>S!>W!>G.MKN.X.KOZ05&+D!>L.VV<=>@>(4YV?>K!>R!>H!>P!>S.OJ!>U!>J39M!>WNIB6<+>
MC0!>H!>H!>#>K4#>S0<=>VZ>2.OU33!>M6M!>1D6I=>H!>F5S9!>+>M!>UR!>H!>E.DY8!>+!>M!>@>B<?>T!>Q!>AD!>@>I29!>H!>7V!>5V!>JZQ!>P!>L+A=>#E=S.Y=>NUNU!>?>M6U!>Z!>G!>+EX4 M&S!>
T!>A!>5!>+>L.H&A.W!>(A2S:>RFU!>U53YZK<@!>O!>HTZ<@>+>Y>2!>8=>+>B2 M9?>+!>I=>GGXV!>P!>5!>C!>W!>R!>R!>I?>1!>5"E!>E!>C!>+>
M&A!>O!>37X?>W!>10X?>@>FSW!>JO!>U!>9!>U!>K6B3Y0!>2!>UR!>J!>L!>C7A!>+>C3.AXZ?>DZGW!>F!>0!>6K!>TQ!>+>J.M<=>GR.OY9!>1+>J!>E!>M!>#>AX!>TF!>@>IB!>U!>N!>7X!>#>H!>O!>+>@>B9QA67!>I63!>+!>
M!>G!>H!>N!>W!>+>@>O!>A!>H!>+>?>Q!>F!>12O!>=>U!>H!>1&2>3F!>H.VK!>A!>+>T!>S!>A!>A!>P!>W!>O!>0!>6!>J54!>+>P!>T!>P!>Y!>W!>N!>K!>Z!>O!>W!>P!>H!>Q!>X!>N!>K!>S4!>W!>N!>9!>4!>Q!>W!>N!>W3>
O!>T!>8!>+>N!>5!>L!>B3!>+>M&S!>@>24!>H5!>U!>G!>U!>L!>6S<=>A!>P!>N!>MS!>(K!>!>E4&S!>O!>0!>KZ!>W

[illegible]

UJH.BVUKWBZEOH(U&T<13X9.0C<D&L.M9L'2'1.G0T@H'D'>H'.*G69+9MPIPY#<E(HR#>JHBUK<W11<15.UD<|<K'P'.W+M.FVJ)28'1\$0<6'>
MR8'>L'V29P'0J<+A8A\$25<D.K9B<8'P'0'Z3P/BRXBHAI=F5@<4.T9NP<M.MQ'1/2UJ.LK.P26B5'>V7H.W3.VT.JM9B0<#/?H8W'2?IGPOS.V0>+Z4H=H@<MUWB6
XG2+M2V39P'2A2319P.VF9P'2D.L=8'P'3+Q0B'P'.AWROJ'>WMPMR'<B'>M+>1F<#A16B'>HJFM'>VKKPK@R5K5M7'U4A.VZWJ.MM.N.U&H:
<KPI9C199451>81X. OKM'D'>N>.E:FBYNN'0<.V+>01X.M58<0P'>B085'>1RZINLEQ0HTF>BWGE.G7KM106P'>A1'GB1E'>B62LP'>M0.EB'3GBJ'>94H\$>K>ISZ2=71.E#
>9&5&W68'21'>3FEM'<@>7L58<>D9F'>L'>9UJ'>H5H587<1<=>PN'RBI'>L'>3H.M'>2X0U'>J1C5@>R1057'>T0BB06A9N&1<=>C'>F'76%>N63-GIF-BN'MZJ#>4)71
MW'>KYQ'>A1S1K1-4#50IFNFVH=H'.N'W13E'>C5>@0%>BKRH'>YLS1L6F'>H'>MYBU<=>%>HDXNNXUJ55\$P'>2>HAGS'>IQ<1'5'2'>LQ7EE3-FS'>S'W'>3'S12'>M1<8<=>F!<
(71+>Z&KNI+4-10WHWW1'>4H'>T'>17&4'>)OUT<=>0.X.METIUFG'>20'<C'>7IRDJ'>J'>2BEVH3'>3'>Z.D6H0'>1<=>6'>'.M1=F>GKN'MUA<=>'.PV.XA#2'.VPHFDUE<=>7
OGX'>00X@>IX'>Q'>46Y6G'>EWO'>17'>1JWB'M'>IP8H'>J52>TA.Y3CQ'>0'>AJZPPGK'>H'>HV>JYB61JBYC'>875UBB'>S'>M'>M4'>UAPIQ@>B'>K'>#>16X18'>A1O<=>YBM3H'>@>Z<=>
N\$>3'>=>Z.WD'>0\$>K'>@>28&Q'>W'>AUNCT'>BB1<94KH<+>U'>MUUV'.UH16P'>Z'>H'>2L'>U1A'>@>32'>C'>2D'>C'>W'>O'>1<36E16'>C'>SRIOZINE'>5'>M45T'>XG'>IRB<=>SFFZ'>P1@>T?>
#>1-X'>B'>4XOWI57'>+>BT'>X5(DN\$>OE7B'>BZ6'>790Q4'>U'>VU1'E3<C'>10CB'>M2'>87KEX1J'>2'>J25G9W'>H'>O9'>Q<T'>65H'>MB3'>G'>NY3'>3%>G1S18V'>U18T'>U9'>LO'>=>NW'>C'>7'M2'>X'
IAR>=>SRHS'>7U'>S'>YV'>BXGIN'>JUM'>BG'>(ZHOXV'>U'>W'>T3114'>C'>OIN'>M6.D5XMB'DIF&#xA3IE'>O'>C1R'>Z'>3A2'>YJC'>H'>C'>GSQVM'>D<=>L'>=>UP3=8.M15=
1'>S'>H'>C'>3'>L'>FYF'>Y'>24G1'>#>4F'>X'>9-ODV9D'>#>+>YRD'>T31740.61'>M'>+>1'>S'>152'>IYJO'>C'>FG'>=>1'>TZ=>CA'>A'>3'>F16'>M'>P8Q'>60HJ9N'>+>1'>OZ'>I2<38'>65U'>M2'>#>RW'>F'>YZT455'>X'>1<
@>S&4'>D'>IK5J'>G'>M0#>N'>6'>@>G'>Z6'>=>?>R'>=>Y@>M&G'>ZFN'>G'>IMATF'>'>11H23'>5'>HESNHV'>5'>FN'>M'>+>UNTZ'>X'>BT'>'>1U'>C'>S43'>R
M&H'>@>1'>AHHH'>H'>Q'>1'>O'>(DTS554U'>V'>#0'>(D'>C'>4'>L'>K'>OHTX'>K'>MUU'>D'>Y28'M'>=7&57'>OZM'>X'>T'>'>9'>K'>+>'>YV'>=>NWL4'>6UX'>7'>9'>9MKBD'>=>1'>F02ACG5'>G'>L'>1'>#>S'>G'
MPJ23TOKARJ5'>@>46A4V5BMQ5'>(S&GK'>J'>CA'>G32'>L'>1'>66&S'>J'>'>=>3'>C'>M'>S'>J'>4V4'>2'>U'>P'>J'>U'>M'>+>B'>F'>N'>H'>V'>T'>S'>=>F'>X'>J'>2VZ&8X16'>W'>P'>S'>1'>6'>K'>U'>P'>8'>(O'>U2Z'>A'
M'>N'>A'>B'>8C'>'>2'>K'>'>P8GAZ'>'>O'>'>M'>C'>A'>3'>X'>66'>'>F'>S'>+>'>G'>'>2'>'>4'>D'>G'>K'>'>M'>+>'>Y'>R'>E'>P2'>'>9'>K'>=>K'>=>N'>'>7HRZ4'>K'>K'>8Q56'>+>V'>1'>O'>Q'>6'>S'>H'>9DKVPZ'>2'>X'>T'
M'>S'>D'>C'>'>O'>F'>A'>U'>L'>=>W'>L'>'>I'>S'>R'>'>8'>I'>M'>T2'>P'>1'>A'>G'>S'>'>D'>+>'>9'>G'>D'>M'>F'>O'>U'>N'>'>D'>M'>G'>O'>X'>S'>I'>A'>'>B'>O'>P'>C'>1'>=>7A8'>'>82'>G'>5'>T'>'>A'>@>1'>T'>D'>I'>=>I'>B'>M'>F'>U'>Q'>F'>A'>I'>R'>U'>Q'>F'>'>P'>H'>'>P'
W57+>'>6'>K'>O'>J'>'>B'>O'>5'>'>M'>'>O'>'>2'>'>A'>'>I'>'>L'>'>#>Z'>'>1'>'>U'>'>G'>'>S'>'>M'>'>E'>'>9'>'>S'>'>B'>'>P'>'>P'>'>F'>'>9'>'>G'>'>S'>'>M'>'>9'>'>M'>'>W'>'>H'>'>O'>'>D'>'>B'>'>O'>'>B'>'>O'>'>M'>'>+>'>Z'>'>N'>'>M'>'>J'>'>O'>'>P'>'>C'>'>O'>'>K'>'>H'>'>2'>'>@>'>9'>'>I'>'>X'>'>Q'>'>N'>'>Q'>'>3'>'>U'>'>S'>'>7'>'>A'>'>S'>'>+>'>E'>'>Q'
M'>'>7'>'>K'>'>6'>'>M'>'>2'>'>M'>'>'>Y'>'>O'>'>R'>'>R'>'

[illegible]

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

[illegible]

[illegible]

[illegible]

[illegible]

3 P8.59LTZM=NR8Q6+A2V>.DB6H1L|H|3P1US>58|8^8^?Z\$#S0Y8QY3P2QU|=R|=ER<9/F%Y0:J|8B"\$L_&+CHFV>6LM^79%>D8NJ#|ADP\$L(<J5E9<|U|H
MRY8M|WOVYSG9N6.3>|/ T69-6U:N.#|FS(0GCK>#K J2BQC D\$EHAXY?KW M_P\$W|_P^+0J8.BA|/_WGN 175U:<G+&G0\$545|H^S)|#|+76L7=CHTK
M=E\$57M0?R>|>^|45|Z4A0.TPY0?|OVGN8|0F.YY?_D&R&N|9R9:|_MV00L=|VKUOM.W4N5|Y^N|Y=Xa(J<4=|M9J|N2Y=L|L|Z|Z|MN 86^|0X M<_)KHHP
-4D>|P95|H4|6B5N<|F.FB|XQ2|H5.02H2-X2.N8.F0 M<|D1\$&4D6.RXG|<F^>YX=94|H3|H50K3I+&S^06.<K>_FIJ07K%L|L<_DFF^4C_ B|0C_(<=B&K<=7

[illegible]

Q>73<^M:4S:36JXA^IX YZMF7WJ1J7T2OUO7^KMH:HS&7HHHAK99<1:Q1^MW5QK MI>G5<7RU:M6KQDX:G<1^AV<2%W:S:R&^AF9DIR:XD2>S4S%>IMS^14SMW
M(C9FFA)SZ=VZ=S=W=VC<2>.P8N7QW<1H94GT#2/>2/>_OY<^VS0V:Y<_8^1YA6GHU<1D#4DR> S\$G</GJ^J4QA8G<^LE66<^M20W%BV^EWKKH^V^H4KYV00.
IXY>=<#H5H0U92>+E<38S<1N7W<KLU<=5fG<#>1X40R<_SA<P1J<MG<^#AXY<N/VAICXN<1B0I<2>=>KY<G8>U08IK2T<WHD<X&S<NN<1N514
MR<+2XIC1HWK<WJ82>5.066MD#Z<6#4DE4JS<1N31<Y196YE<65<1Y<^4 M>2NNW1<23D14DB7<#48X8RO<39>K1Q0<^OG<K11<^S2Q<@>191N<MNPJO<?2N
MAYP<8N2UC4<A<MXYKJ4146X<M1P0GS2H<#>1V<+1<RM<+>Y<^0<V0US<HJ5U<1J<11(MYVG<#M8A3TP#N<1BBS<734P<S<+WLO8M<70<OJ0<B8L75<
9/3P5>GHW<W3T6<M+1506D<#>71<B1P9D0<C2JH<1<G9U18<@8F<B16<F<C5K9FH6K<F5<6<+M<M^M791<+1(\$X2U<2F6FS<+V<HX<#>XMG6X5<G2<58A>^4)<@P<^
GI<@&U<M:M6>=WIO4G<P<DQ<1>2&#>Q3Q1<GS<+EUL<C<ZFUM8SYZS<D<Y3%>29P<M<M<F0S<_CIVP217<V<#>1DV0F<R<24U<+71L9VZ<=>PIUEZ97KMY<#G<1A3P2
MINT<+UWY<1<#7JLY<MBX<+34M>?0HSZJ<1CDZNS5JTWK<GTF9<B<+>+>1M<N<4TY<+1<1W3KUI34H<MR<10=>G2S2466<5YXX1<5NT<+>^Q23<312778R8<CNL5>Q?>
J9FE<T16ZV<M<=1<1<Q<4FMN<6<U3<PVO<@>#>GSU1<H<3%3%Y<Z1<1W<OW<G1T<CQH<JY<MH<#>N<1PV<+>Q<3R<XZ<N<UV1<1N<2<#>2DF6<81Q<^>A71<67Z<OX<#>W1Z<
MRDC<_<?>82>=>RWG16N<9K<_HX<381<11<217F<Y<B8F<C<1H1U<N1<M6Z<M4<+>1<Y<N<0<^>0G<GWRNR<NV18<+>F<C<=>PIY<M<29<N9<S<XZ<AYR1<=>11HMV<N<S17<10)>75T<V1H<X
MT<+&MPO<G0<1H2<F7<+515W2P<+Y9<O<H7<R<#>BFB<7<3KE<MX<5<1T7<P<=>Q2L6M<=>9G57HUZJ<E9VC<S<_LY2<AMCQK<C<GRH<1<M7L6)<M<=W2W4Z<=Z<U<_8715R<1
0445X<9<OG>+>EMTFM3<S<2S<RJK<+>M<PX<O<H7<@>H<3T<=>1L<1EWE<515YKAXQ<21<=>T<Y<E7JWOH<P>D9F6<OLM<M<C<Y<Z<#>MOHUIS7<@>XZ<P1>3<#>MEWMQ<+>LXUZM<ON<9<M<+>1Sf<70%10H<#>AYD<+>1YFN<M<V1B02FH<_24115<=^>A7Q<0<AH<MZH<M<16JMS69<_R<_B121<P1<OG<+>PW<W7F<74S1<@>O<MG05<3<=>WOZHN<O<M3<_8E<@>N<DD<6<2RKP<2<YCS<=W<T<#>CQY1<@>K<D<BS<@>K1W<V<JDT<S71P<J5<B<A0<Q1<V53<S1<21L>O2M<N7Y<M19<PHE222<SH<=OG<T1<QFD59<E<H<NWK<K4<YA5<MYT2<_L<E2<P976<9W<W<M<=>K0P6<6Y<ON<MU<=W<M<NWX<2K9<_9S<1L<WZ<1EWH<700W<=>Q4<N4<#>97<21Z<UHKH9O2Z<=>S<T<M<XD<@>H9F<U<ZNA<1<HY577KTHG7<CUCU<#>0X0<NE<CQXW<7W1W<V59<M<B2H<F2N70G7<K<N0215<+G2V72W<@>M98DZQ1<12S<U<=>AYU<+>1H<MDANVH<13K<N<=>G<1<5H<P7<DQ<8St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f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

[illegible]

0.0420Q/W1+VW2J.M(7Z-).7(RD)PSKPZJ%\$3-113P1XO%#26.%SC<.&M+TH+!*R-.15V.MO/OI(CNS54>0X1'S<D80)X7T(4F-1)5B2)DU#4-Y?WCI226IWA1X'K
M7K1Y101133T1T1.(HX5-%!%Q<4LN%0\$+<\$(K8B579\$)+L<=>X=2D.MIFDYJ+H1.PG%1.PPO/KFXPC'1J-1J-5%6K1ZW'X6D15W0A3)BL<0-7S.M8T;@3>."AA5"/+
135X<+P6LR.PK210Q.01<+7+R1&0">1>\$(3Y117-M+P1XU1F7R1.C1R1Q1V1%\$U1*J2R.N8B0<+1<C2+1X0S1X7>Y\$X'G\$<#MCDP.<KBNXLTE2>+OJTF+<E-@LZ
5K<=>#&Y1Y1%0%\$NH%#&D2.0B.QB9.WF> MX3B.97E1Y121Y9>1=AD1>3T141.RM17.H6.18GDCUKAKO744221.MP+J<E.FEBWMO&B25.AL8K2
M'31H1L+3A'EOB71R13-R.WOC1B9YNG.M6P8CDD273.8Q0C0:GRE-H+0W&S41#E+(ARQ.HRR)<#OPOL.PB02@141>1M1<4<4
L1J%LC633X'HJ1>V7ML14109AC8#J1DP5L11>1-Z-W1\$ML%1M31UH1YGG15BY%(A<#S460.16D1>49%A689E'9D1JKE9.GG(YE-)%M5B5M)V1A(@CX6R?
=&PQ8H9&40D16+SZ1D41Z0>O310H1Z5>0%>=&PMD1.MXJH1**2.117XEPD<F6XCG1.%\$&699HGQ&OISEB/ASYS4T4CB1F8X.MAA58>UVDRLJ1&1+00-
(U4Y+YC'7>8X1K(@D52D.6&53A8RHPG7.657E1A82FEBWPE9G717>6610.0.19AD1C%KCN.M08Y5A1+TQ2KX52\$SF<-1B31\$40.52<=&C.5FC/P.FER<21.07LRP2
MA'4E13=NPWQ.UZ1K>4YGN+XAF&Q(OH=>8M%J1P8H1DGH1GW1B1E7523.(T.M1QL<0.NDUY1\$9KAJW<C7)GPM1D>F212145HAF&9EELF&C18T7'E%D699.MB6&1HP
+FPB9&10P.CUR1'EL0D+Q7F.COY.34W5Z 4<MOX&A1N7O'0G0'K(C@VYN7.H.GD>C11>F2P6)BWF11.01'>4>Q&4V
MGS31+>+KHB6B&6E=PAEPD)81J9B>>O.L1H1L>H1G+70E1F1KVNO.06Y0'LSJ'>2W1T0&S1GR+M9KKXQ21Z# Y8ID'JH0&1#A01@MN'1J1'>=&8&JVZ1=\$N5.'K5
10.PK%#1849.1GDE+M21(S.K.K1P>DY&5130G1RTE3XFEV1T/M<B0KW10J1'1'BY#2N#11G4+MNA.D1RU1<=>OJ1.V1JF#B11)#A04123D1>37+D+&C3552A.3\$SMHT.0
MHTV>#%(KSFJ3)U>N.M7CM.X=>YBPF&S. QRZ7+5WU+3=H17510D1SDYFQO&SIGB>Z1.(X@E106+4A.MPX&3A1>67=>1H7(Y^H)SKV(P.TH'')M7\$6%0Y<X1L8D
MS7(E165W61+>O717D1K1H1G2Z2ED1E1E1&E91&1#AE=>N1011.V1L1<M8RPM+4Y341VFW3WSKY4V1P.O1ZUK>>2GV.EZ2410Q.0:ESLMB41
MHK27-7>93J10P31XU1#EP2T127>OW1B<P.RSO1Z10.MCG2S'OHAP1F'LP'PROWMAU'U25Y1M'>1@141Z11V'E.O60L1NV0H1N39T1ZQ'0L1C'U'GDE1%1678Z@=>O&Y1K
MOW5U>=>N4LN1K61V1.K4J=>F5J1>=>PYVMO.(A>4K>=>EY<=>MKMSU1H6.MUDZ1M>N6NKG1>4WEN71H3B1H'W+(J4&46)H5A11\$B1D)W1R0<O:J1&V1V91<MB@SR@R-
HJ1<6NFO.ME233.W67.%231.TN:>#VH1SH.WQ&8UT1B91021P6KA021>2.MU.MZQDR9GR<6.KUR11G9N1RZ1+MA(CA<4R9PM=R.S71C%\$WMHMY1@X>1>WF
MPV#1RU1L6K2.H1C4YO.%Y/E'WR)-'771.2N7G5Y=>44ZB%)G'&N1+H.M'24115\$ZONG7KON'FZ=>11>7@0.1#D1.GK2V11)@X+5JTY=>#<1/2.M'W.L'>M>Y'11%
(U&X'W.M1>L6S6MYLS>7#AD1P21L1G71H1V6K5H1.M2LPZ1L>1N3XHY'>421K%#W1<C7U'12KY'>#1/W1Q>41W1MVK&CQZ>3.3P
MX'117KU1R29RDM1D1.G+ES1D1.QXZ>O&1J1T10>1#S'E=>01.BB2U10.AH'M2U'>XMDM+Z=>=&1PH231>91C1X1Y'>S'K8'>ZS1P9-A1R051P8-BQ4G)JPP\$>9.T>0TF&9<1
1CFK1.M.N.F1P1.VXU1.UA(F65D9.R71J1=O.A+MUZR'>2LH1D1B1B1(AD4K20>V1K3.7GE13T3U1U0-&O.W.S.MPL1.Y1WWY1=D9/AS1YV
MZY1JG<67OMU1MTCAN1G6111+Z1H1H1P1.KAX=&8X<=>1QW4&6P4.MP.PU=>4N2Y1%CO1R0:V1K.S1&OW1Z1P1E'1P1LTHGVN.H1XBC=>YGA1W.MF1R91RR+@>2>
(EE'W1U1008L%#H17K#(21D1Y)16=C.V.MS=>T1MW'1MSTX+1C30NR1)J1M7K(D1L1#X1KP513K1#=>=>F'UO17G%\$O1M14TC1O.OH>3=9EDW/R#BW7KV.O5TU'W-
K1010X>=>W>N1+&8H1+1%&1H61.M2DM11H1BB5.S1D1FV105/GKNZ1J1M1X40NGNO1L1Z13G9.=>1.18N6+BP.M41=>N671G1U1=>ZAH1UAS111%1@41+1>1B1C7+&
<1H4Q6P>3'>KKP1<RX701F6.MC#>6Q171+1.YY1.AHTLK'P#>K.R'>VZ7P13J1E03431P7<3&BZBP60X1T6.963DD8=Q6%17.1U+1&1DD05%#BX.G4.MM351>1>1
W&111+O.XK1X'4N1'W.'04N1Z1'>4U10.YP<=&HXZ=01G'1F17%1'>1Y1>=&B30.3A1>7A1#M4E1U115F10.MV401BKP1.%0H1Z>1>L614K6G1F8V<6.SYG'>2E9W.R#>T.MV%>
(1Z%#M.89-1V'70Q1H6FS19Y5B8F1UNH1#EV1X%#XG1XZ1(6.O1ND.M751Y19.P9.H'K11WU.618M0.D1L.OO.'3'F'D&11+>9C.2.F51>=>2R1J=>EVH71'0G1
M1#8V%771JUG31H16&U1@41=2#D2L5YB>Q%L1'0H1'=>P1A@XPD9.7.MKS.865Z10/P5FNT5W'1WK9>=>W1M1RL1VX7237KXZ#&ED0150('M#E#17?
M1N1W1K5C1L>=>8F9D1Y.>@6UN7@(<16D991M1#H'0.HQ'>1JLC14W7K71V1JY4.MR1K1+PD+>8DC1P+>V7U1#A%CPR10G95H1+U1X14.M7%1YV14.121E1ZV1.N1Q91>=>1W-
P1MME1(4Q4B'N0N.L&1'HZ'<=&P1M%#M6643AD1H1OY'>1O1A1K'<5.6MM1G31C1+M1X'1YU>#51G.11H1Q0BM>07'>K1P1V1>1VZ121E1Y1Y1R3'>BHND1+SQY
MDK91W51Z4Y1L.C3'>111&95151>4.7W'>101ZU1>ONM51>1V02(210'M1W1S'>1Y1Z1Z12U1H6.O5T1H1NB15207F9M19V1X1C865G1>1G171AX'01TK'>U.M.RQ1(1?
41=>=>1J251D71WZB1EW=M1R1'JAKW167.60.GG.V1X1J>9.VT1<6'R1DBRW141<1R1Y'>1FPAW1XZ1Y1M1OLK-W.9N5#<71.1S1\$1%2T01'>(N2F13MMW1.U1ZOG7>.<19)5*U1O
ME@11'1.4GW.FRUP1'2G1>.GGWPZV<6L1OWX'>BPN'>FF&31>5J1>67X1M.2.M.011S.K.31HB>7J1QY1.S1.&S1H1@U1S1.BK0%1.0R'>2U1>=>BRR>X.MY0R5@GLY
>1GML7&F12&00.&S&21%>1H1D11E1F4RE1H.871>1J15.M1K3Q1K'>@8.&HQ&Q'>1\$W'51<1.CF#>26S1H1NE1>10F'01+>DTZ=>1XR8&?G.M41=NTX1TH1H1A1XZ
H9&41BDN1PT1>1F4RC9551H1BM1DO1DHZ1+U1CR.O1M=>=>Z1J.G10Q'&Q'>

M146)28GK-JP;-6:DZ+&C!@!V?5ZWVGJFY5-YT5BS=SE.C1"=!~*97*N>R MIB;L^WGZK+Q)HX8.:%>Y^N[GHP>KUVWD>)&XP4M_-B8F9C^~MF7/AXU="=FCE45Q2MG-70E1TC~12T>EJ5%10!#<>G.SBZ65K9G;IPJ3A M<G>1~!8X&ZAH9PH3!WHWM~289YNH4,Z#OJ_MW^P%&IPU\$0D21~D4M_&8!_1 M(8-~22~15JYLRZ 7K->R=(Z?119P-10CJ2IBIR>U&GJDN?~.0M&G!<MUV=8_1<=2&00IO-FVZ6ELZ^A/7#1+!U+K!OHW~98THV? WRL#>DRJ2!_1L M.CC%QS<0!>29E3M=2^KF3X670? M.CG~5+U;B0!<IRB75~XWZ.PISIP8H3!52PH22@0U@<ZZ>S_ZCV+FEI!8@D-/MS(Q)22U>K6%>2810?>7CQZ.D5L0V~+JZ!_N_P>J(GI!HMW7CMGACAF MSBJ7R6~.M@YX4>H1M.T.@>B/LHF~561TI7~BP3YN5+QRX#S2R!_)BUF>M5UZA-WL.ZBUHJ2612@;<~# M&G86I<4.1#Q0-1I2~.VIPZJ55H_4B+7_4 M3I5~.BLN9U+IWH7KQ<K1<54EKA#0P!_M+RNTR=O<~3TSLV>KB>~3P!9S!<BPMAN(XJ+Z!>TP>|@>2R85_X^8PBNS<~>FYT96?KZ!>W~4#HBPUIGD+P\$ M_!A2D4D2<~>A7D>~>IHG7>~>4M^VYXV>~>2M^YU5X<~>IMJ!>~>1L!>4K85ZJIP!>~>1S!W<K&UJF!U3_5HLP+<4Q>M^%FHTZP!4W~%N7+>K>~>D:6J!>LH2T_W4HIN+EX~>6^>ASU?>56G5HJ#_M!<OO>7:7RDZ~.3FYUZA1Z>Y_9NZ5TH1_2L17+V_MLW5723>@>T^6KUTO~*RCB2V_Y%3^!6U=/G_~>NVGTF!<P#R.%T1+X^X6\$%;>MY!<A1OJ!<T^C3^K!G!U7~!5(R2V8^M_90G^K0X)25S58^!<A8V1K;ZCP4^2OLZ!<@>Z~>#%ZBGKY<M7^ M5:OJQI5OT^C!NHUK!POSOA46^ADIUM3^!F3%L=GCB^XTE(BV9IE^S_Mi6I6JW7N^FU4D/L(1)C4HX?R^H>~>WNY1H^>M9D@.\$&E#R>7GYV|>)>K-MM^Z- &C>9MY#JL<~>0215.WD-2+N8342K4FF.F0K<~>EESZ!AGAF!AGW&S6G!M1=PJM149TXE-HAKI6#0&1597>~>K!<XU!<S^C!AAQ!>L!(9YVYI &B:6G9IBD<~>#0P+P7~+>D!>L!>#Q2T6F7~>WQYK4B&B&ULBN^QB#MR~M&SJO:G300Q(BO>3!37P_T\$~+!)>#%D/68EE615!>!(E0^GM_90U!M50? <C@>!(SBNW8N3L(MS.WXQO_WXV>7DL=<~#19F!<A8W!#R~!P>|>J.G.MF9~>W-SRW^CJ!B4+N+Y!<S&WFP^C^Y3MOXV!DYU>Z!<NXXDJU>L7_Y!<A1 M- &N49~*#R<~>Y!5;K<0UA-8K5-KT~>DD9^VLOU5_0!<X>~>Q7K1WZ&Q!<P!<MB=VX9J!>~>7B.H.U!5 C<~>HWPQ:7F0!U<=>1)<CJF!XG+!<1!> MAAAAC2IU2RVCUC^ZXK^ROJ!<0!<AIR!<#1YRH65%_L!>47&AF!<6%7B5^!<T4-OU<!<DEB!<1DVH2?AA<!<IKD^<~&/%W1L M3L!TDH#<@L^<Z!7;MW<="<XP7^TZ>B08- &UZIE!<1J0%<C0^<0B11^<~>D21 G M^<~>P/!<C&W~!2S<L>LWH~!<4M^+612WICKH!<U!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!<Q!<6R!7^%<5^!<1!<IF<~<3X M^!<A5J~<3DN!<OUI!<GCL_V7KZ M^<F8!<SYR!<G8M^<N^<APU!<DS9!<F86!<J9!<EU>O!<T+<P!<K>~>B.G2N^!<FH<~<6^>U!<G^M C CCFX0<LZ<~>@<8F!<M^W+<F^>=7F!&

[illegible]

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

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

[illegible]

[illegible][illegible]

[illegible]

M=1JXMF6|G|:HXX|6@L04%8AU1K|1<5 GPD2 D2&B4ABD|4>OMP U(8U(\$% MGLAX "RU/DZ(9?>WN9 O@E MNJ A9N7X.O1%N2M##K4&+\$(@T2*QQ2J5%1 MR= '606+-
UR=XOG<1XG|X|S/TFN4MM.C.8=9A2B92Z>2<@:YBD&HR2X MTH<70P8.W T OMN0H&S<CD6 "2I2AQ98ZHL2&15D1IE32KJ3|>(855T
M\$<@>>1UR<U<17|13NPOU<XE3RA.05(8IX(H4JHBDJ O%>L@RV5<+> MB.A.C%<AD&Q<LQ1<4T@>:2ZFZ.<@<9.D0B.R\$W\$1|/L 2 2I86YJ6& MZ:@A7CZ2HV%=(+>
>W42><S G|UW<Z3.>N>2>PG30.TAK VY18 9V?P>*>MAYEMN&+6M%BX.BY AEO.SQ.MI2|K.3%6P0E:8M<Y5BFIZ5.G<02&K|
MR^1450 0I091S2\$B.S@NBLOX&E\$4.)C+&/1=TT.M*BF@%C7ILZL:S6DGK MV9\$FXRG-^Z*:MEZ ZW^<WNNK.OZ?WW\$|4^5RLG+|>73|U|<43#|T>KEAXH
M7|W<G.N.=vY25:F.5|1 K5V0Q0F<|>MENYZE"V1XE"IRU|>+>@OZF.N1 M7Z.= DMROVIA=1ZJR&Z?>HUVT:QO3Q8:VA4A<S04?7>+|Y.W R#J<H M TXPE5%&9
5UW^<478V0C<ZD>=DE|J JBC.19N2|>L@>O9JHEB00?> Q M(\$%PNW<U> O7DGG0V(ET MTODE5Y8KUZ|>L0R:XA:YEBN&M/HD?<+>M#J1
%>f@L UAP@<147+06.17>S?>Q9"BX5 OQX@<U\$U.O.0.%51<=>U?> M1<D70>=<CZS91>+R/G #0#>5E4H Z1#>#Y@<P1.FO Q1W7F6:UR ZRG<0%>C|O=.%LGR*O1:PCS M0D>N8N:
(T=:@DDPDS:LRB4N#31=AF\$J.P1.NA<%%>S\$N:(1%>|B&C<MG: M|O.1|H44<^<M4HMDP1>9E.8FR9<LRY@Q19V *7:BC8-NK<5H.U 9|LV7:|F=P4>6ODIB#?
P0)ME%9\$6E|4E11.U\$A5U=.)M0U2Y.K1PZ\$1.WZD.|>DP5WA?>IG MHT +?K@<-<8|<U+?>V*UXS7|BE7|DE> M=33=^JRM79&:
A<.:3Z>YVWBK45:5"NBICB|G|G|K|M(5AD\$8C6H..F2@>0&6 M8Y.P8<+>.GB*K<D Y1>3|B|Q|E+ADX*(B|&?E=|<N|Z1\$#&0NWO1%)93\$O M TDA2|4|TFC
C8\$>Z>X|LV0:60A9|JA <= O>"BIPH"b1<|>=<L@DRL M.(AMU|<TRL T|>C">L2LAG1%|00.Z|>250PH.>.>DK)<S>Y5\$M61 L M<=>G|>8M&XG> 2 %29C?<
|<+>H>VTC1U0<200R">CC05\$%9\$?> IRZD 1& M N|RPY3|T|>66|FJ\$P0%>NP|GG9 RL8X\$UCG<+>0=>19PO<O|>DDIYK<?>M|>+>O<KTFM0H(1@>9C&J5+1|/W1N L Y1W1V0
|0>:RZ B?T M.<8%>M>|>IGPH=FERO7>IX8.MR<4C<.>YVW<^<M67:P9Q|FH6|>3>N3|Q|O3.D< M1?>EVL|OF=(4%|>T.05MNI<?>7%>9>=>NEATY?<HLZR>DUG<?>W)=A
|V|<C>|JH/9K<W/M?>V5O|HMA?>LRENRIJ|>6|BE?O+>|T:|>|=LRE<^>6G6BQ..4AHW8|H MID|26RZ4=R6T|7V:2|D|D02QYB MMAX|MJC<1 2@L*S|S|F<NY\$ZJ=|
(20H5?S?C5<=>D\$S?<Z 93|NO8.S?M|>+>M6&S8 BP.2RDP?>@<L>..#%Y1|P1?>M?>|>R|Z|YRBTX|T1FZZK|8?>M56SM2|2|D|D015
^<OP+>RHP=>O=L1?>F|>6|>E..6C?>7|19N37N2M?>M?>MT8 R|O5Y|Z|ZHM9|H0Y6|QZ|>|H|..50|A?34SM2>+>70Q4F&C82A1\$ M?<2.97<|>E0S0+>K|<S1DD20>MJK&?
W|T(C7<W|>48.<=<4\$FZ|P\$31 MY8 P.N DK0B20.44?V4>+>8|9:B|V1|D|H.O<L N|>6 Y8?>S3\$N WP M.C. &6&6|D\$>H|E15E\$%8 XC9\$N1%>M-DY|>1%1=0XPE<B5?>=>.9\$<70
MH12=|W|1LAK5<=>M|>4|>S|K|>20?Y2|>Z=A|H|JZ.<|>GEZ|>V|N|JCT.(P M|C|>P1?>M?>5:|<L<#8M80:UP.5>5J Z@>M0|O?>L=BX&C<M0|>5|>6|>B|>J|>X
M*:MOOYC8M.+>O+6|D|X\$>#E|0\$>#O3|CVRJ5<Q4G|0>/HG<|>IVB069D2&Z=O M:XAHHWYFONMQAR/>S@P<C?2-Q*DEE@?>8&S04@>2|T|>D"C|HBNXL|>S+R:
MMFE4ZQK\$>Q5C5?J5N<U=ISOM?>71<4..6 MU+>?>V|ZV|>?>Y.A<S|A9KMS\$>S?>FNB7|>DE VJ.<W2P320>MUC3|VJ+IFG0& M C<?>7135WZ>X|Y>=>2<?>ZU?>K|>5ZDU:
E|L\$RYTA.X<?>7?>Q7?>+>M|>4|>W<^>|>S?>Q1?>?>7?>C?>=>?>V?>M?>1W41=2?>J?>CXH Y3 8-Q<XQ\$ WB-AN|E|>IS2UCH.8V6V M5 (LKY3HWTG30>M2+>M0+1#>M(MW=>C|>M6|8|E?ZT
|C@>?>U0<8X:X|G:|M1 M.EG.O2LEW7?>D=OQGL&OHM(R|>9?>R|>MHGA?>X|>E?>OXXW|M684|WTFMOMFO<|>G\$>MH<2?>PSMYE|>T|V31
<S?>71>=>D3|>=>D3|>=>EGG.PQ|OY|MBVJ X|2.|>DZ.VK&A|>+>163X&T5B5YXN+TAAOGY|E|>H|J|>E.T.<M|J L?>H51+Y|H|YK?>
(Y..HQEF3?>XU4EH@>WY3PSLRGA)PD.F9XT+>U6 @.5 M|H100|L%>H%>|>CEAJ&U>+>1EXP&9#2 6Q9C1?>Q|96+>1\$21=GTW'3NB-M'C@>MY|WV4H?>NM?>5+>S<=>L?>C9SR|>LSL#>
<6|UF>?>Q2F4W<X7&P4?>F?>F?>J3|=H1<4W.N.M|>@>M2>|>M2>|>O?>M?>M?>|>O?>L?>+>#>J?>M?>J?>|>KKU|>NG&9H713V|>IG6|>MD@>H.OXP.NW<^>Q<TCQ30:|>S|B&|>8?>IER8XR<:
|R5>?>H|H|0>X&G|R"RV"=FR M(4.KW<N<EUAAM<U>|>M<=>V 1<8?>S<=>L01?>T?>+>|>J0 L P#>+>T9T.DP.>+>G.M60\$P?>TSX&MCIAC0> S M?>FIQ5?>H6.C?>F:
N9:DE7EZ?>R|>7 1+>A0H&XZU?>M1">A0:L8?>2|>O|M.M60P?>D|>S<H|0>2+>@>A81M4BHU|>@2N|>66G|E|>W5.0|FO1TU<6PF>|>S+>U|>MN&|>P|>(<?>7<?>W<|>_KS=>3W+>I2
H|X|U9M68(D|>1+>O&S<=>L6 W3?>L.M=>R2@>IY9D2N?>H?>P?>P9Y<|>X|>9.XU<^>Q|>D.H28?>H%>H..XA0MP0.12F-MTL=>I3."5|J|>M?>
M|HYK?>H|CNS0HHGN1.LY%>ADZ5|HLZU|>LX8 TSW.R3-CIE?>B M#>=>XZ7ZA.P?>G4+>SPP<OY3|N36?>Y|>=>084=>=>D?>EJ?>=>T.B.A=M2?>=>MVF|>L V?IM<WOUF0?>S?>7WR|
|>7K+>3&CHMWWY V?>L W|B?>F|>@>JCPX?>+>D M2<|>F?>G|>0-H&V>C.E|>#>42|>IGWS>Y.NW|>R?>W|>2W?>Q?>L> X|O|A<=>=>DE|>C<=> M X Y<=>Q?>W5-G|>W?>M?>F<?>X?>V|BQJ4H4|>WD70?
28->(>D&B#>AE\$S"VAC">4|>8">M|>C+>DP|>P M4<|>EX"X&H3DPOH71?>4Z@>=>?>X"X&H"00SATEO">7|>J>=>O>.>PNEC&|0|>M|>2"6">16 YC<=>4|>H17 M1|>|9G2|>@>D6<VCSRQ9
>:5|P?>=>6|>F|>G?>P<=>=>EC6PDDH<=>.& TBV>?>Z3<=>1<=>M.S<Q.C.OH|>=>1<=>P1?>K?>=>G|>B|>5|>J?>Z?>K<=>FF.NM|>TX47|>S|U<=>A?>P?>MR MZ1G?
A|>XQ0|5<=>DO|>B&G Y9|Z<=>L<=>TZYSYWG|30?>G|Z<=>V|>8G|F8<=>3<=>74|>M0ZNI4Z?>=>@>O.A|>N|W<=>2<=>C K?>M14<=>(&+>B|>O)>AE0MT?>QOQ?>Q?>RQK2?>P5SDX M|X>=>L.O?>
L|>N<D>4M|>+>SVC5W5+>VRNG.M.XNB6|H2S-M-B|>MW=C<=>N|>N1|>XG01-5N88K9X|>A|>VB?>=>@>B|>19|>U|>J6&SVC47|>LGLV.Y7E5@>MM..T<U>=>V|>G|>L49ZV|>=>XUV<=>N|>U?>7CE4V|>Y5NC
MNA>7|>V|>O|>P3U0<O>V.C?>H1R=>|>S|>I<=>F526|>H7A|>58|>3?>T|>P<T|>MP&242WCH?>@>F#M5019P?>5M?>J4%<751=H+>^>ABV|>=>6&B|>=>H?>9|>^>F|>N35
ME8>1|>N02|>N0|>E.FN|J.VH|H|>K|>P2?>T73+>YB9D<=>O|>C|>P|>K3|>1|>#>QMS?>.<X?>7 MR>=>A<=>O?>R8D&B.XRQ|>1@>.&5|>M|>Y6|>F4<=>71T2|>1|>N?>=>H+>HFE|>G|>S85?>Z25
M6M>=>S>U|>L>GCH|>F6N83|>S=>C0?>25<=>M.W.M|>B|>15|>B&B?>E>@>P|>P<=>5?>M|>P|>R|>B|>H|>BQ9Q|>A|>O|>F6 M X|B A|>H|>F|>M&M|>P|>H|>N|>D|>B4@>3>D>=>E&B&S|>@>N<1|>#>H3<=>7|>
(O|>M|>Y)>S>71L M.GN|VY KE<W.M?>P?>G>=>7EGH5+>M|>G|>H|>7C<=>L5|>E|>U|>F|>UOY.R F|>M|>J|>B|>K3 M.OU|>TZK|>W|>Y6+>0|>L@>=>X|>X2<=>3|>EDT|>H|>Y00L|>I|>NSR.4\$>8VP1 %>XU M?>FZ?>
(=>?>=>S<Q.C.OH|>=>.\$1<=>=>DFF ?>H|>S9&9?>TX261YD6%>A|>I9X?>CR) MP&P|>T|>I&C|>F|>J|>!=>=>D.1=>=>ADP>J>Y&S5KPV.<^>W|>V7K3-VB0KUXRLAF3
M|>O+>F<6|>HTRM|>UW<58?>< K|>C<K4U5R|>V9 B4Q6K&N|>N9 4 /K1<K|>K4+>Q4CQWDW?>L H+>Y|>Q|>M6|>H7|>D|>B&EAX3N|>Y6%<=>E?>Y?>M|>L|>7 M<=>
|>S|>O HGS<6|>O H9W#1<=>=>8&S&P0F<=>O|>W=>SFRB.68T8OY2B|>0|> #3&.(M+>N|>Y4?>P|>R2|>D|>B<Z>KUGZ<=>N|>B<=>+>15|>R2?>=>E?>2|>R|>N+>25U.EU8|>U|>VP7 MRPR+>P|>J DZ@>31 1A
8KQ0+>8|>8&C0\$<=>=>I\$4<1+>?>P+>85 4<=>(<M|>J?>Z#6 |>Q|>S|>T47?>Q O|>T|>K5A6|>I|>Q|>T521?>M N<U|>.>267<=>6Y|>I|>Q3|>T|>M2.S6D0ZL?>E=>X UL(O|>P|>+>W0<2WT|>K MP29L2?>TS9 K72
K|>I?>#C.OC6B|>4N<U=>64|>M&S<=>77NPW2B|>H63&D|>K&P<7&?>L|>Z|>U?>=>=>D|>H|>B|>Y|>C|>O|>H|>W|>A|>S|>Z|>M<=>+>F9B|>R&K|>D|>D|>C M|>H\$>S P-4<=>J<ZVY|>=>FW|>O|>J7OKH6+>
V.9O1\$|>8=5E&Y?>(J=2)3VY..12 M|>W|>G|>F|>G|>O|>K|>W<0|>J|>6>+>N|>J&N>:>31-4N=>|>P O|>G4|>Y5O8|>5EH 2U|>F.9|>7 M U|>B|>X35=VS?>8R.P<=>W0A
M)?>=>7|>R3?>|>D|>F|>7|>M|>6|>1\$>H|>1%>=>H|>G|>A|>F|>M|>B&S?>=>X|>B|>B|>H|>P|>F|>A|>Y 2122C?>P A.A|>U&U%>+>Q|>J 7 DK<=>+>H|>C+>U|>TW?>G M|>2|>P|>DZ|>F|>J|>U|>=>B|>L79.LG9.L75-
L7976S|>D35T=>6AWY|>O|>U<=>|>B|>B|>K|>M|>U MFZ.O|>D|>G|>H|>U E|>I|>B64|>F|>F|>I?>@YOD|>J?>B.W|>B|M.P& M=K|>L&|>I&A|>R|>L<=>H|>BQ|>N|>A|>68\$>@|>^>=>S&VE.U|>2|>U|>B|>U|>9=>)>I|>RS<=>5|M2?>2?>
M|>L|>D|>A|>V|>X|>U|>2|>35%>20 L|>X|>H|>N|>O|>C%>62?>=>|>U|>B7|>W|>Q|>F<=>=>L|>E|>R|>L?>6B8<1 3 M<=>4-9>ZB<O5?>T|>FQ3|>T|>H|>D0.G42Z?>Q.<^>=>L|>U|>Y|>W|>D|>G|>C|>H|>Z?>7|>1>9>C06L1\$8 M&X\$>G?>P)0W|>1<=>@>
(J|>H|>W3|>1E.U|>H|>T|>B O<Q>10|>H|>W|>T\$>H|>M|>O?>5>D|>A|>=>D|>H|>R|>R9279V|>O|>=>N<C?>2&A M|>G|>V|>+>M<=>C|>S|>R5|>S|>8=0W|>H.PRSV?>
+>S|>C|>A|>B|>J|>F|>2D|>X1.36G#>C0|>J46|>B04E3U8@>8U2 M.N\$|>L|>I|>T|>3& V4(I*G#4W|>J0)?>=>9|>7?>=>TR6@>R|>2<=>EAE|>H|>+>J95|>Z2<=>4(&0@>R|>O M|>I|>C?>
(<F0\$4|>V|>G|>Y?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%>M48|>F|>M|>H1 M+77.>ZZ1\$>4N4H0?>B&K|>+>4|>R5V\$>8#>#|>J3<=>S|>N|>V|>Y?>3W4?>5AYH?>(|>A.%>K)D M94<60%>O.8|>L|>B15>?
N|>@>F0G|>@>Y7?>3QV<=>F|>V|>U|>V5<=>R|>O .|>C|>I774?>@>XU|>1%&gt

[illegible]

MD-KEK59(=>#L 216H7Q85YL0 M1HE24-QS5UJ.3&W# HYVWV(4(45644DSQ(=LF(=ZNFH1&7KE 6D%6Y4T
MP8J!0J.F&J!<7LKF<24-QS<+3VTUJYJG:MEU45(2T=>R53=>TY04=3QML.MT<M=>KP:EA44O.C#GN'EFZ=348^UX'\$.S1=>\$. J8I=N=1T<YLU.WOE'L7S
M# 1D=>8P.6E.1D.EK66-6+4P<K53P1P1>7D10P.5Y<NSD>D.#F08U.M#.#5Z1A.MHIZY3#R#&#D=>S>2.XRMH5#<-1^3QOM\$PU.7>.90>/B&8MCQW-1-T<Y MA(=8-BQ M\$WYTP1
1Q=>78LF.14%>M4AD=>DN(3419N<4Q.MIT<V.WHL>AV.L1)HKJ1P.M3X1)VIA9<+1J2LG.P<+U.2S-P<LS.S5U=720UZW2D.MR1BXT+9W2+
1HXORQ/HP3<40GL=>R<RDOF\$J20.S<A675.07?E2NI.M0+P&A084!<@S<131R%PJ\$Q8>7HGF9F5GY<88&16M.ZJ16=0MVW>(1
MXZ<2OR8EN\$2\$Y(=>GNZ.HQ>=>WU'8@IS.1+6A#U-L+7KT.ZP=F10<=>8)W\$XXPLF/EX1+RQ2LV25=6TKR>OG<8NH73.RDFT
MDS&1S02ZLU<S/J<LWV.18\$FDEF&DK.R<2.7VMHZNHY=>HE.H49T2M<M>AW\$H\$/\$.22MTM+LK.LSRIN\$E'W#BRN'8QNI48NP.YB-Q6%<0L1Q&#<MW'19HJGCFY.CFY?<
<UB\$YA&#<D.P.C.M7H1#<1E.OPYCF&B#R1P<#<SMG.R5>P1\$<BY.IY3+<XQ'3H<1VGB.MK\$H.VH>85%+F+L<1AM06KBLO/R=>15%19KC8CE)6UFW>L=>E.7#
M220.P1N.1%T1HHLANF.MYJ=J\$MFV>=>AE(Q7B1U8123P.CE0240WVWXH.M1J1=H24A4510W+2+P20D9.<DMKT62ZNG/T#VF.09NPE.GASQ4.9H<M'101^F)LE>.C784A
M2A1'P1+<2.GV7&5N5.FU5.M3MEY<@WEQ+1W&0.<1WV.WK.XS(1<1JW544L1N7UUIR01W>+<6\$E+34Q/TQU=>4<@V1.F99PHH>=>6(095%
M2.KTV>8MVY<YNI<8=2DQ1B.954<4T5>BKI7P1B1=NV.<W'GXZ<QT.LU+1ERYI=G8<=<K3Z?W.WOB+L.MK\$0219)<3UJZN20+5NVM;RM.TK6-JV.5+JWOW'E
DA<1HBPX+Q7@19.MI7<H.H2T3.Z52.<M1.QW.#AWSB1>4...AY0C(B08U>Y=>1PMK.MJ51.MP<0.MOW7K316\$<
1J=>JNVJGCEE=>1R>/'1.L656<=>52926LQ1U)\$U5.E4V'V>9.F1)21=>C.M08(2<C.G7J9F.G1L3\$PD.M'59%18SAS\$M.2.ZOSY.29)6K5KEY=>G964U=>K4Y1<7818-C&<8.C-S'Q8M
M7%<VX08=>C(=)XBS.U\$R'P'PKMVG'N<5F.863DFT\$>P%Q1T6AWH9E1+12KOWHF.18VMF.35T0.P.3'3(AF%<631.M'20ET9P/G#M22U>
Q.9'G17K1YF.CXD)=3M\$S)ZP>'2AN'2'<R5FD.1HV<14<=>L&UN.WYJ.MH5S('=<+<CHZ284+>1AJH1(GHJ>DQ.WW+>7=>V.B00WZ1>W=>K-2CK2-SU.MW+G6=>M<5J
&EZ11>2GX1YH(RIAB#<819=>1SM<VYLKYS'2FH1N2+<M'2FOLN\$F1'2APX1'P=>6=MJT.5@W<A...Y1T<9C/G1P23N'<M?>
X1.9CCG\$55ARTME7K7KEKXINPRW<31%2R+TUT.<+<A'<FAYU.8M.OHW.M.FIA86UJ.M\$A0J<1=WZ#E'Q(3.LZ37J15N1Y09LW+BED4C.Y.NYO.M#X8@N.W>=>
G+O.<WJ.B?<N10V<=>=>Z@8T>OW@1141+1n=27&E1V885Z<K6.MMJK0Z.OH10JH5V1A9E.3J+<EZYRL.K2N<E\$?>L1.8JFM6T80KEV1Z>1N:UK
M'JAOJ'4151U1Q0A1'1440636EXR9>KD08.<W.U1BV59C'BBRCS1.UNO4U<1.MH1(3%4.0500@5N1'AN\$1SKR>A15VZ'3K8VCEY>1DX.C(TT+T0@.Y.O100.<M#4?<
LML769&QLK<QOKYV>7.M6K0\$W/<A>7H)H1<1.W6Z76P'6MXIDEHQZ1Y1U.M'M<MINP2=>+K.P42N<1<96>J16E6M3HB8M7K4C6E1U6HV=4P.CNDU'H9.MD.1%<K6%
<0QE'QZ7.7+G1N<AHH'D'AFEG661R7H+5J+1<VZ6D1=6R9.ML46+J6V5=>V\$Y41HFEZ9YJF1=>1.612J(G#ZC)2D\$X1Q@<H.ZA>+>+6
M014=<NS417N45=>QHB#14%>015U21Q1@H<H<H7@<321@N4B+SBOL26HJEJ1=<K\$RKP<+<P'4+GSCY1H1M&Q+>VKM>T.H.YJH<N5XDB41\$<4\$>1.F982MEF'ZM5K+?<
EH6E9N4YVWUY.MT'ESMA'JF11LU>1HL9<0\$N'PD0%WB<1/KL.V<.&#GF<5PXQ'.<GCO7.MPDWK'M6J=>ND.G5100%4T+41Q1T<(<3)DUQ=0.TLG78LF.WF4IM.0G21'R
M0313&DG.M7Q4EHP1M71FT1'=>R9Q=N<M.V.MJ1=Q15RU>'94Q@136D.PH3ZE1'<M'6=7CX-0D141Q1'JH=<+>'TF>.<.&S1.M.M4A.606.M'A4<SC1011E90+9HJ'2090P<
1+1PP8.0178R01K1ROX<..MM6639M6J57E1>1C1K2G1B&02LSM.2&44QV)19V=6<=>S1Q17511198.MATIP.W&6
4.1270TC1H8P3=>EY>7=>NW>WLLK7KUZ2Z&C(GCUIZDM+<8K2.Z5.K3.NW7N=HKL.H=FN.C9\$90Q791G6K5L6C8'CW0H.JK9X31P'ZLBM61FELT
M2=85%AZ91>=>RKH6U49>2H6.U5IZ6Z69B98DEKMGGT0B.1MORZQ<R0RPO.M.O1<4D1.CY13E1J&I&Z177R'K<=>Q61Q174BOK\$A1P'ZLBM61FELT
1:0&OY.D&A'W\$A.JZ'1T%V1T.GSW\$1.R9.F9J9F85M>'BLA7+MUGFIUVOHWVCIPF7@D\$413CLI+1J1'IDXV<=>6517<Q<1PZK0?M.16V1V
K&R&C&SALH5C1T133L'<NIGL\$ZW'<RA#<=>1L0451\$FAU/AX.M.YY141+2Y1Q131'1'<HBB1Q'653XQ-WD/AN<59X>7F<3L61+>KX=8.M.H)K=<FV2'0)B1<2**6698P=>
DD.S1<C61=N142(Q1<1.BHHH165C9V.MO>149J'UEJH6Q<34H9>5.IV=7'OKY+MOY7K6M12PCC'1VOS+ZSM'P
MZE<=>X1D+<L'<M'Q.PEE4AV610<O(G.YIG<3K<A017P1'1J'7G&G498LWJ9'7E%#<H.9L9F184F7.MSMW119P'JM=07*(CFD1F'X15)<082R151+U9Z>=>ZS9NF#>'JNVY
M2.UL1NU;WEL.M&M&3&S1.MG1\$1.R=>S.'6WL.R.E=>G9J.L7.Q1M'=<10L7K1NMPGV'>M2'CHEXFE1T+8@B04+6UE1SY1U.EVE16.G31E
M9F51+RO<1>=>HDN21H=9<Q@<=&5CMW13UDR1X2IEFN1QY..113Y1ZM@Y.M3F19V3ELIRH4ER<=>L6+5X.W#3.PM+1'=>P4.&O1H.8E@AOH1D1+9N96.M1+>C>S>R<31HT>
MKJ\$<S.R=>QG1+ICE9.K<4JF>M5H7<Z15HVBVCL1.NJ.W'P0W31Q'<M'>M2+3HJZ.5M96K1'JPC'.AG6QF2M.T451T@PAW>1FF=>3B<7H+>+0)K.WP.8W.BAK\$QY0195Q?<
W5SZKZ>OCL1'P1'<MBU<01'<K'<H\$K'166315Q'<QO.IZ.Y.F36K4J&Q'F.HJ>6BXH'YB1'<MPC<1WJ8C.914'E=>=>1PWX1'16J1'<+Y+MZ>FZ3UB'<=>9V.G1DLS41Q<
M18<55ZU14M485AM'U'P10+XN5F.65G6W1JZ.99K3R7F12L10X<=>J5<PZ95.M18V1M12LV.RYUAT.LT=Z1.N'JUNW+UZZ.2\$B&N'<K&G9CFK510GQW>K971X<#M\$J1>)*\$G<
<4Y'HXN'44FE491<K'<MUL>1+>JZ54XO6

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w<@JF.&FLRM#<A.ML<=>B008<A&9&=G.V.Y.0?3H15*TA6NT=>OGU<U<1+CYR.MDZBL=IVY+OEQ<+>B&SD47KQV7F<=>6*TOOP33PFR2U<A.MZ&3GO.TSSFJ=NF.T&=>G9I&L.N<2+HFZ.N.7L2U&D&S.613%<#BKZ>Z<3>P.#G.WAWI<1>3D<+VZC>K6;A1<+>R.I.G.MBV6<E%>K&S&X&K3O&+4O<66I&315MT<S=O&QO.G.FO7H1<M<1>=>2TF.FIGY>P.B4&K.B=GBA)<@P.5U1146HLLP.L1L.MW7W1<ZHT6EX4*8I2J<11MMWU.KM7&CHA<TA<M<@OPS>1>2V2S>PO.L6<M964EC&HBU9J1PEHA/HFKZ&0&#PUJ-OD(S<F1JH&6s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amp

1. MP+H J9PP1D5I.MBOX5J2#170T#01P(P<S;.011%6254GDDM2154C5F0. MX<S:BZ8=DIAE13VSJGWWT(-XMC.V.VLWUQO#2.5-G-C-MNP4PLAS:6K900+3+1-X-
10PYA<A>G3>.-:QN!9!6C8JD2=UBBB)H.M6N(5M0)H#BE&C/ZIAQ.B10WJ5=>=>B24910?4P#%#(S.W3VNA!>L>A.4M06+G21+>+>11(4U)18?>=>10>91!>P815%<C5@<?
K1WTF7EYK.MSHI#Z%>B.8DB20HK2JHXV1V#P+1.5P910%#ZA.Z2FPB0K8B.XX.PQ9.3M%A02>H08M71%#>#>@>W>=>A&EAXN(H#&8)(G@<S.V0).M#K1:IB+X#D4
M1B8G9K3C*U12TJ21.0A5 TK+H70. C1=H5:5XB7?>RS-M1. D6B8A<=<A61>+>S>#>H12D4TU92(3@<F?P3?7018P. 480G%<Q#C1#926<YH4D.19<41X&@%#>H4<
A1N5X3C0Q9P2.0A0<0AR1<H17L1.M1BY151-80(41382<FH6DH31#35%ZPKCFXQPOZS.X20. M&WML10U8<DH%<@<#P.L00+<GCUHGA34D75.0R(H#J60X?<
(K&Y6L<M25.0%UQ>10:DXG.K2>@OY1X&HFM+VS*.C2GSL815%HA378.79A0-M<1%>TAL.8W&(S2P<15+1L21*APEW1+10%<
M.GX&UAA6K990@J81W1W4<4.S1Y1P1P57017KUL.L7XM+GOBR1T0?>A9A&H6.M1D2?51P1M1/JL19X+<M%K%<H/KH. (=20?2121<1Y%SSI *D+8K9*<MZO
M.3.Z6G.FE0511DH<?>8K07K9+Y#0+<G.0RJE5K&<9&IA50%>8G09Z? MO *TL1Z151@<RB>=>1S07<S41B.Z8KQGG8X?<S.MX5%#KX0+H&D1TX7
M28.86512R?>Y3.A1(10)20D+48N.CC<1?>FF?>S8%>H8%G?F1=<J&U.M. #H1.V1?>+BD?2DST.Z%>@15HDR@#7? O=>9X1U+23H9K9E.QZ(L1*MOE
XP%<FJ.Y? 3Q1<=<L(US1@<L+U7X.EYZN. (0P=<=<OQ62X41&XJ.NH1.M@L3C&#<RTR.E5&D?7E9L@<K#DK.CCH0240.556M.V1@<X#H181@<1=<R
M6K6C1Q167S1P1W1HXW4.10FYNVZD?>W&1K25.W02141270RNX1H1YKZ.X8M.#MRB)SHU<10UX1APL:2E@<1.N.9Q6C(K)2A10Q810@<1#6H8.E*Z%>Z.MCQX1M659<
<IK(69S)M&SF01=7B.2P1P&A1=10.2&3.Y.FF6H.P14#1?=<M1P21.ZNWPF1E@<W1P7V1XU.V65EUN(F@<1X.7?>TWWUO#XB>Z?P1FYE3W.L674?HER11. MKY7
^RZ.RR.YKWH.H1.X7<?>TWWZ.WY.Y?WPWTW0.&7. OR1<1>?H1Z0W1P.#JW#N.KLWRORZ>ZBZ?K1FTR4VH.B=>20U-O.U?H1L.06T0@>?B<=<17.1R=1.%T%#H:0
M6T1O@?H1?<=<17.P=2E1X?<@OH1.WP1123N1K.H9.J.BMX?>@OH1.W.MP1123N1C.N5.B2V1U0071F6M1X+<G1W1UT<05161U007T1M1X#>5.7.OV1#<GRAPHIC26
image4.jpg begin 44 image4.jpg M1611PTF&G1H.244A4G1 G1Y1?<P=<68. @E8051X?>R1M1Z5101717F1?>2XB.N1P1T(3H1?<6F159.0Q8H4%***D\$U1L1&G41#M<41@A.1
1.01.11?>W1G01EGRT1L1X1G.B1P/G.JD.E1=F.G0S5.701A.C.M?Y0X<?0.HGHONVNSO<S#7+7?>M#W1.C1K1V.Y1POT?>N1H3YZ.MWU1?>U1@<1.W310/
11.2.G01N1WK.N.YOC<=<WGR.<P1.10X.Z.M.B10.21/CWA.W12B3.04?<LGO.LHO.U3WNV1@<O.A1H1.41.#1Y<50.GQ.W=<X.M1Y3Z.W1?>Y.0.O1B5J0X.W3Z
%W19B1W1H1S1&1W>110>?7T%<G1RPO?>M.1HRTHU2R1(9H.94.RL=2<6K1?>U.RRH>.>UT1712.JAYR1L=>O>0P1X14U.M310KMD?Z3PZ1E1=1D7CM&+OVZ%1X+OT1?<
6=<2D.7W1+>WZS.Z#R1T571M11Y>A1Y1XU7SK1.W207?>O1.HNE@>T1+>W&ZYYW1A12=11TP21T14Z4F1M07D1W1O1<N.#<MTE<=<N.O1?5<
=<N4J5.2?>#F4.2?>W3+>1.R.#/SO?B?=<9K59T3.T.M.A1=<(HBNH02.09<6815912?>71490=<N1CQOM1L9ANX&K7J1S.9LZ
M11.8TENC0E<=<YB5XSA11?>11.UV0V1Z2=<S6B19<S6K6ZUQA.XE&A.XC.WP.M.#S.LMP.6@MT.LT.OHMB&R(1/<1&695D2.E#>?>ZG1J05001?X15(GF
M12(91C<G.41@<1B3BZKR720KZBH1DOZB1.01@<O.TC315Y1?>XN9N12.?E01(H.VA)S11?>1X&G5?>1HXOE.ME?H1+<C21Z14Q5=F81O1M301T3B2F?
1G>1Y13QH7=<741=<7N31>1V2CWE>MX#A1!<1LPG4FO9.(71<C:RD&86ZBI8J3=<H>D2EFG.8C0)Z9=<0(6K.2)0H?M\$1<1H1MN>ABB2.A10)8#0. MRW.T1YD4G)EH
<(HRECF.421UT8H61P1=1I9?Z2?1H1K?P?>641QO.MPD?<=<B1.PQ.DN0K.W1FLUFMUE>F.H.0=<#NH21F1W8XNEHBRU6%ZKK+2B.M71HL1K1F910/HO1H<D?0
M1(8D2461T1.O.T0?>F610811Z&X%>@O.M1E&S95F13?0H1A11?<6%YGDH=<?>2.CE5?7<3T5.K@F1.7&8Z?2.6.<70>HHD.X&01H1(W.BD1H1M.#BZB+>
<P=>15>E1<Q5)240?>1P=<A&S(1K1.#2N51H1P=<1?>FHA&R1.O1#<KT.MB%<1?>JY6J16(4M1R&C1A34.O1S91T4X71?>2U.FK1H1?>1O1<7?>2.C7HN.M512.45?>T1?<
P.DW1&8NX&Z=<H1.B0P16.(81&.#<SS51P1)A1#<1R.<M81C&K.Q1+<N1#6C1WAHUCM8CZ4621R4D51ZBZVT1?>T6Y1A.(R1B0TFB1?>9E.M1#<8.F&1<
(B.A#TPS+12S/24G.O=<Y644TQY+5&XD7Q.*?>H.C&S.UM%<FG@1A=<MW<+<WTB&2F4Z23@MG13?>.<P9PCLU9?>21611P.C7S1?>AEP&A<K%<B#?>T1?>QK.M1<W2.F6.
A.L1@<O2<=<O1A>R<C/G.E1X5WH.41YJR1DW3?>16A&#<XP+<MAVH.N@OQ1R1+1R1S#M1N1V3D1@<3A144XL12FVA1COOLEF12TO1RT6BWW1M1#>7DY?>1<=<WV?>1<=<4&H.
H1L1=0W0S.FEUM10Y1Z.3D1YH1(ETE.YH1.M11Z1(4T?>9F&89E.1911?>1SFKM.1+1W1E4688P6X&=<?>@>BUFE71P1MAZB1?>S1M1<1V1Q1EE?>D1?>2K1.K%1%<XKM9.V
1+.#.P.1?>2AZ.M4R5#<GS14.S1@<1SH1E551FT1M1?>9HNM1JH6@<1L1A11451=SENV12?>RDY319@<OM=<CM.04=<M1H<=<8%>01.<S.DK8S8G%<X.DK1YUV.X781?>1%<7B.
(KBT+W191.L1P.MHFH51@0S?>H1E.(B.P1G1?>2B8VE1412B=<351JF145C1@<10S.06GR101(E1K1M2LE1@F0U1<1CZ?>@<7YEFH71B)A?>2S.HV1=1C1E5D726BE1D3B=TW
TM71&W10S1YH1P1@<1NM76C1151JDL11DN?>Z1H1HDB0788R1ZYA8611Q8.ME66516BR1?>T1Z1Z1Q1X1+2K6U1O0?>V3?>E041?>HP<=<71

12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182838485868788899091929394959697989910010110210310410510610710810911011111211311411511611711811912012112212312412512612712812913013113213313413513613713813914014114214314414514614714814915015115215315415515615715815916016116216316416516616716816917017117217317417517617717817918018118218318418518618718818919019119219319419519619719819920020120220320420520620720820921021121221321421521621721821922022122222322422522622722822923023123223323423523623723823924024124224324424524624724824925025125225325425525625725825926026126226326426526626726826927027127227327427527627727827928028128228328428528628728828929029129229329429529629729829930030130230330430530630730830931031131231331431531631731831932032132232332432532632732832933033133233333433533633733833934034134234334434534634734834935035135235335435535635735835936036136236336436536636736836937037137237337437537637737837938038138238338438538638738838939039139239339439539639739839940040140240340440540640740840941041141241341441541641741841942042142242342442542642742842943043143243343443543643743843944044144244344444544644744844945045145245345445545645745845946046146246346446546646746846947047147247347447547647747847948048148248348448548648748848949049149249349449549649749849950050150250350450550650750850951051151251351451551651751851952052152252352452552652752852953053153253353453553653753853954054154254354454554654754854955055155255355455555655755855956056156256356456556656756856957057157257357457557657757857958058158258358458558658758858959059159259359459559659759859960060160260360460560660760860961061161261361461561661761861962062162262362462562662762862963063163263363463563663763863964064164264364464564664764864965065165265365465565665765865966066166266366466566666766866967067167267367467567667767867968068168268368468568668768868969069169269369469569669769869970070170270370470570670770870971071171271371471571671771871972072172272372472572672772872973073173273373473573673773873974074174274374474574674774874975075175275375475575675775875976076176276376476576676776876977077177277377477577677777877978078178278378478578678778878979079179279379479579679779879980080180280380480580680780880981081181281381481581681781881982082182282382482582682782882983083183283383483583683783883984084184284384484584684784884985085185285385485585685785885986086186286386486586686786886987087187287387487587687787887988088188288388488588688788888989089189289389489589689789889990090190290390490590690790890991091191291391491591691791891992092192292392492592692792892993093193293393493593693793893994094194294394494594694794894995095195295395495595695795895996096196296396496596696796896997097197297397497597697797897998098198298398498598698798898999099199299399499599699799899910001001100210031004100510061007100810091010101110121013101410151016101710181019102010211022102310241025102610271028102910301031103210331034103510361037103810391040104110421043104410451046104710481049105010511052105310541055105610571058105910601061106210631064106510661067106810691070107110721073107410751076107710781079108010811082108310841085108610871088108910901091109210931094109510961097109810991100110111021103110411051106110711081109111011111121113111411151116111711181119112011211122112311241125112611271128112911301131113211331134113511361137113811391140114111421143114411451146114711481149115011511152115311541155115611571158115911601161116211631164116511661167116811691170117111721173117411751176117711781179118011811182118311841185118611871188118911901191119211931194119511961197119811992002012022032042052062072082092102112122132142152162172182192202212222232242252262272282292302312322332342352362372382392402412422432442452462472482492502512522532542552562572582592602612622632642652662672682692702712722732742752762772782792802812822832842852862872882892902912922932942952962972982993003013023033043053063073083093103113123133143153163173183193203213223233243253263273283293303313323333343

[illegible]

[The following text is extremely dense and appears to be a mix of random characters and symbols, likely representing a corrupted or encrypted document. It contains no meaningful information.]

Y16 \$HBSN4HB<7#1#07Z1L\$K0M7JE1UJZ_K=-W3R*F4*0716:7N M(-4^4YMKX55L02FU:5Y> MWLJ.KKZ^2@:#WGS/D>5?2
55C1CV960_6+550_ZUUVH1+6=V/U7H16 MJZ5L B10QONQZ&QY6&S_-JD=95.4/>67A6V1-X%6AE MP5 93KYR^X5/3^K=1T/ 4/E6_-MG_7FGFIAQOE>P>4V1/V17-UT0
M4I/AN/S+<T25#>+W50/C4:WPP^OJD^>+QEMD^K5?S=+VP6L6&U6KJLEJL M^>65RBEQELHGF_0L715 MSG<0_7L?>+<?QAQ^<@HJ3W7Z5714L_Z=IX1H%7QSA1-8-B
55HE4L_-M<KJ2J9_0B^1/2-D.MF64JX10<^>1?2U2E^>P&AOJIK56>PP9>A@_M+164LS_ZA2<2H.S1:YBK^<J=7 RI^M^<U/T^>=>S2^+YH8=-,087M20 M-9600>22.
<1P>S(S5F_-J?L>TKIH158RS?>JN_00< @>WZ<#X?>R6<ULW0L2GEV6-W M69.A^<IKNG<1+H015NWJ-CW/IL M_<QZ81<#>L9Z_5YH0<10U422A2(M L\$1\$ M_-
(L#V1+0.8%8B/PL^U_7SPMQ2^U^031Q^U_P4.C(W/B(8=910+0.10%92%>@+< S3G1KAGJ^204IV^8PQ0U^+<9\$1A41 MS1_502_50HJHW^>Y0A#GY:GD2<^D^+H>+;S1B^+62WT^PG^
L17 MVE#<OKXH>^<MZ_?>HIGFTPPR<#D8_88E?>A1CY6<R-RTG_12WZ7W&A7ZP1 M_<L6J1+<S<+AN_->0?>C^<CDP^<HFD?>D<#>#7>^<H0TK^<M^J_T7&@<U^0
?P18>+<1>L5.50R\$<#K&8E8DE<W6.W2QS?Q3PO10_<RM M ROFG_Y1GU<^E_ R7?>+<E^<CE^<ELH7D&S<C1>ZS IRP_0^G51<+<5\$<C<2ENL^<IKX^WY^?7D M M@2(2^<
YQH(U<196+1+<7GGL^<3>GIV<AW^<HP_5V<^<IN_<V^<VYD0471>B1 MBABZHJ^<^<OAE^<WP_<AH38&S<E_<U1S2HO^<17_19PPK12X<G(AH15^6 M_-
C\$<P0\$4F\$<#15\$<+951R^<A/B_<U7 L^<T^<Q/RK0IR^<MOH13^<WJ(H_<N^<O18&01%<XPL+BYX1^<7KLV7^<U^<LSE JA2VOK<+<2(41 M70L2E^<01?>
Y&M3X083J0\$8WQMSJ1_0%<XK-004Z4-DQ^<F+<I20L2^>#AT<=-BPL^<03HT^<TP2T^<U^<C\$<W+<6MS>02B<^<UO6.H1+<R^>L_X2>U_S6<+<N^<00\$<@<0^<+<00D^<Z^<M35-
NWSY2N1^<D1&1<@<A73KUD15<+<4MA>=>?<JAQV^<P7^<HAN7^<OGAAR<_M^<1>^<PYMVYG^<XM^<_<L>V>J^<M^<^<^<LWDFE^<1^<S1^<F^<?>^<1BDS_G100H4LW_M7^<1^<V^<GCU1843WCG8X^<?>
777P2>S<UN=1+>1>9H75=3TFU_63U^<E1H89>^<M^<@<5=+<Z076?<QOLUB54WUOX9P2H1^<0C1\$2L M_<04NU8=>S5EH^<HJMF2>Z<=<7<51#>1>1VU36Z
M#5\$<N>A_V=LW_K^<P^<RNZ;Z8^<S^<H7<+<+<S^<M<@<0>1>23YTF MMANST^<OASK3C1^<J556>@<XW^<S^<W+<P42&1E2LSHG3<^<L1XILLU(DI^<1^<TPBD^<JH^<8X&S_<0\$<
<(HX0@<@<NR_<10?<P90L^<Z8^<Q3^<E_X>1>6EDS<CGR ME^<ESM^<MVV_<R6^<BPA>2(2N)59S2<17HFFQ6@<YR+<L3(3VC 3L^<U1A^<2^<ME^<0^<OJW^<HJW5=1PC9.0Y^<B_-
5BUW7=8K^<AFA_<SLBFU^<P^<G^<@<+<PIZTFHP^<1>5 MEGP5@<MR9FLEJ65G3N_CXP^<K^<AT^<@<E^<5W3>@814^<(4DD1R^<P_<9.5<FE^<M4.6^<SKEQ6>...?>3H4Z^<M^<Q_K^<Q>#9?>
M=Z1H00W^<Y5C7_<5.544 M^<4 M^<50L5YW6^<?21^<F1W&M=Z06?<53_?<X(3XLDN7^K^<8DBN1HXP3^<M>^<HYNX M^K^<LJD^<V^<W_<C0PF&#>+<P^<0^<#<KBN8D1603K^<S^<R^<0
83\$<05C<@<V^<MANP2K^<A^<D1UG15<1A1HJ^<XEEQ10A4=>41^<2V=WGS&M7^<XC0^>+<718P^<8M^<N>^<M>^<P=LL(3T^<L=DMEFXY^<J^<PH^<1^<HBD0J2R1A^<+<70IR2^<ZB6Q\$>+<@<S^<M^<C^<
0^<X\$G61^<S95FE1D1^<HGE5^<P^<B1G^<#<VZHL^<E^<JZNWD5^<+<Q9W^<M0Y^<@<JF_<M^<1005?>D&BFB6^<A^<G43X10L7^<OEFQ^<HOAX<^<BBA<+<MO^<C^<@<7L1TXYA<+<^<PN_<PC65071A86F(XQ9-U_-
+<LL NE^<TV^<HY^<G16\$<53 M&T53^<D1L5_<304C4_XW+<EAPJ9I2^<D2+<0D^<AAN<=00U^<D M&0F9^<C^<GH3&M MWVN^<5>55U6:UHNH7R155B?<74LXK9^<7(4L2K9^<1JH^<R3_XZP129^<+<F^<P+<U28K
MB6.WJ0^<0EL9_<90MMJ^<U=>#<KJGF^<W^<F^<U^<H<+<G95^<+<G^<BKT1^<0 M\$ B2_2^<AWU^<Y^<S1A^<QPI9V^<=N^<CV&96I&U_<5V^<P0&K9UUM13T^<JGGDK>
<01MUIRC>Z>E2>?<BHHK4J^<GG<G36L^<N^<J%<S_<SYW9HT^<7H1 M^<GJ/3^<F&N^<F^<S^<09<81<=6^<J^<6^<F8S6&^<12I710_<51#<9&K<D6BXN/NEA-
MRYASZ4 M^<FSYS=>OUJ2I6H5^<U216_<65Q21^<QOX1G^<H32F^<BY0^<=WRMJED MW^<KEFWZ^<F5Z4_<A^<M6_<VSQZ1^<=S8Q7<4^<F5U5HM4NR^<B^<E1U0CB&@<JQ#<=N
MW9D94 M^<N6^<5>A4I6J3H^<W+<5_<7_<C7^<1=<M^<3V1^<MX^<N^<X^<7^<F(UH1K)^<F_<E_<#<HW#0B_<I0^<P^<+<U604MF^<W^<MUZ M^K5^<W^<3_<C&T^<R^<Y^<G3BA_<??>1#U>07KJ
YJ&C1H5^<E2H14JFS^<O=A<_<MSQ_P5P7\$^<P31^<BQ8V^<4A21Z^<N^<V^<WR8&1A^<8%<X&3_<ZL^<2^<YYS^<N^<M^<W^<PDA>CBY^<GS^<I6-D^<1>48M<+<6^<R^<I&X^<H2B7=<M^<L^<E
MLG3J^<N^<N^<K^<M1^<55^<M^<QNK4_<I0ZB7^&

[illegible]

[illegible]

!HSD>90H+<H%<P3ZIM6S0X%K0).AI RGHU<)-M5?2FDPBX<)>Z%615B+JCS&713H6<+<0S_IL_?>0#F6W18B14A<B_MU3WA#>#L1A3<=>D/O8<IGSLF682B10Q<OQ)HGLSDU76 N1 OV<=>#0A_M(2031H<)-?T#1#3H<~<31~004 M_FJZ<C1HVV=>623TF<=>CFP@Y63XS#>#>OSHI79KVI<F>4CGU@AM4<1F+<+MSKB50+JG7Q0S?>?WV0#9KCC2KY<~<#HPK)<ASJ424< 83 5 @-H MB0854?B1?GZM_O=>G1ZVHE,SUEU9JED=JUL>S61+LYC2T?FY<=&L4LB6~>MHOCYVIK&HNLRL384OJY<W/KO<L1ZZ<=>OCMN>GP+1A2LEF%G#<-)M<K+<+1.O(LW?>7)<N7N9>13>1>66.18Y1<=>929.92H<MY6=5BF.MLS:5.WOS6RZ<XKKP16BV41J_V=0@91&EQSONCM?>CLDW.M+15NCHUNKULYVXUS+01T2ZNOEFN416B#>ZS1(CW4,1Z6E?9 MPH/B.#Y @>@3@1.8239#KK<98ZD722HDJ1A<4.06@<BW(C&J0+86%#F4Q M#7FEA%QIYV5.<VA~>Q6P.75PQ4.0)RUX<+<1@J15PL8B@<(<2ON.8?M4U@<1PVA1.S>HG3V0<N*(<83.<=>0P912?>#>#1BIRGK<=>(H74?>1ZUFAZ M4E 46+<+<4#>919VIDEO&JFEM2WYEUL>4JHHD M#<=>R69?Y9+PYM1<=>@P.M5U1<=>KOV<=>CZTGT151<R74M<K2BY<?>#>#1&Q10?>67\$<L_?C<+>M<=>YT 2 OWPXK<=>NSGVE73.I3JPO<=>EV6D.0=>EVIJH<+<E1 MTR=10)XRI49YB0239>EFBY+<+<7.0W>8@BB.#OB<LD>~<44MR3Y<+>1PS MQOHEC<=>D1>QOLGV2LGV2BF.6EC#=>SEVBDD?UBWTVNATB7DZYOD#>#>CH M10)OIY151#MYUUIZYS1%>FOW~%>NQC#>#>66<1LBJ MF#74+V.H<H01>HPWJ3AJ2JG<~>21<=>2.0<JHJ2IDYRC<~>S#O~>MPC&VBI<?>73#VVY YQCEIMHOCIL?C2<=>GAG<=>XN96.V9QYIUBW#>#O0<M0214/4~>#>550G.6RN<1V1R ZIF?>#>#1=8YGRUB+17U<=>COHDDU<FG4#>=MSD4P.UEL2.HIEM.KM?>15XFJ.DDS S<T61Y1YVUA1?>@6>?>R 61%>=>A<F&S?>#>2GD<1XEHF%>ML5PO<=>P7A<+>1?>=>6ENZG.SDUZ<=>#>#SMBXWD/HYQJ4C?>0<JURH4A+PE08H1L92.GU>#>MZL?>MFXB6.M@<=>CBIP6+?>J.BBF=ID1.G0SH2S<=>X<+<IKD&S<=>X<+<IM&S<=>3.FCEI MO.BW1@<+>9?>O.3D>J42?O?>(<S<C8<5Z&C0&HJ?>H_YR8?>9YVXIHS.M4L?>R2P8D0@<=>#MIV)M1@<=>R5JHA+0S?>7YAN?>H>W<=>6<=>G?>Z9<=>KRK1<=>MLOQT?>9P95S<=>#>5D?>7VS.M61YTC<=>V>?>8U.D1.TA2P#<=>RFGH?>R.D1<=>3F2W+<+<F?>=>=>R6.M5:38ZB?>+M?1=>?1=>?>=>=>D.M0.6B1M10NDG5?>7<=>1V2<1>.\$H<=>MY95HSX9<1COI7.9U/VOE<=>?>?>SJDQ2A-M22<=>N9X?>1XRRQ<=>1?>69.R/<N.2<=>45.M?>T.JBOWDEORB>~>Y1XWTB?>W~>VM&=>XN>OET.Z7K U~>M<=>RNVGB?>67F%>C?>12)E?>F5F6.FF6?>F2K7J31S?>+3QB<+>G+Z0B<1?>M2K<1?>S1<=>OG.D1<=>X<?>H.Q.0.5<=>ME6IEFIO4T?>C1#>I8AH&S3BHJ2?>U&2H%>ZC%>M44R<=>CY?>H#0?>Y&92607X?>#>86L7K480F13P5FE0)GB3X10Q.M<=>P?>S?>Q?>X8S?>1?>H&VX31?>F8SV1?>9?>F9D163Y?>3?>=>=>5<=>19.GPP.MK.O?>+>Q5<=>8?>2<=>ODI?>CB/O&N&S7HT#8?>TIL@B%?>V.U.O*K1JN_6Z+<CZW-M?>?L?>5=>8D9<=>~>DR.LY<61?>9#>E?>Z.O.U@<=>LE2<=>@?>01?>X&T@<=>R738CL?>T>R*=>MAH.BZHB%<C?>T>UB M4A@<=>S7CHP+<+>T5F10<=>4YFUDA3RI<+>V1O?>WOIPG<=>F?>1&4X<+<C*23&C MYP5@>21<=>(34)0FT<1?>+>1.6<=>G1H5?>K?>F>=>WMEK<=>K@<=>A0P84?>K?>M1C<1?>H04R0?>B?>T1?>0&S?>7X24?>T<=>ENX<+>1PLHPR1.71HK5?>+>2.M>?>#>DV<=>@<=>M6M&H&ECTFZ<X98?>H1?>G8C+<W?>HEGH62S<=>(HJ7L03 MOZ>+>66?>+>C?>?>5EUMJ2A031PWDD?>XG0 RZ71?>H&24+<48R<+<5F1@<=>0.H1?>M6H8 4HJ@<=>H&4A?>+>15?>7NOILM&=<=>OBJZ&S5014K<=>CJHJ.MN5<=>KNEG9 MGA17?>A.W?>+>W?>S?>G2?>G2?>C6?>M51&A0161<=>OF 4E.<=>X&B8?>)CH1UJ?>M&MAXO<=>H&4AXL&R798P&R+<TRK7US.O.R.2US.PRR.ZYFSRS?>R&RO1?>2S<=>#>T?>YD.MGXHG938WYS199FCH?>~>MTERK?>RQ M03GOK?>MO#>IR6)KYSLKUNUYIYLSH.%W3<=>419XHISU4I<=>R1WK4HH6<=>~>L>Q MP1ZC13ULCO7010N#<=>T.N.S?>BVR<=>F?>Q>=>K7<=>=<=>IS0XG6A8I&IYAGHDS9 M=>W1?>?G3.A51MGU<1?>MKEHHH2T640?>Z&5ELOS50.R1+OCW<=>+G124.>PDP MYAW?>+>?>N<=>6<=>Z1?>H.Q?>D?>=>(<FV09.P.IK&#>W<=>N.H6?>=>EP=XQ M?>0 M+<=>BC6.4GT&~>12<=>K9AY&EX1YMXQYMKXOHO49EY19Y?>MX9?>HIZYV?>#>FQ MHHKD4M2WEN6<=>Z?>H?>F1480?>SO ZGA1U?>6=>1Z1.PS?>795?>WU2J?>P=>S<=>MGU1Y148&IAN.LBOFD7?>H?>P&66?>PP.M#>C19RGD?>1D.0&L M KGBQ&RG4?>H&A&LX1P&E?>5&PC 24-K&=>201P<+>B%>X51MWVR?>M1VX<=>?>M<=>~>2Y1O=>Y&B1MBU+<2D&SQOQ<Z.O&S0.2?>2?>+>E&A1?>ZL<=>MTM<=>1?>7F?>F246EUF<=>LZ2H161Z?>Y<=>77BO?>~>KVL800RPN&A1XV<=>18M31?>ML?>BSGUO?>1?>YI=>H0 MHD&EG 6Y9?>2=>S71Z7J@<+>+>10H<=>N2?>1A&6#<=>@<=>S#>M2)0HK<=>ZKN<=>~>~>K&S1<=>2K 7IG@<=>J%>6W?>~>1?>#>@%<=>~>P.S+QIR512D?>I/M?>5G?>~&

Q052C2.2R+K6R1J-WJ.XQTH1IPR&BAM/M7X\$X00.MQ&HDFR.5@WJ76APIC/CS7W52BRDV@4s~&8B.#0#K.BB15*HJEP[SSM.MEVX]3I/BI.~>).GJW8&R@A7DSC7~1
B4%5V26I0RWPV&57+Z1PDUD1APJ33Y3R68M.M.PIN0HDDYX45Z1M+N*XCQTKG=C1GR1R4CQO.Oi&~>@PPDJPS~11M
H7262003P3=1JfJ3.KKVC%=-V7G6T1ACEZ0.~<K~>%GDD1P^U~EAGVH.M.O.P^O=Eq64P.PDD07~.ER6^K7V1E2N&S316K(L7J364ZIGU>AF0EU5.KW^YQ1^1.KZ2"
M.V78IG.9VWD31S44B040AH86.M7~1A0.Z#1JF2K28CCN.8.M%DD5ACE7A7D1?2?D8C+O.FL11^0G>J5G7365K8~>1JITCP<~7N
MPL5C)DTH~M1.UH=3X%Z.XLR.OF5%G9+8.263CF1F7H86K^R7GL.MB%K6.8>=>51H~>Z7V^NGNHR=H0X^C9JAI4W0.TU6G0.0.3ZMK&IP~M^OYI.FKMX>
IZM2Y7.OV3YVZT.AQXIH+16L1YK&295.14J/ZH7@=4~>Y^MC~.INHRS5+D.NA<0L0.=5%2A)2/E72L.UF.LF.CDD@D.D\$A.M2OV=QXJHD+X.26MTW.TIGIPC)/#<2YCI.
LB^H&@L~%3W^1QA>.(0@Z.L9.M1?^1AJ60B^K\$+?+K+N\$A41%U\$SE1P^V^IDH=R<^&7&C.X&=0@B28M.M1FL#XJQVY~1^U~1Y^XM^#8~19%6%
T^B#H@>UJ3BRN&2R8FN.YOT?~1^G^JOK^O=3R1\$5^A^O1F7KV^7F7B1~P~.M^KB@XP~.8HKUM.LW^RFSIC@
C.SYD&Z+2^OQ^V7J7TUKI.XP>~.7^3\$U.HDV=>N2^9BR.^8K.M~1+P^W^W>~>?X<~.3\$UM.U^7^HH\$PNY3T678F8OS~>11GK.G.GSNW7Q
M.V1.3HDY.61=72Y.Q^KHWF3419R.MQOP.M7C).CONR.16+VYVD8VU1~PPAPJZJ7.YK+V~.95\$HNGY3C0~072.N0N7M.MSD19D\$E418.CP.1.F9.D.VB6X~%B.9.(COPIV~2.B1
SZZZHON^T@H8.M.T144)SSMRK^Y6LY%^(M^MAT^6@+^P1(P.R.M^KXB1B?E.09P@719.VLM.0H1V1^&Q.D.HN^RD.M44.MTM%0.1E491.%68^P1(13+~.1^H8P8H7
4?)21P^%R5>1&W.T1&(12~.W~.~6~%KM@B?~1VH<~>#J=^@R2^M1OS1P7C.W@0.79U1P^WTDB%\$(S4)^&9D~1F1^VQTB=N1D09.MN.HJ0521^+~.0&T>J1
4^1DXDUWR50N7G2>BW.H4XJH^RCS^N^78B8B.M^SYS4UD^46R0S3.2P1J^T\$1%&VUZC^?2^PM0X.0KF1^X.Y2.H2.FF.MW22J^#OT^>~&~>
FJSD^0220866K4^M03C1J1BHUK51@.H\$E1@P^?~<1.MO~>^5VD603).YF1.DH~%>K6X\$5SIZ=9.Y~1HJUF9^51^<0D%G4\$9FID=ID^4~.PD^4V^D.J14U)Y^Q@!N0/S5^#^<02
G.X3.YL.OF91&X.O03.0.236V1H67.(3Z.F0?1^U9F0O.S1T2).5M15H1WGN1R^%KX78.9.M86EAVM172RM+N~.R1BP^HKE10GS^Q@U~.8V.D2B^P.369\$EAS^T.MPT.M
~.S.RCX0(56G1P4\$#6.MQPSKIE0&G@.YNNH429CQXXM^BHBHF12X1@.E1NO.M7K1U967USG0O.^G7W9S>K7OT&N8Z.6%1A.ID\$~.UM.I^X<~.M^H1(0%Z^&R14Z63R8E
1C.WX\$0G6)EVSF7MCI~.BE^NWFEE@OE3A~.~@U~IPRW.M1R4.6X(573R&C3C1OE7PYGH9.J5.H3~.6%6AIC(%.9N^26^D>5PP~1~>MIXS^>#O~U~E4X0N~1WHCB^
7C0C0P^1(2^P4D^AFQKW1F3CT.LV7~S.M^E4.UYF&N1Q^R.YVAON4^558R69DPV^P^Y6KAGD1QF^F&0\$9AGF1V5~M.8S~.P1C@4.BHX18E.M^KZ1~.0@0\$S1C1~1S
8^4~>^PP^3C^&C&B^MSK^~N^Y^<6@^A^1VHLEF&B.MZ1Q1^KQ\$5WO1Q^J.BG<+V.M\$T164~Z@9@H1QZMBR~.ZXAZQ6Q~B<2R0\$5BB(N^F^C~MWS^X1.4~1@4L~51^
M~<6702U^S>SWKGS&T^2^683.Y^>1^7H7E~1>^YUD~0651E14M.H1@P8&+5R5P5^7A1Q(40S3B3G9.OH\$1N0013H~1^E.JTS.RERUI.M1.X~12^39W~1@J51~.D6%
F~>@QUBT3M>2>23A2>O7^X.P^>=P0?T.B~S~>E18.M6M18UE)0?STN^1F3?U@XNHGXV^U.U.Q^UC1871G<~.55(1D+P.T1W2>P\$O^M^FLH@5%
MM7@Q\$UB1HWF6P0(C@.~@T1+DAFFFN1L81V;E1POLM1J1V5+HH4~==M~%C1ZWN1CHK.HGC&A.30W8~.1F1@1^29PN1P85.L1.&T@1^M1^MW1D0FF7A3?
1^FE1@301^MHP=619(LR4&~C^T1C0>@0261Q).4&B\$1+M1YM117T=7KM@>BDWR1MZB17T8.NRRX1K^P1C1V^M~H5E^C^X1^E~>19P1~>@.5GM\$6(OT&@T@
M1+1&S^X12Y\$1LBW59VW^K~+1YR~9D7B^1R^954<MM~.~@L~&4~1^T7P8.LK^01.EQA.Z~M8B^N^4W\$=7KM^JZS^L5B~1X1.M1THK.2V~1^1WRWH\$1&X4
X8E1H10T\$1~1P\$~#76&(M<~\$T1J1L98.M^T~>1LW20^VO16.80B1P~>~8@5R~+P.OW~>1~1T95610M1M1L~2MU121RXV36%PT&~&1NKG6.CAD1M^FJWGS1^A1Y\$1~1
@1N7@~9^RWP~WNW^P^C~MNV7K.6WH1W1U^1&Z~>=1G.O^S~.~HB^5N^~2H\$~P~W1Y2\$3.MB1M.6M91V.R~12HN.M5J73G1.3A0IGJUK~
CVH4X+ZMW>3QOY>A.WU5POE1Z16H1W1FUI@M1.DM1.C810.1H\$50F/GCY1T1B.O9Y1HP~.K1V0W5+3@CG^C1~.G1^HVI^1~M1^<9~3~E4R4~1#~M1A1U1H(\$57
WL(NP&A^C^%5~.AZ1ZC18X6&W).M1D1JYTF&D~&3CAZ~7P.NN1H1M4P1R=42%888BMD;@R6@<3A6A784^F8J.H1H0+P~31DF>ZRR%R^#1QYAT1^318E&2^
(1Y+5BW1Y^K9<33ZNOA7432Z.MB@HDX1H^1.69P1@.AEV151^5P.Q^KQN^KH2(1OY~2~.1NH4AD1C1M>3R&S:57^T5<~@V^E^1FA>E?
#G12~>C\$H.14T~.B8E1E.19T^O&T\$~.5\$9.MC60Q.~1~(00LXR).QG~GBR^C3^G1OM\$^RK4W~.F5H31H1M^E1A~<7Z
M1FW&K1.M1K.B.C1F.51W1U19&8.N.BW1J1H%~SD>~AQ.X~>1~CGT2@.M1A1O1Y^C.2&7L7H&C~S~.1V^6K3071=Q?1^3NP1ZCULW1^4H.51S8M.MOH3&B\$BZAW^
1L1P7.D01&~8Z1P&WX@P1.B9^Y19.M.ABU.W1Z1(CF1Q21B.H1214Q+2UNT.&0.z~>1^81.P1^E41L1H1MH191<9.F^N~1PWA^T1=69J1<75%Q~1LW1A&+H^<~
M2;P1\$E1^RY1>~>ERU8D)B3190J21^5"C(OO)J1K^1&~&55;15Z~>DR9-34Q>?ZIGF.YEN67/GV>~>SNG7K1T.MG7P1+M1F1FWWTR&1P1YR11VGLN.V.#6Q<~1^>O1+
~1M1O.6M1L.T92M.N<~>.G7CVS7VYM@X1BP.J20104W17LT^Y4G&W~.SM~2~.B1J3CD1W1Q~21MZ~U1H1L9N1P4.831R1^1^XK1RLQ191V120T1Z.O6X~>ZNTK1FNL~>~&1M1J)~
M^OF.O1A@Q.O.G3ND\$H7ZVX.YK61.W@T~1~.8C.GV^N^N1O4M.TZK~1~2~.1832P1R1O~2K1L.W67~>?G.C.Z4&H^K4T1Z^<9NB1^2M1^MB1@H^F6C^P7K^FNW~>~&K1HARG~>
~K1H1A00%~.JE~>~&1J1.NHXOY1A~<G1.M~>GGD9BD1G.C^Q>23^1ZGB02\$6661^ST8X.C.V\$T\$9~<~NPO1OS18~.M^A&O1T7~7^YRK1T1F1D>49B1.9^#O1M^
~1G(1E1?IP\$2>71Q4K01^>~1P31^FOY0AMW.D1C^BO^#6~#H8R@<M^S1V936Q0\$5&Q~.~1^D61PAZLW1.7T1U1P1(HY0H\$@.

01B:557D10><S# 1410>1CTBE Z1V27@A.MUZYVTO2LWNI@IM.FMV@Y*.MO+192.561QA@1.YS*9073S(Z1V10Q+*LW%267121=6.253=Q7136.2LPZ51224180K-MI3-\$0-
<S0E# 05(0915Z)>X>S1M#06.0S0&0317DHI#021LK.4S0.M-M3#X9.5\$SA4(-51)D-C-0GQ&R?=>JHW4KP@/-L10.07A\$SA16.1J-3717U
M1#EAG.<S#>910HJH081VH1745@Q0Z4<#.ZHL5=3ZE1FHU.M-MG-ZX9=2C4(IN6XIN4X1>0 M1#>8:0L=E-Q95:151=8Q1=E-1J-17H1S008(SJ)
(4E=EBXZUP-3CKLWDUO./OIGS<GHV4A81+QOC2.MHFW7 MM-94WYV30.N=>TYWKV+U@OZZK89.7Q.EOLR- 29D1D@AQ+&70L/D7-X M9M<D>A<C
CR/S1=<S#>S&9.ZG.FMI1=RWYO<AS1@1UOCIS1? C1W5XH M.<330=DPX Z.4<AKU1MPX>\$.E\$FZK=6D(1)@81S1Q@>18X OWHYK MP.
L-8&222H8P.F.98M5-21K51-B6%29DOUT14X?CT4)AK2-8&9BG7.M(HT16=1(K0.6E)*1M2N<X3>#1/A-N-Q?6G1Y8\$E1J3HJDX<=>=/M=
6:61H.HIOQF0?E1W1GB0\$@.E.DQ0W<D.P-PRMBX521.3H+@+F1%1D10G.M1.M.F=>?2\$T1@FNMBB=1N187/2&A=<4QZ>32H
MF/+>WSSKPI3YZ1=&A36/KC1A=<=ZX7BYC.AMOT1=<6FY+ZA9H*60UD<M=<021B96B.SZ0E*IR@Q1PK&(+L14D/F>9U@+Y#(U@VX7F193F6Q7VC.M@)OD>%=1-L1
<J>PVU<0G78AR>145 Q7?/K@<@H1XEG+BW41?1 OXUH MG&+C1C1H1-U1L7& .AXWU1ZJ@.550.XBYU5M-8?G@LR>1DIMA+V1K1M1?/MSU719X2<817?>
L1V17C701Q1%145.P.EBV#<MG81H10%92P1R7@O.M71ZN2D1 ZN2T1U@V1Y7RK1M1<UQOH.=<1Z8DG1Q?K27UPR1B1BM> *7W1M2.41HK<6.90Q<EC
FVUS1<1VA121M161YJ+G1RH+>1JR=>1M&A<K1Y31+1H1K23P1FV1T+2P1K&P1B1DURR1PORS1TWS61V16TRX1S181Q1V1M1Y1A18Z1Z2MR0X>7%01F+75?
01Z?>1X1K1M1X1R1A1Y1G1F1212U1+1N1>U1LM1ZEWMT2?<1=L12M1H3SX141+1H1F581Q1C.14C1%1.L1L1R1
MXPP0*=<048%T1H1R1+1+@>1D1L3.141L1+01NH1A=1P1Q1&@P3VG&8-0-0 M51B1B1DKL&SZPU(KT.Z11.L1A<7G3>1%113E>QX)>&RS.%@<1^1^> RK-M<=>1H2&
(M1E?>ZOK1T1<1^1M1Y160Z1<1&5BVBV@V1Y1V1R1.W1.2 M1M1A1+@<8T9X1M1A1+@840S?<GX1H1F1YDRN1U7C5?1P1<1H1X11
WLF1 TR JCS171<1H1K1R1>1L1C1+6M1F1RP1A11<1411S1ND31+@<@/S1C1= M1&=<G1P6AR@*4V1=>HN6#01R1F1D16X1+U1Q1.9R1Z=>#=<1+VTO1J1.8S1
M1Y1T1D1.E1SR1<1=NH111W1C1<2D1T1W1>1.LH1255281T0P1D1S1K1M1L13P1C1G00S01F1Y121DYOX1717#2M1M1C1A1516.6S1&C1F1D112110K3K.CPW7
M&H1E1UK151E15E1ZB1V1J1N1%51?>71L1W1=>H1E1M1S1U1H1&E1C1X1L1S1P1C1&6T1G1N1F1A151H18151060H1V1>1>M121R1H1W1C1H1J1D1.GZG1J6H1M1+Y191M?
=<1G3V1CFY51X1RR1NT1K&S1+R1ODQ771A190=7=0.2?M1M1X1GL1Z1L1CW1=<7C/PT1V1ZS=G.GQ.LSW=N91L1M1L1R1P1A1?1M1>M1G1V1U11W1E1S1H1E1X17121P1L1<6531
P1R118%51R1G1@1+1P8E.C6V0?<MEX1M1FNT0F5?>18 2DT141/1S121.MP5122@E1A1F1T&A1F1EDH11@<2W1TV1M1C11D124\$1TS(S116K1D@.11#3 MBKQ1*H1B071F1B17+Y1B1-
Q&H1212.M1R1@1W11X171Z1Y1Y1<1CW1=<1X191Y1W1H1M1Z1W19095ZS1N1?21X2@1206511TX1Y1J1@51L1R11J1/8<1=1P1K1A1==>
M1Y2.HWSW21 VUCXN1V191G1&E1C1H1M1M1?>541KK031T.C1G101?<2D01?>71P1S1(AA<M1H1M1>1@<1M1Z11+1B108=6134181H1B1SG07351L16E1X1MH1-B3G1-57#ZW1#
H1@<1+D1M1R1K1H1R111@<1AU1163G1*27>1P1UAME1E1M1F1X1B101@<1Y1S1H1D1>1F1K14R1>151@<1F8141M1J1H1Z1G1X1Q1D1X1Z1J1+1W1C1141SP1&1H1H1(30 MW<113161
Q1K1B1>1%\$1YL1Z1TS1(X1S1Y1G1H1W16Z1<1@<1&T1N1H161R1I95Q=<M1C1Y11Q1N1C1H151B1A1+G1<E1N1%1P1S1U1>52A&.<.<ZHW1G1W1=<D1W1D1N16Z1K1M1
Q1H1E1Y1P1S11Q1X1001E1#1B1B121@<1Y1E1P1L11%>@<131M1J1O1H1O1Y121+441C1S1G1101F1M1B1P1RR1=1@+U@<1D141H1V1=<1P1Z152%3A>AP1G1
MSD0F1+<1&11>Q1K1T1H1362111LG151K1W1O1GM1O1V1O114118Z1OK1Z1V11AY1M1>53Z1CN1D19151Q1V1SE1X1<1T1M1M161141K1H1B1L1B1W1Y1C1V1Q1L91K1@75%Q1Z1=>MU1-W51R1D1
Q1N1CS1V1+1OZ1><1D1E1O1F1H1171@1K1F1?>01O1X1D1=1S1X1M1O1J11&1614191H1<1+01G1D1191F1WSZ171N1E1+1NOD1Y1M1X0P1H0F152P4S1@X1M1.S1G621@1H1U1H1F101?>
Q1AL1XD1PE08WH31?>1E141A1F1&1>1?>1D111V10<1E1Y1D1E1<1D191K1A1+1E1D1G191HR1>1X1V1M141B12F1M1NZ1W1@14661T1F1V1U111U18601K131I1W1R1M1+1Q1X14566C11
M1CT1.41CB1WP1Y1A1W191*0E5D1<4?>31W1V11#E1O1M1MS1H11277E1W1>1Y1A1M1J1U1K1J1N1H1S1E1C151X1&Z1EN1E1DU1S1H1M1ES1<1M15F&1H1P1Z1G1O1(5U1=G1M1+9C1)901ESP1364?
51WS151A11J1NK1P1V1O1=Z1T1W1KZ=<N1J1M1X1N1W1J1O1H1NV1W151AOZ1O17151Z1X1M1T1U1K1Z1H1S1E1C151X1&Z1EN1E1DU1S1H1M1ES1<1M15F&1H1P1Z1G1O1(5U1=G1M1+9C1)901ESP1364?
(1Y20W131X14151Z1B1W16N1<151451X1M1B1H1B1M1L1R1M1=Q31BR1Y1E1W1P131<23A2<>OQ1L3PZ1U=<=<1N1R1QW151W1B1<1S1ZW1QV1MR1
61L1O1M115151Y1U12691&1Z1N1X1M1191&14E1D1G121X1U114Q1E1@11%<1S1C1=>1M1R11*0R1VO1EH1M11Y1&1%<1S1L121P1Z1453R131#1AF1051L1W1P171E1H1Q1MZ1F1U1X1T1N1S1A1M1
M1=1F3N1=<1A1*02DAZ12231Q1G1&1W1M111Z1Z1O1G1&1741Z1Z1N1Y1R1I1G1S1G1X1M1H1B1X1O1G1O1F17151Y14114151W1S1Y1P1=<17261V14570M1651NL1U1D171+1Q1M1
1F1Z121X1A151J1M1M1X1L1(1E14V154SH1H1@1SEF1Z151Q1A1?>1J1P1U1J1U111MO1Q1N11Y1QO1771U111&121P1S1W1U111J80K1E1>1B1C1K51N1@0AT

00D1+V0>YG1DB%+M/N#S8 JF#R*+IWQ>A:660X-X1+DB@JHD>2.AFIP#EN.NIIR-.55RTZT%?G MCH@-AYSQZ)RPI>N:JZM>JA2Y2P%Q=BF)@R3I=9?IT8Z+1+&=QWT%
(M7A+W%6K<.>9F>B(BZ-FS9D+P2)ZHT+H+D(FEHM)ZC+C6+AD<AS87G/M+2+H/H.M/E@/OVI+H.3ZR/G*1=<SQX9%1/I>IQY>=<_H#X1>5<?7RL>EJVL
MLDGHZBKK<_>KUIPDI00?E2F54G)0D*BHZ?>PQNIU.FF=2670EQ08:M.MQ0?1L?LR#H%>HJL?>XANI?>H#4HH0T?QZGKY%>U5S1N+H01P<@4K
M7U?>W@30HQW3B31Q<_>E\$S052(P=>+LXSNL10_4/A:92M/1_11)5 MDLH?790N<6WHI9?>FVBY3Q<@B4G5P3+1/L MY@<H:~X@KDGPHJHTZ-R/D?>E%Q=0/P1N#4+X5
=>EWI<D)HQW@2K2R#SB.M11YVYQ<=>N=>0MW)MZZ<@FWX?>2P7FS-QKG14?<=>51+8P/M#1R/L:OSLNA2N#Z5+4WV.W>S.L+1#01#0?<4-15LK
=>QXW3ZK<=>OHLKIR_#E<B/B\$P<C1Q5OKW@C19>OVSJYNEN.AIQF#>Q1 MDJ?>W<SIGHEN:NZ6M6M14.PTB2U@O:M.VY?>E#P?>2DI>?>
IZ<OY>3HL73HO>4HS7%>X08%>US=0C<I.30<1=00>=>M<S69HW1<_>70M.MF790EHB1?>OGF%>1?>M>5IGR%>P<ALBTOF0A15F8@>R=HH<1?>JMG%
<1=>O1Y+>BOH#SM-BJZQ4M@OJKDIYIO<_>WK?>ICTR?>=SYOX?>+>ERL M9/52I9.6I9KVM=>XYL2IRU<=>W5+9+W<?>JML+>A3ZL?>
V5RU.HIMJIGW21_0XNPK1+554+102YK?Y17G R<=>(OYK2D)2TI6 MBEEFV66L+A<45(DR 04IHK00%<@<K%>1L_4RL+>S3(R#P<QDBB?>WJ?>V19W/M?>
UHVYT?>+>77P>=>HVT?>JL?>2PZ6>A8R@O>L=10M>=>@UUIHWPB1=N=OVDY5U3P/M/OIDQ01<=>BDS-CHH/3Z?>QRRIR90M3VYI/U1%>2P\$E EGM?>D1.M.FK8I<=>I2
I09I>?>GQ<A19?>2G<2DGGSYUUPPVY63YI+GPT<=>G<XMY-ENG3-MA1-9.RD1H1H.SJQ5GK<XN.M@<(Z0.7D157\$1/8_>U%G.9I\$>M1_9RH\$Z@<P+>8 GYCD#<=>58.F.EY302
M7I:BN01P0M5E)F:4L+>(075H0W4Y9I+L@>4P9044P)RRHCHZ>4JIC?>MIA:SBIB2>=>P?>B1#F?>A.E147H?>PZ5VYX34Y1X#X3R<=>=>#B/4EWFH
MB1N?>3U>=>S%N9G+CJLNA\$PL+>#0N/35Q/ZLIE<?>M04B2@CD?>F#0:8#WY/JHD>=>=>J=L?>7?O1Y>SZOK M7LO?>1<2\$>GCE P<=>ERU?>G.@IC0<_>9?>GVNNNG?>
63J?>CAXI<=>MM MMV.OJ.NO<=>S3#DHL?>29AAN5\$2:8>XY8T1D5%CHZ/H91ZT1+<?>5U1U<?>P5Z22=2.Y.O.<1+Z(M6S\$>M&O@DOJ\$2K67?>I>#JN?>JWVIGW7?>U<
(HUNY?>#>PPN?>A3 M35.H4<O.FEJ?>2N0#31+>A2HY6P43R<LX1 JX+WE@Z7IKA>W6E2WBJOGIC6
M.MU<U/EEH144W.G+CLT=>A&8.N:G3J9NR.URZ=>E2I6G+>@J<G6 MR0H1.GMMWQSHI>O>1663JH9Y.TWV1+37B.6=>IMK7J.HHXU<=>@/E1B MDZ#>K.A.N+Y?>
(K#B?>+4.P<2A.H44MISIVJ.MOTXIO.10S8R1.LMOU.V<?>33MD.P52AD2B2D10A8>R16I8=QOH<=>P2344 MI=9?>25K1<=>R.K03Y+EUH+3.C8F3XJ
GWS<?>3XZ<OF77FEIY4 MO<=>PI5W=3S1IS.014U1>IP?>D.X#>MY5_>13RR9(H?>MSI/<=>@<?>1?>@O<?>M.OHLH.%@P#>+>WMK965%1H?>G?>GMAIO.GZ>S=>?>6J<=>M
66IUV2=>Y8M5?>20D3J0YU067HZKEW.OB M&=>=>2M?>F>N9H.YI/O9IK94H01.7+V.U<=>V9(I)5\$MZ+Z1QG@>IAA186H75\$1 M4<4?>0?>K?>KJEW2<55YH?>=>=>K1#L?>
<1AWE25\$M5Y-157&8@>150(MVY?>20?>2ANUX<O23JG F<=>1.N.DKFXO>YH_>H<=>U?>6HWH IZ.M#>10A173L H2HOU1M080WKZJWNE2
<@?>1?>+W.K<=>4&H<=>=>W.J.KCQOWG IY<ZUY<3MK.M4F3\$1GWS_>L*6C4?>#N1#>56UYVQNS.PG.FK\$>IHLN0?>U?>@OT68GE.M-ICE
<=>1E7&H?>=>ORKEO8N059?>2N75Q.3418N7MK5W1Q?>PXX?>N.M.#M1.28I0?>T*G E0\$<=>1?>W2M?>DI<=>KUE?>=>CEW?>I2YU<=>IV59M.SM28N00.2H#>8&FZ4
83I3=1?>363GI.FGA%>E.MUTSOVR?>4G3GSYRS-14I>=>HLC9/77.G2%5IY5/5HR/L@ERH&6UKWR.EI&YA5#AR4FLR1E4<=>@8?>M=<(X7&)955-5L<8G1UT<=>B?>2W9M?
J1 X1<=>2?>CCHUYX\$>2D<OUPPE\$>M5I\$55/82?>1?>R1?>J1?>B?>#>+57 MAH0.2IDP>A0U291.9355D25M5E2G18U100R=M=<K/Y1/35NR=>L&3E6L
M7A+W(91)>1M1V>2R.HL3ENR#6IKL7+Y7IAR<=>390613BW3?>WDEL<1MZB>9?>PIPKMR7LFL?>P-BBLWZ.9DIF&3-RR<=>G-1Q<SZ813GQ2PBI9I2?>MXH?>AMOR?>M96?
Q=>8K22Y5=>6?>X@>WHJNGWYKIFCVZ0K<=>U<UPY.MR+X5YX+OHS8#DE6?>1?>=>6?>YVD9I3<=>8LCPD.N1?>AKP 2.MR?>I?>G=U1/SDG57K/EAD2.3+1+22N?
Q>+15Y1FGGW76-VA0QK1<=>9.M.NIS=E6<=>W(KN<7IHL?>AP\$?>=>@H.#WFPD?>I.VJE?>7I04HN.UWVPYLEGG68L 2U.V=<=>56WIS15?>C=U1/6AHSI=>3?>PI?>1+>
IXZ3U=5=URNXY@K?>1?>1@LL5.GIS<=>EM<=>017D?>7&H1 EYI7WWE7?>9 MDXGIB@AWJJ(#>UAD:6IUP?>50\$XLOKDE/3?>G39CS.RL IYVELLY#<=>V#>B MK+>B>CGQX
-<?>7WZELKJ&AWS>1ER751.2ZFD13.M@30P1L@>J61&90I&A?>M?>@/U?>?>3?>CVP.146BMF5.E3E:IAN4>5?>T&X%>W@>MJLR19Y5
<N1M5J1HJPHJEGAW\$061FKP01?>WN.C.SU<O2JHLHW39?>5?>1M?>@/P?>L2 10=>=>EC<=>1?>HVI+L+L?>P?>1J9?>3W<=>L.3WZ P10F3?>MI?>UY MPO?>
T?>=>1CVRV?>2.PVD<=>3?>@>9N?>4?>X4>=>2ZDYI?>N246VZ57(4OX>=>1.B.M07 M&M&1&WV?>PYQ7UE6W?>Z?>HH<=>H B M I.FEM.5J1?>@>V1/IC15?>Z?>A?>220Y8HRRS?>01Y?>@<=>C<=>
I=1W+1Y.G+>MZ?>1?>X?>J3HJFI=1?>A01.699D879YX.M4D.>PZY.NM9R9@B?>HHRIR?>I?>X155<=>0I?>L?>H7X04Q.M211D?>1?>1?>5.

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j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gt

00 MKKO T%::=-HF"7RD!#Z.0G@?43L(ZQ\$7NH.CEH+8UP.5045??)=;+N.6EH6 MMG>IPHJ:4.\$0%QP2^*.fE"LO^&T"!1/0FE)^=(E*!Z:ZS5OIGWU0:2<95&/M/%A? 3RUI1797E=-J5XB<7E%8P@.0 P1XN!Q0J3L7XN7@.&N%175ZE?% MDBG!MP7%BY1XJ.3FU.~W.7KMV?>7KIUVK<~!8IH 7~!)JSL\$%>?YVH6B UL3B YQ2T@E M0:4W:LV:NFOQUVY?>I-SM\$%\$U.~S\$(SRU;&B%L~N.MTK< MWK7OIX>Z<+KHTS7S3?SW-SIK%V=M.~5UQ.3L42R7J.EJ&PYQ0P5?M7DQJ@ M0<Q<C?>=106^A_4+~5TFC(U: IPT>=1+1&F3M.Q?SSN57K!T.CXK+W.O.MAW+2S\$Y4!T.PAN9I?>?OW8T!MIZ2M=2BIUXH>H>\$S!T(#!~2345E12+HKZ2SR!\$4S!N4! BD5V\$3S.PMFEX7 MUO:K7LTAIV@&8CL"(G5Y#J!<^@VL76^CJT.~^AM(RLU^F9<<13GCV?QZ?M^#0N(3GE9B7%- MY7YN@<~WK~VH16I2\$.4&\$%ZF!#8N4=O>V>W M#FEVZE144HYD>14B234\$8AE/QOQ<?)WJVS.MMN.<~3HH221E.6V4+SYVCB MEID/8V\$34EX^?03J.C)^>?GSR?20DYIT?T03WV!>EY3?>(MGYO4VU>G M8I>?>KS-S? (ZG6\$55X-OSB!M7K!OHYNGGI?>~>N\$KMW>~RLE!N(D6XE~.FMFH74EPB~0H.6\$%?Z?PHU?>H!IDW-KVJ20+ 60E!>T.C-2G5JQ813! MZ.MD/(-@F/D=>2=6T^@>S#J~K8V~\$S2IE69?FH.HS:14X%YQ!>?#<A-MHJ0B?>IE6LU7-9H7WU7OXYE2Q@>(ZOA.U.G3D9\$1!<OH6&K~>#BHKH<7H7T& M3B1B5!&L6\$SMX6M1.17H7E.~23D.XBAJ37MRVY?>?2BTGE1U1K5.2.~(#8BC MOSQ?FF>?02DW4M^M!L.M9I87&E?C80Z?O.H+H!>L2+049&C)RLK!R^OHM+ M\$D4A8@F6+2XNOGCOXNC1HZUM;\$TL*\$(Z<3UX!3>96%>Q@<\$AUK.Y^!>+56 MH4+U)P^%+>#PM\$2&5X0^%#EB@>ZLN7+CKYO=B>^>I<.&*)DRW.\$8+14&1 M#~W9.TA3K.LM2^K>+!BBD@B0.26Y?ASYRZ?MHO4T.9.GAXN!+GA58FDM.M51H_9I^<CJ&SO6M^%8X?I22M(1WNW9.C.6.(C@PE0CBH&O=>J3C^03+J1B-0B~QA@>T M!A1Z.T!>=IS@L.M7!>H~>M32.NS~?Y?T0144IPX4K7~L!8BXN!E&4.6MDM%M.MQW4X&M323OCOTM@L.G.NT.V~X~\$&5S\$Y@4BY\$5?>5.D.2NCDNM&QMOW=0H/OYB16 M0CD3~>?9J@<R^X~R^B9>?>M2I209W.O.N\$=285^F96\$52R2514\$RPP\$5M1&CZ.B!W.N).G~Q3TQ M7:=1!B8X1!CN.N.8XK^<A8MV1+>2A6%>?2C@>L!D6GCF.#H7>NBXP<F6.96.MM09.KG.7!>F\$XB16DM\$S<D^M.R=9LU=)D)W^HJ!>I^WY151527!L^J2^*LO.MIVD>F^\$%Z> OYZ>0VWVDN6K.S)S4.41H@ID)5RA!L!G3HSMW\$U^!P>BP<30MTC107XX~!>V9V4-7RGSSP3W%MM3\$*>2.SC!P\$SR96.P!4^#@<E4<15^+<F.YI~GGRE~>~#0UM3=OV9:3 M^>0B.M@XW.J<?UCS0H14^<?>K3CB1H!>@?Q%>VJXN?>L!~VJ8B\$)M1!>C!P!U!E.F53M7?/NAJH8YV?J4^<@&H/HJF!FMDRMID\$<~<M!>#&M!>VOMY?=-OZJ26H^K\$<~<9!>L.P^M(H6I6IR4!>=9AP!R!E@<60%~M@L^RHH~>N^XW~BR>7!JKT?7SD!>90U3GD@>N%~N!UMZ!16%YJ28!>M7\$!T!X8&K!LL2RPG:44J52Q3133.L!0 L6T5!=~!NOS4!K2V.121W2M.M0.K6X<G!TW+S.FE~9L(H!70V^X~NNGEY!HQRX!B.BB^8!30IH~7GZM.MK&P+VX5%~127\$320E! 2"DQOQ^A>73MG.B(K<O?OUNU^W+~W7 %YBEI&~M5~>~JWA@XX(EFH58W>~>(K^K@>C@>GIMR3P517NYU?>QOD8&3^O!>4.M.M9512!>Q5MP2DM\$T@>E!>(FJC1\$EWA^67^9X@6+~90!>#3N?WLB8R~M5@H\$Y)&~UU=25&CQY77UP.ID:192IQ^*ER.MPN7KUKKINT~Y.Y!13.&*&IAR\$8CF3XQ.2D!P!>~!<78X3Y)#(\$X^VF.MGU0HO&>~<1 L@>E@>Y<~>L.3\$5LW+G\$>GS.9K&F.J0!>@&R+95QX^>L52.MYMF^QOZ!NMH7J0Y!R.JC~TM~!>IA8H~?>D>N7K!T9NC4^M3O^CUO!1.MH.D?>3C5~ G33SRVYME8N!>=NR0S^T?>O@P&K&D33HIX27!>KA=1%K&P89.MH!(DJOC?>G+D1\$=>~5T!>@>I+N+~%X\$7226>D.5VJQSGVLV>T?30H3FY\$M!)M4FO60TL!<Y\$+<~<G>YV!>~<O1XHG>~<1CE>66LV&GVIEZ7FO@>.COXH.M!>O!M!>I~M9!B.IXD3>000!9U@>BD!>GVYK2!06.59AJ^AWR29>OVICU!M?>~!<S&~<~<OQKB!#%C!>P=I5Q<N~<65Q94H2R7\$>7E!K.M\$=15\$>@2!>CGB!>GB.D~>HP2P8G^H7%>5>QW0>?>GU76~R6^!>L8P.QQ!\$>~<M^>A!>PZ2M8!0!>6>~<GIZ!LC!G!S "O)GGO!^OHY^K@>X>VW:LJNB0(C.M19X#!S!N2H0(O55!5K-Z^C^U_431^\$3^F4J<~<UK^2H.HAR!<7+Y.O66-K8.M6=C8N70HK?YO!8^L8M!Z^CK=N&NKA!HJZHJR!C= >1\$5!>N+614W!M0(QO7?>7^0NA.O5AK9J9L^>96MAYM0\$>ON^>5%BM^K\$>96-DXFEK8A\$U>M!>P!>A!AFU?>Q?5BZK34Q.NGGG606MG~\$>+>R!OT&I^4&5!>E~&I2.F M6KJ!HS20DNY^QSD!>1@JR12!>P~>R!>2~>F4DQ5G7S!MSWL<?>P~G~T^F.Y!>5DEI22\$8\$SP\$KBSJFKE<~>G3!ERN^CS\$780.49V!>M=M\$&L.K\$>L=8?>=A@<~!KA\$<8S~>?>5E969T!>~!>2HJ7U7B~!>18^K!>~<GY.M!>O6!>J2W7!>76.OIES^\$>L!>~MWRZ77A&S<@>Y!T3!R8T0\$!>7!V!>2B0^FVOW!>WH>EPL!>~<67%9=O6+2)0!>H M!GVL4A+^<Z^K<6!9LXD3F>I9:7)D!>R.MM2V\$>~>QO46T5(0T^>M!>B!>K22!>OZ~L!>005!>Y3\$9H!G6A!>M4DM+Q!3\$~!>H Q)5\$%75U^~>~(E!8#0">+6H2F>SIRI^6=G.6#P^?>Y94.M5M(B9.P!>ADT^>76IK>~>CY+~%JXMK5.3.12380AQW!>ML>F7+OXF&X.MC~29^~N76~8X2NNCK&O7L.N?> W\$>G!>BGS58V\$Y.09IO\$>Y>~>Y>O4~>3K!>3.FOR~>N>A:9@<ME%94M@>N!>M+~!>VH6VX~4%>@>L>9\$Z?>Q!>A4@<C^!N1E2F+NP!>FMDYN+0!>6!>IO!>S^>T^>TM M^>NXW?>2!A8V9M~VY~M!>ZFO~>.02!>0MKK5!>F\$H!ZX<O>~>5!>DLK^>D.M~\$A+TAP!>IS!RAX~UV~.2E%>0M&Q.O@>6C!>P!>3F&N!>~<X\$>IR~>?+1M.M.VFAH2YV=JHM3(-7)JG0=0DU+4G@ORR!>A~OOL~N.X.M~X&OGH6!E5).WKA^OVU.A&E!>F9I26%1!<~>F+!>M07&K~X^>?>T29.2!>QO+>BORI!>JE<K ES<?>0D!>0786~0B!>~52?G.6&G=Q.M^G114=<@&S2~>4!>GGR!>H101X6QA7WUY6\$!>SID!>9<~>@>?>T!>OZ?>P~.645!>3HD!>P!>A!>LEMUZ? R5@>%9MM32TNW7OFKV2D40N)<4!>FZ29^R!N!>M=KFX>G.LU^TC.U>NID!>B.LF#>+T>3R.9ZW^GC)775^>Z~>~>D%>UEFLL.M1PRL!>AMF&1^0MJ3\$U!<~> FVUM!>9!>UT!>3.1KV2KEY2M^>N=<~>(OB5\$M.6&Y9B.6E9I!>K~>Z^YF4>L^V^S2M8!>?79W!>V!>30!>L&VXVXNGN96EAV!>+GG!>I&F2@>?>M?>?>FHAP!>HJ!>1.6+5^>FEP US2RX?>Q?>(>ZJ!>AH=>?>O.MWY^8!>H!>B!>S2~.3B&AW.D!>ZHG!>GKX+5F!>I!>#&~%T^F.Y!>5DEI22\$8\$SP\$KBSJFKE<~>G3!ERN^CS\$780.49V!>M=M\$&L.K\$>L=8?>=A@<~!KA\$<8S~>?>5E969T!>~!>2HJ7U7B~!>18^K!>~<GY.M!>O6!>J2W7!>76.OIES^\$>L!>~MWRZ77A&S<@>Y!T3!R8T0\$!>7!V!>2B0^FVOW!>WH>EPL!>~<67%9=O6+2)0!>H M!GVL4A+^<Z^K<6!9LXD3F>I9:7)D!>R.MM2V\$>~>QO46T5(0T^>M!>B!>K22!>OZ~L!>005!>Y3\$9H!G6A!>M4DM+Q!3\$~!>H Q)5\$%75U^~>~(E!8#0">+6H2F>SIRI^6=G.6#P^?>Y94.M5M(B9.P!>ADT^>76IK>~>CY+~%JXMK5.3.12380AQW!>ML>F7+OXF&X.MC~29^~N76~8X2NNCK&O7L.N?> W\$>G!>BGS58V\$Y.09IO\$>Y>~>Y>O4~>3K!>3.FOR~>N>A:9@<ME%94M@>N!>M+~!>VH6VX~4%>@>L>9\$Z?>Q!>A4@<C^!N1E2F+NP!>FMDYN+0!>6!>IO!>S^>T^>TM M^>NXW?>2!A8V9M~VY~M!>ZFO~>.02!>0MKK5!>F\$H!ZX<O>~>5!>DLK^>D.M~\$A+TAP!>IS!RAX~UV~.2E%>0M&Q.O@>6C!>P!>3F&N!>~<X\$>IR~>?+1M.M.VFAH2YV=JHM3(-7)JG0=0DU+4G@ORR!>A~OOL~N.X.M~X&OGH6!E5).WKA^OVU.A&E!>F9I26%1!<~>F+!>M07&K~X^>?>T29.2!>QO+>BORI!>JE<K ES<?>0D!>0786~0B!>~52?G.6&G=Q.M^G114=<@&S2~>4!>GGR!>H101X6QA7WUY6\$!>SID!>9<~>@>?>T!>OZ?>P~.645!>3HD!>P!>A!>LEMUZ? R5@>%9MM32TNW7OFKV2D40N)<4!>FZ29^R!N!>M=KFX>G.LU^TC.U>NID!>B.LF#>+T>3R.9ZW^GC)775^>Z~>~>D%>UEFLL.M1PRL!>AMF&1^0MJ3\$U!<~> FVUM!>9!>UT!>3.1KV2KEY2M^>N=<~>(OB5\$M.6&Y9B.6E9I!>K~>Z^YF4>L^V^S2M8!>?79W!>V!>30!>L&VXVXNGN96EAV!>+GG!>I&F2@>?>M?>?>FHAP!>HJ!>1.6+5^>FEP US2RX?>Q?>(>ZJ!>AH=>?>O.MWY^8!>H!>B!>S2~.3B&AW.D!>ZHG!>GKX+5F!>I!>#&~%T^F.Y!>5DEI22\$8\$SP\$KBSJFKE<~>G3!ERN^CS\$780.49V!>M=M\$&L.K\$>L=8?>=A@<~!KA\$<8S~>?>5E969T!>~!>2HJ7U7B~!>18^K!>~<GY.M!>O6!>J2W7!>76.OIES^\$>L!>~MWRZ77A&S<@>Y!T3!R8T0\$!>7!V!>2B0^FVOW!>WH>EPL!>~<67%9=O6+2)0!>H M!GVL4A+^<Z^K<6!9LXD3F>I9:7)D!>R.MM2V\$>~>QO46T5(0T^>M!>B!>K22!>OZ~L!>005!>Y3\$9H!G6A!>M4DM+Q!3\$~!>H Q)5\$%75U^~>~(E!8#0">+6H2F>SIRI^6=G.6#P^?>Y94.M5M(B9.P!>ADT^>76IK>~>CY+~%JXMK5.3.12380AQW!>ML>F7+OXF&X.MC~29^~N76~8X2NNCK&O7L.N?> W\$>G!>BGS58V\$Y.09IO\$>Y>~>Y>O4~>3K!>3.FOR~>N>A:9@<ME%94M@>N!>M+~!>VH6VX~4%>@>L>9\$Z?>Q!>A4@<C^!N1E2F+NP!>FMDYN+0!>6!>IO!>S^>T^>TM M^>NXW?>2!A8V9M~VY~M!>ZFO~>.02!>0MKK5!>F\$H!ZX<O>~>5!>DLK^>D.M~\$A+TAP!>IS!RAX~UV~.2E%>0M&Q.O@>6C!>P!>3F&N!>~<X\$>IR~>?+1M.M.VFAH2YV=JHM3(-7)JG0=0DU+4G@ORR!>A~OOL~N.X.M~X&OGH6!E5).WKA^OVU.A&E!>F9I26%1!<~>F+!>M07&K~X^>?>T29.2!>QO+>BORI!>JE<K ES<?>0D!>0786~0B!>~52?G.6&G=Q.M^G114=<@&S2~>4!>GGR!>H101X6QA7WUY6\$!>SID!>9<~>@>?>T!>OZ?>P~.645!>3HD!>P!>A!>LEMUZ? R5@>%9MM32TNW7OFKV2D40N)<4!>FZ29^R!N!>M=KFX>G.LU^TC.U>NID!>B.LF#>+T>3R.9ZW^GC)775^>Z~>~>D%>UEFLL.M1PRL!>AMF&1^0MJ3\$U!<~> FVUM!>9!>UT!>3.1KV2KEY2M^>N=<~>(OB5\$M.6&Y9B.6E9I!>K~>Z^YF4>L^V^S2M8!>?79W!>V!>30!>L&VXVXNGN96EAV!>+GG!>I&F2@>?>M?>?>FHAP!>HJ!>1.6+5^>FEP US2RX?>Q?>(>ZJ!>AH=>?>O.MWY^8!>H!>B!>S2~.3B&AW.D!>ZHG!>GKX+5F!>I!>#&~%T^F.Y!>5DEI22\$8\$SP\$KBSJFKE<~>G3!ERN^CS\$780.49V!>M=M\$&L.K\$>L=8?>=A@<~!KA\$<8S~>?>5E969T!>~!>2HJ7U7B~!>18^K!>~<GY.M!>O6!>J2W7!>76.OIES^\$>L!>~MWRZ77A&S<@>Y!T3!R8T0\$!>7!V!>2B0^FVOW!>WH>EPL!>~<67%9=O6+2)0!>H M!GVL4A+^<Z^K<6!9LXD3F>I9:7)D!>R.MM2V\$>~>QO46T5(0T^>M!>B!>K22!>OZ~L!>005!>Y3\$9H!G6A!>M4DM+Q!3\$~!>H Q)5\$%75U^~>~(E!8#0">+6H2F>SIRI^6=G.6#P^?>Y94.M5M(B9.P!>ADT^>76IK>~>CY+~%JXMK5.3.12380AQW!>ML>F7+OXF&X.MC~29^~N76~8X2NNCK&O7L.N?> W\$>G!>BGS58V\$Y.09IO\$>Y>~>Y>O4~>3K!>3.FOR~>N>A:9@<ME%94M@>N!>M+~!>VH6VX~4%>@>L>9\$Z?>Q!>A4@<C^!N1E2F+NP!>FMDYN+0!>6!>IO!>S^>T^>TM M^>NXW?>2!A8V9M~VY~M!>ZFO~>.02!>0MKK5!>F\$H!ZX<O>~>5!>DLK^>D.M~\$A+TAP!>IS!RAX~UV~.2E%>0M&Q.O@>6C!>P!>3F&N!>~<X\$>IR~>?+1M.M.VFAH2YV=JHM3(-7)JG0=0DU+4G@ORR!>A~OOL~N.X.M~X&OGH6!E5).WKA^OVU.A&E!>F9I26%1!<~>F+!>M07&K~X^>?>T29.2!>QO+>BORI!>JE<K ES<?>0D!>0786~0B!>~52?G.6&G=Q.M^G114=<@&S2~>4!>GGR!>H101X6QA7WUY6\$!>SID!>9<~>@>?>T!>OZ?>P~.645!>3HD!>P!>A!>LEMUZ? R5@>%9MM32TNW7OFKV2D40N)<4!>FZ29^R!N!>M=KFX>G.LU^TC.U>NID!>B.LF#>+T>3R.9ZW^GC)775^>Z~>~>D%>UEFLL.M1PRL!>AMF&1^0MJ3\$U!<~> FVUM!>9!>UT!>3.1KV2KEY2M^>N=<~>(OB5\$M.6&Y9B.6E9I!>K~>Z^YF4>L^V^S2M8!>?79W!>V!>30!>L&VXVXNGN96EAV!>+GG!>I&F2@>?>M?>?>FHAP!>HJ!>1.6+5^>FEP US2RX?>Q?>(>ZJ!>AH=>?>O.MWY^8!>H!>B!>S2~.3B&AW.D!>ZHG!>GKX+5F!>I!>#&~%T^F.Y!>5DEI22\$8\$SP\$KBSJFKE<~>G3!ERN^CS\$780.49V!>M=M\$&L.K\$>L=8?>=A@<~!KA\$<8S~>?>5E969T!>~!>2HJ7U7B~!>18^K!>~<GY.M!>O6!>J2W7!>76.OIES^\$>L!>~MWRZ77A&S<@>Y!T3!R8T0\$!>7!V!>2B0^FVOW!>WH>EPL!>~<67%9=O6+2)0!>H M!GVL4A+^<Z^K<6!9LXD3F>I9:7)D!>R.MM2V\$>~>QO46T5(0T^>M!>B!>K22!>OZ~L!>005!>Y3\$9H!G6A!>M4DM+Q!3\$~!>H Q)5\$%75U^~>~(E!8#0">+6H2F>SIRI^6=G.6#P^?>Y94.M5M(B9.P!>ADT^>76IK>~>CY+~%JXMK5.3.12380AQW!>ML>F7+OXF&X.MC~29^~N76~8X2NNCK&O7L.N?> W\$>G!>BGS58V\$Y.09IO\$>Y>~>Y>O4~>3K!>3.FOR~>N>A:9@<ME%94M@>N!>M+~!>VH6VX~4%>@>L>9\$Z?>Q!>A4@<C^!N1E2F+NP!>FMDYN+0!>6!>IO!>S^>T^>TM M^>NXW?>2!A8V9M~VY~M!>ZFO~>.02!>0MKK5!>F\$H!ZX<O>~>5!>DLK^>D.M~\$A+TAP!>IS!RAX~UV~.2E%>0M&Q.O@>6C!>P!>3F&N!>~<X\$>IR~>?+1M.M.VFAH2YV=JHM3(-7)JG0=0DU+4G@ORR!>A~OOL~N.X.M~X&OGH6!E5).WKA^OVU.A&E!>F9I26%1!<~>F+!>M07&K~X^>?>T29.2!>QO+>BORI!>JE<K ES<?>0D!>0786~0B!>~52?G.6&G=Q.M^G114=<@&S2~>4!>GGR!>H101X6QA7WUY6\$!>SID!>9<~>@>?>T!>OZ?>P~.645!>3HD!>P!>A!>LEMUZ? R5@>%9MM32TNW7OFKV2D40N)<4!>FZ29^R!N!>M=KFX>G.LU^TC.U>NID!>B.LF#>+T>3R.9ZW^GC)775^>Z~>~>D%>UEFLL.M1PRL!>AMF&1^0MJ3\$U!<~> FVUM!>9!>UT!>3.1KV2KEY2M^>N=<~>(OB5\$M.6&Y9B.6E9I!>K~>Z^YF4>L^V^S2M8!>?79W!>V!>30!>L&VXVXNGN96EAV!>+GG!>I&F2@>?>M?>?>FHAP!>HJ!>1.6+5^>FEP US2RX?>Q?>(>ZJ!>AH=>?>O.MWY^8!>H!>B!>S2~.3B&AW.D!>ZHG!>GKX+5F!>I!>#&~%T^F.Y!>5DEI22\$8\$SP\$KBSJFKE<~>G3!ERN^CS\$780.49V!>M=M\$&L.K\$>L=8?>=A@<~!KA\$<8S~>?>5E969T!>~!>2HJ7U7B~!>18^K!>~<GY.M!>O6!>J2W7!>76.OIES^\$>L!>~MWRZ77A&S<@>Y!T3!R8T0\$!>7!V!>2B0^FVOW!>WH>EPL!>~<67%9=O6+2)0!>H M!GVL4A+^<Z^K<6!9LXD3F>I9:7)D!>R.MM2V\$>~>QO46T5(0T^>M!>B!>K22!>OZ~L!>005!>Y3\$9H!G6A!>M4DM+Q!3\$~!>H Q)5\$%75U^~>~(E!8#0">+6H2F>SIRI^6=G.6#P^?>Y94.M5M(B9.P!>ADT^>76IK>~>CY+~%JXMK5.3.12380AQW!>ML>F7+OXF&X.MC~29^~N76~8X2NNCK&O7L.N?> W\$>G!>BGS58V\$Y.09IO\$>Y>~>Y>O4~>3K!>3.FOR~>N>A:9@<ME%94M@>N!>M+~!>VH6VX~4%>@>L>9\$Z?>Q!>A4@<C^!N1E2F+NP!>FMDYN+0!>6!>IO!>S^>T^>TM M^>NXW?>2!A8V9M~VY~M!>ZFO~>.02!>0MKK5!>F\$H!ZX<O>~>5!>DLK^>D.M~\$A+TAP!>IS!RAX~UV~.2E%>0M&Q.O@>6C!>P!>3F&N!>~<X\$>IR~>?+1M.M.VFAH2YV=JHM3(-7)JG0=0DU+4G@ORR!>A~OOL~N.X.M~X&OGH6!E5).WKA^OVU.A&E!>F9I26%1!<~>F+!>M07&K~X^>?>T29.2!>QO+>BORI!>JE<K ES<?>0D!>0786~0B!>~52?G.6&G=Q.M^G114=<@&S2~>4!>GGR!>H101X6QA7WUY6\$!>SID!>9<~>@>?>T!>OZ?>P~.645!>3HD!>P!>A!>LEMUZ? R5@>%9MM32TNW7OFKV2D40N)<4!>FZ29^R!N!>M=KFX>G.LU^TC.U>NID!>B.LF#>+T>3R.9ZW^GC)775^>Z~>~>D%>UEFLL.M1PRL!>AMF&1^0MJ3\$U!<~> FVUM!>9!>UT!>3.1KV2KEY2M^>N=<~>(OB5\$M.6&Y9B.6E9I!>K~>Z^YF4>L^V^S2M8!>?79W!>V!>30!>L&VXVXNGN96EAV!>+GG!>I&F2@>?>M?>?>FHAP!>HJ!>1.6+5^>FEP US2RX?>Q?>(>ZJ!>AH=>?>O.MWY^8!>H!>B!>S2~.3B&AW.D!>ZHG!>GKX+5F!>I!>#&~%T^F.Y!>5DEI22\$8\$SP\$KBSJFKE<~>G3!ERN^CS\$780.49V!>M=M\$&L.K\$>L=8?>=A@<~!KA\$<8S~>?>5E969T!>~!>2HJ7U7B~!>18^K!>~<GY.M!>O6!>J2W7!>76.OIES^\$>L!>~MWRZ77A&S<@>Y!T3!R8T0\$!>7!V!>2B0^FVOW!>WH>EPL!>~<67%9=O6+2)0!>H M!GVL4A+^<Z^K<6!9LXD3F>I9:7)D!>R.MM2V\$>~>QO46T5(0T^>M!>B!>K22!>OZ~L!>005!>Y3\$9H!G6A!>M4DM+Q!3\$~!>H Q)5\$%75U^~>~(E!8#0">+6H2F>SIRI^6=G.6#P^?>Y94.M5M(B9.P!>ADT^>76IK>~>CY+~%JXMK5.3.12380AQW!>ML>F7+OXF&X.MC~29^~N76~8X2NNCK&O7L.N?> W\$>G!>BGS58V\$Y.09IO\$>Y>~&gt

.EAKI:R>5P.7AAZ+K5^91DV: Q4.4^WP:F6U2:XD6HLNY=/M4:>XOZE5^Z/HI^M>:Z: P %"/A-?77E3S:QIZ;MHGN-/3Z. *6/Z5L?LM?LV7//1VOZOXF5:A
M=60K>Y(NIUUD^T4+EAN^IR/E :i6Zi@#/:ZB187L^ #/60#1UMH=E=>^5V\$ M61H%=23^1%TN:K@1P518?SSE^25JUD_P^O4L^SC^0^LX:\$8P-MZ)H0^OD?0GA?Q=H_C:1?2
5!"/UKWU73+@9CNK60.A108CN#R^Q_B9150#OPAI_M+K0BBH>OTUHTMA^D32GS&^C^@GHHYIJ_GH^FXE:W^SGI>?)^FKR0H=WT_MITG5K/=(F^M^O)UIP<<HU:OJ/_@H>A
C^~L2!ML21UR5.15^TL^5Z_M<16:1.ZJ6=2KY25Q^C:I3O=>:/<100:1+>/(17:3J9D9D#7MUFI\$V.5_M:=OQMPIWK+Q^WWA)-1Q7MH-1U#6BK:3-IMDSQ?@S%<-A7Q%1!
70#~/EG-MVWP-T2)E@((Z?<->7.DH^V=NIGEL6.CI:GU/YKZTTW_@G+X^MI:WOI:U-MRJU5E_X-HISB16QU\$6TC^L2:I-V79:EI5PO=5MI^'=+SISCHYGFF8T8SP=)) M6U%V1
IAWK1=^4T16/V<-CP:6&1 M634_#1E+P^P^>/(R:1T:1^N17V1^TC^R^X7)=0^+?B3>:EJL&K)I37-V-MT+IY&Z&-E-05)P=HSS55LMP>IQ5^PL^TJ2U61(6E)D.D: 84\$1%-?HA1^2V
M@O1/QJN1HMO^6I2:A-I2))<^IO)1L#\$A?O_9^Z2RK1WV4?@SFOX^5WH.M-M7M196L.FO>"2Q^ARP=%QE@>,,>UPH+11_P1F/PI^SI2:Q=.%?ZE>OJ<<<4JW
MSH0H0L1MVJ1QKXCC@:_R14TXC(O+66_@H2%ZU^2G1^M^P^TX.GNW1C1-JPLIR_M1_="V2^J_7EN1C_+7HLSXW7PI^EH5FCQ:+KTC:E93H_:8MNEC!1ME:YAL,*^QX%
I73=30H:OI9Q+%=VDC1M61@319:SL<@<@YIC7T_6^M2^XBA4P-MM65&JK-V%Q+>%THUJ3NF25&L02^SI>12Z5X5TV74-9U&UTIOB&N+R58D-M^XDUX?XV:
(TCOO^SW13/\$_@BIGE72IK1+QHS^F0JHU>=N),@G2G1PI6 MNUR+1M^35V%7Q5+1#1U2;MUT5SF/CE^WEX:~^&^J7FB>^/_P^\$KUFU)CFF
M\$PCLX1^P5+IER#U^C^O7AMO^TO^TA16BTGA32)X:*3KZ-HX.8^_%UEW_7_M<1^PK1+?#_Q^*^FH/XBMX10M1&LA=Q6%P_R3RF0^&=3IX+UQTR1FOTTAABM_M:>.&&-88\$
5(XU)H8<-+513C8U+YK#PFIHTE=RV^X^P2Q^=4WB:E=TX-MNRGOHW9^07QTL_B3^~0_~%IOM>FLPIN+Z2-W\$&YL>7PIN\$Q7ZM?DU^S="EQ^U=X?>5A&HUR=6..3Y@_M
_S^U^KMU_Y_SDF^U2VWUP.E^?HK:PG_M1^91HD1^*LG4&12.JT5GA>PP2>N^*6YVS/CE14R6#PIX?2VB+_M%1^I&FM>.GLTKY7X^"O(OA:HT?QS_)/TVU157.DT>N:M+
>1TA#2@_GILMD-M^%M7Z0^="1TOPOL_F:/HMF60^\$BMK2((BC^H1^O>M<53P>21A^="VEH1_M1:V7R.<14QN?2G4A6IE3LDMW1S1MCM%1:9M-TN^~:1_9LMT5LH1PHS
M:221^R#MSR:~O/O^~36<3;GABIE#1/CIN21@^DIUW/!:_DA5+1JANX_P#0(ZV:6>(R2-1 MP4:RV2LMV+3+Z2UN&-SL291M8^@W(IGW%>A6E&.8X)S_)?QI1F8>IY9CE#?F
M^YX^&?B#1?1?2V2LO_@&A-X:EEDN(9X=\$%RLKEOG;S^#6D8_"NY_X7A^U_MAW:ZH?^Y7_>)KU3_@GG13K#50AE=>#)KM%U^1KF2:*1FPTM(=P91W-OB%15^/_PPM;2:Q^JT-
@WU^YUN2NFFP=@H^MH1.2.GDIHWKPS_@HA_P_F_P_&>21_B=YO_H.E32S&ICL9A>FHI+TMIOR+JY_M3R_180EJN.O^QFW+1_L=2H16E+?_P7@A-?~1CI=M%*P^F1QK2\$14Y^
<9H\$1M4XU(N\$U_~_3XG1L+?S_P#1#S^&K=O^VE(V^~YL&\$5VGINBR#D>1\$_A7^0_~\$M^IH#PX@TY=21=VHC^00R6IP0&:_1BAZU^LF>1+N+>U?51XCJN^CB:49VZM:
MG01AEE&=%JIRWZ(-33_@+1N7?1M1XDN&AB0>PD?P5^_T^M_@:_R21^A3XK1):IK#R:RWB>9?+>%MA@5&4=@1DC:=QZD#@51#1CN(HZ1
MPKAQF>8C&01E%\$%IDN0WX/(<@Y^UFW..5KM1H1L=>^WQD_9S1:-JPAZR-MU2XND):ZIH<1G66.GHZ\$C(^L_9_UU\$-Q^U1=H#14HUVVTN:HU)-NE-MVY700:K\$>H&?
I724#K2-VSS73+B&=1^52C^4UU_:2#E.FW&G6G&#^R^F7FO_M7YV^&S^W@?PWX6A>TO/&L7_G&KM9(1^WRE(1.0QWQD1GKQTKIH^>BW_M
1^~@/K2M4M9+44:2X8-BVFOQC<+@Y^P2^N14IC0TTF=UYT+S:OCJ:~7E_M:=^IZ>"RC^X^O^M0NN9)6ZYL?M_L@~/10Q^U16_1NE7FMZ#=#737UK-HS_M<6:1QN:>?NUT/YRI
M1%>E&(OV%2%NE_742\$5%V1_B+X47_U-MXTRRD1RXRV)21C1H(O)=(N^%OVU:>=>=:MZ_#EJF&X/0X/Y51#1^HP^~+GO7B.ZQ&H/H^U_~W10>1W87)<@ZZQ%&_MZ:507S2F?
FO^~SY21^TNNQ_/_&L_8_P#PEAO?MNQ?+CI46SIV<+>_0_MWOEX/TOX@>%14VZU_~M+U^%HDX141^#YV(^#ZBMC/S^I+U+N^~XUAB1MR1XYPDTDX)16-1%EE^Q1B1VU-
W=~/H2F=10V:3BE1^2%_U7P2+17:&VIZ.X21B7^ZZ^Y12N0?14-O17OYGM31CN%_%C2G^@KHP63/_Y0_/_?HW2_M<1@G->M^B^H)HM>^M(1%<:J^SK))=ZC/HOY,\$\$B9.5_
161C^2^E^YVO-OB#Q1N%72^#6E76M-MZDNJYTH@M@&?RU20%CDG@&C1Z^A=V6Q14G1:9CBN1IG%>MB^=>27N:)^R/01_MY+AV/AZF^BW^1W:=V5YC_8+^~?BCX:~
OSMGXGT2ZTZN-4\$145VH#.GE^P_MP3QD8KZ>?7(T1_XE5MS&O.Q6)EC^1JU9R/3P>%C@Z\$*\$=)^YN_M?_#_MXC^/V@/%6LZ+X-U/41N+BIH:N15^2*(HP2.MY(("-OT/U#1X=
<1.W&E7-D.MV1Y:~+WVLA5A^1-L_2X8Y/KBG9ZBNK1YX5Q5.C2FD09JRM1OCCP>6TL4K_M58-OVCN1_A/S/RM18?LO?%GX(^+FO?#^FZ1PVIC.SV&O:~1H.@153N1L!
M1&O451%_L^@C1KWC558OB^GB^21&T11JUH88DF61>1J_1.5)^OL7^C1M2C2^6^XXKNO&=SQE1TJU+:E:W-U:PN141%B%5HU9^_100^?70?%)::#R#,MMQY:_NRC1DN=ZEKEG^
12A&1<:1^1C^O17=1CZ5)^1D>GZUX_XML_30_R1.htm-IDEA: XBRL-DOCUMENT

Document and Entity Information - USD (\$) 12 Months Ended

Jun. 30, 2024	
Aug. 22, 2024	
Dec. 31, 2021	
Document Document And Entity Information [Abstract] Document Type10-K Document Annual Reporttrue Document Transition Reportfalse Document Fiscal Year Focus 2024 Document Fiscal Period FocusFY Amendment Flagfalse Document Period End DateJun. 30, 2024 Entity File Number001-36587 Entity Incorporation, State or Country CodeDE Entity Tax Identification Number20-8737688 Entity Address, Address Line One14 Schoolhouse Road Entity Address, City or TownSomerset, Entity Address or ProvinceNJ Entity Address, Postal Zip Code08873 City Area Code(732) Local Phone Number537-6200 Trading SymbolCLTL Entity Registrant NameCATALENT, INC. Entity Central Index Key0001596783 Current Fiscal Year End Date-06-30 Entity Well-known Seasoned IssuerNo Entity Current Reporting StatusYes Entity Voluntary FilerNo Entity Filer CategoryLarge Accelerated Filer Entity Emerging Growth Companyfalse Entity Small Businessfalse Entity Shell Companyfalse Entity Common Stock, Shares Outstanding (Shares)181,463,702 Entity Interactive Data CurrentYes Security Exchange NameNYSE Title of 12(b) SecurityCommon Stock, \$0.01 par value per share ICFR Auditor Attestation Flagtrue Entity Public Float \$ 8,100,000,000	
XML 31-R2.htm IDEA: XBRL-DOCUMENT	
Audit Information	12 Months Ended Jun. 30, 2024
Auditor [Line Items]	
Auditor Name	Grant Thornton LLP
Auditor Location	New York, New York
Auditor Firm ID	248

XML 32-R3.htm IDEA: XBRL-DOCUMENT

Consolidated Statements of Operations - USD (\$)	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]			
Net revenue	\$ 4,381,000,000	\$ 4,263,000,000	\$ 4,802,000,000
Cost of sales	3,428,000,000	3,223,000,000	3,188,000,000
Gross margin	953,000,000	1,040,000,000	1,614,000,000
Selling, general, and administrative expenses	935,000,000	829,000,000	844,000,000
Disposal Asset, Not Discontinued Operation, Gain (Loss) on Disposal	0	0	(1,000,000)
Other Cost and Expense, Operating	80,000,000	164,000,000	41,000,000
Operating earnings	(749,000,000)	(163,000,000)	730,000,000
Interest expense, net	254,000,000	186,000,000	123,000,000
Other (Income)/expense, net	24,000,000	7,000,000	28,000,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(1,027,000,000)	(342,000,000)	579,000,000
Income tax expense	16,000,000	(86,000,000)	80,000,000
Net earnings attributable to Catalent	(1,043,000,000)	(256,000,000)	499,000,000
Participating Securities, Distributed and Undistributed (Earnings) Loss, Basic	0	0	(16,000,000)
Net Income (Loss) Available to Common Stockholders, Basic	\$ (1,043,000,000)	\$ (256,000,000)	\$ 483,000,000
Earnings Per Share, Basic	\$ (5.76)	\$ (1.42)	\$ 2.74
Earnings Per Share, Diluted	\$ (5.76)	\$ (1.42)	\$ 2.73
Goodwill, Impairment Loss	\$ 687,000,000	\$ 210,000,000	

XML 33-R4.htm IDEA: XBRL-DOCUMENT

Consolidated Statements of Comprehensive Income / (Loss) - USD (\$)	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
\$ in Millions			
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]			
Net earnings		\$ (1,043)	\$ 499
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(32)	32	(110)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax		(14)	9
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax		4	(3)
Other Comprehensive Income, Debt Securities, Derivative and Hedge, Gain (Loss), after Adjustment and Tax	22	18	27
Other comprehensive income / (loss), net of tax	(50)	40	(77)
Comprehensive income / (loss)	(1,093)	(216)	422
ACOI, Accumulated Gain (Loss), Marketable Securities			
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]			
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax	0	\$ 4	\$ (3)
Accumulated Defined Benefit Plans Adjustment [Member]			
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]			
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	\$ 4		

XML 34-R5.htm IDEA: XBRL-DOCUMENT

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]				
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax		0	\$ 4	\$ (3)
Accumulated Defined Benefit Plans Adjustment [Member]				
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]				
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax		\$ 4		
<i>XML 34 R5.htm IDEA: XBRL DOCUMENT</i>				
Consolidated Balance				
Sheets - USD (\$)		Jun. 30, 2024	Jun. 30, 2023	
Current assets:				
Cash and cash equivalents		\$ 289,000,000	\$ 280,000,000	
Trade receivables, net		921,000,000	1,002,000,000	
Inventories		574,000,000	777,000,000	
Prepaid Expense and Other Assets, Current		813,000,000	633,000,000	
Total current assets		2,597,000,000	2,692,000,000	
Property, plant, and equipment, net		3,643,000,000	3,682,000,000	
Other assets:				
Goodwill		2,333,000,000	3,039,000,000	

Other intangibles, net	841,000,000	980,000,000
Deferred Income Tax Assets, Net	7,000,000	55,000,000
Other Assets, Noncurrent	332,000,000	329,000,000
Total assets	9,753,000,000	10,777,000,000
Current liabilities:		
Debt, Current	48,000,000	536,000,000
Accounts payable	361,000,000	424,000,000
Other accrued liabilities	622,000,000	570,000,000
Total current liabilities	1,031,000,000	1,530,000,000
Long-term Debt and Finance Lease Obligations	4,857,000,000	4,313,000,000
Pension liability	95,000,000	100,000,000
Deferred Income Tax Liabilities, Net	5,000,000	76,000,000
Other liabilities	161,000,000	147,000,000
Total liabilities	6,149,000,000	6,166,000,000
Redeemable Preferred Stock Outstandings	\$ 0	\$ 0
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Value, Outstanding	\$ 2,000,000	\$ 2,000,000
Preferred Stock, Value, Outstanding	0	0
Additional paid in capital	4,787,000,000	4,701,000,000
Accumulated deficit	(781,000,000)	262,000,000
Accumulated Other Comprehensive Income (Loss), Net of Tax	(404,000,000)	(354,000,000)
Total shareholders' equity	3,604,000,000	4,611,000,000
Total liabilities, redeemable preferred stock, and shareholders' equity	\$ 9,753,000,000	\$ 10,777,000,000

~~XML 35 R6.htm IDEA- XBRL DOCUMENT~~

Consolidated Balance		
Sheets	Jun. 30, 2024	Jun. 30, 2023
(Parenthetical) - USD		
(\$)		

Statement of Financial Position [Abstract]

Common stock, par value (usd per share)	\$ 0.01	\$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common stock, shares issued (shares)	181,000,000	180,000,000
Preferred Stock, Par or Stated Value Per Share	\$ 0.01	\$ 0.01
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued & Outstanding	0	0
Temporary Equity, Par or Stated Value Per Share	\$ 0.01	
Temporary Equity, Shares Authorized	0	
Temporary Equity, Shares Issued	0	
Preferred Stock, Shares Issued	0	0
Accounts Receivable, Allowance for Credit Loss, Current	\$ 23,000,000	\$ 46,000,000
Temporary Equity, Shares Outstanding	0	

~~XML 36 R7.htm IDEA- XBRL DOCUMENT~~

Consolidated Statement of Changes in Shareholder's Equity - USD (\$)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit	Accumulated Other Comprehensive (Loss)/Income [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]					
Redeemable Preferred Stock Outstandings	\$ 359,000,000				
Common Stock, Shares, Outstanding		170,549,000			
Beginning Balance at Jun. 30, 2021	3,915,000,000	\$ 2,000,000	\$ 4,205,000,000	\$ 25,000,000	\$ (317,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]					
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		935,000			
Stock Issued During Period, Value, Stock Options Exercised	0	\$ 0			
Stock Issued During Period, Value, Conversion of Convertible Securities	362,000,000		362,000,000		
Equity compensation	54,000,000		54,000,000		
Payments Related to Tax Withholding for Share-based Compensation	(10,000,000)		(10,000,000)		
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition	26,000,000		26,000,000		
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	12,000,000		12,000,000		
Dividends, Preferred Stock	(6,000,000)			(6,000,000)	
Net Income (Loss) Attributable to Parent	499,000,000			499,000,000	
Other comprehensive income /(loss), net of tax	(77,000,000)				(77,000,000)
Ending Balance at Jun. 30, 2022	4,775,000,000	\$ 2,000,000	4,649,000,000	518,000,000	(394,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]					
Temporary Equity, Carrying Amount, Period Increase (Decrease)	(359,000,000)				
Stock Issued During Period, Shares, Conversion of Convertible Securities		7,818,000			
Redeemable Preferred Stock Outstandings	0				
Common Stock, Shares, Outstanding		179,302,000			
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		971,000			
Stock Issued During Period, Value, Stock Options Exercised	0				
Equity compensation	35,000,000		35,000,000		
Payments Related to Tax Withholding for Share-based Compensation	0				
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition	4,000,000				
Equity issued in lieu of cash consideration	(13,000,000)				
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition			13,000,000		
Net Income (Loss) Attributable to Parent	(256,000,000)			(256,000,000)	
Other comprehensive income /(loss), net of tax	40,000,000				40,000,000
Ending Balance at Jun. 30, 2023	4,611,000,000	\$ 2,000,000	4,701,000,000	262,000,000	(354,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]					
Other Comprehensive Income, Other, Net of Tax	40,000,000				
Proceeds from Tax Withholding Obligations			4,000,000		
Redeemable Preferred Stock Outstandings	0				
Common Stock, Shares, Outstanding		180,273,000			
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		725,000			
Equity compensation	68,000,000		68,000,000		
Payments Related to Tax Withholding for Share-based Compensation	0				
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition	9,000,000				
Equity issued in lieu of cash consideration	(9,000,000)				
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition			9,000,000		
Net Income (Loss) Attributable to Parent	(1,043,000,000)			(1,043,000,000)	
Other comprehensive income /(loss), net of tax	(50,000,000)				(50,000,000)

Ending Balance at Jun. 30, 2024	3,604,000,000	\$ 2,000,000	4,787,000,000	\$ (781,000,000)	\$ (404,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]					
Other Comprehensive Income, Other, Net of Tax	(50,000,000)				
Proceeds from Tax Withholding Obligations			\$ 9,000,000		
Redeemable Preferred Stock Outstandings	\$ 0				
Common Stock, Shares, Outstanding		180,998,000			
~~XML 37 R8.htm IDEA: XBRL DOCUMENT~~					
Consolidated Statement of Changes in Shareholder's Equity - Shares of Common Stock			Common Stock [Member] shares		
Beginning Balance - Common Stock Outstanding (shares) at Jun. 30, 2021			170,549,000		
Increase (Decrease) in Stockholders' Equity [Roll Forward]					
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			935,000		
Stock Issued During Period, Shares, Conversion of Convertible Securities			7,818,000		
Ending Balance - Common Stock Outstanding (shares) at Jun. 30, 2022			179,302,000		
Increase (Decrease) in Stockholders' Equity [Roll Forward]					
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			971,000		
Ending Balance - Common Stock Outstanding (shares) at Jun. 30, 2023			180,273,000		
Increase (Decrease) in Stockholders' Equity [Roll Forward]					
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			725,000		
Ending Balance - Common Stock Outstanding (shares) at Jun. 30, 2024			180,998,000		
~~XML 38 R9.htm IDEA: XBRL DOCUMENT~~					
Consolidated Statements of Cash Flows - USD (\$)				12 Months Ended	
			Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
					Jun. 30, 2021
CASH FLOWS FROM INVESTING ACTIVITIES:					
Proceeds from Sale and Maturity of Marketable Securities			\$ 0		
Payments to Acquire Debt Securities, Available-for-sale				\$ 89,000,000	\$ 20,000,000
Proceeds from sale of property and equipment			1,000,000	8,000,000	0
Settlement on from sale of subsidiaries			0		
Proceeds from Divestiture of Interest in Consolidated Subsidiaries				0	(3,000,000)
Payment for acquisitions, net of cash acquired			0	(474,000,000)	(1,199,000,000)
Payments to Acquire Investments			1,000,000	2,000,000	2,000,000
Segment, Expenditure, Addition to Long-Lived Assets			(327,000,000)	(576,000,000)	(660,000,000)
Net cash (used in) investing activities			(327,000,000)	(955,000,000)	(1,884,000,000)
CASH FLOWS FROM FINANCING ACTIVITIES:					
Proceeds from borrowing, net			1,200,000,000	715,000,000	1,100,000,000
Repayments of Long-term Debt			(1,116,000,000)	(230,000,000)	(78,000,000)
Payments of Debt Issuance Costs			(16,000,000)	(4,000,000)	(15,000,000)
Payments of Ordinary Dividends			0	0	4,000,000
Proceeds from Stock Options Exercised			9,000,000	4,000,000	26,000,000
Payments Related to Tax Withholding for Share-based Compensation			0	0	(10,000,000)
Proceeds from (Payments for) Other Financing Activities			(3,000,000)	36,000,000	12,000,000
Net cash provided by/(used in) financing activities			74,000,000	521,000,000	1,031,000,000
CASH FLOWS FROM OPERATING ACTIVITIES:					
Net earnings			(1,043,000,000)	(256,000,000)	499,000,000
Adjustments to reconcile earnings from continued operations to net cash from operations:					
Depreciation and Amortization			489,000,000	422,000,000	378,000,000
Goodwill, Impairment Loss			687,000,000	210,000,000	
Foreign Currency Transaction Gain (Loss), before Tax			13,000,000	(9,000,000)	30,000,000
Amortization and write-off of debt financing costs			14,000,000	8,000,000	7,000,000
Gain (Loss) on Sale of Assets and Asset Impairment Charges			(29,000,000)	(98,000,000)	(31,000,000)
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal			0	0	(1,000,000)
Derivative, Gain (Loss) on Derivative, Net				(2,000,000)	
Equity compensation			68,000,000	35,000,000	54,000,000
Provision/(benefit) for deferred income taxes			(28,000,000)	(127,000,000)	9,000,000
Provision for bad debts and inventory			82,000,000	143,000,000	17,000,000
Change in operating assets and liabilities:					
(Increase)/decrease in trade receivables			79,000,000	53,000,000	(73,000,000)
(Increase)/decrease in inventories			109,000,000	(192,000,000)	(128,000,000)
Increase/(decrease) in accounts payable			(84,000,000)	(21,000,000)	37,000,000
Other assets/accrued liabilities, net - current and non-current			(166,000,000)	(128,000,000)	(423,000,000)
Net Cash Provided by (Used in) Operating Activities, Total			268,000,000	254,000,000	439,000,000
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations			(6,000,000)	11,000,000	(33,000,000)
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents			289,000,000	280,000,000	449,000,000
					\$ 896,000,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect			9,000,000	(169,000,000)	(447,000,000)
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD			280,000,000		
CASH AND EQUIVALENTS AT END OF PERIOD			289,000,000	280,000,000	
SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING ACTIVITY:					
Stock Issued During Period, Value, Conversion of Convertible Securities			0	0	362,000,000
SUPPLEMENTARY CASH FLOW INFORMATION:					
Interest paid			226,000,000	188,000,000	116,000,000
Income taxes paid, net			43,000,000	99,000,000	53,000,000
Capital Expenditures Incurred but Not yet Paid			24,000,000	18,000,000	6,000,000
Restructuring Reserve, Settled without Cash			7,000,000	\$ 18,000,000	\$ 0
Debtor Reorganization Items, Pension and Other Postretirement Related Charges			12,000,000		
Other Operating Activities, Cash Flow Statement			\$ 1,000,000		
~~XML 39 R10.htm IDEA: XBRL DOCUMENT~~					
Basis of Presentation and Summary of Significant Accounting Policies			12 Months Ended		
			Jun. 30, 2024		
Accounting Policies [Abstract]					
Basis of Presentation and Summary of Significant Accounting Policies	Business				
Catalent, Inc. (“Catalent” or the “Company”) directly and wholly owns PTS Intermediate Holdings LLC (“PTS Intermediate”). PTS Intermediate directly and wholly owns Catalent Pharma Solutions, Inc. (“Operating Company”). The financial results of Catalent are primarily comprised of the financial results of Operating Company and its subsidiaries on a consolidated basis.					
The Company’s common stock, par value \$0.01 (the “Common Stock”) trades on the New York Stock Exchange under the symbol “CTLT”. The Company provides differentiated development and manufacturing solutions for drugs, protein-based biologics, cell, and gene therapies, vaccines, and consumer health products at over fifty facilities across four continents under rigorous quality and operational standards. Its oral, injectable, and respiratory delivery technologies, along with its state-of-the-art protein, plasmid, viral, and cell and gene therapy manufacturing capacity address a wide and growing range of modalities and therapeutic and other categories across the biopharmaceutical, pharmaceutical, and consumer health industries.					
~~XML 40 R11.htm IDEA: XBRL DOCUMENT~~					
Revenue Recognition			12 Months Ended		
			Jun. 30, 2024		
Revenue Recognition					

REVENUE RECOGNITION

The Company recognizes revenue in accordance with ASC 606, *Revenue from Contracts with Customers*. The Company generally earns its revenue by supplying goods or providing services under contracts with its customers in three primary revenue streams: manufacturing and commercial product supply, development services, and clinical supply services. The Company measures the revenue from customers based on the consideration specified in its contracts, excluding any sales incentive or amount collected on behalf of a third party, that the Company expects to be entitled to receive in exchange for transferring the promised goods to and/or performing services for the customer (the “Transaction Price”). To the extent the Transaction Price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the Transaction Price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the Transaction Price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment.

The Company’s customer contracts generally include provisions entitling the Company to a termination penalty when the customer terminates prior to the contract’s nominal end date. The termination penalties in customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated durations of the contracts. The Company accounts for a contract termination as a contract modification in the period in which the customer gives notice of termination. The determination of the contract termination penalty is based on the terms stated in the relevant customer agreement. As of the modification date, the Company updates its estimate of the Transaction Price using the expected value method, subject to constraints, and to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment.

Where multiple performance obligations exist in a single contract, the Company allocates consideration to each performance obligation using the “relative standalone selling price” as defined under ASC 606. Generally, the Company utilizes observable standalone selling prices in its allocations of consideration. If observable standalone selling prices are not available, the Company estimates the applicable standalone selling price using a cost-plus-margin approach or an adjusted market assessment approach, in each case, representing the amount that the Company believes the market is willing to pay for the applicable service. Payment is typically due 30 to 45 days following the invoice date, based on the payment terms set forth in the applicable customer agreement.

The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material.

Customer contracts that include commitments by the Company to make facility space or equipment available may be deemed to include lease components, which are evaluated under ASC 842, *Leases*. For arrangements that contain both lease and non-lease components, consideration in the contract is allocated on a relative standalone selling-price basis. Determining the lease term and contract term of non-lease components, as well as the variable and fixed consideration in these arrangements, including when variability is resolved, often requires management judgment in order to determine the allocation to the lease and non-lease components.

Manufacturing & Commercial Product Supply Revenue

Manufacturing and commercial product supply revenue consists of revenue earned by manufacturing products supplied to customers under long-term commercial supply arrangements. In these arrangements, the customer typically owns and supplies the active pharmaceutical ingredient (“API”) or other proprietary materials used in the manufacturing process. The contract generally includes the terms of the manufacturing services and related product quality assurance procedures to comply with regulatory requirements. Due to the regulated nature of the Company’s business, these contract terms are highly interdependent and, therefore, are considered to be a single combined performance obligation. The transaction price is generally stated in the agreement as a fixed price per unit, with no contractual provision for a refund or price concession. In most circumstances, control is transferred to the customer over time, creating a corresponding right to recognize the related revenue, because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date. The selection of the method for measuring progress towards the completion of the Company’s performance obligation requires judgment and is based on the nature of the products to be manufactured. For the majority of the Company’s arrangements, progress is measured based on the units of product that have successfully completed the contractually required product quality assurance process, because the conclusion of that process defines the time when the applicable contract and the related regulatory requirements permit the customer to exercise control over the product’s

disposition. The customer is typically responsible for arranging the shipping and handling of product following completion of the quality assurance process. Payment is typically due 30 to 45 days after invoice date, based on the payment terms set forth in the applicable customer agreement.

Beginning in the third quarter of fiscal 2023, the Company began recognizing commercial revenue for certain contracts in its Biologics segment that have a notably long manufacturing cycle, and for which the customer exercises control over the product throughout the manufacturing process. For these contracts, revenue is recognized over time and progress is measured using an input method based on effort expended, which provides an appropriate depiction of the Company’s progress toward fulfilling its performance obligation.

Development Services and Clinical Supply Revenue

Development services contracts generally take the form of short-term, fee-for-service arrangements. Performance obligations vary, but frequently include biologic cell-line development, performing formulation, analytical stability, or other services related to product development, and providing manufacturing services for products that are under development or otherwise not intended for commercial sale. They can also include a combination of the following services: the manufacturing, packaging, storage, distribution, destruction, and inventory management of customer clinical trial material, as well as the sourcing of comparator drug products on behalf of customers to be used in clinical trials to compare performance with the drug under clinical investigation. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service, and each service is generally considered to be a separate performance obligation. In most instances, the Company recognizes revenue over time because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date.

The Company measures progress toward the completion of its performance obligations satisfied over time based on the nature of the services to be performed. For certain types of arrangements, revenue is recognized over time and measured using an output method based on the completion of tasks and activities that are performed to satisfy a performance obligation. For certain types of arrangements, revenue is recognized over time and measured using an input method based on effort expended. Each of these methods provides an appropriate depiction of the Company’s progress toward fulfilling its performance obligations for its respective arrangement. In certain arrangements that require a portion of the contract consideration to be received in advance at the commencement of the contract, such advance payment is initially recorded as a contract liability. In certain clinical supply arrangements, revenue is recognized at the point in time when control transfers, which occurs upon either the delivery of the related output of the service to the customer or the completion of quality testing with respect to the product, and the Company has an enforceable right to payment based on the terms of the arrangement.

The Company records revenue for comparator sourcing arrangements on a net basis because it is acting as an agent that does not control the product or service before it is transferred to the customer. Payment for comparator sourcing activity is typically received in advance at the commencement of the contract and is initially recorded as a contract liability.

The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material.

The following tables reflect net revenue for the fiscal years ended June 30, 2024, 2023, and 2022 by type of activity and reporting segment (in millions):

Fiscal Year Ended June 30, 2024		Biologics		Pharma and Consumer Health		Total	
Manufacturing & commercial product supply		\$	1,151	\$	1,577	\$	2,728
Development services & clinical supply			801		854		1,655
Total		\$	1,952	\$	2,431	\$	4,383
Inter-segment revenue elimination							(2)
Combined net revenue						\$	4,381
Fiscal Year Ended June 30, 2023		Biologics		Pharma and Consumer Health		Total	
Manufacturing & commercial product supply		\$	450	\$	1,452	\$	1,902
Development services & clinical supply			1,528		835		2,363
Total		\$	1,978	\$	2,287	\$	4,265
Inter-segment revenue elimination							(2)
Combined net revenue						\$	4,263
Fiscal Year Ended June 30, 2022		Biologics		Pharma and Consumer Health		Total	
Manufacturing & commercial product supply		\$	608	\$	1,474	\$	2,082
Development services & clinical supply			1,926		797		2,723
Total		\$	2,534	\$	2,271	\$	4,805
Inter-segment revenue elimination							(3)
Combined net revenue						\$	4,802

The following table reflects net revenue by the location where the goods were made or the service performed:

(Dollars in millions)	Fiscal Year Ended June 30, 2024		Fiscal Year Ended June 30, 2023		Fiscal Year Ended June 30, 2022	
United States	\$	2,823	\$	2,768	\$	3,084
Europe		1,359		1,257		1,506
Other		356		355		327
Elimination of revenue attributable to multiple locations		(157)		(117)		(115)
Total	\$	4,381	\$	4,263	\$	4,802

Contract Liabilities

Contract liabilities relate to cash consideration that the Company receives in advance of satisfying the related performance obligations. The contract liabilities balances (current and non-current) as of June 30, 2024 and June 30, 2023 were as follows:

(Dollars in millions)	
Balance at June 30, 2023	\$ 180
Balance at June 30, 2024	\$ 255
Revenue recognized in the period from amounts included in contracts liability at the beginning of the period:	\$ (145)

Contract liabilities that will be recognized within 12 months of June 30, 2024 are accounted for in Other accrued liabilities and those that will be recognized longer than 12 months after June 30, 2024 are accounted for within Other liabilities.

Contract Assets

Contract assets primarily relate to the Company’s conditional right to receive consideration for services that have been performed for customers but had not yet been invoiced as of June 30, 2024. Contract assets are transferred to trade receivables, net when the Company’s right to receive the consideration becomes unconditional. Contract assets totaled \$602 million and \$417 million as of June 30, 2024 and 2023, respectively. Contract assets expected to transfer to trade receivables within 12 months are accounted for within Prepaid expenses and other. Contract assets expected to transfer to trade receivables after 12 months are accounted for within Other long-term assets.

Performance Obligations

Remaining performance obligations represent firm orders for future development services as well as manufacturing and commercial product supply, including minimum volume commitments, for which there are incomplete performance obligations for work not yet completed under executed contracts. Remaining performance obligations as of June 30, 2024 and June 30, 2023 were \$618 million and \$335 million, respectively. The Company expects to recognize approximately 50% of the remaining performance obligations in existence as of June 30, 2024 after June 30, 2025.

RheinCell Therapeutics GmbH Acquisition

In August 2021, the Company acquired 100% of the equity interest in RheinCell Therapeutics GmbH ("RheinCell") for \$26 million, net of cash acquired. RheinCell was a developer and manufacturer of clinical- and cGMP-grade iPSCs based in Lagenfeld, Germany. The operations became part of the Company's Biologics segment and built on its existing custom cell therapy process development and manufacturing capabilities with proprietary cGMP cell lines for iPSC-based therapies.

The Company accounted for the RheinCell transaction using the acquisition method in accordance with ASC 805, *Business Combinations*. The Company funded the entire purchase price with cash on hand and allocated the purchase price among the assets acquired, recognizing \$4 million of current liabilities, \$1 million of other liabilities, \$14 million of intangible assets, and goodwill of \$17 million. Results of this business were not material to the Company's statement of operations, financial position, or cash flows for the fiscal years ended June 30, 2023 and 2022.

Bettera Holdings, LLC Acquisition

In October 2021, the Company acquired 100% of the equity interest in Bettera Holdings, LLC ("Bettera Wellness") for \$1.00 billion cash. Bettera Wellness was a manufacturer of nutraceuticals and nutritional supplements in gummy, soft chew, and lozenge delivery formats and became part of the Company's Pharma and Consumer Health segment.

The Company accounted for the Bettera Wellness transaction using the acquisition method in accordance with ASC 805, *Business Combinations*. The Company estimated fair values at the date of acquisition for the allocation of consideration to the net tangible and intangible assets acquired and liabilities assumed and allocated the purchase price among the assets acquired, recognizing \$361 million of other intangibles, net, \$72 million of property, plant, and equipment, \$23 million of inventories, \$23 million of cash and cash equivalents, \$16 million of trade receivables, \$17 million of net other liabilities, and goodwill of \$531 million. Results of this business were not material to the Company's statement of operations, financial position, or cash flows for the fiscal years ended June 30, 2023 and 2022.

The carrying value of trade receivables, inventory, and trade payables, as well as certain other current and non-current assets and liabilities, generally represented the fair value at the date of acquisition.

Property, plant, and equipment assets were valued using the cost approach, which is based on current replacement and/or reproduction cost of the related asset as new, less depreciation attributable to physical, functional, and economic factors. The Company then determined the remaining useful life based on the anticipated life of the asset and Company policy for similar assets.

Core technology intangible assets of \$338 million were valued using the multi-period, excess-earnings method, a method that values the intangible asset using the present value of the after-tax cash flows attributable to the intangible asset only. The significant assumptions used in developing the valuation included the estimated annual net cash flows (including application of an appropriate margin to forecasted revenue, revenue obsolescence rate, selling and marketing costs, return on working capital, contributory asset charges, and other factors), the discount rate that appropriately reflects the risk inherent in each future cash flow stream, and an assessment of the asset's life cycle, as well as other factors. The assumptions used in the financial forecasts were based on historical data, supplemented by current and anticipated growth rates, management plans, and market-comparable information. Fair-value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors. The core technology intangible asset has a weighted average useful life of 10 years.

Goodwill has been allocated to the Pharma and Consumer Health segment as shown in Note 4, *Goodwill*. Goodwill is mainly comprised of growth from expected increases in capacity utilization and new customers. The goodwill resulting from the Bettera Wellness acquisition is deductible for tax purposes.

Vaccine Manufacturing and Innovation Centre UK Limited Asset Acquisition

In April 2022, the Company, through its wholly owned subsidiary, Catalent Oxford Limited, acquired a development and manufacturing facility near Oxford, United Kingdom ("U.K.") and certain related assets and liabilities from The Vaccine Manufacturing and Innovation Centre UK Limited for \$134 million in cash, including \$9 million of closing costs. The facility and related assets and liabilities became part of the Company's Biologics segment.

The Company accounted for this transaction as an acquisition of assets in accordance with ASC 805, *Business Combinations*. The Company funded this acquisition with cash on hand and allocated the purchase price among the net assets acquired, recognizing \$1 million of current assets, \$165 million of property, plant, and equipment, \$18 million of current liabilities, and \$14 million of other liabilities. Results of this business were not material to the Company's statement of operations, financial position, or cash flows for the fiscal years ended June 30, 2023 and 2022.

Princeton Cell Therapy Development and Manufacturing Acquisition

In April 2022, the Company acquired a cell therapy commercial manufacturing facility and operations near Princeton, New Jersey ("Princeton") from Erytech Pharma S.A. ("Erytech") for \$45 million in cash, subject to customary adjustments. In connection with the purchase, Erytech and the Company entered into a long-term supply agreement, under which the Company agreed to continue to manufacture and package an Erytech product at the Princeton facility. The operations and facility acquired became part of the Company's Biologics segment.

The Company accounted for this transaction using the acquisition method in accordance with ASC 805, *Business Combinations*. The Company funded this acquisition with cash on hand and allocated the purchase price among the assets acquired, recognizing \$22 million of property, plant, and equipment, \$10 million of other assets, \$1 million of current liabilities, \$10 million of other liabilities, and goodwill of \$24 million. Results of this business were not material to the Company's statement of operations, financial position, or cash flows for the fiscal years ended June 30, 2023 and 2022.

Metrics Contract Services Acquisition

In October 2022, the Company acquired 100% of Metrics Contract Services ("Metrics") from Mayne Pharma Group Limited for \$474 million in cash. Metrics, based in Greenville, North Carolina, was an oral solids development and manufacturing business specializing in the manufacture of drugs containing highly potent active pharmaceutical ingredients. The operations and facility acquired became part of the Company's Pharma and Consumer Health segment.

The Company accounted for the Metrics transaction using the acquisition method in accordance with ASC 805, *Business Combinations*. The Company funded this acquisition with a portion of the proceeds of an October 2022 drawdown from its senior secured revolving credit facility. The Company estimated fair values at the date of acquisition for the allocation of consideration to the net tangible and intangible assets acquired and liabilities assumed.

The purchase price was allocated to assets acquired and liabilities assumed in the acquisition as follows:

(Dollars in millions)	Purchase Price Allocation
Trade receivables, net	15
Inventories	5
Property, plant, and equipment	195
Other intangibles, net	52
Other, net	(12)
Goodwill	219
Total assets acquired and liabilities assumed	\$ 474

The carrying value of trade receivables, inventory, and trade payables, as well as certain other current and non-current assets and liabilities generally represented the fair value at the date of acquisition.

Other intangibles, net consists of customer relationships of \$52 million, which were valued using the multi-period, excess-earnings method, a method that values the intangible asset using the present value of the after-tax cash flows attributable to the intangible asset only. The significant assumptions used in developing the valuation included the estimated annual net cash flows (including application of an appropriate margin to forecasted revenue, selling and marketing costs, return on working capital, contributory asset charges, and other factors), the discount rate that appropriately reflects the risk inherent in each future cash flow stream, and an assessment of the asset's life cycle, as well as other factors. The assumptions used in the financial forecasts were based on historical data, supplemented by current and anticipated growth rates, management plans, and market-comparable information. Fair-value determinations require judgment and are sensitive to changes in underlying assumptions and factors. The customer relationship intangible asset has a weighted average useful life of 12 years.

Property, plant, and equipment was valued using the cost approach, which is based on current replacement and/or reproduction cost of the asset as new, less depreciation attributable to physical, functional, and economic factors. The Company then determined the remaining useful life based on the anticipated life of the asset and Company policy for similar assets.

Goodwill has been allocated to the Pharma and Consumer Health segment as shown in Note 4, *Goodwill*. Goodwill is mainly comprised of the growth from an expected increase in capacity utilization and potential new customers. The goodwill resulting from the Metrics acquisition is not deductible for U.S. income tax purposes.

Results of the business acquired were not material to the Company's consolidated statement of operations, financial position, or cash flows for the fiscal year ended June 30, 2023.

Blow-Fill-Seal Divestiture

In March 2021, the Company sold 100% of the shares of Catalent USA Woodstock, Inc. and certain related assets (collectively, the "Blow-Fill-Seal Business") for \$331 million in total consideration (\$300 million in cash). The Blow-Fill-Seal Business was part of the Pharma and Consumer Health segment.

The carrying value of the net assets sold was \$149 million, which included goodwill of \$54 million. As a result of the sale, the Company realized a gain from divestiture of \$182 million, net of transaction costs, for the fiscal year ended June 30, 2021.

During the fiscal year ended June 30, 2022, the Company settled a post-closing purchase price adjustment, which resulted in a gain on sale of subsidiary of \$1 million.

All consideration received was measured at its divestiture date fair value. The Company valued the total consideration received from divestiture of the Blow-Fill-Seal Business as follows:

(Dollars in millions)	Fair value of consideration received
Cash, gross	\$ 300
Note receivable ⁽¹⁾	47
Contingent consideration ⁽²⁾	—
Other ⁽³⁾	(16)
Total	\$ 331

(1) The note receivable, which provides for interest at a rate of 5.0% paid in kind, had an estimated fair value of \$47 million and \$51 million at June 30, 2021 and June 30, 2022, respectively. The fair value at divestiture date consisted of a \$50 million aggregate principal amount less a \$3 million discount determined using a discounted cash flow model.

(2) The Company determined that the estimated fair value of the contingent consideration from the sale of the Blow-Fill-Seal Business at June 30, 2022 was zero, and therefore no contingent consideration was recorded at divestiture. If any contingent consideration is subsequently received, it will be recorded in the period in which it is received. The Company has elected an accounting policy to recognize increases in the carrying amount of the contingent consideration asset using the gain contingency guidance in ASC 450, *Contingencies*.

(3) Other includes \$8 million of transaction expenses, a working capital adjustment of \$6 million, and a \$2 million assumption of liabilities, resulting in net cash proceeds of \$284 million.

The following table summarizes the changes from June 30, 2022 to June 30, 2024 in the carrying amount of goodwill in total and by reportable segment:

(Dollars in millions)	Biologics	Pharma and Consumer Health	Total
Balance at June 30, 2022	\$ 1,566	\$ 1,440	\$ 3,006
Additions	—	219	219
Reallocation ⁽¹⁾	(15)	15	—
Foreign currency translation adjustments	12	12	24
Impairment	—	(210)	(210)
Balance at June 30, 2023	1,563	1,476	3,039
Foreign currency translation adjustments	(8)	(11)	(19)
Impairment ⁽²⁾	(392)	(295)	(687)
Balance at June 30, 2024	\$ 1,163	\$ 1,170	\$ 2,333

(1) The addition to goodwill is a result of the Metrics acquisition. For further details, see Note 3, *Business Combinations and Divestitures*.

(2) Accumulated goodwill impairment charges amount to \$897 million as of June 30, 2024.

As part of the business reorganization discussed in Note 1, *Basis of Presentation and Summary of Significant Accounting Policies*, the goodwill from the previous Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services segments was reallocated between the current Biologics and Pharma and Consumer Health segments.

~~XML 43 R14.htm IDEA: XBRL DOCUMENT~~

Definite Lived Long-Lived Assets

12 Months Ended
Jun. 30, 2024

[Finite lived intangible assets disclosure \[Abstract\]](#)

[Definite Lived Long-Lived Assets](#)

OTHER INTANGIBLES, NET

The details of other intangible assets subject to amortization as of June 30, 2024 and June 30, 2023 are as follows (in millions):

June 30, 2024	Weighted Average Life	Gross Carrying Value	Accumulated Amortization	Net Carrying Value
Amortized intangibles:				
Core technology	11 years	\$ 480	\$ (205)	\$ 275
Customer relationships	13 years	1,076	(531)	545
Product relationships	8 years	242	(223)	19
Other	6 years	20	(18)	2
Total other intangibles		\$ 1,818	\$ (977)	\$ 841

June 30, 2023	Weighted Average Life	Gross Carrying Value	Accumulated Amortization	Net Carrying Value
Amortized intangibles:				
Core technology	11 years	\$ 482	\$ (164)	\$ 318
Customer relationships	13 years	1,079	(451)	628
Product relationships	8 years	243	(216)	27
Other	5 years	24	(17)	7
Total other intangibles		\$ 1,828	\$ (848)	\$ 980

Amortization expense was \$135 million, \$136 million, and \$123 million for the fiscal years ended June 30, 2024, 2023, and 2022, respectively. Future amortization expense is estimated to be:

(Dollars in millions)	2025	2026	2027	2028	2029	Thereafter	Total
Amortization	\$ 133	\$ 125	\$ 109	\$ 102	\$ 98	\$ 274	\$ 841

~~XML 44 R15.htm IDEA: XBRL DOCUMENT~~

Restructuring and Other Costs

12 Months Ended
Jun. 30, 2024

[Restructuring and Related Activities \[Abstract\]](#)

[Restructuring and Other Costs](#)

RESTRUCTURING COSTS

From time to time, the Company implements plans to restructure certain operations, both domestically and internationally. The restructuring plans focus on various aspects of operations, including, among others, closing and consolidating certain manufacturing operations, rationalizing headcount and aligning operations in a strategic and more cost-efficient structure. In addition, the Company may incur restructuring charges in the future in cases where a material change in the scope of operation with its business occurs. Employee-related restructuring costs consist primarily of severance costs and also include outplacement services provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods. Facility exit and other such restructuring costs consist of equipment relocation costs and costs associated with planned facility expansions and closures to streamline Company operations.

During the fiscal year ended June 30, 2023, the Company adopted plans to reduce costs, consolidate facilities, and optimize its infrastructure across the organization. During the fiscal year ended June 30, 2024, the Company extended its restructuring efforts to reduce costs and headcount in its Biologics and Pharma and Consumer Health segments and corporate functions.

In October 2023, and in connection with the Company's restructuring plans, the Company committed to a plan to close operations at its San Francisco facility and to transfer those operations to other sites within its network. Results for San Francisco site closure are reflected in the tables below under the Pharma and Consumer Health segment.

In connection with these restructuring plans, the Company reduced its headcount by approximately 700 employees and incurred cumulative employee-related charges of \$26 million, primarily associated with cash severance programs through June 30, 2024.

Restructuring costs for the fiscal years ended June 30, 2024, 2023, and 2022 were recorded in Other operating expense in the consolidated statement of operations.

The following tables summarize the restructuring costs by type of cost and reportable segment:

(Dollars in millions)	Fiscal Year Ended June 30,		
Restructuring costs:	2024	2023	2022
Employee-related reorganization	\$ 26	\$ 38	\$ 9
Facility exit and other costs	13	28	1
Total restructuring costs	\$ 39	\$ 66	\$ 10

The following table summarizes the charges recorded within restructuring costs by segment. These amounts are excluded from Segment EBITDA as described in Note 18, *Segment Information*.

(Dollars in millions)	Fiscal Year Ended June 30,		
Restructuring costs:	2024	2023	2022
Biologics	\$ 11	\$ 41	\$ 1
Pharma and Consumer Health	19	8	5
Non-segment (Corporate)	9	17	4
Total restructuring costs	\$ 39	\$ 66	\$ 10

The following tables illustrates the change in the employee separation-related liability associated with the plans.

[Restructuring, Incurred Cost, Statement of Income or Comprehensive Income \[Extensible Enumeration\]](#)

Selling, general, and administrative expenses

~~XML 45 R16.htm IDEA: XBRL DOCUMENT~~

Derivative Instruments and Hedging Activities

12 Months Ended
Jun. 30, 2024

[Derivative Instruments and Hedging Activities Disclosure \[Abstract\]](#)

[Derivative Instruments and Hedging Activities](#)

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

Risk Management Objective of Using Derivatives

The Company is exposed to fluctuations in the currency exchange rates applicable to its investments in foreign operations. While the Company does not actively hedge against changes in foreign currency, the Company has mitigated the exposure arising from its investments in its European operations by denominating a portion of its Senior Notes in euros, the functional currency of such European operations. At June 30, 2024, the Company had euro-denominated debt outstanding of \$883 million (U.S. dollar equivalent), which qualifies as a hedge of a net investment in foreign operations. For non-derivatives designated and qualifying as net investment hedges, the effective portion of the translation gains or losses are reported in accumulated other comprehensive income (loss) as part of the cumulative translation adjustment. The unhedged portions of the translation gains or losses are reported in the consolidated statements of operations. The following table includes net investment hedge activity during the fiscal years ended June 30, 2024 and 2023, respectively:

(Dollars in millions)	June 30, 2024	June 30, 2023
Unrealized foreign exchange gain (loss) within other comprehensive income	\$ 21	\$ (30)

The net accumulated gain of this net investment hedge within accumulated other comprehensive loss was \$119 million as of June 30, 2024. Amounts are reclassified out of accumulated other comprehensive loss into earnings when the entity in which the gains and losses reside is either sold or substantially liquidated.

Interest-Rate Swap

In February 2021, the Company entered into a new interest-rate swap agreement with Bank of America N.A. (the "2021 Rate Swap") that acted as a hedge against the economic effect of a portion of the variable-interest obligation associated with the Company's U.S. dollar-denominated term loans under its senior secured credit facilities. The 2021 Rate Swap effectively fixed the rate of interest payable on that portion of the term loans, thereby reducing the impact of future interest rate changes on future interest expense. As a result of the 2021 Rate Swap, the variable portion of the applicable interest rate on \$500 million of the U.S. dollar-denominated term loans was effectively fixed at 0.9985%.

To conform with the adoption of Topic 848, *Reference Rate Reform* and the Eighth Amendment, the Company amended the 2021 Rate Swap in June 2023 (the “2023 Rate Swap”). The 2023 Rate Swap continues to effectively fix the rate of interest payable on the same portion of our U.S. dollar-denominated term loans under our senior secured credit facilities. As a result of the 2023 Rate Swap, the variable portion of the applicable interest rate on \$500 million of the U.S. dollar-denominated term loans is now effectively fixed at 0.9431%. The net amount of deferred losses on cash flow hedges that is expected to be reclassified from accumulated other comprehensive loss into interest expense, net within the next twelve months is not material.

The 2023 Rate Swap continues to qualify for a cash-flow hedge. The Company evaluates hedge effectiveness at the inception of the hedge and on an ongoing basis. The cash flows associated with the 2023 Rate Swap amendment is reported in cash provided by operating activities in the consolidated statements of cash flows. The unrealized loss recorded in stockholder’s equity from marking the 2023 Rate Swap to market during the fiscal year ended June 30, 2024 was \$26 million.

A summary of the estimated fair value of the interest-rate swap reported in the consolidated balance sheets is stated in the table below:

(in millions)	June 30, 2024		June 30, 2023	
	Balance Sheet Classification	Estimated Fair Value	Balance Sheet Classification	Estimated Fair Value
Interest-rate swap	Other long-term assets	\$ 36	Other long-term assets	\$ 62

~~XML 46 R17.htm IDEA: XBRL DOCUMENT~~

Fair Value Measures
and Disclosures

[Fair Value
Disclosures
\[Abstract\]](#)

[Fair Value Disclosures](#)

12 Months Ended
Jun. 30, 2024

FAIR VALUE MEASUREMENTS

ASC 820, *Fair Value Measurement* defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which Level 1 and Level 2 are considered observable and Level 3 is considered unobservable:

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 2 - Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses of the Company approximate fair value based on the short maturities of these instruments.

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification as of the end of each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis and the fair value measurement for such assets and liabilities at June 30, 2024 and 2023, respectively:

(Dollars in millions) June 30, 2024	Basis of Fair Value Measurement			
	Total	Level 1	Level 2	Level 3
Assets:				
Interest-rate swap	\$ 36	\$ —	\$ 36	\$ —
Trading securities	\$ 1	\$ 1	\$ —	\$ —
June 30, 2023				
Assets:				
Interest-rate swap	\$ 62	\$ —	\$ 62	\$ —
Trading securities	\$ 1	\$ 1	\$ —	\$ —

The fair value of the 2023 Rate Swap was determined at the end of each reporting period based on valuation models that use interest rate yield curves and discount rates as inputs. The discount rates are based on U.S. deposit or U.S. Treasury rates. The significant inputs used in the valuation models are readily available in public markets or can be derived from observable market transactions, and the valuation is therefore classified as Level 2 in the fair-value hierarchy.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

Long-lived assets, goodwill, and other intangible assets are subject to non-recurring fair value measurement for the evaluation of potential impairment. Except as noted in Note 4, *Goodwill*, there was no non-recurring fair value measurement during the fiscal year ended June 30, 2024, 2023 and 2022.

~~XML 47 R18.htm IDEA: XBRL DOCUMENT~~

Employee Retirement
Benefit Plans

[Retirement Benefits
\[Abstract\]](#)

[Employee Retirement
Benefit Plans](#)

12 Months Ended
Jun. 30, 2024

EMPLOYEE RETIREMENT BENEFIT PLANS

The Company sponsors various retirement plans, including defined benefit pension plans and defined contribution plans. Substantially all of the Company’s domestic non-union employees are eligible to participate in employer-sponsored retirement savings plans, which include plans created under Section 401(k) of the Internal Revenue Code that provide for the Company to match a portion of contributions by participating U.S. employees. The Company’s contributions to the plans are discretionary but are subject to certain minimum requirements as specified in the plans. The Company uses a measurement date of June 30 for all of its retirement and postretirement benefit plans.

The Company records obligations related to its withdrawal from two multi-employer pension plan that covered former employees at three former sites. During the fiscal year ended June 30, 2024, the Company decided to withdraw its participation from a multi-employer pension plan as a result of recent restructuring activities in its Pharma and Consumer Health segment. These withdrawals were classified as a mass withdrawal under the Multiemployer Pension Plan Amendments Act of 1980, as amended, and the Pension Protection Act of 2006 and resulted in the recognition of liabilities associated with the Company’s long-term obligations. The estimated discounted value of the contributions related to these plans is \$44 million and \$38 million as of June 30, 2024 and 2023, respectively. The annual cash impact associated with the Company’s long-term obligation arising from these plans are \$2 million per year.

In the twelve months ended June 30, 2024, the Company terminated its U.S. pension plan and settled with its participants by a lump sum payout or through the purchase of an annuity contract, which was dependent upon the participant’s selection of payment. The Company purchased nonparticipating annuities for participants who did not elect lump sum payouts.

Participants who elected a lump sum payout were settled during the fiscal year ended June 30, 2024 and resulted in \$7 million of lump sum payments made with cash from the assets of the qualified pension plan. Participants who elected an annuity contract were settled during the fiscal year ended June 30, 2024 and resulted in \$21 million of payments with cash from the assets of the qualified pension plan and \$3 million of Company cash.

The following table provides a reconciliation of the change in projected benefit obligation and fair value of plan assets for the defined benefit retirement and other retirement plans, excluding the multi-employer pension plan liability:

(Dollars in millions)	Retirement Benefits		Other Post-Retirement Benefits	
	June 30,		June 30,	
	2024	2023	2024	2023
Accumulated Benefit Obligation	\$ 206	\$ 242	\$ 1	\$ 2
Change in Benefit Obligation				
Benefit obligation at beginning of year	246	268	2	2
Company service cost	3	3	—	—
Interest cost	11	9	—	—
Employee contributions	1	1	—	—
Settlements	(36)	(4)	—	—
Benefits paid	(11)	(10)	—	—
Actuarial gain	1	(28)	—	—
Exchange rate gain (loss)	(4)	7	—	—
Benefit obligation at end of year	\$ 211	\$ 246	\$ 2	\$ 2
Change in Plan Assets				
Fair value of plan assets at beginning of year	202	240	—	—
Actual return on plan assets	3	(38)	—	—
Company contributions	11	7	—	—
Employee contributions	1	1	—	—
Settlements	(36)	(4)	—	—
Benefits paid	(11)	(10)	—	—
Exchange rate gain (loss)	(2)	6	—	—
Fair value of plan assets at end of year	\$ 168	\$ 202	\$ —	\$ —
Funded Status				
Funded status at end of year	(43)	(44)	(1)	(2)
Net pension liability	\$ (43)	\$ (44)	\$ (1)	\$ (2)

The following table provides a reconciliation of the net amount recognized in the consolidated balance sheets:

(Dollars in millions)	Retirement Benefits		Other Post-Retirement Benefits	
	June 30,		June 30,	
	2024	2023	2024	2023
Amounts Recognized in Statement of Financial Position				
Noncurrent assets	\$ 13	\$ 18	\$ —	\$ —
Current liabilities	(1)	(1)	—	—
Noncurrent liabilities	(55)	(61)	(1)	(2)
Total liability	(43)	(44)	(1)	(2)
Amounts Recognized in Accumulated Other Comprehensive Loss				
Prior service cost	(1)	(1)	—	—
Net loss (gain)	58	66	(1)	(1)
Total accumulated other comprehensive loss (income) at the end of the fiscal year	57	65	(1)	(1)
Additional Information for Plan with ABO or PBO in Excess of Plan Assets				
Projected benefit obligation	93	129	1	2
Accumulated benefit obligation	89	126	1	2
Fair value of plan assets	37	68	—	—
Components of Net Periodic Benefit Cost				
Service cost	3	3	—	—
Interest cost	11	9	—	—
Expected return on plan assets	(9)	(9)	—	—
Amortization of unrecognized:				
Net loss	2	1	—	—
Settlement/curtailment expense	12	1	—	—
Net periodic benefit cost	\$ 19	\$ 5	\$ —	\$ —

(Dollars in millions)	Retirement Benefits		Other Post-Retirement Benefits	
	June 30,		June 30,	
	2024	2023	2024	2023
Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income				
Net loss (gain) arising during the year	\$ 6	\$ 17	\$ —	\$ —
Exchange rate loss recognized during the year	(14)	—	—	—
Total recognized in other comprehensive income	\$ (8)	\$ 17	\$ —	\$ —
Total Recognized in Net Periodic Benefit Cost and Other Comprehensive Income				
Total recognized in net periodic benefit cost and other comprehensive income	\$ 11	\$ 22	\$ —	\$ —
Estimated Amounts to be Amortized from Accumulated Other Comprehensive Income into Net Periodic Benefit Cost				
Amortization of:				
Net loss	\$ 2	\$ 2	\$ —	\$ —
Financial Assumptions Used to Determine Benefit Obligations at the Balance Sheet Date				
Discount rate (%)	4.3 %	4.3 %	5.0 %	4.7 %
Rate of compensation increases (%)	2.7 %	2.7 %	n/a	n/a
Financial Assumptions Used to Determine Net Periodic Benefit Cost for Financial Year				
Discount rate (%)	4.3 %	3.6 %	4.7 %	4.0 %
Rate of compensation increases (%)	2.7 %	2.7 %	n/a	n/a
Expected long-term rate of return (%)	4.3 %	3.9 %	n/a	n/a
Expected Future Contributions				
Fiscal year 2025	\$ 4	\$ 8	\$ —	\$ —

(Dollars in millions)	Retirement Benefits		Other Post-Retirement Benefits	
	June 30,		June 30,	
	2024	2023	2024	2023
Expected Future Benefit Payments				
Financial year				
2025	\$ 12	\$ 14	\$ —	\$ —
2026	13	15	—	—
2027	12	16	—	—
2028	12	15	—	—
2029	13	15	—	—
2030-2034	71	84	1	1

Actual Asset Allocation (%)				
Cash	1.0 %	4.5 %	— %	— %
Equities	2.9 %	2.9 %	— %	— %
Government bonds	37.7 %	36.8 %	— %	— %
Corporate bonds	16.8 %	16.2 %	— %	— %
Property	4.5 %	3.3 %	— %	— %
Insurance contracts	16.6 %	14.9 %	— %	— %
Other	20.5 %	21.4 %	— %	— %
Total	100.0 %	100.0 %	— %	— %

Actual Asset Allocation (Amount)				
Cash	\$ 2	\$ 9	\$ —	\$ —
Equities	5	6	—	—
Government bonds	63	74	—	—
Corporate bonds	28	33	—	—
Property	8	7	—	—
Insurance contracts	28	30	—	—
Other	34	43	—	—
Total	\$ 168	\$ 202	\$ —	\$ —

Target Asset Allocation (%)				
Cash	1.0 %	4.5 %	— %	— %
Equities	2.9 %	2.9 %	— %	— %
Government bonds	37.7 %	36.8 %	— %	— %
Corporate bonds	16.8 %	16.2 %	— %	— %
Property	4.5 %	3.3 %	— %	— %
Insurance contracts	16.6 %	14.9 %	— %	— %
Other	20.5 %	21.4 %	— %	— %
Total	100.0 %	100.0 %	— %	— %

The Company's Investment Committee employs a building-block approach in determining the long-term rate of return for plan assets, with proper consideration of diversification and rebalancing. Historical markets are studied and long-term historical relationships between equities and fixed income are preserved consistent with the widely accepted capital market principle that assets with higher volatility generate a greater return over the long run. Current market factors such as inflation and interest rates are evaluated before long-term capital market assumptions are determined. Peer data are reviewed to check for reasonability and appropriateness.

Plan assets are recognized and measured at fair value in accordance with the accounting standards regarding fair value measurements. The following are valuation techniques used to determine the fair value of each major category of assets:

- Short-term investments, equity securities, fixed-income securities, and real estate are valued using quoted market prices or other valuation methods, and thus are classified within Level 1 or Level 2.
- Insurance contracts and other types of investments include investments with some observable and unobservable prices that are adjusted by cash contributions and distributions, and thus are classified within Level 2 or Level 3.

The following tables provide a summary of plan assets that are measured at fair value as of June 30, 2024 and 2023, aggregated by the level in the fair value hierarchy within which those measurements fall:

As of June 30, 2024 (dollars in millions)	Level 1	Level 2	Level 3	Investments Measured at Net Asset Value	Total Assets
Equity securities	\$ —	\$ 5	\$ —	\$ —	\$ 5
Debt securities	—	91	—	—	91
Real estate	—	3	2	—	5
Other ⁽¹⁾	—	42	25	—	67
Total	\$ —	\$ 141	\$ 27	\$ —	\$ 168

(1) Other, as of June 30, 2024, included \$12 million of investments in hedge funds related to the Company's U.K. pension plan, which were classified as Level 2.

As of June 30, 2023 (dollars in millions)	Level 1	Level 2	Level 3	Investments Measured at Net Asset Value	Total Assets
Equity securities	\$ —	\$ 6	\$ —	\$ —	\$ 6
Debt securities	—	107	—	—	107
Real estate	—	5	2	—	7
Other ⁽¹⁾	—	57	25	—	82
Total	\$ —	\$ 175	\$ 27	\$ —	\$ 202

(1) Other, as of June 30, 2023, included \$20 million of investments in hedge funds related to the Company's U.K. pension plan, which were classified as Level 2.

Level 3 other assets as of June 30, 2024 and 2023 consist of an insurance contract in the U.K. to fulfill the benefit obligations for a portion of the participant benefits. The value of this commitment is determined using the same assumptions and methods used to value the pension liability of the associated plan. Level 3 other assets for the same periods also include the partial funding of a pension liability relating to current and former employees of the Company's Eberbach, Germany facility through a Company promissory note with an annual rate of interest of 5%. The value of this commitment fluctuates due to contributions and benefit payments in addition to loan interest.

The following table provides a reconciliation of the beginning and ending balances of Level 3 assets as well as the changes during the period attributable to assets held and those purchases, sales, settlements, contributions, and benefits that were paid:

Total (Level 3) (Dollars in millions)	Fair Value Measurement Using Significant Unobservable Inputs (Level 3)	Fair Value Measurement Using Significant Unobservable Inputs Insurance Contracts	Fair Value Measurement Using Significant Unobservable Inputs Other
Beginning Balance at June 30, 2023	\$ 27	\$ 8	\$ 19
Actual return on plan assets:			
Relating to assets still held at the reporting date	1	1	—
Purchases, sales, settlements, contributions and benefits paid	(4)	(2)	(2)
Transfers in or out of Level 3, net	3	—	3
Ending Balance at June 30, 2024	\$ 27	\$ 7	\$ 20

The Company's investment policy reflects the long-term nature of the plans' funding obligations. The assets are invested to provide the opportunity for both income and growth of principal. This objective is pursued as a long-term goal designed to provide required benefits for participants without undue risk. It is expected that this objective can be achieved through a well-diversified asset portfolio. All equity investments are made within the guidelines of quality, marketability, and diversification mandated by the Employee Retirement Income Security Act of 1974, as amended (for plans subject to the act) and other relevant legal requirements. Investment managers are directed to maintain equity portfolios at a risk level approximately equivalent to that of the specific benchmark established for that portfolio. Assets invested in fixed income securities and pooled fixed-income portfolios are managed actively to pursue opportunities presented by changes in interest rates, credit ratings, or maturity premiums.

Assumed Healthcare Cost Trend Rates at the Balance Sheet Date	Other Post-Retirement Benefits	
	2024	2023
Healthcare cost trend rate – initial (%)		
Pre-65	n/a	n/a
Post-65	5.0 %	4.8 %
Healthcare cost trend rate – ultimate (%)		
Pre-65	n/a	n/a
Post-65	4.1 %	4.1 %
Year in which ultimate rates are reached		
Pre-65	n/a	n/a
Post-65	2040	2040

[XML 48 R19.htm IDEA: XBRL DOCUMENT](#)

Other Income / Expense

12 Months Ended Jun. 30, 2023

Other Income and Expenses [Abstract]

Other Income and Other Expense Disclosure

OTHER EXPENSE (INCOME), NET

The components of other expense (income), net for the fiscal years ended June 30, 2024, 2023, and 2022 are as follows:

(Dollars in millions)	Fiscal Year Ended June 30,		
	2024	2023	2022
Other expense (income), net			
Debt refinancing costs ⁽¹⁾	\$ —	\$ —	\$ 4
Foreign currency losses (gains) ⁽²⁾	20	(8)	33
Other ⁽³⁾	4	1	(9)
Total other expense (income), net	\$ 24	\$ (7)	\$ 28

(1) Debt financing costs for the fiscal year ended June 30, 2022 consists of \$4 million of financing charges related to a tranche of U.S. dollar-denominated term loans under its senior secured credit facilities.

(2) Foreign currency losses (gains) include both cash and non-cash transactions.

(3) Other, for the fiscal year ended June 30, 2022 includes, in part, total realized and unrealized gain of \$2 million, related to the fair value of the derivative liability associated with the formerly outstanding Series A Preferred Stock.

[XML 49 R20.htm IDEA: XBRL DOCUMENT](#)

Leases

12 Months Ended Jun. 30, 2024

Leases [Abstract]

Lessee, Finance Leases

LEASES

The Company leases certain manufacturing and office facilities, land, vehicles, and equipment. The terms of these leases vary widely, although most have terms between 3 and 10 years.

In accordance with ASC 842, *Leases*, the Company recognizes a "right-of-use" asset and related lease liability at the commencement date of each lease based on the present value of the fixed lease payments over the expected lease term inclusive of any rent escalation provisions or incentives received. The lease term for this purpose will include any renewal period where the Company determines that it is reasonably certain that it will exercise the option to renew. While certain leases also permit the Company to terminate the lease in advance of the nominal term upon payment of an associated penalty, the Company

generally does not take into account potential early termination dates in its determination of the lease term as it is reasonably certain not to exercise an early-termination option as of the lease commencement date.

The Company uses its incremental borrowing rate, which represents the interest rate the Company would expect to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms, in order to calculate the present value of a lease, when the implicit discount rate for its leases is not readily determinable.

For operating leases, fixed lease payments are recognized as operating lease expense on straight-line basis over the lease term. For finance leases, the Company recognizes depreciation expense associated with the leased asset acquired and interest expense related to the financing portion. Variable payments are recognized in the period incurred. As permitted by ASC 842, the Company has elected not to separate those components of a lease agreement not related to the leasing of an asset from those components that are related.

The Company does not record leases with an initial lease term of 12 months or less on its consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term.

Supplemental information concerning the leases recorded in the Company's consolidated balance sheet as of June 30, 2024 is detailed in the following table:

(Dollars in millions)	Line item in the consolidated balance sheet	Balance at June 30, 2024	Balance at June 30, 2023
Right-of-use assets:			
Finance leases	Property, plant, and equipment, net	\$ 252	\$ 274
Operating leases	Other long-term assets	77	59
Current lease liabilities:			
Finance leases	Current portion of long-term obligations and other short-term borrowings	20	18
Operating leases	Other accrued liabilities	13	11
Non-current lease liabilities:			
Finance leases	Long-term obligations, less current portion	312	323
Operating leases	Other liabilities	\$ 70	\$ 55

The components of the net lease costs for the fiscal years ended June 30, 2024 and 2023 reflected in the Company's consolidated statement of operations were as follows:

(Dollars in millions)	Fiscal Year Ended June 30, 2024	Fiscal Year Ended June 30, 2023
Financing lease costs:		
Amortization of right-of-use assets	\$ 30	\$ 21
Interest on lease liabilities	21	17
Total	51	38
Operating lease costs	27	35
Variable lease costs	16	10
Total lease costs	\$ 94	\$ 83

The short-term lease cost amounted to \$9 million, \$10 million and \$8 million during the fiscal year ended June 30, 2024, 2023 and 2022, respectively.

The weighted average remaining lease term and weighted average discount rate related to the Company's right-of-use assets and lease liabilities as of June 30, 2024 are as follows:

Weighted average remaining lease term (years):	
Finance leases	16.1
Operating leases	9
Weighted average discount rate:	
Finance leases	6.2 %
Operating leases	4.6 %

Supplemental information concerning the cash-flow impact arising from the Company's leases for the fiscal year ended June 30, 2024 recorded in the Company's unaudited consolidated statement of cash flows is detailed in the following table (in millions):

	Fiscal Year Ended June 30, 2024	Fiscal Year Ended June 30, 2023	Fiscal Year Ended June 30, 2022
Cash paid for amounts included in lease liabilities:			
Financing cash flows used for finance leases	\$ 19	\$ 19	\$ 15
Operating cash flows used for finance leases	16	15	11
Operating cash flows used for operating leases	14	16	19
Non-cash transactions:			
Right-of-use assets obtained in exchange for new finance lease liabilities	57	133	59
Right-of-use assets obtained in exchange for new operating lease liabilities	\$ 38	\$ 1	\$ 31

As of June 30, 2024, the Company expects that its future minimum lease payments will become due and payable as follows:

(Dollars in millions)	Financing Leases		Operating Leases		Total
2025	\$	37	\$	17	\$ 54
2026		39		15	54
2027		37		14	51
2028		34		13	47
2029		34		9	43
Thereafter		337		36	373
Total minimum lease payments		518		104	622
Less: interest		186		21	207
Total lease liabilities	\$	332	\$	83	\$ 415

~~XML 50 R21.htm IDEA: XBRL DOCUMENT~~

Commitments and Contingencies

[Commitments and Contingencies Disclosure \[Abstract\]](#)
[Commitments and Contingencies](#)

12 Months Ended
Jun. 30, 2024

COMMITMENTS AND CONTINGENCIES

Litigation

From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company’s consolidated financial statements. The Company records a liability in its consolidated financial statements for these matters when a loss is

known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary for its consolidated financial statements not to be misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the Company’s consolidated financial statements. Any legal or other expenses associated with the litigation are accrued for as the expenses are incurred. The Company intends to vigorously defend itself against any such litigation and does not currently believe that the outcome of any such litigation will have a material adverse effect on the Company’s consolidated financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise.

City of Warwick Retirement System Class Action

In February 2023, an alleged shareholder filed a complaint styled City of Warwick Retirement System v. Catalent, Inc., et al., No. 23-cv-01108, in New Jersey federal court against the Company and three of its then-officers (collectively, “the Warwick Defendants”) purportedly on behalf of a putative “class” consisting of persons who purchased or otherwise acquired Company securities between August 30, 2021 and October 31, 2022, inclusive. On September 15, 2023, the Warwick complaint was amended (together with the original complaint, the “Warwick Complaint”), which amended complaint expanded the class period to between August 30, 2021 and May 7, 2023, inclusive (the “Class Period”). The Warwick Complaint purports to assert claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and the related regulations, alleging that, unbeknownst to investors, the Warwick Defendants purportedly engaged in accounting and channel stuffing schemes to pad the Company’s revenues and failed to disclose adverse facts that purportedly were known to or recklessly disregarded by the Warwick Defendants. Specifically, the Warwick Complaint alleges that the Warwick Defendants (i) overstated revenue and earnings by prematurely recognizing revenue in violation of U.S. GAAP; (ii) suffered material weaknesses in its internal control over financial reporting related to revenue recognition; (iii) falsely represented demand for its products while knowingly selling more product to its direct customers than could be sold to healthcare providers and end consumers; (iv) cut corners on safety and control procedures at key production facilities; (v) disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company’s financial results through premature revenue recognition in violation of U.S. GAAP or stuffing its direct customers with this excess inventory; and (vi) lacked a reasonable basis for their positive statements about the Company’s financial performance, outlook, and regulatory compliance during the Class Period. On November 15, 2023, the Warwick Defendants filed a motion to dismiss the Warwick Complaint. On June 28, 2024, the Court granted, in part, and denied, in part, the Company’s motion to dismiss. The Warwick Defendants’ answer to the Warwick Complaint was filed on August 12, 2024. The Company believes that the Warwick Defendants have defenses to the remaining allegations and intends to vigorously defend against these allegations.

Husty Derivative Claim

In August 2023, an alleged shareholder filed a derivative complaint styled Husty et al. v. Carroll, et al., No. 23-cv-00891, in Delaware federal court against certain current and former members of the Company’s board of directors, (the “Husty Defendants”), and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities described there led to, and will continue to expose the Company to, costs and damages. On February 20, 2024, the court entered a stipulation staying the case pending the outcome of motion to dismiss that was filed in the City of Warwick Retirement System action. On April 23, 2024, the plaintiff voluntarily dismissed the action without prejudice.

Brown Derivative Claim

In September 2023, an alleged shareholder filed a derivative complaint styled Brown, et al. v. Chiminski, et al., Case 3:23-cv-15722, in New Jersey federal court against certain current and former officers and members of the Company’s board of directors (the “Brown Defendants”) and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities described there led to, and will continue to expose the Company to, costs and damages. On January 8, 2024, the court entered a stipulation staying the case pending the outcome of motion to dismiss that was filed in the City of Warwick Retirement System action. On April 19, 2024, the plaintiff voluntarily dismissed the action without prejudice. On May 2, 2024, the Court dismissed the action without prejudice.

Merger Related Claims

In connection with the proposed Merger, as disclosed below, three purported Catalent stockholders filed lawsuits alleging that certain disclosures made in the Proxy Statement were materially false and misleading: *Garfield v. Barber, et al.*, C.A. No. SOM-C 012027-24 (N.J. Super. Ct.), which was filed in the Superior Court of New Jersey; *Moore v. Catalent, Inc., et al.*, No. 652403/2024 (N.Y. Sup. Ct.), which was filed in the Supreme Court of New York; and *Clark v. Catalent, Inc., et al.*, No. 652407/2024 (N.Y. Sup. Ct.), which was filed in the Supreme Court of New York. The aforementioned lawsuits are collectively referred to as the “Actions.” The Actions alleged, among other things, that certain disclosures in the Proxy Statement filed in connection with the Merger Agreement omitted certain purportedly material information. The *Garfield* Action asserted violations of New Jersey Uniform Securities Law § 49:3-71 and negligent misrepresentation and concealment and negligence under New Jersey common law. The *Moore* and *Clark* Actions each asserted a single claim for breach of fiduciary duty. On May 17, 2024, the *Garfield* Action was voluntarily dismissed with prejudice. On June 26, 2024, the *Moore* and *Clark* Actions were voluntarily dismissed with prejudice.

Subpoenas and Requests for Information

From time to time, the Company receives subpoenas or requests for information from various governmental agencies or private parties, including from state attorneys general, the U.S. Department of Justice, and private parties. The Company generally responds to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred.

In June 2023, the Company received a demand from a company stockholder pursuant to 8 Del. C. § 220 to inspect books and records of the Company relating to, among other things, the allegations raised in the *Warwick* Complaint. The Company has responded to the demand and cannot determine at this time if the books and records demand will lead to litigation.

Fire at Biologics Facility

During the three months ended December 31, 2023, the Company had a small fire at a facility in its Biologics segment. The fire activated the sprinkler systems, which then caused minor flooding in certain parts of the facility. The Company accrued \$9 million for estimated damages, repairs, and lost inventory. The Company is insured for such incidents and has submitted claims for reimbursement. Proceeds from potential reimbursement are not included in the financial statements for the three and twelve months ended June 30, 2024.

Entry Into an Agreement and Plan of Merger

On February 5, 2024, the Company entered into the Agreement and Plan of Merger (the “Merger Agreement”), with Creek Parent, Inc. (“Parent”), a Delaware corporation and a wholly owned subsidiary of Novo Holdings A/S (“Novo Holdings”), and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein and in accordance with the General Corporation Law of the State of Delaware (the “DGCL”), Merger Sub will be merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Parent will acquire all the issued and outstanding shares of Common Stock of the Company.

At the effective time of the Merger (the “Effective Time”), each share of Common Stock, par value \$0.01 per share, of the Company (such shares, collectively, the “Company Common Stock,” and each, a “Share”) that is issued and outstanding immediately prior to the Effective Time (other than any Shares held by (i) the Company, Parent or Merger Sub or any other direct or indirect wholly owned subsidiary of the Company or Parent immediately prior to the Effective Time, or (ii) a holder who has not voted in favor of the adoption of the Merger Agreement and is entitled to demand and properly demands appraisal of such Shares under the DGCL), will be converted automatically into the right to receive an amount in cash equal to \$63.50 per Share, without interest (the “Merger Consideration”). The transaction values the Company at \$16.50 billion on an enterprise value basis.

Consummation of the Merger is subject to customary closing conditions, including (i) receipt of certain governmental waivers, consents, clearances, decisions, declarations, approvals, and expirations of applicable waiting periods, including the expiration or early termination of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, with respect to (A) the Merger and (B) the sale of three of the Company’s fill-finish sites (which are located in Anagni, Italy, Bloomington, Indiana USA, and Brussels, Belgium) and related assets from Novo Holdings to Novo Nordisk A/S (“Novo Nordisk”), of which Novo Holdings is the controlling shareholder (the “Carve-Out”), and (ii) the absence of any order, injunction or law prohibiting the Merger or the Carve-Out, in each case, without a Burdensome Condition (as defined in the Merger Agreement). Parent’s and Merger Sub’s obligations to close the Merger are also conditioned upon the absence of a Material Adverse Effect (as defined in the Merger Agreement) on the Company.

~~XML 51 R22.htm IDEA: XBRL DOCUMENT~~

Segment Information

[Segment Reporting \[Abstract\]](#)
[Segment Reporting Disclosure \[Text Block\]](#)

12 Months Ended
Jun. 30, 2024

SEGMENT AND GEOGRAPHIC INFORMATION

The CODM evaluates the performance and allocates resources based upon a number of factors, the primary being its segment earnings before other (income) expense, impairments, restructuring costs, interest expense, income tax expense, and depreciation and amortization (“Segment EBITDA”).

Segment EBITDA is subject to important limitations. These consolidated financial statements include information concerning Segment EBITDA (a) because Segment EBITDA is an operational measure used by management in the assessment of the operating segments, the allocation of resources to the segments, and the setting of strategic goals and annual goals for the segments, and (b) in order to provide supplemental information that the Company considers relevant for the readers of the consolidated financial statements. The Company’s presentation of Segment EBITDA may not be comparable to similarly titled measures used by other companies.

The following table includes Segment EBITDA for each of the Company’s current reporting segments during the fiscal years ended June 30, 2024, 2023, and 2022:

(Dollars in millions)	Fiscal Year Ended June 30,		
	2024	2023	2022
Segment EBITDA reconciled to net (loss) earnings:			
Biologics	\$ 272	\$ 277	\$ 777
Pharma and Consumer Health	597	548	589
Subtotal	\$ 869	\$ 825	\$ 1,366
Reconciling items to net (loss) earnings			
Unallocated costs ⁽¹⁾	\$ (1,153)	\$ (559)	\$ (286)
Depreciation and amortization	(489)	(422)	(378)
Interest expense, net	(254)	(186)	(123)
Income tax benefit (expense)	(16)	86	(80)
Net (loss) earnings	\$ (1,043)	\$ (256)	\$ 499

(1) Unallocated costs include restructuring and special items, stock-based compensation, gain (loss) on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:

(Dollars in millions)	Fiscal Year Ended June 30,		
	2024	2023	2022
Impairment charges and gain/loss on sale of assets ^(a)	\$ (29)	\$ (98)	\$ (31)
Stock-based compensation	(68)	(35)	(54)
Restructuring and other special items ^(b)	(178)	(98)	(55)
Pension settlement charges	(12)	—	—
Goodwill impairment charges ^(c)	(687)	(210)	—
Gain on sale of subsidiary	—	—	1
Other (expense) income, net ^(d)	(24)	7	(28)
Non-allocated corporate costs, net	(155)	(125)	(119)
Total unallocated costs	\$ (1,153)	\$ (559)	\$ (286)

(a) Impairment charges and gain/loss on sale of assets for the fiscal year ended June 30, 2024 includes right-of-use asset impairment charges associated with under utilized facilities in our Biologics segment, obsolete equipment that could not be sold or repurposed in our Biologics segment and under utilized suites from a canceled project in our Pharma and Consumer Health segment.

For the fiscal year ended June 30, 2023, impairment charges are primarily associated with an idle facility in the Biologics segment and obsolete equipment that could not be sold or repurposed in the Pharma and Consumer Health segment. Further detail is provided below. [1]

For the fiscal year ended June 30, 2023, the Company identified an indicator of impairment related to one of its facilities in the Biologics segment given the plans to pause any additional spend on site development due to a lack of demand, leading to a partial impairment charge of \$54 million. The Company primarily utilized a market and income approach for real property and a cost approach for personal property to record the partial impairment on its idle facility. Impairment charges are recorded in Other operating expense in the consolidated statements of operations.

Also, in the fiscal year ended June 30, 2023, the Company identified an indicator of impairment related to obsolete equipment from a terminated project in the Pharma and Consumer Health segment, leading to a full impairment charge of \$18 million.

For the fiscal year ended June 30, 2022, impairment charges are primarily due to fixed asset impairment charges associated with dedicated equipment for a product the Company no longer manufactures in its Pharma and Consumer Health segment and obsolete equipment in its Biologics segment.

(b) Restructuring and other special items during the fiscal year ended June 30, 2024 include restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization. For further details on restructuring charges, see Note 6, *Restructuring Costs* to the Consolidated Financial Statements.

Restructuring and other special items for the fiscal year ended June 30, 2023 includes (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition

Restructuring and other special items for the fiscal year ended June 30, 2022 include (i) transaction and integration costs primarily associated with the Princeton, Bettera Wellness, Delphi, Hepatic, Acorda, and RheinCell transactions and (ii) unrealized losses on venture capital investments.

(c) Goodwill impairment charges during the fiscal year ended June 30, 2024 were associated with the Company's Consumer Health and Biomodalities reporting units, which are part of the Company's Pharma and Consumer Health and Biologics segments, respectively. For further details, see Note 4, *Goodwill* to the Consolidated Financial Statements.

The goodwill impairment charges for the fiscal year ended June 30, 2023 was associated with the Company's Consumer Health reporting unit. For further details, see Note 4, *Goodwill*.

(d) Refer to Note 15, *Other (income) expense, net* for details of financing charges and foreign currency translation adjustments recorded within other (income) expense, net.

The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated balance sheets.

Total Assets			
(Dollars in millions)			
Biologics	\$ 5,326	\$ 5,746	
Pharma and Consumer Health	4,643	4,867	
Corporate and eliminations	(216)	164	
Total assets	\$ 9,753	\$ 10,777	

Capital Expenditures

(Dollars in millions)	Fiscal Year Ended June 30,		
	2024	2023	2022
Biologics	\$ 171	\$ 346	\$ 453
Pharma and Consumer Health	164	214	183
Corporate	16	34	30
Total capital expenditures ⁽¹⁾	\$ 351	\$ 594	\$ 666

(1) Include both cash and non-cash capital expenditures

Long Lived Assets

The following table presents long-lived assets—consisting of property, plant, and equipment, net of accumulated depreciation—by geographic area:

(Dollars in millions)	June 30, 2024		June 30, 2023	
United States	\$ 2,625	\$ 2,758		
Europe	828	765		
Other	190	159		
Total	\$ 3,643	\$ 3,682		

[1] Refer to Note 15, *Other (income) expense, net* for details of financing charges and foreign currency translation adjustments recorded within other (income) expense, net.

[XML 52 R23.htm IDEA: XBRL DOCUMENT](#)

[Supplemental Balance Sheet Information](#)

[Balance Sheet Related Disclosures \[Abstract\]](#)

[Supplemental Balance Sheet Information](#)

12 Months Ended

Jun. 30, 2024

SUPPLEMENTAL BALANCE SHEET INFORMATION

Supplemental balance sheet information at June 30, 2024 and June 30, 2023 is detailed in the following tables.

Inventories

Work-in-process and inventories include raw materials, labor, and overhead. Total inventories consist of the following:

(Dollars in millions)	June 30, 2024		June 30, 2023	
Raw materials and supplies	\$ 646	\$ 781		
Work-in-process	138	186		
Total inventories, gross	784	967		
Inventory cost adjustment	(210)	(190)		
Total inventories	\$ 574	\$ 777		

Prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following:

(Dollars in millions)	June 30, 2024		June 30, 2023	
Prepaid expenses	\$ 46	\$ 53		
Short-term contract assets	585	399		
Spare parts supplies	29	24		
Prepaid income tax	45	77		
Non-U.S. value-added tax	60	38		
Other current assets	48	42		
Total prepaid expenses and other	\$ 813	\$ 633		

Property, plant, and equipment, net

Property, plant, and equipment, net consist of the following:

(Dollars in millions)	June 30, 2024		June 30, 2023	
Land, buildings, and improvements	\$ 1,987	\$ 1,887		
Machinery and equipment	2,538	2,287		
Furniture and fixtures	62	61		
Construction in progress	971	1,043		
Property, plant, and equipment, at cost	5,558	5,278		
Accumulated depreciation	(1,915)	(1,596)		
Property, plant, and equipment, net	\$ 3,643	\$ 3,682		

Other long-term assets			
Other long-term assets consist of the following:			
(Dollars in millions)		June 30, 2024	June 30, 2023
Operating lease right-of-use-assets	\$	77	\$ 59
Note receivable		56	53
Corporate-owned life insurance policies		48	41
Venture capital investments		47	36
Interest-rate swap		36	62
Pension assets		13	18
Long-term contract assets		17	18
Other		38	42
Total other long-term assets	\$	332	\$ 329
Other accrued liabilities			
Other accrued liabilities consist of the following:			
(Dollars in millions)		June 30, 2024	June 30, 2023
Contract liability	\$	250	\$ 167
Accrued employee-related expenses		181	160
Accrued expenses		115	134
Operating lease liabilities		13	11
Restructuring accrual		10	19
Accrued interest		37	35
Accrued income tax		16	44
Total other accrued liabilities	\$	622	\$ 570

~~XML 53 R24.htm IDEA: XBRL DOCUMENT~~

Subsequent Events 3 Months Ended
(Notes) Dec. 31, 2024

[Subsequent Events \[Abstract\]](#)

[Subsequent Events \[Text Block\]](#) SUBSEQUENT EVENTS

~~XML 54 R25.htm IDEA: XBRL DOCUMENT~~

Pay vs Performance 12 Months Ended
Disclosure - USD (\$) Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2022

[Pay vs Performance Disclosure](#)

[Net Income \(Loss\) Attributable to Parent](#) \$ (1,043,000,000) \$ (256,000,000) \$ 499,000,000

~~XML 55 R26.htm IDEA: XBRL DOCUMENT~~

Insider Trading 12 Months Ended
Arrangements Jun. 30, 2024

[Trading Arrangements, by Individual](#)

[Rule 10b5-1 Arrangement Adopted](#) false

[Non-Rule 10b5-1 Arrangement Adopted](#) false

[Rule 10b5-1 Arrangement Terminated](#) false

[Non-Rule 10b5-1 Arrangement Terminated](#) false

~~XML 56 R27.htm IDEA: XBRL DOCUMENT~~

Basis of Presentation
and Summary of
Significant
Accounting Policies
(Policies)

12 Months Ended

Jun. 30, 2024

[Accounting Policies
\[Abstract\]](#)

[Segment Reporting,
Policy](#)

Reportable Segments

Effective July 1, 2022, in connection with the appointment of a new President and Chief Executive Officer, the Company changed its operating structure and reorganized its executive leadership team accordingly. The current organizational structure includes two operating and reportable segments—(i) Biologics and (ii) Pharma and Consumer Health—which are summarized below.

- The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA (“pDNA”); induced pluripotent stem cells (“iPSCs”), and oncolytic viruses; and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; analytical development and testing services for large molecules.
 - The Pharma and Consumer Health segment comprises the Company’s market-leading capabilities for complex oral solids, softgel formulations, Zydys® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
- Each segment reports through a separate management team and ultimately reports to the Company’s President and Chief Executive Officer, who is designated as the Chief Operating Decision Maker (“CODM”) for segment reporting purposes. The Company’s operating segments are the same as its reportable segments. All prior-period comparative segment information has been recast retrospectively to reflect the current reportable segments in accordance with Accounting Standards Codification (“ASC”) 280, *Segment Reporting*, promulgated by the Financial Accounting Standards Board (the “FASB”).

[Basis of Presentation](#)

Basis of Presentation

These financial statements include all of the Company’s subsidiaries, including those operating outside the United States (“U.S.”), and are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). All significant transactions among the Company’s subsidiaries and reporting segments have been eliminated, other than as noted.

[Use of Estimates](#)

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, revenue recognition, including determining the transaction price and any associated constraint on variable consideration, allowance for credit losses, inventory and long-lived asset valuation, goodwill and other intangible asset valuation and impairment, equity-based compensation, income taxes, derivative valuation, and pension plan asset and liability valuation. Actual amounts may differ from these estimated amounts.

[Reclassifications](#)

Reclassification

Certain prior-period amounts were reclassified to conform to the current period presentation. Specifically, certain line items in prior periods were combined within the operating activities section of the statement of cash flows to conform with current year presentation. These reclassifications did not have a material impact on the consolidated statements of cash flows.

[Translation and
Transaction of Foreign
Currencies](#)

Foreign Currency Translation

The financial statements of the Company’s operations outside the U.S. are generally determined using the local currency as the functional currency. Adjustments to translate the assets and liabilities of the foreign operations into U.S. dollars are accumulated as a component of other comprehensive income utilizing period-end exchange rates. Since July 2018, the Company has accounted for its Argentine operations as highly inflationary, but this status has not had a material effect on the consolidated financial statements.

The currency fluctuation related to certain long-term inter-company loans where settlement is not planned or anticipated in the foreseeable future have been recorded within the cumulative translation adjustment, a component of other comprehensive income. In addition, the currency fluctuation associated with the portion of the Company’s euro-denominated debt designated as a net investment hedge is included as a component of other comprehensive income. Foreign currency transaction gains and losses are calculated using weighted average exchange rates for the period and are included in the consolidated statements of operations in “other expense, net.” Such foreign currency transaction gains and losses include inter-company loans that are repayable in the foreseeable future.

[Cash and Cash
Equivalents](#)

Cash and Cash Equivalents

All liquid investments purchased with original maturities of three months or less are considered cash equivalents. The carrying value of these cash equivalents approximates fair value.

[Receivables and
Allowance dor Doubtful
Accounts](#)

Allowance for Credit Losses

Trade receivables, contract assets, and other amounts owed to the Company are presented net of an allowance that includes an assessment of expected credit losses. The Company determines its allowance methodology by considering various factors, including the Company’s previous loss history, aging of customer receivable balances, significant aspects of a geographic location’s economic conditions, the current and anticipated future condition of the general economy and the industries in which the Company’s primary customers operate. To the extent that the Company identifies that any individual customer’s credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of that customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, trade receivables and contract assets are written off against the allowance when the related balances are no longer deemed collectible.

[Concentrations of
Credit Risk and Major
Customers](#)

Concentrations of Credit Risk and Major Customers

Concentration of credit risk, with respect to accounts receivable, is limited due to the large number of customers and their dispersion across different geographic areas. The customers are primarily concentrated in the biopharmaceutical, pharmaceutical, and consumer products industries. The Company does not normally require collateral or any other security to support credit sales. The Company performs ongoing credit evaluations of its customers’ financial conditions and maintains reserves for credit losses. Such losses historically have been within the Company’s expectations.

For the fiscal years ended June 30, 2024, 2023, and 2022 the Company had one customer that accounted for 16%, 10% and 10%, respectively, of its net revenue, which was primarily recorded in the Biologics segment.

As of June 30, 2024 and 2023, the Company had one customer that accounted for 34% and 20%, respectively, of its aggregate net trade receivables and contract asset values, primarily associated with the Biologics segment. After performing a risk assessment of this customer, the Company has determined that a reserve is not warranted as of June 30, 2024.

[Inventories](#)

Inventories

Inventory is stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company provides for cost adjustments for excess, obsolete, or slow-moving inventory based on changes in customer demand, technology developments or other economic factors. Inventory consists of costs associated with raw material, labor, and overhead.

[Goodwill](#)

The Company recognizes revenue in accordance with ASC 606, *Revenue from Contracts with Customers*. The Company generally earns its revenue by supplying goods or providing services under contracts with its customers in three primary revenue streams: manufacturing and commercial product supply, development services, and clinical supply services. The Company measures the revenue from customers based on the consideration specified in its contracts, excluding any sales incentive or amount collected on behalf of a third party, that the Company expects to be entitled to receive in exchange for transferring the promised goods to and/or performing services for the customer (the “Transaction Price”). To the extent the Transaction Price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the Transaction Price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the Transaction Price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment.

The Company’s customer contracts generally include provisions entitling the Company to a termination penalty when the customer terminates prior to the contract’s nominal end date. The termination penalties in customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated durations of the contracts. The Company accounts for a contract termination as a contract modification in the period in which the customer gives notice of termination. The determination of the contract termination penalty is based on the terms stated in the relevant customer agreement. As of the modification date, the Company updates its estimate of the Transaction Price using the expected value method, subject to constraints, and to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment.

Where multiple performance obligations exist in a single contract, the Company allocates consideration to each performance obligation using the “relative standalone selling price” as defined under ASC 606. Generally, the Company utilizes observable standalone selling prices in its allocations of consideration. If observable standalone selling prices are not available, the Company estimates the applicable standalone selling price using a cost-plus-margin approach or an adjusted market assessment approach, in each case, representing the amount that the Company believes the market is willing to pay for the applicable service. Payment is typically due 30 to 45 days following the invoice date, based on the payment terms set forth in the applicable customer agreement.

The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material.

Customer contracts that include commitments by the Company to make facility space or equipment available may be deemed to include lease components, which are evaluated under ASC 842, *Leases*. For arrangements that contain both lease and non-lease components, consideration in the contract is allocated on a relative standalone selling-price basis. Determining the lease term and contract term of non-lease components, as well as the variable and fixed consideration in these arrangements, including when variability is resolved, often requires management judgment in order to determine the allocation to the lease and non-lease components.

Manufacturing & Commercial Product Supply Revenue

Manufacturing and commercial product supply revenue consists of revenue earned by manufacturing products supplied to customers under long-term commercial supply arrangements. In these arrangements, the customer typically owns and supplies the active pharmaceutical ingredient (“API”) or other proprietary materials used in the manufacturing process. The contract generally includes the terms of the manufacturing services and related product quality assurance procedures to comply with regulatory requirements. Due to the regulated nature of the Company’s business, these contract terms are highly interdependent and, therefore, are considered to be a single combined performance obligation. The transaction price is generally stated in the agreement as a fixed price per unit, with no contractual provision for a refund or price concession. In most circumstances, control is transferred to the customer over time, creating a corresponding right to recognize the related revenue, because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date. The selection of the method for measuring progress towards the completion of the Company’s performance obligation requires judgment and is based on the nature of the products to be manufactured. For the majority of the Company’s arrangements, progress is measured based on the units of product that have successfully completed the contractually required product quality assurance process, because the conclusion of that process defines the time when the applicable contract and the related regulatory requirements permit the customer to exercise control over the product’s

disposition. The customer is typically responsible for arranging the shipping and handling of product following completion of the quality assurance process. Payment is typically due 30 to 45 days after invoice date, based on the payment terms set forth in the applicable customer agreement.

Beginning in the third quarter of fiscal 2023, the Company began recognizing commercial revenue for certain contracts in its Biologics segment that have a notably long manufacturing cycle, and for which the customer exercises control over the product throughout the manufacturing process. For these contracts, revenue is recognized over time and progress is measured using an input method based on effort expended, which provides an appropriate depiction of the Company’s progress toward fulfilling its performance obligation.

Development Services and Clinical Supply Revenue

Development services contracts generally take the form of short-term, fee-for-service arrangements. Performance obligations vary, but frequently include biologic cell-line development, performing formulation, analytical stability, or other services related to product development, and providing manufacturing services for products that are under development or otherwise not intended for commercial sale. They can also include a combination of the following services: the manufacturing, packaging, storage, distribution, destruction, and inventory management of customer clinical trial material, as well as the sourcing of comparator drug products on behalf of customers to be used in clinical trials to compare performance with the drug under clinical investigation. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service, and each service is generally considered to be a separate performance obligation. In most instances, the Company recognizes revenue over time because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date.

The Company measures progress toward the completion of its performance obligations satisfied over time based on the nature of the services to be performed. For certain types of arrangements, revenue is recognized over time and measured using an output method based on the completion of tasks and activities that are performed to satisfy a performance obligation. For certain types of arrangements, revenue is recognized over time and measured using an input method based on effort expended. Each of these methods provides an appropriate depiction of the Company’s progress toward fulfilling its performance obligations for its respective arrangement. In certain arrangements that require a portion of the contract consideration to be received in advance at the commencement of the contract, such advance payment is initially recorded as a contract liability. In certain clinical supply arrangements, revenue is recognized at the point in time when control transfers, which occurs upon either the delivery of the related output of the service to the customer or the completion of quality testing with respect to the product, and the Company has an enforceable right to payment based on the terms of the arrangement.

The Company records revenue for comparator sourcing arrangements on a net basis because it is acting as an agent that does not control the product or service before it is transferred to the customer. Payment for comparator sourcing activity is typically received in advance at the commencement of the contract and is initially recorded as a contract liability.

The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material.

The following tables reflect net revenue for the fiscal years ended June 30, 2024, 2023, and 2022 by type of activity and reporting segment (in millions):

Fiscal Year Ended June 30, 2024	Biologics		Pharma and Consumer Health		Total
Manufacturing & commercial product supply	\$	1,151	\$	1,577	\$ 2,728
Development services & clinical supply		801		854	1,655
Total	\$	1,952	\$	2,431	\$ 4,383
Inter-segment revenue elimination					(2)
Combined net revenue					4,381

Fiscal Year Ended June 30, 2023	Biologics		Pharma and Consumer Health		Total
Manufacturing & commercial product supply	\$	450	\$	1,452	\$ 1,902
Development services & clinical supply		1,528		835	2,363
Total	\$	1,978	\$	2,287	\$ 4,265
Inter-segment revenue elimination					(2)
Combined net revenue					4,263

Fiscal Year Ended June 30, 2022	Biologics		Pharma and Consumer Health		Total
Manufacturing & commercial product supply	\$	608	\$	1,474	\$ 2,082
Development services & clinical supply		1,926		797	2,723
Total	\$	2,534	\$	2,271	\$ 4,805
Inter-segment revenue elimination					(3)
Combined net revenue					4,802

The following table reflects net revenue by the location where the goods were made or the service performed:

(Dollars in millions)	Fiscal Year Ended June 30, 2024		Fiscal Year Ended June 30, 2023		Fiscal Year Ended June 30, 2022	
United States	\$	2,823	\$	2,768	\$	3,084
Europe		1,359		1,257		1,506
Other		356		355		327
Elimination of revenue attributable to multiple locations		(157)		(117)		(115)
Total	\$	4,381	\$	4,263	\$	4,802

Contract Liabilities

Contract liabilities relate to cash consideration that the Company receives in advance of satisfying the related performance obligations. The contract liabilities balances (current and non-current) as of June 30, 2024 and June 30, 2023 were as follows:

(Dollars in millions)	
Balance at June 30, 2023	\$ 180
Balance at June 30, 2024	\$ 255
Revenue recognized in the period from amounts included in contracts liability at the beginning of the period:	\$ (145)

Contract liabilities that will be recognized within 12 months of June 30, 2024 are accounted for in Other accrued liabilities and those that will be recognized longer than 12 months after June 30, 2024 are accounted for within Other liabilities.

Contract Assets

Contract assets primarily relate to the Company’s conditional right to receive consideration for services that have been performed for customers but had not yet been invoiced as of June 30, 2024. Contract assets are transferred to trade receivables, net when the Company’s right to receive the consideration becomes unconditional. Contract assets totaled \$602 million and \$417 million as of June 30, 2024 and 2023, respectively. Contract assets expected to transfer to trade receivables within 12 months are accounted for within Prepaid expenses and other. Contract assets expected to transfer to trade receivables after 12 months are accounted for within Other long-term assets.

Performance Obligations

Remaining performance obligations represent firm orders for future development services as well as manufacturing and commercial product supply, including minimum volume commitments, for which there are incomplete performance obligations for work not yet completed under executed contracts. Remaining performance obligations as of June 30, 2024 and June 30, 2023 were \$618 million and \$335 million, respectively. The Company expects to recognize approximately 50% of the remaining performance obligations in existence as of June 30, 2024 after June 30, 2025.

[XML 58 R29-htm-IDEA: XBRL DOCUMENT](#)

Revenue Recognition (Tables) - USD (\$) \$ in Millions	12 Months Ended			
	Jun. 30, 2024			
		Jun. 30, 2023	Jun. 30, 2022	
Disaggregation of Revenue [Line Items]				
Disaggregation of Revenue				

The following tables reflect net revenue for the fiscal years ended June 30, 2024, 2023, and 2022 by type of activity and reporting segment (in millions):

June 30, 2024	Weighted Average Life	Gross Carrying Value	Accumulated Amortization	Net Carrying Value
Amortized intangibles:				
Core technology	11 years	\$ 480	\$ (205)	\$ 275
Customer relationships	13 years	1,076	(531)	545
Product relationships	8 years	242	(223)	19
Other	6 years	20	(18)	2
Total other intangibles		\$ 1,818	\$ (977)	\$ 841

June 30, 2023	Weighted Average Life	Gross Carrying Value	Accumulated Amortization	Net Carrying Value
Amortized intangibles:				
Core technology	11 years	\$ 482	\$ (164)	\$ 318
Customer relationships	13 years	1,079	(451)	628
Product relationships	8 years	243	(216)	27
Other	5 years	24	(17)	7
Total other intangibles		\$ 1,828	\$ (848)	\$ 980

Future Amortization Expense

Future amortization expense is estimated to be:

(Dollars in millions)	2025	2026	2027	2028	2029	Thereafter	Total
Amortization	\$ 133	\$ 125	\$ 109	\$ 102	\$ 98	\$ 274	\$ 841

~~XML 61 R32.htm IDEA: XBRL DOCUMENT~~

Restructuring and Other Costs (Tables)

Restructuring and Related Activities

[Abstract]

Schedule of Restructuring and Other Costs

12 Months Ended

Jun. 30, 2024

The following tables summarize the restructuring costs by type of cost and reportable segment:

(Dollars in millions)	Fiscal Year Ended June 30,		
	2024	2023	2022
Restructuring costs:			
Employee-related reorganization	\$ 26	\$ 38	\$ 9
Facility exit and other costs	13	28	1
Total restructuring costs	\$ 39	\$ 66	\$ 10

The following table summarizes the charges recorded within restructuring costs by segment. These amounts are excluded from Segment EBITDA as described in Note 18, Segment Information.

(Dollars in millions)	Fiscal Year Ended June 30,		
	2024	2023	2022
Restructuring costs:			
Biologics	\$ 11	\$ 41	\$ 1
Pharma and Consumer Health	19	8	5
Non-segment (Corporate)	9	17	4
Total restructuring costs	\$ 39	\$ 66	\$ 10

The following tables illustrates the change in the employee separation-related liability associated with the plans.

(Dollars in millions)	Employee-related restructuring
Balance, June 30, 2023	\$ 19
Charges	26
Payments	(35)
Balance, June 30, 2024	\$ 10

~~XML 62 R33.htm IDEA: XBRL DOCUMENT~~

Long-Term Obligations and Other

Short-Term Borrowings (Tables)

Debt Disclosure [Abstract]

Maturities of long-term obligations

12 Months Ended

Jun. 30, 2024

Maturities of long-term obligations, including finance leases of \$332 million, and other short-term borrowings for future fiscal years are:

(Dollars in millions)	2025	2026	2027	2028	2029	Thereafter	Total
Maturities of long-term and other obligations	\$ 48	\$ 49	\$ 49	\$ 3,350	\$ 569	\$ 884	\$ 4,949

Fair Value Disclosures [Abstract]

Schedule Of Carrying And Fair Value Of Financial Instruments Table

The carrying amounts and the estimated fair values of financial instruments as of June 30, 2024 and June 30, 2023 are as follows:

(Dollars in millions)	Fair Value Measurement	June 30, 2024		June 30, 2023	
		Carrying Value	Estimated Fair Value	Carrying Value	Estimated Fair Value
5.000% Senior Notes due 2027	Level 2	\$ 500	\$ 498	\$ 500	\$ 482
2.375% euro Senior Notes due 2028	Level 2	883	849	904	784
3.125% Senior Notes due 2029	Level 2	550	532	550	481
3.500% senior notes due 2030	Level 2	650	627	650	566
Senior secured credit facilities & other	Level 2	2,366	2,107	2,284	2,141
Subtotal		\$ 4,949	\$ 4,613	\$ 4,888	\$ 4,454
Unamortized discount and debt issuance costs		(44)	—	(39)	—
Total debt		\$ 4,905	\$ 4,613	\$ 4,849	\$ 4,454

~~XML 63 R34.htm IDEA: XBRL DOCUMENT~~

Earnings Per Share Calculation (Tables)

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

12 Months Ended

Jun. 30, 2024

The reconciliations between basic and diluted EPS attributable to Catalent common shareholders for the fiscal years ended June 30, 2024, 2023, and 2022 are as follows:

(In millions, except per share data)	Fiscal year ended June 30,		
	2024	2023	2022
Net (loss) earnings	\$ (1,043)	\$ (256)	\$ 499
Less: Net earnings attributable to preferred shareholders	—	—	(16)
Net (loss) earnings attributable to common shareholders	\$ (1,043)	\$ (256)	\$ 483
Weighted average shares outstanding - basic	181	181	176
Weighted average dilutive securities issuable - stock plans	—	—	2
Total weighted average shares outstanding - diluted	181	181	178
(Loss) earnings per share:			
Basic	\$ (5.76)	\$ (1.42)	\$ 2.74
Diluted	\$ (5.76)	\$ (1.42)	\$ 2.73

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The diluted weighted average number of shares outstanding for the fiscal years ended June 30, 2024, 2023, and 2022 did not include the following weighted average number of shares of Common Stock associated with the formerly outstanding Series A Preferred Stock or the weighted average number of shares of Common Stock associated with outstanding equity grants due to their antidilutive effect:

(share counts in millions)	Fiscal year ended June 30,		
	2024	2023	2022
Series A Preferred Stock	—	—	3

~~XML 64 R35.htm IDEA: XBRL DOCUMENT~~

Derivative Instruments and Hedging Activities (Tables)

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Net Investment Hedge in Accumulated Other Comprehensive Income (Loss) and Statement of Financial Performance [Table Text Block]

12 Months Ended

Jun. 30, 2024

The following table includes net investment hedge activity during the fiscal years ended June 30, 2024 and 2023, respectively:

(Dollars in millions)	June 30, 2024	June 30, 2023
Unrealized foreign exchange gain (loss) within other comprehensive income	\$ 21	(30)

A summary of the estimated fair value of the interest-rate swap reported in the consolidated balance sheets is stated in the table below:

Schedule of Interest Rate Derivatives

(in millions)	June 30, 2024		June 30, 2023	
	Balance Sheet Classification	Estimated Fair Value	Balance Sheet Classification	Estimated Fair Value
Interest-rate swap	Other long-term assets	\$ 36	Other long-term assets	\$ 62

[XML 65-R36.htm-IDEA: XBRL DOCUMENT](#)

Fair Value Measures and Disclosures (Tables)

Fair Value Disclosures [Abstract]

Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis

12 Months Ended

Jun. 30, 2024

The following table sets forth the Company's financial assets and liabilities that were measured at fair value on a recurring basis and the fair value measurement for such assets and liabilities at June 30, 2024 and 2023, respectively:

(Dollars in millions)	Basis of Fair Value Measurement			
	Total	Level 1	Level 2	Level 3
Assets:				
Interest-rate swap	\$ 36	\$ —	\$ 36	\$ —
Trading securities	\$ 1	\$ 1	\$ —	\$ —
June 30, 2023				
Assets:				
Interest-rate swap	\$ 62	\$ —	\$ 62	\$ —
Trading securities	\$ 1	\$ 1	\$ —	\$ —

[XML 66-R37.htm-IDEA: XBRL DOCUMENT](#)

Income Taxes (Tables)

Income Tax Disclosure [Abstract]

Earnings/(loss) from continuing operations before income taxes and discontinued operations

12 Months Ended

Jun. 30, 2024

Earnings (loss) before income taxes are as follows for fiscal 2024, 2023, and 2022:

(Dollars in millions)	Fiscal Year Ended June 30,		
	2024	2023	2022
U.S. operations	\$ (1,158)	\$ (410)	\$ 224
Non-U.S. operations	131	68	355
Total	\$ (1,027)	\$ (342)	\$ 579

Provision/ (benefit) for income taxes

The provision for income taxes consists of the following for fiscal 2024, 2023, and 2022:

(Dollars in millions)	Fiscal Year Ended June 30,		
	2024	2023	2022
Current:			
Federal	\$ —	\$ (1)	\$ (8)
State and local	(5)	(1)	14
Non-U.S.	48	43	66
Total current expense	\$ 43	\$ 41	\$ 72
Deferred:			
Federal	\$ (15)	\$ (99)	\$ 6
State and local	(11)	(4)	(5)
Non-U.S.	(1)	(24)	7
Total deferred (benefit) expense	\$ (27)	\$ (127)	\$ 8
Total provision (benefit)	\$ 16	\$ (86)	\$ 80

Reconciliation of the provision/(benefit) based on the federal statutory income tax rate

A reconciliation of the provision starting from the tax computed at the federal statutory income tax rate to the tax computed at the Company's effective income tax rate is as follows for the fiscal years ended 2024, 2023, and 2022:

(Dollars in millions)	Fiscal Year Ended June 30,		
	2024	2023	2022
Provision at U.S. federal statutory tax rate	\$ (216)	\$ (72)	\$ 122
State and local income taxes	(44)	(13)	10
Foreign tax rate differential	(7)	(5)	(28)
Global intangible low tax income	11	2	6
Goodwill impairment	80	9	—
Other permanent items	25	4	2
Unrecognized tax positions	—	(1)	1
Tax valuation allowance	160	5	94
Foreign tax credit	1	(30)	(43)
Withholding tax and other foreign taxes	3	1	1
Change in tax rate	1	18	1
R&D tax credit	(4)	(3)	(2)
Swiss tax reform	—	—	(83)
Other	6	(1)	(1)
Total provision (benefit)	\$ 16	\$ (86)	\$ 80

Components of the deferred income tax assets and liabilities

Deferred income taxes arise from temporary differences between the financial reporting and tax reporting bases of assets and liabilities, and operating loss and tax credit carryforwards for tax purposes. The components of the Company's deferred income tax assets and liabilities are as follows at June 30, 2024 and 2023:

(Dollars in millions)	Fiscal Year Ended June 30,	
	2024	2023
Deferred income tax assets:		
Accrued liabilities	\$ 70	\$ 57
Equity compensation	18	13
Loss and tax credit carryforwards	293	287
Foreign currency	3	3
Pension	18	19
Interest-related	101	50
Intangible	6	—
Lease liabilities	37	38
Euro-denominated debt	—	1
Other	—	1
Total deferred income tax assets	\$ 546	\$ 469
Valuation allowance	(315)	(159)
Net deferred income tax assets	\$ 231	\$ 310
Deferred income tax liabilities:		
Euro-denominated debt	\$ (4)	\$ —
Property-related	(205)	(247)
Goodwill and other intangibles	—	(71)
Deferred revenue	(2)	—
Right-of-use assets	(16)	(13)
Other	(2)	—
Total deferred income tax liabilities	\$ (229)	\$ (331)
Net deferred tax asset (liability)	\$ 2	\$ (21)

Deferred tax assets and liabilities

Deferred tax assets and liabilities in the preceding table are in the following captions in the consolidated balance sheets at June 30, 2024 and 2023:

(Dollars in millions)	Fiscal Year Ended June 30,	
	2024	2023
Non-current deferred tax asset	\$ 7	\$ 55
Non-current deferred tax liability	(5)	(76)
Net deferred tax asset (liability)	\$ 2	\$ (21)

Reconciliation of Unrecognized tax benefit, excluding accrued interest

A reconciliation of unrecognized tax benefits, excluding accrued interest, as of June 30, 2024, 2023, and 2022 is as follows:

(Dollars in millions)	
Balance at June 30, 2021	\$ 5
Additions for tax positions related to the current year	1
Additions for tax positions of prior years	1
Settlements	(1)
Lapse of the applicable statute of limitations	(1)
Balance at June 30, 2022	\$ 5
Additions for tax positions of prior years	2
Reductions for tax positions of prior years	(1)
Settlements	(1)
Lapse of the applicable statute of limitations	(1)
Balance at June 30, 2023	\$ 4
Additions for tax positions of prior years	1
Reductions for tax positions of prior years	(1)
Balance at June 30, 2024	\$ 4

~~XML 67 R38.htm IDEA XBRL DOCUMENT~~

Employee Retirement
Benefit Plans (Tables)

Jun. 30, 2024

12 Months Ended

Jun. 30, 2023

Retirement Benefits [Abstract]

Benefit obligation and fair value of plan
assets for the defined benefit retirement
and postretirement plan

The following table provides a reconciliation of the change in projected benefit obligation and fair value of plan assets for the defined benefit retirement and other retirement plans, excluding the multi-employer pension plan liability:

(Dollars in millions)	Retirement Benefits		Other Post-Retirement Benefits	
	June 30,		June 30,	
	2024	2023	2024	2023
Accumulated Benefit Obligation	\$ 206	\$ 242	\$ 1	\$ 2
Change in Benefit Obligation				
Benefit obligation at beginning of year	246	268	2	2
Company service cost	3	3	—	—
Interest cost	11	9	—	—
Employee contributions	1	1	—	—
Settlements	(36)	(4)	—	—
Benefits paid	(11)	(10)	—	—
Actuarial gain	1	(28)	—	—
Exchange rate gain (loss)	(4)	7	—	—
Benefit obligation at end of year	\$ 211	\$ 246	\$ 2	\$ 2
Change in Plan Assets				
Fair value of plan assets at beginning of year	202	240	—	—
Actual return on plan assets	3	(38)	—	—
Company contributions	11	7	—	—
Employee contributions	1	1	—	—
Settlements	(36)	(4)	—	—
Benefits paid	(11)	(10)	—	—
Exchange rate gain (loss)	(2)	6	—	—
Fair value of plan assets at end of year	\$ 168	\$ 202	\$ —	\$ —
Funded Status				
Funded status at end of year	(43)	(44)	(1)	(2)
Net pension liability	\$ (43)	\$ (44)	\$ (1)	\$ (2)

Reconciliation of the net amount
recognized in the Consolidated Balance
Sheets

The following table provides a reconciliation of the net amount recognized in the consolidated balance sheets:

(Dollars in millions)	Retirement Benefits		Other Post-Retirement Benefits	
	June 30,		June 30,	
	2024	2023	2024	2023
Amounts Recognized in Statement of Financial Position				
Noncurrent assets	\$ 13	\$ 18	\$ —	\$ —
Current liabilities	(1)	(1)	—	—
Noncurrent liabilities	(55)	(61)	(1)	(2)
Total liability	(43)	(44)	(1)	(2)
Amounts Recognized in Accumulated Other Comprehensive Loss				
Prior service cost	(1)	(1)	—	—
Net loss (gain)	58	66	(1)	(1)
Total accumulated other comprehensive loss (income) at the end of the fiscal year	57	65	(1)	(1)
Additional Information for Plan with ABO or PBO in Excess of Plan Assets				
Projected benefit obligation	93	129	1	2
Accumulated benefit obligation	89	126	1	2
Fair value of plan assets	37	68	—	—
Components of Net Periodic Benefit Cost				
Service cost	3	3	—	—
Interest cost	11	9	—	—
Expected return on plan assets	(9)	(9)	—	—
Amortization of unrecognized:				
Net loss	2	1	—	—
Settlement/curtailment expense	12	1	—	—
Net periodic benefit cost	\$ 19	\$ 5	\$ —	\$ —
(Dollars in millions)	Retirement Benefits		Other Post-Retirement Benefits	
	June 30,		June 30,	
	2024	2023	2024	2023
Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income				
Net loss (gain) arising during the year	\$ 6	\$ 17	\$ —	\$ —
Exchange rate loss recognized during the year	(14)	—	—	—
Total recognized in other comprehensive income	\$ (8)	\$ 17	\$ —	\$ —
Total Recognized in Net Periodic Benefit Cost and Other Comprehensive Income				
Total recognized in net periodic benefit cost and other comprehensive income	\$ 11	\$ 22	\$ —	\$ —
Estimated Amounts to be Amortized from Accumulated Other Comprehensive Income into Net Periodic Benefit Cost				
Amortization of:				
Net loss	\$ 2	\$ 2	\$ —	\$ —
Financial Assumptions Used to Determine Benefit Obligations at the Balance Sheet Date				
Discount rate (%)	4.3 %	4.3 %	5.0 %	4.7 %
Rate of compensation increases (%)	2.7 %	2.7 %	n/a	n/a
Financial Assumptions Used to Determine Net Periodic Benefit Cost for Financial Year				
Discount rate (%)	4.3 %	3.6 %	4.7 %	4.0 %
Rate of compensation increases (%)	2.7 %	2.7 %	n/a	n/a
Expected long-term rate of return (%)	4.3 %	3.9 %	n/a	n/a
Expected Future Contributions				
Fiscal year 2025	\$ 4	\$ 8	\$ —	\$ —

	Retirement Benefits			Other Post-Retirement Benefits		
	June 30,			June 30,		
	2024	2023		2024	2023	
Expected Future Benefit Payments						
Financial year						
2025	\$ 12	\$ 14		\$ —	\$ —	
2026	13	15		—	—	
2027	12	16		—	—	
2028	12	15		—	—	
2029	13	15		—	—	
2030-2034	71	84		1	1	
Actual Asset Allocation (%)						
Cash	1.0 %	4.5 %		— %	— %	
Equities	2.9 %	2.9 %		— %	— %	
Government bonds	37.7 %	36.8 %		— %	— %	
Corporate bonds	16.8 %	16.2 %		— %	— %	
Property	4.5 %	3.3 %		— %	— %	
Insurance contracts	16.6 %	14.9 %		— %	— %	
Other	20.5 %	21.4 %		— %	— %	
Total	100.0 %	100.0 %		— %	— %	
Actual Asset Allocation (Amount)						
Cash	\$ 2	\$ 9		\$ —	\$ —	
Equities	5	6		—	—	
Government bonds	63	74		—	—	
Corporate bonds	28	33		—	—	
Property	8	7		—	—	
Insurance contracts	28	30		—	—	
Other	34	43		—	—	
Total	\$ 168	\$ 202		\$ —	\$ —	
Target Asset Allocation (%)						
Cash	1.0 %	4.5 %		— %	— %	
Equities	2.9 %	2.9 %		— %	— %	
Government bonds	37.7 %	36.8 %		— %	— %	
Corporate bonds	16.8 %	16.2 %		— %	— %	
Property	4.5 %	3.3 %		— %	— %	
Insurance contracts	16.6 %	14.9 %		— %	— %	
Other	20.5 %	21.4 %		— %	— %	
Total	100.0 %	100.0 %		— %	— %	

Summary of plan assets that are measured in fair value

The following tables provide a summary of plan assets that are measured at fair value as of June 30, 2024 and 2023, aggregated by the level in the fair value hierarchy within which those measurements fall:

As of June 30, 2024 (dollars in millions)	Level 1	Level 2	Level 3	Investments Measured at Net Asset Value	Total Assets	As of June 30, 2023 (dollars in millions)	Level 1	Level 2	Level 3	Investments Measured at Net Asset Value	Total Assets
Equity securities	\$ —	\$ 5	\$ —	\$ —	\$ 5	Equity securities	\$ —	\$ 6	\$ —	\$ —	\$ 6
Debt securities	—	91	—	—	91	Debt securities	—	107	—	—	107
Real estate	—	3	2	—	5	Real estate	—	5	2	—	7
Other ⁽¹⁾	—	42	25	—	67	Other ⁽¹⁾	—	57	25	—	82
Total	\$ —	\$ 141	\$ 27	\$ —	\$ 168	Total	\$ —	\$ 175	\$ 27	\$ —	\$ 202

(1) Other, as of June 30, 2024, included \$12 million of investments in hedge funds related to the Company’s U.K. pension plan, which were classified as Level 2.

Reconciliation of beginning and ending balances of level 3 assets

The following table provides a reconciliation of the beginning and ending balances of Level 3 assets as well as the changes during the period attributable to assets held and those purchases, sales, settlements, contributions, and benefits that were paid:

Total (Level 3) (Dollars in millions)	Fair Value Measurement Using Significant Unobservable Inputs Total (Level 3)	Fair Value Measurement Using Significant Unobservable Inputs Insurance Contracts	Fair Value Measurement Using Significant Unobservable Inputs Other
Beginning Balance at June 30, 2023	\$ 27	\$ 8	\$ 19
Actual return on plan assets: Relating to assets still held at the reporting date	1	1	—
Purchases, sales, settlements, contributions and benefits paid	(4)	(2)	(2)
Transfers in or out of Level 3, net	3	—	3
Ending Balance at June 30, 2024	\$ 27	\$ 7	\$ 20

Assumed healthcare cost trend rates

Assumed Healthcare Cost Trend Rates at the Balance Sheet Date		Other Post-Retirement Benefits	
		2024	2023
Healthcare cost trend rate – initial (%)			
Pre-65		n/a	n/a
Post-65		5.0 %	4.8 %
Healthcare cost trend rate – ultimate (%)			
Pre-65		n/a	n/a
Post-65		4.1 %	4.1 %
Year in which ultimate rates are reached			
Pre-65		n/a	n/a
Post-65		2040	2040

~~XML-68-R39.htm-IDEA: XBRL DOCUMENT~~

Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

Equity [Abstract]

Accumulated other comprehensive earnings/(loss)

12 Months Ended

Jun. 30, 2024

or the fiscal years ended June 30, 2024, 2023, and 2022, the changes in accumulated other comprehensive loss, net of tax by component are as follows:

(Dollars in millions)	Foreign Currency Translation Adjustment	Pension Liability Adjustments	Derivatives and Hedges	Marketable Securities	Other	Total
Balance at June 30, 2021	\$ (268)	\$ (47)	\$ —	\$ (1)	\$ (1)	\$ (317)
Other comprehensive income (loss) before reclassifications	(110)	8	27	(3)	—	(78)
Amounts reclassified from other comprehensive loss	—	1	—	—	—	1
Balance at June 30, 2022	(378)	(38)	27	(4)	(1)	(394)
Other comprehensive income (loss) before reclassifications	32	(16)	18	—	—	34
Amounts reclassified from other comprehensive loss	—	2	—	4	—	6
Balance at June 30, 2023	(346)	(52)	45	—	(1)	(354)
Other comprehensive income (loss) before reclassifications	(32)	2	(22)	—	—	(52)
Amounts reclassified from other comprehensive loss	—	2	—	—	—	2
Balance at June 30, 2024	\$ (378)	\$ (48)	\$ 23	\$ —	\$ (1)	\$ (404)

Schedule of Comprehensive Income (Loss)

The components of the changes in the cumulative translation adjustment, derivatives and hedges, minimum pension liability, and marketable securities for the fiscal years ended June 30, 2024, 2023, and 2022 are presented below:

(Dollars in millions)	Fiscal Year Ended June 30,		
	2024	2023	2022
Foreign currency translation adjustments:			
Net investment hedge	\$ 21	\$ (30)	\$ 121
Long-term inter-company loans	1	12	(37)
Translation adjustments	(50)	43	(169)
Total foreign currency translation adjustments, pretax	(28)	25	(85)
Tax expense (benefit)	4	(7)	25
Total foreign currency translation adjustments, net of tax	\$ (32)	\$ 32	\$ (110)
Net change in derivatives and hedges:			
Net (loss) gain recognized during the year, pretax	\$ (25)	\$ 25	\$ 36
Tax (benefit) expense	(3)	7	9
Net change in derivatives and hedges, net of tax	\$ (22)	\$ 18	\$ 27
Net change in minimum pension liability:			
Net (loss) gain recognized during the year, pretax	\$ 8	\$ (17)	\$ 13
Tax expense (benefit)	4	(3)	4
Net change in minimum pension liability, net of tax	\$ 4	\$ (14)	\$ 9
Net change in marketable securities:			
Net gain (loss) recognized during the year, pretax	\$ —	\$ 5	\$ (3)
Tax expense	—	1	—
Net change in marketable securities, net of tax	\$ —	\$ 4	\$ (3)

For the fiscal years ended June 30, 2024, 2023, and 2022, the changes in accumulated other comprehensive loss, net of tax by component are as follows:

(Dollars in millions)	Foreign Currency Translation Adjustment	Pension Liability Adjustments	Derivatives and Hedges	Marketable Securities	Other	Total
Balance at June 30, 2021	\$ (268)	\$ (47)	\$ —	\$ (1)	\$ (1)	\$ (317)
Other comprehensive income (loss) before reclassifications	(110)	8	27	(3)	—	(78)
Amounts reclassified from other comprehensive loss	—	1	—	—	—	1
Balance at June 30, 2022	(378)	(38)	27	(4)	(1)	(394)
Other comprehensive income (loss) before reclassifications	32	(16)	18	—	—	34
Amounts reclassified from other comprehensive loss	—	2	—	4	—	6
Balance at June 30, 2023	(346)	(52)	45	—	(1)	(354)
Other comprehensive income (loss) before reclassifications	(32)	2	(22)	—	—	(52)
Amounts reclassified from other comprehensive loss	—	2	—	—	—	2
Balance at June 30, 2024	\$ (378)	\$ (48)	\$ 23	\$ —	\$ (1)	\$ (404)

[XML 69 R40.htm IDEA: XBRL DOCUMENT](#)

Equity Based Compensation (Tables)

Share-Based Payment Arrangement [Abstract]

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]

12 Months Ended Jun. 30, 2024

The weighted average of assumptions used in estimating the fair value of stock options granted during each year were as follows:

	Fiscal Year Ended June 30,		
	2024	2023	2022
Expected volatility	52%	37%	37%
Expected life (in years)	4.0	4.3	3.7
Risk-free interest rate	4.4%	3.2%	0.7%
Dividend yield	None	None	None

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

The following table summarizes stock option activity and shares subject to outstanding options for the fiscal year ended June 30, 2024:

	Weighted Average Exercise Price	Number of Shares	Weighted Average Contractual Term	Aggregate Intrinsic Value
Outstanding as of June 30, 2023	\$ 71.19	1,008,747	6.22	\$ 2,225,819
Granted	47.39	473,432	—	—
Exercised	47.02	193,508	—	1,862,358
Forfeited	97.23	33,550	—	—
Expired / Canceled	72.90	67,624	—	—
Outstanding as of June 30, 2024	64.81	1,187,497	5.7	8,655,393
Vested/expected to vest as of June 30, 2024	64.81	1,187,497	5.7	8,655,393
Vested and exercisable as of June 30, 2024	\$ 65.78	521,898	3.21	\$ 4,499,875

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

The following table summarizes activity in unvested time-based restricted share units for the fiscal year ended June 30, 2024:

	Time-Based Stock Units	Weighted Average Grant-Date Fair Value
Unvested as of June 30, 2023	1,026,729	\$ 83.07
Granted	1,611,350	47.77
Vested	220,139	87.79
Cancelled/forfeited	263,348	65.22
Unvested as of June 30, 2024	2,154,592	56.14

Schedule of Nonvested Performance-based Units Activity [Table Text Block]

Performance Share Units

The following table summarizes activity in unvested performance share units for the fiscal year ended June 30, 2024:

	Performance Share Units	Weighted Average Grant-Date Fair Value
Target Number Unvested as of June 30, 2023	273,985	\$ 99.58
Target Number Granted	46,899	—
Target Number Vested	84,342	88.35
Target Number Cancelled/forfeited	76,554	105.33
Target Number Unvested as of June 30, 2024	159,988	\$ 103.17

Fair Value Measurements, Nonrecurring

Valuation of RTSR Units

The fair value of each RTSR unit is determined using the Monte Carlo pricing model because the number of shares to be awarded is subject to a market condition. The Monte Carlo simulation is a generally accepted statistical technique used to simulate a range of possible future outcomes. Because the valuation model considers a range of possible outcomes, compensation cost is recognized regardless of whether the market condition is actually satisfied.

The assumptions used in estimating the fair value of the RTSR units granted during each year were as follows:

	Fiscal Year Ended June 30,		
	2024	2023	2022
Expected volatility	52 %	57%	41 %
Expected life (in years)	2.5 -	3.0	2.4 -
Risk-free interest rates	4.0 %	5.0%	3.0 %
Dividend yield	None	None	None

Nonvested Restricted Stock Shares Activity

The following table summarizes activity in unvested RTSR units for the fiscal year ended June 30, 2024.

	RTSR Units	Weighted Average Grant-Date Fair Value
Target Number Unvested as of June 30, 2023	342,546	\$ 82.36
Target Number Granted	326,062	39.52
Target Number Vested	190	63.13
Target Number Cancelled/forfeited	81,389	63.42
Target Number Unvested as of June 30, 2024	587,029	\$ 51.98

[XML 70 R41.htm IDEA: XBRL DOCUMENT](#)

Leases (Tables)

12 Months Ended Jun. 30, 2024

Leases [Abstract]

Schedule of Operating and Financing Leases Presented in Balance Sheet

Supplemental information concerning the leases recorded in the Company's consolidated balance sheet as of June 30, 2024 is detailed in the following table:

[Lease Cost](#)

(Dollars in millions)		Line item in the consolidated balance sheet		Balance at June 30, 2024	Balance at June 30, 2023
Right-of-use assets:					
Finance leases	Property, plant, and equipment, net		\$	252	\$ 274
Operating leases	Other long-term assets			77	59
Current lease liabilities:					
Finance leases	Current portion of long-term obligations and other short-term borrowings			20	18
Operating leases	Other accrued liabilities			13	11
Non-current lease liabilities:					
Finance leases	Long-term obligations, less current portion			312	323
Operating leases	Other liabilities		\$	70	\$ 55

The components of the net lease costs for the fiscal years ended June 30, 2024 and 2023 reflected in the Company's consolidated statement of operations were as follows:

(Dollars in millions)		Fiscal Year Ended June 30, 2024	Fiscal Year Ended June 30, 2023
Financing lease costs:			
Amortization of right-of-use assets		\$ 30	\$ 21
Interest on lease liabilities		21	17
Total		51	38
Operating lease costs		27	35
Variable lease costs		16	10
Total lease costs		\$ 94	\$ 83

The short-term lease cost amounted to \$9 million, \$10 million and \$8 million during the fiscal year ended June 30, 2024, 2023 and 2022, respectively.

The weighted average remaining lease term and weighted average discount rate related to the Company's right-of-use assets and lease liabilities as of June 30, 2024 are as follows:

Weighted average remaining lease term (years):		
Finance leases		16.1
Operating leases		9
Weighted average discount rate:		
Finance leases		6.2 %
Operating leases		4.6 %

[Schedule of Cash Flow, Supplemental Disclosures](#)

Supplemental information concerning the cash-flow impact arising from the Company's leases for the fiscal year ended June 30, 2024 recorded in the Company's unaudited consolidated statement of cash flows is detailed in the following table (in millions):

	Fiscal Year Ended June 30, 2024	Fiscal Year Ended June 30, 2023	Fiscal Year Ended June 30, 2022
Cash paid for amounts included in lease liabilities:			
Financing cash flows used for finance leases	\$ 19	\$ 19	\$ 15
Operating cash flows used for finance leases	16	15	11
Operating cash flows used for operating leases	14	16	19
Non-cash transactions:			
Right-of-use assets obtained in exchange for new finance lease liabilities	57	133	59
Right-of-use assets obtained in exchange for new operating lease liabilities	\$ 38	\$ 1	\$ 31

[Schedule of Maturities of Lease Liabilities](#)

As of June 30, 2024, the Company expects that its future minimum lease payments will become due and payable as follows:

(Dollars in millions)	Financing Leases		Operating Leases		Total
2025	\$	37	\$	17	\$ 54
2026		39		15	54
2027		37		14	51
2028		34		13	47
2029		34		9	43
Thereafter		337		36	373
Total minimum lease payments		518		104	622
Less: interest		186		21	207
Total lease liabilities	\$	332	\$	83	\$ 415

[XML 71-R42.htm IDEA: XBRL DOCUMENT](#)

[Segment Information \(Tables\)](#)

**12 Months Ended
Jun. 30, 2024**

[Segment Reporting \[Abstract\]](#)
[Net Revenue and Segment EBITDA](#)

The following table includes Segment EBITDA for each of the Company's current reporting segments during the fiscal years ended June 30, 2024, 2023, and 2022:

(Dollars in millions)		Fiscal Year Ended June 30,		
Segment EBITDA reconciled to net (loss) earnings:		2024	2023	2022
Biologics		\$ 272	\$ 277	\$ 777
Pharma and Consumer Health		597	548	589
Subtotal		869	825	1,366
Reconciling items to net (loss) earnings				
Unallocated costs ⁽¹⁾		\$ (1,153)	\$ (559)	\$ (286)
Depreciation and amortization		(489)	(422)	(378)
Interest expense, net		(254)	(186)	(123)
Income tax benefit (expense)		(16)	86	(80)
Net (loss) earnings		\$ (1,043)	\$ (256)	\$ 499

(1) Unallocated costs include restructuring and special items, stock-based compensation, gain (loss) on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:

(Dollars in millions)		Fiscal Year Ended June 30,		
		2024	2023	2022
Impairment charges and gain/loss on sale of assets ^(a)		\$ (29)	\$ (98)	\$ (31)
Stock-based compensation		(68)	(35)	(54)
Restructuring and other special items ^(b)		(178)	(98)	(55)
Pension settlement charges		(12)	—	—
Goodwill impairment charges ^(c)		(687)	(210)	—
Gain on sale of subsidiary		—	—	1
Other (expense) income, net ^(d)		(24)	7	(28)
Non-allocated corporate costs, net		(155)	(125)	(119)
Total unallocated costs		\$ (1,153)	\$ (559)	\$ (286)

(a) Impairment charges and gain/loss on sale of assets for the fiscal year ended June 30, 2024 includes right-of-use asset impairment charges associated with under utilized facilities in our Biologics segment, obsolete equipment that could not be sold or repurposed in our Biologics segment and under utilized suites from a canceled project in our Pharma and Consumer Health segment.

For the fiscal year ended June 30, 2023, impairment charges are primarily associated with an idle facility in the Biologics segment and obsolete equipment that could not be sold or repurposed in the Pharma and Consumer Health segment. Further detail is provided below.

For the fiscal year ended June 30, 2023, the Company identified an indicator of impairment related to one of its facilities in the Biologics segment given the plans to pause any additional spend on site development due to a lack of demand, leading to a partial impairment charge of \$54 million. The Company primarily utilized a market and income approach for real property and a cost approach for personal property to record the partial impairment on its idle facility. Impairment charges are recorded in Other operating expense in the consolidated statements of operations.

Also, in the fiscal year ended June 30, 2023, the Company identified an indicator of impairment related to obsolete equipment from a terminated project in the Pharma and Consumer Health segment, leading to a full impairment charge of \$18 million.

For the fiscal year ended June 30, 2022, impairment charges are primarily due to fixed asset impairment charges associated with dedicated equipment for a product the Company no longer manufactures in its Pharma and Consumer Health segment and obsolete equipment in its Biologics segment.

(b) Restructuring and other special items during the fiscal year ended June 30, 2024 include restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization. For further details on restructuring charges, see Note 6, *Restructuring Costs* to the Consolidated Financial Statements.

Restructuring and other special items for the fiscal year ended June 30, 2023 includes (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition

Restructuring and other special items for the fiscal year ended June 30, 2022 include (i) transaction and integration costs primarily associated with the Princeton, Bettera Wellness, Delphi, Hepatic, Acorda, and RheinCell transactions and (ii) unrealized losses on venture capital investments.

(c) Goodwill impairment charges during the fiscal year ended June 30, 2024 were associated with the Company's Consumer Health and Biomodalities reporting units, which are part of the Company's Pharma and Consumer Health and Biologics segments, respectively. For further details, see Note 4, *Goodwill* to the Consolidated Financial Statements.

The goodwill impairment charges for the fiscal year ended June 30, 2023 was associated with the Company's Consumer Health reporting unit. For further details, see Note 4, *Goodwill*.

(d) Refer to Note 15, *Other (income) expense, net* for details of financing charges and foreign currency translation adjustments recorded within other (income) expense, net.

[Total Assets for Each Segment and Reconciling in](#)

The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated balance sheets.

Consolidated Financial Statements

Total Assets	June 30, 2024		June 30, 2023	
(Dollars in millions)				
Biologics	\$	5,326	\$	5,746
Pharma and Consumer Health		4,643		4,867
Corporate and eliminations		(216)		164
Total assets	\$	9,753	\$	10,777

Capital Expenditures by Segment

Capital Expenditures	Fiscal Year Ended June 30,		
(Dollars in millions)	2024	2023	2022
Biologics	\$ 171	\$ 346	\$ 453
Pharma and Consumer Health	164	214	183
Corporate	16	34	30
Total capital expenditures ⁽¹⁾	\$ 351	\$ 594	\$ 666

Presentation of revenue and long-lived assets by geographic area

Long Lived Assets	June 30, 2024		June 30, 2023	
(Dollars in millions)				
United States	\$	2,625	\$	2,758
Europe		828		765
Other		190		159
Total	\$	3,643	\$	3,682

- [1] Refer to Note 15, *Other (income) expense, net* for details of financing charges and foreign currency translation adjustments recorded within other (income) expense, net.
- [2] Unallocated costs include restructuring and special items, stock-based compensation, gain (loss) on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:

~~XML 72 R43.htm IDEA: XBRL DOCUMENT~~

Supplemental Balance Sheet Information (Tables)

Balance Sheet Related Disclosures [Abstract]

Work-in-Process and Finished Goods Inventories Include Raw Materials, Labor and Overhead

12 Months Ended
Jun. 30, 2024

(Dollars in millions)	June 30, 2024	June 30, 2023
Raw materials and supplies	\$ 646	\$ 781
Work-in-process	138	186
Total inventories, gross	784	967
Inventory cost adjustment	(210)	(190)
Total inventories	\$ 574	\$ 777

Prepaid and Other Assets

(Dollars in millions)	June 30, 2024	June 30, 2023
Prepaid expenses	\$ 46	\$ 53
Short-term contract assets	585	399
Spare parts supplies	29	24
Prepaid income tax	45	77
Non-U.S. value-added tax	60	38
Other current assets	48	42
Total prepaid expenses and other	\$ 813	\$ 633

Property and Equipment

(Dollars in millions)	June 30, 2024	June 30, 2023
Land, buildings, and improvements	\$ 1,987	\$ 1,887
Machinery and equipment	2,538	2,287
Furniture and fixtures	62	61
Construction in progress	971	1,043
Property, plant, and equipment, at cost	5,558	5,278
Accumulated depreciation	(1,915)	(1,596)
Property, plant, and equipment, net	\$ 3,643	\$ 3,682

Other Assets Non Current

(Dollars in millions)	June 30, 2024	June 30, 2023
Operating lease right-of-use-assets	\$ 77	\$ 59
Note receivable	56	53
Corporate-owned life insurance policies	48	41
Venture capital investments	47	36
Interest-rate swap	36	62
Pension assets	13	18
Long-term contract assets	17	18
Other	38	42
Total other long-term assets	\$ 332	\$ 329

Other Accrued Liabilities

(Dollars in millions)	June 30, 2024	June 30, 2023
Contract liability	\$ 250	\$ 167
Accrued employee-related expenses	181	160
Accrued expenses	115	134
Operating lease liabilities	13	11
Restructuring accrual	10	19
Accrued interest	37	35
Accrued income tax	16	44
Total other accrued liabilities	\$ 622	\$ 570

~~XML 73 R44.htm IDEA: XBRL DOCUMENT~~

Basis of Presentation and Summary of Significant

Accounting Policies - Additional Information (Detail) - \$ / shares	Jun. 30, 2024	Feb. 05, 2024	Jun. 30, 2023

Common stock, par value (usd per share) \$ 0.01 \$ 0.01 \$ 0.01

~~XML 74 R45.htm IDEA: XBRL DOCUMENT~~

Basis of Presentation and Summary of Significant

Accounting Policies Property and Equipment and Other Definite Lived Intangible Assets (Details) - USD (\$)	12 Months Ended		
\$ in Millions	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022

Depreciation expense	\$ 354	\$ 286	\$ 255
Interest Costs Capitalized	10	24	15
Gain (Loss) on Sale of Assets and Asset Impairment Charges	\$ (29)	\$ (98)	\$ (31)
Segment Reporting, Disclosure of Major Customers	16%	10%	10%
Minimum [Member] Software and Software Development Costs			
Finite-Lived Intangible Asset, Useful Life	3 years		
Maximum [Member] Software and Software Development Costs			
Finite-Lived Intangible Asset, Useful Life	5 years		
Building And Improvements [Member] Minimum [Member]			
Property, Plant and Equipment, Useful Life	5 years		
Building And Improvements [Member] Maximum [Member]			
Property, Plant and Equipment, Useful Life	50 years		

[Machinery and Equipment \[Member\] | Minimum \[Member\] Property, Plant and Equipment, Useful Life](#)
[Machinery and Equipment \[Member\] | Maximum \[Member\] Property, Plant and Equipment, Useful Life](#)
[Furniture and Fixtures \[Member\] | Minimum \[Member\] Property, Plant and Equipment, Useful Life](#)
[Furniture and Fixtures \[Member\] | Maximum \[Member\] Property, Plant and Equipment, Useful Life](#)

3 years
10 years
3 years
7 years

~~XML 75-R46.htm-IDEA: XBRL DOCUMENT~~

Basis of Presentation and Summary of Significant Accounting Policies Research and Development Expense (Details) - USD (\$) \$ in Millions	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022

Research and Development Expense	\$ 17	\$ 18	\$ 23
Concentration Risk trade receivables and current contract asset, Percentage	34.00%	20.00%	
Segment Reporting, Disclosure of Major Customers	16%	10%	10%

~~XML 76-R47.htm-IDEA: XBRL DOCUMENT~~

Basis of Presentation and Summary of Significant Accounting Policies Recent Financial Accounting Standards (Details) \$ in Millions	Jun. 30, 2024 USD (\$)		

[New Accounting Pronouncements or Change in Accounting Principle \[Line Items\]](#)

Operating Lease, Liability	\$ 83
Operating Lease, Liability, Statement of Financial Position [Extensible List]	Other Liabilities

~~XML 77-R48.htm-IDEA: XBRL DOCUMENT~~

Revenue Recognition Disaggregation of Revenue by type of activity and reporting segment (Details) - USD (\$)	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	\$ (4,381,000,000)	\$ (4,263,000,000)	\$ (4,802,000,000)

[Greater Than One Year Member](#)

[Disaggregation of Revenue \[Line Items\]](#)

Revenue, Remaining Performance Obligation, Percentage to be recognized over the next six months	50.00%

[Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	(4,381,000,000)	\$ (4,263,000,000)	(4,802,000,000)

[Operating Segments Excluding Intersegment Elimination](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	(4,383,000,000)	(4,265,000,000)	(4,805,000,000)

[Biologics \[Member\] | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	(1,952,000,000)	(1,978,000,000)	(2,534,000,000)

[Biologics \[Member\] | Manufacturing & Commercial Product Supply \[Member\]](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	(1,151,000,000)	(450,000,000)	(608,000,000)

[Biologics \[Member\] | Development Services \[Member\]](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	(801,000,000)	(1,528,000,000)	(1,926,000,000)

[PharmaConsumerHealth | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	(2,431,000,000)	(2,287,000,000)	(2,271,000,000)

[PharmaConsumerHealth | Manufacturing & Commercial Product Supply \[Member\]](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	(1,577,000,000)	(1,452,000,000)	(1,474,000,000)

[PharmaConsumerHealth | Development Services \[Member\]](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	(854,000,000)	(835,000,000)	(797,000,000)

[Total Catalent before inter-segment revenue elimination \[Member\] | Manufacturing & Commercial Product Supply \[Member\]](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	(2,728,000,000)	(1,902,000,000)	(2,082,000,000)

[Total Catalent before inter-segment revenue elimination \[Member\] | Development Services \[Member\]](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	(1,655,000,000)	(2,363,000,000)	(2,723,000,000)

[Total Catalent Segment | Intersegment Eliminations](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	\$ 2,000,000	\$ 2,000,000	\$ 3,000,000

~~XML 78-R49.htm-IDEA: XBRL DOCUMENT~~

Revenue Recognition Disaggregation of Revenue by Geography (Details) - USD (\$) \$ in Millions	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022

[Disaggregation of Revenue \[Line Items\]](#)

Elimination of revenue attributable to multiple locations	\$ (157)	\$ (117)	\$ (115)

Net revenue	4,381	4,263	4,802

[Europe](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	1,359	1,257	1,506

[International Other](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	356	355	327

[United States \[Member\]](#)

[Disaggregation of Revenue \[Line Items\]](#)

Net revenue	\$ 2,823	\$ 2,768	\$ 3,084

~~XML 79-R50.htm-IDEA: XBRL DOCUMENT~~

Revenue Recognition Contractual Liabilities (Details) - USD (\$)	12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023

[Revenue Recognition and Deferred Revenue \[Abstract\]](#)

Business Combination, Acquired Receivables, Description Metrics								\$51 million
Business Acquisition [Line Items]								
Payment for acquisitions, net of cash acquired								\$ (474,000,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment								\$ 195,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory								5,000,000
Goodwill, Acquired During Period								219,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles								52,000,000
Metrics Customer relationships [Member]								
Business Acquisition [Line Items]								
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles								\$ 52,000,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life								12 years
XML 83 R54.htm IDEA: XBRL DOCUMENT								
Business Combinations Net Assets Acquired (Details) - USD (\$)								
	Oct. 01, 2022	Aug. 01, 2021	1 Months Ended		12 Months Ended			
			Apr. 30, 2022	Oct. 31, 2021	Jun. 30, 2024	Jun. 30, 2023	Oct. 01, 2021	
Net Assets Acquired from Business Combinations								
Goodwill, Acquired During Period								\$ 219,000,000
Notes Receivable Interest Rate						500.00%		
Bettera Holdings, LLC								
Net Assets Acquired from Business Combinations								
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment								\$ 72
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	\$ 31							
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities								(17)
Goodwill, Acquired During Period				\$ 531				
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents								23
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables								16
RheinCell Therapeutics								
Net Assets Acquired from Business Combinations								
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				\$ 14,000,000				
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities				(4,000,000)				
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities				(1,000,000)				
Goodwill, Acquired During Period				\$ 17,000,000				
Princeton Cell Therapy								
Net Assets Acquired from Business Combinations								
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				\$ 22,000,000				
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets				10,000,000				
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities				(1,000,000)				
Goodwill, Acquired During Period				24,000,000				
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other				10,000,000				
Vaccine Manufacturing and Innovation Centre								
Net Assets Acquired from Business Combinations								
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				165,000,000				
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities				(18,000,000)				
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets				1,000,000				
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other				14,000,000				
Business Acquisition, Transaction Costs				\$ 9,000,000				
Metrics								
Net Assets Acquired from Business Combinations								
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	195,000,000							
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	5,000,000							
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	52,000,000							
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	(12,000,000)							
Goodwill, Acquired During Period	219,000,000							
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	474,000,000							
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	15,000,000							
Customer relationships [Member]								
Net Assets Acquired from Business Combinations								
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life						13 years	13 years	
Customer relationships [Member] Metrics								
Net Assets Acquired from Business Combinations								
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	\$ 52,000,000							
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years							
Product relationships [Member]								
Net Assets Acquired from Business Combinations								
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life						8 years	8 years	
Core technology [Member]								
Net Assets Acquired from Business Combinations								
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life						11 years	11 years	
Core technology [Member] Bettera Holdings, LLC								
Net Assets Acquired from Business Combinations								
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years							
Core Technology Bettera Bettera Holdings, LLC								
Net Assets Acquired from Business Combinations								
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived								338

Business Combinations, Divestitures (Details) - USD (\$)	Oct. 01, 2021	Apr. 30, 2022	Oct. 31, 2021	3 Months Ended Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Oct. 01, 2022
Business Acquisition [Line Items]								
Goodwill, Acquired During Period						\$ 219,000,000		
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal					\$ 0	0	\$ 1,000,000	
Payments to Acquire Businesses, Net of Cash Acquired					0	474,000,000	1,199,000,000	
Blow-Fill-Seal Business, Woodstock								
Business Acquisition [Line Items]								
Proceeds from Divestiture of Businesses and Interests in Affiliates						300,000,000	300,000,000	
Business Combination, Acquired Receivables, Gross Contractual Amount						50,000,000		
Business Combination, Acquired Receivable, Fair Value							47,000,000	
Disposal Group, Including Discontinued Operation, Assets					149,000,000			
Goodwill, Acquired During Period					54,000,000			
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal				\$ 1	\$ 182,000,000			
Business Combination, Loan Discount						3,000,000		
Business Acquisition, Transaction Costs						8,000,000		
Business Combination, Working Capital Adjustments						6,000,000		
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities						2,000,000		
Proceeds From Divestiture Of Businesses, Net Cash Proceeds						284,000,000		
Business Combination, Consideration Transferred, Other							16,000,000	
Cash and Noncash Divestiture, Amount of Consideration Received						\$ 331,000,000	\$ 331,000,000	
Business Combination, Acquired Receivables, Description						\$51 million		
Bettera Holdings, LLC								
Business Acquisition [Line Items]								
Goodwill, Acquired During Period			\$ 531					
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	\$ 17							
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	16							
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	72							
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory								\$ 31
Payments to Acquire Businesses, Net of Cash Acquired	\$ 1,000,000,000							
Vaccine Manufacturing and Innovation Centre								
Business Acquisition [Line Items]								
Business Acquisition, Transaction Costs		\$ 9,000,000						
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		165,000,000						
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets		1,000,000						
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities		18,000,000						
Payments to Acquire Businesses, Net of Cash Acquired		\$ 134,000,000						
XML 85 R56.htm IDEA: XBRL DOCUMENT								
Goodwill - Carrying Amount of Goodwill (Detail) - USD (\$)								
Goodwill [Roll Forward]								
Beginning balance					\$ 3,039,000,000	\$ 3,006,000,000		
Goodwill, Acquired During Period						219,000,000		
Goodwill, Transfers						0		
Foreign currency translation adjustments					(19,000,000)	24,000,000		
Goodwill, Impairment Loss					687,000,000	210,000,000		\$ 0
Ending balance					\$ 2,333,000,000	\$ 3,039,000,000		
Goodwill Inputs Percentage, Discount Rate Minimum						900.00%		
Goodwill Inputs Percentage, Discount Rate Maximum					1000.00%	1050.00%		
Goodwill Inputs Percentage, Long Term Revenue Growth Rate					350.00%	300.00%		
Goodwill, Impaired, Accumulated Impairment Loss					\$ 897			
Time [Member]								
Goodwill [Roll Forward]								
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number					1,187,497	1,008,747		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term					5 years 8 months 12 days	6 years 2 months 19 days		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term					3 years 2 months 15 days			
Reported Value Measurement [Member]								
Goodwill [Roll Forward]								
Debt Instrument, Fair Value Disclosure					\$ 4,949,000,000	\$ 4,888,000,000		
3.125% Senior US Denominated Notes								
Goodwill [Roll Forward]								
Stated interest rate (percent)					3.125%			
3.125% Senior US Denominated Notes Level 2 [Member] Reported Value Measurement [Member]								
Goodwill [Roll Forward]								
Debt Instrument, Fair Value Disclosure					\$ 550,000,000	550,000,000		
3.500% Senior US Denominated Notes Member								
Goodwill [Roll Forward]								
Stated interest rate (percent)					350.00%			
3.500% Senior US Denominated Notes Member Level 2 [Member] Reported Value Measurement [Member]								
Goodwill [Roll Forward]								
Debt Instrument, Fair Value Disclosure					\$ 650,000,000	650,000,000		
Softgel and Oral Technologies [Member]								

Goodwill [Roll Forward]		
Beginning balance	1,476,000,000	1,440,000,000
Ending balance		1,476,000,000
Biologics [Member]		
Goodwill [Roll Forward]		
Beginning balance	1,563,000,000	1,566,000,000
Goodwill, Acquired During Period		0
Goodwill, Transfers		(15,000,000)
Foreign currency translation adjustments	(8,000,000)	12,000,000
Goodwill, Impairment Loss	392,000,000	
Ending balance	1,163,000,000	1,563,000,000
PharmaConsumerHealth		
Goodwill [Roll Forward]		
Goodwill, Acquired During Period		219,000,000
Goodwill, Transfers		15,000,000
Foreign currency translation adjustments	(11,000,000)	12,000,000
Goodwill, Impairment Loss	295,000,000	\$ 210,000,000
Ending balance	\$ 1,170,000,000	

~~XML-86-R57.htm IDEA: XBRL DOCUMENT~~

Definite Lived Long-Lived Assets - Other Intangible Assets Subject to Amortization (Detail)	12 Months Ended	
- USD (\$)	Jun. 30, 2024	Jun. 30, 2023
\$ in Millions		

[Intangibles \[Line Items\]](#)

Gross Carrying Value	\$ 1,818	\$ 1,828
Accumulated Amortization	(977)	(848)
Net Carrying Value	\$ 841	\$ 980

[Core technology \[Member\]](#)

[Intangibles \[Line Items\]](#)

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	11 years	11 years
Gross Carrying Value	\$ 480	\$ 482
Accumulated Amortization	(205)	(164)
Net Carrying Value	\$ 275	\$ 318

[Customer relationships \[Member\]](#)

[Intangibles \[Line Items\]](#)

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	13 years	13 years
Gross Carrying Value	\$ 1,076	\$ 1,079
Accumulated Amortization	(531)	(451)
Net Carrying Value	\$ 545	\$ 628

[Product relationships \[Member\]](#)

[Intangibles \[Line Items\]](#)

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	8 years	8 years
Gross Carrying Value	\$ 242	\$ 243
Accumulated Amortization	(223)	(216)
Net Carrying Value	\$ 19	\$ 27

[Other Intangible Assets \[Member\]](#)

[Intangibles \[Line Items\]](#)

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	6 years	5 years
Gross Carrying Value	\$ 20	\$ 24
Accumulated Amortization	(18)	(17)
Net Carrying Value	\$ 2	\$ 7

~~XML-87-R58.htm IDEA: XBRL DOCUMENT~~

Definite Lived Long-Lived Assets - Additional Information (Detail) - USD (\$)	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022

[Finite lived intangible assets disclosure \[Abstract\]](#)

Amortization expense	\$ 135,000,000	\$ 136	\$ 123

~~XML-88-R59.htm IDEA: XBRL DOCUMENT~~

Definite Lived Long-Lived Assets - Future Amortization Expense (Detail)	Jun. 30, 2024	
\$ in Millions	USD (\$)	

[Finite lived intangible assets disclosure \[Abstract\]](#)

Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	\$ 133
Finite-Lived Intangible Assets, Amortization Expense, Year Two	125
Finite-Lived Intangible Assets, Amortization Expense, Year Three	109
Finite-Lived Intangible Assets, Amortization Expense, Year Four	102
Finite-Lived Intangible Assets, Amortization Expense, Year Five	98
Finite-Lived Intangible Asset, Expected Amortization, after Year Five	274
Finite-Lived Intangible Asset, Expected Amortization, Total	\$ 841

~~XML-89-R60.htm IDEA: XBRL DOCUMENT~~

Restructuring and Other Costs (Details)	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
	USD (\$)	USD (\$)	USD (\$)
employees			
Restructuring Cost and Reserve [Line Items]			
Payments for Restructuring	\$ 35,000,000		
Facility exit and other costs	13,000,000	\$ 28,000,000	\$ 1,000,000
Restructuring Reserve	(10,000,000)	(19,000,000)	
Restructuring and Related Cost, Incurred Cost	26,000,000	38,000,000	9,000,000
Restructuring, Settlement and Impairment Provisions	\$ 39,000,000	66,000,000	10,000,000
Restructuring and Related Cost, Number of Positions Eliminated employees	700		
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general, and administrative expenses		
Biologics [Member]			
Restructuring Cost and Reserve [Line Items]			
Employee-related reorganization	\$ 11,000,000	41,000,000	1,000,000
PharmaConsumerHealth			
Restructuring Cost and Reserve [Line Items]			
Employee-related reorganization	19,000,000	8,000,000	5,000,000
Corporate and Eliminations [Member]			
Restructuring Cost and Reserve [Line Items]			
Employee-related reorganization	\$ 9,000,000	\$ 17,000,000	\$ 4,000,000

~~XML-90-R61.htm IDEA: XBRL DOCUMENT~~

Long-Term	1 Months	3 Months

Obligations and Other
Short-Term
Borrowings -
Additional
Information (Detail)
€ in Millions

Schedule Of Debt [Line Items]

Debt, Current

Long-term Debt and Finance Lease Obligations

Debt Instrument, Unused Borrowing Capacity, Amount

Letters of Credit Outstanding, Amount

Payments to Acquire Businesses, Gross

Installment Payment for Acquisition, Next Twelve Months

Unamortized Debt Issuance Expense

Amortization of Debt Issuance Costs

Sale and Leaseback Transaction, Gain (Loss), Net

Stated Percentage, Draw Outstanding | Rate

Accrued Liabilities [Member]

Schedule Of Debt [Line Items]

Payments to Acquire Businesses, Gross

Senior Secured Credit Facility [Member]

Schedule Of Debt [Line Items]

Pledge Percentage Of Capital Stock

Pledge Percentage Of Equity Interest

Maximum Percentage Of Voting Stock from non US subsidiary

Revolving Credit Facility - Two [Member]

Schedule Of Debt [Line Items]

Debt and Capital Lease Obligations

Revolving Credit Commitments [Member]

Schedule Of Debt [Line Items]

Debt and Capital Lease Obligations

Four Point Seven Five Percent Senior Euro Denominated Notes [Member]

Schedule Of Debt [Line Items]

Stated interest rate (percent)

U.S. Dollar-denominated 4.875% Senior Notes [Member]

Schedule Of Debt [Line Items]

Stated interest rate (percent)

U.S Dollar-denominated 5.00% Senior Notes [Member]

Schedule Of Debt [Line Items]

Debt and Capital Lease Obligations

Stated interest rate (percent)

2.375% Senior Euro Denominated Notes [Member]

Schedule Of Debt [Line Items]

Debt and Capital Lease Obligations | €

Stated interest rate (percent)

Capital Lease Obligations [Member]

Schedule Of Debt [Line Items]

Debt and Capital Lease Obligations

Other Obligations [Member]

Schedule Of Debt [Line Items]

Debt and Capital Lease Obligations

3.125% Senior US Denominated Notes

Schedule Of Debt [Line Items]

Stated interest rate (percent)

Term Loan Three Facility Dollar Denominated [Member]

Schedule Of Debt [Line Items]

Debt and Capital Lease Obligations

3.500% Senior US Denominated Notes Member

Schedule Of Debt [Line Items]

Debt and Capital Lease Obligations

Stated interest rate (percent)

Term Loan Four Facility dollar Denominated

Schedule Of Debt [Line Items]

Debt and Capital Lease Obligations

Stated interest rate (percent)

Stated Percentage, Quarterly Amortization of Principal

Term Loan Four Facility dollar Denominated | Minimum [Member]

Schedule Of Debt [Line Items]

Debt Instrument, Interest Rate Terms

Term Loan Four Facility dollar Denominated | Secured Overnight Financing Rate (SOFR)

Schedule Of Debt [Line Items]

Stated interest rate (percent)

Reported Value Measurement [Member]

Schedule Of Debt [Line Items]

Debt and Capital Lease Obligations

Debt Instrument, Fair Value Disclosure

Reported Value Measurement [Member] | Debt Issuance Costs

Schedule Of Debt [Line Items]

Debt and Capital Lease Obligations

Level 2 [Member] | Reported Value Measurement [Member] | U.S Dollar-denominated 5.00% Senior Notes [Member]

Schedule Of Debt [Line Items]

Debt Instrument, Fair Value Disclosure

Level 2 [Member] | Reported Value Measurement [Member] | 2.375% Senior Euro Denominated Notes [Member]

Schedule Of Debt [Line Items]

Debt Instrument, Fair Value Disclosure

Level 2 [Member] | Reported Value Measurement [Member] | 3.125% Senior US Denominated Notes

Schedule Of Debt [Line Items]

Debt Instrument, Fair Value Disclosure

Level 2 [Member] | Reported Value Measurement [Member] | 3.500% Senior US Denominated Notes Member

Ended	Ended	12 Months Ended					
Oct. 23, 2017 USD (\$)	Jun. 30, 2024 USD (\$) Rate	Jun. 30, 2024 USD (\$) Rate	Jun. 30, 2023 USD (\$)	Jun. 30, 2022 USD (\$)	Jun. 30, 2024 EUR (€) Rate	Dec. 19, 2023 USD (\$)	Oct. 18, 2017
	\$ 48,000,000	\$ 48,000,000	\$ 536,000,000				
	4,857,000,000	4,857,000,000	4,313,000,000				
	1,100,000,000	1,100,000,000					
	4,000,000	4,000,000					
0,000,000							
	50,000,000	50,000,000					
	44,000,000	44,000,000	39,000,000				
		\$ 13,000,000	8,000,000	\$ 7,000,000			
	\$ 15,000,000						
	3000.00%	3000.00%			3000.00%		
0,000,000							
		100.00%					
		100.00%					
		65.00%					
	\$ 0	\$ 0	500,000,000				
	\$ 1,100,000,000	\$ 1,100,000,000					
	4.75%	4.75%			4.75%		
							4.875%
	\$ 500,000,000	\$ 500,000,000					
	5.00%	5.00%			5.00%		
					€ 825		
	2.375%	2.375%			2.375%		
	\$ 332,000,000	\$ 332,000,000	341,000,000				
	\$ 32,000,000	\$ 32,000,000	25,000,000				
	3.125%	3.125%			3.125%		
	\$ 1,404,000,000	\$ 1,404,000,000	1,418,000,000				
	\$ 650	\$ 650					
	350.00%	350.00%			350.00%		
	\$ 598,000,000	\$ 598,000,000				\$ 600,000,000	
	200.00%	200.00%			200.00%		
	100.00%	100.00%			100.00%		
		0.50%					
	300.00%	300.00%			300.00%		
	\$ 4,905,000,000	\$ 4,905,000,000	4,849,000,000				
	4,949,000,000	4,949,000,000	4,888,000,000				
	44,000,000	44,000,000	39,000,000				
	500,000,000	500,000,000	500,000,000				
	883,000,000	883,000,000	904,000,000				
	550,000,000	550,000,000	550,000,000				

Long-Term Obligations and Other	Jun. 30, 2024 USD (\$)	
Short-Term Borrowings-		
Maturities (Details)		
Long-term and Short-term Debt [Abstract]		
Long-term Debt and Capital Lease Obligations, Repayments of Principal in Next Twelve Months		\$ 48,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Two		49,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Three		49,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Four		3,350,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Five		569,000,000
Long Term Debt and Capital Lease Obligations Repayments of Principal After Year Five		884,000,000
Total		\$ 4,949,000,000

~~XML-92-R63.htm-IDEA: XBRL-DOCUMENT~~

Long-Term Obligations and Other	Jun. 30, 2024 USD (\$)	Jun. 30, 2024 EUR (€)	Jun. 30, 2023 USD (\$)
Short-Term Borrowings Fair			
Value Measurements of Financial Instruments -			
Carrying Amounts and Estimated Fair Value of Financial Instruments (Details)			
€ in Millions			
Reported Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure	\$ 4,949,000,000		\$ 4,888,000,000
Debt and Capital Lease Obligations	4,905,000,000		4,849,000,000
Estimate of Fair Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure	4,613,000,000		4,454,000,000
Debt and Capital Lease Obligations	4,613,000,000		4,454,000,000
U.S Dollar-denominated 5.00% Senior Notes [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt and Capital Lease Obligations	500,000,000		
U.S Dollar-denominated 5.00% Senior Notes [Member] Level 2 [Member] Reported Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure	500,000,000		500,000,000
U.S Dollar-denominated 5.00% Senior Notes [Member] Level 2 [Member] Estimate of Fair Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure	498,000,000		482,000,000
2.375% Senior Euro Denominated Notes [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt and Capital Lease Obligations €		€ 825	
2.375% Senior Euro Denominated Notes [Member] Level 2 [Member] Reported Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure	883,000,000		904,000,000
2.375% Senior Euro Denominated Notes [Member] Level 2 [Member] Estimate of Fair Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure	849,000,000		784,000,000
3.125% Senior US Denominated Notes Level 2 [Member] Reported Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure	550,000,000		550,000,000
3.125% Senior US Denominated Notes Level 2 [Member] Estimate of Fair Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure	532,000,000		481,000,000
Senior Secured Credit Facilities & Other [Member] Level 2 [Member] Reported Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure	2,366,000,000		2,284,000,000
Senior Secured Credit Facilities & Other [Member] Level 2 [Member] Estimate of Fair Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure	2,107,000,000		2,141,000,000
Debt Issuance Costs Reported Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt and Capital Lease Obligations	44,000,000		39,000,000
Debt Issuance Costs Estimate of Fair Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt and Capital Lease Obligations	0		0
3.500% Senior US Denominated Notes Member			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt and Capital Lease Obligations	650		
3.500% Senior US Denominated Notes Member Level 2 [Member] Reported Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure	650,000,000		650,000,000
3.500% Senior US Denominated Notes Member Level 2 [Member] Estimate of Fair Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure	\$ 627,000,000		
3.500% Senior US Denominated Notes Level 2 [Member] Reported Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure			650,000,000
3.500% Senior US Denominated Notes Level 2 [Member] Estimate of Fair Value Measurement [Member]			
Fair Value Measurements Of Financial Instruments [Line Items]			
Debt Instrument, Fair Value Disclosure			\$ 566,000,000

~~XML-93-R64.htm-IDEA: XBRL-DOCUMENT~~

Long-Term Obligations and Other	12 Months Ended	
Short-Term Borrowings Interest Rate (Details) - USD (\$)	Jun. 30, 2024	Jun. 30, 2023
Debt Instrument [Line Items]		
Long-term Debt and Capital Lease Obligations, Repayments of Principal in Next Twelve Months	\$ 48,000,000	
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Two	49,000,000	
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Three	49,000,000	
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Four	3,350,000,000	
Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Five	569,000,000	

Long Term Debt and Capital Lease Obligations Repayments of Principal After Year Five	\$ 884,000,000				
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Incremental Term Loan One Month					
Debt Instrument [Line Items]					
Debt Instrument, Basis Spread on Variable Rate	11.48%				
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Incremental Term Loan Three Month					
Debt Instrument [Line Items]					
Debt Instrument, Basis Spread on Variable Rate	26.161%				
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Incremental Term Loan Six Month					
Debt Instrument [Line Items]					
Debt Instrument, Basis Spread on Variable Rate	42.826%				
Term Loan Three Facility Dollar Denominated [Member]					
Debt Instrument [Line Items]					
Debt and Capital Lease Obligations	\$ 1,404,000,000	\$ 1,418,000,000			
Term Loan Three Facility Dollar Denominated [Member] Minimum [Member]					
Debt Instrument [Line Items]					
Debt Instrument, Basis Spread on Variable Rate	1.75%				
Term Loan Three Facility Dollar Denominated [Member] Maximum [Member]					
Debt Instrument [Line Items]					
Debt Instrument, Basis Spread on Variable Rate	2.25%				
Revolving Credit Facility - Two [Member]					
Debt Instrument [Line Items]					
Debt and Capital Lease Obligations	\$ 0	\$ 500,000,000			
Revolving Credit Commitments [Member]					
Debt Instrument [Line Items]					
Debt and Capital Lease Obligations	\$ 1,100,000,000				
Revolving Credit Commitments [Member] Minimum [Member]					
Debt Instrument [Line Items]					
Debt Instrument, Basis Spread on Variable Rate	0.75%				
Revolving Credit Commitments [Member] Maximum [Member]					
Debt Instrument [Line Items]					
Debt Instrument, Basis Spread on Variable Rate	1.25%				
Revolving Credit Commitments [Member] Secured Overnight Financing Rate (SOFR)					
Debt Instrument [Line Items]					
Debt Instrument, Basis Spread on Variable Rate	10.00%				
~~XML 94 R65.htm IDEA: XBRL DOCUMENT~~					
Earnings Per Share	12 Months Ended				
Calculations of					
Earnings Per Share					
(Details) - USD (\$)	Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2022				
\$ / shares in Units, \$					
in Millions					
Earnings Per Share [Abstract]					
Net earnings	\$ (1,043)	\$ (256)	\$ 499		
Participating Securities, Distributed and Undistributed (Earnings) Loss, Basic	0	0	(16)		
Net Income (Loss) Available to Common Stockholders, Basic	\$ (1,043)	\$ (256)	\$ 483		
Weighted Average Number of Shares Outstanding, Basic	181,000,000	181,000,000	176,000,000		
Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities	0	0	2,000,000		
Weighted Average Number of Shares Outstanding, Diluted	181,000,000	181,000,000	178,000,000		
Earnings Per Share, Basic	\$ (5.76)	\$ (1.42)	\$ 2.74		
Earnings Per Share, Diluted	\$ (5.76)	\$ (1.42)	\$ 2.73		
~~Text Block [Abstract]~~					
Weighted Average Number of Shares Outstanding, Basic	181,000,000	181,000,000	176,000,000		
Weighted Average Number of Shares Outstanding, Diluted	181,000,000	181,000,000	178,000,000		
~~XML 95 R66.htm IDEA: XBRL DOCUMENT~~					
Earnings Per Share	12 Months Ended				
Earnings Per Share -					
Additional Details					
(Details) - shares	Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2022				
shares in Millions					
Series A Preferred Stock					
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]					
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0.0	0.0	3.0		
~~XML 96 R67.htm IDEA: XBRL DOCUMENT~~					
Derivative	9 Months Ended				12 Months Ended
Instruments and					
Hedging Activities -					
Additional					
Information (Detail) -	Mar. 31,	Jun. 30,	Jun. 30,	Jun. 30,	May 17,
USD (\$)	2024	2024	2023	2022	2019
Derivative [Line Items]					
Derivatives used in Net Investment Hedge, Increase (Decrease), Gross of Tax					
			\$ 21,000,000	\$ (30,000,000)	
Net accumulated gain related to investment hedges			119,000,000		
Derivative, Gain (Loss) on Derivative, Net				2,000,000	
Embedded Derivative, Estimate of Embedded Derivative Liability					
				\$ 40,000,000	
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases, Sales, Issues, Settlements	\$ 1				
Federal					
			0	(1,000,000)	\$ (8,000,000)
State and local			(5,000,000)	(1,000,000)	14,000,000
Non-U.S.			48,000,000	43,000,000	\$ 66,000,000
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax	\$ 26				
U.S. Denominated Term Loan [Member]					
Derivative [Line Items]					
Debt Instrument, Interest Rate, Effective Percentage	0.9431%				
Total Debt, U.S. Denominated Term Loan	0.9985%				
	\$ 500,000,000				
~~XML 97 R68.htm IDEA: XBRL DOCUMENT~~					
Fair Value Measures	Jun. 30, 2024 Jun. 30, 2023				
and Disclosures					
(Details) - USD (\$)					
Fair Value Measurement Inputs and Valuation Techniques [Line Items]					
Interest Rate Cash Flow Hedge Asset at Fair Value	\$ 36,000,000	\$ 62,000,000			
Trading Securities at Fair Value	1,000,000	1,000,000			
Level 1 [Member]					
Fair Value Measurement Inputs and Valuation Techniques [Line Items]					
Interest Rate Cash Flow Hedge Asset at Fair Value	0	0			
Trading Securities at Fair Value	1,000,000	1,000,000			
Level 2 [Member]					

Fair Value Measurement Inputs and Valuation Techniques [Line Items]				
Interest Rate Cash Flow Hedge Asset at Fair Value	36,000,000	62,000,000		
Trading Securities at Fair Value	0			
Level 3 [Member]				
Fair Value Measurement Inputs and Valuation Techniques [Line Items]				
Interest Rate Cash Flow Hedge Asset at Fair Value	0			
Trading Securities at Fair Value	\$ 0	\$ 0		
~~XML 98-R69.htm-IDEA: XBRL DOCUMENT~~				
Income Taxes -				
Additional				
Information (Detail) -				
USD (\$)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Income Tax Contingency [Line Items]				
Undistributed Earnings of Foreign Subsidiaries	\$ 568,000,000			
Deferred Tax Assets, Valuation Allowance	315,000,000	\$ 159,000,000		
Unrecognized Tax Benefits	4,000,000	4,000,000	\$ 5,000,000	\$ 5,000,000
Unrecognized Tax Benefits, Interest on Income Taxes Accrued	0	0	\$ 1,000,000	
Deferred Tax Assets, State Taxes	37			
Deferred Tax Assets, Gross	546,000,000	\$ 469,000,000		
Deferred Tax Assets, Federal Taxes	97			
Deferred Tax Assets, International Tax Asset	183			
International Deferred Tax Asset [Domain]				
Income Tax Contingency [Line Items]				
Deferred Tax Assets, Valuation Allowance	148			
State Net Deferred Tax Asset [Domain]				
Income Tax Contingency [Line Items]				
Deferred Tax Assets, Valuation Allowance	50			
U.S. Federal Deferred Tax Asset [Domain]				
Income Tax Contingency [Line Items]				
Deferred Tax Assets, Valuation Allowance	117			
Domestic Tax Authority [Member]				
Income Tax Contingency [Line Items]				
Operating Loss Carryforwards	546,000,000			
Operating Loss Carryforwards, Subject to Limitations, Section 382	225,000,000			
Operating Loss Carryforwards, Indefinite Life	493,000,000			
State and Local Jurisdiction [Member]				
Income Tax Contingency [Line Items]				
Operating Loss Carryforwards	\$ 461,000,000			
Operating Loss Carryforwards, Carry Forward Period	20 years			
Foreign Tax Authority [Member]				
Income Tax Contingency [Line Items]				
Operating Loss Carryforwards	\$ 364,000,000			
Operating Loss Carryforwards, Carry Forward Period	3 years			
~~XML 99-R70.htm-IDEA: XBRL DOCUMENT~~				
Income Taxes				
Schedule of Income				
before Tax Domestic				
and Foreign (Details)				
- USD (\$)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	
Income Tax Disclosure [Abstract]				
U.S. operations		\$ (1,158,000,000)	\$ (410,000,000)	\$ 224,000,000
Non-U.S. operations		131,000,000	68,000,000	355,000,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest		\$ (1,027,000,000)	\$ (342,000,000)	\$ 579,000,000
~~XML 100-R71.htm-IDEA: XBRL DOCUMENT~~				
Income Taxes-				
Components of				
Income Tax Expense				
(Details) - USD (\$)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]				
Federal	\$ 0	\$ (1,000,000)	\$ (8,000,000)	
State and local	(5,000,000)	(1,000,000)	14,000,000	
Non-U.S.	48,000,000	43,000,000	66,000,000	
Total current	43,000,000	41,000,000	72,000,000	
Deferred:				
Federal	(15,000,000)	(99,000,000)	6,000,000	
State and local	(11,000,000)	(4,000,000)	(5,000,000)	
Non-U.S.	(1,000,000)	(24,000,000)	7,000,000	
Total deferred	(27,000,000)	(127,000,000)	8,000,000	
Total provision	\$ 16,000,000	\$ (86,000,000)	\$ 80,000,000	
~~XML 101-R72.htm-IDEA: XBRL DOCUMENT~~				
Income Taxes-Income				
Tax Reconciliation				
(Details) - USD (\$)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	
Income Tax Disclosure [Abstract]				
Provision at U.S. federal statutory tax rate	\$ (216,000,000)	\$ (72,000,000)	\$ 122,000,000	
State and local income taxes	(44,000,000)	(13,000,000)	10,000,000	
Foreign tax rate differential	(7,000,000)	(5,000,000)	(28,000,000)	
Effective Income Tax Rate Reconciliation, Global intangible low tax income	11,000,000	2,000,000	6,000,000	
Permanent items	80,000,000	9,000,000	0	
Unrecognized tax positions	0	(1,000,000)	1,000,000	
Tax valuation allowance	160,000,000	5,000,000	94,000,000	
Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount	1,000,000	30,000,000	43,000,000	
Withholding Tax and other foreign taxes	3,000,000	1,000,000	1,000,000	
Change in tax rate	1,000,000	18,000,000	1,000,000	
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	(4,000,000)	(3,000,000)	(2,000,000)	
Effective Tax Reconciliation, Benefit from Swiss Tax Reform	0	0	83,000,000	
Other	6,000,000	(1,000,000)	(1,000,000)	
Total provision	\$ 16,000,000	\$ (86,000,000)	\$ 80,000,000	
~~XML 102-R73.htm-IDEA: XBRL DOCUMENT~~				
Income Taxes-				
Deferred Tax Assets				
(Details) - USD (\$)	Jun. 30, 2024	Jun. 30, 2023		
Deferred income tax assets:				
Accrued liabilities	\$ 70,000,000	\$ 57,000,000		
Equity compensation	18,000,000	13,000,000		
Loss and tax credit carryforwards	293,000,000	287,000,000		
Foreign currency	3,000,000	3,000,000		
Pension	18,000,000	19,000,000		
Property-related	101,000,000	50,000,000		
Intangibles	6,000,000			

Deferred Income Tax, Operating Lease, Liabilities	(37,000,000)	(38,000,000)
Euro Denominated Debt	0	1,000,000
Other	0	1,000,000
Total deferred income tax assets	546,000,000	469,000,000
Valuation allowance	(315,000,000)	(159,000,000)
Deferred Tax Assets, Net of Valuation Allowance	231,000,000	310,000,000
Deferred income tax liabilities:		
Foreign currency	(4,000,000)	0
Property-related	(205,000,000)	(247,000,000)
Goodwill and other intangibles	0	(71,000,000)
Non-current deferred tax liability	(2,000,000)	
Deferred Income Tax, Right-of-Use Asset	(16,000,000)	(13,000,000)
Other	(2,000,000)	0
Total deferred income tax liabilities	(229,000,000)	(331,000,000)
Deferred Tax Liabilities, Net	\$ 2,000,000	\$ 21,000,000

~~XML 103 R74.htm IDEA: XBRL DOCUMENT~~

Income Taxes- Balance Sheet (Details) - USD (\$) \$ in Millions		
	Jun. 30, 2024	Jun. 30, 2023

[Income Tax Disclosure \[Abstract\]](#)

Deferred Income Tax Assets, Net	\$ 7	\$ 55
Deferred Tax Liabilities, Net	2	21
Deferred Income Tax Liabilities, Net	\$ (5)	\$ (76)

~~XML 104 R75.htm IDEA: XBRL DOCUMENT~~

Income Taxes- Unrecognized Tax Benefits (Details) - USD (\$)		12 Months Ended		
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022

[Reconciliation of Unrecognized Tax Benefits \[Roll Forward\]](#)

Beginning Balance	\$ 4,000,000	\$ 5,000,000	\$ 5,000,000
Additions based on tax positions related to the current year		2,000,000	
Additions for tax positions of prior years	(1,000,000)	(1,000,000)	(1,000,000)
Reductions for tax positions of prior years	1,000,000		1,000,000
Settlements		(1,000,000)	(1,000,000)
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations		(1,000,000)	(1,000,000)
Ending Balance	\$ 4,000,000	\$ 4,000,000	\$ 5,000,000

~~XML 105 R76.htm IDEA: XBRL DOCUMENT~~

Employee Retirement Benefit Plans- Additional Information (Details) - USD (\$)		12 Months Ended		
		Jun. 30, 2024	Jun. 30, 2023	

[Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block \[Line Items\]](#)

Multiemployer Plans, Estimated Annual Cash Contribution	\$ 2,000,000
Defined Benefit Plan, Benefit Obligation, Payment for Settlement	3

[Lump Sum Payment](#)

[Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block \[Line Items\]](#)

Defined Benefit Plan, Plan Assets, Payment for Settlement	7

[Fixed Annuity](#)

[Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block \[Line Items\]](#)

Defined Benefit Plan, Plan Assets, Payment for Settlement	\$ 21

[Eberbach Pension Promissory Note or Loan \[Member\]](#)

[Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block \[Line Items\]](#)

Stated interest rate (percent)	5.00%

[Retirement Benefits \[Member\]](#)

[Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block \[Line Items\]](#)

Multiemployer Plan, Pension, Significant, Future Employer Contribution, Amount	\$ 44,000,000	\$ 38,000,000
Actual Asset Allocation (percent)	100.00%	100.00%
Target Asset Allocation (percent)	100.00%	100.00%
Actual Asset Allocation	\$ 168,000,000	\$ 202,000,000
Defined Benefit Plan, Plan Assets, Payment for Settlement	\$ 36,000,000	\$ 4,000,000

[Retirement Benefits \[Member\] | Equity Securities \[Member\]](#)

[Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block \[Line Items\]](#)

Actual Asset Allocation (percent)	2.90%	2.90%
Target Asset Allocation (percent)	2.90%	2.90%
Actual Asset Allocation	\$ 5,000,000	\$ 6,000,000

[Retirement Benefits \[Member\] | Cash \[Member\]](#)

[Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block \[Line Items\]](#)

Actual Asset Allocation (percent)	1.00%	4.50%
Target Asset Allocation (percent)	1.00%	4.50%
Actual Asset Allocation	\$ 2,000,000	\$ 9,000,000

~~XML 106 R77.htm IDEA: XBRL DOCUMENT~~

Employee Retirement Benefit Plans- Accumulated Benefit Obligation (Details) - USD (\$) \$ in Millions		12 Months Ended		
		Jun. 30, 2024	Jun. 30, 2023	

[Employer contributions between measurement date and reporting date](#)

Fair value of plan assets at beginning of year	\$ 202.0	
Fair value of plan assets at end of year	168.0	\$ 202.0

[Retirement Benefits \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

Defined Benefit Plan, Amortization of Gain (Loss)	(2.0)	(1.0)

Accumulated Benefit Obligation	206.0	242.0

[Change in Benefit Obligation](#)

Benefit obligation at beginning of year	246.0	268.0
Company service cost	3.0	3.0
Interest cost	11.0	9.0
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	1.0	1.0
Settlements	(36.0)	(4.0)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	11.0	10.0
Actuarial (gain)/loss	1.0	(28.0)
Exchange rate gain/(loss)	(4.0)	7.0
Benefit obligation at end of year	211.0	246.0

[Employer contributions between measurement date and reporting date](#)

Fair value of plan assets at beginning of year	202.0	240.0
Actual return on plan assets	3.0	(38.0)
Company contributions	11.0	7.0

Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	1.0	1.0
Settlements	(36.0)	(4.0)
Defined Benefit Plan, Plan Assets, Benefits Paid	(11.0)	(10.0)
Exchange rate gain/(loss)	(2.0)	6.0
Fair value of plan assets at end of year	168.0	202.0
Funded status at end of year	(43.0)	(44.0)
Net Pension assets (liabilities)	(43.0)	(44.0)
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	1.0	1.0
Other Post-Retirement Benefits [Member]		
Defined Benefit Plan Disclosure [Line Items]		
Defined Benefit Plan, Amortization of Gain (Loss)	0.0	0.0
Accumulated Benefit Obligation	1.0	2.0
Change in Benefit Obligation		
Benefit obligation at beginning of year	2.0	
Company service cost	0.0	0.0
Interest cost	0.0	0.0
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0.0	0.0
Settlements	0.0	0.0
Defined Benefit Plan, Benefit Obligation, Benefits Paid	0.0	0.0
Actuarial (gain)/loss	0.0	0.0
Exchange rate gain/(loss)	0.0	0.0
Benefit obligation at end of year	2.0	2.0
Employer contributions between measurement date and reporting date		
Fair value of plan assets at beginning of year	0.0	
Actual return on plan assets	0.0	0.0
Company contributions	0.0	0.0
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0.0	0.0
Settlements	0.0	0.0
Defined Benefit Plan, Plan Assets, Benefits Paid	0.0	0.0
Exchange rate gain/(loss)	0.0	0.0
Fair value of plan assets at end of year	0.0	0.0
Funded status at end of year	(1.0)	(2.0)
Net Pension assets (liabilities)	(1.0)	(2.0)
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	\$ 0.0	\$ 0.0

~~***XMLE-107-R70.htm IDEA: XBRL DOCUMENT***~~

Employee Retirement	12 Months Ended	
Benefit Plans-Balance		
Sheet (Details) - USD		
(\$)	Jun. 30, 2024	Jun. 30, 2023
\$ in Millions		

Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]		
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Pension liability	Pension liability
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Pension liability	Pension liability
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Pension liability	Pension liability
Retirement Benefits [Member]		

Amounts Recognized in Statement of Financial Position		
Noncurrent assets	\$ 13	\$ 18
Current liabilities	(1)	(1)
Noncurrent liabilities	(55)	(61)
Funded status at end of year	(43)	(44)

Amounts Recognized in Accumulated Other Comprehensive Income		
Prior service cost	(1)	(1)
Net (gain)/loss	58	66
Total accumulated other comprehensive income at the end of the year	57	65
Additional Information for Plan with ABO in Excess of Plan Assets		
Projected benefit obligation	93	129
Accumulated benefit obligation	89	126
Fair value of plan assets	37	68

Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]		
Service cost	3	3
Interest cost	11	9
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	9	9
Defined Benefit Plan, Amortization of Gain (Loss)	(2)	(1)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	12	1
Net periodic benefit cost	19	5
Other Post-Retirement Benefits [Member]		

Amounts Recognized in Statement of Financial Position		
Noncurrent assets	0	0
Current liabilities	0	0
Noncurrent liabilities	(1)	(2)
Funded status at end of year	(1)	(2)
Amounts Recognized in Accumulated Other Comprehensive Income		
Prior service cost	0	0
Net (gain)/loss	(1)	(1)
Total accumulated other comprehensive income at the end of the year	(1)	(1)
Additional Information for Plan with ABO in Excess of Plan Assets		
Projected benefit obligation	1	2
Accumulated benefit obligation	1	2
Fair value of plan assets	0	0

Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]		
Service cost	0	0
Interest cost	0	0
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	0	0
Defined Benefit Plan, Amortization of Gain (Loss)	0	0
Net periodic benefit cost	\$ 0	\$ 0

~~***XMLE-108-R79.htm IDEA: XBRL DOCUMENT***~~

Employee Retirement	12 Months Ended		
Benefit Plans-AOCI			
(Details) - USD (\$)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
\$ in Millions			
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]			
Net (gain)/loss arising during the year	\$ (8)	\$ 17	\$ (13)
Retirement Benefits [Member]			
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]			
Net (gain)/loss arising during the year	6	17	
Exchange rate gain/(loss) recognized during the year	(14)	0	
Total minimum pension liability, pretax	(8)	17	
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax	11	22	

Estimated Amounts to be Amortized from Accumulated Other Comprehensive Income into Net Periodic Benefit Cost		
Net (gain)/loss	\$ 2	\$ 2
Financial Assumptions Used to Determine Benefit Obligations at the Balance Sheet Date		
Discount rate (percent)	4.30%	4.30%
Rate of compensation increases (percent)	2.70%	2.70%
Financial Assumptions Used to Determine Net Periodic Benefit Cost for Financial Year		
Discount rate (percent)	4.30%	3.60%
Rate of compensation increases (percent)	2.70%	2.70%
Expected long-term rate of return (percent)	4.30%	3.90%
Expected Future Contributions		
Fiscal Year 2020 Expected Future Contributions	\$ 4	\$ 8
Other Post-Retirement Benefits [Member]		
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]		
Net (gain)/loss arising during the year	0	0
Exchange rate gain/(loss) recognized during the year	0	0
Total minimum pension liability, pretax	0	0
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax	0	0
Estimated Amounts to be Amortized from Accumulated Other Comprehensive Income into Net Periodic Benefit Cost		
Net (gain)/loss	\$ 0	\$ 0
Financial Assumptions Used to Determine Benefit Obligations at the Balance Sheet Date		
Discount rate (percent)	5.00%	4.70%
Financial Assumptions Used to Determine Net Periodic Benefit Cost for Financial Year		
Discount rate (percent)	4.70%	4.00%
Expected Future Contributions		
Fiscal Year 2020 Expected Future Contributions	\$ 0	\$ 0
~~<i>XML 109 R80.htm IDEA: XBRL DOCUMENT</i>~~		
Employee Retirement		
Benefit Plans-Fiscal		
Year Maturity		
(Details) - USD (\$)		
\$ in Millions		
Jun. 30, 2024Jun. 30, 2023		
Retirement Benefits [Member]		
Expected Future Benefit Payments		
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	\$ 12	\$ 14
Defined Benefit Plan, Expected Future Benefit Payment, Year Two	13	15
Defined Benefit Plan, Expected Future Benefit Payment, Year Three	12	16
Defined Benefit Plan, Expected Future Benefit Payment, Year Four	12	15
Defined Benefit Plan, Expected Future Benefit Payment, Year Five	13	15
Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter	\$ 71	\$ 84
Actual Asset Allocation (percent)	100.00%	100.00%
Actual Asset Allocation	\$ 168	\$ 202
Target Asset Allocation (percent)	100.00%	100.00%
Retirement Benefits [Member] Equity Securities [Member]		
Expected Future Benefit Payments		
Actual Asset Allocation (percent)	2.90%	2.90%
Actual Asset Allocation	\$ 5	\$ 6
Target Asset Allocation (percent)	2.90%	2.90%
Retirement Benefits [Member] US Government Agencies Debt Securities [Member]		
Expected Future Benefit Payments		
Actual Asset Allocation (percent)	37.70%	36.80%
Actual Asset Allocation	\$ 63	\$ 74
Target Asset Allocation (percent)	37.70%	36.80%
Retirement Benefits [Member] Corporate Debt Securities [Member]		
Expected Future Benefit Payments		
Actual Asset Allocation (percent)	16.80%	16.20%
Actual Asset Allocation	\$ 28	\$ 33
Target Asset Allocation (percent)	16.80%	16.20%
Retirement Benefits [Member] Real Estate [Member]		
Expected Future Benefit Payments		
Actual Asset Allocation (percent)	4.50%	3.30%
Actual Asset Allocation	\$ 8	\$ 7
Target Asset Allocation (percent)	4.50%	3.30%
Retirement Benefits [Member] Insurance Contracts [Member]		
Expected Future Benefit Payments		
Actual Asset Allocation (percent)	16.60%	14.90%
Actual Asset Allocation	\$ 28	\$ 30
Target Asset Allocation (percent)	16.60%	14.90%
Retirement Benefits [Member] Other Assets [Member]		
Expected Future Benefit Payments		
Actual Asset Allocation (percent)	20.50%	21.40%
Actual Asset Allocation	\$ 34	\$ 43
Target Asset Allocation (percent)	20.50%	21.40%
Other Post-Retirement Benefits [Member]		
Expected Future Benefit Payments		
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	\$ 0	\$ 0
Defined Benefit Plan, Expected Future Benefit Payment, Year Two	0	0
Defined Benefit Plan, Expected Future Benefit Payment, Year Three	0	0
Defined Benefit Plan, Expected Future Benefit Payment, Year Four	0	0
Defined Benefit Plan, Expected Future Benefit Payment, Year Five	0	0
Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter	\$ 1	\$ 1
Actual Asset Allocation (percent)	0.00%	0.00%
Actual Asset Allocation	\$ 0	\$ 0
Target Asset Allocation (percent)	0.00%	0.00%
Other Post-Retirement Benefits [Member] Equity Securities [Member]		
Expected Future Benefit Payments		
Actual Asset Allocation (percent)	0.00%	0.00%
Actual Asset Allocation	\$ 0	\$ 0
Target Asset Allocation (percent)	0.00%	0.00%
Other Post-Retirement Benefits [Member] US Government Agencies Debt Securities [Member]		
Expected Future Benefit Payments		
Actual Asset Allocation (percent)	0.00%	0.00%
Actual Asset Allocation	\$ 0	\$ 0
Target Asset Allocation (percent)	0.00%	0.00%
Other Post-Retirement Benefits [Member] Corporate Debt Securities [Member]		
Expected Future Benefit Payments		
Actual Asset Allocation (percent)	0.00%	0.00%
Actual Asset Allocation	\$ 0	\$ 0
Target Asset Allocation (percent)	0.00%	0.00%

[Other Post-Retirement Benefits \[Member\]](#) | [Real Estate \[Member\]](#)

[Expected Future Benefit Payments](#)

Actual Asset Allocation (percent)	0.00%	0.00%
Actual Asset Allocation	\$ 0	\$ 0
Target Asset Allocation (percent)	0.00%	0.00%

[Other Post-Retirement Benefits \[Member\]](#) | [Insurance Contracts \[Member\]](#)

[Expected Future Benefit Payments](#)

Actual Asset Allocation (percent)	0.00%	0.00%
Actual Asset Allocation	\$ 0	\$ 0
Target Asset Allocation (percent)	0.00%	0.00%

[Other Post-Retirement Benefits \[Member\]](#) | [Other Assets \[Member\]](#)

[Expected Future Benefit Payments](#)

Actual Asset Allocation (percent)	0.00%	0.00%
Actual Asset Allocation	\$ 0	\$ 0
Target Asset Allocation (percent)	0.00%	0.00%

~~XML 110 R81.htm IDEA: XBRL DOCUMENT~~

Employee Retirement

Benefit Plans-Fair

Value (Details) - USD **Jun. 30, 2024** **Jun. 30, 2023**

(\$)

\$ in Millions

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) \$ 168.0 \$ 202.0

[Level 1 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 0.0 0.0

[Level 2 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 141.0 175.0

[Level 3 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 27.0 27.0

[Fair Value Measured at Net Asset Value](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 0.0 0.0

[Equity Securities \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 5.0 6.0

[Equity Securities \[Member\]](#) | [Level 1 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 0.0 0.0

[Equity Securities \[Member\]](#) | [Level 2 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 5.0 6.0

[Equity Securities \[Member\]](#) | [Level 3 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 0.0 0.0

[Equity Securities \[Member\]](#) | [Fair Value Measured at Net Asset Value](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 0.0 0.0

[Debt Securities \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 91.0 107.0

[Debt Securities \[Member\]](#) | [Level 1 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 0.0 0.0

[Debt Securities \[Member\]](#) | [Level 2 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 91.0 107.0

[Debt Securities \[Member\]](#) | [Level 3 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 0.0 0.0

[Debt Securities \[Member\]](#) | [Fair Value Measured at Net Asset Value](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 0.0 0.0

[Real Estate \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 5.0 7.0

[Real Estate \[Member\]](#) | [Level 1 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 0.0 0.0

[Real Estate \[Member\]](#) | [Level 2 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 3.0 5.0

[Real Estate \[Member\]](#) | [Level 3 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 2.0 2.0

[Real Estate \[Member\]](#) | [Fair Value Measured at Net Asset Value](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 0.0 0.0

[Other Assets \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 67.0 82.0

[Other Assets \[Member\]](#) | [Level 1 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 0.0 0.0

[Other Assets \[Member\]](#) | [Level 2 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 42.0 57.0

[Other Assets \[Member\]](#) | [Level 3 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 25.0 25.0

[Other Assets \[Member\]](#) | [Fair Value Measured at Net Asset Value](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) 0.0 0.0

[Hedge Funds \[Member\]](#) | [Level 2 \[Member\]](#)

[Defined Benefit Plan Disclosure \[Line Items\]](#)

[Fair value of plan assets](#) \$ 12.0 \$ 20.0

XML 111 R82.htm IDEA: XBRL DOCUMENT

Employee Retirement Benefit Plans-Level 3 (Details) - Level 3 [Member]	12 Months Ended
\$ in Millions	Jun. 30, 2024 USD (\$)

Employer contributions between measurement date and reporting date

Beginning balance	\$ 27
Relating to assets still held at the reporting date	1
Purchases, sales, settlements, contributions and benefits paid	(4)
Transfers in and/or out of Level 3	3
Ending balance	27

Insurance Contracts [Member]

Employer contributions between measurement date and reporting date

Beginning balance	8
Relating to assets still held at the reporting date	1
Purchases, sales, settlements, contributions and benefits paid	(2)
Transfers in and/or out of Level 3	0
Ending balance	7

Other Unobservable Assets [Member]

Employer contributions between measurement date and reporting date

Beginning balance	19
Relating to assets still held at the reporting date	0
Purchases, sales, settlements, contributions and benefits paid	(2)
Transfers in and/or out of Level 3	3
Ending balance	\$ 20

XML 112 R83.htm IDEA: XBRL DOCUMENT

Employee Retirement Benefit Plans- Assumed Healthcare Trend Rates (Details) - Other Post-Retirement Benefits [Member] - USD (\$)	12 Months Ended	
\$ in Millions	Jun. 30, 2024	Jun. 30, 2023

Effect of 1% Change in Healthcare Cost Trend Rate

Fiscal Year 2020 Expected Future Contributions	\$ 0	\$ 0
Discount rate (percent)	5.00%	4.70%
Discount rate (percent)	4.70%	4.00%
Post 65 [Member]		

Assumed Healthcare Cost Trend Rates at the Balance Sheet Date

Healthcare cost trend rate-initial (percent)	5.00%	4.80%
Healthcare cost trend rate-ultimate (percent)	4.10%	4.10%
Year in which ultimate rates are reached	2040	2040

XML 113 R84.htm IDEA: XBRL DOCUMENT

Equity and Accumulated Other Comprehensive Income (Loss) Equity (Details) - USD (\$)	Nov. 18, 2021	Nov. 23, 2020	3 Months Ended Mar. 31, 2024	9 Months Ended Mar. 31, 2024	12 Months Ended Jun. 30, 2022	Jun. 30, 2024	Feb. 05, 2024	Jun. 30, 2023	May 17, 2019
Equity [Abstract]									
Common Stock, Shares Authorized						1,000,000,000		1,000,000,000	
Common stock, par value (usd per share)						\$ 0.01	\$ 0.01	\$ 0.01	
Preferred Stock, Shares Authorized						100,000,000		100,000,000	
Preferred Stock, Shares Issued & Outstanding						0		0	
Preferred Stock, Par or Stated Value Per Share					\$ 0.01	\$ 0.01		\$ 0.01	
Auction Market Preferred Securities, Stock Series [Line Items]									
Preferred Stock, Shares Authorized						100,000,000		100,000,000	
Preferred Stock, Par or Stated Value Per Share					\$ 0.01	\$ 0.01		\$ 0.01	
Preferred Stock, Shares Issued					650,000	0		0	
Preferred Stock, Issuance Value					\$ 650,000,000				
					1,000				
Preferred Stock, Value, Issued									
Preferred Stock, Issuance Value, Net						\$ 646,000,000			
Embedded Derivative, Estimate of Embedded Derivative Liability									\$ 40,000,000

Conversion of Stock, Shares Converted	384,777	265,223
Dividends, Preferred Stock, Stock	\$ 2	\$ 2,000,000

Convertible Preferred Stock, Shares Issued upon Conversion	20.32	20.33
Stock Issued During Period, Shares, Conversion of Convertible Securities	7,817,554	5,392,280

Preferred Stock, Shares Issued & Outstanding					0	0
Stock Issued During Period, Value, Conversion of Convertible Securities					362,000,000	
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases, Sales, Issues, Settlements				\$ 1		
Additional Paid-in Capital [Member]						
Auction Market Preferred Securities, Stock Series [Line Items]						
Stock Issued During Period, Value, Conversion of Convertible Securities			\$ 362		\$ 362,000,000	

Designated shares [Member]

Equity [Abstract]

Preferred Stock, Shares Authorized	1,000,000
Auction Market Preferred Securities, Stock Series [Line Items]	
Preferred Stock, Shares Authorized	1,000,000

XML 114 R85.htm IDEA: XBRL DOCUMENT

Equity and Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Earnings/(Loss) (Details) - USD (\$)	12 Months Ended			
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Accumulated Other Comprehensive Income (Loss), Net of Tax	\$ (404,000,000)	\$ (354,000,000)	\$ (394,000,000)	\$ (317,000,000)
Other comprehensive income /(loss), net of tax	(50,000,000)	40,000,000	(77,000,000)	
Other Comprehensive Income (Loss), Defined Benefit Plan, after Reclassification Adjustment, after Tax		14,000,000	(9,000,000)	
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(32,000,000)	32,000,000	(110,000,000)	
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax		4,000,000	(3,000,000)	
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	(52,000,000)	34,000,000	(78,000,000)	
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	2,000,000	6,000,000	1,000,000	

Accumulated Translation Adjustment [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Accumulated Other Comprehensive Income (Loss), Net of Tax	(378,000,000)	(346,000,000)	(378,000,000)	(268,000,000)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax		32,000,000	(110,000,000)	
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		0	0	
Accumulated Defined Benefit Plans Adjustment [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Accumulated Other Comprehensive Income (Loss), Net of Tax	(48,000,000)	(52,000,000)	(38,000,000)	(47,000,000)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	4,000,000			
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	(4,000,000)			
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	2,000,000	(16,000,000)	8,000,000	
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	2,000,000	2,000,000	1,000,000	
AOCL Derivative Qualifying as Hedge, Excluded Component, Parent				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Accumulated Other Comprehensive Income (Loss), Net of Tax	23,000,000	45,000,000	27,000,000	0
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax		18,000,000	27,000,000	
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		0	0	
ACOI, Accumulated Gain (Loss), Marketable Securities				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Accumulated Other Comprehensive Income (Loss), Net of Tax	0	0	(4,000,000)	(1,000,000)
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax	0	4,000,000	(3,000,000)	
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax		0	(3,000,000)	
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	4,000,000	0	
AOCL, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Accumulated Other Comprehensive Income (Loss), Net of Tax	(1,000,000)	(1,000,000)	(1,000,000)	\$ (1,000,000)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	\$ 0	0	0	
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		\$ 0	\$ 0	
~~XML 115 R86.htm IDEA: XBRL DOCUMENT~~				
Equity and Accumulated Other Comprehensive Income (Loss)- Minimum Pension Liability (Details) - USD (\$)	12 Months Ended			
\$ in Millions	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	
~~Equity [Abstract]~~				
Net investment hedge		\$ 21	\$ (30)	\$ 121
Long term inter-company loans		1	12	(37)
Translation adjustments		(50)	43	(169)
Total foreign currency translation adjustments, pretax		(28)	25	(85)
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax		4	(7)	25
Total foreign currency translation adjustments, net of tax			32	(110)
Net Derivative and Hedge (gain)/loss arising during the year		(25)	25	36
Derivative and Hedge, (Income) Loss		(3)	7	9
Other Comprehensive Income, Debt Securities, Derivative and Hedge, Gain (Loss), after Adjustment and Tax		22	18	27
Net gain/(loss) arising during the year		8	(17)	13
Pension liability tax		4	(3)	4
Net change in minimum pension liability, net of tax			(14)	9
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax	0	5	(3)	
Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax	\$ 0	(1)	0	
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax		\$ 4	\$ (3)	
~~XML 116 R87.htm IDEA: XBRL DOCUMENT~~				
Equity (Details) - USD (\$)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
May 17, 2019				
~~Redeemable Preferred Stock [Line Items]~~				
Preferred Stock, Shares Authorized	100,000,000	100,000,000		
Preferred Stock, Par or Stated Value Per Share	\$ 0.01	\$ 0.01	\$ 0.01	
Preferred Stock, Shares Issued	0	0	650,000	
Preferred Stock, Issuance Value			\$ 650,000,000	
Preferred Stock, Value, Issued			1,000	
Preferred Stock, Value, Outstanding	\$ 0	\$ 0		
Preferred Stock, Issuance Value, Net	646,000,000			
Embedded Derivative, Estimate of Embedded Derivative Liability			\$ 40,000,000	
Redeemable Preferred Stock Outstandings	\$ 0	\$ 0	\$ 0	\$ 359,000,000
~~Designated shares [Member]~~				
~~Redeemable Preferred Stock [Line Items]~~				
~~Preferred Stock, Shares Authorized~~			1,000,000	
~~XML 117 R88.htm IDEA: XBRL DOCUMENT~~				
Equity Based Compensation (Additional) (Details) - USD (\$)	12 Months Ended			
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	
~~Share-based Compensation Arrangement by Share-based Payment Award [Line Items]~~				
~~Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized~~	13,657,302			
~~Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)~~	1.7			
~~Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price~~	\$ 21.95	\$ 37.14	\$ 32.07	
~~Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value~~	\$ 2,000,000	\$ 3,000,000		
~~Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition~~	3 years			
~~Weighted Average Grant Date Fair Value of Restricted Stock Unit~~	\$ 79,000,000	76,000,000		
~~Stock Option Granted Contractual Term~~	10 years			
~~Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost~~	\$ 68,000,000	35,000,000	\$ 54,000,000	
~~Restricted Stock Units (RSUs) [Member]~~				
~~Share-based Compensation Arrangement by Share-based Payment Award [Line Items]~~				
~~Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition~~	1 year 9 months 18 days			
~~Weighted Average Grant Date Fair Value of Restricted Stock Unit~~	\$ 46.05	75.62	109.63	
~~Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value~~	\$ 27,000,000	\$ 39,000,000	\$ 33,000,000	
~~Employee Stock Option [Member] Minimum [Member]~~				
~~Share-based Compensation Arrangement by Share-based Payment Award [Line Items]~~				
~~Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate~~	52.00%	37.00%	37.00%	
~~Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate~~	4.40%	3.20%	0.70%	
~~Employee Stock Option [Member] Maximum [Member]~~				
~~Share-based Compensation Arrangement by Share-based Payment Award [Line Items]~~				
~~Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term~~	4 years	4 years 3 months 18	3 years 8 months 12	

	days	days	
Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Dividend Payments, Per Share	\$ 0	\$ 0	\$ 0
Performance Shares [Member] Minimum [Member]			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	52.00%	41.00%	
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	2 years 6 months	2 years 4 months 24 days	
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	4.00%	3.00%	
Performance Shares [Member] Maximum [Member]			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	57.00%	47.00%	
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years	2 years 10 months 24 days	
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	5.00%	4.60%	
Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Dividend Payments, Per Share	\$ 0	\$ 0	
Stock Compensation Plan - Omnibus [Member]			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	473,000	151,000	183,000
~~XML 118 R89.htm IDEA: XBRL DOCUMENT~~			
Equity Based Compensation (Option Activity) (Details) - USD (\$)		12 Months Ended	
		Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price	\$ 64.81	\$ 71.19	
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	47.39		
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	47.02		
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	97.23		
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	72.90		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	64.81		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	\$ 65.78		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	\$ 2,000,000	\$ 3,000,000	
Payments Related to Tax Withholding for Share-based Compensation	0	0	\$ 10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	13,000,000	\$ 9,000,000	
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	\$ 6,000,000		
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Time [Member]	3 years		
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,187,497	1,008,747	
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	473,432		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(193,508)		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	(33,550)		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	(67,624)		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	1,187,497		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	521,898		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 8 months 12 days	6 years 2 months 19 days	
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	3 years 2 months 15 days		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	\$ 8,655,393	\$ 2,225,819	
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	1,862,358		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	8,655,393		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	\$ 4,499,875		
Performance [Member]			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,187,497		
~~XML 119 R90.htm IDEA: XBRL DOCUMENT~~			
Equity Based Compensation (RSU Activity) (Details) - USD (\$)		12 Months Ended	
		Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,888,000	1,124,000	
Payments Related to Tax Withholding for Share-based Compensation	\$ 0	\$ 0	\$ 10,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years		
Weighted Average Grant Date Fair Value of Restricted Stock Unit	\$ 79,000,000	\$ 76,000,000	
Time Based Restricted Stock Units [Member]			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	2,154,592	1,026,729	
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,611,350		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	220,139		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)	263,348		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	\$ 56.14	\$ 83.07	
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	47.77		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	87.79		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	\$ 65.22		
Performance Shares [Member]			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	159,988	273,985	
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	46,899		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	84,342		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)	76,554		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	\$ 103.17	\$ 99.58	
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	0		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted			

Average Grant Date Fair Value	88.35		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	\$ 105.33		
Restricted Stock Units (RSUs) [Member]			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	587,029	342,546	
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	326,062		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	190		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)	81,389		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	\$ 51.98	\$ 82.36	
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	39.52		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	63.13		
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	\$ 63.42		
Restricted Stock Units (RSUs) [Member]			
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]			
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	\$ 55,000,000		
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 9 months 18 days		
Weighted Average Grant Date Fair Value of Restricted Stock Unit	\$ 46.05	\$ 75.62	109.63
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	\$ 27,000,000	\$ 39,000,000	\$ 33,000,000
~~XML 120 R91.htm IDEA: XBRL DOCUMENT~~			
Other Income / Expense (Details) - USD (\$) \$ in Millions	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Other Income and Expenses [Abstract]			
Other Nonoperating Expense			\$ 4
Foreign Currency Transaction Gain (Loss), Unrealized	(2) \$ (20)	\$ 8	(33)
Other Nonoperating Income (Expense)	(3) (4)	(1)	9
Other (Income)/expense, net	\$ 24	7	\$ 28
Derivative, Gain (Loss) on Derivative, Net		\$ 2	
[1] Debt financing costs for the fiscal year ended June 30, 2022 consists of \$4 million of financing charges related to a tranche of U.S. dollar-denominated term loans under its senior secured credit facilities.			
[2] Foreign currency losses (gains) include both cash and non-cash transactions.			
[3] Other, for the fiscal year ended June 30, 2022 includes, in part, total realized and unrealized gain of \$2 million, related to the fair value of the derivative liability associated with the formerly outstanding Series A Preferred Stock.			
~~XML 121 R92.htm IDEA: XBRL DOCUMENT~~			
Leases - Schedule of Operating and Finance Leases Presented in the Balance Sheet (Details) - USD (\$) \$ in Millions	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	
Assets and Liabilities, Lessee [Abstract]			
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	\$ 252,000,000		
Operating Lease, Right-of-Use Asset	77,000,000	\$ 59,000,000	
Finance Lease, Liability, Payments, Due Year One	37,000,000	18,000,000	
Finance Lease, Liability, Current	20,000,000		
Lessee, Operating Lease, Liability, Payments, Due Year One	17,000,000	\$ 11,000,000	
Lessee, Operating Lease, Liability, Payments, Due	104,000,000		
Operating Lease, Liability, Current	13,000,000		
Finance Lease, Liability, Noncurrent	312,000,000		
Operating Lease, Liability, Noncurrent	\$ 70,000,000		
Operating Lease, Liability, Statement of Financial Position [Extensible List]	Other Liabilities		
Finance Lease, Liability, Statement of Financial Position [Extensible List]	Other Liabilities		
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, Plant and Equipment, Net	Property, Plant and Equipment, Net	
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, Plant and Equipment, Net	Other Assets, Noncurrent	
Finance Lease, Liability, Payment, Due		\$ 323,000,000	
Operating Lease, Liability, to be Paid, Greater than Year One		\$ 55,000,000	
Lessee, Lease, Description [Line Items]			
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	\$ 252,000,000		
Operating Lease, Liability, Noncurrent	70,000,000		
Lessee, Operating Lease, Liability, Payments, Due	\$ 104,000,000		
Minimum [Member]			
Lessee, Lease, Description [Line Items]			
Lessee, Term of Contract	3 years		
Maximum [Member]			
Lessee, Lease, Description [Line Items]			
Lessee, Term of Contract	10 years		
~~XML 122 R93.htm IDEA: XBRL DOCUMENT~~			
Leases - Cost (Details) - USD (\$) \$ in Millions	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Lease, Cost [Abstract]			
Finance Lease, Right-of-Use Asset, Amortization	\$ 30,000,000	\$ 21,000,000	
Finance Lease, Interest Expense	21,000,000	17,000,000	
Finance Lease Expense	51,000,000	38,000,000	
Variable Lease, Cost	16,000,000	10,000,000	
Lease, Cost	94,000,000	83,000,000	
Short-Term Lease Costs	\$ 9,000,000	10	\$ 8
Finance Lease, Weighted Average Remaining Lease Term	16 years 1 month 6 days		
Operating Lease, Weighted Average Remaining Lease Term	9 years		
Finance Lease, Weighted Average Discount Rate, Percent	6.20%		
Operating Lease, Weighted Average Discount Rate, Percent	4.60%		
Operating Lease, Cost	\$ 27,000,000	\$ 35,000,000	
~~XML 123 R94.htm IDEA: XBRL DOCUMENT~~			
Leases - Schedule of Supplemental Cash Flow Information (Details) - USD (\$) \$ in Millions	12 Months Ended		
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]			
Finance Lease, Principal Payments	\$ 19	\$ 19	\$ 15
Finance Lease, Interest Payment on Liability	16	15	11
Operating Lease, Payments	14	16	19
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	57	133	59
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	\$ 38	\$ 1	\$ 31

Leases - Schedule of Maturities of Operating And Finance Lease Liabilities (Details) - USD (\$) \$ in Millions	Jun. 30, 2024	Jun. 30, 2023
Leases [Abstract]		
Finance Lease, Liability, Payments, Due Year One	\$ 37	\$ 18
Finance Lease, Liability, Payments, Due Year Two	39	
Finance Lease, Liability, Payments, Due Year Three	37	
Finance Lease, Liability, Payments, Due Year Four	34	
Finance Lease, Liability, Payments, Due Year Five	34	
Finance Lease, Liability, Payments, Due after Year Five	337	
Finance Lease, Liability, Payment, Due	518	
Finance Lease, Liability, Undiscounted Excess Amount	186	
Finance Lease, Liability	332	
Lessee, Operating Lease, Liability, Payments, Due Year One	17	\$ 11
Lessee, Operating Lease, Liability, Payments, Due Year Two	15	
Lessee, Operating Lease, Liability, Payments, Due Year Three	14	
Lessee, Operating Lease, Liability, Payments, Due Year Four	13	
Lessee, Operating Lease, Liability, Payments, Due Year Five	9	
Lessee, Operating Lease, Liability, Payments, Due after Year Five	36	
Lessee, Operating Lease, Liability, Payments, Due	104	
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	21	
Operating Lease, Liability	83	
Total Lease Liability Payments Due Year One	54	
Total Lease Liability Payments Due Year Two	54	
Total Lease Liability Payments Due Year Three	51	
Total Lease Liability Payments Due Year Four	47	
Total Lease Liability Payments Due Year Five	43	
Total Lease Liability Payments Due After Year Five	373	
Total Lease Liability Payments Due	622	
Total Lease Liability Undiscounted Excess Amount	207	
Total Lease Liability	\$ 415	
Finance Lease, Weighted Average Remaining Lease Term	16 years 1 month 6 days	

Commitments and Contingencies - Additional Information (Detail)	12 Months Ended Jun. 30, 2024 USD (\$)	Feb. 05, 2024 \$ / shares

[Commitments and Contingencies Disclosure \[Abstract\]](#)
[Commitments and Contingencies](#)

COMMITMENTS AND CONTINGENCIES

Litigation

From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements. The Company records a liability in its consolidated financial statements for these matters when a loss is

known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary for its consolidated financial statements not to be misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the Company's consolidated financial statements. Any legal or other expenses associated with the litigation are accrued for as the expenses are incurred. The Company intends to vigorously defend itself against any such litigation and does not currently believe that the outcome of any such litigation will have a material adverse effect on the Company's consolidated financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise.

City of Warwick Retirement System Class Action

In February 2023, an alleged shareholder filed a complaint styled City of Warwick Retirement System v. Catalent, Inc., et al., No. 23-cv-01108, in New Jersey federal court against the Company and three of its then-officers (collectively, "the Warwick Defendants") purportedly on behalf of a putative "class" consisting of persons who purchased or otherwise acquired Company securities between August 30, 2021 and October 31, 2022, inclusive. On September 15, 2023, the Warwick complaint was amended (together with the original complaint, the "Warwick Complaint"), which amended complaint expanded the class period to between August 30, 2021 and May 7, 2023, inclusive (the "Class Period"). The Warwick Complaint purports to assert claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and the related regulations, alleging that, unbeknownst to investors, the Warwick Defendants purportedly engaged in accounting and channel stuffing schemes to pad the Company's revenues and failed to disclose adverse facts that purportedly were known to or recklessly disregarded by the Warwick Defendants. Specifically, the Warwick Complaint alleges that the Warwick Defendants (i) overstated revenue and earnings by prematurely recognizing revenue in violation of U.S. GAAP; (ii) suffered material weaknesses in its internal control over financial reporting related to revenue recognition; (iii) falsely represented demand for its products while knowingly selling more product to its direct customers than could be sold to healthcare providers and end consumers; (iv) cut corners on safety and control procedures at key production facilities; (v) disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company's financial results through premature revenue recognition in violation of U.S. GAAP or stuffing its direct customers with this excess inventory; and (vi) lacked a reasonable basis for their positive statements about the Company's financial performance, outlook, and regulatory compliance during the Class Period. On November 15, 2023, the Warwick Defendants filed a motion to dismiss the Warwick Complaint. On June 28, 2024, the Court granted, in part, and denied, in part, the Company's motion to dismiss. The Warwick Defendants' answer to the Warwick Complaint was filed on August 12, 2024. The Company believes that the Warwick Defendants have defenses to the remaining allegations and intends to vigorously defend against these allegations.

Husty Derivative Claim

In August 2023, an alleged shareholder filed a derivative complaint styled Husty et al. v. Carroll, et al., No. 23-cv-00891, in Delaware federal court against certain current and former members of the Company's board of directors, (the "Husty Defendants"), and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities described there led to, and will continue to expose the Company to, costs and damages. On February 20, 2024, the court entered a stipulation staying the case pending the outcome of motion to dismiss that was filed in the City of Warwick Retirement System action. On April 23, 2024, the plaintiff voluntarily dismissed the action without prejudice.

Brown Derivative Claim

In September 2023, an alleged shareholder filed a derivative complaint styled Brown, et al. v. Chiminski, et al., Case 3:23-cv-15722, in New Jersey federal court against certain current and former officers and members of the Company's board of directors (the "Brown Defendants") and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities described there led to, and will continue to expose the Company to, costs and damages. On January 8, 2024, the court entered a stipulation staying the case pending the outcome of motion to dismiss that was filed in the City of Warwick Retirement System action. On April 19, 2024, the plaintiff voluntarily dismissed the action without prejudice. On May 2, 2024, the Court dismissed the action without prejudice.

Merger Related Claims

In connection with the proposed Merger, as disclosed below, three purported Catalent stockholders filed lawsuits alleging that certain disclosures made in the Proxy Statement were materially false and misleading: *Garfield v. Barber, et al.*, C.A. No. SOM-C-012027-24 (N.J. Super. Ct.), which was filed in the Superior Court of New Jersey; *Moore v. Catalent, Inc., et al.*, No. 652403/2024 (N.Y. Sup. Ct.), which was filed in the Supreme Court of New York; and *Clark v. Catalent, Inc., et al.*, No. 652407/2024 (N.Y. Sup. Ct.), which was filed in the Supreme Court of New York. The aforementioned lawsuits are collectively referred to as the "Actions." The Actions alleged, among other things, that certain disclosures in the Proxy Statement filed in connection with the Merger Agreement omitted certain purportedly material information. The *Garfield* Action asserted violations of New Jersey Uniform Securities Law § 49:3-71 and negligent misrepresentation and concealment and negligence under New Jersey common law. The *Moore* and *Clark* Actions each asserted a single claim for breach of fiduciary duty. On May 17, 2024, the *Garfield* Action was voluntarily dismissed with prejudice. On June 26, 2024, the *Moore* and *Clark* Actions were voluntarily dismissed with prejudice.

Subpoenas and Requests for Information

From time to time, the Company receives subpoenas or requests for information from various governmental agencies or private parties, including from state attorneys general, the U.S. Department of Justice, and private parties. The Company generally responds to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred.

In June 2023, the Company received a demand from a company stockholder pursuant to 8 Del. C. § 220 to inspect books and records of the Company relating to, among other things, the allegations raised in the *Warwick* Complaint. The Company has responded to the demand and cannot determine at this time if the books and records demand will lead to litigation.

Fire at Biologics Facility

During the three months ended December 31, 2023, the Company had a small fire at a facility in its Biologics segment. The fire activated the sprinkler systems, which then caused minor flooding in certain parts of the facility. The Company accrued \$9 million for estimated damages, repairs, and lost inventory. The Company is insured for such incidents and has submitted claims for reimbursement. Proceeds from potential reimbursement are not included in the financial statements for the three and twelve months ended June 30, 2024.

On February 5, 2024, the Company entered into the Agreement and Plan of Merger (the “Merger Agreement”), with Creek Parent, Inc. (“Parent”), a Delaware corporation and a wholly owned subsidiary of Novo Holdings A/S (“Novo Holdings”), and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein and in accordance with the General Corporation Law of the State of Delaware (the “DGCL”), Merger Sub will be merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Parent will acquire all the issued and outstanding shares of Common Stock of the Company.

Consummation of the Merger is subject to customary closing conditions, including (i) receipt of certain governmental waivers, consents, clearances, decisions, declarations, approvals, and expirations of applicable waiting periods, including the expiration or early termination of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, with respect to (A) the Merger and (B) the sale of three of the Company's fill-finish sites (which are located in Anagni, Italy, Bloomington, Indiana USA, and Brussels, Belgium) and related assets from Novo Holdings to Novo Nordisk A/S ("Novo Nordisk"), of which Novo Holdings is the controlling shareholder (the "Carve-Out"), and (ii) the absence of any order, injunction or law prohibiting the Merger or the Carve-Out, in each case, without a Burdensome Condition (as defined in the Merger Agreement). Parent's and Merger Sub's obligations to close the Merger are also conditioned upon the absence of a Material Adverse Effect (as defined in the Merger Agreement) on the Company.

	\$ (1,043.0)	\$ (256.0)	\$ 499.0
	(1,153.0)	(559.0)	(286.0)
	489.0	422.0	378.0
	254.0	186.0	123.0
	16.0	(86.0)	80.0
	155.0	125.0	119.0
	29.0	98.0	31.0
	68.0	35.0	54.0
	(178.0)	(98.0)	(55.0)
ated Charges	12.0		
	(687.0)	(210.0)	\$ 0.0
	\$ 24.0	\$ 7.0	\$ 28.0

\$ (216 000 000) \$ 164 000 000

\$ in Millions				
Segment Reporting Information [Line Items]				
Depreciation and Amortization	\$ 489	\$ 422	\$ 378	
~~XML 130-R101.htm IDEA: XBRL DOCUMENT~~				
Segment Information				
Capital Expenditures				
(Details) - USD (\$)	12 Months Ended			
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	
Segment Reporting Information [Line Items]				
Payments and Accruals to Acquire Property, Plant, and Equipment	\$ 351,000,000	\$ 594,000,000	\$ 666,000,000	
Biologics [Member]				
Segment Reporting Information [Line Items]				
Payments and Accruals to Acquire Property, Plant, and Equipment	171,000,000	346,000,000	453,000,000	
PharmaConsumerHealth				
Segment Reporting Information [Line Items]				
Payments and Accruals to Acquire Property, Plant, and Equipment	164,000,000	214,000,000	183,000,000	
Corporate [Member]				
Segment Reporting Information [Line Items]				
Payments and Accruals to Acquire Property, Plant, and Equipment	\$ 16,000,000	\$ 34,000,000	\$ 30,000,000	
~~XML 131-R102.htm IDEA: XBRL DOCUMENT~~				
Segment Information				
- Assets and Revenues				
(Detail) - USD (\$)	Jun. 30, 2024	Jun. 30, 2023		
Segment Reporting Information [Line Items]				
Property, Plant and Equipment, Net	\$ 3,643,000,000	\$ 3,682,000,000		
United States [Member]				
Segment Reporting Information [Line Items]				
Property, Plant and Equipment, Net	2,625,000,000	2,758,000,000		
Europe				
Segment Reporting Information [Line Items]				
Property, Plant and Equipment, Net	828,000,000	765,000,000		
International Other [Member]				
Segment Reporting Information [Line Items]				
Property, Plant and Equipment, Net	\$ 190,000,000	\$ 159,000,000		
~~XML 132-R103.htm IDEA: XBRL DOCUMENT~~				
Supplemental				
Balance Sheet				
Information - Work-				
in-Process and				
Finished Goods				
Inventories Include				
Raw Materials, Labor				
and Overhead (Detail)				
- USD (\$)	Jun. 30, 2024	Jun. 30, 2023		
\$ in Millions				
Balance Sheet Related Disclosures [Abstract]				
Raw materials and supplies	\$ 646	\$ 781		
Work-in-process	138	186		
Total inventory, gross	784	967		
Inventory cost adjustment	(210)	(190)		
Inventories	\$ 574	\$ 777		
~~XML 133-R104.htm IDEA: XBRL DOCUMENT~~				
Supplemental				
Balance Sheet				
Information - Prepaid				
and Other Assets				
(Detail) - USD (\$)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	
\$ in Millions				
Balance Sheet Related Disclosures [Abstract]				
Prepaid Expense, Current		\$ 46	\$ 53	
Contract with Customer, Asset, after Allowance for Credit Loss, Current	585	399		
Spare Parts	29	24		
Prepaid Taxes	45	77		
Value Added Tax Receivable	60	38		
Other current assets	48	42		
Prepaid Expense and Other Assets, Current	813	633		
Payments and Accruals to Acquire Property, Plant, and Equipment	\$ 351	\$ 594	\$ 666	
~~XML 134-R105.htm IDEA: XBRL DOCUMENT~~				
Supplemental				
Balance Sheet				
Information -				
Property and				
Equipment (Detail) -				
USD (\$)	Jun. 30, 2024	Jun. 30, 2023		
Balance Sheet Related Disclosures [Abstract]				
Land, buildings, and improvements	\$ 1,987,000,000	\$ 1,887,000,000		
Machinery and equipment	2,538,000,000	2,287,000,000		
Furniture and fixtures	62,000,000	61,000,000		
Construction in progress	971,000,000	1,043,000,000		
Property and equipment, at cost	5,558,000,000	5,278,000,000		
Accumulated depreciation	(1,915,000,000)	(1,596,000,000)		
Property, plant, and equipment, net	\$ 3,643,000,000	\$ 3,682,000,000		
~~XML 135-R106.htm IDEA: XBRL DOCUMENT~~				
Supplemental				
Balance Sheet				
Information - Other				
Assets Non Current				
(Detail) - USD (\$)	Jun. 30, 2024	Jun. 30, 2023		
Balance Sheet Related Disclosures [Abstract]				
Operating Lease, Right-of-Use Asset	\$ 77,000,000	\$ 59,000,000		
Loans and Leases Receivable, Gross	56,000,000	53,000,000		
Cash Surrender Value of Life Insurance	48,000,000	41,000,000		
Alternative Investment	47,000,000	36,000,000		
Interest Rate Derivative Assets, at Fair Value	36,000,000	62,000,000		
Other Assets, Miscellaneous, Noncurrent	38,000,000	42,000,000		
Other Assets, Noncurrent	332,000,000	329,000,000		
Deferred Income Tax, Right-of-Use Asset	77,000,000	59,000,000		
Contract with Customer, Asset	17,000,000	18,000,000		
Pension assets	\$ 13,000,000	\$ 18,000,000		
~~XML 136-R107.htm IDEA: XBRL DOCUMENT~~				
Supplemental				
Balance Sheet				
Information - Other				
	Jun. 30, 2024	Jun. 30, 2023		

Accrued Liabilities
(Detail) - USD (\$)

Balance Sheet Related Disclosures [Abstract]

Accrued employee-related expenses	\$ 181,000,000	\$ 160,000,000
Interest Payable, Current	37,000,000	35,000,000
Deferred revenue and fees	250,000,000	167,000,000
Accrued income tax	16,000,000	44,000,000
Other accrued liabilities and expenses	115,000,000	134,000,000
Other accrued liabilities	622,000,000	570,000,000
Accrued Operating Lease, Liabilities	13,000,000	11,000,000
Restructuring accrual	10,000,000	19,000,000
Other Assets, Noncurrent	\$ 332,000,000	\$ 329,000,000

XML 137 R108.htm IDEA: XBRL DOCUMENT

Supplemental Balance Sheet Information- Allowance for Doubtful Accounts (Details) \$ in Millions	12 Months Ended	
	Jun. 30, 2024	
	USD (\$)	

Trade receivables allowance for doubtful accounts

Beginning balance	\$ 46
Provision for Doubtful Accounts	(6)
Accounts Receivable, Allowance for Credit Loss, Writeoff	(17)
Closing balance	\$ 23

XML 138 R109.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD (\$) \$ in Millions	12 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
	Jun. 30, 2021	

Subsequent Event [Line Items]

Goodwill, Impairment Loss \$ 687 \$ 210 \$ 0

Deferred Tax Assets, Valuation Allowance 315 159

PharmaConsumerHealth

Subsequent Event [Line Items]

Goodwill, Impairment Loss \$ 295 \$ 210

EXCEL 139 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M45L#110 (/2)ED04UB@0+0.9&IC4)O<087IP+GAM
M:8V/OL"1\$ 110Q:=(P4)B0+2L+/O>OLO&1#LD)OCGICVX>QA&WPIG-M*N1#BV&5(C/H(/147BK9.7:=N)=H6-Y*OGDK7A.YNJ0<46PZ4A10W1=0U/R:UEA-6#MI7E1+
P04-M"="TBB99ON021^X K @ 0 & 108U/R:W1S+V-O&LS9+1 M:L P#(9297B>R%&82;UL:G#&8K:QE+4UBQ-C:R11^SE9FS^V1HC1TN1/ MGT"
"=+T\$9IC5"2PWOW^K9+TH0U:Q\$%#9#^U:94YTN7GHH>4G \$(091/M2400G* (VFK2<,+))9*Q1QH(FOIXP5NSX-G;>8-8-M>NPH0556P-0T
M:9S^MH\$;8(111^V@7XES1\$SMW@%Y28W)+AB&GW^RY3@XK1@#P57144E12U%13ZY-O"1^?O>NHA-MQ1970=7 K1M07U1+ P04-"TBB99F5R<(Q<">P>P\$P^AL+W1H
M96UE+W1H96UE,2YX:6SM6EMSVG@4?N-O^AGIFT+OC:IMK03621A^ 1S80RY0-19)N1L1^S1^V%1^?H:GS|BYBZ;(E)X M0-DOV1:IMR>X%#BVR1^+ M41B1%G1@M
MNN01+5)3(C/PB=AL414P1^DOE1&<^+3&K1@<6YVWQ@C(VXV1ZM0FCU7 MH5A)VH3X\$8:XIQSYG/L144:1E6W^:7614EOC^>^HU+76>)71Y<M/1T3SLV4^P91AI@S
M&L%&KOMUAVC2/K^12F<0HACA^FNVB<5@%\$ 9Y>PTG1Z(1+90VX?H:5,VPLCO=U1="Y1FIS_LCO^MHY19^Y55FF?H1@H%)D>/N5Z>HWEL44Z">P^T=HWPIOX@L Y M?
Y1SZ7ON90IH=^W-R1913BUO>1FY:Q1NN=K7^XH8U=RS750LS01=R2^JVE+ZU)CA^M1+<\$X>RPP19SR2^9WH1TU^_9=N0C131FETX&D^>VYZG=PZ1Z8D:D*
MTU^01YZ<5X&N1Q3219A7>?8T="YX1L^O08=QXCRHB^NH8-8S1-# MAWE1ZYAGE<90-1M^*PD+\$.W8+C712P4X&1@+1^@Z11-O)256-Q618#*Y1B-M?5R1>APYV=
<7^/ADN1IF6U;11=OEM(EYPPF8\$V>KRMVEL<%5<156^*P-MOFHIM15:5 Y9KFQ09Z:RWRT^"2O:B%D2XDU=1=76FYRN>B1V1=I-W MP6#R-7#11P-E^=71U%KGIW>Z;L
12\$R<><41-71%-B:5^86\$S+D4:22 MD 83>LX=SFWJXP6GL UC6^ODRWSEPVSK>U1F M\$RQ#111?8F@<1&K8KZZKT^Y)9PIM^OO@2^_111=X-Q1U^M:160K531+ MWPF?
D=9CC^OT^<%&^M1K&MQMHQ#F 61/H68WXW=%FAHSU8NL-8T^T^5-M0-4-V10^-/8-1R1H5XQF:8VH^1."CS<N1L+<CN^MB114\$1#110 (M-/2)ED^=1S_1@<\$XM-8
>4P0>V1R-W:H965T&UL MM9IM:Z,X%#7-B14=K12TX#1YRVYD5+21E:FTZE:S(RZ1W@@).@L11B-M2@TD41ISU:2^@X1H@P<G@<^?
&74:TH>HG^6%RTUE)N/GAZPEO3B(=S MMJ&Q^<F7>^22D6N6KCMAP20RL^*H1V+1ZG8@<\$<6MTG6V1XZ-SEL@PB-D=1R^M(L)^+VG(GB1=FNWX3Y9K66Z3Z.WZY 5G5Y?
7?U5JG4/&#B,8B8#B="G1-M&MN?1DX +4O^R^HR1^?@2-7%ZUA^_ET29)0WK/G^GV@G1H-MGL="D?V/GO-1>1B%O\$1(%FV+U1E509S_121\$&1^NE9- =X6X^<%=K>FP-D6
M11+>C4%W6U1-R:37TK&84(D9U51HQXN1=220BHRO-QN1A1^#B1^3^ PYUBG^%NY13LB%R1)Z@QA-M7%L^@+X3DJH1H1L4&Z>H-D-MCXU/8D1>M%2SP51^1-
MCH7H0>Y^01LFA2;&^KP-T6<+N0>@EW-KJA-FOP-MN6YUO^CX@%5^1@2J_1#1%7QZA_-\$9QW^"0G1L-XQ+2A81_1\$A1<^%Y1^B16-M=400/41\$BM>^19/5#"
MT1-7>2F8VZAS08U126G\$K&\$1:1@U(AWE7K<=>2\$JUPV26&1-KUB@Q^JP-M:A-P/H^7-U-D_1Q62%8Z^1L=1#RYH2-B1661L19>S^FM0VY:D1=2KE1-M-NV1^JQ6K=>="191Z56)??
\$1=0QY1&UW404G21-O^MPOKH1^("=>H1E410CER6Q1^1K^1ONW1Z1K-M+4^PJ#%:0V15=>?UTMT^SNP.X1RH1Z1L>SRP+^S110N#>1^@Z<071XU1(S-MZNO-J57HE=
1>AMWYEM181Y6Z-TMH1NU^_H6Z1O<L1P13-OS5BX9HF@Z)X1-M7XO1-P15%6&8-&_NIS&ZZ9K1QIOG1V^&L1PG(S%E\$N1#S5@C_."\$RI5<65 MD<^&??Q1<6#1XZS1R#V1
T0UK1S1F^1841MB^11#10ZHCNF)^#10X5-M:1^EC1&1F1L1T91@21W^K8P-N5LLWXY11348X(%3@8-UKW<^<ZQ1B-MD0-LB#8L_85F(6K,81^P219M/08LK2TC\$8%4VK5-
ZEE51^PP91SX1Q1M^11P+1=31V+CSF1GV^S17&^K1JH5-7X1X1OP3U=1^@161M:5FF1X1A-M=SPVWUS=SD-1181TW(SS&A1J56YE0\$1^Q007&5MN>14T1BG+^@+?>62@Z4L
M%#M21-N#H?1Q^009E^@URL1=Q0:10E1^N1/B@<1^1AVZ-E7E^T1S&@<91-14BT81#>S10F11:4^MO21Y^K_3-M^"10VMT^40M:\$A0-E_1G^X@/55:EP56-
1Q_<^N13^<^?Q-X%22P1S19-M<3YM/R1Y216Z-GY3:E581>1SG^<^%RU51-QA1C#(1U1@A2433V1^P1SE1R2-M2VKY&77^1M21_\$K6CV^CON5W18+U^N192R@%N58Q1-J06
12%1Q1^P17<9V-MC^2-RR2-81_03+21BBRT2HGX6^A1/P9P76->QT@31D\$^C(1VBMU7@)M-T1K16PX+K&DPI.\$0B<A-X1P4^A2EBRF=(YCV>*G1\$0M12Z20)YBU8G(
MM1FF6\$<1^@QE(U?K96K1^1#G31V1NWUG8-SS:E-W3%#&5-&N7-KP:21GR^M5^1LR21#BM@2V2AD110:P=1B@1617?R#>6:9:5^MVL1^X1HVRM1D75Q+U&A1^56)5K&!
(H4^KETTES1015EVS5^F&E%M1M:15101-L-FFKJ51:101^YZ721^?Y1L:68+^#S1HAYRMW5F<9226H1U0K1M415-9P-U(WD^>3>?D6R336="E9E^VN^%13W=00R19D1N1
1^M%K121U1-M-P04-"TBB99@YD1S4^"P10^&^AL+W=OCVPB3^X@P13^C=1.9M\$1F1EGY:A275C-912LZ-83T1JBE@V81^E4-M0?^TYAZ_VW19P1Q^XBHOH@K_?
(^F1E1N1^<=>G\$Y1Q1D123^<3WE\$0U4^L1M:5SF52:01+571>?>1B132K0N&1-K1^GB_Q31F-UIA:EEU4&V1P1^@EH<4^M48N4D^&V4CTV81Z7-7#^#K16^3
1PVZBM2&_501@^T11/UU1JL:97B:Q:7^MO)8A5E11^>88@>?NFXX^=&@RM0GLNX92V:00GPO6R+1DV^NFM-MKU:K#DFC5M+H59)6.CW1+H91JDK?
U177K^#U216KW:H-0TFK6C3^211J>HF-MB1>71V211UTBP>S1K+LU97^N1^W78L1)=>SH1G:69^65:E111Q1U=MDZGG0^Y@+GU1C12AWLS1Y\$^QB50?^LU1AQW0#NDDH02P.%
@1H1F-M6:BOBY310_1411^1X^1W:W1K1T^G-981>Z+3216H6G:HH(Z>OY\$?MBRZ=5X\$;Z1U1F176TU.PCY5619T^@USPU1A1O:OS05L6415<BOPORR
M1M^C^GVES^C=VDM2P1-HSC-A^Y:64%YXK+SW+1.SHHHML183-7V2C-9H2M2313G17A9U8FC-R1&211M=8^MH&20M:AK8\$G125)WVM-W1L@<^HPL&06T00-
4@K^W_&C52AF-MF&SHZGETQ0_<Y637H00F:6WP>6^SOM32_1-G9X011^%901EG1J6816VGR81&1%MO1HVC01:74NDP^?EGZ<Z^OYZYFGS40024#1L-D1-LP-11\$(>?^O2N2^EZ-MZ1
SHV13)2)HA/Q^GQU-V02T^*#B/@F12W>^AX-YO^S8F#1F@3\$3^@<@O^MGIH\$Y^P+1PKS8:6T-OA+RC8E0_0=F+Q)W:T83=>TP54\$R^L1A^1PYA(
M1>K=11^Y1@ABV000=WNP80K3^2F-1%#F83#1?ODW1UZ-M0P1(211-TAB03G0R)CW1&4X(R:0BAM5Z^B&5:04&4^C.G1T\$)1^1(8&1-M^F>G1J
81LH1@11P\$414SDAD+0#Q11HG3&3G&15^)=<^Q1A\$;75KC=M1M3MOEF^X15FB^L1#4R&R1(BFF1CY\$N1W:M5H:81F^%9R<^1W&5(&1>6\$M3\$<@1DZ:2-M/A^Z02TY<
16^=>D1PT=11Q191948W1^M^1C191-P:11F1>@<4CR1M0\$11V1N1V1BBD0R1OF1975.ON>+1Y30Z78-MW1U:3.O1S.O0:00^T51U1YR
(.SN@1Z1U1\$SANKN1-FREEUQ5.WMCVS98=K1_V@WG2\$1W-EZ3X1P-H&MC614251\$5\$N-Y1D^XN2&1#<11.10RZ\$1F16R>1)=5-O1\$="F7:2Y-MZ1N66B1?
MR1)+F73BCGLMN&6.^+LZ^O#2?N(MYU41C=3C7)1^FEB^W5#(7-M8>5K?#SHT>TX.F<#9/@V)=8?1FY8<7B+1F^N1)8@HY1F=NR#31&U1@QB-MZLL4P
SD-X(N1^Z1F0281G1K15-R6>4R+3W1Y8B^CY3>Q=H@F1G121@LSY-M:7^A1^47M^9T0YD1YORK1SVA1T+79Y1M2^11R1A3K1XCOHNK41G:3751
M1^%10U1HBYOCTK1=PG1W1WZD1+72D1M121:BS1NF741^1K1+<QA=M^17+U^M>HY-Q=02P1M^@1H1F67%B>9^1&Q41@
1X1^1W:W1KR16^8X6T^1L1G=11O1OFA1H0W1V+Y1C1&K5E-Q1MME92K1FM16X0K21^X9FN@Z11XPF6:LF7MEASP%1E:2VY5A1G&61-L^NV1-M3T91LV-
1X3GL4D25+>05Z^V913&2W1G=&^7G1R-7^+E-B-MD@-54%\$8831VIN1M1A1U0BK0&X&=>1TGHNC^E1L1M@AA^126P>FOA.M1G&ED190>?<
^6@5K&G5BR-OZ&3YU75LRQ@1F+7R>17CYM&PM%L16#ZQW0?1M^>HO)1%1OU%NUS6L5^X\$9(EN^R("T>^+7G(B2@G+4K.#E^FY=P3^BT15-MNJQ1R1)^-
+G1A0FERB^3Y:47R11-M10H>B1QK(H1K945FEL1PMN:LL1Q1X^KH@5&Y3ANA^D&1L1^5X5W1M-M=U1CX1L1>HV23@=YCN<@1J1=KMX1J>6W1L-WG2+>33O.X10&D8:D-G
1H-MHUPL1P1R^ODS6G1567^8HH1+MZ1MWU1>WF51QO^<31M^1126-M11^>P1^>VW=>1#^?EC0&EBN11@V1V1^GVCZ^Z-8RYE1V176174N1Z1=1
M7Z71MDR1QX7U04^K1@1U2U5+Z1HMN\$1@1@57>9-M1Q1QW811E1P51CV-EOM21&G1GLZ141GHU5@YEZB1^<9U31-E8*4
M1-MFD7612171-2@<1M^1U2H51G1W1D1HPO121D&KQ^<1B1T81E1YD11YPDFC-M6>=66-C1G1U1F123^X-NH&S1G1E1P1^<Q^1JG6TOB1A2@TD5P+T1F=M
MK49+SF5K<1\$G:M#B:NNE:R1@JR^TB63K^YK%15^=>K&>M1@<0+148C^1M0:U@-F-KSU16G6:R1@Z11K5=RCBWM0X1_..S1P1^TZ&1W-25C@A^21Q\$6=^MTFRQ2+
G1P1X19R1X1@T^J1DUG^1J5S99&CD1F1M^>E17>^F9C:XV-G-N-M>^%K251578VU1E29-Y1M^V+Y1M2+A=^#C^N>W1UHZ\$;MN71THG80R^M^B&QM9_>1@7S;E1
(%1%55=>11^1=11161HG1US26<3W1D11K1=NC\$1-M1^3V5>AAK4-E=EE2_&N1&1O=M1^W^N800BW:PV37AF19-61+55V)8^CCG-M1^1RA64AD114\$1#110-M(12)EFA1E1P19104
^X-8>4P0>V1R-W:H965T&UL MM9IM:ILV\$1="X-10LXM401E1CG^76K4161DW:O:8VB1E7P1C1YVYR:A1QOEF\$1M0:41F1MOUKS1B12WQ68B1@4E224H2R?
M<<S11E1@<6LRK\$Z^Q9R71F4K92NM-M1^>1O1X14%E19_01GJ11E1F7^01HS&Y8G1E14U1+14HOE19Z^FP-D-M1=OLG1H:W10#CZ^?O^H@E?1K(B>2Y1^RQ^Y01H-
1RBA:U^F1@L_1\$6:@+M-M+<1JA^1AH1VPB14ET+RK1FL%&0LK^2AV8BC@8H1-W-S1P1^@0%>Z1^MN4FMK-KKADBR1?1@
1FMK:SHBV1N1M1K&KQW@O1_4M4^<D8LES16:5\$D3-M1J2D11EN1M1N1+1W^YOF:0ZW1P640V4^C11P1=1X:P1W29X6>53%61)6ZCO14^RC^LBAH+A\$10@5V1<53_1^1A1
1H8+L6:01U1M1^1T&S11X1M70FA1PZ1H6<16+1UW11^?1^>ADH1M1G1G18U1Z1913G1O1C^B-MKEV1E2M=121GLZOU6KV_5^14@154=192Z1E8HOR-M^B&QM9_@2,
(.NZ18TU198901H4:6-5^1S1+1+G1G1^B1?2^#0>2\$>DW+1(1L-M11L:686451%?06)61-N1M1H1U1X1+>1T0=51H114PVO-M10-74141H1G1MCEW141L1N^<ER15K>^X8B&ID2
1H3&R1U1J1A1H1T1U1LL1QD13G16G1M1=1JURG81Y1K1E1@1U81U11M11S1H4ZZ2PM1321\$5W+6-MB1H1U1H1V1UN1T1^2)@142#1+3_1R146Z1M1WBG11Q1C1KE5D-418+DF
M8=9.V#C1U1DMT1+<=&90W&Y15=<L14-75-51@GZE1<1H^@K>6B:S1^H1NTS1(K+(10+1V001X2>>Q1L1751>^#>?2DUB@%3\$<^CFN&4A637&X-M&H:Z<
@1(M1+155FQES12%2K^Y1N1^_FW1>2E0_1Y1+1V-MY1M10E11RU35QZ4-A1V1^E1YH738=65T161CF1)=18AV1Y^SOM4^E1BRI1<^*U-MF01^E1WM1^5V7^7M8+W1B1=1%1?
K+43^1F1DU1(AG1B@2\$W11^WPXZGKA51X1RN7-M=5-MRC9&1K1Q+>11^P1T=LO6:168-D1ZV1(N^>9PX6GB1T\$U1Y1L=1H-2V:M1H16@1^N1O@O-WR99>=>B+&+H1
K+6)X1Z>=>6GT11=V&S2A11%1C1M^B<M811_YO1GMD1H1M^1T1W@6#M1J191M1CMTBOO11@M1^UT87181D1R+WD1O-TN911-M+013EF1@1E1C1Y1M1G1P173Y1GQ-M:4F1P1-
11V1Z1Z1Y1Z1R1AF1R1JM^>9-CF-R8J1D11DY1GH12R=4Y1M1A3&K6-B9Y1>6B8B1656E164Z07-81>@W8-W1M1V14&1A1@1Q1E1F1U1A1O1E1M1=7M6R116NEM:
Q1U1H1SK6R1\$FPHN1^U1=1@3Y=<^1Y1B-79>H1U1">AUD13L-MD^R1M11-9R3V1U>1X01KZ1H6O1H1^#6#1E1#12^M4=U1U1U1O1^N8K1W1^1L5(S019P1T781N1XY159=BE146@#1P1V1<
@FTHU19M^<H1O1#4\$1L1#110-M(12)EGB1U1E1^<1\$-8>4P0>V1R-W:H965T&ULK1R=M11L1V>1^"1S110D1T81D1H&1^?%K28\$=>BY\$01:EL\$1(1E31L-M=H1^1H115121%<
^88G21P1W1X1D1^7ZEZ1G1@S1C1O4R1U1K1-Q21VGD1%1M1710^<8C548-M76U1D1FCBGG1M1\$S1C1#1AS21NV5+1^K1PG-E81^1^+1J1MQRUPN1Z1H22PX1YM4V12^+1J3K>P
O1E7R1L17644A14@1_1^<A1Q1E1X1L1P1M110192&6P1U1P1W0S192WEO&Q1311=8N1O&QN1X14^<11^<1D1^5U0K1<131A1-M1T3_4X1CG1751L1#1+Y181+21AA31-91L3L8>B0N
MMD101Y8P1&11EE7Z1U1N1+84V1Z1250135H1D1-G4V1W1-EK3K1-MO71CX1O11^1V&F1&X95N1F1V1D11SA1J1&1W&1%1UG9<1J1<1^D1^85(P1^1M1M1+21%61F1DQ<OY1W1K1NV1?
RXZN:V1^9ZH90?1W1%1>1\$EB8^HW1^1Z11^>W1W-M47^M1H151RY>1X5X^X-Z1D-D10R@0E4S2@G2ZF92ZZ1Y1MM1^<8TU2R1C1M1YMAV1W=WHG18P17A151&1&9O?
@F1P1LFX1P1^A2^76N1M1N1+CL171@6D1RR<MOR015611^>O1H1M1R017>1XH91C^C=9>11^VRWB1MT1N1K1B1U1A1^Z1BY75/W1MNS^O2N1=11D71A4^08O1\$V1L9<11488/R>S^(>U-
R15^X1RU1F13U14Z161M1N1X1N193C0@=<^X11101X1Z1^>1J1-NX+11^K1B3E1^QK1<66Z1MN-EH\$<LDBT1GC1D101S7Z1HG1D1F1(16&1N86D\$1J1H1Q1>1PRPSY@W1H4#21
MC1)H01T1^O19)QO@9W1A1-H1CL1L1^1H51-T1^X7&\$<Q41XGK1R11H1A1=1M179Z1K1C1L1S1L1M141+1^53=1136T1F0Z1HW81AS1XU1@61@NO1XB1
1>B:PR691H291Q1K69XT1R1Z&1WA1KX11^1#L1#1M1V11#Q11L1C^H71L-G6O44^<M1X674:V1-J41@1J9_0QH1F1+11<A@<1JA^1BJ1X1H&T1FK1J12X1%NKM-M11E^E#7

MNWZ:SGOEHF56==PQK4%1419W6FZJ2C8BCA15DF61RRNN10G#ML30/OIBH1B-B\$5=-LSLH/MY14/1PAW.EBE.Y2=00QGXVZW2==
 MDP.UL5+=#Y2=-E85F5914/X/NB%V%MC>@0.7<9*%XIPX=0%WKX/LM.%JPMX<O5.G8-2%W%OC<@0%NL"@/NJL=2FR==@EA.3.KD.1R%>
 AN1.RA^PV@J2W9+H.DCNDR@A.MUL@XLT^PGGV7THWY/M@J>#ZU3ICVY=97B%#1J1WTF@KJ^CZ+151.M@VABM-T15=L9KD22^DH^Y.L.GOW?
 (%.92Z1^I2=13>1%7F^TV=MR21H00?T^5BLIK9331^@VTRB1X1TOE4L4>4^D^E7S.81^KQ1L^WHJ4KQW.2GWW-MZRI.
 9R14.0A.6NJO6>98Q53Y.51^W12>6-1^R>R<5>6%*9N2F^MV.Q3C%200Q7UWJFJH-J4-N>.CEJ^HFYFONXW6>9>5<4(RRKON1BR)^H^ON.M-UE="01^X?
 (B=CIQ.4%5.COKW>2%AK8A813C%3^Z6GLH2^X%>6%M3=IY=I<B@.9.016HG.VUWJFJH-ZPPPS+448TABBH^UD5>=22715)MGTBBS1M.D.D^Y22?
 B&MUB6.YMLE^VME=VSIOE^H^5.1.TW7X^S.LH.M20V2Q@.97F#F=U#5.HM1&VYQ.O>D.8K(X<3+9IAC%&-(8HKIP2W10W^O.ME=KIB1).OUDEPL>5=RT66%A0B(?
 (5%3.HT.MD6>+VMM607>16EBZB)A=A.IVD.SV7>NKP1S)44XPA2B6GFCFV^SRV7^MESS7%0035.G95072%&XIWDE4UF=CHZTBS8G1^6F3V+Y8^W^H01
 (M?H5%6).&6Y.&1.HD.T7OY4Q=C.SBJAK1B)57K%1^B+AQ3K6+P+W^XU5M.F%O:Q161=B^&98AB2DFVE#R^R50QOHHBM99HVW.Y.6.YGM2.4.UH>2.MU+@.2TU98?
 A^Y.K1=4U1>@.AVY8H^976GJHJBOV1^L1.G%N.TI.UZD.NBYZ^EVS7O(6Q.MT50710Q<1^L^PUUM^XU1F8-49G+T7S1ER&L1.V3.5&X81HJH^SUYCI
 MZG3.YFL>7.W69AX^E95A4H6-1%ALC+H.O.Z&O1@C9S95=S.52.S.M.6%G%6.GT6#^NN.D1F3&P8FO&X1.F1>7(R840627525272^H1R^SBBG^M71HJZ.^9H
 IZU^5YAH^C38%R55.4F.#S.1213462FEHJL\$KX@+4.HHD.MK64^2@24LL&K=N1&F.DVC)4^H^IE5V%&HEK6X4YBNT9>2>B^1C1&5AG.M&MYP.^2L.S.O.TF3Z.SIG)J-
 W1^8H1H<1P1=PUVVS1TPAZJ(YFL.7^M%55MAJ&4=48EIK.^1KT8.^83CM?N6C4M2X#M=5A.O1.3H(\$S.M#17H^H15661LZXV^2IP8.YV1<@Q
 Q5Q>?K5%5^H.PU)3^61PEO.O.MJGGV.BZA.K53QSO37&KNG&CR19Q^DSP>79X.K19W1V.I84%3ZAJE4-B.E.MIEK:P<^ADJOFX\$@I=>
 ZR-D>G9..2%K.BPU=21^P2%91GWIJ^5Z6U9.A8^56.M=JFFS.GA9A2GPURCSK0B@.O>V.2T.(3=9A(=6F91.CC6.16199>Z^ZYBM4VMNYT^C=QW3>J>
 56V&S91U1B6FMH&D&SCPI&K1C<=J5D1L=UE.MU83WI<=J51.900.^J15.H@.Q.3762T30N&G67K@.S1.9.N.CP12.M1J1H1@.A1A)A09(CJ-
 G>.VO.4RPIV<24^LUR@X+DYU3G@A1&>#P31A1P.M4-48EIHBP.P71G@O^JH6VJH^TZH^FC^#0L.5^Z#IL.PU%0C&RICOO^2.M1.MGM<
 M>X&A.D.H.W%W^C4EOUAEJH5&Y@+PR&DR1^+JU&+F@W@VA>U.MGH/C4M1XS/LZ^X>Y>#IM>8L2.FHUAP+R1+52UF6785&TJ^&95AHM1K1&^=1&1//
 M9TFLV.1.24RX^JW-0L5+42588566YOHDP03H1.SOZ.7^F@C%6EM&NIS.M7^AJ^A&42URK^S\$R(X^@/9=+1)D#NPS1^@ZF.TSH(81+VAR@X(H8C
 M8L^FVBM.HJC=PS6.XCFD097081K4.4HJAK#4E10<T&CQJ&P&O1M.O1>.B155#5^H.PU)336T@C0=FLUR(I^VZX&B.G=JM=W3Y1^J7N8^FTM.<.
 K2(X^T1T3B^U1^FT^DCK.MK<=>6.QX.D1U.458U1A55&1G1>6UUVQ.S7(L+1+DIS\$.%6Y^L&KFRZM@.MU1+1KLM76=^D0J2K1W2^51P@W.ZW.IN+Y2.%VL+VB2^%1
 P04.M%#TBB29.LDYD00^17^P&^AL+V=OYW^T\$1.90.W>J1&7.F1WV59)3=2HVPV.Y7.ME9.T68HUI1.2^J1VY+<IW^N3<9N.FYG(Q\$H1GE.)=(%7E.Y.4F-B.
 MOH^6LO7OPY.YH5ZW^DH^145>+H.L.S.M.5E2^ZK0.P9A&+5=0&9NS^X4Y18.Y0719^238H>D76VAV8ZCZJP..IM549P.MFK.Y4.G3?
 E&S^VAA0MM&E.R#42^S3+^%#012C148D9^E(\$4NOQ54V.M/33RJF5>6Y^O-BN1OYVN^RWQVDP.C.M2M&)ZLT<IKR)<@.Y%RWTHHPV1MFF)84PR=^VZ+@RFL>=>4K1&4.
 (3..2^FUTS1H3GMHEHMMWR.BT19>^GZ(C1M^@P2)53KEOS^UKY<=1+PR<KBK.O1^PICR&SATV1ZVP0S.A8>2>5^<I@.0BD^L.N58(M1-WKX)
 M1^QCCD>1WR.R-HH^W&Q&O@STUJ^VXN\$T7<37RTXN1&J6WY^H759451^@Z2B&K2.O<=74^T.UKR.2.T12>5^<I@.0BD^A.N1).MH5=(AXAR1.Q1VL.F2.51.8DPT.5.0)>+>
 1+1.BVON130M.(5^6.MDGZJ1L.FM^XU<1+1^EEOQ^FJ@U=4>+>JL.W.OC>ZH?J1^L+1F5)Q18.MOE\$3P^A00D.<#J)60%^>1.P.#XJHVS0QJBC8>YR^TU%1)GEU^?GT&3Z1P
 MD76<KX30DCP.C.6U1.OU4S1^H.O(2^2EELLF2.M7.P^5^8.>+P.O.VIR.W.H965T.H1W^H65T^UQK<^X%OTK.M^G9K^UTM%#ZX1THBPKX=J828H^J?
 DHI&16Q>GGLKUH)@3QM0^7.U41.M-7.T1U=7=VCAZ174.HK6Q^M^LR3K^OH^QU=V.P169(FSK^F^)/R7>4J7MF&OI^F=K2C/H2RTC-MFH-M+W&4
 &ZOY.4QO.U.URR.S^F%LOEYB^R^R=O.M^GK3.IK^Y/H<=<A2.M10H.DREA3ZLOY=..RKAM1^1)4H1F1^@C^WWVS^
 M^@4DXF=70K.ISTA499.F0127073ZT(GG(\$F#1^917X1&G1X<S>S&W&LMBID^X<6^K^3E>+5F>+N&G5Q2R04VCUT^AF>US^JZO1D4R^V.O2.I/
 M1Z1M=<1@G7&TN6F<^993D?^AHH1D.WI^Y^61^4^&7%+V.Q3^1B.M.O:H19.5GU.EYW29R&C.ZHNDKXV+<K8D/DG9U751><1HHSR2>CMVZ.M.9^F<1B1D(T?9
 P1P^6H7217PMTFWWI.RT^40Q?+>+9ORHF@IV.S<M^W^X^L^O&AHD^THO.M.NOG(0B0^3YX^>P^1G=3.^V=7569T5.CNF#3R^M2=WIQ^RCNG51F&#XTF1^M^H8.4-
 H/PHU7^S.FQ6A^S.OY0H^Y^X1&Z.M1W/IK^T.W1V^C.M3J>74.VLR=M.V1J.M.JWVYS=-T+^#UIND13^L.SDO18+&F57L7>P1.MFU^\$X1G.^4H^
 <3DB&=<1@9VZDxB^+<=JL+MMHV+10N13F<3^6.B.V19P.MM&B&C.DAG<3Y#N.1KR>+<Y5H.M^HC.W+155TDH^H1O^5THJXVOFZU.1K^AU0EHU6
 M611H&P=<9@91ULH^1J5T14D6-2143+D-13<1U7/35CNFK4P(NX1&4P#>+1.M^>91L.N>SC.<A@K<1Z^OXG51Z^7D2T8L.C@U#N^P&K.RM6D3.CHOQ@Q.MSMDGU2
 1CBHO@WEYV12X^O1.DY3>ZT.E7VE.MQ1S^O^BQ8-2+<C4OF49E.M/HZ/H70V0^1JFGRWIDF^X^Y.RT@>@.01P9^VRG@1@1@L^T^N1.M=S75Z1P144>2^K1O1L^H1T3H?
 H1^K9K7H6V.JL^0S(F&2HEEN.MO1^NY^C.AK&+076.NHBI^<@<CKPKS191V1JFGRWIDF^X^Y.RT@>@.01P9^VRG@1@1@L^T^N1.M=S75Z1P144>2^K1O1L^H1T3H?
 H1^K9K7H6V.JL^0S(F&2HEEN.MO1^NY^C.AK&+076.NHBI^<@<CKPKS191V1JFGRWIDF^X^Y.RT@>@.01P9^VRG@1@1@L^T^

[illegible]

0FA#LK2C=>+N180*GHSH7\$8MH.F2FVE\$<#1.MA<#\$.UZ:>09.90P4\$1#10/(2^)*FFTB0RH\$P(+(\$ 9>+&PO.M=VJR.W.
H965TT<.>+HJ\$8L.D:0YLFJH8P5\$5TK08+D35=+P1-7LJL@I:1FY085*+M(MD87@i8***JF+J5PI7J.E.SFK6\$*(C4P2.WA%CBW(+3Q
MTCI4+56VJZ.L=N-JOES33<2OZIS\$FTQM*)GE9CITH.M5/-3B3W4A1D)G(C+1HJZ&MP5MPH)8&*%WD(U/Y,C<87.***0ZVAXX7 M7>N/V5H:A9W0HURY6URGF.G9:IKED%
<1P1#W0Y.V17 Z8+7R>:UO"3383XVY9X\$<#E\$W.MXW\$X.NP#>1PF4I+U1 P04 " #TBB9N78.NF<= "NT3E&C:R=N2K0FY">V.GVT(2S.255\$(C.Z.PIY07N)W-CYH.H.C1Y+
QMOM7\$12NKK61660\$E4>=>B.FYV5D*61)M0KK&I1<=<4I\$H.MX010B6GRIUE.M\$MH.HA+I\$RJIY+(IRDPT4R1D)=.W.WUHGT7)W%W%UK25--I8EFSY+3\$KBB.M@B.)IXFEWJ*F
(UO0*GY2.3.&M)EDFVJ.FGWB+0@89.HR\$*BP.P8L72F.MC1=H1F635%P\$<T5574R1KQ*845JIN10Q6Z>2XL7R.8.M3.7E\$<7F.UB\$>+MAJHRE0M
9VA<T63CMZ>QEB.PRP\$90WQ4.4.#A/Y.G0KNX4<1.0SR1J.F.E.MWVJP.74.<7150.S%K04>T4I#1Y3*P\$PPX<G)K<&2.I1<=<SA_P@_)=+M%PW367>X4A7)8.*9ZZI
11+WK79C7U0U)DEG2739Q(OZ&=<CL.DXXPW.M@H)00JF3=<VULM.DR41#1E.\$PE<#RG:;H=1F7371V)0=V8H.1X.M&Z>
+19#1P.F=FY5YE.R0Z.N;F\$;#8Y=U@;5\$<+00S<@H\$1S<2@B1.M#>P1.0L1<0.02P.\$@<1(HF63JL.C5%<@BP8-ID.X%<W1.W)K.M&ULG95;YLP#(#.BL6D/7ADMN6
51+25H+8K2.M.GMVY.E3.5366.C0*66#8E5.H.1.Y.<M1*HN2RQ25H\$DWBWA=USBT8K0S=L%APXKQ.CZ1H619N.W%<@XHF*CB3\$1V19.M+ES\$<U2
E8HU.D8HV4H0CS.9H8D7F\$=<#S&F+0\$;V.PN\$<#>+A1.Z7.VZD3.M31=<E.NZEEA07<?>+<ETDWO+Y27/6HGU.3I=<V.EXI.C30(3RG.TE1+S\$<R07IVNO<X.RLHZU.662I
M%<D.H071=72%\$R\$<GRCUOM%1H5\$B1K.D(C8..%>719(WNL=.HJX.N1<MG3=H1XK6%>#135FV1NH9\$34/OA+<2%>T@1V4HD.2PT0?OPEGP.41YTBM/MANGIME.PF
W00U/M=<2B\$K.2BMICM(PCYT">+1#F+S8=Y*P7.#0*N6H6W\$M7FYVU.DJ@32?;\$@<LOIRWV>NIVO/KAAOVN13-1\$&4<7/1A71.UUVROZMU;
I3+ML&1\$>1..6/>41@<U#F+R13M1FV0G.B17>7.S4YHTIS\$H-ID.IX.M;7W)KKUL059;CJM&LOXK0&QV80.F<R0G40G.M8#QV\$B.6R23IP+GX#Q09\$0JF"(5-CECY==0?
575%VHHVYLX+((NMD=C5U76.M<1HJL.FU.EWW<5+7HFC=<=M03D1.L3;W1T66U31+INFW>0=<=FN3MYV.M.7G)BS;5ZSL2L6D)KUT.PTSS290=ZLU-Q=<W1<MY+XQ;
16.XX27G.M.E.961HJWZT1=<@>+C.F=>JL<=1.UJDT8571H.N@<@G*WU.Y37G.VD5\$A.70)00H(F.C.M635IT05VJ1@H7.7A\$4SG<107.M91.LPW7/1083(OMR.R?Y1?>
\$Y<7ZB.YXRT.Y>NRIU<VS.W68NGH1H<+F.MYU.Y2%G.W#EMFO15XKN10>OYT*HNLUA0\$WZLM.O+<FV1.WUULV11011.7W>V7F4W364+<USVVRJZ.U11TF+H&FA+P21.8\$#B?
9<=<NEN1MISU=FG(CX)1.\$XXTIT=Z-9\$<^/>L/F.G.VR<=<GZ021)TOKN\$3QC>DP/PODI.MOU<+U14D40W=F\$HJW0<Q3L1?>=T19\$<=T7V=GE1+9/I9/
MHZ">0#4K4HN<1\$LFQ9\$P3KW1BBTZ.\$1+ZH3*90B4G+16%#RO1>5IOLG*1M.GY6V5SHJFKE77FVWSKJUR2+MMK%UOQB1H.5937H<4.EOH<?>2.M6690/HB
M91@+TG23*OCI=<2.9I07N2Q8Y7?E)DE<=<BM3F\$<UC0%UW3&@<C>6W.MT=<=<F1N3*MGIMMUHE0Z.<=J2@B1D7Q7V.HVY91%1LTF5+<=U424E.M.ZLQ(\$9.M
)=<4"MM27LSA5Y+1LE6V19J1+Q11<L03553HMG319P.CG.TXV1.G06J.FC.MY1<3<1.70+<2*MK10%K.C.9Y9.<X1C.GEX10B6AE7Q1VXVW=(N.MA(SKS(BWIEC#ZOG69TH
K<4ZLD55=1O461">T4HD.MUO@<XM<@<AUR.W2(A1PPZ9.ID122U1X<=<W3.IB122B71R3L#1+<E\$108)0%<=<MH87E2.F0P1+<H97>729IK
1W636.BS(Q=<=<LL5ZISB1<?>71M1N1TK01.TE.MUZWKGU<1ZK%1H>C.G.MULB1+<N1(G8FR1)X1A<=<HNBQB@.UL18@1/LJN1
1WQVQ37M.0&K03LNB>#BB1136\$EH15516QB#<1@<=//NK906W\$X1X1B.DC.M.C1K#P.OMDGGH075.KR.HK5174@YOP#11U.MG.\$H1X(COIBTKN.1EYC3OI@<\$KH06VIN-
1F0D)XRLK(C2E9B.8.G.BXP=<1.Y0PYE8364L1<RSM5IE.A2M0#>JGGER82L/NR.MFR2R1@<C03LR&1Q0.C3P3<GG.GGGP@<PH17?4>B.R.C.0\$5B15BF.M0?
X%#E6200F1L\$<>S/SEL.M4POX\$S40M#E1\$385\$1L1FOV9>7%VJ3F<1@PC2%=>98L>CH7=<C6.P9).M.DS.TVDRZ<5S(I200L1\$113.80S1%THB74?>OBD1@<K*DIK&!
(05(P.31DYVC">71<=<T=<MV>.>80.Y1#FAB>1?>T97WHBIE<7%1GRI57H1L1G+07K6%#E.B2.Z010.M#6R(\$5E%G/L1L2AH1W.M\$729H)X\$<Q.C.D3B5\$4L5"U1")?>
5L\$<Z(8H514B1Q.D68#6=>A29>1.M+Y<3=YD183LB>4+<U.#4X(OE6.CEHY\$<1XDKKFV1T.WN47G0>=>3.OZD.VL?>A\$>10.A4=<@Q9M1)1>JRI+
M7Y2)0#E\$T.Q.YP6W=<N=PO22P.4)MK1UB#K3UH7LD#C5#R(2V3Y50LV\$Y.M#<5FY&V1X3PTKWTJCRN.#<Z=1.6FC.<@<5\$SK.R8HN.V62P4GGW*500..5%I
M3\$3\$..XY9B01<1M\$M+1YF.TG1A90.6MX%671.51L10P1PZQE)21.MEMT.<1X(2721.2K/O.VWY7.X.MN1AKV0&33>XOPK(OWC@<K..0A.TM&F.MPD20MYP?=<X9(CGS6Q)!
1B#<96.1J20150BZ3GS(L.N\$<+SJS7AD2)4GR.M#DY2926459JRLR1K8RS.K.MVN4B5J13Y<7H">1.U1+1(Q=<A\$<6L.P598K
M.X7N190RR..YF3>ET1(TS0R*8Z<3Y4H#1\$Q\$DHC.C&#NEEO1DY10KK6P5.MC/(N1N=VDS5V31>2>9Y10J.\$<=GFU#Y1H(54)M<=<UKD40.5BRQ#1+1H.MH(XKB1+H/
(0G587R.RF54T19>@<S>R*F6ETP1L2=<9R.3QB>=>N+<SC.MG.O9P1F5AEZQ1@1(PB.8.<559%7Y.KC1T28@<(K07NB#DEUDN#K.03IV.M.NROL\$1L1P1@2Z2
>5FU1E.05GW9H4<=<EU0140N)1?>A">=<N1I\$?1D.MTBS.HUF83YTF.MV3@<Y1V\$5.87CVN1.G(21QC8<1)1L1P1H>F">1M58TB1E+<MIS(<@<972<76.FGP3HG+VRLZ;1#=<
(34T).9D6.B.W3GO.LSM=2.D@<31.M.8#ALN1A0\$5ZRZ)1E1@M7&M71%506.11E.Y.2Y41.Y12H31K.MLP6B@6VE+MBA9>10ZM1.81U.ZM01H4(FB&R.<1#<9-
7Z\$<X+P12?1/1)=0.021"MG632D.WG<35H1A)ASC#11.5#MC6.GL@<1Q=Q32#1+<@<QES7E%Y#1J1.M<0SLZK.S0DAAX.81R#M#<R1X00F91\$<FB&+AB0Q\$A-ID
Z=00/F=9R.M26%<+H9D#<0%<D1+<=8FEGW71U1.B7AY17U>7.5*5

GL2J5iA-2%BYB8J0722<1F@TPY1#CS@TOS:2G MJHID:7&MF3#2^1SP@16H138.PYCK:7BKICJ:F-MQL@#RS@>-ILVZIOB.FJWV.M9E^=-G9R=9X^PQ%INE2=O162
&FTFM3#B9E9V.FB3&P#E2V.91WD\$97V<MG^P#BCH=FIYOCMDR@V6D#LD;IAHG.01^,A4MFX@=I=40R20>F4&N085;+I=IWO>+5Y6A\$IS8A9L#M7;ZTSI>9L@D
ME=Y)0J.BBTF.H9I.877A/HN/57.#C#C=L5Z<C#E.YFG#F+CF.MGB-11.CS;LE@<0E.A1/(7E21M8852>IQ^K)0151Y%JH;L+BIAH%MOA^=PH\$35I70@Y^DHI/X+CR2
GOG5.NS7.-X2010E=KA:LOPIC.3R.MIX>+J@PUUM<+>N2>2412>5VP^11.AIG\$M\$;6176VYEUU;ZU^M8D6.M50Q0>-PW#P^*0HPK0P2L2DM.S5C^MPL34^QB1^>-08I;
<XH3>=^1MJ(GRZPS#/(P7F46XV;K0VM2YI(H0>G+I12Y2(JU0U07YBP^7JWM.M6F0R20X8R^RA6.KJZ+&G%DE^R^3A%0PZ2>Y^L;H1JCL#2VT;2L#Y%ZEF;P
P8(&@X537>06V;E2;1+V3F30+1W8/H#L^L^75;UTL.M+JA;1#6D018;TIZ6S(TG3.L2L%3XVA.MM.H06:6#1Q#5@.WTVS2JV828^I2E=-I.ZM%QDVO.L.B15045^PW^<4X
M\$<=UY(UZ1)>+12KVI%BTQ%+KJB@>-1/Q>0?T#H\$>RCIT=OAMCFI08.M016-(EUU@Q.C@OK?>=VYA(GT2A)?
VJ#R3M=&Q.6&6.5JRW=IPRMI\$OXWFOCIQ^Y=I^DF\$A0?765.ZIOYH;.MRZCQ<=>CPW17H0I5EV+6.>)<2#R1P;L#=#F?<^OYO=-NS0L^WT
M2K24.Y1^T(ZP=OIX^%)>L#CSF@<C=KR^P13LM(7924H+1.L0Q@4JER.MFLUW68.SPBJZX.M^T598M%Q)FEI9R2V.X;AH0R10%NGR^64K20D28GHMX.M^+12
(ABLYU29Q640B60W\$>S/LP+CFJVN0M+>.955.7SL0@<WV^\$>PK\$M^1EIMU#D2.3#1L%+H=T598MG1^2<\$R#W;I.H0R10.7.5BV%VYN06.17U7@>M5HB=9+19;
F7H\$&7533;+1Q(6N2.0@%P.LTDA^BQ^#8U>TKS8P;F2.MLE6G;W%GZ^1.B1%L^SY33.D>4^%6F7S/>7Z1+0<MEZJ6(EVQ^\$E.DLI=(N75^7**12>U)7IMW4W13+GJ3^#T92
M2=1WR.K49H78DBDU=>L.K4M1V5&S;ILD7M0^F<+<\$<C;IRI\$754HHC^MC@<L/BFXH1RQ00BK40E>-ORDP+184I^XY=N^C/F4+E2+3DMV71622.X3-MADM)
(#69L#W7>3KJP&FHC&64;7T.28122^;1IGWK^P&C<1^S1WPD4^MNC@VTK&G^;R&^7(LH@<0>VX75^5(RX7BXO)Y7=ZN.(9)624M3W7G6D5.CI
M1UVSY5>+DIWOF@U.7/L50\$>YLFIL^@0W^RZ92.AM02P.5%>1IHF.M63Q20MG&S0X3D.ID.IX;1W.W)K&UL5LMK.M.QNYU2XK.W>I2
^9EB7+JN8Y-1MBN2DN61%>2G9JA)XKX0^UPOK.VU.NU.O^V7H2Z3.U5P06Y^ED+X322M3^UXOH=UR>+V;8I
M3:60ZRUZIJMZIE.F4^2Y^T=A0>F^6JH01.ZSS;J^7^HON^1JGVY^4V<V^WH6Y>ISDB28:67Z.VXG01F.CI21MVLH^R/C.CEMG31W8K\$Y7^F5YQZJH0H^P=I4IE?
=>3TD^ZI&O9.(0.MRTT.9=05^>^OM;5.3TZ&+UA47^W6Z\$5&C=#4=9>77B0;H15.NS16W7MV6M.37T1H.Z52;=I=UINC.EB8WVCU@=MI@3UYHFGOZK3^Y^#H.TGV.ZBN
M7^V631D>W^9B/DI#QHF1P^25B29P^\$S)N@>3WITE\$#4Z8W.IT^+>7^M<2>?W-(1^2)@=I=43MU.VY6ZSL&ZOM%+HIP16G^DIWIH^OH.X0.MIH=8>@S1MWI^1^//
I/W.U^150WU1E5;IS-BEY7Y33N1ME.T15ANZ7159B;I7VXG5V+T.9Q(CNS23+3GL+6E;U66VTRKNG>JH
MYEM.R393.DVUS;6%B2\$=18HTZ^2LB524>D6OBARRXKXDM+JH1.S5+;424HG72^N9JAD-4BDME>#=-8WG^2.SIX^A.P^36J.J^C/J^Y8Z;1WV70;L^S;
MO^AL^UHG8W1FU9D^+15H4X3A.S.6^10QKN&N^O.L^L&ZJSAZUOL^L^MYE6RMIJ20>JPTV/(^2>R3LZL^N3^X&XWK+B<+F734.G^Y.Y.#12.6M4IUE.9.P^JH0/
MG%<U7H8F^H^=EHH^01@+A^9^DGLSSMH.P6&K3UU@+G@9ZL^T^MAA101^>A73MW.E76^I=NX6IYX3FZ^>72B8IC^T.XDKC+G66+ULW9\$S^
MA2&C^H+&7UL#6XFR^J^61P44QJ2>2.RZD.16I^RY.O+5;LA>#&^S^T.M+2NIG8S&C&^UM56A^&AFON00PDW^#15QZ0ZX40R>73IMT^=IY@IN0?T\$JGT.M<I2^
DH\$>R^XR.C^74^1SO.E31M\$<^SRSRJ1.18D.X.G1H1X21^5V+1^M^CPO..108A@IAP2YH1PR.QNV72=5I.HGFS70%=>C%F^W1^KJ^ZPCPU0^MOAT^#P4^9CVHJ>5;R-
DEBBW^EMNP2D2R^KEAT^=>ND4V+1\$34>=>^ENFM.OX-&M.CMVDYD3734XW.XB\$^BEDCUX@OHUYXK15^>C>@<FVJG(33^T6&T^M^L^I^R^Z1^A.R0+DA.
0E^VX.T0310@#530.10660B4H7GZ^J.L.RH04S.MFU^H5KWS0R19UO@#>2&S^2F%V3EUVI^>39GJY^RE5M^W^SV75=^X1ZNOEA.M^E7^B.L1>DSJ(E06%65.X8MD7ZR?
94^F+435R%>#SIO^>#0)BHY.MGUZL\$C(I4VZR^XN\$2>-(315+14LRIH1>#3%321V@C07155MWC.L.M25=I^<IWX2&E.L>+>N3S7
MI=5WGF6E\$2O.2EYJ46A0BY&2B44&SEVK;^F8UVPVH5HBZHX1=RIQFP.M\$N#B^H^2<5/>I=I^FE80A.#1NP.^#JHT&10X.M&2>=77&HJ84P7=-JY8PHBMPH3?
P6H1^G4P(GM@S^TZOK(O^#B08.FJNP.Z81L^P^HEI9UIZ@I\$2H854T8N&K3JHNOI0J.L6^F5I&@<M5SG^00M^3Q2E.67T85Q2H1A.X9>+1^WF<#<1CDI^<Y1&1&4&XSI
M7>+>61&4V5HJ31WYUWUC76>(D>+>38T^R.S1LH^W4C^DSWUDG^9I@8Y@I.XMJ^7278B8S@MS.MXIM41CBI^TCKYVBA9.ZH1&4ZLH787R?
AWSC.^>A\$;V2UL10CA4169.M.U8.Q8P61X8&8^1J.O.4W^P^XIB.^S)1^5^OX^IH@I.MG17&C@<G1H^6R@DMSN^#T^>0TC^MI^>0982CE=LN^V=QOFNH>X^H.DG19.M^F^
WE9210K<=>S1^2^K128Z1H6(N^Y4M^5OFT^+Z71+4^Q.O1AD(ML^74171L(CI@A^OJOST^<IOYXZDZFCXDR.128J30I@D^R<I@QV^7UO0^M.H=4@^=-<VW+60F9-
E/RJVE^7V75.98^EJO.WK=OHS90.Y9I^#2F<0^25M.MMFISRHE.IV^57B1^EZA^6.QI&C^1JH+7U^K9.BF^GDR.9D&=>7>+LY%
MQW1X1NMP@61H@I8016.^DAY^HE1680^X144Q@>H1J2JER.Q.M+WR^<MK0H9I>JH\$OEFEDJEDIE^FK4EH10^<#>#SL\$0.0>W9^6^8^%NA@6?>G8^5G6QKJ1+>102
C+WE>33HHUA<+M+EU@<UK1M2^PM^YN^SFS+HJ1N.G55\$>K^R^>VHP=O8X0D33D93Y.MIPK^I^1^JNG<U^3E9N^POZHB^<I(V0F0?>?X7L1&039+VBE97J7A^
M32UBXK^S782P^A9W12+PHLT^R4H+D>6^GRG^H6U.GK=H97.0>IREFX0M(M79.GT\$^N0\$<=>BU425&16C.YQO^CR6P66IMK^P^X1^77^00D^=#JKV6X6GE^M^#4^%<
<G>=Y9^7>3WXXFE2B+>P&CO^R.M99J9GJCN85ZP^\$ESIDW@(<7WZP4I2&M&P6Q15Y.G.B6L.O<65%Y^>W.M2^WL>1^FU.OX6K8^F1V1W\$S0V9U^4C;13Y9.Y&W?
&525T&@Y3.FZIE^Y;JHW.^T@+1#^#U9^F.MH^V52U^1^2HDPJ^C.ACFH^PW.E&3MWE0(M5;1^HJ3.X2C%Z^>2S54^M2>&gt

0J03H8U56N"ZP+(VD.MQ+9B.EB<02WT\$H99F).#WTJ)IMG-IE.LNNRU=2AIJ7-i-0002BJG.L2CI.M.L04E9Y1Y5CFORRKC@7GXCO>90(U)1%<(ZTT%0EB^NB2 ZCJG
IKK12%>8323XHLNCL-1SHG1223J00B0I0GX<+>G'2 MB<G:X3Y2TS134SK3L7H29SU413"1\$1-1-13-VVY\$SRM:>Y^>_O.PE.MXKD0RB2KK<+>
3X7P=H5Y&E.C.5Y^N^F.E=<S&7F7/WZNU&QNC-B=MDPY86P)3-X.UH(WRID>@EBC/HY9Z5S<8^NR(NOP)1B_10X&XAF>>R
M31XS%<1D=IEB/RZ1VP<8NZ1N#J)62.P.<72K9JHCL-1FEMRRK&AC4G01WMD NHRKQSP1HWS15
MIR6<PF=9+GD/AD/CL.D4><QXPDD39,2ICX4EDB>^UP+UHS6*OPR3^UM52.B5B1@B&C5H0:IP9S<F^R.LV4>1B+<J2M.Z6ZJ.M0J&E2FH2<^YQYWA.X).M-+I^N
E2H'A15Q7Z.3Q>2.N2^5<CNXCV7%OE07M%SI#>2U1Y17(CTDA.MDF6^6@Q^T12CWB/34BQ7Y9J2&I<433^5<5F.YUG&E.MTA+RE6/IFA#<E2I5.M^YF:<#0ER-
I3N^S#0I07LB-N=X4P0<2D-L0V1^6DJSK)HK&BL<+>#IY^1.MQOKI000H^100<+>1A6SIE.TC.<N^I^N^>1S.&5N1\$2BIW8VK7=K41X1.M^C53U.L@<H82P%EHDC\$%FG2<
1^<U5BK^E^#>11Q@O2RIMYMA4(QO.MUMQ0.M.M:CT4X&S:JHN=213.Y>YVMR>G1.M<2&289B1>@40R/1EA<K-4I19H&A<W=<S<O8)1^52FW9\$NQS7^F^H<1/
MQO10.RBT<(ZR.ADPY^KZ+<K&P&S3Q<0<1L%P&S1.MG51G@I@V%2D-B^M^2.T.MG&S3<1UP.M<WVOHDI%KX6QEI&S&I:VPZ60P105F5212^GFKIS1-\$7I@R77.M&XS%YQV
R030RMJG^HX.M.MU^ZLXH2DD<1H2AMV^RQ.17C5K7N00>@1.M6S9<N.M^0:Z^1.QI0H.U>1P<M^1ES.P.L@<C>K>K>RBZ72G1Y6F5212P.M.2KN^HX(F<?<
WA<^%Q2@09/2#>A1M^<M^<ZDR^%NF51.4@JIZWU1^>N6<810Y.3J7&0<6SAG+7H1&+&M2H9Y^9.OB.KB^1532^>YQF^ZA@>7BF^XR^XV1=2^YA^NR3J^MS^%8ZKN+<
M1^<M.N.97-N^>F1JR7R5^>1Q<1B(PRW4+BSA&E.MZNXY<2EIFG5P5RM50.T2RQXSX1V9L^1+6B1H)FG21^ISR-WZ.MHJ5^3V2M>ROY5.EU-IV2^F.M^N0<5LL3RHFH2N<6#>KS>?<
+>^5&25(1^<GWO49)EFU^FZG%291\$5P7^QW^TFNECIG15^FS>TKB51)U.M5L3L^1U^SPG406X14GBPRE7^/16RK1=1^3MD2N^>@RQ<@F7>2^1E1E
MJO/31<+>Q3.6M8C1&12P+T67K3V6<MPC^7B4BUSUQ^<FQ<1^<+>3^P2^2&H1<1.9EEV.XXV9^UAD@02(6D4).M^&8BBK&S1&5.50&EKP67UEBOR>@9<9UV^:Q?<
4<1.ZZZPZT.X6(1-M72^X7A31^1%2E.6.NRC@IUT6)1KDR76JF@<D.D1Z>1E<E^SP16^<@I1.C6V.22H1858-L<1^S15V2-3^W810D0ZNI^Y&FBN<@1<2UIG5V9=9U1^#MA
MH<^<1N12H6TKF.F>=>P625TX6G2P^X2A15N^M.K1M1>SCUEF15H-M1Z.OV7.0T(K.OV2VDN^>@P131<L1\$1P=<^Z^H^0^>Q6R9D1X>1>+<O&M.MRTS?<
U.M%<M%<G7Q1A<1Y1Z1\$>MRRYTQGR&M^<#>B06P^7M%2/9+J9+<CTR.G%EXHH@<71%N11^1QXUH+D1\$596.EF.M4.W9K\$<@<C1\$1+2^YAI4<@<R.PB3XD-R
G15U=1\$&E43VDG57R.0^H\$1Y^>XX>7K^ND5K^1^15\$50C.H.WN@D<3^>3\$1B.B.FEDW/P^JH2VYG+>MNX8-Y@<XB.CE7D1<1^X^<=>0T.MN4^H1/U1^2FG84A&#?<
75ACOFXT<1^>1J1<1E.9KSQ5X61U70R.M@N^M^RC&S115<Q6Q<@<1E.M2^2LUM17E@Y@<1L1=1L=LRNX^<1BN^2VGI.M^>P.9R0R1H^1A91^1L1^L^P^<15^>D1^E@80(1^<@A76FG-
2^<NT.HGS:(W1.M<10G0)31.GR161^7Z.R=Q<1^023L&LEC:<#<B<1<=<8&E79FG^U69.M196J1\$1>K^>ZCG1.41\$<G9W1\$1.AY3^<#<G6J9(48MH\$2EY<Y5PIRE6W.MH&S<
Q.5G/81+1X<@<C1L1).KBWP1<#<H^E1H0<DAF@<61^1Y.QO1Z>MS.QD.20H14C^1>1WL.M^TNU421016LFDG22-48U.216<BK.M%<KLC1V17.V9X8W0^<@<F8M^70.MVTFET^
1ABXJN13X1Z@<1M1.H-H>=>#B8.#<E5HUG4ZT2>S0\$5Y&AC0W1LSU29GK1YR>@<O.F^G&T45665.FEBV21HFBZ4<MP16^K12A1AH(M56CNR1Y2TB8F^<^&LR0A1Z^>Q?<
1^OY=<86A.L45C>SO>-U.M-4@S^P2.<C2178M121<1>C&A-9+70^TOJ3/Z3IK.MR6X6%<1^99.H44W41WT1A61<1^2JHK>1IGZ?<TFBW.DQ^<A^UO>NO>9T^M^150M9K^N1L^X
A@<O.OAWUUF^>XMTMY-43CSA1^BA3K1P^7HY+1EA)M<=<1N.1Q10E1Q0>2^2A1Y5QXT@<@S1.(1L1+>2.U3T^A1J&8741&U@<10
M.M5.N51P&P(PQO1)>1KJMSIS.XXIV1Y@<1^H1^21FS1)UC34<=<8QZDX8E.MTFRM1(IQNA^SH^R&R&U9.30.QO1P^2W1Y^N<1^<O&EUK1C5J.7DD2TZIQ>V.B.M^M2U.0.AIKO^<QFM
K3U>XV2RUX^>1^SOVY1Y&4S^YMSKSGYO.M^1L<Z&GLC@<U1C5/GF+T29.RB22^7PZDNI361<1>1JFYOX1L3U5>6S.M^T^F1^<=>A1X151^N1YA154G<1
1P^R=B89Y1).U\$81+5Y(1^R1&S=919^RPG<4&S:CL3V4X^<1^6<S^XF.XRH^Q<@<R0S^MNL=8(E)XZ52^DE1S:<S^<Z57YVGS^N^6H^XW\$<V.E1S.MA2R-
WR<=<G719R^X^<K1R2.BIA1Y1(2=>D)LAB(CRF12=0(K.5T^V8^M.0RR3:4PK21P^X70FOPNC[6Z1)2-E.YBVPT7A11^UFI>X0<@<B\$1P^MA=K
9H4B>>NQ1P@<C@F0K^MOOZF.Q^WM.O23LAVIMR31.HGHA+>0=>Y>Y1GJHS@EK^N^<W^<L13^F1^C1B=B>M>6HKY.DF.AE.A5X1UH6.TMB&SX78Y1L^K^HSX<C1AS-
2>1RCQ21.MJGR&5B0+1413YQ\$41^DVX<S\$X1>7A^U>PQ=VIR.W.H96571Z1<1HJF1@>+<@<0=1F.M^JU.D.E8RG.M^<9C.G3BZQ^<6&S12Q^<T&R1P^Y^G1^N^PQ6<8D3ESO+1&O^?<
M1L:7GE1^1T.EP3A1^13N6H1F.SG&IBW^K.M%SE<1>OTLNSD0^E1RE1E14>41L1^U.PF(4L8^6GN.0^C1P1B2P8<1^E.MUAYQ1<@X9H1@<1<O#<
14Y=5R.#2.D3R3PDDU^212E1F<1^0RU.0.E1G61X<1>3>1.61D>1+6+9.41X.6CK5.Y1P.MH0.AU\$P1^<P1.T.EW0.7HX&#<1>@<70A.M^<Y6T2Y5L1^6C2G
QT.ZXV1^M4B^PHNMV1^2.&S(800Q33^9@W.H4>2>0@1=>2^YSF4.60B5^24GB(2.M151)^MRIZC081.K.BS1&XH10+2.6DJN.1WS1=X15.32Z^T6T1).9YBB
MAV14W3.#14YN651J.CA1K^UP=>W(F)3^Q#1^>=>1XG61J&S^P^MD3X>S^M^E-M-5<M@<1Y12F1^%S8^<9R8NH1^%YK>=>A0EXOR^VC5<@&

MHXK*8GIV\$& 81&:6JZ3M05 MJ4H3 2GDKRNV T371-K7JUMRBR+&K61254Y6QYV7QCGA7?1TJBSC+&E L M2P59E%OY<Q<7/<<8M9\$H(Q-Q-K=#X:80
 M&F&B7L?W=3<+<A-#<0f>J0Y<X<175-2A5#P0*NA1-MDO-I6%76JW4)>9>5B9H%>O MTIOY9:ES< F02%<IYV7H8:ZRAP<#<7H9N>BG6I&WJ<+MM<1<+2:<CX
 M=Q+1+<?<IY<C> 9J>1>P9W<5+U- WZBOGTMT3 M1%&PIA&XK&W<19>1D(WT9Y)>P?IUN<+D=<1-G&S<2 PC4I MRZ=00Y<1G1YH5V4UJZ<R/KH290?<
 & D-M72?<WRXGQ?<MDRTQV8X<M&C<K11H(PIL?2T73R<W<G<155 M5%<N&XQ?GX21DRK<3D0DK=<1<? T H6FW4H1 Z1-L5=15D?O2<4FLZJZA -RWJG
 JHNE624&SR4H40 M<?>H13>+<?>MVCB.KG-V<Q?>WGRZ+1<A-HW<A0=<5%<KQ?>KW57?>7M M<123JHJ?>QK7QW4H Z1-5@O-UJ<U?>I<Q?>U<?>UOIRK&L78 M
 V44R<ACGE?>F5CJMUQ.O19896B 2)M9PTH&H?>TPE6:0%Y.V(BINT#0-%<M1.MINH<1+4D/B%<QEM35<Q?>Q?>DZP.8G<?>QE.I&H1%>1+87H42K?>TIEB&XU
 MA018C<7ZYK5CJMUZM01PX=<?TWE560%VNY<+<?>BD:<?T1252-12J0R08 M<1+WSN<09.O?>W+<C0:>#>1+4*81M?>1<+<5K?>KMY2HV&L4&C<ZIZI?MP-N=<
 K<H?>B82?>TG535?>F&H<1C.AV9T M<0+V9T=<?>W-Z1&#>#>RTH98?>8 M7HP?>T&GIRA?>7TH&H?>Q?>2<1<?>IK<30?>#>B82?>TG535?>GCY58C<?>Z?>1?>I0INTLSNHL<U/L/N#8<
 <=<=<=<?>JY M1YHCU<CK5?>KOW<13.9N<6Y<1W?>9D9V1=S214>>9RWL 3.2:Q28AM9YE MH<L4&CZ15IMB=25CB/M<1-12.0:JHJM PL13Q20L<?>AQS<?>3LODC+T#
 M<Q&S.OD<?>ZR12I<?>SUOITFOV76<6D17EH&X<Q?>9+1JWG#>A12<3K#1J/RN-MM<1VH7T<?>JH0M-WYJNP<A74<?>XT?>94?>VPV?>P-LPL.G19D?ZJMQ?<M?>0
 *N1=YMNSY5?>016?>3D7<B25Q56C?>Y:70+>21M?>T?>F&X<?>U(M<151+P04 M<?>TBB929PR1?>9K5#<?>U0<?>A1<?>W1=Q>1A+76V1?>P<?>SP<?>E.D191.F1&5A6WS)<L5<?>M02F?<
 K<DKL?>1=EM&H87&E3DMN1?>I=<?>S=P1J?>M?>P<?>O<?>JLJGMYO(L92002?>418.FW<?>O<?>4D<?>OK<?>D5<?>G A25C<?>G A25C<?>X8K?>Y5R<?>L5<?>K6<?>Z0<?>W<?>P<?>T
 86?>+ZSYUHHVH2?>DJ M+FC1+I4?>2F RMN<?>X8G<?>X+1+V3<?>P<?>C?>9>=<1?>UT M1<?>1QW?>IV<?>6X<?>6O MZYKOTAD U>49U?>Z=<X M<?>6&?>A?>7?>20?>1?>C?>X&G<
 U+UWS<?>+3?>A3V9?>K441<?>#>31O<?>O.95A1#<?>MKW<?>AS8HJ5SS<?>Y2?>K2.QR<?>1R1T#>H1?>RVQ?>T?>T9?>F<?>AP92I4W3ISAN.O<?>60PFGC?>V2
 FHR3>=<1?>A3V9?>K441AD1W1T.KTFK#>3.4?>2R(SVGG93?>T?>M29.M1 K<A>21Y?>5?>?>WB<?>4:AS5Y?>3YIOS GS0<?>M2<?>L9RC0T4&C613&E+ M5WY.L6<?>DLB/Q7&=<
 (<?>F0&S1M4B2CLH6C15Y<1H?>G<?>24?>U?>L<?>HEU&S MHH?>74?>8C.V?>2<?>N<?>N01<?>Y50B7H17?>T<?>O<?>33&A0D<?>O>3&M HOM M6.11>N<?>5C KID7&C<
 CLH6C15Y+J?>H<?>6?>K<?>2ZRG4W?>O<?>9&L1M&TGUH/MK7Q6&O1RRSZXF0.46WYRBA=2F.UPWVWQ?>OSHWQ2.510<?>IY53<?>OXD.M55?>2.3NED?>?>3?>O+YFF?>QZZ<?>N1JN MB
 MB102P.4%<?>1HFF6<?>16BVVR<?>@<?>UK55M1.P5AK5D12-WRUH1H&Z%<?>DLB.K3X<?>B<?>Y M<?>M5VN.76RGW2CUV.X+79=5053&85M5W5WSW.6<1+BXE26
 0G<?>S47+BE5M1+EQ7 MB95460IQ<3&39LUU?>A97?>BL<?>5&S&PMTX5<0/>B1P?>?>DBB3J?>B3&AM<?>SP4<?>M65<?>5<?>O?>70/ENXO<A<?>1D1G<?>9L&US<=<
 59+HG<NXY<0?>0EG2.IZXDPI MBUELL?>W9IP(N<=<?>A&F<?>U&N5>91L?>DH0R91?>P?>QAIH0.O&W&1Q.3Z4L. MQ UUA 16L0?>H1&2?>U4)<?>M+G.THCA=<?>I?>T2 MOEJCF8750G1K<
 H29?>EXKH<1=2I?>2?>RU0?>5H&C<?>20MC&EM+XUIN<CP2M M13E=<?>CA0F5+1&HNK?>HY?>G<?>Q<?>7220.F1NU 2<?>=<?>3?>T 76G4H1?>L?>M8?>KL<?>U?>W?>R<?>H&X<?>G<?>0&Z?>?>8?>6 M
 M<KEW8/D<?>I&ZC<?>JW05?>6H?>0<?>MNYX<?>?>B38R?>7?>PV2.9027<?>8H0O<?>10BT9 MPl.21C M1AIPF6 2?>HJ3 HM?>KQFIDAKO&C11<?>O2H.K&C.P<B<?>8N1?>M7<?>1?>W<
 <2Y29Z.VZT?>1&V5J?>ZGIRIRYC?>P3B3).:NWI&GK134HAGQ54.O MC9V2?>ZBTH?>VRU+&P<?>VIR<?>W.H965?>2.R)OJ<?>98<?>X<?>L7 TVTV6=602?>Z=<?>4R1X<?>6.61?>
 M.VZ6L0D&G9XOY<+<?>K07<?>6WN).<?>HK6190>?>V9&1 M1ZP?>PX 90?>P1AIP&A?>M?>X<?>02<?>=<?>M5Y06B 4T161D?>95LV.>=>15PX01Q951<?>159G6?>Z<?>11 U?>
 M1G>=<?>6LS?>8RR.M+AHYU68?>M2Z01&8=<?>WZUZ?>ZCVBYVL1<?>680?>=<?>MS>?>7&148B?>BX1V?>80GB1 LP?>HY=<?>P8CWHCOA1CT<?>1UWA<?>P?>M<?>91XNA21GHE.V<
 P?>?>?>#>=<?>2?>7?>1=<?>W8THG7X9?>=<?>S

[illegible]

3IA0DYP8H E6LW8063UHHKLG 0.08H0%5~ MG6X(C)Z7145SRP15E%EH*W*O* F0Y8PM1N.17N.1=0.57)R501*OY.ZX&Z.5.S.M9XX(C)3182X.7150)CHHT.0WE5%? WSPD%5EV2.92P.7.3H.UHD1P4(I5S%\$9UW%K QUKMFGR1.1EF6GRK+1.B+>07..3/OW#=-EPTTPGK+C20 OMWVRWVKK221EY7.W*E30%QRRKQ3N<5 VTPFG/7E77.W+NSXPSCM.P2CYBA=X.M8UUVG+IVP01.L9LBD.F3R7X;*OH#N.1JR*F4.724+V.U-^6W3?2)VP01.L M9J)MO20IK48. 60)82A<I!&+>RO+1%SWD.QXEXHT. D352?3%5Y&L5+>1?1C.M12L.FHJ7E*Y66FE2CD.BX>E77#Y1JA.YKJ2=C)EJBI.M.#5:H9V.ELGS2MIBG+6Z=BKM0RBBU.X:|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vL.M5C.M710YBDDU71YVZP*G)B+R-6I2KB MR*ZALHGO.G+AMGM.\$5AF.23\$<V4Y4.U%QI5#/.5.278ID09DFU2L+LPG.MI01.AO.JXS422.10-IN\$X.61D2>5Y84W\$F0.EEULJ# VMML\$E72 MD*IRV7*HGGIGB5CD7P\$1-0AL317JWV8+M.MR-OR.OH#H*TI>?0JE6E.8L%#JBD131A*#BXNKAJZNO*YPL-2*+>S7P.MMM.MWK6B.+K0J14XF#663196Z.05S=&5%B5?

[illegible]

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

[illegible]

Accounting Policies Property and Equipment and Other Definite Lived Intangible Assets
(Details)Sheethhttp://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetailsBa
of Presentation and Summary of Significant Accounting Policies Property and Equipment and Other Definite Lived Intangible Assets (Details)Details45
falsefalseR46.htm9954495 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Research and Development Expense
(Details)Sheethhttp://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentExpenseDetailsBasis of Presentation and
Summary of Significant Accounting Policies Research and Development Expense (Details)Details46 falsefalseR47.htm9954496 - Disclosure - Basis of Presentation and
Summary of Significant Accounting Policies Recent Financial Accounting Standards
(Details)Sheethhttp://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRecentFinancialAccountingStandardsDetailsBasis of Presentation and
Summary of Significant Accounting Policies Recent Financial Accounting Standards (Details)Details47 falsefalseR48.htm9954497 - Disclosure - Revenue Recognition
Disaggregation of Revenue by type of activity and reporting segment
(Details)Sheethhttp://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebytypeofactivityandreportingssegmentDetailsRevenue Recognition Disaggregation of
Revenue by type of activity and reporting segment (Details)Details48 falsefalseR49.htm9954498 - Disclosure - Revenue Recognition Disaggregation of Revenue by Geography
(Details)Sheethhttp://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebyGeographyDetailsRevenue Recognition Disaggregation of Revenue by Geography
(Details)Details49 falsefalseR50.htm9954499 - Disclosure - Revenue Recognition Contractual Liabilities
(Details)Sheethhttp://catalent.com/role/RevenueRecognitionContractualLiabilitiesDetailsRevenue Recognition Contractual Liabilities (Details)Details50
falsefalseR51.htm9954500 - Disclosure - Revenue Recognition Contractual Assets (Details)Sheethhttp://catalent.com/role/RevenueRecognitionContractualAssetsDetailsRevenue
Recognition Contractual Assets (Details)Details51 falsefalseR52.htm9954501 - Disclosure - Revenue from Contract with Customer
(Details)Sheethhttp://catalent.com/role/RevenuefromContractwithCustomerDetailsRevenue from Contract with Customer
(Details)Details52 falsefalseR53.htm9954502 - Disclosure - Business Combinations Purchase Agreement
(Details)Sheethhttp://catalent.com/role/BusinessCombinationsPurchaseAgreementDetailsBusiness Combinations Purchase Agreement (Details)Details53
falsefalseR54.htm9954503 - Disclosure - Business Combinations Net Assets Acquired
(Details)Sheethhttp://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetailsBusiness Combinations Net Assets Acquired (Details)Details54
falsefalseR55.htm9954505 - Disclosure - Business Combinations, Divestitures (Details)Sheethhttp://catalent.com/role/BusinessCombinationsDivestituresDetailsBusiness
Combinations, Divestitures (Details)Details55 falsefalseR56.htm9954506 - Disclosure - Goodwill - Carrying Amount of Goodwill
(Detail)Sheethhttp://catalent.com/role/GoodwillCarryingAmountofGoodwillDetailGoodwill - Carrying Amount of Goodwill (Detail)Details56 falsefalseR57.htm9954507 -
Disclosure - Definite Lived Long-Lived Assets - Other Intangible Assets Subject to Amortization
(Detail)Sheethhttp://catalent.com/role/DefiniteLivedLongLivedAssetsOtherIntangibleAssetsSubjecttoAmortizationDetailDefinite Lived Long-Lived Assets - Other Intangible
Assets Subject to Amortization (Detail)Details57 falsefalseR58.htm9954508 - Disclosure - Definite Lived Long-Lived Assets - Additional Information
(Detail)Sheethhttp://catalent.com/role/DefiniteLivedLongLivedAssetsAdditionalInformationDetailDefinite Lived Long-Lived Assets - Additional Information (Detail)Details58
falsefalseR59.htm9954509 - Disclosure - Definite Lived Long-Lived Assets - Future Amortization Expense
(Detail)Sheethhttp://catalent.com/role/DefiniteLivedLongLivedAssetsFutureAmortizationExpenseDetailDefinite Lived Long-Lived Assets - Future Amortization Expense
(Detail)Details59 falsefalseR60.htm9954510 - Disclosure - Restructuring and Other Costs
(Details)Sheethhttp://catalent.com/role/RestructuringandOtherCostsDetailsRestructuring and Other Costs
(Details)Details60 falsefalseR61.htm9954511 - Disclosure - Long-Term Obligations and Other Short-Term
Borrowings - Additional Information (Detail)Sheethhttp://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetailLong-Term
Obligations and Other Short-Term Borrowings - Additional Information (Detail)Details61 falsefalseR62.htm9954512 - Disclosure - Long-Term Obligations and Other Short-
Term Borrowings - Maturities (Details)Sheethhttp://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsMaturitiesDetailsLong-Term Obligations and Other
Short-Term Borrowings - Maturities (Details)Details62 falsefalseR63.htm9954513 -
Disclosure - Long-Term Obligations and Other Short-Term Borrowings Fair Value Measurements of Financial Instruments - Carrying Amounts and Estimated Fair Value of
Financial Instruments
(Details)Sheethhttp://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsFairValueMeasurementsofFinancialInstrumentsCarryingAmountsandEstimatedFairV
Term Obligations and Other Short-Term Borrowings Fair Value Measurements of Financial Instruments - Carrying Amounts and Estimated Fair Value of Financial Instruments
(Details)Details63 falsefalseR64.htm9954514 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Interest Rate
(Details)Sheethhttp://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetailsLong-Term Obligations and Other Short-Term Borrowings
Interest Rate (Details)Details64 falsefalseR65.htm9954515 - Disclosure - Earnings Per Share Calculations of Earnings Per Share
(Details)Sheethhttp://catalent.com/role/EarningsPerShareCalculationsofEarningsPerShareDetailsEarnings Per Share Calculations of Earnings Per Share (Details)Details65
falsefalseR66.htm9954516 - Disclosure - Earnings Per Share Earnings Per Share - Additional Details
(Details)Sheethhttp://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetailsDetailsEarnings Per Share Earnings Per Share - Additional Details
(Details)Details66 falsefalseR67.htm9954517 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information
(Detail)Sheethhttp://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetailDerivative Instruments and Hedging Activities - Additional
Information (Detail)Details67 falsefalseR68.htm9954518 - Disclosure - Fair Value Measures and Disclosures
(Details)Sheethhttp://catalent.com/role/FairValueMeasuresandDisclosuresDetailsFair Value Measures and Disclosures
(Details)Details68 falsefalseR69.htm9954519 - Disclosure - Income Taxes - Additional Information
(Detail)Sheethhttp://catalent.com/role/IncomeTaxesAdditionalInformationDetailIncome Taxes - Additional Information (Detail)Details69 falsefalseR70.htm9954520 - Disclosure
- Income Taxes Schedule of Income before Tax Domestic and Foreign
(Details)Sheethhttp://catalent.com/role/IncomeTaxesScheduleofIncomebeforeTaxDomesticandForeignDetailsIncome Taxes Schedule of Income before Tax Domestic and
Foreign (Details)Details70 falsefalseR71.htm9954521 - Disclosure - Income Taxes Components of Income Tax Expense
(Details)Sheethhttp://catalent.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetailsIncome Taxes Components of Income Tax Expense (Details)Details71
falsefalseR72.htm9954522 - Disclosure - Income Taxes Income Tax Reconciliation (Details)Sheethhttp://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetailsIncome
Taxes Income Tax Reconciliation (Details)Details72 falsefalseR73.htm9954523 - Disclosure - Income Taxes-Deferred Tax Assets
(Details)Sheethhttp://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetailsIncome Taxes-Deferred Tax Assets (Details)Details73 falsefalseR74.htm9954524 - Disclosure -
Income Taxes-Balance Sheet (Details)Sheethhttp://catalent.com/role/IncomeTaxesBalanceSheetDetailsIncome Taxes-Balance Sheet (Details)Details74
falsefalseR75.htm9954525 - Disclosure - Income Taxes-Unrecognized Tax Benefits (Details)Sheethhttp://catalent.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetailsIncome
Taxes-Unrecognized Tax Benefits (Details)Details75 falsefalseR76.htm9954526 - Disclosure - Employee Retirement Benefit Plans-Additional Information
(Details)Sheethhttp://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetailsEmployee Retirement Benefit Plans-Additional Information
(Details)Details76 falsefalseR77.htm9954527 - Disclosure - Employee Retirement Benefit Plans-Accumulated Benefit Obligation
(Details)Sheethhttp://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetailsEmployee Retirement Benefit Plans-Accumulated Benefit
Obligation (Details)Details77 falsefalseR78.htm9954528 - Disclosure - Employee Retirement Benefit Plans-Balance Sheet
(Details)Sheethhttp://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetailsEmployee Retirement Benefit Plans-Balance Sheet (Details)Details78
falsefalseR79.htm9954529 - Disclosure - Employee Retirement Benefit Plans-AOCI
(Details)Sheethhttp://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetailsEmployee Retirement Benefit Plans-AOCI
(Details)Details80 falsefalseR81.htm9954531 - Disclosure - Employee Retirement Benefit Plans-Fair Value
(Details)Sheethhttp://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetailsEmployee Retirement Benefit Plans-Fair Value (Details)Details81
falsefalseR82.htm9954532 - Disclosure - Employee Retirement Benefit Plans-Level 3
(Details)Sheethhttp://catalent.com/role/EmployeeRetirementBenefitPlansLevel3DetailsEmployee Retirement Benefit Plans-Level 3
(Details)Details82 falsefalseR83.htm9954533 - Disclosure - Employee Retirement Benefit Plans-Assumed
Healthcare Trend Rates (Details)Sheethhttp://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetailsEmployee Retirement Benefit Plans-
Assumed Healthcare Trend Rates (Details)Details83 falsefalseR84.htm9954535 - Disclosure - Equity and Accumulated Other Comprehensive Income (Loss) Equity
(Details)Sheethhttp://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetailsEquity and Accumulated Other Comprehensive Income (Loss)
Equity (Details)Details84 falsefalseR85.htm9954536 - Disclosure - Equity and
Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Earnings/(Loss)
(Details)Sheethhttp://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetailsEquity and Accumulated
Other Comprehensive Income (Loss) Accumulated Other Comprehensive Earnings/(Loss)
(Details)Details85 falsefalseR86.htm9954537 - Disclosure - Equity and Accumulated
Other Comprehensive Income (Loss)-Minimum Pension Liability
(Details)Sheethhttp://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetailsEquity and Accumulated Other Comprehensive
Income (Loss)-Minimum Pension Liability (Details)Details86 falsefalseR87.htm9954538 -
Disclosure - Equity (Details)Sheethhttp://catalent.com/role/EquityDetailsEquity
(Details)Details87 falsefalseR88.htm9954539 - Disclosure - Equity-Based Compensation
(Additional) (Details)Sheethhttp://catalent.com/role/EquityBasedCompensationAdditionalDetailsEquity-Based Compensation (Additional)
(Details)Details88 falsefalseR89.htm9954540 - Disclosure - Equity-Based Compensation (Option Activity)
(Details)Sheethhttp://catalent.com/role/EquityBasedCompensationOptionActivityDetailsEquity-Based Compensation (Option Activity)
(Details)Details89 falsefalseR90.htm9954541 - Disclosure - Equity-Based Compensation (RSU Activity)
(Details)Sheethhttp://catalent.com/role/EquityBasedCompensationRSUActivityDetailsEquity-Based Compensation (RSU Activity)
(Details)Details90 falsefalseR91.htm9954542 - Disclosure - Other Income / Expense
(Details)Sheethhttp://catalent.com/role/OtherIncomeExpenseDetailsOther Income / Expense (Details)Details91 falsefalseR92.htm9954543 - Disclosure - Leases - Schedule of Operating and Finance Leases Presented in the Balance Sheet
(Details)Sheethhttp://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedintheBalanceSheetDetailsLeases - Schedule of Operating and Finance Leases
Presented in the Balance Sheet (Details)Details92 falsefalseR93.htm9954544 - Disclosure - Leases - Cost (Details)Sheethhttp://catalent.com/role/LeasesCostDetailsLeases - Cost
(Details)Details93 falsefalseR94.htm9954545 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information
(Details)Sheethhttp://catalent.com/role/LeasesScheduleofSupplementalCashFlowInformationDetailsLeases - Schedule of Supplemental Cash Flow Information
(Details)Details94 falsefalseR95.htm9954546 - Disclosure - Leases - Schedule of Maturities of Operating And Finance Lease Liabilities
(Details)Sheethhttp://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetailsLeases - Schedule of Maturities of Operating And Finance
Lease Liabilities (Details)Details95 falsefalseR96.htm9954548 - Disclosure - Commitments and Contingencies - Additional Information
(Detail)Sheethhttp://catalent.com/role/CommitmentsandContingenciesAdditionalInformationDetailCommitments and Contingencies - Additional Information (Detail)Details96
falsefalseR97.htm9954550 - Disclosure - Segment Information - Net Revenue and Segment Ebitda
(Detail)Sheethhttp://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetailSegment Information - Net Revenue and Segment Ebitda (Detail)Details97
falsefalseR98.htm9954551 - Disclosure - Segment Information - Reconciliation of Earnings/(loss) from Continuing Operations to Ebitda
(Detail)Sheethhttp://catalent.com/role/SegmentInformationReconciliationofEarningslossfromContinuingOperationstoEbitdaDetailSegment Information - Reconciliation of
Earnings/(loss) from Continuing Operations to Ebitda (Detail)Details98 falsefalseR99.htm9954552 - Disclosure - Segment Information Total Assets
(Details)Sheethhttp://catalent.com/role/SegmentInformationTotalAssetsDetailsSegment Information Total Assets (Details)Details99 falsefalseR100.htm9954553 - Disclosure -
Segment Information Depreciation and Amortization (Details)Sheethhttp://catalent.com/role/SegmentInformationDepreciationandAmortizationDetailsSegment Information

Depreciation and Amortization (Details)Details100 falsefalseR101.htm9954554 - Disclosure - Segment Information Capital Expenditures (Details)Sheethttp://catalent.com/role/SegmentInformationCapitalExpendituresDetailsSegment-Information-Capital-Expenditures (Details)Details101 falsefalseR102.htm9954555 - Disclosure - Segment Information - Assets and Revenues (Detail)Details102 falsefalseR103.htm9954556 - Disclosure - Supplemental Balance Sheet Information - Work-in-Process and Finished Goods Inventories Include Raw Materials, Labor and Overhead (Detail)Sheethttp://catalent.com/role/SupplementalBalanceSheetInformationWorkInProcessandFinishedGoodsInventoriesIncludeRawMaterialsLaborandOverheadDetailSupplemental-Balance-Sheet-Information - Work-in-Process and Finished Goods Inventories Include Raw Materials, Labor and Overhead (Detail)Details103 falsefalseR104.htm9954557 - Disclosure - Supplemental Balance Sheet Information - Prepaid and Other Assets (Detail)Sheethttp://catalent.com/role/SupplementalBalanceSheetInformationPrepaidandOtherAssetsDetailSupplemental-Balance-Sheet-Information - Prepaid and Other Assets (Detail)Details104 falsefalseR105.htm9954558 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment (Detail)Sheethttp://catalent.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentDetailSupplemental-Balance-Sheet-Information - Property and Equipment (Detail)Details105 falsefalseR106.htm9954559 - Disclosure - Supplemental Balance Sheet Information - Other Assets Non Current (Detail)Details106 falsefalseR107.htm9954560 - Disclosure - Supplemental Balance Sheet Information - Other Accrued Liabilities (Detail)Sheethttp://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetailSupplemental-Balance-Sheet-Information - Other Accrued Liabilities (Detail)Details107 falsefalseR108.htm9954561 - Disclosure - Supplemental Balance Sheet Information - Allowance for Doubtful Accounts (Details)Sheethttp://catalent.com/role/SupplementalBalanceSheetInformationAllowanceforDoubtfulAccountsDetailsSupplemental-Balance-Sheet-Information - Allowance for Doubtful Accounts (Details)Details108 falsefalseR109.htm9954562 - Disclosure - Subsequent Events (Details)Sheethttp://catalent.com/role/SubsequentEventsDetailsSubsequent-Events (Details)Details109 falsefalseAll ReportsBookAll-Reports-ctlt-20240630.htmctlt-20240630.xsdctlt-20240630_cat.xmlctlt-20240630_def.xmlctlt-20240630_lab.xmlctlt-20240630_pre.xml-ctlt-20240630_g1.jpgctlt-20240630_g2.jpgctlt-20240630_g3.jpgctlt-20240630_g4.jpgctlt-20240630_g5.jpgctlt-20240630_g6.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024trueJSON 146 MetaLinks:json IDEA: XBRL DOCUMENT f "version": "2.2", "instance": f "ctlt-20240630.htm", f "nsPrefix": "ctlt", "nsuri": "http://catalent.com/20240630", "dts": f "inline": f "local": f "ctlt-20240630.htm" }, "schema": f "local": f "ctlt-20240630.xsd" }, "remote": f "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/rrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/rrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/rrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/rrr/role/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" }, "calculationLink": f "local": f "ctlt-20240630_cal.xml" }, "definitionLink": f "local": f "ctlt-20240630_def.xml" }, "labelLink": f "local": f "ctlt-20240630_lab.xml" }, "presentationLink": f "local": f "ctlt-20240630_pre.xml" }, "keyStandard": 342, "keyCustom": 86, "axisStandard": 25, "axisCustom": 4, "memberStandard": 48, "memberCustom": 62, "hidden": f "total": 49, "http://fasb.org/us-gaap/2024": 35, "http://xbrl.sec.gov/dei/2024": 1, "http://xbrl.sec.gov/ecd/2024": 4, "http://catalent.com/20240630": 2, "contextCount": 412, "entityCount": 1, "segmentCount": 111, "elementCount": 2861, "unitCount": 7, "baseTaxonomies": f "http://fasb.org/us-gaap/2024": 1666, "http://xbrl.sec.gov/dei/2024": 39, "http://xbrl.sec.gov/ecd/2024": 4, "report": f "R1", f "role": "http://catalent.com/role/DocumentandEntityInformation", "longName": "0000001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": f "contextRef": "c-1", "name": "dei.DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "ctlt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-1", "name": "dei.DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "ctlt-20240630.htm", "first": true, "unique": true }, "R2": f "role": "http://catalent.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": f "contextRef": "c-1", "name": "dei.AuditName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "ctlt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-1", "name": "dei.AuditName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "ctlt-20240630.htm", "first": true, "unique": true }, "R3": f "role": "http://catalent.com/role/ConsolidatedStatementsOfOperations", "longName": "9952151 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "ctlt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "ctlt-20240630.htm", "first": true, "unique": true }, "R4": f "role": "http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "longName": "9952152 - Statement - Consolidated Statements of Comprehensive Income / (Loss)", "shortName": "Consolidated Statements of Comprehensive Income / (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "ctlt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "ctlt-20240630.htm", "first": true, "unique": true }, "R5": f "role": "http://catalent.com/role/ConsolidatedBalanceSheets", "longName": "9952153 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": f "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "ctlt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-4", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "ctlt-20240630.htm", "first": true, "unique": true }, "R6": f "role": "http://catalent.com/role/ConsolidatedBalanceSheetsParentetical", "longName": "9952154 - Statement - Consolidated Balance Sheets (Parentetical)", "shortName": "Consolidated Balance Sheets (Parentetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parentetical", "menuCat": "Statements", "order": "6", "firstAnchor": f "contextRef": "c-4", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "ctlt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-5", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "ctlt-20240630.htm", "first": true, "unique": true }, "R7": f "role": "http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquity", "longName": "9952155 - Statement - Consolidated Statement of Changes in Shareholder's Equity", "shortName": "Consolidated Statement of Changes in Shareholder's Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": f "contextRef": "c-18", "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "reportCount":

```
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://catalent.com/role/DerivativeInstrumentsandHedgingActivities", "longName": "9952166 - Disclosure - Derivative Instruments and Hedging Activities", "shortName": "Derivative Instruments and Hedging Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueMeasurementsAndDisclosures", "longName": "9952167 - Disclosure - Fair Value Measures and Disclosures", "shortName": "Fair Value Measures and Disclosures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueMeasurementsAndDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueMeasurementsAndDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://catalent.com/role/EmployeeRetirementBenefitPlans", "longName": "9952169 - Disclosure - Employee Retirement Benefit Plans", "shortName": "Employee Retirement Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://catalent.com/role/OtherIncomeExpense", "longName": "9952173 - Disclosure - Other Income / Expense", "shortName": "Other Income / Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://catalent.com/role/Leases", "longName": "9952174 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://catalent.com/role/CommitmentsAndContingencies", "longName": "9952175 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://catalent.com/role/SegmentInformation", "longName": "9952176 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://catalent.com/role/SupplementalBalanceSheetInformation", "longName": "9952177 - Disclosure - Supplemental Balance Sheet Information", "shortName": "Supplemental Balance Sheet Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://catalent.com/role/SubsequentEventsNotes", "longName": "9952178 - Disclosure - Subsequent Events (Notes)", "shortName": "Subsequent Events (Notes)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsNotesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsNotesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://xbrl.sec.gov/cod/Role/PypDisclosure", "longName": "9954110 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://xbrl.sec.gov/cod/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InsiderTradingArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InsiderTradingArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://catalent.com/role/RevenuefromContractwithCustomerPolicies", "longName": "9954472 - Disclosure - Revenue from Contract with Customer (Policies)", "shortName": "Revenue from Contract with Customer (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "c://t-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://catalent.com/role/RevenueRecognitionTables", "longName": "9954473 - Disclosure - Revenue Recognition (Tables)",
```

"longName": "9954483 - Disclosure - Employee Retirement Benefit Plans (Tables)", "shortName": "Employee Retirement Benefit Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true } }, "R39": { "role": "http://catalent.com/role/EquityAndAccumulatedOtherComprehensiveIncomeLossTables", "longName": "9954484 - Disclosure - Equity and Accumulated Other Comprehensive Income (Loss) (Tables)", "shortName": "Equity and Accumulated Other Comprehensive Income (Loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true } }, "R40": { "role": "http://catalent.com/role/EquityBasedCompensationTables", "longName": "9954486 - Disclosure - Equity Based Compensation (Tables)", "shortName": "Equity Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true } }, "R41": { "role": "http://catalent.com/role/LeasesTables", "longName": "9954488 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "c:ltt:ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "c:ltt:ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true } }, "R42": { "role": "http://catalent.com/role/SegmentInformationTables", "longName": "9954490 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "c:ltt:SegmentReportingInformationNetRevenueAndEbitdaTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "c:ltt:SegmentReportingInformationNetRevenueAndEbitdaTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true } }, "R43": { "role": "http://catalent.com/role/SupplementalBalanceSheetInformationTables", "longName": "9954491 - Disclosure - Supplemental Balance Sheet Information (Tables)", "shortName": "Supplemental Balance Sheet Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true } }, "R44": { "role": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "9954492 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-393", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "R45": { "role": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails", "longName": "9954494 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Property and Equipment and Other Definite Lived Intangible Assets (Details)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies Property and Equipment and Other Definite Lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true } }, "R46": { "role": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentExpenseDetails", "longName": "9954495 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Research and Development Expense (Details)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies Research and Development Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "ix:continuation": "span", "div": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "ix:continuation": "span", "div": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true } }, "R47": { "role": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesRecentFinancialAccountingStandardsDetails", "longName": "9954496 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Recent Financial Accounting Standards (Details)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies Recent Financial Accounting Standards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "c:ltt:ScheduleOfMaturitiesOfLeaseLiabilitiesTableTextBlock", "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true }, "uniqueAnchor": null }, "R48": { "role": "http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenuebyTypeofActivityandReportingSegmentDetails", "longName": "9954497 - Disclosure - Revenue Recognition Disaggregation of Revenue by type of activity and reporting segment (Details)", "shortName": "Revenue Recognition Disaggregation of Revenue by type of activity and reporting segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-95", "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true, "unique": true } }, "R49": { "role": "http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenuebyGeographyDetails", "longName": "9954498 - Disclosure - Revenue Recognition Disaggregation of Revenue by Geography (Details)", "shortName": "Revenue Recognition Disaggregation of Revenue by Geography (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "c:ltt:EliminationOfRevenueAttributabletoMultipleLocations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation": "body", "html": { "reportCount": 1, "baseRef": "c:ltt-20240630.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://catalent.com/role/RevenueRecognitionContractualLiabilitiesDetails", "longName": "9954499 - Disclosure - Revenue Recognition Contractual Liabilities (Details)", "shortName": "Revenue Recognition Contractual Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "


```

http://catalent.com/role/DefinitiveLivedLongLivedAssetsOtherIntangibleAssetsSubjecttoAmortizationDetail, "longName": "9954507 - Disclosure - Definitive Lived Long-Lived Assets - Other Intangible Assets Subject to Amortization (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true, "unique": true }, "R58": { "role": "http://catalent.com/role/DefinitiveLivedLongLivedAssetsAdditionalInformationDetail", "longName": "9954508 - Disclosure - Definitive Lived Long-Lived Assets - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true, "unique": true }, "R59": { "role": "http://catalent.com/role/DefinitiveLivedLongLivedAssetsFutureAmortizationExpenseDetail", "longName": "9954509 - Disclosure - Definitive Lived Long-Lived Assets - Future Amortization Expense (Detail)", "shortName": "Definitive Lived Long-Lived Assets - Future Amortization Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true, "unique": true }, "R60": { "role": "http://catalent.com/role/RestructuringandOtherCostsDetails", "longName": "9954510 - Disclosure - Restructuring and Other Costs (Details)", "shortName": "Restructuring and Other Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsForRestructuring", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsForRestructuring", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true, "unique": true }, "R61": { "role": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "longName": "9954511 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-192", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "unique": true }, "R62": { "role": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsMaturitiesDetails", "longName": "9954512 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings - Maturities (Details)", "shortName": "Long-Term Obligations and Other Short-Term Borrowings - Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "unique": true }, "R63": { "role": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsandEstimatedFairValueoffinane", "longName": "9954513 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Fair Value Measurements of Financial Instruments - Carrying Amounts and Estimated Fair Value of Financial Instruments (Details)", "shortName": "Long-Term Obligations and Other Short-Term Borrowings Fair Value Measurements of Financial Instruments - Carrying Amounts and Estimated Fair Value of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-170", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-207", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "unique": true }, "R64": { "role": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails", "longName": "9954514 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Interest Rate (Details)", "shortName": "Long-Term Obligations and Other Short-Term Borrowings Interest Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-180", "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "unitRef": "rate", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "unique": true }, "R65": { "role": "http://catalent.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails", "longName": "9954515 - Disclosure - Earnings Per Share Calculations of Earnings Per Share (Details)", "shortName": "Earnings Per Share Calculations of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "unique": true }, "R66": { "role": "http://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetails", "longName": "9954516 - Disclosure - Earnings Per Share Earnings Per Share - Additional Details (Details)", "shortName": "Earnings Per Share Earnings Per Share - Additional Details (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-213", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-213", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true, "unique": true }, "R67": { "role": "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "longName": "9954517 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail)", "shortName": "Derivative Instruments and Hedging Activities - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseGrossOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseGrossOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "c1t-20240630.htm", "first": true, "unique": true }, "R68": { "role": "http://catalent.com/role/FairValueMeasuresandDisclosuresDetails", "longName": "9954518 - Disclosure - Fair Value Measures and Disclosures (Details)", "shortName": "Fair Value Measures and Disclosures (Details)", "isDefault": "false", "groupType": "disc
```

Taxes-Deferred Tax Assets (Details)", "shortName": "Income Taxes-Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R74": { "role": "http://catalent.com/role/IncomeTaxesBalanceSheetDetails", "longName": "9954524 - Disclosure - Income Taxes-Balance Sheet (Details)", "shortName": "Income Taxes-Balance Sheet (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredIncomeTaxAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true }, "R76": { "role": "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "longName": "9954526 - Disclosure - Employee Retirement Benefit Plans-Additional Information (Details)", "shortName": "Employee Retirement Benefit Plans-Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-4", "name": "cslt:MultiemployerPlansEstimatedAnnualCashContribution", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "cslt:MultiemployerPlansEstimatedAnnualCashContribution", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R77": { "role": "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "longName": "9954527 - Disclosure - Employee Retirement Benefit Plans-Accumulated Benefit Obligation (Details)", "shortName": "Employee Retirement Benefit Plans-Accumulated Benefit Obligation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R78": { "role": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "longName": "9954528 - Disclosure - Employee Retirement Benefit Plans-Balance Sheet (Details)", "shortName": "Employee Retirement Benefit Plans-Balance Sheet (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-236", "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-236", "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R79": { "role": "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "longName": "9954529 - Disclosure - Employee Retirement Benefit Plans-AOCI (Details)", "shortName": "Employee Retirement Benefit Plans-AOCI (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-232", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R80": { "role": "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails", "longName": "9954530 - Disclosure - Employee Retirement Benefit Plans-Fiscal Year Maturity (Details)", "shortName": "Employee Retirement Benefit Plans-Fiscal Year Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-236", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-236", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R81": { "role": "http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails", "longName": "9954531 - Disclosure - Employee Retirement Benefit Plans-Fair Value (Details)", "shortName": "Employee Retirement Benefit Plans-Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "cslt:SummaryOfPlanAssetsMeasuredInFairValueTableTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-218", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "cslt:SummaryOfPlanAssetsMeasuredInFairValueTableTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R82": { "role": "http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details", "longName": "9954532 - Disclosure - Employee Retirement Benefit Plans-Level 3 (Details)", "shortName": "Employee Retirement Benefit Plans-Level 3 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-223", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-223", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R83": { "role": "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails", "longName": "9954533 - Disclosure - Employee Retirement Benefit Plans-Assumed Healthcare Trend Rates (Details)", "shortName": "Employee Retirement Benefit Plans-Assumed Healthcare Trend Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-238", "name": "us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-321", "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R84": { "role": "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails", "longName": "9954535 - Disclosure - Equity and Accumulated Other Comprehensive Income (Loss) Equity (Details)", "shortName": "Equity and Accumulated Other Comprehensive Income (Loss) Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "td": "tr", "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-212", "name": "us-gaap:ConversionOfStockSharesConverted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true }, "R85": { "role": "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails", "longName": "9954536 - Disclosure - Equity and Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Earnings (Loss) (Details)", "shortName": "Equity and Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Earnings (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-27", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R86": { "role": "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails", "longName": "9954537 - Disclosure - Equity and Accumulated Other Comprehensive Income (Loss)-Minimum Pension Liability (Details)", "shortName": "Equity and Accumulated Other Comprehensive Income (Loss)-Minimum Pension Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R87": { "role": "http://catalent.com/role/EquityDetails", "longName": "9954538 - Disclosure - Equity (Details)", "shortName": "Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "td": "tr", "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R89": { "role": "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "longName": "9954540 - Disclosure - Equity Based Compensation (Option Activity) (Details)", "shortName": "Equity Based Compensation (Option Activity) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-

gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
"unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": { "span": "td", "tr": "table", "div": "us-
gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first":
true, "unique": true }, "R90": { "role": "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails", "longName": "9954541 - Disclosure - Equity Based
Compensation (RSU Activity) (Details)", "shortName": "Equity Based Compensation (RSU Activity) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang":
"en-US", "decimals": "0", "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef":
"shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true,
"unique": true }, "R91": { "role": "http://catalent.com/role/OtherIncomeExpenseDetails", "longName": "9954542 - Disclosure - Other Income / Expense (Details)",
"shortName": "Other Income / Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor":
{ "contextRef": "c-7", "name": "us-gaap:OtherNonoperatingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "link:footnote": "span",
"div": "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-
gaap:OtherNonoperatingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "link:footnote": "span", "div": "ix:continuation", "body":
"html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R92": { "role":
"http://catalent.com/role/LeasesScheduleOfOperatingandFinanceLeasesPresentedIntheBalanceSheetDetails", "longName": "9954543 - Disclosure - Leases - Schedule of
Operating and Finance Leases Presented in the Balance Sheet (Details)", "shortName": "Leases - Schedule of Operating and Finance Leases Presented in the Balance Sheet
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-4", "name": "us-
gaap:FinanceLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div":
"cslt:ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-
20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FinanceLeaseLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
"decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "cslt:ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock", "ix:continuation",
"body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "unique": true }, "R93": { "role": "http://catalent.com/role/LeasesCostDetails", "longName": "9954544 -
Disclosure - Leases - Cost (Details)", "shortName": "Leases - Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "93", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
"decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-
20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body": "html" }, "reportCount":
1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R94": { "role": "http://catalent.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetails",
"longName": "9954545 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Details)", "shortName": "Leases - Schedule of Supplemental Cash Flow
Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-1",
"name": "us-gaap:FinanceLeasePrincipalPayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-
gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinanceLeasePrincipalPayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6",
"ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1,
"baseRef": "cslt-20240630.htm", "first": true, "unique": true }, "R95": { "role":
"http://catalent.com/role/LeasesScheduleOfMaturitiesOfOperatingandFinanceLeaseLiabilitiesDetails", "longName": "9954546 - Disclosure - Leases - Schedule of Maturities of
Operating And Finance Lease Liabilities (Details)", "shortName": "Leases - Schedule of Maturities of Operating And Finance Lease Liabilities (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-4", "name": "us-
gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div":
"cslt:ScheduleOfMaturitiesOfLeaseLiabilitiesTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true },
"uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6",
"ancestors": { "span": "td", "tr": "table", "div": "cslt:ScheduleOfMaturitiesOfLeaseLiabilitiesTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef":
"cslt-20240630.htm", "unique": true }, "R96": { "role": "http://catalent.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "longName": "9954548 -
Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" },
"reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-393", "name": "cslt:BusinessCombinationPurchasePricePerShare",
"unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef":
"cslt-20240630.htm", "unique": true }, "R97": { "role": "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "longName": "9954550 -
Disclosure - Segment Information - Net Revenue and Segment Ebitda (Detail)", "shortName": "Segment Information - Net Revenue and Segment Ebitda (Detail)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef":
"usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm",
"first": true }, "uniqueAnchor": { "contextRef": "c-126", "name": "cslt:SegmentReportingInformationEarningBeforeInterestTaxDepreciationAndAmortization", "unitRef": "usd",
"xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "cslt:SegmentReportingInformationNetRevenueAndEbitdaTableTextBlock",
"ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "unique": true }, "R98": { "role":
"http://catalent.com/role/SegmentInformationReconciliationOfEarningslossfromContinuingOperationsToEbitdaDetail", "longName": "9954551 - Disclosure - Segment
Information - Reconciliation of Earnings/ (loss) from Continuing Operations to Ebitda (Detail)", "shortName": "Segment Information - Reconciliation of Earnings/ (loss) from
Continuing Operations to Ebitda (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": {
"contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang":
"en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "cslt:SegmentReportingInformationNetRevenueAndEbitdaTableTextBlock", "ix:continuation", "body":
"html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true }, "uniqueAnchor": null }, "R99": { "role":
"http://catalent.com/role/SegmentInformationTotalAssetsDetails", "longName": "9954552 - Disclosure - Segment Information Total Assets (Details)", "shortName": "Segment
Information Total Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": {
"contextRef": "c-4", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-
gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true },
"uniqueAnchor": { "contextRef": "c-128", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table",
"div": "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm",
"unique": true }, "R100": { "role": "http://catalent.com/role/SegmentInformationDepreciationandAmortizationDetails", "longName": "9954553 - Disclosure - Segment
Information Depreciation and Amortization (Details)", "shortName": "Segment Information Depreciation and Amortization (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "cslt-
20240630.htm", "first": true }, "uniqueAnchor": null }, "R101": { "role": "http://catalent.com/role/SegmentInformationCapitalExpendituresDetails", "longName": "9954554 -
Disclosure - Segment Information Capital Expenditures (Details)", "shortName": "Segment Information Capital Expenditures (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-1", "name":
"cslt:PaymentsAndAccrualsToAcquirePropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table",
"div": "cslt:ScheduleOfSegmentReportingInformationCapitalExpendituresBySegmentTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-
20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-126", "name": "cslt:PaymentsAndAccrualsToAcquirePropertyPlantAndEquipment", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div":
"cslt:ScheduleOfSegmentReportingInformationCapitalExpendituresBySegmentTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-
20240630.htm", "unique": true }, "R102": { "role": "http://catalent.com/role/SegmentInformationAssetsandRevenuesDetail", "longName": "9954555 - Disclosure - Segment
Information - Assets and Revenues (Detail)", "shortName": "Segment Information - Assets and Revenues (Detail)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "usd",
"xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div":
"cslt:ScheduleOfRevenueAndLongLivedAssetsByGeographicAreaTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first":
true }, "uniqueAnchor": { "contextRef": "c-406", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6",
"ancestors": { "span": "td", "tr": "table", "div": "cslt:ScheduleOfRevenueAndLongLivedAssetsByGeographicAreaTableTextBlock", "ix:continuation", "body": "html" },
"reportCount": 1, "baseRef": "cslt-20240630.htm", "unique": true }, "R103": { "role":
"http://catalent.com/role/SupplementalBalanceSheetInformationWorkinProcessandFinishedGoodsInventoriesIncludeRawMaterialsLaborandOverheadDetail", "longName":
"9954556 - Disclosure - Supplemental Balance Sheet Information - Work-in-Process and Finished Goods Inventories Include Raw Materials, Labor and Overhead (Detail)",
"shortName": "Supplemental Balance Sheet Information - Work-in-Process and Finished Goods Inventories Include Raw Materials, Labor and Overhead (Detail)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-4", "name": "us-
gaap:InventoryRawMaterialsAndSupplies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-
gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors":
"span": "td", "tr": "table", "div": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm",
"first": true, "unique": true }, "R104": { "role": "http://catalent.com/role/SupplementalBalanceSheetInformationPrepaidandOtherAssetsDetail", "longName": "9954557 -
Disclosure - Supplemental Balance Sheet Information - Prepaid and Other Assets (Detail)", "shortName": "Supplemental Balance Sheet Information - Prepaid and Other Assets
(Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-4", "name": "us-
gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div":
"cslt:PrepaidExpenseAndOtherAssetsTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span":
"td", "tr": "table", "div": "cslt:PrepaidExpenseAndOtherAssetsTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first":
true, "unique": true }, "R105": { "role": "http://catalent.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentDetail", "longName": "9954558 - Disclosure -
Supplemental Balance Sheet Information - Property and Equipment (Detail)", "shortName": "Supplemental Balance Sheet Information - Property and Equipment (Detail)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-4", "name":
"cslt:LandBuildingsAndImprovements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "td", "tr": "table", "div": "us-
gaap:PropertyPlantAndEquipmentTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "c-4", "name": "cslt:LandBuildingsAndImprovements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": {
"span": "td", "tr": "table", "div": "us-gaap:PropertyPlantAndEquipmentTableTextBlock", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "cslt-20240630.htm", "first":
true, "unique": true }, "R106": { "role": "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail", "longName": "9954559 - Disclosure -
Supplemental Balance Sheet Information - Other Assets Non Current (Detail)", "shortName": "Supplemental Balance Sheet Information - Other Assets Non Current (Detail)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-4", "name": "us-

```
"gaap:OperatingLeaseRightOfUseAsset","unitRef":"usd","xsiNil":"false","lang":"en-US","decimals":"3","ancestors":{"span":"td","tr":"table","div":"us-gaap:ScheduleOfOtherAssetsTableTextBlock","ix:continuation"},"body":{"html":"","reportCount":1,"baseRef":"cctl-20240630.htm","first":true},"uniqueAnchor":{"contextRef":"c-4","name":"us-gaap:LoansAndReceivablesCarryingAmount","unitRef":"usd","xsiNil":"false","lang":"en-US","decimals":"3","ancestors":{"span":"td","tr":"table","div":"us-gaap:ScheduleOfOtherAssetsTableTextBlock","ix:continuation"},"body":{"html":"","reportCount":1,"baseRef":"cctl-20240630.htm","first":true},"unique":true},"R107":{"role":"http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail","longName":"9954560 - Disclosure Supplemental Balance Sheet Information - Other Accrued Liabilities (Detail)","shortName":"Supplemental Balance Sheet Information - Other Accrued Liabilities (Detail)"},"isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"107","firstAnchor":{"contextRef":"c-4","name":"us-gaap:EmployeeRelatedLiabilitiesCurrent","unitRef":"usd","xsiNil":"false","lang":"en-US","decimals":"6","ancestors":{"span":"td","tr":"table","ix:continuation"},"cctl:OtherAccruedLiabilitiesTableTextBlock","div","body":{"html":"","reportCount":1,"baseRef":"cctl-20240630.htm","first":true},"unique":true},"uniqueAnchor":{"contextRef":"c-4","name":"us-gaap:EmployeeRelatedLiabilitiesCurrent","unitRef":"usd","xsiNil":"false","lang":"en-US","decimals":"6","ancestors":{"span":"td","tr":"table","ix:continuation"},"cctl:OtherAccruedLiabilitiesTableTextBlock","div","body":{"html":"","reportCount":1,"baseRef":"cctl-20240630.htm","first":true},"unique":true},"R108":{"role":"http://catalent.com/role/SupplementalBalanceSheetInformationAllowanceforDoubtfulAccountsDetails","longName":"9954561 - Disclosure - Supplemental Balance Sheet Information - Allowance for Doubtful Accounts (Details)","shortName":"Supplemental Balance Sheet Information - Allowance for Doubtful Accounts (Details)"},"isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"108","firstAnchor":{"contextRef":"c-5","name":"us-gaap:AllowanceForDoubtfulAccountsReceivable","unitRef":"usd","xsiNil":"false","lang":"en-US","decimals":"6","ancestors":{"span":"td","tr":"table","div":"body","html":"","reportCount":1,"baseRef":"cctl-20240630.htm","first":true},"unique":true},"uniqueAnchor":{"contextRef":"c-5","name":"us-gaap:AllowanceForDoubtfulAccountsReceivable","unitRef":"usd","xsiNil":"false","lang":"en-US","decimals":"6","ancestors":{"span":"td","tr":"table","div":"body","html":"","reportCount":1,"baseRef":"cctl-20240630.htm","first":true},"unique":true},"R109":{"role":"http://catalent.com/role/SubsequentEventsDetails","longName":"9954562 - Disclosure - Subsequent Events (Details)","shortName":"Subsequent Events (Details)"},"isDefault":"false","groupType":"disclosure","subGroupType":"details","menuCat":"Details","order":"109","firstAnchor":{"contextRef":"c-1","name":"us-gaap:GoodwillImpairmentLoss","unitRef":"usd","xsiNil":"false","lang":"en-US","decimals":"6","ancestors":{"span":"td","tr":"table","div":"body","html":"","reportCount":1,"baseRef":"cctl-20240630.htm","first":true},"uniqueAnchor":null}},"tag":{"cctl:A2375SeniorEuroDenominatedNotesMember":{"xbrltype":"domainItemType","nsuri":"http://catalent.com/20240630","localname":"A2375SeniorEuroDenominatedNotesMember"},"presentation":{"http://catalent.com/role/LongTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsandEstimatedFairValueofFinance"},"lang":{"en-us":{"role":{"terseLabel":"3.75% Senior Euro Denominated Notes [Member]","label":"3.75% Senior Euro Denominated Notes [Member]","documentation":"3.75% Senior Euro Denominated Notes"}},"auth_ref":{"cctl:A3125SeniorUSDenominatedNotesMember":{"xbrltype":"domainItemType","nsuri":"http://catalent.com/20240630","localname":"A3125SeniorUSDenominatedNotesMember"},"presentation":{"http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail"},"http://catalent.com/role/LongTermBorrowingsAdditionalInformationDetail"},"http://catalent.com/role/LongTermBorrowingsandOtherShortTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsandEstimatedFairValueofFinance"},"lang":{"en-us":{"role":{"terseLabel":"3.125% Senior US Denominated Notes [Member]","label":"3.125% Senior US Denominated Notes [Member]","documentation":"3.125% Senior US Denominated Notes"}},"auth_ref":{"cctl:A3500SeniorUSDenominatedNotesMember":{"xbrltype":"domainItemType","nsuri":"http://catalent.com/20240630","localname":"A3500SeniorUSDenominatedNotesMember"},"presentation":{"http://catalent.com/role/LongTermBorrowingsandOtherShortTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsandEstimatedFairValueofFinance"},"lang":{"en-us":{"role":{"terseLabel":"3.500% Senior US Denominated Notes [Member]","label":"3.500% Senior US Denominated Notes [Member]","documentation":"3.500% Senior US Denominated Notes"}},"auth_ref":{"cctl:A3500SeniorUSDenominatedNotesMemberMember":{"xbrltype":"domainItemType","nsuri":"http://catalent.com/20240630","localname":"A3500SeniorUSDenominatedNotesMemberMember"},"presentation":{"http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails"},"http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail"},"http://catalent.com/role/LongTermBorrowingsAdditionalInformationDetail"},"http://catalent.com/role/LongTermBorrowingsandOtherShortTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsandEstimatedFairValueofFinance"},"lang":{"en-us":{"role":{"terseLabel":"3.500% Senior US Denominated Notes Member [Member]","label":"3.500% Senior US Denominated Notes Member [Member]","documentation":"3.500% Senior US Denominated Notes Member"}},"auth_ref":{"cctl:ACOI Accumulated Gain Loss Marketable Securities Member":{"xbrltype":"domainItemType","nsuri":"http://catalent.com/20240630","localname":"ACOI Accumulated Gain Loss Marketable Securities Member"},"presentation":{"http://catalent.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"},"http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails"},"lang":{"en-us":{"role":{"terseLabel":"ACOI Accumulated Gain (Loss), Marketable Securities [Member]","label":"ACOI Accumulated Gain (Loss), Marketable Securities [Member]","documentation":"ACOI Accumulated Gain (Loss), Marketable Securities"}},"auth_ref":{"cctl:Accelerated Amortization Of Intangible Assets":{"xbrltype":"monetaryItemType","nsuri":"http://catalent.com/20240630","localname":"Accelerated Amortization Of Intangible Assets"},"crdr":"debit","presentation":{"http://catalent.com/role/DefiniteLivedLongLivedAssetsAdditionalInformationDetail"},"lang":{"en-us":{"role":{"terseLabel":"Accelerated Amortization Of Intangible Assets [Member]","label":"Accelerated Amortization Of Intangible Assets [Member]","documentation":"Accelerated Amortization Of Intangible Assets"}},"auth_ref":{"us-gaap:AccountingPoliciesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccountingPoliciesAbstract"},"lang":{"en-us":{"role":{"label":"Accounting Policies [Abstract]"},"auth_ref":{"us-gaap:AccountingStandardsUpdate201602Member":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccountingStandardsUpdate201602Member"},"presentation":{"http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRecentFinancialAccountingStandardsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Accounting Standards Update 2016-02 [Member]","label":"Accounting Standards Update 2016-02 [Member]","documentation":"Accounting Standards Update 2016-02 Leases (Topic 842)}"},"auth_ref":{"r868"},"us-gaap:AccountsPayableCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Accounts Payable Current"},"crdr":"credit","calculation":{"http://catalent.com/role/ConsolidatedBalanceSheets":{"parentTag":"us-gaap:LiabilitiesCurrent","weight":1.0,"order":2.0},"presentation":{"http://catalent.com/role/ConsolidatedBalanceSheets"},"lang":{"en-us":{"role":{"terseLabel":"Accounts payable [Member]","label":"Accounts Payable, Current","documentation":"Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."},"auth_ref":{"r140","r1218"},"us-gaap:AccountsReceivableNetCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Accounts Receivable Net Current"},"crdr":"debit","calculation":{"http://catalent.com/role/ConsolidatedBalanceSheets":{"parentTag":"us-gaap:AssetsCurrent","weight":1.0,"order":2.0},"presentation":{"http://catalent.com/role/ConsolidatedBalanceSheets"},"lang":{"en-us":{"role":{"terseLabel":"Trade receivables, net [Member]","label":"Accounts Receivable, after Allowance for Credit Loss, Current","documentation":"Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."}}},"auth_ref":{"r1395"},"us-gaap:AccruedIncomeTaxesCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Accrued Income Taxes Current"},"crdr":"credit","calculation":{"http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail":{"parentTag":"us-gaap:OtherAccruedLiabilitiesCurrent","weight":1.0,"order":7.0},"presentation":{"http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail"},"lang":{"en-us":{"role":{"terseLabel":"Accrued income tax [Member]","label":"Accrued Income Taxes, Current","documentation":"Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."}}},"auth_ref":{"r142","r228"},"us-gaap:AccruedLiabilitiesFairValueDisclosure":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Accrued Liabilities Fair Value Disclosure"},"crdr":"credit","presentation":{"http://catalent.com/role/BusinessCombinationsDivestituresDetails"},"lang":{"en-us":{"role":{"terseLabel":"Accrued Liabilities, Fair Value Disclosure [Member]","label":"Accrued Liabilities, Fair Value Disclosure","documentation":"Fair value portion of accrued expenses."}}},"auth_ref":{"r142","r1503","r1504","r1510"},"us-gaap:AccruedLiabilitiesMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccruedLiabilitiesMember"},"presentation":{"http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedintheBalanceSheetDetails"},"http://catalent.com/role/LongTermBorrowingsandOtherShortTermBorrowingsAdditionalInformationDetail"},"lang":{"en-us":{"role":{"terseLabel":"Accrued Liabilities [Member]","label":"Accrued Liabilities [Member]","documentation":"This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered."}}},"auth_ref":{"r142"},"cctl:AccruedOperatingLeaseLiabilities":{"xbrltype":"monetaryItemType","nsuri":"http://catalent.com/20240630","localname":"AccruedOperatingLeaseLiabilities"},"crdr":"credit","calculation":{"http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail":{"parentTag":"us-gaap:OtherAccruedLiabilitiesCurrent","weight":1.0,"order":3.0},"presentation":{"http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail"},"lang":{"en-us":{"role":{"terseLabel":"Accrued Operating Lease, Liabilities [Member]","label":"Accrued Operating Lease, Liabilities","documentation":"Accrued Operating Lease, Liabilities"}"},"auth_ref":{"cctl:AccumulatedDeferredCompensationMember":{"xbrltype":"domainItemType","nsuri":"http://catalent.com/20240630","localname":"AccumulatedDeferredCompensationMember"},"presentation":{"http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails"},"lang":{"en-us":{"role":{"terseLabel":"Accumulated Cash Flow Hedge [Member]","label":"Accumulated Deferred Compensation [Member]","documentation":"Accumulated Deferred Compensation [Member]"},"auth_ref":{"us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccumulatedDefinedBenefitPlansAdjustmentMember"},"presentation":{"http://catalent.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"},"http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails"},"lang":{"en-us":{"role":{"terseLabel":"Accumulated Defined Benefit Plans Adjustment [Member]","label":"Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]","documentation":"Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent."}}},"auth_ref":{"r7","r9","r26","r42","r166","r1366","r1367","r1368"},"us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Accumulated Depreciation Depletion And Amortization Property Plant And Equipment"},"crdr":"credit","calculation":{"http://catalent.com/role/SupplementalBalanceSheetInformationPropertyPlantAndEquipmentDetail":{"parentTag":"us-gaap:PropertyPlantAndEquipmentNet","weight":1.0,"order":2.0},"presentation":{"http://catalent.com/role/SupplementalBalanceSheetInformationPropertyPlantAndEquipmentDetail"},"lang":{"en-us":{"role":{"negatedLabel":"Accumulated depreciation [Member]","label":"Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment","documentation":"Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."}}},"auth_ref":{"r72","r276","r972"},"us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"},"presentation":{"http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails"},"lang":{"en-us":{"role":{"terseLabel":"Available for Sale Investments [Member]","label":"Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]","documentation":"Accumulated
```

```

"r42", "r166", "r1451" }, "us-gaap AccumulatedOtherComprehensiveIncomeLossLineItems", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items present financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": { "r308", "r309", "r855", "r857", "r858", "r859", "r860", "r862" } }, "us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets", "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth ref": { "r41", "r42", "r167", "r285", "r967", "r1012", "r1016" } }, "us-gaap AccumulatedOtherComprehensiveIncomeLossTable", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "auth ref": { "r308", "r309", "r855", "r857", "r858", "r859", "r860", "r862" } } }, "us-gaap AccumulatedOtherComprehensiveIncomeMember", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquity", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive (Loss)/Income [Member]", "label": "AOGI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth ref": { "r4", "r26", "r42", "r802", "r805", "r900", "r1007", "r1008", "r1366", "r1367", "r1368", "r1379", "r1380", "r1381", "r1384" } }, "us-gaap AccumulatedTranslationAdjustmentMember", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Translation Adjustment [Member]", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, attributable to the parent." } } }, "auth ref": { "r5", "r26", "r42", "r164", "r165", "r309", "r310", "r857", "r858", "r859", "r860", "r862", "r1366" } }, "cItL AcordaTherapeuticsIncMember", { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "AcordaTherapeuticsIncMember", "presentation": { "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "lang": { "en-us": { "role": { "terseLabel": "Acorda Therapeutics, Inc.", "label": "Acorda Therapeutics, Inc [Member]", "documentation": "Acorda Therapeutics, Inc [Member]", "auth ref": { "r469", "r1147" } } }, "us-gaap AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": { "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "http://catalent.com/role/DefineLivedLongLivedAssetsOtherIntangibleAssetsSubjectToAmortizationDetail", "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth ref": { "r469", "r1147" } }, "ecd Additional402vDisclosureTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]", "auth ref": { "r1288" } } }, "cItL AdditionalInformationAbstract", { "xbrltype": "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "AdditionalInformationAbstract", "lang": { "en-us": { "role": { "label": "Additional Information [Abstract]", "documentation": "Additional Information [Abstract]", "auth ref": { "r155" } } }, "us-gaap AdditionalPaidInCapitalCommonStock", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth ref": { "r155" } }, "us-gaap AdditionalPaidInCapitalMember", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquity", "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails", "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth ref": { "r1030", "r1379", "r1380", "r1381", "r1384", "r1501", "r1576" } }, "ecd AdjToCompAmt", { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount", "auth ref": { "r1301" } } }, "ecd AdjToCompAxis", { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation", "label": "Adjustment to Compensation [Axis]", "auth ref": { "r1301" } } }, "ecd AdjToNonPeoNeoCompFnTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "auth ref": { "r1301" } } }, "ecd AdjToPeoCompFnTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to PEO Compensation, Footnote", "label": "Adjustment to PEO Compensation, Footnote [Text Block]", "auth ref": { "r1301" } } }, "us-gaap AdjustmentForLongTermIntercompanyTransactionsNetOfTax", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForLongTermIntercompanyTransactionsNetOfTax", "crdr": "credit", "calculation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails", "parentTag": "us-gaap OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails", "lang": { "en-us": { "role": { "terseLabel": "Long term inter-company loans", "label": "Adjustment for Long-Term Intra-Entity Transaction, after Tax", "documentation": "Amount, after tax, of increase (decrease) in accumulated other comprehensive income (AOGI) from gain (loss) on intra-entity foreign currency transaction that is considered to be long-term investment with settlement not planned or anticipated in foreseeable future." } } }, "auth ref": { "r1514", "r1518" } }, "us-gaap AdjustmentsForNewAccountingPronouncementsAxis", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails", "lang": { "en-us": { "role": { "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]", "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth ref": { "r262", "r263", "r264", "r265", "r266", "r267", "r336", "r337", "r338", "r339", "r351", "r416", "r417", "r422", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r480", "r481", "r491", "r753", "r754", "r755", "r756", "r757", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r777", "r782", "r783", "r784", "r785", "r786", "r792", "r794", "r795", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r843", "r844", "r869", "r870", "r871", "r895", "r896", "r897", "r898", "r899", "r900", "r918", "r919", "r920", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016" } }, "us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteService
```


"r1315"}}, "ecd_AggtPnsnAdjsSvcCstMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]"}}, "auth_ref": {"r1335"}}, "ecd_AllAdjToCompMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]"}}, "auth_ref": {"r1301"}}, "ecd_AllExecutiveCategoriesMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]"}}, "auth_ref": {"r1308"}}, "ecd_AllIndividualsMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "All Individuals", "label": "All Individuals [Member]"}}, "auth_ref": {"r1263"}, {"r1274"}, {"r1284"}, {"r1308"}, {"r1316"}, {"r1320"}, {"r1328"}}, "ecd_AllTradingArrangementsMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {"lang": {"en-us": {"role": {"terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]"}}, "auth_ref": {"r1326"}}, "us-gaap_AllocatedShareBasedCompensationExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": {"http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail": {"parentTag": "ctlt_SegmentReportingInformationUnallocatedExpense", "weight": 1.0, "order": 2.0}}, "presentation": {"http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail": {"http://catalent.com/role/SegmentInformationReconciliationOfEarningslossfromContinuingOperationsToEbitdaDetail": {"lang": {"en-us": {"role": {"negatedLabel": "Equity compensation", "terseLabel": "Share-Based Payment Arrangement Expense", "label": "Share-Based Payment Arrangement Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."}}, "auth_ref": {"r697"}, {"r707"}}, "us-gaap-AllowanceForDoubtfulAccountsReceivable": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": {"http://catalent.com/role/SupplementalBalanceSheetInformationAllowanceforDoubtfulAccountsDetails": {"lang": {"en-us": {"role": {"periodStartLabel": "Beginning balance", "periodEndLabel": "Closing balance", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable."}}, "auth_ref": {"r286"}, {"r422"}, {"r437"}, {"r439"}, {"r442"}, {"r1541"}}, "us-gaap-AllowanceForDoubtfulAccountsReceivableCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": {"http://catalent.com/role/ConsolidatedBalanceSheetsParenthetical": {"lang": {"en-us": {"role": {"terseLabel": "Accounts Receivable, Allowance for Credit Loss, Current", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."}}, "auth_ref": {"r286"}, {"r422"}, {"r437"}}, "ctlt-AllowanceForDoubtfulAccountsReceivableImpactOfforeignExchange": {"xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "AllowanceForDoubtfulAccountsReceivableImpactOfforeignExchange", "crdr": "debit", "presentation": {"http://catalent.com/role/SupplementalBalanceSheetInformationAllowanceforDoubtfulAccountsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Impact of foreign exchange", "label": "Allowance For Doubtful Accounts Receivable, Impact Of Foreign Exchange", "documentation": "Allowance for doubtful accounts receivable impact of foreign exchange."}}, "auth_ref": {}}, "us-gaap-AllowanceForDoubtfulAccountsReceivableRollforward": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "presentation": {"http://catalent.com/role/SupplementalBalanceSheetInformationAllowanceforDoubtfulAccountsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Trade receivables allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."}}, "auth_ref": {}}, "us-gaap-AllowanceForDoubtfulAccountsReceivableWriteOffs": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": {"http://catalent.com/role/SupplementalBalanceSheetInformationAllowanceforDoubtfulAccountsDetails": {"lang": {"en-us": {"role": {"negatedTerseLabel": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance."}}, "auth_ref": {"r441"}}, "ctlt-AllowanceforDoubtfulAccountsReceivableWriteoffsandRecoveriesnet": {"xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "AllowanceforDoubtfulAccountsReceivableWriteoffsandRecoveriesnet", "crdr": "debit", "presentation": {"http://catalent.com/role/SupplementalBalanceSheetInformationAllowanceforDoubtfulAccountsDetails": {"lang": {"en-us": {"role": {"negatedTerseLabel": "Allowance for Doubtful Accounts Receivable, Write-offs and Recoveries, net", "label": "Allowance for Doubtful Accounts Receivable, Write-offs and Recoveries, net", "documentation": "Allowance for Doubtful Accounts Receivable, Write-offs and Recoveries, net."}}, "auth_ref": {}}, "us-gaap-AlternativeInvestment": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AlternativeInvestment", "crdr": "debit", "presentation": {"http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail": {"lang": {"en-us": {"role": {"terseLabel": "Alternative Investment", "label": "Alternative Investment", "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund."}}, "auth_ref": {"r821"}, {"r838"}, {"r1208"}, {"r1212"}, {"r1213"}, {"r1503"}, {"r1505"}, {"r1506"}, {"r1507"}}, "ctlt-AmendedDebtInstrumentQuarterlyAmortizationRate": {"xbrltype": "percentItemType", "nsuri": "http://catalent.com/20240630", "localname": "AmendedDebtInstrumentQuarterlyAmortizationRate", "presentation": {"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails": {"lang": {"en-us": {"role": {"terseLabel": "Amended Debt Instrument Quarterly Amortization Rate", "label": "Amended Debt Instrument Quarterly Amortization Rate", "documentation": "Amended Debt Instrument Quarterly Amortization Rate"}}, "auth_ref": {}}, "dei-AmendmentFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": {"http://catalent.com/role/DocumentandEntityInformation": {"lang": {"en-us": {"role": {"terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission."}}, "auth_ref": {}}, "ctlt-AmortizationAndWriteOffofFinancingCosts": {"xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "AmortizationAndWriteOffofFinancingCosts", "crdr": "debit", "calculation": {"http://catalent.com/role/ConsolidatedStatementsofCashFlows": {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0}}, "presentation": {"http://catalent.com/role/ConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Amortization and write-off of debt financing costs", "label": "Amortization And Write Off Of Financing Costs", "documentation": "Amortization And Write Off Of Financing Costs"}}, "auth_ref": {}}, "us-gaap-AmortizationOffinancingCosts": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOffinancingCosts", "crdr": "debit", "presentation": {"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail": {"lang": {"en-us": {"role": {"terseLabel": "Amortization of Debt Issuance Costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs."}}, "auth_ref": {"r177"}, {"r546"}, {"r1373"}, {"r1522"}}, "us-gaap-AmortizationOffintangibleAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOffintangibleAssets", "crdr": "debit", "presentation": {"http://catalent.com/role/DefiniteLivedLongLivedAssetsAdditionalInformationDetail": {"lang": {"en-us": {"role": {"terseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."}}, "auth_ref": {"r14"}, {"r466"}, {"r473"}, {"r1176"}}, "ctlt-AnagniMember": {"xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "AnagniMember", "presentation": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails": {"http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails": {"lang": {"en-us": {"role": {"terseLabel": "Anagni [Member]", "label": "Anagni [Member]", "documentation": "Anagni"}}, "auth_ref": {}}, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": {"http://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetailsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."}}, "auth_ref": {"r365"}}, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": {"http://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetailsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security."}}, "auth_ref": {"r56"}}, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": {"http://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetailsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}, "auth_ref": {}}, "us-gaap-AntidilutiveSecuritiesNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": {"http://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetailsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."}}, "auth_ref": {"r56"}}, "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentParentMember", "presentation": {"http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails": {"lang": {"en-us": {"role": {"terseLabel": "AOCL Derivative Qualifying as Hedge, Excluded Component, Parent", "label": "AOCL Derivative Qualifying as Hedge, Excluded Component, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, attributable to parent."}}, "auth_ref": {"r256"}, {"r300"}, {"r309"}, {"r310"}, {"r1366"}}, "ctlt-ApplicableInterestPeriodAxis": {"xbrltype": "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "ApplicableInterestPeriodAxis", "presentation": {"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails": {"lang": {"en-us": {"role": {"terseLabel": "Applicable Interest Period [Axis]", "label": "Applicable Interest Period [Axis]", "documentation": "Applicable Interest Period [Axis]"}}, "auth_ref": {}}, "ctlt-ApplicableInterestPeriodDomain": {"xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "ApplicableInterestPeriodDomain", "presentation": {"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails": {"lang": {"en-us": {"role": {"terseLabel": "Applicable Interest Period [Domain]", "label": "Applicable Interest Period [Domain]", "documentation": "Applicable Interest Period [Domain]"}}, "auth_ref": {}}, "us-gaap_AssetAcquisitionPriceOfAcquisitionExpected": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionPriceOfAcquisitionExpected", "crdr": "credit", "presentation": {"http://catalent.com/role/SubsequentEventsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Asset Acquisition, Price of Acquisition, Expected", "label": "Asset Acquisition, Price of Acquisition, Expected", "documentation": "Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition."}}, "auth_ref": {"r1494"}}, "ctlt_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumed": {"xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumed", "crdr": "credit", "presentation": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails": {"lang": {"en-us": {"role": {"terseLabel": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed", "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed"}}, "auth_ref": {}}, "ctlt_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {"xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "crdr": "credit", "presentation": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails": {"lang": {"en-us": {"role": {"terseLabel": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt"}}, "auth_ref": {}}}

```

Non-current Liabilities, Long-term Debt"}}, {"auth_ref": "I"}, {"cslt": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPPE"}], {"xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPPE", "crdr": "debit", "presentation": "I"}, {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails", "lang": "en-us", "role": "terseLabel": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, PPE", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, PPE", "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, PPE"}}, {"auth_ref": "I"}, {"us-gaap": "AssetImpairmentCharges"}], {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": "I"}, {"http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "lang": "en-us", "role": "terseLabel": "Asset Impairments", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."}}, {"auth_ref": "r14", "r70"}, {"us-gaap": "Assets"}, {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": "I"}, {"http://catalent.com/role/ConsolidatedBalanceSheets", "parentTag": null, "weight": null, "order": null, "root": true}}, {"presentation": "I"}, {"http://catalent.com/role/ConsolidatedBalanceSheets", "http://catalent.com/role/SegmentInformationTotalAssetsDetails", "lang": "en-us", "role": "totalLabel": "Total assets", "terseLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit."}}, {"auth_ref": "r226", "r240", "r280", "r328", "r370", "r403", "r407", "r426", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r788", "r793", "r847", "r960", "r1074", "r1167", "r1168", "r1218", "r1249", "r1438", "r1439", "r1530"}, {"us-gaap": "AssetsAbstract"}, {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": "I"}, {"http://catalent.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel": "ASSETS", "label": "Assets [Abstract]"}}, {"auth_ref": "I"}, {"us-gaap": "AssetsAndLiabilitiesLesseeAbstract"}, {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAndLiabilitiesLesseeAbstract", "lang": "en-us", "role": "terseLabel": "Assets and Liabilities, Lessee [Abstract]", "label": "Assets and Liabilities, Lessee [Abstract]"}}, {"auth_ref": "I"}, {"us-gaap": "AssetsCurrent"}, {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": "I"}, {"http://catalent.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap Assets", "weight": 1.0, "order": 1.0, "presentation": "I"}, {"http://catalent.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "totalLabel": "Total current assets", "label": "Assets Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."}}, {"auth_ref": "r271", "r294", "r328", "r426", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r788", "r793", "r847", "r1218", "r1438", "r1439", "r1530"}, {"us-gaap": "AssetsCurrentAbstract"}, {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": "I"}, {"http://catalent.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel": "Current assets", "label": "Assets Current [Abstract]"}}, {"auth_ref": "I"}, {"us-gaap": "AssetsOffDisposalGroupIncludingDiscontinuedOperation"}, {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOffDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "presentation": "I"}, {"http://catalent.com/role/BusinessCombinationsDivestituresDetails", "lang": "en-us", "role": "terseLabel": "Disposal Group, Including Discontinued Operation, Assets", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."}}, {"auth_ref": "r3", "r129", "r135", "r196", "r269", "r270"}, {"us-gaap": "AuctionMarketPreferredSecuritiesStockSeriesLineItems"}, {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AuctionMarketPreferredSecuritiesStockSeriesLineItems", "presentation": "I"}, {"http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails", "lang": "en-us", "role": "terseLabel": "Auction Market Preferred Securities, Stock Series [Line Items]", "label": "Auction Market Preferred Securities, Stock Series [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}, {"auth_ref": "r1", "us-gaap": "AuctionMarketPreferredSecuritiesStockSeriesTable"}, {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AuctionMarketPreferredSecuritiesStockSeriesTable", "presentation": "I"}, {"http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails", "lang": "en-us", "role": "terseLabel": "Auction Market Preferred Securities, Stock Series [Axis]", "label": "Auction Market Preferred Securities, Stock Series [Axis]", "documentation": "Disclosure of information about auction market preferred security. Includes, but is not limited to, liquidation preference, liquidation value, par value, rate setting interval, redemption requirement, dividend distribution, shares authorized and outstanding, aggregate value of auction market preferred security, and variable interest rate earned."}}, {"auth_ref": "r79", "r80", "r81", "r82", "r153"}, {"dei": "AuditorFirmId"}, {"xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": "I"}, {"http://catalent.com/role/AuditInformation", "lang": "en-us", "role": "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier"}}, {"auth_ref": "r1253", "r1254", "r1266"}, {"dei": "AuditorLineItems"}, {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLineItems", "lang": "en-us", "role": "terseLabel": "Auditor [Line Items]", "label": "Auditor [Line Items]"}}, {"auth_ref": "I"}, {"dei": "AuditorLocation"}, {"xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": "I"}, {"http://catalent.com/role/AuditInformation", "lang": "en-us", "role": "terseLabel": "Auditor Location", "label": "Auditor Location"}}, {"auth_ref": "r1253", "r1254", "r1266"}, {"dei": "AuditorName"}, {"xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": "I"}, {"http://catalent.com/role/AuditInformation", "lang": "en-us", "role": "terseLabel": "Auditor Name", "label": "Auditor Name"}}, {"auth_ref": "r1253", "r1254", "r1266"}, {"us-gaap": "AwardDateAxis"}, {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": "I"}, {"http://catalent.com/role/EquityBasedCompensationAdditionalDetails", "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails", "lang": "en-us", "role": "terseLabel": "Award Date [Axis]", "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted."}}, {"auth_ref": "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480"}, {"us-gaap": "AwardDateDomain"}, {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": "I"}, {"http://catalent.com/role/EquityBasedCompensationAdditionalDetails", "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails", "lang": "en-us", "role": "terseLabel": "Award Date [Domain]", "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted."}}, {"auth_ref": "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480"}, {"ecd": "AwardExerPrice"}, {"xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExerPrice", "presentation": "I"}, {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel": "Exercise Price", "label": "Award Exercise Price"}}, {"auth_ref": "r1323"}, {"ecd": "AwardGrantDateFairValue"}, {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": "I"}, {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value"}}, {"auth_ref": "r1324"}, {"ecd": "AwardTmgDiscLineItems"}, {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": "en-us", "role": "label": "Award Timing Disclosures [Line Items]"}}, {"auth_ref": "r1319"}, {"ecd": "AwardTmgHowMnpiCnsrdTextBlock"}, {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsrdTextBlock", "presentation": "I"}, {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]"}}, {"auth_ref": "r1319"}, {"ecd": "AwardTmgMethodTextBlock"}, {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": "I"}, {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]"}}, {"auth_ref": "r1319"}, {"ecd": "AwardTmgMnpiCnsrdFlag"}, {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsrdFlag", "presentation": "I"}, {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]"}}, {"auth_ref": "r1319"}, {"ecd": "AwardTmgMnpiDiscTextBlock"}, {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": "I"}, {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]"}}, {"auth_ref": "r1319"}, {"ecd": "AwardTmgPredtrmndFlag"}, {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": "I"}, {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "
```

```

"role": "Bettera Holdings, LLC", "label": "Bettera Holdings, LLC [Member]", "documentation": "Bettera Holdings, LLC", "auth_ref": "r188", "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "BetteraHoldingsLLCMember", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "lang": "en-us", "role": "Bettera Holdings, LLC", "label": "Bettera Holdings, LLC [Member]", "documentation": "Bettera Holdings, LLC", "auth_ref": "r188", "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "BiologicsMember", "presentation": "http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail", "http://catalent.com/role/RestructuringandOtherCostsDetails", "http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenuebytypeofactivityandreportingsegmentDetails", "http://catalent.com/role/RevenuefromContractwithCustomerDetails", "http://catalent.com/role/SegmentInformationCapitalExpendituresDetails", "http://catalent.com/role/SegmentInformationDepreciationandAmortizationDetails", "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "http://catalent.com/role/SegmentInformationTotalAssetsDetails", "lang": "en-us", "role": "Biologics [Member]", "label": "Biologics [Member]", "documentation": "Biologics [Member]", "auth_ref": "r189", "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "BlowFillSealBusinessWoodstockMember", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "lang": "en-us", "role": "Blow-Fill-Seal Business, Woodstock", "label": "Blow-Fill-Seal Business, Woodstock [Member]", "documentation": "Blow-Fill-Seal Business, Woodstock", "auth_ref": "r190", "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "BoltonCSMember", "presentation": "http://catalent.com/role/RestructuringandOtherCostsDetails", "lang": "en-us", "role": "Bolton CS [Member]", "label": "Bolton CS [Member]", "documentation": "Bolton CS", "auth_ref": "r191", "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "BuildingAndImprovementsMember", "presentation": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails", "lang": "en-us", "role": "Building And Improvements [Member]", "label": "Building And Improvements [Member]", "documentation": "Building And Improvements [Member]", "auth_ref": "r192", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "http://catalent.com/role/BusinessCombinationsTables", "http://catalent.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "http://catalent.com/role/SubsequentEventsDetails", "lang": "en-us", "role": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "auth_ref": "r467", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "http://catalent.com/role/BusinessCombinationsTables", "http://catalent.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "http://catalent.com/role/SubsequentEventsDetails", "lang": "en-us", "role": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations.", "auth_ref": "r94", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "crdr": "debit", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "lang": "en-us", "role": "Business Acquisition, Transaction Costs", "label": "Business Acquisition, Transaction Costs", "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "auth_ref": "r104", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "http://catalent.com/role/BusinessCombinationsTables", "lang": "en-us", "role": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r467", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "crdr": "debit", "presentation": "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails", "lang": "en-us", "role": "Business Acquisition, Goodwill", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "auth_ref": "r104", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": "http://catalent.com/role/BusinessCombinationsProFormaResultsDetails", "lang": "en-us", "role": "Business Acquisition, Pro Forma Net Income (Loss)", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net income or loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "auth_ref": "r772", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": "http://catalent.com/role/BusinessCombinationsProFormaResultsDetails", "lang": "en-us", "role": "Business Acquisition, Pro Forma Revenue", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "auth_ref": "r772", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquiredReceivablesDescription", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "lang": "en-us", "role": "Business Combination, Acquired Receivables, Description", "label": "Business Combination, Acquired Receivables, Description", "documentation": "Description of receivable acquired in business combination.", "auth_ref": "r97", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquiredReceivablesFairValue", "crdr": "debit", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "lang": "en-us", "role": "Business Combination, Acquired Receivable, Fair Value", "label": "Business Combination, Acquired Receivable, Fair Value", "documentation": "Fair value of acquired receivable from business combination, excluding certain loans and debt securities acquired in transfer.", "auth_ref": "r774", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquiredReceivablesGrossContractualAmount", "crdr": "debit", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "lang": "en-us", "role": "Business Combination, Acquired Receivables, Gross Contractual Amount", "label": "Business Combination, Acquired Receivables, Gross Contractual Amount", "documentation": "For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the gross contractual amounts receivable, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables.", "auth_ref": "r98", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred", "crdr": "credit", "presentation": "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "lang": "en-us", "role": "Business Combination, Consideration Transferred", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "auth_ref": "r10", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredOther", "crdr": "credit", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "lang": "en-us", "role": "Business Combination, Consideration Transferred, Other", "label": "Business Combination, Consideration Transferred, Other", "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.", "auth_ref": "r25", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "lang": "en-us", "role": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "auth_ref": "r103", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationAsset", "crdr": "debit", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "lang": "en-us", "role": "Business Combination, Contingent Consideration, Asset", "label": "Business Combination, Contingent Consideration, Asset", "documentation": "Amount of asset recognized arising from contingent consideration in a business combination.", "auth_ref": "r102", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "presentation": "http://catalent.com/role/SubsequentEventsDetails", "lang": "en-us", "role": "Business Combination, Contingent Consideration, Liability, Current", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "auth_ref": "r101", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": "http://catalent.com/role/BusinessCombinationsDisclosureTextBlock", "lang": "en-us", "role": "Business Combination Disclosure [Text Block]", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "auth_ref": "r218", "xbrltype": "pureItemType", "nsuri": "http://catalent.com/20240630", "localname": "BusinessCombinationEnterpriseValue", "presentation": "http://catalent.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "lang": "en-us", "role": "Business Combination, Enterprise Value", "label": "Business Combination, Enterprise Value", "documentation": "Business Combination, Enterprise Value", "auth_ref": "r193", "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "BusinessCombinationLoanDiscount", "crdr": "debit", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "lang": "en-us", "role": "Business Combination, Loan Discount", "label": "Business Combination, Loan Discount", "documentation": "Business Combination, Loan Discount", "auth_ref": "r194", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationPriceOfAcquisitionExpected", "crdr": "credit", "presentation": "http://catalent.com/role/SubsequentEventsDetails", "lang": "en-us", "role": "Business Combination, Price of Acquisition, Expected", "label": "Business Combination, Price of Acquisition, Expected", "documentation": "Purchase price of expected business acquisition prior to consideration being transferred. Excludes asset acquisition.", "auth_ref": "r1345", "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "BusinessCombinationPurchasePricePerShare", "presentation": "http://catalent.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "lang": "en-us", "role": "Business Combination, Purchase Price per Share", "label": "Business Combination, Purchase Price per Share", "documentation": "Business Combination, Purchase Price per Share", "auth_ref": "r195", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumed
```

"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}}, "auth_ref": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "crdr": "debit", "presentation": {"http://catalent.com/role/BusinessCombinationsDivestituresDetails": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}, "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."}}}, "auth_ref": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "crdr": "debit", "presentation": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."}}}, "auth_ref": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "presentation": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."}}}, "auth_ref": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "presentation": {"http://catalent.com/role/BusinessCombinationsDivestituresDetails": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."}}}, "auth_ref": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "crdr": "credit", "presentation": {"http://catalent.com/role/BusinessCombinationsDivestituresDetails": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}], "lang": {"en-us": {"role": {"negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."}}}, "auth_ref": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "crdr": "credit", "presentation": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}], "lang": {"en-us": {"role": {"negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date."}}}, "auth_ref": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "crdr": "debit", "presentation": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}], "lang": {"en-us": {"role": {"negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date."}}}, "auth_ref": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "presentation": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."}}}, "auth_ref": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Net Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Net Assets", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."}}}, "auth_ref": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": {"http://catalent.com/role/BusinessCombinationsDivestituresDetails": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}, "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."}}}, "auth_ref": {"r96": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "presentation": {"http://catalent.com/role/BusinessCombinationsDivestituresDetails": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}, "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date."}}}, "auth_ref": {"r96": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "presentation": {"http://catalent.com/role/BusinessCombinationsDivestituresDetails": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}, "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date."}}}, "auth_ref": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."}}}, "auth_ref": {"r96": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "crdr": "credit", "presentation": {"http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt", "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date."}}}, "auth_ref": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "crdr": "credit", "presentation": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails": {"http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."}}}, "auth_ref": {"r96": {"r99": {}}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": {"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."}}}, "auth_ref": {"r99": {}},

"cslt_BusinessCombinationTerminationFee": { "xbrlType": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "BusinessCombinationTerminationFee", "crdr": "credit", "presentation": { "http://catalent.com/role/CommitmentsandContingenciesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "BusinessCombinationTerminationFee", "label": "BusinessCombinationTerminationFee", "documentation": "BusinessCombinationTerminationFee" } } }, "auth_ref": { } }, "http://catalent.com/20240630", "localname": "BusinessCombinationTransitionalServiceAgreement", "crdr": "debit", "presentation": { "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails": { "lang": { "en-us": { "role": { "terseLabel": "BusinessCombinationPurchaseConsideration", "label": "BusinessCombinationPurchaseConsideration", "documentation": "BusinessCombinationTransitionalServiceAgreement" } } }, "auth_ref": { } }, "http://catalent.com/20240630", "localname": "BusinessCombinationWorkingCapitalAdjustments", "crdr": "debit", "presentation": { "http://catalent.com/role/BusinessCombinationsDivestituresDetails": { "lang": { "en-us": { "role": { "terseLabel": "BusinessCombinationWorkingCapitalAdjustments", "label": "BusinessCombinationWorkingCapitalAdjustments", "documentation": "BusinessCombinationWorkingCapitalAdjustments" } } }, "auth_ref": { } }, "us-gaap_BusinessCombinationsAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "terseLabel": "BusinessCombinationsAbstract", "label": "BusinessCombinationsAbstract", "documentation": "BusinessCombinationsAbstract" } } }, "auth_ref": { } }, "us-gaap_BusinessExitCosts": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessExitCosts", "crdr": "debit", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Facility exit and other costs", "label": "BusinessExitCosts", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": { "r14": { } }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Capital Expenditures Incurred but Not yet Paid", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": { "r51": { }, "r52": { }, "r53": { } }, "us-gaap_CapitalLeaseObligationsMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalLeaseObligationsMember", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Capital Lease Obligations [Member]", "label": "Capital Lease Obligations [Member]", "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time." } } }, "auth_ref": { "r244": { } }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsAndEstimatedFairValueOfFinanc": { "lang": { "en-us": { "role": { "terseLabel": "Reported Value Measurement [Member]", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": { "r122": { }, "r123": { } }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodStartLabel": "CASH AND EQUIVALENTS AT BEGINNING OF PERIOD", "periodEndLabel": "CASH AND EQUIVALENTS AT END OF PERIOD", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": { "r48": { }, "r274": { }, "r151": { } }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": { "r49": { } }, "cslt_CashAndNoncashDivestitureAmountOfConsiderationReceived": { "xbrlType": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "CashAndNoncashDivestitureAmountOfConsiderationReceived", "crdr": "debit", "presentation": { "http://catalent.com/role/BusinessCombinationsDivestituresDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash and Noncash Divestiture, Amount of Consideration Received", "label": "Cash and Noncash Divestiture, Amount of Consideration Received", "documentation": "Cash and Noncash Divestiture, Amount of Consideration Received" } } }, "auth_ref": { } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r48": { }, "r185": { }, "r325": { } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r2": { }, "r185": { } }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING ACTIVITY", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": { } }, "us-gaap_CashMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashMember", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash [Member]", "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": { "r274": { } }, "cslt_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "xbrlType": "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "documentation": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities" } } }, "auth_ref": { } }, "cslt_CashPaidToSettleInterestRateSwapAgreement": { "xbrlType": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "CashPaidToSettleInterestRateSwapAgreement", "crdr": "debit", "presentation": { "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Cash Paid to Settle, Interest Rate Swap Agreement", "label": "Cash Paid to Settle, Interest Rate Swap Agreement", "documentation": "Cash Paid to Settle, Interest Rate Swap Agreement" } } }, "auth_ref": { } }, "us-gaap_CashSurrenderValueFairValueDisclosure": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashSurrenderValueFairValueDisclosure", "crdr": "debit", "presentation": { "http://catalent.com/role/FairValueMeasuresandDisclosuresDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash Surrender Value, Fair Value Disclosure", "label": "Cash Surrender Value, Fair Value Disclosure", "documentation": "Fair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI)." } } }, "auth_ref": { "r1503": { }, "r1504": { }, "r1505": { }, "r1506": { }, "r1507": { }, "r1510": { } }, "us-gaap_CashSurrenderValueOfLifeInsurance": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashSurrenderValueOfLifeInsurance", "crdr": "debit", "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail": { "lang": { "en-us": { "role": { "terseLabel": "Cash Surrender Value of Life Insurance", "label": "Cash Surrender Value of Life Insurance", "documentation": "Carrying amount as of the balance sheet date of amounts which could be received based on the terms of the insurance contract upon surrendering life policies owned by the entity." } } }, "auth_ref": { "r1357": { } }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote [Text Block]", "label": "Changed Peer Group, Footnote [Text Block]", "documentation": "Area code of city" } } }, "auth_ref": { } }, "us-gaap_ClassOfStockDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://catalent.com/role/BusinessCombinationsDivestituresDetails": { "http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "http://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetailsDetails": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails": { "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": { "r261": { }, "r282": { }, "r283": { }, "r284": { }, "r328": { }, "r356": { }, "r357": { }, "r362": { }, "r364": { }, "r372": { }, "r373": { }, "r426": { }, "r513": { }, "r516": { }, "r517": { }, "r518": { }, "r522": { }, "r523": { }, "r553": { }, "r554": { }, "r556": { }, "r559": { }, "r566": { }, "r847": { }, "r1022": { }, "r1023": { }, "r1024": { }, "r1025": { }, "r1030": { }, "r1031": { }, "r1032": { }, "r1033": { }, "r1034": { }, "r1035": { }, "r1036": { }, "r1037": { }, "r1038": { }, "r1039": { }, "r1040": { }, "r1041": { }, "r1061": { }, "r1084": { }, "r1103": { }, "r1125": { }, "r1126": { }, "r1127": { }, "r1128": { }, "r1129": { }, "r1340": { }, "r1374": { }, "r1385": { } }, "cslt_ClinicalSupplyServicesMember": { "xbrlType": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "ClinicalSupplyServicesMember", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail": { "http://catalent.com/role/SegmentInformationCapitalExpendituresDetails": { "http://catalent.com/role/SegmentInformationDepreciationandAmortizationDetails": { "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail": { "http://catalent.com/role/SegmentInformationTotalAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Clinical Supply Services [Member]", "label": "Clinical Supply Services [Member]", "documentation": "Clinical Supply Services [Member]" } } }, "auth_ref": { } }, "ecd_CoSelectedMeasureAmt": { "xbrlType": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation":

{ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": { "r1300" } }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": { "r1300" } }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Commitment and contingencies (see Note 14)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r148", "r231", "r964", "r1060" } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": { "r200", "r503", "r504", "r1134", "r1427", "r1432" } }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquity" }, "http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquitySharesOfCommonStock" }, "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": { "r1236", "r1237", "r1238", "r1240", "r1241", "r1242", "r1243", "r1379", "r1380", "r1384", "r1501", "r1575", "r1578" } }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "http://catalent.com/role/ConsolidatedBalanceSheetsParentetical", "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": { "r154" } }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets", "http://catalent.com/role/ConsolidatedBalanceSheetsParentetical", "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares Authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r154", "r1061" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheetsParentetical", "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": { "r154" } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquity", "http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquitySharesOfCommonStock", "http://catalent.com/role/DocumentandEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares, Outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r27", "r154", "r1061", "r1080", "r1578", "r1579" } }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValueOutstanding", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedBalanceSheets", "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Value, Outstanding", "label": "Common Stock, Value, Outstanding", "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares." } } }, "auth_ref": { "r154", "r1061" } }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": { "r1305" } }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": { "r1304" } }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": { "r1306" } }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": { "r1303" } }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": { "r11", "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r108", "r221", "r304", "r306", "r313", "r956", "r978" } }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPolicies", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": { "r11", "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesConcentrationsOfCreditRiskandMajorCustomersDetails", "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": { "r58", "r59", "r124", "r125", "r415", "r1133" } }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesConcentrationsOfCreditRiskandMajorCustomersDetails", "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": { "r58", "r59", "r124", "r125", "r415", "r1018", "r1133" } }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesConcentrationsOfCreditRiskandMajorCustomersDetails", "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": { "r58", "r59", "r124", "r125", "r415", "r1133", "r1348" } }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPolicies", "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Credit Risk and Major Customers", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": { "r127", "r250" } }, "cslt_ConcentrationRiskNumberofCustomers": { "xbrltype": "integerItemType", "nsuri": "http://catalent.com/20240630", "localname": "ConcentrationRiskNumberofCustomers", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesConcentrationsOfCreditRiskandMajorCustomersDetails", "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk, Number of Customers", "label": "Concentration Risk, Number of Customers", "documentation": "Concentration Risk, Number of Customers" } } }, "auth_ref": { "r11", "cslt_ConcentrationRiskTradeReceivablesAndCurrentContractAssetPercentage": { "xbrltype": "percentItemType", "nsuri": "http://catalent.com/20240630", "localname": "ConcentrationRiskTradeReceivablesAndCurrentContractAssetPercentage", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentExpenseDetails", "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk trade receivables and current contract asset, Percentage", "label": "Concentration Risk trade receivables and current contract asset, Percentage", "documentation": "Concentration Risk trade receivables and current contract asset, Percentage" } } }, "auth_ref": { "r11", "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesConcentrationsOfCreditRiskandMajorCustomersDetails", "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": { "r58", "r59", "r124", "r125", "r415", "r1133" } }, "cslt_ConcentrationsOfCreditRiskandMajorCustomersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "ConcentrationsOfCreditRiskandMajorCustomersAbstract", "lang": { "en-us": { "role": { "label": "Concentrations of Credit Risk and Major Customers [Abstract]", "documentation": "Concentrations of Credit Risk and Major Customers [Abstract]" } } }, "auth_ref": { "r11", "srt_ConsolidationEliminationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationEliminationsMember", "presentation": { "http://catalent.com/role/SegmentInformationAssetsandRevenuesDetail", "lang": { "en-us": { "role": { "terseLabel": "Consolidation, Eliminations [Member]", "label": "Consolidation, Eliminations [Member]", "documentation": "Consolidation, Eliminations [Member]" } } }, "auth_ref": { "r11", "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": { "http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebytypeofactivityandreportingsegmentDetails", "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": { "r238", "r331", "r370", "r380", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r409", "r513", "r514", "r515", "r516", "r518", "r519", "r520", "r521", "r522", "r1167", "r1168", "r1438", "r1439" } }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressGross", "crdr": "debit", "calculation": { "http://catalent.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentDetail", "parentTag": "us-gaap_PropertyPlantandEquipmentGross", "weight": 1.0, "order": 4.0 }, "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentDetail", "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress, Gross", "documentation": "Amount of structure or a modification to a structure under construction. Includes

recently completed structures or modifications to structures that have not been placed into service." } } } , "auth_ref": { "r195" } } } , "cslt_ContractWithCustomerAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "ContractWithCustomerAsset", "crdr": "debit", "presentation": { "http://catalent.com/role/RevenueRecognitionContractualAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer Asset", "label": "Contract with Customer Asset", "documentation": "Contract with Customer Asset", "auth_ref": { "r568", "r570", "r580" } } } } , "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationPrepaidandOtherAssetsDetail": { "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer Asset, after Allowance for Credit Loss", "label": "Contract with Customer Asset, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } } , "auth_ref": { "r568", "r570", "r580" } } } , "us-gaap_ContractWithCustomerAssetPurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetPurchase", "crdr": "debit", "presentation": { "http://catalent.com/role/RevenueRecognitionContractualAssetsDetails": { "http://catalent.com/role/SupplementalBalanceSheetInformationPrepaidandOtherAssetsDetail": { "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer Asset, Purchase", "label": "Contract with Customer Asset, Purchase", "documentation": "Amount of increase from purchase of right to consideration in exchange for good or service transferred to customer when right is conditioned on passage of time." } } } , "auth_ref": { "r438" } } } , "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": { "http://catalent.com/role/RevenueRecognitionContractualLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer Liability", "label": "Contract with Customer Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } } , "auth_ref": { "r568", "r569", "r590" } } } , "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "crdr": "credit", "presentation": { "http://catalent.com/role/RevenueRecognitionContractualLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer Liability, Increase (Decrease) for Contract Acquired in Business Combination", "label": "Contract with Customer Liability, Increase (Decrease) for Contract Acquired in Business Combination", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination." } } } , "auth_ref": { "r184" } } } , "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": { "http://catalent.com/role/RevenueRecognitionContractualLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer Liability, Revenue Recognized", "label": "Contract with Customer Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } } , "auth_ref": { "r581" } } } , "cslt_ContractualLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://catalent.com/20240630", "localname": "ContractualLiabilitiesTableTextBlock", "presentation": { "http://catalent.com/role/RevenueRecognitionTables": { "lang": { "en-us": { "role": { "terseLabel": "Contractual Liabilities", "label": "Contractual Liabilities [Table Text Block]", "documentation": "[Table Text Block] for Contractual Liabilities [Table]", "auth_ref": { "r581" } } } } , "us-gaap_ConversionOfStockSharesConverted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Conversion of Stock, Shares Converted", "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } } } , "auth_ref": { "r51", "r52", "r53" } } } , "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred Stock, Shares Issued upon Conversion", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } } , "auth_ref": { "r38", "r80", "r153", "r204", "r562" } } } , "cslt_CoreTechnologyBetteraMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "CoreTechnologyBetteraMember", "presentation": { "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails": { "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails": { "lang": { "en-us": { "role": { "terseLabel": "Core Technology Bettera", "label": "Core Technology Bettera [Member]", "documentation": "Core Technology Bettera" } } } , "auth_ref": { "r1" } } } , "cslt_CoreTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "CoreTechnologyMember", "presentation": { "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails": { "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails": { "http://catalent.com/role/DefinedIntangibleAssetsSubjecttoAmortizationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Core technology [Member]", "label": "Core Technology [Member]", "documentation": "Core technology" } } } , "auth_ref": { "r1" } } } , "cslt_CorporateAndEliminationsMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "CorporateAndEliminationsMember", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails": { "http://catalent.com/role/SegmentInformationTotalAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Corporate and Eliminations [Member]", "label": "Corporate And Eliminations [Member]", "documentation": "Corporate and eliminations" } } } , "auth_ref": { "r1" } } } , "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Corporate Debt Securities [Member]", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } } , "auth_ref": { "r1192", "r1194", "r1208", "r1219", "r1234", "r1572" } } } , "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateMember", "presentation": { "http://catalent.com/role/SegmentInformationCapitalExpendituresDetails": { "http://catalent.com/role/SegmentInformationDepreciationandAmortizationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Corporate [Member]", "label": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } } , "auth_ref": { "r1389" } } } , "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } } , "auth_ref": { "r170", "r171", "r916" } } } , "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales [Member]", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } } , "auth_ref": { "r1" } } } , "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails": { "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } } , "auth_ref": { "r512", "r1436" } } } , "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails": { "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } } , "auth_ref": { "r512", "r1436", "r1437" } } } , "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "presentation": { "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "documentation": "Cumulative effect, period of adoption, adjustment" } } } , "auth_ref": { "r264", "r335", "r343", "r351", "r430", "r436", "r481", "r753", "r754", "r766", "r768", "r800", "r802", "r803", "r805", "r806", "r807", "r813", "r816", "r818", "r819", "r898" } } } , "srt_CumulativeEffectPeriodOfAdoptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionAxis", "presentation": { "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Cumulative Effect, Period of Adoption [Axis]", "label": "Cumulative Effect, Period of Adoption [Axis]", "documentation": "Cumulative effect, period of adoption, adjustment" } } } , "auth_ref": { "r264", "r335", "r343", "r351", "r430", "r436", "r481", "r753", "r754", "r766", "r768", "r800", "r802", "r803", "r805", "r806", "r807", "r813", "r816", "r818", "r819", "r898" } } } , "srt_CumulativeEffectPeriodOfAdoptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionDomain", "presentation": { "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Cumulative Effect, Period of Adoption [Domain]", "label": "Cumulative Effect, Period of Adoption [Domain]", "documentation": "Cumulative effect, period of adoption, adjustment" } } } , "auth_ref": { "r264", "r335", "r343", "r351", "r430", "r436", "r481", "r753", "r754", "r766", "r768", "r800", "r802", "r803", "r805", "r806", "r807", "r813", "r816", "r818", "r819", "r898" } } } , "us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease", "calculation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total foreign currency translation adjustments, net of tax", "label": "Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)", "documentation": "The increase (decrease) in cumulative translation adjustment before transfers included in determining net income." } } } , "auth_ref": { "r1518" } } } , "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": -1.0, "order": 1.0 } } , "presentation": { "http://catalent.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": -1.0, "order": 1.0 } } , "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail": { "http://catalent.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "Non-U.S.", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } } , "auth_ref": { "r1354", "r1377" } } } , "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://catalent.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total current", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } } , "auth_ref": { "r752", "r1377" } } } , "us-

```

CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": "http://catalent.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails", "lang": "en-us", "role": "terseLabel", "State and local", "label": "Current State and Local Tax Expense (Benefit), Continuing Operations [Abstract]", "auth_ref": "r1354", "r1377", "r1493", "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesConcentrationsOfCreditRiskandMajorCustomersDetails", "lang": "en-us", "role": "terseLabel", "Customer Concentration Risk [Member]", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "auth_ref": "r191", "r415", "us-gaap_CustomerRelatedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelatedIntangibleAssetsMember", "presentation": "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails", "lang": "en-us", "role": "terseLabel", "Customer-Related Intangible Assets [Member]", "label": "Customer-Related Intangible Assets [Member]", "documentation": "Customer-related asset, including, but not limited to, customer lists, and noncontractual customer relationships.", "auth_ref": "r135", "r1413", "r1415", "r1416", "r1417", "r1419", "r1420", "r1423", "r1424", "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "lang": "en-us", "role": "terseLabel", "Customer relationships [Member]", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "auth_ref": "r100", "r1413", "r1415", "r1416", "r1417", "r1419", "r1420", "r1423", "r1424", "us-gaap_DebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtAndCapitalLeaseObligations", "crdr": "credit", "presentation": "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Debt and Capital Lease Obligations", "label": "Debt and Lease Obligation", "documentation": "Amount of short-term and long-term debt and lease obligation.", "auth_ref": "r227", "r230", "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtCurrent", "crdr": "credit", "calculation": "http://catalent.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_LiabilitiesCurrent", "weight": "1.0", "order": "1.0", "presentation": "http://catalent.com/role/ConsolidatedBalanceSheets", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Debt, Current", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current.", "auth_ref": "r281", "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": "en-us", "role": "label", "Debt Disclosure [Abstract]", "auth_ref": "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowings", "lang": "en-us", "role": "terseLabel", "Long-Term Obligations and Other Short-Term Borrowings", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "auth_ref": "r201", "r326", "r485", "r486", "r487", "r489", "r511", "r512", "r524", "r530", "r531", "r532", "r533", "r534", "r535", "r540", "r547", "r548", "r550", "r866", "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsandEstimatedFairValueOfFinancialInstruments", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails", "lang": "en-us", "role": "terseLabel", "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "auth_ref": "r37", "r141", "r142", "r227", "r230", "r331", "r525", "r526", "r527", "r528", "r529", "r531", "r536", "r537", "r538", "r539", "r541", "r542", "r543", "r544", "r545", "r546", "r1178", "r1179", "r1180", "r1181", "r1182", "r1216", "r1375", "r1428", "r1429", "r1430", "r1521", "r1523", "us-gaap_DebtInstrumentBasisSpreadOnVariableRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails", "lang": "en-us", "role": "terseLabel", "Debt Instrument, Basis Spread on Variable Rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "auth_ref": "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsandEstimatedFairValueOfFinancialInstruments", "lang": "en-us", "role": "terseLabel", "Debt Instrument, Fair Value Disclosure", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "auth_ref": "r538", "r846", "r1179", "r1180", "r1504", "r1505", "r1506", "r1507", "r1510", "us-gaap_DebtInstrumentIncreaseDecreaseOtherNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIncreaseDecreaseOtherNet", "crdr": "credit", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Debt Instrument, Increase (Decrease), Other, Net", "label": "Debt Instrument, Increase (Decrease), Other, Net", "documentation": "Amount of increase (decrease) in debt instruments, classified as other.", "auth_ref": "r1375", "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Debt Instrument, Interest Rate, Effective Percentage", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "auth_ref": "r144", "r551", "r866", "r867", "r1216", "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Stated interest rate (percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "auth_ref": "r144", "r526", "us-gaap_DebtInstrumentInterestRateTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateTerms", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Debt Instrument, Interest Rate Terms", "label": "Debt Instrument, Interest Rate Terms", "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "auth_ref": "r144", "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails", "lang": "en-us", "role": "terseLabel", "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r331", "r525", "r526", "r527", "r528", "r529", "r531", "r536", "r537", "r538", "r539", "r541", "r542", "r543", "r544", "r545", "r546", "r1178", "r1179", "r1180", "r1181", "r1182", "r1216", "r1375", "r1428", "r1429", "r1430", "r1521", "r1523", "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsandEstimatedFairValueOfFinancialInstruments", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails", "lang": "en-us", "role": "terseLabel", "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "auth_ref": "r37", "r331", "r525", "r526", "r527", "r528", "r529", "r531", "r536", "r537", "r538", "r539", "r541", "r542", "r543", "r544", "r545", "r546", "r1178", "r1179", "r1180", "r1181", "r11
```

```

DebtInstrumentUnusedBorrowingCapacityAmount": "crdr": "credit", "presentation": "http://catalent.com/role/LongTermObligationsAndOtherShortTermBorrowingsAdditionalInformationDetail", "lang": "en-us", "role": "Debt Instrument, Unused Borrowing Capacity, Amount", "label": "Debt Instrument, Unused Borrowing Capacity, Amount", "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.", "auth_ref": "r145", "r511", "us-gaap-DebtInstrumentUnusedBorrowingCapacityFee": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnusedBorrowingCapacityFee", "crdr": "debit", "presentation": "http://catalent.com/role/OtherIncomeExpenseDetails", "lang": "en-us", "role": "Debt Instrument, Unused Borrowing Capacity, Fee", "label": "Debt Instrument, Unused Borrowing Capacity, Fee", "documentation": "Amount of commitment fees for the unused borrowing capacity under the long-term financing arrangement that is available to the entity.", "auth_ref": "r145", "r511", "cslt-DebtIssuanceCostsMember": "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "DebtIssuanceCostsMember", "presentation": "http://catalent.com/role/LongTermObligationsAndOtherShortTermBorrowingsAdditionalInformationDetail", "lang": "en-us", "role": "Debt Refinancing Costs [Axis]", "label": "Debt Refinancing Costs [Axis]", "documentation": "Debt Refinancing Costs [Axis]", "auth_ref": "r145", "r511", "cslt-DebtRefinancingCostsDomain": "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "DebtRefinancingCostsDomain", "presentation": "http://catalent.com/role/LongTermObligationsAndOtherShortTermBorrowingsAdditionalInformationDetail", "lang": "en-us", "role": "Debt Refinancing Costs [Domain]", "label": "Debt Refinancing Costs [Domain]", "documentation": "[Domain] for Debt Refinancing Costs [Axis]", "auth_ref": "r145", "r511", "us-gaap-DebtRelatedCommitmentFeesAndDebtIssuanceCosts": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "crdr": "debit", "calculation": "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0, "presentation": "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "Financing fees paid", "label": "Debt Related Commitment Fees and Debt Issuance Costs", "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.", "auth_ref": "r177", "us-gaap-DebtSecuritiesMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesMember", "presentation": "http://catalent.com/role/EmployerRetirementBenefitPlansFairValueDetails", "lang": "en-us", "role": "Debt Securities [Member]", "label": "Debt Securities [Member]", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "auth_ref": "r69", "r1238", "r1581", "us-gaap-DebtorReorganizationItemsPensionAndOtherPostretirementRelatedCharges": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtorReorganizationItemsPensionAndOtherPostretirementRelatedCharges", "crdr": "debit", "calculation": "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0, "presentation": "http://catalent.com/role/SegmentInformationReconciliationOfEarningsLossFromContinuingOperationsToEbitdaDetail", "lang": "en-us", "role": "Debtor Reorganization Items, Pension and Other Postretirement Related Charges", "label": "Debtor Reorganization Items, Pension and Other Postretirement Related Charges", "documentation": "Amount of reorganization items related to pension and other postretirement related charges.", "auth_ref": "r1529", "us-gaap-DeferredCompensationPlanAssets": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationPlanAssets", "crdr": "debit", "presentation": "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail", "lang": "en-us", "role": "Deferred Compensation Plan Assets", "label": "Deferred Compensation Plan Assets", "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "auth_ref": "r1357", "us-gaap-DeferredFederalIncomeTaxExpenseBenefit": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": "http://catalent.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails", "parentTag": "us-gaap-DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0, "presentation": "http://catalent.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails", "lang": "en-us", "role": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "auth_ref": "r1377", "r1492", "r1493", "us-gaap-DeferredFinanceCostsNoncurrentNet": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNoncurrentNet", "crdr": "debit", "presentation": "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail", "lang": "en-us", "role": "Deferred long term debt financing costs", "label": "Debt Issuance Costs, Noncurrent, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "auth_ref": "r1520", "r1521", "us-gaap-DeferredForeignIncomeTaxExpenseBenefit": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": "http://catalent.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails", "parentTag": "us-gaap-DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0, "presentation": "http://catalent.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails", "lang": "en-us", "role": "Non-U.S.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "auth_ref": "r1377", "r1492", "us-gaap-DeferredIncomeTaxAssetsNet": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": "http://catalent.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 5.0, "presentation": "http://catalent.com/role/ConsolidatedBalanceSheets", "http://catalent.com/role/IncomeTaxesBalanceSheetDetails", "lang": "en-us", "role": "Deferred Income Tax Assets, Net", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "auth_ref": "r717", "r718", "us-gaap-DeferredIncomeTaxExpenseBenefit": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": "http://catalent.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails", "parentTag": "us-gaap-DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0, "presentation": "http://catalent.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails", "lang": "en-us", "role": "Total", "label": "Total deferred", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "auth_ref": "r14", "r258", "r1377", "us-gaap-DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": "http://catalent.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails", "lang": "en-us", "role": "Deferred", "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "auth_ref": "r14", "us-gaap-DeferredIncomeTaxLiabilities": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails", "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 3.0, "presentation": "http://catalent.com/role/ConsolidatedBalanceSheets", "http://catalent.com/role/IncomeTaxesBalanceSheetDetails", "lang": "en-us", "role": "Deferred Income Tax Liabilities, Net", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "auth_ref": "r717", "r718", "r961", "cslt-DeferredIncomeTaxOperatingLeaseLiabilities": "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "DeferredIncomeTaxOperatingLeaseLiabilities", "crdr": "credit", "calculation": "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails", "parentTag": "us-gaap-DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0, "presentation": "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails", "lang": "en-us", "role": "Deferred Income Tax, Right of Use Asset", "label": "Deferred Income Tax, Right of Use", "documentation": "Deferred Income Tax, Right of Use", "auth_ref": "r1359", "us-gaap-DeferredRevenueCurrent": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail", "parentTag": "us-gaap-OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0, "presentation": "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail", "lang": "en-us", "role": "Deferred revenue and fees", "label": "Deferred Revenue, Current", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "auth_ref": "r1359", "us-gaap-DeferredStateAndLocalIncomeTaxExpenseBenefit": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": "http://catalent.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails", "parentTag": "us-gaap-DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0, "presentation": "http://catalent.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails", "lang": "en-us", "role": "State and local", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "auth_ref": "r1377", "r1492", "r1493", "us-gaap-DeferredTaxAssetDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetDomain", "presentation": "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail", "lang": "en-us", "role": "Deferred Tax Asset [Domain]", "label": "Deferred Tax Asset [Domain]", "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "auth_ref": "r1488", "cslt-DeferredTaxAssetsAndLiabilitiesTableTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://catalent.com/20240630", "localname": "DeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": "http://catalent.com/role/IncomeTaxesTables", "lang": "en-us", "role": "Deferred tax assets and liabilities", "label": "Deferred Tax Assets And Liabilities Table [Text Block]", "documentation": "Deferred tax assets and liabilities.", "auth_ref": "r1490", "us-gaap-DeferredTaxAssetsDeferredIncome": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsDeferredIncome", "crdr": "debit", "presentation": "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail", "lang": "en-us", "role": "NegatedTerseLabel": "Non-current deferred tax asset", "label": "Deferred Tax Assets, Deferred Income", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "auth_ref": "r1490", "cslt-DeferredTaxAssetsFederalTaxes": "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "DeferredTaxAssetsFederalTaxes", "crdr": "debit", "presentation": "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail", "lang": "en-us", "role": "Deferred Tax Assets, Federal Taxes", "label": "Deferred Tax Assets, Federal Taxes", "documentation": "Deferred Tax Assets, Federal Taxes", "auth_ref": "r1490", "us-gaap-DeferredTaxAssetsGoodwillAndIntangibleAssets": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "
```

"http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGrossAbstract", "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "terseLabel": "Deferred income tax assets", "label": "Deferred Tax Assets, Gross [Abstract]" } } }, "auth ref": { "cctl_DeferredTaxAssetsInternationalTaxAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "DeferredTaxAssetsInternationalTaxAsset", "crdr": "debit", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, International Tax Asset", "label": "Deferred Tax Assets, International Tax Asset", "documentation": "Deferred Tax Assets, International Tax Asset" } } }, "auth ref": { "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "totalLabel": "Deferred Tax Assets, Net of Valuation Allowance", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth ref": { "r1487": { "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "terseLabel": "Loss and tax credit carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth ref": { "r1490": { "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 10.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "terseLabel": "Other", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth ref": { "r1490": { "us-gaap_DeferredTaxAssetsOtherComprehensiveLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOtherComprehensiveLoss", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "terseLabel": "Euro Denominated Debt", "label": "Deferred Tax Assets, Other Comprehensive Loss", "documentation": "Amount, before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses in other comprehensive income." } } }, "auth ref": { "r1490": { "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "terseLabel": "Property-related", "label": "Deferred Tax Assets, Property, Plant and Equipment", "documentation": "Amount, before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment." } } }, "auth ref": { "r1490": { "us-gaap_DeferredTaxAssetsStateTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsStateTaxes", "crdr": "debit", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, State Taxes", "label": "Deferred Tax Assets, State Taxes", "documentation": "Amount, before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes." } } }, "auth ref": { "r1490": { "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensions", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "terseLabel": "Pension", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Pensions", "documentation": "Amount, before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from pension benefits." } } }, "auth ref": { "r1490": { "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "terseLabel": "Equity compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount, before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth ref": { "r1490": { "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "documentation": "Amount, before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities." } } }, "auth ref": { "r1490": { "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "terseLabel": "Foreign currency", "label": "Deferred Tax Assets, Unrealized Currency Losses", "documentation": "Amount, before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions." } } }, "auth ref": { "r1490": { "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail": { "en-us": { "role": { "terseLabel": "Deferred Tax Assets, Valuation Allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth ref": { "r745": { "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "crdr": "credit", "presentation": { "http://catalent.com/role/IncomeTaxesBalanceSheetDetails": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "terseLabel": "Deferred Tax Liabilities, Net", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth ref": { "r1487": { "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "terseLabel": "Deferred income tax liabilities", "label": "Deferred Tax Liabilities, Gross [Abstract]" } } }, "auth ref": { "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "crdr": "credit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "negatedTerseLabel": "Goodwill and other intangibles", "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill." } } }, "auth ref": { "r1490": { "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth ref": { "r1490": { "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "negatedTerseLabel": "Property-related", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth ref": { "r1490": { "us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesTaxDeferredIncome", "crdr": "credit", "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "negatedTerseLabel": "Non-current deferred tax liability", "label": "Deferred Tax Liabilities, Tax Deferred Income", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other." } } }, "auth ref": { "r1490": { "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "crdr": "credit", "calculation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesDeferredTaxAssetsDetails": { "en-us": { "role": { "negatedTerseLabel": "Foreign currency", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences." } } }, "auth ref": { "r1490": { "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "en-us": { "role": { "terseLabel": "Pension liability", "label": "Liability, Defined Benefit Pension Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan." } } }, "auth ref": { "r84": { "r85": { "r147": { "r208": { "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "crdr": "credit", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails": { "en-us": { "role": { "terseLabel": "Accumulated Benefit Obligation", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level." } } }, "auth ref": { "r616": { "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeLossAfterTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeLossAfterTaxAbstract", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails": { "en-us": { "role": { "role": { "terseLabel": "Amounts Recognized in Accumulated Other Comprehensive Income", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax [Abstract]" } } }, "auth ref": { "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax", "crdr": "credit", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails": { "en-us": { "role": { "negatedTerseLabel": "Net (gain)/loss", "label": "Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax", "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth ref": { "r42": { "r628": { "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax", "crdr": "debit", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails": { "en-us": { "role": { "terseLabel": "Prior service cost", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax", "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth ref": { "r42": { "r628": { "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsAfterTax", "crdr": "credit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "terseLabel": "Transition (asset) obligation", "label": "Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), after Tax", "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "auth_ref": "r42", "r628", "ctlt_DefinedBenefitPlanActualPlanAssetsAllocationAmount": "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "DefinedBenefitPlanActualPlanAssetsAllocationAmount", "crdr": "debit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel": "Actual Asset Allocation", "label": "Defined Benefit Plan, Actual Plan Assets Allocation, Amount", "documentation": "Amount", "auth_ref": "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "crdr": "debit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": "en-us", "role": "terseLabel": "Actual return on plan assets", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "auth_ref": "r598", "r1194", "us-gaap_DefinedBenefitPlanActuarialGainLoss": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": "en-us", "role": "terseLabel": "Actuarial (gain)/loss", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to: interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "auth_ref": "r591", "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 6.0, "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": "en-us", "role": "terseLabel": "Defined Benefit Plan, Amortization of Gain (Loss)", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "auth_ref": "r585", "r623", "r647", "r1194", "r1195", "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "crdr": "debit", "calculation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 5.0, "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "terseLabel": "Prior service cost", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "auth_ref": "r585", "r624", "r648", "r1194", "r1195", "us-gaap_DefinedBenefitPlanAmortizationOfTransitionAssetObligation": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfTransitionAssetObligation", "crdr": "credit", "calculation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 4.0, "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "terseLabel": "Transition (asset) obligation", "label": "Defined Benefit Plan, Amortization of Transition Asset (Obligation)", "documentation": "Amount of transition asset (obligation) recognized in net periodic benefit (cost) credit of defined benefit plan.", "auth_ref": "r585", "r625", "r649", "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "terseLabel": "Amounts Recognized in Statement of Financial Position", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position (Abstract)", "auth_ref": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "lang": "en-us", "role": "terseLabel": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) (Abstract)", "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) (Abstract)", "auth_ref": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax", "crdr": "credit", "calculation": "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails", "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0, "order": 3.0, "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0, "order": 5.0, "presentation": "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails", "lang": "en-us", "role": "terseLabel": "Net gain/(loss) recognized during the year", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax", "documentation": "Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.", "auth_ref": "r166", "r167", "r209", "us-gaap_DefinedBenefitPlanAmountsThatWillBeAmortizedFromAccumulatedOtherComprehensiveIncomeLossInNextFiscalYearAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsThatWillBeAmortizedFromAccumulatedOtherComprehensiveIncomeLossInNextFiscalYearAbstract", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "lang": "en-us", "role": "terseLabel": "Estimated Amounts to be Amortized from Accumulated Other Comprehensive Income into Net Periodic Benefit Cost", "label": "Defined Benefit Plan, Expected Amortization, Next Fiscal Year (Abstract)", "auth_ref": "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "crdr": "debit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "terseLabel": "Noncurrent assets", "label": "Assets for Plan Benefits, Defined Benefit Plan", "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "auth_ref": "r225", "r583", "r584", "r606", "r1073", "r1194", "r1540", "us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails", "lang": "en-us", "role": "terseLabel": "Assumed Healthcare Cost Trend Rates at the Balance Sheet Date", "label": "Defined Benefit Plan, Assumed Health Care Cost Trend Rates (Abstract)", "auth_ref": "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "lang": "en-us", "role": "terseLabel": "Discount rate (percent)", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "auth_ref": "r629", "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "lang": "en-us", "role": "terseLabel": "Rate of compensation increases (percent)", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to: pay-related defined benefit plan.", "auth_ref": "r630", "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "lang": "en-us", "role": "terseLabel": "Discount rate (percent)", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "auth_ref": "r631", "r652", "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "lang": "en-us", "role": "terseLabel": "Rate of compensation increases (percent)", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to: pay-related defined benefit plan.", "auth_ref": "r630", "us-gaap_DefinedBenefitPlanBenefitObligation": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": "en-us", "role": "periodStartLabel": "Benefit obligation at beginning of year", "periodEndLabel": "Benefit obligation at end of year", "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "auth_ref": "r586", "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "crdr": "credit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": "en-us", "role": "terseLabel": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "auth_ref": "r593", "r655", "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "crdr": "debit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": "en-us", "role": "terseLabel": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.", "auth_ref": "r590", "us-gaap_DefinedBenefitPlanBenefitObligationPaymentForSettlement": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationPaymentForSettlement", "crdr": "credit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel": "Defined Benefit Plan, Benefit Obligation, Payment for Settlement", "label": "Defined Benefit Plan, Benefit Obligation, Payment for Settlement", "documentation": "Amount of payment, which decreases benefit obligation of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive

specified benefits and purchasing nonparticipating annuity contract. Excludes decreases to benefit obligation for rereasurement due to settlement." } } }, "auth_ref": f-
"r1446" } } }, "us-gaap_DefinedBenefitPlanBusinessCombinationsAndAcquisitionsBenefitObligation": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DefinedBenefitPlanBusinessCombinationsAndAcquisitionsBenefitObligation", "crdr": "credit", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Other", "label": "Defined
Benefit Plan, Benefit Obligation, Business Combination", "documentation": "Amount of increase in benefit obligation of defined benefit plan from business combination." } } }
}, "auth_ref": f "r595" } } }, "us-gaap_DefinedBenefitPlanBusinessCombinationsAndAcquisitionsPlanAssets": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DefinedBenefitPlanBusinessCombinationsAndAcquisitionsPlanAssets", "crdr": "debit", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Other", "label": "Defined
Benefit Plan, Plan Assets, Business Combination", "documentation": "Amount of increase in plan assets of defined benefit plan from business combination." } } }, "auth_ref": f
"r603" } } }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DefinedBenefitPlanByPlanAssetCategoriesAxis", "presentation": f "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails",
"http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails" } } }, "lang": f
"en-us": f "role": f "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "documentation":
"Information by defined benefit plan asset investment." } } }, "auth_ref": f "r607", "r608", "r610", "r611", "r612", "r613", "r614", "r615", "r634", "r1192", "r1193", "r1194" } } },
"us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DefinedBenefitPlanChangeInBenefitObligationRollForward", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Change in Benefit Obligation",
"label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period
to the end of a period." } } }, "auth_ref": f } } }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": f "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details" } } },
"lang": f "en-us": f "role": f "terseLabel": "Employer contributions between measurement date and reporting date", "label": "Defined Benefit Plan, Change in Fair Value of
Plan Assets [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": f } } }, "us-
gaap_DefinedBenefitPlanContributionsByEmployer": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Company contributions",
"label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which
increases plan assets." } } }, "auth_ref": f "r600", "r610", "r651", "r1192", "r1193", "r1194", "r1195" } } }, "us-
gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod", "crdr": "debit", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Defined Benefit Plan, Cost of Providing Special and
Contractual Termination Benefits", "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits", "documentation": "Amount of cost of
providing special or contractual termination benefits payable from defined benefit plan." } } }, "auth_ref": f "r637" } } }, "us-gaap_DefinedBenefitPlanCurtailments": f
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanCurtailments", "crdr": "debit", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails" } } }, "lang": f "en-us": f "role": f "negatedTerseLabel": "Curtailments", "label":
"Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment", "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan
from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees." } } },
"auth_ref": f "r588" } } }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DefinedBenefitPlanDisclosureLineItems", "presentation": f "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails",
"http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails",
"http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansDetails",
"http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails",
"http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details" } } }, "lang": f "en-us": f "role": f "terseLabel": "Defined Benefit Plan Disclosure Line Items", "label":
"Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": f } } }, "us-gaap_DefinedBenefitPlanDivestituresBenefitObligation": f
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDivestituresBenefitObligation", "crdr": "debit", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Divestitures", "label": "Defined
Benefit Plan, Benefit Obligation, Divestiture", "documentation": "Amount of decrease in benefit obligation of defined benefit plan from disposal or classification as held-for-
sale." } } }, "auth_ref": f "r596" } } }, "us-gaap_DefinedBenefitPlanDivestituresPlanAssets": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DefinedBenefitPlanDivestituresPlanAssets", "crdr": "credit", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Divestitures", "label": "Defined
Benefit Plan, Plan Assets, Divestiture", "documentation": "Amount of decrease in plan assets of defined benefit plan from disposal or classification as held-for-sale." } } },
"auth_ref": f "r604" } } }, "us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesAbstract": f "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesAbstract", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Effect of 1% Change in
Healthcare Cost Trend Rate", "label": "Defined Benefit Plan, Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rate [Abstract]" } } }, "auth_ref": f } } },
"us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1": f "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1", "crdr": "debit",
"presentation": f "http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails" } } }, "lang": f "en-us": f "role": f "negatedTerseLabel":
"Effect of 1% decrease on APBO at balance sheet date", "label": "Defined Benefit Plan, Effect of One-Percentage-Point Decrease on Accumulated Postretirement Benefit
Obligation", "documentation": "Amount of decrease in accumulated postretirement benefit obligation from one-percentage-point decrease in assumed health care cost trend
rate." } } }, "auth_ref": f "r1445" } } }, "us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1": f "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1",
"crdr": "credit", "presentation": f "http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails" } } }, "lang": f "en-us": f "role": f
"negatedTerseLabel": "Effect of 1% decrease on total service and interest cost", "label": "Defined Benefit Plan, Effect of One-Percentage-Point Decrease on Service and
Interest Cost Components", "documentation": "Amount of decrease in service and interest cost components of net periodic postretirement benefit cost from one-percentage-
point decrease in assumed health care cost trend rate." } } }, "auth_ref": f "r1445" } } }, "us-
gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation": f "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation", "crdr": "credit",
"presentation": f "http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Effect of 1%
increase on APBO at balance sheet date", "label": "Defined Benefit Plan, Effect of One-Percentage-Point Increase on Accumulated Postretirement Benefit Obligation",
"documentation": "Amount of increase in accumulated postretirement benefit obligation from one-percentage-point increase in assumed health care cost trend rate." } } },
"auth_ref": f "r1445" } } }, "us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents": f "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents", "crdr": "debit", "presentation":
f "http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Effect of 1% increase on total
service and interest cost", "label": "Defined Benefit Plan, Effect of One-Percentage-Point Increase on Service and Interest Cost Components", "documentation": "Amount of
increase in service and interest cost components of net periodic postretirement benefit cost from one-percentage-point increase in assumed health care cost trend rate." } } },
"auth_ref": f "r1445" } } }, "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Expected Future Benefit Payments",
"label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]" } } }, "auth_ref": f } } }, "us-
gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract", "presentation": f "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails" } } }, "lang": f
"en-us": f "role": f "terseLabel": "Expected Future Contributions", "label": "Defined Benefit Plan, Expected Future Employer Contributions [Abstract]" } } }, "auth_ref": f } } },
"us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear", "crdr": "credit", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Net (gain)/loss", "label": "Defined Benefit Plan, Expected
Amortization of Gain (Loss), Next Fiscal Year", "documentation": "Amount included in accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan
expected to be recognized in net periodic benefit (cost) credit for fiscal year following most recent annual statement of financial position." } } }, "auth_ref": f "r1445" } } }, "us-
gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear", "crdr": "debit", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Prior service cost/(credit)", "label": "Defined Benefit
Plan, Expected Amortization of Prior Service Cost (Credit), Next Fiscal Year", "documentation": "Amount included in accumulated other comprehensive (income) loss for prior
service cost (credit) expected to be recognized in net periodic benefit cost (credit) for fiscal year following most recent annual statement of financial position." } } },
"auth_ref": f "r1445" } } }, "us-gaap_DefinedBenefitPlanExpectedAmortizationOfTransitionAssetObligationNextFiscalYear": f "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedAmortizationOfTransitionAssetObligationNextFiscalYear", "crdr": "credit", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails" } } }, "lang": f "en-us": f "role": f "negatedTerseLabel": "Transition (asset)/obligation", "label": "Defined
Benefit Plan, Expected Amortization of Transition Asset (Obligation), Next Fiscal Year", "documentation": "Amount included in accumulated other comprehensive income
(loss) for transition asset (obligation) expected to be recognized in net periodic benefit (cost) credit for fiscal year following most recent annual statement of financial
position." } } }, "auth_ref": f "r1445" } } }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": f "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "crdr": "credit", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Defined Benefit Plan, Expected Future
Benefit Payment, Five Fiscal Years Thereafter", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "documentation":
"Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year." } } }, "auth_ref": f "r617" } } }, "us-
gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "crdr": "credit", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Defined Benefit Plan, Expected Future
Benefit Payment, Next Twelve Months", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "documentation": "Amount of benefit for defined benefit
plan expected to be paid in next fiscal year following current fiscal year." } } }, "auth_ref": f "r617" } } }, "us-
gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "crdr": "credit", "presentation": f
"http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails" } } }, "lang": f "en-us": f "role": f "terseLabel": "Defined Benefit Plan, Expected Future
Benefit Payment, Year Five", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "documentation": "Amount of benefit for defined benefit plan

```

expected to be paid in fifth fiscal year following current fiscal year." } } }, "auth_ref": "r617" } }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "crdr": "credit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails", "lang": "en-us", "role": "terseLabel", "DefinedBenefitPlanExpectedFutureBenefitPayment, Year Four", "label": "DefinedBenefitPlanExpectedFutureBenefitPayment, Year Four", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year." } } }, "auth_ref": "r617" } }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "crdr": "credit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails", "lang": "en-us", "role": "terseLabel", "DefinedBenefitPlanExpectedFutureBenefitPayment, Year Three", "label": "DefinedBenefitPlanExpectedFutureBenefitPayment, Year Three", "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year." } } }, "auth_ref": "r617" } }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "crdr": "credit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails", "lang": "en-us", "role": "terseLabel", "DefinedBenefitPlanExpectedFutureBenefitPayment, Year Two", "label": "DefinedBenefitPlanExpectedFutureBenefitPayment, Year Two", "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year." } } }, "auth_ref": "r617" } }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "crdr": "debit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "lang": "en-us", "role": "terseLabel", "Fiscal Year 2020 Expected Future Contributions", "label": "DefinedBenefitPlanExpectedFutureEmployerContributions, Next Fiscal Year", "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year." } } }, "auth_ref": "r618", "r1195" } }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0 } }, "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "terseLabel", "DefinedBenefitPlanExpectedReturn (Loss) on Plan Assets", "label": "DefinedBenefitPlanExpectedReturn (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": "r585", "r622", "r646", "r1194", "r1195" } }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": "en-us", "role": "periodStartLabel", "Fair value of plan assets at beginning of year", "periodEndLabel": "Fair value of plan assets at end of year", "terseLabel": "Fair value of plan assets", "label": "DefinedBenefitPlan, Plan Assets, Amount", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": "r597", "r608", "r610", "r611", "r1192", "r1193", "r1194" } }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "crdr": "credit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": "en-us", "role": "terseLabel", "Exchange rate gain (loss)", "label": "DefinedBenefitPlan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan." } } }, "auth_ref": "r592" } }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFundedStatusOfPlan", "crdr": "debit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": "en-us", "role": "periodEndLabel", "Funded status at end of year", "netLabel": "Net Pension assets (liabilities)", "terseLabel": "Funded status at end of year", "label": "DefinedBenefitPlan, Funded (Unfunded) Status of Plan", "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status." } } }, "auth_ref": "r583", "r606", "r1194" } }, "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails", "lang": "en-us", "role": "terseLabel", "Healthcare cost trend rate, initial (percent)", "label": "DefinedBenefitPlan, Health Care Cost Trend Rate Assumed, Next Fiscal Year", "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status." } } }, "auth_ref": "r633" } }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": "en-us", "role": "terseLabel", "Interest cost", "verboseLabel": "Interest cost", "label": "DefinedBenefitPlan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": "r585", "r589", "r621", "r645", "r1194", "r1195" } }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "totalLabel", "Net periodic benefit cost", "label": "DefinedBenefitPlan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": "r619", "r643", "r1194", "r1195" } }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "terseLabel", "DefinedBenefitPlan, Net Periodic Benefit Cost (Credit) [Abstract]", "label": "DefinedBenefitPlan, Net Periodic Benefit Cost (Credit) [Abstract]", "documentation": " " } } }, "auth_ref": " " } }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "terseLabel", "DefinedBenefitPlan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "DefinedBenefitPlan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes amortization of gain (loss) component of net periodic benefit (cost) credit for defined benefit plan." } } }, "auth_ref": "r619", "r643" } }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "terseLabel", "DefinedBenefitPlan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "DefinedBenefitPlan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes expected return (loss) on plan asset component of net periodic benefit (cost) credit for defined benefit plan." } } }, "auth_ref": "r619", "r643" } }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "terseLabel", "DefinedBenefitPlan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "DefinedBenefitPlan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes interest cost component of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": "r619", "r643" } }, "cslt_DefinedBenefitPlanOtherAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "DefinedBenefitPlanOtherAssetsAxis", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails", "lang": "en-us", "role": "terseLabel", "DefinedBenefitPlan, Other Assets [Axis]", "label": "DefinedBenefitPlan, Other Assets [Axis]", "documentation": "DefinedBenefitPlan, Other Assets", "auth_ref": " " } }, "cslt_DefinedBenefitPlanOtherAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "DefinedBenefitPlanOtherAssetsDomain", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails", "lang": "en-us", "role": "terseLabel", "DefinedBenefitPlan, Other Assets [Domain]", "label": "DefinedBenefitPlan, Other Assets [Domain]", "documentation": "DefinedBenefitPlan, Other Assets", "auth_ref": " " } }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "terseLabel", "Additional Information for Plan with ABO in Excess of Plan Assets", "label": "DefinedBenefitPlan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]", "documentation": " " } } }, "auth_ref": " " } }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "crdr": "credit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "terseLabel", "Accumulated benefit obligation", "label": "DefinedBenefitPlan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
```

"DefinedBenefitPlanPlanAssetsBenefitsPaid", "crdr": "credit", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "Defined Benefit Plan, Plan Assets, Benefits Paid", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": { "r602", "r1454" } }, "us-gaap-DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "crdr": "debit", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets." } } }, "auth_ref": { "r601" } }, "us-gaap-DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": { "en-us": { "role": { "terseLabel": "Exchange rate gain/(loss)", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan." } } }, "auth_ref": { "r599" } }, "us-gaap-DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Target Asset Allocation (percent)", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": { "r607", "r1194" } }, "us-gaap-DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1", "crdr": "credit", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment." } } }, "auth_ref": { "r1444", "r1449", "r1453" } }, "us-gaap-DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails": { "parentTag": "us-gaap-DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 }, "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails": { "weight": 1.0, "order": 1.0 } } }, "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails": { "weight": 1.0, "order": 1.0 } } }, "auth_ref": { "r587", "r620", "r644", "r1194", "r1195" } }, "us-gaap-DefinedBenefitPlanSettlementsBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "crdr": "debit", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement." } } }, "auth_ref": { "r588" } }, "us-gaap-DefinedBenefitPlanSettlementsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSettlementsPlanAssets", "crdr": "credit", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract." } } }, "auth_ref": { "r605" } }, "us-gaap-DefinedBenefitPlanSpecialTerminationBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSpecialTerminationBenefits", "crdr": "credit", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "lang": { "en-us": { "role": { "terseLabel": "Special termination benefits", "label": "Defined Benefit Plan, Special company contributions to fund termination benefits", "documentation": "Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement." } } }, "auth_ref": { "r588" } }, "us-gaap-DefinedBenefitPlanUltimateHealthCareCostTrendRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails", "lang": { "en-us": { "role": { "terseLabel": "Healthcare cost trend rate-ultimate (percent)", "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate", "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan." } } }, "auth_ref": { "r633" } }, "us-gaap-DefinedBenefitPlanWeightedAverageAssetAllocations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Actual Asset Allocation (percent)", "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage", "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": { "r1447" } }, "us-gaap-DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "lang": { "en-us": { "role": { "terseLabel": "Financial Assumptions Used to Determine Benefit Obligations at the Balance Sheet Date", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]", "documentation": "Financial Assumptions Used to Determine Net Periodic Benefit Cost for Financial Year", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]", "auth_ref": { "r1447" } } } }, "us-gaap-DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate": { "xbrltype": "yearListItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails", "lang": { "en-us": { "role": { "terseLabel": "Year in which ultimate rates are reached", "label": "Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate", "documentation": "Year ultimate health care cost trend rate is expected to be reached, in YYYY format." } } }, "auth_ref": { "r633" } }, "us-gaap-DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "documentation": "Disclosure of information about defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans." } } }, "auth_ref": { "r19", "r86", "r87", "r88", "r89" } }, "us-gaap-DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "presentation": }

"http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r14", "r71" } }, "cftt-DelphiGeneticsSAMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "DelphiGeneticsSAMember", "presentation": }

"http://catalent.com/role/BusinessCombinationsDivestituresDetails", "lang": { "en-us": { "role": { "terseLabel": "Delphi Genetics SA", "label": "Delphi Genetics SA [Member]", "documentation": "Delphi Genetics SA", "auth_ref": { "r14", "r71" } } } }, "us-gaap-Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": }

"http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": { "r14", "r71" } }, "us-gaap-DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": }

"http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation and amortization", "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": { "r14", "r71" } }, "us-gaap-DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } } }, "auth_ref": { "r370", "r383", "r407", "r1167", "r1168" } }, "us-gaap-DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": }

"http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative, Fair Value, Net", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": { "r46" } }, "us-gaap-DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } } }, "auth_ref": { "r14", "r370", "r383", "r407", "r1167", "r1168" } }, "us-gaap-DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": }

"http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Derivative, Gain (Loss) on Derivative, Net", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": { "r1498" } }, "us-gaap-DerivativeInstrumentsandHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsandHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }

```

us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": { "http://catalent.com/role/DerivativeInstrumentsAndHedgingActivities": "I", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": { "r222", "r796", "r808" } }, "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": { "http://catalent.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail": "I", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": { "r117", "r1350" } }, "us-gaap:DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": { "http://catalent.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail": "I", "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": { "r292", "r293", "r822", "r823", "r836", "r846", "r1042", "r1043", "r1044", "r1045", "r1047", "r1048", "r1049", "r1050", "r1051", "r1075", "r1077", "r1078", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1155", "r1505", "r1506", "r1507", "r1576" } }, "us-gaap:DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": { "http://catalent.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail": "I", "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r808" } }, "us-gaap:DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": { "http://catalent.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail": "I", "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": { "r28", "r109", "r110", "r111", "r112", "r114", "r116", "r118", "r119", "r121", "r808" } }, "us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesMethodsOfAccountingHedgingDerivatives", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesPolicies": "I", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities", "label": "Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block]", "documentation": "Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts." } } }, "auth_ref": { "r795", "r1500" } }, "cslt:DesignatedSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "DesignatedSharesMember", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails": "I", "lang": { "en-us": { "role": { "terseLabel": "Designated Shares [Member]", "label": "Designated shares [Member]", "documentation": "Designated shares" } } }, "auth_ref": { "I" } }, "cslt:DevelopmentServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "DevelopmentServicesMember", "presentation": { "http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenuebyTypeofactivityandreportingsegmentDetails": "I", "lang": { "en-us": { "role": { "terseLabel": "Development Services [Member]", "label": "Development Services [Member]", "documentation": "Development Services [Member]" } } }, "auth_ref": { "I" } }, "us-gaap:DisaggregationOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Abstract]", "label": "Disaggregation of Revenue [Abstract]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r579", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191" } }, "us-gaap:DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": { "http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenuebyGeographyDetails": "I", "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table Text Block]", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": { "r1442" } }, "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail": "I", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Compensation-Related Costs, Share-based Payments", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": { "r662", "r666", "r698", "r699", "r701", "r1203" } }, "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "documentation": "Share-based payment arrangement." } } }, "auth_ref": { "r91" } }, "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": { "http://catalent.com/role/EquityBasedCompensationTables": "I", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": { "r17" } }, "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": "I", "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": { "r3", "r129", "r135", "r196" } }, "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfOperations": "I", "parentTag": "us-gaap:OperatingIncomeLoss", "weight": 1.0, "order": 4.0 }, "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail": "I", "parentTag": "cslt:SegmentReportingInformationUnallocatedExpense", "weight": -1.0, "order": 4.0 }, "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 }, "presentation": { "http://catalent.com/role/BusinessCombinationsDivestituresDetails": "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", "http://catalent.com/role/ConsolidatedStatementsOfOperations": "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": { "r402", "r1373", "r1426" } }, "us-gaap:DistributionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DistributionTypeDomain", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails": "I", "lang": { "en-us": { "role": { "terseLabel": "Distribution Type [Domain]", "label": "Distribution Type [Domain]", "documentation": "Types of distribution made by the entity." } } }, "auth_ref": { "r207" } }, "us-gaap:DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails": "I", "lang": { "en-us": { "role": { "terseLabel": "Distribution Type [Axis]", "label": "Distribution Type [Axis]", "documentation": "Information by type of distribution." } } }, "auth_ref": { "r207" } }, "us-gaap:DividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPreferredStock", "crdr": "debit", "presentation": { "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquity": "I", "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends, Preferred Stock", "label": "Dividends, Preferred Stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment in-kind (PIK)." } } }, "auth_ref": { "r12", "r206" } }, "us-gaap:DividendsPreferredStockStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPreferredStockStock", "crdr": "debit", "presentation": { "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquity": "I", "parentTag": "cslt:SegmentReportingInformationUnallocatedExpense", "weight": -1.0, "order": 4.0 }, "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 }, "presentation": { "http://catalent.com/role/BusinessCombinationsDivestituresDetails": "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", "http://catalent.com/role/ConsolidatedStatementsOfOperations": "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends, Preferred Stock, Stock", "label": "Dividends, Preferred Stock, Stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock." } } }, "auth_ref": { "r12", "r206"
```


"role": "document", "id": "r1287", "uri": "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".", "auth_ref": "us-gaap-DomesticCountryMember", "xbrl_type": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": "http://catalent.com/role/IncomeTaxAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "label": "Domestic Tax Authority [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction.", "auth_ref": "r721", "us-gaap-EarlyRepaymentOfSeniorDebt": {"xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarlyRepaymentOfSeniorDebt", "credit": "debit", "presentation": "http://catalent.com/role/OtherIncomeExpenseDetails", "lang": "en-us", "role": "terseLabel", "label": "Early Repayment of Senior Debt", "documentation": "The cash outflow for the extinguishment of long-term borrowing, with the highest claim on the assets of the entity in case of bankruptcy or liquidation, before its maturity.", "auth_ref": "r184", "us-gaap-EarningsPerShareAbstract": {"xbrl_type": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": "en-us", "role": "label", "label": "Earnings Per Share {Abstract}", "auth_ref": "us-gaap-EarningsPerShareBasic": {"xbrl_type": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": "http://catalent.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "terseLabel", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "auth_ref": "r314", "r340", "r341", "r343", "r344", "r345", "r347", "r353", "r356", "r362", "r363", "r364", "r369", "r770", "r786", "r819", "r820", "r957", "r979", "r1159", "us-gaap-EarningsPerShareDiluted": {"xbrl_type": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": "http://catalent.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "terseLabel", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "auth_ref": "r314", "r340", "r341", "r343", "r344", "r345", "r347", "r356", "r362", "r363", "r364", "r369", "r770", "r786", "r819", "r820", "r957", "r979", "r1159", "us-gaap-EarningsPerSharePolicyTextBlock": {"xbrl_type": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": "http://catalent.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "lang": "en-us", "role": "terseLabel", "label": "Earnings Per Share, Policy {Policy Text Block}", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "auth_ref": "r56", "r57", "r366", "us-gaap-EarningsPerShareTextBlock": {"xbrl_type": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": "http://catalent.com/role/EarningsPerShare", "lang": "en-us", "role": "terseLabel", "label": "Earnings Per Share", "documentation": "The entire disclosure for earnings per share.", "auth_ref": "r352", "r365", "r367", "r368", "cslt-EberbachPensionPromissoryNoteOrLoanMember": {"xbrl_type": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "EberbachPensionPromissoryNoteOrLoanMember", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Eberbach Pension Promissory Note or Loan [Member]", "documentation": "Eberbach Pension Promissory Note or Loan [Member]", "auth_ref": "us-gaap-EffectOffExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {"xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOffExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "credit": "debit", "calculation": "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0, "presentation": "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "auth_ref": "r854", "cslt-EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxIncome": {"xbrl_type": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxIncome", "credit": "debit", "calculation": "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "parentTag": "us-gaap-IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0, "presentation": "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "lang": "en-us", "role": "terseLabel", "label": "Effective Income Tax Rate Reconciliation, Global intangible low tax income", "documentation": "the income earned by foreign affiliates of US companies from intangible assets such as patents, trademarks, and copyrights", "auth_ref": "cslt-EffectiveTaxReconciliationDeferredTaxValuationAllowanceFromSwissTaxReform": {"xbrl_type": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "EffectiveTaxReconciliationDeferredTaxValuationAllowanceFromSwissTaxReform", "credit": "debit", "presentation": "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "lang": "en-us", "role": "terseLabel", "label": "Effective Tax Reconciliation, Change in Deferred Tax Valuation Allowance from Swiss Tax Reform", "documentation": "Effective Tax Reconciliation, Deferred Tax Valuation Allowance from Swiss Tax Reform", "auth_ref": "cslt-EffectiveTaxReconciliationGrossBenefitFromSwissTaxReform": {"xbrl_type": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "EffectiveTaxReconciliationGrossBenefitFromSwissTaxReform", "credit": "debit", "calculation": "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "parentTag": "us-gaap-IncomeTaxExpenseBenefit", "weight": 1.0, "order": 12.0, "presentation": "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "lang": "en-us", "role": "terseLabel", "label": "Effective Tax Reconciliation, Benefit from Swiss Tax Reform", "documentation": "Effective Tax Reconciliation, Gross Benefit from Swiss Tax Reform", "auth_ref": "cslt-EffectiveTaxReconciliationNetBenefitFromSwissTaxReform": {"xbrl_type": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "EffectiveTaxReconciliationNetBenefitFromSwissTaxReform", "credit": "debit", "presentation": "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "lang": "en-us", "role": "terseLabel", "label": "Effective Tax Reconciliation, Net Benefit from Swiss Tax Reform", "documentation": "Effective Tax Reconciliation, Net Benefit from Swiss Tax Reform", "auth_ref": "cslt-Eliminationofrevenueattributabletomultiplelocations": {"xbrl_type": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "Eliminationofrevenueattributabletomultiplelocations", "credit": "debit", "presentation": "http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebyGeographyDetails", "lang": "en-us", "role": "terseLabel", "label": "Elimination of revenue attributable to multiple locations", "documentation": "Elimination of revenue attributable to multiple locations", "auth_ref": "cslt-EmbeddedDerivativeEstimateOfEmbeddedDerivativeLiability": {"xbrl_type": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "EmbeddedDerivativeEstimateOfEmbeddedDerivativeLiability", "credit": "debit", "presentation": "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "label": "Embedded Derivative, Estimate of Embedded Derivative Liability", "documentation": "Embedded Derivative, Estimate of Embedded Derivative Liability", "auth_ref": "us-gaap-EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {"xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "credit": "debit", "presentation": "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "auth_ref": "r223", "r1505", "r1506", "r1507", "us-gaap-EmployeeRelatedLiabilitiesCurrent": {"xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "credit": "debit", "calculation": "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail", "parentTag": "us-gaap-OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0, "presentation": "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail", "lang": "en-us", "role": "terseLabel", "label": "Accrued employee-related expenses", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)", "auth_ref": "r142", "us-gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {"xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "credit": "debit", "presentation": "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": "en-us", "role": "terseLabel", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "auth_ref": "r700", "us-gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition": {"xbrl_type": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition", "presentation": "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails", "lang": "en-us", "role": "terseLabel", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement. In 'PnYmMnDnHnMnS' format, for example, 'P1Y3M13D' represents reported fact of one year, five months, and thirteen days.", "auth_ref": "r700", "us-gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {"xbrl_type": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "credit": "debit", "presentation": "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails", "lang": "en-us", "role": "terseLabel", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "documentation": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "auth_ref": "r1481", "us-gaap-EmployeeStockOptionMember": {"xbrl_type": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": "http://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetails", "lang": "en-us", "role": "terseLabel", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "auth_ref": "cslt-Employee

```

http://catalent.com/role/EarningsPerShareAdditionalDetailsDetails", "lang": "en-us", "role": "terseLabel", "Employee Stock Options and RSUs [Member]", "label": "Employee Stock Options and RSUs [Member]", "documentation": "Employee Stock Options and RSUs [Member]", "auth_ref": "1", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddress", "presentation": "1", "http://catalent.com/role/RestructuringandOtherCostsDetails", "lang": "en-us", "role": "terseLabel", "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "auth_ref": "1", "dei_EntityAddressAddressLine1", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "auth_ref": "1", "dei_EntityAddressCityOrTown", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town", "auth_ref": "1", "dei_EntityAddressPostalZipCode", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code", "auth_ref": "1", "dei_EntityAddressStateOrProvince", "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province", "auth_ref": "1", "dei_EntityCentralIndexKey", "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK", "auth_ref": "1", "dei_EntityCommonStockSharesOutstanding", "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Common Stock, Shares Outstanding (shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument", "auth_ref": "1", "dei_EntityCurrentReportingStatus", "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure", "auth_ref": "1", "dei_EntityDomain", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": "1", "http://catalent.com/role/RestructuringandOtherCostsDetails", "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "lang": "en-us", "role": "terseLabel", "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains", "auth_ref": "1", "dei_EntityEmergingGrowthCompany", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria", "auth_ref": "1", "dei_EntityFileNumber", "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits; the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen", "auth_ref": "1", "dei_EntityFilerCategory", "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure", "auth_ref": "1", "dei_EntityIncorporationStateCountryCode", "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation", "auth_ref": "1", "dei_EntityInteractiveDataCurrent", "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)", "auth_ref": "1", "dei_EntityPublicFloat", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter", "auth_ref": "1", "dei_EntityRegistrantName", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC", "auth_ref": "1", "dei_EntityShellCompany", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act", "auth_ref": "1", "dei_EntitySmallBusiness", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)", "auth_ref": "1", "dei_EntityTaxIdentificationNumber", "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS", "auth_ref": "1", "dei_EntityVoluntaryFilers", "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act", "auth_ref": "1", "dei_EntityWellKnownSeasonedIssuer", "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": "1", "http://catalent.com/role/DocumentandEntityInformation", "lang": "en-us", "role": "terseLabel", "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act, Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A", "auth_ref": "1", "ecd_EqtyAwrdsAdjFnTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": "1", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [TextBlock]", "auth_ref": "1", "ecd_EqtyAwrdsAdjExclValRptInSummryCompstnTblMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclValRptInSummryCompstnTblMember", "presentation": "1", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "auth_ref": "1", "ecd_EqtyAwrdsAdjMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjMember", "presentation": "1", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]", "auth_ref": "1", "ecd_EqtyAwrdsAdjMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjMember", "presentation": "1", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]", "auth_ref": "1", "ecd_EqtyAwrdsAdjMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjMember", "presentation": "1", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]", "auth_ref": "1", "ecd_EqtyAwrdsAdjMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjMember", "presentation": "1", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]", "auth_ref": "1", "ecd_EqtyAwrdsAdjMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyA
```

"EstimateOffFairValueFairValueDisclosureMember": {"presentation": {"http://catalent.com/role/LongTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsAndEstimatedFairValueOffFinance": {"lang": {"en-us": {"role": {"terseLabel": "Estimate of Fair Value Measurement [Member]", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value."}}}, "auth_ref": {"r538": {"r446": {"r1179": {"r1180": {"srt_EuropeMember": {"xbrltype": {"domainItemType": {"nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": {"http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenueByGeographyDetails": {"http://catalent.com/role/RevenueRecognitionTables": {"http://catalent.com/role/SegmentInformationAssetsAndRevenuesDetail": {"lang": {"en-us": {"role": {"terseLabel": "Europe", "label": "Europe [Member]"}}}, "auth_ref": {"r1580": {"r1582": {"r1583": {"r1584": {"cIt_": {"ExcludingSharesGrantedInConsiderationForAcquisitionMember": {"xbrltype": {"domainItemType": {"nsuri": "http://catalent.com/20240630", "localname": "ExcludingSharesGrantedInConsiderationForAcquisitionMember", "presentation": {"http://catalent.com/role/EquityBasedCompensationOptionActivityDetails": {"lang": {"en-us": {"role": {"terseLabel": "Excluding shares granted in consideration for acquisition [Member]", "label": "Excluding shares granted in consideration for acquisition [Member]", "documentation": "Excluding shares granted in consideration for acquisition [Member]"}}}, "auth_ref": {"ecd_ExecutiveCategoryAxis": {"xbrltype": {"stringItemType": {"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": {"http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "documentation": "Executive Category [Axis]"}}}, "auth_ref": {"r1308": {"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {"xbrltype": {"stringItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": {"http://catalent.com/role/FairValueMeasuresAndDisclosuresDetails": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, "auth_ref": {"r824": {"r825": {"r826": {"r1212": {"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {"xbrltype": {"stringItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": {"http://catalent.com/role/FairValueMeasuresAndDisclosuresDetails": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."}}}, "auth_ref": {"r824": {"r825": {"r826": {"r1212": {"us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": {"xbrltype": {"textBlockItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock", "presentation": {"http://catalent.com/role/EquityBasedCompensationTables": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value Measurements, Nonrecurring", "label": "Fair Value Measurements, Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3)."}}, "auth_ref": {"r1503": {"r1504": {"us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {"xbrltype": {"domainItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": {"http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details": {"lang": {"en-us": {"role": {"terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of Asset"}}, "auth_ref": {"r827": {"r828": {"r829": {"r830": {"r831": {"r832": {"r837": {"r1210": {"us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {"xbrltype": {"textBlockItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": {"http://catalent.com/role/EmployeeRetirementBenefitPlansTables": {"lang": {"en-us": {"role": {"terseLabel": "Reconciliation of beginning and ending balances of level 3 assets", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of asset."}}}, "auth_ref": {"r827": {"r832": {"r837": {"r1210": {"us-gaap_FairValueByAssetClassAxis": {"xbrltype": {"stringItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": {"http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details": {"lang": {"en-us": {"role": {"terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset."}}}, "auth_ref": {"r827": {"r828": {"r829": {"r830": {"r831": {"r832": {"r837": {"r1210": {"us-gaap_FairValueByFairValueHierarchyLevelAxis": {"xbrltype": {"stringItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": {"http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails": {"http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail", "http://catalent.com/role/LongTermBorrowingsAdditionalInformationDetail", "http://catalent.com/role/LongTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsAndEstimatedFairValueOffFinance": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."}}}, "auth_ref": {"r610": {"r611": {"r612": {"r613": {"r614": {"r615": {"r821": {"r823": {"r824": {"r825": {"r826": {"r835": {"r836": {"r838": {"r906": {"r907": {"r908": {"r1179": {"r1180": {"r1192": {"r1193": {"r1194": {"r1208": {"r1212": {"us-gaap_FairValueByLiabilityClassAxis": {"xbrltype": {"stringItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": {"http://catalent.com/role/LongTermBorrowingsAdditionalInformationDetail": {"lang": {"en-us": {"role": {"terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability."}}}, "auth_ref": {"r827": {"r828": {"r829": {"r830": {"r831": {"r832": {"r837": {"us-gaap_FairValueByMeasurementBasisAxis": {"xbrltype": {"stringItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": {"http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail", "http://catalent.com/role/LongTermBorrowingsAdditionalInformationDetail", "http://catalent.com/role/LongTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsAndEstimatedFairValueOffFinance": {"lang": {"en-us": {"role": {"terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis."}}}, "auth_ref": {"r538": {"r1179": {"us-gaap_FairValueDisclosureItemAmountsDomain": {"xbrltype": {"domainItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": {"http://catalent.com/role/LongTermBorrowingsAdditionalInformationDetail", "http://catalent.com/role/LongTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsAndEstimatedFairValueOffFinance": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."}}}, "auth_ref": {"r538": {"r1179": {"r1180": {"us-gaap_FairValueDisclosuresAbstract": {"xbrltype": {"stringItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": {"en-us": {"role": {"label": "Fair Value Disclosures [Abstract]"}}}, "auth_ref": {"us-gaap_FairValueDisclosuresTextBlock": {"xbrltype": {"textBlockItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": {"http://catalent.com/role/FairValueMeasuresAndDisclosures": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value Disclosures", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."}}}, "auth_ref": {"r831": {"r833": {"r834": {"r835": {"r838": {"r839": {"r840": {"r841": {"r842": {"r952": {"r1208": {"r1213": {"us-gaap_FairValueInputsLevel1Member": {"xbrltype": {"domainItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": {"http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails": {"http://catalent.com/role/LongTermBorrowingsAdditionalInformationDetail": {"lang": {"en-us": {"role": {"terseLabel": "Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."}}}, "auth_ref": {"r538": {"r610": {"r615": {"r823": {"r836": {"r906": {"r1192": {"r1193": {"r1194": {"r1208": {"us-gaap_FairValueInputsLevel2Member": {"xbrltype": {"domainItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": {"http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails": {"http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail", "http://catalent.com/role/LongTermBorrowingsAdditionalInformationDetail", "http://catalent.com/role/LongTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsAndEstimatedFairValueOffFinance": {"lang": {"en-us": {"role": {"terseLabel": "Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."}}}, "auth_ref": {"r538": {"r610": {"r615": {"r823": {"r824": {"r836": {"r907": {"r1179": {"r1180": {"r1192": {"r1193": {"r1194": {"r1208": {"us-gaap_FairValueInputsLevel3Member": {"xbrltype": {"domainItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": {"http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails": {"http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details": {"http://catalent.com/role/FairValueMeasuresAndDisclosuresDetails": {"lang": {"en-us": {"role": {"terseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."}}}, "auth_ref": {"r538": {"r610": {"r611": {"r612": {"r613": {"r614": {"r615": {"r823": {"r824": {"r825": {"r826": {"r836": {"r908": {"r1179": {"r1180": {"r1192": {"r1193": {"r1194": {"r1208": {"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {"xbrltype": {"domainItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": {"http://catalent.com/role/LongTermBorrowingsAdditionalInformationDetail": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value."}}}, "auth_ref": {"r827": {"r828": {"r829": {"r830": {"r831": {"r832": {"r837": {"us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {"xbrltype": {"domainItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "presentation": {"http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value Measured at Net Asset Value", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "documentation": "Fair value measured at net asset value per share as practical expedient."}}}, "auth_ref": {"r610": {"r821": {"r838": {"r1208": {"us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {"xbrltype": {"textBlockItemType": {"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": {"

http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "lang": "en-us", "role": "terseLabel", "Fair Value Measurement Policy", "label": "Fair Value Measurement Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." }, { "auth ref": "r1", "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetsHeldatReportingDate", "crdr": "debit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details", "lang": "en-us", "role": "terseLabel", "Relating to assets still held at the reporting date", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Assets Held at Reporting Date", "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Assets Held at Reporting Date" }, { "auth ref": "r1", "us-gaap": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuesSettlements", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuesSettlements", "crdr": "debit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details", "lang": "en-us", "role": "terseLabel", "Purchases, sales, settlements, contributions and benefits paid", "label": "Fair Value Measurement with Unobservable Inputs Reconciliation, Recurring Basis Asset Purchases, Sales, Issues, Settlements, (Settlements)", "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." }, { "auth ref": "r1508", "r1511", "us-gaap": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "crdr": "credit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details", "lang": "en-us", "role": "terseLabel", "Relating to assets sold during the period", "label": "Fair Value Measurement with Unobservable Inputs Reconciliation, Recurring Basis Asset Sales", "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." }, { "auth ref": "r830", "r837", "r1210", "us-gaap": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "crdr": "debit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details", "lang": "en-us", "role": "terseLabel", "Transfers in and/or out of Level 3", "label": "Fair Value Measurement with Unobservable Inputs Reconciliation, Recurring Basis Asset Transfers, Net", "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy." }, { "auth ref": "r1509", "r1511", "us-gaap": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details", "lang": "en-us", "role": "periodStartLabel", "Beginning balance", "periodEndLabel": "Ending balance", "label": "Fair Value Measurement with Unobservable Inputs Reconciliation, Recurring Basis Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." }, { "auth ref": "r827", "r837", "r1210", "us-gaap": "FairValueMeasurementsFairValueHierarchyDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details", "http://catalent.com/role/FairValueMeasuresandDisclosuresDetails", "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsandEstimatedFairValueofFinance", "lang": "en-us", "role": "terseLabel", "Fair Value Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." }, { "auth ref": "r538", "r610", "r611", "r612", "r613", "r614", "r615", "r821", "r823", "r824", "r825", "r826", "r835", "r836", "r838", "r906", "r907", "r908", "r1179", "r1180", "r1192", "r1193", "r1194", "r1208", "r1212", "catalent": "FairValueMeasurementsOffinancialInstrumentsLineItems", "xbrltype": "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "FairValueMeasurementsOffinancialInstrumentsLineItems", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsandEstimatedFairValueofFinance", "lang": "en-us", "role": "terseLabel", "Fair Value Measurements Of Financial Instruments [Line Items]", "label": "Fair Value Measurements Of Financial Instruments [Line Items]", "documentation": "Fair Value Measurements Of Financial Instruments [Line Items]"}, { "auth ref": "r1", "catalent": "FairValueMeasurementsOffinancialInstrumentsTable", "xbrltype": "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "FairValueMeasurementsOffinancialInstrumentsTable", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsandEstimatedFairValueofFinance", "lang": "en-us", "role": "terseLabel", "Fair Value Measurements Of Financial Instruments [Table]", "label": "Fair Value Measurements Of Financial Instruments [Table]", "documentation": "Fair Value Measurements Of Financial Instruments [Table]"}, { "auth ref": "r1", "us-gaap": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPurchasesSalesIssuesSettlements", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPurchasesSalesIssuesSettlements", "crdr": "debit", "presentation": "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails", "lang": "en-us", "role": "terseLabel", "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases, Sales, Issues, Settlements", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases, Sales, Issues, Settlements", "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." }, { "auth ref": "r1508", "r1511", "catalent": "FinanceLeaseExpense", "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "FinanceLeaseExpense", "crdr": "debit", "presentation": "http://catalent.com/role/LeasesCostDetails", "lang": "en-us", "role": "terseLabel", "Finance Lease Expense", "label": "Finance Lease Expense", "documentation": "Finance Lease Expense"}, { "auth ref": "r1", "us-gaap": "FinanceLeaseInterestExpense", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "presentation": "http://catalent.com/role/LeasesCostDetails", "lang": "en-us", "role": "terseLabel", "Finance Lease, Interest Expense", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." }, { "auth ref": "r877", "r883", "r1217", "us-gaap": "FinanceLeaseInterestPaymentOnLiability", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails", "lang": "en-us", "role": "terseLabel", "Finance Lease, Interest Payment on Liability", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." }, { "auth ref": "r879", "r887", "us-gaap": "FinanceLeaseLiability", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": "en-us", "role": "terseLabel", "Finance Lease, Liability", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." }, { "auth ref": "r875", "r891", "us-gaap": "FinanceLeaseLiabilityCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofOperatingAndFinanceLeasesPresentedIntheBalanceSheetDetails", "lang": "en-us", "role": "terseLabel", "Finance Lease, Liability, Current", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." }, { "auth ref": "r875", "us-gaap": "FinanceLeaseLiabilityNoncurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofOperatingAndFinanceLeasesPresentedIntheBalanceSheetDetails", "lang": "en-us", "role": "terseLabel", "Finance Lease, Liability, Noncurrent", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." }, { "auth ref": "r875", "us-gaap": "FinanceLeaseLiabilityPaymentsDue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": "en-us", "role": "terseLabel", "Finance Lease, Liability, Payment, Due", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments from finance lease." }, { "auth ref": "r891", "us-gaap": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": "en-us", "role": "terseLabel", "Finance Lease, Liability, Payments, Due after Year Five", "label": "Finance Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment from finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}, { "auth ref": "r891", "us-gaap": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": "en-us", "role": "terseLabel", "Finance Lease, Liability, Payments, Due Year One", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment from finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}, { "auth ref": "r891", "us-gaap": "FinanceLeaseLiabilityPaymentsDueYearFive", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": "en-us", "role": "terseLabel", "Finance Lease, Liability, Payments, Due Year Five", "label": "Finance Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment from finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}, { "auth ref": "r891", "us-gaap": "FinanceLeaseLiabilityPaymentsDueYearFour", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLease

```

http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedinthBalanceSheetDetails", "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible List]", "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease liability." } } }, "auth_ref": { "r876" } }, "cslt.FinanceLeaseLiabilityToBePaidGreaterThanYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "FinanceLeaseLiabilityToBePaidGreaterThanYearOne", "crdr": "credit", "presentation": { "http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedinthBalanceSheetDetails", "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payment, Due", "label": "Finance Lease, Liability, to be Paid, Greater than Year One", "documentation": "Finance Lease, Liability, to be Paid, Greater than Year One" } } }, "auth_ref": { "r891" } }, "us-gaap.FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": { "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Undiscounted Excess Amount", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": { "r891" } }, "us-gaap.FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "debit", "presentation": { "http://catalent.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Principal Payments", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": { "r878", "r887" } }, "us-gaap.FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": { "http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedinthBalanceSheetDetails", "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": { "r874" } }, "us-gaap.FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "presentation": { "http://catalent.com/role/LeasesCostDetails", "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Amortization", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": { "r877", "r883", "r1217" } }, "us-gaap.FinanceLeaseRightOfUseAssetStatementOffinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetStatementOffinancialPositionExtensibleList", "presentation": { "http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedinthBalanceSheetDetails", "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset." } } }, "auth_ref": { "r876" } }, "us-gaap.FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://catalent.com/role/LeasesCostDetails", "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": { "r890", "r1217" } }, "us-gaap.FinanceLeaseWeightedAverageRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm", "presentation": { "http://catalent.com/role/LeasesCostDetails", "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r889", "r1217" } }, "cslt.FiniteLivedIntangibleAssetExpectedAmortizationTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationTotal", "crdr": "credit", "presentation": { "http://catalent.com/role/DefiniteLivedLongLivedAssetsFutureAmortizationExpenseDetail", "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Total", "label": "Finite-Lived Intangible Asset, Expected Amortization, Total", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Total" } } }, "auth_ref": { "r890", "r1217" } }, "us-gaap.FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Asset, Useful Life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r890", "r1217" } }, "us-gaap.FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "debit", "presentation": { "http://catalent.com/role/DefiniteLivedLongLivedAssetsFutureAmortizationExpenseDetail", "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r278", "r448", "r472", "r1176" } }, "us-gaap.FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "presentation": { "http://catalent.com/role/DefiniteLivedLongLivedAssetsFutureAmortizationExpenseDetail", "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r1421", "r1585" } }, "us-gaap.FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": { "http://catalent.com/role/DefiniteLivedLongLivedAssetsFutureAmortizationExpenseDetail", "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r474", "r1147", "r1176" } }, "us-gaap.FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": { "http://catalent.com/role/DefiniteLivedLongLivedAssetsFutureAmortizationExpenseDetail", "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r474", "r1147", "r1176" } }, "us-gaap.FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": { "http://catalent.com/role/DefiniteLivedLongLivedAssetsFutureAmortizationExpenseDetail", "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r474", "r1147", "r1176" } }, "us-gaap.FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": { "http://catalent.com/role/DefiniteLivedLongLivedAssetsFutureAmortizationExpenseDetail", "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r474", "r1147", "r1176" } }, "us-gaap.FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": { "http://catalent.com/role/DefiniteLivedLongLivedAssetsFutureAmortizationExpenseDetail", "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r474", "r1147", "r1176" } }, "us-gaap.FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class [Axis]", "label": "Finite-Lived Intangible Assets, Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": { "r465", "r467", "r468", "r469", "r471", "r472", "r475", "r476", "r917", "r921", "r1147" } }, "us-gaap.FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": { "http://catalent.com/role/DefiniteLivedLongLivedAssetsFutureAmortizationExpenseDetail", "lang": { "en-us": { "role": { "terseLabel": "
```



```

catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails" }, {"lang": "en-us", "role": "terseLabel", "Fixed Annuity [Member]", "documentation": "Contract that provides a guaranteed stream of fixed payments." } }, {"auth_ref": "r1229" }, {"us-gaap ForeignCountryMember", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCountryMember", "presentation": "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail" }, {"lang": "en-us", "role": "terseLabel", "Foreign Tax Authority [Member]", "label": "Foreign Tax Jurisdiction [Member]", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } }, {"auth_ref": "r721", "r722" }, {"us-gaap ForeignCurrencyTransactionGainLossBeforeTax", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", {"parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, {"presentation": "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", {"lang": "en-us", "role": "negatedTerseLabel", "Foreign Currency Transaction Gain (loss), before Tax", "label": "Gain (loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } }, {"auth_ref": "r849", "r850", "r851", "r853", "r1100" } }, {"us-gaap ForeignCurrencyTransactionGainLossUnrealized", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "presentation": "http://catalent.com/role/OtherIncomeExpenseDetails" }, {"lang": "en-us", "role": "terseLabel", "Foreign Currency Transaction Gain (Loss), Unrealized", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } }, {"auth_ref": "r187", "r1082", "r1247", "r1515", "r1516", "r1577" } }, {"us-gaap ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPolicies" }, {"lang": "en-us", "role": "terseLabel", "Translation and Transaction of Foreign Currencies", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } }, {"auth_ref": "r840" } }, {"cslt ForeignNetOperatingLossEstablishedMember", {"xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "ForeignNetOperatingLossEstablishedMember", "presentation": "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail" }, {"lang": "en-us", "role": "terseLabel", "Foreign, Net Operating Loss Established [Member]", "label": "Foreign, Net Operating Loss Established [Member]", "documentation": "Foreign, Net Operating Loss Established [Member]", "auth_ref": "r187", "r1082", "r1247", "r1515", "r1516", "r1577" } }, {"cslt ForeignNetOperatingLossMember", {"xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "ForeignNetOperatingLossMember", "presentation": "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail" }, {"lang": "en-us", "role": "terseLabel", "Foreign, Net Operating Loss [Member]", "label": "Foreign, Net Operating Loss [Member]", "documentation": "Foreign, Net Operating Loss [Member]", "auth_ref": "r187", "r1082", "r1247", "r1515", "r1516", "r1577" } }, {"ecd ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", {"lang": "en-us", "role": "terseLabel", "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } }, {"auth_ref": "r1263", "r1274", "r1284", "r1316" } }, {"ecd ForgoneRecoveryDueToExpenseOfEnforcementAmt", {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", {"lang": "en-us", "role": "terseLabel", "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } }, {"auth_ref": "r1263", "r1274", "r1284", "r1316" } }, {"ecd ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", {"lang": "en-us", "role": "terseLabel", "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } }, {"auth_ref": "r1263", "r1274", "r1284", "r1316" } }, {"ecd ForgoneRecoveryExplanationOfImpracticabilityTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", {"lang": "en-us", "role": "terseLabel", "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } }, {"auth_ref": "r1263", "r1274", "r1284", "r1316" } }, {"ecd ForgoneRecoveryIndName", {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", {"lang": "en-us", "role": "terseLabel", "Name", "label": "Forgone Recovery, Individual Name" } }, {"auth_ref": "r1263", "r1274", "r1284", "r1316" } }, {"cslt FourPointSevenFivePercentSeniorEuroDenominatedNotesMember", {"xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "FourPointSevenFivePercentSeniorEuroDenominatedNotesMember", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsFairValueMeasurementsOfFinancialInstrumentsCarryingAmountsandEstimatedFairValueOfFinance Denominated Notes [Member]", "documentation": "Four Point Seven Five Percent Senior Euro Denominated Notes [Member]" } }, {"auth_ref": "r1297" } }, {"ecd FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldYstngCondsDrngCvrdYrMember", {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldYstngCondsDrngCvrdYrMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", {"lang": "en-us", "role": "terseLabel", "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } }, {"auth_ref": "r1297" } }, {"us-gaap FurnitureAndFixturesGross", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesGross", "crdr": "debit", "calculation": "http://catalent.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentDetail", {"parentTag": "us-gaap PropertyPlantAndEquipmentGross", "weight": -1.0, "order": 3.0 } }, {"presentation": "http://catalent.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentDetail", {"lang": "en-us", "role": "terseLabel", "Furniture and fixtures", "label": "Furniture and Fixtures, Gross", "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } }, {"auth_ref": "r1495" } }, {"us-gaap FurnitureAndFixturesMember", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails" }, {"lang": "en-us", "role": "terseLabel", "Furniture and Fixtures [Member]", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } }, {"auth_ref": "r1495" } }, {"us-gaap GainLossOnSalesOfAssetsAndAssetImpairmentCharges", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "crdr": "credit", "calculation": "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", {"parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, {"presentation": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails", "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", {"lang": "en-us", "role": "terseLabel", "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "documentation": "Amount of gain (loss) from the difference between the sale price or salvage value and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value." } }, {"auth_ref": "r1373" } }, {"us-gaap GainLossRelatedToLitigationSettlement", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "presentation": "http://catalent.com/role/RestructuringandOtherCostsDetails", {"lang": "en-us", "role": "terseLabel", "Gain (Loss) Related to Litigation Settlement", "label": "Gain (Loss) from Litigation Settlement", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } }, {"auth_ref": "r1167", "r1433" } }, {"us-gaap GainsLossesOnExtinguishmentOfDebt", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": "http://catalent.com/role/OtherIncomeExpenseDetails", {"lang": "en-us", "role": "terseLabel", "Gain (Loss) on Extinguishment of Debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } }, {"auth_ref": "r14", "r76", "r77" } }, {"us-gaap Goodwill", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": "http://catalent.com/role/ConsolidatedBalanceSheets", {"parentTag": "us-gaap Assets", "weight": -1.0, "order": 3.0 } }, {"presentation": "http://catalent.com/role/ConsolidatedBalanceSheets", "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", {"lang": "en-us", "role": "terseLabel", "Goodwill", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } }, {"auth_ref": "r272", "r450", "r953", "r1168", "r1175", "r1209", "r1218", "r1402", "r1409" } }, {"us-gaap GoodwillAcquiredDuringPeriod", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", {"lang": "en-us", "role": "terseLabel", "Goodwill, Acquired During Period", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } }, {"auth_ref": "r454", "r1175" } }, {"us-gaap GoodwillAndIntangibleAssetsDisclosureAbstract", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
```

venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": { "r14", "r451", "r457", "r463", "r1175", "r1209" } },
"cctl_GoodwillInputsPercentageDiscountRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://catalent.com/20240630", "localname":
"GoodwillInputsPercentageDiscountRateMaximum", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail" }, "lang": { "en-us": { "role": {
"terseLabel": "Goodwill Inputs Percentage, Discount Rate Maximum", "label": "Goodwill Inputs Percentage, Discount Rate Maximum", "documentation": "Goodwill Inputs
Percentage, Discount Rate Maximum" } } }, "auth_ref": { } }, "cctl_GoodwillInputsPercentageDiscountRateMinimum": { "xbrltype": "percentItemType", "nsuri":
"http://catalent.com/20240630", "localname": "GoodwillInputsPercentageDiscountRateMinimum", "presentation": {
"http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Goodwill Inputs Percentage, Discount Rate Minimum",
"label": "Goodwill Inputs Percentage, Discount Rate Minimum", "documentation": "Goodwill Input Discount Rate Minimum, Percentage" } } }, "auth_ref": { } },
"cctl_GoodwillInputsPercentageLongTermRevenueGrowthRate": { "xbrltype": "percentItemType", "nsuri": "http://catalent.com/20240630", "localname":
"GoodwillInputsPercentageLongTermRevenueGrowthRate", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail" }, "lang": { "en-us": { "role": {
"terseLabel": "Goodwill Inputs Percentage, Long Term Revenue Growth Rate", "label": "Goodwill Inputs Percentage, Long Term Revenue Growth Rate", "documentation":
"Goodwill Input Long Term Revenue Growth Rate, Percentage" } } }, "auth_ref": { } }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GoodwillLineItems", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail" }, "lang": { "en-us": { "role": {
"terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used
to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r452", "r453", "r454", "r455", "r456", "r457",
"r458", "r459", "r460", "r461", "r463", "r1175" } }, "us-gaap_GoodwillOtherIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "GoodwillOtherIncreaseDecrease", "crdr": "debit", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail" }, "lang": { "en-us": {
"role": { "terseLabel": "Goodwill, Other Increase (Decrease)", "label": "Goodwill, Other Increase (Decrease)", "documentation": "Amount of increase (decrease) of asset
representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and
separately recognized, classified as other." } } }, "auth_ref": { "r459" } }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GoodwillRollForward", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail" }, "lang": { "en-us": { "role": {
"terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to
the end of a period." } } }, "auth_ref": { } }, "us-gaap_GoodwillTransfers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillTransfers", "crdr": "debit", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail" }, "lang": { "en-us": { "role": { "terseLabel":
"Goodwill, Transfers", "label": "Goodwill, Transfers", "documentation": "Amount of increase (decrease) from transfer into (out of) asset representing future economic benefit
arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } },
"auth_ref": { "r1408" } }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "crdr": "credit", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail" }, "lang": { "en-us": {
"role": { "negatedTerseLabel": "Goodwill, Written Off Related To Sale of Business Unit", "label": "Goodwill, Written Off Related To Sale of Business Unit", "documentation":
"Amount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that
is not individually identified and separately recognized." } } }, "auth_ref": { "r456", "r1175" } }, "cctl_GreaterThanOneYearMemberMember": { "xbrltype": "domainItemType",
"nsuri": "http://catalent.com/20240630", "localname": "GreaterThanOneYearMemberMember", "presentation": {
"http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenuebyTypeofActivityandReportingSegmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Greater
Than One Year Member", "label": "Greater Than One Year Member [Member]", "documentation": "Greater Than One Year Member" } } }, "auth_ref": { } }, "us-
gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": {
"http://catalent.com/role/ConsolidatedStatementsOfOperations" }, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": {
"http://catalent.com/role/ConsolidatedStatementsOfOperations" }, "lang": { "en-us": { "role": { "totalLabel": "Gross margin", "label": "Gross Profit", "documentation":
"Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": { "r168", "r172",
"r239", "r328", "r426", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r847", "r1161", "r1167", "r1388", "r1390", "r1391", "r1392", "r1393", "r1438" } },
"us-gaap_HedgeFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgeFundsMember", "presentation": {
"http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Hedge Funds [Member]", "verboseLabel": "Hedge
Funds [Member]", "label": "Hedge Funds [Member]", "documentation": "Investments in registered hedge funds." } } }, "auth_ref": { "r1208", "r1210", "r1448" } },
"cctl_HepaticCellTherapySupportSA": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "HepaticCellTherapySupportSA", "crdr":
"debit", "presentation": { "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Hepatic Cell Therapy
Support SA", "label": "Hepatic Cell Therapy Support SA", "documentation": "Hepatic Cell Therapy Support SA" } } }, "auth_ref": { } },
"cctl_HepaticCellTherapySupportSAMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "HepaticCellTherapySupportSAMember",
"presentation": { "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Hepatic Cell Therapy Support SA",
"label": "Hepatic Cell Therapy Support SA [Member]", "documentation": "Hepatic Cell Therapy Support SA" } } }, "auth_ref": { } }, "dei_IcfrAuditorAttestationFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": {
"http://catalent.com/role/DocumentandEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag"
} } }, "auth_ref": { "r1253", "r1254", "r1266" } }, "us-gaap_ImmaterialErrorCorrection": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ImmaterialErrorCorrection", "presentation": { "http://catalent.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Immaterial Error Correction",
"label": "Immaterial Error Correction", "documentation": "Describes nature and related effect on financial statements related to corrections of prior year errors in the current
year financial statements when the effect of the prior year error was immaterial to the prior year financial statements and the current year correction is immaterial to the
current year financial statements." } } }, "auth_ref": { "r55", "r189", "r190" } }, "cctl_ImpairmentChargesAndGainLossOnSaleOfAssets": { "xbrltype": "monetaryItemType",
"nsuri": "http://catalent.com/20240630", "localname": "ImpairmentChargesAndGainLossOnSaleOfAssets", "crdr": "debit", "calculation": {
"http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail" }, "parentTag": "cctl_SegmentReportingInformationUnallocatedExpense", "weight": 1.0,
"order": 1.0 }, "presentation": { "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail",
"http://catalent.com/role/SegmentInformationReconciliationOfEarningslossfromContinuingOperationstoEbitdaDetail" }, "lang": { "en-us": { "role": { "negatedLabel":
"Impairment charges and gain/(loss) on sale of assets", "terseLabel": "Impairment Charges And Gain Loss On Sale Of Assets", "label": "Impairment Charges And Gain Loss On
Sale Of Assets", "documentation": "Impairment charges and (gain)/loss on sale of assets." } } }, "auth_ref": { } }, "us-gaap_ImpairmentOfIntangibleAssetsFiniteLived": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFiniteLived", "crdr": "debit", "presentation": {
"http://catalent.com/role/DefiniteLivedLongLivedAssetsAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Impairment of Intangible Assets, Finite-
lived", "label": "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of
the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": { "r466", "r1373", "r1425" } }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": {
"http://catalent.com/role/IncomeTaxesScheduleofIncomebeforeTaxDomesticandForeignDetails", "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "presentation": {
"http://catalent.com/role/IncomeTaxesScheduleofIncomebeforeTaxDomesticandForeignDetails" }, "lang": { "en-us": { "role": { "terseLabel": "U.S. operations", "label": "Income
(Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is
attributable to domestic operations." } } }, "auth_ref": { "r329", "r720" } }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://catalent.com/role/ConsolidatedStatementsOfOperations" }, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 },
"http://catalent.com/role/IncomeTaxesScheduleofIncomebeforeTaxDomesticandForeignDetails": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": { "http://catalent.com/role/ConsolidatedStatementsOfOperations",
"http://catalent.com/role/IncomeTaxesScheduleofIncomebeforeTaxDomesticandForeignDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Income (Loss) from Continuing
Operations before Income Taxes, Noncontrolling Interest", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense
(benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": { "r169", "r234", "r239", "r958", "r974", "r1161", "r1167", "r1388", "r1390", "r1391",
"r1392", "r1393" } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": {
"http://catalent.com/role/IncomeTaxesScheduleofIncomebeforeTaxDomesticandForeignDetails", "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "presentation": {
"http://catalent.com/role/IncomeTaxesScheduleofIncomebeforeTaxDomesticandForeignDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Non-U.S. operations", "label":
"Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes
that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": {
"r329", "r720" } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": {
"http://catalent.com/role/IncomeTaxesScheduleofIncomebeforeTaxDomesticandForeignDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Earnings from continuing
operations before income taxes", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
"documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling
interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": { "r239", "r981", "r1161", "r1388", "r1390", "r1391", "r1392", "r1393" } }, "us-
gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": {
"http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail",
"http://catalent.com/role/SegmentInformationReconciliationOfEarningslossfromContinuingOperationstoEbitdaDetail" }, "lang": { "en-us": { "role": { "terseLabel":
"Earnings (loss) from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
"documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": { "r221",
"r239", "r328", "r336", "r345", "r426", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r770", "r786", "r820", "r847", "r974", "r1161", "r1388", "r1390",
"r1391", "r1392", "r1393", "r1438" } }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": { } }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": {
"http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentExpenseDetails",
"http://catalent.com/role/BusinessCombinationsDivestituresDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of
Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": {
"r483", "r490", "r496", "r828", "r832", "r837", "r1002", "r1004", "r1087", "r1147", "r1211", "r1545" } }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": {
"http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentExpenseDetails",
"http://catalent.com/role/BusinessCombinationsDivestituresDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of
Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": { "r490", "r496",
"r828", "r832", "r837", "r1002", "r1004", "r1087", "r1147", "r1211", "r1545" } }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": { "r324", "r721", "r722", "r734", "r749", "r1205", "r1489" } } }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": { "r324", "r721", "r722", "r734", "r749", "r1205", "r1489" } } }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyLineItems", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Line Items]", "label": "Income Tax Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyTable", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Table]", "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": { "r1486" } }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "auth_ref": { } }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": { "http://catalent.com/role/IncomeTaxes": { "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": { "r330", "r711", "r721", "r731", "r732", "r733", "r740", "r747", "r750", "r760", "r761", "r762", "r1027", "r1205" } }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://catalent.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsofOperations": { "http://catalent.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail": { "http://catalent.com/role/SegmentInformationReconciliationofEarningslossfromContinuingOperationstoEbitdaDetail": { "lang": { "en-us": { "role": { "verboseLabel": "Income tax expense", "totalLabel": "Total provision", "negatedTerseLabel": "Income Tax Expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": { "r246", "r259", "r349", "r350", "r370", "r386", "r407", "r719", "r721", "r759", "r982", "r1205" } }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": { "r307", "r715", "r716", "r740", "r741", "r746", "r751", "r1021" } }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Tax valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": { "r727", "r1205", "r1483" } }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Change in tax rate", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": { "r714", "r721", "r726", "r1205" } }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Foreign tax rate differential", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": { "r722", "r725", "r1205", "r1483" } }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Provision at U.S. federal statutory tax rate", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": { "r721", "r1205" } }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Permanent items", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": { "r728", "r730", "r1483" } }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 13.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": { "r1205", "r1483", "r1484" } }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Withholding Tax and other foreign taxes", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)." } } }, "auth_ref": { "r1483", "r1484" } }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "terseLabel": "State and local income taxes", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": { "r724", "r1205", "r1483" } }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxContingencies", "crdr": "debit", "calculation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax positions", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies." } } }, "auth_ref": { "r729", "r1205", "r1483" } }, "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxCreditsForeign", "crdr": "credit", "calculation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 8.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit." } } }, "auth_ref": { "r1483", "r1485" } }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "calculation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 11.0 } }, "presentation": { "http://catalent.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": { "r1205", "r1483", "r1485" } }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid, net", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": { "r50", "r324", "r749", "r749" } }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": { "r13" } }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": {

```
"http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } },  
"presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "(Increase)/decrease in trade  
receivables", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or  
one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": { "r131": { "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {  
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerAsset", "crdr": "credit", "presentation": {  
"http://catalent.com/role/RevenueRecognitionContractualAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Contract with Customer Asset",  
"label": "Increase (Decrease) in Contract with Customer Asset", "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service  
transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": { "r1372": { "us-  
gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "  
IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-  
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": {  
"lang": { "en-us": { "role": { "negatedTerseLabel": "Provision/(benefit) for deferred income taxes", "label": "Increase (Decrease) in Deferred Income Taxes", "documentation":  
"The increase (decrease) during the reporting period in the account that represents the temporary difference that results from income or loss that is recognized for  
accounting purposes but not for tax purposes and vice versa." } } }, "auth_ref": { "r131": { "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType",  
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": {  
"http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } },  
"presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "(Increase)/decrease in inventories",  
"label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the  
reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": { "r131": { "us-  
gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "  
IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel":  
"Change in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": { "us-  
gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "  
IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-  
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": {  
"lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets/acquired liabilities, net - current and non-current", "label": "Increase (Decrease) in Other Operating Assets and  
Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": { "r131": {  
"us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "  
IncreaseDecreaseInStockholdersEquityRollForward", "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity",  
"http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquitySharesOfCommonStock": { "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in  
Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept  
from the beginning of a period to the end of a period." } } }, "auth_ref": { "clt_IncreaseInContractWithCustomerAsset": { "xbrltype": "monetaryItemType", "nsuri":  
"http://catalent.com/20240630", "localname": "IncreaseInContractWithCustomerAsset", "crdr": "debit", "presentation": {  
"http://catalent.com/role/RevenueRecognitionContractualAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Increase in Contract with Customer Asset", "label":  
"Increase in Contract with Customer Asset", "documentation": "Increase in Contract with Customer Asset." } } }, "auth_ref": { "us-  
gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "  
IncrementalCommonSharesAttributableToConversionOfPreferredStock", "presentation": {  
"http://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetailsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Incremental Common Shares Attributable  
to Dilutive Effect of Conversion of Preferred Stock", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock", "documentation":  
"Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method." } } },  
"auth_ref": { "r358", "r359", "r364": { "clt_IncrementalTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "  
IncrementalTermLoanMember", "presentation": { "http://catalent.com/role/LongTermBorrowingsAndOtherShortTermBorrowingsInterestRateDetails": { "lang": { "en-us": {  
"role": { "terseLabel": "Incremental Term Loan", "label": "Incremental Term Loan [Member]", "documentation": "Incremental Term Loan [Member]" } } }, "auth_ref": {  
"ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": {  
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",  
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Individual", "label": "Individual [Axis]" } } }, "auth_ref": { "r1263", "r1274", "r1284",  
"r1308", "r1316", "r1320", "r1328": { "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "  
InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": { "r1326": {  
"ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems",  
"lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": { "r1255", "r1332": { "ecd_InsiderTrdPoliciesProcAdoptedFlag":  
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": {  
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc": { "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider  
Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": { "r1255", "r1332": { "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype":  
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": {  
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc": { "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider  
Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": { "r1255", "r1332": { "clt_InstallmentPaymentForAcquisition": { "xbrltype":  
"monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "InstallmentPaymentForAcquisition", "crdr": "debit", "presentation": {  
"http://catalent.com/role/LongTermBorrowingsAndOtherShortTermBorrowingsAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Installment Payment  
for Acquisition, Next Twelve Months", "label": "Installment Payment for Acquisition", "documentation": "Installment Payment for Acquisition" } } }, "auth_ref": { "clt_InstallmentPaymentForAcquisitionYearFour":  
"xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "  
InstallmentPaymentForAcquisitionYearFour", "crdr": "debit", "presentation": {  
"http://catalent.com/role/LongTermBorrowingsAndOtherShortTermBorrowingsAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Installment Payment  
for Acquisition, Year Four", "label": "Installment Payment for Acquisition, Year Four", "documentation": "Installment Payment for Acquisition, Year Four" } } }, "auth_ref": { "clt_InstallmentPaymentForAcquisitionYearThree":  
"xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "  
InstallmentPaymentForAcquisitionYearThree", "crdr": "debit", "presentation": {  
"http://catalent.com/role/LongTermBorrowingsAndOtherShortTermBorrowingsAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Installment Payment  
for Acquisition, Year Three", "label": "Installment Payment for Acquisition, Year Three", "documentation": "Installment Payment for Acquisition, Year Three" } } }, "auth_ref": { "clt_InstallmentPaymentForAcquisitionYearTwo":  
"xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "  
InstallmentPaymentForAcquisitionYearTwo", "crdr": "debit", "presentation": {  
"http://catalent.com/role/LongTermBorrowingsAndOtherShortTermBorrowingsAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Installment Payment  
for Acquisition, Year Two", "label": "Installment Payment for Acquisition, Year Two", "documentation": "Installment Payment for Acquisition, Year Two" } } }, "auth_ref": { "clt_InsuranceContractsMember":  
"xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "InsuranceContractsMember", "presentation": {  
"http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails": "http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details": { "lang": {  
"en-us": { "role": { "terseLabel": "Insurance Contracts [Member]", "label": "Insurance Contracts [Member]", "documentation": "Insurance Contracts [Member]" } } },  
"auth_ref": { "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "  
IntangibleAssetsDisclosureTextBlock", "presentation": { "http://catalent.com/role/DefiniteLivedLongLivedAssets": { "lang": { "en-us": { "role": { "terseLabel": "Definite Lived  
Long-Lived Assets", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets."  
" } } }, "auth_ref": { "r464", "r477", "r479", "r1146", "r1147": { "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-  
gaap/2024", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": {  
"http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, Finite-  
Lived", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This  
accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such  
assets." } } }, "auth_ref": { "r913", "r914", "r915", "r917", "r1156", "r1412": { "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbr
```

documentation": "Fair value as of the balance sheet date of all interest rate derivative assets designated as cash flow hedging instruments." } } }, "auth_ref": "r224" } }, "us-gaap-InterestRateCashFlowHedgeLiabilityAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateCashFlowHedgeLiabilityAtFairValue", "crdr": "credit", "presentation": { "http://catalent.com/role/FairValueMeasuresandDisclosuresDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Cash Flow Hedge Liability at Fair Value", "label": "Interest Rate Cash Flow Hedge Liability at Fair Value", "documentation": "Fair value as of the balance sheet date of all interest rate derivative liabilities designated as cash flow hedging instruments." } } }, "auth_ref": { "r224" } } }, "us-gaap-InterestRateDerivativeAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateDerivativeAssetsAtFairValue", "crdr": "debit", "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail": { "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Derivative Assets, at Fair Value", "label": "Interest Rate Derivative Assets, at Fair Value", "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets." } } }, "auth_ref": { "r224" } } }, "InternationalDeferredTaxAssetDomain": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "InternationalDeferredTaxAssetDomain", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "International Deferred Tax Asset [Domain]", "label": "International Deferred Tax Asset [Domain]", "documentation": "International Deferred Tax Asset" } } }, "auth_ref": { "r224" } } }, "InternationalDeferredTaxAsset": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "InternationalDeferredTaxAsset", "presentation": { "http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebyGeographyDetails": { "lang": { "en-us": { "role": { "terseLabel": "International Other", "label": "International Other [Member]", "documentation": "International Other [Member]" } } }, "auth_ref": { "r224" } } }, "us-gaap-IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntersegmentEliminationMember", "presentation": { "http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebyTypeofActivityandReportingsegmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Intersegment Eliminations", "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": { "r228", "r370", "r380", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r1167" } } }, "us-gaap-InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://catalent.com/role/SupplementalBalanceSheetInformationWorkinProcessandFinishedGoodsInventoriesIncludeRawMaterialsLaborandOverheadDetail": { "parentTag": "us-gaap-InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationWorkinProcessandFinishedGoodsInventoriesIncludeRawMaterialsLaborandOverheadDetail": { "lang": { "en-us": { "role": { "totalLabel": "Total inventory, gross", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": { "r1364" } } }, "us-gaap-InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationWorkinProcessandFinishedGoodsInventoriesIncludeRawMaterialsLaborandOverheadDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationWorkinProcessandFinishedGoodsInventoriesIncludeRawMaterialsLaborandOverheadDetail": { "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": { "r288", "r1152", "r1218" } } }, "us-gaap-InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": { "r247", "r273", "r287", "r443", "r444", "r445", "r912", "r1157" } } }, "us-gaap-InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "calculation": { "http://catalent.com/role/SupplementalBalanceSheetInformationWorkinProcessandFinishedGoodsInventoriesIncludeRawMaterialsLaborandOverheadDetail": { "parentTag": "us-gaap-InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationWorkinProcessandFinishedGoodsInventoriesIncludeRawMaterialsLaborandOverheadDetail": { "lang": { "en-us": { "role": { "terseLabel": "Raw materials and supplies", "label": "Inventory, Raw Materials and Supplies, Gross", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": { "r1364" } } }, "us-gaap-InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "crdr": "credit", "calculation": { "http://catalent.com/role/SupplementalBalanceSheetInformationWorkinProcessandFinishedGoodsInventoriesIncludeRawMaterialsLaborandOverheadDetail": { "parentTag": "us-gaap-InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationWorkinProcessandFinishedGoodsInventoriesIncludeRawMaterialsLaborandOverheadDetail": { "lang": { "en-us": { "role": { "negatedLabel": "Inventory cost adjustment", "label": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": { "r194", "r1364" } } }, "us-gaap-InventoryWorkinProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkinProcess", "crdr": "debit", "calculation": { "http://catalent.com/role/SupplementalBalanceSheetInformationWorkinProcessandFinishedGoodsInventoriesIncludeRawMaterialsLaborandOverheadDetail": { "parentTag": "us-gaap-InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationWorkinProcessandFinishedGoodsInventoriesIncludeRawMaterialsLaborandOverheadDetail": { "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": { "r1363" } } }, "ctlt-KyotoMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "KyotoMember", "presentation": { "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails": { "lang": { "en-us": { "role": { "terseLabel": "Kyoto", "label": "Kyoto [Member]", "documentation": "Kyoto" } } }, "auth_ref": { "r243" } } }, "ctlt-LandBuildingsAndImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "LandBuildingsAndImprovements", "crdr": "debit", "calculation": { "http://catalent.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentDetail": { "parentTag": "us-gaap-PropertyPlantandEquipmentGross", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentDetail": { "lang": { "en-us": { "role": { "terseLabel": "Land, buildings, and improvements", "label": "Land Buildings and Improvements", "documentation": "Land, buildings and improvements." } } }, "auth_ref": { "r243" } } }, "us-gaap-LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": { "http://catalent.com/role/LeasesCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": { "r882", "r1217" } } }, "us-gaap-LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "documentation": "Lease, Cost [Abstract]", "presentation": { "http://catalent.com/role/LeasesTables": { "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": { "r1525" } } }, "us-gaap-LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "documentation": "Leases [Abstract]", "presentation": { "http://catalent.com/role/Leases": { "lang": { "en-us": { "role": { "terseLabel": "Leases of Lessee Disclosure", "label": "Leases of Lessee Disclosure [Text Block]", "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing." } } }, "auth_ref": { "r243" } } }, "doi-LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/del/2024", "localname": "LegalEntityAxis", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Legal Entity Axis", "label": "Legal Entity Axis", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": { "r243" } } }, "us-gaap-LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeasesTextBlock", "presentation": { "http://catalent.com/role/Leases": { "lang": { "en-us": { "role": { "terseLabel": "Lessee, Finance Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": { "r872" } } }, "us-gaap-LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": { "http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedIntheBalanceSheetDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r881", "r893" } } }, "us-gaap-LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": { "http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedIntheBalanceSheetDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." }


```
current statement of financial position date (rolling approach)."} } } ], "auth ref": {"r891"} } ], "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": {"http://catalent.com/role/LeasesScheduleofMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } } ], "auth ref": {"r891"} } ], "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": {"http://catalent.com/role/LeasesScheduleofMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } } ], "auth ref": {"r891"} } ], "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": {"http://catalent.com/role/LeasesScheduleofMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."} } } ], "auth ref": {"r891"} } ], "cItL_LesseeTermOfContract": {"xbrltype": "durationItemType", "nsuri": "http://catalent.com/20240630", "localname": "LesseeTermOfContract", "presentation": {"http://catalent.com/role/LeasesScheduleofOperatingAndFinanceLeasesPresentedInTheBalanceSheetDetails"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Lessee, Term of Contract", "label": "Lessee, Term of Contract", "documentation": "Lessee, Term of Contract"} } } ], "auth ref": {} } ], "us-gaap_LettersOfCreditOutstandingAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": {"http://catalent.com/role/LongTerm ObligationsAndOtherShortTermBorrowingsAdditionalInformationDetail"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Letters of Credit Outstanding, Amount", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."} } } ], "auth ref": {} } ], "us-gaap_Liabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": {"http://catalent.com/role/ConsolidatedBalanceSheets"} } ], "parentTag": {"us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": {"http://catalent.com/role/ConsolidatedBalanceSheets"} } ], "lang": {"en-us"}, {"role": {"totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."} } }, "auth ref": {"r37", "r141", "r142", "r143", "r146", "r147", "r148", "r151", "r328", "r426", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r789", "r793", "r794", "r847", "r1059", "r1160", "r1249", "r1438", "r1530", "r1531"} } ], "us-gaap_LiabilitiesAndStockholdersEquity": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": {"http://catalent.com/role/ConsolidatedBalanceSheets"} } ], "parentTag": {"us-gaap_LiabilitiesAndStockholdersEquity", "weight": null, "order": null, "root": true } }, "presentation": {"http://catalent.com/role/ConsolidatedBalanceSheets"} } ], "lang": {"en-us"}, {"role": {"totalLabel": "Total Liabilities, redeemable preferred stock, and shareholders'2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."} } } ], "auth ref": {"r159", "r232", "r969", "r1218", "r1376", "r1397", "r1512"} } ], "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": {"http://catalent.com/role/ConsolidatedBalanceSheets"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "LIABILITIES AND SHAREHOLDERS'2019 EQUITY", "label": "Liabilities and Equity [Abstract]"} } } ], "auth ref": {} } ], "us-gaap_LiabilitiesCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": {"http://catalent.com/role/ConsolidatedBalanceSheets"} } ], "parentTag": {"us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": {"http://catalent.com/role/ConsolidatedBalanceSheets"} } ], "lang": {"en-us"}, {"role": {"totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."} } } ], "auth ref": {"r143", "r272", "r328", "r426", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r789", "r793", "r794", "r847", "r1218", "r1438", "r1530", "r1531"} } ], "us-gaap_LiabilitiesCurrentAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": {"http://catalent.com/role/ConsolidatedBalanceSheets"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Current Liabilities", "label": "Liabilities, Current [Abstract]"} } } ], "auth ref": {} } ], "us-gaap_LinesOfCreditCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": {"http://catalent.com/role/LongTerm ObligationsAndOtherShortTermBorrowingsAdditionalInformationDetail"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Line of Credit, Current", "label": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long-term obligation to refinance the short-term obligation on a long-term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long-term basis and the following conditions are met: (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision; (2) no violation exists at the BS date; and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."} } } ], "auth ref": {"r141", "r227"} } ], "us-gaap_LoansAndLeasesReceivableGrossCarryingAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansAndLeasesReceivableGrossCarryingAmount", "crdr": "debit", "presentation": {"http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Loans and Leases Receivable, Gross", "label": "Loans and Leases Receivable, Gross", "documentation": "Amount before allowance of loans and leases held in portfolio, including but not limited to, commercial and consumer loans. Includes deferred interest and fees, undisbursed portion of loan balance, unamortized costs and premiums and discounts from face amounts. Excludes loans and leases covered under loss sharing agreements."} } } ], "auth ref": {"r241"} } ], "dei_LocalPhoneNumber": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": {"http://catalent.com/role/DocumentandEntityInformation"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity."} } } ], "auth ref": {} } ], "cItL_LongTermAndShortTermDebtAbstract": {"xbrltype": "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "LongTermAndShortTermDebtAbstract", "lang": {"en-us"}, {"role": {"label": "Long-term and Short-term Debt [Abstract]", "documentation": "Long-term and Short-term Debt [Abstract]"} } } } ], "auth ref": {} } ], "cItL_LongTermContractAssetsLongTerm": {"xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "LongTermContractAssetsLongTerm", "crdr": "debit", "presentation": {"http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Contract with Customer, Asset", "label": "Long-term contract assets Long Term", "documentation": "Long-term contract assets Long Term"} } } ], "auth ref": {} } ], "us-gaap_LongTermDebtAndCapitalLeaseObligations": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": {"http://catalent.com/role/ConsolidatedBalanceSheets"} } ], "parentTag": {"us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": {"http://catalent.com/role/ConsolidatedBalanceSheets"} } ], "http://catalent.com/role/LongTerm ObligationsAndOtherShortTermBorrowingsAdditionalInformationDetail"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Long-term Debt and Finance Lease Obligations", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."} } } ], "auth ref": {"r37", "r962"} } ], "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "crdr": "credit", "presentation": {"http://catalent.com/role/LongTerm ObligationsAndOtherShortTermBorrowingsMaturitiesDetails"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Total", "label": "Long-Term Debt and Lease Obligation, Including Current Maturities", "documentation": "Amount of long-term debt and lease obligation, including portion classified as current."} } } ], "auth ref": {} } ], "us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "presentation": {"http://catalent.com/role/LongTerm ObligationsAndOtherShortTermBorrowingsInterestRateDetails"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Long Term Debt and Capital Lease Obligations Repayments of Principal After Year Five", "label": "Long-Term Debt and Capital Lease Obligations, Maturities, Repayments of Principal after Year Five", "documentation": "Principal amount of long-term debt and capital lease obligation maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."} } } ], "auth ref": {} } ], "us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "presentation": {"http://catalent.com/role/LongTerm ObligationsAndOtherShortTermBorrowingsInterestRateDetails"} } ], "lang": {"en-us"}, {"role": {"terseLabel": "Long Term Debt and Capital Lease Obligations Repayments of Principal in Year Five", "label": "Long-Term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Five", "documentation": "Principal amount of long-term debt and capital lease obligation maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."} } } ], "auth ref
```

annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } } , "auth_ref": { } } , "us-gaap-LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": { } } } , "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails": { "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } } , "auth_ref": { "r37", "r1428", "r1429", "r1430" } } , "us-gaap-LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": { } } } , "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails": { "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } } , "auth_ref": { "r37", "r75", "r1428", "r1429", "r1430" } } , "us-gaap-LossContingencyEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyEstimateOfPossibleLoss", "crdr": "debit", "presentation": { } } , "http://catalent.com/role/CommitmentsandContingenciesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Estimate of Possible Loss", "label": "Loss Contingency, Estimate of Possible Loss", "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date." } } } , "auth_ref": { "r505", "r506", "r509", "r510", "r708", "r1177" } } , "cslt-LumpSumPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "LumpSumPaymentMember", "presentation": { } } , "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lump Sum Payment", "label": "Lump Sum Payment [Member]", "documentation": "Lump Sum Payment" } } } , "auth_ref": { } } , "cslt-MaSTherCellMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "MaSTherCellMember", "presentation": { } } , "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails": { "lang": { "en-us": { "role": { "terseLabel": "Business Combinations Purchase Agreement Details", "label": "Business Combinations Purchase Agreement Details", "documentation": "Business Combinations Tables" } } } , "auth_ref": { "r195" } } , "us-gaap-MachineryAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentGross", "crdr": "debit", "calculation": { } } , "http://catalent.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentDetail": { "parentTag": "us-gaap-PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 2.0 } , "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentDetail": { "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "label": "Machinery and Equipment, Gross", "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } } , "auth_ref": { "r195" } } , "us-gaap-MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": { } } } , "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Machinery and Equipment [Member]", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } } , "auth_ref": { } } , "cslt-ManufacturingCommercialProductSupplyMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "ManufacturingCommercialProductSupplyMember", "presentation": { } } , "http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebytypeofactivityandreportingsegmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Manufacturing & Commercial Product Supply [Member]", "label": "Manufacturing & Commercial Product Supply [Member]", "documentation": "Manufacturing & Commercial Product Supply [Member]" } } } , "auth_ref": { } } , "cslt-MarketMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "MarketMember", "presentation": { } } , "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Market [Member]", "label": "Market [Member]", "documentation": "Market" } } } , "auth_ref": { } } , "us-gaap-MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 5.0 } } , "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap-FairValueMeasuresandDisclosuresDetails", "weight": 1.0, "order": 5.0 } } , "http://catalent.com/role/IncomeTaxesBalanceSheetDetails": { "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } } , "auth_ref": { "r233", "r1358" } } , "us-gaap-MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": { } } , "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities [Table Text Block]", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } } , "auth_ref": { } } , "srt-MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { } } } , "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]", "documentation": "Maximum percentage of voting stock." } } } , "auth_ref": { "r505", "r506", "r507", "r508", "r639", "r708", "r826", "r911", "r1001", "r1003", "r1017", "r1050", "r1051", "r1109", "r1111", "r1113", "r1114", "r1123", "r1144", "r1145", "r1173", "r1183", "r1202", "r1212", "r1213", "r1214", "r1215", "r1229", "r1440", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537" } } , "cslt-MaximumPercentageOfVotingStock": { "xbrltype": "percentItemType", "nsuri": "http://catalent.com/20240630", "localname": "MaximumPercentageOfVotingStock", "presentation": { } } , "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Maximum Percentage Of Voting Stock from non US subsidiary", "label": "Maximum Percentage Of Voting Stock", "documentation": "Maximum percentage of voting stock." } } } , "auth_ref": { } } , "ecd-MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { } } , "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Measure", "label": "Measure [Axis]", "documentation": "Normalized StringItemType" } } } , "auth_ref": { "r1300" } } , "ecd-MeasureName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": { } } , "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name", "documentation": "Normalized StringItemType" } } } , "auth_ref": { "r1300" } } , "cslt-MergerAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "MergerAgreementMember", "presentation": { } } , "http://catalent.com/role/CommitmentsandContingenciesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Merger Agreement [Member]", "label": "Merger Agreement [Member]", "documentation": "Merger Agreement" } } } , "auth_ref": { } } , "cslt-MetricsMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "MetricsMember", "presentation": { } } , "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails": { "lang": { "en-us": { "role": { "terseLabel": "Metrics", "label": "Metrics [Member]", "documentation": "Metrics" } } } , "auth_ref": { } } , "srt-MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { } } } , "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]", "documentation": "Minimum percentage of voting stock." } } } , "auth_ref": { "r505", "r506", "r507", "r508", "r639", "r708", "r826", "r911", "r1001", "r1003", "r1017", "r1050", "r1051", "r1109", "r1111", "r1113", "r1114", "r1123", "r1144", "r1145", "r1173", "r1183", "r1202", "r1212", "r1213", "r1214", "r1215", "r1229", "r1440", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537" } } , "ecd-MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": { } } , "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "documentation": "Material Terms of Trading Arrangement" } } } , "auth_ref": { "r1319" } } , "ecd-MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": { } } , "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]", "documentation": "Material Terms of Trading Arrangement" } } } , "auth_ref": { "r1327" } } , "us-gaap-MultiemployerPlanPensionSignificantFutureEmployerContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MultiemployerPlanPensionSignificantFutureEmployerContributionAmount", "crdr": "debit", "presentation": { } } , "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Multiemployer Plan, Pension, Significant, Future Employer Contribution, Amount", "label": "Multiemployer Plan, Pension, Significant, Future Employer Contribution, Amount", "documentation": "Amount of cost for employer contribution required to be made in future period to multiemployer pension plan determined to be individually significant. Includes, but is not limited to, employer contribution required by collective bargaining arrangement (CBA), statutory obligation, and other contractual obligation." } } } , "auth_ref": { "r660", "r1202" } } , "cslt-MultiemployerPlansEstimatedAnnualCashContribution": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "MultiemployerPlansEstimatedAnnualCashContribution", "crdr": "credit", "presentation": { } } , "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Multiemployer Plans, Estimated Annual Cash Contribution", "label": "Multiemployer Plans, Estimated Annual Cash Contribution", "documentation": "Multiemployer Plans, Estimated Annual Cash Contribution" } } } , "auth_ref": { } } , "ecd-NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { } } , "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]", "documentation": "Net Assets Acquired LineItems" } } } , "auth_ref": { "r1301" } } , "cslt-NetAssetsAcquiredLineItems": { "xbrltype": "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "NetAssetsAcquiredLineItems", "presentation": { } } , "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net Assets Acquired [Line Items]", "label": "Net Assets Acquired [Line Items]", "documentation": "Net Assets Acquired" } } } , "auth_ref": { } } , "us-gaap-NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } } , "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } } , "auth_ref": { "r321" } } , "us-gaap-NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { } } , "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "documentation": "Net Cash Provided by (Used in) Investing Activities" } } } , "auth_ref": { } } , "us-gaap-NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } } , "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "documentation": "Net Cash Provided by (Used in) Investing Activities" } } } , "auth_ref": { } } , "us-

gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by (Used in) Operating Activities Total", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r185", "r186", "r187" } }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "auth_ref": { "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquity": { "http://catalent.com/role/ConsolidatedStatementsOfOperations": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "totalLabel": "Net earnings attributable to Catalent", "terseLabel": "Net Income (Loss) Attributable to Parent", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r173", "r187", "r235", "r270", "r302", "r303", "r310", "r328", "r336", "r340", "r341", "r343", "r344", "r345", "r349", "r350", "r360", "r426", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r770", "r786", "r820", "r847", "r976", "r1083", "r1101", "r1102", "r1247", "r1438" } } }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfOperations": { "http://catalent.com/role/EarningsPerShareCalculationOfEarningsPerShareDetails": { "lang": { "en-us": { "role": { "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": { "r316", "r340", "r341", "r343", "r344", "r353", "r354", "r361", "r364", "r786" } } }, "ctlt_NetProceedsUsedToRepayDebtStockIssuedDuringPeriodNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "NetProceedsUsedToRepayDebtStockIssuedDuringPeriodNewIssues", "crdr": "debit", "presentation": { "http://catalent.com/role/EquityAndAccumulatedOtherComprehensiveIncomeLossEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net Proceeds used to Repay Debt Stock Issued During Period, New Issues", "label": "Net Proceeds used to Repay Debt Stock Issued During Period, New Issues", "documentation": "Net Proceeds used to Repay Debt Stock Issued During Period, New Issues" } } }, "auth_ref": { "us-gaap_NewAccountingPrinciplesOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPrinciplesOrChangeInAccountingPrincipleLineItems", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryOfSignificantAccountingPoliciesRecentFinancialAccountingStandardsDetails": { "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r262", "r263", "r264", "r265", "r266", "r267", "r335", "r336", "r337", "r338", "r339", "r343", "r351", "r369", "r416", "r417", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489", "r1490", "r1491", "r1492", "r1493", "r1494", "r1495", "r1496", "r1497", "r1498", "r1499", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604", "r1605", "r1606", "r1607", "r1608", "r1609", "r1610", "r1611", "r1612", "r1613", "r1614", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1643", "r1644", "r1645", "r1646", "r1647", "r1648", "r1649", "r1650", "r1651", "r1652", "r1653", "r1654", "r1655", "r1656", "r1657", "r1658", "r1659", "r1660", "r1661", "r1662", "r1663", "r1664", "r1665", "r1666", "r1667", "r1668", "r1669", "r1670", "r1671", "r1672", "r1673", "r1674", "r1675", "r1676", "r1677", "r1678", "r1679", "r1680", "r1681", "r1682", "r1683", "r1684", "r1685", "r1686", "r1687", "r1688", "r1689", "r1690", "r1691", "r1692", "r1693", "r1694", "r1695", "r1696", "r1697", "r1698", "r1699", "r1700", "r1701", "r1702", "r1703", "r1704", "r1705", "r1706", "r1707", "r1708", "r1709", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1716", "r1717", "r1718", "r1719", "r1720", "r1721", "r1722", "r1723", "r1724", "r1725", "r1726", "r1727", "r1728", "r1729", "r1730", "r1731", "r1732", "r1733", "r1734", "r1735", "r1736", "r1737", "r1738", "r1739", "r1740", "r1741", "r1742", "r1743", "r1744", "r1745", "r1746", "r1747", "r1748", "r1749", "r1750", "r1751", "r1752", "r1753", "r1754", "r1755", "r1756", "r1757", "r1758", "r1759", "r1760", "r1761", "r1762", "r1763", "r1764", "r1765", "r1766", "r1767", "r1768", "r1769", "r1770", "r1771", "r1772", "r1773", "r1774", "r1775", "r1776", "r1777", "r1778", "r1779", "r1780", "r1781", "r1782", "r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1820", "r1821", "r1822", "r1823", "r1824", "r1825", "r1826", "r1827", "r1828", "r1829", "r1830", "r1831", "r1832", "r1833", "r1834", "r1835", "r1836", "r1837", "r1838", "r1839", "r1840", "r1841", "r1842", "r1843", "r1844", "r1845", "r1846", "r1847", "r1848", "r1849", "r1850", "r1851", "r1852", "r1853", "r1854", "r1855", "r1856", "r1857", "r1858", "r1859", "r1860", "r1861", "r1862", "r1863", "r1864", "r1865", "r1866", "r1867", "r1868", "r1869", "r1870", "r1871", "r1872", "r1873", "r1874", "r1875", "r1876", "r1877", "r1878", "r1879", "r1880", "r1881", "r1882", "r1883", "r1884", "r1885", "r1886", "r1887", "r1888", "r1889", "r1890", "r1891", "r1892", "r1893", "r1894", "r1895", "r1896", "r1897", "r1898", "r1899", "r1900", "r1901", "r1902", "r1903", "r1904", "r1905", "r1906", "r1907", "r1908", "r1909", "r1910", "r1911", "r1912", "r1913", "r1914", "r1915", "r1916", "r1917", "r1918", "r1919", "r1920", "r1921", "r1922", "r1923", "r1924", "r1925", "r1926", "r1927", "r1928", "r1929", "r1930", "r1931", "r1932", "r1933", "r1934", "r1935", "r1936", "r1937", "r1938", "r1939", "r1940", "r1941", "r1942", "r1943", "r1944", "r1945", "r1946", "r1947", "r1948", "r1949", "r1950", "r1951", "r1952", "r1953", "r1954", "r1955", "r1956", "r1957", "r1958", "r1959", "r1960", "r1961", "r1962", "r1963", "r1964", "r1965", "r1966", "r1967", "r1968", "r1969", "r1970", "r1971", "r1972", "r1973", "r1974", "r1975", "r1976", "r1977", "r1978", "r1979", "r1980", "r1981", "r1982", "r1983", "r1984", "r1985", "r1986", "r1987", "r1988", "r1989", "r1990", "r1991", "r1992", "r1993", "r1994", "r1995", "r1996", "r1997", "r1998", "r1999", "r2000", "r2001", "r2002", "r2003", "r2004", "r2005", "r2006", "r2007", "r2008", "r2009", "r2010", "r2011", "r2012", "r2013", "r2014", "r2015", "r2016", "r2017", "r2018", "r2019", "r2020", "r2021", "r2022", "r2023", "r2024", "r2025",

"documentation": "The net result for the period of deducting operating expenses from operating revenues." } } } , "auth_ref": { "r239", "r1161", "r1388", "r1390", "r1391", "r1392", "r1393" } } , "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": { "http://catalent.com/role/LeasesCostDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } } , "auth_ref": { "r884", "r1217" } } , "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": { "http://catalent.com/role/LeasesCostDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } } , "auth_ref": { "r1524" } } , "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRecentFinancialAccountingStandardsDetails", "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } } , "auth_ref": { "r875" } } , "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": { "http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedIntheBalanceSheetDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } } , "auth_ref": { "r875" } } , "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": { "http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedIntheBalanceSheetDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } } , "auth_ref": { "r875" } } , "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList", "presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRecentFinancialAccountingStandardsDetails", "http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedIntheBalanceSheetDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease liability." } } } , "auth_ref": { "r876" } } , "cslt_OperatingLeaseLiabilityToBePaidGreaterThanOrEqualTo": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "OperatingLeaseLiabilityToBePaidGreaterThanOrEqualTo", "crdr": "credit", "presentation": { "http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedIntheBalanceSheetDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, to be Paid, Greater than Year One", "label": "Operating Lease, Liability, to be Paid, Greater than Year One", "documentation": "Operating Lease, Liability, to be Paid, Greater than Year One" } } } , "auth_ref": { } } , "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://catalent.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } } , "auth_ref": { "r880", "r887" } } , "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": { "http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedIntheBalanceSheetDetails", "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail" } , "lang": { "en-us": { "role": { "verboseLabel": "Operating Lease, Right-of-Use Asset", "terseLabel": "Deferred Income Tax, Right-of-Use Asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } } , "auth_ref": { "r874" } } , "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": { "http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedIntheBalanceSheetDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } } , "auth_ref": { "r876" } } , "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://catalent.com/role/LeasesCostDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } } , "auth_ref": { "r890", "r1217" } } , "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm", "presentation": { "http://catalent.com/role/LeasesCostDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease. In 'PnYnMnDnFnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } } , "auth_ref": { "r889", "r1217" } } , "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } } , "auth_ref": { "r750" } } , "cslt_OperatingLossCarryforwardsCarryForwardPeriod": { "xbrltype": "durationItemType", "nsuri": "http://catalent.com/20240630", "localname": "OperatingLossCarryforwardsCarryForwardPeriod", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards, Carry Forward Period", "label": "Operating Loss Carryforwards, Carry Forward Period", "documentation": "Operating Loss Carryforwards, Carry Forward Period" } } } , "auth_ref": { } } , "cslt_OperatingLossCarryforwardsIndefiniteLife": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "OperatingLossCarryforwardsIndefiniteLife", "crdr": "debit", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards, Indefinite Life", "label": "Operating Loss Carryforwards, Indefinite Life", "documentation": "Operating Loss Carryforwards, Indefinite Life" } } } , "auth_ref": { } } , "cslt_OperatingLossCarryforwardsSubjectToLimitationsSection382": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "OperatingLossCarryforwardsSubjectToLimitationsSection382", "crdr": "debit", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards, Subject to Limitations, Section 382", "label": "Operating Loss Carryforwards, Subject to Limitations, Section 382", "documentation": "Operating Loss Carryforwards, Subject to Limitations, Section 382" } } } , "auth_ref": { } } , "cslt_OperatingSegmentsExcludingIntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "OperatingSegmentsExcludingIntersegmentEliminationMember", "presentation": { "http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebyTypeofactivityandreportingsegmentDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Segments Excluding Intersegment Elimination", "label": "Operating Segments Excluding Intersegment Elimination [Member]", "documentation": "Operating Segments Excluding Intersegment Elimination" } } } , "auth_ref": { } } , "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": { "http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebyTypeofactivityandreportingsegmentDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } } , "auth_ref": { "r401", "r402", "r403", "r404", "r405", "r408", "r1167", "r1168" } } , "cslt_OralAndSpecialtyDeliveryMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "OralAndSpecialtyDeliveryMember", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", "http://catalent.com/role/SegmentInformationCapitalExpendituresDetails", "http://catalent.com/role/SegmentInformationDepreciationandAmortizationDetails", "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "http://catalent.com/role/SegmentInformationTotalAssetsDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Oral and Specialty Drug Delivery [Member]", "label": "Oral and Specialty Delivery [Member]", "documentation": "Oral and Specialty Delivery [Member]" } } } , "auth_ref": { } } , "cslt_OralDrugDeliveryMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "OralDrugDeliveryMember", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", "http://catalent.com/role/SegmentInformationCapitalExpendituresDetails", "http://catalent.com/role/SegmentInformationDepreciationandAmortizationDetails", "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "http://catalent.com/role/SegmentInformationTotalAssetsDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Oral Drug Delivery [Member]", "label": "Oral Drug Delivery [Member]", "documentation": "Oral Drug Delivery [Member]" } } } , "auth_ref": { } } , "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } , "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets", "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other accrued liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } } , "auth_ref": { "r142" } } , "cslt_OtherAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://catalent.com/20240630", "localname": "OtherAccruedLiabilitiesTableTextBlock", "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationTables" } , "lang": { "en-us": { "role": { "terseLabel": "Other Accrued Liabilities", "label": "Other Accrued Liabilities Table [Text Block]", "documentation": "Other accrued liabilities." } } } , "auth_ref": { } } , "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsAbstract", "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets" } , "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets [Abstract]", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } } , "auth_ref": { } } , "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationPrepaidandOtherAssetsDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } } , "auth_ref": { "r290", "r1216" } } , "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMember", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Other Assets [Member]", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } } , "auth_ref": { "r113", "r120" } } , "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMiscellaneousNoncurrent", "crdr": "debit", "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Other Assets, Miscellaneous, Noncurrent", "label": "Other Assets, Miscellaneous, Noncurrent", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } } , "auth_ref": { } } , "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } } , "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets", "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail", "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Other Assets, Noncurrent", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } } , "auth_ref": { "r229" } } , "us-gaap_OtherCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsAbstract", "presentation": { "http://catalent.com/role/CommitmentsandContingenciesAdditionalInformationDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Abstract]", "label": "Other Commitments [Abstract]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": { } } , "us-

gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTable", "presentation": { "http://catalent.com/role/CommitmentsandContingenciesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Table]", "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": { } }, "us-gaap_OtherCommitmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTableTextBlock", "presentation": { "http://catalent.com/role/CommitmentsandContingenciesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Table Text Block]", "label": "Other Commitments [Table Text Block]", "documentation": "Tabular disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": { } }, "cslt_OtherComprehensiveIncomeDefinedBenefitPlanExchangeRateGainLossRecognizedDuringYear": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "OtherComprehensiveIncomeDefinedBenefitPlanExchangeRateGainLossRecognizedDuringYear", "crdr": "credit", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails": { "lang": { "en-us": { "role": { "terseLabel": "Exchange rate gain/(loss) recognized during the year", "label": "Other Comprehensive Income Defined Benefit Plan Exchange Rate Gain Loss Recognized During Year", "documentation": "Other comprehensive income defined benefit plan exchange rate gain loss recognized." } } }, "auth_ref": { } }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax", "crdr": "debit", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax", "documentation": "Amount, after tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "auth_ref": { "r7": "r167", "r627" } } }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "crdr": "credit", "calculation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0, "order": 2.0 }, "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net (gain)/loss recognized during the year", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCL before Tax", "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan." } } }, "auth_ref": { "r11": "r167", "r301", "r627" } } }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "crdr": "credit", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "terseLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": { "r295": "r296", "r298", "r977" } } }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 3.0 }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": { "r295": "r296", "r298", "r977" } } }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "crdr": "debit", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": { "r295": "r296", "r299", "r977" } } }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "crdr": "credit", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "auth_ref": { "r42": "r309", "r855", "r858", "r862", "r977", "r1366" } } }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "auth_ref": { "r36": "r42", "r309", "r855", "r858", "r862", "r977", "r1366" } } }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "crdr": "credit", "presentation": { "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax", "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": { "r294": "r298", "r977" } } }, "cslt_OtherComprehensiveIncomeLossDerivativeAndHedgeAfterReclassificationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "OtherComprehensiveIncomeLossDerivativeAndHedgeAfterReclassificationAdjustmentTax", "crdr": "debit", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Derivative and Hedge, (Income) Loss", "label": "Other Comprehensive (Income) Loss, Derivative and Hedge, after Reclassification Adjustment, Tax", "documentation": "Other Comprehensive (Income) Loss, Derivative and Hedge, after Reclassification Adjustment, Tax", "auth_ref": { } }, "cslt_OtherComprehensiveIncomeLossDerivativeAndHedgeGainLossArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "OtherComprehensiveIncomeLossDerivativeAndHedgeGainLossArisingDuringPeriodBeforeTax", "crdr": "debit", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net Derivative and Hedge (gain)/loss arising during the year", "label": "Other Comprehensive Income (Loss), Derivative and Hedge, Gain (Loss) Arising During Period, before Tax", "documentation": "Other Comprehensive Income (Loss), Derivative and Hedge, Gain (Loss) Arising During Period, before Tax", "auth_ref": { } }, "cslt_OtherComprehensiveIncomeLossDerivativeAndHedgeTotalBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "OtherComprehensiveIncomeLossDerivativeAndHedgeTotalBeforeTax", "crdr": "debit", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Derivative and Hedge, Total, before Tax", "label": "Other Comprehensive Income (Loss), Derivative and Hedge, Total, before Tax", "documentation": "Other Comprehensive Income (Loss), Derivative and Hedge, Total, before Tax", "auth_ref": { } }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "calculation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "parentTag": "us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease", "weight": -1.0, "order": 1.0 }, "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total foreign currency translation adjustments, pretax", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r5": "r167", "r977" } } }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r5": "r977" } } }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "crdr": "debit", "calculation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "parentTag": "us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease", "weight": -1.0, "order": 2.0 }, "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions

designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } } , "auth_ref": { "r5", "r9", "r852", "r861" } } } , "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity": { "http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "http://catalent.com/role/EquityAndAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails": { "lang": { "en-us": { "role": { "negatedTotalLabel": "Other comprehensive income (loss), net of tax", "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } } } } } } } } , "auth_ref": { "r27", "r36", "r303", "r306", "r312", "r345", "r855", "r856", "r862", "r955", "r977", "r1366", "r1367" } } } , "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } } } } } , "auth_ref": { "r7", "r8", "r166", "r167", "r977", "r1194", "r1450" } } } , "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "crdr": "debit", "calculation": { "http://catalent.com/role/EquityAndAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": 1.0, "order": 1.0 } } , "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } } , "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails": { "http://catalent.com/role/EquityAndAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "negatedTotalLabel": "Total minimum pension liability, pretax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } } } } } } } } , "auth_ref": { "r7", "r8", "r166", "r167", "r977", "r1194", "r1450" } } } , "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } } , "http://catalent.com/role/EquityAndAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "http://catalent.com/role/EquityAndAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails": { "http://catalent.com/role/EquityAndAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } } } } } } } } , "auth_ref": { "r7", "r8", "r166", "r167", "r977" } } } , "cslt_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetPriorServiceCostCreditArisingDuringYearBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetPriorServiceCostCreditArisingDuringYearBeforeTax", "crdr": "debit", "calculation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0, "order": 2.0 } } } , "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Prior service cost (credit) during the year", "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Arising During the Year, before Tax", "documentation": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Arising During the Year, before Tax" } } } } } } , "auth_ref": { "r7", "r8", "r166", "r167", "r977" } } } , "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "crdr": "credit", "calculation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0, "order": 1.0 } } , "http://catalent.com/role/EquityAndAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0, "order": 1.0 } } } , "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails": { "http://catalent.com/role/EquityAndAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net (gain)/loss arising during the year", "negatedTerseLabel": "Net gain/(loss) arising during the year", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } } } } } } } } , "auth_ref": { "r166", "r167", "r209" } } } , "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "crdr": "credit", "calculation": { "http://catalent.com/role/EquityAndAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": 1.0, "order": 2.0 } } } , "presentation": { "http://catalent.com/role/EquityAndAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Pension liability tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan." } } } } } } } } } , "auth_ref": { "r7", "r8", "r9", "r166", "r221" } } } , "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCI PensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCI PensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationBeforeTax", "crdr": "debit", "calculation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0, "order": 3.0 } } } , "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails": { "lang": { "en-us": { "role": { "terseLabel": "Transition asset (obligation) recognized during the year", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), Reclassification Adjustment from AOCI, before Tax", "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan." } } } } } } } } } , "auth_ref": { "r11", "r167", "r301", "r627" } } } , "us-gaap_OtherComprehensiveIncomeOtherNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeOtherNetOfTax", "crdr": "credit", "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income, Other, Net of Tax", "label": "Other Comprehensive Income, Other, Net of Tax", "documentation": "Amount of increase (decrease) in other comprehensive income, after tax, from changes classified as other." } } } } } } , "auth_ref": { "r7", "r8", "r9", "r166", "r221" } } } , "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "crdr": "credit", "presentation": { "http://catalent.com/role/EquityAndAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Securities, Available for Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax", "label": "OCI, Debt Securities, Available for Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } } } } } } } } , "auth_ref": { "r295", "r298", "r425" } } } , "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": { "http://catalent.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Net accumulated gain related to investment hedges", "label": "OCI, Debt Securities, Available for Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } } } } } } } } , "auth_ref": { "r295", "r298", "r425" } } } , "us-gaap_OtherCostAndExpenseOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCostAndExpenseOperating", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 3.0 } } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "terseLabel": "Other Cost and Expense, Operating", "label": "Other Cost and Expense, Operating", "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation." } } } } } } , "auth_ref": { "r174", "r980", "r1167" } } } , "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]" } } } } , "auth_ref": { "r7", "r8", "r166", "r167", "r977" } } } , "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": { "http://catalent.com/role/OtherIncomeExpense": { "lang": { "en-us": { "role": { "terseLabel": "Other Income and Other Expense Disclosure", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } } } } } } } } , "auth_ref": { "r1355", "r1482" } } } , "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": { "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails": { "http://catalent.com/role/DefiniteLivedLongLivedAssetsOtherIntangibleAssetsSubjecttoAmortizationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Other Intangible Assets [Member]", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } } } } } } } } , "auth_ref": { "r1176", "r1413", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1422", "r1423", "r1424" } } } , "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } } } , "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail": { "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities and expenses", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } } } } } , "auth_ref": { "r142", "r1218" } } } , "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } } } , "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } } } } } } } } , "auth_ref": { "r147" } } } , "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail": { "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other

noncurrent assets." } } } , "auth_ref": { } } , "us-gaap-OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingExpense", "crdr": "debit", "presentation": { "http://catalent.com/role/OtherIncomeExpenseDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Other Nonoperating Expense", "label": "Other Nonoperating Expense", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } } , "auth_ref": { "r178" } } , "us-gaap-OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": { "http://catalent.com/role/OtherIncomeExpenseDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Other Nonoperating Income (Expense)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } } , "auth_ref": { "r179" } } , "us-gaap-OtherNonrecurringIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonrecurringIncomeExpense", "crdr": "debit", "calculation": { "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail": { "parentTag": "cslt_SegmentReportingInformationUnallocatedExpense", "weight": 1.0, "order": 5.0 } } , "presentation": { "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail" } , "lang": { "en-us": { "role": { "negatedTerseLabel": "Other income (expense), net", "label": "Other Nonrecurring (Income) Expense", "documentation": "Amount of other expense (income) that is infrequent in occurrence or unusual in nature." } } } , "auth_ref": { "r179" } } , "cslt_OtherObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "OtherObligationsMember", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Other Obligations {Member}", "label": "Other Obligations {Member}", "documentation": "Other Obligations {Member}" } } } , "auth_ref": { } } , "us-gaap-OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows" } , "lang": { "en-us": { "role": { "terseLabel": "Other Operating Activities, Cash Flow Statement", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } } , "auth_ref": { } } , "ecsd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } } , "auth_ref": { "r1300" } } , "us-gaap-OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Other Post Retirement Benefits {Member}", "label": "Other Postretirement Benefits Plan {Member}", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } } } , "auth_ref": { "r583", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r610", "r611", "r612", "r613", "r614", "r615", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r631", "r632", "r634", "r637", "r640", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" } } } , "us-gaap-OtherShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherShortTermBorrowings", "crdr": "credit", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Other Short-Term Borrowings", "label": "Other Short-Term Borrowings", "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer." } } } , "auth_ref": { "r139", "r1038" } } , "cslt_OtherUnobservableAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "OtherUnobservableAssetsMember", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details" } , "lang": { "en-us": { "role": { "terseLabel": "Other Unobservable Assets {Member}", "label": "Other Unobservable Assets {Member}", "documentation": "Other Unobservable Assets {Member}" } } } , "auth_ref": { } } , "ecsd-OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } , "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } } , "auth_ref": { "r1261", "r1272", "r1282", "r1314" } } , "ecsd-OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } , "lang": { "en-us": { "role": { "terseLabel": "Outstanding Recovery Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } } , "auth_ref": { "r1264", "r1275", "r1285", "r1317" } } , "ecsd-OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } , "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } } , "auth_ref": { "r1264", "r1275", "r1285", "r1317" } } , "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": { "http://catalent.com/role/BusinessCombinationsDivestituresDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Ownership {Axis}", "label": "Ownership {Axis}" } } } , "auth_ref": { } } , "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": { "http://catalent.com/role/BusinessCombinationsDivestituresDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Ownership {Domain}", "label": "Ownership {Domain}" } } } , "auth_ref": { } } , "cslt_OxfordMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "OxfordMember", "presentation": { "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Oxford", "label": "Oxford {Member}", "documentation": "Oxford" } } } , "auth_ref": { } } , "cslt_ParagonMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "ParagonMember", "presentation": { "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "http://catalent.com/role/BusinessCombinationsTables", "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Paragon {Member}", "label": "Paragon {Member}", "documentation": "Paragon" } } } , "auth_ref": { } } , "us-gaap-ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementsofOperations", "http://catalent.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" } , "lang": { "en-us": { "role": { "negatedTerseLabel": "Participating Securities, Distributed and Undistributed (Earnings) Loss, Basic", "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic", "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method." } } } , "auth_ref": { "r361", "r1339" } } , "ecsd-PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure {Line Items}" } } } , "auth_ref": { "r1289" } } , "cslt_PaymentsAndAccrualsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "PaymentsAndAccrualsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": { "http://catalent.com/role/SegmentInformationCapitalExpendituresDetails", "http://catalent.com/role/SupplementalBalanceSheetInformationPrepaidandOtherAssetsDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Payments and Accruals to Acquire Property, Plant, and Equipment", "label": "Payments and Accruals to Acquire Property, Plant, and Equipment", "documentation": "Payments and Accruals to Acquire Property, Plant, and Equipment" } } } , "auth_ref": { } } , "us-gaap-PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Payments for Restructuring", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } } , "auth_ref": { "r495", "r1371" } } , "us-gaap-PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows" } , "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of Debt Issuance Costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } } , "auth_ref": { "r472" } } , "us-gaap-PaymentsOfOrdinaryDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfOrdinaryDividends", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows" } , "lang": { "en-us": { "role": { "terseLabel": "Payments of Ordinary Dividends", "label": "Payments of Ordinary Dividends", "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings." } } } , "auth_ref": { "r183" } } , "us-gaap-PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": { "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "http://catalent.com/role/EquityDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Payments of Stock Issuance Costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } } , "auth_ref": { "r46" } } , "us-gaap-PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://catalent.com/role/ConsolidatedStatementsofCashFlows", "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } , "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments Related to Tax Withholding for Share-based Compensation", "terseLabel": "Payments Related to Tax Withholding for Share-based Compensation", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } } , "auth_ref": { "r318" } } , "us-gaap-PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows" } , "lang": { "en-us": { "role": { "terseLabel": "Payments to Acquire Debt Securities, Available for Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } } , "auth_ref": { "r44", "r317", "r424" } } , "us-gaap-PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Payments to Acquire Businesses, Gross", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } } , "auth_ref": { "r45", "r780" } } , "us-gaap-PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } } , "presentation": { "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails", "http://catalent.com/role/ConsolidatedStatementsofCashFlows" } , "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment for acquisitions, net of cash acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } } , "auth_ref": { "r45" } } , "us-gaap-PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 8.0 } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows" } , "lang": { "en-us": { "role": { "terseLabel": "Payments to Acquire Investments", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other." } } } , "auth_ref": { "r181" } } , "us-gaap-PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "calculation": {

```

    "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 },
    "presentation": "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "negatedTerseLabel", "Segment": "Expenditure", "Addition to Long-Lived Assets": "label", "Payments to Acquire Productive Assets": "documentation", "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "auth_ref": "r245", "r1495", "r1496", "r1497", "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": "http://catalent.com/role/SegmentInformationCapitalExpendituresDetails",
    "http://catalent.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetail", "lang": "en-us", "role": "terseLabel", "Capital expenditures": "label", "Payments to Acquire Property, Plant, and Equipment": "documentation", "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "auth_ref": "r182", "ecd_PeerGroupIssuersFnTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Peer Group Issuers, Footnote": "label", "Peer Group Issuers, Footnote [Text Block]", "auth_ref": "r129", "ecd_PeerGroupTotalShareholderRtnAmt", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Peer Group Total Shareholder Return Amount": "label", "Peer Group Total Shareholder Return Amount", "auth_ref": "r1299", "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlans", "lang": "en-us", "role": "terseLabel", "Employee Retirement Benefit Plans": "label", "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits.", "auth_ref": "r582", "r607", "r609", "r615", "r633", "r635", "r636", "r637", "r638", "r639", "r653", "r654", "r656", "r1194", "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "crdr": "credit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "negatedTerseLabel", "Current liabilities": "label", "Liability: Defined Benefit Plan, Current": "documentation", "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "auth_ref": "r142", "r583", "r584", "r606", "r1194", "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "lang": "en-us", "role": "negatedTerseLabel", "Noncurrent liabilities": "label", "Liability: Defined Benefit Plan, Noncurrent": "documentation", "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "auth_ref": "r147", "r583", "r584", "r606", "r1194", "us-gaap_PensionAndOtherPostretirementPlansPolicy", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementPlansPolicy", "presentation": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesPolicies", "lang": "en-us", "role": "terseLabel", "Post-Retirement and Pension Plans": "label", "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "auth_ref": "r19", "r20", "r21", "r29", "r90", "cctl_PensionAsset", "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "PensionAsset", "crdr": "debit", "presentation": "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail", "lang": "en-us", "role": "terseLabel", "Pension Asset": "label", "Pension Asset": "documentation", "Pension Asset", "auth_ref": "cctl_PensionAssets", "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "PensionAssets", "crdr": "debit", "presentation": "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail", "lang": "en-us", "role": "terseLabel", "Pension assets": "label", "Pension assets": "documentation", "Pension assets", "auth_ref": "us-gaap_PensionPlansDefinedBenefitMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionPlansDefinedBenefitMember", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails", "lang": "en-us", "role": "terseLabel", "Retirement Benefits [Member]": "label", "Pension Plan [Member]": "documentation", "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "auth_ref": "r583", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r631", "r632", "r634", "r637", "r640", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r656", "r657", "r661", "r1194", "r1195", "r1199", "r1200", "r1201", "ecd_PeoActuallyPaidCompAmt", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "PEO Actually Paid Compensation Amount": "label", "PEO Actually Paid Compensation Amount", "auth_ref": "r1291", "ecd_PeoMember", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "PEO": "label", "PEO [Member]", "auth_ref": "r1308", "ecd_PeoName", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "PEO Name": "label", "PEO Name", "auth_ref": "r1301", "ecd_PeoTotalCompAmt", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "PEO Total Compensation Amount": "label", "PEO Total Compensation Amount", "auth_ref": "r1290", "cctl_PerformanceMember", "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "PerformanceMember", "presentation": "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Performance Shares [Member]": "label", "Performance Shares [Member]": "documentation", "Share-based payment arrangement awarded for meeting performance target.", "auth_ref": "cctl_PharmaConsumerHealthMember", "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "PharmaConsumerHealthMember", "presentation": "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", "http://catalent.com/role/RestructuringandOtherCostsDetails", "http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebytypeofactivityandreportingsegmentDetails", "http://catalent.com/role/RevenuefromContractwithCustomerDetails", "http://catalent.com/role/SegmentInformationCapitalExpendituresDetails", "http://catalent.com/role/SegmentInformationDepreciationandAmortizationDetails", "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "http://catalent.com/role/SegmentInformationTotalAssetsDetails", "http://catalent.com/role/SubsequentEventsDetails", "lang": "en-us", "role": "terseLabel", "PharmaConsumerHealth": "label", "PharmaConsumerHealth [Member]": "documentation", "PharmaConsumerHealth", "auth_ref": "us-gaap_PlanAssetCategoriesDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanAssetCategoriesDomain", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails", "lang": "en-us", "role": "terseLabel", "Defined Benefit Plan, Plan Assets, Category [Domain]": "label", "Defined Benefit Plan, Plan Assets, Category [Domain]": "documentation", "Defined benefit plan asset investment.", "auth_ref": "r607", "r608", "r610", "r611", "r612", "r613", "r614", "r615", "r634", "r1192", "r1193", "r1194", "us-gaap_PlanNameAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": "http://catalent.com/role/EquityBasedCompensationAdditionalDetails", "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails", "lang": "en-us", "role": "terseLabel", "Plan Name [Axis]": "label", "Plan Name [Axis]": "documentation", "Information by plan name for share-based payment arrangement.", "auth_ref": "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "us-gaap_PlanNameDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": "http://catalent.com/role/EquityBasedCompensationAdditionalDetails", "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails", "lang": "en-us", "role": "terseLabel", "Plan Name [Domain]": "label", "Plan Name [Domain]": "documentation", "Plan name for share-based payment arrangement.", "auth_ref": "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "
```

```
"http://catalent.com/20240630", "localname": "Preferred Stock Issuance Value", "crdr": "credit", "presentation": "http://fasb.org/us-gaap/2024", "role": "EquityDetails", "label": "Preferred Stock, Issuance Value", "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "auth_ref": "r43"}, {"http://catalent.com/20240630", "localname": "Preferred Stock, Issuance Value, Net", "crdr": "debit", "presentation": "http://fasb.org/us-gaap/2024", "role": "EquityDetails", "label": "Preferred Stock, Issuance Value, Net", "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "auth_ref": "r43"}, {"http://catalent.com/20240630", "localname": "Preferred Stock, Shares Authorized", "crdr": "credit", "presentation": "http://fasb.org/us-gaap/2024", "role": "EquityDetails", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "auth_ref": "r153", "r1061"}, {"http://catalent.com/20240630", "localname": "Preferred Stock, Shares Issued", "crdr": "debit", "presentation": "http://fasb.org/us-gaap/2024", "role": "EquityDetails", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.", "auth_ref": "r153", "r553"}, {"http://catalent.com/20240630", "localname": "Preferred Stock, Shares Outstanding", "crdr": "debit", "presentation": "http://fasb.org/us-gaap/2024", "role": "EquityDetails", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "auth_ref": "r153", "r1061"}, {"http://catalent.com/20240630", "localname": "Preferred Stock, Value Issued", "crdr": "debit", "presentation": "http://fasb.org/us-gaap/2024", "role": "EquityDetails", "label": "Preferred Stock, Value Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "auth_ref": "r153", "r965", "r1218"}, {"http://catalent.com/20240630", "localname": "Preferred Stock, Value Outstanding", "crdr": "debit", "presentation": "http://fasb.org/us-gaap/2024", "role": "EquityDetails", "label": "Preferred Stock, Value Outstanding", "documentation": "Value of nonredeemable preferred shares and preferred shares redeemable solely at option of issuer, held by shareholders. Excludes preferred shares repurchased and held as treasury shares.", "auth_ref": "r153", "r1061"}, {"http://catalent.com/20240630", "localname": "Prepaid Expense And Other Assets Current", "crdr": "debit", "presentation": "http://fasb.org/us-gaap/2024", "role": "Assets", "label": "Prepaid Expense And Other Assets Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "auth_ref": "r1365"}, {"http://catalent.com/20240630", "localname": "Prepaid Expense And Other Assets Table Text Block", "crdr": "textBlock", "presentation": "http://catalent.com/20240630", "role": "TableTextBlock", "label": "Prepaid Expense And Other Assets Table Text Block", "documentation": "Prepaid expense and other assets.", "auth_ref": "r1365"}, {"http://catalent.com/20240630", "localname": "Prior Period Reclassification Adjustment", "crdr": "debit", "presentation": "http://fasb.org/us-gaap/2024", "role": "EquityDetails", "label": "Prior Period Reclassification Adjustment", "documentation": "The amount of a reclassification adjustment made to prior period financial statement amounts.", "auth_ref": "r1370"}, {"http://catalent.com/20240630", "localname": "Pro Forma Results Abstract", "crdr": "stringItem", "presentation": "http://catalent.com/20240630", "role": "ProFormaResultsAbstract", "label": "Pro Forma Results [Abstract]", "documentation": "Pro Forma Results [Abstract]", "auth_ref": "r1370"}, {"http://catalent.com/20240630", "localname": "Proceeds From Divestiture Of Businesses And Interests In Affiliates", "crdr": "debit", "presentation": "http://catalent.com/20240630", "role": "EquityDetails", "label": "Proceeds From Divestiture Of Businesses And Interests In Affiliates", "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "auth_ref": "r43"}, {"http://catalent.com/20240630", "localname": "Proceeds From Divestiture Of Businesses Net Cash Proceeds", "crdr": "debit", "presentation": "http://catalent.com/20240630", "role": "EquityDetails", "label": "Proceeds From Divestiture Of Businesses Net Cash Proceeds", "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "auth_ref": "r43"}, {"http://catalent.com/20240630", "localname": "Proceeds From Divestiture Of Interest In Consolidated Subsidiaries", "crdr": "debit", "presentation": "http://catalent.com/20240630", "role": "EquityDetails", "label": "Proceeds From Divestiture Of Interest In Consolidated Subsidiaries", "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).", "auth_ref": "r43"}, {"http://catalent.com/20240630", "localname": "Proceeds From Issuance Of Common Stock", "crdr": "debit", "presentation": "http://catalent.com/20240630", "role": "EquityDetails", "label": "Proceeds From Issuance Of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity.", "auth_ref": "r10"}, {"http://catalent.com/20240630", "localname": "Proceeds From Issuance Of Debt", "crdr": "debit", "presentation": "http://catalent.com/20240630", "role": "EquityDetails", "label": "Proceeds From Issuance Of Debt", "documentation": "The cash inflow from borrowing, net.", "auth_ref": "r1370"}, {"http://catalent.com/20240630", "localname": "Proceeds From Repayments Of Short Term Debt", "crdr": "debit", "presentation": "http://catalent.com/20240630", "role": "EquityDetails", "label": "Proceeds From Repayments Of Short Term Debt", "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "auth_ref": "r1366", "r1369"}, {"http://catalent.com/20240630", "localname": "Proceeds From Sale And Maturity Of Marketable Securities", "crdr": "debit", "presentation": "http://catalent.com/20240630", "role": "EquityDetails", "label": "Proceeds From Sale And Maturity Of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "auth_ref": "r1370"}]
```

gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of property and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": { "r180" } }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Stock Options Exercised", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": { "r10", "r31" } }, "cslt_ProceedsFromTaxWithholdingObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "ProceedsFromTaxWithholdingObligations", "crdr": "debit", "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from Tax Withholding Obligations", "label": "Proceeds from Tax Withholding Obligations", "documentation": "Proceeds from Tax Withholding Obligations" } } }, "auth_ref": { "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductAndServiceOtherMember", "presentation": { "http://catalent.com/role/RevenueRecognitionTables": { "lang": { "en-us": { "role": { "terseLabel": "Product and Service[Member]", "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": { "r1443" } }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": { "http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenueByTypeOfActivityAndReportingSegmentDetails": { "http://catalent.com/role/RevenueRecognitionTables": { "http://catalent.com/role/RevenueFromContractWithCustomerDetails": { "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "auth_ref": { "r411", "r916", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1149", "r1185", "r1228", "r1229", "r1230", "r1233", "r1235", "r1434", "r1435", "r1442", "r1542", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574" } } }, "cslt_ProductRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "ProductRelationshipsMember", "presentation": { "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails": { "http://catalent.com/role/DefiniteLivedLongLivedAssetsOtherIntangibleAssetsSubjectToAmortizationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Product relationships [Member]", "label": "Product Relationships [Member]", "documentation": "Product relationships" } } }, "auth_ref": { "cslt_ProductRightsLineItems": { "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "ProductRightsLineItems", "presentation": { "http://catalent.com/role/DefiniteLivedLongLivedAssetsOtherIntangibleAssetsSubjectToAmortizationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Intangibles [Line Items]", "label": "Product Rights [Line Items]", "documentation": "Product Rights [Line Items]", "auth_ref": { "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": { "http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenueByTypeOfActivityAndReportingSegmentDetails": { "http://catalent.com/role/RevenueRecognitionTables": { "http://catalent.com/role/RevenueFromContractWithCustomerDetails": { "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "auth_ref": { "r411", "r916", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1149", "r1185", "r1228", "r1229", "r1230", "r1233", "r1235", "r1434", "r1435", "r1442", "r1542", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574" } } }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "http://catalent.com/role/EarningsPerShareCalculationOfEarningsPerShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net earnings", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": { "r270", "r302", "r305", "r320", "r328", "r336", "r345", "r349", "r350", "r426", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r770", "r786", "r787", "r790", "r791", "r820", "r847", "r958", "r975", "r1029", "r1083", "r1101", "r1102", "r1206", "r1207", "r1248", "r1368", "r1438" } } }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://catalent.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndOtherDefiniteLivedIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": { "r15", "r892" } }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://catalent.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetail": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetail": { "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, at cost", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r195", "r275", "r973" } }, "us-gaap_PropertyPlantAndEquipmentImpairment": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentImpairment", "presentation": { "http://catalent.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Impairment", "label": "Property, Plant and Equipment, Impairment [Policy Text Block]", "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment." } } }, "auth_ref": { "r73" } }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "http://catalent.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "http://catalent.com/role/SegmentInformationAssetsAndRevenuesDetail": { "http://catalent.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetail": { "lang": { "en-us": { "role": { "verboseLabel": "Property, plant, and equipment, net", "terseLabel": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant, and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r15", "r892", "r959", "r973", "r1218" } }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": { "http://catalent.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": { "r15", "r251", "r257", "r971" } }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationTables": { "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": { "r15" } }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": { "http://catalent.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndOtherDefiniteLivedIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": { "r195", "r892" } }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": { "http://catalent.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndOtherDefiniteLivedIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Useful Life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in PnYnMnDfnHnMnS format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": { "cslt_PropertyAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "PropertyAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment [Abstract]", "documentation": "Property and Equipment [Abstract]" } } }, "auth_ref": { "cslt_ProvisionForBadDebtsAndInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "ProvisionForBadDebtsAndInventory", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Provision for bad debts and inventory", "label": "Provision For Bad Debts And Inventory", "documentation": "Provision for bad debts and inventory." } } }, "auth_ref": { "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationAllowanceForDoubtfulAccountsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Provision for Doubtful Accounts", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": { "r315", "r440" } }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]", "auth_ref": { "r1289" } }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": { "r1289" } }, "cslt_RTSPPerformanceShareUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "RTSPPerformanceShareUnitsMember", "presentation": { "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs) [Member]", "label": "RTSP Performance Share Units [Member]", "documentation": "RTSP Performance Share Units [Member]" } } }, "auth_ref": { "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": { "http://catalent.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndOtherDefiniteLivedIntangibleAssetsDetails": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails": { "http://catalent.com/role/LeasesScheduleOfOperatingAndFinanceLeasesPresentedInTheBalanceSheetDetails": { "http://catalent.com/role/LongTermObligationsAndOtherShortTermBorrowingsAdditionalInformationDetail": { "http://catalent.com/role/LongTermObligationsAndOtherShortTermBorrowingsInterestRateDetails": { "http://catalent.com/role/RestructuringAndOtherCostsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Range [Axis]", "label": "Statistical Measurement [Axis]", "auth_ref": { "r505", "r506", "r507", "r508", "r607", "r659", "r692", "r693", "r694", "r708", "r826", "r909", "r910", "r911", "r1001", "r1003", "r1017", "r1050", "r1051", "r1109", "r1111", "r1113", "r1114", "r1123", "r1144", "r1145", "r1173", "r1183", "r1202", "r1212", "r1213", "r1214", "r1215", "r1220", "r1238", "r1431", "r1440", "r1506", "r1533", "r1534", "r1535", "r1536", "r1537" } } }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": {


```

http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails",
"http://catalent.com/role/EquityBasedCompensationAdditionalDetails", "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails",
"http://catalent.com/role/EquityBasedCompensationRSUActivityDetails",
"http://catalent.com/role/LeasesScheduleofOperatingandFinanceLeasesPresentedIntheBalanceSheetDetails",
"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail",
"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails", "http://catalent.com/role/RestructuringandOtherCostsDetails" }, {"lang": "en-us", "role": "role", "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]", "auth_ref": "r505", "r506", "r507", "r508", "r607", "r659", "r692", "r693", "r694", "r708", "r826", "r909", "r910", "r911", "r1001", "r1003", "r1017", "r1050", "r1051", "r109", "r1111", "r1113", "r1114", "r1123", "r1144", "r1145", "r1173", "r1183", "r1202", "r1212", "r1213", "r1214", "r1215", "r1229", "r1238", "r1431", "r1440", "r1506", "r1533", "r1534", "r1535", "r1536", "r1537" }, {"us-gaap_RealEstateMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealEstateMember", "presentation": "http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails" }, {"lang": "en-us", "role": "role", "terseLabel": "Real Estate [Member]", "label": "Real Estate [Member]", "documentation": "Property consisting of land, land improvement and buildings." }, {"auth_ref": "r1443" }, {"us-gaap_ReceivablesPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesPolicyTextBlock", "presentation": "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" }, {"lang": "en-us", "role": "role", "terseLabel": "Receivables and Allowance for Doubtful Accounts", "label": "Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." }, {"auth_ref": "r419", "r420", "r421", "r423", "r1396" }, {"cftl_RecentFinancialAccountingStandardsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "RecentFinancialAccountingStandardsAbstract", "lang": "en-us", "role": "role", "label": "Recent Financial Accounting Standards [Abstract]", "documentation": "Recent Financial Accounting Standards" }, {"auth_ref": "r1" }, {"us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "presentation": "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails" }, {"lang": "en-us", "role": "role", "negatedTerseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." }, {"auth_ref": "r36", "r42", "r309", "r855", "r860", "r862", "r977", "r1366" }, {"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails" }, {"lang": "en-us", "role": "role", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." }, {"auth_ref": "r310" }, {"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails" }, {"lang": "en-us", "role": "role", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." }, {"auth_ref": "r310" }, {"us-gaap_Reclassifications": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Reclassifications", "presentation": "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" }, {"lang": "en-us", "role": "role", "terseLabel": "Reclassifications", "label": "Reclassifications [Text Block]", "documentation": "The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted." }, {"auth_ref": "r128" }, {"us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable", "presentation": "http://catalent.com/role/SegmentInformationAssetsandRevenuesDetail", "http://catalent.com/role/SegmentInformationTotalAssetsDetails" }, {"lang": "en-us", "role": "role", "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]", "label": "Reconciliation of Assets from Segment to Consolidated [Table]", "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." }, {"auth_ref": "r67", "r68" }, {"us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "presentation": "http://catalent.com/role/SegmentInformationTables" }, {"lang": "en-us", "role": "role", "terseLabel": "Total Assets for Each Segment and Reconciling in Consolidated Financial Statements", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." }, {"auth_ref": "r67", "r68" }, {"us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "presentation": "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail" }, {"lang": "en-us", "role": "role", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." }, {"auth_ref": "r66", "r68" }, {"us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": "http://catalent.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" }, {"lang": "en-us", "role": "role", "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]", "label": "Unrecognized Tax Benefits [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." }, {"auth_ref": "r1" }, {"ecd_RecoveryOfErrCompDisclosureLineItems": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": "en-us", "role": "role", "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "auth_ref": "r1256", "r1267", "r1277", "r1309" }, {"cftl_RedeemablePreferredStockLineItems": {"xbrltype": "stringItemType", "nsuri": "http://catalent.com/role/EquityDetails", "lang": "en-us", "role": "role", "terseLabel": "Redeemable Preferred Stock [Line Items]", "label": "Redeemable Preferred Stock [Line Items]", "documentation": "Redeemable Preferred Stock" }, {"auth_ref": "r1" }, {"us-gaap_RedeemablePreferredStockMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemablePreferredStockMember", "presentation": "http://catalent.com/role/EquityDetails" }, {"lang": "en-us", "role": "role", "terseLabel": "Redeemable Preferred Stock [Member]", "label": "Redeemable Preferred Stock [Member]", "documentation": "Description of type or class of redeemable preferred stock. For instance, cumulative preferred stock, noncumulative preferred stock, convertible or series." }, {"auth_ref": "r38", "r78", "r328", "r426", "r513", "r516", "r517", "r518", "r522", "r523", "r847" }, {"us-gaap_RelatedPartyDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" }, {"lang": "en-us", "role": "role", "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." }, {"auth_ref": "r418", "r634", "r901", "r902", "r963", "r970", "r1053", "r1054", "r1055", "r1056", "r1057", "r1079", "r1081", "r1108" }, {"us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" }, {"lang": "en-us", "role": "role", "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." }, {"auth_ref": "r418", "r634", "r901", "r902", "r963", "r970", "r1053", "r1054", "r1055", "r1056", "r1057", "r1079", "r1081", "r1108", "r1528" }, {"us-gaap_RepaymentsOfLinesOfCredit": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail" }, {"lang": "en-us", "role": "role", "terseLabel": "Repayments of Lines of Credit", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." }, {"auth_ref": "r184", "r1375" }, {"us-gaap_RepaymentsOfLongTermDebt": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": "http://catalent.com/role/ConsolidatedStatementsOfCashFlows", {"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 }, {"presentation": "http://catalent.com/role/ConsolidatedStatementsOfCashFlows" }, {"lang": "en-us", "role": "role", "negatedTerseLabel": "Repayments of Long-term Debt", "label": "Repayments of Long-term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." }, {"auth_ref": "r184", "r1025" }, {"cftl_RepresentationOfDepreciationAndAmortizationExpenseAndCapitalExpenditureInConsolidatedFinancialStatementsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://catalent.com/20240630", "localname": "RepresentationOfDepreciationAndAmortizationExpenseAndCapitalExpenditureInConsolidatedFinancialStatementsTableTextBlock", "presentation": "http://catalent.com/role/SegmentInformationTables" }, {"lang": "en-us", "role": "role", "terseLabel": "Representation of depreciation and amortization expense and capital expenditure by segment", "label": "Representation Of
```

[Axis] } } } , "auth_ref": { "r1257", "r1268", "r1278", "r1310" } } , "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } } } , "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } } } , "auth_ref": { "r1258", "r1269", "r1279", "r1311" } } , "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } } , "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } } } , "auth_ref": { "r1265", "r1276", "r1286", "r1318" } } } , "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRecentFinancialAccountingStandardsDetails" } } } , "lang": { "en-us": { "role": { "terseLabel": "Restatement [Domain]", "label": "Revision of Prior Period [Domain]" } } } } , "auth_ref": { "r265", "r332", "r333", "r334", "r336", "r337", "r340", "r341", "r342", "r343", "r346", "r347", "r348", "r349", "r350", "r351", "r369", "r431", "r432", "r767", "r768", "r770", "r771", "r785", "r786", "r814", "r818", "r819", "r820", "r869", "r871", "r899", "r900", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1019", "r1394" } } } , "cslt_RestOfWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "RestOfWorldMember", "presentation": { "http://catalent.com/role/SegmentInformationAssetsandRevenuesDetail" } } } , "lang": { "en-us": { "role": { "terseLabel": "International Other [Member]", "label": "Rest of World [Member]" } } } , "documentation": { "Rest of World [Member]" } } } , "auth_ref": { } } , "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetailsDetails", "http://catalent.com/role/EquityBasedCompensationAdditionalDetails", "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } } } , "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } } , "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs) [Member]", "label": "Restricted Stock Units (RSUs) [Member]" } } } , "documentation": { "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } } , "auth_ref": { } } , "cslt_RestructuringAndOtherSpecialItems": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "RestructuringAndOtherSpecialItems", "crdr": "debit", "calculation": { "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail": { "parentTag": "cslt_SegmentReportingInformationUnallocatedExpense", "weight": 1.0, "order": 3.0 } } } , "presentation": { "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "http://catalent.com/role/SegmentInformationReconciliationofEarningslossfromContinuingOperationsToEbitdaDetail" } } } , "lang": { "en-us": { "role": { "negatedTerseLabel": "Restructuring and other special items", "label": "Restructuring And Other Special Items", "documentation": "Restructuring and other special items." } } } } , "auth_ref": { } } , "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } } } , "auth_ref": { } } , "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": { "http://catalent.com/role/RestructuringandOtherCosts" } } , "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Other Costs", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } } } , "auth_ref": { "r492", "r493", "r495", "r498", "r502" } } } , "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails", "http://catalent.com/role/SubsequentEventsDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Cost, Expected Cost", "label": "Restructuring and Related Cost, Expected Cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } } } , "auth_ref": { "r494", "r497", "r499", "r501" } } } , "us-gaap_RestructuringAndRelatedCostExpectedNumberOFPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedNumberOFPositionsEliminated", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Cost, Expected Number of Positions Eliminated", "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated", "documentation": "The expected number of positions to be eliminated as a result of restructuring activities." } } } } , "auth_ref": { } } } , "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Cost, Incurred Cost", "label": "Restructuring and Related Cost, Incurred Cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } } } , "auth_ref": { "r494", "r497", "r499", "r501" } } } , "us-gaap_RestructuringAndRelatedCostNumberOFPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOFPositionsEliminated", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Cost, Number of Positions Eliminated", "label": "Restructuring and Related Cost, Number of Positions Eliminated", "documentation": "The number of positions eliminated during the period as a result of restructuring activities." } } } } , "auth_ref": { } } } , "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } } } , "auth_ref": { "r494", "r495", "r499", "r500" } } } , "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } } , "auth_ref": { "r494", "r495", "r496", "r497", "r499", "r500", "r501" } } } , "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCosts", "crdr": "debit", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Restructuring Costs", "label": "Restructuring Costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } } } , "auth_ref": { "r14" } } } , "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": { "http://catalent.com/role/RestructuringandOtherCosts", "http://catalent.com/role/RestructuringandOtherCostsDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges." } } } } , "auth_ref": { "r1341", "r1342" } } } , "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "calculation": { "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } } } , "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAccruedLiabilitiesDetail" } } , "lang": { "en-us": { "role": { "negatedTerseLabel": "Restructuring Reserve", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } } } , "auth_ref": { "r495", "r500" } } } , "us-gaap_RestructuringReserveSettledWithoutCash2": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveSettledWithoutCash2", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } } } , "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows" } } , "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve, Settled without Cash", "label": "Restructuring Reserve, Settled without Cash", "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash." } } } } , "auth_ref": { "r495", "r500" } } } , "us-gaap_RestructuringSettlementAndImpairmentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringSettlementAndImpairmentProvisions", "crdr": "debit", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Restructuring, Settlement and Impairment Provisions", "label": "Restructuring, Settlement and Impairment Provisions", "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss." } } } } , "auth_ref": { "r174" } } } , "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } } } , "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets" } } , "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } } } , "auth_ref": { "r156", "r206", "r668", "r1011", "r1016", "r1026", "r1062", "r1218" } } } , "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRecentFinancialAccountingStandardsDetails", "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquity" } } , "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } } } , "auth_ref": { "r264", "r332", "r333", "r334", "r337", "r345", "r348", "r350", "r430", "r436", "r481", "r753", "r754", "r766", "r767", "r771", "r785", "r786", "r800", "r803", "r804", "r807", "r818", "r870", "r873", "r1007", "r1009", "r1030", "r1578" } } } , "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } } } , "auth_ref": { "r583", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r631", "r632", "r634", "r637", "r640", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r656", "r657", "r658", "r661", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201" } } } , "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansAdditionalInformationDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails", "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails" } } , "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } } } , "auth_ref": { "r583", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r631", "r632", "r634", "r637", "r640", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r656", "r657", "r658", "r661", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201" } } } , "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } } } , "auth_ref": { } } , "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
RevenueFromContractWithCustomerPolicyTextBlock": {"presentation": [{"http://catalent.com/role/RevenueRecognition"}], "lang": {"en-us": {"role": {"terseLabel": "Revenue from Contract with Customer"}, "label": "Revenue from Contract with Customer {Policy Text Block}"}, "auth_ref": {"r260"}}, {"r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r1148"}], "us-gaap RevenueRecognitionAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionAbstract", "lang": {"en-us": {"role": {"label": "Revenue Recognition Abstract"}}, "auth_ref": {}}, "us-gaap RevenueRecognitionAndDeferredRevenueAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "lang": {"en-us": {"role": {"terseLabel": "Revenue Recognition and Deferred Revenue Abstract"}, "label": "Revenue Recognition and Deferred Revenue Abstract"}}, "auth_ref": {}}, "us-gaap RevenueRemainingPerformanceObligation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [{"http://catalent.com/role/RevenueRecognitionContractualLiabilitiesDetails", "http://catalent.com/role/RevenuefromContractwithCustomerDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Revenue Remaining Performance Obligation Amount"}, "label": "Revenue Remaining Performance Obligation Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."}}, "auth_ref": {"r254"}], "cltL_RvenueRemainingPerformanceObligationExpectedTimingOfSatisfactionAxis": {"xbrltype": "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionAxis", "presentation": [{"http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebyTypeofactivityandreportingsegmentDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Revenue Remaining Performance Obligation Expected Timing of Satisfaction Axis"}, "label": "Revenue Remaining Performance Obligation Expected Timing of Satisfaction Axis", "documentation": "Revenue Remaining Performance Obligation Expected Timing of Satisfaction Axis"}, "auth_ref": {}}, "cltL_RvenueRemainingPerformanceObligationExpectedTimingOfSatisfactionDomain": {"xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionDomain", "presentation": [{"http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebyTypeofactivityandreportingsegmentDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Revenue Remaining Performance Obligation Expected Timing of Satisfaction Domain"}, "label": "Revenue Remaining Performance Obligation Expected Timing of Satisfaction Domain", "documentation": "Revenue Remaining Performance Obligation Expected Timing of Satisfaction Domain"}}, "auth_ref": {}}, "us-gaap RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [{"http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebyTypeofactivityandreportingsegmentDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Revenue Remaining Performance Obligation Expected Timing of Satisfaction Start Date Axis"}, "label": "Revenue Remaining Performance Obligation Expected Timing of Satisfaction Start Date Axis", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."}}, "auth_ref": {"r255"}}, {"r255"}], "us-gaap RevenueRemainingPerformanceObligationPercentage": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationPercentage", "presentation": [{"http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebyTypeofactivityandreportingsegmentDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Revenue Remaining Performance Obligation Percentage to be recognized over the next six months"}, "label": "Revenue Remaining Performance Obligation Percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."}}, "auth_ref": {"r1347"}}, {"r1347"}], "us-gaap Revenues": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": [{"http://catalent.com/role/ConsolidatedStatementsOfOperations": {"parentTag": "us-gaap GrossProfit", "weight": 1.0, "order": 1.0}}, {"http://catalent.com/role/ConsolidatedStatementsOfOperations": {"parentTag": "us-gaap RevenueRecognitionDisaggregationofRevenuebyGeographyDetails"}, {"http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebyTypeofactivityandreportingsegmentDetails"}, {"http://catalent.com/role/RevenueRecognitionTables": {"http://catalent.com/role/RevenuefromContractwithCustomerDetails", "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail"}], "lang": {"en-us": {"role": {"terseLabel": "Net revenue", "negatedTerseLabel": "Net revenue"}, "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."}}, "auth_ref": {"r237", "r238", "r311", "r328", "r370", "r379", "r380", "r401", "r407", "r411", "r413", "r415", "r426", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r847", "r958", "r1167", "r1438"}], "cltL_RevolvingCreditCommitmentsMember": {"xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "Revolving Credit Commitments Member", "presentation": [{"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail"}, {"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Revolving Credit Commitments Member"}, "label": "Revolving Credit Commitments Member", "documentation": "Revolving Credit Commitments"}, "auth_ref": {}}, {"r237", "r238", "r311", "r328", "r370", "r379", "r380", "r401", "r407", "r411", "r413", "r415", "r426", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r847", "r958", "r1167", "r1438"}], "cltL_RevolvingCreditFacilityTwoMember": {"xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "Revolving Credit Facility Two Member", "presentation": [{"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail"}, {"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Revolving Credit Facility - Two Member"}, "label": "Revolving Credit Facility - Two Member", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."}}, "auth_ref": {}}, {"r237", "r238", "r311", "r328", "r370", "r379", "r380", "r401", "r407", "r411", "r413", "r415", "r426", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r847", "r958", "r1167", "r1438"}], "cltL_RheinCellTherapeuticsMember": {"xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "RheinCell Therapeutics Member", "presentation": [{"http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails"}, {"http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails"}], "lang": {"en-us": {"role": {"terseLabel": "RheinCell Therapeutics"}, "label": "RheinCell Therapeutics [Member]", "documentation": "RheinCell Therapeutics"}, "auth_ref": {}}, {"r237", "r238", "r311", "r328", "r370", "r379", "r380", "r401", "r407", "r411", "r413", "r415", "r426", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r847", "r958", "r1167", "r1438"}], "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [{"http://catalent.com/role/LeasesScheduleofSupplementalCashFlowInformationDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability"}, "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."}}, "auth_ref": {"r888", "r1217"}], "ecd Rule10b51ArrAdoptedFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": {"en-us": {"role": {"terseLabel": "Rule 10b5-1 Arrangement Adopted"}, "label": "Rule 10b5-1 Arrangement Adopted [Flag]"}, "auth_ref": {"r1327"}}, {"r1327"}], "us-gaap SaleAndLeasebackTransactionGainLossNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleAndLeasebackTransactionGainLossNet", "crdr": "credit", "presentation": [{"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail"}], "lang": {"en-us": {"role": {"terseLabel": "Sale and Leaseback Transaction Gain (Loss) Net"}, "label": "Sale and Leaseback Transaction Gain (Loss) Net", "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale."}}, "auth_ref": {"r886", "r894", "r1217"}}, {"r886", "r894", "r1217"}], "us-gaap SalesMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesMember", "presentation": [{"http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesConcentrationsOfCreditRiskandMajorCustomersDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Sales [Member]"}, "label": "Sales [Member]", "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business."}}, "auth_ref": {"r33"}}, {"r33"}], "srt ScenarioPreviouslyReportedMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioPreviouslyReportedMember", "presentation": [{"http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRecentFinancialAccountingStandardsDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Previously Reported"}, "label": "Previously Reported [Member]"}, "auth_ref": {"r265", "r332", "r334", "r336", "r337", "r340", "r341", "r350", "r369", "r767", "r770", "r771", "r785", "r786", "r814", "r818", "r819", "r869", "r871", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1019", "r1349", "r1351", "r1352", "r1353", "r1382", "r1394", "r1398", "r1399", "r1502", "r1526", "r1527"}}, {"r265", "r332", "r334", "r336", "r337", "r340", "r341", "r350", "r369", "r767", "r770", "r771", "r785", "r786", "r814", "r818", "r819", "r869", "r871", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1019", "r1349", "r1351", "r1352", "r1353", "r1382", "r1394", "r1398", "r1399", "r1502", "r1526", "r1527"}], "srt ScenarioUnspecifiedDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [{"http://catalent.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"}], "lang": {"en-us": {"role": {"terseLabel": "Scenario Unspecified Domain"}, "label": "Scenario Unspecified Domain"}}, "auth_ref": {"r351", "r660", "r1343", "r13
```

[http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails](#)" "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails"
"http://catalent.com/role/BusinessCombinationsTables" }], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition", "label": "Schedule of
Business Acquisitions, by Acquisition [Table]" }, "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and
liability." } } }, "auth_ref": { "r94", "r95", "r775" } }, "ctl_ScheduleOfCarryingAndFairValueOfFinancialInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://catalent.com/20240630", "localname": "ScheduleOfCarryingAndFairValueOfFinancialInstrumentsTableTextBlock", "presentation": {
"http://catalent.com/LongTermObligationsandOtherShortTermBorrowingsTables" }], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Carrying And Fair-Value Of
Financial Instruments Table", "label": "Schedule Of Carrying And Fair Value Of Financial Instruments Table [Table Text Block]", "documentation": "Schedule of carrying and
fair value of financial instruments." } } }, "auth_ref": { "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": { "http://catalent.com/role/LeasesTables" }],
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
"documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": { "us-
gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": { "http://catalent.com/role/IncomeTaxesTables" }], "lang": { "en-us": { "role": {
"terseLabel": "Provision/(benefit) for income taxes", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular
disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit),
deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax
benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset
for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a
change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": { "r1491" } }, "us-
gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfComprehensiveIncomeLossTableTextBlock", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossTables" }], "lang": {
"en-us": { "role": { "terseLabel": "Schedule of Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular
disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments; foreign currency transactions designated as
economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans." } } }, "auth_ref":
{ "r163" } }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfDebtInstrumentsTextBlock", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" }], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Long-term Debt Instruments [Table Text Block]", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular
disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation.
These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } },
"auth_ref": { "r37", "r80", "r83", "r126", "r203", "r205", "r1179", "r1181", "r1378", "r1521" } }, "ctl_ScheduleOfDebtLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://catalent.com/20240630", "localname": "ScheduleOfDebtLineItems", "presentation": {
"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Debt
[Line Items]", "label": "Schedule Of Debt [Line Items]", "documentation": "Schedule Of Debt [Line Items]" } } }, "auth_ref": { "ctl_ScheduleOfDebtTable": { "xbrltype":
"stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "ScheduleOfDebtTable", "presentation": {
"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Debt
[Table]", "label": "Schedule Of Debt [Table]", "documentation": "Schedule Of Debt [Table]" } } }, "auth_ref": { "us-
gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": { "http://catalent.com/role/IncomeTaxesTables" }], "lang": { "en-us": { "role": { "terseLabel":
"Components of the deferred income tax assets and liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular
disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax
liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": { "r1487" } }, "us-
gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansAOCIDetails":
"http://catalent.com/role/EmployeeRetirementBenefitPlansAccumulatedBenefitObligationDetails":
"http://catalent.com/role/EmployeeRetirementBenefitPlansAssumedHealthcareTrendRatesDetails":
"http://catalent.com/role/EmployeeRetirementBenefitPlansBalanceSheetDetails": "http://catalent.com/role/EmployeeRetirementBenefitPlansDetails":
"http://catalent.com/role/EmployeeRetirementBenefitPlansFairValueDetails": "http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails":
"http://catalent.com/role/EmployeeRetirementBenefitPlansLevel3Details" }], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]",
"label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit
plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair
value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or
liabilities (Level 1). Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": { "r19", "r86", "r87", "r88", "r89" } }, "us-
gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "presentation": { "http://catalent.com/role/FairValueMeasuresandDisclosuresTables" }], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]", "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
"documentation": "Tabular disclosure of derivative liabilities at fair value." } } }, "auth_ref": { "us-
gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTableTextBlock", "presentation": {
"http://catalent.com/role/BusinessCombinationsTables" }], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations", "label": "Disposal
Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited
to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref":
{ "r18", "r32", "r39", "r129", "r130", "r131", "r132", "r133", "r134", "r136", "r137", "r138", "r197" } }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock":
{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": {
"http://catalent.com/role/EarningsPerShareCalculationTables" }], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table Text
Block]", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per
share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } },
"auth_ref": { "r1386" } }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": { "http://catalent.com/role/IncomeTaxesTables" }], "lang": { "en-
us": { "role": { "terseLabel": "Reconciliation of the provision/(benefit) based on the federal statutory income tax rate", "label": "Schedule of Effective Income Tax Rate
Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax
expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax
income from continuing operations." } } }, "auth_ref": { "r723", "r1205", "r1483" } }, "us-
gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": {
"http://catalent.com/role/FairValueMeasuresandDisclosuresTables" }], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on
Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and
liabilities, including financial instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The
disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in
their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and
significant unobservable inputs (Level 3)." } } }, "auth_ref": { "r1503", "r1504" } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": {
"http://catalent.com/role/DefiniteLivedongLivedAssetsOtherIntangibleAssetsSubjecttoAmortizationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-
Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes
indefinite-lived intangible asset." } } }, "auth_ref": { "r465", "r472", "r475", "r476", "r478", "r917", "r1147", "r1176" } }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": {
"http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail": { "lang": { "en-us": { "role": { "terseLabel": "Statement of Goodwill [Table]", "label": "Goodwill [Table]",
"documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": {
"r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r463", "r1175" } }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType",<

"ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Maturities of long-term obligations", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": { "r16" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": { "http://catalent.com/role/EmployeeRetirementBenefitPlansTables" }, "lang": { "en-us": { "role": { "terseLabel": "Benefit obligation and fair value of plan assets for the defined benefit retirement and postretirement plan", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": { "r210" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "presentation": { "http://catalent.com/role/EquityBasedCompensationTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]", "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units." } } }, "auth_ref": { "r215" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": { "http://catalent.com/role/EquityBasedCompensationTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": { "r215" }, "ctlt_ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://catalent.com/20240630", "localname": "ScheduleOfOperatingAndFinancingLeasesPresentedInBalanceSheetTableTextBlock", "presentation": { "http://catalent.com/role/LeasesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating and Financing Leases Presented in Balance Sheet", "label": "Schedule of Operating and Financing Leases Presented in Balance Sheet [Table Text Block]", "documentation": "Schedule of Operating and Financing Leases Presented in Balance Sheet" } } }, "auth_ref": { "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherAssetsTableTextBlock", "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationTables" }, "lang": { "en-us": { "role": { "terseLabel": "Other Assets - Non Current", "label": "Schedule of Other Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": { "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": { "http://catalent.com/role/OtherIncomeExpenseTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Nonoperating Income (Expense)", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": { "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": { "http://catalent.com/role/BusinessCombinationsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": { "r219" }, "ctlt_ScheduleOfRedeemablePreferredStockTable": { "xbrltype": "stringItemType", "nsuri": "http://catalent.com/20240630", "localname": "ScheduleOfRedeemablePreferredStockTable", "presentation": { "http://catalent.com/role/EquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Redeemable Preferred Stock [Table]", "label": "Schedule of Redeemable Preferred Stock [Table]", "documentation": "Schedule of Redeemable Preferred Stock" } } }, "auth_ref": { "us-gaap_ScheduleOfRestructuringAndRelatedCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTableTextBlock", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Other Costs", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": { "r74", "r198", "r199" }, "ctlt_ScheduleOfRevenueAndLongLivedAssetsByGeographicAreaTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://catalent.com/20240630", "localname": "ScheduleOfRevenueAndLongLivedAssetsByGeographicAreaTableTextBlock", "presentation": { "http://catalent.com/role/SegmentInformationTables" }, "lang": { "en-us": { "role": { "terseLabel": "Presentation of revenue and long-lived assets by geographic area", "label": "Schedule Of Revenue And Long Lived Assets By Geographic Area Table [Table Text Block]", "documentation": "Revenue and long-lived assets by geographic area." } } }, "auth_ref": { "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": { "http://catalent.com/role/SegmentInformationCapitalExpendituresDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": { "r63", "r64", "r65" }, "ctlt_ScheduleOfSegmentReportingInformationCapitalExpendituresBySegmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://catalent.com/20240630", "localname": "ScheduleOfSegmentReportingInformationCapitalExpendituresBySegmentTableTextBlock", "presentation": { "http://catalent.com/role/SegmentInformationTables" }, "lang": { "en-us": { "role": { "terseLabel": "Capital Expenditures by Segment", "label": "Schedule of Segment Reporting Information, Capital Expenditures by Segment [Table Text Block]", "documentation": "Schedule of Segment Reporting Information, Capital Expenditures by Segment [Table Text Block]" } } }, "auth_ref": { "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails", "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": { "r663", "r665", "r667", "r668", "r669", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r691", "r692", "r693", "r694", "r695" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": { "http://catalent.com/role/EquityBasedCompensationTables" }, "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": { "r217" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": { "http://catalent.com/role/IncomeTaxesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Unrecognized tax benefit, excluding accrued interest", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": { "r735", "r1204" }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "presentation": { "http://catalent.com/role/EquityBasedCompensationTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Unvested Restricted Stock Units Roll Forward", "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)." } } }, "auth_ref": { "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": { "http://catalent.com/role/DefineFiniteLivedLongLivedAssetsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Future Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": { "r1176", "r1421" }, "ctlt_ScheduleOfNetInvestmentHedgeInAccumulatedOtherComprehensiveIncomeLossandStatementofFinancialPerformanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://catalent.com/20240630", "localname": "ScheduleOfNetInvestmentHedgeInAccumulatedOtherComprehensiveIncomeLossandStatementofFinancialPerformanceTableTextBlock", "presentation": { "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Investment Hedge in Accumulated Other Comprehensive Income (Loss) and Statement of Financial Performance [Table Text Block]", "label": "Schedule of Net Investment Hedge in Accumulated Other Comprehensive Income (Loss) and Statement of Financial Performance [Table Text Block]", "documentation": "Schedule of Net Investment Hedge in Accumulated Other Comprehensive Income (Loss) and Statement of Financial Performance [Table Text Block]" } } }, "auth_ref": { "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": { "r1499" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": { "r1499" }, "dei_Security12bTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://catalent.com/role/DocumentandEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r1250" }, "dei_SecurityExchangeName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://catalent.com/role/DocumentandEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r1252" }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", "http://catalent.com/role/RestructuringandOtherCostsDetails", "http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebytypeofactivityandreportingsegmentDetails", "http://catalent.com/role/RevenuefromContractwithCustomerDetails", "http://catalent.com/role/SegmentInformationCapitalExpendituresDetails", "http://catalent.com/role/SegmentInformationDepreciationandAmortizationDetails", "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "http://catalent.com/role/SegmentInformationTotalAssetsDetails", "http://catalent.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Segment [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": { "r237", "r238", "r239", "r240", "r370", "r375", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r409", "r415", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r478", "r497", "r501", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r1164", "r1167", "r1168", "r1175", "r1232", "r1542", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559" } }

"r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1573", "r1574" } }, "srt_SegmentGeographicalDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": {
"http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenuebyGeographyDetails": "http://catalent.com/role/RevenueRecognitionTables",
"http://catalent.com/role/SegmentInformationAssetsandRevenuesDetail": { "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } } },
"auth_ref": { "r413", "r414", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940",
"r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r1044", "r1046", "r1048", "r1110", "r1112", "r1115", "r1124", "r1132", "r1135", "r1136",
"r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1150", "r1186", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1231", "r1238",
"r1442", "r1542", "r1546", "r1547", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563",
"r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1573", "r1574" } }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": { } }, "us-
gaap_SegmentReportingAssetReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SegmentReportingAssetReconcilingItemLineItems", "presentation": { "http://catalent.com/role/SegmentInformationTotalAssetsDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]", "label": "Segment Reporting, Asset Reconciling Item [Line Items]", "documentation": "Line items
represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to
the table." } } } }, "auth_ref": { } }, "us-gaap_SegmentReportingDisclosureOfMajorCustomers": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SegmentReportingDisclosureOfMajorCustomers", "presentation": {
"http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails":
"http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentExpenseDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Segment Reporting, Disclosure of Major Customers", "label": "Segment Reporting, Disclosure of Major Customers", "documentation": "Disclosure of the extent
of enterprise reliance on its major customers. For example, includes revenues from transactions with a single external customer amounting to 10 percent or more of the
entity's revenues, the total amount of revenues from each such customer, and the identity of the segment or segments reporting the revenues. A group of entities that the
entity knows to be under common control generally will be considered a single customer for inclusion in this item. The federal government, a state government, a local
government (for example, a county or municipality), or a foreign government each will generally be considered as a single customer for inclusion in this item." } } } },
"auth_ref": { "r192" } }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SegmentReportingDisclosureTextBlock", "presentation": { "http://catalent.com/role/SegmentInformation": { "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting
Disclosure [Text Block]", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables.
Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment
sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10
percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of
all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } } }, "auth_ref": { "r240", "r370", "r374",
"r375", "r376", "r377", "r378", "r390", "r392", "r393", "r405", "r406", "r407", "r408", "r409", "r411", "r412", "r415", "r1162", "r1165", "r1166", "r1167", "r1169", "r1171",
"r1172" } }, "cslt_SegmentReportingInformationEarningBeforeInterestTaxDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri":
"http://catalent.com/20240630", "localname": "SegmentReportingInformationEarningBeforeInterestTaxDepreciationAndAmortization", "crdr": "credit", "presentation": {
"http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail":
"http://catalent.com/role/SegmentInformationReconciliationofEarningslossfromContinuingOperationstoEbitdaDetail": { "lang": { "en-us": { "role": { "terseLabel": "Segment
EBITDA", "verboseLabel": "EBITDA from continuing operations", "label": "Segment Reporting Information Earning Before Interest Tax Depreciation And Amortization",
"documentation": "Segment reporting information earning before interest tax depreciation and amortization." } } } }, "auth_ref": { } },
"cslt_SegmentReportingInformationInterSegmentRevenueElimination": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname":
"SegmentReportingInformationInterSegmentRevenueElimination", "crdr": "credit", "presentation": { "http://catalent.com/role/RevenuefromContractwithCustomerDetails":
"http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail": { "lang": { "en-us": { "role": { "terseLabel": "Inter-segment revenue elimination", "label":
"Segment Reporting Information Inter Segment Revenue Elimination", "documentation": "Segment reporting information inter segment revenue elimination." } } } },
"auth_ref": { } }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SegmentReportingInformationLineItems", "presentation": { "http://catalent.com/role/SegmentInformationAssetsandRevenuesDetail":
"http://catalent.com/role/SegmentInformationCapitalExpendituresDetails": "http://catalent.com/role/SegmentInformationDepreciationandAmortizationDetails": { "lang": { "en-
us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent
financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
} } } }, "auth_ref": { } }, "cslt_SegmentReportingInformationNetRevenueAndEbitdaTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://catalent.com/20240630",
"localname": "SegmentReportingInformationNetRevenueAndEbitdaTableTextBlock", "presentation": { "http://catalent.com/role/SegmentInformationTables": { "lang": { "en-
us": { "role": { "terseLabel": "Net Revenue and Segment EBITDA", "label": "Segment Reporting Information Net Revenue And Ebitda Table [Text Block]", "documentation":
"Segment reporting information net revenue and EBITDA." } } } }, "auth_ref": { } }, "cslt_SegmentReportingInformationUnallocatedExpense": { "xbrltype": "monetaryItemType",
"nsuri": "http://catalent.com/20240630", "localname": "SegmentReportingInformationUnallocatedExpense", "crdr": "debit", "calculation": {
"http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail": { "lang": { "en-us": { "role": { "negatedTotalLabel":
"Total unallocated costs", "terseLabel": "Total unallocated costs", "label": "Segment Reporting Information Unallocated Expense", "documentation": "Segment Reporting
Information Unallocated Expense" } } } }, "auth_ref": { } }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": {
"http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Policy",
"label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } } }, "auth_ref": { "r394", "r395", "r396",
"r397", "r398", "r399", "r400", "r410", "r413", "r1163", "r1164", "r1170" } }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingRevenueReconcilingItemLineItems", "presentation": {
"http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail": { "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Revenue Reconciling
Item [Line Items]", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "documentation": "Line items represent financial concepts included in a table.
These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": { } }, "us-
gaap_SelfInsuranceReservePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SelfInsuranceReservePolicyTextBlock",
"presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Self
Insurance", "label": "Self Insurance Reserve [Policy Text Block]", "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to
incurred but not reported reserves (IBNR)."} } } }, "auth_ref": { } }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": {
"http://catalent.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": {
"http://catalent.com/role/ConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "terseLabel": "Selling, general, and administrative expenses", "label": "Selling,
General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and
administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products.
Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General
and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } } }, "auth_ref": { "r175" } }, "us-
gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SellingGeneralAndAdministrativeExpensesMember", "presentation": {
"http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentExpenseDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Selling, General and Administrative Expenses [Member]", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary
financial statement caption encompassing selling, general and administrative expense." } } } }, "auth_ref": { } }, "cslt_SeniorSecuredCreditFacilitiesOtherMember": { "xbrltype":
"domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "SeniorSecuredCreditFacilitiesOtherMember", "presentation": {
"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsFairValueMeasurementsandFinancialInstrumentsCarryingAmountsandEstimatedFairValueoffinanc
e": { "lang": { "en-us": { "role": { "terseLabel": "Senior Secured Credit Facilities & Other [Member]", "label": "Senior Secured Credit Facilities & Other [Member]",
"documentation": "Senior Secured Credit Facilities & Other [Member]" } } } }, "auth_ref": { } }, "cslt_SeniorSecuredCreditFacilityMember": { "xbrltype": "domainItemType",
"nsuri": "http://catalent.com/20240630", "localname": "SeniorSecuredCreditFacilityMember", "presentation": {
"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Senior Secured
Credit Facility [Member]", "label": "Senior Secured Credit Facility [Member]", "documentation": "Senior Secured Credit Facility [Member]" } } } }, "auth_ref": { } },
"cslt_SeniorUnsecuredTermLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname":
"SeniorUnsecuredTermLoanFacilityMember", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail":
"http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails": { "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Term Loan
Facility [Member]", "label": "Senior Unsecured Term Loan Facility [Member]", "documentation": "Senior Unsecured Term Loan Facility [Member]" } } } }, "auth_ref": { } },
"cslt_SeriesAPreferredStockDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname":
"SeriesAPreferredStockDerivativeLiability", "crdr": "debit", "presentation": { "http://catalent.com/role/FairValueMeasuresandDisclosuresDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Series A Preferred Stock derivative liability", "label": "Series A Preferred Stock derivative liability", "documentation": "Series A Preferred Stock derivative
liability" } } } }, "auth_ref": { } }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SeriesAPreferredStockMember", "presentation": { "http://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetailsDetail": { "lang": { "en-us": { "role": {
"terseLabel": "Series A Preferred Stock", "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } } }, "auth_ref": { "r1360", "r1361",
"r1441" } }, "cslt_SettlementOnFromSaleOfSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname":
"SettlementOnFromSaleOfSubsidiaries", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "lang":
"en-us": { "role": { "terseLabel": "Settlement on from sale of subsidiaries", "label": "Settlement on from sale of subsidiaries", "documentation": "Settlement on from sale of
subsidiaries" } } } }, "auth_ref": { } }, "us-gaap_SeveranceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts",
"crdr": "debit", "presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Employee-related reorganization",
"label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated
under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued
operation or an asset retirement obligation." } } } }, "auth_ref": { "r141" } }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedStatementsofCashFlows": {
"lang": { "en-us": { "role": { "terseLabel": "Equity compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash
expense for share-based payment arrangement." } } } }, "auth_ref": { "r13" } }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": {
"http://catalent.com/role/EquityBasedCompensationRSUActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based

Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value, "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } } "auth_ref": "r684" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } } "auth_ref": "r682" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } } "auth_ref": "r682" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } } "auth_ref": "r679" } } "r680" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } } "auth_ref": "r679" } } "r680" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease", "presentation": "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)", "documentation": "The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period." } } } "auth_ref": "r1468" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } } "auth_ref": "r683" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": "http://catalent.com/role/EquityBasedCompensationAdditionalDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } } "auth_ref": "r686" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } } "auth_ref": "r683" } } "ctlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPaymentsPerShare": { "xbrltype": "perShareItem", "nsuri": "http://catalent.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPaymentsPerShare", "presentation": "http://catalent.com/role/EquityBasedCompensationAdditionalDetails" } } "lang": "en-us" } "role": "terseLabel": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Dividend Payments, Per Share", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Dividend Payments, Per Share", "documentation": "The estimated amount of dividends per share to be paid to holders of the underlying shares (expected dividends per share) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends." } } } "auth_ref": " " } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": "http://catalent.com/role/EquityBasedCompensationAdditionalDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } } "auth_ref": "r692" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": "http://catalent.com/role/EquityBasedCompensationAdditionalDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } } "auth_ref": "r694" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": "http://catalent.com/role/EquityBasedCompensationAdditionalDetails" } } "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } "auth_ref": "r663" } } "r665" } } "r667" } } "r668" } } "r669" } } "r671" } } "r672" } } "r673" } } "r674" } } "r675" } } "r676" } } "r677" } } "r678" } } "r679" } } "r680" } } "r681" } } "r682" } } "r683" } } "r684" } } "r685" } } "r686" } } "r687" } } "r688" } } "r691" } } "r692" } } "r693" } } "r694" } } "r695" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } } "auth_ref": "r30" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": "http://catalent.com/role/EquityBasedCompensationAdditionalDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } } "auth_ref": " " } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": "http://catalent.com/role/EquityBasedCompensationAdditionalDetails", "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails" } } "lang": "en-us" } "role": "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } } "auth_ref": "r686" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails" } } "lang": "en-us" } "role": "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } } "auth_ref": "r678" } } "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails" } } "lang": "en-us" } "role": "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in

Period, "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": { "r677" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": { "r675" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": { "r91" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": { "r671", "r672" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r688" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r688" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r688" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r687" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r687" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r687" } } }, "ctdt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedandExpectedtoVestExercisableExercisedWeightedAverageRemainingContractualTermdu": { "xbrltype": "durationItemType", "nsuri": "http://catalent.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedandExpectedtoVestExercisableExercisedWeightedAverageRemainingContractualTermduration", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement by Share Based Payment Award Options Vested and Expected to Vest Exercisable Exercised Weighted Average Remaining Contractual Term (duration)", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Vested and Expected to Vest Exercisable Exercised Weighted Average Remaining Contractual Term (duration)", "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Options Vested and Expected to Vest Exercisable Exercised Weighted Average Remaining Contractual Term (duration)" } } }, "auth_ref": { } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": { "http://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetailsDetails", "http://catalent.com/role/EquityBasedCompensationAdditionalDetails", "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails", "http://catalent.com/role/EquityDetails", "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails", "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Equity Award [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": { "r667", "r668", "r669", "r674", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r691", "r692", "r693", "r694", "r695" } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": { "r676" } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": { "r678" } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": { "r677" } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": { "r675" } } }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel": "Equity-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": { "r662", "r670", "r689", "r690", "r691", "r692", "r695", "r702", "r703",

"r704": "r705" } } , "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Share Price", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } } , "auth_ref": { } } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "crdr": "debit", "presentation": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement." } } } , "auth_ref": { "r696" } } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } } , "auth_ref": { "r691" } } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } } , "auth_ref": { } } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease", "presentation": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease)", "documentation": "Number of increase (decrease) of non-vested options." } } } , "auth_ref": { } } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails" } , "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } } , "auth_ref": { "r216" } } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails" } , "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } , "auth_ref": { "r688" } } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } , "auth_ref": { "r687" } } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } } , "auth_ref": { "r686" } } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberofShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberofShares", "presentation": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "documentation": "Number of options vested." } } } , "auth_ref": { } } , "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "presentation": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } } , "auth_ref": { "r213", "r214" } } , "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": { "http://catalent.com/role/EquityBasedCompensation" } , "lang": { "en-us": { "role": { "terseLabel": "Shareholders' Equity and Share-based Payments", "label": "Shareholders' Equity and Share-based Payments [Text Block]", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } } , "auth_ref": { "r202", "r212" } } , "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "http://catalent.com/role/EquityDetails" } , "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Shares Issued, Price Per Share", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } } , "auth_ref": { } } , "us-gaap_ShortTermDebtInterestRateIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtInterestRateIncrease", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt, Interest Rate Increase", "label": "Short-Term Debt, Interest Rate Increase", "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument." } } } , "auth_ref": { } } , "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } } , "auth_ref": { "r141", "r142", "r1429", "r1430" } } , "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } } , "auth_ref": { "r140", "r1428", "r1429", "r1430" } } , "cslt_ShortTermLeaseCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "ShortTermLeaseCosts", "crdr": "debit", "presentation": { "http://catalent.com/role/LeasesCostDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Short-Term Lease Costs", "label": "Short-Term Lease Costs", "documentation": "Short-Term Lease Costs" } } } , "auth_ref": { } } , "cslt_SixMonthMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "SixMonthMember", "presentation": { "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Six Month", "label": "Six Month [Member]", "documentation": "Six Month [Member]" } } } , "auth_ref": { } } , "cslt_SkeletalCellTherapySupportSAMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "SkeletalCellTherapySupportSAMember", "presentation": { "http://catalent.com/role/BusinessCombinationsDivestituresDetails", "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Skeletal Cell Therapy Support SA", "label": "Skeletal Cell Therapy Support SA [Member]", "documentation": "Skeletal Cell Therapy Support SA" } } } , "auth_ref": { } } , "cslt_SoftgelAndOralTechnologiesMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "SoftgelAndOralTechnologiesMember", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail", "http://catalent.com/role/SegmentInformationCapitalExpendituresDetails", "http://catalent.com/role/SegmentInformationDepreciationandAmortizationDetails", "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "http://catalent.com/role/SegmentInformationTotalAssetsDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Softgel and Oral Technologies [Member]", "label": "Softgel and Oral Technologies [Member]", "documentation": "Softgel and Oral Technologies [Member]" } } } , "auth_ref": { } } , "cslt_SoftgelTechnologiesMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "SoftgelTechnologiesMember", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountofGoodwillDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Softgel Technologies", "label": "Softgel Technologies [Member]", "documentation": "Softgel [Member]" } } } , "auth_ref": { } } , "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": { "http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Software and Software Development Costs", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } } , "auth_ref": { } } , "cslt_SpareParts": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "SpareParts", "crdr": "debit", "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationPrepaidandOtherAssetsDetail" } , "lang": { "en-us": { "role": { "terseLabel": "Spare Parts", "label": "Spare Parts", "documentation": "Spare parts." } } } , "auth_ref": { } } , "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail" } , "lang": { "en-us": { "role": { "terseLabel": "State and Local Jurisdiction", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated state or local jurisdiction

entitled to levy and collect income tax." } } }, "auth_ref": { "r721" } }, "cslt_StatedPercentageDrawOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://catalent.com/20240630", "localname": "StatedPercentageDrawOutstanding", "presentation": { "http://catalent.com/role/LongTermObligationsAndOtherShortTermBorrowingsAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Stated Percentage Draw Outstanding", "label": "Stated Percentage Draw Outstanding", "documentation": "documentation", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": { "http://catalent.com/role/GoodwillCarryingAmountOfGoodwillDetail": "http://catalent.com/role/RestructuringAndOtherCostsDetails", "http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenuebyTypeOfActivityAndReportingSegmentDetails", "http://catalent.com/role/RevenueFromContractWithCustomerDetails": "http://catalent.com/role/SegmentInformationCapitalExpendituresDetails", "http://catalent.com/role/SegmentInformationDepreciationAndAmortizationDetails": "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "http://catalent.com/role/SegmentInformationTotalAssetsDetails": "http://catalent.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Business Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": { "r237", "r238", "r239", "r240", "r268", "r370", "r375", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r401", "r402", "r403", "r404", "r405", "r407", "r408", "r409", "r415", "r422", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r478", "r484", "r497", "r501", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r1164", "r1167", "r1168", "r1175", "r1232", "r1542", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1573", "r1574" } }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": { "http://catalent.com/role/BusinessCombinationsDivestituresDetails": "http://catalent.com/role/ConsolidatedStatementOfComprehensiveIncomeLoss", "http://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetails": "http://catalent.com/role/EquityBasedCompensationAdditionalDetails", "http://catalent.com/role/EquityBasedCompensationActivityDetails": "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": { "r261", "r282", "r283", "r284", "r328", "r356", "r357", "r362", "r364", "r372", "r373", "r426", "r513", "r516", "r517", "r518", "r522", "r523", "r553", "r554", "r556", "r566", "r847", "r1022", "r1023", "r1024", "r1025", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1061", "r1084", "r1103", "r1125", "r1126", "r1127", "r1128", "r1129", "r1340", "r1374", "r1385" } }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesRecentFinancialAccountingStandardsDetails": "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquitySharesofCommonStock", "http://catalent.com/role/ConsolidatedStatementofComprehensiveIncomeLoss", "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveEarningsLossDetails": "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": { "r27", "r154", "r157", "r158", "r264", "r308", "r309", "r310", "r332", "r333", "r334", "r337", "r345", "r348", "r350", "r371", "r430", "r436", "r481", "r567", "r753", "r754", "r766", "r767", "r768", "r771", "r785", "r786", "r800", "r802", "r803", "r804", "r805", "r807", "r818", "r855", "r857", "r858", "r859", "r860", "r862", "r870", "r873", "r900", "r977", "r1007", "r1008", "r1009", "r1030", "r1103" } }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": { "http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenuebyGeographyDetails": "http://catalent.com/role/RevenueRecognitionTables", "http://catalent.com/role/SegmentInformationAssetsandRevenuesDetail": { "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": { "r413", "r414", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r1044", "r1046", "r1048", "r1110", "r1112", "r1115", "r1124", "r1132", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1150", "r1186", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1231", "r1238", "r1442", "r1542", "r1546", "r1547", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1573", "r1574" } }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesConcentrationsOfCreditRiskandMajorCustomersDetails", "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentExpenseDetails", "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquitySharesofCommonStock", "http://catalent.com/role/ConsolidatedStatementofComprehensiveIncomeLoss", "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail": { "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r332", "r333", "r334", "r371", "r873", "r916", "r1020", "r1041", "r1052", "r1033", "r1054", "r1055", "r1056", "r1057", "r1061", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1075", "r1076", "r1077", "r1078", "r1079", "r1081", "r1085", "r1086", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1103", "r1239" } }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": { "r11", "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": { "r11", "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": { "r11", "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": { "r11", "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": { "http://catalent.com/role/ConsolidatedStatementofComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": { "r351", "r660", "r1343", "r1344", "r1383" } }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesConcentrationsOfCreditRiskandMajorCustomersDetails", "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesPropertyandEquipmentandOtherDefiniteLivedIntangibleAssetsDetails": "http://catalent.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesResearchandDevelopmentExpenseDetails", "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquitySharesofCommonStock", "http://catalent.com/role/ConsolidatedStatementofComprehensiveIncomeLoss", "http://catalent.com/role/SupplementalBalanceSheetInformationOtherAssetsNonCurrentDetail": { "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r332", "r333", "r334", "r371", "r418", "r873", "r916", "r1020", "r1041", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1061", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1075", "r1076", "r1077", "r1078", "r1079", "r1081", "r1085", "r1086", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1103", "r1239" } }, "cslt_StockIssuedDuringPeriodSharesOverAllotmentOption": { "xbrltype": "pureItemType", "nsuri": "http://catalent.com/20240630", "localname": "StockIssuedDuringPeriodSharesOverAllotmentOption", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Stock Issued During Period, Shares, Over-allotment Option", "label": "Stock Issued During Period, Shares, Over-allotment Option", "documentation": "documentation", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCOrTsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": { "r1260", "r1271", "r1281", "r1313" } }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": { "r11", "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockCompensationPlanMember", "presentation": { "http://catalent.com/role/EarningsPerShareEarningsPerShareAdditionalDetails": { "lang": { "en-us": { "role": { "terseLabel": "Stock Compensation Plan [Member]", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": { "r1387" } }, "cslt_StockCompensationPlanOmnibusMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "StockCompensationPlanOmnibusMember", "presentation": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails": { "lang": { "en-us": { "role": { "terseLabel": "Stock Compensation Plan - Omnibus [Member]", "label": "Stock Compensation Plan - Omnibus [Member]", "documentation": "Stock Compensation Plan - Omnibus [Member]" } } }, "auth_ref": { "r11", "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": { "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquity", "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquitySharesofCommonStock", "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Stock Issued During Period, Shares, New Issues", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": { "r27", "r153", "r154", "r206", "r1022", "r1103", "r1126" } }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": { "http://catalent.com/role/ConsolidatedStatementofChangesinShareholdersEquity",


```

http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquitySharesOfCommonStock";
"http://catalent.com/role/EquityBasedCompensationAdditionalDetails"; "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails"; "l": "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": { "r27": "r153", "r154": "r206", "r676" } }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": { "http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquity"; "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails"; "l": "lang": { "en-us": { "role": { "terseLabel": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": { "r27": "r154", "r157": "r158", "r206" } } }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments", "crdr": "credit", "presentation": { "http://catalent.com/role/ConsolidatedStatementsOfCashFlows"; "l": "lang": { "en-us": { "role": { "terseLabel": "Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments", "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid-in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components." } } }, "auth_ref": { "r27": "r153", "r154", "r206", "r1030", "r1103", "r1126", "r1248" } } }, "ctlt_StockIssuedDuringPeriodValueOverAllotmentOption": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "StockIssuedDuringPeriodValueOverAllotmentOption", "crdr": "debit", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails"; "l": "lang": { "en-us": { "role": { "terseLabel": "Stock Issued During Period, Value, New Issues", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": { "r27": "r153", "r154", "r206", "r1030", "r1103", "r1126", "r1248" } } }, "ctlt_StockIssuedDuringPeriodValueOverAllotmentOption": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "StockIssuedDuringPeriodValueOverAllotmentOption", "crdr": "debit", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossEquityDetails"; "l": "lang": { "en-us": { "role": { "terseLabel": "Stock Issued During Period, Value, Over-allotment Option", "label": "Stock Issued During Period, Value, Over-allotment Option", "documentation": "Stock Issued During Period, Value, Over-allotment Option" } } }, "auth_ref": { "r27": "r153", "r154", "r206", "r1030", "r1103", "r1126", "r1248" } } }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": { "http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquity"; "l": "lang": { "en-us": { "role": { "terseLabel": "Stock Issued During Period, Value, Stock Options Exercised", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": { "r27": "r154", "r157": "r158", "r206" } } }, "ctlt_StockOptionGrantedContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://catalent.com/20240630", "localname": "StockOptionGrantedContractualTerm", "presentation": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails"; "l": "lang": { "en-us": { "role": { "terseLabel": "Stock Option Granted Contractual Term", "label": "Stock Option Granted Contractual Term", "documentation": "Stock option granted contractual term." } } }, "auth_ref": { "r27": "r154", "r157": "r158", "r206" } } }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://catalent.com/role/ConsolidatedBalanceSheets"; "l": "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://catalent.com/role/ConsolidatedBalanceSheets"; "l": "lang": { "en-us": { "role": { "totalLabel": "Total shareholdersEquity2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": { "r154", "r157": "r158", "r193", "r1063", "r1080", "r1104", "r1105", "r1218", "r1249", "r1376", "r1397", "r1512", "r1578" } } }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": { "http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquity"; "l": "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": { "r105", "r106", "r107", "r264", "r265", "r309", "r332", "r333", "r334", "r337", "r345", "r348", "r430", "r436", "r481", "r567", "r753", "r754", "r766", "r767", "r768", "r771", "r785", "r786", "r800", "r802", "r803", "r804", "r805", "r807", "r818", "r855", "r857", "r862", "r871", "r900", "r1008", "r1009", "r1028", "r1063", "r1080", "r1104", "r1105", "r1130", "r1249", "r1376", "r1397", "r1512", "r1578" } } }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note Abstract", "label": "Stockholders' Equity Note Abstract" } } }, "auth_ref": { "r27": "r153", "r154", "r206", "r1030", "r1103", "r1126", "r1248" } } }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": { "http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLoss"; "l": "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": { "r202", "r327", "r552", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r563", "r564", "r565", "r567", "r809", "r1106", "r1107", "r1131" } } }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": { "http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquity"; "l": "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity, Other", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": { "r27": "r153", "r154", "r206", "r1030", "r1103", "r1126", "r1248" } } }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": { "http://catalent.com/role/SubsequentEventsDetails"; "l": "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Line Items", "label": "Subsequent Event Line Items", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": { "r863", "r904" } } }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": { "http://catalent.com/role/SubsequentEventsDetails"; "l": "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r863", "r904" } } }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": { "http://catalent.com/role/SubsequentEventsDetails"; "l": "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Table", "label": "Subsequent Event Table", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": { "r863", "r904" } } }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": { "http://catalent.com/role/SubsequentEventsDetails"; "l": "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type Axis", "label": "Subsequent Event Type Axis", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r863", "r904" } } }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": { "http://catalent.com/role/SubsequentEventsDetails"; "l": "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r863", "r904" } } }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events Abstract" } } }, "auth_ref": { "r27": "r153", "r154", "r206", "r1030", "r1103", "r1126", "r1248" } } }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": { "http://catalent.com/role/SubsequentEventsNotes"; "l": "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Text Block]", "label": "Subsequent Events [Text Block]", "documentation":
```

TemporaryEquityParOrStatedValuePerShare, "presentation": "http://catalent.com/role/ConsolidatedBalanceSheetsParenthetical", "lang": "en-us", "role": "terseLabel", "Temporary Equity, Par or Stated Value Per Share", "label": "Temporary Equity, Par or Stated Value Per Share", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } , "auth_ref": "r38", "r78" } } , "us-gaap TemporaryEquitySharesAuthorized", { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesAuthorized", "presentation": "http://catalent.com/role/ConsolidatedBalanceSheetsParenthetical", "lang": "en-us", "role": "terseLabel", "Temporary Equity, Shares Authorized", "label": "Temporary Equity, Shares Authorized", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } } , "auth_ref": "r152" } } , "us-gaap TemporaryEquitySharesOutstanding", { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesOutstanding", "presentation": "http://catalent.com/role/ConsolidatedBalanceSheetsParenthetical", "lang": "en-us", "role": "terseLabel", "Temporary Equity, Shares Outstanding", "label": "Temporary Equity, Shares Outstanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } } , "auth_ref": "r152" } } , "us-gaap TemporaryEquityStockIssuedDuringPeriodValueNewIssues", { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": "http://catalent.com/role/ConsolidatedStatementOfChangesInShareholdersEquity", "lang": "en-us", "role": "terseLabel", "Temporary Equity, Stock Issued During Period, Value, New Issues", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "documentation": "Value of new stock classified as temporary equity issued during the period." } } } , "auth_ref": " " } } , "cslt_TermLoanFacilityIncrementalDollarTermB2Member", { "xbrltype": "domainItem", "nsuri": "http://catalent.com/20240630", "localname": "TermLoanFacilityIncrementalDollarTermB2Member", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Term Loan Facility Incremental Dollar Term B-2 [Member]", "label": "Term Loan Facility Incremental Dollar Term B-2 [Member]", "documentation": "Term Loan Facility Incremental Dollar Term B-2" } } } , "auth_ref": " " } } , "cslt_TermLoanFourFacilityDollarDenominatedMember", { "xbrltype": "domainItem", "nsuri": "http://catalent.com/20240630", "localname": "TermLoanFourFacilityDollarDenominatedMember", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Term Loan Four Facility Dollar Denominated" } } } , "auth_ref": " " } } , "cslt_TermLoanThreeFacilityDollarDenominatedMember", { "xbrltype": "domainItem", "nsuri": "http://catalent.com/20240630", "localname": "TermLoanThreeFacilityDollarDenominatedMember", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Term Loan Three Facility Dollar Denominated [Member]", "label": "Term Loan Three Facility Dollar Denominated [Member]", "documentation": "Term Loan Three Facility Dollar Denominated" } } } , "auth_ref": " " } } , "cslt_TermLoanTwoFacilityDollarDenominatedMember", { "xbrltype": "domainItem", "nsuri": "http://catalent.com/20240630", "localname": "TermLoanTwoFacilityDollarDenominatedMember", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Term Loan Two Facility Dollar Denominated [Member]", "label": "Term Loan Two Facility Dollar Denominated [Member]", "documentation": "Term Loan Two Facility Dollar Denominated" } } } , "auth_ref": " " } } , "us-gaap TextBlockAbstract", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TextBlockAbstract", "lang": "en-us", "role": "Text Block [Abstract]" } } } , "auth_ref": " " } } , "cslt_ThreeMonthMember", { "xbrltype": "domainItem", "nsuri": "http://catalent.com/20240630", "localname": "ThreeMonthMember", "presentation": "http://catalent.com/role/LongTermObligationsandOtherShortTermBorrowingsInterestRateDetails", "lang": "en-us", "role": "Three Month" } } } , "auth_ref": " " } } , "cslt_TimeBasedRestrictedStockUnitsMember", { "xbrltype": "domainItem", "nsuri": "http://catalent.com/20240630", "localname": "TimeBasedRestrictedStockUnitsMember", "presentation": "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails", "lang": "en-us", "role": "Time Based Restricted Stock Units [Member]", "label": "Time Based Restricted Stock Units [Member]", "documentation": "Time Based Restricted Stock Units [Member]" } } } , "auth_ref": " " } } , "cslt_TimeMember", { "xbrltype": "domainItem", "nsuri": "http://catalent.com/20240630", "localname": "TimeMember", "presentation": "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails", "lang": "en-us", "role": "Time [Member]", "label": "Time [Member]", "documentation": "Time" } } } , "auth_ref": " " } } , "cslt_TotalCatalentSegmentMember", { "xbrltype": "domainItem", "nsuri": "http://catalent.com/20240630", "localname": "TotalCatalentSegmentMember", "presentation": "http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenuebytypeofactivityandreportingsegmentDetails", "lang": "en-us", "role": "Total Catalent Segment", "label": "Total Catalent Segment [Member]", "documentation": "Total Catalent Segment" } } } , "auth_ref": " " } } , "cslt_TotalCatalentSubTotalOfSegmentReportingMember", { "xbrltype": "domainItem", "nsuri": "http://catalent.com/20240630", "localname": "TotalCatalentSubTotalOfSegmentReportingMember", "presentation": "http://catalent.com/role/SegmentInformationNetRevenueandSegmentEbitdaDetail", "lang": "en-us", "role": "Total Catalent sub-total of Segment Reporting [Member]", "label": "Total Catalent sub-total of Segment Reporting [Member]", "documentation": "Total Catalent sub-total of Segment Reporting" } } } , "auth_ref": " " } } , "cslt_TotalCatalentbeforeintersegmentrevenueeliminationMember", { "xbrltype": "domainItem", "nsuri": "http://catalent.com/20240630", "localname": "TotalCatalentbeforeintersegmentrevenueeliminationMember", "presentation": "http://catalent.com/role/RevenueRecognitionDisaggregationOfRevenuebytypeofactivityandreportingsegmentDetails", "lang": "en-us", "role": "Total Catalent before inter-segment revenue elimination [Member]", "label": "Total Catalent before inter-segment revenue elimination [Member]", "documentation": "Total Catalent before inter-segment revenue elimination" } } } , "auth_ref": " " } } , "cslt_TotalDebtUSDenominatedTermLoan", { "xbrltype": "monetaryItem", "nsuri": "http://catalent.com/20240630", "localname": "TotalDebtUSDenominatedTermLoan", "crdr": "debit", "presentation": "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "lang": "en-us", "role": "Total Debt, U.S. Denominated Term Loan", "label": "Total Debt, U.S. Denominated Term Loan", "documentation": "Total Debt, U.S. Denominated Term Loan" } } } , "auth_ref": " " } } , "cslt_TotalFixedRate", { "xbrltype": "percentItem", "nsuri": "http://catalent.com/20240630", "localname": "TotalFixedRate", "presentation": "http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "lang": "en-us", "role": "Total Fixed Rate", "label": "Total Fixed Rate", "documentation": "Total Fixed Rate" } } } , "auth_ref": " " } } , "cslt_TotalLeaseLiability", { "xbrltype": "monetaryItem", "nsuri": "http://catalent.com/20240630", "localname": "TotalLeaseLiability", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": "en-us", "role": "Total Lease Liability", "label": "Total Lease Liability", "documentation": "Total Lease Liability" } } } , "auth_ref": " " } } , "cslt_TotalLeaseLiabilityPaymentsDue", { "xbrltype": "monetaryItem", "nsuri": "http://catalent.com/20240630", "localname": "TotalLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": "en-us", "role": "Total Lease Liability Payments Due", "label": "Total Lease Liability Payments Due", "documentation": "Total Lease Liability Payments Due" } } } , "auth_ref": " " } } , "cslt_TotalLeaseLiabilityPaymentsDueAfterYearFive", { "xbrltype": "monetaryItem", "nsuri": "http://catalent.com/20240630", "localname": "TotalLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": "en-us", "role": "Total Lease Liability Payments Due After Year Five", "label": "Total Lease Liability Payments Due After Year Five", "documentation": "Total Lease Liability Payments Due After Year Five" } } } , "auth_ref": " " } } , "cslt_TotalLeaseLiabilityPaymentsDueYearFour", { "xbrltype": "monetaryItem", "nsuri": "http://catalent.com/20240630", "localname": "TotalLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": "en-us", "role": "Total Lease Liability Payments Due Year Four", "label": "Total Lease Liability Payments Due Year Four", "documentation": "Total Lease Liability Payments Due Year Four" } } } , "auth_ref": " " } } , "cslt_TotalLeaseLiabilityPaymentsDueYearOne", { "xbrltype": "monetaryItem", "nsuri": "http://catalent.com/20240630", "localname": "TotalLeaseLiabilityPaymentsDueYearOne", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": "en-us", "role": "Total Lease Liability Payments Due Year One", "label": "Total Lease Liability Payments Due Year One", "documentation": "Total Lease Liability Payments Due Year One" } } } , "auth_ref": " " } } , "cslt_TotalLeaseLiabilityPaymentsDueYearThree", { "xbrltype": "monetaryItem", "nsuri": "http://catalent.com/20240630", "localname": "TotalLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": "en-us", "role": "Total Lease Liability Payments Due Year Three", "label": "Total Lease Liability Payments Due Year Three", "documentation": "Total Lease Liability Payments Due Year Three" } } } , "auth_ref": " " } } , "cslt_TotalLeaseLiabilityPaymentsDueYearTwo", { "xbrltype": "monetaryItem", "nsuri": "http://catalent.com/20240630", "localname": "TotalLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": "en-us", "role": "Total Lease Liability Payments Due Year Two", "label": "Total Lease Liability Payments Due Year Two", "documentation": "Total Lease Liability Payments Due Year Two" } } } , "auth_ref": " " } } , "cslt_TotalLeaseLiabilityUndiscountedExcessAmount", { "xbrltype": "monetaryItem", "nsuri": "http://catalent.com/20240630", "localname": "TotalLeaseLiabilityUndiscountedExcessAmount", "crdr": "debit", "presentation": "http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails", "lang": "en-us", "role": "Total Lease Liability Undiscounted Excess Amount" } } } , "auth_ref": " " } }

"TotalLeaseLiabilityUndiscountedExcessAmount":{ "crdr": "credit", "presentation": {
"http://catalent.com/role/LeasesScheduleofMaturitiesofOperatingAndFinanceLeaseLiabilitiesDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Total Lease Liability Undiscounted Excess Amount", "label": "Total Lease Liability Undiscounted Excess Amount" } } },
"auth_ref": {
"ecdd_TotalsShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalsShareholderRtnAmt",
"presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": {
"lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } },
"auth_ref": {
"r1299": { "ecdd_TotalsShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TotalsShareholderRtnVsPeerGroupTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": {
"lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } },
"auth_ref": {
"r1306": {
"ctlt_TradeReceivablesAllowanceForDoubtfulAccountsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://catalent.com/20240630", "localname":
"TradeReceivablesAllowanceForDoubtfulAccountsTableTextBlock", "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationTables": {
"lang": { "en-us": { "role": { "terseLabel": "Trade receivables allowance for doubtful accounts", "label": "Trade Receivables Allowance For Doubtful Accounts Table [Text Block]",
"documentation": "Trade receivables allowance for doubtful accounts." } } },
"auth_ref": {
"r1307": { "ecdd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement", "label": "Trading Arrangement [Axis]" } } },
"auth_ref": {
"r1326": { "ecdd_TradingArrByIndTable": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } },
"auth_ref": {
"r1328": {
"ctlt_TradingSecuritiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "TradingSecuritiesAtFairValue", "crdr": "debit",
"presentation": { "http://catalent.com/role/FairValueMeasuresandDisclosuresDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Trading Securities at Fair Value", "label":
"Trading Securities at Fair Value", "documentation": "participant directed stock and bond mutual funds" } } },
"auth_ref": {
"dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { "http://catalent.com/role/DocumentandEntityInformation": {
"lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } },
"auth_ref": {
"us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseGrossOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseGrossOfTax", "crdr": "credit", "presentation": {
"http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail": {
"lang": { "en-us": { "role": { "terseLabel": "Derivatives used in Net Investment Hedge, Increase (Decrease), Gross of Tax", "label": "Derivatives used in Net Investment Hedge, Increase (Decrease), Gross of Tax", "documentation": "Amount, before tax, of increase (decrease) in the cumulative translation adjustment from gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity." } } },
"auth_ref": {
"r1513": {
"us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease", "calculation": {
"http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "weight": 1.0, "order": 1.0 } },
"presentation": {
"http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Net investment hedge", "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity." } } },
"auth_ref": {
"r1517": {
"us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease", "calculation": {
"http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "weight": 1.0, "order": 3.0 } },
"presentation": {
"http://catalent.com/role/EquityandAccumulatedOtherComprehensiveIncomeLossMinimumPensionLiabilityDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Translation adjustments", "label": "Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in cumulative translation adjustment, after tax, from translating foreign currency financial statements into the reporting currency." } } },
"auth_ref": {
"r167": {
"ecdd_TrdrArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrAdoptionDate", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } },
"auth_ref": {
"r1329": {
"ecdd_TrdrArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrDuration", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } },
"auth_ref": {
"r1330": {
"ecdd_TrdrArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrExpirationDate",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } },
"auth_ref": {
"r1330": {
"ecdd_TrdrArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndName",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } },
"auth_ref": {
"r1328": {
"ecdd_TrdrArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndTitle",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } },
"auth_ref": {
"r1328": {
"ecdd_TrdrArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TrdrArrSecuritiesAggAvailAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } },
"auth_ref": {
"r1331": {
"ecdd_TrdrArrTerminationDate": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrTerminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } },
"auth_ref": {
"r1329": {
"us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": {
"http://catalent.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRecentFinancialAccountingStandardsDetails":
"http://catalent.com/role/EquityBasedCompensationAdditionalDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Type of Adoption [Domain]", "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } },
"auth_ref": {
"r262": {
"r263": {
"r264": {
"r265": {
"r266": {
"r267": {
"r336": {
"r337": {
"r338": {
"r339": {
"r351": {
"r416": {
"r417": {
"r427": {
"r428": {
"r429": {
"r430": {
"r431": {
"r432": {
"r433": {
"r434": {
"r435": {
"r436": {
"r480": {
"r481": {
"r491": {
"r753": {
"r754": {
"r755": {
"r756": {
"r757": {
"r763": {
"r764": {
"r765": {
"r766": {
"r767": {
"r768": {
"r769": {
"r770": {
"r771": {
"r772": {
"r773": {
"r774": {
"r775": {
"r776": {
"r777": {
"r778": {
"r779": {
"r780": {
"r781": {
"r782": {
"r783": {
"r784": {
"r785": {
"r786": {
"r797": {
"r798": {
"r799": {
"r800": {
"r801": {
"r802": {
"r803": {
"r804": {
"r805": {
"r806": {
"r807": {
"r810": {
"r811": {
"r812": {
"r813": {
"r814": {
"r815": {
"r816": {
"r817": {
"r818": {
"r819": {
"r820": {
"r843": {
"r844": {
"r869": {
"r870": {
"r871": {
"r895": {
"r896": {
"r897": {
"r898": {
"r899": {
"r900": {
"r918": {
"r919": {
"r920": {
"r1005": {
"r1006": {
"r1007": {
"r1008": {
"r1009": {
"r1010": {
"r1011": {
"r1012": {
"r1013": {
"r1014": {
"r1015": {
"r1016": {
"us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain",
"presentation": { "http://catalent.com/role/RestructuringandOtherCostsDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } },
"auth_ref": {
"r494": {
"r495": {
"r499": {
"r500": {
"ctlt_USDollar-denominated4.875SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname":
"U.S.Dollar-denominated4.875SeniorNotesMember", "presentation": {
"http://catalent.com/role/LongTermBorrowingsandOtherShortTermBorrowingsAdditionalInformationDetail":
"http://catalent.com/role/LongTermBorrowingsandOtherShortTermBorrowingsFairValueMeasurementsandFinancialInstrumentsCarryingAmountsandEstimatedFairValueoffinanc": {
"lang": { "en-us": { "role": { "terseLabel": "U.S. Dollar-denominated 4.875% Senior Notes [Member]", "label": "U.S. Dollar-denominated 4.875% Senior Notes [Member]",
"documentation": "U.S. Dollar-denominated 4.875% Senior Notes [Member]" } } },
"auth_ref": {
"r1329": {
"ctlt_USFederalDeferredTaxAssetDomain": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "U.S.FederalDeferredTaxAssetDomain", "presentation": {
"http://catalent.com/role/IncomeTaxesAdditionalInformationDetail": {
"lang": { "en-us": { "role": { "terseLabel": "U.S. Federal Deferred Tax Asset [Domain]", "label": "U.S. Federal Deferred Tax Asset [Domain]", "documentation": "U.S. Federal Deferred Tax Asset" } } },
"auth_ref": {
"r1329": {
"ctlt_USStateNetDeferredTaxAssetDomain": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "U.S.StateNetDeferredTaxAssetDomain", "presentation": {
"http://catalent.com/role/IncomeTaxesAdditionalInformationDetail": {
"lang": { "en-us": { "role": { "terseLabel": "State Net Deferred Tax Asset [Domain]", "label": "U.S. State Net Deferred Tax Asset [Domain]", "documentation": "U.S. State Net Deferred Tax Asset" } } },
"auth_ref": {
"r1329": {
"country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": { "http://catalent.com/role/RevenueRecognitionDisaggregationofRevenuebyGeographyDetails":
"http://catalent.com/role/RevenueRecognitionTables": {
"http://catalent.com/role/SegmentInformationAssetsandRevenuesDetail": {
"lang": { "en-us": { "role": { "terseLabel": "United States [Member]", "label": "UNITED STATES" } } },
"auth_ref": {
"r1329": {
"ctlt_USDenominatedTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "USDenominatedTermLoanMember", "presentation": {
"http://catalent.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail": {
"lang": { "en-us": { "role": { "terseLabel": "U.S. Denominated Term Loan [Member]", "label": "U.S. Denominated Term Loan [Member]", "documentation": "U.S. Denominated Term Loan" } } },
"auth_ref": {
"r1329": {
"ctlt_USDollarDenominated500SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname":
"USDollarDenominated500SeniorNotesMember", "presentation": { "http://catalent.com/role/LongTermBorrowingsandOtherShortTermBorrowingsAdditionalInformationDetail":
"http://catalent.com/role/LongTermBorrowingsandOtherShortTermBorrowingsFairValueMeasurementsandFinancialInstrumentsCarryingAmountsandEstimatedFairValueoffinanc": {
"lang": { "en-us": { "role": { "terseLabel": "U.S. Dollar-denominated 5.00% Senior Notes [Member]", "label": "U.S. Dollar-denominated 5.00% Senior Notes [Member]",
"documentation": "U.S. Dollar-denominated 5.00% Senior Notes" } } },
"auth_ref": {
"r1329": {
"us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": {
"http://catalent.com/role/EmployeeRetirementBenefitPlansFiscalYearMaturityDetails": {
"lang": { "en-us": { "role": { "terseLabel": "US Government Agencies Debt Securities [Member]", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debt securities, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA) or Ginnie Mae. Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } },
"auth_ref": {
"r1158": {
"r1192": {
"r1539": {
"us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "presentation": {
"http://catalent.com/role/LongTermBorrowingsandOtherShortTermBorrowingsAdditionalInformationDetail": {
"lang": { "en-us": { "role": { "terseLabel": "Unamortized Debt Issuance Expense", "label": "Unamortized Debt Issuance Expense", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } },
"auth_ref": {
"r1329": {
"us-gaap_UndistributedEarningsOfforeignSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UndistributedEarningsOfforeignSubsidiaries", "crdr": "credit", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail": {
"lang": { "en-us": { "role": { "terseLabel": "Undistributed Earnings of Foreign Subsidiaries", "label": "Undistributed Earnings of Foreign Subsidiaries", "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile." } } },
"auth_ref": {
"r23": {
"r24": {
"r242": {
"r712": {
"ecdd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct",
"presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {
"lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } },
"auth_ref": {
"r1325": {
"us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail":
"http://catalent.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } },
"auth_ref": {
"r713": {
"r735": {
"r1204": {
"us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": {
"http://catalent.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Reductions for tax positions of prior years", "label":

Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": { "r736", "r1204" } }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "debit", "presentation": { "http://catalent.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" } }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": { "r736", "r1204" } }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": { "http://catalent.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Additions based on tax positions related to the current year", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": { "r737", "r1204" } }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": { "http://catalent.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" } }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Additions for tax positions of prior years", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": { "r736", "r1204" } }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "crdr": "credit", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail" } }, "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued", "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued", "documentation": "Amount of interest expense accrued for an underpayment of income taxes." } } }, "auth_ref": { "r1486" } }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": { "http://catalent.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" } }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": { "r739" } }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { "http://catalent.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" } }, "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": { "r60", "r61", "r62", "r246", "r249", "r252", "r253" } }, "cctl_VaccineManufacturingAndInnovationCentreMember": { "xbrltype": "domainItemType", "nsuri": "http://catalent.com/20240630", "localname": "VaccineManufacturingAndInnovationCentreMember", "presentation": { "http://catalent.com/role/BusinessCombinationsDivestituresDetails" } }, "http://catalent.com/role/BusinessCombinationsNetAssetsAcquiredDetails": { "http://catalent.com/role/BusinessCombinationsPurchaseAgreementDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Vaccine Manufacturing and Innovation Centre", "label": "Vaccine Manufacturing and Innovation Centre [Member]", "documentation": "Vaccine Manufacturing and Innovation Centre" } } }, "auth_ref": { } }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail" } }, "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]", "label": "Valuation Allowance by Deferred Tax Asset [Axis]", "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences." } } }, "auth_ref": { "r1488" } }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": { "http://catalent.com/role/IncomeTaxesAdditionalInformationDetail" } }, "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": { "r742" } }, "us-gaap_ValueAddedTaxReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValueAddedTaxReceivable", "crdr": "debit", "presentation": { "http://catalent.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetail" } }, "lang": { "en-us": { "role": { "terseLabel": "Value Added Tax Receivable", "label": "Value Added Tax Receivable", "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities." } } }, "auth_ref": { "r1362" } }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": { "http://catalent.com/role/LeasesCostDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Variable Lease Cost", "label": "Variable Lease Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": { "r885", "r1217" } }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": { "http://catalent.com/role/LongTermObligationsAndOtherShortTermBorrowingsAdditionalInformationDetail" } }, "http://catalent.com/role/LongTermObligationsAndOtherShortTermBorrowingsInterestRateDetails": { "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": { } }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": { "http://catalent.com/role/LongTermObligationsAndOtherShortTermBorrowingsAdditionalInformationDetail" } }, "http://catalent.com/role/LongTermObligationsAndOtherShortTermBorrowingsInterestRateDetails": { "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": { } }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails": { "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": { "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480" } }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails": { "http://catalent.com/role/EquityBasedCompensationOptionActivityDetails": { "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": { "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480" } }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdnCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdnCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "documentation": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year." } } }, "auth_ref": { "r1295" } }, "cctl_WeightedAverageGrantDateFairValueOfRestrictedStockUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://catalent.com/20240630", "localname": "WeightedAverageGrantDateFairValueOfRestrictedStockUnit", "crdr": "debit", "presentation": { "http://catalent.com/role/EquityBasedCompensationAdditionalDetails": { "http://catalent.com/role/EquityBasedCompensationRSUActivityDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value of Restricted Stock Unit", "label": "Weighted Average Grant Date Fair Value of Restricted Stock Unit", "documentation": "Weighted average grant date fair value of restricted stock unit." } } }, "auth_ref": { } }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": { "http://catalent.com/role/EarningsPerShareCalculationsOfEarningsPerShareDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per share or per unit computation." } } }, "auth_ref": { "r1386" } }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": { "http://catalent.com/role/EarningsPerShareCalculationsOfEarningsPerShareDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Number of Shares Outstanding, Basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of basic shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": { "r353", "r364" } }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "presentation": { "http://catalent.com/role/OtherIncomeExpenseDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Write-off of Deferred Debt Issu

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[XBRL](#)

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[Subparagraph](#). "(a)". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"). "r1570". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"). "r1571". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"). "r1572". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147480109/944-80-50-1"). "r1573". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147480109/944-80-50-2"). "r1574". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147480109/944-80-50-2"). "r1575". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "203", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147478009/946-205-45-4"). "r1576". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147478795/946-210-50-6"). "r1577". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"). "r1578". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"). "r1579". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"). "r1580". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"). "r1581". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"). "r1582". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"). "r1583". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(bi))". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"). "r1584". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))". [Publisher](#). "FASB". [URI](#). "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"). "r1585". { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "985", "SubTopic": "2", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2") } ZIP 147 0001596783-24-000087-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001596783-24-000087-xbrl.zip M4SEIHL0 (<E>JFKQZ3KPP)J5-ZYGT86QE/GMTC R-#85 M-AE=>NLM15QM<INX\$2->GXSZYTPS(I\$2J?<IGMVE)RG.3MCN9/<M8(8)=2140-0EN7-Q>=7BC1BLPIMLX2(L2/L)U3KOZ3WTFUO-Y55 G@HGBMG@UNT<> MON(H0Z6F7\$5%L/N=>GSWSVY2CYVN=GKLEWM Q%LUHFHIBX IN-M5IW=>6WI</V046-VLC& KM-LXWH I-V2-IYP-XA3RJA3=>TSLWKSYGIDY GMW%>37KU6<?>1HG1-IN/H8/TWIK/PFBZ<1#0f62IQ3L/2ZG 9WW>13PB%7U M2ZJ)< O RX3B+VJ->CJF78G4V-W+26DR/L WN+B=&6 M2S>=&XIG-NONK7IFVM6?>EVHLBI-M@H6/TRWG/C&GCVC(W58C1?K?1@-MJS,&LBHW F#Q%1?C:IC5G6< @P=MWT82?>MGP1OTW1L J-FTY LJO-SODDER& F.OOK4J1STDE7I)->JIG M8KUZE74IC N%8/Y/-<I9G=>#8>M2ZCK<1/3=1/(HTGO< EVGM B M#&FERA IW:IFOY=>M>2LKJFU6UL M?>2ASELY12WEV-> A^#RJ<- QMR.NQG:6PA=(MQ9>PB+10JQU/OV-R3J3?<- ZUR#4+NY^<AC995 MWI:OTS3US3T+9&>13@<- KB->1JFIWRWC+8BP)GO<?>2?>9-D^>1<CNJ1G2H6^<M1<+IRWPA#1IOZB&=>7WTA2IECEP.T@<14~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

(W)40%+70"P6"9=0D4SS")K).V4C-E0-1UGHRYAL-6'6WP)FSG;E8:0MCRKTP&4Z3-GJ;C'A6A>B-M0+1N2\$LK@NM2H2LV3ZU\$;EDB:1UF4D2.11-4.B.7/C%DBL-
PSPX*P+M.BX;E0:RZJ+OQ;IHW.WC6N17A+15080"1-T=7JG=C:P5A-M+X12.P1PG9.M5E6V&X3J/#8Y&3S;1-T=N0#(BOX)"T=HP@M:CV07?&MZ=8.U3
H0?Q223J+IF.F1Q1H1OZRR+DEW.M.87726E1F2I@C.K+K5+V2=418Y0700/DB2+&4Z&R#M5#FFKFNLS&A87.M.TT15V-W>YD2&8SF.6S0.H64PHU+G&E8.JH1+<GB-
H7?>H873DBL+MPPM"B.J6H+1<=AO2.FH14"=6F.R8+<C2I(C+HNN)ODIP@40ERXIC(MCIC(MQ03BGH;E1"U1.27+Z=SVL40H"V.E4S0QU2D1241MN.A.7-
818HW>70.4D.6JX.M*8PS.C%9RF1Q0.0.8D7.OLR.=Q\$W\$=4S;6XN15"1YQ2Y31X&BYM+ME\$8/8<8C0QZTL.M65@B:7D<.<73DFI"QGG6JLAH\$>QT<0\$DFI90
211Q."H0L6YVEOH"U/METPT232.8G(MUR)0R1RSPNE2)8A"XRHIH-MR.T=R-RV.M"RUZ"3#"#-K2=&(L.Z4<1=&7>8-BOSU.P)27E(21V-1&\$M.W&MIF6.6NT@'DM6BL
2-34H"FS1P>PU@FI+OQ@IGH.F=5I2P2I3L&26VHA33W.<94NS"2GM4F+MFFUKLNSTFY>=1&@CQ02B#6M1M"E0R1Y>OHR2WC=;X.U.19J9C MRQUG18.W6
4780IRXW"CG886E.CIX@IC##H39A9E1P1UG6TA.M.=<S&2&GB17KAHL-T@>K.XXLS1LP0W1"WO>>4GT.3&7ID"/J.7467WV.M.#.H7ITG4C>FPFIO=RXRAX.A6H
R"51&A)3?BFOFOJ.HWTL1SRM=PM.MKKXBH160B(WK62.6-3Z/DO233#H57<9-ID%OE&5LYDQUP.SHA7Q.
@P@S&52Q0LH1.E2040G&BCZ+L1.W8JQCDCE3A.3077849G0.DN21P8S?Y0:7Q6H144M+MT4.5JUBJG1Q12>6D@U'BW="NIF'WNO&8<.<D.@Z.RZ3I@T."Q1CN
53LEQ&E1>41079V6&U>R"FY84CE13B1FM13ZJ3"TO@H.Z\$7.362W2.M2.C6BOQ%B:U.L0.M2V"QOIHIDV(<7KJY5UPLZ1&W%>H@0\$PU@I0ES-H"EN6XE@0I3B@
HJ"50>6H7F"K1M2"=5E9L?..#Y.MP=&SV73%&1R+>G10A2.B)SJLH.MF@R5C&#5.5%4H36<=&C5:PW2#1P.M.744YACGC0M&#JZFN15U7>H00.M@82H7Q1
KJUG=>2V=VKC17H152U#M.A.C.(NIQS.M27%OMS<0?>CFNNVRIGNX"4Q@>V>2?2NLS&U@I1@U9L3.NDIE12&=0.MW47&TVC0C8=>3CQH.26=>K7C6C>3>6.36
558MRDPTFM>#<0@I@IWB-MG%K0.GF1&GPK.P21.9J3IHW680QY2.SVJONWSY"NKPI"4>BK1.2QA.M.#.1ACQI@M1@Q/R08R&ES:OHVC.GMI.
45.VS*N4AJONT>1&W1Y1#<#J.OE@ENF2Q2.SWG01.U1MW2T/PKW67L1.AGWIHOMJH52P.U491V\$R(X)<#J.OXUV#PYR&E&C3N.71E6>3&K2+12V1W)M-
+5+&>H\$95HV"14@X<4W3=(V*991LAT9UG6<@WPIEWA.Z144G.MH251B.EH%1A"0SYO=ED7C?>1V<=GEV+%"13KG#K(24N&KW)R.M"#=?.(18#4)I.8>.<CQ
84.19PZ36C1+01#PAZ71P05&44L+TQI.M=091VZVW8N@N18741T8JZ"X=KK107HW0Z>FZ5.V<29>B6K+@/V
55>7+7(E.G7VH3F+T.H03HVSXCY3.2D&2C5.ZV%HF0AYS.3MYBX24Y.M5CR+5M=I8EFOI"U=<Q\$>P2SARZSH1+14)\$*AM1\$4TIBTC@+R3@H0M?<
67YX1+U>=U8JPL11&1#1=LM"X4E"4@<A1S+11.MKYEQOIO@QX"=M257+7.LD1QI.Y.YBHY867D@00%KOC(G.ZRJIHA"9C.3&-M7Y1(P&PP%#M7-8+M*HADI+SG(K1
-HYE.OB7NBQ.35\$JH=>9V"1<5=1LS1U>N.N.M.2+<(8YRT1*6WN;7.2WG+Y3E.O#DI0123351@<QZYG.O1M=?<
75FB&US770Q8ZVH.5J.9DSISN<2H.LR8&C&Q">Z27H.FH.FH3V3B1>M/U.M3CY.KMX2IXUH9FU.LAR@2ZTK?WFD6Z7>K17KRO/ED361Q.9\$<(Q#2.M\$U-D-
M=YE@YB>A%*XJ>DEF25%7E\$6V+L7%>@>HNV9VWV.LX\$<10?M21XU0V0G1+U9F2+2331L.C"("T=ZK5E.U5)7RTO>2F1VGM30KJ)3.5.
22XD8BLYS@6D"C1CM"FL41>Y=PLU>#MUWC"SA2T462<@I@EAT>I=U.PI0V.5985E@C@I@XJHU@49<13629.GDV.MG3B035F1P@.1%W2LKY=SXHC\$1>
5HE&A=6F82H127N457>=A\$&3.MA08TISN15J@N<U.U7H13H.U.M.1>H3X22.I.MV2>H6M1+4AJSX&C&PW.MC@2?P2VRBZ02H\$3H*+1HN5-#Y3Z=>=41G1YV>
0)CA7+1LNAU&GHJ.RFTWR.B2190+01Y2.ZA&W0>?BPYI@I=4&E\$Y.CAOH4Z12370#>DUOLQ1.SI<1<=<X.M.BBHVIW(18.6+3JHUV@XVY+>W"174.
66C3M310R1F4P@H\$T1B.M.4<6J"XO"NFENU&W56<F&M@X(C).UA>MVA92>3U7.6&(N@-B4R=CPOAL8&8HX.80Y.M.#.S6<7KS55\$N"1H(TZX.MMEU2NPGCZ"YK+?<
0.01&9IHSENNR8.(C@W1R6M@E)1E"X.MJ\$CZ9Y4CM2F7DJS1B@/PEIBZ1R3E.CSF4131@<I>Z65Y14&U%FEZ1MMI2+9W>E&JSY0A5P.1.HH
22XD8BLYS@6D"C1CM"FL41>Y=PLU>#MUWC"SA2T462<@I@EAT>I=U.PI0V.5985E@C@I@XJHU@49<13629.GDV.MG3B035F1P@.1%W2LKY=SXHC\$1>
5HE&A=6F82H127N457>=A\$&3.MA08TISN15J@N<U.U7H13H.U.M.1>H3X22.I.MV2>H6M1+4AJSX&C&PW.MC@2?P2VRBZ02H\$3H*+1HN5-#Y3Z=>=41G1YV>
0)CA7+1LNAU&GHJ.RFTWR.B2190+01Y2.ZA&W0>?BPYI@I=4&E\$Y.CAOH4Z12370#>DUOLQ1.SI<1<=<X.M.BBHVIW(18.6+3JHUV@XVY+>W"174.
66C3M310R1F4P@H\$T1B.M.4<6J"XO"NFENU&W56<F&M@X(C).UA>MVA92>3U7.6&(N@-B4R=CPOAL8&8HX.80Y.M.#.S6<7KS55\$N"1H(TZX.MMEU2NPGCZ"YK+?<
0.01&9IHSENNR8.(C@W1R6M@E)1E"X.MJ\$CZ9Y4CM2F7DJS1B@/PEIBZ1R3E.CSF4131@<I>Z65Y14&U%FEZ1MMI2+9W>E&JSY0A5P.1.HH
22XD8BLYS@6D"C1CM"FL41>Y=PLU>#MUWC"SA2T462<@I@EAT>I=U.PI0V.5985E@C@I@XJHU@49<13629.GDV.MG3B035F1P@.1%W2LKY=SXHC\$1>
5HE&A=6F82H127N457>=A\$&3.MA08TISN15J@N<U.U7H13H.U.M.1>H3X22.I.MV2>H6M1+4AJSX&C&PW.MC@2?P2VRBZ02H\$3H*+1HN5-#Y3Z=>=41G1YV>
0)CA7+1LNAU&GHJ.RFTWR.B2190+01Y2.ZA&W0>?BPYI@I=4&E\$Y.CAOH4Z12370#>DUOLQ1.SI<1<=<X.M.BBHVIW(18.6+3JHUV@XVY+>W"174.
66C3M310R1F4P@H\$T1B.M.4<6J"XO"NFENU&W56<F&M@X(C).UA>MVA92>3U7.6&(N@-B4R=CPOAL8&8HX.80Y.M.#.S6<7KS55\$N"1H(TZX.MMEU2NPGCZ"YK+?<
0.01&9IHSENNR8.(C@W1R6M@E)1E"X.MJ\$CZ9Y4CM2F7DJS1B@/PEIBZ1R3E.CSF4131@<I>Z65Y14&U%FEZ1MMI2+9W>E&JSY0A5P.1.HH
22XD8BLYS@6D"C1CM"FL41>Y=PLU>#MUWC"SA2T462<@I@EAT>I=U.PI0V.5985E@C@I@XJHU@49<13629.GDV.MG3B035F1P@.1%W2LKY=SXHC\$1>
5HE&A=6F82H127N457>=A\$&3.MA08TISN15J@N<U.U7H13H.U.M.1>H3X22.I.MV2

&LH\$75I/M/JX^WN#46S<+POSL+^=O3J/MX/U^>75R<^KT^B.Y%#BK#I\$5IM>^M^BE9RE^RO8^>F>(^=A78<3BU>CVHVOI(X)VJ^HKD=W3+^#IM2.^^?

 &5X/SR/FAT>586V^A0H^L^X1ZLX<I^T2O9D^RG0^&V^V+9T^H9LO9^MH\$4JXDJ^DDY7^HCBC2>^XRP^LRSH^>I/S^I7SH64Y^G-Q>Dl8X2>?C7^MWO/I4K^G\$D+B6;\$>JEX?

 &EJF/RG^N6JMAH^J59BO1^>5L37D9^M^4L^W>^750>^>DIGE^>I^P.PP83P^KH<^&Z2,5W1R24I23H^MLW0849^PP2JQO^QJH-8^>G^&O08Y7^2Z^R0V^>S^JXYM=DT#

 &(C.FH2305^MTJ^C^U76^6UFUQO15VA0L^>2^RU^ROJG^EMWBCPA^<^>VW>HG2B^I^M^QC<^U9^O^>3D7&RF+R^YYS<^R19=3P7N5^ON<^>(HUGF9I0=^#P/Q<^&C4H01A1&^I7-

 QE2<^00IR<^3*(H^U^K5A^Y^<4^AHC0SFNE4I^>UW0K^>X(D^#^,^Zl=71MW^A^Y^UX0Z5&^>7U^HG61^=2(XQ2^L^&MAG<^&5IEQ^G^J0ZCG6I4^I)4XG^4ARN0B4L^L63

 MV1^LGLH^>6XA7I^I6T/NAM^OJ/AI^Y^4HR+8788.GFA:<I9%LUF0U>^9JX7^&I^FGMM^Y^GV12?&7Y<I^VH8>I08ETE^W107^?&9^OF^ZXG^&9

 M^BU\$2U^M^&ME9>^OBD<I9^2F1KH^E.N72NG^>LMOI7U7A^B&8<34^MMXN9T^ACI^<D.JI^>I5^VCINSJFZ^>IOV^>V50L^>O^+S^W^P&^>N^I^>Q^>7E&5XO^F^/YPM

 M^IR62U^>ZFMAZAI^>U&4YC^&PZ4H^RQ^>7W^L^0L^<I^W>WG26&7^M<^I^H3L>N^>WHIY?>^3N5&6^&0U3501N^6NVAQ^>I^VSYNR^6W^F2%53^796^>M^>XNK06^#WW^L^

 &SLN^I1^<6^>EE>^>V2ONT^>#A1+<I^8W1L^M^>TR^<C^#8S^YH=^&WLO6MSX72^OHP6G^>V^F.D)2Z>+^>W^UWOBZ7U>V^>VJH^&7RB2^40MM6^>F0F

 &I49N^R0^14^M^4DD^&8SF5D^M0+3^I?>^8M^R.W^>^>Z01^+O%23MP7^THJ^<I^>XZ?^>I^U^L^MIX^7GZU^>9U^N^M^K^&7L^>L^>S>6^&66L^XZ7

 WEEF^HN^03BI^U5MM^T^&M^KJ<6^&6RUF^>VYNND&K^AX^?^C=^3MHUEN<^&UZL^S.GSM^K=<KV1?^>I^H0LL^>L<^MUD^>+^>LS>5^I^PKIX&GWAT>^M^A^I^?>X^>0

 0>&I^MFG^>W^>ZQ7N=^>T^P8^ML^X^&I^?N^H=<C^M^>7H^H^T7^>L^>PSO+L3MW^7PN3\$>M^>ION^7Z&GS^>I^>L^>KLOB<^>I^>M^>W7FT^>U3D^>N^>=SPURP^>I^>F>I

 IV>RQIV^+>98Q^>ZN^7I^G1JN3Z^>ZB1^>M^>L^>910.Z7OIP^>NFO+K^<#Q^>#67H0#^>I>2Z8NR&PP>GWGL^>OZH^>IR^>W&57A^MEM^I^>IRN6^<I^>83573^>^F6^>GFXK^>N8^>09OYZ

 PIZI=>A8W<^<I^>+^>QVH^M59<^>X^>Q<I>^<I^>5^>U6PP^>WZM^>I>AY^&MG^>D?2?IKPF^>EX^>YV^>D^>BW^>^>IGX^>M^>09E^>D2T^>^>P7L^>OX^>2VEIQ^>X^>S^>MXZ^>8C3W^>9I

 &P^>YZ^>W^>XW^>PW8NA^>X^>P^>2XMU04SSSS^>WGLIE^>SH8P.

[illegible]

<JELG N> @M6;YQW1A OX\$A3R1L>S< SF(M7X-1)<@1&X<@HJ<WWYVHFVZQW>Z>Y>P<NUTPNUM3G2A2S1> >P31ANU/M M< <AR>B>2>=8G>4R3NOVRF<+EJW&FV1F49>\$-
 H<Q\$5Q%G#PDIYQW1A OX\$A3R1L>W6 W6;S1<@>=AWAGPW82HJWS<KLI<NM8- <C>X7<X&LIGBB>X>P&KEI>MQO<Q53YHG6F12>T>ERH<+W<O:ROOQ.E PX98G<C1C1G1<61<1<3X19D?>
 <X>4H3<@C17<0H1>J2&N<H<L<^8 MHHY97 F=-1U/F/W6L3JH2H4<^~R/W3PZ\$>2 #Z<LH>Z>J0D21<BU4:Z M7_MZ<7VR>K2G<R<I3R0N1<V>GWZXO<B<L^M>UUT_6V7<?>
 <GKR19+2O BINN#>4Y7SP<XG<FOHLL\$>?>X<L<0691JPKVW<SOJELX<?>JEMNP M<?>N2RJE1M<+>8-2>2>W17P<VH>WHJ<+>7-+>6#BR<R>HW\$=1R<US6.DH1
 M&BG<HOK>Z<E<_J<V&KPI<_<27M1J<L<^<G&WV12PVV<QKM3F<M<200I<U<M<VYA< <ZQ>H<=H<AZ19<W0I<@<7LJH=5LKJ PRXC<C1 Z<=FY<LH8D<43W6M>@<L<RPPD\$<+>
 <9K13X<<KKWV<G99>?<C<C2>M>+>J<SZX<ROS<QENF<M6BW<MFG<8I<IRW7<R1J<NWDL<61<65Y76<?>2MNO<MY.N<=7<100%R<U<U>I8E1<6 M<=<X<U<6I<=H<E<9J>I<+VNI4#<+E<F
 Q>YDEXT<HOG<N<P<T<MF&+>L<MGO<J4I<@B#>5G28<W6G<7R3QO6H<_MHL<66<M&8<J<U<G<X&8A<B<6AWCS<413?>J2<X<M7XUQ2D24VQVC<J<_L M<8<_5&<P<I<R<IY4J>
 L<FFCHXV<N5<Y<ZY&Q<@G<+>B<1&TF<C>Y<M<VY<9<R<DXD9X<F<=NZ<U08<C<#Q>8W12<AXL1A7<8X<#>H M81<+H<V5<Z<5<5.1E84VC<7V<OKN<U<M<SK<_<+>
 <OVU&KJ<H0E1Y<?>7DSBB<LO M1H<=<O<I<F<PDI>=@>D<VZ<O0Q<FOT<M<M9<UMK<=L<Y<LKH1<H<=A<O<MD<C<MZO<=<3<IVK<_<+>
 <@<DL<C<W16Y<?>H5Z<L<1<76L<H<L<DX<GWHV15D77Z<L M<JCGV1H<R<Z<J<R<+KTTGQJ<=<V2VS<Z<F8FBMP<4BA<+K&C<3PI<257M1PX<MLNPQ<@<#>?>
 EC<+>=<#>X<#BB<81JZ<CV<1<6&ZAXT<OM<FUYI6<1 M<V2<#SM972BVV<H<LX7<4Y<C<U1X<2<45<6 M<=<1WY3<6N<JL<KA<Q2>A<ACFN<3NP1H<A<+>U<T6C1CO<DF?>WB9XV<@<2X<_<+>
 MUXU<P<Y<IBTK<I<#<6U1Z<Q2MOAB\$<IA0FU1U<LS6DE?>W<MCTJ<WGZ4J<APGO<+>I<MXG<8<48<6>M<L1W<00ZEH<+>Q?>WCAI<@<I58Z<2D&S<B09<YU<QJ<VNY8R<I6F<_<+>
 M5P<L8MI<N<N<OPTF&ML<#<#<+>+>INHN<25<1<WX<A<E<?>G1<G1<A<C2<76H<+>R<QD<X1 M<A172<GE<95<M<5<=AF<=<0<V M<JDU<+>K1Z<?>P<L<WLDH<D&V<VWTQ<HYDZ9 M<9<fQ>XN>
 <NQ>+>H151A4E4<L<F6<H<?>T1<=<=<D4S<J<102SEJMPY<_MC<R8<WPZ<GON<63FU<M<A<QD<DPC4<U<V<P<X<35T<GGQ6ST>2BMR<V<EWIBKDYW8>_<+>
 MIG<B<ZC<@<57L2<MS8<YR6<WMLVIZ<HOPN<P6N<2<AHJ<K<O<H>+>U<=FVZ<=5<J<MX7EB<L<WQUA<TPBZVILPC<98GK<BTE<=<Q<Z?>GK7<UHN1<UPZ<C<614 M<T<_<+>
 +>F<=7<H8R9U<9>URIR<X&XU<S<8U<A1N<M<E<FA<+>+>J4DGJK<+>2<ZIR<0OEY3<W<_A1X<+>Y<N8<=5<J<I<S<S1<#<50<S<FZY0MPT<W W<_<+>
 M1LAUQSYO<_MT<H<?>G<4<A<A0L\$<?>H<1<L<P2<ODRX<AV<M<5ZZ<=4U>+>R<M<AAKR3<+>K50MHU7V<ZYF<_DBM1WXU<L<H<=0YXP0A<?>H<27<MR<H<X&Q<D4>_<1>_<8>
 Q48<919/A6<=RQ<5<?>H1LW1<1<R1W<K75M1VP<M<_M<7<1X<=X<R<J<KH<+>L<2R<_H<G1S<A<=<H<MGI<RV&S<*<+>O<X<J<YGB9A<R<?>WW<+>P<M2<B&M<MLT<#W<+>5<E<WNO<L2<K<S<K4L20>_<+>
 <M<C>4V71B<RQ<3<OGS<FX<S<=<M<S1B6<L<2D39<M<L<M<P13<G78C135<JL2?>@<VESB1GVK<+>ZLZ<J00<7<1R<1 M<#>MP2OHD<AV<@<2<B&+>@<L<J1<#1<@<PJZ\$4<_<+>
 J<I<OH1<S<EFG<+>B<+>Q<KIGM<OGU<9& M<E<L<U<C<Q<C>@<Y<C1<6Y7<L<H<8BPSS<=<=<FV300<PREURM<M<LE5B<=R<S50<5 G0B<GRH<+>XWEU<P<R<N<R<N<R<2HE19<+>L<T<=<Q4J2<HHM0?U<_<+>
 MMDP<=<B6H4<IPK<91X1<H<=W5<?>CL<V49R<CM7J<7GLS8R9<C<#J15?>=<Z<#V9J<MPPI<K1VJN<I8ATW7<F<FD<2G8<N<=<6<V>J<2I<B<KR9879<=<S<+>L<A<+>23M<1MR9RD<3<1<+>8>+>KW7VR<_<+>
 M2<=>V16J<16H1<+>G<CML<+>U<?>A<4U<9<+>HHH<+>U<EYEF<G620\$<@<JCU<CH&X<M<J<O5<O<RPL<_<C<6<S15CH>+>PHOTO<K<+>5&K75<+>C<OC16<X<W1GFI<AL98<_<+>
 MK08<66G7K1K19<+>IRW?>A<E8Y322<B<J<SBL<?>+>R1<=9WED<MLV<_>#4I<=F<M<N<=1<J<Z<D6Q61<H<S<48CP4>_<45TC<+>AQOY1F9<KPAV1WT<=38B\$>_<TH10&D6P<_<+>
 M<=>7BF<=1<TNO<+>+>1<V7<61\$1<M5<#<A6<LDY<YZ24E50<NLG<=<M7<M<N<=<S7<M<P<URUN<R<+>YUUKW<K6Z&A<_<=<J<DY<S6<K<T<E<=JKZ<?>+>QO<A<+>3<#L<3C<G<G<ALM M

SSQK:UNJ31=FL=JHDK."JCV4CR66%:CS%:CDD-EX MJ5 0:7HJZCS:R!00%92AAR2@:J7F511-NV=MK6:@@31"7T2-WB#ET66.CMB+2A5@)7P25N@M"8-
@ZJE.U8=J@04K@F+GT7BWFESJ98P16W%6WJ%#-MJS E 49%K# PE25X%2L1@84HD.K@.I@S#M#H1@>12:DZ7DM5U5HK.N#9L M5@E:
J33K3=J1=JL%=&K<9J3B4KE1RLU48EJSPKJAO@0E4X1)3F5YFY=>N/14@EJSKHJOX%:4I@Q&:
DXH8=BB3Y7P%5A12&6.K5G3)3RE5M7M@.C@&S.1RC.X.BA+3FNJN.WDXOJ2B@UH8VA.Z M6V18Q0A2PES U@DYU7@D@B@H.Y4LOAMBP+IC@H M#0<7C+0TR#%SWG=9JF8-
@RL.M.PF@NOS%.0%G%K%6FZD1U72L@M- MDL@W@B@B@TIESDSNOTU@U@EVTIMAK@<25M07KPW<474XPYV4A6B3 M9&MB+8L L057@<@V.#) 9AXR1H@B2#@<?>
B3B688U@<9(KJ9V)8\$Q.7IX<@FA56X98=N@.@N1P.MH8IDQ+6%54VQIS<9JH1-W=NN815.YT((S51P2O:THC17@)@EM>@)@CWI4DL=+
M2.515%5.R2.E1@<0+647F22<+O4K77.LP2YU@PFW+16Q1@K2V@PH&M0YF@J0 M+@I@X:8@+@>#F@B7V+B AUGV&V62#@3^A47FM3B23_H#M#WP8>
M#157<5.D#F7A1@H@D92<+Q3Q7 V^LBP2YZ<@&DDEI@M#40.1QW2>8@C4+50 M+MB Q:Q>(WY33#>#F@OTN 1U77%FINS5WU7U@M=MD.PY8#&@7%1C1YX>&(AV@7 UN
@7P2.GM1SLIP50.6%8:IB9037K@&S@CULW27 H1)X:4VU24)F+M P54XSF@K@UC <&P. MQFA6@MEH1@6B7I.82FE4A507B@-O5N#N.WUW7U1N#1@>2DIA5EM1 M1BV2@
7W57C.G.SIC(2IFD321H1"X%.(9TZT:Q5K1L2Z2R1U@E+MPL54XSF@MTF@M@)60\$@>Y33P3D4DT7(9?+@BTIA56L7B@VU#WU7F8K7V9W MRRF1%8I@V(17
GLP.Q3V@FDRX&Q@E#H@KH@L@X3#1 5Q@>P@FJ5&JRZ M8>"G1<@I@X@>"E IQPRAMA6VJZD.E677927C#H5M@B@LX49.S1Q@US915= MFBDD
(=SD7CVVAT7:24F7) @>AD+W+Y6.&R@O= *P1A1FBW#X#B10M7Z#J>D55A-.0Q4W8 M@P@J-A=N^030>@I.HTFW%:54969>ONB(C M_KL+Y)@(# \$A4<".P1Q@B>
M#W4YCY@H8P4@.02<@<@QOGB@S:FR9>6H+IBX.5.W4MAYMR#X14E M2H4H.7%L1W1P@P@B1DV07 TC1P5C@KJ1 R1K<=PW4L4#XH.D5# M7H6U#9?>
PN3U4.34384GOZLGPBX@>Z.7.2.2.BI2M0RSTFFHUB4V6R61 MKR<1@>@G@W(KT1R1 2Y@S52U4YGS>Z>6+CL565WXPXQ9S@<U@.S0CJG663D1L1M2X(R08A
4/HK9.S1YS@AVKVS39Y1VYKQADDS@#R#R)RBMJF7J>Z>C M@K.C@KCR@>@Z@H4121M46 F9 YGS>=>KH@:ZTIB1@160\$&XLY159. M#@JZ2AIGZ +
002@860TE43HHPH1K9S@Q@EB1.JH10.U15U7.8.F.MRJT.V132 AVS<@JL2T2RGODAW35<3B 1U5 CU-0I@ZB-IFIA0R.L2.3#O MBR.H6@807YX@K@O<+
X&CKGM1+7&B@RO:R.F.CX9N@GACZOR.F6ZATQ<9U.MQ2@C@H@80A.AP1F7X21M35VAC73@#Y3YD6GG72A5B8K@P2L8QPKPH@RZ MD1@<CFWIDJ@H8B31+0(D@RH:PE<@F
<9JP K2A>#1BBHVS7UE401M1W8@F0@<?>@QIY48@E@<846>FKH CFA.X1 M3@2SU7\$@V2N@<?>NT.8\$+<3J1 @<WTT03H1@PB81V^=>#X\$Y M#L:Z7@T1E
(18NFO3P@BD1+>B@O\$>=>1D7:7=957R.H91^2V2V9&H35 MBBDQ10XQXN1JFS^2R9Q4AH4N13680+M#2\$@<@WCD7#7)T1T1>81OM-1>
M#V5.A55.#=>.BK1\$@741L5D6.CJ1P88 M7DZ.PG2Z<3T.DP1473M1M2KR@>=>W@T3@)0PEKT MC9#0528IM2V5D3\$@ (M910P2@M#<1^00%L87.027H%E\$5)2
EAK>=>@1H%G3WZB@>YKMA8#MEJM7HJP8R@<0+0JE7>.T=8<#20EQ9A>B1XOX00D5A1<6R55A1.20XO MQZ7P@BT)3SPG+MGG1JZM L@>2JHKAU4U44U4JG:8%17YS D/1
@>#0 M#M.S@YK@N5.TS0P045@95P1.D.WE&PG6COT M+<@/M1327K3/\$3MG<1%&X@J@B1S4C4FEEDW.B2B)ZMA.EPQRY.OQY.FZM L.W@U5U@<0@EBEPAH1@X.C36@D@>:
ZX:PY@P.6S.J\$+4+7TPA@>5+>+>M\$S.9MZI&F=0^009>ZK@N61 O8Y%:1N# 5DIF7 WT7=D4Z2>P+4E<7.781 M+HS^F7 M@<SC#3C UFP@O2^CL+@>LYSD4:42+>HZ M
4N43R3LXK6\$>8F2C1&I&AGB.N02.3LP.YOBU 8.SF@13 D5Z6&6O WWP7U MILD@3WON2N<H257+U6>PPT3X9D2@0W6@>@9+V4+0T9P M>2@>L&G)7
R@9L^0QOH<93DQPP>.7.Q008.X0\$>XQDZ.GXU7=>7DIZ>UR MIKYV>BRB5C01=88M1<607@21VGE1 \$1V@.@DX1/DS16GT>JXTX17N2N#
M#CHVTB6RFRM#<427H1@<2DC 4826&#&C.PWW&W@J0F9S9BQ18H7A9>&@I M1X^H/Y\$Y2=AB/>+>B1021U13UGJ@C1W1L1Q1XC5&4G+GY>B#R1HG\$+>#PO:1^SELK&@TJ
B4@E@E7=7.F1K#1MEMB=BXK1\$1LJZPX7Q9SF1JD49J6N@<Q@R3L^2M=0Q1(Q@<@>@UZ@D17 MRLD@>@.82E1Y=05X<7X 17^T^R^D^F@R>1>@>MEC1H =%KRBLEP)9F&Q
M1W-MH1K^3TOXZ7.6F\$>7)5CQ<11Y784A.I-N03ABO@R10T@<L1=XG/MR)KHTE6G (QUA46ZJUE^H1Y(T:1=8L2.D.FIXU/U=1>5>@TY8HT4 M1B5V\$@SREC3.
<1LHPBIF GX^R7>#>G.W# M127075H1+4ZK(R)@>N5.M-1H1XJ1U981FLOX2@>Z@A1M211ZBE+R3<3 MCY2913M3^72T X^PBD22^0
B\$1M@16(41JRTMCGBBZ)DPDUG10W15D(V12^47@N1W.MKHQ@>8^DR4.CWBUS@F1@>@VQDQ9E1M21.2RA^HEB3X@ R1T3#9MNLOP(M1M)PA>T5/AL0MW26@M1YMS1
@G160E@H1@HROXFSV7>55NK26=150WK M1+Y2M^0Q&S2Z501E12+T207P2=DJUALD)E Y=<E@<01M+1^2XM1<1^2%23>=>M.D1X1^9XEX=44A0ARJEX15BNV@>
HECU20@.5K@.51X(A61H31.MK@<N.M1>BH48K&K4XDH5.KH1@<@>(L1.M212K\$@QD1=D+1#T6D198JF@FEI<=>M.D1F1MB1@N1@16<@>N9@<J2T>CL712K5IGCS>2.HJ
JR<1=549M.%@OZ1M1Q(D2LEOQUIP2J.66C.V2G91+FF+K_0<=>Y#IMZ4ER10R31<#T.5\$1A15.M15#Y>G8R55VH>#>6+15HP5#F.BT1.ME41M9J&M.SY^P.T%ZIUO2D017WJFY
YJF77\$%&@<Y^F079J15Y1W=MWGTF71+HFX1>@J52%AVZ1Z>9TUM@>3UKO J^XU R.M9.LM@<@>65L^O68DRH@WO N=O19V<=>1M+^E2H@Q@F20?WJFHXZ M
56U@<G=>A+D+MDGR)5.JH3:Q>1ZDGR.\$Z3K1R1P1PUPF=>9^8Y8E@>GWA@C1P0 MEBKCO-R2ETU@2T21(HH1GZA.NA2REOYGLB<1&092D+NJ59P2YK\$>4L@52
30.Z6<@AD5RE7UEM3A1X+C8101VDEEFP1M1+2EB@B@S@J1@ON=5+11N1\$5B-9ZG.FDHDH1.30.>+@U@C HXGT1M1(S# M0KH12SSA@QM<@>#6BX&1+4%G@WED1K
=C>ZT@H+>W5YUW16GMPD^P.1M1 M1<0Z10/PULAS1A WY1KBS5HJ622XHD1=^#1.J8P.D1(SK51)145

=N:UY4JH:M>L0 M73#L:|!-8DPJAH#(.0+*R782\$.0.,
 D/!BG9^*RZ"OJ&DQ0(0.VMWFPJB&,
 MZ>=6)%.,!ISA0H,^E>O>4R0*"I0\Q%=G4Y5+,I=X!OEH07H*V6G_2POUIPAM%#R/NP_U
 +,/F9EL28@ M6WL>SCV%Q|/.=Q9S#K"X|C'W<+G0.#GR.FLH ^46#ZI8-
 O;O>TF@OB<>=.:+= MJ"N6KV1(.K?\$(I)NUM.5TC-2RB)"I0:E_T\JQ_>"@/VPXV8A
 \$,@06V:- M8:,4C62+M@8*-V/BE6\$V@16A |MNU2:C)(T75'R:C_ (^|1_>>|_
 +!6'M5RHU^ _W|_N|^@Q "SF8(I)@;@2.: M|-'#??UHVR7W05O|H?|>V\$FY
 =AR/|^|. %C_4.JH3|?D2X1@ZFYCD8TMEA MUO_F(Z=F4-
 DB|\$1P>'|CY>I5W'D3@1<1(=M0(F' XC%8X98T">YR5H;D60P MR5T@+6?
 F'K;:RG3HKY|_|PJM3MNM.*H7"\$_.|)^481FL"1Z\|D3&Q*9JTJQG)
 MOE@C^6|V\$UE5"TG0!@L5938;YH@<51%D7YH+2^CQR!I&I8&N.PO+9@='?H
 MLX(ILWM64/5N(^R4G@4=_T:9T|^+2C9/4?2Z'8TY2EN>,W)^>T962I;
 (N.QEU1#"HURS@.S<.:1+UV=HF,>PR:KW|.D# M|<2U;:-
 R'>^R5#"78@A.4F9|6\$^J63^@UC0Q%|BG)(O7:8PX=8U #E%F@/N@9 M;J;|E|; M|S
 |G9|YR/6IPVEB88S|X9%L)_2:OHQ@FHH8(RN051J16+*
 M|>1X!>Z6)=3'1FD=||=MMVCQ8"=546I&_VX&*E:.)K,,DG)L)!*Q)(|N/);D MPBU_14,
 |TI+WG?FA/:U0J)'A|!R0M<46|UPVN4-;,+6S(*3JZXW\$3J)K'(|S MX|?
 63I,>>O/"QUN1>|AM4K\$O "4;V;Y:%B-Q"&M(|4UQ<;-&KIX|JDO1-QIK MTG-TM!-
 ,50^/E3 HY"|<*GN^F6|;BR7Z1A&TF3W M >L"
 <@3&"G6,,B8M'F9W0M1IK72&#"|Y_&#+|2/ATC&OC9B%HQ^^>'4 ((W/ M|B)
 <&KU|DO\$.N?8Y.";-/WBMQ/0)|SUW_ =V'SZR.%4!|4W"IA*G|/
 MZDKNHK2P2AH58'&EJ4L"WOW!%M^">DI 2!1S4LX2|;REK,P!5\X&(X).*=TL
 M+!_IA^4BY#%QK%H:E+'M@)*C3AS^5UG4T;M("XNB:G4?H-89|_PIJRN!Y8;# M 8V(2,
 YN//XI0)+A250<_T:O=^*:,H5F,7FC#41^')^6+6KJO*M|X3R_D2 M.0S;8DC?U&Q|?
 26 ^D"A6H6 "P0RF&2 P SWCUOTS(\$77K@+|3C73#\$.R|< M;D-

⌋M'WX070<|>1NA!K"S3IA7^ZZ2^1\B'\$FN'[^XH',%%D=:M'T#LE M!⌋JP.I2VQ;"W,,L+
HJZKY*FAY-ZUO;MXF0M9->4|Q(16=HQJV4|_fQ""9H M2\BR;6>L*"GZ5%FSHNX1!+-
N7NBI>FSZVYKF4|SE/U?A*0_K#^%_CR7AA#^| M2ET)CHW!\$,2=|<81!);F?
MT3QDFXUS.PD>,|^QL""OLKGNV2_,94AK,&QE^+ M|;4G_L?
L!>U^MW3.HWVJ"/N\$LZR;2 MJ*O;94'T""2D2|"V)TY.E3LE++1)P\$>4 M&49OJ(FCO)ISD
\$*:+H|62@PV6#MTJ|0B19=K,W!42Y MB.Z2*:O)ERH@E&% \$?Y-1BV?
Q|4*!56+DR(L^V)Y(KGV)JS!|DP4N>)+EJ1 M/I&GQ=|,"H>P*_PW>524():
(|B"D4FB:.\$Z""=<8<9V^)KCCU)Z&0?=[2,:0 M/G-)TO#5:~VK(:| M278#|70+~7\$0
H,UT11EJ""^% ^CLJ19%)OK_B_K|9N);WO*(&*9DZUTO MD\$U+%\5IS/F&;J>4 &V1\N?
U*BF AD3*17(%YZM;6I6&|B1*/O%- 'Q/=QH MI=;#|K,BB,)|&-&Z3H4_O&+%&..RU"A&
JF;WTWQ;15%;T0>2?|T.@%X(MI'%5Z_-1*KH#A, M0U^=&'M%,\$3T)2+50BKDB0,
|F|0ML%2TNO3,37<*+TC#@_215'2X-WX4/_J M&C|E=)0X\$87NV1X_1J8
FNL&J9UXH\$W'8_1#&|A,GIUA*Q3 M;(<29)?ZN>?LF""|Z,S7;ZL\$3B^~
NVEOBI.D(HJX#+)?P?3'\$O&7Y7N;E+U M!58W'XL'R#.V|.P9|ZC &5D--M'?
KN4&^O3@_N+@_ ^K* AN;TT1YJ;V^:*I M.WZMM.PXJ
TY1@XF_BPFYE&D5&.\$:X.WQG)!%K&%">+>*8KQG5I/S^Q+W?/;| MU6L?6GM>2RI-L/94"
|A03,V";PNM55Y|6.L5HWTQ7.21K#95>IUNKCKS0VT0
MJ;OFQJ%9.3GJK;I;B#>H_()0VF2WUL/B M:'^@GD!\$@;#SIN-6?
IY:KUK\$;R;I,HENGZ0A9OX8P+*@@?LCA, "NS,&P';J M|KC.2=MR;X;PG4AA5H=9GY-
TA'V?DO*Z@22_CR_EJ0KN\$YAU.;0G"2AV|&
M/110H|8OA^4|%VREGB4@-.JAN19)%ZL2T/:|4.DO)7>X!D#=#N3'&,>=>U
MD4A3"M):2D1L.;H1F*WDH%T9\$G>\$S%55WK-IF(6MUY'2JQ)9)2?S6&PX?#!+ MBI
(%3&Y5Q ^/S K>4:1QH5_KEJUI'86&_XKP'E,|J M3I8STJD>N\$::YIZ=-
&6(8=>.,#+;09V6T_0^>+.;BWN4MD|SJW-X^| MWPW^@E:0^_O)7YF6LOH_K8>
|B;_4_8T@0,"E;Y2*I;N*J5^RAOCKPF2;WV^>#Y8GS%?_=8(:&T
MY|O#P9|I4!'84#1J&>)1@VM5'W;&(V5G|E)XN' |IU(J5|ZDL8;|#|J09"|Z M!%(Z1X&SFI-
!AM;V1=+NS5OOMHD@I M8%W*71|7AJH|#.#|I.(#=#I
M9/HM+9"LFMT|U/W!_"Z5V0)S)@MX658#\$&-/I3UFA6+OOJ'_L>3LNX7LV+|
MC|K|H?"C_)N\$GB0|PTV|W!6R"OB;?GCZ(7OWF-/?-F%_RWUSO+Q;OCHVV_
M/|RW^^CA@|&|/INWNC?Y|VZ6^VWWXX/NO5_J8*ST<_T2O|"UFD&1+X!%FV1R
M.;|ORUOQ\$T6 MRT>.V_?
YHWOWOHX%ON)A_MW7L=|U|74D9"2^|@|= "4YK;|XMWR*L^83DU<-K
MF|SZ<14N050!:'B+I+VW#|-(&8N82B)RP\$K|BX|;8M;_7<%2EI+FLE;J7
MTHV4G52S1;:H6B|J|2|.340=D,V2\$JB6(:KD<2E@|^K/D2@18'E,@=0|61,X>
M4(("E8OP%<+;?2&|R-|26-QE2BMW)&O*-G0&TQ'GCW3IK?G3D3R)|&IYAF
MC)|EEX8KG0W>R?=7;F;|&|/XZ;*,-<"3Q?NKLEJ1MBES?Y/M,\$=ARU4YM;I
M85-.Hj;+|@PMD?28MX|T2-1OUXULW;R7J2NP|-.8I;J304)V+.P09J8'*>|J8,)C?
F50QF&CTF(&Z-;G|Q_9|9&=MF?X=(ZMBZKR-V05@F5UU37@_M*032N*R8P!5'T=
|WWXP%>AZRM;?W#3BK&B|=R|5VLU?6K1-L@-V"&.1BT3_ ^
MKB1V7>Y^Q*50|B4"M|=;A1+!;4X'AQ*9X6HRU=|UBZ9R|*RF%F
M: ^+ #A7R,R6B!8S8>B(*<Q*Q6D65T5GU_UQFWUB<,XL#&:%M:SJV@L)^F=#B07Y3&
M|<*=0\$02>2Y?"S(\$X.QV1>%&U';+G IK14R6<3N6.?P%W;\$^XVP)!KB?EDM
M^J\$64RJDIJWZ7\$)*&|8QG)O7KV1HFKVU*X A@;M*E8Y,64"|A@9:E^~L(NI%
M+MI6^/B2?6%L7AO|;E&PW@KDJ&,%5B7"|L4W0%F%0";L"V(T|S\$BT.T)PS^/+
M^ZM7S772G'S'PW|P^?>J9C3E%PY0!VA-U*9/D%0P**VBDRHUS-!/9Z<"Q)Q>
M>"/U1I7#ER\$;O)V27AAH*_B_|4#Q|;D6*(#0%J&.CK*J|B&5R|A;%ADDB*|=A\$<
M+@7C&H*!NG%/T4X/ZFH*!|(|TS0\$6|R=%Z_|/OS"15;|DK(RVG/&UYG54SH_M45?;
|8@:'^H71(A'_ M6WNYH5-'0B=5^%R|2/8IY3&6*XD>D)M16I>|SX0?
3J|. ^C@AZV1VY=_3E^ MU: &UG_OQ0R1FC?1%.=&?ONX^=DC|T|;JZCI
K>_2\$8.6;_U>0XC@BF<)" MY=PY?CPA/4%FV|^0_|^+71D;#-(33?3/-Y*JC-;BN!5
M>Y(<\$B;"R5Y| M&?B?H_ONL>N;|_OA|<-/->F7AY'YL,Q^\$&VZ|&.YX,^:~4GYX^U"!-
>)Z:I M?5@XID@9PH;V|,D7.?MO#%H|LFA;|27,2C/O_O*Z1CFEHV&;N"#!>-&F|Z
MDBTLOX@Q^E4V| M;Z?_#;.:!C?OSM|^V?WG|M_NQM_?AQ>6)/-(E/25|)3;I0LB*0D?4CG.
D"" M^!>F|.T59((CL%J*?;\$?P>G?QG#5W+9U!RVKG054)SB32*T|6'_DW#F@
M_36HN%W#Q(H|4K_PQ_JKJZ"NS>4?|.UW|=GR9(0,_)8GC;Q&2G!;(E:MLH:
M|;^D1+309+\$7@T(|"@(|)RDW+V9A|9=K-8XST1#>|#+3 L&9!GN>,"?*W=3
MBXI&OB4IGJ/&N!;+X?SVP?Q2QHA0%+6ZWI1(%3X44!DD7=5-UT?8 M> ?TH/8C-
5+U.:V=GMIA9U5Y'/F6^)"(K="AI_ZIBQH.)+7^AJH28OD&O@<

MRL*,41^VBUK%N!"35'8\Z@9IR>@5AUF&:98UJD@'%IREYL0D86KH>AIJ7U>
M5IN4S)()W\$O*Z_/V5&85Z4&JD6MM+>CH5)E(#P2;4+V->UFQ\$.!OI9;M-
1KM%+QQQ=:\$K M>Q:CX-.Z.@N;Y3FWFRI#0R\4ZK K\$I8HVT\X)G3LSN-[WX28-?
RE137LSGW\&\BIL#CX)W?VPA^#CZ5+GNC#0X1: ML2/D;J-%^>R7P0I
*LW^T/&LV%.4\Q<#?&*4\$">F'B6^F0J.-IS8D'1MW@"
MRVH<:FU#J:X7284.E3\8X&5Q;.)OL4K1\$@X20_B\I1J6G()MIHX69IJ"2@#
MS\2T*A@<,9!&=A>TA\$+NJK4_U\W\JOP)*00^.2\$)%GG%XENON2@9M@,1867!
M:82TF!U7N@6AVD,X-;\$J.C3Q\GS+FVC=L)\Z5"+'P!X\$;DC;885H3=IN2>D
M%K,T^)*QKC:(N>GZ^"U;C=OFJ)4(P)5N,JVC5XS\644PTAW
MIY'F"%5V\$!9:F(3"0PL\$!"B9TVD+|=YY5=#2G*XHZ\PT%0-!"IQ1A&@-18C
M@0ZJWU^!K6=.B'95JN,^Y?^#?#M>RA_J2'3C-"5Q.\$PE#>V;N\+:EV;<#J>-7 MX8Q>
[S RE?+ONE2O"+>.9V*">O\TC"=:GK4\)#L=JMC2V)#D"U,@9:G\6*2
MHEPA&85()_@\$##=FMHM!&X+Q^"4G\$!.?UPM\$5Y)3\R^HM\=*BF4 MUN:(V0X(Y/!
<%\$O8?1QR\$>>:0^W/11",2F\FBCKT)6'Q*,LK*6%\$5=6':K*2 M8IZY3H*@U?
T2,3"TN\FAMMTK5DZMCY:\$1PVV+X3+B,*MF=1)084@EF>J\ATB6. AUEX&3_W?
J_::3.AQB9B>.:TW\$0QAW\S4SO_R\Z@ M=\$I &G EA?4W1(:V
+W)JD%=UR4+'OVQ8VJKQ;L-=??GR;W;\AI(G58.4_. MK>#JFMN\RBV W-!'/6:.1=RTT-T
=SE7G',JFBA^V\$'\+E%UL3D;Y6I\I*
M:X@_Z1X?::\$EXQI#7N;N7\$H^3.DWLD^_A>6G;+Q%\$!_V-!|%|M=LREW?
VK_=OH,>LB,G)F^(JOFO M\$5C-
59EM#A+1'BQ/:.9.B>B%+)7,JK50,=3:D19S7U59\1#PD=T5%SO7E5:Y MU&9)
JOWWJRXKQ\ZTJ0P_&>1/T""V6#=#::GK:.%\$!*6)##| M_YK21EU0TMCJNB<"
=G^3EFX""*O58YG6+51-DJBH@Q/L.OCYN%#\$TR!8QXK MBH/73FDK
=,A4^RV<%F"4U:RXEQF"*1^5).<(
MH3FJKO"OB0HZ>=IS3Q#+LSEES6C./#2EE2*#/,C\H5KV;T+I-(UQ";.=BY
M4\8O5%2"/>H7=5>YK'(O/15TUQWD'^E1#9;\$>MW;C\H24&H_Y#WXA.2L*B.T\$:-
L*JI_JU*(J#1)4=I49, M\80\$%L-?J"J:-C82_\$=W-VVICKC5BU7X5\A\DTs =
)>R*X&&VJ(!:K2P#F MK7&9(#SSBIC-
^HC1J\V;AY\$L".0I48ECE1-.30XSD\O9T\64J3@IZ+J9'2(/ MFYX<@N;PIQYL0D_3REC
YZ'7_I+KJ;422%CPGFA77G""\$=\$Z<8%C (GS8_& M\WUVQ^"8H-
O\HAI02_JI'&J;/I+3+9Q7\IVG\!UCV^#U(1G=(?B+-\B1_#99 MHQ?KIEO-D?H;I"&<'?#
<6'4/5M;'&XB:Q20M!57R7P\ML(0GC\$&"4O/&\$@\$
MA0POV/K^52"FB#D,,/0ZH;C'04@O'^)6:L :)3L-C;:!\$)MJ)"*??JC=EE4N
M%=H\$:"5.R%HK#&&H!02(OQ!C!UPIQ\JOQ17=(O,: I.8,'2&71*T&3^I(A+ M
+7A6"!OI9#M#49?R\$Q)'T_6_N=05#8K(P03"JW\TMLQ(F"(N*;B@_ \$Y/R0T9EC>,-
Q#LD%""6SCDS\GKU_A^QU,R">2O(E"#V.G_A#DNZ%U MEE
U5,KLKOTAY\?,W)@A@L)1U\93,R.\$)L0CUBTH3K'ZBK9*;#L^--QFO
MPVZGTK*HI5LRC(LG;JL\4XZB:6 HY'O;I(7U!+YX^X-Z+'>Y8\$E_X6M1*Q'A
M&V2H(%8/GL"\$=\$>8)@JMKW#4#3-L\$P!Z1_I-V-FO/
MF*PDS&Y+3<+_\$&8\H2EZ)^;TQAB\B%N;I\Z,"=#_ULP(RW6753\I"Q?B76,>+?
M*^OCJB%\$YT(X^R(SV\U37GX>?CMMY2XI67Y_15KT###_/3=___I^#T!2S2
M_Y@2LS=3?S!#V\$H_P\>|/_FXKC%MYG3FX\6B>_&.0M.F)90>8!^ R.MP_2X
MW"4W\&9\#I\Z3&<15D"D"4_6R\$J:DR4FQ6\$)I_?9MEG^&Q:E;PHLE4\5N1M\3
M2'H8@547I>&?&=O7VP39Q;CBZ'/2:;Z21K6,Z@\ \$OV\PAT-MUNX95T?
A.K.1R1ANILS2AS_3PJ+629M*)3URCCLRF'J9G4I)>+UO8\$VIR* M\.&?9HC\I9&T_E&SX?
VT7/E"0S(QD2U\$BTUR_O>3ML.U M5<^)% 7)1FM)4%%PQJ.)3VUZ9>-
*.ZNG2\A0D0'&OJ%X5(;WBTX4 (8C#"-Q M,=
(!^'JR;\$FJ@2=XIHUCR2K&%)%#\VCW,0D9<_U\$F0.S07MPXJQX<8>77Y%I M?
3@L(.F'VP-+Z#WQ,75N\7P.=R=GMYP?@N/?Q#^MO;5_|\@FW94T&KT.:BJIS6 M5X@>P\4
Z.FKY=*R5:XG "E3/)>, #NL\$NV?CK=-1YV7)!J,KIZADC\K+U2!UXL-V-
H9"R)GYZI_>@#I00\$_=R_EXI&\$%OSD;3YWQEM
M_C4""WEW/U\#R';N\6CUGCSV=LD\$?|B\(?H0M^N(0,H.WEJ90^+;%;1!*
M#\$,0OU"SN/AQ)\.H95/K;+E6*E--6>&4"Z)A3/XK%)P,5EY#,\$\$VP7'H\K.=4-
M.EOYL3(FW)H;16X>%H5!T0E.&6;,:#\$_8AF*/>2-6' M5O9^!;ASXRG^W4X@H
IOU'%/S2'^9A/I<,<)=N1EXXTDI^I\M)Q M:/_&YO\ M:U73M/-
-6CGC1CZ.B;B8=\$\$2\J28335G#F\$=,6?.TJ56SC%=GW<;I+FI/EU2
M,%XB|M\|\$#9PCUC*MZ4*U=+= "88SM?\$AR8)-J9!+=|7%(&Q<1>J)\2\I6(% M\@&-
8#C>[XH]=2?EE4(P^I\ M I6P=_)\IEP?EW@5%(_P>AH.'3OPHSL75^@?

MV;ZW8HF*4R=ZV>K3=14E47HJW9Z|>*T-7.2[MEQ 63*!4
M0M>5953"7:0I%+?!DB%=1A@,,?-O*NYZX2S?("J*";%>+CWT\$4KF2WZC+,V
MO7D@&RL|OKUFPX27);,^FHXE@I*63/>,BF"Q=#VX:*PQ'?B4U|2HN\$2D3J6
MK4/5IU!LZ4POFF8%(CUZ\$I,=WQRCX?W_@L#|)F7XK3_JJ1!7WO+A.7?3/ZW6
M+3@|1%5C\$LF5F|,)%DE2/\$.9)\$#|_+ #F2:NLM024<'VG^7D16NKI_+|9 M*J"J(A:|H>R|
SHYD79IJ2=*0H9^LTI9@ZE%6)@VPI/X_4899J2*@TFA0,/ <
M=-10TV=4,:YPCLAQQ+:'GE=Z%#RI)|S)DC=^0E4HE>.)9159L)9E>,A|AID1N
MG5;=8.80K!'%S_DAO/KAHW&\$EZ-'(!3Z4.G#!X6DI18B4Q++(&%0ZI+0:-B
M|!1TPW2:DE3B96S\$C?!4+SSJA-!8@S3V>WHM8R%+NN:.'>&5C-4D 2\$ V!@&
MWX6D6GD221!D_N'7Q+J%9 +""X\$O%KD=XM>M%&"@0!J)0ZSYQR54?W?")1KV M| <
1K\$E@+XG+E M@W*UGD|GUKLAI06RM67*, "CF,-6VN.4#=5%L-
"H^=R0WZ8U#VRW)=DE|(1 MO P8|,QN>|?/>3LZC(G3Y(!HY_|7_JU&00JZ-N13
@DU1@)(%:5:SCWMU(0!.S%N6#C7./B|#.)3|F%3=&RR-)AHI5 MB#S(:;\$_'H;Y#5|18!|A'
FG1S<^M*|#)_=.3PX?'H7UO-IW8)K-0RWN.%O
MDJ1PS/J2&9\;Z"4!)/\$+>^*X'6|A&HM.5@SM.WOO)6\$TTN+L9^'EY^A.|3/
M|KQ|H0+YW=WLD,-#AFD;QUW\$@;G'Q|)E?3X_G7G(/_ ^|:W|UV>Y/|A| R(
MZ)9P;W!3G9&.=5;-J->AGM!24FG;0;^QD".@&4:4""6Q+/UP\$QS#=#UXI:."%=|= .99
M|9!|U|,)4;KL<0|P./MK(4D,=|V|TW.F8#"7PM !AK+C|0+^+H./VT=VF31
ME\$:NQ3/*7V3 ^7 O_UWG_Q-/GI ZS2_!A@;-G2%MHRT%TOHD&>9VE5|+|K:-^9/8A/T@&
M|YI5",ECLZ5Q5D_K_9?W1*&+|1#17TM7C5F1E7"MC/T3;)Y%%PI@S_#;JHOX
MIB(KE""9/VK:|NHA2RD|TGB9(T@Y:)1 2OB.& OGW(|0)YMEH(|NZ|3ZH8H-%VCG?|0
MT@&)WH.#M921@4!;7L(I=&?OKI0'N(=2D#2&FBT6UC"E =!,E=|NW+|K(K&P
M_28|16E:%*:"E4SPAG#F(VCT0*0|M'T|6;'.6:?'G'/(ZQ.TN1U3N.X@*P>
MW""7VI)&V<>5M@""|J'K?1#+Y#"Q0=5?"1@'X2 VF7:V|H9JO
MC)\$7Z1H5'W)96Z3\$2|Y1M22E)|1M>FW=X%K4QW"46_R,""OJ/VV67|?9YU|G
M3&CLJG*4?LN>\$H+SC:K:_0HAXK8;'!6^'|@Z@,BN/'C?\$ZP.WH3|H%DY)
QX;.|>FJF0@!_5 =C0%|C0;&#=#D? MJ0V<\$ (V2:-8Q6|R:6AD7\$5S+DH,C>.A?MK6/M7^
+BR@*R08|J:3L|330" MB89
4A'|H(Q1)0.WO.F,,ZVCYC&BR!WEX#ZH&D)6_G\$|7#2@+7|)^_G/:PIDO M3L(>^,(KYMS?
3'T&\$#,BPLA9L>9@ 7TV3-A-%F#.P), \$2K)LJ4=O(AR8RO5 M: ^DS_-MP4A&'O-F-
<%1HZ6BR6C(|.1LB^/.8G3*K Z77;:_A;NLEL=T|E6 M4*OGO3C?3/|Z)>Y#&2AQNJ
2Z:93_**.AP6#HINJ.V<>4VXRHFFI %*+" MHT7>C/JV5.X#^|/-IG=PZ?
ON.N54K8RA|Y(1L;7_6NF#|)-5'SK"OY_?#C M#^XY'MS_!AW;&MT\$|>E
IB1(LMNO!60;7S_WKWMX*|H@_MQA6I5S7:D?YR* M|I:@\$8%S>=+!P=E>+-3| #
|_Q6D|,6?11@CLN"P|(-M%%%.?CRH|E>0LC"AQ|JV5* S,IKTM6)!5I
RT6|D0IF1)W7A34\$*&/+M2| ME8?I,)G-
A*F:IUJ84716_83<_XYUR8:|'"%38HTT053RR(4TOHG@S=*[3:~0P
MG\$63U5\$|R>9D>HABILO^OJ?%|.#(V'9UCU*X|S+;;X U7 |MJ0;F>D@,2NA?D
M::AHE0|6NY8LB>I2YF\$W.|A2JH|J81EQ)LH0RT(LV*|;TL:RMYA6_0P-M^G5)
<:.#X*FG|8KC3<9@="=*?.7CSTUW",8900:\$_3F@(_ M5F+T"UF#TCP6.2 MKF"URC?
=>O'L+D|T&|!
_WBZ38\$4Y(.5<8#I?!!Q6<3N9\$+0@BNUYP8M+LAU\$F>X,JAY|Q:HJ&2ZI8E?
72"1WZ'H/HN1)D1.EA*2&QPPF)4^88
M8.NSH@+RC&BF)HXI8|KES9H"H#B#,LZ>X9'_|E8OL*J.7P6%EFF">AFL'ZD4F;U%,A3|;
(S|":V3#%N*EX6M8@)B"0E8QP* MDVY5,TE%= F5+4+85J,"J#GNN>!<:3A@KY M"G23-
0DHBR&;M1,14M#. =8">!WL7BJ>4_35V0T@VSHON??+\$3\$VKZ,H.|4BD0-;C1>|31K0X?
GG\$*B M(7(MT"XAN'= /LA=9I\$O'OV=)\$^JB""=H1<9BJ90#E MTZ1?UZ12"&RQ%(FDZP-
SU:D;76A!|-W)>JU-P)008ITE.'|^-|EC%!D2< M(G.M)=,?.2;0V6S-?
/N"!^"C'JH_7X@&9AZX8XKY+T2*PK(A"" "CI M:D|Z|A.NNW@1*S?Z-[4\$MT:)?
<8=9*H2A3RA-RD)(L)BF""+|OIK'S#"|SI|,;;3)>|23< M|5.|(M<|2UXK30M5ACU9/M(-
&B'K 3)M&YC3H@&ZL?NCT-OH?FQ8:+55F_#C'_O*<; MOI>T,P#*: #%QYWMZ.&
<|1QL645E3-*:"WK7I@!@J'8|7^:U>^KF%,I\$(>5 M&|*SNHS4J*P:9N%A|>?CNM?
4!:LHK8A)@/H*W|X??NWWC|WE8G^J_>QOYL
ME+,GEG;=|*Y|!1)U8XD=5UZ1*Q"WL_#W.B#N8?D+3<1@PIE|#.FVIB)(D X^,I3
MLMTE*CT9Z8)!-DC31K|V,S@_|)3|TWH|A|!%?3RWE7J_@\$.F<|QQ;B MQQX
FO%H^*!:=6\$C9539EW&Q*>BYJ!:'Y#RZ3-4#42|>!MNY SD4ZF|COEI
M<6,FCQOW4=WX&V>3NINLYN(+_:&U?TT6>MDBGK04&3G T3^5\7?!1*X|@1H+
MPRB\$0+,"I&U")0A68^!ZM-T""F&IFHBN<8GAZ0/KFU(^M8(1T(LL42!|N;'

MH\1?'(U(E0^*GWPF=,^95B98/T8,3,#"85&3Y\$HMB*00JE70\AUSV.4LA,V
MVO%&70QX\;3-.XG-^M41M3UB_W\ #96J?7T=OK?
H'+&_TZV:>%VLV=J^H0R;G44=EI=L/D#|H.XG|E3
M5|I"8(@="MW\$ZJ61(\$5H,N)AC<#Q#R&I-GDL.6AZ\F*|#" MQ7;
I=IJKX:9PNR0^E"6KD| S5\$1SXZ;37GLC;XYA-!OZG,ZF%VQ|\$6X>4*5J
MG=UQ^G;7QPH8: 94761^%:/S+V)!;7#G6E)%?Z":J |2V\ " M??
1B|Q>V\32TS%E&X|'4&58'#7|CMC#\5A9A&\$K^1& QI3VOX6:H<9.3I7IK
M6Q: A?OJ7HK690>M-IT-6VQ61"X3RV4CCFL?!(E;8<4#"M! ZG*IX\$IA
MFJE@"E0|B9':C|N5%T+!8C*R(7GON!TND 9:DE'E+QCVKY*UO!M= !:LP' MR>/,I.Z=P;
(&-H<"Y;=(L@?OR,DG0M6)(.62B=I@T?#U8D+UV_N>GD)/8 _K_?DQ=SXBGB
M>&Z7()8E=3KQBMU,ZL1/>9YDX^=<=,PSSLLJE1@@00HGF7,WI%IHA:D7:W'4
M@HXZ|3P'QT>>>.9|;VLGXK\$06JY^*PXHEI *PQ5R89W405J'5;DLZ6@IEQ_MN
B1".3C3XK?@^VC : "S2,7CPVD3/^AMM:&&%_>,.U(X!\GFO>*Z=ZR7BDA@EN!-#5A3!
<75(|S!DV M\$*UF"+3+F3@QKBAF>*UM*X0G;?2|X!9WC6Y\5701(T+9-\$Q|-'CID)VZ|.V
MZU:+9?;&H*!F!'|9_>=N=A#F:.B3M0P|#HW M/|I|A_6&+&U/3(>H%;
(>+MQ&:\H\$/86>XW8W+EYN&)XS<,^E@SX+U;\$ (Z(L_B=IEY4M6=LZBT
M064"PTV4Q,83\$ZQ.-=@08R|(Z3W*T%UZ=;NWWPX2NS%Q^0B8ZJO*O=%'WZ>A
M:AA,+3Q1G,NQ0M%3<2AL+;D:X<)|Z0PG4!; W)0\$^P RM#!KH^|MWG=/Y#0
M>7Q00F<|U<-?G>/Y;\&% '5 C*>!9?!92NFZ2WT;/SRD>QJ?KB4UV"R)O8GEH
M4|HU@:538WC"OH)Y@?G/?U2,Q,Q_E0|FB@ILB%4#!EYPQESD(X^G2.?
ICKJB|U/"8P2|UD52*7IU=RQC<='H;;
M"7V|NQ^X;0E\A5HPF4IN92N9D)/!P#:*TNNE0M>D ^|&6\$WY
M%K0I@^|N",RO\;|.ID.B&F0V*"MWW(H4/&Z*8#MA7E>OZ5E:RT^DS/KGHLL
MC\$'2YFU30PW!+S(T.\03+SGHM@V*#ML@?'\$YIIAH;^|\P@^/7|E/A4/A3?DE-TY7LCS!
X: ^XX^!N|D+N\$=LCRNAH0ZLK M9?:JNBP|4:ZR8 &SN*|SV I^2+3Y+\$NG9@BJNO-
7M?L|^_137|JS^%QX=V M("V&H#7N_H+SS6B(F,52%*% *RUB*J.^H9E|U
#GV|N7;9>*3J8/?H!,-;#Z MAC7A(@,AV#[597I|R:Y3 /%:TED
@J>'193\$DR|/>6RUYM+R9T>!8(1>F.B M7TO'A2, 24|QL(P';CYWTO:6RT?);!EK@L4NY0
8J<&|>#-6@WD|F:P6&M++M|!&|G)P>*YER81@'\89 UP|+F2"|F9)|@B=
M;=A:7J>/L:"C23C>;N&N<|+K|2\$)?0WR!^K.=XO&CCG\$FR?4P-GG,6NJ*<+S
M|J4Q+0|Z!'|B16OW@UL/>5X#F|9<\$#:Y|B+.0|\$I-P^*LE M0TU?1+()/: XIXU|
7)Y4I%B=0B><7Y)6GT|N6?|/-03STW (4=3KJ|E+JP
M)0IGB|E&DD+G(2ZK+I3=O*X@_2SG\$R)A.2(D?%|Q1VB\$I'%,?SD)H+'^Q><
M5H|*Y"MSXX87^6"|(%WF).7AT4P2&Q|;/'D^W)WUY^&!PAYV^VP_103 LWW_2 M'-
W_N%Z4=R|>=>=_| #VZ|V308)?_8/_0OWT)_9RX-G|UZ_/?QK.I#&_'9F
M.%E;J6FV9\$.GFF=F;43E9H+L5<8|+&3FJ;*5#Y3P1@H\$N5,'D,H"X|R*/AP;
MX=JQP*&6=|99GIC<+E"?(*-^\$-/8_#S\$S\$|!(K0LG#|J_N.LV_)):?1H|3,!, M)|2&?
*X1/|2<\$3@/YOH(:.?7J4Y)F?6Z2|\$*OM?ESZKC7Q72;J,J|T:P: ^J MCIP#G|_ :D_;
L=V1A|LJLQ=_HOCZ=G4B0#S3|C.CEQP^|814/C&5AB6H=*MQDQ)C55(|(DSTZ7T-
3DGRCA:FSMWJV7MEN)=@I!JJN-",Z&Q:;057)\$H AUK\7"/
MZU190G4%)UL0D?;@*HA&_>^|!"@!9#3QR|8'\$&%SC+Z%L\H(<0,3_G7HOE
M)\.F76C1<|=|13&W?ZU>@H.|8=\$QFM^|T>CG |*BWXR;|UP*6:I# M=WF
KI7"*C<8|\$&OJ:).#.ON1R/(HQ2_ND-B4Y3P' M_VH%:L(C# #A8|W'2&1&8#?FHB%BEF-
@\$V(1DQ)_6(T4015|20X,Z.L*^",K8(CO&|B&|A0
MUUY(3Q0NX3Q^9QJ|:.)',BP3\$18%M30B/^V G@,|"3-\$ OD*UO:O"^ S+(")?
MAL>L#TC+W(X\$*=3T80(GE2=W%+S/\$ WC?!M@%|KJM!6H\$EI':ZONM\$.B9S4
MURG^|Z=845#AG"63+13!(WMXLK*\$9':.&("Q-0V.W8;GERS)6^B9_9.-SEQ+M|?
376#W)CQ&(-M4/1\$P#CF*^:~?>A#GN:HXB)H" L8|?LYL?3HE\$R*541L4(>85*H1TR
M("VE4\$-X@5)^+|Y#K!98EG;S8I_&Y
M)EQR6TF8*0Y<.1W/X^|W\$>5W95%)>X^R|NC@JLA|.32A!+YP2V*/O%B7%P
M%&^'I:=-*7L==IUFHA4&8(;YM^\$;H\$?|4+/DGWUY-WNAT*0.AR5-,MWXJ\$HY
M|P<#H/_X?%3JYBP^=:JU:3"|8DU')^)+DE>8L>J"7|5@ME3<\$N@%/8B/%N3
M@|O90:)%BCGUU^K"BU%&G^"ON/_K|1/6?M"%|B."D3#CU F<,:)R6%>U;|Q M)|+
(A8K7| K0(|@KUCO+=B?|OZ12N|DD ,M9@8#>>4\$79|+&XV=JE|0&8H#E MF4IY8FJ-
+G3.X|H@|HW65"0Q;|T\$O>?Z1_6AH,')-^YUF>L.^J.K3H@&):DT M)'-6&*2M|X*S7TOJJ
:I=>-|N?C9_?&4%/K6.->?AQ(Q=|9(
M;TBHR\$ER//A9W9.DA33.T41V&0O(V*J|Z+\$^|B0>,|?B<_A QBUB|1=W;-MH4?
A=X#A)<)B"%-SI-RUY\$C"2^|V+9M%^76=#@R|G--@=VM\$SZ:<|/\$EXA!

M>WCC.QENEL-^N00+GT>"P)5-:'S*5X63MC_OE&5;OF-@P,XY#9
M@Z,&HB*8&!H@=3>-,>BK-?ESK.IXZZ9R*F P/20GN%-TL.1H>5EK?X3,R3I G//*4>S8
MSY7E'^^I,GG(WQ*QL?(&"G?].D..MR(=H,^SM1GK_Q&)FJO,TV"H5300)T8(
MLT@\$(^6^\$A9@2?&J69(Y2TB##P[Z/?ICHM&YASLP).5S">71,@.'84#DG-O
M)V'E?:013KRS(RA@_MY3)K1E42U+-1HQ/'@UN5S6>PRFR_PIDGV0EH;60G3
MDI5C8S+!@=!=;1:C!==%K@=#(99_4QWV4X7!,\F34M820341A8*_B/(<1)ZIU\N4;@W-
-^;YJ0FUB8VS_M#-UZ==,\V9%,U3%.ZJ-Z23-H 3/7C"!I:@/48 MY\.%0,,.2,7U08^8?
P'1R!.&C9YF=G/&1=9FDE^I@)'1&P?>,((M4&RWR5&C1<<\$6\AEC\$U,*^,H7C(<#!1)HQ
M9.4.,'#D3W?E1P!.I;"7KYS!,RR*6E!D9-X\$93CK-A7W!=\W#+6,?!W3;H MX
8(061V!"G'I>&11"/3X!;I2Y%%\ (U2,UY'F)=ADL8I6HY\$7T7!XBJ^UAP MY#Q=
I*FCIH+5A,@2IB029T;1B1U-?2;IRH57K.?JOA,'!Q56F-%H:IP;&4J M:H:GK\$-<^A;G!
2_Y;:SSTGGB0W,YL5SX<_4;I#M.,SQ;4IG6B(>MX03;JCP6#R6UC"%J9V6TLI@7
M8.T8P1L9U%B+6XVH<_V;I(T%>#S*%QI;>,E=J\$FH:C%#I^YT2JLF71G M:-
W\%M:4L#&S\W1>(Tl."IGIZE/.,IR4L0\N;%7)1YDZ_S#LXLVGW%5TPMW(M0_Z2?A@
5!"_8.=W4ZG\43Q NS@4I&_5K.48>ALZ*/LS!"=Q>XCTUS64\BJ M+K&/8G M'(ATFPF'%
7BT55=)P=C7_F+D&P!\$0LG#Q.;CBZ\#4W/%H4SN3/-%)>W;.
M?+I<(WZ4Q\$BUWD#.2X2K_SM\$A0?.^H,?+IPBX'R2I(RI?O2A56SPLV9RSS5
M=1A>9%K/E."/;CY\|>QF3LTEC\;TE0H(?%\$O2-8N*O,2HBAW%T,RX=SAV JQ_M@RK-
KA:4.A^FU\^BH3X:#?7H*QKJ<_8NG=NF/|XI?V+F5CI6H)IOA\IO\YN_ZM,/B-
==Z=B=^PINB0X'Y M(':+\$"XFA:R(6G80*CS;G.M5B1+NAQ\?I/Y14A(*5;BD8Y?
T,ZOB&QZX\?:M)(>SD?I_S(B#E<2U8I5MS#6.)A"WQYG+
IM@K:A&SY1%XDYHLR;VOI*!M(!4! MD44(O>D)XH&/DCSN(1"4TD5I:0_Z!!)4NJY\$0&
(UVD5-|!"!4J-Z+M#5"ABW3P>&3FAF4R93+W\$#D%\$A26Y>,IXR\N\$5JK?@1-
*\$,0'RY'52)M%#%H M5H;E%H\$QTP+1AH/5,=\$UW;JW?W^3&:W(GK5F)UQMVU-
@CWY#6:QYJE_,9G7P M57MKBI#G\;M;;48N8D.DV%;;-:SA,PL%|>URV+*~?R4W
'40#;9LR'U_-):?@|B2_R27G5_MG-!)";,="3_@,^*W>Q?5\$)RXJ;0;I>|6:LN=/I%*N'E.I_0-
<;PW2ORB_MH" LZTE!;*7'C=:\PS\HE\%MJX\H6^K_*ZR,C;K4'_B/
M\SY\U\&Q\31;&VS/EI+%AY*2H=2IRP?N\$!?!0)APR#(!&0U(Y>: M2B37I?K:%?H\$?
P\|S'Q8_MU"0(+6%_A\$<*CWJKJHE.EL1^-74'_8MAH3-9+*N
M947RL534I46_J"8K3BH909BMFMAD:>TAL"5E"QO65&2_BJX&HVIPV@<(<=3" M:H'3|-
+!%0I-,CNN^7SKCKI+1GV_-L*QE)>=%R<08XPI*:'I!K.@PZ21>:O%_M#13IE-
SQ!)C;B\,?"&.IO*2C<;DDV?69D_L%9CYY+%D_0B>("B(T1;S;_"!G MSR3<7=*FOS)
IM;+E542I%M>Q57C&E;:TZ=&&2M8MVKW+*C(DM/(*A&75HUO.J=)=Q4L5866BZ5"_9-
MZ;AJVB%%ZEELR-.4/I4"DBY(+|!3FR\|)SN!71:ELQ*)E32)"!0'R?25(OL) M_%I9-
0#F\5^LDB0)**M(S*_%3Q%:H1<9TS_J1|2WZ\$)1H9\RL8!"#6@ ML\Q/EX51/-
;42K@A/CQF9Y5V'7'+SW@*:7IUB,@T_E6\I,UH2!=W\^7.GRSSB)*YX+_E+4W-LSXKFK':-
\$OZ,MPL&\$#TK30%JD;:+15!)+Q1R;U5(M5OU*C%;P\ M98E-
CF(K>+\$/8#BQ7L5UCCLFUB>#-3S5;X!W\ M,6L^ZU;TE^I969E-
FRT'5_20%:57=6V9C'P&FNU?;3E#%\$P6=1IG^)^N\I.L M/6+816'.'?K#S) KZ>Z&=
DJ;H4N%7W\@PHIR2#)+VW7&YD;*4@W)=B2V,3U9_M17KH;R0:I>&|+A8UZ6M+4Q\$B?
ELB8*W5S^_*M1PJA5S%?;FAPBQ;MD%2;K MJ*S"/2U\Q07"\$G="=>I&3<&|B:M68;RZ\$
B\4>:-_HA M4)0(|B-1>'QM3CPH*G5GF9?X_%0+*THCZ/7L\ 3B#D,7P3)VB031AT_%;\$
M6<|2"7JO@18N75YT9ZC#/FS4E=.) (7X\|Y^X6DMN_-1>);J:5_N:GTV4"/V
M%K1;S23H=TQO\|57'+\|)YJU#::0OV,'SG"(-H
MBNR/B4)+YVPO&JD#^Y'NNI\$*TC?Y/2/^ D87B2TW(GH0OS\$Q*,E@UIF< M<+Z!
11)K8_*)\TQ0_,(TN=(*&RB8J4XVJXDM\$.0R-)XU7#BZ4J.>5^Q+ @
MO7EXX0@-8Q2K16Y^07G0\$6\DD2SR;.#PD4G"FI9&SMWZ5'L?F6^";@W7!1\$)
MY49&Z/-5J>=" @06Y(B(8+/+!TXIP3>'?C3DD\(*HQ<|TA,|)=HG-E8)2VP+|;I1%_O+Y
6.ZG\(\Z&/B&?C0@WGY"D:*29K>6K5\>4.OW (MX"(_GA(?\$|A0@HJ)1U97?Z9?>?
N_RM%\N_I#(N>ZDE70D8O>L%X'47M<|9 M:9P(7G&1L;.,>|4OI&N;=:Z;|I>>%1\$66B3-
O>(|\$^_MB1:WU)>6M%!X-A5 MQ"MBD@9A:MRDK1E\,?O./GAU1M. G6K8Y-*IJ4M'8(R
:2_R^4SX\$DT69<= MK^I2TC|B)2\$Y(46AGGTUC?
UP2I2K226YPI9<,6AAG?/;ZW="WV.S.2??>S<
MEF13U(FJ&N2!30XY\2|0%D"N^1"5W6@W+44\NN/"\$NN>B)3?
K2PG\CG8/-5MV3NN%9'ZS>2HBI>|OQ\ M@ZRWI+=D:F1M2AW9E=E3_BP(I
G%=0G;8<"MZ MI;:0HJF9!;7I3L;5Z73S_00(> M#//GU= VO-MB?2L8*,QJR0C*5N8+!-
Y7J>OT\4_E83ZD;G-B7B1K7C\$QB@;/#Q@\$LP')^8|XJ2CA&"FTB+E5UQ)A.QY;:-FG-M?
U6V/A."RRDV#;ND%PMS7,\$H^*^@67_N7_-/%S(>7/&/TM_9AJ \$@X1EKD?: M-

^PJHMQ5AD-D:0%/X#*RJC%L,-67'W0>8G:ZM)4I<@PY"6C^S<"<>Q)5"
M,-3S(^ (F8\@\$94V#?<=(HF>X9*Q'I4=XM>(R?+A,,/HU6P(%4/2:W#Q*BMN"
M>JRD52/3P&T7.-\/=X?GG/WH>S=9I)WWUA9Z8"
(W=0_X%3TTI#0R+#A(^>HAM7(@#|Z G+BJ.*T3|UX2;@(H%VW\$/BGRPU,H7"^^:
MG,9H**JO1.,DV1|L,3=MLX.!B+1H5@Z#=\$L6",&Y,C",?:KI%C)ZU\493N^P MWC1-
#Y+.,*KH3A<&)\$F=|+@F,) ^&2,'NG%8SE1R9A'G"B/&N/FZ1!P27Z6N'FI
MY\A<,HJX,QS;W 55A+.,<,W?%%??.5L0DYD/,I>H|U+X/RL\$C/^:Y|S|4!2|Q M
N\PG#%L%>U-7/ELSB&X)|FOP"X*[A.:8|EA#?)!)2/DP>.:6 M|7|17',^DT;:63A&
(1BK.HQUML@N<|=DMDBOMS#B4G)U4WHQ=-\$/(/C2L*?
\$Y5HRMV;IT1*N=|9V|U'WV\$!= M;=YI_ OOS;LOH.82!I6L/4|JJ34Q91HS%;N'-
Y=N(C4922(H5|(K5G*<1G9P M'@U-L9HO)2GN,CQQ+7Y64RWT?6C;Z|/|=BV9'UH.AR#
H'<#AYL99F.,*/.MC@MRP6CS9@S\|H#\$6NDT=TFNRZ>U/BZKQ8^GB:W-MO-
:3F#R;TCL_B2?<.0FO@8^\$4X":U4!\$SB.KT'6|FM+ M"Q.'FNY@&7N6?2=
_*\$>5/^|JT/G0|7M\$%_R3L09,'FAD'G|0*VGD+@?FW"7.@UG!X0_2SM_PU7!1U@L!)
(E!GY!'T"U%9ZCN:9M9
M<|EV!)06H;OE,KX:*SJJFILLETT1YJS5+|R(H|CW1R_ J.OGY\$(EC^4*+^/* M)<&YE*
(@!YY(&W 10V8Q!R %T1P!K^S.B|=O|HJ/Y",#P.J9G2%&\$MQ0+&4| M*Y-S?@S>)|JF
5IP_U%JM8|JQ3DO=,)H6@35F?#?4VZU"*GZ7*C1H(T=Q!W& MF>-P0&^,%Y?A
M"NB^)|BW;R4EX|)%FE7NE*LA-^:NW.!G=G&19V+JVK=|7P(U!.LUB&ZX98NF 5
M^SE5+C3>|H'V(L79RGZCL-:&2"|>#F>DR9MC>|<*DCMK9IOVP RBWP9| MPU<9?
>X0%V0J#^V4D)8P-|OC.VI 7>Q7I>"|+LR_87SL?AB@I\$TBO'M72=M MU|9+;G.URKX8
!+*64JB/.P6RC;2FLD|F*%?&H<5(3DU3I>7E2,M\$|%-@S1
MSO"PT4_N%I#P/*9)J8OFM:I0G!63=KV__^S|^.-<5Q'MOA7Z?#AQLIHH A
MN\$BB&>|)%4!1I<|9:GB"/8OYZ4>BN!LJL|FK5 K#|Z=-D\O-6U6-A20(\$ (C M;:-
=RUWR9O+R7,H*%ML-1VZP|R-K)R|G.8Q996EJWQJA5.H:X|KS|CM+4LW M>J/TK-
"NR;.#|. &1=68B:/&D|0-.|W4<+:|=T-#.C4,!L!6 X3;I//VPE+
M("X7Q9==Z<(Z'N\$4U=8'/E5VG4N>,H13;2A,98^_*,9M:D@J++@;YD\Z2PTW:[V@2'R!I8.
+7CULL MGAW+:W_V0V|)\$P4X1 !UP|XM_++M5,^'G|LMV4H2C!:TCJ.UE!:'<3G/R*ZB
MHU(?;0X!*TR>*#+44S3D_051&*+WK\$GHOR,&TLYS%S0*(00!<(R+6!GJ;\$4 MY%P^?|?
<.6ZV1;B M|E&@!E4>6!Y4/Z*<(.7A%\$URX0097CL8(\$M*\$5J?
ZYS"X#&NBHK3N(H7!"EE|BC_,^:'=:\Z8PE'Z0&E,5I+'4RK&E/S)M&7%0S|&QR1A*"G/+8
+MWB_!WAR>,%A^|8!@NU(FEUKQ!// YV@=,*+(GPFOD.TV501C"^(PT@|\$!*! MU78
H,/F=D1*#V.F^B|)E9P8/QL'5IOFC.L0('M3S_PBW+?|VMXPWY2%!
(XGM.A|_N7J09W3(A^|0;F;)+&QT5SGY+<5,1Z=G>V-WOF\$Y14B*I< M*B 5D<+
&1HU(0#S%|Z?\$6W%!.:'4FIS6S-NO6?Q^N<>|;L/&5>^CVZ=)!2 MU35(Z^&
|_)N/>PQ.)CG\$179!T3%ZTQ937=%OEUUI0!*D&S|4^R='O0PSHT-
MF=5J5#V.:N3S!L7(A;=SQCQ@|4^9N")2/I\$EDS9.'/W\|7%X)U!L#+843&(M/+LAQU(+
%+B'&AEDP?DX2.IDLY A1'Q@2,_>MMA?(G2WR.|KNDLNFVY Y
M#U9,S5MAN9:390ON>"%D \$OK8 K"9B8"!X9J|G9|?4##?^.\$J?!"N_|VH?;
MYFCSX#^%?|]"5_YK_*P|WIT5Q7KVMFUR8;7|6|H*S>|:A@5E#'_L_EHM%>+#7 M.?
F)G,HT:I-9D|<<"PAL"NX?70HF#?:?_6;"97P:NZ*\$DB@.%-=ZZ^.-
I8,D|H7KBKF1TG\$N!E/W |4|=Y.Z2W%C8I>K M#>'3V9F|I6*|U5.|<(LCL!|#--
(E%.0;UH:'|*Z-'M%A;V7FDF@-LCC2|3+N/)436'J|5(' MX/2R,|@5X%<|/)3E-
VX^>=*,+MSBC=OASY5+K(I:44L|U3E\$X@>_<&P=3#U M5O:%3QA|H&R>(:C
."QP!C)^I<_#\$=AVHLV#FE|S#1&W(AUL?|U7%|I8! MF7\O1FI6&N5;:[*1 F<),F#ANY1G
M@?RNB*!|4Q6S**|7-ZH8&O|2|+!9!WVO*_5>M#.+B|H;-=G4;"MH|2(NLZX
M&TU>#G"!0/S#\$.:G"K-=|QV;TP42/3,0_-4X?N@C|W:8EXIM9PW:3RFE5#>= ME528H-
V;:.(H(1\$#FD'4!!L*G10LGGH;@01,=SR-(2QGW/2T +08|N;Y>#DZ5T M@6E0Y @53|@!
(.K1=&Q@DFGI&1B+ G*O9J8;|@&)'V3:FJ+|63:Q%RXA<=0|
MQ5Z.B53T1"|^CUJ#*M@85UB4'5-'6;?/3>F
M2;E@>IB@|82|G55>I:|+9KL*>,5\$\$F^0#?B|T%ADG: ^4%8 ZMM8+Y@*9>%#J MD>
|++L&.\$?O|L_-ZBOLY1<6C+)|@R^X19ZM?4Q.6_9 AP@|G>"L\$_.!^JN2K-
M&=^_8(H.|FJT&3|AKK2FKBC@@|0\$O96S(?\$1F!ELP8%?ELR3OC8S5 V;EGB M09|>BO,
<(:R&0B; 9A8E@@94K^>2N/-/@.8;
M=@9%!D:G:TI'.9P+;F%8NZO&9),X379YMB4QPR;:7?I%SWM2D9J#;EQ^?\$SS
MU,D#X,IT1O"D_?GOLUE8317.TPN Z|E/PHQO'IL;:T(UP/5K!;D^=L5""T9 MXRZY,|_\$@
SVU* M|R*0Q.>SM*RW UR:#DZ69%|GTK|#_8.! MCVQD6M#XX<1= 2B=I8":@D
^COUKE&|Lj>\$??PD:R.NB+^H9|V%\$W&&#^C

M0;04/3>5"RZ#+\$)C8K&L0Z;X#123S=U/P3PJ?)LFN;\$@:N@E>N8D'F2B7I %
MG!>58\12JL.*/-&R! ! P5BC1M,7TPB4.45P=2-LLPXA;#@U&R\Y84+13 X
MPT@BH6&Y8HD2%S; *N\3R7\5\$XJ%I>OLA>0-K0)JV@:LY)VTR<_L3&^9L+)>,X-=
(=E3;F1LI2! ,GF)^&:+Q)\$@T*P!+! |I%CV|R' MWH1=%N7@|9 |# E+J:M=XZ9!80!=6D
27-*\$F0I*/4VYJL,\K;F\2\OKPS84E8H5\J<\$M\$#>TIXECV" M.-&1FKU!..S%IZ-
\$1C6R";5KN%K76&5@;N1:WRJNED-80>4ZX"QZ2 ML=EB;(0
JTU\$1H|@#/?2*6B0R\GM=1^%68)-WX, U0ZFTVQ7B.8!64^'7Y?'T/7DS("I;SL--Q4 ==>^Z
I2,?"H2+M6%N?\$LTT9J62*QG ? M:B-3\,?PL-"V\$R(T8OP#A\$?U;4 ?HSR3-
-7RZ&X\)/G'D8A#.JJOZ&+A6XZ(
MJ_BYM+FZ\G#D7^)\I;'&I)Y4SGPN*5(IZ)&GERBENXD(D>8 M'21(&3I-
+;+M<#L\6,"2)@2-ML=3MSI(;V6GJP600\DC,13A\|KH^WG5?F.^==>^#
I;.^'D\&AF42JE\$^C?: M0+3K?LR;;855?=B%=4CL<&W8A<'TOPFG=;G(82L.S*Q3A<
HG<@M;);W)
M_R*,Z@;ZMBI^>&AV9UT_YGB0<0UWA7%AEI+E.R/U"E=H7;.27(#BUK?
JSV.\$^F*N/E(^J^ M8L8F+""BLMI:4U*3FOY/E+-'LQ6\$ AP\N20?/:!&
MZ5+8^8Z@A%::OET!\U#::?*6T*4^BXD3S#+M5"M,@0^612
MO\$|C*CO\IS3TJ@Y51@|BG3_9<:XT|- \$KDK25*|&Y\$7R|_ =G04M7L5.1ZFXJ M39K:
<|)+G#NNV<2JDJ?RH(N\32#"%"_9A# PX5Y4E;QM,E*.>F._'L_\$N\$AT3|_
VF(%#R4HX26C#\8Z@D9T2":L-NA#,N1'IES%24", (P;"7:N#N4U:Y;.)@N%C?
R"\Q"0HA&|C%Y#K=N1'*)&1?B%F@(-M2-YA\N0:0.W(MMB#%ZNCFNFU:*R2DX+2&
6,%R5Q2FF2\TM;7YEJ77-JH@Z/ MJ\JL7X0BP&L:DTGA:
M.WS'<806SF2S(OC1"A./7MDLJBB@W*:*!^6?;?;?,<3\X-B9T5PD|+'G'WTW&
M&JKC/:.*3E1QLR=1=_ZP*1.*OB("OKI:N-HJ8V%Y|^B6PJ0K_.6NAUD70?:H
MK\$U^84Y#>E2N3?TBHKKI9>Z^ELBSHS=7CF|>;;4-74WT^VA)\I7)Z4EG&:TVE
M\8>)>L=8M*2%(L)4+"LK5X6\;P68VDD.WI%9"1S+5Y|^1Y8/2:-L6TI/+7\|F
M#?.KL*^_HEI\SN!7MDF\E-8Y., ^VPG\$'_NJ"\$\$\$\$C1HS(/&I8VH'<5?C0(H^K:-J?
S>=|X("CK
M#_0)AE\Z81RJ)&JNK@EKXAAKN!*1G"8*A+^8@GHB1Z)HR'8G)Q+7+|MBG>"
MMZDW4!&Q)@F4EH/O-\$H<7H5>E!@|&V5"UVC@WSM0!%90PH128&VED5EE
*0/:G3>&>&8515"GVY;GK"Z+61#|F?_1W/Z?. M8\T)Y'YN J/-
:8#_VV9UGZ\|S\$ _K1L/K7M2;_(@,(+AZT162Q=%Y2%NH6N&9 M3%#/,2
3NBZC\574IV=P,NXC(.#@_1PG;V\J&F+R6S!7-I(LN56.DO.'+
M1Q"L4\1,8DKBY\|P7@WU(|B?B3Q=[9B-/AJ'Q@D)FLF<', =9*.W0H?LAP\$9U
M/KG(:U;J7*,WD8M5FCM(:!PR5&Q,'0!^MUDE:LS-2<%RJM H(Z')CAP_F!OF M4>_/L\PT2'
KD),D^#VZ3NAL6*)H'FX(R8NI(AN(1Q%Q&*#UJK(B4X42&
MA:'B2\|'EV\3#*N_U#*)R0;;UK@P@Y:Q=3B.!.N'46.@-7I7S(L*ZQO/I;J
M%KWMFY2>*|J#?<2*17B\DF05@|K*TN3GBXS3YY*'^5YTR?1DK?|;:P0
M:'L.KD|.=@6Y(:!OLP\J'!U! Y0WGD91K@R2)6P*UJ1\|R'M/4G 0.GARS() MW
/W\O>3LN)LKN>\$WFQB.HH5L GH+&)A*RR'S2A9+KE(E_1KXY8G<.'R5*3
MG+FHV0(9D-:BO1X-(136L?ZUNE#AWDK*&*)>*KTLMU%4>KDAE"7-7::&/0|
M>IU#;P.400A>BT";J1M25H#"&1QOS20!#NRU%WQG2IA+#1<^:CA\A*FA8Y MG-
SGG_1^>F5WH<\$#^#F/#3HVU4*;;&W/KG=JY#K'V3FWD;X,FWM1N&YQ8;;I
MFTX>AR8EZ>B^WSOV\|RQ\$FGH>PWA;&4Y-H\Z1|; M:Y'B.W\^@>B6LY)
I)^F*":.338\6&P&661*.8:OQ2S/#TE; B*,63P|^2P>A M(Y#;Y%G'1XBD1+3C;-
;A!STT5CMPNR#FHDB1(69S\)"SRLWL9P^<7G4,+W#
MSMJM)FS5^#E\|DQ)V@""%S"E\Q\#6D.FZ ML+#!XT;.'7,GV@V5/?9X\$NTDU*R-
3<22;\$C.+4AZ#RV?EHU+ MF2P3:\$S;.&(3TK&H6Y6(=T/00Z3(Q_YDI;|G@9=7/9 M-
:>D\|R9)LU(RX4J"\$V\|_5TP>AN\TXJU W56&)H.TH 7)&8^M-GI=K)C_#PJ'9RHCC;
MR<&E@G;/3?8/VR?OMX6?Z%M(W1+>H&VX/\$LF3B8.7!O1):4VD-I^B8%(T%
M_|H^/S_*N;*7SX4)H^,X"-P7#"^D;X\NI%,O7*8P!\$NT(:78\|WFPOC*(X)2J
MK9W6)1ENYL#LUP+W3W?4^>GQ7R8J QJ7K-%<.\$D&&7%@A\|0N<.28CDI0%!&B+
|0GFA\$=5;.EUX"YSC+.;T6M6N6966UC/1\ M,(;.&|1R:S/P9;(\$G-
;:\$%B+&TLOQ7@&OSKK+M99_|+TR*1-YI S/#""FJT(4
M)X\|:@FJSW2"WQKDN4I\$Z(D9N7QF(:KH|R"W&'HZC?QTN1G8/);-.B40W.>5
MIBO92%N2K#N);@>W78.5%*U.\$MUB==UOHTQ%(\$ZI3-@COZ\B/O6HGG./OZ\&
M,LK4FN:|TS^(F7A6,KR')&'?3W!\$V/7-GH=&#K1->J#7/@#PB N"RUY:H5
MUQ\UJX#\B):I(A\@HD0941?A?5OJLJNL'J0M8)\#LEK&F>1_JX9*:BPKHY MX@6=
+'Q.T78E:3R=T&#"./%!F!P1W5NF6!)^6!CU5%K/0TC WB.>WS#7OQ+

MV#W;9*MS0U:8;LJNY8*DIB!#HJR2:207P0+G4M'T7A[UXWM;O:TL/Z8N6IJ MA;
I@CB'5;:\$|^#;T>2\X#;N1=*EDQ /&H-UO=[; <0G-/CA+9H*OT; &07<80
M_&A#3217+N*/C%B &" F.;G!\$431K)SP)Y,Q(+V-V! =VOU;|@|ZDT\$"7IO* M6BEC!|-
#:VO6U-N\HG;^?,M)%8;;P_E(R7L\$T,-[QWR&/R "[A6#TK6-#4_ <#8NZ>D> %\$,4"*>-#-?
(@-'K>H5TSV\$ M7-(84%G<0C@0B2;-R/I:(L7>:6@\$XD)W8H=#\$"(C-)
(7I9,W01V!HC>M27 M%1@!NX;|3Q|OR 3T*N^;LA4_1(27VF20I?2\$&|!'IAK!|H6(%NS:
(HX(+ M*U&|D5\$CF\$?%C|JA.T_Q^+.M!<;X,(PEWP%!6(+6&04#TPIR8D7LJH7O%P1^
M1G_-0 1DMBK?BS|>3*AEA1=-'/XN;>,VBYSXT_3P?\$L|OPXW4Q;(AZVLSPHQ
MWJ_G%%UX@&+K(>R)?VQ#R)0@<;O\$D=>"L|)0!\P#NHZ*G;:_I+%X\H:W7!
M68N!EL0J_V-.?%&L G M<; ^:PO|3"5HSIC@IP,9.
M-.TRHB%,H'7.%J(K6R6',8Y8T5;AO|-.9\$|F+"KYK1|'ZOK6<-Z|#2!
Q|@K'1FQU#Q4R>3&1.(,\$3F M=1MJR-D)&%6&#=#N>_LZS% |Y:H1^#T1|
f@(NU6H%2ZN*Z@X*HIDDBB(1KH. MIV,8!4?.K5SNQD/:F5=%81"Y53<
8LF>Z34B.J3R1ZN5<|"3Y&AOS+L-X?4!'">@01(%Q%49M625&_GW)KADZ;>Y:E4
M:PQH\$^RJ=*X90|M9!/J:/HU)/WR,>5\$\$PZAM.ISUK+G\$+/GYP+^#|2;RLO&T MD)|_O-
5Y(6!-&=S6|"8C)-V8*68D@4CXV67#L;QJ&SLOHSQ5V>QX?*>^Y5X%
MIR1(H!R0+-4PKYMPK"3%OR7,4@0&605&_1^VB@F;F\$!B=GC*KK-
U!VY#V:CZ98!.%EX/I3R.-6X@'?+BGP|(F?D9YB2W%@':7A3700Z4JYHUA+2|)OHS<_.ES^
M|(T&0>,,H_H|XJ(#\$/C&#R@&A_ML"D)(X!@KCG)SLW".1QP@|CPV3>HP>;PC
M(6|#/IV>,M&52037 \$R8DRAZ:LFE&,+UIB*3>1|"9C11\F!DT0%W;(/>4KQ
M\$ASBL.L7!+!HT7XS-|J(A.JY@6YQ;_|.C!AZCDN(Y%:'RQ&58=P_\$029>N|
M:>JS@MW2^)"VCS6-0+^++)?==L_.DT=5R")H9<| (T%JW\$*Z"M66V'=G@@+F
MI3RD&&>2|"_VVK+3."L3A+*W(I0A^)^0&FTPL%G?==8<"AP)Y+\$U3:QQLZ7
E9T02T88QPS.@> M\$4J4%D+"&N)/BN"A%JWH=L<8"!&ALZEO+K?GD6R@P>-
_5ZTPLO0X03\$:G- MGJAF\$J@>J|3M\$>4AHU0?
A"B^1BL@(C*O"M8'6FLK9R&4ONS7POBH&%J2G?K
M>%%FKXW\$.7AH)! =FU),XYXA.28:< +M,O_6CK|Q@U,P|ML MUPWY7S'FEGQ
'0|18|EL8,D+O(T8>01Y|_79|1(&I:4U)L#+QIE61D?/BW+# M*@!JRQ6N
R|VJK)EXV9SQ00B>MZ&%+D;).FP-;:(HD;=TYRSZF6"F2TN3, M^Z1-
3W""#/=A|%>B2'DM(?ES7 M"VEOCEA#/6O(2)&&RCI&%>EAM&0Y,O_!
(5G\$J\$W@HIKL540.:TNLCV@1'W@0 MK@7O\0!
/W"=.0|1*X9A8V\$XVZ!NCY&#AU@'RLJ<:J:E3W@TVD8O@P&M9@>9 M)9%=:J(D.)-0
G!F8Q,9+>,M %W?!R&U?-3@O|!:9L8_CJ^3=B%/*NJDEV>Z M*U#;?
+_A9J;1KLVFL^G&K400'.Y?DS8.4? M.(#.DZ)6;*>L,\$!G|^3,R68 ML?
^HC5UOGF|@+AE\$1A?R8YKM/LO\$."%:9ZHB-"QR82RXBWZ0|R>L^Z|H|?
M618IG2|+X/^"M!"N|\$I+S7_C|3HGM3:&^+8XYL1%Z"LT M1<+;(F_V9U,= M\$7C:?
B5E,U4@4%X=)M+|4LBPKP=FG|<9\$50?Q:NVJD_7D9/XI8T@\$I1<%C
MA3IP'FFJJ"1,10>XLZH3H5G*M&ZA411FG_ ^P2\$3TSR1.1D? \$J.'KA!:=:H* M07/#+1+\$9-
JVD4_1;_+1D?D*>1|W-VZ/MZC81/U;:GV2&[5J7.=\$.A?:\$% M*2*G3,J2"0UO6PQ?
5;TB+,=&.GD2^J=(|@2>_|1T1'&& M9(E&A(R^OL)E|>S;H0PKM:Z(23J&|JDK0_1#/.B
|-C8|X(2E:R/YV8#9 M&.G1N.AG|+G^9Q^&|G&40IS4G_C8
24Y:4GWT&B#X:.*%?/'FE>TZ,|!+*0R?_PY/TW?8_0:L\$OK=-|:.*PSU#J;>1^S*JE|D
M(KGPJ6Q3IN5,U_29\$6MR?IUGN,,O; =!N|RH.0712'*G(D^>
MJWAVC8B.G<)*#*CD4AC"S!L%Y,#5KE1M'2S"
MG:Q.T|@4C|E/2MV!"4\$*=08F@6!7ZH:'GJ:!)18|= "ON?%|C@U1!***!,|D8
MT!DXK05Q4S@&@D>X)^3|PY!"%="&.\$ 0<"JD*>VJR5*(DL))&)*N8@B#OI0|Q
M/OP)3"3|^>\$6LJ%@@69",VB1ZL|):>:&/FY@PS%:62"C@_G7MJ
MKX5)*QX6_:A8%|M2@9F,49J;=A="M-%-'@000_15VZWANO0%^.@\$7^BF|Y
M*T2K&^;@'9\$|D)<7:V|33%7B|_I9|_107CZ:K!V!5X/_0FZ0RX_*9%_8^QM% MS"PJ3/5
U#=';\$-UBO*DYJA7EUWXD+&11;+M9H#G,S-UZ4?2>IM7TW+*B-'T MNGGV@W;9K"
(OT<1V|CPF#|>OM8W@WO\$?\$120;EBQC)ZFZ|2_96)Y6S-M|:Q
MPGE2E2P620""NH\$PM+"7Z"VD &E'5B1:%/P?)6<,P.BD!>*AJ@&*;2Q@8L|.
MZLJ"7:|>4M.J9((#8NG=90F_5|)J_V6I3LN%M-P!VB*32!M\$PEL4S7W&R5Y*
M#6/8J,70%@@%R06COX|NOJ/4!,#U7T.ZEJ94BK1A_@>KK--F&U8)^UYC4H@N M?
T_MWEB7IH:FT(L:4|3|L:|GNC |EC"GJ*3NUT|9)BTPI7I(6#QL^YFFZU#:HYH|
MHUAQ.&_Y:.*IFOXK|>540|%@'S|_IAHFU5IOH^8H^+F,|^2T=!=!T40X='K0A@
M@SD)+LX5|D|I12)YI:'&X3A.V1%G7T.P.6-B O9-HX,LEY#KIM_7.VU/_*Y
M(2!&+3D1=8AQ/Z|1=J6#%|^%7|#:R6+CV"+X;I12QR&B:|I0|GKVZ-_41SMB

M'0DD[BGY1!:@&PO7&H2+'/'0+ZM%OD MUKPH;87CKW7;f1D+(1.VIS9L7!#0?
>F8Z6@ZXT:G6^)^37/CC^~^*H#4,>O\$^B M0E65
4KVJ)*J!P"=MPD^GY;15/= '.8VS1K&Q'J44Y9K M81C+Y&T>_(OIS(JD\$@FIML+.L-
#&2YIJ;ZE"7-CS4T%N9L.*C9)Y4E6) TW MDY"8.8J01AM3(7@&_R02WK&KA8YB:JU!E0-
G):OXW/%IO)3#,C\$N,%ZC#9N= MZW-X%#01/=9\$?&8"1(#9_NX!>";>E4I.*I=M!L(.
f%C+A-G50W&KGD?8N3/ M1@8R|P5G"Y2G#9\$KF0K6V'UWM/8YC)+.71I:YM/X5
1.996^HYG\$EQ*<|D| M37QDH6RMW5=)ZR3SY|*O)X;:"
%Z\$84;9GWFWNO',DV^U+FZB& MM^'TS1)9AP<\$CD/(@/+V#")P;&DM9|
(N!2Q*YXQT|EU1AKW#(I-Y&SIN8K!%X M&0Q8#?IVP\,(0KD)-=BT>_+S =^
(N9NDWPA!-G-D+Z,FR#E6_1!"1.(E^1 M2P-FCQ):+)_U1^UY:
(DI7K+NY^f|\$"#"\$4+F%K0PK7L0"/RIJ+ M7D+-^#PJL|\$R-)GARJXTSS?
L_,0XG9ZCW\T\DR@%,Z@EE2G8-1AIGKN SA-?
MJZ9*,KF_89(-CJ(C*96<0MIK#CK2R*J@?LM#1W&Z:f4=-,2')X-
6^!:%CM%OSE2&:U5IK&,R=,%:JTO'!G-DX1& M%>B9FWRS37J0N?
CBVBOW9S_Z_LI2Z:&K_(@R<;5Q0E.&1KI:_="YY0MZ\$7T M;++9<54?22&0I'(81^G4O?
CHH(-F>_!'C6 M.\$:+9R6M-J<=!(X,I L\07 MNJ)GBQK+;N02T)-+3?
9*U3(= H""37=VKJSP^PH?5XT42J&RNGW7G?X>HN M'4H'G&VU,92U-
ZCK,Q&PEOVFAAX"?:<\$J2&|Y>#>[/N&")2S_Y9\$WT;X10@H)YF@J(>BV!E61;>Y,??
ELL,VU,+OH3;fW CKKY!*#,^*3Y.?J\$ _IARYS| MD-05>N,-">9|-28E\OHQ
<<_ =2Z5"!# \$V(#,-.XS>I9K;PIN:H2P)9|HP%U M* @Q8O)69T* M?VEN,+JND"YND>
(R:AH)B6&fY DT')!WHP5>fX-!SI34." N)\$19\$S>D!;' M%/HAD'C-Y/GZ%4>+>W)9
K%P!2YOK75*!%|_CT S_9Y)=S>OIX(YOSL/&CKW M\,FGCA|3;(M\$=\$R=DYPM2:
*DC4C*R0WfSZ;4PKS?,W6KR2= N8M76ZM (OY M8%DC \$<3:
<fARD)G0%"P7DL9VfH5W)AG
MCEH1/K&")MFY@:'E|A2V6R)V@F7NU_9;+&DQ@,X=.L,5T621E+
M>7%L!.UD^'KS>R^M=OPTQ9+C;_L58;7L^UDXUO*_I'f5-Y|_10FK7^BY704
MULU1)*^CY>^/!>(P)O3&GO3QD<%fY;<9+GIT;9'0A1YCSH"XF";:\$&TXM<\$C|2CE
M_)5O,*Z|^J(WLO#fJ3R"QONNE3R&U!^-'=f|& .X@;f|D<'K(10W"HEGTK(N M7'?
F1CN:NC#B7)K1.I-*RJ?)V51JCG6:>D):R1!7GIYP4&^4f MDTY&5?
G2:G#%O#3A,T(&2S"TE9F("0\$0Y:Q35/\$FK" 6/<)&EP.QR(/OIBJ^
M6I1WM\$OMO"&:U6W&f?HFR.MQ_E.0=)>K*SJFPF!@S4
MOZ.RPK"CX7+RDYfL=5^SCN6N@P.K^=7\$"@O3!DM&?fD2UM\Z5T
M54U;:&O!Rf|JL#|@.ORRXfD#LN-3f61J6MN #\%(@*TS!"4fVfVK%52!|@Yf
M<+9*YC4G=Z9"RYQ"3,DEV9,D9N1SS(-\$RM>M:4Z(BQ1(GYf!fIZ>'L"fJf^
MXV+2!*>,K4(FR6FCTf+IVPG"X=A1D8Jf!%4"L, 14BPV,CNT?f|4EYf&GA
MM2'D=FSXNC'FNfACfMfRVONSB.I!VK5%;0;,Q@Z'.GC31(^f,?:TfF"?fV9.!2 WCN
MN\$1#B',!:=;OP+O\BU+G.E#5)C0f|fO90Jf!%:;A;f9Y6(@JK@8\$?8BWMJD)U
MLD,%+_,/K;N\$APIHW;-MY,MG-EMBOO<7 M.L,2XLEEDD-
FOL,R\$BT^?!R9ZJ=XT%WZ,4;*,RQ!0_%0N6E\1"CfUfU#8 MZA?
2.E)464Y1fF*3*@9fJZRE f\$PA:R-f5#RI0%CA#.\$AT/+f|7EMNfX>K@(- M.W71f ^:;
<3'1W!f!)B_BX9LHfCQ>SD_f,)HRORM\$NK.1P75JfK1fJ"P>XWQfLX)*1 M&@S"H/?J5Y.fC1
PXU06B5BOF)X:Z8%8)DO:=6)DVZ+K*fJ5.%fNJ2110B4*N@NfJ?)J1PP,;A/P-
+,@1*fJ09Af">%QJ MA%):T!CG(O0PSP-3D"f(=&SfH-
GTG:8K12X#R9Q"8^9!C_:8*Yf3;R43/J;# M1?@=-2 JHH7\$'Tf|<6,M+Y%|Q)fMMf|8*V'0?
JG^L=:MWL9+><>-Vf|<N(A2 MK(.C6POG129=|J1OBRZfOYf!(0^SUL2,<42)_fI>S!f|;-
CX=WR"+L02f-9J MR>%T%|RMfJ'S-!1f\$O^f^fI>7V>SGPf|^)f!;A\4f9J)5*3@%fF*?
QCFDKE;%= M9Q2,T.'>NN9=#@U;M55=%H^GB5TS4O(!&5-L6/LFBfI('5f3fBfA61N"
M3QZ#U (f HK*P3-O3TN\$'_.&fI(E("/8'fG2V/\$ M2*,8fS&,1;fF*_N1,H:)-L*>5H&Q783
W>BUT-?%&"9V\$fV M2K+Xf7@ =T;X0"45-7FXPG%4"U&fI"51:>C,>+OY!_?SfLPRJ4Q:2<
:NCHHX MAf|"-BDH\$KAQ2;NM3SXN/6T?16KERfO.fQ#H%FS?&1O "-",J1\$fL'YA/2>/P(KP
MN+&4(J-&D9:Y1;,(G;DXCEL)(%\$SfE\K,HL7 FE W=Y,fF^2&W:fJWP9BN;Q1X9IRUCB8= '
M1WfJMW4,BSG+;fHH<3+)E;M,-2;HLfY&fGG%@f?ZW(+JfJ(SV#WQAU(U+@GFQCTVf|;-
>8L2)ZO#Q\$(6*fJf>%SV:XfZ M:-P?%f!f?*(C#ONIGVTfU@>_A2@-
Y@f!#_ (=98XZ\%WOES;/fSfSfY&6"!OB MX)OL^:-'CMZJE<0NfJf;1!>1:VB.GfI6+5*PPN=
fSf!fOJf>\$O:HfZXP43f5#?! MAKU9= _AQK/7/9T+V8R?8W98f_YC-+O?f|fH)E^V9;
fW2fCF200L MCK'77LGVC R N/0N%_f?;,\$2;/(Hf4^U-H:3RM*fLf^+f5TL f^>.GS@fP67
MGFLBXZ_PM45D3XX;?M/f!\$WBJ*N\$""* f&*C9-C^\$

4f;f7(fG1fL fM34*f1+fD(-_f6\$7D#_ 0f;^6^_W^f|_f9)+f;OSRAB92;fY 54FA%>'>'#_V MA5%

(*4N+BXB63;XJT"NU-/P=GI710VZ;QI_M:8W'F5}OHW&YMJLW&RBS6.#!
M0^4ZQ+C&4N/= @N\A@|&.0DJMXDP| HHPD6O3,<3Q<96WK!\$Y3&_G8:R.B\3N
MD2O#@9-%*F=463V!

3 M#=\$? RAVP;T3EU-,B3FH*Z;5/X-UOH|U_&_N8!W_5CLZ+&3%_2&2D.3:J5
M@|TW5H9)S8TUTAP|E>N@^B2.CO0X6.LVR3Y12MKZ)R@9@A|8@R<;4)@2CVL
M\$)0)UI\$U-)FU4UQP%|Q=4PEK%3\$ MIF/.4C |H|MA; ^_9\$C;;=P=6'=-,|K=
|HWBLNW\$F7';))DD!F+@(|TB%2H/P-77'K=
(|2#.,4JO%FL:*MD+E9,XVLC6SC|@P)*G'3@'"/NA#-
S0(")|8\$RQU%DK,G AB7^:914N91M9?|25H& MR-(I-'U_|G)H\$AD"LBK;GNCP=?
%0_V+L#|NL|8Y6-\$8(0 M#T4GK678|N+%2J;K?Z1&DTX+WB.ASH>Z27!\$B>X
M^1_CB|GH_!?'8C(LXR90Q0Q%FMM8"H)BVY/OXLWSG2|Z>!CR119-?D;2>4PB MNB+?
0U-JR<,F0 @* M*CT1:Q)5?|QM "D|LU,2M0XS%|/#3M<"E'7OVD:FLRSACQ5B4^'R<|1-
R:M, ME|7LM8:GR5+7>GQTBH!^;0:DV-U17L7(>),,FLW6? MI^"
""*,1Z4A9!4ET53DW+BL9 /12@XMI!Z,9*V.PGO"0;KC1O.*+8|0S69V MJMW*!-
_U1YNCI5V4OHD|,"NO9#:L*0>,F!;DT<0I9<0SY2T@19@PRZ-"PQI
M\$D:@1=W"6E\$YRM=H1&ZWU&N21<3O|XU5\$W(UWN_JL\$;#T-^EC=6YE;_:2GQ M-
:=.7(C|>0Z_YO_*P|;KSDA=_&W;Y'7'4'_+5|GDS.KPFEM 'Y6WX
M8|E8A%7|&DJB"5MJ=|PGR9)3MA"-P@3QXN2,!|CG?9W?8%?E" RC/>HDGL:
MVWE|@S3.4;^,!X7&04%1RXV*M)JL*YU@O!MORYR&0K-9/B.6)-BZQM1& Q1
M*^76N4:W>|/&|8TW/8^"#H^|VQ*,RIY31|+O4QE#HP2M5!|L<-- M,(|)PR-XG B
8@>TYE8HHS9'V*%|'|')=^'S;5FAHBUZB\$'O_=O%MQ:H>? MM#D:GYA9X?
|FH^(X7RM3AS#TV|;B&+-E'I"65@="^|%'_.@HL>?'|:1Z2_';|B,%9H)
(|*P\$U2J22>','6="O%#.XQ?M='3;,.95, MGFJ"N)*FZ;T^;7|f06<2ZKXT7-Y4?JB+!"QGEQ
N01U="31;P1(7X|@ (5W- MG!FE1B|9;+D>\$IH3A|Z#0(-|)I%D08G?H"O.VE7T(.MZ
@WFGU:@TYI^H,8= M!WLI&&,+=HI1'B^Z,':7-5EY<%,?IG&M.|4539?
79NY3M5,O:D\$J#7'J/ 43\$V|),:|E^\$EW*831R.Z\$.*H<&6W86L 9MN|-41R
M2X,JUBUIKA#7//K|A3!-*+L@U9*"^PPYEE\$X^AFV|'W\$C7S|@!OY3"|8Z+U M@Q2=
|'JN7('+>UGUE)Q*|/%?Q7GC>D7_2303O8U%7;):1 C*12Q%&'-.:)))- M#801X?S|TE@;+H?
PBL>HT(6QT,A#O_047:/R|RL8YL6>U9\AB"X;^6B|+,9
M=:M\$O5;)S3(3;P\$VT),)IO(413B-|L(0U"MI&WF|_ ^3;9_|V.V0*^Y|J6C|D M!QD|W.|2"4K|
G|WNI,-82WBQ:C6%U>0|A+GZ_%R-!|0/&OG6SO\$J*8'9BQ: MKSMD9%(G>(
JG=P04B@D%YE;/F*^_-SY!/7Q6\$3J,!W4<^N"UKF.3%G*DRZH^ M8Z^C*>!O1-
72(9R%E\$M326%|BL'CIV@ (37JXD?9)|\$7M2L=(|KJ:Q#/?#=#C@
M;D.OIE^K#M',,6XOXM=8#Q;|)O1#ELUY"L|T=1(A(!??27%-%"#(!|:(@;5
MPI&HV>T)&P=43NN)5.(W/D |8KET=|Z-\$1KM2-+|V|E'L&\$,,,\$,"+)80F)
M\$,-82I=1U&|E3'=5%3Y|";U08VH_1R'F(3:|0B84N;LP|\$W8/ZBI6;H|>@B2 MQ!K%;):+B
F%|B+?Q5KX_?NJ1Y\$|F;>\$",N9TU1,KURPI3_F)HC+4JH@6,
MIH|0D+Y(V:\$8|_ .2LZ93+;^(4%3'> C\$|8|04)05!R72GI'20Q4: ^\$G2CNR)
MXWCV|D4)HG:@)RE)R%6-D|H^OL8E:3?J?*PA6QW9XB?W1|*1I-5<|Z#=(|AA
MMQ(#."&8/>+^(HND AQ\$5@;VZ";A3WJ42W8VH;:*G3.FAV=">+7,')H|H#M|X\KEFO!\$+#
(=;+|J=M,0BSZ*'.B1AX;Y\$U!#B"VU M)> <|V*D1|LIM9H1'FDEEZ+
(.WUY|+FK|K#F: ^PFO+GK^_+J#2X4KQF|3:X2:%, M"JZET8MO65X5:RAO(N4^H
&HQ47FL"&DYMR7: ^WMKNKP,K29@T,F*Q#-.-3X
MJ,@8SD5^RGYS#!43|0(RNRFJT,+!;V<^5DP79PA;H1A/(=+,-N%",4!6N?,O+>|)_
ML)_',IY;NG_UM)J9*HIE,G(X'P< MI82|A!
(9@'14N\$+T+S.=0<0%WA,TGA+RDQWR&0Z4?4ZT|+ 0KF??
AG^0=Z|K0.'D+ #7BSL1P(BYJ%?3VT<+ #YKW6 M.6OG)\6BER!/:+

_=\$P>=

8MZ M#L1H%\$YB5N\$Q"G8(ALR)*U&RH06WV|U7\$'B8QFL|0"7/,LBM,*73(,R@P@N
M%^-;=S*Z6NZPO|O3@IR.-3=\$C*Y!FU7EC|L\$K^!;FS@MB?ODZW>S|LZE2LB/
M|N|&+4FV6+-#% ^D%.*|,>WE/NAU_N5:_FS5_4B27|X;_XVUR|9V83S3:_M."<#M2Z
6Q12-3)KM-#;34;B5)G0Q\$.&CSHYX2U)LY|>@LHWUSINV681TW5MO>S.@*_<;@
|!1NF4J.H5 M+I(=/S|FWI_|K(\$@-EG&1 M<='.'@ "PJ&9PS(.QBX@=%LWNG?4794|D%ZLL?
&85;>) ^P(|J:|H|=|@L.*)M^ M(MS1'OHC0Q(8V>2 M@N87">^|&E;-
|="N6X"7|J0",ZRMHF2I8:%AF.Q65HN->BEJL"AUSPW0KT*B MFB84XA;(OQH!|'\$/SKE-

WUGAAR:X_C0C\$64Z9\$ME0D*[L)25(.XBB2O[^E! MB.AW@#F/G0C:-8QQ#
(L2XLC62\$!5P!DU87-5"Q!EA4Y1[T=Q84G8@/1B%Y_ "
MY'DDSQZTY1)L\7=W\$%M\0V/9\$!;O7Z-6'+!9L,U0|HFV%TUFU+0W#=-1#1IY MG27-
E!Z2U'Y@DK\JO^9|M,>;T!U44LQ5 X1N!_3 M&%(43[2F_9I"1M|Z7Y6#>W+K7-
V4QT"A*N<>!2<-/(KK"!GD:=<=5N&J%1 M*H34JFT-'T-#1932+-
JS(*S2F5ERO:@T@,/09C1>O'A%:B+%N7M<>RN6\$-^
M#;:@HO(0\$C<652FM+416PB|J+KA2XWNM5+=418>|086LTN4D>\$"Q\$.*0 FPZF
MF/'!E>>U@|2@(\DO53,W%^ (2NJ'1OL,#2|E,G%!?05V:I+RYY3+!|H)*0Q>|
MXP7|NQ8UW"5(-+DU//:6?|2PG':*.3|FHB8XXUU2_B:|'|,*M%%QH?_SN
M4<0Z2EO1DV_^S>;*.CR?4B9*X=[D5!L#@F(! (RY?T(Z:S7(3GMQ:\$9>('Q%9
MMCLPF1&-;P96MHT56:;!N'1:OL\$%),3_5*7M)96H%2M<) MX-W@F3,.,OO M*
(."ERANR#S=SADEIDORG%?PP1>|+G/N+;9U:VIUR_RT;LXSPAVT.T3RQK|H
MC/0'(L^Z"J/R-)B:;!WR61*H;MH-\$A;1H|HH; MW'R#1AVVSLG?4KV:|!+ #&/#H+AX2!9T#.
XJ*/;-4DA(* (6W"2\$!,9Q9#F M=N>)F'WJ ^|+9,F|HL/TDE-SVP6&|OWV: SX0!S&.
26T<%62SH+TGGQ5%9IYRTV6SX
ML^0&VIYH|EAN2TFMRT0+9Q5"J%:BZH<.9(RG*'|@T\99HZA7&?9JO5X753;@
M>F5:94W(I.0*:0G':0%IHNWE6UI-W5\$MN2AA|"0P?/@34ID")=86BD|EL-=959&;=
MQW,5R@)?2|>\$USZCGATD'MCP#&ZXXZMA<1: |0MTW/H
M3)C|+#+WH%_ \$4JZ93!N68TS\$2E^=H%+\$N8A((IW |\$H@.^0SB&CU!FJ"@R62
MO* @E/N45@=I\$ \$DS,|VB|JK(|\:/%AP8S!").N\$2F+6PM)+M==;=.*B|3FC_
M+,JP4A>4V5#NS%VG9R8)8RTS,8<> 5/7X=HD>9*:|C#1/>L\$LLN;?PI'8C'
M7Y9X2C|=JK&U_J><|V@A JB6BV=)\$D5(6L:|)9<7TI@| ^;(+V^8^K4%|)?+DJ MSH?
#Y>_ (D?+;I*V2+3'@_M6K2<=3C3CHO=#XRA^I#!N!|JU9/|S=KM&X-
Y7J_EL@)478X\$>D;!#4<9E7: M0"/,X%3DRIZA245Y40'//>&DR6O52V60?|D\|G%-0-
10/NFQ'F/Y%U\$#L;R MU'&CC_K%VR5T_K+6N*1'A'Y%6&@KD#.SYF;+|P\$?
>BH0=NB+. %ZN&!Q2A8/8
M*#+FI(@*/",7@=H"VD00X|SJQX!ZL.QZ2\5\$1<^ZDB#BR@| SNC=2D_'GIMC
M(3"S082!.(=NMOWXCV*2%7C#E6+><5+! ?HY-) | M";W;8*?>%:-EE"%KNO1=4|R#!2
MMKH&E(E89NVS#00(Z#G^0.@Y^IC.>W_.8J|_.|.)84YY+R^
1'7H+|P*D+L8%1D8XAPX%X;J,TB1.&;5-V&I2Z;F\$!"RNRGL:@SL/|@|S*"# 'DAH
"I02F2@^"E#1M I2G3R MYVCX,LXS,TJL%R(/WQHW#=#A/M#I\$WXY+448'H'F/DO'>M
M0KH|P3Q? \$L<_D#:1ET KG:PD\$LSN; >#ON-%*UTX|'|#JJ1Q55| M6RBV'OC@
MQ>S/3_>?'W!|+,41GBPQ>C5?PV&L_.@S;O<1G(52\$>CA\$AUS+*#E|,^|Q|
MLNM2*A+5K\$5Z@;BR6B:MU\$_-21.P&TJ|AXNZA\5%|:U^/75UG|K| |P-")_M-
N/CRGY0E)U#6&&-^1OF1#1L# @C_|-TT8F))M3|)K?#MDU0QVR:X9_/?GF
MZ8OO'C^|Y%/0|2)-9Q9>X-EE7V#7DS_9/WB|@Q|T^? %GH_H06GXO_D\$S_",M!G?
B&9X|&CQ#^ (5_!D:<=05Q >|0EET&Z5L=L.&@Z>D07RB)O?Q3Q)KE|KUT
M)ET')T4X3/|Y,EC&PRH":PY>N? MKW;E5_RY-W)E"W&E1^//3VT,<1^S)V\$|GI-
5X(O=D&O?\$ M3_.TC5QBG_%=.8AW!F3K2?WL% MAX@Q('EGSGWDQ|9G>5@7-
|4NAJ37 UIN71VR*D9\$|FOR2!YF|YK91I &#GL* MH23ACRD>|>10!-P|3&"|W(|B8?
B>DGU76\$?JVD!7C%9@|+J.&.1X@OH0C.G M|Y: ZON"\$7+5?UZ'Z#W7FK_9D22M.B0-
|3AA2?^"FF.9TP=ZZX!Q! \1J"=H M\$A|_N10B|83-<#OR:4D#SQUE7&7_|+
*OV:&EDS;*HXU<.K/TJXYO,0|2O' M_.D:DH3Q|0O\NG?2 I%2)J|
MOPES2+P%7,#""%&N+:IT:A\$AE8+/T)U+ M<)L_/WYF&<%LIN>#| |Z|/R\$%??#XB64;
(3T96WP5%T.?8U"7%""SDLK29 VD M=:/FDL5"ZGG,Z\$W_1 17OB\6>UV|MZOJU&H
|2SZXWD4KE+WG3+' MH)) ^-B M)90,BI*.;KV+-| \$%YE7&-!"A*=D?9;93_LOI2.9B\$E6O
6\$E^104@,_PL_.MXSQ|8^?|KW0#|<2%HQG@4#@7|BF/LZ\$^@?OVGY_|5'DX=_)J5: 4-
1|8(H%^>&;W5NC|=S=M-
|!R9|^6'/B&.L6K(UF443@8ZPQZK^%#:P:#!B=@7GCA9(O^TJ4=-7YK(M99_MST_(:?
#:@MH|QIHUY"P?A5_""TNVYKB(?==G_!,")8(-J23VAD&|HH9_1+5
MNJ@L62S&.GT>I169'NM!DWR|Z0!#)\$3#4#"J;Q7K4,_.6C8W%_<|M*CA_"R:
M52L>*3Z@.1J6-,<5PDCN<9.E'/?2+*F-Z&A#XTONTI=V&) IR9 'QDU\$:QB3" I='PI-
RTD51N>L7NSWY+\$#.??ZZEU:0DXJ*,Q
M+M8"GE":8|H"W.R)Z)=E>^QI#HZO?!V(>BNZP7O'F:R882YS_NM\G_6NX;C
M\$@P!NSJ")F&H5?E'7RY04KX|B|TG;_FXAZ#-IX_N(&CS|HZ|GH63T@BI\$XN(
M,=/.#9&1R'R*'/6:.*2#JR,S1M--R6C P|BV1 MBHM,TV#I4Q_JH!R
3>YWG/K|CFD:D)4\$NN.&<=T)VU9""%H1=3UQR>|"RT3
M4(ZU2\$5+*A|9>@V71#P7RV8G?\$@H8?P%|D)X^6S=KXZX.\2ON3|"L&94:~W0 M)H-

V53.JF7ARFE29E\|V\7\&XS!5R%:%AR8NI2C2-+0\H6-!4RRY6HG-E69BJ
MA)>AY;/AJUAKA9L/4*+&|LO\%P70;-"-S4|TLZ\(*7F4*F!H82#U8Q2WS
MHVACX*IP,8C="8P"BP\QNW#UKZ4'+ZRE6\3Y^(^2?
T(J7UOUA!=D9%8+EDG.+8#9V*T7U\ E&1 M\UV?S7--/_=3B)N)2;L08L.I.6)=
0JHW_A1\RS.T4!\$&F/-CX43NW(\$)BF' MU@6 ?\B-0<)\$UT
6X01:LDM0!SO7*D(J6Z!4\YCY(XM-.9L_P\$C)5G/_6)NO ME'P?
C/FT8('!\U4%]=.@DEW)N'>S.--!;U+8H'
M\$|7#1/\$ZCE|&I'N!=1H60:5PJ@7F|"+W6LG|;?S?#>/8Y|TXY12/\$)X!C/@
MROG%^IC*EL0BN"E(EYW< BV!=4UXAWPN0'-NR(D7Y>MYR'GXRL\VFZ\0W=J*
MP:D9D%:B(j2Y\$>\$1V,WH!E>GVL%V\A7_<715:3-OJ90!PF2ZRZ\%B%(7ZOV\
MU!'.9MR@&?7.CL;BG9EY,/0\$N\$="36N,Q"N M-2'R:9F'%1!2+W?<*J='P0HO"D|/\$K-DWA.
_6BHIF3P "J\ 7M/9 A9NOY'Q M,!G7:P)AX!
O5\5PHRP?)N5&)H7TM\$)X5!0.8OC0ZO#YFGJ*;3SX53X#"K
M9\HC:EM;CH%3)GL/K7VX<(XC0-6GTZ2,B'E\NRHDK\PRQ<|RRPC+VM_*HL
MUJ(F^S#LURI^;-0VV6Q5-,<<5F C\$)P_9\ODRL+\$-U15IG\$-"V5,(?
*CMJ#F@W;32>F:F%H_!VV?=)RRAD;K, G&\$A@| MK7>6WZ'-
H,GR"K!3)D1&!4RZ)5FI&@" .S_K'XA_PO!1U2'VOM?C(A0@%TT! M0SD@Q.F!Y?
|A1#1\$9:P?Z|X1U)E2K?/J";SBU.;S;_M0&|O2-TTZGU8<\$T L\4...M34?BX\$@-
MGI7,G5M'3(X:"COJ8TF4P=J3V1*S25X)6NW2HB#IF;H#[5L:"> !60)P9W\ MV1O\$1?
EJ0P@LX5Y/= @P3-%FLNG?,RG8HIK8J1JF"N1L.'9(U#(Y+1SDS/(J! MG:#+H'0|5(2*G_.,
>,L;N04UZ1K-OC^0",@12B.F3+2+UNOIV52QKV6HB"R M8\X&P+_={S;U3FEV,JR("+
(T9=TRBGU1K#:J#:3C0|WP836)0(F)X6V:0D8I M5KVG\!(U24+ NTSK&2F&:+P=
|ORA=D6'1!191&U"D9OJ&B1C>W92 MK*GM@;E&P4=X%1S1%S!V%
|8..B>*AL@Q.JX=M=5NP)@ &!/"/-Y-|>4.Z2C?Q;0 Z^ ^ :0A_S(Q^='.=CK82(-78*SF'KA7|
(S2 MF((HIU*U*=E-%8XZV(,(R\|K^I^0M8BBYP? WH0NWGF6L;JXKAL>0MF3O-H
M<|?Q4G4+5XG4'B"WQ:96E2TB0%N4ZE)A-
^W5,>,@3M6BR2|U|;^1,\$9|L.M%4S>|D2_5PI7 MAI'M6_OH;%T4BY&&K?
7)+L|Q688!%R|D;JCEA%Z6RK|,DG&>LYX5ZS|M| X MMTAH,?;=:S))R3ZJM;*.:#H:AMT?
8^\$+;4H+!GS.|4*L4\$YCO0C>S78'N5?+ M0HT;(K-DW?NF4)|K77(>16&=IV++F'>
(F'D7/&VAY8. M*;>J|@W|1=*OPBM7%+Q.V_E)>|T2E|G5Q;
_&_BOYSYP|&X0%U361VS|%^KU M@;2,S?(D4X"H\$4._#E*)>E-
IY|8|1UFV3LFF|JT;.B2JZ=>/9/DX3QXV;((?
MGVX\$U5AW0.'EQ(!&@3(:S>FA;4/49O&'K03\H'(+I<7*%_4&WU/QRFZX+/BV MG()I-2N
\$8P^B7:*"PL#|PXL>'E#;D_S"=YH*39-6!Z0A*:Q!""D7'588N\$ M\$|C:/?
8W2Z%GT0@U""%9_'&+3PD>I(.IFG8L7MN'1?OK\X1R ORDNC53O-
MJ|X0W09);#/QCG\8L88@N:|JUO|L#4_Y"@1HY"i!1+I8Q!9+K<.PB"O/U1I& MF30EF;"
M';+;!M&HD:YZT J\$2|IBDTo@F?+QP-/ \$KA#G1H!RNX+K:9|\$(Q(93>X:O4 M1QC?^\$(E
^'.(8C42-8^A!)?JOD*VXTDTR@#2SUPG2\BB22Y;7S08YS8#I;.*WI-JT<>Y7M7)ZH ZMZ-
)-75\$WSD+,6.92:FU0,TE0DD MOJ(PE^4I^R6HJ'0+'OG"0YA5\$T4T|R|T|"V (SOR M2
OKLCXGWBYI"N7'0BZ+|R"D/HN&|4=E>9_5#<51COQ@Q;C@7CDN6@(|(+@F5 MNH|*!
|"!UBCHEZD>6VYU6>?RA)^Y8^7MSP|3%6>.GAR4IM|(Y\$)TFV4&+|J M7"Y3-
+@MG11A)DEM DR"PJD)Y?(! (2%3,')@:D<_.|C8\$QA\$'(_)=N %OZ?|
M@7<'4\$HOXG_L|S?U(3;O)\WWF\W\0VN3WRA6=K%6M=PM_S3*MW3DCXZF>4
M:/*&+= 'R,65ZN>Q<"CVRZJY*(E,HE%?
D|99(S*R,&O|LQ^'UXA5:\$FKM)WL@5C:#GL:Z"H-...5T=(K1P:|NB1| MP,?
I*NQ%|N3*=OSLL'NE(,=@_L:O5Z?R6,&A1=P0S%:X(E5O.VZ)3@|I*ACC
M42(:0!_*)B#WTVISA_Z9NVSS'E=EC@|DPI??34_/6!":YST>|I M_)XTNE|JR.JGC1X|>
<|P0|H?,|JL|)A (_V3+DX-%:BA!%|FB216SK6P@|M MPW20>_)
<+I"IE|UJ>#TZN"DT8);RN.C6(O| ^Q>U+""*XF!(|>AP6@%D5K>.;A
M_RK,%|42JX(U3=S|0FR4PRP&MG"/|>^6G8!Z?T5!/%>DC6 (#B8AL0"| =CUY
|0E3&"6L)W\$|04^Y|21NW-\$ MR#:L8,8F?29|(\$'FJTX&'7E.Y26?GY3%:2'>XH=8>@NP_?
V)AM<9Y,SC|13B M#=(9F=FJ10L;GK16DF: +OT!&/8Q6W;?5ECMI=WS5Q1V,?
F*CO==="\$HJ+GZ4 MS,-VK4TE|ETLY&F'1D H)K62UH(|^ (X9*Q5F\$@J_EQ.*<|H@|ONF
QT=UPU0Q*LR6*\$)%M8R8DUPV>;_ (M!;@.\$!|?
AQ(6Q|*M8OU41BO)F\W#AJB84!140V\$.PQC)WYT4V99MY^M7,21Q M%|HHJ16>!/:-
M7\$9A9F6_!/B8|K(3_!S^!H3;Z<|CZ^%&V%2C,"0@RZPHBM M?|">|P-
^030D,=?/#3DEOHE!X|9C)EL0M_2_CXJ*+,=UO!MP_CB46|6!8U'
M>\$MN|_.7^|A:'QR|")O?'8R_V,&8W=X!O#&0-!Y!8\8JBK>7%EXQHGIQ2DLG'.

!*/[G9WN)H"P@FYB&R@57&,CT0M MJB'H6@Z0FDIDQ&;,=\$QRFfB'^' @1H4| N|1 SLOB
!2-4Y++OQMS/N@TEZN M)6.:EN^KFC0?CSLZO| ^N@ _N|SDV\$.7@@4S=ON8%*W&&N
0H3>:X5;/L|SNFI MY|T|_US*%A9T0B-PFRM1K:8@45UP(*?ALR7| M,/3AB72E-
2+F#1J,4F+O=*1=97(I/\$.S!/N48D7XD V7EL!>XNDLHO5@+ #P5S@PJ'^J0A+AU;2.Y&(I
<34|PF37=1=G9Y\$- M|7(I&W\$4(L*3R^=2/LZU&.)!SD_Z7IQ3\$;54#?DM_3S.?
23XZ#03HKW5/B-R ML3""0-HT/X*%@|A;(- V9%_Q(M\$"T#)#FM?T!X!Y\$GR L|9.160U
_CO@H_UJ%&JZRLR\$W6J+0G%!%F_=9&.GQ'JW M+:1C=M =>C^(-:
|HZB(#Z"8=FE39*J#HOD.E'(-R|_O)OVG@ _G'HBF23' M82Z(*!|!@T&)X6N2#YPX-
:FXJAA&^68.|206.HQ"2?R): G#(5,|L+W#[?ZHZE5+1T-#TCA?
44MD*GA|OI#YX^WO_F*7WNL-@ \$|T@: M*,|Q^0-9F)3#HT|^.=A _HP^2 S5!|J8<71-
K0IN>|YLA|:1CV|=G095(C8|S<,>L+HQ=:K-E=(%_MOZ!2:H2YSZMMR|&U00(>B
UOP|S5D65-V| ?YN;:V0|CTC09-2S&.|G|GW3| MOX1G_
A1U8&\$G?!3E.@MVJIR(T:YV%KWNCT"WS)<*72IX((A\$TGQ1VMM-T!
MOX302O;JAK)V^;SH.XK5?0|"7G4GL'UO!K9U#NR.<|!L4.4^IKN.# M1?U<\$T%-
FGVPC9S#WS4)0XE4%!?"S(48G=J 5&,Q"|Y1U^VJ@/Z3W2||"IE M+F>G5*Y_/A52P,Q
<|HT!A^O(X&:Y%|6!^?Z|05JOK|H6IKXG;D-R C|J|)
M;+OEHL|^|C(|\$1AJ0I/\$_JY)C0R)"2@UW0R/1I6Z6GS=|6:4TE|B M'=#Q9Z-
+'EF6)A;G'J;^6J=>?.,VKW:4&LPCR4! #S,UC4+?G%0 M01&,D)S3ODPE6E#?
V:|=|++&XXRA+'N;VFKTN:/AR M@^&.N+*33LJ>42%4||L;0DF|X=|QCWA?
N9%T45&;MI>|HKMC23F_K|JH;C+A?/>7ODVN-3FN8N2
M%;U;)NH%QC"8YT)9EX5Q6AHNIZ.T|J1L%BC6" !9LUN,1:K ZL8G09/TABW|
M9AV,"@.XI0'JP>1_QD"|<24ZF(+3HJHWAKCS?6YQ5@'U\$"!E9^U?1G"WX=)
MNU9QNW(AF6,\$.)E!M:&^LC"8*>|3!G5*MO|Y,*=Q6M(-^"P,33YU,,NO';S
M.V1CS=>"\$C=(BV0UEN(R>1?Z87ZN5V|U?#2ZA_6D6W|^|H<_|!T|#|=>&,45-M#DJ)0
/8&+A#%#.|CTDL:AH_E,HT-HZLJ"7X?;'UP/22W| M|F|?;!|<)|H|1VX#
|O|D^8>88@CC8@0+E:<<.L;@:E2YV/*4,4665BS'(-M M6_AK#-*1#|J\$UT^4CG_%G8O,X*
83L|.2758GDDC3ECGP7H2GT+9YD0R\$|X1 M/M8)-243R)SE%+W,_O&N"=:P-
/2T!;^WM1-V;ZRV7%1;VKZ#A5VA0Z%1.|X M6. "+U%!M&FD|,'L#OFSl?J\$_\$&
FIZ"PK(|L.(W_N MB%UN6*6?2CN#RB-O%i6C|Z)#E4KT4Z(-
Q9GOJZ@JONEDE)"*PVI;=%PHC-. ZB M/Y;|MH7:3L_A;#C1 M;A(^XG4-Q"5+0Y>ON
WFJZX^+N!@O)E)7PCG_G')?:|R#;Z0O+U>|Y7^54;B M: ^WH+-|C|!%.ZX+ZB(D@GW*
<|Y-BQ1Y8|#/%|P|' MJW"L4^|,1 V\$B5S:@9=P"Y&?|_<&Y8*="O#RYN_(U0A_"|= @UX-
;DN+3|X=| M2CM(G|SV9G|'|H0+#1
N77=7O1DQ&P^._AVNDWD!HVL(Y.GQZ1FS_#HS\$UP MHWT-DIQYY10+WQ@J|S
VEE/FOA\$9N#H&|3IRTERV7%G\$XQ=NY5EQHSTYS|H|
MH4NZL;W6R#P\$9\$QO&"Q=TWGY'O6,._#B<30N>@..8(C5E7R9.O7X8=#|CN4H M-
9\$6'^^VN^|_7;\$'^^OF">A'FAV*Q>5%"^HDZ?^QX*&4 MS=H(|-=DK*Y+|X6X/_S\$LDG-
|(|05?|+7%"2L9,NXU|G@%,:B"&X'(0).|W7G MDU8C'&X\$;YD(5'&VTD9|JW<\$VL\$DV|*)?
0R8G:E:2' W9=^H (-AF;L6HD M.C&T1;&IZJW1ZZHH7,;:;=*
(@7&2S4TX"1ICWL L&RKO@8>;O,WD1PZ2:O+4* M;Q*QDZ2&6TV|_-
V:|!@912&98J=|05VF?5XZU)4 MO|GM3)0 M1L*'+&LR'F@!(E4V)8+.39X)>Y1!GJK*|
|FL/N_*1=R\$|W^M|0Z;Z#)S&_MYN&=FE%FT@*)#\$\$#C/#'U/-B&&"|T*V&
<,16<8<9 |Y.HBN9@30TY-|OX(5@7 M>8*|FN1/(3,7+
AX|)9E)0P(UXS6BOLY<&80|=,E|!M4U)Y|*00RR:??>IV9 M(6-
H|\$,YF)2F#K|ANE6AB8W|K#^-E'U.68%=9-H!,Y _MGKE=M M%+->6V7&D?J|<,^J^>L|
|^-KLOF-F^@_J\$A8=/SR"B+U1DZ(<)?B'=1M7!5B2 MODJ).)W+X!Q33+?
GTH(9.,VKKTTW6/W0EL%C&.OS;!449@B(_8;D%=>Df' M/9A)6C|5-
EN45=|)|#789^=8|)NW>+.=.|"H'J^~LJM?\$J52\$)R^%J4T|F#1RQ(0
:8|, #):G*;W<+WEW%X>8(%>\$T0HO M-
E7:IG2DVE@V.GS|!D;S_!G++YJO)# #2!R+LX.S@T=|_ \$>B|W0C6.=XMU|+ "
M63AZ|K@TT8)PG\$HD9\$*;S"H+K1"4%RRSU+>1PCB|R|^W&@M| (9FXW|_D#",^ M-
YQ4&>5+R/8@^"&%3,H88>#ROJLIK79-UX7UH2Y5);T_-E-JA-AAU#%<=J|D,QE|JSC6(
MDWSAM'QX3T/W9_U'#VDN=M&PQ3;DBTR|T?9T_MGI-JKT#89-T1F*22X%U/?
MW9_JP*+*T#CG"C52C&;\$NI'YLNN\$:_|1AUFFV|97LCON|)G9V7.4X*OXE")-
MLG^@K,PQVKQLYOV*7#<5L-?\$JU>(XYG<,8'A!WF# TYSL_Q*7"WGDF.S5FIC60
M;O<69|3@KJ9AGOD+&+"PR;>X<,R|K.-\$"T"X|L9ILM0'Q|<+_G^DUO@SMVF M%-
B|K54#O;|G9)Z)5T6 MFSBT6@Z0"@/U82#H|UC(=*V2<%JX.-I2NQMV%I>GUZA(|-
&F!4Q/J.!U^V%2 M,N YFBR=G!5X3Y,@B10:V6@L|7F|JN

!G5KU:&JH;G542X@.V)&UC1R1)*;*M0T"/A.LM)?
#YNLBS16O'.X086#4E;%JN073/T_F3I%!8Q#O.#=+:RJ!0!"
MM0166_@5J^U^8?"F7.C=E)P)6/L:QP^!1_.M!?!J.;KM)8C2UBEZ2D*E?<,MNYO\C_8J?
7P/4_9AW<|D25&:=0!;5U_G5CD8D1SBWIKD6S!*OA!E(7=L6Z(I-W4@&AYN"[KL.W?S^!1
M-?Q|S3B_AW5SK1UBXBP,?61=NF//ERL_ ^5#Y|_#Q_N2;HT??.5/G^5'^:/G3|X|^:/Y
ML_G\!OGSXXKO_ ^WS/TTLGD%).UFFSYX.LCQ|SW:OI8-PW^#|;2=%ST M|K?
7/H(0Q<'W^_RA? ^XZ=?7Q_ ^/?_?OW#|/"WEV_>S%|_../KW_ZI7"W
MS3POJ75S.^>GX\$).&)/+S?2SI^_??;LNX-G3|H|HJL.^:N=<_|J?|Y_>OA_MZU?
_ ^/7M;_!S&K/(M*#3+_P\$ _DDTSYZ82C+OMH>42(D|.OP/ MF9MT>Z|J+
| ^KS*TJU)&K%H TJ . MOM5_NL(2>WfYB@* GKJH16081&.Q'
GAC%G4XD5:B.99DF(^L@V&^4W*W8(M|C#?H/A+=!61SWP6=\$HD_ZM_I*
(H#/%L^,KR300AU<^4>U#=#1+4Y*XD\O M#I+FI&?6K"1J\6V/?|M+-^&:_!GBK&
|>S;ZB0|Y>_Z9G3ZV+BX)R^G<;|NF M!Q|/"@OS)"2(H(&6#N6""%K"\UNP,+^4"OF!|M&
(0HEFZCWC)PK/N-3|1Z%H MOPT&|U97)4L0 |H05HV 6:'1"-5(?
@Q.@N_>!GYQ|QI#;!7D(AOE=|FI!C+\$ M_XZ"(6,JPA|88Z\LS.4I!64R>"
|5|VF7R/"4V=\$)CS+V"W\$ZZY&\$Y//W(*%9A(T'X|B=(>/20%O.3=1C08^K\$.RV;>LV8_M
VATPUQ*(2RN\$5IU8KV%91L=(,|O16|O/*R0YWA"PF:A-81PEL3NX|^4_M7+
|8A)5!3:V<9)+, _RWD\$\$.659Q47LXY\T)T62JO\8Z(Z+%+O0\$AU75D2#HVM#-P>
|Z_&GD))IU@!6EH2YB=EL4Q='UODW|^ ^ ^K5V|. ?OY9&VN&GW8=^_IKK_MZ?
3Q+|/SOS|SKB'*T*G)\$QOAF4IMO5F%ZK6^%/H9.K?._Y|+T)X@7T!=-^1>_ML>YQ-
(|NAN2=7|/5P3JA/M6NP)(W/^@="Y*|W;_ |S61|X,E|JC\$>U(9AD\$
M|F4C|>>"\$|@3W#36,I-%"V*=)T*YVW=;!*32|H|S|X K)%|_I\$2U|SZP!2FP2
M%U|L)|=!XF0.L*YP+W9S|\$;UUUV"68|^\$A>5B/Y:0^(T56X%/0_MK\$>,(P1D#,@W^3KV!
<11:*R+1Q(@::@#;L|J8GWBFB(BNK %/'DE\$V%&JEI+5)C MAUY%
H%*(@)^8R|8\$C<7Q!\$"N"7:*O-J^R^O5@9/)1Y_9#?S;"30@00A)"3
M8"25N!=19R1H-.VA_);L3"-B:|@^GOMRK;V==\$<,_X2KCZ_"/=)ZE,DD(M
M)F(.BNJ%J(E<=>M"J+;Z#5/7:V|89C>56!J5>_O#<\$Q@'V@(%LPU;,_-N&P M.
<\$%5F1Y&J6A82@'K;:9(T4'J=8G|C*1BC0*5E*'-6_7|O"|NN,|=,^I=BX
M=7B!|Y!CH!AHL0"|HXI_2#B)|J|+2:@;#C(&\$7D'6AOAE"L! ^.<%\$\$.POIP
MOA^O48QLK(ESCQ8/DV+X)&)%J0,<)|@82("6P>^.#-+|HL>CGN50JR3#T(#,
<9|_%LJ%EN-?C1R(@'V|H3EJ78N?D4R.L|^9'0HD|0&0!L0R(Z;|
<"U&8JB:WK+3(.CRTT"YM_0?)2.2X;DE6=G|7+J82#)|@!@NT(>LB_M^??6)?
A!1R#5+B4Y6PF3\$:4K&BV=T9>S"C=G^X0)KNH9""K>^V):|_V^%E MN\$3G,B?"O|
&CVH!@50C85)CA5TK!"|G;G7-@GL>Y7MW|MEXT0HD9E(R|C^RY:LP&Q7/DXYG!;X
MC2F7?_1>XT81W5V|_1&T3<5?(D-IN605KM7_|TVA0I>XMM:\$)2?U@C'67=|U_M|501
XEJ5EISR5.1|0K7JY3/24H6ZQCQ#H%%-4OC/F.5F\$8MM%C)Z0YKO,H
M873VJM|H5|H|S'A|LSOC=7ELT'>/_2%I'1_8"EQSOQ2K|^O,O MKW_|
|>WKP|M@TN25;|M!%.4#'\$):0.'(HD6L5-7L'^?|=|. #H'|!^4M?524TY MK5^#"H)L?"
M@VYS_A9^W)2/062!4_Y8D1^|J0K_Q:"F'ZV5J@%MA1=;_3G9|L(_&|Q+ WS_M*G'I#VW=
(=I,#@G8)E0G1;4>OC66U-W.6?XON:\$7<,M>.EU?%;/"7A)W5E2_M;BJVRI-!"3#2,%A("-
'4|TLRZR&,_ "ZXB56%N.Z/GB9M2=I0Z\$-T+W"Z7-\$ MB9=@QC.Y;.
(EAB5(#/FT*M*G!;A)AURA)1W,Y!"/" R;AME15")|/(QLM_V(9HE|H|JW|3%7_0?+Q9E
MNZGR|5_*-2Z%+|U(WY8,'B4D:1/+*^)^M^<_QU-E_Q"=/UX3_+O3.|N?)|*?_
M&/_ ^Z<' ^MT^ ^F?S3H_V#*_|^V9/IF^SZQJZ'.GB|_3YIWJH)|H|O7T/=2M' MZA,^U+
'C|^|U'|@C?(Z#5N!-LS_ ^M.3/PVZ0_|R>/-^=I|N;G)RAKN!+*G MWN_?7>3B8+?|_
=JW7XOC8-W,A'6+BU|O\$;V<#-/51H%/M-LT#M^7E*D(|=H|M??|)?
B'8O5T;WM@|NT.O04#FZIP/R2@M2G^7|SS4+GS-ZO=S@_%83<<2U|Z>
M|5|8FSVB9K|1CH_|J;W'^|^ ^-O8VCO"62E>)/_NK@Z|X2E-Z@76?Q^.)|7
MQ7+Y0IPBQ'6;:;@;5@1F|^HLKSG2XPJ>>Q^<7.7N/N"^)?F78;.'HG\$0M|Y M%)?<
9|V**>-QHT-YL'PPA^Y@^>QC!COS!AP|N %|_&TR@E<^&H08|TLY_M
|K_B,/@,\$+7WGM7#Q@MVR%H+O||8N'P;K,8#UY&*;K,|OW;IB>?IQM'AQS
MM|TVO^Z;>G.9V/;:#00Q9V5||S!;EQFFYP_#=.N|Z"|HF+ZY5|HRR|;|W|)
MY|0B^G!>|/C*M^((NW?#|+ "F/GA-W76'&56)6Y|\$|S#DTTW6|0|H2B0!+L+
MZ;&#;Q_&|UKS)1^6,'D8WVO-1ST,|R6'|Hf3|8'S|^"\$79&W|.EW0QCPXV|O
M#!'|U<'7_K/8=D5CL6E%|X6@Z_*;K_5CA=IEJW7PE=<\$(.88@O1#E>V#&S<
M#8R_-\$"5X>W# #OYW5V|R"8|)%T|@ "A|K?U_51.|W%_%V|O|U|HLS7C#_Y&R%1_M"
/|8|Y|J3>""&6/F3Z&V|QW*KW1S4D>'S|I&|W_ 'D5V7X4>1\$&:49JGM_M2|8Y1F)6(YO:|
TIN|4"#;8&_*^S@G+B@X|D)VJ|:>I_,L/HE@IZ31?5-6'

MF99GT<^/(<[HAOJ!)_JUKA;1%@0;|^BS,:)BE\$|4- 4|="L'2(*P1&G:>C6: M)UQAP3!D
2DSS6R_#5-IWKT8:>TL'_4D%X4(NXB\N300X|V-MXX"Z>+89:)2T1_>/OF2>3D
DO|4DZ\$|^ 8?.WB>Z97+TZ+:9M:@7*|Q2&%# MO{\$.Y,.HN70=
|ZKU>R2_3+/AATOX0.E"<|.U#^_OJO+|^|^77GU^|?OW#
MVY^>G@>+NO#'_A".H,4/GX?53|>4&<=U'Y%0|T5\$'A<5I7HS!F 4,3;|%-M
DUYN72\$2)M\302QX?@C6I2&&3>5G<=H|>G/U/_A:I'S:N!+U*M<\$-8)M11-C)|3Y>KD
*U-I'8%_U_)4W&0MM#"?'N>E6#05#4XU0.>/'-812 M)!NVNC2S8+|?Y<U5%#DB?
I5A?|O9HM|!;K% MG-4%-P"RSHL>#G%XU,.F#+2\$&UX:8,+A84C^=-
&.UUV"@SE508D+/#|6)&.^,N8T0-1H#\$D3W6B\$H MS-
";XJCI:=/|_|>A+EQ8TL7_"L(A_V>JH.B15)KU71'R*HJ7|WK6J94;C_/MQ\$0""0IN\$"
%XM8|J^?LV4B00(4J8T@A1?Q:I=%()'+R;.:|_0/^H;.:7" M2S?70@1|:Q);.3P!80X\$RC-
|JC+ZNQN?U73I\$B"A/UPX6^/^;T5ENN_Q%>&,
M.#==Y|*%X:CZ|C+RNAT'VVF'3X13L=HQ=\$#YZ3K|P;YWLW_0ZQV>L6V6
(_"9A3C*AQUVXXDN9D!*-Y8_:38%PU9)7'&-R"70PZ<(KR M"V%W8\$3OFA\$G|8;6TE|/\$GV|
|/E393(\$Q<9Z/L=F)E/SUZ-@_>5F,V%|#;:@/: M%PF=P|J3-8HF<*S7-
I\$ _H44Y&+KU7>8(&%,HY*-*2|HU);J/K3_P#JW8D^5G/P MV"3*';P%#?
>9AM, SX0K7|LAJCTS?^53W?0!^*|HA0V)=;8R|WL'>D\$&+^P=| M|BL-\$?
ONNW17)=.CH16*&6_I2|7)&89;|. %Y5'0T7=;.-,|01OJ.VO*)#M MD=7SZQ*?
5M&8%'.L3/<(/5+C%^&Y1 HUU!SD(U9<>|<*9P2|/#;X7,9) M'S>7U!|X4!
\$E=&#T;H0|ZP|C1E"C7)S8G1_8"UXQ&EHF')JN;|LJ-7;1 MD-"WP03.\$T5VJA>#P?
XW|;:@YX'=W 1Q:% 2+=XCN|P(H&'AU7H>ZF>Z@90S
M>_>JZ^R)Y*;_ ^/7|_+,6VV|@FC#/-,?6-N'(9>|)_&6W?>\$5-(?
L/RRD#A|9!"Y%&T)|@OC^)^M&2S\$|3BIS0! N+9Z7A>=U4MZ-
M%L'^_GOILY.8U\$#+=")C^B-PT26VM"5/M*-L\$NN.(,!#)|@'B>ELO&&G=\$'C4
M3>PW;"NB&3G|4PW(Q1HXNKC&B1M)FQ6"X6=^!06E/YHJ>RF_>K"QK_@+?Y:
M2;R5;"EZ:SH(-! FB20F)QCXX3H|?FPV)\$@>Z|C"Y;.67\$S*) 48R4C2ZV MC"<:
|=X*|3!*5T:PE)51\$.T"Y?0*Z|7GP&PO,|Q|!V1S@?E+>^QC=-M^RT;|LC_!ZS|5KOFV6F?
@/86-LY;?W!ZUB..|;4C!DCWE4YZW6,RD|=0;5' M+?2\$JFCN;KOU:&>JO-4X(G>G)P-
#OEL.=M"M+8Y^\$DP"CR63??T0AA#U-!,6 MGG<"T)
|AVBG#M#0!NU/%TV%\$S;|EDM0\$OJE?02%6RZ|.|@'|
M0P//KR%NTA|:|:|)5+|97+_|H1J1=G#ZVI=.D50P,8SC;ZG\$.;PX|>L('>O>VRT\$V^-?
X\$3A|H!-C2=D6%VK_7(PYZZVCFG MG_>4Y%|;7|7^Q_ :D&X33Y#8^F8=.LUDM
T@Z92A+0QANPZ6LH:*'5V4AX8I M3_!
(C*VJ_ =P+T!7EYJEMUW"\$3N^=V(9ZLS:Z2>P#)5.U'XA8>.&^H)UE _JX
MN5O;WNLFWVNRPU:BMD;8TIL\$YJBN_1>7E9/FPVFL(NP\$7)*T9Z2|J-D7A?-
_DR^OC6|HTB MN_VMPG=9N|-&AFEFVB+.#4|NF2)77GPT5/2-
)>K%LMCM(NO"BA_:@_!6"J|B M3I6>8-U/HI5L:5D/JT+(EXQ.0YI'C?\$X|C?
=|LED1;^:T"FI&F&?)9X^!GG;-Y)D/EQ_?5?G|H|_=-Y>WEU M|=NGJ|^_K-8(>2%;?7/7"JZ-
8L7#Z6-T, #_K;7\$^SEY
M\4S'47U7/Y|_ ^>I<7MZ74YT=;CVG8J9T5,^NSK_|Z|U7Y_VG+|Z7=|H>7GW| M?=_W|Y|
<|./|;^==W;YVKKY|N_06/3|^|^|??% M^7#^|^>N|+U?.^<>WSN75U>_PA^_?
|GXQ_G5NROGTWMYU|EZ=_|ETML"|;# M2L=7"@GI?
N8P|6|*L)|@2"L/H7.D+=A|=84P(D810KG|H^H=8_:5?L4WE;|B MQ^?
2V|DPKNXG600"_5SK?QYLC>4*U-??OE:ZS9NQ.;V-;LX.7+%S<@!S|0AS MJK|)6IEA=-
QW3AP=9X4G;S-%R|;#X_SLBA%-JVZCNC/A1L9Y91;Z?P%\$;3
M!;\$6#*5(C0+2>.,9E>O.KC&?3-8D_|U!C8#W)E\$P?V/W,GC@=9N;N!|MO4# MW^'4
B|DR% \$IKLE\$#98\$9B4D: ^1U=4&JD^MD?F2CN|7;|L@SRJD\$F7(=AHJCZY)?"/JDHKA0
MHFR@W(KD6Y,MX:LI3TZHXH2OZS)H'&V^H+R,I>*YZ;6VXB<,NU<4&(.9KD'H M-
")NSA7561)X_(!A"-CSB1A,*:&2.XHJ_4!%-TU W!|JOVB|!?!8.JT(|1 MU<\$;HM.\$|
OZ=*3HVE|!3'8QC@BISV\$71#RW|>1J&>7X3|O/0W|EZ*A|F 9^ MX";D1"G|!^/
HNX.*P^/P)T9%02+|Y1\$=7M";" ^BZ05GB#AO-4X@YP=@1#
M35H04V*2CN5HU)|@#K0TPHS(?W|V|\$(IDUG7N5+5GN1FB*3-RNL/;@3V"VZX M*85|"
|TD^|A:.E|^03<.KG28*02\$0,|E,7FL:V0L^X0^)|LR_#|HCS*
M9G9#%L_1XD:PTVEY.IW<&|P7\$5(JY&<)|L_&DN&IH0<"PPVMU>N>.46E|Y5
MWB|0;|CB\$|LVPX%J<1U%.(V9;JLJ&INRNP5(D,|8LWYK|HZ73W*^)|J!EHGI@UU""9
G4:5E0RHLY0TPS&7OS"=671%VW3(M*FL&(IG;)H@;X8JGQ#E8J.2JO>_MW,GTS6?GZ.
^XJH|_1H^Z_(!PK!#)0_1G//\$NTAPU@;:/<%4HY8*GRVES ME4N#OU.*2!|?S.Q-
89S".|IO*W^4DJAEVRS|)5V!;(K#D!|"9'8|V^Z10D-H MCLG#%P./JPGS;|@.E&&+ 9|B

!T3.0N1WG5L,%D[*2)!Y7S:FWY';MJ*I! ^Z^C@40(I)UL>Z-F&X;IW; ^
MI9>\$2U3&TBF=K!_VM[D:VH!_T5^B).@IAB3H'0QV212<M'312%)PLB8-
_//_UW8=W5O;LW=^OIJZ_/21@MOPP&]_7EU24/OJY7MY[IY%YI^OKWJH!H!57,I)
5I^Z_4E?EXH M\7I9#^Q:~?N R%*M7I@57QEK 'M(O0D6MW(:Y%IY9%7TK-
2G33I!&.01IGXS M;1*F4^4FC@I3-2,<"MVVKHH1LTK#4D&V#6D<@I5.^VICIE#5\Q>I/_
MU9K<_*@5XU1-;SW03A0.X1+,"D^ZFP:6(JHEQ/'G@?VKYA2!EXW0
MS4G#JN;Q0E":GLOW&JYXCS5K08/I?
ZUX508=J40T'I^K=O5+Y>I46T!)&9HFL+4^AEUG3_C7 L)!&T?Y9S#[U87O#Q'*&E-
MJH5@+G6=@'VB!:/Z%^DW;&.^!.DW1PAJ8RD&JZ&PJ2#5:W N5JM.'ZZ4Q/#*+''Y7@2?
&J+(LU3BA8M+@(QC+^-O-6TW\$OB M%#^?)X+P1ZH%9THG@KWN_!O8M[I,08*-WR-
?!"(HES\$5/071-B3'G/8=">/_M=!HDW,K#!UT\$COW6R91W'='*N!,I9OP9^Y\$TBOUXM
JKW=AH;>\$FHFCD\''M)0?T+5IOQ;,"M41-@J@)D&ZT<'=Q"MA\$?
4;UF19DBEI>_CF"&[WN*SY_X\$9@Y;R?6M>W7U MYQO/8FI UN#IM^?-W9K-
YOB_TL8.\IM*U79IQ3QN.4,'_I2A>2<9RT2N\$2\$4
M"HIQUR>N29'YKI*/C(F'R>QZQ<7>OF7L>W6_C6HX(HI,LW=QOB;%E+I6C@:
MV+&A88)Y/IP<6[XYG*6VXMANW8L1,8 MK;DIIZ(3B:~;1LG ^I=(*<-YCU|BCVBK+4
M=#/*P4>))F27JK%D[I>S29*;HWP;RICA|<I3P*&&3(V(X1++3(C,HBF|\$^*B8'5=+9+P@
MG==O0R?+!E /MR"?P!IO "*/Z=A T/L;))I@A#*>6<:9Z11AMHQ0YUOL/_:
MDB2;#;:PW|@(.<I\$?1=T%B #G?
1E5G\$=J)'S[KORM>/IPQ.A)05FT=!.U_IV^(66I0YJV73<3Y5ZH4#OV KIP3-XXTI>K"[%-
X@@HX!85 M:5#@@6VDS/^U=-U+A&Q+XV+699D9TEIK9ISU\$TH7@W'C S7\$6E<<+
(;N\$9D M9:D1W\$WL|''++QOK"5AC\$OACF5H',?,B8C@\$IHA"!K+A/D=S!1SEQ0-6T^D
M2PA&+'9#"8&.0B5RLOI8I#DI;.&TON#ID 2Z)#90ILUXMSI HM.;DUHR61-
MJ.ID#SKD X?-3>-1-E.A?:#PU_GUL?&D;!EI<,_X%D4967;\$"VT?#*YY2'@ M?
JH9_S6,_U9X5>&:(1W4C33-?YC,"G^Y+(KF^M=MA3 M;62BJ%U, I8#@(:(_@^
1E"IXD,=>A4WL M_(K|18K(I8A^|7XKSIXG14IJ3(A8>ZTP+H.G\$EV&.G!%M.,?
B.D.40W3B: MIE(@GW0DR/5P5V8N^G%TY-WD#G"##TX9SSA>5IX0Z4-
I#K1^H^P)N>21N8XQ
M7H0UP7Y1\$4B%'Y^)K>LL@>".ITO'WI67^=NNOW!/8";0IX'Y,H7FZNJMKF4
M=UU&:2^P!MG5;M/-*@H>@8P)L1U-PC82;[5%HJRW MX^GC"%QZJTG2%OY4-3O-
N*:"*%DA/..@WZPL5P' IM%UOA. &YM&F|KI8RD
M^I*_EYATV7^,&D2&9^!>#WM('BG|SNV/W"V
MF*O(2.*L%9L\%R7MJ::E?""WV)^IWA_)F^%L%>26G(#:6YD1H#B0;I4-@QT M;
^5(W*VX(?_ROTOBI8B|XNQ+S1P>&/U2;*3
ME>%D/E|@>P;UA\$=8UNX8K6&0<.5N8,Z956,H)AJ/T-#NIM^P1,6J+VF(FP8Q,F3-
<1(!&IM+YI7/?.\$H|YX",\EZLBRNH#^X3/G=I2J MB75X%3<*W>!E!>/(U**GHX^
VIE_*\$8GZ(44C.N02:A\%8+IGLF#IAP&KM| M)^Y?<2)]#VG4/
T:(2<@T8CSH)MCP)\$M9IA&"DR R)^ M-OCLOB=Z+W!..U 6C\$)<0?
=+Y"VURC=D&UD/Q&TPS?+F MDJG,%EC%)?I;H,)%**\$-@%^\91/2@VY4"0Z*58_@^4K
M+L5RYBY<1TL?O1Z>.)I.-5 1+00^Q*AG(KTZI|#+#QCZ=^7.\$S^+IF#X7I61(
M6FIUL18'475KEU;XC@H@:&&F|0U3)5Q15@;3.9)R W-314-U;7N1O1^8H, M9#+?
S6*K7^08&TA+3,025Q\$V>.4K)IY*1CG0/LOEP15.H|BHU?,OSV/PNN" M
KL5I_JY*E67B4;2#L5)+\$NC".6(:0PX%)TFCDJ0FI\$%, "I>I:M>*63ID!7 MI\$GSX%0HW?
7IZD)&>>4<'QO7NY*:E1Q;4AY(<I;H<IX+S7D;Z>X\$ TTS,R(6 MD:
<4X(^>.DXSEMSW@:I3PA,F|E,B/276DPO* (YN'>N\$'(&9JSPOYAU=?@ MDM>.
(W3K4MN#_6F8I_LLSIE_2FUW,\$KNN#Y*;)C8\$PP MM0)\$S\$B5RW,WKJ.)J.@)5134\$/-
MQN05#&90TP=9FZP%UHL;P&9%Y/F/U%N*K'#)Y3)JGV5H_R<"3SJ&>=9FZ8
M%6=+3(NF#)%^*+W+=!I! BGDA6.*HI@>!LJ>+85J1K4I'&^. MWGQ3, M"BJ:7R:V-
!07E83(X;^*Z)O9DC&LCY(!&#*&EH*>97IM;E)5AXO<)T2AA5K
MA;):.K|HIFODH+6+B,A.SV8IL=X'#KC>KH7+IDD\N2(I22M/MMZ/Y)@M82ZS(5:4L?
I% A-ODLX M#1OG%O|DE)Q\$.EJ1PD2E>C>(ZIA /EU@# M@UV*JYD)"F|CID\$B00,&7-
H_"?SRMZHECM6/HM1A<8=VH'TOQ\$%NI;5)"# M3.W_1C|<@CX?C0/<I'-
R6S|)#LS=F2()(_YHPHU.F(U'.'*N\$;&&LA9I./ME\$6+:P/2)6H.BCVNBR?(F(*ZQZWN-
:N@;S/6)XD@D?'/MZ"KGUZ,C*PL(F& MHV-A: @EFU' L*Z#*5KB.I,LNZI&P0JCV!I_C?
P.IT\$|UA*A<*S.*NRS 2N MF&2L8&*#,F*@L/7I!*\$(@B!(.IJ
VP2&7,RYC|HB";8\$I;LGR/E9X>:))SI' MC8SOXGO"B(-"#@#?3;\$BVI&+LL3#_.+
(GZP2I@@"|R#1V<(U| #:TXA% C7' MXWQA4JF(|'R":I&+D12J+P>+I;H\$#?
4@XJ2EDCR85TT*.&W'|(N2&>IMU MG8IJ|0S4*J:BNPI@^# U M/?9-

'WNDQLR\$I<[H%@_5*'59@CC45&[2GF&CSC I\$A7PVFESQ%:ZX\$8GXU:=
MUF"0(W1":;18K>[H5+N&:_SUDU9-OTR!;GL4*,*3R5PYABYT*G4FKEB\$9=6 MS6/N;E:
<)<KG0M,?=?(<,)Q4Y!|RY>_N\$Y+PY^KSZ',^UX\$QV,FEF-M,
6H0S8C%BMC990.JHK1R.%@-C3I;6K#C77%_ "D*"?"%_:!0U;8ZDRPY%*DMY
MNH+!;NUU:7_*QD?I%,0,:+RU;:C,VX,/:C(;G!=;I!):1X,EPTI*#D:PIDH3
MC9M0859IZ@R:EH/_BTIUN:;#<'&L\$S &VOM9@/2UV61\G,Q1T_-:G86%)P=N
M%Y#JHHL65LN?W8KLSC5\N;JH(804@KTR\NG%;=(6W.F"LF)9NN617Z@;@E8P
MYVHD!VI@-HC=>E4YXN=7%|Z@:*G0C&O7L: ^<|SSHKG?JHDT"F&564+H-Q*HV
MN4==YW?-F**ZMR/1\$T6BO96=RC<'\$2@N;GLR,ZXJ0W>!TO'+4E5 C(HW%> M*!
LWJXY?42A '<7-'?|IETY@;!G,,|_YVZ2L37.R-@%E&PLT;>R@Y=Rf&>, ML"6N7C>R/URD5
MZ,NV/FT/)2%LB>A,BAH#3-G3@?,*G5P-69('7M>8!0POP.V73/%L_%9GA,7
ML:B=?/9WVDNR.C95VJ:,3)V :%-634<(:!+UVP,D_(!_F! MDYQK-I9PH%*J\$,I9,'VLV?2
M4@B=OFA(=D|VR4Z;RS/%:;%^!DSZFKW,)F4TAC+I=+7)2))NHJ6(I/KSHQ=!9H\$RBX4
MTZMOS>W2P!8A)PW5BCF3/(@HGSC)48 W*)|U|2"=_*"N/89%4JJY6D:5L_"\$D
M!R(/2_0L::USD:5ONK IS4#JQ:6GVZ4\$|")7)8*)H+74!/SFH'OTDRFE)4N/ M.
HASA)P%:KOSG["H^|=_(14A N0!.FS,T\$!L+=W2\$IH6R.?G|H8|MZ5BTW%&I
M/<5(XW5|KBA6Y+)|HP NHNP8,>/7:I!\$6>8B"|=/;:|H%7I?E"ZL(%P;9\$G\$ M"-|/M|G7,'>
|B2IQXLG@"-&%\$I=-RW1(REW56B6/5RV|T1TW 9+#ICGZM2NM#8&|Q|!#
(5@\$E7+*.^M7|!#E|H MJKZP^62#ZE#R>%|TRZ8?9X-
3!|:,RL'(42*RDC"BSJA,B07TKJOY5B(39* MZG\OG*US234^|E*C\$G?W>UW5_.EUQ*J5Q-
LUH:-1JR659PX MS;Z:):!T7_1A@&7<>FU<><:5W
_A0*\$C^O@7TJIXR%G'>O"T,=XLWT99=5 MY#)&!
|S%1J(I"S/*ZEIY\$J2@18B_2U<*S'0*KRI_W0JY"*RR2=0 BM-XM?!' M ZM\$(/4"J(GS1&1,
|)8BZB*!3E% A,,|\$!8*CN\$LO5\$F/10HHAT" 3'65\$N/) M8SP\$;K&|Y>Z=\$B\$6)2!% 271
'VX1)KD>@,3#C@7<8!K!OVL9YHO,7/Y<.LS
ME^^4U1OGH\$R-4)DPYMO+NN4*SYBR|!#JF<*^J:5F(+
M'#:VK_P<=DGUS==|S6IX2WLA\$-N+WY'GN7TMD2AQC ;\$<1H(3_15TY30"1J: M<6KD
0:GXWU@NNAP%K(:A_&0^I:.*X8S_ ;Q>5|(1J./:"B17R|_ ^WHP\$3P M^+DWDIT9"K#Q&R-
D)87"AY;GHU2\$.H6>4C|/\$|VI&_A<
M2O2:PGH3;|P%P|37,MDG;OGN|K9XC>/TIF_Y(3A>N W7GW-^MM/U!E|:&
MG+8XLW+3GX^??DN=06 D+1WLTGP440CUR*WEX/Q#=_;JB2MJVC.SSTQXM08-
M*)^#NPS'DDK(ZQ)"|1S5"^UYU!Q7^;DG/J.6LXF M/-_Z,PI*2(AK54-5(Q7:=(@T
M<3QFG%T552M?.O):Y#L:|*ARSL^JB:0S'8\$LFM916_@JWU?9Z+T_OS>..JVI MP7Z8'-
_TQR9M 47|YE1 ACLS23M">|J3J-!""W0B"SI.=0FIG-NG\$Q_CVS0
M(_2HVC@E19F:1C=+JMAZ5!M?ZQVL>GFF\$3GY!!50#01!|RIBJL\$XK<&|/S|M%_|OBNT
K;|@;FE!QAF:PL%RFP)*6%;?70M9K*294B-3A<2),YL0.@P|Q"5C MS'(GD^|GB+NH4NP?
&*37>-|36:*4E0M(HMY A #|J\$1)PYM:T0&@56\$Q|_E MR|HOQ-
D'G&408(|;N4:>SGC'3"V4RHB"0^^CK_<./((0R&\$J9%7?.5;N/Y-
0,5I9S|MPUJ9E>ET4IPM%T M"U'YP&HS(!&IV|^W|J:9-
%R^2Q\$18+H!H|OM5FU#BKI#H3,-,:ZWZ ^O((
M<:ZOP;|D|1I^_3;G1&6CJ2DP3(|V)50_"%D&^6/E09 M6\$)?
G<^IUIVJG5|EG\$=SO_4,&\$&|%>2L.)G:,6:>\$|T. ^*P9F2\$A5M|JUZ39-#
|FKC\$FK:,85+>G&MG4A"LOH"PO!W8!%UWXP A=8,'7PL%#\$-|9JV (P!Y)<4WLOQ\$..(N9A
M:..H X,"RQ#7-E3M<+8,505BS1B:3^;#)5R\$5QVL,-|:5B|5ZKJH*1HA0B-_M|
<,:%+|1R^2!#T\$FAP+,#;|T;8RW<'0:06TK>/*X5SAL\$O'8@ M\$72J&*D4-(H;-H-,5-
B463%S8.+@NI=5BB#@6R<|H*5AJ .S&2A:B=745|B MVI"7LZ'Z/6|A!WVBW*VD')=X-
4T9W* @6HW7=5.G\$45,|4^/I!?,+P\$U5?=2 MTU6L6O4CH"9U!,+?
ZOB0EBMM"VVF_*2!N,X?*@RYTXYS8+K|UU3
MJ@GZO39(J(D|,V3R:7)K7=VQOEPEJOE!A^O'T/1/DX-=7SN'0VKFM| ^!>3 M%/"0-@7-
2D\$|VOH4M#M9W8:V|C,0GJTCI^RU/%\$EJV)DRP:93 M:.'*F" ^T,:|B)-%
/_M8V_K7=^XNDNI_D8|/I%1^3+E03F+RH+GODYO0@> |6 M\$;|/;>="E_'O)P
%GXFHFG2|D.. ^&/"|\$*"B"LSCYADY=SF(3Y="*.75,|NY?1RZGT)*B^=|/ NB M7,|&:8I(N/-
MZ:(?=IS|A4:6T;+3|M96.XX!SL8%T=!29R2*VXV0|. @M6=: M(|%>LU'+?
|&6K2DF@.5XBL:YJN '??C5_1N=7Q\$%'3O.>3*F?E%H,Z7P^S|! M*XK0;KM5PA,IGN-
&KH|O|=EL26?N&1NSIWHK%U5WP7I^+>^8%#^_52%IU
M\$A#*90%Q2<77*=@=)HM5=D178F(/X21(%0T4HOQAE*)4<:"10GETFP<'G&M,M=Z,
+)J1PX3#0M0P)T\$8#F<")"LMOHJLF'(J.IN@'A6/6-7ITIL->^P4#403 M#BR1G4
;!GMCE+F!/:A6XKFO#UPS-8XSG6Y.+@!J|QB81K&E/9,M(AZBHYBQ M|/GFEI?

2DCOGJULJL9E,&VTJ@4'-Q%/[1GKRVX4^M&H0;B;!6%N=*SH8|C+2(D.5*M>NTF)ID-
!)Y,-I^V!*V.60.TB.14).MY@[?H%QVL70D("C_)=@BWQA:V*2\$ M%,^*UY/=D.QW!;O-
UYXL#)#" E/H4X"G%\$W 3X(;;JA4Z=:0|O.9_<6|EBG MV^?
#4&#L0(S<4)";%684+12C)HAF:MQKB1X@"TF*XE;SD9_69:BY=68.@0F M.L=#
|VQY3WFC.Y@,.,@%R0'5#BL;(:.*QI099I72@KK8W^&OP|1|%,Z1|2Q9,=MOR2>,
,C9.2/"QRSC+VI(-BBX'47345<> /<"W@|BCG|9QA_N5_N9|F|?. M%598+*VOW!K^?
2'LP4 "-;H;H"HGH.HF M.?F=M,;;2R%W7%*?*56WV(W*XS%|M*,|Y:V:Q&.06=&J_V,A?
=_PCMANP%U|JG|5_@(:.INDJW_@4GAJFN'G1R28X WRU.,& M4T9-T>+'MRN|YP"
<24<5WQ2_1AFPVL8VX3LKDZB-B5LQ|>,V)OY\$6RL%WD*Z M)(:0N
0%OH2!J#7*1Z&XL!/"6.@""85XL|-2*|!9A65!C*0:9X5:4ZE+Z&^MVN?
LD_O"H3_N1A'@Y4,|%'2M46:R#T(R\$V7.OF|V>OGW2^77|^>2QBQB_5N
MQ5*7\$N""@GL++TWM?"^+C|HF= E| #EAVP"60,=&V>-Q" |H7P-%)GKX&%TU+4
M?;#1MD+5)-&|T@S0JVR<)&N|;7(|Z|178I0*8.! SUWJN|@ M-:)\$@W_G@8|VA'!X
5&>PR6RODCU8ZE=PE4XN+;#E8 MO/ACI'2> M?(Z\$;B4^WBE6*V 8"Q-
>\$C2\$|6,26L>RORGW.EK*SHOLI43)*?&UP\$GC-EGN M'U:-
X*/&J3FWT^@@#5(OC,D@K3ED095,+5U&NHK(P61Q'+*U7:I3XRZJ|. @M;
M5Z3ID| #XFA55_MR1:6X6=ND_ESB+
\$PY+1%V;2A;2827D;7B3E%;X3WSN4!ZTN5S4H%
|+P5U"36_H@P4J27C.M+@08|:J0+\$X,/%%|5;- "H-YRU M)IW>EO,\$JX^O2>|PX?PXVH?
>|R!#7#JC.5%=W_#69,*(_YXS629(OGX QX'X M@|JDP|)/+:RA9B(UPH2VP*IVPOM-
(>W"3/^P""#Q%JY)GJ::(:Y-WUW.042C MFTHV-2G9Y52U4|P%SV&).R7;,%UZFA'*&6/Q?
ZK M0DLNX:/! _/%1YGH<24XS-:-%;)|5|&=|@9RG+*X6"@KN7^# M@U#,S0)1UU._+
(35IEL4Z%Y?+Z|+|GV&)|08J.7>>\$D49|NL":D.PYQWQ3 MDP
C"OHES1.5DDX)@@IN5E%CKAL341+KV.5N.|I/2-%& =|DG'+,L8";,5='1P3?
|-=S@)A%3UN?MI%G#^("D7EGR=.TQG M3Q+Y"@W)32N903.8|69%4NG^MW)I*_J-
CT"Z,E9|UK|1)4@?KN'5PZ;.&%-9(XY\$#S,- \$T>!*Z'1X|# MS@JNH,".54S4W#EJ
V:LL;1N:SL;|AR?E&>FZ?2|)NB|3KS"O_*,4|Q4@C_
MW|,030P|,>|=FM|)RX2T+ #Z4R*3XUYN2N#ES5N3VRZYY"PMW=W|'J|3.MK:T
MBPQ|'"@1^5&J#+2THC27* !M^X?S2D0+!<12G@W&2D8V34+MW\$Y0N1K=-)G1|
MC!;7B|^MJ(EXH,17-K|8XW R'B;.&^M=?61<"S *^EOX7|;-ADTM1= #4-|F MXN?
&F|;)Z,9|EB@K"F|7^Y0-24Y6T0XDW9\$3|P67&X,|T8CO:P&QM.!MJ77@ MP!%5<-
!YSTS!/6#3YY|G>F4?SABDKSE;?0@=^A=|EY60CH4,-'?)C)NE 2SM M#|9XEN8!G M*P
Q;Y"M+8%DW@3R.M+C|DB?YD@-V*@YEI*\$S/|TDH VR#L7JGT'B,C2RB
MDN,M|@T#:6% @AV-D%O|H#_ |9#Q_ ^EK* 0*.|SJ=<^'|9.#;:);^1G""H"|2
M_M*P4O\$,D_NO@ZD.'LVN8|0=PI_|Y8R/!0RMI08HAKH82LLC_LZ!C|J=-4: MZ-
&JOP_ R*8NHO MDFBHQ(*|Q?<3"4^3-V>Z|QI_*'ZK)GLN72E|GX^_
:N(: "WWFE30<8)>.:2'5 M*7ID7GU77DYCEMV.)GOO#_ '\$UXCO=
|ZV,Z5WNN|LAJD(BJQ|K_\$K+E85Y@7 MEEV'!N,&A1UGK_ ^JG/|@QGW-
D_2NW519C1!X\$ _8&KW1B2NFSM>8+.6#_ (CME MG|T/|L(.SF&J53P|
K9*T5(7>PP7S")^3SW,'7K&H9\$!|L;RI?1L1PBV/Z;
M.0=6@09(|18"8HY'(VP")\$J2K;|5;.,4&VD3,. *H;N M+_VOQ2U# 'Y
|)P@C_C(%DY9+52KQ,I.(5PS_@@7H&64X|@9..&<60|3(KHVO:0BQ;3(>Q MKTQ&-
RQGTJF/1*|M2SCR)|J0';V|A=J9M-V"(E9NNFD@^KI=*74|JP9PE9 M;_ |V?
Z4R#,%O+L,O:RPZ5&)"T.T24B;A*F(3|O,Y9%V*=Y0*7D;!=_&2DB&A
M.R61J|<*8U)KFBV:6=M;C;13:EI';2\$Z&A2D8T-!=|BQ\$S-/E\$|:I=58\$XL
M\$>01@J47W|HV_>&NIA-*5"D M;H_3RFV3#-ZK;C|\$*P&9 S..@4:|1WN9@_-AJ;
C5_)VL;)@^|T02V)4JEXYP_#LZ< MB0!08EE|SF J-R2R|LF"TO'Q5*&8-,DN+
;+JTBD%PFQCQ*WT8Z!RE5SMPSQ M\$VHP/U?#81(Q)'FTSYUB)70#X_UX=H O_-
B#Y\$C9@E3!;G;/8 ";QH?4BD_Q9*5IT MGSF2+P-
MDI/N=K<|ZAOLK_H."%S^&|:SM6;2|P@VKRGE0(2;YYQ4=|1L1.RP
MU|HLOGZS&'N1'OR_Z|MM@5J*"PT|U|<;G&D%XM-2(YGVUY19P_Z|IR%O?
&5"11T%H(TQ>O;O_@=XJ3TV&(-1/|7,23L70@>B8B#B9*,2I M%FJ5Y^
M_!*\$S9TYW)7M&#@ "JY?C9J^#R=A)\$P|V.@NS?12.!!>#@_ |9#|I_3<<_.&Z8 M_>#07_Z'?
=KQ4,^1R3| MNJ|MW|EEZLC6<.06>FBM|5?R&7Z@A3D7URXH:W|^?C#4V5'#)M7\$
MC8(Y'2W?|Y^)U)GFR.=GH7 MMZ=+N_>66F5R^PD.BZ0FE?
WGS"|O|6R5;.)NT:1%+DHG9K:D5?\$_M:NE=NF+ MIWN
"QYI# #W0|>_I112D8F(M'&I>X|LO57|K_ +=6)\$/W\$ \$I M(J-1@L-
SW#?;T4O>JFU\$=6<%"EHP2|HTP:/QW8>8V|?W!%<4,R+)<&/#2?@ MI1K\$S7G=EF!

M|R\Z^#Q/J=%HW6.%"3Z_G7O C2*+=O#S|^&N1:Y,V?.1A7D%;=B@1||WOKM M=2?
XR48M_+S..V)H0Q46X" KK45|>STKCMGL^6A%|*"?>!/RT)MR2|O20|
M:%EP2|J;3+^G)(M)O^;J_MWO/XR6FW>F_:8=Z6:VX:=U?(&U21|;8Q-BECW5
MYKNA2FN=),NN0|6*MX3B!YW#_NF:5%|HOD_&J^8^MS:OVN;#Z??7U?+;PWDN
M6=&>3\$/IG>ZKAQOC^:9CN9X P>SE3I4M5^=#_FLR!'A'5UO9>T9^RX|?
C!1|IWMG10LI=>Y|;?)X-M.LZM5.NVS35VI0B)LZ,QU;@&U_4G012D6<(8*.9E|POSG9T-
CEH|LYE'<|H_M:X^FF4?
3NLT:>C"|@_9HFGHTFW!H;H&"I6O|HCA2|934/O6PIYXI*7BC9/=K M'/NS(-P)%#-(N-\$G-
|{-B|S"WG-|7T36|;.-"H^GW#MJC;>;1" A.>SS-M/)
|{#DQU@:;@|3NKAX;:T_EN4|EJ/>|H(%/K,=RC7|9!0|H""8)IM9_MA'|RV*18?9MZ|>#
|1T/V@/=H0=-W6@/=+&'^G>T=D:ZL:V">A#LGM;OU2#
MM:A+W6590%'S2K'\$UL,Tf.-UPUWMR3Q7 M^F-;KFCT((60M1?5Y=J8+!|-T|F|V1M
|4|E&:& M|MKC>2Z)?4^@NB:=3)LZM*I.U>R(UV|(KC!4HSA1#BL83N9^?
QAJU|>G:Z0<;-N!K0!^&_W: M1J_-I=&B"M?
-4\$5J%&3U|<)VT|{#IK>N;:"ALYLGLW=ZW/IM&GDO2\$KWI#^T1K&<7L_VOOQ
MLN|/4'|VAO2WI 7|3=7;@ M_WV,,V>BW BF-
_K#HK1Q:U:OUWO%6MSB_UY):8.I\$Q\$;FL>2")83N-%6O|3_->Z L01/19>NF-MC"6"\$
ABP=>(.|4_OYD%?
G:-8J5|0*)%|S#YLOS#ZH_4O5\$WJ/>/NV>%Z(SW|G(ZZ9_T|O_UP*:.B"K7TL;?YJA.Z&@M
ME2;T/4IB(0|OX#N2.|X@78YC|_%|SW_FD7(&M!YW")
|B5MO\$N4^K>8|S\$XZX2XX|WG+N 3_|I&8/^ZCU9P|3EP?7<||:|W|SQ(|*L|G4!5_"'+;N
%;NWHW=L2;:'R|M& M#7'Z|(QDK=8|+N!69RZV>|F31\$7>+?9|64UM?
VI16ZGYK5AGTC@&46.|ZFW>MQ)U|D+PD,-I'\$^K/I06-.BFF_=Q O|9%1PC2V T|KU2
RG4&R(G4=,X07CB M32H-N|A*'E77V,7KO\$%-O|\$.0/6^?(TS-
|0(2BOW&YN5M,.R|P79\$|17D+|6 M>XM1VS?3F,WWUXD*J6=Y\$90#N)SUGE#60?
&*.P1"RK/Z5Q8|JOL*\$A^=E4.@ M|O|>)|T6H8.SVAXERO^V|(YCL:S>R%03L>)|M\$Z?
_4P>(&53!"|/8B>|5LZ(@QNW&-Q0%-S 6 8SQ,%!A)H'4=|H|(A>%S_MX(T|0?
_5>_*|_J3E|5#E2 Y|:=C3|=,_O@U032L#|2 K5C?4IKAU?!T|C=R;..%|F>M@E.%W
MX9|Z.8PR";YWG#"> 8F%0.MABN/F61-&?|E|JT)/OPI+)|9G'SK+7#NWS9
M<9#@)LAN.P|RA&O8"QC*B|,L=49)/+%N3CI5E+"\$7\$RZ)|81K!'24Q%LF")N
M!/^&Q7@*NS>GFF_|\$L !CO'VI&J.O|2Q++WG^&(0P>7-XN36F25!IO;QN4>|
M0Y0.)|NT5 R,+1KL,'N"W4:M!K0&/-ZH8&P=BTCHP<|A#.-|O|O|^KWN" M#&^)|R-
\$VAV6963_L'MDWN2D-7RQ@D1I:.*#H.\$EA-JF7!\$,8PKRI;H(X3_&X M79
LT^N=Y|O)7"CA#-.XXOX* 3MR0;|Y#RI|EN>;D:R:>LFO4.!!H/(AOMS>MF|V*
<7>"PG0G0UG6MPOIC MK_B:GB:-|KZ*WS>#|BF&|^\$J|G:3T);%"-
^319INTD|_DUCOT9+|!:'F0 MX-%@UELMB!)F|S@V_Q#N2'|#|9|
<@U60&W/RA:D\$/YX6TH|\$7>_X
ML+#ORI>V0K|PILJSQ6)9|S|NNT<'QX^G@|/#%QJV**8 MG04W|
X|B^|%ZA|F="ELO7,8)TD|0|_G=A#OTB-%A0!C8V)T!!%L|40KK:"Q
M)Q&9)GE2L6(91_|V4T2W'W1-&"/K,.B@|'_F 3?|5P@B>TCY/T-K#>\$:/D#9STC1MYKC#?
JV00_OBG7PQU;G2TZ0K<"|1NLO>Y<5C9R:05%U M-
:'WUB@/EX;K|C709I2U4BM3\$E"%?*\$UK62WU?AH1O-97F+UTW!&?5M'|=_1
MS>9&).5>G|1L|6#UK1Z|0<0|?7KW1F|QJ_F'3>2 HZ,*GCKLI<1>,H8\$'9R. M|O|>;S+;
+S'9:'_6(H|/*PW@(|7YHF"O'KZ5TY""BG^07M-K,*- M&^;BLPY!7T2W-"AAQ&|R>J|VDKS
E*+C@ZU/*:IUOCWW7O|>O>HZ|Y6/02NZ M3FG&-N9()63|
BF39R;M:)MSOC\$%7SFVI/F2PHV(;LE,,GF#HC6&JT;V:Q1' M^_3%XIK" O'-
U1Y@'8NONJ|PE?B6N6\$:B^G-'V:3VS *G%|AF4_!AG\$CO&I^ M@"E""J|7I^PZZF#,B^R(|
*P(^!7,S,S%,!2;ACH(-1>|@BV)V7\$-|!48GGP: MAV!7.|"A?^=F0B!_Q<+RE15BHV0\$%RU-
S5YP!&(<'B77H|DS#FO|3=3*"E.Q M'ZZ&_U;&J1/EQ>.(& !^&K8\$1O"8L_J8/Q%/V3-&
(2:SOWB(G:H!*@A'SW 8 MQH|;HDK+3%*PU,|AGGMHH\$IH<5/7|= *V5|P:JD?>+R;M-
6<|8%CD0?D1>O M*(>Y.EO27E->?%\$%|"#Z|HOHGJTEZ_M8Y:)VH>G?QULKC#?
>8Q7GH.U,7@Z88=)_D\$|_M\$3+K.A|1<<#"\$P|QAY) E;Q#|_(\$=@3.Z?
<(ES)1\$TQ2(V8(SUV|&+Z/F-N@ M!/<)/H)OC<.=+T-'\$(SP"W(8|Y:A%
Q9Q=|T|WRMWDUNGI-!;_D< M("|!7CUHUQ|H_7"Z/K?SHUSQ,EY"6((H5ZB1*=8\%|/"?
Z6*M|JW?Y@CA5I?FQ8JH,2: MC?EC|JP00J*=>|0%C)Q_\$YE.%YFD)\$2=3838SC6
|G2DUI*LCVWOUR^?7M M."P/AH8Z:O|H|M@6N|O"P>W;4?Q1
MM|/NZ>&Z8')/#3+7Q#GUX(6CDX9-JHD;A7,Z73K2|B#0|;U%AI"0 2>^OK2^
MC^79*DML'ES8XZ+#K8GLN!T|H|_".V_M3|J38;54;>_PE0J(G"X|_O|HNFBG8/U,#@

0:G/18QVK,UY];&9
MVH"P)O<#;"Q=H.158!3MGIFFWZ_N3NSQLQ>5L=0I>Y!"&KFCO:DVJ*N4KW. MV5%
="GS[,JK:6U)JT-:UDW;[J+:VUM'8O6CMH":TQA['+A+8W6+^O;P.(MS+S?WTE\$]
IW^QY*\$]7^D[L7F1SG|8<\$"68FV*Q:);3=/UE785|RT\$!M=E:QO'?
U:.\$|:HVGFTR=RSCTYL\$|NJM?0G|H#::#^|B'LI7ZT_UZ0FPNNE(
MS/1DK1_:JU>^R_#ED6!MEQ='O'Y:E:JQA|_:0V1IAY.>VT:>C*]_CWI
MO;1^|1<|2!@|JDAFV0+=*G^|.EN;[SBZ&Q=>=V&DI|K:ZW-V=AQX_FN#V8
M9ALX;J*5'LRSW0RF^!E6ZE(5OJ|,\$>|^O"<>V54F\$P"1@=Y:5YJ)X|A-:
M<>VA:;>A"!9)Z_MXM.Y1U2D|E>0<@VY3C^8QUM8O-MAU_"4^TA-"HA:M%1|"
UXJCV\$|CS5'D(#GGJF1#H;?F(S/I??(T1G|P@'^@*[9SX)T,0QP9#?M%VABT*TU+.
)OI50!|HP?=ZW5Z1X.V2^..Y7|NB/9XGNW6MG!UN|UYF'K00-I_46->VKG0X7^61(@-
|9G+GA@S"T-HVZU+|?L/>?VZ;:
M!;|^~*K5W3!A.PS7L>+BFRVQ#SN#TW53|]=:S.H6.O!Z+4TO?LTW3^^9RI>
M2LM33>2IM*|L/M\$Q-R@I6T|"MGCRC/ES/;/:NSR88O_#-'M9/0H"=3MT_16#+U#
#C5W\$=J2>P!?(K;AEI MVMZF|W7Y2-NZN=W%A;2JV2/L3K/EV5|_=/VXVR-
M3>,TN_;"M!F3B7X^)^Y% MN^VE:2-2|TT#W,0M%>FO3(O|LKL'1V=M(K9_4=^A#UH-
H%4)&C|3.W(|^Y_M+NO<1UIP^O", \$|SO:"Z_WS_L'O0VUF#^/UB+/|OQSAS)LJ-
8#FC/%RU?SV M;|U7=%G"K2.S0Q8\$=MZ-8-6KN3UWJ6M&F+.?NFO?U/Y;Z:|N0H#
MZW^OC?-WZH|5_C|1|K=|P23?>V&_X4_?=KZ=|N8O&PB,4)(B_?>
>4D*LV2W,OR!!9+L-'15'F!&SI! MIB9!|Q81>|_V^9IX|62JHI2N3|
<9NT&D_6QP@5(7!\$@|8 M3-T@(:02|QKV5|&'@@(?#/.KE4"0R;3.(&)|?
M!HCPSP0|-13^#;|ZNW8RN M;
3|K%@.W%1XR!%0%+C4J3.*X==9^GI%5H>!"!0*Q34DX>=A^_HJE|K?|S1 MR:9!1)M/+
|V1L>3N5M3A\$(7PSP4A=P^8F,43*U^6G|OPT|^+?S_I=T|&U3|=M='N5?Z;JM?
K'O?.UAJJ_N|CSBI_O*/K|@5?;Z_7SSXKI:BRIKSZQI2YO=
MOP|2F(CSIW(3YQTP1=^1=2+_Y7^,X^4.SCHW*?;?;/.M7H'|MXBMTB0P3HP
M>HB*QH*-4J6K|TS'_Y!_|#ACAS##4V8+F0 H! MZAP_H|IA:QQNFJHL?9H_|
(N%N57S06|AKEM3F+M&Q'^.?VOM|3?;0;'7 M7Z..=MVU;P@4JJ7=%T*[9Z?-HMT7A*-
>8Y_,\$#UO>,U*'#)8;=EZH_;/+GH MV4|E4|JR|?W;H++|9<&)QXZSDBMO&_7CX4-:
|87K'6O=[*^;&V ZK?KQW(/MC>>).5OC\$1?:"3X7E-K*>NM&
|H!GT%41J#Y5618JV|_STI37WAHPZ:WR^DRG MLE\$(K&?28FU,Q::Y?
7^-8W|6A&%%Y'@;|5?OA>J0OZ=K):.U^NNS>9M|!TU3 M8+
<1*'991'^5_U\$QOF>^HZ..4*HxD2H; M:K'Y2*K;%L0>/L;1OIU,*.E|.FL/>-
A+ZT'6.UK#X=TJ_|IG7S_L>Q|=?U7 M1!UU|OETXN?X6D^<5)
<_K7'D'0+)Y%F37COIW'DSIB5&<.*XS36(_|S+^,85-#D9PB/"SKSQ<+6:N^VJ"
M\$|E^HJ&UH5T:PKO/-!5<74G22T(EV8^JEI\$|L#6P1H7#@?V)?!A;#F6 M6SP4G'4U
<18G*C_|"LHC+|AQ7GH4Y764"%C@2<3)U'3'\$Q%S%B303_#O"8N
MC7011VD^48GS#^6&2)5R|_|H\$KZ:AVSHY"|YM=EUHI0S@<>OT^J3G|'-0_X&
MUQ%^Q*.(?+B8&6P>G+5UH.2=X|JW.")"P(M3ODK5IS8;A1?LVD('X!IB|=MW@AH
780G7|G>E41503FP9PNKZZ46',Y^OG"M|RG1 \$#WZ9&47'"97K\$Q_# M'ZJC|(#
4<+2N:49_!|N5L2S,^!DZQ<;|!M._3N*-WXXGN
MPB(|(O0WU|E4,@DB>@Y(X2|_%PF|E'C1'VJ.|*C9)=-T|-73|F LQ>|FBM/KE,J-
\$<3(9+J+P+3|1(4N3CL!F|4?"WE#Y/D-F A,-|Y9^=J.(M'#Z*\$AI?%?8
MAA4@\$9'F#QJ|N@E M9R=CEI5'& @N5Q\$#
R'H!6A23/*\$|J@OLK<(\$2T"!#L'V,OPH>=IPEE%R=\$ M(|X,EBWM|*9F8-YXFDMG02J*7*
(AD>|!|4D(O9V913#W3!Z!'^4N#%:"V7* MUX0?I*O2O3\$|MY2T-TG9SA.3=M,E@K|\$.1X|
I0BXND=-8UZ)!OIDNSL5|X| MMEQ+D?R-
\$!2J(G+Y|Z.F)9L|0VN,#P\$+X\$6E">)BCQT8R!IL'5M#^3D&,9(MKURIUFA>*/E^3N*;
'=JJ.)XABS3I=V+4'TUBC#N\$S!H!))+D: %:GT.8|T> M=NDEXJ+U=PT7K6IG6_BL.X=JX;-
:.^"QK52U5@N?U<)>G|0A|UD;2<\$7PWCP
MTZ'/|%C:T*ZAI_0Z!X=KY,VUX%\$M^39HX7O|H^F\$>_IVZ_5=,\$PV@FBN1.
MT%OZ|TM\$CCHV=M,G5!;P'7GT?3OV4.U(25?\$JAS-SO)B|Q;Z@B-
0JR>M_*;Dj7WCT|S|9R M_|DM@M,U#(+G\$?E;"VV;3K)TF|-|
|0VYJY9|B@AC.3M5HV/_KN--MYUMZ|
M%W|_UN_0W(@|LE9=:2GKX4E3;J9,N%JLR|*GT.91|!%0>1:7V?C8??I4CV_X(
M|H%SDW:=4.Q6Y2<@'D9^Y|@00N4H<%-15?(0=F=/_L3):BTR0SSH?TOZD9%
M>3UQM7M7O7=7(E'9KMQ\$2LA&|;I/5#OF/<2I_S;H'FJ|MX;-M/'F?>S!;|MM
H;>:I(1\$M/.TY/V^Y\$;?P\$'QTB^6E|HEHP8V%-ABA#IE+'6ZX^KQ#EV%|6

M4IAO'Y'B.UE+=5;<#114A1LY:>=IR>7H()!%XJ(M5W9K,'A%RVA\68GL\$ M):3?
LO36LO//EFWJ^CT(N@K-W2>Y-IN;A@UR/. M7N^!J+6YM^H?2X?K2^'AQC@!@8&
(Y).!Q3#XCL*R\1 MU(H)>.O\.)#L"JE@[B;O^G#NKD8>YKW".MC(\,BHG6V3O4U=U-&
AR!8RD MKO/U6IE).#,WM7!5_81@7V%B[AUXSPBY),
IAAM'HZUCF[M*3X/"8;Q3"5.B)#\$M'. M&2PU;06&8G%.DC%9M"Q+J%OY.KI_"Y;'Q
M7S:?"W4W&MM*&. U*V^A:=J4JNW-96A3JMJ4JC:EJdVI:E.JVI2J1FW)/4NH
M=JO;T89)'K29#ZM'V5&:>@D:DLM*;) +*TO?0%5Z\$PB\+8N_:fV 8;3!,K8 MO:3-
1NN^SY"TN?6*2_4>'6T()!)#/+N*DV/F33ZX47OZLT\;>EYTT?P\HR M9TE:W?
HL[T>U';:WTC30L&AIZ@70U&YI_\$^6KEJ)%+/IZ8&/JCSTE(\$-Z.K MOQB:?!?
DNJ7)G4Y;72'9JLB&PSS&7G^@N;!0\$N/1T^:PEJ>L)W)X={B8@/Y
MU3,6!8=PD_3""8<27!1!L/:TT2E7A).R2R1)LFY"3OL DV\3*M2!MV:7\$@:3A_6-
1^6_G+'RK#\$YV8J#"5IN:!' +EON#<_EJ\$W.CAI%^=_7H?4JZGU)?8-)0
MWHV=:AK9'/[2Z\.._*'X6N']_*R!'&L56LE\5#(%XD'W32-K<:KP?(C&I
MO//D#26:FTN\$%#JW#:GG"@RA;^G038,4;T00)WH'ZO\D^O3V%78K\BML6^/_Y0W#4/W
#@^A>WCD#MVCL\%H^3L MR.N-SL\4Z?_T^B<_W'G:S^U\1W!2?
X6P#'Z07;+PL*=8A*Z\T6EP'=JXH M"C>0&;^P'&("5SQM6LSOJ;)JAPLW07XLD?
!\$=0#+6TZ#) "BC+Q@BDH2K137 M%YHCO :I-50@J308LC/"IL18/Y%0.
<@<3#AM\$5(I7D\$0*&\$^+1=GM L,PW M^,G%JP6B0(GP+&:0R_[2Q^
>X34:@5VD/P)W"+^AQZ,F"C!-(T@ H=Y&I#6
M!2+.35/ZD%VY\$^BV*U/WEOM2QR@6AQG7I+C1+>"\$? M!5,1-&-!\$S;/!?:H85\5*P-?
U\$TR(*29_3,'I1:(Z*1X7\ZB/WZ\$5U:VKQHC5%"..^!FZ8K ME54U!\$:
!>BV+A1.+;)#YE:48K?#28+VM:9I62WN#XFT4AR&S7JF!RR=H!/Z-
MHDXL,73O5+M!7%?\$=GW9/>_MZ6/5S1V>#)I7S-?
021T_1H5AHXKFULF2J:B2VZHZH_L6PMVC8'173GT;2;H& MJO
MEVLCOGLSKYP';7SX_H\8_M;RF\$4 MD318, QO_I_C07LY^FV#Z-
7KA^0?;,KENU=RP\N:W".EO'*2QEF3B;7PK!7> MR8?4^NQ:8!;J)38[F:1_?
+JU+69;2MJ2EN/EWE+:2VEW2L=?\$. \$)DBZZA;H M 9?
1C4KOJP=4K'K7\DS5\$IMJ9_8&_9.U.P5M01/AELJ:M+:JLZ.CELJ:BM)?C""@?1&{DM8Z
W5&:3UKKK#F'LTPFP5CW>9K/5:E*>C:/_?%&^;VV>V?LUTL,ZBU&YN"+Z005+/_:/
M3XOZ+;M4"9.">T56L%WX\&/_J/A!)ZY1\0--K.M0UC?^"-S%5) M<6L UQFJ2(T"+(MTL(M
*>VTJO*I7%.UF/DM TL? CM[F;)/AVZ(G052NUD!
MIKRG.NG\!N9'.7#X5TX\WZ\SFH:*EQ?+_QF2(B: ^C_,^P+Y5@PP&UG?BA+I
MGQT=&=*7PB'YB^*J)V'U9GSE542RIE(8=^H.!,L5_E8/4\$,! ?N\L0)8UCZR)0+XM>65!,2
D\$Q M(GYVL980'TJ11^!3=D%Z'2?9/GW,XMXD-J2JCBOEN,[4+FU<.AG<+OA+[K&0
MH1JX,6S0&:7Z&S?,R<0\NZ)D'2S.MGZ767>R7EXH_5LZ0,NFU*HPGRDJ)2P7_M>&
(#MHA;L"E_K6WH:/%(JO"D\KHE:ZX7G2_@WEU&SD>P6B<%*, 'B32113BH!
M;*QA8_!>USFIXV7.'OY5ZGRO\$+!@NR\>U76^7>=SGJ0Y5E/*_ N/5DUH+WA%
MUO6D"5:9!53H*79"WL\3\#%5>3"5"2^" YPV60\5I\$S6BQ*EYGJ;,""-M3\H6A@CA/";+G
MCCMJ;9V\,6G,A<#PR"WAD(<^5NHF:NH&/C,HG++!E7%NI9#@MP'+4\6+-; M6>!--
L!8Q(:YT\$*"CP\$6Y>SU7I\$.S%Z(CC,-Z;Q7V:8^B^6"A.QTV,"FIQ#9%\$LI>4++D\7
MKUH>O^EJ%>GR1YT4;J:O.>F7G_,6:YU(O%1#OP"tJC7TJN<9#%ND*MDP8
MH,MHY.R=OP+;Y(8\6?_6*K<6;^AWA#\0K?_"FW76@T/WW5MQAPDMVH7-J:LJ
MRIT)X0"N\13L,L-%)JPDHCVXU""4.X36D.DEY_MZ.KK0&SUH")FL U3.VK
MT'4^X4BS(%5WR'7KIBQP(H0@FEQ)S;2_UZI5!>?6W=Q_:94+W2\3GW5<&5?
MRD<01HL\$)0!Q1_H" U:M)8L5Q)%[_!CE9)H013-/HQU&BDM,N(=1DXXIZ&
MUR)0K1(G'*K(NT:4\$,>=3L&4(![R+%ZAZ<_:),@701>,-'PJ!GM5@N?Y4T
M79H_SOL\$Q&"YI@D0J\$.?Z!_WCGL/_: @IAOD"CSh'O9/^!\$ M@2#IC-@?%(
CV'K.YKKP7.&%PA36CA59DUP\APA@&\$?Y;)N\9W%&?G68B M9TXZ!
IG\9W677\N&L%CVV=%3/E_&3H20LO@!/_/B)\$.)DIPO. 3O@KA^AM) MY_J@2
&'3USF"F-B-Z 'HDKJYC 3A!5B48:(1_4<_LIE1C!/OMAHF@F:W4H(M?
ED\5D2,ABW0Q^+\$2%>&M&>;0IS1#M(A.>R>>'0EM WAV\$4W(#\$U8.7!JK
M@OJ%8*X4YV_,F>_W2C'.&">@.!W6FO2K2@D57=E,ZRJP)FR1UW990G1%SF
MSM1<&:#=\$=3J/O<#@XY;>S\T7?/M1>CL/_RY-FNQP#>>M\GB; M>F?
WDB*!7OW5F%K:(9_A&\$D1_YQ/NO@)&K8<6MFBN={EK.Z*UDKL6+MGOW:NN\4^
M+"_6#@U+M=:^GB5^&P_V8HB:('+R!1%9CPX(O2?N5;1Z7)>VH\#35:HJF: ^V.I+-X;-
GAEV.!6\$/7J82!:_!'.CD2
M#6)!+JCT3&Q%>M=T31'IKK(_#" '\$BH;Q<9W0TRO!@,YD0B+&47#9NFELL&M-
8E1CGE/2-A@'B'(+*%5XM_&(!'!'^2HTA?"FRN3YU+RAH6(:XO1<@QO)=F

MUS'E4,W0&4Q,PN!/@S*N;@ "Q=;6E@&;'3LCD'!N="GX>+@?[: M8!30#W"T6<|+%/R1WGH6<,5G'M%1",P M5?&A.(UPl>B.-JG/W-.3@Q?
L&78%S7.I1'65>T7%I>'^(WDWZ,YL@/DJ./MX'2&J),9RUD4G81HP9\$+,B4W=I1/NLZE?
C)(.9N-<=C4)-C'W^GD,;,\$'9"JZ M)/&#VB0XHJ_)IW%LY8)(YGP\!F\$M%K+E-
<1UZ,!/>4'VOP)*W_BJ#Y_8BLS M(2K8ZH.VUG#\$D9*| \$+|34T3!Tj>@_N)<1>B?
F2*1*%+XSKU?G9X=-JWWRU4
M)&WPS2C8\$VO_.,=U^)83\$ _O@WMYE@*|Z>)M/UNAW!R='SGO\B0N:8Y58OOT
ML<3VAGWJ;"K"@@X>(+E/YR3WZ6Y(I M/=EMRGU9);G <=?N1.R2V7Y@&26SXH
M/0RT/Z.WFN@^72JZGY^GJGGF<7^>RLZCA A5C.IPU<|:%PF_MQ)%JSTMRO/UT?3'<7|
!1U\C*P#%_0Q*13_HX.B^8AS|\$'M\$3&.B&R!:T'U6_MAJ/>-!==4Y,NKU^S7&
<+!QXZ|UK(\$7>JV""CL^#?N!|@N1L3I" <|88@.=MM
M07)6+4@,48@9>':W,) &+8X3)2O+#+^@ZGT^9CN"(K&W|G|Y0@#Q(@<\$MU@DV0
MHR"F4>:DB*>D,VWB5L7S-OBV|\$XY9=/XQ='5XYP8'6|+BNQBT%49_\$(<>
M')0YM/IO+>?09AF|R:&+Y94Y| #D<=,BJ/CRR G<^*CGI5N+.|@T:7?H_ " !%7O?WHB^!N-
\$U\7&UA+L2>D%Y.!8\$JOLC,V&86C\$>P,EMN_M_:|30FOEWP2<1I@"K1_0U7Z\I0>T"Y_?
L/9"YR|D+HAMX3\$SE@*<3)*W\# M=((9)B8OT=64E3KC^\$9B|_7G0635M.D,<%#_/B<+
7O5C>RV.Y&A_IZZ81L; MEY7V93|>|>.?DCCDLK34Q.SUN7JP-
)@16#1(006<.:LNTZR|D;W3O+5R,W# M|*Y|A G%2EG18S5%TEJQ7M@4#^C/@
JF(K8:T)'G.,@_0_4"+DQC^X"?NK-P* M+T,)2|FPF)JTK\$U@=2IE\$"U.C'45)M%BI?
CJZ6|^C*Q&&NCD@K=A8I M!7^IX=_%1S8LI9HSVSDV6IFV?
^^"IA:JY54=1J\$MS2!"GH\X)9C^@|TC!%|M|(8D"1; >/\$ZV:|4
6%!WZ|TL*6.LWU!*KB|+&0A#@U,54|LN%KY3^2BXRAV># #: M'9U|
M*#@XZ|,8&K2U,G%_D3O9V8-9AT6S=ZOR|=(,K6O>M-);J*0K&)H\$EYR_/V_P MH5?
9..98@T1'Q KV7ME(0 _|U89.1;4064=EP(T|<=_!E12%(RN;,>8|78&E' M&C=MSM*R!*<
8D4:\$BC%IVZ5O|+K<#AND'7KM#7ZY\.)CW| X+? 7\$E)Y)(S MSEOA\$ T2R|
(U=EZ|92FO&/N2.8JOL\$LO5_KB|R5-#&L*H0I%D8R+M&2#),KF
M3F!\$Y.1>1L>>I:|OJG(\$Y43Z543EJ^#VA:X2H#WY1LMAAV."D145:F>A?"2U|:U8
MTMAM;T:5DSHN=&WXG7S4I7W^?
8L.C8B75%J1"N2V*>O+N1|%=S#YIUTM:@ZIBA/_9J@O%"6_5:<#*J,MPA"%5(S^_*+)384
M3"8@#(\$&!750-H:YA)#L)A.D'CY!&?J*%;|ZD:5|N'4QMO-D2P(VA.|T??
M>QXKU2+GK9!:(WJ4+X2Q?E\$IL'YO%\0N4_76_RIRM/IB,& S':P?
#7M\$V)5+|3_1/%QKBR2;L1XL0*?!.^*",>\$??"&X<.
M+9XB3H:,63,C:TN0Y9.BP\$ \$HYB3\$,G2154?/6E|7NA+(HC=+6U\$D'RS9+,
M%FMU&975R|\$R"Y@?.|+\$+GHH+LD+N;H9GYE*Q-V%,OI&>)BR%08B"?^<@#A@C
M@^8V-RPFV|G+O5.Q*71,(!>_IA#9=:C">&:K>ZY6_%GWHL>TK?#_L_>NS8DC
MV:;+H7U%P>Y_KBL!NWH^JWD10+EM ME:D'2(\$ B3(B)EJ&Z-4YLU?
EZIH3F.=@.9)!F"Q64^*NG_@PR CX0P !0 M(*+H).I/PC(-&:0I
I0HZ**"T5_ '!HSOLQS|^UZYHJJX2+|KCZJ#ZNOR/;"2 MQ?ZS8-
2_EA8KB0,P(X?|G=DOCCH","E#T|2U_*BW0&BE./V;ILH@XG+AOTS M?
3Q&0PYS/\$'J&N_JB9O.|1,WDD33_PXZK*"2T'A7QKM;EA_:6\$|HXX|/8I M2%
|82,"I26^R/9+M\$9_4^BU@N^A&K|_|CD:OEOP.7|\$.^S |W"Q +,<&MX|M
M(E%0"2F0A*4*?YV/!_@\$U2A2UH3MF'J"EI&VJV6G6KU&'= M^8P|B5"=0;D-WYF!'8&)
(0!#*L9%8>U-;M>ID@(*^7U-Z#Q37@|?U)9Z=KF M_,>"GA!V)RIYI2UD<%#(&SL9T!F
M(JH#8^:|,1:/AB&5(W\$#9|6X.Q7Y|G7/J^.!0Z\$-HU^ M,G=JO|FBV8K?ZL MSEWVT?
_A\$RHYIOK^T; (:O30+@P%,(UJARO!V#;Q9O'G&_C3K_ '/NAV;6J.1
M^*?:33WQ|W5+U>LWK6XSTU+K/VWDU^RTZ;:&Y?;:NHN:7A2|+5^|&L)DY(X
MESO./!*!>-C52S+PC_>5?F.5ZAZZ+I=%""0%RTIE0Z|.C4|*FJ#%
MJ13)&@3:-12'7!#QM8ML76W^0AOW4)GC"_ M1
N|81|6PT3*3EPJ%V=#|>CDJM%K%K%8JMN)@EP7I2
_POZ(52J1>^%>2M|!@7=EP"HH+'DR/#:|/V@?2(I M)/6#K8R|7FK|8)=|#++'\$-7|_E
D97T5Y,/LI>I62*7&%5L4'Y8JWCN\$M!XB! M4";7A|,_NQ0T=2V+2<4H&K^;FYDU
C@SX37_36C|<9G|)4^I\$Q;R9JWJ| M:;DE)8PHEUEA>S(AT;C/48+?Q26IG)X+_(I.P)SHV
M!O1,EA@#OB AE)FLBEE1F"LTH)=GMS"0YCL<^#S"*2Y,MB6C(C%213@6I!|HU!/I
M='1AJH!T)Q3T8F0=S4Y>3|E!68D4;_PJ6_,PL/1Q;:66D>#|=88+5+U/4ZYT'@+<
(Q2376(^MY2<333|30"T ME'VY:C8/*?3WZ_L.@<(G=K|N
M/D(B,O|HKS\$28A#\$/@/5Y"2(-\$O)21|R\$LOASQF=!%\$5HYG#T5&*KGJJ! A M!T3(
1%R0(1TXF^O7I(#(B3ZEA=|SW5_1(E|PP|CW9_/LL)XO|LL'A'5F^TT M6J_,@(M K-
R3)|J1_YIWZ|3RYEQG;YTJT^&E0N;N76J3(7/#N5<6Z>65^YD M;ITJ4^*/U?

L@: ^M4J1#L5C-[A:-)19&LFJNH#>3N76JU!*R SFOUJDE%D.R M9JZ@-
Y.Y=:I4\$'9P/1ZE=6IYI5#FUJE2/S@6X\[-.E7J\!F!G*(-UV6H"9D; M<\$DUH=#=-:2NL(-
+,=>NG266/-)G4-";.8=..S\$6L)JD4"B(Y)=XJHP22'H0-M"GHQYZ
:E(L='+'9'9WD%4^8>G5)E*#2/*+C*4)[4QXQ36.!|F,G RCN-I;/'M-
);RBN+,TUBDDG2T>H8,TUB*11N5PVT2:TJZ6Z^A\HI8&4(IZ,6<:*B\$U'KN
M7,^8)=84ZD\%8,K.,(4K 0F42+=IGF9NLU5/4,YH-1KCG8KC0R%;L52;\$K,
MVKX8KN8PCV&7'FQ&@@QNS"PV,3R>0%)&QM:ZS!&:5UDH2&IM1V-LO:~SSR+
M'K%:*R7LG22XU\7P?I19B%QLJ7SF\Q>;T'9-#2Y\$JX<-BI_\$W\O WWIG_S\.
M:VOWX&_"WS'OK7?D;JH9>SP7>W=E'U4B-WBL(>=%8=?)W<5 XPH\TWT6)N-
M4SQ_)_,(QB#G5>NEKE6@\$+V\#*Z \HK_\$\&UMEEAY2CIBL?6CVDVCO&.U
M0:J5"17ZEQ=L*ZK8T0WLL*Z74?!TL@J>M/&.\$G.#1",6G1LTLA80%B=L*%&M M7*B66?
#D&0J-#::Q7\O:F5B_B0)KO;XPEY(Z M8XP7?B"9ROSA:--
@=|KJJ;!I6!%#0U'@15>#70ABM\$-)D,-EZXL ^JO9F- M#40E4TJVCFLX(Z
WSF0*T.X3@/-\3#D3J+AW4RA":ZXEM\RXDBD4>-UK<|H M Y\!Q\|HXW=%G<_-
=^1Q^*3KJ=|"LYUW6L-1*8F\$ _@*7QEYQS."_%X\AZ@:' M/RZ(?
Q6Q6CNH#A"))MY4\114^54_LBN6 V/L'5%<&6FWR@CV*GRJH+P95Q M(UJ:0Q6-
%O/3-"A'>&.#5S*5?YBCGU).-!BP-!TH^,"3WO\^2*Y\$S\!\$%< MCDH3AQ;N
D@::LZP)@|HSP*."1+.UG"<)*(%;<*V4 \!|(@LY1+U\$XZT#Z
M!+307Z@Y182Z.=X@|:MCPS2|=T1'G4V8XXB\2|HP#I^?+R<@ (0L!MX665C,
M1J*U\$9MQ)\9S3;P(E_-N.KRRF*F+#P1600_8*100+-.@IR_)%1JU&6DF9; M 50,%'
"^5O@=Q7T4!4\$B;68C<'4\B3M4\2!:>S8"HJ2.J8B\|G%B* MX+I10FX4,
<&\$&+HQ%#/5Y)>^J:Y2|P62ZY(NLG.HBW07,|R|*_4#_3W+00*_M,!+,7)NP&9(?K+G ?
|)\9LB#V\$Z2_X9)|>64N:>3("DP3J-^# MQGPXSMW*AFO*(VPI1Y)O\$0\$#7(OA7!4Z'7;IP
^9\ OX9^G\7 MC':CK_::G7&M,U9::76LMOO-7KW::VOU2;/_>O\3;S4J6Z>|'O\3;.6/A@?8
MKFT.%!+NC5_O@PM1OJ-<_FZX/Y0_5 N@M51?O.?0O|_-. 6|:@K7KTQ!;|\$= M-
+;\$\RQ8N\$P,JX>#7D)"X;^J<5*\$9'9|P\|V<%VC-#BRABKR_49^|)%GJ5@)T\ MAK-
SPQ%1WM8,DI\OAC<%DG*4B6FKB/+|,7AH!D8.G\$IQ;4XW7_\$3JPF=62'#
M5C%!>'HH,|>Y>HX*8CA(GQ\A+1>L@77""5GXCX^*#&'|- WPW\$8;#@%V
MD%UHOLX82EHAPY>!XXM??#N>9OD\OG*RGF&G1X\MLW80<4)HO_030HO+'891
MJD+4'JO6#S\Y\$X02:~C#TT40'#;Y?KP,F%,3.SZZGN,?%|CVT=(M\1J<,&9
M^BZ:NRS(105_(&YB@XR=,OT%21%\$J\$Z8@C;68=#O1)B SE;8\$A1^A0..(R
M8#"0/66A2>78H%CKKS/C)Q\$S,H%K6FN9 PF='?|@&ERQAY>" 6'6-YGA"*|?
SACR'*5^YOAC; C-9+' M\&HZ-.R\$ _G>.GX;8WL! T\@O8FLER:QZC@@U;D&=
(/U+6\;A/R3CVS%+X.B M!88)_*=Z0 MC*9XQ9:-|5KJ1@X%K?^+&HG)P-
&MT0IUJA3FY%#8\$9^-U;C@K#\$%-5A#H
M!@48P!/M\|GANW+E+L;_1LQ%0D&2LTEA!E9;^Z\7)UNW&#<4IG::PR4TBHG
M!;BOA>GYD%V^L.H2VJ^BUNK1X"^_M&M+OKM4)W7I/%%%@B.JSEM:>Z ^^^5X) MP-
W:3;_?:_7S4%"ORDO=8|QRL492\ULHTS /H"<8=&5ZO;-|Z=V)APP*LS;C\'
M^0UJ+R0)""P(CR:2<+C>2J^*|A*SJDHJQPE=)# B>+)\$)!JT!9N.*; 1/+ M(C72""^W8-
)A*>'KQO\$0+.) :0^S\+9PD&%"+F3M3 |>T:MG#LZPC&A/%' M\60
@T+W7S<3C&\$WT!;\$"FW0).(E\V""Y.0/K:6J8Z+. #5='Z0E.!H\FRH1-) M!?
CK:>)"R%HA"VP&M/ZB^K\$T.@_JOH*1)&R;T)=VALHXP\$MH!*DIC\$6+0*/ M2Q2<2-
MBD\KR2Z^W% GL\$:)CQ;..&2Y;?&?!.#A\$S\$T(I"VT<47/TBP(H M/-2-0K(;K_8>-
|T0FFKQ);1Y1Q%+%Z\|V\$E#Q\$QN#EV4@448(A8< M@Q=(N
MNK.O@9W^Y,\$'?;H728+AQH8Z8:K+5Q7W/G*E0E,Y^=[7XZS;D\)(*3Y_(3/3 M,V;D
_-\$C&@9P2\|0"F-|71 W(. ^8K?^3+JH\$70!X0M I5<' 9A2DUUIRA^
MW\Q(Z,EMCE9S:%8=G@&A00|P< 3CV0N'VSIV>"DT7/-2\!(MS1,_,1?
\$KBAP+K*7EM=8Y\+ATLDS.3<40#1Q%W'PD@L+_09<=XFZJQ@/Z\/
M5V7/D1LN+'HM1_'5%PC\Y1!<|QV^0*=NMI;,>J9M!;6JW*B5S!6!*U+9;*_M? MMJ>SJCH
L;_3#36VU<_OL-CSW1\|<<'>'-^N"L _GS^'\^AY^#SZQYTRO/^B MP??-^_C)YNOST_
GHDD9?G\X\UGY8_C\?|H*H'3 _^|_+P\KBL&|);8 M4I"?M*1"KKBI?!+!WO(CXC#1W;
|P#1A2R+BZ\$+4|L@1U?#E>N'#-/U>".PG> MG+7Q&%
/H8VE1&90T7*UT7)9;!%!EMDL*6XP19%QA)RBR6H;H+K6D8,9,1@ M?
<2@?'Q%&2K3|SD.5J 2/45=HY855YM\$ M_)ZP)Y*5^(FIBD|?>;
|OU&>#+2|R!%J+8"ATIGP"9>9)IT,3"#0K<&TX4=\$
MIV4D4'0=>|+1"8#|!*Z4.2Z&/_0;Y1&T)6S ZP?X#E'1;JJ#)T7S%"W\
MSYM\|^.2SH_X%,@(^PP*9 M&^4!=KX,G>!5 %+,TB*HDTL_J%M!:*@F7?
6+;,>NN@(_S:FC!BP5 M/?F-*8(I'X?L/P8R?;\$*T15_URH#3Z EZ0IVF+V8)?()DVRT*%L

4_+UYTL4R\$T8@'KP*E_!B78")K8"4BAI
M0:P&8_DU@1|EVSLA709UAB08L023^#@C8#L+;:HY7A/;O<|*2*)>^U6J7(V) M:C?
(W&OK*?@=TJ>,<\$0C'/5\AQ=&>\$X>(2C=Z.LK?|?W0_O;T?#;|K3|Q>MN+M_?J)(QI.?
CX_?Z/?A|W|I7X;/PYV3?SJU:/+/QCJ0H_=2Y)"Z_W+W?Y7G M!R41&IF43A^MND?0,-
=D+VU-5UAG8P;5=7ZPA+CS:C'>:K9+|_#|T\$AKDYP(M-L%=-D8B
1>F!K(:\ONYRS|Z\WSR^XH:%BU%#WU:+DY-Z\$-%>,#_+ #A2OW_3
MK761*8D.8^+@%E_=P-9^C7_>O:G7ZXE_J=TD?|YNI4|HIMYMY|)4HW73JK?
E(7B'>CNPWM3|!4:8.F_OW MY?)P|6:F>.7B1B%|!|V%CB>6H|8
58O_VJE0A82KFW_^W;8|D/4"WW|H41 M/#EG).F5|^S%<'F(|G\$Q-@U-
&88MJ:X:SHS.NMF3?|!31V3>*?JJ73W>#A|^M*Z,ORF_&3^S/?;^@\$#6%-
^OB/MZ1:'4&>Q+9|:'X4(W/-M!V(WT"BF9
MD^M6':=#|W|I|=6F9P;:|0|G(DP33BYJZK5=BI*#)2%+=9I1,(I>9/ :AN6\$*M0D;|
(N07I'9S'DC7|;4;5&|N'\$R(^5_J;/Y)^1U+_44RF6,B76|CD|E= MRO6X^F:|H@?1*%1RG;-
!@%Y-LPGS"OL!3VX1WN-@> MJ-|H-S|9V%|X|Y+|G
TF|J2_4CVC#O_2LV^9|,YFSNN|>03\$8R MF6,B7;QLR"V. |V:5^3;I_(Y=T?|SU*'6Z_-'O
M(SF3.%&8?HCU|0,4%0 M|"/ N6!4S(48KD7E^EB\$?ET,_29<|)6J?&&_885:2!FYD+2?.
%FHNQ: ^B& MZF#97K1'LNB)X#='CM12*&%)A)C%1|M8VM.Z2K?J2AG?E4FN75|
MS1IS4UP MP3:RP?":U4A+Q&@!|1|(PI6K0"/?JT4*\$A5_Q\$LW%5>;GUA1NKW>.>#\$\$?
Q= MJ;>OU |7C0_.*%59!/|T G&#KBPV:2JC,X L.?E4,?)7E_ EL_ N0-SKB1)U&Z=,U.5=?
9+P.,0/ M7A&+W3E"!G-Q,(I4IB)D+AD4F=@,%KGSOCs8MY5:|T3&-L|YE3^..D'UA%D 8
M!WC!W|D|,HKT3|L(/\$-NI-/9|GE|N(N+,@7,H|S. ">HY-P" H<40|HT'? M(G-? _-|^\$3TP
?JG0#O\$1K2U1)P@8,+ #DT)F3Y+KD:YI! |8N8OE=[#:1S; M5&Q8.|)E'=-)2J;=V\$G|9J|C;
OOk.@;Q:X6Y:) 9(+.#|V_4ZLV"|; >^<<>^ MY<#0^X<|A-J1/3@O MJB4&K0?H|PSFF
Y6&' ^*|/V\$>|VX>DAQ MDA;QM EDDPH6+U\$OS)#NBMI3| M1%'-
AV4IJHXXR'SYGF6P7&&).*:PUSK8|X4:|2&/%*K|.1QUC=G%6ULD:6G4
M5X8K\$HAW1MC".XFKS(*)| |SGRLI3|F|AQO%)H9;^2T;1ZG*).PI8#|5;0N;J
MB(:W|C+GK#;BHR9H.CNA<1VP79ZTCB2@4K,5T,2%MCOF/9Y|R|YR>\$JHWXS%
MYUK6#HUH9@P'44B|U|&NXB S>(&JEFT;=G"G\D..UV8R_3|%#Z|WPBZ*D7(
MVU^2SG3F@A7D%?8E8GKD_E+5@Z?YZGM1O|J+E^,R67*W%0Y3\$%K|)Z\$=%WT
M)APL,,-2)GJVA9='T|2=>C5ZMA>>-B01K0#VD!4\$X>S||#>P=PGSFVM'&Y!<<|J|
|JP^FI#UO MV5\$U"J_5+2|8.2<0W8P0_**A-'6\$B7PY. |H"0ADT;|C&J'A83^/(L6!:"'
GB0|Y|AGSW_1LP+^AC1C2S@:|*|4"|8|!1E*)L9U4|7O|ST(@Y5+7 4.4JJ>|H M5*
|J'X2;^G(|BEH85R!&SE|/%AH: ^2^>./\$C5' "OZZ@WKU39?A1);
MMHE!WC>P#4R362^D-XG.Q<8KJ^);,5|ALI_*OQ?ZBU @2)@\$MRGTC43IXBJZ
MS5P^_#_%M;IN,:XVB82HL745E*:(? MH1A)<1=|.4FXJM#PR\$%WL:|PV5SEG;"7L2|189
\$Q_7TJ(M)F|8GL^RCN3@ M.FY7LWJM=E/CR1?
K|^AEUFVQ;+T&>OW;OJUY#^E|[#.6|;.\$;ZT=IY\$Q|NS MYT7HH4W7|;MMZV|&V(
XR|1PR"CGYCO|>*U-NR9K;NB*VWH|,=P@'&K<_& M|&S(OLP)ZFG3+P|WR7|?
|&/>|^8Q2-BIU@6F-;FUV+;),A/&O/9VB3OEV(W MOGL%70XX:|3R#(|/*)@CC&C-
M4;T(='RQL*|(9 M'F/F81|;N3=H(TX+^3E^J79;P3=
|Q5:*YA1@6Z7<#6#M|QJHI_J..Y8YA*M7<0J4IWDGP-Q=,WR+N1)CN#B'700*8
M3HOYT",>\$VT;/8C0^_XIG>' \$"AKQZ|^*0CCG?C?&VKL1T0_QXN7|"-R>;TP M<@&,\$:-"
^,|H +R6:D_V|JW(04E7'|!;XRH"MC|'PPFU&L<!'*|4FZ118W!/<-87X9|6>4^WP&JH
M"A>IKYSCI#7X&JBC\$T;1"*|G|H(75@F@!;@!/^"2^,E^6|;B>;|;HHIL\$Z|
M@UAB|R7G+C?7YRZ7) M9JOM2\$PR3@*;!&C_DM<+>|Y=O?DB+M\$Q+ON-W\$/I
MS;9AT:B-X@C5"U1#*!6FD|!;G_+|>B)&'07D0(7'J17+DC68H\$73H\$.PF6"
MDHRZ+T|P\$M=+TM+>0XV(BMU@: ^T%L*J.A"\$ M20=(JIT+ 4J1;J"/Q35/ZLGQJ'SDP
",I.'1+E.NQVZ_N3RJ&X4G'UJN!*|W M<)U,Y(@T%BA|01GI-1I5-)/TVAY:CN! (^@
SJRF\$B)K9(?->&|8YQ;@R?\$ M- "A2ETU/T3U+(-2(OFQ:<2Q#HS&>1>WZ(9|L@P>?
D:C1J20(%7/&=P;K-Y M.D@%(O%|P<*T!2V8/Q6"W|>V7\$_,H"(N(7 W:1=33
M,'O8#QU'KWP)9|)>=6C@N9@I#V# "X57FN|XY478;;D0U|V,N<%|81^|HL-A
M29F/).5S/3CZ-.5L(J#BF %T|R3HD@F|+/H+I<#N|HK5;|E%Y:)|R4;FH7|0D
MB^|R|;4>A%/7>-;H'3_ZOZZ,I(\$6W87IGHs>=-^2..?^0C_9+|E^@1/A
F1+@"KI6A4W1?I" _#==PF=;RYS4EN | (6) M>S0&N-B,J,|&<9,4T7<%A?B3FS_MR
/|0UD//G|PN05OY+&
M#R(HF"!)Q/W3"W;HH%*=%Z(MM/0PVV|M.VCU3+>2Y3E2>;SE1@!O!_K;Q
M_>RR<+DL^(PH>|;EP6N2NA((A3))=#8Q-(-/L^=9U^-(L,?'VN!;|J9K4! A
M)5YC7KMFK\$|_W?@,TI\$U6CVSEC|BA@"XRE?DZ)&+U=\$.J/P)67@'9P3^1(;UG\$|_Q!6

=>4H.RFR?HZTT M?DB761::7T#H(C6("UW<3:P;UD,E.D733RD#*^H.F(Q#191G7>?
*6J&HRUF M/.7HDPC7;Z"9>2\$+DGYJ=8J\$1U4GO&94F..)9@ B+*K<=(#YP@%[FF>+
MK3+1A*Z'B7UB;I2)(.3YERNTYCEH\HO\%;;[&"N(I]<6 ABHE;;LO/&G2P M;
IO.OTX&602^8(NHAEG%0RS0J80'0P6..K1B1UB31#PLZL\$UN*H6MM3\$1 01 M\0S\$"?
(DSUWQ.GRBO.N-E\|M=&TMO(T\$-I Z#|R&C\JAV;\$8L-/O-I G&'OHE\$
MO8PT9LQ%GB>H<* '&1|=P?)1: =MCQAT=.F85FHD:D;J FW6B|MV57\$P|B(FM
MPM)/3DU+),)-0R!R?;|=|<(L"TL?S<\$"!#|_%*KF%99%073JRUX8PXD?O\$| MV=)>F+IP
X3BT7 MN"5G'S(AT|6I<<" F1:@&N)H*P3/EG6/##G>H'8+?JG<&(4K25\A.J0\$%N
M.NYJS+ +-AP%LA_E(H;B3Q\$LG!19S7\$N4VW4V^PPBDFMA|)%D44D<9*/G?M1+3(-
IESX-IC"<#@P& MW2;FE.3I<(CY<+.\$| \$AD1X'42L|!)JL3N(X#'^M8C'(EW|&1GFGRZ|S?
B) M":'W'^JT32 A/B.LW>TZWT%L=09IHXR^X^0)RS>PP<5&@0SN6XU*H-X>N90
MORZM.2ANNB:O+,L*@6\|V|W\40*&9G!RY#(73WWE^R9*|_&2944GG|E*'3E;
M2\52;NR&+ M-
YLB|;\$'9I'Q.OZP;^X\00D+;.,@ (7*9GYCJL=LDI:UQ^2>&&HH0LO|G;LISYD4D2D.5ML3S51
%KN I?6: MG9.Y799=|VG4M9,Z"&^C\$NNS|C|H1|DE7?HI'N ^H*-(F1+%HH|KQ\$XU=
M|C7Q|1WQ&YQ2_>?Z|@M)_O|FW:G'NDX*5Z|N9=DMW'3Q|#VAEZ2:9>JUV_:
MC6Q+K?^|W6SEM|JGF7KTR8SV_-G|MH2>F8|K-|@O+V_\$|FWU6B|>^_X=XH.H
M#RVU5;M<.#27X+ %,>=)XC2-L>S3\$ X#@|3^*|HC?7JZ>WY*-K@QYWN M?
UU/Q%_GO/9TBTVN X6^1?3O!Q\$=%^|DF;HKMYGEJ/7E&+QK>2C_|+7\$:-' MOZCJ M_"
BR-#2|3|W(7H.O5O5<3!*^0|L= RD 2>'ISI!+DZK,FCT^G|RC;^3 <|V MV0?
T/F&EOH)\9(8D@',E@/9A*" "-!% K" 'DI)>D\$V01,UP|?XU?/H|'(QD?
MGAV5"BTT|A|2Z<\$;4:KLB+8T7G6E+CL>=..)EZ 9;.*(\1V',%BX5)@Z)*BN
MU27;C9#7+\$;2.9!\$OGU&/4-SMD M;|+??GY=O"=.=.M=M_H6#
(IOEQ/@?'2P)|ZK5,G@B;ZV_UD8OE1|?+|*A+>-0|1Q|OL3DM;PJU3RY5
M3NENN3|_.3ZKW\78=RD2=Q6)/@2SLJT>JH|-PK@9I/@|HOC;%6?Z*.IJS;TS MU
HHZHK-)OW^AYYJO1A!*HZ;..X>V?0AR M:^^D\$!GQ+"#";
(UX|H0P|WVF|V=3,*T8CU<8B8<@24QS=?|T51=J (HVB
M5'|EJ2@6);.BN0Z;9U0D||%MITU5Y'R.E6V9SW\^Y)XJ<22C5PU|8O>KW79>
MGMC4|W(BE5K2E;2KG7)DLM)5MS*HUZH Y9*(?@|'\$S/4WX4.2|XT|7?N.YAPG
M)"^PHU(|FXNDV5VB,E//;YG83)':*B7K,Q|&PT_C|Z-GD=W3|KP_HOR|+?A M|
|N_/7S|O?O= _AP|_RNAEO1RT@;|)BS^)\$6#R>R!DOIY_:ND\$4>|
M6VOHW;#'_L+M(C;W9>">-.X;O|"!(/L-3IQ9|;|+>1,%8VMGN|Q^IKP3J|R
M:/4* XK4|@B(NL;Q(9\O55;|)R_N50;L9|T8AG?.O5^_|8 R5|^QZ8!TR^_; MZ>.1
W(MIG=KE4&S(I,YSA%%4O;XV(HB=1#YC;+T.+@K!
M|^6267HWGRE=;&&A2;20*231;5\$_L&9>.FE%+8GG!DC-;TQU MV4,(|:P\$U0&|L-
IKRTSG<|2H;>SX(!B%/8"KS<*T";N<>/C#NH&C/#UYW?I M>=VC4
26US|S"W|P!&"QQT)\$@|F4!MO%KLM|UP5(AVP!;6=|I-
F\$NB,H@E=|3EMMMO13LRGR.8?UB;C5FKN< MO+1GCOQI8EDI-8->
S0#&>4_2S1)\$|= *BR9-0)-629K6E| #I@;|D2; (=M)I
MK3S.)K;0|@VA9720|5J50:=.;Q6E^934=D|3 G&/9H8W MHU;U."P7'H
#,\$N#2U2N7;.4>|MC2KW|X9*J;PHONN4&CZK|%)N&GZ;JPZ:V
MJ3/'|4L(L9>Y|RZ'ER=PY=*,>D5>;>-;;>U'=?-DU\$?F\$%9L5/P2.J'P5SSA
M&QY5Y|Y|E2/Z30(.%PRC6BO!;*|4QG4;FIQTUZ9JX|RBMM_4M8>Q<4WNGN<
M@K;L#A?>U'8 U'JPP7ZP0:Q C^|.!D3M)WH*C|"HKJ*7|?6\$QIUJH*H|9H
MD>"\$YK|G2-A/O/J;4:NNX@<(52?>G"\$7L(A9N(0N,,>|LV.SKUWC#FD|!= M;=B;
+!!S_::T(7G>O #T-QZ8.@9|LR(.U:|D@#D#I-SZB6I\$;&G6*AD87U!@|!-HR
5DV%QEL;EJ+QE&N9 M0+%SBX0 IH| TI\$E|O:(\$T*7Q=LQN"KEC4X^P*4'S+;21 M=T:-
%ZZ&FK;8+4PT7>#.)X9F>|A4AWDJFEW8/_RT M2C7?!5#O!\$PCD/_ "9|
&/W*H)O@CHV%4*46>VJQ#V&8\$SY7G>1J',L^*_:_:COF?

59_)E\$(-G>JQ9L|H6>F4EDM(@;%N.GA,*A1&33;!
<"@LD9ZKP8%KUWI;A#8P!|1R#&X+>Q@VM%\$X7*OP;O M?L=T+,OV4"-RX&-
+,6!G+PYE#3@>C@;RILOE2 &\$">2@G1B6:FD&VL.8K8?% M:N|-6C!;_C-
T;^J38>0Y@9^U!|%U#^M8>.L? M*0J(N|V53+;|O|A=I&RCW>BK_69G7.N,U59;:OM?K-
7|_;;6GW2H|>_J2Q M:EX;AK,N)NK+^QZ|##UQ|4Z@2-^5,TW|=U%
HOB'B#>;N#7P2P)2PU+!_!J M;#3PR0W('KOKXU|3.&G"
|A50>&'#525D:6M1|W";#=#74|32'Y;M01Y'7A;D?0Y:TI@98=:(TL?"/?4OA3.\$CN
MF:X/W>\$W(Y"SB2XWA. M:TE:%T1:G0.1%E4/-#HYAXHD:14#PR1H2"M|H%

(JTS;VY=5\HPR"IXFJR MM[9+@0T7;NG22G)R5.\$0C ^3WVU;IS G.:>+,%JF^.\YT*X-
>0XZ:4><
MV2*7=|>9'N!,*Z:W8(8W,45N[^KAJ5@CUFX;G*\$+|:NH1N|(V=X|RQCOQCN MW:
@FZZF-; 'OS.1 !)1BH0HW5P1!I5!M04/ M2&8>_E"(I**<3+.+QJ^8<;|??N\$|Y82J.8E?
9X1?;K9TV%5NP9\MN'*R<\$H<|?LZ3,|#,KDX8&2\$MOO*C M2UIQG 5=&B"3>QV)+F>
(+C'QF@.ZX#3N>L&9=@ZBY=="/ERJ + ^K"[5+V, M<-.6L/6];=G+FN7Z?,MV"Z1I4=
(M95#RL;M'FC2!AM\$#LTL/H+D:)UFPH. ML!%9)GUT=O!MR0]_5|>>W?(T20!;
MV*WL|IT*|XSWLG=3|I1;.&I3KO(X-7* U?+MC4|F\$KZ|F+6EL=ZF(MK\$/
MIY;UL^>%QNE-Z@.B<1Q3>Y5!LQ5O@B7Q|(SP-\$==Y,C8V;VMV|"Q=E87@N M'G=?
EPG=!&-FL8GAQ9B%U.W3N@@".A\$J_6<.T01:Z-0PIED0S5|:R?4#5)A
M2|TR2""V2T=!X1 E=^&<"CT:>63U'L=-^C5\$NT*CO:Y1FW6^9B<7QJ5P:MOO1N%4'!*?
V.N^U%:61_\$|%/3/?&|H4C2*0GI MY-F\$*A?TBZ-9/S&>
<70/45|,F)*#JBK,VQ#N4'#V5D1O>@);64:SW:0|*PE M:VCXJAHFXMRS?4L8|^39V@^!<
D":|O7IUL|O->G"+:YI#Y)?3LXMC)37YS MZH?V?DGRDN15+*,RBX-O-Z)J5
:MWL&G.^6E)/L| |:|KK)UQI+|7SDE\$TX MBFXO4'==.N:N2\NM>3*27;0-RL->|F'/J)=-
U\$B^|XBWSDQ9PYW0'Q<&US9 M|_C%4TJ2Y7UN<=PR/HKM|HFD?&?E,=|
|GY|E/6L4#TG5:APSY^)^H#I^YF"C M70RZWCE\$,NAS|2I4"+7P4;/W"-
SGE!IV>@?:ZOUT/E*D+_,LL>@%GH,FI5! M^Z;,@Q^N!-XVB?Y%.MM.Z-) &?UQ//5-
'@7+\$OTE^N?F.%Z'_=T5|_1Z=N5 M0>.F6Y16BY=CF7TQ3\$QGD<:.*-:DL2.-G8L2=|K
2Q78C \$|>W%44YFKCJ?8\$|6;IV:R 7_N@P4_6,5_;IS="|J2|O(L|OUOFOQ% CZBCF\$/P.W7
M/E(4\$&_P2@THO_B=E%"&>U&7^TW.^:9ZRVVNI8;?>;O7JWW|JDWZ?|?Z'
M))AX:AHD3L|5%W8|=ICZXUJ=P!\$_JN;.^NZBB(GB'B#>,N#7P2P)2PU+!_H
M;#1N>'KF.F2/W?7Q+R#F=;+N%4|T 8LKZJ,+&T|:A9FNU'J>@IH"LG0%NC4 M85-FN4
KBF@2S5.&"W^LJR^V;:J."TQ%>5-|WY(?..NUW#9G(-43T78RZHC
M+WD+V!5EQVIXY+G+/OH_?/(=>H9%Z|!%#GP35"1Z'|+GJAD-H#|+TNWW;UKU M-
E*O|.*%PO"OH'|_1K_O U/I7J)?ZK=U|_7|=407|3;G4S+;7^|W:S?>;
MV@ST+6|=C3|S>COVO01#EQ/1<+RTPS/*Q/MJ._"K
MI6@+QV&6|JYX#JQFTG0F1=7_07|C;|2S'OI_'PZYF(G:=
M)M=&HEBNK"RF0YZX1|<=,33WN<(S2P;YX;|MOS/-5%W7F,
%1N9|KME=!VQ.V32ZK+2QGW?O9"2!&?)QK).C#@N'7|=66W+&MLUYEL+<|+2=H*&
MIJ#|/P\$MA)W_D|@E|7B)7C^W02S2X"PBRC6.A7(QU.K7DM1/B53%1*IL#MEF M#OK
ONA5KPORR.4XL.P_?=.#DS90*+&/QC%>J:C&551+5Z9,?|E1MRFOA;!? MD(9S
LTSO8\MZ,O;:Q%IA4%X 5SX&|(VH5PR*N@(|4X(0-CV8R^3
4Z;GFVPR6|J503N'<&O1\$V@O&=^.%+C9A&48^HMC60&S326JE2OY
M9!/?=2N#;EP'*A9KR|F%45PMX7:|?I!5#O47(2KK5P95X2DNM@HB?P"=\$9M)
MJT\$E(\$WN_FCD,>|>DKHD|0LA|1QK(P|X(T: M9ALD!
(1V|!>ELJE_19(&|S|L+)|SK5Q%KB)7D:O(562_9-DO.5<0|VKK^R67
MO//QQNZUZP@B97|H|,|2W.Z_9|&#F5HP4^T(=3&FD1-3VP0SRJ4*A.XGY>X_M"|+
|+_SYDIHQ5Q7V4V-H"N*Y%#B|BG_VIO8"7J7GUZQYTV/'|:(;:"FQEE! MEC;*C=9-
O=_(I3EP|Z;7RMJ8>'W#XN1WR#W)/1UH3WDZ'U*=KW_3|F:CO*/ MO+WUW?O|D3+&
|X_3-7A=|-|H><7I7Y#BF;I(.CHG0XVKV=DS9'4K%0Z@A M|!4M-|4'U7"-#%;M6Y
7IT!M(Y*X|HVF*V,\$DG|R>_*5?8BT8SO%@8|_*! MPM.KE|G;.,M|/D&5DH%9B?;:"|!;?
WB!>+P|*-3G@.|,9FY\$Y|^BP"7,<
M,J73R<0#E4@40V=*AM=GU50MC2FJ|_@S4)1&K5&_B#*(="|:&XGCX4;R^)^K
M+87T8|_#N:9!*,F5MX>%YWHJ;.:?I4O&:8?"^7AG4N|5JNQ5OZ>+?X D4?G MRV?
7C@|+|%5C&^?7|WQ/7I"4SMO:G-M#+\$"(=2|_TKIP1)OR0|.73XC*5Y2 M_
K%MX|#!9GR|1NU9F70JC9J;KAE !LK"!)7I*)/D< MSIVMCB|MO?
#AB+|=&33K12|ISK.\$;|(|L*3DLZ;D3(3<*Z0^WP'BKO;K4K@7 M1;@G14TDMY#
<8IE;|+/9W'94YYVSBE05<3"7>S@#|'G+C.)1=9B5*-B|0/MM MZ>S?A?(U)2U&&2;?#
<48%(UUU@D;|5*(&?Z9@0Y;+LNAZK+M.I-1JS7)J. MSZAVHNV|KD2CO/H%' +;YZ!;MZ
M+,%+UR5O1|Z.O)U+O9T\DR3|J9S;9R2/E;KUVX_\$V9@%H.I'I'L@>SGKW-9U M|4
6|H9&Q-H3L'V#S.;YD!GL;LP,+MG\$HB.8O*/|KYELWO *B;|9||81T<6 M95Q:9-R-4\$>!SC
M1|E;-5E#|X7QGI*PJY6S:D_!|SN7R_//RNXM(.YQ+"O
MZDZ5.=!K%9O7F09;8/B7D=>@BN%&'LO!G>%\$MW-O6\$+(P'|%0&IPR2%&A
MRW1WEW<|F9R=VRS.1_6=5(-OO%#CV7Y6?_XSY%1?;8=TC|^KND>25M&M#.HY
M#\$R7""3)6|Y.^6|'AD8/&K4Z'|_O720?EX:A#CF? M^7CZ:@Y3XJ|@|85|& M'(OE5)
(1Q_+>W>7=SA|V7WMG|W;I&3CH/3|G7>)<(7%.<@1Y M.S+P>|J;/D7@;7?6#T+I8EF_
#-E_#%O.W.V-^UWQH2-.5|XVA1(5@\$X|); M*D.-,M18:

Y23@|C^6|G)+FM,77#YV^D=CP*[O;HV""^..MM)< A1A=:|E,^
M')0<0MZ.C%:>_J8+87GF+@H:ERL*I"4J YXYWT(X 54W7@V=6;IR|4N|<=.N
M*7/F*-3P9W-KI/7SC00CSLA41D:++N08R8V1|H|H|JVD9HR-=F70ZL?; MY4G4*"1JG
WARKC?|>)^6WE YX)Y@+339#@NYUMX|*;;H5:G#ILRRS5>F6("'
MZ545"RPX>X)|.62|K5CN'AEO*^_=R=N1MR-O1|H.(:.*AC91=ZTGFWT9%?JAR
M@_|H,'E6?R:IWMW*H-L|K^"(#,,=8FS"K@C8.S|\$E-&YDU_<64?GNHFW|%DU
M54MCBNH|?U|83&G6JDJCUFCL\$ZD3:K9\PU&21\$1-1E\$&4=2-H+O*^QRO*
MV\U\$532?00FP|%Q/M1J6>=-OJ50;W;KS9K\;1T_P9/0M|H>')2HTW|Z.7
M0B:|)JFDSQ=@N|\$/|"%>,4K(T;0=7'|H>8XQ7GB8\$|YLW|L6OL"Q3=C7
MRPA>!13E):@,36PC((FD@\$|LBR2#UG'(((TXB=!(O3)H53NM>%!%THFDDY/0 M2?
M4X|)1&;03YGA+0I"\$D!ZW;84 P44 TENT+7'O'#Z61E/?*LZSCM 8S@#|'K+ MI/.H.LQ:
(96)\9|UW\QQTZBDG;@S#UC.BFJR|E\B4;D|50,UUV@Y|E5'#Z%
M0/%LQ2WMT.6C)%&N<3CW-CN<27;20'+|R|)!B4F|3KCS.=J=T^| KR=XFIN= MRJ#?
K9>S#:=,DR|Z\$VF>LC;D;CDQ'RKW2).8Z2Z4@T4#D-?I1>N.H
MN|XX*C^6RIREDU_<6>!DB;17 KW*&>!8OEN)Y.|M9|3S|KQ
M:L_:K7UI22M)4C1ZE4\$S'JB0R%9(9).L0-|. ^06PRW?
3.5J1I^#Y_C@PTGOZF=S<1V\49HMRJ
M7RSGEX:B#\$\$*&_J9WMCN;2|Y"42U+V:TCZYO!%>@^36|6=WH(E:8!FI*YCVLW+9=K2
M9)2QO0-,P<|NZC*46"SOD@PEEO?NY.W(VRG2|63JY|.LI>SGLVT.3JM5&33:
MES>JM'SX<3;4*V.&>7*5>-M5S|0ODP^((TU&=|PB@L@VAO|V%8,M)W@DB?
M|!,7^N+D|I5!O5>K-KKQ1(7R M=|!.BC:ECXI>"H\$D*:2QR:Q'&M|0ZI=
|_%4!B422P>YD<*0I<-G&/;1K-.ZA M%N|JR+>E\$TLE)Z.1(8^+BI% '<=&1
D,2PN\$((5NZ3&P0W+"7|4;V&QIG_%7 M94/)(Z=YG!EZ9|'N(TTYS*@.-6D:;%VJ0T64
G+Z56KR.>3PJW;K'(9?;2.3 MHCJ|60*9W4+-TRDW:D, M.KW+
|!%:/F23K\$#>SOF%@,MWTUF8?KUX/+|HN3Q?VI6R;T"A|TC)5@\$R)E9H M|E%?.
V+Y;F<_PS+/_5+M7F70+V<8_-/+01A*UO!T9K#O|3>|N(A9H@%2|?|&< M7QJ*,@!9|
%2,@@I@Y"%YB#E|!&6|W9VMQ4+/\$"J4|M!^9 8*/F#O)VSN1T9
MF3R4V9G/_*A. 6)YMC08962Q2..C9"!1!A(+S2W*Z1>4MR-OYV1#8 _J|38_
MU@&D@X:;J|56O+MF^J8W\$GLD;Q5-MAO1.8/GM.HBJTSX_!)2QO9-?W%G'|C+-
H&KM\$^N|E%|:YJ"|H|W@ZK3X3.H M^OUX'75Y&@!G19N3AE83F?
AA*:)H/..7@|ULZALM%B-(TL#|&|;#S8HHM,M M|ZBM O("2?"2X+<3?*MV%
(+|&!SKT5"O7E=R|,D1)\$M;V&=E6\$N++TX4N"?D2"#D3'1=0 MK>|6*X-FM9-
W%*M+F9"W*4.I|LRPO>0P^FZC7,83K>-3(X9B?J5K@+^JQNO
M@|_@'_;D:=I#F:0,S!;V/GUP#8|C'YF'SLD(_EQLKJM6V|K(&|'G*%%7#
M=%W50KZM6+8'J^..01|B, 3M|<513F:L.3|Z=,I>A@"#V19,?)X:E6IH!7W(|
M^(#Z;=RL/??4W|Q-&_8WMUWJF?&1QD@:K^S3FZ%|4U|*19|CW.YC+7Q\$'<,>
M%M|Z1XH"8O2>1*\$1_1>WB|+.:#?Z:K_9&=8IH!0D*FQ'H'PU|3>W|*>X^@)F
MC^JXP|D46-|=\$GP?,NV:%)0JDDGTG#1N+|/#_!L|T:_SS-CS5ZR7^J7933_Q|
MW5+U^DV|U6#LS%3|);,E#V 5US%7*I3|UB@VUC@EK& U2T)H2:-F!ULA" MBGFEA
+H3G/(@V^'3WY2OWQ|^&:1|_?|PA_+P>|=|^#RZ_ UT9WCZ/_C%Z'MT|M?4R#1GLY'+?
AUY|AB408W)&J53FBKJ|-!L@R"U*,<.YT+8NNL'+U@P*RU8(#
MK:CGNR2:%RRFE'SR|&#E|!,6Q/&==P7*AAXECXX|;Q=..@|T<^@|4)PZ%\$D(
M9TH(G1T((8|K+=%"VAV)Z1+3CWJT+(B^9:KM9OQN5P:M?E%:AF|1W?8O4"W2
MM^1A#V4^1K1R|;S(C6CX*YQ<3X^T>5<|6W\$8D+1FF(SZS:PH|/@%_%A#C_O\$
ML6>*/1R4CXA|8 M7_1|!=L=%:.)O=US>1J\$*YN,LO\$L?1@!;|D|H
D|A5%\$LNV)#DB3,P2R0=A MNH PC7C-HT28TB/,%HU^5X3I50;-;E\$&C^>D\$19?
ROYNV_J;89J*,9NKAH,Z MGZ)-5>>%E:"Q?.\$%EK_340#2=?9MOS+H))2!%JG?
INRGO%N*=S,G'.G5*H-& M/=Y52>)((7'DI!US+|8VO+>M: ^YPL!WXW%*TA>,P2WM7/
=6%?1Y|:(UH>P M5:XT&O<-RWWEX+X5T'X.@?T|@!HYV&>&5Y+<'ZY7KPSJ|;B<-
D*B3_|A;-R MO9M&TMRP, @:YSAMC|C(B#|-OFF!4|JT|%@& MN-
Z:9*#S5AASL#MI*&,4OD-+ _Z=C>.QA,GF8?/5A?(L@3B*2%HCE>-&T-#!* MCR|KI/*^&-
*N#/-;VTET*1ZZK"L|HLNG MPB%INX>'|R+4T^3IQ|Y2^CT*3/B%:_LB7F>R?
1_&M|47GA8?|A((H9N#L0@ M|9GB(4SG4 C3PU|2\$F/..#V.Z^6!,ZLXOO?
|ZSB_2(#X^KHQB 5?*|FR???1@_4\$0'8?)D.",28JX _A|=SRRTF@
MJ#Z&YO:;B9*64/&0*&UU1AY(5*|,\$N9\$2"0J/1*E=7'G@42-RJ 9|RA<2"/|
M|.G^LDY""O9H@X6+GTQ!W5J0QZK+|*"S;-,\$Z| "(A!032*!F70DR6^9X@HFQ('LR-
*LU;##%-9^7&&F+(I9W 7 M3,\$2H:(D2%V,-?O(+!|*J+B68R!KP7/JLC
'%OS/;>5\$MD3<|MC,%; &.GCP M|LQYM%W/89|A\$-B_X|P.|J|-|#5K#;15")V2GNER,7

!G:.*?#L78/(1E_-I MPED0"G*L5\,S+BW[?#=#LDRJ00)U,M|-?,40A/B5'C8P8T8//AX8!&|
(!IP4 M%0R02E*/L*GXVGF9>8Z@*#Y#!^74>F\$XK2K"U"ECC>TVD*%SC
MS5,7X31\$|GP|M+#+4-("6YWX/@)W\$*%N505>V"3U#Q\$F;\$K|KXF
:B_00EP1Q,H7MMV0Z|8HP M6%9>@"\$012AB*YQ8|F.QQEX"N;2>I>,
(Y%\$(Y"3ZP*R66E\$R%*0S|J2)4%M0 M!6Q,^_&H@DR *C669):|6|"DCZ&G
B15YNDZ;W8+|&FY|J|&9;J0LR!<5:\$> M*7/U'96CR_*C'V3ZK7*H!:=/O)=M*4N-;?
N;N1LPIHZMO"7& M%|YCCF+=;L 3K.8^LR2HDMJW/"K-
PON_@N!U%FPIQ\$M691KT7_MOYG.8IWT|X-3S7O65+0KHY!N|X^TU&E65-
E,EL_&9:F59!;|R) M,B>UA+. @#,ZH;>SCB)9M5V0GDF-
T(DFM@IVF4ZT_0Y8*JG50L|;OFL,&=X|P MCVU'9|XUG/Q15|?O_3Q3K(A*R|)\$Z(-M1=<|)
|4S|("SM)6M|N)E-J_"B!|7W!N+Y%4=P/U|N ZPEM-R2N2UP_!;YOT7#W MP_4>:+C-
>"19XOK)_&0GP,;;X=/?E*_'?O|Y|SY=/=%&=W#_YQ|_0|NO|=
M&=X^C_XQ>A|=/>V5|YOJ@DZ5D'M&F|N8XJ.A|H^%X1K^S"DP+8#C>>_DIF7P
MI_DLZJ25|=.,YL*C^HX=)|M K3#0,#H"Y0EC/>P39(F_W'1D%*R"F M;%&V=|&41JTR:~?
W|=|+3"D@IFQ157?"E'IET.G\$YSR6-1FX^((5+@5VKKO*
MQ+%GRDS%.24@5Z_F"IT>;JBYS/Z"|G:G.#^9AE%MOF89?V;7LM|1QBCREK8#Y M5P
Y=HH?6OH? O /DS|"4#|%D\$X_'*;9:.0V'\$9&P(J'65FE|_!5-4Q\$H^V M@Z@6XA3V-
4G"GV9ET)/YB5!G8/*Z^RXTZH,&OL(|P+F%9=(>/LSH1Q?%|I M_3|Y%|!^-%7+
^%|Y|,XB2;:20T'9#5DZ;%FFR3>#VLZ.4QFEEA3/*S9)H.S M8\$UZFZ!
H@,CBR^AG|)&C)\$ID.YB|JZH3K2BMZOR7\$(UPV5.%9"XWH? M)(LA4|-6&10_4?
DHC:Q.-_99^\$MH@(\$:AJ=%)1%(>4J"5;DO19?MK/(-4|> MN/ ^UV7N/?,>)I@4)?
ZB9^#*S7K1-&-L;9TRF+T1J^+8TZ@,6EU9.7YF2)/5 M3YZ:%5F+V;5N>|=B|22,PDK':KT?
#|#('"/@QY#BVNW(|NM|+LLL/FDQ&17BC M\$+1)B-
|*QO=69XDE7@IL&33B'P1%:W%FF#LI1W MUU+>A4N3D(5^),MX-
Q;8'*2QV9K"KY%_ (1L+OYK=G%+U99'A>6!=VN9H^V\$= M#M9MMR762:S+-
LDY"l9E|*|@Z|-J+XINC|(&-9|:U*_'Y0OHINA->WL@"U
M=)N3.O_EQ#N7DHT!31S|/4XE!_7DEUX|%*5W'X MB""LY6)8<%-
HEO.'L/N:\$:Y#&#N+)*_L|D|L/DFVV|/#-GMA.-|&A^778N M/CAV2*,U^-
/'\$6P9+|9@)|D|B2!'C&AF09_VZ&H%Z&,M#?V+;?2_!MK\$A#\$< M3F1<9/R(5*BN*
|M:|JZWMIN8O-#JX+R#TZ< 2LOL!-E0*5&D6QG(Q,SPY"4 M>5
L,01G0>80?)6&>=H)N@9&*RU|16)>A/5|%'YX 45.<|&R&PIZ6++<|
M9OQ*+4OWP:%V3>|0R7#H,.(V 8GBR%+?3R&39KI,):'E0X8Y&)W/YFC&2YQ
M%>/9V@_%GB'^="|(#7.H3FX(UP<.5A_>236^|49EL'<|3&EM%P|7LO1O2XLK
MS20=0.)*Z7\$E2|>VM+B"@;^XCU=BFJ13 MMX!(BF1"Y?)%&-('4N.JKX^D0
U\$,R#|)*-5;+MWGZ|/6|5#YYO3_2X.RY MHEA/\$G5.8VKOACH=K)**MX8H.%|>D>|C&
<*X*Q3P7WR?O#S\$6IOC)^WZO|M90|
<9"E++B)+W"|D^!;WRHN"2FY(98"QGW6Y9D(GA4|2F|JKSW+F>/Y%JUQ M/SQO5
;M1KS#Y/D@NL3RS63" M-!K%)0"?| 4;>\$XS->><1@3*J|> !+JY\$>T3W(;^!ANS!
M0@:'|=99J_ I2;29RM51GD4"Y5"!TR)R=1.:7K
MP3V/1|)'G/F9U|#/TRM|B6/T_ ;P2,C9J0R:.01<3J:#E;|YX?W=LS*ZO_U^ M-
WRZ4ZZ^W/&?/L|G"05%'-Y_4>|^SY^C?PR_W=T_/AF|HOT=8WM1SB/LW@;#
M2W.8ZK(OCAT?C<7"- \$HC7*Z32*U;@ZYPS)=I(L/6W_Y.C(%8!:=_89)R3Q
MKX#XEU:E.#W^|2N#5FN?SO/%2GOAR66E/6N_ (J-2H#K|HB37G;LS8)W2"9%1(2I>4?
EH;I95LHTA*EY0N*?V@E'YT&|*=-;\$-*4K|D M1^+3GX^W^|^ #MD^/U?2C"H31G=?
WWX_L?P>?1PO|MDMGC(14.*> M)<6FNC@C?O|>/,4)D\$|/T|,WY+4F
+3L>=\$+SY%1&)Z4=!!8GJ:XI@4F(|Y M+@FS,TZ#Z1?
38V5D:?,8?,T,3"FJEC,VR=6=&94FW3" LZ':K9H8(L4JR%Q_3OQ?:LVE@;7ZY5!NRA|
M_=R3299|MUI&3|??'H^_'Z'F23W#_??Y,T=W?_C|ND9,T(Q|>3KZ'YX?TN_
MW3Z/_C%Z_M=NWMTT>=N7^/SEF !B'AF66|_!LOGP%NJ%K4P<>P8V>Q2-9!|
MP(9=Y#SP/8?IC,U4=&+/'39A#GR@T,0#:3IN7" T MJP[|>Z_24) Y7IG,)|B,V--F5?
16G1N>:M|JG#-+-(R%P|IR11>VD M|,|+H
|V_L4H+)5\$W^W*H+'W7"@9?)4\$<\$I%/<[ME>W;_|65QWXV%(,V-F+HYKD:45-
U|LR4&D|P2G|'<6 M^9W9X4NN!Q^0/7*S|MO3?S,W;=C?W'8-Q-J/#HY
_E|9IS=#|Z8^E46>XZCV ML18^HHYA#PMO_2-%
7&OL=*H/O(O;A?)V6@W^FJ_V1G7.F.UU5;:'KO?|-6| M_ ;96G_3|K/<_ =21W|=34|
<|P5U_8|=AAZH|K=0)'_*B;:^J|BR09@<3,L*Z7 M_!*_L_4X&
|O!F>|P'J8+KYBB!T)RK\$H58,/8?2H!J6J /|X|D9EG M*|=16OH:T-
)30\$OQH Z1\$F'ZML0WZ!.._1N7A8Z-!R\$P\$O.JK_EG:Z!4AY?W

M=X)2(Q64ZC=G /XPI,5,+?GD: WX^^ MCFZ'/_*V/VX<HBE
^/GP;W8[NGI8AR^7H_6(&6]7B5MRRV/ZLNH;L'D\$ M<0U0HJEL0TM_K0R)B_@+6!
(/'5A>>C7@=05#.8^PW*?350[\$0KP'M<5#&O!
MJ*\$G/L.7,1#V<169|J&Z|O<,A+*WY\$U<304ES4YX4+G(D)R!JE.X%3C5:P
M_12\$GU=ON3|TYJ%CLC4ZXT8NU&NDLK9UGK3CK5)=)4W0F7PE'J+GSJ)X6/
M@M.!00\$Z+/A\4W7"8YIGOH*IKRMO4-N%'^URE5QJCHS
M57E"RPV'V4OQN7D+#W/FJ*A%*I(1;D-'=&6\$S@C0S!>FYU+BF(HZ-68.P;H MT+
!9T>CN&"V<4=&|D/OVZ D-N /H+L6L XCN@W./H#W79+S)&\$^%&N02-M./
D"1!1BD;WDXL@QI0|2KZKHA-)><7XMO+++)@?J(^-SKS=VHOK=?XVY4NEE
M%%=_5)T'ATQH'E/ETPSW:@66FC|RJ|V4XM/75"NBJSBT-6HGYUK<%Q)U"PN
MC\$|&L&@+'Q3/477..1"7<-E_V+9B|01\$BO&?D?PN|:M?U)6GDSY%U03^=3)@#^S9(
M0NOLE9DVI>.04(=@V)0!8FG:>@;XW|%%0&AKDR9:GHTXU9?;.*!-J)YB
MO|+G\$V/BO2NP#<.D5"J%U1S;Q4TL'. \$M1^*PX N.16(#;K0*?Q9P21Y73FRN
MLM@6C|E8NNKHH(F,4*%Q5-BF8?T;|0,UO%-@;HS-^1VWD'H)@&|.-=19@V
MM>A|M'?3;IB|&;!ETGU0ME|;DVLXZ#7&A@1@ \$*FZLZP5/?5H'?1H0\$XJ|Y
M7P&WIL|AS'@"78?JP+GA;3KCCSGV&W|'(8X(2MG,UE4?//WOB*#Z|(X/#M6-%C
)T(#)&+PIW-R0C1Z/NX0=7?D^X)|'V|3;18QK96,&^@*'NXDI_8"V+@
M=S:WG5*O*HU:HX'4BC=N;XI\$PDB(JOSN6U8E/^))\$J%FP# Q*&|C.T
MVZG!)J!*,&U|ZSY,)H;&G"H|W-'KF=PD|8.C!W |062)A,,PG9>5 L.PI_'M@B5-!DJ,XTZ-.3
.=4:Q9 ?=3.8|MCX<\$38(E|@Y\$0^@;-?L!@V)L=V0!_M;8 @KD 0D?
U|97Q0/OO\$L5,ERFERV8MA1::W:V"J/K>N|DR\$=*2N>\$2LIR)++>XE%'Q*#PG@42 M1
3Z1@F.A%;O"0!ATZ_I/B3=;-MWE%H@+!%T|/#":KPN3B*:@/7UUS?'!Y*8H-U"
<;KN,GG>K@N;P2Z|&-MO*!A7*&.6*AW#L^'*@K(-L=0W_A6U-IL|C6"MPIYG*NP9Q7X#!
<93)!/# 0 MU2;P"l-MR F1!9: EO/0.*WUE;E1T!&X>8*0_F'>-LL!7Y<:^^HJ8@\$^;
Ml'="IG|QQ)J"7:T^|V9&41H^?_>=<,l") ZE-NP'4JQE"34FZZ;|1|J_AM8 M;@
M13MMCZ=*FA!"#917>|:@ ?P|;FHKVC\$@T"YV#60^>^.?FO9?#)5J MX |JB^
/GS*Q&6"0'CU&5|T-#\$MUN9TQ58&G|*<C)QW!'R(/" 0I&V9GDCX|H
MMT*?)%V0O&M@E.%V4+U-T#MOE""8L, #;>=Z3I5:Q-40>'A\$?R.&Q1W,N/5H
G#%FFKAR00(\$XPP M5XS;^!>G?*Z/T^U(9/MP'0&KU;|=!<:FWJ4#*&"M-
/'0S@(@#)7S>Q"N9DX M39-""CE"P_YO---AEE|B9?TV8;|""N*&OPZ?/_A4EN1?
V3U1;24=;|UXH MJB,A: SX:'AO-XFB&WEJ67QJ?YS.E7R=E7/MF--@+IA_/7.5^T8!EU
;PIBB2 M0|YH+SSDYK3&GY;!F\$VQ-+=XKU@MV=EC|L|Q I@9#C>|12*|=Q%V1&@R
M.%X A*!++AKKCO*',9+(RW\$Y?(3 81*?PO?1G@WNJWD/OP|L%(Q|N\$?_IF?J
MNXB=|KY;O K,OSW=|YVU?7""|&:ZPO!CE_2E4D&?6>:"3@3&<1,=1,\$\$/- MC-
XG'Q2N!W8_B.3N).")|(X!#|*|SW M|(J8J;" K&\$'U"3E@FP=C>Z:Q*@_H?F>JL|)@;8,XJ-
0!WU\$EDD8*H*L@6 MR9N)/%SS_!ROI?S0B)! MM"P@H?B@4""/PO70+
(&ML89\$0)N=+"Q-!|C|X\$R\$?:I(JX@H,|?1XJ(NZ2)4#JUR,@65Q:9+"A--M^E
M;INFZHA:=4U;4,2"^Y15TI%L2|"ZR ?"&|;HAKTRGRU;>'!*_|BXY)8S#6# MG3
^1)=XZBL&JC^459&HU;O+>=H)M7V*A8#0,"EW(0^>%4:Y6=._PS2E<
M&2QC6!..>*KSSI5>X&0|K6KATI*R46_P4&,VC!B-ER;"O>E
M&7,U:M+8R/T9F063!;6KA"X-\$4F3>2 M,)C+1NEW2@^_PT.\$3727N
*!1L@TXJH&EB,)HB:(G3R%SK-5O@U|RP:8W+:"J+|ZNV0+W=\$PRX;|ORT|B M9-
P30XKW7'TGSK266>7IA12C7U<&QJH5&=OGH3/B<7E,&W^("R|8Z,TPA7|MY*8!1|(C7-
X-&E<*6(H!AP'% M00T3W42Y5'(-)798WQ:QRQ:24;2?TGJ&?
M"F'&0IB)A%#5<<@3R\$O:PIJ9""|_&!%?'_BD2(UF/<,W@<4LQZ3 M.PG^C&2|_6^|<_,:YT
7Y.CKDLZ_K."92L&KFHH^|F|9R6 MT"SC.2OAVC/F36T=<|>,2/!)TA.()2#/X|+,%0Z
I8|7\$76""7R0&IU+>B|L3U5^8_>*H|RG0)YJ1 M>!.A9@K;!:V4*)=KOFYUR9'\$_-?
BAIB|4\N#KOLHK|>QX+M?)Q(IY\$"YR?/! MD|^.=
<+OP1E|BQD4V6=^VX#3%#S!JXS>/B5"H3_,%J;X&>SNU= 79!CS!<,B M67|'?
@4/&G|TMX;M|AB= '%@TP!FPYVRR)6|'"@|,"LP|C+ '<|@AC|B;P(MU*@)|@T;|W>RC%
<8"<+*70L-*U@4K\$X_10OHE-*5*,=@X5%M\$.*"?^>*#@R=
M(@0!U#XI4Z"05RHZ6*4OO|F2F)\$V|@9P"VL%% %|*..(1#'=SCI_5-P2# M+?
#@5\$F#@)|@X"80B)K1Q#+7D|Z%Z|13CA"7"E|P|MSD/OIU"\$=-!-\$2/= <1,@2 M!'B|/4=HA
%=1|_JOU&X!(14?M5IZ,SJ)=AG+<>?4SV9?E,=EVPFCCXI\$,R)>HHAS*.:%(2G/[BA441I
MJ.*K|+Y,#&RD0.\$3.*2%CI>_+RRF-&M4TM:B?YM%#%UR
ML.Y78/D%M@=W|EK#PX184|"90HZ- W|_16J|8WOSDVRVZ7_-?AS;78FPE6 M&U_>W?
_E<*N)+Z_ZS(SREJL^,:%>*|(RJD*1>E/'="L)"*0" V.%7)=4EDX" M?S D5K1\$#3X9-%?
#"JGI(-Y%|3EZVO8IFF=Z<36&C*&(>8RN'ZZ!WPJ%;8CZ MVB-S|#GUA07=4ZX;

{3!B90Q&07_%<7F=)MOGV#SCB" W*,-%?UE(Y(B2C[ZQ&-6D; >1RU? MTOFAD3?
5<51+1-6L39G-7KDYU&M<<.T:0\$T\$ CL7'1H_ C&);E=^/T%9W]7 M1
4\$8WH0;;+E:0"Y\$#A_R+? U\$0-5(5'IB."Z>N"1^ B-5N\$-65,9(M/2U?7(T\$J?%#|A.,2:-
&Y/+@%*J^'H7-G0|@T?A=6'F7V!|AU 4S\GTN;,. M
'OHP_OU>., 1"C=RG8I@BN_X\$+X9C/HY;R 7CBL216S\8951..L;\$">N@A4Q MMAWAK
+3>|I4/6=Z_5UD,P)G'059C,14W?CO.@,U&RR=;Y@9R0D|L.M6 EVW MSH6N?3
=3K< >8@M2E:|H4NEYT\$<82GU=37IU15-90(L43"!-KGD|>E6;:9K
MU5.%&C,6MBDA);C*M?);|% H/2;.%#)G>*|29R\$?V+O=GI_"K<|0^/@+09B8
MY);MEUB=G"K8-G|B2*[E5#?C)|VJF/1)T=|J#\$SE;>+8#<+/Y4KR,%'G<1D-M6,>K6@
4T^|O\$_- "X=B4*G0"87".T)+I(Q)X/NOHLXR!./#Q%Y#<%ARJFN& MHRUFZ-
I';SK|D^&RX,*V%\$+SQU8VC6HA|S,+<0S+S|@Y+0@\$&R;|X;:D-9:0
M72/;#&)*8=C;CVNMK(QN9\$;MS1#OT,6Y%%Z_4;YR=3(ET?1NNX\$02\$.+Y3S
M2|NP;W@5P* Y=F*\$3OA^WX70%-N!+-?1N-6(KU6@BC_8G1_+MZE73AB-N0+|
MATM|J@+^(YK!=^>)GBX(J5|Y>V@3?/WK#EVX*/F84-\$^-YL2G9 C M3#"|M
YZ;D@&50YDW.G&|XE3B\$JMY;HLO|0FB'(&6>)5;H|FK_G=_A8NI|P
M3JHKER(N+^ _^|'\$<466'KQ^K0MNOYR^ MHHCV)9BS\$.8.BWB?T,MR |"?PS=+
(B/(ML5>3=F9"|K&1>6^2H^))KJE|B-M/B?
>T)5218)2R87+)|@M36\$E"JOG)16\$R#BJ;.&J;5 3JP#)A,2V7HHQ_1:&Q MC-B'%=;U+;
(@0S0POL*.-@+KF>-RGQH)R_OA7T)%Q4T0S/3*E>!K6":R|+N#
M36Q.TUC|U|KT%K|\$8IY|\$6;UH|@,QIB9HDHB-U@(?HY;D3Y5BLUSO|)&_QF M3)9;Q
...1^!VV,H,Z2#3F70C@7H0%IOWDS|.)OIPF9JL=U0|/43:@2@NC%G M!
<:I@!>+9N:SWUYET,P.O%AT,Y_-4+!U"?"(VA:..901M4">P\$YH306_WD&V
M7*_M|!+_G|TW;6X;2|*0%_PI"TS77CJ#8W!?!7D7(LEVM&=OR:ZFZ8CY-@.2A-MB#)(L+%
(9O_Z-S//@H.-)\$A0 DET1+MLB03.DGL^F3D|S&*;%U?|J./+)\$Z8
M(%X|_&'M_/1DAEU_27)\$;J?9@M/J)C.0!N@5FZIJ|/%
M((WE6E!_OP5U8\$'=;N:"2%*1FX"MO'-A&;I2P5RY=I(Q4*\$MM(JN82#*/5? M3-
,@BA&S*UCW8+D:2H=QA<@3(^@TB3>;5\$A!HY3YDSADEU?;TM1EWL\88WZ@ MH#?
MMG#:01400L&%WX0K2KNIKBBZH#DS&>=8%JK"UCKV*IN@!;P/-V,PF|ACQ
M%EA4\$\$_^?+?(00H-(O)LL9J1|K;..!W=0-C?3# MCXG4<+KEO|X%D<^00*
|0K.8/((Z7Y>NDYU5=,G4KSM&:0@1J-C|SN))T' MA%51+W1L,1F)Y(Y6HBFLC
IHSG,T+A_S_>/=4LA;DS5_*;%?ZA %>A3|/4M M(V;J^&31DR%L2><1'O?
+1V@M3&V\$ _8F|DJ>/8IDX;4QSJ258\$UZ:0.=%69B&7CIAML2||"XC=-D,9SA?>V MV>
(107U:"Y83Z-%P2YKM+|Y(AMJK"Y)HLPLQD)?=!=?C5=() (V'WC2ID.^ MQ|Z/5-0A
(3K)G!&7F)FH\$^!;BO>/G\$G'P,J|;P.S5*(?>W.(_%|8'H3K
MV<|)P|)\$^%L"T0;6%Q: ^WBWN<3D;LJ|^O%A/YRJS9VP_>5XG&TX%1:PX-Y M:0=
<>.OB:C@XJ!MWP;6WP4!;F="I!S'65*7|YW|T>XWW6:4I"2^Q2!#E=|Z1
M\$39+R9|O8+Z|S+=7).A@ ME|G#1;3?;T|TW
MV1L%URVM7|!|)_"DHXWKD#:X*,2/HFAV.XV;J/N.&N8\$%T%3U|2Q8!P6Z%+X
MTGC#)S"M+N4=T'6|52|2#PI;5\EGP1T'|L*(M&L5#YP&)+OXLZ).ITK!P9VY
MU@1K*K&!'MXC4#84"> B3: ME8>&58|K;@|S"81/'!;_H
OB'I6D4R|>GA_V>0B|488Y95@CB%@^"63I2"JG M#K_2L<./K2P&+@JXCNCGRW
/L.ZOV*/%FCG)Y*8|*|9DP\$=|+"N9L#!_"8N MIL6K#EWB1?+Q
K">0CMTQ:CPRYF6XC_) /5^%.HK9S T_3AHYD3.8H# MV%I_6|0DP?
&BG3Y1+F.>PR)-29(?Y!\$D@S1:A MG 5LAL<9;?4;_J&-
_361HF+;G0%*QV>5G"RO^Y<)ZY=1,L5):0 MN@/R1F!4V%P/YPTK>D5Z%-*7H+;|>M/*.-
QX"/#017B-W+^C |#12Y5A|' MU3PF;S6M)PG?IN/&3%-Q-
*YV=^3IR;%V\$G+0*8|LH1."N\$%|SL&|X\$RU% MB.ITI+4"5C,5K"MZE|*4@P?;)T)
(I*)&C0A+RI.\$JQ\$US>C:3T;.: MPD;O-")BQ%P;2CQ'^2MZ@KJNXR*Z3K4&R,AHX6V<:
(JQ_>S27F*NSRB#W.TP30*C\$MR3.FT4PO(O<|W "G>.&!6/:P\$NS0^
7V;+AG5CU"/NH"#L8&WX) M)E.&L!^..3+3QKS-F/J&?
@3#@K)%R:!,P|7LB78U))VS)N*9(!>B+DA.A8?C\$S|!*O. ML7G+|^@*
C'FW20W&DR0?:|M42*|B@D*(X(9Z,*TA 9|5|D0_59Y3I%LD13;V M4^Z3MZ1?Q
8X:B.*@)#^|FB=EWBO)V^,3G1U_2|Y;=|&_-F DA-Y0J|A-D3 MGDAL|D|A41W%.(:U^".
(R&NTQ2G\$Z.&Y6 O."-343|, M UO163&&-JGMSV1>54-L|^OBI/E.*H%13@#>.,@*.
<":QTM)QF,W\$-7-XCL: M2 9Y"0SKA1Q\$K! 8FD6LNXG4H- C^T5|H*HFP5Y:~)*1S
7WM1>F|_%9?.& MN,G@--CK6ALCR!LP1(Z")J.<@#|1MYDVL0W)3=|/A4'?
D7G>ZV::AB%B;:D5|A;:QAO,H(Q|TD=G78EG%SA'R
M&&J|Z|7D8U@C|HD7HL9!G;.,4!34!%04E3X*N03L+@RHVSTA?#>/Z2I0E\X\$"

MZHB2)861LN4?&SX[%\4_X/4569J\EIY3,-AM;!S??Z'ZY-R+@XMH'A;=ON<"ML=-
X^140[-D*1S19+VC19-1,EVL'_.^,<>U6V6L=9NGX:JD?LU8,,&[-@H
MRZS%HQ*OGN_BAA>?M,'D;D/W/:-%A5+>-713HUO)IHDC9ORJCB M2-@Q'M/6LD%6V
LD5GRHVG^EW,D;9WWT_=1,7SV;1;4!AXSQPZJ/C GMC60 M(92UJD@RI
1;3/327#EYVC^_Z;KIWICVU.J.D MG8NK1KV14G#U!C*.5RWZO^/.,IX)9NNC?X/
MREOM!L+35BO0W_SL7%(2_9H4PEE;0J7RO%17DJDGL1SY4Q\$3&H(#N>=[L M&O;
IHR<=HJ-Z:GW!\$RFX!K@2 /KJ_6+L6/1MW#B2,67Z)/M*&5T?\$2 M-
0T5MHH;!O\$0#1Q_"H+-XH! Q)5M+KT0IR:L MZ@ !Y>!EH).%C93PX<(T1D+F10(>'D-
L9A?M&\$UL+A^C,Q5D6D)#089E&KA> M52D@&CB10C?
="6\$*QJXUXK6;UL*:@XVAL/L_@T10+V8S\J0D&I7Y.I0P8.\R=|VJ5U*A.32U|#"RN.,
9"%I4BZWIME--9>K'(G^B
M@.&B\$8%IBY1)>'*\$,D"P1UR87C*CHJ:'QLNFE#LD"ZV)HY!GQ.M7 O\$JA;P
M/3WJF;T0T'-#2DI^751+EZJ9BL7BC1 N^X#YFUQ@ !N.KD[2M#2K#,,3L)Z
MTKISM'.#0L95R-3H(.P=!/X03,K8=,TX'(\$??-D_9C?=19<;9^?
G*689THBD>0\$SR93:\$CD*Q>V#-!3 !0H*L/(NT1 MYZ7RHO_DX!S&01YK,V>)HJLJ)
<8*WU ^D8#WNFRM84TKW^1+A31MW)>46@ M.D\$JKU'5?'!%6_+2+85MZ@)F(")D?
X9.UCG8"%T^U!)\$SI#W4XI@O*P)U M,0UM;A+=#1HR8TL\R<3M9Z1 3VJ6XZ8?JE?
\$C\LYHZQGI.O3#_26%,6JHI* M_E[V?8A\GXH&;8(Q<(<^JBRPODQ?M>Q,^P9_7NOKU-
Z#+2:>I(O\$>Q01(-K_M<1H233N?2C44ALNA:1 &IQ\$2XUXJS4EC
M7FKQ8HMH%T5U=/,!F?HI7IZ>,=7T\JD1(9(G&Y;+\$IM1Y&H> 9?%RZ+Q (6-M!'K.)19
P_) \$F!P3.^ Q^+:8^!3BUFLB:DZ<(0BR=)6ID?1+OP,)"
M'24/2JBH009A@QK8UAY)TMCI^"#PVX9QKVPE3V,JA07\$SA_ECJZ.K'U| "QL M>H*Z=-
'C6\PD/!/%^F6'.Y//U_0<15TP_IS^6I*IDRNKZ_@^5JL&G7#;Z94M, MW.K3<(")?U#
@QCSG@1'-SXJ1^55\Q(*H?S"2:T6#&^1G.E/&W*&%;&DJNV
M1.6@=P49BCF#6.VK\$IC:U +N>=,<0FHDSLO"/K(QIXQF5)>&Q+P|\$AE4(ICC
M49T:MX;APSB?B)\$I?<81O M FO+\$1<'+'?D4421
M(7GN_Q#29%AV:1*&N,LF1;.:F.J+R1E5<11=D(Q60M%3PB\8V=B:3A8-8\R" M1WIXXW
^P5;K&"Z>Q+3QF6H*EXKBHJY %P.XP+9\$1\$F\$1**5>&2)B<|A2 FX
M102T*486&XNIXFNB8XVJ=0F?R M0(^%|K 3>)!;%-J44>0%I1N|/A1H_(@1
MOJE)N4CLUO+B+WA9";8U(K= @7:.L,)^-JP0EXLA1*O;&IK#=#F_4Z(W,3M<<
MF=UA>1#L#|OCYG0X9(/:0Y|Z'1MRR#)I30JSB<9V.:L)VASN=?2MV|NE^
M0DLTR\$W^F1?D_106_?OL.O,/^"3BG0X\$>7\$C!M=DIME3"M+.*05I/S|H.W
M/SX9/S|=W/W^1?;A|NY;@A_7F@A)ES_M+C/PZGQ%*>ML93)4>>(--\$ V"IP4
MD3"TL.G6LH*XO4:01&8);430&JHEY0FDG*2V%|+*J\$%9DT Q82,)WJ;BV M5>
(%H.U6X=:N M+%QRK'I=CW<*0XN|-)\$5\|W7L-V6'/^#<6Q.3X:/SSS1.EG/L@.1ENDW."!
M(S8S12F9!&@+N+RZ<55+)K=YG-(3DV+(-K1YN%ST7J&LL6SY1<4'HJM("/'" M?5JX-
WZGZ+3Q6GH!3(O(MJERHX='A@Z=_E!Q?>.)5R@=-+H:WER8HA"6ZW^C! M9(J5R\G
NF&'0T\$&D&LAW|@U@&%>P'BN|S9EVIJ/6*42U|BA>Q'I M;:\$>. M>%(UD\$2
B=SE;K(!S+V^)-K*E(=^@W61-(#"A\$<=74"5I) ""_.1ZI@)9
M:OB66*D4LET6MJ#|H+Y9TIWJ/2!J%8(4;#P2&5!|\$QJR9|DV\$.J#@PP6-Z
MTU_IYQC%*DA4-T0I16H5(* M-9T<0J"5:7VD0)2,A?UC-6;3W'4Q2HD3?4>^2GFB>A7.
2+WJ|6QO&T-E: M4:Z1,VSR)<)W3|G(\$ZI/K"%L@UWI37!0K+WS47H2H?
QXV7@8J=:3_:7Q; M0V=|S'B^\$@|6=.G1IBN(5HOHR/LS-6I=MB-522*UR\$1U?9BL-
16G(KNF3(GZ MS=R9*.1+C/5|"QR_H|T#Q&\$ATP0AH_Z"*FKS?
UDA,IRD=)K:NP'\$V./>H
MS>5"5"_%NG&MSB6RG0FU^HUDL2B4+SH6:PV_A25%R:14K13#:_+Y\$PXQUV
M4'1Z*<+=B1D?)<1.!9. MF*%(M:!,Q"N)?GT77\$?K6Y1%V'X5O^:LG;M%-7%)N
MITNZ)R5IW5+Y)#.)P>/ M@*NC:*.3.DD9R88L@YG%X!WY^9-IAF
N)+^7|CV2ZN1P%KYXD M)KLB#V!_HE(*!=KNY:TG+FY(ZQ_ND#1CFVTBM0|
<_GHN3&#'|&ZQ|3|":< M9*\$E\$S\$'\$1VA@LKGLX,W?8.,@.6WZ5\$T;*R G3.M"=JHE2B:28?
XA6:A06ZY MIV<4P=HL %%=1_\$3".5ZO&3)O/*65PFSSUF1ZJ0'C?
^+:6>I'FW1GE>013|R|D7^#D|D!^/%.S9"J_ O*RBE^L\$MN'>L'8L
MNB1+6VL=SPU8;BV#F)F""1161VG33=10/TNT8DZITPB'A0E?8OWAGP)6|6LD-M-AV?
YGSYGBI'17#ZNP.A.W_.(L|@ '\$X/OKK)^W7|4+WR??0^8?)GF'+@?)_M.3/!IAZS@#?
9A,6ZHLNFPN%|OPU;1|BB&@;1\$>+0(8S<2.4<3KSD=E_L, #<
ME:5H4H@D(EB>%I>0D8;(^|C?5(I)Q-VTZ(I)Q^>86QY8Z#.>H?
M2FW1XQR;3'R9SPF\B@RYB4(P.LU'MR3WHV+59P.STA0B\$|DC+2Z-DD>@CEK
MRI*\$E^>F)4A_N)\$%UXWTN\A0H/A82+)1)PHNKX\N06!X/.PH7!TZX6F8CJ*+

MXR62(2:83^94\5./(.):9\$^K*^&Y/L%6<(4>4C>5\|8*6\|: BR/&=/ I\$5:
<(A6V0^LC6&N\$0:8-;K4\7\7G1-1!R#<
M\J;B@|J#*86#JKE09)HJD63A052X.R'>7C*2/FL5-Z1-.XFIBC1<.W|^JSE#-KN92&
MVPS^H#"3)A|".%2-F:R_=91*|?/+|HTZM?_@>%@!4GP8\$BV_0|&
|%'#N,F8CX|0<+ZP"ML:.*&T(E8F+0"2YD139YS_0=K\88IB57 MUG'34G=2-'N9LCF>?
LPPEH7^U\$Q*KQ8BR#P\,Z7L)%Y,GZ9"U=@D:|\$,)+(C
MI%0V1:KD4<\$)>M5\9ZK*7TXI!PL/LWE@Q5KCM49&U#8Q0"5/1038\K-LD&W)
MO32>M-Y3^%YW3FXD:;MLG.B/*1"V5+@ "5MT2R2-!)990'GD^M:,*6.7\/-+ M-?
@^XOE^STA&(82@1AB"J:O2J3)L.1*L#L+ MB|QX3KSO;2Y, M>\7\8G!;Y"
GY0.K/6H5WI* (|7""E AAD.K>CR+XQI.4V#1P9T<*!V/=6! M8FR)843=H8<_Z19036L
M:L56:34LV/!="XZ?SFW""^! 11W\4-;J5Y)R(XY\6 M5F!T?ED9WM!SQ^E\PF07=7
*JCG40L?B:Y^P/-;S?@H>'-*R8!!MG+&3*%O M>003UFXZ.SB@A!LG.?
%4&1E0_9\62JX<+!H&V;,:2=HV8%&E&31*=R:#!!M.VC7*ZRERN"4@VUG*U.M;GP23;6X(
L|UV@-UK0S M('FB9J\FTE|BYI%L?J ")@GXB#Z>\$Y|Y>:(E"30"J4+XMU0V^K-JO,NF_,8R
M=/3\$)%1|>*CHD ^YQ>K.TG#M+?YN|%.I>.Q?-38XM9UD= H2
M4:*K=9HY\$ _G,B4NU4JE\,?4:KA%SCW/RH'5PTZ
M5T2FN:6.LFIEZSC^L#41^C!,DKEF+E\7\9#.3IPK0|(Y^'2/!AOK;MI+13^G
MA.JH(M2Q"/7P."+4|=0(=>)_4PL95_93ZA.%(EY7#.2L|S)\AV!A8)Z2=2JE/%XP+Y(KF#D4
MD1%OH1?R7X>47&|P:09=^/|SOEG|N@Z_ ^GORY|U^?= %)J5?^ZB TR7RBP1:03+|?
Q<@:934 MHU+_ =ZWE+Z,9)4"L_H^3"Z>4HGE|L*GNG|CQ,^?8_T\$%^\$DQ;+(-F#_98;-<
M095INRJ_DF-C#=R6H(9CW_JW E;Q5_#(4-1)QC|HZ.N9'LB#XYMV9.;>#MI
M8('C(&!70JFWZS8&UE(RTQL89PR-AV\$4*.H?>\$<#.JM8|@|Z:~4,(|AK/YV
MN/WK^Z901*DVGF?88|>EC|9J9W2%\39,STH.?1Q>7#5KS6YRD);H37.HJ|'?
MYKJB3&FX45|HTK1BK8JU\$JS5/@AK=7 ::;W;3PZDK5BK8JTS8.W.IAG%._)6
M|^*J5>NWD0.42\A;N>U=\$5 ^)GLW%00DS-YHCBS3#6JE^C>IPN#(F:*|I;Y)
MDGWKXFJ0_01T+=.\$?1C6L=57/YRH.UIE&ZZRVRG#56X40!ON>"L!=HJ7WS^0
M0^_MEUR):_5VUL/(EW17F*V/<#D!ZXWV|8X M(Z-WOZ,Y(9\$Q.)#(Z*+
(&'9;Q=K#>UU;N=W0BEDK9MW\$K,,#;6L/G==.N^"8
MZPDSZUFSX_DP7*|Q((;K7UQU;NU!^|)#1HL.8VLUT=[KTOM0MIJ(O);)(|4JO M+=FA=-
^,N:."AC<2EW|'Z(2^R<4TS5@ (AN> O?DB44,0"\$E>.-M%EML=|:' M(|=H 'EN|X;V=!%
AES@:9S"('M(Z3L? JB5/4^92;1G-)H-:|U:0J^W# MV,E|W-W.HNWO!& =ILJ|L^6
:=:@6=+ #9YM5^ #9T**5N#9"CQ:@6Z1P\$'=MM8L.R4W3&LF*MMEC+G,S2IC*_
_:'D!:'M*HQFH433 MW|GR|UQ<# =IEP6!65%\$H51P(AM?M(K*GW=L::%
A=ROD;CD,|@H,*\$3&@<" MW1|9ZOV""*JE.& Q8,60%K!N8M7|@(&&WC_JI-2BXI/N\$F?
6LV?&,*YY((8; M(2HU=O;#7LEY&YWKSA6^6AB=TC0%D|G&8-X^_N/OE!O-
UA+A#OGI=0H7OS MH'LK%&|H7.%XM5%4/LP*K57X"J\X.*;TJ|X_Q|IBM4;X7JW005VZIO
MO:<%8JU0016JMT+U50"IPBW6K9L+)HW2YL55KW\$4W0,K|&'%/(=@G@-A#WN\$
M/>ST@7BKC>G'OJ#"|9:.\$*"I<;Q'<./Y"ME; (7M+=CP56'-
MD3\$X\$%BP1V#!;KM@3_B\$P8(5LU;NHE9#P0T| T(V=NO>O)6R-X*V;LSW(&:
M^_6HN=^@<;S(WIRN5NF=K":|1|;3UC9/ @WKHH/S*XW|BX2OJM%3*X0@97 MR.
*&R%"#K0\$,=^DYL AOE:|_K(X @P.'ZFW?@I?K0|_ '198^D;>^FXE0? M|
(DA,4/MC/^&9X="\$<&)|J\$)_ANP"|6 (_Y+JS%!.#3|NU:'D,@O3',MBN/- M&%"(3O/"
#C6&B736TV|CU=)AJCE>'#9V'#=!:&|XRYC'|TZ#@3SWC&?|_- M"3,29(WP3276BVD?
OW*QWSW|G.9^WY MY.GT?8|GT|J#)I>Z#(P3EGU.I_6I=ENS0,QRWE1%J? M. T,#X2.
|/>1!EK=G##|P|! ==5TU0?"UO4'U&&_D;,0IR00^5)KNCM_QERC
MZ%C/5M"IFG5,^;BU(2*:8#4@I. FMN3RE52?AQD% BDW)
\$L*>\$|VD8@)L@RX"Z=N#PQ200C"00F+=BG5+ MR+H'@CH->B?
4';|BW8IU2|BZ!T)2#?JG7;ZV|6 +_35_!9YO35>'HPIZXCL+ M#'YKO|Y W^(UMPL?
K\7X8IDCR|9|2X-&KZ|-2|E662KIU*|L<%>&RVS3IY#E MV/1FR.-!03#_YS^S/2I5.
|&F<."5_#L;.>&%7IF),G=\$4% M>C,FGCF1A77\4R,X\$NX!UXVU18|-B(L2:PG':8Q,&U?
K&6_&@>MB3P.*P6>|TV@55W U|PT|HKKU
MYF#|#)N|X"YGP93ZV"N6%YT#IN,#EUP&".R)|7"%FMIG8"V?J.&|H;6_5,1_ M6O|L!G2-
WL:N15FJ\$|O+AJ#AK'D9I^1>E3O?K5Q?T1PA RQ/TV%>&Y,H|
M9P%+=W+;B_NT+9Z.N+|.LHK|H>-BZO6_@"U3|@E6MNK=0X8K
M,|.RZ0%,5;)0FN@I:4B?+=L&P:D+XF>@:1"TS98QAZ_-5,B0:|,P;HA!PO\$8
M)31|>JX*)UY=0;|V W@A_K;,,SHSQR/9;|7=A:/#+N;F?K+S:D//|S|_6+A M?
W:N^O1>.5:&IO)8T3B>;|T/L_ |HZBPM83"^.&OT5CFR+JV B_8HX|QPH|
M|*|DVO"|4FA|V(B=C;_GS UC8H_L+2.C95|^|S|& MK6;_08>Z=D+,8=H&J27\H\$C+Q+

(WR,HJOAA)C)GYA"8>6X0I#^E38Z%^/6,4 MX*%;*^;S#UN+)P<>,M%R'U%!4C?BVT')
C18>%/FNO!-W(V+O1?Y4E%? M>35JW_@18X04G29VY1_B.QR!Y,,
/'1::L207XR/2#Q;QMP+1HTA22C==B##S
M9H.'+9PHFY4+%F%YDONUYIX1RBMX|>V+JTX*|FV|DS=!YO" '4-[M=;LC&J
M!GN50#SV"W^I2(@H*I6T_V-RTR(?_M2(#U2R!Z#&|/+7@_BE%ZQ&%3_+*9I(V(-
+&'9A||JY9"HZ4F_F3/2: M +";ZG%GC&X%/6\$.N?NBF\$N
M@51_P3M|^+R1N6M8SP@L^WC59"\$[AQ^BXP"&N;JRRU:XX|/%53>9POI-!L?<
MC70,TH|LCR?4: ^#3JB?#/YL^Y6OA:NT.JVAN:PW1LU>B.STS5'9G?8'C3I
MP^ZX.1T.V>!_F/AQ6:%(N(?EQA3\$Z(S(DTOUXK3)KQ|N),X;6T"*IX;=<-M_-
JVF""Y^1\|#Q|D>7QZ IW;1L;VXX'XC4)'KVD\A83\)/KPO_WMMT_W M|;-W=NS'&G?
ATTRNT<%D|'*&9'17|SUS M&487T3G!|RU=B_FFNZ(|J
84C"\$W>;8D&>#T9\|C|'^;"G;% M-V-?,<'!%S7B|F M&FP:?
@2&8YFU7^06NSB';X,K@S)3@*BU1\$*MO,>R^WET&XV+JZPZ2NT|
MG'A:I<2G<0M>T>+1PLA6|M.@Q.SFX|/4*P0CU8CW<%P/Y;,@(WM8(LGC^5T|M6:
H(VG!|X1PR+U';!R(?B)@0XOL'V/:WD+P^M"6%+, D,FZ/RZ&+7)B/=|MV)>?U#?
2C|(A:L84+GC!XSTB75;#P48DR:98=BZMV+VEA&PGC.CQOCB_(M:6&#ZGK!<_B.'>==?
_7=-A<^?.(3?)9B-5N>2O?B|I|S#^B'LA1O|E+? =7 M DR^)O?A-%^42)|@|XZ|VO(P>D
BZRG\$SD_ ,|WB|+%F0X<&I 803*O0MCZ!_M<94R_D@_AX"Q0 F_H6%;RCW@? X
O_DCQ!RL>6Q8"?Q9(Q8/Y84;%*)CV|I M0(4|@6&JLZJ? (7(D^&)O?SQ9B/2!|M=H#|N-
M9L7%QUUW#|A|X_WEAW|LR MFOD\$C@L6F>;0I"
I=;%!CS(_;&UI*72;17RQ;+)S>8O6#K@?*TXJ->"&S3=
MC;C!4R2T&P>1Q6P!6V""=)7B7^774NTRNSY-;/'>3N+&E/).9RKJ.WO)J_ =J
M!ON%V>+!T\$)(CIX(*=0PR,2#"P0/%YXP?CU^K-J3)70QE-%(KPACNO3-7|H2
MC/-6ZH.=A<2*89T8'.38Y(CF"JYNCP0F761RY;KP/<+!(VL;:2 H_+NS<4B M-
V+EHVVJ#C6T6T;Z1Y?(3KM5 M;B5)>TH>=1PR7!4\$5HJB1*E7X&=P&#!6B-
M@WUGUK0(.WQ@M(I8E+HB?W2=9W|&+ FL"ZN":R#V0=M(,#,7#)>(EC9=\$I#6
M@JL#M!FHQ/7M%)U?K9P M*OD76+^F,+EV_5.||J_10|ZX1=X7T2=
@6,WTT""QVO4)5BSK811V=RY^R|
MK"CI>=,U4HV7%G#FBGISI@>%O#=\$GE\$!&|G)HDE)G_|+!|
(R3_ ^V_@_"#AG>&4FHM7B!HY<<"\$P&RK4L:17) M_ ^, _7"=XG:\$Z|7GF8.@\$I
_,0%=9)L9L;DR?(L|&W2\|L8D|NYJ6%|N M6H6_19XE"Q#
(8%8:B(DH9V\$92E'TN)X!+U@+.,>FO#O7*Y&G_< M@%-T-
Y6+_@0VE+|Z"!/B^_N4@2G=9@_"T+| MM=!3Y9\$-ZY/5A3I@-;C(J)IT
'GEU\$!'8K&/EM11;17Y'G!_)A|JO*C,*S MB'GOGLWN5@C?:%
(A=Q;OY0YC5^A|F|P+'LOJ_';X: (+TXW>|##FSBV?%/I M;Q9>/G=)
<_.QL#@L3_ ^8LQHGS8H08'N0|IL!UJ|)&E/CJ8|3EY4M_!7|XSGVQD
M58FX,C|&+ /RH=:U9B&=05&4|7+K"%G^TWI!9'A.E\$X("Q+)D5(W5;_E_Q=S M;/92?
I3Z;8C'1@_ID|O""*&, %MW7K^OJ*^)WNP.XFXW^@5TB+&/*;F@0>D3@ MP|I%QM2-
B\$=;L#|2G""QT/OKX SBXA=L'%I8NAE54R?%F|AI:%1"QA-0U(&+
M#+O"/8=AOGH,L8U)&^HH9ITA'2 'Z' G8RUTPCB\$#Y.+UV:XY|8H@42EFN1
MG4(\$BB'D54DHB=)5\$2@65"3IKW*7#NPN5<#PH_67B025!L?G'K2P+_2F!F?%
M>P>#E|. R=@-S># =W,M64T|;3)^= _0N7XY|G>96JU<_O;N;4O>2S%.4NM
M=AYZ*1+2VS|4I#>YQPZ(C@T.8?E|O_-U;XRWT6#3W54O)>=|ZXJX|6|IOE
MSSSDQZ6^\$34)?MJK48J??"^|ZP3+?9)2F|K"|O3_6CB\$NK|Y*567IU\$+
M.^W|#E|X@D^!|H5-|<%&^W&=!TX=;/&*VA! KI8&(LS+S>UPE%B SO8
&=RQC1!=GOY."?),=V K->%1X&7-K&XMUB4 M5U5L>|Q;JCZVEO)4)5G52K/R@3&
<64.D",G3%C\$T^ M4F=69-YX;_ /NA5#_JKVD(+AW8N!6-
@|*|HDL%S.9+/QXCT.4UH&)'U01+ #L M;DPY_V^R%3#(QQL>AOVZ-B)S;:=2UJQTBZ-
6)*|T|^XJH9^OAR1K^*SWT'2 MY-VN&HUDS6_E2(X6"@_AZAN&Y|_5-0DE3-
*=U1_.|CV3TD@'\$9C*CF2BK|C M:1Y8NY6.02EI/#OE"|Z(T!'B;I"5DTA|UQ>NJ/-
_1,>AVS*WB6|(!_S:3-K MN4,/OV9K_ ;R'E_-0V^U4#S4'T-(EU
MF/YHS02|_K#|T=H=/69PSOW1-K0S1MC2R|0QKMH7GQ9A58WWRM1X#X|;|YG
M+I+|H:VW^.(?XOLE5R-^"04/=9_#|N58CWX_JC?UW\$Q|. 7|A=7'KZ)5'FQ
ML%I#!;*VKO9"[P,|@=|)/2-H6#KU(F3<9+Z-YRK91Q=V33ZJ5F
MU:3'78.3T29YQ)AXN#EI\$;/_+^|LW4T_6AYH*_.F0L|;&23YB+\$'42MR)|5: MWOKK-
G8MZV3EV&+Q+!7-V;VTO+EAANG61M>7MP<55=V-M^37Z|_QZ4V+5Q%B*
M+GG!2K0QB@@??40I2C;>)&3KX@|B|N^PEB^.Y|TMY,=SGQ%.#1ML MZ-
W!0|H|)J^**D5 ;3L3J7E>EBRGVBW.)58>#NSNVT1E<)>G^I6QP&^|HHW12

M2<;DY,L#>H)"X8:0C/'6PL[,Y#I8\$-M^&'H5%!GIY'6(\$0-?CMWW71MQXT8
M5|A%I(SFX-I2N:SI4Q&M+J|H;Q6FLZ*(A'V0LL,LY342|*DH+&_-BM>N^5
M#K<:3K.^HK9|'!6U'?F XRC;|-4|_78Q990->K05K|HV3ZMLW.(0\$AT)I|R M^>PJ.&^H?
R=LPT04D^5|C3/&9*V;O.G!\$@;OF34IM-,CIKL#3I;2Q*4+@N18X=)F_42\$CMM,2G&(%
|@9;N>8D9@VA4?-JL^39FYF3#_MS4|=5=|*#R*5T2..M)AP5YS|1;Z;Q*8%#|
|'IL<')7XT9;|@N?|3<1-1<.4*N M; &W/E:=4)D5YU=;
|4E:K'AT <, #L\$1)_ ^Z154LY2P\$TM,U.44B2|20/0ILOU M16_I9H:POZ_O:W+^XY-
(|U:@5/E(U8^X@|V9K\$PA4XG':902M|P48ZT5>I\$ MO/H2F4
D2MYO2*!=!)^EL\$|Q\$VAH^28"=#N1_%HG.K;-N2L8@?|*HMDVK=BZMN/1F5^,U8
MFA:ES' ",=2,F4GE|VE-5//G\$0MWXO*EN3N|-1Z>Q- @#&8#6'^;FJ.4=7|D
MWMBUEAR@ (9?4|VG<;H5:(N,GRK(X
M,M8L"+^5|RQ^QS"M; '<>F#87G+DO%+\$=FV8CF(^/+GO\$?2|QZI&UQ.)F>AU' MV>
<^@ S,%_%ERNZ...;BHZ@0RKW!(>B'#!?M3U4<;J)_ 7*ICJ= "CL+)H|DR8 M73P4X_@\$?
6NMH)=Y|\$BMA"CXS!*O#HD(I2A(. \$2DK\$V2QYE_!;E|O_-7*8\$?:O 'Y'16S+(C)>T(C_\$F
Q'Y|COQH%&&!A|+,Y|M|;N/B:HM!MCH8\$"MJ%AY5RL8+ M:S6XV@|PLW60|12-
^R= |PU_|74XO#W&300KI*AEQ@JDLI-#V|\$|5S\$OL=H MKF|KXFK31+>PA!8O-
C)_*JR& HFJRKSUF0|6EY;)&V_,1|=-G)W*?1AM,8 M;
((2;P,8PP=:W=;0'+9|HT9O9':ZYLCL#MN#9G_8'3>GPR\$;_&^K 3Y:4E *
M'!)Z^4/(\$F67)S:V\$9!->/MQ)2+8V(55(2';J63)RO8^5A0A'0|IV\$-#X)|& MXVG|,|R?3F)N
OP,GP6.E|E\$W>2"TWCU^|W=QS|OOWR).U01F|NUO/OOC\$T" M&ZA-
+C1E>=V4Y763R|N L?&MK*.\$32#5SJN63W#,)QE?'(,7S&'|!#>%4'6
MYY.1C)8OIQ)E_H(MF/AI9XT|H(H35*\$|RND1=7-Q7+\$\$7MV2#4.-'O"Q3'WH
M|>K|=-J|0^."PWFSG R)F_|S;3G_|J:OI6@M
M&EQ=O<@H02Z|1IG&0U2D4B2I; &B,E)=2CFF0B\$PAP\$)9 M-F\$=RZ=>HXT,6(-
WM335;:5C+|O)48EZ2C5O^>J!DA82MLR'OV5) M+EG_DU8VWFNESP|'^; %>!?
C8)TXDA|!^UE)&N| IUA5YE(D|MK1X-.K8VJ_|J M=0KSJUZFIO?US997-8&..)SRV7'AGW(;
@*YD5YM <,,X9A5M&7_:(LXZQMOMU_A2K|J|KYK*)2HTK+*M1@N)/4L,#3-G
0V5"&5XR:0 M+5779OH8EH0^"O(52ZV;I" E|7U|PCU:J)2|!?)YBQOJ"7=%K/0;'&J9U8;@
MK_%VN XU+^P-|<+.W9JVS#U; &=J:Q+VL+|W/BKO)54\$5VJ".Q2YM0B.URX* M\$O":
<+S7#W" _8+#|1=8;;;+790V!|MHVK@90|Q>S6_LU&RZ?J*XLZ0XEZ\$WC#%
MG_1L2D1O+Q3EY(9"^1#!83CZ&'>|W.-Z,^KZFS(Z9B3X_.AXF@1?;N&!C,1F M9T?
#2_2+;|-13YP N|_)+52="0H|H'(+C'P:97"@9,D0N1N' M5/Q;|6|N_MTPFW97_AT0DJ/9+
|B03|6_%?|6_)LOM*E |L7>|;5V^S2T;_HT M;GH;?N;|Z=&9TR|
(&G(66\$TTL04#82P3778>1IG" \$>^(XR5?FN|88?A|. M;J@;GQW7F 8NS8R8,-^T;*)F>
(P9-,&Z7;89)&I\$C3:V#1H**2K,'(AGL&&X)6B|SE07ZZ)"EDCYM+#"VRB+2<><=AF
MYMR@=7\$U&":#\$+*M&'24(B(VYR|RZVFR6SJA?^:@V.N/6-
INDHFC"0_NNHV|TC6K1C+0%W)N=J@|G#>*PT>9.9Z) M*1?
(9RC_#>#*ZZ5KV2A"D)SFS,09*01%&@F))#3'<7)35PU|LZ8@>29_L|HC
M|KFF2Y!"0#MFY,7LE^7Y=:0<|Y|98>|G^U% (=W89PN=-N_F.E&P|V*|?1)
M,X^B&X<@F48/<+X|K-O089;(%S'N_9TF# M_X!_*40;Y4O@BS@F\$J?
W+&ED(WR6/O.U(|=-!'QR-R86OI>+;(:Y^;8=1A< M@#/G\$YM\$4U<25F-
?;FHLES;C2Z.Y0|9(-J'.5RCUX%)G_8W>52MS M|VG)|4C3M3C|;FJN" UFCW/%GH26@
M# A:JO@.1XN-"&|-J-9(M+4FI\$VCM|RB%G|FCL3D|^02YP-\$("QTH*RB>SB527 M;?UDL-
_!@M9.'XXK34YHS7^6'P@.F+^-/U\$@I^A|?;L:V)M:\$WB?.F_\$7 MYUT9^X5#Z23Y1-
XN*2+W<<'&:-+(.L5_TSD_*MSE*#R23_AC-|DS23QJ9RQO(X#(-(|@*!X72=< P8| YMPMI
MTZE1M!GV7%3 !"A<3(-3/|@:P+1L >M|=)UG%+&;QLR|!P^QY!YY?XOEH'O M?6,#K.
(7| #O|/M1|VA=7|7H2J_(:'9@:9TTB%OYJ\$26:3 G|)B6.X E!
MVB%|),2 (&@@4*ZS>=0B)5*5>^AG00"802|= *-B3Z2Z4/B!=8&WEF%;!2X
M=>//F66S"-N.F&T!H_QA^&T5 |U!+T,Y@4Z/A|SH+&"^);0'|9L!'0Z:F
MI>&WGRSV3\$=H2KF"@20+9|HO0%C(&8IP|C_92G|730PCYK-8R9J1LB?";S7# M=F
YQ"@N;:FYW/C0J7IRF'@_C:1^H1S>1RZ^FHTV\$ M/BK?^N1|Z^YK^~9H*W3/+I"?
>N=MK;|:STHOK?>?|6Y?&M\$3#?JW<.YUV:.*
MAYW;P2ZLO>*PD=X^+Y>"14\$Y^P2DB&TNW|1M7|V+&1U6T-SV.Z-&KV1V>F:(L|L:
^;_6%WW)P.AVSPOZT&2,57RW3N M@*D3_'2YEJ&:L-WA3F??VC3&G V>2?_S>2HD|&
(;-2|19T RC/D3:%S_#9S(0HDND3#=@%U=W#_X M|..X ?
9P->WWVP|?/MW7C&^?A+8@F_?;0MI38U;\$-0ZE)P\$|89#M,VEQ|D)OIR7'9VL!1T%?
>F|>+P0MRE->B% M_->A%*DWN"01A9|BS>+7=?C5WY,|_3JG68G|5>-
>C/UYUF/:C;KG7X|UZ.R M?JYMH|^D6M1!%|5?^Z@-9<3E|(2<4\$G\$)&NKA//MC9LU+|.

IP5;^Y/^>;B M-2P*:/CBS5E.3:9VA=@_WM^2:MPNX,"1H+
EE+ML@;\$2LK^SK_B4/TA@8U
M9TQK6AE'V6_R6C.HJ@O-J5OS"-I11ZIZ" BRO6ESN)G:7J^!B6_YCG85KH[W
M;@N=O4MDO=%/@&V8 M=^Q2EN<:3ZT#1-H6CX).MX. 3M<0+IEQ:-&||C2Z[P'=JY-T?
_S3 M<\$MNH0<>|)FYHIC467@S:|E;5;BY)6EIB3|+4&^|L*'|T.17:"A?KZC4O-)
MLPU@KIV6;;Z^9<.! =AUL|/#_1KYJ\6TY+<7=ZRF\$I#B^NNNT"9J=4U',JPBC5
MM.HU&D HG;U-JW)-<3X"T^J|ZV!-8@&6U0F&0#LO:EGU&DUMLEA(Z!;R;+C
MG=.03Y9MF%&;V38:13
4>PDA[X<;BG@R+*=.ZK2XXX|)E1MJD56+D/SS#K'G5;"*4W^"W@|L4G40KGI5
MK.K%A=R&V6B|F%08>R|J D8532B91;4|O>2PJ#!P7<#@Z(IX3D769!A4 Y T
M01\$T10:BRFU//3B^:2?J|X7^#@07&#WZ2SG@#0HZG1.1WQM&#I4<%*OUZ!1 M@(.4-
;B;OUC0A984^U,Q<|7,N0S9W;EY>S.VV;BX&O8+& =<|6|%NZ?-NR_#
MNNE>1!.3>9TD\N'H|&R>B7|%W_ PJUX?T2.M&F9L?-0Y|Z8HY;+.LF%&>PO?
MOFJ8<8HU|U7#C*IA1M4PHVJ8437,**?H.!\41|4PHUI902L|'|QXU3 C%=HT
M>%EH4|-5->\$GNU. SER=HC1|G5. M LQ?,<,Q,<-
+|4)&\$JQ|<=4N#&Q2IN*\$DEOH5<.,;\$.||*=[7K-7M4PXS6D M66?O5G#YL'7-
/F^8L7>EB"?=K7CW+'CW95@WW8MH8|>:PH8GEJL-
M1BR>EMT60W_-7X'G6|,5_Y&UF+"%_Z|5*;YUQF;,,,5K3@WV:AD6'C.>3<_X
M6R|O4Z>:VV^?|\$|%-|2UWTSCED)%-\$S\$SR7\$@!AR!#7^IY5M?KYCU-<+U8?%-
M.YEL"M=G+B;YUM@O?(TX43>E@|Q<(HK;!CB:QM3"|_)PL,&)"<&|FG@+"J: M-
71XRP: ^+_A;JV:XS%LR>.03LU=U8WW.|Z9^_&,30*.,=,U\$N5SX)?@|4C +OQ/OY
|2:X'WKN^4 MZ0S+UGZE6E2UJ#(OJCTHJ\$T4+*JW?G 'T&=HN\8&;SZB^
1M9BVDMO,2CF&^ M+9:OW1!HX>Z+=!Z=8?9LOEYM3?"COTD@>*<'(
MW@L"C94W"YK:"6O+7/-Y|C3S;?YTXI5|=-Q.QA6^P7,?GIG|Q+|'"2V:I@:DN
M!G|V|JKGNJY70M=4C%8QVH\$8|7^8Z3X|.VG|A>BT5E%SH"O^*@FE5?SU\OPU
M<5A):*WBL! ?GL,|X*8Q&(+&D5-D*L8K"2D5C'8RS,8 M?#:-P8:
(*:GXJ^*OBK|VYJ|KC*BN8;). ZMDBZHTJ|BL)/16<=F.7#;V;7|-
MBR%7C6.H90KZ4|A/\$|.%.K6YK: |;O5&C-S(|77-D M=H?M0;_|{(Z;T^&0#?ZWA7U1-
|T4D|NX1%YZUVK5NY+%;!'KRDO|L@|2;|+A M3J35VI2=(0!EKV|P>TO^F0|2|X-
YOAN, <"%S5XO)C|8A|\$CPL|R+>9|M+RQ
M|7B!FP)|P\X|<>A;IY6\$OOWX=/_PXX^;AS|^W'|W;BYNW^XWPG>QI^=|L;6
M.M#;1ASLNHL|+|VL^O.#1^>B+__&^~P)\$WSAP6LS*L^=)F U^
MRE57QHPQ<)%I+0QGR5S>&*IF "O-C(DS1T0A,)B|(O2DA0G&!7T&?U8W"N U
MKG|X@U39QOX!ASZD^E:#OS5), E_&@:>8VU&-L!LD@-,8WP=2H?A%|@N>#C
M|*UP5R0:X\$OP\$|E;.+5@:LK7Z@|UQ0*M?^~O9LR LWV"R^I'/3=7N*?C9W*M>
;4Q.A5!%OE,\$|XU|CTX,?/F"B&12|VT|5,&S^_>&3RX|X85ALY.N/9@ONQ MX\$!'
9P3|^!DQ_!;KVV|@MMV5HQ=NIP+XRN|37ETD);G&TL7M(4+%(E|QBV M9UB,F?
@0/R_/;\$<\$*PAIN-XQT1)|VGVROK#XI>L|61...67BY;@EQYB93|P8
M,0:|MWAR;+@#_B|8Y-Q:T.+P'9-@:0.1^=>L%XMG;#L\$WVK|!;TA;@A)PQ|PQ^)OGN>;
M+5HB'362|0+^,0U?O,1E(?W0M|AX(|Z"MS-SCFRJZ"*DMGKF9)TC\$C@?
Q:A|C,WG0H#PXP4U1:QC^8:0-Y>>R1"VA.@>|2<>D0@L5X|4DR430 MQ-
7_';E_O|KQO5*0%P*VKT"|WHU|9P3G\$R+W45@ZP(C4/YI5_:?_S%H-?OO
MX|= %A!;|V|\$SGUN^P,B;| G|&S(PT|6"Z=,5WL.O/Z-4!|IQ0O; '%:&R1=DT M95B,\$/LZ_%*
()#"/|5JO((H%|Y|=|V?=-,IL'V/BAFBK|'O2)%BF"|JV*E- M1KI4"63:@00"'?
8,/L&\$|7J(S226AY*R*>*(B0N5=PHA>;F&3)1T,-SJ1#R
M^@BH80E*!|>57H!ZRW39E'9<6X24Z/&=85|?@-P!RQ>XY&|ZW>\$:TOMD6T*U
MH35=-H75^*),MJ0K7-.0TL"=BK(0L:P6=4GU!6A;1H0*'^+7*/V,7ITOIU M.,F<-
GO|+7@*BG0:UAF%-H><64+1M%,LT;@;|=| MV%%K?|<\$*#XR"Y'8 'JO"3HXS03?
C97'GKENK\$#ED|T"..|S|Z%3>Y=*_/X MRB2,Z\$A_|DBJ>|6V&<^,U,480RND+:AYG=1.,, #
(388'CLZ!) "Z'C/ 57QWDF Y5K<| #7*!'! MR/43?C6G#=
U_HK|@O@#NG:7@;4H*O*XCG^WNX_Q6DI9KO@H*@N|PWJW7U!E
M86D'NY=P4;W6^D/?L@HL%6'?|XGQ/XSUQ*8#C, ^1?S:/+C|/68LEZ|*|J#K M2<_2Q/(?
FR92;YWX*#?MH0&R37NW06?DGLQQM:OCRG-H'7K5=&^*0W"8 MF=X;R.'E#J:SBX
MNN/S29SDEB16'>4!B;*@=J|'0\$#;_)F2B|03-'L-+STQ MS-(1SF?=\$/7M:5'?
HQV&4Y'D49'DKHW5DI#4-='6Y\$?P;^G8>3Z%U?ML@P.
MKEB@8H'M^O85R@*#BZN|R_3*.-:HU 2|O466!9PB3S/3)ZB&5&R8@?H!H/^
MP:E20JN9QA5#?9IV-0#GA,AC@S&Q%7ETL6RE+%~Q*)X046|'7E@7^&24,"&
%Q>3"9K'!2<6E3Q9"!S984-5L5Z-*0CH)(NEQGL%U503HPI

MENK>|P|:GS/R/41VPASGG>R= M,:|PF!6Q'Y|8VWL3>^ B:O^^G!6Q5!1^<&+O|"_9^P5
H)S+4=3X|.*I= /66K|N'Y333)DXZ%/.%4;Y%' MKNZ500'O7'Q*N8#C(/KOYHK&H)X9FNS-
SF2?D/CR M!#|;H0!TLA|>"53F)#\$A"(X&%E)JP4TV[1\$WKIAU78;C#'DVYI40N5&\$1
M9F&|5(M:UXVUK9V1.PYSG7M9|UQ>4B.5C=UM =-#|>E9;|BIWWWZ_?/CTXZMQ|^'+
|>_7#|=-WW^Z-ZV|?C?M_W/UXX+_Z M,?^|6>-X4YW|Q=;CM&7PUT3*B+!0*H'23?
=M((-> M!64)V&|Y-&O=E|,|A?9KI"E <;V2\$W+/%I8#UAT;|RZ#|/<(?EF|,^501:TV|
MLJAV';OV GF17B+L;@-1"JM'/#Y6/9:CN539Y4T>\$ SVG;@Q5,YY^?#9=MX MTZ|WNH/?
TO39-KIHEPA<^<(GG|G(#4QWA=L>+%+'KJA8CHO9C0V+F(OLAX.O& M7&+KV2_,|
A=Z!1>&+R|/|L'Y|Q;|_'+B^)?B>6E!*AR+4NLTRE*[41%3 ML<34>E%B:A\$Q-
ML/_!GAS|B0J7(V&PU=GXU-^<)S8?,1=%>K_RJ0\HTM<#.O)X05/K%YM<_INY
M3HJDI|RCI41(7J)*D8@EI/6|OVG0!|=.@411(J'1@V?*'JG"|A!@R/9V\$6#M;8 M30*VN_P|1D?
BOP)|5=B.S|@LS"HZ2X72".\$/>W+_:=I!ZDPPEXA
M(J+R'DI)AL*OG.02;|,9)"H'2N28HO=MWRJEOU=K_|F|\$"UTG5*2I,4^CB
M>@F81=KJ4K"WF-^<^;=-3,'8C,%3P_1=7;YIOM;HG(83|M5TOLJJWEH0;>A
M.64.03>XN!H.VB4QF2LR*99,-K2IS\$ \$FPXNK86G2VN=0?|^N-UO==.=J>#;,
ME9ZE*637E>6<+BEZ&UJ6;B|H!MCCNUL6R|DBDV+)9 LTU99DTBP3F9Q#U2^X
M*AG1NG;C;')\$UTO7L@O;22FH%T4E;3+ M1"45F*Y,"RPA\$CIWRD8-M%SC AO?
M5DD|BHI:Bj66;M'4T@5JV7|&|7'YGGZ^5WMOZNO^M"W-
@.?!F\$P\$S#%LQZ?.41.X.L/RO !;-!H0|@*,RPKPW3_|JB|+;_8^5AQ MD%
<8%+Z"X<55)YGG?_WFK!7M%DR|6^!#MI?%L_4JH39LE,7\$K(BI6&)JOB@QX73DVJ!3
MEN')Y|7^L(|YU!8RK_2UFBWP(4X4P-|.3KD.QOK"?+O5*SFHXS|,^X>
ML|.S1^/XQ8"6^1S;C@%I;%T!UBZJ)X.I9YN6M%2WD%2N6D)JX#;|0_2/8\$)
M4J^H|/|+41.VP0:TDM\$K9?(9-WZG&H%1C4 I1D,@DV+&K8%NY1|9RMW_DDU,J
M3JXXN32V9,='P.#8U)'X;|PB1#-+; M#XF9XF/3=5>(H7Q"N#(?&F-Y5-
8.M|MPYM:"Y@M3HN_9Y\$48OF-;1R")5QH M>!90!|QL(ORD)?P?ZW
M?/&IUOKXU#WP&G_JL2@RS(+>^(-MVT%E|9&Z8Q-2T;=N!DRYM^4+##H|
(|&+ZAC/F8T\$E64TM?+FQ8J9K ML,6\$3;*=.|>GKB.Q1^UCA"#.D3J<0XAWLQSN&&|
|'K,8Y4&)S^)Z M#B= DR61Y_H25T?'>)QX70|XIKX"=6,"?WJXG5M4A\$S8|Q|L21%XP|
M|H|/F*O#),_JD9OPEYLK<;|^-)/H0|WW;VO&|P:SY#@GZP)|Q*LSG6C^@P-MQ'
MW!B(2M/P\$TUK;_!3-ZN|(2TY;95AA0H':W"Y>+Y:"O!Y=K,AP508USQ-M(AH+|DP"%XD?
4)8W;BV;3D>3&T_UN4RXX_Z?1TT*XQBHC_E.Z|?.\$7;X#%^MH_C0S-T8R)N!%V-&%3;
|!|OA>AL/T@';18)\$MH)2U!OSK2\$0-+1X8REFS7+U-M:LK\$/MXH\$01*R).O?
P;'PA|"'_B6 +|K^&RB MW4J25NEE;T9OM57#<^>63X^;MB2P^5YL @|9
CUV^VNFTY5/9N3JT:M^(:Z MD4/ 71R|8+Q=&'KGSU8M2<,&C6TB70KZ0FD/^%
|=Z!MO-*EQ3X0R"S|CI466 MHJD9R|!%L!;2FA" R?>_L=X2L0C>M^"RV2|A|1*B32>)-
U+EN7Q@N.\$\$/@CT
MQ23ZS5!FO.44;,\$+G9\$/M@M|)Z>M%"G+N_WV^1#)O&%H00W!@JIG3G8="4/* M?
(03AU \$ #>%S<+;/|D.8\$'6D|_Y%1Q MK-VE?EMHO+KT&<<@(|(?=CRF?X9+/5RY_L692;
(5Z1.6"0(=37R#6VXU'#.9 M("GJBH_#^)DB:<%6S51G,!)H5?"|P-
<1@|"&K4#T\$;B@?"SQ2,^B@S23-J MJP.62I)'9POR".LV/YB@W>_A;W)W>*?
IFNAW_<#%M7 M%5Z_M*+OX,+%)=&6-V""S?>2)%W|_E':!,1H>0^S-|+*8|P1820C/M (LE
M|?ZKT4@;22-U(U=:WP:OOH8%N_%&#YOI3.Q6BVF30S.1&(V9GX"&|!":<)
MO&C;XL;3F^NWX#R#_\$77&KZ%@Z\$UBZ)5\$U8%Z=4/G+F&39#1\$Y#O(&0=5VH0
M|3IX;O:N,-?MW0H5@A=V3Z|?=>BW\$HXN_SWUQ5=?E,N4'AVP4+Z=M\$&
MP!&SBG|P#7^O|"D"%3\$<(&I2'R_895,EH\$A;H_%M39%\$O "L*GGF-?J><+;"
M!|WYV#N>+KR3K&\$3|'<):<1HWWF-'4'D3OYA_=T|(E10/Z QS0Q7@&,O|F &>#="UJ"5
MQ#_M?S"J(|)%7#*UJ1'K)30%@F+,4TYU|9IYV8CHIX?LN-0&#|.*L:??>+? M):H?
6X|Q#5S*T|5\$P(^X53T|LL+#H4AR:"&DIBY\$!:"&YHP&S21LJ/-"9H' MP!
(BYOR(|,0&F|<#&"9|#5A+)JV09OG<13V?_@N>C||*XP73/ECXG2;E%7_9OT-UL9Z4-M^?
%DC#>1S;FNVP.,QE0 M+=|UHV:QG3<\$7#>^:X8Q?B+YC%H6(RQ\$EC=?C':PYU"|7,B3?
F-X<=7+'(8P
M3T1HP2D&^ET"18:QVJPT&%GU.)62*YJH!!2_^H*_DK=01|L_^BO*LYD|J&J;
M|J6AM"Q<&+9-NC1%|F0|B)4J^S\$ZQM\$&^<^H>|KZX
MW68#>X.FNO@83K3\$WC!>L|>VNMMD%0K=5A-#3VG;>B_3BZ0 A52-79TW;VT;
M(QJ86B6<,GQR(7?|!#=:H6N/\$U:76/:50"BG8"Q=+\$Y6O&&*^|JQLB=
M9PMBT2V@OLA,TYI4|Y3%UQ*E|,&0054&I+#!|/NV_RY^9?^?7,JUMI*|Z7>Y
MCBVOE**BJ91?*Q2P"+%K(|B_PT"+Q*%P'>R?|5R/57PM5)%?&4I7P4U?
M'1%KBMV"340*PU0Q3^|2MOG7DBT!|HYA@LW*-&KI818F/S+CF"NDUH|QCT>

MNX&P (/TK0FH13C\;-%-BAH@S'=[IV"5;X^1"P,4(G_BUJMR\G 7SPWBS M1#F
06W('HS*D.' =6.?PU\$A\$#42?
M*7U;L%/JQG4:)H5(4)@K""=\$2\$;IQ\$!6POK@22!,"%ID#0G03)BGXC#>@KTF
MF5@<[N=L3C@GR#@=\$1Y&?F1:-@5-Q^82?A.1'IDL &0LW3CX38!1VQ\$74*\$Q
MIU"L>,GZ.I-0J37WG4Y:27MX9N8TA;>H.@P5!^\$N?D@#_A&G-4U6:DY@00I
M9C<#N&!(S) L.%@\$/IPU=OG)=3,"\$[S'421LD2_|ONZF_%V:?)'I3QC^32P>
MR0:WPO[6\$LOI8%+%C\$!3?V6/N-R: ?XN"66R#NAGYWD7 F?PQ IV)=/W""=
MPLLXLC,G"*G@OC#|9L9 /V,|H56::^3VH99|1 =T&MCV2EACL|LNW\$W|V2-8 MOZ
0&3H'FX"%U0[X3K0?P9\CJ|-C\$>^/CB,CT1+6/CSTY@BY87SY;'N(/.:8;XB ?@MR_2*
(WV\$R,Y MA5KE|+4X6!W;1_5'%U># M%,S5EJHN=|
R'_BO4)'5:@@:31%9J33*5OE5B;R93>1|Z&5O8G168.JP&5',M3_5.K5<
M3/A+#+;S00T.GWLC4XH,7T.*HI2/>Z":UGJC'S5+K6^=#ARFI3M;&L7J=0M_] *V86V-
*CGHDZHZ5 @,L^*/;('2& |173H\ M:Q7 W|P<==,E#DJ(V;|I9S||2<2KGMEJ'C|Z4-
@TU'ZKG3|F|E"V6#ZD?|%" MHB,(P'AY3:KH9E.%,EZR|94*
MU:RAFH<5JGG|"6G6K<96Q%#7P2,6RL<"3^OL6_4-8LMFIG4|/)1UNS8I6%Q| MT>
50XXM3#5!UM;EKVXSNA%=4:*Y1Y:GYKAJ;"8#41C5G;GUG9G-R,9ILU3
M/B6|,1Q7|,P'&Y3B;0SL%,R73|H7.Z|;-*M|E0D|U\$)2ZG5|I-V)"!7X0
M+56D'@P);+B>GD@\$.D37!ET|1');X2KBYJY|^Y&;NVH;IQF&#+<7M>;Y?'D* MB,%'"K?
D7YZ7AMF|M(7YKAEDXF3H3.|&OI,OV*B=*^B\$#%-;7LJ^IM@TH\$(O MK<|J?
IT:54V(1:C=\$!@ (XC;'-O@27-SC/S|0#L8T_F2V3QM%EM
#|R.#1DW>^!.YXA!OQ&/X>3R/G|S2X89|"P|B>|,|S7&|?Y:7R?F>|<&IO&
MER|WQIN%|VS6DZPC8FR=? 70;LY%|HJ?J%<'2W,TYX+-U&(AH77=(|4B00? #DH7B
M*K@,G#H!25FLC_.4JM:E#J+_12|UH;;GYH3ISPZ|!5""-3T?PUK\$=G,4^#2
MD)GRDQ8""8|8O\$3_?/,4?|Sj54|0?SH-LODT\$SL|(G4T\$B|QAEGV8*2644!C M-
A5*|)#)\$K'X!WN+= \$4>|94|H"!&.>.\$U5ORWHM(" ?_GLN#^I*Q?W5(P%JNKZ
MA@*:1%06|8Q-P,JFW|EM2Y_G=3O;WR|+Y SSB@^V,?X;_U^<;2W L;_V MQ<_P!0R8=
(F.)SC|%U?A8S.GV=1\$7PDR'*)'DC^O4/#,^WX|8^:|E#"UU%D|
M>C0)+VX:D/FJU<>2|_ \$N7HP4)7WXG3AB;A&IHX=C+@OOK^4#QTS=4|:T&/HB^|)%WL
MK&+VAWBO",#686E_3_Z|W:VW6NW47S7JS=^R6^3+9<,|LER?VFI9_7IKT-JT
MJBW_WAX,|Y9M37A.;_5VC!=J!2SL@>4>5IKD_&IMAJY M9V.T-X5F|Q(#7(N4??D.C&
<%RW5D8(YWMSBA+2^>| ^?XY;WYPSIL? MGNWF'S!'2W"?|ST""+P=V?
T+3:9|U<%-63YZ/EJWOPAC89-AWJ>\$|3R;?YT
M9H1%0CWMW4:\$_9""*#RM5|KMXAN|Y>&9V4_L*|;C2PT,=
<|EGF|%=177%2U^Q7;D(L&*|K#=#S&5I=1;M?L5X%>-5C'

7'5|E4JL6*|B MO>)|9|QH#S6NXX|XN!H,DKWS*NZKN.|N""^<-N.^6XEXNX&F^,O_)
9|YJ@ MG2;XA;7A\$;B&E*KY.Z"*5%0M#&)7%E1=[A*"D6_<>EAH,T:0LN>? HJ6=F7)
M78UI5Z;G.6.+VKNH0H+(\$3)8W/"E%_>2QHB|J|"2S6%CH+^,Y;A<..U*|AA9@8
MX,T'BIN\C: L*DPH<=-U5_APU<>7EZ_R:<(3V 35S-J_K|-AM;_IG:9Q/M2
MQUO|"H|(\$%3AAE9CS/!8V:8|,>1R9-KW=FS'FBI'|J>MRF6QJCT,DGT2MEFU-
M\$UL,DW_P8V#IQQE.)7L6+,*5 M^)|B!35NOCB+FS|_ O"E'>Y=ZM**P74!'O#D\$;9
M1\$&YY|&L/YOHT 4U|H|D<=KF.Q=7S?8:3'FNM6WH;IAW;5VPJPNDJOX^|M)
M4|V+J_X&DDH95>5ILZJB=":G'0ER;|7|)02*<7Z7M<>>:%;WYA-/CL)|R-QK
MND\$A5+NU^X0M;E>=K1NQ(DT>|Y#"B#%|H".CE3GH"D@J|%"
M*RIJ|^\$+%I4@: 7O4|>VJ>9%V1|H%>|4%8Q%>.*|. \$IN|7*TD3O!(>+T22& M|P_WO
OC";#YTC)QZV="U&9TP<.&UP#R*E^6|K^,^_@*_18!F#_V""YF>_
MQHSF4'GOMN8&X:)|AIQORTEU|"]|A:##=Z)Q#26H)X? M=ZO>C|Q;:D6J2|_34|/R_+NH
(WO?2IL2_.;Z?1!3:>|/1(%HJ+TSL,G9)/ M87?QZ5|!|(9L1)"ZC|&&?3!ZA#+5/6-BN<-P-
XS9A/3;|7'V(X 1|CH?3 4 MYRF&2Q_>+J>5:U*!-QKBQ%|3;@.6(=-PQE78;B+Z;#/6?
&-5XSTD<-:8F&#- MO_7H|<*N9ROYB|K'LSUV_FG@|O,)C\$<_)?
6FTGI6<*DA.>=)84CZN>|T:A|-\$#1FL^J3'A7X|6ED3BA^';Z|;_%*=L
MYJ&X)%5SV=:R_5#O*|F\$|)|85X8+LUKW/0/(DM%_D(%%|[W9,21!D*K
MICN1L*,0(%PRH>) ?:\$_M6Y|TCI@1#9BX?? X(%1MI?:6VNLBWL#.7-
0'AZ|Y'WD5MMBRTH M;|&EV'MP^|&(HHIDYCYBPSI< E9U|WYJ;YD8.G|)|@R75U|'6F<-
)9L4;-'HZ*R<.G|_|>MNS8GCBQKHW|)%0:SU1D^\$S2")JWL?(MQN|RSOMZ>
|3|L|Z^Q|.P041C-"8G2Q
MV^O7G|PJ20@D@81*4(B:#ST8=*G*>C(K,RLONSDK|^@1"+3\$(I=L|1U_R>&K M-
1_%2,CFI^0Y5Y;:L-XV|UD.<_D6P\$@/IX&|E:X(X9F9LV M.^H.*ZG>)<|IV?5A0=7();--

J%_J1>8B9?C+?0U3,CE/>4*;T*7330DIGY3 MV/YV>_N-S=[TDAN@N<2*DHA=:@(:^VQ?
D5!Y!>;6\$!5E7-),/(6-)L#>X>O-M*V4&O,/*4=%IW\$,YWX?
X_KC\$<*A>%=*N*J8/14R=JY'H!:(Q!+EL>W#.H6C M%E],H49]"9M-9>KFC?<50>-
E4<6M27'E.&PMETMSW5X7ULUHGA1W&86TH)
M0NB\$ZE8LMD*U*ZG!O4_&=EPQU>V*WO8>W/PN%X\9WHZW;GWMYIXMP0S6.F&L
M\$N7K8.\$ML2;&A,6,>(!!"?!"6.Q###3PB:V%CR&PKS%U\$&7 MT!\$28H@-(S'/
U="@::W%B"TO47D2!<8Y=%OZS_!H)XSAK(P+I =; CDYEOMQK=\$"BAN\!8K4
(TY)UOH0!&\$GX?A++L43F)%/+-M<,GV?
3;S4RQ#1X3%^HV'5*5U[11V8!)18VJZTV")PYI&IC&I+K\VP9<6: ^ZPL.+I6
EN9EFLN2"+*H6W6V\$! M*K!#&@&#DR4+6H
S+JG&@ZVGE#|B%QLZ7P|NM+#+>6BNV;#C)'JUJX1Y-8MK, MD3;4_1@|*_M*"\$2L\$C
QSO1&14=\$@UM,G"3F|KF*EE7?4G\A4/H\$S/7Z|;3/EX0Z*Z"7I0 M4>?^)=J3\$G07=
M9P9+2T4*"(. _B+|^J.%^VF\$+6|2=\$@V_KP*_*);>D9|+JB|5T8F'MKS^(&
M9V147\5;C-K00;.^3+G3;ZZ0+W3XE0X'9YN/%.3.Y/#./1D.K28?# MV1WWF/I;9\&Z7AB
X^VI*GOI9W^J2&=_.25^*EDQ,D;Z>A&;^)^3CI"N|IM3CE=DXO4A'B.I%3TYE
M#!6D3WAT4X44L@ "2+("TIQ9#;T_ %@|T6S?'93T;%(Z*[4-E|4S)0Y?&0Z,"
MC3(+|A#6H1G)3@B2ARZ-AWH;MN4X"%=[D.2ARZ1AT9|JHZ5X*\$N-N1)=VH6
MC8=*&|ES^M_Y&,E:6Q_T_JF0P'4R+>4B|0,/H4+#+|. &M"6>ZC;5R!,N4FF-
2I7)|>PD1\$F(SX67|/#UGA008T!)Y@T_@!';ZM:+_L ITACYT,(T#"U=(=I
M7TA"9!"LB1*BW^\$F(;- \$+<.7P)X@"1,\$AL)-^L% #?NZ;S<'Q(F0L&DOZ?^ M?F8J%*:-
!8F(V|62Q\|8;J(#!IO,M4;_D=Y2;:CRVTBT
MG>UL2P@('0M75|Y'T'M#0)1HG0XOE'0!)5I>3Q;)DO-&BXDBL5!T.:Q1
M.10-.E06=1OFM66 & FM*P<3VE6X-L_E@??ONZ=PK8&FA=N7GG|SI)\$Z.#0R
MH:0T4EOC|M6(6Z!DF;H8I_#Y2%Z3O);>^0^-\$RS);WA:>|7:"DO>4WRVF7P-MFCHX-
\$.F)*_IR&O#8>6\$9\EKDM<\$FGBY?>W0L,62O(8IG5?=_J_P^%IYK?\$G
M0C|@C1T8RW_(*|N'_;5F?BTDO\$V#*&ESMGR)/^=.EZB6RG08Q/H,HLP%LN-M-*@
3|_!SO62>HS=J'\NNZ.G,6|O;+!2=Q'T ?YD18>J2|258FE@_74V"VW M'16(>|T%G.2N-
#=_DMGU?XCK9_%JT!K3IH_>T&BLFF_WV#(SIXZ/Y^@V++K:~3K+?!;)?H7,H
MCN07SW&49#^Q\$ "C9C^?1%\$?V8R=4O",O)/N)A4#)?CQ/J5BR7SV'506Q'S6>M?
Z5J8..^EM|:4NWHF53S.YRCG0R>|K(&.G|2:<_;;H|8V+T10I0'8QZ4W4^
M&I'A_VI:OY71"RB<| #6R(^V\$GO'^C6|HUSO:I:OP|M%!*-7V=0RBS8:'|?1!
M&/OWW>>OCX^_*/>WW|H?/GM4?EV_UUY_-?M|_N='<1U0=^O<;A*>JV*+KD
M#>KI%+ +-|N S*X-@+SQ3!3@V0EQL:6VMS!<;+P=^)YOV@D)?!-BQYIFK8R M,
I&'|4RY_:HF!Z(D>6*_LUZFOO%GCU7|ISE\$F32H^|_H|XUAH*/J807?Y M"\-77IW
FBD30L|681@&_&^)SR\$_B3LU/:(X+LHZ&(H7MGLW+\$M9.3ZL@&D?
MW|B,S!>2;_">5CY&W|+L/I;MS!>|&P9 ;!A0!" +U1 M5^/@O:>0OP/3?X.I8&(@/G5E
524=QXAM)2;HG:OE)T,5!U|H(DWN\$^8TP)X
MI*MY_0%VE!F=#K\$|2IZ:1|ES3+|0>KMD;L&2I(\$ _>5.,U0JFQSJ2ATOFN|2I
MZ1L,%O&Y)/|F;65;RXFB?J.,C=Q(Z3M;*^2B|>>|8_&|SY-8,KOHL|N|-M^8Q>D@G>3?
0|PK2!&K?P|,&"UZPW^A|3-&"3)+-:/_P.WT. M%BMX\$W<83+))7
EILXRG0*8VG|EQ%8F^"861)'D+MIWS4G^KD#@>X,P|N0 M!2F%,H(*C85C-:
XJ)U0LH0K|\$;PY2ZQD3&QRS#;;Z)VRU?A"N\$;X9-&H6#@ M0RS+>?5N(ITE)&'&
|LU!"D|HM|?QWUDTN>_UVKK.IF|JK5'>D^T-NG" M#FK(HW?|2;H)%2\$N77+::IKM?
3|Q7:KEHN5V_:J M>C!^+^+1M9WUSG;GI?P;E7:E|EMC|:K331|DEHY5\$R+
-IHZV;)+#FLMAJ;H1
M!3@LS418Z*B7+G,D64BRT%FR4!D.VA/WLIMQAMC8MO(I^C&XYT@%LD|<>L_S
M;A145B,M->4G7<4.X:2'--<.DM4Y|2E?#-P6N;*((\$&C_&A54?38W0GLUM|MHL.>K?
^./G(4M2+7B:L?,0MK'Q>+N4L@3VZ3\$|X)>&F0;F=Q7#@1.6+M0)EU)O,DY_:VHP?
F\$&T#E9/|6XZ_!| M#S; BZ XN'TQ3(N&/#@L)HE&5X2 R|BJ|OOQ1GK|?KRS|D!
(|FLB|Q5UWY7F MOC2#=>OV\4GVDNPEECFY1R7FP%0H(%7.8FM=LX*U>-
H!!%!>S0(^|B)X8E9 M;F4JU))S?H%#NP1CZ-JAE+T21=EGQ.U3_X?
ZGD70'N3B;6!9\$\$.GW59 ;UM2 M1M2^9<3^0G,3OLYI)+3W=4WR7#F)I_3"|
J5164XHV=3B|6XHV<@T=-@|QJ MECU#0_|E|Y.QSZ&I=D41P:~VLO:H&
<9&65Q1M=UF#1\$T|4V4T\$N_4R6WX8= MYBJE..=VA@DYF/A7YH!)'L4V'6/|\$V-
LV.%714YB3\$R;+Y%|8&DMJ:ZP) M@J)+,~!9%<+7\$F9ZF-Y:Q5"OX-
X|>TXZS(3/XZ4L#M)XFF%"R-(S-5I^)?! MG"XQ)S"P5U0!G==!A4;MYSJD,=71|J-'%HEZ
SOON|&=T6Y|7?"-L6IMH* MB">,JY2,D.3:2ZYC%YH_Z?P_9!VM509J"#?-
TH4TSRB@9F>\6E3N;J>QJ>6& MK656S8I5KLY:Y>JUQKUVQB'-T0)CU!H5L)?

I+D=!/A^9_AC>\$2[FW9/2OB+M)\$FP_0|^VT|^@Z+'H0'O JP:R(#[YU#;/F:
IVBO'H@@WT=(OTF?\$NL=4 MW\$+9+'OL++J)DY@EF2 QC/ @:K;#>8855;>)-(A!3>:
MU;>HV#,,E.2SRKE<=7F3Y=E[9+,1A=;NG;0515ZI>N75\(!3R1*#9Y15LGI#
M%\$'I=J4LB8"RGHDF+ZR,%@9?;#.">L"#^N#EE?37T0E^>, M\$VWEJZU|
<5X(42!)>&UCM91WN%U&+.C==[3HA*&!,?%'28^PIOHK^K|7UB9
M_Z@*O3//G^RZYG_)TV!-W=|H'[Y|VA9IZ|]%G=.7L3/@N^B-;K%4|83DPTBR-M?
N|*T|+|"+XIOPN+Y_RC7FG=? S#SQ03\$SKR8=&PR/NTWD#K\$5K6L<+>H=#2N
M16"O#!.P-9VZV#ED%CT?8 *XR6XZL@D)=4@AH6Y XI-IP4\$A3-9&B8%>FEX-M;#7#
(Z*WWAKKP^[58#(#(!<6N^1X F(V9Z>7P4FA*W7H@E.KT<\$@_CEN0_E%&
MP;J:S7W8;^:3ZRSO;L0NC^DVW>D6G4,L1C^9E...JY4HDXAJ?#+G7V.JK4)
MF0\$2;?'WCNX!NO)M&<(/KO-2+;Z&QF>YTO-@TXCVIX0ML2UWC:&GO|,063VL=|
VX.4JD+R!DV M9:C4 J1R(XLS)%BEYA^72+!2;3|.
IS>1#BA=HG:3(D!8;7/+4|89@HU":==P7 ZD#B5.,W:;>|H.\$WC<=@:GTWQ
M0G%U**E|RLD>?(Z=|*2=<|O(OE'|=.5XYG(FS|J3H?C?A#,7B-YM%-
OO/M8>&1T;76S3TQ4F&JHX,(K^WS;5#"C|I, MY*?_+7J'P?+
IWPVP\$HMW:|_ ^16;/6)X%MI>7J.G\$U'*(|/,<;L2V M1|,R.S6#
|_#EVV>SGV|_ |PQ^W3PQ_WRL.7QZ?O/WZ_+TJ-Q^ ^:C|Z_|C M;P|??E-N|^#GAZ>' ^|?
=>/>NSF|VSM^Y8T?K8A#|QOO2!*:<%UN^|Z?VE_&|8 M
'\$DN?)U|B>9TD,H9Z|\\#4:KTTWKX3J5""(&1+GGKF(_@89YZH AGVFFV)Z
M"OD)T@|#!OOE;@53GZTK=8_C@2_H4"ZQIV_8/GMAV,|s<0T?@S96*R!XU\$K#
MIYT(|BM*\$1O!D4?WFHKSHJX|)%MY=|+TR)1| P=P,R!9^%)J\$ \$7P7I3%L
M1#&>#1/X0F'OW'A@-**KC0,1V0,ZQ2")#63FN'Q|GXTV/Q#8=5_GB^&R\$!![BL6'-Y|J
MB(;UIB">H0;31=;|VLJMGWENO#G%&7W%=3P|C",@\$W_CS!7>4BHV0NT-JP33
MP!O6,NJ38;I_&!9(E;2*K'5:XV%&A>|X#.+=C_9C&|;| V,R"9_YR
MI;PN3*#,WP%PS!S|3|":1@(@%F)"AV,1/+%L>OC|!:L"+@4 Q!V/4,&J9T@J/
MW|DKWNAZ>MN/I2|,5Y"=2;-@2*PZ_N"|P'P6DWX4I7AVCJUF<-@NQM_@#? Z
M&*OQG0;+P*)O=^!F%XB_7+ED06P/'VW2DNI1IQH8\$(:@12|*|7KDN|TXLI=
M;05Y;#IL&?1.+U#!DK?|_>B)4)""WCR"6,1>%R2R,7VN:EO^7\$(BC.GY>,C
M.N,>1TS|=DVH|\$XF88"!1GT)H0|T5+TJ=U1 M4|.JHZ:F=|>GC>
+%D<0:F9D(X0)*XOLF(%Y22,*"P:"1!\$@^A50WUN14.C= M'+3GTKE4W97.)7)BH+
<|6KG8@KQ'J6H|.I "%U.@@^KQB%,X|5%|L8/XCW0+
M*'T&+|HY.%0)1N\$42L\$#|X*GQ&=+|W,D7_CSM)^V&|!#6W###+-968BT;-^1H MW|>X.?
@K7T&HKS5U,|.2+K\$UM|HSPOEIK0NN*|^"NIS6RT#Q M1ZY"-A_+|
M;|KOZ_S)^FE|6/D?.T5!P4YHI%<=QE<5TM3NKH8\$%,L.C4VJKN(0ZF:T^9.
MZ^M#"S;IAZ":!W41F#GF;:B/I'->H|)",^_*^9MV'|_F>0+6NM2_'O1^!M,M
|T#7^WU*>|M_|1H%;Y-R"9,P/^RN4=K%VJCO+=50;U?:2M^+;"3HDC+K4
M,CP/_58S|,11AU41TM'\$GW5;(?S&\$|_.O|-32/F%./OF/L&G0>A_|8EGCDC MU'|KTN<#Q|
|00^,%\$W0%8J:A|:98YM|!<^ALIO*5S*X0PWG_@/8-8/7Z.Z9H
M/KX:JPJS\$B<+Z<%6/I&)&QCN&|T1W'3|4J..>ND+N@)?<6/C |HBU<|I/(Q
M|!)VHD&S<#X8|E|(Q%QJ3S*4+^W;|D;J(> MPA/8V5F:T|!RMRS6R|2%|,U49A>1P-
5G(F%KGG&5>E)OG -|)HSTU?FQM2TJ%1@;M+-":_ =N| E M-
Z)Y4|B|^C=C|;|,MZH=|RQ&6FV?<'Q>.B:N63R!JPY"Z:15|"\$>3\$BS0,?
M#R/B)|-71<<|,3MW|G/%0@+ K(&UP&^"JS8,|PYEZL-FF|,7%0L_ENN*1D
M\$F5*UTFX>FD+ SPJ^/'X<;U@3T"?ST">+.F+90P|:=4EF3.)XR|!=R#TNL)
MJY4|/9;5EHA8\$|'|.992"2.<"7NH_?#MH-^&..9%,N5QDKP\$4GZK7&G/1H-
M>RFJ_+.*^C*2+;LL_@#'W5T5<;!U4**KL6&,7-6\$=:?G!4(I6%W>!7O" MM+
(_AWCJ(D)|8QCX4^<0|UCW#DBU".0?/?XW0+W""N&>|:;K6OX|ZW)W=@ M8|G.<|*B%
|4TZN-\$ _;V_JJGH=X*TK|%I|1>7B2OB7""NQ*H #)-BWPG<
MXCLH7KQ_!W>A/2SWX0&W#8A-*.<5TH4/^T^'|0|D-=/>W9^R=#,+4IJ0V\$
M%)I%F2*A<0(SG!K>0IE;0!|VIAX67:'A)H2JEX#UR9;Q1,TBIM.VZK2%1U6
M;+SZ=)0_06=|)1;|+8"%K;P*!|>+U> M0K;PL5'R8E@!#01B%D(>Y0
|AC,5#!ATULEQ4!H3<#V@W8 ?&T_.Z@I8|/I M4\$V/@>-E&@I;PS>BK0L7-
AG/0!^SKUQC,F\$%!(ILL\$C_BNR"K7D|?%7@&|V1,%6AC:+M):CF>LF0*KNB.,Z \$)^
#M1%&?E>;C\$Z|'O,PE-JX'U !8=0ETN1RBD8@;JE M*V)&\$I@3AQY8.24I61-A@3D!|
|J6*HMRG/>F0EJ.|-I.KC(P(DO"6|4+EDOT
MMX22">9L+BG_SPW355"ZD>BW#&_+SM"IB6%A5)+B+0CQZ99#94I,8NWF1#@
MIOR2)V5-N#,)X|%ZH%?L+L=Q@MB;?KO;%2X@J/&#TH==;H/H7YYE1(O!2|; M"1>A4|!;
|)-Y.AK=+B#|=|2|DJI^Q-*#RV"E*5>D44R|&?KZF|W@4 MS#K>E.5#S4N++#RGL,

(RGKKN|I2|D)MFPS%WB|B|W9FDI^NU#67M,:+C\8, MI-L:ZVG'G_E-J08E6)4"
(I*,I/=05J%*.IUKB?KO@NFK J4\$BER-^YD= 7 M67I%W_2^'UAZ1=?\$+
|V"H>O"E%Y1.YQJK\1|O:ZMXF6<:073Z>-Z/YT^_NGV MX;ORQ^WG' ?*
|_>WCS^ ^W|J* @>E=-/GGVL8| ^WCG3+4.J+%WZT= LK0Q, # % M/D*LV\X18<
,?.DESOH-+RQ:8OK*"O!"6,3,JQ-8LS!0AH! I7\$S'K\$!#)^ @ M*A0& =/.(MA: 9.,Y@2C-
RS3F&#TUEN;>4386TP,XV*1!M<3 |N^+-VE:>L|VW&X0<>|;8: =22&MC");
|C3Q90"Z\$I#|UQ"% (N| M\$,MCX7OXXKBO|R#(|/N-/BDI'RCYK"BM0;V-
V!T94)8:ZODK'=4Q?WW!D|P@1X(&ROM%&*YFNM09&&TON,9ZR1E7|@
M)LAH|8P0D_\$4U|6TWN/EC|JA1,RB UPS!5)-4.JXK@.6"(MA>4M>%,6F&;Z!
MO^"5)"PL%+| #N^L5QCW_*\$O!6\$(7@B5^I+>Z-0B\8!4&,4TP4=#W&1KL.!0Q
MKG+\$|@6BVX#H| (S*|L-N3ADA4SE" |8| ("4FI%I&BL'1FL%M> >|YM\$T+1J|'
MH<1+XB^<&1#QV<0J70G^2* @/.%BP|YU"2=S76"1\$P8,I89HRC8GIMM3|VNI=3GA%
|0G3%B5_F. M&0(T0/4#ANSRVL_\$L6%8"++KL@)Q8990% >,E*(?UJ7K (-&-
&PHQ%1TY+7\$ MEU&J|H5EV/LOC%>|/"I7%>2:KE>O|I.>8220F%\$J|KLT?CU,>0Z?
0=7M&.:7 M%|: >CDO'S-!Y5"PN;T?V EK^DQ: 7!,\81-Y#/=NC'L;JH|7QR(L2G!Q'1!B
MN'14XZ>@V3C/#|)68KW##|2 ^00"R6E,I FK!%|@XRG! ^#8K7SO%!)SLGMW;LHS/
%RR9:""J*DIM,UI)\$26W9 MZ|C4,Z:X9;
|4R*J_>5BYO@HQZID^H<&V3^A|J_CU!VU=*QLG6G=0:|_ =Z8L6
M:"O'5'A,@|U/:E3X9L6ZB=D-1|1SC=FE&QANI+M=O(V+XJVLJ3PD09%Z4/3 M@&7X9
F*.;E?)+(IPFRU&|YQ4'P)>>B3Y)AA2|IT:M->;5/\$F K&.) ^:9B/M>*,@CUND2|1/U9H#
|'+BJ ^N(*8)>; M BAY0O+\$R8PDKCS1\$XTG0J,H>D|\$A;SSL&K(. ^_X/OE.;\$|AC_?
JR1YQ8IR M\$,D=5|WX|I&#I^3|@MU_:)" /# X55=N1|TMM4>"KSGJ_ %:9.M'0 -=4!5&-)
MS6Z?8TE-Z0653%"C%U0|0:C(0#20J.01R2,|>\$2K<:L8RJU"LL%YL(%^A,S M?@'G?
_,&IV):P5 M>F|^9A(+%C)P7|*N U'/ OJSA^6^X^Y"V&M@ZU.EO?"PM0#| M^|FEI4S?V
WL(!&\$ _|HNR63%X5-#Q|? 8V:P#(KQ8IA6V E"6043RYS&
MH4/674|FV.,5GCAWG65&"Q#:88J96UCZ|JRYO7Z025LDN63N8! ^CL|XYKH 7
M=S@*QXIK>+W5.RF_ ;OW>-F@GZ/_!K:O"%|>^;GQGA<_8^=6BV&(EV*^49|>9
MO9J6Q8-4M:KQ#?O9I" T30DK27B5QG7X0C|?KVN|JKU3CE|C\$QA_Y?C86|>P
M%'.Y@AQOTK9R_W-*0#4&A-JT%P_ @|PM|4+JB-;|+|+237*5O+7#^VI@+6+K@8
MLX#^2IG>1%>.|D8,%Z4Q4#M==)|% 4>E|H4MF2"|D6XWQ>QN\$>C ;J0|V8VT M7#=2-
:;<Z<.7NZ^_WRM/M_? >-6|ZL#6WL|V%-G23|0;95|?C)^?H3_@9"? MWMJS3_
|0#&GF4=|V|D4'OD>0Z%F.;2%Y!.;J3?&ZX-4/"4=Y;C>; ^MLD*5#).20_&-
GZ%697AA1Q+6|2D4.6O)S3G>.|N:EG2HCSYI2|N8ZE.25T5VBD6I% @0Q!E77"JD&+^/C;2
MDNTEVTNV%|&I.J.+L:FO<&XSX^@M/Q/\$Y>2SK,,B#HR+OG.7*L8GM>U&\$)-#|
M_N>*V|Y0&PR_ VIC=P7)D6%0D M#=26<9\$R+O*1>X+NJ25M|3F'4WK)%^?
\$%XS\$C6'ZPOE83.HIC5(V AH?J5W64Y@&0)8>*6?")A;NEF5Z+GK<5VDBPW "OW+?
S:\$%0 M77>3S'KQS%ICY%";#L\$ _2_-MB?7=9.5|X9/OA-XP-2T3-J&):?AQZA3O>\$'F^B?
@>>|I?-'B!; MNW>R+B"WBKM!@:C=Q|KF|P#U@K|?KC.DO|F&S^!
|,M5X).98OBL/0B+ ^<2K M_@Z>.|D)%J|JUS-,3S&|L!>)1SN1T)>S
MK@)O!.OJ\$H6(+,SR<&-2?8N8;<|.T:*IN,+ENH|'V4;*&2|ZB"C38R73RR M*8EL2G*N;2-
D4Q+9E*0^4Y)OL?X(A|Y&N&9HB)%6)VLR76;%BUI" <=;6 MW89=DV-
WT:EQA|C5&Y8AQFV|D@%CL|P91:25?6G1\$#C)(+;\$_\$QU|6%6F;!
M&LF\$D@G/D@GK%L-T6^_N MS,IM&H JJD)E (1!S>GZL1) P@&H_FV| #&SZ
!M>|I*"9'4+O16'.8'KT|J9 M.9|3K,1IRB99->| %V|F8J+A^3)
^BS<&6=F8,G7WO"%4<4L^!\$=#V7ZM>3@J M6G"% (XY&K;%6I8VES PO#(7?+&=" #67?
L)|-C)6QG%>Z:3/; ^<*L9@X) 5/? M|F^*Q-K@S378(&=6&6=!T)>YLL\,7!H,<'@_X
M#X^'LJ"O||@RD!:/@+C9TZ" I(FZZK7&ZLKFS\$S?G#YC 7=C9LYHZ|/_S_IV7^
M|&_FYD|RN_X/<9TL_/5:8YHIHKT7!%278#1_|1?558\$%LG&=HJF3Y:7=KZL M|:3!
(.;*=.7"B+DPFK2,ZB+M#QLS-Y|MN&5&O9(O+>@ ^|6|J#^P8ZJ6,(%MY?'? ^/B/BW\$>VS
MN&\$!6)&XWUM"(GS>'SOLN@-KQ@|EV5
MY"EI"Q=>|7^;_F+A6#A>NK5B5J| #P|GZPWWXM)2ZHKO|FFXV+Y|LIT)82.U
M|Z)3\$ "U3&BVG-X&+P|:/04N3L!\$0-H?9ND5ADWEL(6W:NA:>N2"P@F->7:6&
MZYO^T'V_*ZN3)K|S\$R4@4ZA)&&RNEWVN+ P7.*RBVW)'(\$1\$XUO_)>Y&@=
M<43.GNTV*CT. R7Y.#N7JR|!L/_ ^?XSEZOW'JO|R|H6JY6S*.G, ^DX|T*ZG
MBRPN5UMC64JJ:8 Y3*DH!A@MR^@#D|>FP_8/2L3.FC ^82+|;5|/S
MF+5.,*!8VNO5"D^D/_;ZWA>6.CTD^LL*<'154CN\$E'<6E=&<3<97IL;<._H M!
(NI5""J;|FA>^TCC"?NWRK/MX";\$79@77:P13JMI.L,<>EOK(E?2!N)4 M8)%FC4BY5\$7
DWDPAWA|9-Q7J-17 S\$@ (WG*QB!H&1X#OLD^.;5J(1L:L) M4X4.;?(BNW,?

@4!B2Y4Z%)A|W;E'.|L5=98N" 5BSK0K& M-+|?Y)C)<4-
V*X"L2C\$K4|5|!QNB*Z2FVXP/|+E>&B|A4?(?>N'X4!AW3
M+TOX)GW0+*"736GXFA==\R<9|=8+WQ84(HQX|4|@4;V?A27
—I&^<0:3A5<25L"PK2!UGEE#@' H^|E MU? 4RW"?B?6FS%S@)EN9O—" 8.C#1\$5-
WZ(:QM_AI=GR3B|>X/TPUK@(J6-MA8-X3I=)9A.)J7?GV!Z*\$.5?
Q+#+|!27.!|YW9D!9GT3.:>2E>-B91DZ(:#; MOYQ7 I+JBMV/0
IC_*\$2VN#*W'66BA=,X5%KBB%,@.LL+\$D&"^#16Y?&GXYK M^F|(?8J!C*%&-
R/|U|5!VJ#K:!(Q:F&X!0.IK>@MX&3|PHO0(X>#9,V_/I M';3W>-
CCDD|;HPT39V&B/LM3HZGZ|<\$IQ"V\X24P;F_A;2\$@=MO|,|N\Y# M-@"*4,:
M;FF+UQ3\$UM^4 +/Y>FPKDX/S++)"N=,4+(-3R?S7@!K QWD>B4 M;-U=RK&3|
NLJD=(9BN/(P/HN29B.(BY-JP:1VD&!3#4! Z^OFLN.6L*%# M1HH0A-.ZRG|
%B7#H4T!LV!(-E"/OCTFZI^! M:WHSDT(? &<"CF')@3@12;SVH0^2#YGB?
NS\$/14EH7@Q.XF(.L|7'3 HN&| M)D(F2L.,R8OYF CZ4'0GM@(/^==>
26'_%N+).7H#NL.4+KJ/&:%@-Z2X(M>>F_G8FGW\$|I#3X.8>AE# 8\$|(!O|!
|@E8Z+BA!X||9V=\$7WK57@X@CHS|>/ M=J@V|E6.|=:|UJ_2C*ILC!FY41V=|?
(F'##@+4G("Z-+L/1_YU'N8?/P83
MSYR9P'.9*5%ZMS7N|=/_A_;\$8A|D\$R1>L:4/E;@ "&2Y!2|%)J"S)Y|L82=/-87M_) +A'T"1E
M9;Q161O*&):8MA| :%VR-'T?-P"CVY-T>"WQ,*&2IW>L3<7_'&Z '%ED:_S M5&T7;,-
H&A.3|!/:.*HG>-(RYG^M5|S7@OF-C56*#N)N*-8CG9U!#T9S8 M0\$J^&"^Q U5R\$9"@R
ME,Z'VJR#^/4BV:;JK<-2,|X9\$^4-|J^\$*@C|Z5.1Q2S06(W&FW"3OLG=6O:"
MX50;2S1BIN3\$9B2UA&\$0EK'RR\$WTX7V4(&':|%)'TIO?AW\$+;\$XVM+2N8SI;|
MO+;#VAUFBX5'7N&;PY_+|.OZ>|>KNC:9D_==|JYO=YCU+5=G>@EWI4_O<|M/?
LE!PVJM_-1>XX)=QXGC U*79?CDF!/@.+ZGX19&|D5G9CF@FG)RCTU8D;'
M\$"IS|&.D1FSXA J2ZJ1^R6(4>/<1&="E*G.H3W@I9W66+|B\$1TML#*"8Y37A M3-YH*
'T,AS1B,C|/#&TFW-MOB@!HC_>X&K(.BK'E-;BSB W*,<.USBCA EYT^Z
MX.B|99944@6M\$HC4M%.WK"F*#6B_ HF4D0H?HN_"HS1_ G+!7@?SE2()GA0B
M*F'-9GDO^JWQH\$EE"6/-)5'>J?CD4%KW\$N?TYQUU:/SV!3O_P|PD G|.K"
MU*|HREKW\$7N\$H0&+@GC_|S'A>&2#WB&D|S@SO\$R0S>&LMI-0P%6701S 1B&
M|52E65MOYB./|^_SR.G6.FW#^&IV&(-'ODD3.8(ENIS761K(;!;!4U;H
ME@.. "L#)B\$&2NFWM&(C:54P#%|J5WZ1BRTUV8A=-%K!V%Q+W,XT_S&* S%)*
M4ED|?|!4E9ME0*+ YJ+4D" _@6EPJ_@,K2%VGP (>DSV:'+P^*7RJ> <*K- MXM|%IQ|
:20(G"Y*)7W_ :B^=IE9Y2H);"#9Y3|4J;:'RY|',?8&,T>|7'MA|/#?L+:G<
M<|MTHE1\$D!MK^K*?LL3'4-9@.Q_ :TVJKF0@NG1C(L+A6Q/LY @N\U.F.6F.|F&&U)L%
M!\$|*|^8.GEX'P"-*W JEZ'XLRBM PG>L9L9VE::/: 59ZB'
M<|D"W6XOA%6D*%S*O*=R*V4N|4,! 54ZO" '4&G@:(UK%WH>(O7P0N:7H4YL MB-
!49_ILP)<1F+KL_ =!D^/0.@D:)MVS:>_8B/8.K/AT?@V(LEO2Q=; + #W_
MYK|^:1^LFZ:|5KC7I>7OU6(NP!PA_IXHU5#)%J>ZQX?%*J
'K9S2:F_6U\$^BRN&;3&NMKC5@1=V!KG M\$F8UR>-B,,,|T%Y:.(L%LTLP>
|X07QH|TN@YHM\$#B,N2"*/66--Y^8.%V'WJ M,'DD'S66C|NM-
E\U,>3;I57T9YC;*_1("+"Z31LYX!"EGP+_M7RJG./*Y6% M1-?L(PN)-
JHFIBPD>@#19"%1VD!F'3MVX=5\$&|/1"3_"XSRJQR()=RTFUR^ML29?
=B).=Z,S2U@Q)6K0DF49J:UQ|_0=064=TPMCA'T (7YH!<6E|3+9#W
MHHY&HV3>"|VOKW^|*),MW=?10.%P#'|F)YU-!Y!K44<+H G&XZS>SHP+DH
MAR'*96:MPFC333/:.9:%1SD+TIV9X|75C9YHZH;,&SJK"U7E:"/#2K29|9' MM^DN2E&-/:
N=N(*@7P-9T'#I*OB3H+%DY" _D#T#-.KV5(|;2>4AQ2"2Q/ MZ>_X^=J97P<>R0E?
D|MSU8H;E,A?YS^|3*&\$49WIK)5S=+%*I%0MK|\$,*=EM
M.J3B)O.^11*)1;2U0/S=04=j:&IW-R=3(3U"OT!96
M:HHW(|"CGTN5N5VUT8;:+#1:55RN632AN0E@29^N"TL.5356;|C\$9:5!B
M,=,|F1N"Q*4*/;A+T&(VADWC1%/E7:3#O!V*=#:K&|"@.G."B45B.DNYS(U
M8@ONVFW|+('=S3+S*V7;<5@HL34DR:H7SZKU1Q)D|6H/>)62;G4B/J5:PJ^ ^ M
2^,"|JS&7T)EK :TXV2^ (MH%=H|6)B5XYDX YQL:9&J^D/>OYLQ?1/(S<5|X
MN<|Z%F,"|PC|_%M2R6K'OY:&8U(| :UZ^XE_%|'6NC*>R?7\$)<9?U|8<1GMC
M6*_&FXM_9L(RX EOP) M;OY@.=_UJ@&@!/^@J7P W(YJ(L#?
<9IH!0'\$72TK1GL#XW6O<4#1*TC1B2 M=:D1&KN7|&1A,J|_(K*)5."#*-0R"N&2Z*?
Y@Z6F,&?8/:(T?@FH#)E.H+ M-#\$L+\$C> M"W^,KF_+MFB|>0F^O ^ ME|2/.0A1
S6|Q.5X'|O(93N|, @%1H X9O#G|OPTZ_HP=ZNZ-I
MF3|UVFKF|WF/4M5V=Z"7>E3^|ST|^R4'#;JW\U\$R8UUFK,N,=9FQ+C/6|SPN MCGW-
^LAG>5YJ*|C6- NM|/S%-L#J/' :59|H,&B->75A\$L(=LL-3+E)|M*!

MOHQBO#1LC7OD)\$4!F>DB3C;R\|MGX:\$.&(I<2DY# #'-'@CM-'F,I8Y%.X@HO# M9-@!?:
42 F/6+L\$3XG?UN;EKR0.D(!);BISB\>H_0K\I^7.?
K/. M@3_PP\WYR_B7(<=>)MU)'=%3_*PDZAAORD+8Z; M"5#6L!0;E
8GZMZL6(|G*>^B=4P./U=9.I;|. (M#6^| |%IR#MEZ^?Q26->E+2
M_*).#==|FSONJ^'./.69*_|H(YHT;8|BL>XP#A"|2|XK2T#IV3W?HO.M*TZ#_MHY\$&^2-
|#"9_DJG_Y'PVEZ9/&|EXCX2^3Q|J6>/&_#@M;6E'XT:ROB|,Z8*> MW'OL|8K0*;Z|3
3X&PE?(!"+|*|D/T?| C):|H_SHI-@#R8\$?Q1'0W|5V! M*#
I>@3Z#B|7% ^JGE0*99|276">6"VWE";"T-/YT7#|!*(R@*RGZ|/>P7;9JP
M\$6S)NP00%N8|Y& #'CXI-XJV)39HF+0|> T|_PY,%C9&Q>JWA8&YC^00Y;.! M^I'A
V&)=P7OF+:O<.LW@2#A55,24-TG_OF;X1K/;+8/I@,+^F).UW?^;GBT MVSBQ+.4WRYG
:/\$'Y5W(C?QL"C+ DS3;+R^L0>8Z>"3UL!60/#MWW3L*PW;.,@8SB8/.,K& M0@!AH?
FS^N%.8.UNL\$W#EMC_Q76+3KHN\$9X;#Q*@1F8S@SXKAAY8>#7|J/
M;6X4'O"D|* @UUO0IDM)KC%;4TTARIV8TT8^F-0K?4.&MIQ#C2 MLALQKH<9;Y Y
;-7L&UX*|0?7HCU!IA_ACT\$P&SZ7H:SWV.Z5;2&&* =KPG8%
MEZ#|6?;.%>8&086W(XGYS_Q>=
|)HWWA;|'"#,%%="AAHOTKC!*&19|*+WE=D.V7NP1XYC_A M408^(6/Z-T5Y;/047:-?
|Z8|W,^5UR=D2ZI<|4^HM&^22Z.!^JTQE8%HT=#U_M)#|
SP^5&R|1*1879PJKA(|J9|Z9-L3T6B_OGN:# ^1E'%>=V:GX\$SW8-UY_M>5|D0?
MR0;DLZ#SP_Y?0PL.N!W)P8UDC?O7)<@4VAONFS,PY,""*\$4|NTQ&7_M"7EC91DV-
24|S0J|@SVWGM D+;D.1V<7(?T|6|LK^3FU_N^47A_4+D"<,-E" MY4F6'*&
|PX81DJ|5%U>CLY+'2CQH((0^GM#E8E4,|E'BX7&5Z2UR=#+X W=>
M:N5|'"ET7&8J3,@M<7)5/_P.ZY|3PX\$>J1(7?00'UE*7CHHOC M+U!;84QPL>WX^,'?;#1?
G<":A=H;H;_@.\$GH7_%(YG#B(1R^)RFOIK^(\$M;2
MYEI"&UZK'<9J99E3^N4&Q9+5H(Q74&L?@#(@\$BBQJ38#Y/|@|0&O?-T)-VK#> M/_
|0EK|N)WD-DZ)ZX.JC'=8T0US, T6^*AX2#&;!8(/S%=' \$UMU|4RE92=|M*
M497QA_AM;.|GF4=Z:|P?IN/58_/H.>H|L|YX6_D=:/M,*"1A6#@)RA, NQP6
M*.W&&!6L.K/3&\$P6I+.#Y?7,|;_#IZX)T_7|4-U!|@%ZWQ;.,=\$C;2GF-FR62L*K_
|&LBER\$F;1P7@_M2F8Z>H%%!1BZX_+*4|MVG:QM0,|MM6|=Q5N.%Z#CE+*\$;F%3"Q?
F05_M,\$\$=^9CY_6*|CRXB;!<,W;3%\$FE,(''^QL5BOWUT/M,%|!|*Q
MGV%LA#^#%S3FYE39E!*|K'?) M5L!C8F*8B+H**/J5|JMT@.B@2@#
<>\$FIT|^&K2#.7T#\$R|*+BXNLC370*32_M7#N9|\$0D@N4G+X# ;2:AA@:+^%C!|DYUQ3
*2^MT1A0XC% D5'7%+;I@X;/M? M.7BBB>AV
C^V7Q#2@1UMCOABT_"JE,N8&B@_P9S)Z1TPQKDQ\$8#Z+-Y2<%
MPYIO*\$.Z9.I@Q,Z\$V&2.5|*76E"16#8#A1I2L(*|RWAC74|MO:&&VBYN|R!+ MIJ8| #9:
{Q312\$-|OVD\$|T|TW5HI"8W|JO6.Y, P(0%*!A-F:"(Z9R;=|ZJ)!
M|PPGRR+G)B@E/200F6V&.46TH\$&O|T_V0G/A M@'J@IK@N\$,M-
*052\$H4!G2!|OTP.JVFPC2\$T|OZ%?, 10>7|:Q:9/9,93"N M2PS").5BC94^D4P7-E7H;_\$.|
X4<;)?B*P.9+44M%|3J!CAO)G/7*F@#_M(I)N<^)CTK%L@_K:P8%S>-(/&Q'T;,"_0-
WY\$+)8VID-8K'3&N>'J'^_@L3#
MDB#VVF%68Z%BAM'0'J<+,@LL|G6>,|COCF5|8C9+=G%#&+/*Z&':@*!;/_H2
M7|99|/"6C_1PKFPND|EV"!//D8.%S|84|!YP.S|3KU"0)|/ MKK|AAF;Q-
^KZAFN_12N3R;)Z:YQ.C3FL:X,@E7_.GH% Y6;.#>H4N+ ^I?7S MS\$=2E6>Z"A&P;FHO/
(_%|B_J^9#_S(W%%@N3_-OW%\$ _6>W:Y|L9GLTO|EZ0
M1|8>7^>)H@:9+-2OQD)B;2Y"L|Z6_R0*1=)D_ ^"ZYB^VM"@5A7*8M,CD^ '\$
MU|D1.YZ>V'5RQGNM/PX<%X_R7AZ)6?)'?-/ %33|AOP*G0JR.Y| %TZP5K'JX
MYD).P_Z)G(RC<| (|:JFY'Y8MU?G?#>|PUDW(|ZY=K>.VFF237H6K'\$ \$MX|<
M^(|HUE'5<|@'&|!A(|>MH|N(&!D14|&^7_FOCJHEQ9G* @)CF;=4U>W7.=YOF
M6*RD+O-4E3\$PC73J7(AE>!C75(Z"43.C8\$2S!|_9J=.I, A M*W*6Y>:|956=B2MX
MLUHF5XHYI^GOY.|9F2QS%3V+*\$S|. *X0,TWQ9C/:XNED>F'|R1B+SUZ5)
MM/E9|T(24M6V*L/\$<_?BO,"MQ-9\$O|FZO1:F3/M)&'(3|C9(V\$F9=&|4>|8
MR;)1|NY7.VZ<2|Q;EA>9*2?ZK?&.*DZ81+R55%F_7%VNW_V;R.F;E|BS!?
Q!UDX5)YN9/_KO^#W&= M3*H/|@.H,+2&ETTM0NJ0
@<\$|H1\$SS%*,*R(F0ZKI<7+N9E^"C\$QS')K9TT;& M2.I/.OV)T>T9\$Z,WTH?J8-2;JO|1B
S_5|AY.6J|;.(*UR:6H47CPX2:MJ^ M7%)6<4,+!4|ZWW+)W-|
>&\$9(7OV%8LK@9'DN|0W63&FV+PRO:GE>(&E'I _>_W7YZ4#_=?|C|/|"G?/M|^>50.
M2|5F|H: @E8R_UN_+2M5S,Q;_4M@N:L7_Z1E@#M4M#RT&CL6H8P+8=\$^,5CD
M*BQ2L6*KRRZD/!1=@>2B!47CG|,Z|^7THHIK_6,C'Q!#| BR7%G.&V&E(1@0_M"9"6=M
5E|9;E3?D=:S8U>|U^'LR"PY+<|X@E.D@F-C03BX;+L*4R0MEZ9M+H-E

M5*>+E57&*D<@%UF)M[!Z7+BN23@%=/M4EL1=J;DQOHHVUI+7,HE+!*76!VJ
M+VV(B37)(.3-V#GU+30N+@^/.[H)VQX:(.L+JVYDL@IRK<@A^XE6Y5N3,BS'-
[4,SV.HIN]>PII)@JJK(/Z.PXY"6YL MRC<<J2UV\$V5\9E0Z8!DA,MNH!KPE
M5#;3E;U(O)@E[0U-UW;KCQNT1A*5'L\$9H;%FL(N\HD6P+P/KIE+#+.6UD/*
MTB3U8UT\|S\$>P3MJ\,8LG^6PP,A@VJCZ5.#6\1UMH_&%ZPM9BT
M'49DBWG)G8B';4K+.*:HZJ|U'@+ZED[F#N20IFDE++2M,.28E|AA%2=B\$?2>L
MW.B_\$NN%*\$NX?N\$E)+R2+=OQ;.&Z&@JDJ+KYIM".S>40)ANBWV:5'0W%"I8K
MT#>6|.-;^H^U8M8^T^J303N=&&P&"[Z4#O FF-4,&B1(H:5A"=D16AQ&2U
MR^C=Z|?%R/2(%4I8/" SWN*(OY:|S|.;W)3XV+OCTKH;& O)S1TFWT
M%=M3*U4KF4|I9(TU|SD)K+YM\$X<2!7?4U)K3/3?"RJR)T\$_|DY6*+505%L2*WAKO*.B-
^WB"-
DQY6!HSIJ(P(1P|LM8EOR*HLFF4PHK\$DF*|1D>YJH<&"RS!HJDL4DBUT*BXWJ9C&|PZ^A
MYS&JM6Q%M^CT0/:Y)|MKJ\ TSNOP37PUUEK_?|5!U+Y+WG_#^BRB9D1&\$
M@OE!SZ9M8ZB(Y>MT|B;N,7T-17MVLK.(TZ5H7AN+!(S6K=3#V8P\Z*?3F.1 MF&D
9LI;^<4PHW.P.R1BA\$1,..U&&*ZXB"&9\5"51=<68M+#!#WQ9QB*JGG
M7UAM0JY)L5GY"92R&-F>B?S,>/O3-&#A:1U)K.S-.RZ/E;|S2D.QTMU3|0/
M5HJ7F@+3H3MOA*MNEF"RE&2(B-M; >X^C\$?7HA18EP,NB96V?
6CI=EKCD01+\$|%27FO;|S\$OQS1;>Q&NSE5-2\$DH5 M=ZD24-)\$@|)%>=S"(F);5=NDSZVP
M<|P.>;KL+B/QU\;6F!>="IQ.|>\$|TK(|%6IZ)X8K3U14-;+9VN+N\$J M23@!NH(*;
|U4;6Y_0M9|J1:&|4Q)0M%#++3;3&>CJ6|^C-MZ4?B#-R#H@: M*(F<858O:
DP3!+MR44)'HCD4);1.'E+ !UJ|CFC0DFJRM"\DX<|B
MJHLZ5HK*:BHKPYQ=V&E2W:99:@N+B/T-:)VY::F9-4)'IR4O7:^GMLW*0T?#
M5A<2.N)#IV;K;-IR2NC0NF@^>HFM\$YMG_+#5%0U;4EN6QOC|^>MVZ@>&:QJ6
MAHS==_"L*-F=3DF|F| V|^YV5*CAZ'>|CI+CP3=-F#&<G7MCIM\9:NB2%
M/,\$0#CT)=@8.;N6|;|7VR|_|+S;Y P*=||3X;I M*B^&%1#TA*T0R09%,K^3.Q?
B:2YOPB+M_T#2?YW3T 5*|TRE@+8,Y|4'4IY0 M"(6;|EV?BN.&=L%.IZ)(W#0-^4-
^QSAYQ%S1^,E+<4E?N#:"N CH0+*G KN.176=TKHK_;NC7N@=0V<:@-
J5OJTYSV#G"S62&'H^65-*N%A(XI7,IR@"G+_,E&HJ;|MI>+FY*
MLJROVC#4<5O&RN!*MEKM"\$J|R|(\$)"K?LVIM!)5O+C08R6(J3052Z69558-T
M|\$@@-11(Y;M4%0=2|8U*/N8-AQF-6Y)|6 F>YR>@|S6ECM@E:/<)WE"O
MV|Y(6M|B0J9*>Z |D.G*2CQG@9CC|04Z|&1N*N0-
AQ3O/M\$IB2G4.;B>@|W55U&U^K?>N?7UTM,S)2VOTI@9EBQ|X_\$
MC)#:N\$|3"%/_^NED?0'+?G+P M
4GNDMQUS.IYHSZ7ZGF2NR1W"31QT60%C;CW9I6<)Q0)><)6E%OQ+V+K2PD
M+^>7A>2KRY/L00*?8/ADICSZAA_ (O)-NO|2CFA#|H407O|:@WW39<|H4WY
MDXKW|:8T9P*#:0F9>@"VY4Y7\$96'L><.G)2KA"|P8\$P_)E&UCS@I+P O(&C
M9M6>D+@Y=|RD;%C>N-&\$B;J2H8BG3@6)J^VM\$K:OK2PR|92Z")BV8/=2O:0Y*)'L)-
"1K,9>-:M1=S)UGFU8Q-F#_<\$ 2DW)XX(0_PE?^01/^F YTI|21|NPA3+M
M@,QN_>A+?!,|S|_@7;X;\$ \$ 8##:BW=)PGTV;DFA\$#Z^/C#X-T?
>T(KC1+#+/1|. ^0C/1|&^1:1--HJV!F*|:"4SFB+8(E_%W\$(Q,IX M)M<3EQA_71MS&.V-
8;T::OYR2A)N@+5-&FY/GTUR_%|3%WDL_=ZMU4F@'X&>
MA7^ME7M71QU=Z^F|.|MN"3|)%D! S>IK5&B)M@)D8EAOPE@">PO86//B+("M M90-
:WPWL;C:P>WN S<100+QT!X4EL8R51VZB#^|C;ZH4|+2F|Z'SPHQ@438 MVCWITK.?
0_J.1FVM/T(2A:|8|.4A|=I O5_3WW?|H8XVS/RITU8SO|HE*JV M>_U>J4?
E?|_3^W)0QQ_4.:>CJCKZ,X_81JTM%@E!OU?/?)|2?|VH:EO(M= 8):MX,DLPG68;997(AL?
=Z'A%"6WF\$1V_JQB;WQCR4*W M|HP>;>&AEAN?::7YQPOI_WE-
_DS>T&2*91/!M\$=9KPE,N@3368")JZ++ TLE M-G/A*A|+N|U553PRW(1K7'MA?O>JZF-
1VU\$|KCFM^IC@E|TN.[7?&O=ZLD5= MXP%#684L#JA!:|R7?3*;!RC.>F1Q0-VY)(1*/
F&)|Z*8G\$|C;BD0\$HGXY\$ M/#F^8>77QREC-
U7+ASY|9JF|9HS6X5,=4HBT>TZF^H5#KNXZ*IK*IZZDA%QC M(%=W;1&-
SW&)1%QC\$%=WO0U-YU++|A0M%|12+1>*F#WR_O.|OUEF2ID,C-OI M-
%@&%BUT0DU0Y6@?OK"NJ)>=0EG6M|<
MTX\$MDK@OYA2K(F^/.,^JOV&1D+M4|&Y(W0=|ZBS)%^+3|7ADRW\$JW'GDIGI
MWV(=F2?C9Z8JUI5^Y"8B|7_16U(XU/"4B)-K,B6|AD#7/|5/-1%ZXL6*2TA M>.HX_&-
#D'N?5WG.5B#@BOB*!>:HAN|9..WJBTBTR/K% ^Q?0W6 \$/?0/\$VZDC
M#%OC7N5421D*#R3&ZE9)BV)LU!KW^O)C9X(QOO%8-6-+|ADD2:BJB8-LRBJ
MQ&@9> D.31::920..1QZR#'=..1@6J5)E_\$7|. >+->##GK|X<6|B(A|>WCG MX!1
U4'%3:>O2* V#:@U19*= K)|Sj\$D6:L#UJ)!:*< ZQET8^,2OR9J4(J

MO!:@GC,SY7+BUV"HR)=@B#W8[*P&A0Y\4I#!E5?37RBW"[XJ^7\SI25^YJ3M
I8=6"TBMO,\JAG',AXZ?= ?PKG7-!YDTQD)SJV2G.!\$9E[*R0W4PW7\W%
M<4,M@NH+_P9QDE!%PJN^QI3W'FPF7EA8/),MM_/_+H'?2;QFJ?LRJ8]^:SRJ
M7&%7.IN%1&'IDK0G0^\$ M&!M)&'82!B6/D@/!&0PS*R%(\$#8!A*7/W4X&PLSR
M",*85ETP2J8A(<=)R+R5:H1:[JX\LI\BJVVF-AY45#!FU*R0.3ZCGEL8A!F!H ME6/&)!"%!.
()-=W20,PLU2!AV 08GE#7+0W#S/H-,I.A+B!],DQ7>3&L@.#9 MQ
K/)K);MTGC40Q%%Q?L#UROY*^9G-1MC?7*(672>R\$D \$^HX18'8*U\LN, MFV8"(2::0X
B^=,=OFE[4IT"HG.\$RJ\U=')+Z.7K]>W6KR7J&\$;A OY:PUY.
M7RQ)U*LDX23A).'.XBD)N&,5JA/:@Y8=#(Q) 3!=K&?IS:6L#/(-'N3,S*D2 MJH[*W:J]=>
<8Y'WIJUI"',3CY99>+&=L:F6-S43AITP#<-@:5X\ E2=Q0F)%
MYXV5D<1*0\252MA\;C#J=<1K82<1!?)%7;H4H@214-2UX4\$+IQ-
K:P5#JB0:E2_"KW?IT_FKOCECK[,V:-E'XMQA4UJ3*PF;@83-6<"F9I5N%VI*
LI#T9PH\$E@G M5O X 6LD&K NP3MWNW1@,/IA%<*<.4###C;M>WLB@@
:=+Z.\$9'B54(0K);?5 MD>""-.JY=&\$6;!^1I4KT.^)DZ4KMM.9CCYH@E-EY1\$*H M 1
J;SGO0\$YQ^Z:OB6;?2%R=V'#F@RM=-%Q)A5GF(^R(V_9)BS8;^'4:N+YA M6OA9(3)7Q/;
(C_B>;ST/7;EA"W7:#N(@#PYZU7P;NW9W7HA/#53QF"/\$E&J
M/H#_1,'\$OcbW\$8DJ,5\$5*AER>>3R7&1D# 'KX5E'N9%1Z-RNH>=^DP^Y' M;#(W.I!
JY@03B\0=D*KUOQ*. M,+_E.Y%70S*P9&
A-.T2##QHC3GW/97*_E7\F^E@X,_BWA W>4>;B>Y6W*W MY&X>QS<ZG-
RZQX/DOY/VK.?,7\$202 MJX5\$ZJQO,29 C\#/#OR5!BBG!O*,C(UO#,:F8UILD1_+?15P+GG\I,
I-^M%8WQW1E\#B(?H0W)O\1,%&?MYO1+M#EN-
T,D6OCG\N0T_9K^OMMO=J5NYD^=MIKY M?=ZC5+7='>BE'I7_?4_/?
HD<5*V#&NQ\U!X7\DZ/\^JBUQ0HAN/?N.,J3 04X M"L2P4.V\A0W77J\<<=<84VE3\$
GM>2*3>_ =1J0;7\$Q;06>;F\$Q\U2:9I;UW)@%UCL: ME\>\$IR7.-
(EH>E5IT5"Z2#;!5!E.S8A)W*"/W<*PGPF5ONC=45@*JV+8L\A2 M:-!8@(A=LUI5A*
=WG,%=2FP- M9L\H\YX-T_Y%,5S3@[\\$KL\#%_P%S*6_\$<*M\$LC?4F=J4=_R^:!"!21F
H3,"OW!Y5<);GJY'\$A)^.JX@?1@R8F MITJ6:R\+B:H=EF
YF;?;E*LDX23A).'.XJIFN;/S2CA/J2M;<0V?;+?:NJC?
M/I=:3)1F9DE6K>B\56UHZEM^KK*152F3K7V*OV=C+L>!%P-Y-.Q= MPA'PD^,;5E)1-
6W% H5\$5TXVH"C,SJF(?)63.5S-2NOAV9.'B)KR=_1EX/OMV
MUX'6L#4>5F_#T9#L3,F(9\Z(I53M/2I#CCB>,\$NV% J=DBV%,:C.Y,:BROB0 M>_MOR:I"
(5:RJC 'WE59E7M_1?J+.%33F*"@JLX\$9U9NI"AAK'=6MB#,:L'(%
M376H)Y'AU!'W\OX+3"K(ABC9>44*?CY^9LN8!JNZE9J;,HNT 00,U),Z+
M.24H8\T\I\Q,/R.(#"I^_L\Q58<:EGP1)\$Q,1F9*[N&?8E G]^BML=:@?F"2
M>OK+/8=Z9+AQ3PEKKRM;_+)D+F&^LP3,1K@I\U14B?2D-NO\2?"E; M?>
(:PV_8^_5JY_P?IE-(M-PA")P+C\$>X7>/8G\$RV%O/2@89\#SWMQ0N4E;S27-P9'YXV!Y W)
M&V?!&\-Z>:.\$#XI?XR').9)SZN>%P0LMH^&?UC(FZA>GDN_ MOUEG&-DB\R-
(+ #R\8*4_WOTSOWW A:4@V\%R0MP\=GIW_Z:1\$"XH6^X,:XIG M04"F**U7(G6
E.3XWWB6EMO%*-.JQMZR)L\$J=9K7_6=@PFT9VVM(^-;E6B M6Z*
I3G0/3XENK37NM3L2W1+=-:%\=\$ITZRB\[*^=&-P7=S;?*?LV>,6%"<.4U^
M(87=F2UIRXO/'C+H:9\$T;A)\2 @DBF\B_-U?I=8FH=P9;+9M\I::J79ET?L MH
CLR\Q(+>MV%1%NL\B?73.RG/ N7VKX:DU8&T:I;SM-H10GX"=QQE?53
M_F=7>>5S#^2^J\LOP0I@7JX2XA'@.Q\$^QJ(P0XI7/S)H"
M\6:9U\$<J5;B@8\^"ZN,:%4"-00NS+. ^J'G M"Y)6E^%:C1).%,NQGZ_Q-
(\$Y64\$_'XH6Z3.LT1,LT7>Z,E_Q M.
<3WLK<(33I@I>E^SCK1(:#7T24\DJ"7L00R\ID(@O4AH)U%.X;U(+_H4@-@A MRAW;J8
11LEI>%@74V*//L<=ID70\$=L2=;,"%Q,K=G#RS\Q
M\$7B_7%G.&Y:C34C"O75NM\$X7#!\$1-#)9C%DR2\$TUH*HQ2"^K!ZMD\$&%)!FD
M'X(:CDE5M7B=&,D2_R\<:#@KXYE<3UQB_5MS&&T M-
X;U:KQY2/;\$D:F?;U)P^WILTF_ VOBXH*EW\NU.A'.NH(1_ ^1&:W?OSU MH)5\I\H97'?
WDYTB9KV4M#TGD+R5AZYB3Z\C\H\FS8E(KWI_=)PGV'.X?KC MA+?02=_'?E\3HMUA\
B\!N&;PY_+_.OZ>^I_797\6;^U&FKF=_ G/4I5V\IV! M7NI1^=_ W\I.R7R\$'5.JC!SD?M\4GM\
(&-6ENL\$();W=>LJGV*MXZSUPX+.62 MQ\I\I>84;I-%?+&72'I:1891"GLK7Q\$JYW6-
,DHNE5I45# MZ5(\$3)=(%_WBS\;C<@?7?C#=44"H=KW,11W6='HEU@OY'=ZS6(<%)P\Z
MAJVO*ELM2>XX ^ZH&(OR">,@#LJ\VA)H#<(7S\R5\N*YXKG9\$ZZR M3GVQ)SQ91Q6-
=;AF)R!O=67^;Q',U P*NOI-9L1--"A.C0Y>SSD"CBKRB:"T>"3'BML#3(M1J*!I-
+A\$D)SRJ7OC)"3(K!&@='FJAM+^%A!%_M3 71JKT%#861ORU0@:C
MXONUHHGFQY\$8\$UTI+(TQ732,79JO<"1JA/UN5Q>"RM;R%A5(-. MF>C'@^=4,)

(2!C5H!-2&)78K_F5Z)(8\$Q)C->B\$93'&KXZ5!|,>HA/JG6OX M)S^!6YL.O!5#9)%UT3?
O:4%<0JMZ9?+'L#4>J(*82!(D%UE3+(>K46L!%;!E
M9XFKVE3'4KC2!;1#PJJ1L.*K+9:#E2H.K\$(%,7I/1->@,;HE37D_8+=WZSB
M)=D5@&ZG?F!8"FWEI=Q:EC-E=5|W|1H|QTH>EW|_19V.W!G>0IZ.|&P:V-UH
M&JCOW_3=|&9K*-T|R-0XPWA-"L@%OL5H)2H@W\$N+#DT)<
MK'9_(D#|HKS3OSDP&AO/396)8||.LPW.U_HMS:RC8VA5P|98!0'TLDGG3CU
MP+C7.0.;1P#C?KMR\$W,)8PGC"!BKIU2=NF(5>Y80;R3\$M9-"7*RBS")_*)
M#.X<=^6XAD|J<->78|GWCA'&TL4P%@Y:55.L=>F0X@|C8|2Q='4*8R'!%0TD8 M-
Q+&O9-J3F)5R)80;R3\$^R>%N%@5ND6 ^\$4='7QSG14,YTT>&>QFTL\$QU*F^M# N6?
J@Z43P!|HH'K;'+>%J)|E41Q(U\$|.JG")%9|= GQ)D*|WSDIQ,6JSBX"
MQ"_JP.#!|@+7L*>\$PA)77AX:|. %7|0B*5:|!#O:V5>|!TQ4Z7KBCN,-. 6:|
MUM*5^082QK7!6#^E|M03JU: ^A'@C(=X|*<3%*M4O L0OZM#@|H|@KCPQV,VA MQTA
|F\$"&4A/5&TP/D8&<@|SD-5VY8*\$SL82QCDP/FD*(7=6;PY/B&5>648.*X,^)>^|J!B?
M.98Y4W#L>V6%UV=@_1FA=;R2Q+|!\$O'09/JK/U^>4^2!;0.;&1 M+4X:X=?GER_=?+;
(:7>BG:+=28+,,M!RY@03BVS2^52=0.30ZA|:1;=6N5W" MS'S97Z5)|U_4B7)6?
Y7*/EWA9OF/2E,46RTHU2QNLU?,NEGFM<.>!6,H-DAO-J3B+1
M)M%V5+1=U)&O|\$138&_OU; ^W=UOCR@&@/,*P94|M|NCIUX^>7FLL1\$:A1-|W M|
PXHV?/&4HG@2JQ>JY(-""UO"XV\$I*++&:G5R:IU;V&BG!):/Z|^|A|_|" M%OB?
#PHX;/5X*,>^(Q:XX\$0>3<2/MSAHYY_QN(U55#8HL|MK23Z7|!#L=I9
M7)K73W:3*,XD|9|R#_"46X@V\$M+&Y@Z?^L^%!WIKK%>V'B1|A(0|/Z.'\$NJ?
M6'T3)+:X8XOWP40)|4^LA@67YOZ3_0(*<?O@Y<,+NBWQD+T9)6F-7?T|#Y:
MR4#/H#46HC&U1 |W|/ ^V^KS/(TIH?6*5I+|TIY^L"%^ . M47B?O*098MB1CK_&PH?
WX4H&?-366.=5#\$7"1RSX|#YV**X"#L6J?2ZQO1U; MO_|DBJN 0|&*CE^:XT_6_-
f'&O6G>@R|L&O+:*UFPJ?^7(|AKS7NREC19L+G M=,D>0|&J6TML<=|,ZU0NE X
A3/E"!W^09)! T(MB@M6KN|S|G:65(V1C|
!;I=DKMSBV/4PUPA|2%4NE2692RR82>;,SUQ'UFL3 M-M/H7\$IO2!;3C,>?
!8X703C.T2ZBM_62XSUA5
M.U5; ^Y^RK':3|K^H0|NLLMJ7ZMG.Z36R68JZ0/NIM1|"1,9:5GPC|I3800%,
M.ON*C+366*W>@:HI|1'E(0UW*!>|/F6|->|*MN,2RN)7Y97XD/@0;|X7W"E8
MEHTNMIGWCK:9=UMCK5VY/02/H%H1F%%&C'. 'A+*%<)>Y0WSN,+ M-
"8M!N42W4E'8I76EC!O),R')X>Y6%6^18#Y17FN99GQ<@P|.IJ*-6R-14%;
MB/(Q(G"E|WPQO)FV?-,L3P"+/?:0A32DEAN)):5\$RM2>D>L4NP2YHV\$N79R
MF(M5%5X\$F%_4J8(L2U^*7X|5|*)W,.B%@XK5%">^JJX8_E842|Z1Z=8YI4J
M);\$LL;RS9O)|!"BQ2O=+F#<2YOV3PURL+@ (BP/RBCA=D&X-BC#HXFF|5EQ'%
MTD55)Y2'1X/RH#76VT+469-0;B241R=7G|1J|2!AWD28;|:,. G,Q>HZ(0+;
M+^I00;|*,VSZK&T++5#G;%|;Y++U5-6-:AF45L-R5>0L2R|5A63^U+J6*
MU1H\$PKR1., ^>'.9B=2D1 >87=; @VZ04X-)CI3;K*J8V=^2Q@G12U8;E8^4V MZRKF-
JMM(=K_2"PW\$LNG3F|65;%;R4B8-Q+FITYNUE6QNMJ(-/+E?G,*M3
MQI0/B_>R2=QLU^^M4\$U=)B4Y6|I> H9=J7I=*I7|.2XJ&?)^T?V@TGFR6>>
MH\7|J2/))YA*9S:>8YN5ZIU=551K*59*N3L=7)HQQVUNGK&7!Y;43/O5|^
MN<+^_9^;+F%(4E|RT |H(X_ ^"KZ-1+F\$%39N28LNH^S/P?'/^OKXR|1FLZXW6
MI:UQCCQ-C9IT"Z+<.4MX|QN%RN"|ISS8+|3S:0TK^&EI^CXA"EFN+.-?4POE
M\$I@6KN;U!/#YEV*L5JYC3!>*:0/>?>(N31M^57QXLN7 9?B50E/YL8|@P>-# '@ M 5-
X55OYE^GYCHO048#R?|!\$3%<,E0,M@9I(907X|E,7Z8I=8|(G>PEQYRH3X
MKX38"@DK_=+|*(|W*:,DM""KEP"M'XA,S9.ST'CC%|AX-:;8DRG9.7C M-<,*|,-
APF>TZ&365KX1&-C,| WZBTM>3/(*C_0=M9;H@
!9<=YB*Y|C&A\$T2AT,A!*2!U|O\$|H*S'O|.6T1H;O=|!O',_ \$2V|8 MRKZ0H
@_B(2X8G|0AG66=|B3\$!B!7|^+0DN1G\$,O|T/*NJ^A:|!\$O|NXKY; M*|@OKB=
|;^NC3F,|L:P7HTW#W?YI*0",;5)P^WILTF_VOB8AN:|NW5B?: M?CKJZ'K =D7XBUS
H1/G6>;7@ \$S)+@';@XA_ (M@29P,S 50S)_TI8FG@F0F*+B7QI_EB!; MR;/CON'7;
(8W6WR8OV3A_GZ-'LN;|G#_(EZ?<,O#?4|KQ|KA8>P22ZMP_#| MN'!DN|&;XI%IX-
)MZ8KM2=?AGI3|@6V,(*KA=KIQA-@ (0> M@N7OP\$S10|Z-IC
I6'S'IWM/#*,E|1?+'RBOP@8VJ<6.V87@"@AA@_9F| M\$M1|1LH|8N@IF^Q
P7S&0\$^M,58|OIOZUP=>=)/*\$F8P4SLO\$=E4@>@LF9 MH&Z#:BY|3F
GO@C1PA070(CPU5"A>\$-A(>W8&,P)T&H&L#|L,U"/XF|*@DE; M@TG?U@28\$?,E6
()IUL&E|K1C?,Q6 +>WK|.UU;5|Z%P?K_@0S| |GB"2?V M!;_X@*ILPG("XJ 1;7"7=|R-
GN5YM;|;5?/%2S7T!-!;728U1"C"2T|42 MY^QG!D75?
P%!5E2XI+//6+K0P0\$X90#G|OPTZ_H_5.

M6QWV,W^"7S*_SWN4JK4/O4&I1^5_W].S7R(='7&#ZN^&9TX'X&Y6!V#7>=UV M-
PK1?W6X)6"SVZ_>QD)0B:7@NOD*\$A?W6@7>:.'FM[,9:SD2,-M3)" +0W9IM
M!>J!\|SKDJH(TBB:I\$H>8'1)FJW_GM"?H2-WFFFJND6CHRB0&??M9
M05K;VU\$001UUXNE'.B#8&X1C_V6AX\ONMUT-9/?J0W?I\$/MOW+/.@-OEHY+W3CHO.
I/O^E,I>^D>:IW:+.?L_Y9:N57;G2QYK_OB(66 MG" M=GS.XYZ_)SE/*
!*SBO\$>7H^N3@3/1)3@EJ0G/#1S+Q=WAYR@2-RF0.Y,E MNL??C/@5J>51BJ?.\$?
B,+/A7#5*^,3MJC4>JA\$TC8=,NBC2N2=F24R)A:G! M\3%/(2M)8DHL3
UKV\YT3:#M\1).A+^O@|EE<<=D#_ ^\$.C._0A4_*^4Q-0: M4V/Z#O?T;FLL1)\?
B1KNJ.%U;)6!&BSD%*'32-0<_A%%ZMDHL04=TS5=YB@_MSDC&FA@>P0>TQN_4
M7S93QN0Q1P:S'O^80Y?" W'5'W"/JH->Y6UD4E;(2\$#:JCCC1LNAVP8"HK
M#A(V0L+F^"<977F2T7!,U7>2T=5:X_Y\$-
AA>/2"MKJ9)_)?*_LVWRH!;-6M*SJ0,K=D;LG<: ^;F=0R9
MP<(#T*W\PT:P;T8WBH)UEEDQVNS:J\$?&!JU/^T\J1:&!!5>Y166OHI+%,^4?
MI?;)48UZ'K;02Y\1M4>TS67E069/1-E#DCR6-<)5IO=SVB_-I/?JO*BM@>
M/@G+|EZ%)7%?R6;99*!8=M'M7S?
J).HDLMIU?J_JMZ^6TEZQ?J*BK.,^5+R^OMK%&VW3L2?E+##LO,L*A*'Q_IL M%W?
IA.QF+"5/%=4AF\(|GLIVOTSV\1+.A"7P\&8?_A#T\$|AAZ_ER\$M)GHKPU/Z.|SIJ>8;-M)=
<4RS7I@_OL:!)X^%RYYO""+AT)G'_F/+6_XX1.JS(HJKW_U\$X,)/"P:!!>M@I
>_J"C(P\ZSIRG\G?0T>E%.6/)!DFV+99G\HGYVN!!X^6\8Y_%%&1QYE MG#=#/J?
L\RNCT*X->6:#S+^\$D0P/(2_2D@T\$;OXXJ+NOGC@)C2:%6PIW5+CW
M=R\752L#M504R9P48"G 4H!3!'A_1Z1=30/(2_F5\KO?J/P(WK6\UD,*MQ3N
M_0OW_FH&NBTPS8VBZI?#!#R\A#)|YD#\$S6V\B)MJ/'!K%\E<>.%\$H\1 Q)G
MPRD;SS\RK#',I%IK%0I.O"\$G\4T%90*3G0B?28XM;);8P\5"7ON&JZ'/X,Y M&Y;K.
JHU8L0+N"U(>R0R\$14(/O'-"6P2?3;D.Z_80R"(CCOHHH^@Z,K<=CRQ
MC_C#N8Z":0!5O.AMZX\PS>OR"W\9X8++YW-#-IS!?XU9AYS9LABBN^"-)0-M+K
@KLZ?S?D+<24SYDUM8_S?Y5S!1Z4W" S8P#7UHF C7)J8\$0I@C@|@ (6:2N MI-
(/5Q.^=0X;@V!<; #F5HL3S>).W&>2,N4_-J%'R'K8Q\Q\%EXNS1K8)7 MLMG5WH
M\HTST\$1_-FX+2?9G":\5#RMRQ9P:L MT7E7+-
MCRIOA37&'=HZ/6_H@704=70V\$#1+C;|O|+ \$3|A84ZHJ9%E\$0GK>KZ;VL89V+Z(A^'
MX8&!D_ELSLK&T%_P2\X<_T\5#"HY6G9\(|HDRSP^=:5I7(HF!_:0 A:491 M=3\$-1)3,1+(
*X34_EL<'E(8QI;B\$7T(-M#WLA_9.Z+DAHI'55M+!(K\0UA M).>PS;6AP_2?
-7T"L\W6S3?HW47S"%6WH&OC-%Q>/E_DX.I#!PU\|KU+NQ-P
M4T/MUWJ5U;#MZC(#A_8LCMK^:'U'- '9/F3#MKSAY4/@7BOZ%\|6',?QH.!
M431I"BF@|MUN M3|)%&T."N+\$-DW\|C=0:P=*\$XGDUQO.'11>E R!6ALR6)R% M#Z
H.JXRA\J)9H=T7Z")%S;LC8'%@?_BXZ.I;KV0<#N!3>""*6=\$|+N8T#9!B M?R4F6-
Z%=@(%W\|L.S"\$R\|P;:'63_L\SV2D"*IQ95&-:@M\O>YQ)V*N&^/K MI7V&
(VU7J.A.X@*!EEK7^OE@XS\!WKOUUCMHL&P)!2>UFN@9\!:&BQ^J/LW
MA%Q./G(2^AH)\B#3=" _U58"W)*?I#_ ^@3SA,ACA&YPU&8H9#12K-^=MYTO+K+M>
<%(=0\ZZ*|3Z%O_8D\U'AI0NQ>%XE1OZ_UG\^APMH3_S NCEB+?QK>-!\$(MN_%
(.!XV4U!-PZ2FB'O%EP:<^N&@E.(+DL*FNJ;)_"!2B&7W4@BE\$%ZL\$*XY
M83^\$\$/8:E8'/P4IO_0XX\|L\7C(5AWF^8RGBB%DDFZ\WB%^VZRZ\Q.S+'6Q+JN;&!H62
*|N)YB.2T#K>%8G*9)3CM73LL>#@ (IVU>\|TK'4#9 M&O\A^<|2T_|5);C>WW+4;L1+-
!@X\N\|KC:T7%R807PMST&O.%V\N%F/KBN M3S5
3XL|3=4SK>'7AXPGb5@NTHMN\%2E2KBL4\F8D\GX\9@RB%._65>:E"TZT,MFB4)3&2
?)!4S-ZY+\$=P7!STG>3!40+@&A3.0VJZ?GDTW25D)>YY"TM&Q5TK MKULF@0
.1Z#S44":M@9\|Q""OU&\$35\A6_SD;)K*>A2T/?A::P!;CZ(H*L%
M7"@BY5S*N93S3#DOA4'74G%:3E'0XQA-(9)#% GH5%OPEX%""M YRAQH.\$+H
MD8G)1A\OH#=MZZ6&T"K 4\XP3HC2_O&+*P998)DLL%TX\;\$;0E0_A?=PR!71
MJD\#V7,L(4#F?B<\$%=B\$*0*FV C=8HT5X(XW^1>.P<^1%P8\$|YH\@^A^G1(Y-^L743!
.3|_%7.^POWW!8Y-077Q\!GG\$)!053N+ X M'OXPW)\UY8'_9MBO.;P9!YQ2T5UL,B/8UR';2
30UV"O)\H!;062"&O-1,;! MIA"0A_!O)D\ZNZ\SS%R'&:R5^P*-=D+%<02 M^6EY0-
4%#|+D\!=,H>.:Q_"3D>"9F6Y8'OP_H\$|(-1>#;)WV!P;'5+L^AUW^ M!;K08^8I_-?
X5=)4EIJ9\0^|L(M(%N2!T10H\|?Q A.|4S86>#YZ?(X0X?, M#/_A7%|
L2XGF,%X2<'B;)R^'OEYI2T/._V"U\7/G%.1&NFB5 MOD*UH!H/GK=HED;?I8?
G\$3TW0CWGD9XCJ\$0*B\2/X)D9\!5X\;=-H"JV.TT\ MQO,%G=/1/FOMDN_S-X?
5.NTB605.XAS;^DT00UOB2=*J2/U7?KE)W>%8%Q8 MF4<&[&W\|K+6>E3LC)!:>-=?
8>C/|J9>_15T)Q4(M\^J#-KUG=.P191T'&>+
M_K8W6RM9FEA.:SA+MRN#5KTH9)&39^DBW:|S<+-|TZ-<|J9^|HE#&IR(|&|

MG[V^5:!(KVMGUUP3'>2M+JL^'/'_MTN[V\F?_\$8CPSE1TQV1#CHB.R,G M%-
%2509'1#85'MVWWHZ_NY*-JY2V*,T_C4\$65@WP2ZY"U|GAYW,.%L;H>+Y?
M!N=\$)JOEPEHFK,OD2)JT@'G)">OTTJXF8G>OW6KNVKD*67ZW;K',W*?GG=?_IX^Y
M7\K-USOEYO;VOY'?IPK?SX^/044 M3%N%UAF/V!Y7D;)HJ1NO/P:C\$;-#
IS!T0830F/NR#FP:6UM_H<'U6>/'OT M|_00BHIT#&+CF^Y|4|N|YZDERW"Q2RDSQ^U.
(0!PEW/<:^ZI@9?;:(NH|T3/ MWX2OC\$,H6?ZL-K:|FA@L3'3WPVBBU>B 5-
0;R5HH98F6VE:C"RM(6\LL8|Y,#BP"(Q>Q5Y&T!_WI_|G8T9FU\$+8<@6YZ*I
M@;6^Z.^*UE#|U2A3B>YG8J<<^JRIQ>XS:NRNS|1&VL4#*=J,8+@+UFA:|QB*
M0E4S% 7U4>,Z4>RUQL.TPH10VI9^J'Y4KW.#EY|)^Z'*VXEU
MWO^L+^N1@#V\$|*)SA!8MJI0?DQ<;&l:,Q"^!5HZ&7^NHES;S,U;| MZ(WY-
T"K##KM1K619D<7'(<4S2(EM8+CO4TO+PY|0<+-(20B|JWDQ-6+7KJ<_M(|D-
XW"VVC|39I69G"5*7=GDP(R8,O|4|F6|HS5GYW&+.4_ZW/YA|5X'//
M8@YL|_U: 68'9GJKZ@T2961^N"RM|NBU^RT6&|>+8;(34W=X/KI*_90CCUB
M:;PJ\$|>><I_09D(W!N;H#HKWJB+EP|_+SB,=)|KL_ M#0&ED;H+
=;X9R_H1|EFO9(%Q@6N%G @@@:PU+BFCY'1"/1BPCBVBNZ100@W MBI0K |/'D2S0=?0)
8+T\$3HXW"FH*#%5.N1),BAG;&M\$RF%\$Z#Q^IX?#RW M70-)>.W016>O3.
PB+.IR',"Q:&Q>\$0?@AGRO>Q'\$NW-1Y)G56W'R1'|00+%\A?%%ZU9)Q_=6?
MKNXI/XHZ=|R\$>1>="Z>9J.;WD|J5@=9I5S4M"?D!\$T"6|SP_*.9 M\$ Y;.%FR|PT,;,>-
TF<.YNM+<4XV6'.C_FMK5@@OR|3<44|6;V7B|GBM"MH !@ MP=61(!R?J6(^"JM&P?
L40&2AMP*C%2X#H3,)3IF//B_\$X88|CDH"%Y (09|" M#*|<)-;E4&
|VNQK5:VW,EL|DR0;@&>L5|L2I%;MO*B|ZM 3# %BC_/U#@K M\$FRI.%A9-
GWE|_Y;A(=#ILS-@=J>M7#(6FIE MT.RUJMUN\$@LW8*PMM&IL^LEJOI5*=-;
Y:WO3LVX1FK9W<\$T;4J;)|6L*=3;7 MKV*/CN(+U;CKN/WO6K8(
@:D.GQ;8@QT'(DS;,,,0?SILIQ*J:GUM^,Q2A85QF)MT+>=;,U5
M%:DE6*3ICW.OL=E8L|80U;>?;"?3OXI|TXR8T=8PMS M4--=
?.LFV8P;J1@96%4,E|%;.I;D?/2S.J*VQH:<|2;T8C?^9S1B>84Z*Z MPZ,;"
MPS.AVN;B%4")FS%8:XZ*#?;,'N4=Z:#^|/+5? F*UYP&%QG17\V^7#P-XTZ M3"
U@STQ/7V1W3' (1Nj>V|@-!M>*I7"!TJUL8(3|S">UFNB|H%2K|=. \$
MJ>906PJU@=^CU*!|#2ZA.SETZLU6?76'FH!?'S"M<-WZ6>|V)F&41H!#YVQ>NQAE-|J(P
M%+|R+WK-\$|G_NZ#|G.G-IF06D4X7S\$101H_XD?
D,*"P"1_ #UN(#"IHJ&EG>5*E*W3YZ",7L;B.:B) MRE6RT(FP4"|G-
F&S;YS;XIB|9YLLLYO4|/1UX8.7+?MRB"EG_<4H|S9|"\$S?=&O;5)--
M(">;A3MS|Mj+93|(GR%84;=? UV":>1SS96;\$|V/).L8M&5I_.)5+?^/CZ
M'.5L4T>|RB;SRAC% 7(@8!%?^L8;IPKH)X8;G.5C8P-D|E*|W#YVGK*\$L@=R
MY|C!7H:A^1,//9K%Y1*D.O97O; 4"!YPMY96E9>K+D1H6(4@;4)|)/>ZF#V!=G:97!+GEC
MR50E5%)K2@;VQ4K-(KQ0F9+86TI"@!.FI"7VZT>7CG";EQ;E7G^YE<@)|I&!6
MG7+BA1\$IZ!_E"A|*"'&E.%Z&.:8;;H-NY)72M7FAPNM=JL6G6=.20K<90C<
M7O)GQ8L>XL2HNU0F'#!-%DPBH#-;R@RGMO@^TC2,.'G7)R=@4T MAIU@8(7|>QSU
_O7T|\$|=NHZ/7;O9NF>OZB<.[+7%0+G?> P>A%DO3&ALQ'> M"P*|9)41R&Z?
L_4ZUD7==*?"JI |@GUGC:GQYW=@,OSFQC'PCJDH N#JT|IN M:D+O%)/#4F!.26
*B(L/*2:|\$N6H:O(6DC2&Q)9*7TET1?U(W8 MOY|45CO5)8I014+EU8/_2QXXD;O!
|K.Z.+:OG%EIN4!|01;|X'8JR MT|663*6FE2_)NK3YZSB?-4M.4NK#)*M5 MS
M2IHBDL)V'L)6F"NX#UG#.|B3|9C;I9*DP)6*|Z3 |>HA|T|@VF#<=@ZV#B%P
MA90F%0^3763QCYS=WHI(2JT9XV%2YH5"VU4G%511=G;/7U2&?8_529MFKDI'
MD|P%TV?JF4+@L1*@C4IYNC|Y.C3|S:'EJ@=RM3-P
MY&\$G8Y?|R(+AN1BY6+E8B^B9TCB=)4X4LTRYWV)V64ZW%6Z6"V#JSH|UE%*
MABJANCIHL)+%6"4"&;R|+O/,HQR)VR5Q2W)Y/HU#ZI+-@+LZVBYK;..9.4^P M+)?
|NBOS+IUFFN:3V\$=2AYR1#BF=?|NAZL ROZ1PE@L+28JA%,-3CPHV%,=V
M<6TQY:|!+*B@Z*P P,H|NPL,"7G)-TI(H;EOM*=#*)3K8#=U'AGR@"E.AD M\$D!FQ|M/?
E@.@Y4""_UAFTB7H\$#BT5IT*PNEH"_S'3O_U2,7|UQ/C%QK7_ M,=.|5 Z%?!>|JJ?
2Q),O,_3|2I,JTM@-\$V@6(5(KH="L#"60FA;|!^:E=
M(^/|B\$^O%">SL@BH3!.4BY6+E1ANF;5L%P;=J"K)F|>=CXDCQ5Z^^0:9DLR5;=1&B2
(PE=55RZ;R+A"7 M(.U,H@#T-K|SM(.@BST>+YY
YZ..U+VX4&D'Y3G4DU9T>KJXK2HGDx*OQ3^ M@R76|M^BHRGUI-*Z9;2+:6|+ "<A-
5C/&U'B&\$3^9|NAG9,;G T-RV?C&R_X\$-(@#WF|\$|/
MA5EE8#M4)3,OD&FH6,95&)|MK/RW;S%N"9J-JH(UM!;|V:P2SC7|3:02HSR8 M35FR<-
LOK#9TF/ZSIB.:YK5NONGO+DI7 M5)1 CN(T7%X^7^3@|T/GM^5MH3|A;P3W45-+A"V!
|_UGKT=:948T\$LC|6# M#2-U T0V|;G+KH._? Q.+0R+2\$4/?11CB5W&92VI&ML_ O5BQ?

4&7/5(BX@W MBZ_K\5OR<\UK=YJJE*_:M35U,^SAE*UNM9HY1HJ^_
V, TEN2<%7S3EI\$YV
M4HUZJH4OX:3.W95#K4E/EB(+V5M2UJUT!_(-.97C\GY:T3&OVR0C(V6R,U/
MF18)OBK\T^(^Q*WO.,P:O2N1J^>5A?..8^UKBJ5/BD2BYT7Y,^BACI#\$O5": M+ #
^8TJA % ^J<3XLCB?6,1%TH+BH.N=.W/MJ>;L:5?5-71)?Q*:NB9_4IN MZ)G|2F|HF?
U*;NB9_4INZ)G|ZA*ZY#_HFZ-F*)|=.:BB.,656*H|6O|9W2Z MW&QN"B"
|X8GBRF/D3F6@=9*7E\$B,(REJER!JV@%%K5L9M JXN41*6JD8|F(E
M+9^@-5>71.:6KQO5S|VBFS*D!):.*\$2|6 G/:NM8!:5T_K4*G2#|C|_C1P2
M4!*1|9Q^"_LRJJ<1JL(.(:,"Q!6"!L:&I>Z-XT-7;2DR\E*A#'|: 8|A&S9J
M%G#5MN2D4G)2PLSOEY.:E8&6-/22E
M%=/F^>W>.8).GSF?':S=?!NEU:T,NKM4!AP&4_8L"H9N9K SXW\$K&RL3!Q| MEMET+
<\$K|12R<4%9%H//0.@-K"3R)+D)J5C+|U:>43X|RG2VW&H=-??E8|Y\$AU'Q/-YS'? 9I-^;
|<:,>,E|Y|5|VJ:1>Q&|UP= _KU|VU7<)>1^@'K@N_
MC!Q8LY7H9=IGS4F|T0!OTDJ2|)+IU()|@N.T&+0;*O@'G=U;=R0_E4LU';3# MH-W
1I6=6PPD*Y60E=0U.9K#%/*V&TUYH'C,:9L|,:3)0>?M22?G3.?|7#|
MX#9V\$4|+=KYQ4)Y/EZU6_'2;*PH-(<|47=1NR*Z>,V>|3:/A/=<7M1O=RF#G
ME(ODL5+RV)H0^6C*K;A&&,EX)62|9\$|!+-W6+^XV;,EB96*QM<'TL72;6EP?
MC&2|)\$C)>6=PV5:T,DH<:Q^&P2SA?SB@+;^YR>GS191K-5J*Q9V|U&FWP2_80
M=#+9K_VX;H2VFJS,F@G@VS)?6?\$??F8+|&34#S/M2#V:5|(Y+UD MO\$T9K^A^A/R14?
O2+F*X9*|_:8P/UZS05CL7@9DNF6|)#YCL<7'|;|4(8TMZE M7%S"B)|DN?CIYL;R
:P64.'|&:@.3_%\$V.C|V8')|U??6&/ZETD;<3/^M^|Z M,V9Y*R6NEUI1+K%72|=HN?
@L\$;OOM<9)|DD6=ZUX^W#W=L MZ#VQD>|8GL'<.YC0*|#+*P-5|<;O|#?=<-
"IKJ9>,Q9:"345.FLI#6 E:0^
M.@\$V\$J&JE)R;D^~|#+1CGR4RFNM.*PZR6+|ASX+*57Y|N MJ)V=E-
VDI30;B;#K",5NVC- @ (PR6)2 |CMR;D!UIQ3'ZO*4L|C"?'=U(M ME'I|A'G|TO:)?'+|B\$4|_
(MC6EFA7?"W73;#VV/:')@N/," V0N_B"51N MK9.S3.2_9_5:IU@DZ0+V|D@9/BG-
4IKW(LV;|M(4(">=TU:|Q_X K5_TZ;@4-AM%PO-
+69;R+&4Y(LN'NVBCW50AAFX4=|G!D629\$O6_>3|A\$/X|EX' MM"
(DJV'Y=\$Z1|)|G|,%C83'=>#(NFUP?YYEPR^/OOP=\$%*6A; MG6&C;|1;:7VHM_O-
GMKMMT?H-JGO?_1VLU*|"GQ)K'6&DKOM=8*1-JPQLSR
MKFOX20:3JO"F_E9,JBTQ:7>92=4V,*G;JBN*|O3|>/M_:Y|NGN|OE-O'+|_N MOS|=/#|?<
@W(4.S,EL4G?69*<@|2|RW*,EBX;4S>8|1=0=Pl:@--<#SE"DH
MH+KU3AYQ|Z,+4|!'/VM#W65C*C(#R27.5 R7%YT9^(T|X3|4|)#F5#585A|F> M8XQ
|L4WJ\$W@|SESR#>W1DR,FO5+W4I^5|^0R/LC((UX;7BP@:/57\$ \$DU1|J MBU8"?
^DICS/+&|JN HH/MAHK|;Z9>J2WJW#.R=2%AV*!|PM7WJHJ7@IO#6W=
M(=X9&PX;>;:C*OH8.(B-^>|C,U;|!)V,/|*5F?YOVS&|= _P7?N=.=6_019_/M'?L5"|
(|B>+|A%:N| ?X>JWQD7Z'G|*_U8|ZLIS|#C|& LOZ|XMF*/:17OL*O;%B'\$:P#7@)_=
WU4S|J+HV--Z*;"IUR-MV01V.*P,F6F_?<@0,2":|@K@+42UZ;O'=&>;|YB|X(-
R.)TY4J"P/9QL%N M+3:C%|L,FAO\ 3_'&?HF\$-H"EM3?@&54A?'H=2%C M|FBYL;H.
GAF|"KUT#)\$=W<)>RE5|-(P:~@C?5/5C|!UB,9X/JP"W+|+8X M5Z^L?
7CX^GG9T7K"ISZA0KV-:D;|Q;"&?73^^(GW_1WZA?"U7WUD:L?)S=@ M0\$1W:3?
N3<^4,T|41_'LRF6/ZN-:|F9A-Z;(V(QX:75C2KG7:WVFPD"R4"
MN04BP%QGL/8G8M(KHJ_<4MPA*FI@^TV1E;W!-TOAI^4)@^FO*A\$R/CH^AX
MI3VLS'T'OK7X:Y.B8SOIXL1Y P38-.'\$8W_\$.%R+R(DS@*>8@T(AECM|WVG/MM=0='Z|?
|>'RCC|R-1%L/-|N7O4"XNHP^/T=X_|=L_7AAN-EX?7D9:|BZ5S1
M7(T^+%>F,UM%Q6X8H(\$>0I0!'^@O|PX| 5"!E!_ID^|*<2>Y\$BPPTP?8^|T M/.R"+H2|?
6=C@E,JX*0H&WUT0C'P8X'F"#:!"NB(''<MA?*ET/01F/,T4L|_8^1-ZRH2"OWO_#O|
PB#+ZX6!S!Q.) 2NT7"~V-\$C_Y M<#:&X#I7O/?W&Z7|SUS>(.2|@;|!%|%-
|NK%:C|/|^U74|_36:T*H-.LB! M 5J;)\$>YEK+FSHT|+P6OX\$@B?
2V6@LHUUW+6';N>3F=RB%(R58#C+EQ;#'
MJ/20HW!616BG;>1SS|'0@*MKOM>5%8R.@?.BAPN&=1F|P7JH*B_, K8V^:CZ
M>&98!C@>U/D=/.VB^GN#|_" (U@+>?^P%I=|J8\$*!INA,).1SX(VD6M0TI_"
M\$/D.'PPD#0*JT<@'"WF:NE+X,^>B'85-#V.05(=W|/MH1E=P)#D'%U0V'4* MSWZ!7'G
FWF=T&8GUH|5*-H_0=Y/W%G-
'_@\$@756W685|B8OL|98>6R9KZG,#\$B::L\$C7QSGBWXP=|TRT+ M_V-
8X(Z8IG!'P',%IWYB^TZ-8I YA5*|.O='0P<&9T7OJ2H|O_~"@NG/1<@S MU_'4P
"=XX7NNS@'@(GQ6(9|W3!?)!1|MGL|/31-O0W*!P(M3#A-:)*::ZLLF\$2"NAQJ67,V<6266"
M;@=*C)+A5@3+@9|AO%B)@%(.|H&5P?5ZL((M+"T(|3_XJVB

M5@M_Z5:52"9QX>X*!1^D\|V&:/&G@I"86>A<|E@3C6I\$,2(VH+A M1N-
6|+F%DV|C8@|j>&-Q#6T(TA,LHR',19#VP8^YN>!OB0R|G-7'=XT9DIQ2
M^+Y+:11XYL|CWI|6GD93&Z*VA=8':Z FS9D&OS=S!XSD|Q_S\$DB(Z%T)|_B
M@GP6!2"89-'G7DB2=2_#>?,?T^N"! (ZG_V1H0F\$O,*(WQB)TI_\$,-!>8MG\$\$ M+SH,M@J-
ZN-R2*8#&Z;|W9LED@QH E?6F2F!|EST>_ER7F0\$P-F)A)%^\$Z?
MY|YTL+I@3,=LSD@7U,P>D@:&G\$Y&-J(Q4-?:31E8|HDPL|)Y-SO17*2I.&;
M2/&AO_&/@ (01Q?N,F>MG>-LG\$WX=\$0-X+0,7:8X6V/%9Y335(+(|_P'N+ @'
M6&?:G@4%<,\$ >6=OF-@\$29W8IFF_N=?:&Q(@
M&)5S+ #PG*A!|PIGZW&77P5|^C@UW;NKOUX9%RZ>/'HCAA;N%_L52Z0B|D'^|
M<#WJ#>Y^B(YA6;Q=1V^^BWY>;M;;VOMU*!:=37U||RAZFJODVND|_S?1W
MR#G).1UY3OW5TK*FYWIE%W|S4L<9|T>+5YRMZL_F_=9A:@=[ZVJ?2!UIYFFH M?
Z%^OK3YAY9LU&->KM0KS^9K3+K,|+;JFM;BGE0-O4K4HR3E8>6V6 M).<6Y-
3R"/99P/#A22R=J;S:F\$8S#>|JZ7ZZY=>>E;8M=>+5\,D4|W-J94M MV|0R?8: \$,H%&F?
@BW|1|ACWR'4#)/+-2T24:4#6OYM\$ZVQ%:2/9)%L%FF5_MDT6:"|A6:04+-(N)XNT-
F"12X|M"HVE:4QXZ1E9Q-|.QOQ^OKUEY>CT|.& MS4YQ%2ZK6!:SZNHf:?
5V9="J)_+J6VfV38"|+VvWN^7:|0|N=E/N|HYVNU>N MW<8;P!8%VJF|?0GQVW?
#_5F:.\$P#5AGYH(|:K60!^YGS0;N\$?-!N5:-E/:CRPNY M|@QL6;7&RKO!S/'%!5JH70;?
F\$,|E^3E3FK!*Z|3VD?R(-@=|7MW;-E!PZD
M|UVQBZS(ERN5@9?;8LEV%SZ|/MED^YIL8DFV>0H;-(|+39I;L(F&: UT1#R M%&O.
|JGUGU^^^/304'\$8;^7"VC*6/.FCJLCP|Z"3553|4UD9+T|4I8U3P_5L M!WEZ>8S(-TNC+ "
C(L6Z,1@)7B?JL,>Q5"H9FSVE7L4(HDS3<./SQ"8UW:%" M-
FS%Y54;S|C^|30OW)%01K|(#B16)GB|"1@V)1A=%!%'R_EJ03E?>0%LLL)U
M980=^D|/+-GYI%%ZU|LH3!FP.T>B,%AB%" MF%@SU_XESG<@J*8-*B)6Y)Q!%#?
+OJ64-2.D<|ZRYN/;\$RK=IWIBCFU 1<'^ M#"8+@|CQ;C/F=-O>SA1U(|:69C;6%Q2@04
M;#_H0G8IOUJ3&#O^!/>PV.#K\$,*1M-V|=P5Q;?',HI('3YX*8MR-JOR#-P4 M1?
@IRGW0C_@-^Q%7Y12RR4*PHN=9%?LUA/_B'>|:,\$>C4J9#@FDB3IX)GUMN1 M)56
M|P7|:O3TJE<9=-6ZVM_U\$KZ|37\$|7|Y*F)-5AN-7K7;2IZIEIDK-
|'I<^:%=*%TRTFHE8%6U;1V MM5>T@=_M3* @-70|*.D\$XK(3;.*
<0\$*691S"KW+^4Y9ZZ)(M)9>&|11/S>TK0(XIRX*R-.Z&X OK^# MD8MSUN^.
|>9'I>|T^>T#K6:R%_SD..P\$V8A@|K6/DKPE)&^ZB?I@,G\$^\$H(
M(6|:Q|I6/EC*BD|)\$_DKH@P5|L;T;UB(W+.5&T.TBP/(D=<:J|; M;?6304(EE*/=3-;I-
0(E|"O+V0C4:54&|37W|%RVR3VB;MCQ++S;K@QZU4Z|
M76WVBSJcDDY_*9W^\$TS"_H-0B7|+@<,|6T&@XL("@"-RO<4 .R@D_A>W5CC
M|!HX&S_*-DEK<|7=3D\$NO|S5'L'EWZ|%7,|MVSK-W55.|_ \$9;S<-+WWD??G(
MO>)|Y|.T2N73\$"&ZZ:X^=+|'UHFSLOLOY|@XIS+@;@FB#PNNE1@_O=Zyr"^
M=+38'+XC;8FGJWM+%1'<+|@P;T30P|U,+,|5^T?|1! W,F1#@|BPX4#.,@,1
M5MPR7.BIX/=I:K77+XHG5S+)|@;/M>>8BPXS=E%|6|*%N\$'WT-+IS6MT;JBOO M?
I^IN=|_|2>J?()|56OU_M=9.7\$^Y!&L@|6!|VOE=|XK7 M|QGAK2KAY:.+.U'=
(%Z#Z"U^">GZ2T=7%F8C*|QVG2%Q'8B\$HM7B29OA@1J MF_7?F^KAT,MW=:\$(C?
6JF,J;F?2!= M*:1*K@L-SXSUF_EWME-2UL>+440!^IT2L3YVRZX@RNFS_DV8=HO?
D+KFPN25-MB9ODGMW|Y|;ISM@30OB|= &2_6%C_ MF;HOMN+ #S|\$PP.|=J
|HNCf* @D+|C4?D.5(YXQ;S M.^= '"<.:F S!C@D&81.4.WWI69_LZ%
=F;"3YS22YF##-5I\$> 'LK0|K;" M?XP-D '/AF|K-(FFZ
UU)Z"1=K*%3Z*#,0<|SV4L|@06_3+#!|'SS"DL|@" M+G|X".HED#!|-(7OY_
3H&=@@RBHH1NC+<;'P6% @43,0=KZ+5|A0HC4^)|L:F M<>E+|>.'NO)D6"-
&@SY|>ZS27P+B3\$""@Q4DR+,@0_H;Z\$>)K|RIHO':(E(9
M>|VY,3'@:ZXI7%0J;|PT|_ ^YQYV"VE%&\$.GIX,S @ "3'L+I:H/GPQ4A"A_WE
MP_2I%S(D5.0!0=(HI>BU6;|TJ|&OHC>L?^#>1>KF9JPMH+9P-|A#MI=;O3>4
M%1X'X8S)*YSJ8R\$N8|RMU1>.: =:SWZ@,NMD^#RVQ"">NZ&FK..ULJU^_
_5Q5>9L:H"XR=?-) &K|P/#%:;B|?+|(P=^'SF^#M/?F M,:1'HEAH;-
)JMDV/FO;40WP/FMM|?|! >GS2WX|@L9SGJ6ZE8CKG3F|V-0(M
MZ_6J0.6DW*&:R\$F(SHD2@G>U0,B42HB%|Q+U.N+ZJ*|2/H|BNTLW*4JVGEb-ML|EC
)M5@PA|JR;X2W3,-'< M*Q?3G88|Q6C&XXD1WW.9%Z1)O*G#6 T=^|CS(|S17=
<>&>190!G>E/MJ9!ZY MY0|>|_1: (O|BL;O=JL&EK65L3@^&KI\$|
%%_N#QQ7ZK0X"S@Z7:8!)^4: U M104!|/S_ |J1XH&-8Z#-Q+2_2'?
22J6WB!CG,|QWP7=,|C:|Z|+I.J87|/WY MZ7MY:.,>E38? B:K*Q!>,^Z)QYC0.4OW_8-
#\$H9_JO&IM, M>)+A)GSPT|/SW8TR?"?) "1(+2I:8L*B, !^?^"88H|&!WL@X<,:A%00)GS'=
M|H1TQ,Y@,)CS&#+X/|L?|:>Z|OO-S3<2%(B)ZP_#1/'J,>8S6V(*&"NIC&# MH)IT*Y?

OE0H8INF_18\$;P:"YUB.!\$=N5K!N\$*KP6S!)0'G@R=S4,A)T9%J
MB,HUUUG!=MRC.OK+UQUX."6!"3\$2=Q=356X0;#E<)>8I2SGA!B-
\$4.@{W%}&#DZ3;&3"T*D:50#S0.9##M<-J.P40,J:%A@LW#YT4DQ_=A MP0R!M:~3?6
+H*NUT.V1=|?ICJ_>1\$D'VAB<;PAI'""X YT,|R+|@^~+J RJ M3!Q|IC3^ABO2P\$VLHOV+?
*.VZ;-)9.LBZ|G:ED7<#&_%>)RD<@P=HAE6D(WXZ
MTMTPXQ|325P1*C6QHF6SC0JBQI>6)PA_819()J*=1_A|\$BX#?VBL\$'D-!W.. M%KS&
<8%~P=R69A^1/MIZ'<|N#6 YCT RNA|=>G8,"I8,2I M4,AY^CE|%/5HQ@\$8YDH!
|>69WEQ#7|3,>1:_B6118;=>W(-":36I I/ M|2&|ZQS.8""_D)%L'5#&X5UL7<+O1+
W/O(D' @I2A?1@O/&,OS1HL9T:7 MU(M0ZCBX%^_P0#O%'H|H6S?
X0:~\$<1LCD^(&;V3:~C()~M/T.USK+G=_)3@ MN-N;4UN1V:~! 58D>*I
(T*""TJIS'0(I"4E|G(0G/2DY-/<&C1@X"<|HH<|P MWB<3OHJ\$M:T*~"TC?8XY*L=GE=(2?
|TN7'B8I(|-,#|81!R@(|@*Z CX@EI9 MBC*BH99(|/*P&F"7R5/4J|@|H-7)|?W\$C?U-
XSI&NK#>XRE(TY8@WBZ_K|-5O MR<|:KVC|E_~M35U,^SAE*|=;7;RC54|N?
M9OI+MH4=^50:QJ9@F+!\$!8B M9E?>E:2BN|?J(GCX<;24H|<#V=?R73>U A.=A1QM,-
H5J6KXW\$6<,S)2G| ME!~|X F>!8C)C|#/2;9<-G?I#|~|3_I26L9:1SK
"OW|+7O&^EC@6VUHG6I7 M*_CB|?7,<\$#|B:A|W2|SET|F-^|~|RKW^\$Q7B%5W(2Y)
<7!_RYI*|MC F58X|
ME4&O66|4!1.S5QF^!~*B#WWF5F@0F7&TWVR=;^\$'(3!U5K39+>=M1#F%*C3P0
MC#M7&H3VD0Q"G\$6WLP|H|NE"XN|-5*(A%+R'\$XCU&\$FRKG'H_W@&67^_W*P--
M:U359E'!4@GBH4OES5)J_3B#;J/U.XT&Q_*@|H.IJT5=87IBW M13DQI?
F9:*=1GM5F6AI*W C:XW5W>8K-SY^9>8VY:U99?>YBEIE2:@L";WD MDE
"-5A?!IFA9|ZO*~1#>LBR4#G!|YO@660MGGE/+8|@%5DDNJ<41?=44Q2= MRD#K-
JO|WLY0UK)\$M(SR+TM\$92D% VWZ|O?-QE2P1W8?5E06C&|G0
MWDD6C'8:6(G7J?;Z.Q=ER,/B8|/F2MO0.Y5JT2@#3XQ?;%S|~W/L5-
|M'/H\$|8>#M\$PN<>AVD=|~|A MPN%
|EX1+|=AH:AE_P'0!ODZ8I6N,~5K|M*&";HIMW<;A3#~*|<|8F<|DS?ILRU(|TQF5R
MT)*#^Q!P0!~O#5B"QE^A+"|RSK!^F>X,@|T1>E'P|~BB&T^DF%^/7%S@B^NF MQ?
4A@7)(J^~"B5Q,2+I&ZKDIYN1=%=T"|B+ OZ3J)_OJO5V|YA2|79=|75*
M5CXOY|3QG/K:WKH,-+6R)>"L^~^Z*!\$4?F F#_S;IY_H0ZX3W;SY"FU7TF|
M_C+MD@|A:1%N9?*LN7ZUT05?#;6:>?CI+~*Q|&U|Z|V.GIX|H9>ZN/~*IUJ
MB:SE4HZDUXCF2|Z^?BXL2Q(-N/_*MBY?X0;|QU"ES)4M,B(7>W,F@7W)B_
M7MKS93>.L|5_VT1%|DR)8^F|~8E0.S@12J<&@6
M%VH4M+)R2K|R:*G2*\$BC((U"0:~+~*FH:PW\$4%YC%"ZA&C&=DQCPI0KPZ+D
MHOMA*UY?O_|RJ:~5YWP4P*1P|' |QP|S<.PS MLMY.G%KL9|/1@>?H%RN8GK|X;
|LS9Q&%,,E!SF>HJ#5W;~+L,29:IO MDS|~#CV(+|4N:RV:D,VBFR>=3,
M|B6HZH/FCS=GAVXL")*J6JKJ"U35!TWX;BZ;"-13|A|/^#.>#7&S!HK|P8S MLUO-
^~<6M&_5XA-W/.(TS,@SO?V<7 2|(|W|O+F:V'/^"_+W9SMAE5H3+^Y7! M5|MB"3;?
6R).LDE2Z96>39J-3=@DH|\$J6H^?LT/= /D@?1?ZG3)0ZTC\$4U)5SF?"|:OU
M5K=9LN)|N@-@=R_G."I3_L0G8)^W|(H)A>ZT2!8H8 MJ|'2JNU6,AU20LAP"?N?
EY,E|~^NV+UUDB@NS69ET-/JS9.0X40(JTK8_RUL MZ+\$NB|~|H_K_9 A.J=:J-
3EDNX980GOLQ#L>Z)#XW|G|~*DL:~!2?OUW9M<)8BG M1/<_0QNPC.Z?
(D&=RD#MEZ*~0Z+WGYV*+P"|JO|FM##K-NKHS3K-\$|Y?H_>>N M|PM"
|V_V(|6J|V>O/+KY%FTE'9A5_3^9I^,PNZW#DF_7X+WEU1PLVQ+YT3/ M9%J-
RJ#>ZU8;VLY6I12@W!~|OS2G.A*~|V|=T|RV*~E@J)0Z_WSN.,C'W9_
MSA)/K;Y71/R5=8PWH>&/5V16E?|:Q:U)+HW=25|K++/I_6QNVN^,/3'GU1BQ
M=*X-.8X8U'VV/=V.?G|KN|Y7V_L7@|<&*.N+D?A#RUP<|F8GPHL:~|&;R(D\$%
MZ&N*JP|~*P+DG@1Z)V1UCC00A"7"L?VZ*~6Y5M;
MOW~|I6\$ZO|&O=Y+ITNC:@(=13QBO(-Z<_~^,|GL7D(N;;Z|G;<"A,M2DA9+. M2=0
="L#~+8FI%AB W:2AU OOX5'KBH7O*B^E7GP?%|B4N'BXP*5|\$G!@8RV MUM?|SYF0U:
M">N@QV|TV:~! JW(|H5(:N\$O==9U)I>P;V+ACJE'OME;?9W*\$-BX8JMANWZ2Z
MK4/TENW.%FJ|=~%U:6UX4(^P-7K<5G\$IL~|B8|7^>LH;;J34E-TSP M)F62ES6Y0U?
O9=QEC/'TL;"1V! /((2:&I5MT0R^>2KAARJ+0*742C?9I!B"
X#WHWZ(QXYEUP<|5YV53DEO?EZ?ML1RG|C_|_5TU3M
MX|G6.TIND|PFN4UR6|YJHN53FC75&>2G?|4M>~|XER8/OQMv?T17'LKF/;9@?
GOX7|'MOT3 M6/B'Y3!8 _8HOTZZA)IF-|M26NK|+Y>QT)7>7BHL|HSWIEU\$!TIP3F)|S_)
M_~=FFIVBK7WIG59J0=MEM-1'G)|8+9W:/X|1>3 ZP2|G.8Y>CGGV0B^K9>3
M2/+PTLQ5J9YV>5(|\$CR@2)Y)>#7%|OSV+DB>.1&>R>4*YTTBK^>5;F60;\$;8 MW/F5N
^;XSY@=|2J>O|3J M0%I RJN4U.GY?();+|R2#:#Y|!25&5HGHAHEI@U)!+4CL-

UGBRBS8;-P MJ|T>4V95__>F8/:4 4#ZOZAR>V|5FVQ_BF6C6" N ??;=QGE//FU__JMO;
MVUOI|U| OZ|;S|IO6:#1 <^#KWX+?BAKHY0KHU;<.:!N!V&O*H;|B|2S97OWN!
ME52=U\$JJ* I-9'53!.YSH| SNN(Y|.V4L!Y^U)_JP+_8258##K!G\|3|CCDS MQ;1A.V%5P,T*
D"XS#* 3BX;^0|'V| ?!|2'QFFX1G,K=.D DH/-FSN/3\$N MU7)OJ;8MEZZKB.
P04P!S3!51KHH1YK8(@: <-;G DM;|L20\$RRM.SV:E5 MI?
H:'5WDV:EJ':L95J)DA"K(2V#.X"?C| V*:>A#5"KO MBNZZ|LB@!|,8'5ZU'9FS#'?% =OW7
_H@9KN"9X&YKE1OCELPAQ44(2DDU! *MR_R^/6 'KOB4 3LZVP%V)*X|_I.!:F*?
R>BP/Q%TVDW!Y^@T4S R.LTD/L>? M|S=|/T_* =E@OC;|_/K^0Y*M
"H&>S(Q1BQBDZN*"9|7E5=6= M=Q"Z,3/?X2G3F|K^RU29(8| =5"-GAHR|XTQ;PU.7%^-
6)QCGF& 1XGM_!+ MU!8;0+EUL' A
>2&"UKS=JV0M|<17BL+1V|HJZC+PF@/EJ*/1A"|\$.H@:=N; MIUNEUI+V4IBPF!6->&V
E3-&&|RSJG =L^=9K9F#%Q'+\$&G1!>|:NWFTQD>* MXVKVI.:|C#Y2/Z(Q8Q|Q;V
_2=2BYLZC@2&>|>D<\$#(1VH\$?XTR4PRV?!JQ)U3G)TIT0Q.AO M<9LG/VOZ!&9|
MK9MO^KN+F9.H2@9|' *2A|O+Y(@<\$))VWA7NAY;N?C1SNA|'HO,+B(BCFR!8
M8QM&!9|9|?2?R.^8.@#SX -#S|&3AA4"LX/M@Y|& H*40&U%H#28,0BDEW|E
M!"6B('0W6Z#IU?9"E(\$6|+9::.\$@NV|H;'SRA/^NG;YZC?J|/'&HL#SXX<6B7L MQ=!V'/L-
/4\$'5EP%96J P7"8L |NT<= &68(11SHLV#,-|LWQ|(R(.%!>Z&% MT?%)
(V5(P).L#VP80@Q3.|CU38CM@"O\$O6?'=F(T/3P+))K &\$@|B77D4)<
MRI7B,V|F1KX93"IATW0^(*Z*;<-GS.;@+P#|C"&DIO?3DM#F(&6\$6CNX
1XMI&%K|_PC;|(B&@ 46"#=Z6%|S3..'"61A"J."+M\$3)O|AR3B';
M>|YM!|J35_ZA.P9!|V81PA!.'% = 0)XPX0:NS(TKO \$N,+QY4T16-OD
MKI305RZ;ZT*V; '<96%%PL:*_. (PK)|Z5STC>M.A+C|Q)?YA*M|1C%(R|MTEA,P)|DX
M3_Y|;@:FT+!X,-^|X\$ "CD6(^M,PN<%9:B'_8O,)BJ|'<16W1"X|BH.=HJT!
M^Z)#JO9*P1|L|6KMSKYX#LSP3@W0F;= M|/-FKU78I#JKP49/
J|RT6%2+&+E22WR3|3|AL=F@0;(5B2|+?V@4(4;+EZ8
M&|OBQ2!85U|,EQO=|8RH\$|>|O(2*|N^1O"AW;B,PX"004@|.(5A><.,|1M2 M-5*WY
ST.19N;L4Z)W@K|S<'PW7,&8-S9WE+QWBIK1@|JQV5C@@@2EHL'A:TU MX
1DWA2MX^3'RZ|05V;6KB!M|JTRW;KL2CNS3&C|X43|YKQJ_:U|B/F75- M|E|,=W?
2PE8%PN<(2RV|?'I7OR\$<|9*<@8QV P; >NE)LZFT#?=Y3KK\$VSL M+= *A7RTL1W"?
HD0XV\$0SH5FD7S"t=O\$Z|J)O\$"S(.2|49*D>3*1)+X!|*? MOX24"
=R|I:*P0QVW,1(Z9Z728YS3W(\$@B!_|_&8;>&V4.8(!WIN;S4F?RU MR\$EL6/^RG=-
VNF@L>TH=|E4I8IM237\$;A\$0EN5)'4A.V=1G2^44<0^O>^>S MKS#2|QLS7|D7*L=
(Y1ZM,E|W|LN5;Z;|7/%^/HY/A8(;?PM&287TR8OY'- M: (+4EP5^5;Y!
|09O/\$J@V/RVHX6<-'.B(\$R!5#^YR|A!?' 5& =E&D"F 60: MH#+X,RWFK_)B|E\$|12 C_4(C?
5!#H06.6|LR:*IG5"@@N66=YT9=|ZFL|FQ_ M8MIT8_R|P| Y|'FJ6_|BNO-HI6(6=3O
_MK.3K|,|66HG^|X/SO\$WSE4*|V2 MY5!NUT244C!PUS&
MCU1&PB+)3L2|%+|JKL000B%JYV1?
MHNO+W)R%;F:8DOY/'45!0!%|@XR@%6K9;EM|I;.(OX" #?;2I8Y|,W;DG59.-D!GJZG*JD.
OV4)"J7_"L&)#_NB"\$=NY M|D1F;7+O=(BAOZLRE3%X E7NDW*H-^|F|RG?C;
M.^U+20^EI31*:2S\$VJ^61K4RZ!75OG^/70N&|I#
|CD!U2(3/Z&FCG%3>T;W^%_\$83BERP?&WYL|K8 M|FIBB, @:3!);B;(-<_NGN;9
MG*GN:87|FJU"21V2!|JVZ#3@FMJCC, MQ7L8C5=FOB_ =Z|X%EW>%+MT4ZQZ(C?%-
BO97U-'T8FH.OX#O*,1M#B0%;AW MIAO6(OW.|;2!N1._C_ =N701XG)|4\$I%+8V;J"3*OJ)-
C_<.|6^3?V|84W0J M#43|1EWK%M-ATZVWMH,?
<&;|NX!E<%^33BVK0Q=UQ7DYY&|4U!|)&& M|X+0.'5&C)_B%<.*G4C\$4@P?
GF#R.&%M8E|3=N8E*WEU27*|H7FYL",G""F' M\$+RMPE1IYK!|=X)7OP.K?F/.*
(JO4M,BHMZM##KUG<'%BCB3.LZ&_&T?>NTD MY!C^WIAA33;2.)*(|RQ+/8J@U9|Y_*!
(DIM2B.+28R9>-(M%|K,TVC*OK|) M'B>WNCOL;-
IOT>OK<9M,V_4=YF:AT/3|>>%FCI|JBBY1,2SN_"# |%&S+&" MA.D(2%*; \$T48S8'SE-
TQW#ORXEC SU(30UQML,'29*/2.&R\$V9L,+|K?TOVO M@5Y7-BH-
SE3!F;J*X8)4>KIA+D;D229:%26)KJ(H'9O"UIQ*BJD-MKNQ% @XF MQ9(%|P;A8?E 8|K-
|*GD!HW1ZJW^ZIS6\$9!L2CJH=J,0>)TU5>TI3+|8&4! M:9\$@-
@>D3U/29R5|M(N#^\$%/2YGKQIC!|X0C|A9(|,7;L!6P/N;J:HR@/'(MF1T-P*C4@K'
OHKXL|H+N*!;|H!;"L0.Y3374!9W)F6M^4 IOCF@*XVYKH9 M7!244N(\$-
K\$R4'>^&+@|V622|1^5|W,@;6S&^:KD?,GYI#YW:(Y'V|1|;.^ MT%
(SIN*|YJ@.HVP7W!|TEQ"V1RN(|'5|)JRQ?1,>68+%+->:95A*J6/%-" MGLEAU7/R3+M%
|V>=3YHM7FW|Q=#|B\$C=*DE(;MB|ZSTHSL@:\$4UIY8@@|I0|
MLAW^SDH>Z1;A|D>*2&/K# '@.7BD5Z),U!\$@!8|)(BB?O| S/+H_'KTUSX%1 MN,3M|?

AZ\$YTJGSJ: T6IF?5[2A^O/?1T^"58;!?HZENO3"*-RQX9RREF//M)E=/&+PL700QZ/8Y
?K7FSQ9IM)O5TU: H5P;MLJ#)2S8Z8'O2*!NI6"+0 MW!D61_)1"?EH30Q3+!^IH(YV#G-
D7G):L-2JO) CH.L:;C FH8" *",NJE3 M58J6X'4.)?FMR!\$
O3/K8FZI5Y/*Z97MEMO=;H%-? 6UNIP8.N[I]"ND-F=[#U< '\$D*-
:J=AMJ!LN<|5|N>F=4(GUH^|(2\$6 MY5073HCDG:27<-@%EKB=-QMXF1<
Y%O|^00#K^ MG#>4@>5U=M@6|OB1\JXH2V-9-|\$(&BJ NK)?>< />=L
M:%HS&:9;&;1V=N5EV)K'LO9EV+I7RVJHCN1O2(LJPP|3H|K;U!J|D>A5L|.ZI M81F G!
|O;&IDU_0GBY(A+P+8J\$-3.UZKFGBF5194A^7= DX;5O&%|PND>X. M59!G*26;&NE4Z:
#E)T!#TZAN%;RV.%L>2JK(=IXH_REIY+5RF|S4|FK4QET M|.|-DG-
701\$WO5=KE|P#0'5QK1CB4@(9?A=JV7|88|_=:T|-K|_-0)2W|#-
MJZG2@2TT/1D|72#OK#39N7BH5QEH9<\$ZD2QT1%_+19EL3?Y87?:_-\$9 M-
W2%!\$1,\$Q8_MGT\$G"%W2'8D|DJ:L|NT0@)&1#
(8::VO|YN=8::SU%MM?:BW^|V>VNVW1^JDWV>|_!\$Z\$,"N@U,,
M%E%#,2/HR1@696T%&*4*+^YQO5/_.I O J-4NW6^G|D_-|U#+3|K3V;&1XE
M4V^L|2V1|X59(P@.|B"N,VW7=|) /5L|SKI ?#:_^|8(A05QK,_;QR|?'IZ_ MW'J|?
E)NOMXIMX|?GQ^_^G|_|?;A_BFYIX(|:6.6|C?R;GQ-VMNU5=BB^Q_- M&O':
/(\$T1AMLWT|O>|W0DC;\$|2PQ*NIGQYXI'HRH>#;_|PZ'.M/?E2%3#.O5 M-E_Y_0\$F>X%0=.
|8H&!0NEQ%=PP7@?O@2WP6=I\$|X|I|+#00+QJ3Y2A#S|@ MKEN%WXQ,'Q^K*F^&-
|5|#^)^9X& B)W|HEV\XP+R\$I#HR=6/F(J>,F&/A*YCU M:CBVA?P.DT-6
J)8G+UT5WECIHG_-<=HG%T\$R=-EWWA).\$QBW%=CG-0|!&| MU#7H^RJN:;R/O##,?
J|^"2Q_ FK8=W.MJ/,0=WJ+ _B/,9L@7FPU.E^|6,%A MQFR(R|>ITB=(FI'M>D@/D_|K*&-
HK| 65'%OS)E/M6=F3YB/NE4F.J+ R1& MV:|&'L>=@?^|38W1%*ELCG&37&
O8P)/6EY=>?+AJYGN> P'L6SEQ=<=&,(Q#H)+6^H!' \$KWNTN!|@|0<,GLC?'R
M6_W5=D#MOQ-#15B)2"#&P,IG8_\$L.0*8/GQN)6+'S?
E|D8. #YW?!FGO76&RM'23U%X+&Z|C#A"@+U!HP"DC!=K LT\$&@:W_10G*/2O;1@KI'=
M50M?0@D/EXHCC;FCQ?B4009=-|I.0Z(IH-MV@G<(K0A|@88!|!"81326J\$Y6N1&?
TLM>P.T MXOX"7HF.AH8 UBVDE>ZZ|LB@A|D*T^PC=AML\$K 0^*#|0G7=%70+'B>;-
O(= M9YDK|8C:&A.E7XT7&Z(B%|:*AAKV"DC,3."9%\$!_8\$Q#T|/D,8QMQHE +R"K
M.62FP5|7&,7C.&3%UEBP|>W7@Q7*\$F?.*=-;SKB9!F# #FTD5/0-29*ZHM0
MTG"XNA<;9D%.%!"|PNA;D.RN4|V^>H%T5X"L|+Z*_,D/ T=13KR## :B^.
M/N/R0!O|9KBLGND?9^K%--6|R7/'CPIN472 %_ZIP|I/Y7OS#,<|OX|O;NP M<N* MUJR-
7FL-56WT,)2@E?TWRANH5P.OH#!=|Q0_*ZG=L\$AY% &|S^6#5| AXU
M>G570\$>3D9|N0DB L|JHU/N(P73O2,. Y^S2E^K'#\$|K<=^:V V'(FBC;9GJ
MH'Q08R|46O#CR+.'L'=-E3|41(#FPL3JRJ.E M/+ \$YT!U_H::K8ENC:U|LX1M:=|@K-
!A7GOW"2-N'FMUV#/'|+:/\$ \$WP@L|H@ MO-O@VX"\$51'E!\$,O7@B60*>/*#
(BT1)^!AG'|#5_@9BV&RPF7"Y,>C\$=+JG? M: +A@)MS()8:|'#9&
|QN#|A+Q(&^A>S^)\$)-M7\$U_\$ 3T|I7^@?<6'SCTV*C
M@FMK4\$7@UVJ_V:HJ\$;H&;@L%|/!OH=5YW\$JBAAR#|JH*+Q|R|JE<|A8@@@=K
M;SMN?A6!/OC56:|4%R*;M/"C:,0%V9H:,1%/D@&?.B.I@RU"+QCKH|3S1FX
MB0PL"S<.\$YW\$WX>N\$VA4<006|R|IW,&X:GW#V\$IRBV'OTTP6U"JVZX0-2=
MW)3A>|2(|J>0W2*H;&)LNNE|B-75>|'"OJ?0Z,J?H+^M#!:;%|I0^B
M-:;@M?"B'6;RX!+B|O|@K8+? UE?#900-&|TC_I37?G|YN;;1W@#O,(%VI*' M'OH;Q#Y8
*%N4%D2H5XEDB".+9)|XHX"PY# O*W@VDAQ8'/1/T\$C ?#19E(B)0-1LSQ
MS36/XUY0!IUHJ|1-9%?^2_14T:4GP;-H/&
(L5).^RW|D>BZ|4KL(BICWZ2Y0Y#"8,=3!401+\$ M@7AET8!%'V*::_5*0753.&B-
6!4|:J.V?_+T5&1'2/D;=,?YF.?B:-(MLB:C|15\$887-BLASX(K,;*
(95TH05;GLJ*NX/|XA92B|>*W1Z%7|4)HLS&Y M'G/=|?C|P3,S8A|&"/_N,E7PTN>,
|T*H|H,ZKYQEDM79,AB?&%V: !5C4W
M'BF)D&:USJ,0AJ(GEX7A*_*A01G9:&X5E|LR^HKX7:CW%X|F(X65_G!9?/X_
M@+;00"S">.7.W"U:_K/T|04C;>39CQ<\$23CYG&3<: ^?^O,*VTQUY!N|ODJ" MUK("&-
JAI_)K1*/HHY@L,'+ MGCT7;584YB4?S09D|AJD@OR|FRW?
\$F\$R45|L\$OUB'G|P'+Q7|B+XX6)| M!:/|;W|_4>2)*KE/#KK>%Z'D%N'NSGJ.J%:-
*KHIB+_E_C06JNX6:;IYS;6= MVN|R^'M|VF%*O@OS%?
A9;N47TWW!OB>R&E+UY59|_ZU;|EZ)Z3XU'YAB@|' MQ;2+EG2:MU6=9YQ)_L*
<%Q#E|R)N)W7KCGJ6^7:|\$(9S;|2LL<+)0 FP(%6\$ M*0/3?JN*1&V8)0J5#ZS!'OWD:CJ0-'
=71^CWEB&+%2BX|!, "H(Q?E:<@C.5IJ" A ZQ/"1.N9L-
CN.OPM/_0G)1.XM|U9V(P9XK9P6&KWY3)T=?%D>L+HYHGD A01#.3@,WAZ_%*
|51HJWB-1TUK* MU=?Z?V-QU)PYX)%Y|?|(6\$PZ3>&|0@S!:9SX99|+)F8?

!\$Q\9IY.'9<64'!BE4Z>!!*M!XK>%!9JMDf/-ZAPM+'B0-#P?;*.U3EAV4@-
:/H7-J;PJ6Q'< *JW^=;/6Y<>W M%GL!P\ (HJ'3#TZI%Z0Y5" ^OF+
B, @! ^/F#B0C;P5HBC@+63=,NX@J?6C;E) M%6T)6#HH<@P8&Z)W/ ME/,U
!V+HD<%/ @,!GQM@?&1C_CWWOG9\B83BL=J/Q M<+D(72;U@98I/>M
*CR29UBOX6LIS#0,S"=# ^?&95OW#%ECNE M\$U!M+A;A\HSTTN#QHWTO\$GG?
[MP6)_4H^S&&"!<(97((UW,H!;2YD4G,ZSX M!1".89#7SWL+>/\$!DIHJ>"9-
NZ+88'JHB(JG.>-Q\RMWD@FZKH+8;03YMF'P)J%12Q+L,I/H7B5%C(4KZJE M!%
(A3#%!27+;K)ZN%A M.@1^!<"WACB,%PBZ%M4_/2(EY-1%M7."LWBASR.;KB+H+)<
M9D<2N-(:7?^P\$.H,JC=^X6 MU77\I 7\$W)NZ"B!#O@/=,XM4C2^HJE.X=,= !\$/IR>>E
U&796+BCLLA>T M;YS[^0.8.>(UJ_"1"X;.^FG"^UPZJ70#4X0%^B
&5\$X)\$@#V=F+;JEBT(H>Y M&QV+LX42"V81%
!6@S^B_MH9Z:."0^FS7773CO!^+3JO'R3?1'H8_J"C.7=VWYLJK8\FIBU\$BO?NJM-
+!DTR17!!8>=G(%HY5+.35#4=T)E/#<5C3 MN=00A;8?DV>|TI=|!+ # QI@7;+3J(K
:PB28AE=SG5,NF%3N,MMT=S&%C=> MQAIMAL;|
(&HN!@LM+,,JJEK!AN27O#'S=8DCR4B*(O_619T5WUO8Z/5@86K5 MBF0PD5+?
3)WJ@'EZ\Z(46+3;K!TO.A =G*+JPK"\$95U%NEA9S'R.-*I@N'A
M+7S\4_FF.XM2F"OQ)/P4D*XJ&L\$VSRWG0AB 3;|H/=NOV%N'80//&7*(&' MU'ZUE3_
M:-^@YO?GL(WQ+Z)URKR>8G)0PP8%!L.PF^F/#-BX'C_3*)U+JH M|G>#-
I6@AQ^|&*YMX#W_9KR!@%?)6+S/D9<+82POY?4YAB4JCJE)Q1E387B8
MU/^=1T"PXXM584HYZ+NAT O^\$2X_NLEWO|_ ^N:#?8G\$AW,\$./Q(9'5'V'(<| M2++,\$J-
\$?PS:|J5X#4RN>!T&.:MWH!|L!,U,|(&A_TU#&:|KB\8AV_ = K_(B M(BIF(Z-
XRS/@3Q@M+'GZA|"CY=\$8-|PJC#?F8D4?N=&"(BEJX#|A(4YCL;>4
MAR7Z+I.WBJZ(JL;/EOM:7QCSA..L.OQ-/O_J_ Q\5S&AJ0;=';@ "L>'6+R M\3_P E8M!-
_(YVHW*H%%O)"&"L5.#KZ^Z'!E>|?0"58U=@08Z_4+?AZC37 " MR%NI1E-43.+W.VP^)
M!E2>=L8S9C8^PJTX%6&Q!& 3Q_8\Z Q*/?0D-88>E6=X08O> M(MS\$LBSF4"L'?
N82#-\$|MC;/_^%.HZ A/V7#5Z 6)77'=29P\ZLX+?\$|&Q-I MU)"WT)V\$*<;|U"B|0?6W"*
(!'7K=G2KL+Q_>"#|I6((H>V3@"F"C1D*5*%O MHM_VFV,,"4C!S"..21&KE)-
(J3AWXU66D:M:01T#>|2.\$TBH#M9-&* Z)-A21
M#ODEW'6CMPEE2CUHEV6M;JDCQ\A2#J/_ @Q0@R1:FAOE.5\$2>81-VMR,+
LS&";)>W7R(N6K8 M(OF)?P0:4?@- DL@O?'1-&L0!J@TEP#@62N1)|EIW;(UUH!M+?
!\$,+6! M_F"%/IDVUMV>(CZ\0#|J%NZ\N/IAA/V\$RS"94CF3|Q|,?S9!Y'Y\$|@?|*4G M8O-X"
\$+H@^^(G2;^S,94H@O%EY.B#X6\AP Y<=NW#-T-441BK68J|KZSV MZ'OQ;
(6L&IFKH4LU&P'<&;9(DAV|=& 0N XXYV;6H,^8Y'=D2D#<*W4&,%
M^6983;_0NKKRR8>A+3S,0#7+14.YP)C!ANT2\$|LV|L|@><=;BJ!"|3B(/K8 M'II&D
M'B32#MH&>=IMA9"GAZ_ |W!|DM;7")NX=4|575Q0E'WSJ\$| |M?P_
\$E9BIK;.*1|P|682, 7I_G<\$3"6|U_ O'W_?O/MCX=;|3RIQ^|?;IX? M'K|N!YS*WY4VA97
J6OA1X_IR5 F^O'NB|+0F2,->H"6> !!!>9!7I3,P& MIQR!;0@'AS2EKG! ?EJMJ-\$"Z
3!1)^Q,&R%QXW1 |&|:RBBCN"EP, 4? M J
QL!LSS*//N+ ^# #KKC!TB@=&9=77CNBV=H\$,73?RT^XU@ *JE'I=*Y7::4\0CCF_U M4C
#H@CB@H4,"|Q@7O?BL@V \$|6!4ZR.)X(MO/1JQ&@;:CI>7/|*0%|/L>+<9F.1H-
#NPRQ2|P<=YY6\$?X8>M^N&Q3R4!=G<%%#H)(6M1.HZD1\$LU!W M(DFR^'\$!P5N?0
5!MH)EOL"AN_%!I^2ZQC+PIP)_R X3XN/@LA442P;D:0' MVD-
PQD3X%R5;V\$4;Y'F"6A|4SR;H|@CH,3@GXT@72;L9)"C@=|D-L2-A1"ET0\$ BFN|RI M=+
(M;JC3HNB@_WV!=16P=10?;&)@ODEY!X,?/2_FJ:5F"\$41=/R/"0CO>GM5-M"H3ERPI#%
|HD ?/A^MQEU%?/D)/(3?U|VO#(C+10Q_%|"+>05=|Z8X%>B'_
M>N"%UQO|AT<|=QKIOIK808 MB%VO|E 4'*H|%=4L|H?,FV75|B9KY*%^F5;YF>N??
X'^4>YCY2JQI69LNY;V M|7'-DKR^I9&|P:7<-\$ (5G+GQ.1>
<>B_HF1*M*8F6GVA:FMSM>HWH.CT+I-N| MQY6^XB6G"@N!P>46)|P6|Y0K!
(W_\$"9\$KC?AJ=R7K>=AMCQWMUWHY JZ>KX,
M7)M^ZUI8|S+M<+G=NE>VA+/_Y_ (A5>NLN#YO17|JSS77)TKD/HAL|+/_^ZRZ2
M;H6P^R;2;\$V|>: _=!O/0W?FNVO+F@J)3E)G@I*E)4LD6E
M=62KTJT,NJ41E3.*=M)9XQO=H/* M2*|R:/=WEI%T7CW&C>*2MQ9|DD?V5/K
6JV>9*TS9"VU=5RUU6D;_62K;G' MX:TUICTX;82)LFQ6\5?R<7F3_9Q!=O>=SRY\|V|/-
O)YQ9O|T\$F*W#1=_ M/JJ_V6|?5_6KE4&OL|JS|5|)4V-2,&
|+,\$|:CJEHX'@:6TI>%+P+DWP#AGL M;-+!&Y7*9F6@5IN=3NGE|D
)T*.RU7=1XL%;7MC,S:CTV*70X|CE\$J5|_D 5
M&2%C14J28RUXHE#T&'SWPPK;M,8"SW,O_3 =ZF!<-YV4YE)4)|5F;6H&EO)
M<(#*X\$K|\$"_JEG4GIWA">)4KC|AL6%V8/_QM4PL;X?M|WNZ7WX"VT("J|6;|

M@ "8*HN5INI25XIE*(OHK0%92Q*%=&;3;R?2*%(8R,(P4!B\$,B8AL/* Q5:/
M9&AU<&\$H*8ZC7.(NU6|^A=62/*,-Q6'W,B;|^M6!JV4,|-F5|>W9>12S*R
MR/|>|>G;AR/|M5>CGGY,YD88S\$4S,GOHO!>(8=OP*>O4_N/UE":HPR0B)Z MC,?
Y|+>J6Q(22">|!@&=M3+;QD)2=U?|ZEVU*96T@\$KDO=1M027'3249+L|-
MJ42YN*XV%W.!!DXE9Q70|RVTO|&HMY\$ S:LP'SG1KW)'A-0?;FR/=1L*%,@' MZJ61?
K, ".F2|=G@=<@<&E: "5 _;X1K0B83.U M@;@E;V;JUN1"MR,*;|T+1R
M5K9I;J9?;D@M.C(|B&0KMG|,X0ZN JS80*>R-M
N98Y)>F^0FEAHF"!4D1%|2R3^MT'2JH Y4LMK|OFF%Z^%3X8TZK/UQ1Y,|J
MW)^<&5E!7|HJ+%NW?>QRQ|*R1"KBMEMS0K"8U++J*Z0H#D+\$V^|AR=TI-E6V,
<8^BS3HG/JH-MQ28-A%;+VJD7S0:F7E1J.S!B=D\$) M!8U2" X7_+^1%KU_DJA\29Z/W?
@T1(+AC!)!E|<|.G?D"VOJBOLN,BO+W\$ M-C-#KMCBUYVTEK=Z0OR@+V^/T@?
^5\$L_HOT-K)MS|(|RL_3PHG:X4=|&|HS M!'G33U=7KZ^OY5|!#QRS;SLN57*E4KX
VZ%5X;5K>=>CJ/SFO@TV7G5+6;H@ MD\1=G#YYR2>)8 MXL-,9C9;("X_"XPF8(APK-
=LC&-|-C1QG!;.,QE,#DM M|"K/A|_28#OD^(*|T7AX#;XQZZ@?
CL:>+6>NZ3|.A>7=TI%-9VP/LRH|\$LW)17/RO6W:09J3QXL*
M#Q317E"EF(:\$2M@5ZF!Q%2P89'J\$M87JNK6%JWJ#G|3UO=|BBVU?|R)-@563
MS!BEP_FD;>E?@400WGZT!L BCZ,V8Y!4BUD!D-E!,OWA/5U+0M2"FP0WK:XT MV
\$WM2H7U\H.TLD%-Q6\$K@0W;9KSL@MNDBZNJU*1N6G?+3X.00R#>(>H*-C8
M.*VT'7IS!| 5| MN;2>VLTJ?UORQ75C&P\$C\$O&+2"|K:A^WH)|EQHV1S|O9R-
FZN_\$(D,3L!|T'X"IOP/V*6>9)|XY\$N8VELT%QIZMM.GMO.B6D\$G\$;MP6Z'C/!D-M
W=0SW H;|UEHOH<.*U2&.:%945(|J=4\$A|R-NA1677|*R6H^TV
SL^*\$WBV.1QS/_LLO%UT@A@MJ MMFI^A:V9/M@>_*|Q&DRJ1R68LZR<|)408^-
(|C.U07!W*RSKH18D6M/>._?8W1!Z,(%L:T+XL&V;"Y_L*H_UEHT5?3(8&-N
MDYDB3,P"JBXK\$M_6HY#JQ?6BETKT52PFE>PRWVT|JGA|)S# |DY.\$/@8"|C
MG3C"WA=|RPO1|G_C|##8V2C+LQ/N:P>W-;OMX*I85NE<@C;OXA\$LBPU;TB
MP9),&V|: @2CK-A?^AAN+3TH_HRT.F^:Y|1N?8?%K77JJ89)#!>/_*>!:OU2TWZ=A|
M#1_P9H;&?P^R;1BV)DY|&XRBS40!J*CALG_?9'X7@"5E=E75-P)W|O^RD*7
MRP.1#O,N)C8L|N\XZB<|55_HY="AZH|+=01O^TDU7|4W%P\$|SC'+LD|G%|^
M7^3U_PR=J^NTY|Z=3J2CUFM@|B|Y<_52YE*795&UO>CCZL6H|S1>A-TD5-NX
M\$X6<,3+@*N1<2P<1Z|&-0&S\$6_AU738NMRVF\$PQ4*DH#V=R5^"_C?IB;L
M#>|P59D| @8?C7N*IP-NZH*7H3&@9V%F=_@36Y'B@^Q2_I1(3U |H\$YAJ_02
M,;F*1|'_.%5!;U|3JF/P&^UCNY555IQ!OW<+00G-%X4)CK!7ND\$CIDE+| MUG"B&C;-
># _"^^!P=C1?HGP"0K=MNG8I7/4|<^FB7 T4'X!B %UV M74SUR2=,YWANY*>5HVW
<,JLAR,UL,%I@Q7.8|B^GN'PB0G|SVN8BG,S6;*H=('IG'^60Q/_IE(\$
MXU2FGG&!Q3/;S+!&CAH^""2>YJ"AB^|9|PT &C|0V"BA|3-S./4E2T,E#S@
MR)I&Z7VR6&?GQN|XR?" <+0<)>YD|KDX|6'@(P@H'UW3B|OH69(G%B&<02>Y3 MD-
7Y6"6?2Z4Z |I+I#57+3WZPI608)S1_!OBO>ZI
MYR"BJAJ@+;=DO>\$GA6L\$DA|R|7*V9X7I;|!&&O5PF-47ZH\$NIY(|J&E:U 4:
MN*'F=&R40"IX8Y:B;11|U-V?L#6;Z)L>KFBYX5G%*DB|\$O6YPA"=J
M'NEK#;"LSSN)X2/,I=ILJF6?CH#^ <8U4EU)+NTB8^I7FO^Y*)0:% ,R#V0 M'T.?7J(BX"
@B|2&7TCP!>&KW%%&^0;7 1? I7+=OQJ:6|<)>S(#E5A'FN4^MR,B-B<3C0!-7?
6,718"1K/ TMSG(K0T%UIJ'\$5HB0>)>\$G""Q6S+INS#X1D
MH;G&A7.S;|IRD\$:Q|=UPN>X59?3%OI\$?-C5B|(!6\$YQ0-S?)H:I@H.'U%Y
M#J170/(!\$1E5!3X E^G/)1M9#!|+&DZEL%,8(1^:-!.WA%FT;EK,IV&&|" M#32+;F
7J0Z+;? ;H>J@3FR?|S;J"+-@180;,8\$|RLEL%J/O&)O/4|\$WFS,A0+43_X'A-W",^\$|;J
M&HM;0/U:/<@.21V3^TQ (/E-D9.4MV-M5J(-7U|-CSZU=ZTR'+FU8O)+
M,\$QMO=J:5@7'OI2J|F(VIV;M\$TXD|5|PUEGO5NU|>*N.O-6L'05OI:DIQ>'\$
M;7;HXL PZ4:S'&LK|L\$;CXKI6:M062SI%6|KCIQJXP_M031.HM78NM=3L=H0-M%!!S+
(ZPKG@11=S|VZ 3PHA< M"+&FYB15+JZ54C.EAK;|+|V+K_4JIV=R5V5.X
MM@OSI=.Y,B1X+PMM3'7?I(^C)5TM.CP+F76TT U6'/3E+4R?P/=(R9J0Y!Q9
M\$T4+W@<+)?&5'E4,OZZ4FU+KQ&/XA7RIQB X2"U*M/JE^G)'I6YYA_...XF M,HS7"5.?
0<|%.M*BV\$>^VSR,DHJ7JMB7U'V1#Y&S/=I*R=M+JVVW^-,Q
MA22YD6H,;7|27UC>?)M2V|KFN/#)<|V&VM!'?H4-!9Y,E7+@PNZ83U^JFU4 M!=NHN?
5@LK4.Z=@R5P1|G21|5??!7K6+Z^K|YZ|(JA+L53#VJNU%>M4OKFO; M^^3?
G;W.86"12_;2 HUH|\$FC9W\$OD6J6 \$IJ+87-::)V32"@ \$Z1@*3:7B (|
M1Y"TB|*M>@YNIBCUI,PR#==+)|L+>K+4LX)DGHE|Q-T24|VT6X)2*Z@%T\$0
MT\$D24'K*RXX)2 ("JA2\$@/9M#;?23A(-DZ36(3IOQ))BP^9^_)9M|C|ML|JL
M#3:22.15*8+O9Z|L&'2=7+Z|KRJY<5X*3!2<+3EYK2|KN.+EV

M<=UH;.U*00GY\CA/T"V_/+^K5+V3,2@T3JL;PQ6CH?'G[2NT71YV.#:WM4#6K1D*N'V&-
M!*Z5L,4&70XS.S1FM+E,Z_N9WA.U./TR)3FC7^84;)DUK,4!.ILHZ M9,N?
L;FEX;*&V/8H&OI58F,F/#XA(!J8P|K9LL&AFN9/?#Y42J?P#(VW+PWN
M.7PC+Q&!82KQ=EBC(40C M%UN(X.?!5N(<_@S>_ZJC*A 1'5X+T.'UH&;H=S
!00MB0UJRFR85G^VV50!\$ M7K7(JV;QX@RO:=@C(=,E\D"IM3LGR(V+;IG4P,'C!
<^P%#@4,@M%VS&@93LWW M831,L" TUZXOCDHO&.: =0RM#U\6S/4=D0>=\$Q
&@M;4:TG/I36+QU<0W_%"0# M6N30IY96E-
W2BG)OW6OLK76);/GA76E(+1R5F&/HEZUIQI1!^4IEA%_CO)7).2)A+QI\#>
MJ>NJB|GR.YQ\$(U)L!4<+CEZS,_9N.;K*+HEGP1'YTB U73H.?HLLQL.G+!-
M#AGY#CHW@'PIU3!= H06C/%FV8>Q3\$)CUO*!|-0F!|E,BE|TG6S9&!FKZH
M(.^6X&CW%XM5++|S"RY|G?(B\$2 G&759495J8UAI#-5.71VJ=-:7.DH*79-&
MBD);_Y2;S8N5&9LA_?::522E1#KLY1+BDN#!RD8+EU_WQBN9MHNHNG9\$|7:QPC@6!
MP?>G|ON???AN7U'OK3OV@^+=AE\ZW:??>_A|K%_WW|N/3XLHL)PUY639W
5*:V1'&=YX,^=83%_<^#@9\$|5CO;GZV83H60X^%CZO\$<_H MH3KFWWF+6=-
N"LND;E-ADMY|D".9SL&=3>H&XCH/"H="._WUO\$=9\D4A>H: M%0)%H:D_.;
<'O;_EU+\$UZKJ,3(S9_L'/O%K\$45\T)!<|!'2:\$C%54-X0KP-MPGQ,5;U,>*%|-M!/CUFR2
MD8X;|<-!4G(-| ^O'T=MAM8NZA#&8G+NOCE*I^|F..-)|20FQ\$=J\$5#9?4AD
M;4L?!"26ZJUH7%PWCF-\$ "&35 53G2Q3U=^!J9H7U\W6NX^%V)E_|T34@|G M<>?
L*=%->VOI@CO;LY|X?J;2/W:KK8I?D M+;,%7U6)P(V!;R=J'/S:AYT?
PK;G(:@I8JL,3LJF|NT2T#05:|Q?|LLI(N
MKI7&UK.DCT@WYD10+3+X1L<&ZW0|HNK8.PCC6F>F+G|X#X3|735YV+-/X;5^
MHN,-1EGA"QFNR\XPH6Z?%1\$DA6S>9IF_&D\R"QJ3S@WK6);|/Y)CDT 61P/\$J5_M_7@?.
(E>Y0H'2"C?S#|.8=WX4U!4;T_66<84"7-\$J M2I|_ \$3C=(W)N2#%U' 6N;-
TG3\$11U5_I>5#UZL5U3>A|IT@9^2SF;_JH872|O1Q\OK=@VU=?B\RN2G:OKT
M\$EZ;ZALCWWF(|Q7(AVF@M(W|""3>IQHU?F*_,Y74ZQ?7#=\$>^Q2)9-4(KD,D
M#3|X=S46Y|R+|,0+|JOK=G%%WN.RE# "AZ*|HF+I4LN|=AA&%.7DIT@?R1=M3OIH
7WLJMUN093^W','#ETC,|U,!!0E,R(=_^29EF&|C)(42ZN6|*.(^ZB MDD:PKF#=#;-
C!NOF*|"9JQW 5ZD6J/MS.%VA1*8X7X\$W*.;A MB(42L:B7K-U8JRM TYNR&E-
+OD)S||U++V0L2#E8|<7!5E%Z+L0I1=%*#< M0)1=G&79Q1U_Q+2%Z@|_1B
MM+7VS*J&?'\$ME9364;3E\$K4:@MGVG&BW6V;#+DZEUG\$PV\D'.Y5;0P?.F|)
M(TK\$|#;UN\$8;&C?&@W:0ZW)*|>):+M5%*^F3I*,5|K|=TE\$=Z4C>'G&+%2,L
M+JC>^@XA21:04E87"V=3RKJJ)(XM*55J6|>7A2J9MZYN>:Q3|5C/>C\$F
MY)W2IS*BZYM03|-R<5TOU>N|JD@HNI|94.&.,H%V2X424J'^J7I4!VJ8.G"
K&OKF:G(NYQ!\$M02F|B.PL\FQ1^E|H3&|;^'_9Y)I^M
MSV(|H"@M%FF+@2;'37\$KH/IP%,>B:G5EL=V@F(ZR;YT|GM\$IBC|!\$GGAK!TM_T)DEHN|
MTINV|<*,J:9-5UFK\$&2@C:GNF_1QE&,(1S//\$(Z"C=Q(WS%1Z"\$*/42A1P\$*
M'\$2AQUD6>CR".J)Z!*K\$I*1+"1/2E_;HTG?I97I_F(W|R6>D%*|;_.DHO D; MMKK0
24DKSNDKCX^XW'TW:5,04G5:9N|Z("XUF\$4V_X4;'06;%3?,10AQ(U=
M==1^/S8Z^;RY!|L#F1KU.#RS6.#NY,B=#:_1MG1&_ ^ZL:22+H'=4QWF#K6E/ M8-
O2V0%';6P|R4E\$|I(-|N|Z%>YS* |NVE>* M>HP"D|NJQ..R\$4&K4-'6"H0M RY_4|5(|=
B=(7?:F>E1 MQV)#|GO1?J;2.@|R*\$I5IE K|PB-^4D\$TRZ*8GF|6|7@&D\$JS==W0?-
"8RP@S:R Q6V(IDAE MWR>O-SY1R|6S%A,@-@))UE4IV\$-.W:DDW;RXWKX)MU
/'T@6Z5|'G&31 K(H M2D^@DU<)
|Z*\$L|EYYT2HAOE0K_=PF^PF!SOZ#!L:#K'FE!Y^FDKQ6'6^JZ"^M4
B+1"G|UW5**4MD%-@HM<(UI8\$+YV\XKWO#U:AJA:U???|MK3L 0^*M(N9
MAD(K+""|Y|!M@Z|R&(V'.G8|LY>7>8CJ4%%*5@#ILP)JB!PJJ=1)"J
M/@6S%D)9L^R@|;D5 X;RCE-W"UW2F5ZV6)CY7|QN4=4TOVK0_TOGH<6
M+0Q)PK!|UAHDL;1Q2&8X=>OSU'8-O.230TT6()G5'OYWLI(S.+?*|OJ\$(|(|M|
|_*LE!L=:R3TENS6U0|_
^Q,ZL5>Z&70X>J|R|5\$;SM)|5|5=|LBBOMN6N5Q^8JW&4>#L|6G#;N9J215;>KU!J=N?
()KJT6KNL M'K12-X7B1;&N*-85Q;H%*(5Q;IG6:P;^M\$C3'X3M;FBJ!'C#|(-'5&P0_0^
M_4DMGRX92JPT+J|E>J7P|82B+% =PT#X|^FMP\$.8"-8I?V|IR,<_6"-T,C7M M-
THOF1&_-'!|2(9:F-YT@VVM,IW-&8/+V,,E@TE!EN<(KVL0,_-Z 5SB1H; MJR+%BH<>
5QN@X|GD0J5)UZ7B|:5"F9!I30?%PESQT|E>7)\$YO83?B%.C_3:B:52@UH?%=>6:\$F%HE
EK>U MRDT@=2"07>42"0TOIZUL!%700BW4.*IOX06N,7X0|S+'MO*9_77#(BE\$-
Z;GL2|!\$JF#+IEV5 MIAY'8=D2W5TPK6#;00^&6)H<7I"O|P,'G,26.;9JPCE?5T;%H2'/L\$
MBY|A5VK^I&0"IQ^|!'M?ZR2L.R!8>T\$,EZAN4/SD?LI_P,=1'-4JUYNMW=0A
M*65Y19V5J\$,ZJOJ;./!P%I4X7U03MZ&40(J.Z73GYBV)VH).EJ*!|QU:SLW

MH\$1Y(I\ \$S0Y'T\0&UZ2J=-@A:%>NO*7%AR!MZI8J48*G*1ALOK_*;L(WO M/7?
O.O_Y&VIW. MX >'YS9^ \/@_ MH^,J^<-M!:.#|T>NT| &KG|G'PO=-
ZWTNBLOVP;9H.>6E M|*E_>S3E_M MC>%JINWB|\$\d+6UP8T1*)::@\${3Z,Z?
+P8;B&AG2P#1:8I&X94>= /T')1/5 ML#SX/!%GZI?BZY|&ZR?>6/6("A?H%
(UBJA//)M1BWV%_,ZR1\4QXXSB'_MLW M''\D(:W9ZEXQ/8=^/O4=CP7M J0N"S2T?
VEC57KA9*VYF%0PZ\$:BF.JQ-! M=?%UY\!<\$:X6= \7X;N.VKX8WAUBQD GM\$IK
EMNX2=PIZRC#*HFG^Q.?M&?! "S9Y,0"G2V>P M3%P6G D('AR_5!*D0|-
'YF9_Z8P-.H)%4LU'@4| 7C(TS+^!.|W^?FM8H"<9 MJAG^O83!'74*6S!U# 'A2"9_\$
D=LG>8;4|S0\$8\$|H(Z|('1|L^_U2V3M046 M'BZQG=C1EHAEPZM|("?)&.
|A2DUS=LKL#5FQ\$^ZZ!G0Z1>>'3HEMP?-!QKJV
MO8))JAM.1\;HE@8K^HEO@|N.=\,7BIX_-! ?5<"/@O1|?9^/&L'/TIVKZ_ (#@ M)<".Y
^U@)S"MH%|G;%5XG'#W_#>;A"C6Y\$+3W|D5,??>T07CV| T^!0H M6Y8;|AG1 N|1T?
GA"14V9&P!OC/N).5\$ M70K>-6\$?EO*N|Q56 F3BS3:142)H|9.L:AC7+?
AQ,Z5P")P+U+IPZ0_J5E> M S4O-D3;_8L3209HO8_(.0*;A<-G2>,6?!0('/(U!
(|17XEL,\$>MJDx0BD) M:EP0N%/L|(D4A(\$^ZJ(1!23'BON 2D,AQG|7?
IPW*81|FZ\$.+B|2.RC:(>= M<(>1,W0*?
^!RHL_D@E15+Z7ZA|%'|A"IK@>_I8LL#F/I3TU| (HH6HA*7LOZE
MX33Y>:Z+0'CX5D+,GCW;|0%DN L;K Y1@_3AW">RJDSH<*9.6KV%V)DZG9:
M""G\)&:A%1LVHIV-0/EV7?A3#UVXBQDC;#BZ.SY*-C|)_* @3+ZVVT_|@ (QB
M|4)^BN)BDV;2\$ LJ_|/R03?/-8NS:TQJP?!WVR4X^3 M;|NNU|L>UW;A1884J6BBA@9
RDU5WQO;8*:I"8**B75.<_9V94>U4)J|JWP2)\$-; N.5B4B.|2HG\$ \$"0)ORD--LW
M=3#)0"M1T=2DN.>|+4%L;IJGD>QY"?PO5%-A0W\$##6M,,6N:F 9PM^K-6?BX
M7Y;*3(D7AT8;_ ^0#E3*_XH F_8L/V_?' "%TY'C"R:8.4P0Z8T0.9&&|L=\$C; M=&WFH?
D7U2)F5ZVWF/V*GR0M;P"MD<_>/733(*ZX/K,=0VGH&.Z/D'8"DW2B
MO@'ZL%).6\$;HZ0^#3;.&*VB"J_5 D 7:>9!*JL 7AP;;A3;K#*Z06+.T)GPF
M+AW>\$P7M>='CG#&&#(U^N'1GBKV6MIKBBRB#20R/^'|IF^4UX_.X4RCV&G|X M"B-
'G=!7V_G!:|XL*CA+YFM!)^X\$V;CYSU ^|)%FS6>G1?5B@LFO/(@9\%%_MA8-FWW*93?
6A|SAX_(C"|9U!;/3,C/OU(YKT&E_C!"W|.D=MP/PXGARZNR0>Y
M(E4_AAXMANUS9SFG#.1V4^6GKE=4DN+.JK0XS@8,>)R|S%Q2S^_"L|S+.J04 M=\$?8)
<|_|B""/H"|8'IS_W1U3+@GN NJ2>.8@R0S78H|1J3\|TF<%^#|6@0Y|G>W/!4E?X.0-
O&&;5#9V) MHRC<.@NBI*,O:B4Q0&3J?\$A>6HR|9DHVZ,D(YE|,VY| 7SVTS7J@ "8.8)2-5
M8RL;FA"+!RJJ;Y5L*G@-Z-LE(EIJK|P.>@:?!E!%CO,(7O)?<"BX>KC6,7A0;Z8HM.)E!9X-
8P.A MFIE|D|&&1 M,Z;X4FV,T6>3F3-@H5@:O"!T;31' MDFX_/B+#>A?
XND|@;C2\$5'M;:AMQB30Q-D'#%P="E+(16GM!\$3,Q PC;'10 M,5=9&'Y+C**\$3P\$3&8
NJ2>RMVMBY8WRG9W98%SF|0KJ+' +0SYI6.L@K0
MP0WF&;7,7S0C(%1R@FRB0#6(:QD.=4&N:|'D*V| K2RN-
C8<_1)T/^|M/%M,@@KUL5A&7H&|L.R7T%A M?:%1! V4/W0W!|&R0*T/->%5NB30#G-
9@=ESBZ!!GMA(RF M@4(#%\$)#X1% @+/M0!!P|@="&/FF>1DFI:FE+IXA#,3(W
8A03V5P"+-|Y ME)E,#|P|/%Q_BBE+/%04(3|0 1RA,8"L5.+H("SZR\4IZAQHQ!%JH(|C!
(\$5|=AXO@S5P|-+VOKKN"3\$J>WAU,*|<|)TCIYFDL H+85Q"V62|V(
M38_-C;VT:B6RJ76R8\$K2|8S)LXIKMV?.L=?0|OZPF-.)EX*6R(3LDA#9-!,* @;|H/P_*|:Y@P-
5=?82|I. M\$<)&"0X,3GM'#IUHM/JJK3-W/4M7."|6=1F|&;OHH|FK|JC+*2A'."Y:5'^
M3BS?*J=-|9|GT3KO|NJT968FH(:S&MBJ4RZP1| MW" %'^^0;)E/R5^%J(|^9F
|&>:C2A'RMA90RB5\$*41T'88JS,(>O|H|#&I5& MB033HHP)Z H"T3U|PBG;O<(LF8-
W*M2"1&;^\$F&9%|NO MSH/7DNZCC%JXL1L6688(2:TQ9EC.ZR+(R%
MK)\$P^!;|2E1\$G8#R|*|LQ;>*02.J R)ES-I+ />8SS*?@T<&:HX+>W\$94*;-|
ME0&FL=H)_K+<0EUBI? \$CC?8G=&| %XM\$-ZC7"S@!A:X2-%QA\$0=EKXI:R5V5)
MH>|@,IYDCMB&>AIW2O,^"
\$+QJH!6>J1/%F##-5)F;6IQ3Y8|D@KP98+3M"A6ID8/L_ \D95)X6KJEG*TWH5
M#/\$B:'QHQM-D9J|Z*Y MV.DGZ?MU%RRP>-EWILO-Q/Y-0TZB:++>M-P1)4YZ%R>-
RK9A^5R|"/7/SXJP= MINGA");X2=2"T*2J'C"E1|4)UY;YY&E)EI='&|P+E%Y%(:N|=C|
M(K(6P(V_P/R"!UG4F?>4Q1X?;G;8A0R^P|F\$)EH2QYP\$| %I(7KRWYV2Q/_0L
M(/_|^)A(3|*6?9-IH C-ZT^A&?IBVSI+UL7'FS:*<#AY/6S"9TRFJN'\$NG@%
MZ.UR|&T<2QKX8,;!S!"2Q0J*-0M1TWYO<+#S;V /AMQ=LL-A*JLBOAP:E/ M3BJ*4?
*78(|_NQZ%O/_YVV UOMANQ3=+85;:S;DLEK/Y=*A0%M1VZ09WM
M@4IK(|FP!|CG^7=!6K)6-6!Y(|_N5)<^LMP_|RBNR*%GC(/LIG9Z-B_G)H
MDH/JK&@K=EP?N?>)>F;AU=| M8357*VOX
MYOF+GL:\$5=_X^UOJ#.E7K(#JXMSM,\$H9_/\$4 F-WQU6:MJ8C<>4994Z'M7(177*6-2Y'

M;XC')/*\$WM)XM(V#<\$*S#SX*^'N1ON;T.56!4M\2&<"P0;f#@f="+
<6Y313<=%#EQ|Q4=Y8&^T9.XP>*;|>O'f-F2KQ
M'*HR|+|>&'59495J8UAI#-5:71VJ=:7:DH*79-&BD);_Y05^6*5.ZM>"YU9 MH>
<*/AG@ (0F>I&S\$0W(ND.DJ)=^>"I4?FL?"GS'Q;_?7S^UNV3WL/M8_^^M_=Q|?
%B^T^&VUHX|_LA0|:U'%'|+)|Z|.MCB-^CH""H|4|!7G79^#!7-:GNA3X M-
0@&L<1NE5=*L|<%/L-J W?.\$FU #HQEL@OO/1*41M5P:GT|&=^1MQBK#^J7T M0?
O(.HC!FUZ@|R|V)U28FAX5C=S;=^QC(V^J55:'|2/L|T)2C4)8/+OWU, M48;SLEP|C>5
@7|!;|&SIY|4M+6/@0_|F1QXTQMT|AX'W_M=TN|^;?=O>@|? M';!CM_?U@?
SVO=|;W/0ZR)D#|ORM_4R>^MW?NP_/P+.#IR|_0R;WS>U4\$3B/ M;|CK=_H"TVY(Y|'_J-
AO/W?)U|??N_V' M|D.GNV?IE;U|HRV|GID3!>OYPC:RO+4OGT&_H0DEGF3S"
<XASYK;@*O>HOSZ*7*Y=|8\$QRJ@|ZKJ3C;=61\$HW=0I_VZ M'52BT?'E%&+
"D177T#R3ORPJQ"3/(>+929::A;QK8G>N;F_3|64U%>UJT= M'^MR)I6D3/Z=,6WG|?
ZI^S!8KEWF7^T1*YR":0_.M+NS!ZN5YM&RK9S)MG!< MH'(^X_|O\$ @O9;
|PF\$+@&9^|SN/9 OW8^R|X.O/\$|^V|M?N/2JE M^&N_>P="^88;GAI/?
_OV>'<#|B;8EL|PN6!_P?ZGPOY2Y?C8GTC53,X/>9RQ
M+UJ5P/N#|;\$_HL@QKG)66)_95T,\$9ONB#D;|HQ'7RW+#:_R(P)T)A!;_*|
M*|+LC(|_F&DFITPL@|T5B/H/6B;R1\$Z(J5:I@!XZO<>_KTGT.W;G<|C|X?G M-
BATM|TN%P*#;O_W7J>;K<()#XO TC6Q|"PAL+8;"&P4 P*+Y5S_?5'_VXVN
MKYQ('\$JJ+W'8?>M|Z3USM+_MH3L=|?S!;^C^S+8?+=YU;|I?@3S8>!_EU!!Z ML(A!5R-
!QG8VO3SD0-S|0?WX0?J8M8,I30^"IH!|?R&FX7IA!0W^9D/T%P)V
MZK68#;_QFB=TL(!KJS@CI7D/O-0W!VDQ|*!=.BIF@|VHGGJX2W")-M3'7?
DQ"8|T8<'XT2|HE39% I|N8 M1,NGNKE!-GR06I71GCZ1P9|(!@9^R#;1ET6KFWO0
I/!P;U-E1L<&9%FS<1 MN)O-."?M:+"A7FLB"_251Q@V\$MX6U.=NO13^,-
GW7"GIOKVR;#8,|F7/B| "MX4L|00E*|
_MBG|SX'85I1RO2&AY/8<^+|>/C@0ZF58P|7BYR#YJQ4E|4^5 MLI3Z>=:M)+FL*
(VU;I7|>;U;\$R^UWY>JEBN5Y0^_8I3%J00H%ZG|KQ?5BSF7 MR"=Y^HM(27&-NM
|"7JW34WMU8Q,|N/|P@^SDL|S;H&^I^C #)TS=8(E=| MB|3(+Q0PA.7 ?N'8N\8"*
|B|@!;?1|ZF-P*5O 3?-06R8<.ZWORD7RA%IC>
MWIGNR@U(_5CWB4=T79SI5G0M/8M+5D#>4-5^8*=/2|,WE73*|V-
/A<""UVF>7|99/T%H!3B,4R:T#U)-V3N|;+Q?<+|OUSL#Z66^W5C;SV)9 LOG_
|Y^#%VI;:SIER;>F&J0M|914@W2J M?3<%= (GT\$51V5%2VALM&T)B@,4%C@L8*26-2??
2&=%\$59%|87AL9TC7 MM@E_%|XQL5J>32K)4MM9P@9HE_
&V#_VD^M/)JKSEE(HE*R9
M/%2!Y#"S"*W|:VP,C5P58,&JE,2JYGIY'K82%&OFU!>'QJH<^6AYW=;|8\$H- MJ|=4<4X?
7WE4CL;6|B3C:L(|;"-QQQ/X+#YB,H9AT(L"D ?T9LYBS|@)7J
MLRI^A^(LV6C8++8A=J,QMK/WG=TJ>EWX=>)2|V|-|HD|MGV3#Q1QL)4W M'^|Q"?
H4JQXV*H;+BV3GL7F@!B;:ZL.B342AD7"RV#-9|3KF+40|G#" +:QP M^\$9|
ZA^=5>|W"LV46=?V3_8PH,C 6K+ M|GRP&:'OM|_08+1C=U_ EFWE_ZBIFDT@)3|?_
7)V*&COUZ,/6_J M?KJZ>GU|+<-|EE_LGU=M1QL;
(^&OJ/ZB.E<@!|0K>\$^IKC2;K2K|45*JDEP' M,Z>NM!3Y2I>E9KTAZ?
27+)|7"BC#Q;>+:6.|/M%T*Q8*X-| M.AE2QQT;4SX;A|H>>0H'(K1#45XBO+M
VW^!MR6RPISV4@G5"l3LZL2V7D@' M#LAD):!C%;0H,L F07PP;L_2RB7RA>
(@4Y5|LTW!"F\$42"*KE4)8P|J;5* &MQOHJM2|_%NB7V(&
|T\$0N)#FYRV%T|-10ZK2P*';|+P;BX3('R;(&S|^K^@ MQ|U#3"N5>1J36YJ|"-++=
|;NG0|;%|3SV!(WfY|Z@705LPI#!422-<=|>; M<%+-H;Q3&EP^"+U0|"_A+S?45%_1?
0CW?-0|&Q15(K>X^I<33JO;Z9P|D^F M'Q/Y.)7.1>^\$0\$^!GDO14;WE^L1>M)?5?ER^
-:'Z(T)XC6ME,9\$^L7YKC 3H&=6=@IT)/!|VB"|3+|B;Q9=@.&)T>
M/\$'W*2IA389;?X%0!FFG^7XF"E#L%*%4@CD.:VL-*?/M;^6R)UM MZ;:2?8';V-V=0!-
#2FJ@E(^:|3|079D OZH-W_B|Z&=J^|T(&Y78Y>|3L M:(A|_%OL2PY|,5SXW-F/=LCWOB'
FH\$U,A2I5YI8JJB)#>:C7H".JKG#C0+^N\$L "%OEG)X IZ|V1Y(M'|"?
=|0Q8JJ)*3N8X)D;AE6<<9*UK/'2A9A1JZH=#GE2A>AX0@-YU@U'&%, MA<84;
(6<84PI|XRIJC"F!-2<&|1DE7ZU&JU*Y4J7X3.ED4";FLBK79(MF!L M#>C4")|)-
RSP,J2U17=C;2UN@D@_ \$U@KL'8EUHHJAA55#*';5|_(L:A65JE| MM06U3P"2*2S
*3%"@%)8?55U5E|!%68Z-JJ57P!+S1"6ZN=N;L9::82%30MJ MD3HU8
O)P+.U'JO|MA.6I|T_PVKV=)E!A,"J-G6)#DN#80|8/*-5-YL,NH1'+TOJ%:
M3*V4:HA66XH.@?<;>U.CTY%O@M|V=|Y3|1E.IR%7 =U#Q&|76O)(O2D22 ML"YO"-
+1|K 8CM18-Y"U/90S@V%;%\$?8#3\$< ?PMA.|2>1T;VIB;)"YO#ZW! M\$;J&M;6T^S
S=3ZNMV|V39XV&|/X:4=UH<2 X0E|E!NLUV|N^J0GNOZL"D|

MXIB4=8EJBG:17\A>_Z2/4M"B8O"AA"%0A2>M2ALPK^>O5*KS6;+5E>\$(5G MGPV?%
(75#45AV+%,8AW+L;^16'T&7A;G00)@PS9&T>(7A/\$T*62ADX5G+
M0D6JUR2Y=:4W02[*W"RLQ63AOC,9"RX+M_J21OVA!)R4,C!%#E8VZX-0UC9
M*IT"1EXWC(PI6XH:0^>?2I74@;6-Y2!6Y=4K\#S;.:?=FM&MTJ(Y(4#)AL0 M@VO1^\$H-
!ORE!?\$X"X3-1;.^5%3FV%K7US3JNC@?H";O"=:A2_5@01
M!&G>2HVD+&V(6HTEM1D)0=084-!N7TXG)*V0M_62M*(T\AT6)YKMK&RVTQ#-
M=D2SG9,8*RW4X0/XE619D:2F=*77Y&I36?0K<-_8KY2B/C8W5'=G,\JX'2X+
M;5=HNT>L\2I0L_K"4%ZUH*T*C4:TJO-'5--=|OX(>|'6L9_M;B;LM\5_^P9/!B4=@#7
W(HJP';L;J1U?3&I%91<@)Y)Y U@W#."^(F/#ZZ MJH=C98R1
2_VS.>L;.*#-4^>;&W;EM;K0\H/AZFP#!B@5F282803@LI;2IZG!
MJU&@M\$#L,T\A&%3:AGWYR/#I4IMH3N?P9MX?!R%F<%Y%@#/_/W_4_L
MJ\4;/O\BL\$RTFWB_=A--T6Y"M)L0\2;.6M-X\RJELV\FVK\$QL,%5DRR=Q'^! MMX*-
>:4DJYI&@_I@7;:5)Y\U0)89C\JR_4(E-R" 7E6'\$M.8&'AKS/2QJ...
MC6DINL=,S2CE_":^Q^P-0 !8;"FJ;M!1WV#72(JUU0Q42OS-O/5>S1H96(-MF\2?
IEPST6.DD#SDT;SG.ZYFJPTP,2\TIN-9E5N,O=<-4+Q?;?1+!Z)\"+
M)Y\$^3BQCZ+OX"8:"?U+R! B8'\^J;"O>CANE."WY=IG_6,"QLX1QH*QTBW\ MN2%?
Q3QH4DL)/&@S!\HYMT++P+/6UGBVFRY4+!U1:@E\$XAVVHBVOIE=0VBK
MR!A"K32;J;B9W101@43E52)M^GU +D\;(J7B\$QL;-P@0\$V VOF"VJ*Z)E?Q MYU;J2O-
,%NRL5AK52@S4SKY"AF&*/6)%CHZA(3BQA#SRW8J7.I*1\0#L69?=- MR=2TWR@E-
X9#-1;+S_UMC6P+D\J<510\$G6=\$6_GP\$Z_76ZP_M4XQ#LEBEJ M>8_P!&UL"\S!4U@G\
^@7WOC'UGG_^;/_L>I\DH\N9@EQEZ\$& GP\$Z_W3N#
MW;YS8K+)I*A(JT0=P#9X%N(P9(D05O !^_K(& F.;Q<(*!0(!FX5=9 M#I\$05L
@A^'7A@|<&,'@OH=H',UDUD1\J\F'Q (@,W!IF<_7\1R>>H<8B=K
M,Z;&^J,Y87\T.AI1C6' LH^;9K\$,7'_BSAN:8A9I_JU7' S)Z2P'.OZ=\$>:5P MU-"
<(KYF@(^!7RFP&=U\";/_O+.;?09#+ =Z3GD<|\\$H;IB,B5HT,%UZ80%'5
M(93U8>'S9JH5KKWM(&-O=_G@&JWP+?93?=_U7DL0XBA@XNAG?HQI+.;?EA\Z
M,@847HGY*F8.BB'U7K\$T^/O@(. \JG\$J_H0%&_8BPA7:HI51F+!BO59K.6 MF_4B!\
AI4\|= \$TDHO;[*:AA7;\$4D7ZU&A*095S_M;++[V:>:\Y_Z0ZF%7A5A,4N-^RZC+A6A;C=7;8-
_:IO4A=?1'1O@R*6F:>OK_MGGCPK070SRIP3^#>*>+>FE9L#1=1K496;_U^B>'?
V6>@+|_Q2X\?#\J9HAM_M;_1HN#BM;*'1S?!"2ZCRM2*_3ZA\ OK.%?KFZJ?
CX759B=:/3OKPSCX' 7\$\$ MN!1,%8RT/IST;JH0DOY7)-J7(SXB:>HG\YI2W0L', M&L2-
%\$"!@ (!!0+FC^'NN\GAT62D2_(RY5#*[P_L&J_-+GKIK\7EMOG.M_MCD@Y%_
HX'\$E/(H4ES0,9-.8YAIWOP,\$BMX\ OX\$!T4_LX^_IR8N92&A8\$7_M3JKM_0\WW;J'*(_1 &
(RY)EXME\9J\ NQVKL.Z%=8\3H\A@>5^F73&QL2P MW!\K9,JL-5!S(7M&8*/_1H&-
<6R4I\#4>0KO=:2;W(U@8W\HFO1.&S,-)Y MP;4TBZ(AC^%I
\$JJZU'35"U\MO4@6R=0!W\$?24#@#A8G1G*N',G9\$B,YQ4A.
M,9)3*"B\IR76+>;/DBA+W9K6\$,S\SH"DW\YMHBP\;N6D+IK)%\$!'\$2AXZ!/?< M9\;OV3?
1RI_O_#H3_C/K>KBK-^M4GUED>HK8\$ _WL%"F?+9-VY:YJZ.R
MR*"D9"J!"\XI\G4R_8NO5>M?ZGDBTVQ@_4:P-@2*1X"%P4N'@X7A5%\9ULO MY!F
"Y0ZT_DM=AP_/6W7A1=CB'F7T!:C5M*5%4;S(E\>W76V@TN1\$R<_4P#F
MN\>,R9498\$IRK&8,/_L<^(0*PT.DXNZI.IB0\PC(&*M_:E4V\;4N"6#AU>_M
5<3=64")05*IL\EK\>5;NU*;RJMFA1+!A\$E\$|= <6R0COYZ0KF.Y'OF\$S.IE^M)O^P?=
T\^Z>9@DBL-J\+*.6%^!P9+%A;9'B\$7OF1P%H_M".'= #BDT-J#3XY_M1_DU-D7
4<J\R#=@R\NRH;!#(DVT.VIOHYRM8_Q197Y8"UIP42\!H)Y @)SMYQ&T."KZ@
8"JG8WFFV)6"@, # @M(&=8T_U_FJPB2X\N"+ MC.!56/@FL_DZ8X."=A-)WKDPXG(U'=
<7^7-#_J^28E452^EV@?U(J&=X).Z_M'G\!"S6_FSB&AQ9'IY,H,*^+%7K%8X@NCW%
MR&S\|O_BI=*(P\$AUAJI%W!SFN_C1^C)U-JIT!_M/(@)!/_@R!\#L\R>0BTL?C&\$WOK8)F-
)N\HC<MP@|S85\?L(;/_M@>W!L0+/_&JF6XWNX-P_Q4"G*+8^F'PJ79(=#KHVA&@-/LG
MVCF)=Q*,99)^5(.M\#LZ<5P"JE/@R>J\ D#M5G-#PB=QYWG-G(+SB02R2\ M3W(S/!
(#J%+^W0I5G\A!%)M:8Q:&&OAC=.*K7'LHR_D%O? ML0QW"%O)G_-D-2J?
%_+JRA4&Y65P7_2#G69\%%!H%O-4RF(>&C/5:"GP(5_MW';>"!JA7\$1U7%0X+%+@3-
>QX8V)KKA4_TN8Y+K"JZBD1YO<^ \#UQ0HX_13_M_T"B354\$#V,*
JR6780%+);EZ)BS#TOUX8=5E1E6IC6&D;U5I=':IU
MI=J2FDI=DT:*0EO_K%:EBT*TO\$RP2+TVSR+X2<9,2\ V9;.=EN=VNIFZT\WG
M\CV6/F5Q_>UC_YY;B8/O\ ?M_C\R:3>MB6>P0#E\?>|-2;.D;:!>X_HW!*X_M2>? DX"?-
=/7*>!!0AH1@V+RTFFTPQT*ZJS##>Z9NQ/#6K@J P\$=X\=NM"0\$!AN+U6V0VWUXK!
|=GM;:/>TS>FL\NA\?6@_M?^|W!VOQ<J;I^W"TCeH'@P-GF).?C1/ P;/_-)9=
!EOU3_H.=/A>#W_M"\J&&C\$)UK\G;:Z+D (PPN'Z^7P\!%@_VP0\JL9\0A':OF")\$&:\0PAE_

M\N000"V;WU#UO;'MP*KU;:3)V_!|Q>=|W|(+BNMLM)LK-MVN5:NXUC)E+^L
M\RRYJH1:7|S-K"YAPE&ZV)"|Y"G=.5>T7N>YUO|>X=^=9^_G^WW;N;-/PK-C-+@M4
M%51EX3K"H@DDW*M3I*E-%WQ0@ENP5-B:|PU0L*E)OJG>?T;4U M/;*= (3UM4
M6'8C\|L-U81W*65M;6-!LL+XS;|GEE
M*=DKR^,8&QK19^D'DK+|0'D|.L5T+.3T(.QDHACY5I7)36<|GD/UYO9K^D+4M_5I9EM=
2E+*2GVY)V-S M0|* VL< WD#U?(?N);F@!@!OP;'CF.HL_CE6AAV!+KTTN%7N/YLM.
|Y&^'5*> MG, RB\$4"V&=N^ZPX&
|8>;_B.Y;P^Z=W>|'3"Y8|_RG^4CW9DTS7>QFNO#DV-8 MF,%@+O|Q(_OF39
7<<38D;Y|RE7C:L\$|MP'#G)"-WC.I"|_7'9O&?
S=JYYG(|*IEOW3T;GR@_ ^KP#V!>Z>\$>P./_J068MZ+0#R!>)'%6R;W|?YS
MIX%TVOW^X|V=P#V!>Z>\$>TC@V*,!)R@|CFV:_OT\$^H7H!X|W2SIW|<^|4\$
MGP"^4P*^OFV.2,=47=>V!.8)S LQ|I;??O@;N?D_|?ON7>|1H)Y O5-"O5M' MM7Z0=AD)?
\$)-PQ;0)Z OA+ZO_>|7Q_X_R'.9W'WO|}\$1P0Z#?::?'5X>^8)M# M)'!?,T1P0Z#?
#/UN'A_:=S>D6R;WC_WN78G|UL_3!%8 X#\$M|P|,;V5%-G M-&X|U 0:=|Z!Q@4&'B-K!
'>IV_MAUZ7//ZM^P^!?'@+|3@G|!AZ=CE7+H.3Q
M!WT3N"=P+Y|6U|V|ZY+^/|HBTB%@|Z1@#U/ZJ&E2TB^3_ILJHAT"^&;Y+>W.
MWT#K;W|3B2T"|4X*|7Y3M1|X.6MMS MVSB2_|Y_!
<|?;JYJ%;_RF*0FLR6_JYS8|_E|.S=ERV(A"1,*\$(#DG|L7W|H M@!|!)@20_28Z1|7;J-
K*\$;G3CUW@U&HU?_O8XCX-|S%) "DX|HAZ|.I@*[B|/|>W_||2|_ ^>4_!H_-G-Q>|6# X/
MW|X?O_Y1-\$|DZ|ZS=O7X?O7J-WKR>3OTX_'(|D|. #PZ|S^| ^/AZ|GKQ|_M-^|4T>_|#B?
HX.V\$ _W+,L6'_;W'QX>7CT< MOZ)LNG|T<"X_X_/5R-
1=*|H&Y/D6ZW|TXYC%JOSQ/OP|1BE6Q<,LSI;%0Y2A
MF+?,JY#.|T'5@|?'|ZHD|" \$=G\$F29B@)EYRCC VRIP5.#YN)^_|#M4=# X
M.!P<'6JD9LJCP<'QX/BP*F14*E25|,V^_'\$O0%G&R#CA_7'^_Q/4 YMD"= _MYB@F\$X(C;D
Q|A.I%:C|G"\$VQ=D7-,?I H78T(" _B4(%,R7U"6!8E&-D'I
M6(B9LDR0|042 _RO*.0JSAI*ITD@KOX_C+(6 _|O#7|JXX/;IMLUWINOE? T6W
M#1G*GNDF@Z+;4(;&|MAF"R9*|7>ZJ1C+ONTL1D'D)\$;S6&&)A2(\$-ZX5)CB
M|-64WN^'- \$|R|F33!YM(U|NO: _&+,+\$I6Y5'#ZL72<.(Y3+L#-4|<|P*RZ)*J)54_ U#|.O
:=|HA'Z7I4**19@_ M^!_W4HY#C&43^:Q_A">N^G,2DI!_"^UC-;5GI|@^=(7/\$2QJ^*
<),SC=:P> MR_ X|P&)/N|Z|+0!*HO,D(|G390+K?
<%W+X"B7V|OFU=U0HQ.>E6OJKDTU5V/MQA.@T&Y":E|Y-P"R2ZH|ME?
Y7+"O||Q=%UJOXO#HL%,1%D0|"E8:U|JOW MPT:RXDL%0 <27\$IB>EDVO>
MC85HJ0T\$%EPZ0'G _LW1X1OH\$TM:_KG*L_PA#>@D*-GND)JFV/4_!3C7=?>|&RM?A-
D/) M%*-%-1AMXNRT; #Y"@&)&Y2(\$0H: ^&P<@@M+914P? M-EL)+9D807WGL;A7
/|MD(7.+TXSE898S/MGO M&?&:|TC9*4WM<.F@-J)RK(-|%69B=A;L L&O1Y".=YA-
K|>QV0J|V'5M*,9 M91G|=D(9HP^|G:Q@T_4VC,<+R9A46Q2*X\$1AP)CUJ|S/,R#V7;SB,+"
(1TWR=|P-.6-,@SY M3R2SW+#8,S.B|%: ?C13OH,)<|)Z"?5#R|Q&
%XBPOZ,XOY|Q@J:"|BX;S@HV M\$PLC6.|6P0*.@6
9*)X"J0K7'D\$DCX+NT*,='-7BQJ;7=O'%N9,@|U\$;G||7 M,7W"?&.= \$2;|4B9H@?*"M|0N?-
Q=E4J6*^Z&|H>G?;>X@CC.1K'^(&A
M"68,W,TT_#;B|S5.A|LO|39*EKR,2&KNA))UL&0C#Q;_R2WX!|VRIQX!*&W|
M!'%RL&ANSM9Q2FVD1G@T7T/1T02KH,JK1T"(444.(^>/T_!6&Z_&*F/S:TX% M.:
M0U8*1CUJ^RN^2K5;G14EC6VLI_X%88_:%\$YO2;:V@*=4G!3AQ;TJXO<
MV/K;)K_"34SG-7X|_F6\$|I (C@&I#51&"+0=?,&DIV&IHWRQD!P4%R-GG)% MPH*-
\$1HMOU|E6@_!ZBU:XQ3_F7,%SN|AS/A",|M1JYG0B(BVC2_Y!))1)-@
MU:>MQ2;Q#|KSL(RWN+U:WU+LHUXB^_G|:E/AE'\$/TP8G<,|SE"8P7WWTSS- M^
*6N6!OR|H(K|:E44\$:P#I0O.6|?,6|U^A5@E?N8%_NI=.:|2GX2!5"Z() M?I+
<^H1&4U2,/1X=U\$9\$M!U28V1-'S%1L2_V.*Q0&-M>VQ|H|GUL|JZX&7L(|
M++@886DX|>R.P>DC7.WA-"|SB(&'\$2IM#|49F--'G-SB:>RQ6XNO\$4JM:|96 MM\$X?
<5X-P3DMA;('UICPW>' ^CA,6C9|MC|HG@ECX%_O,7.,|G%
<3W.1EPU_|;ZT43|A=L51%MH|AP"4UO&UJ+X7%M M^38&1B@TET=K*%?<
T=&C>^R!::4U8J+Y-IKC@_H(B(SB<7!65;L;&UYW0@CR M/C9T1_B/?
>N;F1@AT;P*K9%\$?41*#PZR!ZB5UH3+>|U-T!|>U\$ LTS_%"#O!8 M,S/BI3D%
|&*,^@CA)O\$HPR@28J"XTHAG.\$/\$ZL+^YJ#8F, M-J@Y8K9B@W5)1;(D(6L
P@IF0MQE4%"JC',WYMG&X,D4S>#"@5HAR'#|*@*!&G(W;N#M3U'M4;::HCZTJ.(MZW*
<:E2XZ<_9(&OE#3"#I?R!(5_T;#J+_/PA4^5|XSI|S&F3YA.&5K, MGIYG|_8&PU#.P9P-
HQEG3OL!5-U_R9"|15!8Q*+8+&+YF:<38)JEK4*DC MJ%2R W45>?|O,W
Y1O#K2C"!4/=X=&^|;N2-HXF1\$KR%5C,7%O1Y"UW37

MZR8'3T&*AWPBPHX+>="^1ACU X3&VV2J@F!9PP[+HFV^X\$P.3./PSYPP'&V(
M92L_(Y:Z(IX12UZ!&DI5%3LP54=B%!YZ1K(L:>X-[-')R#
M=**^MS^"M^1DA\$YS@RZO^X"Q3N0S&'S6%X[M_1>-?5W2**LGXP-|K'?^P
MRRAO/Y:1?SE&66RU/J,A:&XFXZ7B,N!S!4"O"\$3(:% 5966@M4_PM^<, MIGC
MV<&F51C-00-|K646@Z"L>C=J&'%:O2Q?O*^Y#!"IY"JH: ^6 Z3G?+, AIN>2 M"Z>|U"F?
S@>4#I67<3C6'A+83EG4L|:MR!":.734QV M7<5D;'P?B;FZV2UOTV>SZ*9*C(:WG3>Z
E5W)7WTB Z|O?P867U5P|K" _48K:!) ^J29&JW@;+./N70^2TY&
<'5O)Q6^:=ZV*K.OP+Y\$ILZ\$67Y?.| ^W!;U&)T0HTOY&%%512O:I?RIHW MUJ !M>;TZ|
|4B+;F2*#CO9NF#;WP^O1R>UVZPLP(IOX|A+GK6GA6D#*,HOOSV85SD:T=7|
M2!;HEE| _':K"%Q!|J3CK0%:9V=\$4W,EF=\$4-03'.RCU63!-|SF.?L,HSF8A
M8OB.X22"2!2GD _=-ZS""|O|.Q:"H-BCK#43%(LYFMX/6<=H:X-:HZJ|J3R?
W|W(W(!..O2<(Y&A1J,|Z3ZY->UI4\$@2 M%*(L4R|U>;1R!MX:-
|V|UO>907M\$20MWW>!!)|V7\$2'=9=; ^-E/)OL _CK-;J
MUPO1|D5^QLU1;.9G00*U|AQK1U)6H<)=GW9P5EKG=O1U>U@V.#,"J?O!VH'D
M_'N.HOX\$F@-J|<1&E#3_5ML#:CW\$1#YI5H:47B|PO(TA;L/+6WI8%BFR=>.(
M)+SUUCP5W&)M1M3U6XSR|;9!+9QU*8&,7I4RJ*)+*0*2!%R.8'>>*%L&3G8,BS9&J9@=
;X:MR=D(LN8|Z@1Y M=W7.#NRNGV)\$YEOJV-;5&,W
+7E>DY'(VGLY!A/7|!69\$+'9YQDC^?CTD6 M(?ONOP97\$^9OK)
| ^'8CTT"J7NWCLJ2@E*^MCQ|?!J%_5*O-| ^9-569|DN3| MJV)91),THYL;P1;J-
9J)_N)PHYFLW%:KY/G8#WZ*K;GA|B4_*5)0R@2)4'?V M5'D-FF9K/,9AQ<>(M^9T:|);.
|S/3>|K<|PURB4Y@^GMEJ*X34QM.!KQ%1S MJ35A6JU(GOHV|";N.2W#:
MXC25QQ,DG>\$(.O.GEPEONXPR(N|QQWF\$;| ^#9Y1A1E"<7J\$Q99 ;|QZS&4:1
M@T&|A%Q&V|+|=C6/;?U,I&YN(.R)(-"7'7&(@06;QQ LKZER\$A<|"%#I92
M_S40(1"HM8W7%MB7KZZK!:\$>:)|#:.CHIJ*YD?ZVO&
MG1VLH*0 _<;|E,VBMP&@%FJO0P0IDK3(KK*IW9P.-\$%7ZYQ>^0,P9V|81=-5@ MM
+-4VAM!;7^ _P76IK+FG1UTH!2&+,>1=FBW54MH|
D"V|U#Z*C+>R+7ML@' =3DU&P|!|AE:&P;< LGJWQV*7_8?
TP|HL2#24"F| ^(| _@Z55"Z#" +,| ^>49#D?16_3OD*ZTD(|E3M8^-4_\$.|EZ BD|?
M|S(^\$NX%"9KCCWMN!:(2OV@<8|7C<U\$N _>Q|01G _D:58 >X<>J^TQX1OG98-
LSMBE?>108SDX|Q _PF&1. M%C.G"<>)/5DTF0RWODQ3/OU?
|HZ)| ^L)1)"=TB0E\$58BM;2+)?4&RH<,1| ^G MO?"JX"B|8'3.8?J=9+,9C2,XIBM?
2VC5W|+;5^A',OD=|<)|J#B<|;U!|.87 M\$A\$|J16S6U(O06|>IK"N^?00\$=SX2?
7ZK&89"H>&FM5WIK>5 ^"YW=X3N!!X M0=D).#"6:KG\$O.,/V4E,PV^&07| #OL ^Y5LA4-
18--.5TRM|B1OB2MGM!U%32BQ6/ M>*A'OEJ-
8@%"MR+MY;U0YSPF| ^(| CIA1515Q@U^G(MU9T:Y066\$|V YQ(9
M>2U>WDY:\$*T#2N8HKCA|D!66.|G+J#81# 'MAN&DH: 7"JA+!+|"(+|
| (2|HW|X;7|.35F1GAUOC|XNIEC<^OH#O|A|+39_8
M\$)+\$,E|A(UFO!!05EXLO,%, ^!CXX.+8O-|9&E _T#+*<^ R'RL=N?BB _B? MS _E,R#;O
MPK|F*^ ^/74|6KZHY-Y +,V^:0D9^W>(%|/3Y9JLIVA|P2)2VK9)-F+J2|/< MXNK!P?
6D&JLZK ?%%DD! ^+=Z<.5E BY" &I-|+NK9IGES&-K9R|ECB|PE|V|
MP|P:8EM/GHKRSOUY2_7XUX|E#X0W+F 2-|?3S%S\$'H MTSS-^%:5F06OE'QIX?
GJ(L3@@Q-N1BZ:|!7>DO0;WVY_1G|0MA369%MKL7H MBZL)#;+:HVE#^DSJV>|;%,UK
K*;YJ41.|F).F&X|WY@M%|N0|N|FL:B+SP M<6KVL,U2?(@XV&5VURL4FXP
SHTQ?:FN@;K;8|4RR8"E"+U1X/"BYW0<44 MS7'E^Z\$D0BPR#E(N'%|+>:%-
=_,\$%|>P.8UYT.A?%; <'#2 M0?%|*MEK)"XTGQ8!E/*-9!B'62KWD<5!'BX|/|
|K579N=%_#6I"|VT@|ZKE#X M _JGE.03.
(|D(DYFSFU0""P&N5A)J*3GTR'9_8A7VEYX|PZU X@|JN=6|;1==FYX,|%|Z=6PSENK
MA7;2^!H2 _=|/-*/=H-6*>(',*0L0K*1,6E,/:FMM!>JG.",C|CH-WD-)KVZ.C5X55K+>Z'.
|0R3L.S6TGRZ->HD|4*I M&|Y8#W%&*U)V7?
EH*KS^VN.Y|W/ITAK<81T47J#U=Q2&).\$UKX>XQEU
M(=Q8W5HZ,O%"|9.8/EQP0488Q2=YRL5/T|AX5%&PV^&4<6&U LE/V.^=38-
M*2N%O!!|>/SFX&"\$T+9U|J93JA8=./H"|V4M|HP+=LS|\$+A4PIWF.)9 L<
MAD&EN:R':A33KXLV*R1>*%7X?F^Q3\$N0SLC"T*6Z*+Q0J6-+T-V9!;\$7"G|!
M61%?'_Z9\$P8Q4@D&NE9O:!?%BQ|B%K/, *9V/" ^ _#4-)6H0:%6|X91A0=BZ
MW'+FXZD72 E<)*B0U+J:4+^A:/+B!->'_S _OSM*"KQ=%00:|LR'D9X;W&:
MW?)U7WLT7Q?-LT7+'#J\$R _"UQ
4XI&|QFL>9,3:FM;B'<|@510ET07"9&WA:W&0HT _BTQR>Z,?&T8U8SV9P1N#@JKF|
<3Y1V..6K+|CL MHTI:)<6Q9>6K@8"4?)"%!0#_5-%F. ?+O|4|AS)0:ICKER7G:=&,Z*3;(C

MN,O!4+S<(1JSBYGIO-B@@!4U\$WCA5J%83E;HM;;RJ;WI-
97V0I7A!>'1FVYW7\NGT(+4"R7OR+S! M\$5^ \$U4IXH7,\C: Q?
D,EGD65J&HJOE&RRT/_N\ GK4HYI? APMU*8/2X
MN=**A\I**U=&\$4##ZWS(9IU\LC4X^= RNE+IK,L;-H;VTJ_-I#9M&(-.P8C
M8/5Z^_7D/GJK#JA
M,1QFCPP'I'NEO)B)3BE;4+!*2()11O&9UJ4&*B\4*W,!@+|8W'5N79,V%=U. M!/?L"<,*?
(PWB. &H6XADW7^BTIMDI XT\Z+PPN!@%@@8GW 6" MET A7SD?=J (WR)0+A^#
B='AKM\$;DR\4)PO/6A\#YB(85:)?O=@'"4TT_FH M7N7Y9R?
U&NB\4. ^"YNR&\$KCWQ%>0%WQ*+A:7B5_M\&M1*>;K5S^_*S;,%DW@Q;
(I4=2W@HRRU@A&X5MR;U0=GATK)!P-V\+8B\4
M+3PX20J/*.!H=7(Q>.KLB+U05"3^J;P 8/#:M93V0A75SGA%Z#6+|9&|UUK\9?
VWT%N:Q3\4->H)_+BBK1\YTW HU M\$7IZ4*P+|JD)#K>4^=CBH'@+_8^LAR.F\6_Y/
#MP&,M1LU@63@:00?8\!"THDE9/ U6A.LYJ+=*Z(>"Q4E>5=" 4YG1 MJ@L\SYD?RHD%
I(+A?)\$>.-'S\5CSTZSP.MZ;V(UQ19G;.2DD9YKR?B9B!9
M=|PHSAAZN\PRJA3NXUMIJ=#XHITZ@{01KQD%0(?JFH%PSW4LO M&Y?/+A00,0CG;
<>3*:T>46<^_AP^M6\5X'D!\^M7\O1>|'@LKDAN<+O2\$R4= M|-
&XYUN/UTOW\JOFO(ZF!YQ:R7PP1,O7"QB\$E8O:|R(^KN.B;MI_#DJ;LS
M^[C81.4#:M<)_DP34_ ;0U5(^2"XVOA:RZ^5\DY\$'BUD7RWE@^1#_F>\$HTTW
M#ZYLO-A#G,\7,7W"6&SCKA?BY(:O@V\7PT3LP6A%|R;=5@-RUUDGBAU#F7
M)1*VIEYO/^<5S1&|WZS_INY6MB?'69N?KJ&#(KCQ@CSBJ+/+KA;SHDL*H6-4
M;;3#;ETZR#SU)HH+= (A\$=U2^Q5Z\%SMZ0 MSJ@\$'#IZVP1U#D4@;'!8OS VS
MY0Z@|U&:=B)/-1UQ ;BD-ZQXG%+, 'BXCE3T#3UO@ A*W3^&EO&6Z:'BMU!3\|
MU4GDQ9S4(B.?2+AH))V9#JKMZ;U0M_8 ^>I;JIV*"M2'Q;&\$'\$G0*4<%#<5 M;2A\T?
"PTUE1PPM""WOK\;5Q%O5\$|H>X-V243\^X?
9;TB@|A1@3>K:!*2^M5>ZA=Q3\<|G\$QB%U-/P7%|8
M&\$;:H@1.3(0:GV(Z\J^ZNC1W1\|X.4G0OFG>F+&OEQ*7FH%.=7T8\|XG.. 'C
M6@:.)448/) \$U%*4AE;VXJ9X;>)KY05ZG27V S)KXK7PS=1J,YU_ #MB)?.&|3
MSKK9>=L^"NGE\$%/.LRM/T\N';QL6OKKS-
!W\$9?;KR=>T*Y;G@;|7N8KO;|. |S1Z#4X>|UF2X* @8=4&789A0#<0G MF?
Z13UFAG+SFG8GYUF'E:0\7P3FG=+Y@> 9\5*T>=17/\,97S5B6%1^XG8(
M&ZLRF>:92'T/L<+M6\|GJ,K;B;)-65"E& PA3QN4NJ&\N7!&9.A)I1D@G\|-
M\$X%5(BD87(&2P55#1E+>|F5+G(@' /FDXMSZSR^0K\N*RR3E\8JK9?(M,(/3
MN|V%U.7WHT\$F,5XU)E)PDCH3YQ0H"FW!(6I%Y *>3ZFM!QROM9F9\8XKYK
M.Y\$7BC7%\$<(+?%6Q9>XKM5M2&3MS!@9R@E*22KU^PW&\$RK?KSKJ.U9^|6E\'
MN,:|/#UY&DZQJ*1K5+"C\6=@,G;/3;84G01BT#8MV\,IW#4RG@AME@|R,S\$
M2,|;W5'>B\ 31(B(0W.XZ*T6=|{O_P4_B" ;?0F;L/2UTXZRD#9(/IHAAM/K
M>SYA\;V%2#\$CH|PZ\|H6X,GJF8Y %'W*M%&^\$3 S<;GH\|O'5\$LYP2J8B:DIB
M9DJ6T%S:B\Y?CX\|1.1VZ XHZ;7SU,G0(-7C3,M\$YJNZPS#,YWD,5J?F\| #' MY+.YL"C3
Z)6Q%X8<-?VN0SWXCOHW^#:K7):U+;%^;E6^#G%NNHJ0 MTTFTWX"K3?
X^F&DXRS/(&)&)D9I2B:D\ \$4N7\|S87O/95.1KDY:I3&YQA/\$<9*R/ MQ)8910WD_EST;|/4>
/0@O"EK_L)>:H3B'#QS!;RSDW/%5A0>C\$+_8\AS!|' M0\Z,1;
UY3,^N""6#@XP16@P2*XLM/J:D/95Q\KLO.W/Y=T?H0NL)Z2K-I5XID3>8A;:-
;UF\$%H!ABQX2&*AD>C\|V?*\$?N&&XZT M5\|J5 MY(??Y8QCGXF:)V-
86W?;RJ;WI5\$ _898A)6)^A%PUB\(#CE@Y8W(K\|
M.Q_2<8222'6^C,)7YX\|=4%24*_XB*.5">(6@X@B+W=M<"R57G?,>\$&17WY<
MAZ=KA.8-DZUAY6)%ZH75WMZ;-BM#HX#;0D\$CF1?*R408N!; |G1'3S#<_S\$
M,%|3L;L9\$KG4KI..@RI7/K\ZA9IC^M9IDC4X^=HH5_!((X;11\O(J.5-JNG=
M7/CE!ZNJB<)>HG'2\$/#;6\7;SH-)3"7%NN&. ^:RAK^*^J?O(L*01P6CI90(K M(%CS5
I\$KR>K\;>FW%Y;8/S2/|/A_*N/+&H+WK>&06ORMYK"7U M#ZQ\9^98:_H?
MP\$ZT\;DO_ZI\|3>"7Y#^F^L*IOV\$;K/#X,1MB3=U_*6_M)E'OLB;F^^N0KSL-
X>|./Z@AG!1V%_%/F,VQ6R99*9\>|U2V(=++I9^U,Z M'Q=O#Y\|1=|%(ZDA'L&SYH\V-9\|
MWB-N\|Z*CQ<=RRP+2E\|
IHA@U3A'_/_|U*|^+OZ\G(SR%21*:S@Y5"7LB\|8@J7B7"6BD\$;7!|R^_6E8;L#CV>
MX07#H;R/(\$QJK_!V)+K;;C7>WMRZG"\08?#=#1_ =ICCEHJL@J^MDA"#>P_ .MM
L+7|U&XD A#S,13Z9NAHT66*1\7HT4J6EO0>FKTE\|DWH(0B0" XOUCX=|K
M"MXT4\FJ;\$>/_IH@I9#)Q^O(Q=?&4)LW&*?"D.5*#!: M\+7V#6)=QQ*5(H>:-
|I"2722DQCB+Z\|*F2T7OYH\$#|65@GD;>:JDO5G;FL MZH4\U42\X:*(.>7217W;CJ\|S%-
MJY"TF^1**4|U\$9,/CMR3\|@)?=UU+_-.

M167(&/6AYB(VIZ,UX)G4Q\$BG@<|L\$STO@F'3UU8[Z^KGS*
M1%U=BL&6)N0S>Y\$55V7H,#?>EQ|:S_P|D3RC+40818+?5|UP^|/|TW""&
MY^C7O_P_4\$L#!0 (/6*)ED-&+?W,BX #34 0 5 8W1L="TR,#(T
M,#8S,%|C86PN>&UL|7U9Z|?X5NW|>;5NV+P_:\$I%;W*\$)N*B3U>.X3 MHI8L"F,0H|
+?/K)PL+Q9T 40<|E,?MH\$@0Q/FJ|JNLS*RLS#_V|>3R;||MV,W'L^E??
N)_9#|JPVF:Y?'T^"|_?|Q%W__=M?_"/_?@/|/|^?|MLY|G
MZ>P\$IXMGKSH,"|S/OHP7GYXM/N&SO|^Z?XP_AV?O)F%19MT)P%^7?_9J=OJM
M&O|_6CP33*C-VS:_|?YD3%8Q&:<&P|JA0Q!%_%*&Y6L"E:5|O^._|23+)QQ_M_Y?#?
WWC|?_O;|K?/Q36^D MC^7/_-O;S^D3W@28#R=+|
(TU0?,QW^:+U|).TMAL9SU>W\$|N_4=|2?8O_WJ_M2T!3)/D?O|S3W_|P|-GJ^GH9A-
|C^59_??W|V_.'TD(PH2D^<?_G|_MU6PZGTW&N?YN.3TPEN70048?G+_M3VDO64 5-
C.2523_=XM/??X=;0J3=#990OZ6?EY_=H77\$#A^7>TXVJ6-D^>MS-*E-
TVJC&:=YB|G(>)D^>KH;|'(9R.WM!B.<&WL_G|EVYV0B_6X^D9+9|O
MCWV)M!IP|;Z/X2O.7W|==&'6T1(+W;:_O"PEIF'QT|.U_M+&2W@#43O&\$D^1LXYD|8_
M66OI<6V*AW/PNM(>AOP;6A-KH&LE|1*G6;:+D=2D++1!*(-\$4!(SD'9PP-OM
M/EY)HU@_9+P&94=;IX4D_::^&8L^+6CX;SK9A6-CTRD(|P(%1*HP@,\$%1.D
M\$7VV0:1H;SD4RTHUE!8G%;_@_IH(1;G0=MLE1(R>|T: M#V/S|'"&IOH=*|BI='S2OS?
CY:C9?'5?9|_|S'-|/|/\$XX_S";Y)'05N98 M"K#"P@I4"-
F#=>2="10BZ=;FZ>UH|J6K6HF^T>3W8U&^!S&|)X)?IR|FIV<MS*8?
%K/TCT|#\$KOYRS_?IY\$Sj:.*&M!S3B-Q0;#1@T_KL'I630\$^;<|H(;U
ML7W\$;&0@OP\$|"25Q!|X@_|9\$*)B8H_\$?SL8>D.77F"O7'!|2Z'9TG@7NL4X
MC4^7SM|'3&?=># '&^<_C^:(Q|,%9EK!OT_S|Y|?AVY*[YU7S*LIL%+2|Y-O_M*(0E+S&C
<|RK.-(|T3@KLHV-Z=,_|J_T|R%9=VB1-^|J30%5C#:\$DQ&,"J8>
MH"PL630V;6/+J;P^|V=-!VL=:0%;)Y1\$ZVGWC>@D6,5X4)HY5|Y7B?_066Y&X^X|_|)
<>M"Q_:92_RR7A:UQD-|_YU;T*;K=*T>!"MH3\$6,IVCX
:R2,HG)5@POC\$#MD,V*)79FAT|'">=YEM|PJY:U01K#>1|^*2+_MLRX)\$5*L5(Y\$9:
<8;0@908UDIVNF6ZO_#L&%_6B1D)HAFU!*M^W0V#Q-2_M;F>GO|T6|'-:1DQG|<8?
PWC:1W|T73S|A'GAD5D#@I+M(.+A(13)N!9|22<
M8"A;A^L>"4;0JDCNB4=0GKM8G|DT|93R903D|(#N*O))LOQ_XD|A4+>BB2#
M5%E)WX5(T((S5MIBLY8;I5+<|HJ_U:&.<>9L+>,\$5J&0">)L2F.0*<|C;B:PQI|X_?4BY54-
BS@/ET|JKNYNY_M0G"GD5N02=TL_0T+W|:TS?_U|E|43?
F|JG2#C%8|P&SL;#;DAC:TAB=%3+F*&TZX&P|M?"1#TQ;->;J+"C|0&0ZRJ_-5%Y;E^|Z-
YLO.ER,NZ5QN4|G>#>A(=TP&_Q" MHLT>='("E"1MYSC2#J9#"3|YD\$SK7-
V>AC*L*.)C)A+|.D7H|H|EQ ML7?
DZ_*M8QQW0&S433KQ7Q.'IVRXO:CR*.D_R>PE,@V2U:!)|4_T:|B*+61_ML?4&<_G
_KX|GH;QY@QHLX-'B,F%QD7)"NC/R:G,+I+.TO)|9#&('*.TK9V1_M+6_-R;-
X.">N^_)MY='9J1TNQ|NIB_QX2DR6B|)"VY092EC_M.W^Q>!6Z|MMX>OP?87*&
(ZU3P" B(*|Y?+PPB(&^*|X0"YV4PK;."V|%;\$AG_M|NU8T5XFS>CRM|_|#|
Y>A|N^V|B@#;H7#MY58U9X69TF3CZ4M0F9=D:UCOW>MA&/'<_4G0H;|9|R9|_
^_0QQ/5@!RL1Z)|@6"\$<: *J^03%FP02JN2#&FRQB*_
MVB|H1S*;'G_\$|J3Z<_N%=CHF|^_MACD>O'7A<60#%Y&|?E"2;##ER5\$,MS",MN!1-
PJAD:&WV;(-L2+;Q0UEQE><|R*1=|AJ6|92ZE4=:3_2|F>W**TO.O21C+>7D(D=EFI_
|X9P2_9T*_|T**.|6/\$)Z_M?#Z_(GL1&UF_G|?+O>:0|&#TSD_060R;.E8Z25Q^L&JXU_6=RM"-
)K|/@RM_MC07)>T*)0|>D>NOHG?@/'=0N&#>29>4;JT9KJ;8DH'=S.S8;Z|Q=^6#L/((
MY>@TUQZD%K7PED@0F0V^,^GL
13K%9@NK00,/N|DV6NAP0=;/LLDP5/L%M^J1;6|5?+/L_'I^NAT5#CR
ME,5JB8"RL2:H|08RNVB%8\$7)UN*^"|^0S-
L&TF|V|O/L(5FF#83|H"EM67HQ3('<8*KH1"S7G|=HF>_M(^-
::FFS@2|J|3;:\$^OE0@^1C"13R"K*L;6PM|\$U)(NT_1&:BZ(|_4UM/=8WA@J/D=19(
M5DA!36I+.*SEP\$EW;_V|39)(V5HYW_AD&^&;IRA_2>|Z^T5DNZ4.NC&B2+_M;Z/
O52>W&1?G_;%8Z3OD(L.=O(N3'-+UC>AZGED4>D:>::=N*<:YG|6F|*
M>:'|FB=|XEW3H,<^N1QV!"_OLSX0Z'?*D-=9X%0@>M_M;D=(0XIQ-E:W_0HK#XS-
\$PVWK/:(I%G|B)MJ:4YD#R(E)E_HYFTK6W:^S(T_M'A+BC^=73BS-'_'%@"T|ZN"!-
4+B^0H;:_)?>/R0C/(H7T|H/^P_M26Y^U^M=^%8#(>?WSIS51J,&X>O|\$R,5N;|
<@H|""&|)'V"MT_AO1C(DH|NQ_M|!M,?
>.#G)2Z,|PW|4'9Z!1#!EX+&F8LU:I+!;))TJ*,PLI>*OK&K)X;YIU|FLR|MZR6>?
VAO%1)OAMVJ)B)|^I7|6^<Q%J|!&-|O^OR_M"Q?>^0Z|:R>|W;U|L//N/KWO.
I8ZZ_I4Y@>XWL:S.M2;)'^-SH(-:(25:7_M|D)!3\$:"KA>&%7=>6=LZH';0\$39H)%

(AO.MFG\JY^^M2(OOYJ6A\$>1*>%JE3;2P"HI"P%+NM\$E%+HF)H'&+9'-R2S.;G3
M*PCZ9[3?H*>LTZ85?4"%F<0LE.FFG)4R3?O77_D!Z&M,22;I D1_K\$)U;?B_F4|#=-
T>>6FY(M2Z &=KVT7Z#N?K(0BXR<:=I:6D<5 MMTY6XGK W80[(,=U2OWF7J
M&V:MGW:8QLL9H>IGN*)^ ^*DEN_ ^I^7K(V6==SXFB%(94+D8|+DH2\$(E(7Q6
M@;5.O=H&UY#;Z0/1LFX^FXKXXJRS# /PBO:/DR2X# 8T%86#;RFX%J?^SR|
MKYR8YAKGTP RC_,H2@,I@:)K8F M>JL:JYL=X VJCNN!F-27I-
K4"+ZH_\$@7_KVC.3LJY:B<&YJUOQO9F#(Z+%E" M*K5"#J_5BQG3@\$KP&%"E_CQ:?
9V7)^O\$CSO%T2!;0*1-|@.41+7Y)5+K)\$S\$U!;!UZV MA#:DNUL'TCM|"*V=O7/>T*_639|?
E=5%M&J-U6^^HJO/H7NF&8"D8,I(HQ&X[9'VQSZU6.C|XAE*%(AFL%;EFN!;6C
MI2\$L:#+YN)28F&I>.*N_#J'N!^/>(:3;.%80%^JQF7M8\YO'RXKJO^#R^E'I
MW9OY_*R6GU_M\HSHID2P(RMK4UH6CRZ_)G6B\$L>*Y;7U;8">V=/_UG;: MGP;("Z|I?
JH?Z%7/9V.JT+JW'VBO5*520H^" = <"DVY>/O ?45H%+
MHJ/KJ:B:G=CD'9I?!GF2X[7/@*KH)BUWB:3/!6;5L5CM07,NLJ4F9M^Z M=-C-
2+;BR@|6Y6X@DX;.%?*X>?ETK(4*C%;6|WW# =F|SO|USPD1:%JY T\$)IZ)|&86DV)@99:~
<%2-*IU1N76X+;B MW
+28N|7J329GN08Q;H7\$1H058/4T5""K3V?)\$6,7@E/3:/IM\):"OR_&BQ_MW8B.H
"6MJ'&'1ENOBP"V|Q25-W|FLH*8RUJ(>D93FP;3/&M16|'_\$_UDI6
M5E(J\$NCREKLN|5\$#7#:@TH4+8,K66N-.D|>)&S@W'N1M=.M2VALCVXK2OD?
M7B\$U\$5|/?*<NDC)3&*!58&+2Z&+2IK5!\$
MM,XO6Q1K79|V1X@HC/_F.1J*.66S3T28H_0K-4;V8YK^%FI.T^'94;FQ
MB27P+,GP99PA&;XR@=-<@BZIE*"E0FQ='&)GD\$|@(:HYVWH59&|.RJW|C@9
M.;VTK!:2MSJ1|JUU"+-CX(-/6"3W2;:O3K|UO""=FWLDCK427IL3JU7R9'WX MT?
0|P@|G<3|.X|!TVLGT3:K>GM8AZ^JTDW:5&@\$5>)^.#9H)^U|==?
P>^IY!0W;M1WTI^_3%L&21:S8XU*22_BH+%UU%TUDP@O(B2N2-MNB*
I5F8+15JIA>>V?8'\$V|!\$|@>+%9!TVI95TBE%23,75(X\$OM=&4(5I%?-E?4,VWJW4&^,?
9Q_"U%C*H_4%|H|/7,|^;4I%(S9_Q,"H%4IF&<"?/MP1JC7%0>BV|N3#T0ZU.(>/6UT?
4JUUZTV_8Y05Q&5FZ:&FNX47NF36G2WHX_8ZZ! MB^4WJY2T=9!X\$;:'XSA9YZE|.
(O_A6FOF%VL4_5S;/7|H#NPJEYN)J%M_92!PLN%5E@H<"PY"84P%3O!;|)U(?3>BO>L=
MW0|HOW;U"F-ATA5I!1134FT@ZFC\$)4!@BI/W8ES4K1V%^S_*4C>D"_7BAFV M%\$V|
HFWH|K0|^J2G5?O"ZHD&# AZ|F7S.9HQT>%;JWX8.RK9V"W5\$.*J3^
M.*QJ(;>MM\$+%10^I\$^8SR8X*ZL7XZ:FY|_TPWPQ3F&:UY5_5SO%@WI:|?? M?3?*AL-
MM#-^;H9C:Y7J^I?9-&=E_|.UU:|@/SUUT479NN0ZO*^^6^S;:T; M1D.D0000\$GM&?
+@'5J(M?Z!0A|A,EW3RC+WL>:9->^&T^-P&ESLVA7:A@HC MIXW/RDG@19#
IQ,B'<(>TDP^%WS?<%#L(&UK>2|P5_M|HJC93RP@N7H90Z.RYS|_F22^A-
T%SR8&SKH|""HQU26?|?B+P/X<(AK(X: M#YU-5UTGSU|^;7&2+&F;|_
\$QK:%3L/J)\$A<:TFUOJ9+W&*9;P8Q:*RST8# MSS6? YT 5QN0TY?:1Y>A;&X,W-
I_W)+JX_!4DIA,EM |>UWQ#6GG/ 2?FLNL.:06F^YMV%)A
MO,AE_?|ZV8|N&\$:.OFFEQ>V0S:DRZ\$'T4SMY-38WK|.AD?NK-0> MF*K A2<|JO*16-
006)5EV5O'6*4H|]=_K|NZW#;1D(YP1#(1!0Y8JRQ!-5B_R
M*FNMWT65/'B|:XOZ^H!=M#\$GZ<';:DO+;""2L4-2+B46S!953|KS-DA#4IX-
MV7*+ #FTBF-:KXY*|?:(AY8TR)7@:IUA>|J41NV0!17!|:EK2L;4JW0K8D!1J
M_|OI**36_%E;R==!F1!M1JVJTT|/#-IE L7J.FK2K91|YF0T|:9M;(-W)@3F
MMFDAF\$,,\$>|^_?8H-DWCR::5;8LX|ST?WC#\$N|LPFAX3WV!MI9*,SPQ"S+7K_M
<_@.9*UQ8P10:L0FS?8|1DX1+SHTODLN>0UDE,M4LE:@X^B.U-
QS#W6'=X\$X)\$OK@*1K(K&^:74U1%EY_.X MD"|.N|0X3\$919\$TV808KHP?
%;2W#26ZXJ")IL*.2O_M@-(R0R#U2AMXXH94L,'<0|^U;,>\$-Z0;V
176WI+JFTKTPBKWZ1C|Q;IA>|ZR_M%J\$T|3SVE4^ ^IC!<\$|NM"E%E=;%">+>\$-J1+V
>DT%X2ZIL^KSZ1KKS039#> ML,K8_X|P.5L)9S*9?:G%!T9."\$3)"UB='.W-
I=2;NGY9;P"E%F4UB<(^Z/> M|2|VCT*ZON1Z""5&<, >+|V3-0(^G'=J!\$*Z
RDS4^)^T\$Z47,2A?E76|G_?=@ M&U0UP@-
KM(<+J6!*O>O&L^|_8^@NNK%,&28<,R!B|<,D:0("4Q%BB-X|;KBT MK=.,=H
WI&O6!^31WI(ZU.|X>AK28JE\$EZ&V*+@T&B-8S(HV<%_YY)! "V5C_M01=#|N=.T98
=^W%_J/PJ8&X#K>_O<KS?>_P6W | =JH_0?TUA-?%GCZ,H/E^JL^YD
MY'+VM<(H%I43CG-P17G(2)/.4MMO-
LQ)+4C@F'U.:|O&-6G8/I61Z##F:00!M7;_8!::"1'2*9_MX9|V2:-X=:/:9C_L!WTQA?
3SA^V*K,13");-TO(*4?:4D@G.#0DSI(X\$|:6_MW#S=
|&8DK5*4SS^5OMF\MEXF=1_M/NAQ32_2*DI"Y/Y|E_;;|2,R@K'01%VRT+M1YJ\$EABZS2J5
I0@&^WY3P?5,3-<^CO0/_J M0E5"&L%:K<|O+EM8"SZ/O%%!6Q' D>(A8J1-BX*4B&

!T&F'MODUE#|&,:24 MA|O\$A=#9DJJK MA #%;J,,Y3F8:%T2FJQ.U?
N&?!NX(24|'()%)380T@ "WU';U6"W2,LA2^U*: MCGL+|0YK|7Q%W|G\$0B;|P 0UF
UT@W|(F1"#VBX?)-;^Z'A|TU%ML#@F) 2G ML38=)94K:A|E-,+I(%W,K=,\$MT #+6&-
)V5L.F'RVJXKQ SJ|<*-X2K|_ ^F8/*76A(CCZG
MOD='K@9ZZ|::X:>ZBWY>%C8;&1:+X5'5/(J:F<,C>%0)# :A:*A-'GL/-P,
M;4@9"P=QX/874, _L&2FK,V+6P+&V- RI7JO6&;3E3LI2G/5|)%3>|C&10Z0<'
M(=,|H?;9!+D5;:N-0L >9(|/3%TIZ7%; @C6\$"A9>M# 3NPM.0|Q<^|)?=I
M'L|7W3B>+JDH')2(3R6A4X|*=\$N4 M0SPXV)M/=RR:/H37AW*|@/-
V)R4Y+@VO5;>BK9F/@I'76^A+=-HES"JRUI=L M=X0XQ/#^@>C51FP|
<^LNKT45(Y*6Y*MH3BYP58CT\$34D&|/5PI!+TU=UO*U! M#C&6?
R!^M1)=3P|G^SKC1^7W.8X84|BUY\$3PRG=O,K A:|CC%PFR1/,JK-1*V
M|3" /V10_5V;,Z'I%/>L4M8&: ? TSJ+!^%+/*(N H&B4.0LER0"VJ;>Z<#?
M&6+8_ \$|J8G=Q|.O=BW&%U\$-9GFM5QF+|,DPKUPR?\$Q1|YK;L_9-
|LUSV'U2|W=3S%?. '1 MQ*MWV(UG>9S6KRYSC3G09%U3+*7I#N,L42*6;
6I5!EYW/S.E|;8FN@H:X| MYP-VG|<)EP-7/ AG"H>20^V"%A4X6QQ9|D\$JL:PVOHY
!K9QM6?/#8JJ MD7A:|FE7(&VZYBPQ.>.0I1B 659J_+IV<;<,BHO<1)E"R#VD|H|V!:&!1HL?
@MS(,%U"-I:L9.O0M)6!|9-SV:UM?6 0KM"Q|N&K+8E"2, "-.0CHC?&(-K6
M#6=WP;=C6*EWT^@Q&-5(>CWRZV(WSZ/RL2.|8KP44D5Y%"?CX^6O1LQ8*4WB
MP(L4U2|0\$#D6|XIFI00:)GT3K8MP0XMC048S.M#K@>CX;*NP(4=?'63=Q1+ M|
(E)|4(33.D.'CC);FJ 76,2?#40SSL 4@'0BH?/XU\$.C|R/=K&\$ GZ|QL M#*E\$0T: L=R RL9
+&0Y8F(8%MV.FZ;^ GGNH|!X|/"BZ-6; MW@(2%S^|WT#\$K<-H%("XGKOU07?
H.F?|Q300W_6.&-;=#/+|%Q;+39/LD|DADU&6T">V@GK:RS|:L4FN&C%_SX-
JQ6)N2|&^NQ)*ZJMV? @?;G/2W&NG-=M6EP=;R7-^FB)M?=D42#9X&FKA0')2|8P|
MN: T*A|OVW8>=01#"E,-:A\$|'5XUL^3O&NU|3),PGX_+.*WH<3|-M:L/M5BV MGH|?9AU-
R:TN|(5)\$0UIY A)DEB2_6^4|"&O!M2(.1+,ZD.:4X|PA0,*95L M4*MSH/+;B;('6;
<7_;F|)^|F-?9H-Y(R546D(41H\$1MNYN8 VE\$BLOZ9E7K M&Q=#&?
N@8J1:/JD.EJ7|1LG.IK6<8IH=3ZMM_69ZUQ31P#;&|_>A*)ZLK,DB M0E0S(3 /L9@,
F7V5J&3V/|!>8.:|!C@_1=O||&R^^A66-K+.3 M^F&8|QK)W|;3|_X95_ ^..\$=ODXA@BJPE?
B1929EI""XZ0Y935LWS;?<" MW*>!MK|DM2E@LT07TKJ2R(U8OR|?
5%H)FTI=KZFY">401&) JY;IDDI"V3JS MMZ>A#"G#ZG#@!7(/%I17&J= M8?;_YV.7SR:
(L(4OF_D\$AZ P:|*!L!|X49:%S+UM7>KJ?|_ '!K*DAG(^M@L' M?
|P@H9&6|PP1,*"-1\$E6\$S6%|TGZW F=/_-#106%0B0|F&'PY);D8%DZ|_A
ME|H@UR0/EFN/!!W!BV)!A\$+64S3(TD&2|@X1)#Q8 OP@5|_C|V>H-OC&S1DQ
MK704RH\$4+%97&,'1B@;|0W8B|!-8Z_+/-0UE8#-|P;QANIA@ K|2;_IDB1_"
M339R(SG7|E\$5SO)E^QM7/_X|Y&.)O4J3;"W*!M)H,@05-M)O I->
J8\$9AE0VMDVE:87|JV^:A&'|5ASP*1YKID\$N0W|ZFQQ^Q.UG>|:9Y
M/0W3B_ X|/|>Y4DO&_ IU M'"|R6*4-/22-Z@%/V3=5:M^!
|9D.M;PDLG|(.3\$N@/F=*+|Z_-602,2N? R M"BC(B@MR.QGQ>N.#?198?!W3?
1NS|VK|M5;TBOC|OZL%>?0G>|I&>Y"1,>
M33^02(|*I@J'\$4PZ(CI:5@T2,DU|XN2WQZRU1IN\$WZ|1|O;/'(*QV3,/ +MU) MZDD:
|YWOR1?JSM)B>8R^":M.,4T#LW-'/SD7(A9VT"P)K|VL|/3WV8+^CG-IC0/
M9YC778UFT^_Z81(6J'8-'ED+R5Y(T/@5|&-1!7"4Z ML
8ZA%3;|E%_FTT|3.0#+.>ENBV;>-W.|VO^Q|SA\$Z:A|S|VLUY?
X|YV2DYUG4RPN1B_>\$+,_+W M6?>A?1=-TLXGY/-^|MX.IY_PEQ|;WT6VK#9
::QHA<|EVE8M%\$O+P18(MUCA@R?HBA>T(!IO+Q>?O^_F>?
Y9J_KX12LE,EJ('E6M%5/+PA8)S,7(8M-1 M1>N#P|L(AA
^V%O.5|>_-/2:YF95TCN&|R#UY%-A|QOFHEC)Q*AK(47-022MP MD5204U9DGVSDL?
0E|&MH!|7QT)X!^|U^>S:L&,F20D.6.Z00R7|41M'0:I<, M6XL6FA"|I(T!-
RS|/<9S<4L@+WFYY|2N.3SPPA*SP"U-L"(V@./ *UWK\$+JM2
MF#;M@M1M"=|3'>;\$R,\$2-|*PMYJ-)|,F:MUN"CY< 4 M2ANX+AI;MT>|&P/S>=KB-|A;
MVU_6W=9)|K&&+RV+"917U5Q*| (5%|6C/9\$&VS@R_"|^ ^ ^N?6SU|W>|I&,>,Y
M|)PB+0A6:N90_6>D-4:C1MMZ>|H;T9 VIV8|N:J=&@JEW7G=|R(C/^I5^/I
M=8KH^PFN|RTNWK RZHX6LRE&H*\$!&|BV4P\$QV9:U+|337B<5:M| #UB5XC|(/R-M
7ICWZ-(NAE/|UD|Z)4HG'Q<@|G0Q""\$XT.K\$VVN&*2Y:T;:NRBT'8,%|^E
M'?EV7B2: ^/OVDWWY+2;?5YNIC14\$7QVC00".@^J" ZQ) 962B^JX93#=#M'B
MNY|H|)3Q|H*_%"|N-LO-2/ZWD#Z-HA|NS|*DH0VIC 0G@E0N194SDV" &.4
M4(7|^*NEAO"6X8L:JOY:OUOW&<50%.-9 M@+&R'H3R O2* YY)*5OR=T1NK?
YN|3.\$3(D#D*.,)IOX|5LNDK8H\$E9.K|' MA&>^,2RMLL621|V1AFFD)(-!1V

F*|N+DRJWMO;O@+-C@L-3Y4&^4(#|UY#\$G<|P!1B1T&W;
(CR_4GKE+,R=Z6P@;IR,!,J4:O\$K%% MVT1NHHI&8\$)M5;N=R-JU;:ZG:F|&?:
QM"H82Z"C(?^7>PF!>0?>04,JU|\$52V1G873T103;N97<M|%*PZS[2#^!F6#^D:"&(-
CE3Z_&M|_ ^FQV_KA9H+R&@790D+#4|KK,@&OUJ9
M1&M@;)DLT7&1^7T;TE9/&D)%VX/HV|V,|5P*0MY?80]"C:Z@,6#,)9#/1,B_M)#P_3Y@S-
U&;TMH5O@G'D.S8'A7"WB)H1H;O;:2.60SG|.XZN?EY_YV4|FB+A|POSK-?
S'7V;CJ^L)K'YW MV4+>B'ZUY)%3C_=WG:SWMCND0@;;P)0/"W,"TB7A'CNJ?
OC_GV621;|C>3 M>47\$#Y|=6|SY<YG/T\$U^F^Q MN?
JY@_:ZFAF1BZ\OQ|=OA=APUO|=C;R5H/UT1.@4BW/&^4-'CJ>IF2|M#E(_%
(/92JRRGX5.\$):O^+F0^&>8S&>KWW1\$|PB^&<6"MA76|=F'"8P82R&Q
MX\$@V,>'A:|T)U#MBLM&2;BYU5D.MJ4/P_7J^2B'L6
M+LHWNTK"K)U_@_|HPM2WX^;5G^/9""0+)CM%E,804@6!-A/E)#.IM6_B_02 M!GS#'4'
G|X)P<:75Y2#1T|O1^1B!T8V-0FZ3BSVX? 2QS^FLVN(XSR&|*8|
M:WJ!&MVS(?;A|B8@%3F^T?;YQN|*3&J&HO#!V,|1/ U2U5X/%F+7#BN"D. M,'K!EG%&
(@|2;3PM_OBASOC|8)ZQFJ|+Z(<2P/>5@+MXEC+9!|\$VNGX+\$7B(MYK *OS*|FD%H/8
>6(.,!HWBKBTQ43,BG=#\$6|A\$>6 QT4BIKFWD'XK|&_3^ MP9F_#8F'5/Z_N^;|?
QK<92;:7&:N|7FR"R70A |U2R1#+|XH('8I(4&R0%_
M;J@#8!V@T#;J"S8"V@(Q|^S.N&8KJ RB(|> " MLR\$RZ8D
A5I+F\$"Y7^ZV8V+QOE&UHT;:@G5)J,YV:DQ!M-2;!"XBJDYK&V.;\$= MPNXYKL!
|E(R1;N?<%%!4VHJ2|7^J|O:970,0|N &4UX>VP5U1 M|(X|^FG09,M|TZHIT(ZF
6:TD|4QX@C|E8HW& M4|DGOM',L=K6#IL,LY(?3C1/0"
&B.|^MJH/"Z<'E!|JZD.#5(3YN.V.BO66 MP^VR*/#
(4I1\$6HJ|5RD@^!)&BK3>:90NV|AH&6|B+H1Q") 0)8CRWKU1<_MGA00"C?
R)W_7F5JS#L9|?OWT#8?X-WQLDV!<|4+X;L2_0;J_53S@59Y#^PU^,7T0?A"
M473^\$2UZ<|+R3(|(.|8A&R=DXKVBKOLB^2'D;_#|^VAT*E#.. C(3B:Z4D1
ME1*J=D\$M|59E|!;|Y0L6C?'<+_%&\$D;C%D/!4KO?8W|\$-X*&OXTN2EU'A^:MMN/3?-
Z.PTT7VOS<_Y,2|(BL@,???%VBIL%90-1|M9;|@WA.K 2H(IH.QN.
M1,O|2)%"AEYI1|O<0===P@|GIL<4@8<2;999Y3_?(_|_|+%;VGR37U_ZZ07, MQM-
/EQX7WTSPY;_%>+=:YOSC;QDB>7Z+=0V7/O|H)\$UH&Z;+2? \$W-T-GGW&S%Z*UR
M;K8A^,\$2+|J ^M%S;K9B7*|,BUVH?C"14%9JQ:TC/'&#CF+6)%#^24)=*I/G
M*>/9^VQ%8: ^DG5|L.T4? M^#;1RSB.6@Y0PQ4;R(5_00:"6/330PB4Z9 KR|%Z).<@ !5H/
M|9W\$K4WQ_MFR50|S+C\$366IZBG9+.WWE%&C8F.RHSR|6S;WN#.P?Y&(83%;|
|2SWAZP5\$ M1/1KSA#GBWC>^_PJ-=<=P8MA%)00"867T, RD)4):90U:4:-9M|
ML#QC/W(0R"L6,/=#|7A"|KK9)2#EA(@:0)2 MH|G,C2?.1D:H%,Y9J|47|1!GSM%R^X?
BZS:GT3Y,&<#)07_-^';A@7|WF_2Q MF4Q^:|H_?)M&#"TTOJ4B/K%28@ANMZMD&A+-
PI#(-)I_WEMB74A\$:TLCRUFE5/|V|0;RP|O;H +RX(;F MX-P=D)C^_BHZ|W%D?.8V%N=3X
Z5SD04|@E=16D>4%5 |P(<0DJ>_0 B4Y4W V2U;P#9)>3,NC^^[ZR^V:|_0AO';T@C0-
M2Y|)3Z")1/V"8"&18)/PRK\$ @1|&FAY!^4.*5BVN54Q |L,9U@.67()52!|J MK<*-
H='MC:636#9!P_AC@U|UTV1C^?5Y|O|_U_9@ ME"RS2;N
:|5Z/-2BKVRS(8I+9|F('NY7.0PJ<\$|_"G&%KRXO!TA4_Q8CF7UN M-
MP)=|JZ=*|Y0X(IK.NPO,C(|5GXSDNIOTRCK!8|4>(S<6"NQT!1I8&RJD"
MDBV:#M*"0VV>,D&-GC5'EUYVVF7_0Z_IO,7YI"1B8R+|'AT/_=N<1^AN|O| MW'SV?
_YS/+|LQ,3-6TKDRNI^N;^Z44+'FH/'TR* QR.#.>)40'|*"Y4S3Y39 MVMD'NV(|:PD|"
GBFTC0!)O)2/"^TPM M<_O:"IWOZ6=MUR?HGP|W_9NWWVP90QEG&":9A|0H|M2Z\$-
PN^ ^C"@SU#@P_M)&J;REU0))9*0Z1G244:&,NUNRT_AN>|:X:)|:.\$D7>^Z^@*BI?A|ZH?
CM| M-X8;M)_H+*49R'D=J'/99*"9BD(#|:B4N<<|7D&0K4R6LD81+R7#+ZAVKO7
MZ|Y3%&8B|O|D|V/MF87?+M(N_OVNF%W-HKY"J^(CO%^C:=SRM+F.(/F8B56Q
MC\$<3|DJ_\$.N\$ G+2=7NR_6<59ZG@+^C*1GS;:9/Z%V9Z/BUZOK2?,5%&@F
M#S=MO,1/?&B;B|9?;:UNY AG)IO2SPPMC2P!C8P@#"#/&"A^#C|4+=8ZTU)=M
M=Y;|_|!;=FN^X=K+|ND/U M?;>H|^V*>".&NR|Z&XGJPJHR,A),H(3E8)+|1H"K?2&_#;X?
2KSJ<6J-6.T= M_+X'|K5OVZ^X!5Y=-3?3^?=J|,Z5=Y*\$N=DJ: '!&
<2)HM"12M7FXTLU\$| M"KQV\$MO6(|H:O,LS6YMG7J!#9EW3V=D^*Y2,F5FO|L4??
*E(EE:"|YB::2 M-,I37ONF>S_\$S|X.Y8,&
|91RP+Q^YOY;,ZGQ4(<26FUL;8TX;2X%PPKL_VB_M)%FY0%DV+JK:X?/"#Q|4:E&|
/VV.|^?^N);.1.<5NBS* &4R*0UL<(9_H8G_MQR55^F^|G?
GKUHU"=_Q3S^|J+Q0|M\$@#3|4GQ?=:^S_97W1QX|G(1F|X MBX:47N1X?"(X'_&P-
HIS\$6TT3#S9.K3_ZYXMVP>BZ;:<^B,VCUUH.OS(-^7W M/=RA^LFN>_'6|P^N?
KANLXZ|:.43I&8>"K*@J(%'3O)3#">HZ5.ANJFX,!= M9UU.-&8TCV@"7KJ?

2+33N2>XEJBU3J##8!/=CJU=AM^/M%U=ALR/H^NLTX)
MFCCJW^3*U%*@D7B&)I3(R8N,6B3DP83|A+O.;L7HK;K.;D/P@[48|0/J1^|Z
MNQ7C>O4.W87J|Q,)S9RV4G&BRW|9F5PFGNM RA@)(;DK>9+/5Q3VZCL;7Q*V M(?
9!NLY&SH2D7)"@DR)2&T&LQR|T95|,=FMU|7#8R7:=W8HY3W:=W8:R)I"0
MQ_J@6)E2Q(P/N'B>B?,V\$;J-EE)H*)J")S.;BSCXTY)\$L&D*!'@W',J4,I"?M(S@#<.,5S_G,
<.:0BC 0U M*.:ZG*X%.U.),J"UL"!:'%(>7JFC2D&DZW|N7;H-CL|;B*%QE,^;,(#('IN
M(I&V#%"CSI?&+6@#*#@UQ'9^,-7EY@"M>!X|TZG/R>9HB)"V)(CY1((\$
M1Z2T|G20".H/A7C:NJIV1?(1OL#T|NY41'2QN-DNMOX;G|7G148_C)7N)MZ,
M9_|BHH7%C=;|O'SY-Z|9>2:4LB+X,J0N(HJ|(2JYU@5'M*16UY>_K3_C4H
M:Y^_B,H:8;5-Z(0'GS.>\$^AJ>14S465|@=OI5Y>!AT4DE M@A_|OJ.T1_|O-
NDFSMA^WROJK+ERG0N#1E"9^0I46&+QHBL,-@('Y_'R#_7GT
MD.&5""PP|@LOM0|9\$W"A3##.\$JTD(4E*3 KFO(FT5_-P:7'JD4\$%!V+Z-G0= M(*T!|8-
5Y?BM8RJH_-H "3'W5'N:UD*Q*W2(((R0IPRMC:EL%C> X|SS/?38,4G!*H"5>H!/'A!4) M#
(I)U!A7LA' 69WV==C1X6)>!?2ZD3J:KBD;1R.&/_\$J.:H:B M\$6 ^&3S#J6+|6@EN>L-
S9F\$|T@UP8?F8P?|9_IS_,BEM@P*J",K1^4O6 (), M"@G@'"),<.:3""QZHY>P Y_7BT
/NS!@:6L)"E=JA3';,%(H26 -:T:= M(PB+4? (T@M7NU'RZMUGOO>=2%K;-
/YU,KX:+S14D|L%(G^G/'>7*\$K-KZ> M0/>@KC
.#QT=@^0D9)=+5@|E0;\$R=B;:R+6D\$ \$00O;_#R\|!@Y" ^XV&0+4; MJU|N9DB&V>QUJ:
I=7>@S/WKEA|1+2S03>YS5OF?WR|KL+*>_S/AZ,(C%"2B8B|A#&&:AFX10<|H-UG
MG6(2A&?5:|J.)"A/5#<>1TZV(7|M-^F#;_U%;UU&+|(:5U\$-ZUT5Y0V,6*# MX\$1\$IKE@
H3NYP|!|C#NS:5:=Y4(5C-ZX."Y._^T^?2X@Q@|M_Z8Q^(0-8748ALI!+G3@ML0--7
XQL."|CK5|+?='=R+=H+82@0?7 M1(.P8@#|I"Z>E?9 |% ,9:.(X35|F*?X^(R1|\$/XQ89&?
+Y'%"=!*EMP1% MGP1 \$0<^.,Z33|OVEX|B<,3H9/C2<,V-
#|>/P_*8NDQ;PB7ND2BRWHUHT11 M;C1(QX-
RU6V.T^SG4=TJJ|&)CD#4GLBC#5XAD9* MK)*1*|_-
LLXS|JIWYM@\$YOD+0Q4R#|M)#I77^|9;JV+.S2U\$'X.)GC-".3KT MDLJ\$ \$!,O"U<180?
%!^R.OPG6LY>)VJ0?HJ%/=')Z|A)%6@&('ITK4_&^)X M26_.7.!9!L:&ZC.|;M_ ^|F|
(R%KM|;_::LNLEOT+. =C5#/4(C9D>Q*PW7@ M'I&4ICX>!/Y\$1HAXSRK<\$)?_ |K'/EE=
|4JAB;YGOD+R^FK%%H MFPJT'1%-
&:N'5BD|X(:""06>_6IH'CSZ/'BV&Z4>|DV=4##Z==/-|EY,MR_M MJ5M(X_G|^>Q?
^ (B_ ^ |JVM5+P*PNV4""A;A\$4/7^|)SN(AV2-%'Y2|)*.:
MJ*PC+FA%5,+ _!VZU8|NBH\$|KEBV0(1DW8|\$='M|DAGI_R1"+: MV_#SB8CV-
F0|E8CV=QNM|*|?OG|&?|I%6H* @ H/4^8Y:GJ.ZKGH>,%TD(D
M|5*L/9_ |\$3@G\$K/>BLD/7(DZQ!|P;P'K0!;ALCZ0!LH6OT(K..\$K:NO)"G1
MV)/^!Q81H#9*JB1Q!M')8"VQ01NB0>.O4V3"USX5#RX:3X2PCR\$9VY|I"(E8 MVF
/("X3HY+.2C/T#8REJE3E^ ^6%2D M_2#=
|!_LAE|@&B_1|O|7MR6HU%HY:0CUH/\$<%8H\$BL>J9|DKSC,Z@M5EXPE, MYVEA|\$/V
2*5#_&MT"VW1!|A|(|UF\$|&8-C#XX^*2X5V'\$ (T^, ^SI@A1(8. MG(M=U2=N/!<-'K#E
I<)FFCUF_/CB,OV1L@:|H64;+@QQE^XG,%MU!I%!^*0% MP?K8YK2|)*640\$DWWM>
(|8NJ|+Z^\$" M^=&!S<(:DJT+I6K'\$:L3\$".9-!8H>D^U6|L.'LB7@\$>|H@Z|O*Y_DM \$|V|
MY6R=-MY8YFHG'9L(|.?CX1R-^&C* <2R%|MNP^3LB00|+T|82B60)8#@0AP-M:
,85.W>1DZBE1|/Q@CKSVMN@>L\$W&|MV+ZPY|.58D_3)OO|1#OQ*/Z0!S(M^>X!
|SC^=W76|A6=/?ER)!%262:*4!"E+ ^WQ@R)>YTBS53-4BI1|9Z9C|Y'ZFH3?
L|3HW?;EJ|D|DT+"VW|9_E MNy7)A|T=Y&AP)92'FT302/>\$A>5BHD)"Jv/H9S?
D)127*5YXU|1&=_L7A M)ZG(4M!,(I66R "&!(X_YF2\$=-QHK7KE%SW1_?KVA<_8T=B=
<\$-P;RE\$?6!4 MG_URY|6'GP:R('OLV|RE7N0W|7CI66"Q|I<4&6.FRMB5?9XC&!.+(/5M-
>M="9N C,SWJ|F|;@E7FV|^14E M|X:(4R_ -JGF'?WI<^0>303;-AC=O/UQ2|?
%W4)\$S^;=8K&R1R9TY0HRQ:GP|K|I:"YLS;R5-E'"=Z:*#H;<.)7<."N|E.& JNIP8O9\$
M!/=4I6P;=@V19|7D^1^ ^"RNLOGT#7V#2=,&+UWL-B(IHV0F&4D\$ +E+A!' MJ2_L
W">N8|UFU/T!7?X>,^@;+Y_HST(CP:(&K^!ZQ;BN,LQ&4EC%S|M,L=?
9^7G6JGBY:U;Z^N_ ;CM--&E;R|@-E)1*Y|5(4R54A@;:&+ITU*-S MY|*SZ
8H2RL+Q;88G|VP#J4(=K;+*#C/L)UTY8,PS?C6C M#8@ "F":6AU!SHA*SPE" LW
J6::DJHU&K0^N9R?U8E_VAV!|N*_06R7^ _N M.%Z_ GD-
TQD\$&.IWB|2|/U1'JIB" 7*)Z"UQ\$@FS18|Z)CEP=LP|GR@.V(>.I ME >|G>.(A6|T64Y.
|4*7W#C/32D--*K,|;8,CMT;)*&M7C3P"YT0N MIK9B|@.OO ZQ!W#;-
T!;11Q|@!OHVNE18,>Y9*K&QG|BL064R|?(=ER0)
<":.#%'4C^\$=7\$">N!XZCGQL0_HA+G|@G^Z^"M,H?63\$CM* M5TCL65=)-
66QMIMM;CBDH-).E0K0=3Z:YOT7^0-CK#A='UK:AM !|>JZK(MW=1FJ\$X,TA_H-G|?;

l:6, 9R2,7DCC/6 \$D2>#.\$7|>(V>'XCZ+3SN@3@G
M<=B/PH,,/0%EX=Z_6>7!LEJ9_8|".HEX MRSY.2SUR#H&XW/K\$WR\$".,OO?8N-
Q*O;JVNZ@NGXOS+D|T 8WY\$E.X@!': MWRXB=.*2MD@8DXAG0
DO+4YDTB;;>^=*WS8?6V-YMH)R#%X,8I#TOIQP(6L6
MP1,J(JK3&)|>S";",U";6'+>_>"W1'M%289AQ,:+Q1,)|Y9M|-
L8_T4F);|.O6LCT!W;4@.|.U*L4|?T=_K@#J6VF^&U<5-2^;UJ?EMSUM|.I
MGQ@C2F3;M^U"4V9HD\$5B)!HDJDR|2@ER<8*"NS\Z9V#YF|0>^K;W<%L BK
MJ1@E8|)4&@(|&)DY"1E5C;.!6/F|!+#+A=^GU^EYKHP9>F-|)\$T4*Q|'9|CA-@'9&,S\$
|)1|B1|&- MH(0R=-,E!49"T)X8\$YV+V|1RNF%3(D T1+%|L-@R ^!\$EDR
8,>/3);S=0|P7L|!|L CR?|A49| \$?1; M|TDVLV_OFZNKIOH|9XP2ECM4|
|4:ZO:5+\$"8,:?);2614XI8-UMUP'Z,>S M4.K09X#4ZGN8EM<-?4-9)*L!70LJC
I@>W%R&H0|K.G78'S=AH25^?DIPM2WX^9#"U_&SI_5C4#\$\$3? ?S^|WBZ^7(600,-
M@W=C\83-%)&TB6F@'." |6(#3RN/&L"U"/+(!3M9NI;H!R>#OMN+=G-3AR
M.\$&Y=6K>YIN+|P_-K./0K^5B?58*|JZ-9_.13.*\$T2012A5Q1WWIM>?\$6&&E
MD%\$|500::V_0+|(W))8WI0,M.9B|:0WXYF_N&CAHLLM:?.+R M\$^%K =-D'^?C+^+NWE"
|2CU:7A+OD7HS!(P|\$VT&ITREM)K04;U?H?HF|GA(M.G1L!7&L##@5J00F0=^70?
&=M7>^ ^I2BIS#MW<5H_?.7I61,1,=#),5;-)-(\$ M2VQ4C)3HD4T18KR?
K#K4>@^:TE)5#AYT.JI%|%-
)2+E5V+ _G/6ENXYRF1.9=|;F(\$YO@UQJ|!*&C>3YF(_%M|SN>+0LKD:WVUOONEM!"('C%i
(RW"D:6;(#R*'5N>@1\$CQ;DYP0ZTT5FXO!| ^|XSQ8 MO309*E|Y?
FB;=!/G|HMT'X9Q|58F)PRS|9&PJA"9S383+P5N\$;NI,%Q|
MA5N3=>|^&V>J"G\$K#ZQ:XBEUK\$M\$|4%40|0%>^Y-P(Y 'WW_CQZR/!/*Y| M6;H97-
*(+N:2*NYYF8"G2/';\$RNLH&J:%*OO+;3XOHCE^\$'8OHV=*UMROW=
M3V|*U/NF'4|O7C=7;&9V|QX+L)JNKJG7U=SA(!+9:E"7 D7KG|A8&HT7?0
MB5.0YGX#HPVG=O|W'09"O!*"FN')6|L|N|/M8K7RU0@JYQ6B",0G+TMUNR&A
M=\$87HG3\$#T&*^|/2-C|JXRN>/8_K\$*^R%B|^8S,9|Y.Z>X..N45T%|!\$;(QP
M@^N3QB,B="-),HQQ3RD3J5?/^"=4^/JWGY715H' E6WTAXA6+9%Z8*IHM6W"
M<7BCK0:/F7Y'@0>?+|OL8%)U|;H4)2H>:1)DCCN'8H|2K:+R4_-O|GQ?1'
M;+9#|7P;N@|2;-);^.:?7!W\$?&O!D*8,1%5JE1"8KB0|H523/@7M.G0VU"QT? M!738,|X.S|:-
C:E"|"SUE;W/*OX7P27+14D"EWJ;4PDWE-)LF"9*ALUL|40 MOS9_.0,)|J\$DVN|; TR_ADG-
PE_|B|HGDK='<:;!..K\$%@=|^@AO4V"ZZLOB160IN;JLI/(|P/D_"0"|I#N,2L>4YTF<-
ZSWLH:3M&|IWL82BJDSNP=':QEVMM7C! MK6*E?W5DE,@RG".P,I.041&L"C'|?
L; >240EAIC .0GE-HRL+8Q_ ;0&M@O;S MI9^ ^G|+ _!
|Y=F+0KPS;+B),T\$6I2R!*,=ZQ?|MWC|SF52)5.A(-701+|X|^\$3?08M
MTMB)I.L.Q|G')O|/1/%&9&4!\$TS%:(EE N#DSDB/5+'G+>*I=;;\$EQ/,4E\$ \$8 M| "Q+%D?
WN@<B^%BR^%B||/;52
MN'AB56POA8LOA8LOA8LOA8LOA8LOA8LOA8LOA8LOA8OGPNJ7PL67PL67PL67
MPL67PL67PL67PL5A3+F7PL67PL67PL67PL67PL67PL67PL67PL67PL7GP?27PL67PL67
MPL67PL67PL67PL67PL67PL672K#G|U* <3"78D:L-7RK!SK3HYJ42|+E)Y4LEV\$LE M6\$5#
|*42|*42;"MCZMU+)=A+)=A+)5CU2K" _0G/1^NO+KX<940?@=8>KZGH|
MI8>JW7(H*#X;1YA_R90"K1QG7"8V6.#9&*IMK|2)YU*|E:CG5#M'(I3,5-:
M6&^!|P|E3%;K7L->3ZWVJUMY&"KVJUM"|LVJUNSO&J.F&UA?13SJ'0,7, M3+2*,%,<
A<#09VMB""9*I:\$<|;70<53_Z0W_3C)<-)6|&UJD|GV#|/&%^~R%
MM#3I^X"J>\$N| \$4G|^>7MW\$3I9B.7|JB6,Y\$
M,XLK\$>ZFC'(A2^_3KZQZ>1<12|DD|A8BA' M'+ ^@86J)T2"LR)0"%A|9D3.
(_W;1?/EY^<3%IES^|&U/?GO?LV;E;E2K?95| MYV*YRVP^H.!Y\$;REH29P3
16^.,7.2>!Y0:.AS@0C>^7.Y|!RD+|@/J|BH*WXE&O^M!= M""PX|G-E8T)_57CFB01@)
@#A"IF?0Z0_6I4E)UX4?_3-^"KK53DS97-((Q M7H282>9H-|M0BE29
Q*T%3'))GLE_EVN6@6|&_7SGH-L2K';G;HA!9>DJ= ME(\$XZQ61FN-W4JE
L,%>"J9|H=Y|OSJO'=F^D#D':(|WJ.MX92DE*J\$,IFD
M)M(XQ(44(9FAN1(!_W_N_|);JYBTE7G_P#S+7ZOH51'S_:_M/,K1CU:_O% M7:@|>--
_3;7E2G#"5!;E+@IU5)*69.>|5MZ)Y&J|_J?>-+,>Q|?1-'K&C_6-'; AVP:69,R3J7&>\$|
M22(CMA0JGHDP)4HJ='|.+:Z3;-W)F%E<@V@)*|O300*C@JK"U=6-&"4#\$2
MRTHO7M0COAB@EKG*^06\$|V'V":CN1-+:&W4IN!|7,R/>3K0,+:I:N%S|W_Z|MPWKG
G%D2TD"&\$FB0J|#RN2(UZA><(_*S%QDSMI>^WAG"
(>7A|U8UAR!S8>:J.BLP8_GYW99J^ M;J|4J9G'V|:>.EG|
H)!7=FU>QRR|O5|_>|Z|U|+95N?%< 7L7_?3.>K= O
M)8LKJ41DED1>.C5HAGS7:/D|EB7UZ/1#K'U\$/X9G;_N7D*ZF<#|O.8MLU^ ^

MWOEIS>20+N@00R)4:R RH0D^(5# M,N78-
+2/4*ISJ'G0/'C*B,E4H>I6E#AO*,&CGYHLE,Y>#+_!CAED');I37TV M#& 1K8-
5OD7UO^JDW@/(@&'()\\$=)S19A94IQ&- /AQ'8*1"WZ&4[V?-T&)S MI?T.6ON*1DU==
STNY\$^?4%Y(J!Y)#G9@ORUPYL??.LO;IMM<>J8%0D(GM'H M52:GB U4\$!:1%
()F(7M>5G_WV,-I095IWE0A6.T8RJNIOYB.5S?E10BYC\$0J
M2\$0R%T@0T9*0/54T,ZVHLL6YNT\!*,M3*[Z#>0_?;Z\$JC5,)BLTC ?K+;Y> M,
(&02HPE)4X8HJH\$J;W1_::!/'CT67%PA+5KBCY]'^80)D\@W *+_'JM60M M-.WTZM5-
W,+264&1_00Y2I\$DR=\$!;M1S-4>Z'ZJ=.GWW56C*Y,VH=PSMX M?X-
K/Q_ '=>A&&8SG)@1B>\$EK8Y\$3[U(B22CN&>=2-1-B+Y8^Y*QX78N8M?LR M_KJ?
FWESVZLX>:%J(%XY/.6YSL12*HG13\$H5HE):J&+JG8>>%1-W)=9#IJG| M3**
(C_+\$+.8(;%*09VVER79P/S.4K:WYDZ0D|>_?N\K:&Y6&*XT+LPT(2HLR
MP\|*0A%0%L7|COT2-S;|X:PX6X6,#WEK|^LB>PGCZ;<3?J%,5B,:HW)6VXB'
M!\$J:J.A&.Q4,X4E(%Q@#R_HYKH^Y*PX7(N8#YGLJHLD M>-IA'ES!JO7D6*
@M:1GKP"@*G'0>S70E|=A@#A'2!.B(IPLHK7GZ6;%U;_*M"5/LF4RW!M%2SH)W MGH+
+JXC&FF-("Z*1'R,QB>@1GWK&KDU6|PSU8BY1H6|Q>*^D\|Z|YNUJ.
M5|/T=CIMOG3H!^|6Q'^MLD,-S2*CK+ # M@BK3U",>.H)"1L,QQG|JO;M-|O"
<:ME1)|^EP9K MTE%%7%FO4#(IBU3(OHO|=UCSXJCNQ-
L#>|V#EW=I@%"F+^=SN;M34E(6?:H".Q)| %R0C;BHUY0ZHTB*KB2'JS*6+ZL"9Y#0*FU
M29GXX 7AB0R00|G|-G2N?0'J2BA*/A%TW+3_ ^/0&IDV7|_ |HV: ^JKR_K;QV MTN)GBV|.
|B+ZHH&1*7)=+&4! ^*)7! M6L&LJ5YBL06|!N&(I=%>_ '>T#|!O3.7NL#=#R
|9\$NHQS%|F-J?Q&KQK!|+>_7E|BR39&C(T"H1>|FJZL-D5B<|!:>>!,|^L0_LA+ M?AA>
|T|: 2)F'_S7KI-YV89(%|9|S#|'|>;O|VL_NUS^)^8T4T*#!9I*D*ME0 M2I
0M"8Z"W0@00I"!K@NL4AL V^DXBSOZM2_SD86P;PKG|OIA'AO&|^: ^ M_\$.0?
|33V|0;WPW|F\$|P=_ #+?8S14D-@K12<8U)2J6-@|V,N+*=%5M> !F
M<\$_YVCWE=@9|1L)U&(8-6.%WIR| :>8SQJ=W/WQN_726H6T+5LUB|9(PE(- M1*(Z1>
(X2A|DC"&&D\$UMWV<;?&?^T@ M+^9*ES|C?5B0# RJUZ HD5P&XJG31*\$MKA7-
>&3W&D"V7^EH'ZAG*%A#,FN MH&#I\MI,/Y44!|2P|JNN?
6#JU.H':#|=^A9&*7N7C41O+F<7_Q_T2!+:?^|JK<^R4KH7TW3P|/Y M0YD#UZZ_?
ICXZ1P_12M^MNL1/3(F>&V<)SER/+,EZMI@J25: ^LR=,C3DVAT| M#
|*P,Y+5TQ.\$B@5+0RSR|?0+?KYIOXZB|H0XIDFR\$K=P\$HIXR*DDACM ASW;
M6%N/#K*0%VFNR.B*E5BK1?VU:=(?X|EDA?9-E|**)FX22./K8*SA(>38GA ME)B0U:
(DLAM|O/;=)"F|SM->|=,SY# M>U4R-T:VS/H.OA\$J;"C#73WQI2|F,!.429M|?
H!UW@&0GMZ0I&Q8*W(1;| M>K'2Q2=+53PPR211,761 D=O=7\8(MYD>
|*#*|8U3>,W;*Z M3YJ-)\$TR9&|)A<1+#QXT6H(TQ&?(- 3%J^=D#
|04EZDN"JS:U8R#K&N.|19 M|3!)L01\$9%/R^20G@5/J91_MY46(JS*|9JWF^E3EKG\$|S.8?
M_1P643RT_R/^P5| DD|DP3L?(%,BD99(.8@D:1JC9M1D4|O_|X_NC\$1M()4
MK.9|9%>L)!|W|XR_E!TQ>P.SV(ZORU|W!LEC
B\$|U|J3|ND;I>@(@)8J7G!*B.P:ALG:KMN>^#|XP\$|6!LVUS:;NA|A|HA_OW)
M7GF^P|;G#S#?H=|;|ISOT&7C/7C3-V'+-++@6\$32T))_ :3GQ'(AN9:WE!I1&
M6|Y7GN/F=QQ|7\$/RP)*VB?@4BS>1D)RL,L&;4Y4Y3RVI;|J8UKJ,GVO2SH);M80'=
(*N&70D)2=*,TW! DE34OIR+2T4#20W MO>_!>5Z3L\$.KA#5D6(L,QD;FO4-
1=)K(K'2)48)HJ|!Z0CK1TBZ@7L/\$5F M.-|4GKVQMD41!E=0&|5.,U\$9N=
(<.4|97PHO8|= 0XE9U5QN|.2V)N8M>=K
M/%86:!*RGEE&*.ECD&7,E.6B,D)I%);X7_/O^*V\$JHW)^T 6?_OYY?0;M0U
MVD5T_\$E7\$2R#I66R?>E33|\$.Y-4M2^B'H%SGO)1FP|L,K?D5P_VW@P:>>C
MB)R3!;523%@@@CH5_H/A4((2@L;9'T008>8M-?=X,D*V^::ZCH\$8RQ\$"<1FS2
MX9H#YY(D"HB34Y?% 497_S!QV!HL.\$P-|+WNP'T ODS6W9J56T|,W84/1YFL
MF|BS,92T#"|**48*)>,1_6WKE>\$:@%7OY/"|)NL.*R?;D'_8R;K,@X'B+1MK
M|\$"E!HBE61&OF X0'69LK0(Q7L_!|@|"*GM>BW;9_9@+^=.5R+F+6'ZSXR
M|J7D507;6I!(U280164|Z>;65R3+/6/&4H| M\$8MK=59EHHW06J|H63Z3,7"
|>U(|\$^S\$*_C(P0*OE8;H6+#|7."+X|K\$X?I+UO|YD|?W@#BR|%'^\$+
M3&|@%*.56@9+0*A8(KN*N*@M'I89C57'K;QO!YS4!GAR@2|;8%B9&/#NOL9B
M5TOH|/|<=F!R0CFG?2+)9\$ 3/;#N=L(0L,@ H|1Q0\$|8X!|LZ\$7_Z_*|>JS|MX7:##TIE?
*1CC\$KH8UG-T\$8%18E.D)5*9^YALYK;? M-=>6+W|>);.9*24V4"2|FO-HGH&
W%K1FB/66?|. &* M7D2Y,M<'3">NOKH/+5S|'-O9,((-R4SD3J2;3+H:ZJ,9AGZFIX!" N4&5.
|MG4;E;Q(HKY|'?#^|X|YX>;-
E|Z&7QHBU<|Z9Z!OU|LPP:'E!|=G|H82TR@+.2T0/S|-3;|M| MM|VX%=JKD"-
)H;3,EUX1YUPFT3#!0=D0^%-%?<^VM_QS4:R|GF(CMPUU|79 M|_FFBPM>6".@K5

<#FT#&[.98<:0EV2\$-&8CRF>L"207=2+3-?G_8\$ZAE>|M01QQ:W66-
!/*#5I!N2W&K2.=!8N 410XRF;/GJXHA>YKLSU(7J6#S4<@FN@
M@5+KY'B_3IL5=N,'S|_DI<
M)!^2\$ZZ+^2)R)DZ83(31T0H5D^\$|.ZM51/6|Q>^X3%HC;B=U!|76\$%ED\$FLA
M@5H1B62E,,:%|HSH%4D25H+SV4/U21.'6=GSSEN<3EH(UPE|M;NK.YGW=S,:O
MAVI:O^)"YU^|B4?5W^>C3R/-O* @27"&\$1F|)#YR2K*PC"=@5E>?9;DCU/,2
MQR'YM\$:^|KX|6L',,:?^O4LRG!EM#H<|!^T/\$DKE&R 7E808P_WY*C_(O.8A
M)>U@'^%LC;ONUB_N|F<,:=|6BAA9FAX|^#J-DG;/&!B*4QWV02F*+3XP(;KU/M-
&DE72_+|Y&7/&^5R7A&M|J XSA?H/2.D,|>-.6=@%5)W"O>_0 P|>?7,&>M<|D0
8)*XU!|2O,_,:1G1\$H3!8T-Q/E2ERSH!|Q_4K;R0S/%, M@D_%-2.
L*E5K\$O,,:MCK3V/<>|#>JN+B=|3^O>ABFG,JU|TPP"GB@(38%D MU)UX3#)!0N!
K++>Z:5K3XPZ+E/?|F*_3VGOVS#AJ,,|^@#|&7ZR|:LW'JJ MORY|. (K A"R8
FF(HF5OE"BMLSR1Z+7TX#S5UI^H.PX_658.=F&_+5'4?PR M:?[X;3R9?
(_62'19|.DV;R)_UIV!W72E1M/|/*&5+=U!G266@26(.@NNKSL%)NL;L6?9D#BUIX?
LV'Z@N2(*-! 5&"LS\$>Q9?A=(A!UBL(FKD*_M^X|G,|!B9Q97(&'M+?
WI7S!!^W#R2)|V;ZF1PJ!%1(M3'I4B7F1#@"<,@M6* MW7?5-G#XZ7>=%;^R4F M/:?
1);NK|1|HK-UJ;|M>|#)(ERV>*DZB|!\$EO'7'H6./:+5#NE1.A7X;/LV|^MO|,4#?\$P
=KM09W&Y@H^S?V!"T6|6Y;6=|:K+GT @5FB=(^+S.A H;P M@E,(M>-2C|Y(4('M=@Q0
/:#="6NZ4/N(%"!X|".T|8H!H;^XG"CP8(&SP
M.\$AJ-.6<:9(D38N|HBX3UJ"\$DU0)MC:>2A'\$)-GP@7'D8|M2%|1+F;M?/3^
MCRFTL|OQ|6*)SG-@'^&U;ICS:N|(1KTPDC\$?%\$9*@|P?
BK94;8Z&OEP_Q@&P)R/6L7,/*@ZUB5=A;JZBDL/C|VK?1F|")92VP?1
M0&:^0S3'L>TKL;L9A-8#:
(HUR(R4@/HK\$V6@L,SKDI*1\$J&1J<>_*|M4SXRG,,:8%B3D8/(|9-ND|QE|
MXSTCB3L8VPXS46X-|M_|N/U//|F|D1!9".8483+2,@%2H|G/6KD|G(*0_7
M1Y&R6X@_G&#MOIS#&#&7A13_5V&,;YGL8JVI?C;8D+/,|OWN?W-,2
MM9MU*_G;^.)RQ*U3#NT)HKKN+AJ_6.85+BEP1RES21R@|I|>*SAO23P4:RO&
MY6ZK;1:S9?*,|>RZF?D)JN,,:Z|?3.+DI-|;XV|BM|0;2^ ^OELD,;1G|OYFOE|JH(OG=H';Z?
KCX^M"D+Q8,\$3:W17V?\$@="DJH/T6@=:_<#WQ'J&0G2(9A5<3|9IL&6|QH_|:-7
M_R)'JYGS*/>|!')46(#C41|*PTT9>Y7S;J\$R|Z S&H3L!1VYM6Y+;L.14
M.\$F8*K!+ET0GT5,(*E#.70"6#S#5Y;1;!QS,,:AZ2617'7FV2_W|V|:_P0'WM
MK|=S/WF5_NMF-N_L^Y'QOF6@KN@|_&*D(S8A<:S*43DJ>|+|B2W>>L9",BP
ME!YPQ%3M+NLLB6R="X1Z&XC,1@X 3|7&0 M9R|0M1A4<|!1IT^73?!+;SO|
|HY&7=PFOL_?@5|<\$D\$:T9)DIWTDK(S0E<&B MTZK+36/0,@2EDI1/IN?
9X_UG(" ^HOX0HX1>Q=C>?&>*W5X9EK#&D)GA\$D91 M.P5."-)+L;Y,WA(TSH
\$:YV(\$%'LJU|P| %V|L(S'"-.:30=C,-G\$U>")>)_M,V61.3D2J#+\$10I4QL19..5YE|>?:O&LO,
J8G#J8XGN#JR5DG.3J2#&E%Z M-#|B&9H+.C.6@_ (TW ^,G91X'V4P|,,:2Z%V9?>ICB--
OX9V_07#Q,-^78Q; MNBXAR%&B%'CN|B*6A02Y)/<|SDE*H\$S4H* @Z99'>N+7_1|0\$&J.
(QIF&W_! MSS?MUQ%S-#'%T"HW-!|H@D3|R^"J?%;,PN&G?)LC=N%O(AS14;7'\$ (TN%TU
MRMHX3F.9#I8YGD.1+6JF14I*&LZHNN_EGY0('VD|S+,2X|T9_DPF'=V|+W+;
M:6:Y(P71"0>-|1&;HC@7&>+1T|202IKCRO/+W>\$|_ ^Y02CVR(B_|6|=_<
M+)%_ =U_U/G>1P.6:1A:2MRY*PEU01":IB!5*\$06*2?1F@|_U"P&WP7=&4C<8
M6PXTTFA-|<8;F,5V?-VE+VN3#:@HB,,)+6N#1DH((N FP W@_12:WDRGB\$V^+| ME?
K|M'CNK"O@9S)""D0JB4:7@9,,^,(49XG0%5+1^N|DZ0,?O?:(^QS>U M-
F;AD.TPEE@639>Z -FH XGWP\$Y,,:5X(IXSE' & M@OC,%4DN,|+)|9<>P|1_5C>MZ/)P!S?
AKC5&YLV>7X!\$W3!W|=^|AGBY;29 M-!H;B^;|(84T<>FD?C2>E=*_
(|T0%DW5RS+N@GS(<>|WT|#\$|EQHAB)A
M|7\$ \$OXPI+&'&%10DONQ02"|(2J3W'0XM'DAUU-#H: _>@Y|M|_8A4.W- M6.0'Q>C3-
<2QG|R_OH')^NT7Y?04K8&N1!)C-\$0Z5#CV\$@U08|6,7.G-:A>
MO'O^V<^6E17)5WN*P&O|3CZ29EL,/GZ"=HOXWBK'Y0),4G@J|-LPP6;2(O C
MDCAID|Y9BYSZ31)X|W/EJO52%=[>L!2|Z|1^\$G00+UG1.1RFYADR08V%)U,
MEK2E(J,2V>,;/+ _#P|Q|H|J|6(V?Z MX!HH|K0)TW""4/OR|(%\$1V)/@_X2A-
N++PO.H41|HE67|ZL2)CR(0|2)'H5?. MRV&5P="""\$1PZE|RL V=:_O#KP3CZA-
,QTW|CT|O8-I#P!|>C3AE@6T/_|T^+!%'W'*S8XV6'/^;KL*49D*.U U:OA*+T<7Q+
ME\$QK1840I1&O+5,^\$:"*C&BT.9-7C&;1+Y35^Y7GP?AZ#N YK^M@OOEZ^VW M?
QM#BR^Y_/H.OL!DH?2"|4+(\$EXA/MD4@C,BL-J)?\$|_E;9V_J
M#|!>^D/3=I2=W^)S+N/AC"I52XY8R\$YY*K+)M:~Z M/1^Y?<(R.W&QW8:UM:|;/R,15S>
T2%5-"<|E1.>9TN'2JF5'1EM'8Q%#:#;H+).AHB\$@F,L5S,+YV'/BT MALD-Q?6|J3U

IN2MO[?L13X; Q!;16WL#BOT4?44KQC.(4BCGB0FD\#X0I*;)F
M6HE8>|#\$HX#.1P#VI_>PT1QH3""^F"Z:9,7%L+#)=Y,(1QR"-4)+M%Y"
[N;7UN#%XY\G8ZAQ9FX|(M^OK MD=";C_@'?P&CK)P.5DC"N?5\$QC*J5Q@T^+)T/C
NF*FM"ONC>^Y";Q ?!B|^MN(WY')E,>90R\$>\$C"K*TO+2)IB2B&P|>|9=[29P&Z"O|S>
(BWG MG45#+VC HQ\800%6Z";\$2 U-,L3: M(E-I\$<|=V(I+U0&!X>D%_1-
JELN2Y/\$%6M2\Z'PIPP9;J:SUL?Y M_|>NS4WM23KHG|EQW|/7G6_|#CG
9C0BQ/;"1N8O6(I*>H*ZK8EEB0SH7_|MR1JR;-
F6K"&K;LB6Z8AF^@(:7V5^HRHS*R|7I9'1)R-I+8TRAPAX0&."A: MK" 2K*
(B|L)R5DV(/.PR3X+JCY@9K1)#E#ECR/| (Z5J/O_|Q+87.ABT_VE|2
M=&222SZCUX@:U""4,&|BV4JMPHB4#2":R?I/Y|5/_=7YT@|:A O:"2)US_0
MP!_/2UL;TF(2!)764 F-("(*04@82HDBJ5IR;*VK?1CV?UO|ZHH_#H|AOU MX!EL7;
f'55"PJR>Z|G)+(FW)K"T>|.l(^_SB?&0R>KPJ>@|IH^-K2JA\$)P., M!^V\$S"2R?
DT.|GCH4Z594^')>)<(&#)Y/UQ^E^=#@C"S1)Q&EUH""TX^"LRT"]
M8S9+GL/MR3:'D&#YT-,GP0.\$>Y<\$#Y|O=2_.=|/E|)/?4S?T^0B_7TV_6OQ MM8>6:
((B48|25B'W('Q|R3CHG9;TAI-JH|KT??9*\$J"/H#3'J:ME9RYLC M/-
%"N#B_Z&+JMRZ3%%-2EHK6P(- DU"6*2-) \$>HE%(6F6AUG;L3W%,E35LM M;.
+K3SKY;?E)Z1W9:1\87GWQ7*ZUF7^PFHB|?'GR|/|&F6DQ?G)>RHGIW MIMG#)|)4??
Z!+ Z3++1HNS;:P(BX_%<)VOLS9DF2QR594>.THD,-9U MJ48Z&J.SYOTZC&
|_JC8|YT1T"V;\$*3&|=^HTK">"|>34<(#I>CL,BA>E;F
MHZ#9KGX)CY1E^ZBK=CG>J^DL7??)7_58ERZ(S D:DS@IK;%P%U?&@1=9:X^V
MAN.DE|&XZ=;/T-^H3ZF-879H#3KU<5|,3U/LRZ)KD2^OXZ_K5JPBHS++%9C
M5C*BU<@-E\$P8/+PEE5QI84WU3AC;X9PF,6KKH?8&L'(H-L#RRB=O:\$"J2@LB M1
>&IP0R<<|RC|JDT&L;V/Z,T|IY3<\$V2\$'<&*A8=8;2G'*E,OCH.(@4!7C# M
M"DO(^1.1H=SR_!YITJ.V'AH'D*ZZ*\$>|1QZW|T3_G*5^0""#61T#.&YFM")G7SI
!.|P)&L5P1E,6RWZ3F|'/=9B88G&Z3/ MLJ2_*5ZF;ZDR<=V#
(U|G'+F+MT^AELY,A^GL;Z;JU(?U>-?N3=9CZJ.HE0_\$
M<(@Q:MR)|0_D<@:FC/>4Z2A4|9-K?Y0GS9P:FFE@|MR#^(^T&%%NFI:1(*_XXRY
6.^B.BD.;*OQ+?:-M6N-S^F4BH2%EW;|3>)G57V M:CI?S)?7=/'W%GN_M
#+R+W1'W@|>)*L3>>6H|V8A+Q9VGV/5TS)|@HG<#7 MG3.T7X5'Q:1'\$S\$JLM
C|R|K/Q"|<'UT&TDIO'H|62!^DF7EQS4J9Q%2?A MI>^A"PD|JP9"
(#8ZF8W@|Z5BSU/XVY?|H_#UZN#;^X7M*=Q|6^5FRFV|6N M<)|@ CWV-6-
_"2U<6;>\$GUUPF\$<3E41OC#!#0.@0P09.P4O&G226<7M?*>=N M MQZX-7?
P=J;%I'IPG9|C&\$FS52XC|AJ/YQ?3L|6T|FK3ZL.
MS|HEXZ("9DJRFR&E|1\$AD+V*P5MB@NPW./?FYYPYG1|FW&D=R50,S,QGB|" M4D6QO
<-B#W\$+J'#H>|6+!|@?.7C*A;).>|E|E9WAIZX9%OOBN<8#P;ZOO
_E5W"9OP^%9XY9B/;|H%8C@ M*3B5&-"DE244MY-^G4..K<
MIUQ|>TCL|ZNZP'6LUT91W|A=0QH4<(_#(K(+ MJS/9@B6.<\$>HUJE7'&.7|M8?
^@25|V"9M6B\$7YK|= -6?ESVB/BV=_V5.EV)> MIJV3GU9MVBVL|1R:9'W=-
J%,F6(MD")JVA.T !64 (L).USR#+JVC-|E#Y MCD37H32^CW"KAQ'&)-M*#+Y66H@P^<)|
(EX")S&IQG*?+=5KOU MP4>8*/%P&4|K":BB7;6\8_ SJ9N?NU70ROSA/L_|IFSQ=35-3' A
QY!R:&1 M)Z04X (UH*++RE*70N;H+;|&4|6A97\$UB|G_-MTAEM;.9|Q-CX?3Y89CI?0
M='3>HP@E\$Y-@KL,7EF)WVK+DK%1QW|EAO<_YEJ M;+X&F1+W',-V)T>2=IL MT):';%
I3^<"N"30|J1(:Z9MKYVNL0.2\$;_C*XI|P;M,M|HO?Y|LA+_O!.K:GAA-9NP+H-
RPG2HXXK8&|A#JPC:ZQ_C19=>2T?6 MZI"D5&"
|P9JAE'RYTJ*8*|)U;?'EMZ;|NHCA|"APHZ@:W"#>6?+G6D;;!
MR:@\$>)>J<|I(BK#2X3\$%D:7#>:WIE2&1@NG;\$|C8EU.*=.E\$|*:3\$3|7(VV|7|HGJCX(4E6|
8F@Q(I2C5+E%':|=10114;A/?8+>|SXW4.4L<:|+B M;)555K\$)^4;4ZP?Q53|'^XP_GIZG|
|/2M7^6OI9(ZO>T_.'K4J.X+Z6BKR?E MOG-9)P%8YP9|BG1THBK-\$|F:
Z28*A0RDHI:Y=UMUC'J9/T&JNV\$)|J|:0 M1%1Y|M <"#;B2R6U+(-
U,SBJT0FEBAI6NTG6712G3I_|1=VB4?JG5+JC3\$*Z M##|(M/L4K@*H-
^A|>EN:8!@!5I9**QZUHK7WGEL03E#OAPAY@&|GJS;^|_W9 MI6LP7Y77?_HZG2W*
|UY.9|/I7RB?^8L8NZ>Y|>3/)V='|CJO-|##VPOT\$@* M-9J<7WDAF8Z|Y'_? PY*F;KY
MFY_9|W|/TM*,>IQF44|>@6.X|T:K Y>: M,NUKWW7W0S9T1E4=Y=JN0E-
?"2T:7:V@_9|<_&*6EI=@=_!>YG;T=NJC_@^
M0(_41;R!QK>1JIFZCLZQ\$AHW:':#S@YM.|DR^\$ 22"Y%TM+B*FI73#P";NUJ M'?
|8J+6/EEI2:CD%JY, O4Q@SMHZ*WT9+AIPTT9@..(3S*6I-G%DZM|07H/
MG".TD&VGR&V4.5 ++=IZ;H#&5J6F/"FK:8(42H(8E>@|)N>!2VDTBQ;?ENKC
M";;#>6X\$>8@66NX@+W^NB>&EFX^756K1IN@0:6B-NZ@H|U4=40E(#HE+8U6P

MM6?"/X!T:E;QP6)OD&[UH;0-19\$NKG!>?5\$&;J(/AXA7_7%Z0&UD#.!\!^BF
Ml.%JOIVJUUA'+3>.:X E5/"B0\$OPG5\NM%92QJ.30)/A(#3URILSGE5(WN(N
M>7M,7KT=YQYX2T5;.:VG[5-BPG82M7\$72#M/1-N"Y?@S{(&MG\$
MVU\$=QP2NHIT>E#A]/M#I<(O: BV:1+-87 ?2M1<="(Q4(8QH5EV)O3J(_B(
M2;#K!V:\$_M(O':7CK('?BOB17"K#)MNK5XIJ@.S\$'@L0^R# ZNU>MH5 QW M1'>
f@l.6>^=M3WC2FW\JV56L1MD*.L6S'K V;_MIJ/88FWE%;>S2|P&B'.+5 MO82GB33"1
K9Q(24+A/B"&.05,Y4:I&4H(I2PUMVYN\$50(!\$&YS/!=G;2IWU>SUV^ !?'55-.!Y%S|D3
^\$8VD#>)N"\$R)BI MXESU:X6ZZTDGJ.K#I%DODZ\$#|V9Z,?LP15F58I?)F_'W|
\$MXE2^GXRGL|<7 ML^EO:3*|K-O|8|H(*|3HDA>= 1.;> M&L5H|CW4HJ:100?
9\$,2VBY2@Y61@94 M\$D6)IEGW+"K|:A3T'UJN59L ;.:B77@_IS,4|A T^:V*
f|J\$AZ"1RTZ4'A: M@0B\$@7,;C1T:;DXVO5-!%IA0ACINL
^EWH.J^V"FHN;9,;W85N1&)_ (S: M2JNSYH|Y>8G4L1R|S1J2LAS%@ :()S&="=%1KG9E,O-
HO<|33X\$&S:2|O>'(M 5?|;^?SBZL&*->|2:."D4!-*#FEW(
KG2NM\$=8I%1EZGKW0|3<|X!2T7\$-V
M&Q1Z6*COBGI_37<1+UAOE\$#B4:H86A*D:V|D0\$NGA*."9-EO,%+_9YZ"VAM) M>
_3#@O?O>!7481M9|'*"HEEFGNP\$(U\$|Y)(
BY1M\$="4#P1&B7M%^~3M_M07=VK^@,\$W2#):R,VY:.6R4E0 M3J ?2IF
4QHNH'U*M:),>5>|3G0XY>|(|AI"|_O(MW9NQ)(L^;0,+|=|\$MPHC
M.L6MXPZ2+FG'E*%I2J5%G:G\$./?1N'X7=3L?-?P!?!|@Z|@:J:~FR05'O/|Q|
M7\$ZNCV6&:Z%R0%O3YI2!\$(6)N,IEQIQO8&5H1/:):|O|FW,9S\$:7Z08!O<
MOJSCN61U'T2-3O*|:(YSCA^FI7M4?H"(&YSAFY"A3@A-@(1 KF-NYEC-(+E
MGEAA,R6Z|OW;4\$K?<7XWU_D>DFV@Z|O#YOWW-)N,OWQ=O%D5#A6(GZ9Y%5B@
MCA?(BGC0M&A))&"H=J#UI1\$STIXJ?;HMY|0AC_T#|7BG;.:@|550>R?SQ:C
MCV|R9X*>N<0" N|;_C0<^MZ=|X:*K>)U^!6)U9|_#QC|G>|!-'J,AV""OZV^ R17<'?
^>2O MSMQ|6:W-F|43P>0K\$3;.:1FW6'K\$N22(293@.IOU==T\$Z\$F?
FO5%WF!*"OIX,2U^DRM&XO;|5" MO<<"6W>|;|6XHI<&/910VZCZJ-
C0LIUHLX4ZET+\$4QVLP"U>2)+!!4M+"^^(M:Q0^JV:|2)|6W?LW,GUR;-^!
U8_B*\$V46*-Y:W-\$*H%((G R:6C&BO4AG6 M94#DY-
'SYRS'VF&P;5B.V(WR<:A|VD|G#0S'8@N|E,0MF?8CSZVU3*)9E+NY
M&;HD|!0#B01JE&,D>)_%;%P6\$@_MA E@|\$_P*BHAB2X)HH("5R5HMM0
M:NQLYJ!SCC;X2'6N'3|:".0\$:"X@"OV,JA|&OTYN9BG>#5#%IGJ0DD-ZWJO
MC|CW@GKF@)AB_Z/O"D;*"\$;3P+V4(9C:&35|P#L|AK121H,6BN_2 MD|Y^7
MN6#O+Q;SA9M\$Q'F)S|CD:/(*=1I+:-UZ<%1PR,P|H|Z(R3M4>.+<+TPDP|*K8
M&R1:WV3P:L?KL@46)?W_LN./^Y)&3@61/+K0R9<&;H0L*K4&4C.8|!2<5>;
M(/W1G0!5&JFB04;?!>SZQ'V>?HB_-%>)9>7LQ1!/-YFOH-IW/1U88*:(C MD#.-(%
\$X&*YM,F,\$|SLB*ANA.S"= (\$J2KVVDT6"G/=V5D!>)(GSS736X9QW MZ.SU)..
M:8E=)/16%%.%.+.62!IM-0:4)SX' NPMV9J-&E9FR)|3=UYF M!_X|Q?5>\$J|_?
\$N3>1H%GIU5(H.(F8"0@8\$5E@\$M7HZUVJE4^|+|?D1/F!@- M1%ZS8D27!<6?9_?
W)@7@NL6.A/JC:HR(3LC3..UA"1*4^>9HOV:<>QZTNEI^0!);M#S8?U3?
W<_2L+T.KQ_3!>XRRPYZ(F1M.PM M2I8 E"R1AH2&B S12QLB;|I?
HZW|G_/4=5Q1BALT_.XWG4?L*MPX_^|<#|D MW=G/|<.EQ|Y'E%/&M"<0I0FXW1
_AA8'E|J=O\$PVB7ZC,WH^|*GKO(5<-RC_MP=&Z;>'F,"OWV|^EY7^|SH_|,4H&D&|
(!::B"#4PYN#ZA_+I*_*W&_BSNM^4-"TL%9AI<67HQB5W^BW?A7Y|G:C)WH8CW|RB|
M=|YO-#44;W/9>%7|XC2WA(+F3097RS2.BO.*XH"=# S%.I.0J|DV,KF!/@0QU! M;Z#
X>F+ZVA6*972,!DT>C%)X#8F5\$G&=S:#3|JW-/Q35T|\$VH3C!!1_L'@W MZ/S@^_
_5H;4T:*X3%U8FS:B\$)5C0\$H(I)@PI&Q-!=T>ZP)FS7@E6VU+8">H\$
MV%|7|NH<5@X|;>RD9GZ'W^,!M/POB;.QMY2Z/(+\$(TN&|)E0T8IA|R)D'
M*C)E_>9Q|?OD)\R%|H>P(O#@HBWT?XV0XC+H^/_|QRT)(?A_=;_H?EXD\#'_E_U7^ ^^?'
MMU?20L:@)S-9_"U,S_ ^C\$|JUF*ML +9N|T7OJJ^NBP6|4S@Z>H.S)U=+WS^
MRLUF/Z_R;N'OIXOQN?EC;GZ%/R7;^_^R|_2PHW/YC>%,!^?SO;>7/QB%?S
M'|?:N:FURR7=8/73U5/ZL4B3F.+/_F3P|";T|S>BOWYGR|!K1I3"W=64\$U5S
M=+LMA!8B>5JH7F_67(/>?IA26P|Y,K;L_N|&S+IMQ<^S>'|+84_J:RT_|51!(7_R>
<3>SST%)C12L:U=Y"^^<^B=512W M2@=|NUQ,*06>Y0B<>|SIX5(&UX|'_1YX\$AQH(-
N*+5.6 ^UZS:+7V7-C5:L0=*[|'%BB04'^=01A27!ET> MRC13H D=*L>IBE;UT_N3&@7|
<*U7EFG%#B@|QAJ-T|R+1EZ"9%83D2T!FSAZ MSD%H<,R@X1R|CRXKB>+H=X?
4XFGH/TFTJW8S.3><.:*LL"1"R0R-\$9(ZT M-!J7SKU-ENB4^|WJCW_X|X.57\$:
V%;N0|F1-CM!G?((#304(.NF1M%G1I54F)%&2*#^=|OH(N-5_D,#C MH-8^6FD)J:ZQ;R3
%LUF_>>)8\$V.6/9ES9/HQ6&DB206E6_"S;BD!WX1QQ

M1D:J16ZCS(%::#LK:DT,W5R\$Y011YH@3JUUSGV905\$B<<8#"31X8K))V:0S
MC#9!>E86T<\$Z:=7^D)^\$9Y7I>JO_KBM_&I/T@XDMVIX':R!#:_^;1S:##MU7R/E6-
C';4JJX!EM2WR[3-U>Q:C?_+,4,ODN#IV"E%1"-H,R8Q\$(0K;:C M>W=V!:ISI_JRFA
F'TX;I57G# +1K B\$#Q@G:;47(C1&L=,K%X@>*3I9T_ ;MIYI^#IB IE%. Q-
HE2#^,7U#T"DNA; =+H?;7(TUJS.Z#P(+DL_P(Z%0C; M4!U-[09T>T((@Y:&W"(GL-
\$X!%1+ZI3.R=:> MJO+[(0-8/,"!!ZMDLM9'UJ+-TJ,9XW04
MFE32QI: #Z4A%DNLUGX/5,FYZZ* EASM7?6!EX:;JY9J,VO\$8F7609?'I"!YS MQFD%-
FA)&X\HGJ?PN4NF?8,E/FC;(N&P9\$4P.B-*IS @I8(RECAD>=;>T+ MV TP6M?_U=3Q_>?
2_E)J++5Y:U<7+8<^8S_IHME2.VY+|\$"BB246QM=>I5R M\;.%H SC)(?*I-
B\$8^C8)",&_A*MS&MJEUZH&H40=Z,Z#C!XL,U MMH,"!XA|. #
(XE1RC+N#^6)J/,84&64"#C!MBT.!FRI#:7=Z&),&.@.J0'-A' MRLWK-
9=EB9({0GD\$Q4J_\$AHB6LO!0629&2^"CXV;Q)[2YG^@?)L'!=8KB'O@
M>K8EV_OHK'?)J@,./F3)MO#&*L8X1%IF\$PA3PGQ. ?')9ZF(EK>'O#TQ(CR@
M9+L%#_ :1<^V"R^)VOYNZ23>-ZK(IY.>=.L&U|. +\$/(-H94G+|;@')N7!*"JC
M3")EUJJ*>Y^G/J+<|;T4-1U"RK5KL3^F|J.S[V7^S'JIT_/?TU7=SQ\$QVAD M"-
*9I:A#L%Y!Y9012+G7/;<"++K2:>@IJK2K/WF7Y823.;+ K\$515<@5R6A
M+B9C2J"=90E":L3*M(98BDB,DRG?MVA>CWN%)1>7ZX-C, MS+Q*DU14,71N
M0B()+)H%,E)H)1)KA6:O#E7/OCO!?!3\$:5%?Z+6+KZ_.H^FNTZG+%PD HT?
MHHQ#XHIN8*\$%9XTP4>#&E?:T 78-\XFKOZ6\$:U=DWZ+HJ^GY^7C17=2MC!.>
M1'"&0DC.E1;4&L%%#TI%8Y+C+-%^ZM_UI%-0>E5I5JR\7JWX'VXV+A&.V
M=G+W4\$K?\$=9IK?-I)%O;J=OI<4I)B,A\$0%:*@8BX.=KL->@87/0F6L?|I=5X
M?/[H:K8RW/?1XX-\$M NN|J|_YYFD_&7KXNKN<%E\9^F>=4\$0MI J)1X@EF-M
@B!@6/>@0HR)46BIZYV^G1/:\$^6'RU5T&#KWPGSZC=O)S'|\^/27^U9^L^H. M)3.S,0;
(SN'6J-\$J=5I12"9'3K7W/@_ .G_L GSZKJFK^=7BQQ33^;T7P
M(YGUU1LN'(|>UUD'X<|^ ^BC(F?F,S3FW>3+TM-+G-D0DH8415>E6^)M2G3W
M+JEG%3WIU80>/W6-\$/C=-1EN//"'TRP/EUI%.:45B\$LCIP^,?8Z'/LH1NN" M X1_6WT'2*
I%NW@)Q|A\$ V\$,J#>B=*O32\$87@0KN%4?'+4)I93|32-C4">
MNI533\H5NREO!;5*NX!JY&3O 72#?03=0AW;Z2Z56HM+#
<+6:T=07705HF8M2U|_SAE+|CPQI"|"O(MMW8JQ|M)6'9.<6>KY-
&52^ .3E\8;H%*76SZ7T9,,&;(2,=GDB=3|6IG|]UQ5AQ
L:JP%:W9SV@;3ZQ|J3T,4|DRIKH^|#Q%|HK|X! M,2F:,LVXU62'7HCG\$@Q5&E@0A-
|@ (Z?)-NOC:'S+,7P|A>|CS=J*?C|)OT|G MBZ^K"Q5/G=">@*6V!!>U+ZM3P+TJHZ@I*L=
I*?;FYP|VGN|B>?B.X.\$ECU4M7QCW4H M/H3@2,P@;1E6K7!C,2I82\$'0+!2/M.|TR|N?
>R*.:T!8S5,"NW|IG|H-DHOO M)^N9DW2DE
Y,E5K8Q!6>%KARSRT%KH17ECMO;X^#JYROLOW;L4O1WC5H65=)
M\$|W5N5:LN30H)#.EH\$?/H*)!(T,X7UF5&7F6B20/H;>JJW944GJU8WK\Z|3 MY|U5_|H+
+-=|^SGB_/2N/K?'<|WY&S+AHB%4A2-CR>"9H9"#4CB;F/P=&8 M^QG;>SWW:=.@M:
;G"RKAK+W,=C^N9^708?_C;3|+X6^D_ \$?ZL?C|5SK| MOK1QYB-A(UHQTI-
Q6N8(<4F1X\$%!IH8H-%,%MRUZ7E9;P-FW_%UVJ#BMM|B M?
G>+BUDWDGO+LOX|N=GGOZ:XFJ2EH1X240G/9BG!Z*-M%J@WJ,FJLI'N:
(\$I9=#@FLINCDN_+V&1L@21>M9H'I5-N,K|V&7SP|M6+,-
>E547,^;Z07ZQ5EX4|JL=9,&A-\$>C&0!WS|. -8K=DB ?+U'+\$G|Q|%"| M-DC7JHF<|?
9LA95ZF?Y70I4NR7+3|; *7+KGH26OU5_)K!>UNO5>O M-D+GM9M-
RIB8#V5XC)NEV|^_B+|?'=V.3SF@,DY#W|6@0-SZJROTIR<%Y/% M.(H+A;
(A:Y%0<>;US_"V05^ ^!MD|:OI^;>+1<>L|_DVUFM:4ZU<5D8 *R/@ M11D4:
(2QD)BTCFH?->U5@;G'+E\$+ ^|&)V^%KBA=GZ7T^\$-\$R?X:16#HZ,\$"# MAQ=|O-
RL4PJ*YN!\$)J7>I7.^=|45# #7_YRCHT4PRI*2! M:C T&I
A1^<=|XBVMIVZ'<|P#GY=W=TV*RL)OG: ^Y60TK* <_4^KPO?^V&O?Z M|=..?
J|;7V3L5=4; ^F^3Q=4#CP/E(P*!/(++6B=W>Q|U(FHO(%<6QPU M?|E90"J_9=:5VR\$!G';!
(MJ(2Q04?UW/BR#DMT*KI\$ ^NLYDHG|
M<)K<*9M_)#INTGNAP=I<(+@(:2\$*9T%D2\%'5|+J @DJ^&P2>;:|W66P/V|:
M|J/:!G3=8"U<-.:27!F%QJ#0",R'4+J1>6".>LJ2T\$'6;AVT%!DXXAQ0PIQ..JL0 M:N|
<|P+ZQ:2*"FNP'Z%5FZ>S6=|(&K51.D.FB/USZNCKMO==.K(MND4?
I;O(K(HY,:FA)*#!,\$J"HR5N&I6)#DI,(VK??@RE_5U-IX92_CXB;C(\$
M9U:N83Z@|M)L=FD;K MB50%^&.Y!ADX|6IXI3=@|EH_LS)\$=CI96N80%NCK><2-
MOGZ:OIY'N:S;ME MW'S|1KZT*I4Z@0RTM"Q5I,R%8D"X"4+S)-"ZJAS9
R\$_4|8.J>BMYVRU-.W? M"SX|HI KS/=|UF^6>8S/R1EN|IS#TS? MKK_V2JG
./PSB&KCUQZ ML40F|U+V(++3^")R!R8) SR6>ANN@XVU<|U001@JQ?E0G=

!M!O)P23Z6=..: MA36=4T-"<\$(6@Y,6^Y.)#H8&"YHK*SW7DJBVPP>VX/S
)W>VTMH;|DVGPFW M%@KM@VN088+'ON\$ _5&?W4N! @0!)!"/M_3!>_I?GX2|>#0IA?
>OYK?^'O*.YWN 1\77].L!"9GZ6LQ ,M"PO0\ M_3G!-^1L_14_W-
Z%A'^^"O/|R5I=TFP\QU_ |AM|.OBR|/#^ .2EB|4:0'KE8D0 MLL=U,4?
1Q*!"44%YXQH49N/K=;R|&GZ*+3<("7CPVP:4HK\$SEU .Y|?E*2C M|HE,\$\$_G)4AQ*
|H=,Y'<&0,Y912ABJ14-)51G%HJR:6QKM?DTGWRQ/9"^/29 MUE C#=#H7?
KAJ6|/!60%^-9TO4 PD,I.Y1&Y34CJ|!:#16C0.>+3!,Z)B|8O: M^="<
#=#J2;M!>| #KM5YO@=<*PP?|NP"|H6|OWPW=KX;038*0<481\$:U M=CXM(^
2%Q""8SJ\$,E2Z|HW80|/\$^?1H-HJ4&??3N0D*#:T14IBQQ I(R"L*+ M")82#5:H9#F-
6:K:Z18;@3Q|7APNW|I#WNZ2|?5\,3Y'5 _% ^HEJ=970V RVY
M(**4|'B"YG:,48HDK?"W;=>M|>X/ O!TN3"8V.|2Q:8W2|*C> CZ"%27FD4B
M2GP^4PA:&>T(M8;5|FGV-\$L&/'-U,I1%ID%&KZ&\$|L"4X@,N#/5:2*%\$|5*. M.F?NH?
>3JQ%09;#&ZYQ3R0Y*Z*N'D@KV)8TT,3DDI\$6VIERX"(4TUA2(9-H'
M)Q4AM06S%|'GN|NTU|>&'O3BF8J("M.O,!*,9 M3&D
DGDRAHL;/2|3I;G _MT57JHD#8H|,&1KFLA6 ;|U1'7-"@34R03, S M*@@)-
D@T9*44E\$3J4/C|%;CU.:>@T#I"W*#@!X>B.FROW/SK!S>.GZ>?TF)Q
M/=&O4._37^|;BR^SU&6WC1(/:(UXC|0C\$82S"A"O!4G0*C\$(6RC52|>|' G\$
MU=Y&M!L8<' (ZLIN0 OJ6@0OYO.TN+(:?D|N?C%+|?WD8XG/EXA|XGOS|G4
MS|/L^W(+Q1Q _/YV4:>C+MEX7L_ #5S=ADSM+|Q)YPR|>701N9'@%\$6(M+I P
MU@6E.&D&4UPIX@ /|YC|L;S*&MGZ>R M|/1I45/F&SCQX'C;+7Q=L?*>27R' _V #2N-
(="8PH\$EPE(!Q8',N Y.5RF@8 M1;'XLW9|*|NLW 5".V&WJ Y M56KBQWD<.H/J9
LL|")=0S_2/IV|GBSI*('@' M+N'I<^Z8.MW T=HULU>6V:7Y7VI&?QO/2^5<^>Z 048|/_G
NM>'X*|4V7KU
MZ,Z/FI>CZOK2<(.WA7 _AC^ED=L.Y*O^^(ACG%+Y.QO^#OM,U;6,D)!;/B89
M03!6VB*5WLJ\$|S@A# '5CY#6:ZH6|*B+;UFBR#WW1!,"61.+|M:E _PPGI0E- M|@P|5:6?
B+P'K09^5._!ULC'L0GS6.J4KP3R|N?5E_ |Y1D|L%K|^?)>^H.N
M1B|0|AU'(0<72T,FPL%J*R%9DHMUY1QGK=Z%>Y\$=JY|Y1!H&|K*;1!QUE%V
=LHRKJO8 >H|2ZA<:WD;J9NH|.1%D)E01("IX\$%24UTU(M4"JO&*DP7M8NVWP\$W-I1K?
WHJ+6/EEI2:GGST4F KKH;.R8|9Q&T*!<,*EJP M+F20Q*@4M!2R>A_-'>^,
|VDW5.0VRARHA0:UP)N@L14T|G6BUD!*)H.(L=P0
M*PN*FJRD\%%5SZ*Z!|YS(A#M# #0#L(OH2%!:0Z&@I49N4N(P*)|A\$2534ZI
MI+T<@"#|>1+D(5IH4%+|NYO|*W6M|JYK*\$T;.)Q1\$H|QF#"P:JJ<
"5&/2G|EX\$/Z^3W)4(K^.@(QE42+(T** B MH,\$F'%@:(DBK=18ND,OJ'T6|@/TB6&-
EMABK@1OU^.*|I &E<9<6M EDCB)P MKA58?|!% !'PW?-8.LM<|XTOB8_7|A5| ?
C&NL3(;)'K29@W|MPZB;Y87\$> M; >U|(+/@/! 6| \$0T%:1E!M\$37=NH@_O%O
&46K%KQ#(-.9*HXNU M|A9KP\$1B5E/N07(|85R\$GR@:#EF1K,VRF5|RW|?EDE _SU-
^T::!-BHVA^B M;1Q#L*GDC MK)\$^A=(HJ=0-9@Z,V@|4DT>09_KY?|47?)_ZB3V,M-
>@NL75K MO\$*XSOM,E*(&_6).)J07G+ ?9("U|J\$9+RVU3O)|07P%P,'4N|6=A;5LH66
MJ4^?W8_J/?1|?O*!V4(/P5|I6^CJT: ^FDP62+\$W"SVM":>_*58H"FET"(1T: MV"D;
)8K'WU4TM0>27@OH H31.Y|/^|J.RD9RV>,*A|\$\$(*P+TV0)#46Z|)
M| =4C6UO!#)4A4T_W&P9X5)#S8|E-N5K-BX0%U^FL;(7EMM\$8SATN R3N=F4H
M+9|&R640G&MM)A0.\$/B0I9+FID0H-=8:>G@B4E7;C!)C+BC&-V'GM*..P9-B1
MKS\$D%_:1=8N>QXAJOAB'5V5"VN\$GY>5=4DIEX2D\$*HJG%@)XGB)02R5#YXT|
M7WWHSB8@PSLY=?
1TNV3S8"\$WN.*Z40GV_UW,QO,X#FM#ZXV0*A/B<.LL'!HH:5>'L<^
M(|H<72WA)K*|=DJ>M>(4O41L,%9(5>M>!.XXGI'02&9A\$1:%C%
M6QDF6RYP|WW,DU9M92G6GM:W!=GK>M;.Q"KS+|F+;T\$G/;+>(
MR>A2%.08F&@R&\$J3%@E/(\$)|:_ O>1YV&LNM)LT&ZU(VCYI6;S7|FZ>PO-XOS
M41+\$4TY&|JPTPDE?2;C;2.9)%XFEFVLG5>Q'12%^G=.*<1|23SC)Y*3MJ'2-:
+9WX/54V*"F# M\$O% GMQ|XC/@Q0\$B;A
D_G,2Q_/_%:_PO%BF^=K;)0IZ _SY>>#7)X/HYC5Q*) M1U0;EAGSD(FSI3"!@V?9
=\$QDT@,NK2U.P#T1W<*Q&FLD|JNQG:*|=|^67ZS MG(DZ,EDHGL!0R0:R!)L;D+)
|.4|F83"BK:?"K/4T^!%&U%W6!LZ-T ^FT| M^M57-RGSQE^E%,"+.+%\$?2*
<#X#Y#,A334L5YY)NW0"|B""<*2=1" _>42!!L)(*0,"R+-*3UF&
MP%/0O/7Q@O;W&1KG(V8H*BM)(!RAH?-2^C9E#B1QPIQC
M.=/ZXXDW(3EI&NPOZPTOM,."KW@7;C^G?UTQ'3,EN2+9_8B@6+|K&*0
M&G&DDF9)Z?2('A.7 M F3V4J;LF,FU+89'7B.^C^|HUXCO(^>Z->+5MIW7N'U'?
R;VXOQLH'HI>OT MX8;JL'5J&!O&Z;CE.S5T-M.*AP@|!%)D;/3)7!BH*6_%;)P'B5

M@!0S5CB=E:B=ZCDL&7:4Z0W)A7UDW:(#J5(DRWWPQN9Y65V"^(1G+ #Z:J\$ MQW
O--*(YY)(BBNNG9BUBY,PX>GZFCO=K HF)OT"ODM^07;R=X:%Z4A7=O M@!-
#E((96X\$&FL9CTCC14)CS6=N=(J4U^XX=Q?%|4M#M1(DS8 ZXC^<.>K M%Z,/KF:-
#9C.HY=<:C.[J7 @0)040: !9^S).92)&.Z1" C2YEJ:3 N1- F M,T*J3^=E@@!;
(JA>+ "/G&NG_K &4\N\!5ULJ\$0QO/Y=/:SC^DBO9^|F|H5 MNZ.HREG).W#+2|=?
+!\$+1(G@F=;:&6YO9<5LN=#J_M#!&9LA64,>R0QJH|974U47+3S>K0"U9A2|M-
H%'DJ32DP!,V4N7>I:Z.#1;:DTPE-"2*J=Y+T9R?!&3"553:O+N=|OTLD M07#-OWT4|'R
^79PBM=E3R6.NG?74R? MITM@:#27 NH4|C98D)F+W^N_16KR*_ST@10!
(2DD9A*9+#!<@B\I* %H5GU MF8!0G|&=NN
Nfy0X7@;T\IG|(&J53QM(Z(C6;%#*O<>8AVHF<9;W!HZ\$7"3 M5IR#MRJ5!L,63&D,X;5-9
Y_DVK/Q1Z2+|L,VL='EWT44CL^|^|B_-NGB_-/M|F?
9@2^/9N\$ "M1(M=RO+&EG2@#87&O)XO'N;A66J7RANTZI60>S3FC)K M8*B^&?|(|
<5D4HSH52/QB"MTG@ 5A()PDH/168*.W@L?O:.L=GC|+HHGK>U* MPFVPM?^.)|O
M10H!12!2,J5EF007E =+C--1 MO/>CGR&:M!1FO\$7M3V7VG|Y6O!^SW-
W&JZ^EGW2<7!0" /*MOE-4CA);X" MRB%@J2\$(X8/*9:)+|,*RO4\$^0_H-H|&|YIW
5!%;E% LR_K8-=VXA",D1:Q M1I511EK9:'!WR-0HB*WIXIN;UN?<|G/T-N#:&E-
CW8;B'^E!:+ M9<'4 !KVB|DO9-&:,^0:RV5UZ!|VX:, MAN67| W9^,MREUU&^Y,9|2=
MX2%D<"S9TC2.@K62 |!/&^6DS|PUWQPV #MX2'#XFN+%67J?-|SB=^|JB:39 M5?
RAG+DS0|B97AYY6;M!\$Q3= M&P:)|C(4A08P-"O@7A")|+ LUHZK/*ZR|H:;
|U>^OH&AJQ4|H/K.9>O|Z6W MOB7+#Q'ZD*2@SJ#)&")0+=&"E%Z!24(B2&F2YY;SZC-
FGT+Y>A,N|"/K8Y2O MNR 3*:T#B:&E=: TX'4JV:??2<4LT|>GDSVG\O6|M+=O^?
H^HF|P^|PKYW03 MY.Q)2B10B*\$TFK0I@&4T@U4Z,D4H-?5GG.TAT0(U%I!3;J:
|P17SZ>SQ?C? MG4?Z/O|=93(O8U32?)0I|U0"IOH\$:JR'&R.#(|R:J-*UA):OU=";WB/(5Q4
MVS|H9U!"F3O"W6,B,B&1&Y E8&0@AL"UB-N\$P)O:.H39J|/2=|+X3.A4RT= M#;
(UK2;MW("Z<7IV=CG5:>0B@5(-P_B;FRQ&(8L@#)&0?7:E&-V IX:#IE*Y(6F MN7|J#@-
!|U/BM51MBQ+?.PM8^JH\$KNTF5&(CH8@,AA>TDY%9B49PH&S:&@J M;@05UP
MO;M51V%URU9B,>B<(|QU|C'\$I?=WP+C \$9'T9#NTH M!>&S:I,5 ^YUCEP'X65|?
MT+|9E2K)|:|K*LQKC5VR|Q1Q_I^_FH|RU>B M9#>="/|S,9Z/EW|W2L 3X6+
(H)2I2<>B@FI0ZLAF:":4>_1RC3ZB6OK,A0<>6&F#HR5X|TNOMLPM2U0(
M73M=I@>L9TJGP|2S@4(-PO:X|C3^4ASD61F=^?I'Z.14^DDL);9AO|59)..R M!6%5:I&U
A.3 VH<=X(9*GS|J.8#&@#|3&K96\0:B#G%9,+: "1Z\$!B?0!1)"
MX5>."Z!4*FLY9(2*5G&2H>|P3)'=J%|#" C<-DC574WR.7<1L2CF)TB6;KRNJ\$-)(P
M&Y6!)*G1PFKK17O3=2.TQ|"G-MK>O<\$?K*IA\$G.|K@ SM27!)A 7'.5AH/R
'FB?,?:.*'20A)3-35R\$=.B7R7*T"UD\10)><0HY M4^V#<=:Z06^?<
YV;550U3\$^G|5>,P1FEB-% 2"|ME6E&K(1)'CLIV@#K|Y! MXN%WPK6O,-=TI@C/GF>&?
F"9"^@3'DA"9F"4!,:.)4D*T#S%LQO:,WZ|*RAHD MZ:+'9=8:?
L=OEM2@18A@R#&@(|@I4FJ81K(K|!";\$7Y&=,P7-J'21CXQK;
MC1LN(U2T(GB(!ETZD:/\$-|A:0,#1:IMMU.VWN|W8GC'7*BAKD 2-.YRW;AP^ MS|QD?
M:|)%@E=Y2(=I-^)?!*ROV&&2 M,3:'1SE/7"57TGY5F<00&3@F?
5=*E8APF9/VH:\$>D>PJ\$K@H'?C*?("(" + ^?)) M(^4B#R((0)5PY 5#A4FA(=.D/\$4_A>;4?
OEW<#V&MZS|K="!^A@DWK !H|@A M2JIT*&9E:77M 5|3"9(D;8WUT9'VYL\$NSARC,
(TYF2WU"63@N(,0YL!;X2\$8 M;7 SX3QK_3@+TP;JE?K2X9|A??J:TJ)9;|1-
#VG:"W7GJ@;M?2J#4E3)")&6 MD5B12?#&H7GH*64L\$Q),^V;
<1^|H&K@.BE\$*R@C<1S47* 6;@6:00N)!2U?| M57S"O4_WXLZ|3_?
26|H^EP\1^I"D\$3DLIF"(:|D4U()+J4(ME')"DD,7|/8TUR=&AH?U/FW"A7UD?
8S>IZ3D|69-(&@C0)3;0)-%AJR82U1Z MIFSMOBA/J/?I7MK;M_?
I/J)_++U/LPR.9@8J>@ (EK 9>&0-4YIR3EE3HVC'2 M|WH!
"M5;04+U/+R: + ^<<4IE\FXW^G^:R|J2^|+@|%Q:C4B_GC,|@-5?E
MJE2#T5*6LCFKG4SXV_8!BYY@'VM(|#?:1C-#=#,E=74QL!:#FO|QG83NCF Q MBIP;%GP
TM@DR4%5CD.--),H\LB^/892CM /@:.-2';MI5U%X|@VKS\$*L- MSN?R8FKQ;NS|^
Q5F.8C2HTW@93B8,/F:|+VE7)6LY:)\$^H(|4O.@Y'_5P(M,:|^&^2B|H"-
>AKKQGCT48T'8 P|7\$10:()0P7HZ/%URKKZCTRJ@#_Q=-6 M6AZFOFO#/21#
(=F@@9H8<<,7%)PB%KJ#W!6O=6'O MWH|7T_-OL_2UO#3?
T|M)F)ZGDAOR(B_2|+|/|<24I54H|J&40'1H60D<#5N<,
MEG,B2_5:&J3PZT'@'P,C|W!+!M#L0,6'.Q?R1UIT"4U+-7:&|?5E^M421XH2
M'F7\$52GB0\$A|#WWL&F8TK@J\$;1HWINXVG(> XT'(5D-JC=@R",B_X?9N-SC
MO>HQ_FJ6XGAQM:I<{O9"10C#TL QJX M:#W%=VO%|SFGG3N*BWV?
R_(HE=13%H':TBF/QP#6! ^E78Y5DG\$K:K<':|RD MYTKZQ\2481KRKUWP_M=X|?

6^R5_SMY/7/T*:S!/?3ZJ_\$SD52T:=2@U5N[3(U MX @7P*.V*1NBF6Z?
*%EM.8_A!6COAQY^X.8*XDB421&)?-(2B,J"\$*VTB>U;@PVQTL?P.AR)K.1)69-HCS6V_5
MJPZ;9-E9K5%+1I:92DOE<'B&0^0DB)Q5"*EJ6&B8M?
YZQXZM@;W8JL1.L3M&QLW7N2OJ^IA&N0NJD2>\$NS\32. MP^5/2^SM2KI2(-
Q0NJ3I<@=(B+OK07MB/76J.1X^PXJHV-|#'1N|YE4U-,@ MO%#H?
(DI8#DPF#YR4%J\$\$<5FA\$5P9JJ:'9\$JJ6J0T^K%^72V&/^I M,^O>YUN7I^O^\$+X,(68!)
E66E/0,AA:@""E(8WRELV1\$%#'#/CG ME#A, M7ML-X)OOP4?6&BG+I
IC,BFIEM!SH%0"5S\$(HK/WJKTEW@?L,^==!/?4-TL;U
M)NJU2^J1I2I+7;IZ<=>=P=Y:R7\$Y;FY|XXRQ5+I(/Y6>,^<7@J5U" 3AJJS
MEB_S'KJ|X8OT>;K6J_C%)*I/2:8CPU1&9YB55FZBS-86X&40D)4AR6=;VOTW
MYJN#H#|I+K97I"=T
M"BH:I,7M9IS+0W_=E2Z5%=WK\3XOTV;>;JE>5TZ>S'VKO1D3*(?'@I;L
MDXH\$|6FDK^_F!GBPVA\4'+4,@2;RCV;K_.7V_ '\$?@RB/-UWYKOVOL/7K "78,LN).F?
4ATF+7^>E>.Q)NMCN5 /5I?O' UMEFO MU_4/;IKC=>LJ|NWM&HV@,F0*411;0H@
CDH-0CFAHN>9BO;VYM%|NTJ#|I#2 M@7.Q>#/%Q\@T@0Y"2!|HQ!>BLA2><&_7?
3AS6&_7??3RR'N|TE*A;Z,'|LH@ MH5BN(\$H>JY2)ABQ|ONI?
E^O5WWT<"0;3S|X'K.O5WWTEO??IX/ M\$?J@05V3HLA_#<8Y@CLK)24-0Z
0J>'49FVJ%XP^A=ZN3;BPCZR/T=LU*DV9
MS0(8*Z6CF97,5^5*OJ2\$/U<^LMJW)4^IM^L^VMNWM^L^HG\DO5T--XXG%H&A
MZPF"10H^2331/- \$1S39-JY>+//>K@<0J+6"CM7;=5OE|_75CV7!4HZO0RCM M&P-
^Y;)W\$'FDSI: ^8P/;!D \,<:-#K\$IQI>HZVNVNBVUYO=6EZ^;W^DQ9\3
MMXR*I;@*B+V8C>?CR9??+F;XYS*8J|C+EZ2R5M: M-K F:W,3TAC8A!;|JH-
L+VG%CI&-1;,>?_ MWN7L^X9NZ26U_I*6M5Z_HB5A+B9B(>4R6L\8-!E\$J
J5<0Z38GG!W&ZJ0I^ M,?Q4J5\A<)|ZT;)G|GY?)S'H;L&?!'>3%?E\$6_0?
65.Z; >DGD SG=UM0WB= M1\ M#J:8QI? 0!8,%>BM
JPD,H28B5HC\$|%S>O4>J0KV8F&#+*A| M^W&MWV_7L,G
MPKNAREOZ;J(:RV= _7H1N(M\$D;*I"7!11D!UJ\$EK#P5T6?"J*V="-!D(<_Q
MS3@^(QI4W%2Q>:_ W@NMU1:5X\$-1 5%X720LPMARD610%,I.&UYXUVVHMSY'I
MCX(7#2IW^DW#(R=|5|5/DDJ)<4K(^X*!(D>"XJ4,I4B+BX6#T_
MMO&2'@/I:|JH/"86#D%|_FK6_ S7^SL97JQ"C=WUEN_EKQO41H_%F|0%^ZL M!#"N-
HL2?!12K"QI/0H|JG6H5(L;C+_ /WMOMMQ6DJ0-OLIO<^|_Q|Z,S5PH
ME9E5:9:5TDC*+NNYH7EL\$J8I0_6JE0_7@ W\$F0!T\$#;BTM65)E 3X%A&^ M?FZ-
"1'943, ^K'X' _!50)J,@O U\$>;K)U(J*0BD<&)M51:<8X(*("2X^;
M%|;XE,8#A|F)A6,PZB,RN<'P, WM990WX7YV|@+_+;_&B?+!9B@PNED1.G\0
MLA<@E+4F:_JS\$8&1MJ?_U?;|&'YS2SG@I7\1E|^BGGED.5=8K\$N0"NL_H=6" MDV.P_?
X^N@Z'PW=3&"?G,IR1RL"|4H">@=7/Z&7<)>YQ06S18R=| M1HAT5524-
T|"U9Y^JW4ICC-F^U_ /35AYM?Q^2@/\$UL^8-Y*0VU/PZTZL;S>CIG-QXIBA0D|H"
MT;4D9R@2#AHY8_C9,!V=5^J M_GC'!R#^1H(N:XR1M;QH'=E_NY>>!ODD7S M4-
\$::U\$,E&!D-'!1E#DGYA%\$L?G=4_&T?FJ,| (ZL99SWSEKQ=))=^GTT_M?
|KSKQ>P|>>0|2FE\$CPGP5MO*&_1&;SB#(0QG#EGT.E#>O:|V1Z,H|2>D9) MX?
RR6\$Z^UK3NKV=\$:#X'IYJ_G4V7\TDX6S%^*=KHA7#95/>28<59J+L638)
M9|H8*T6, <=[MZ'X&"R|O|O>38>C-A>G)@'B+^=T6=CPA1*RTI064-
DB2S\$5V"PF!5P53SCF>O@@::S^2G'@ M#8J|@17"N+ADQLO6+^Y1A"K?
2_#"8PFTT,"8BW1"Z7C),X59Z&PI-MXO0QS4*
M8X6LZR&9HB@WU55\$J#PD(|7T1L1L6L>)>3P&FL),M#)?U(6_*>?369J\90YU
MR5Z\$P+6_XICT113DKO64P1."*=Q*>|O"%&XC^B.!*<1LO\$3H(1"WAD3FKPS
M)J"N2G<_!0_-*VU/&Z9P'P/JK:11"EX_3A/T^,E6USFS|Y)"I6URV)H# = M+(3
R/RQ|BR.*4"V4@?|!%#K3OWZUD;SG|GVTE6'JM\$|9)V?KR&\$=?>)O-Q)U M&
>WFSIO/VM==#Y=E(H*7;6>ZAXL*2 Y>|N"B) W@;V48%'6SCEW^=398_/N98,Z1\$U?
FK&9,NR08/>G!5\$%\$<#86,-R8+((P MN;0N&M|/R?B>2R-
5S9K+N8/'^^?O|V^Y_FT>E)O/N=IK,SFL+Q#IS58F(P" MQA*VW.QD"ZZZ"!CO)W-
O|WFQ/F|Q DKBO(U MA+.N(LUK\|C(VP\|L84;/2HFM<_L/\$O1D|J@AEB,-?;N(2-
7DDRJ780\$1HAXBGKO(VTAVGI>EFFW% MG^"/ZHQ<-=A8BG!,UAJTB?
3,=5|0(3F36VBEUI/8;FI=;5_%'T MUB'*>*RWZA;9M:OJTI_SZ??|#[HFOZP";YN9MF
%H|!;*KQI*0'4 JL8Y?% M*SMR^|PC)!^#|?6PC2V;YEHJ=E2LFGO)KZUDG_XI.W&
(-0^40;&) MLODBOQU)?37_9HH<9>CY<;(GW_-)SAB+C1(.BO0M.X/(@#_5C)B6,,@GH0AA
MR!!27^VOF2(/-ISB^Q*\M50P>(31?49RY+B> M48@N%/HIZ^|N/D+D,1AA_V1-
2TVU7K9XSQQQ7){AZ65&= '%%Z1IX\01JL2ES

M!;DN'29R23B&%3H8!D.P4C@!;/'<|M_JG.QE#/#&/\$KY>T?H)YY^OF_!/(IT MJY+-
GRAIM*&K&DKPJ79C1D K%7AN"A2,*|U;UQ5VH_0YF=B(.ML8I8XUUHJ3 M^7_BZ5GN-
!UZ^QOZ#K\$^R,^HLZN!,Z\$KX!L|4IK,0!KPUB/DJ*(AU\MEEKL?
MW8//KK*#@*#K&3"\$+.8%*T07L32 I*(51FO_5BI^
MV+O:1|3|7>|KU)VW'PRA|_ZF_EU_XA!-^ST4-=@&|H#R(:RA:&^XJ8!17'M0 MJ2!XS
BVB!A1QUB7=@L@A|QD)R.SKK7;=9N&|6*A/EJ:-13Q*.TQFV=0?G>9I%!YD0.
ME4T*4#D+F+37P3)#P=KKB&!|/Z*WKD8=\$1Q"V.N(X%|J'#S^M8LN1AT1Q!A+
M,,4#YZ56790#S,.(9%GO^@HR=;%UJ<|(MC'1K91P7@C@EB2QHK.P(I+%0B2
M@V/>0K%96>VT5K&U8W+|(X);J6K8B.VF|LAQSW,^\$"HM>)EO(*1;\$G2&
|P^QK"M>P@\$%XV3S...KY MGWVTO9|T. 1|W@F
8W)&"|7J4H@Z45P1R\$76X)QRTM\$S8W1Y-CF&OLK>2|8=-M>BPO"X@_;;C|Y=|G>4Y?
|N7|'_E|/ETCO067LF0)C%&|IKR0)|EP\$LG I=U M.4CKF89AE#W_E\$('76X,RY)^T?
&ROBZ3>X.O1<@7P.(|91AV(K0PV0=>FA|MDU%U4U<'EW-
+HC7YP2E:D((94"XDBK437=HZVL1L-,&V1DL|MMZ)%EQ?*.U MA99ZFM1OTV|GR|5*
OS|9=8<6;\$^@V=U"LS+ B'1@|||S'\$D@MK#?3Y #GC M.T =%;G)9/40H?
TQGVDB0LW';/+SM+9B(Y8YM)"4)R|=N|8ESQKC*TW0CY MSDLSO%VT,-(B_="F68-
9(|P|H_S)#,%X(5)('\$,)?B3'.8FP?(>6D&LHL6
M.B1/;@LA05G^D9>KR'+UX_=Y_O\$+SB|2/4235Q(I'C2A\$+720>".0=(VB)01 MO6F-K+
<=A2_"C-KK:I3YW\$OZWY6KUNT3|=\$E80IXBC-!,5T!M*T#IS'Q&*UV
MI3|^OKVD'6L7_3Y|J3VTLM&Q&:EM?GV?=NN90_GQ71OF'^!DU&YYYG04ONXB
M"ZN%9'1K>"\$,9*E1!^NM&V%&^>#=-|LFP8CQY;\$8*1W>USA |N?E,>8N&L<2:
MHT\$^X6|Y;6QFOV|Y;?1RZ&|Y>U(;Z|3|*2|671=6Z9)D4B"PSD19|<%K0Q\$E
M5|6F*)N#LBSD9BGD;->2O^;|15|Z*%GI'91:UN|>.^F'VH?3Z9?OX)%Y/%
MG|-96.3Y|RJ(531!?!SR;QLGI9#7X=IVK"_"_7SUSF8WYNG@B>|H3&>301Z#
MWI^277.TF7G4%,|P>F^P!LXLZMIPP@RQ&XSEMIJZ\$O8|-G^%,QY&W6W'FO9
MB'R;LU(I>0F>)\$...3T6^#39!1A>DD|+8V|NVCAXX^#@4. AW>!OI-TR^KXA:
MM<5<%|*-%IFH4&\$, G)PY*%8E\ G5Z!\$D3@RBUD/ Y1^|&M>C:.E'GJ^?0_7
M,W..5E3D,NW0@%)\$I2O.0B:3QNB\$1-8ZSGQ.|2N-PH%6&AHA2?|PBGD(L: M
M*RTUOE>/P2|J.GC|2A3,^%0R&**,+E9!CW"HH&+2%A:2=)P^Q6^WPJ;>OC&=:
MVVAIY.)SY(\$%KR+(J!FH\$D-=1|; 2\$J@'|S/*+V5JC5(ZK')^.%@7">C;9(11*S|)6/%-
)#T*Z>= MB|(C\$|=W|NR5"FD:KO.0I |ETO\$1BFBONXMRD5!(X39&+?AM2/#|P_46I=NW
M7W#ZF91^;PG_P^ST|_29_-|X3R=>Z2"U\$V2NFA.#+H+C=.,|FPH7J;|7_8\$7 MAE)
|K&T7^Q0X1|)=SS?ZFJ/RS|GRRYUK9W'SWKEY25TU*9T@|1&)>."NMLSF M.:B.T
5|LEJ3|TM.2.M^G|8|'(.%)|K&? >'&:,IOG<7?GIE-O"S^GD|3TD|/ M;39?
TI_|C,M4HH,1A@#-HI46|\$YA!|(2Y&!=D+%(8GO0(|*7SF=ON|>FZY'R
M@3L>RX|XFAA_)%F M,W?DY_W9/'|15ZL&/MML3BK<<3B8UXNU^U*X,1A|/08'-YN>
<_#|_N)8NM%R?/%'WEY(EFV*BB2N*MY118\$ M^H)M PMUX78U/%X3|-U5E|M?
D13Z+#+J'FD\$9400@H&+-6. L|E5+P*, "GX M7*21TG0KJC<-,T<:HJ"O/?
N:T|SGBZ_1)SG3_,|31_(VUUTFZP8)U=QRVV MY7G4&0P=@PO61BBJU,% R<";6!?!J%
HS@20C ADKNJ=?M5|D|X!F;F|EO!F;O1QZ!F.5\$7@_6RSGMV^!Q4|_WGS. M?
Y0/SKZM\$3!=9#Y5&&42(*BD,@3&'>22LX|<*Z'^+2T8|FU/H|MJ*T7/>@J
M=3|P,0(O,&X'D+C5|H)AWWN !0;M-:-/>PA|@-9106,L1@!|.E\$|J)1#0+1B
ME0H,OECC^;"RX2\$MXJ%E!D=A\$-M(N8JBQZ? 71UZJ?:1-A>J1; MZ.U14|A#Z%T HS?
0%^I*'N|H6\$=\$*N8+W8(<04JFHP|\$HV@-%CZN,3S2U#RF M+6PCZPXVL.K>NO>%7%
-V|+|S>N%"VCBQZ"JCL3! 9P)5M@+ HFHS826|>3 M=B!S_.OX&QW?
AT7=44&CK\$>ZD71|B_/AEABZ2CQ>+HS7-DJ%D8Y46H%KNPB^ M8*X-VE:3|'+*K4RI?
K04UU5^' M..|NQ?4<,*#V0T8*BQ<7/%W^_\$1\$F00W'(P@'U<9H2-(Y2&K1AD5*P!UIT(
M=R#|Y=IE;RV/@I7Y2RDY+M^5=|,*ZQG)T|7/^?V,5'/193)4N-8J;\$%Z&=#A4N1%\$XJ9.!
(&4"K5.=.6-6Y/Z336UY M.@83/Y !|G\$PNEO/T9R.CWG^?1+SFVGZ;;K,|Q85M&_G7W|
-INNFE63E3G4 MU-3\$0K_2%O_&? <<\$5@X|=>WY2F;,9F L
MRP)*.%>A1"C^LIYCBXLX%=1S'XE%67@_#,,=E*A|&7>|GZZQNOE=.O9TL*P?+!-
:UKW|H0 M)BERMQG*UIU;3WBR;|N;V6^R;|N|'JRI(%9<+I@WY7W|JGW2:(^",YN1,|
M?3>_+4|P|-/>?YU,EV#|*W_81T+_CR=_\$|/Y_5>>#UI7V20BF R2%\$'863T1FM M2^
+9!|=G *=5%UT64N %+4!UI7RA:>@8VOHJVUI',L3 MZ&Y7MR_
KLHZ%M_@385|N9R;*,5E)EB";\$M%|N8>0LH&&,^**^TD;|HM|P8!
MAQHZZZOJWV:UL|@|f%/E7*YE_PAJ1TX-!U-+!'E_KIQ|7?>8_ZL|6
M'%RQ,4W5H_@#OUY,40SAJ=.H6@|^#C/FMH>9W(YPCD7'3|5^,4J/%9TINIS(
MU686G%86,,469;3SM'KH*|(O)-V- M|\$JQL!\$*T&1NP+.A

+!FRB,-24X^U@,|L#GCQ-/EYQLI92IS &I7%)%%6^
MUP'954EIO>,R:Y5XM,#C"HC:1D#A!406HM2YI!*:9 |>(NA%^&7M5-*AKGN+
MIHLMN@.(ZN1HW4O083REAHJ:J9)Z:I?G?N*B*,W2EJ:"!"Y^R MT*H4UAJ8;T13>,3Y&-
L2MA%V!PMXD)!*IGCZ'B?IM^E; #99XNG%^BS'A9.U M<I9I;5*"JH0B\F\B\B=B\J;Y\/^#!
(WOB#10VNW8O9G\$. _@45P-DZEE<>3MO MSI9?9O.:LC^AUS"1H01 F-
J99(T"Y&#DYAH&32N W_=YOB+XQ"2T,6<\$D5AU054 GXLBL\|.NNHH\J8-BL,H
M>W\$&U\$1%1ZB^|R|(M63B2>O>>;10\$;002ERRX.FBU\$5f@KCW"EL7<'83,V+
M,YB=5=\$PA%E#|IT@ZV*+P1H,G6\$R+/D(WM8|Z(I5G@JS6A=IL;% "2B4')4->
M^))GK/FF\NW0|WF3M#5)SHGD4G8079VT%T4 .OJ/#=PSR9)HW_-^#QG/V"A:
M";_AS,1C=EKW/*1 !IE= &8J<)>NG_SB.##+CCJ&)3@JH|U5PD'T<1W;::"OE
MAMLT5J3J0G)**:>?B=?ON)O|S|LUG@7|K=/_M|@F%R2D'8\$#+-)U@D;\$O|D&3L2|Q-
9@R|W+4EL^_C|G8V_9|G-3GTKESS>-8_M)C>9GW 4"8-6U>NI"^VS!*>3 "TL
<=):^*L|5/S*%'/V)CZ*:NY=B|NV(G MWR\$AU+% "8;C=-'G:?'M=Y0Y-K0_0|P+L
MI9DZ|H*.W/)+?"A-&|.K_|-IM>&?T)U|HKLC+-J\$&6|D<@H0/?TQ,H4 M;-'DKAW(?
&&U5MY=^W-|U|+:|@)9(%&? MZ35V2-)B6G.I;?8NM4|T|D?Q"
I#"55Z3WZO2VGAW=ERL<1I'1\XB5PPF6NA MW40&2J(-)S@#7ZRPAQ^
@QN/(7>8X|M|H+-D9=7D>QJH>5E M.'N^&S.|N|7V\K\$EF7>7|-H?"\$F;VN:1A|;VT|FK2;
IAM%Z M=TD!/-,0N3**'@ N4^M;;UL:|V|!&O9|Z^|4X&PL=48V MDRQ<5YQG
VY|D%R&UEAP=G2G8ZN7@HYE@H_>CE-<+"9E\$E>O M!T4 |H
KM>+DE#6U)J%8(H&53\$,-)|DE4T'FW|_J9@K/O0>|_|&Y&=&?Y MU\$C*
|+*D;#?:+U:M#:"^VWZ|?2@_U!;L2RED8GNH>;C,U9M(^92/"1N*B"5
MLK6'V\$%R.FMC2P|R6.|@V|G>YHVN HUV>|RT/CC%(@,8)D@'%;P*4"\$G|\$B-
M5=IF:|!\$=.VS^|LE;P^H|E;FPH:PC;|IS(5=78V?YCA=G*X'L/_M=|985BF=J;|/|=|AYP|
)^3&9?GZ+BR^_GL|^?><M/E^TB-;XS*)"8VITP0^@+>8(:).W/%09&@.4M6
|F=F9>/HKS4FQC4&?CZO MVEP'C;@
:_"0%:;\$YR)))1#%QP"PE.!58\$G1YZW3+PC8T_P|ZNJ=L&)V\$VL%S
MO4GD;>#5.Q>E*"A+"09<1@:*XC|POA@H/(CD1?0V=LR=#Z#P*5O-"#KI,%CT
M9A8G5|77JTONS6)UO?
WR5SP|2VO37PGH/I^%=8VEK|9#2V_>OOOMVM&X>&;7W09XH|OEG%INO'8Q(2!Z
M"RH5"^AU 9*.E@FU3=H->|V_>JG;"@C"+OA.-/|MB?TWDFP_Z?G'Z;?L_K
MZ_*2AS6|W@HCA%= 9IM!<2H><^X:Q"-3JF*1M%+AU&F@0E-
MXN5=^81_G93\$N%'2@>%.5!P31^|PQ8|<,-,0.\$/T'J;X(+\$_2!'6%KP4X*
MZQ#K/T3C3|G,YOEVV>3|ORO:69'1H(52>*03(0MX(RK|GN=*JJS1MQZ(VH?>
M9VYYHZFR0W)RT%&)D6=IHP 1R<=3(BBHNX@@9:3_P>B2:(U=|7JAM5=-A|3!
M0S2^7Y<#WDS7LKIW?^JM2/:2+2THF 6*O#CI<MA?7W|"0%4+-\$\$ 5R'.2R|/
5YK8W&K:L4'DG/^BG? 1:ZLQ\$7)G6(C UD)3YH<-G)"KO&
ME|:=M"*SK"79FA.2F&"U8:""B(KLA51..%WB M('8&?
F'OH:0.6KQ1SNHAUV,9/NYZR<:Q(CF11E4N6_@|>K9U0P9:2(K/DB
MV(NC^NGW@<7QFTCYJ>R<&L(3Z|+X|9:&+>5F8RQ>6L7'3|5^V5>TY.@')F7
M)XXBMQ"VVZBVRYSB.:*>><\$D7- B)MR7K4LJJKY0T\$HQS W3@8WT*=_UAL(=
I&)5E(?:6?'M=4T19H21'"CU'6A42H: M0G\$.&"JH?52ER-:KH(|E6U#^D+"#|
^W%RCSX#*Q"i&:KM\$|A()92_E|Z5' MGI7MNIKE|N'1C>5)LH8=P.0%|H(|>JFB3I4F:T
CTZ!Q"04%N/(KQOA)AE| M |!":I\$=A#|FKA|/+D|1.0#C=1 ?+8?
'+\$+PN8@L7\$EZF*MQ%+M^>B5L#^X%)JZ-MW6RTD9AG905M1-ZA:^(>|R:
M0,V%Q1@<+|7?JPL\$#(%UK0"T0O44IOA OA(*C@A|D;=A5^PV:&(0NH)#S7QD:_Y.J
CL*T|.ZS2>6CG9(S"&%: %DUO M%7F>Y* D"E"\$*K\$HELWMR?
W1GA=^%PGBA;G&XTNU!/VME@N3JSAR7&MP3I3
M^|= \$W59#.M#DCC%>BO7A>TW%WR'92V/W,)>!,Z1"V ^DMD|06ZZ
MK)OG92@J>2Q%C+#IRT ^Y: ?9G.<_S@?|.7Y?#7|_W5V-EV^62|GDW"V&N_ ^M-
%O/_9|\$I9T-G\$21M')<1R|5J8>;H|)6I>:8Q-O3>2SL*M05+1YI4?CSL_|
M=9^45A^+IWLW)0|X|";|BMORT CA_|&ZV::RV94!UCYL:5%"M350G.X9|RJB
MGLA12Z27T+;N MN?ZKU3(I==8+M7'M=|8BX(I3 ;<#|3J16N|J K GPNT5OK
M8N"MRV|-B|JK?|&#(5GHG&7,091|-S^?EY\$Z=2_LC__M-C/5|J-N@YK,I_3*N M65^U|Q1E
S5^|E/C;0^QE0|&L@|G2BA.5NAXQ4'5 M.1UGE8-: !7>"!ED:QR)|>SBL<;*PYK%-
J+OT9!PWKRUBBY\$PYQ4#SB&12S M# *S==0_1FM*-IRU!ON|_OTO^Y7961,=T\$-NM?
0-H;:3|W\$. \$P.|V:#BO<0 M:|MUR^R2MN[K|).+MHKM7<)>G1,T%UES_-
@R.@)DA@%)NYR\$<,.!_KO';F_=1
MQ:R?"O@T|?!I%T4.FY;KH>1N|JM+OY1B@=R(BS|8V*|5|*E

ATXWVK@?"LS&6-R=Q<=Y6! M\XA)R2(0-!,!5.*&3K?3=+HMIQ
O:1E:QD)/QVZW&C@_.K/=1K5=!LX7R_DD M+L|
f2_XDA2P^?SS8E64"M&JE\$!7='OEI0+T*4,@Z64CN,VZ=03V(\$/9+1X M*YW?&3=OI,;!?
LO7|^=SG[DO"+MW8VJD1 B%E' 1^5 H4- Q|{NP=,Q:9>L
M:7V#;23FU8H:*.I'\$C?/RVS^M;,{WIB>YRP\$3SYL'6LLM?4,P>G((5J66TKF?E%?
K:.*D#M6>Rf6O;R06XGGS^,K5-RP&3'0/6HJ#*@@@'78N:2?!< MN)
(C_=fT6Z)HfYB7'6NVT5&'T;K|)P?D2\$4=8H:|U)SX)W: ^ZEKUD76'9Z? M>R@K\$/T%
MfC)O.+Z2<0E--/C9&QST0\Q@4-T\$.XA -QJVT-R/4|P9?E::8XZ@S#1UD5^ MY-
0RNI=_UM(|#&>OL'2>KKV==S0B)/P2KFZ_X=
M>E%j'l/GY\$3\$E!|X1',WOG2\2&XOL<|:R*QALF=%"/YUC1#!LS99 M6> %5_/H1\$A
#T%S8Z16*%P3Y5W_TB>HO)UEUL'1_<^\J)W|JXN\$+HHBH@B@ M906/0KI-\$"NF@#':
(S/"R=8SR|>^_F7Z0?QJH0.LPSDI%_ "7 XCI%/S>(.0P M<>_..:KE?070(M-
_9OPB^C#0FZ0H^61*H\$.@FLS* S,F*HHK,NO7,Q @*?B2T M|:/?:41YB-
+SIFOLC|/Z)-61CHNIXSL0I2O8H=!DIH)6MOYL'8.OEWD.CLE8>CP#%YA) M.?U|J_C?
RLRUR1?*_@N?OF+O.4),7KB!-\$G50&.W-,1UHH6?I5B*B,2MX\$
MUOK,:GLJ7YZQJE5DCPKLOL=K-OU.'E5._\R3SU_H?|H|SWAG/I&'|"LS:9^G(,389)E9T'?
M.NN+WZ;KZ^#3;(FGOTV7=\$\$L)G'-8| ZY6@,L%1'Q)+,X"(%-UJEI%"54&+K
M:8DQ^J9Q^*8C*5#P_|E*UJ>?Y^<-Q3=8?GR?*^X6ZS8N|G%1KRC|GRO_+R
M0XZSS|,:F*PY_G4V/_j1_7O|1=6&%<&.*HS-*S.O1@L8*40*:#76K4^&N-R M^.
(.R1\$;4,,^I=4\$|Z.O6|U+>:<_N/9TYN@32=?+.C?F\$9Q-"D)349M,SO|?MMI-
VM^|_18YEHX:MD+L+;\$U@.%O4^+H; W:6W=9?_J"T_WZ#|7Q^|& W3E MC 6FN3,V
Z82*5X.*ZX9L.RS-F@9RT<#'|@7IR_F###PA@VI80|O"5U@3N3KU ME75RM3
NS_#T4YY_/0DZ@B?O2K7HR|M=9#|7;MP!
fM>+RWfS6)Q|O7"J_ ^6Z^/QG|-3^I@*|_R|WI<3|2TWNfZ1,YI> MD"
=8,D.HO6:I4@>/AY-T#>3+W,\$W T9M)R,|3:
M4>OON/T| ^3Y)>7KQ|O>7V|*LY,B8)_ 'f"G(:*0Y_.OZ0BO8Y2(E.X#!W>TRR M7XS-'fE%,-
Y@<0#/YW:NDH|\$)>CM\$@4,"R1Q626N>0;!EJ 9M2_
M&!L_L.+OL>\$V%2F|'+;2S,,X_|N(M;^R>2)GB9-S*GQ! MfE"%
#1UN:G4TB0M;%.ML_I'@%S92|?;2+,GM/>:+WH9148\$Q|fVO3"LR',> MC.'.*>:-
EK*Q:I;R/A>%_SNNN@P/7;HGP(.2|Y|KY3P" _KZ+9\$< ^4|Q M:-)\$@B2#!^6R!(^)|
fUBQ\$A8-ZBHK>"N2_I9ZW\$6AWD|N9)2>&V!*T LF
MA:*WK\$1P7'CZN>8EMHX|GOO(-|XW_4ZZ,.00S"Z(ID-X>@7YWPkd?RLS&0,M M?
1<=/Q60?Z.4MEY9T(@1E*9K.P2N088D:R+DV%%0I&% 6N|(^8U M3/=S:@(3MKA8
!76CLE<|XC2+6J91)Z|Y"(VZEYYZ?NLKWDW7#S,N*FG_@ M_+ S|F*
M|&91\$!O=6U399#R"Y!1)U-Q@K|+_.|9%C"\$HA>fEF,K=3V^F6\$768^SEB,Z\$5#0
M599-15I+O\$"@=Y4N->2249B?4NLFL*.?R|)%8^=N(N-M: #F,.XSH|8-(4YN
ZT/(>/YK>782O@;UCKL(KF. M:SF|L#Q'LD,I: CXV,0>|^0S2^5A,BC|f00#SAU;@H+4<+?
2WC<Z+P?@P3/E M- *WB6X32T&+BP&A((OHBPW6M,X0/Z_F
'MXY;QJH0,^T\$V@|R'\$O(SE %NI MY4'P^%UDVGTy (Z^!
\$2%6)JH@fF(LGM)5M&_.&6OM91_7W MT\$^'I3#WD55_.<|7"9\$9Y_CYLBXAI&-IM7@G
MV52|4RW4^@=XZ|*) KF/C|f.WOW8|>M\$C64^:R*PT3;MK,M15_M@_IS2MUUK
M8*GUKTL@ZO?S2%2VN0U^2K8Y80L*
(f"i4YB;0\$+L?|_S|_ T=8#>T|\$GM\$PM_*^'H=Q)W| MU'-
N5|7C2U#XAW@_L999B2Z"B+*N^E86?
*&+AV?) "OY%9R9E\$%|XK!4I+1UHI&93T/+J223>#EN".>5"VXO#UK!R/ M ?
7:W;0/M|_YB5/fF?S@?PR+973-@+3|)(JE F<2 H8*SI@W8@LND"UCLCC
MZY\$Y)B,ZJD&VRR0BVV3=NC?PDM,BV8'4G (*BL/&"1"=\$Z5B\$F8/OC&(_+X
M>FB.R8AZ-(3N*NX;F"%OIND2X7E6?W0MJ'N0^|0-,2H|""=76YHM!+(R|J\$7U
MA,P%75I7/|+|>N!..EX#;|@^U9G|M|fD-%J|S|S=8%:<+O6 M68J%17PBQVL@QZ_'ZW@-
f)@V99US?
^T66<.>GD3/5:S1'L|AE\$Q.OAV!4,^A0Z=^7H9N)P;_-9XO%24P\9B4C.9I(+V\$,AEA:
MG=R<6)\$EF|N799E|f|MIVM<=INBG9"G@Q@%|T4G5A5MS7*&""CJZ7W8H5L#E'>
MGHU7|Q|9%&jN|JQHOEW3N_D0O,VfYY@;8I2' MX+8E074916D)9CN|*|09Z
M\$(|:|+KML^J:"CIGE"f9C-(4.2B*BY7D&GP6%"8C9FO(OU.AR|:K\$7A|/1W'
M8#3'N"EK<|A0ZZ*H_?VG,M3G*RF+\$@8.*5<:> ?H@^UA7A44O=)?E...R
M^3+|S|&;TN8U7+TVA88AEP1>71++VY?.\$98)@H\$#2V=HW/.\$|Q|6#|N2J/4L4
M#D|ENDE2&VNL8EG<;HG==:WHP7A|,>?KR/6PE:W=VKO5MD@@_
ML24:E64\$;U6L&8?6):L5BH!4RK671.<>"P%D.5DM"E&A=&|f'7=EYF6>D(:Q3T& M?

!2)V^T^S)9[>9I++8")FD,71J4Y"@HN.0V3!.6E"SN[8\FU#^H\H?A_S9USF6YPSIPI&+
Q(T@U*\$@U@2X\$C"A,E+;8)I+. M\BSKV?G*,WJG@-U!*+|X^|E)LX5|U(R:
<'7"2_%/05SB6([5_9#4MGR)YC) M?CU03\FL\ID>W+L-X)R9Q8=|BBNZ/^%?
YPLWR9G=9[X-?9'I9G&_13C#E M@!A@|+2J_%YF#|8\$D;G4W)?6M?
Y=:7UOYCR*4N^OQC95^|VS|Q<>X:|XF:J. M&3|QSMC5Z)3UN6YG-(5"HZ1
V*@BQRB\;;RRB9>7IPU'X51W&/M>U?A+|= & MY?GW2C;/SHSV;G_ ^H
M_CU^PA@)NWB\$Y+ B,JA,KYF7@#PG(R5WK9.DX|+X>O1.!X#NN>|G%?2_Z_
MN*4>DL5_K_Y@|2;J_@^Y*_ZOW|^^.U25728)3\$|H_C|_M_K'3TR|_)LL? M=_C|V/-
W\$Y^4Y_JG->XN1T<9.FQ82D|B@BW_/_X|KVF_R=/X--PRN&1?Y MKV6>)GH.#I1
N#)@)TQ=PLW_8TXU|Z)K^B,!SRZEY*R)91_L_AB9@\$NJI_;; MFZ'MELF<^|=1|I^O<_?
7#MK2S@=AYC5TUT_M@*6|O0|P_#6=X+./8=_|HK9H.(|Q-I?V-MI-
E!MZN|Z6=4CSY"89:EF&/B MJ74|P0T"7O8%O|LN.B I7A)SL?EC
#F=KOA;I!SFCM|#.904O(=D>|X\$YV3E M\$)),+(-CSH RQ@-RQD_F63C*&
MOG34=1=&/W//|+R-0'OI=|7.N3*F8. UYM^~UT<%?SG_QO"A_#4Z;GHP<|!
MWYS=S*09.F=C'1\51/H#O)6LLC46H61-E|6B(X|*6I#H0U2>%>PSI_\$DI';(M\$WJ|9KN-
:EOO#OI\$0ES1^B\$OE0-);8Y:P?W|26I9G"_(T771=6019-UJK3_6_M<%E%\$,HI%I*>1L=>
<-DWH_O_|*|67>5SCKJH|_|>E/=Y7F;SKW5GRTHN%V2A_M4(F'NE\$K909*V@C>A
!;2,PQ2|5L:9V&N9^4%VQ\$+974^J|Y|.GCA|MT7;?K_M&L"P*4\$)P(HIC0\$7OM_DI&N
BX)-6QSV2-?|(+H|D>.B1Z|KOY/GS||YRX_MZ&)BGHASUM/EER2CH+4@.,\$C8@ZZL-
9^T|(\$O6!C;J^P'L'D\$ID^5%F""_0?DQ(*64?9/,9G\$W\$O.SL0QL===BI<)V>_MBQ+8
(HZY1'N4G.8+\$_C=BQM|/|(+#V:|K<1<4.E+^;D(-4|_|639:48'Q1(BJSHJYD&3*AJUTZ(
MGHBP<=;09|Z3<&<_Z^OM@_@F_E\$DE*M'+3B^#E_M7?
2)ZB|G676P=&MHW@576|5)?\$^XATWYG_Z(%+**7PF3@
MVJ_2@0Q0UX8C5(YQ&7BTK??3CZ#@1T+;/OK=1I2':\$;8=(VM!|%^FRZ6|/5_M??
=N^27//WW|Z?G@|N4@WP5JNLOT"#IB+W)ZL@Q==B'R_B*8|*2R@6/K^M|H
MS|UAEK_SC-%1FDV';G8_1F_NZR+//G"A(!L.7F(D1QS9%&#E(8%""X:9_^W-
>_^^)0&\$ERPIR|?A7EG%_|BG"1!|=|0*&B_M24_FD-
S/X^MA.28C.D1O_Y^Y2T\$|M6+6J=>+J&E3K1-=7>E_R%U19;R#)Q/
M"NI/DQ:Y)/ET#M)POE\|U|\$;6X<6EK%PG6|L;_AQ03@9E;"
<@48M0#%>R%W6=|M)=\$65_M"K9X-.M?6S/_>OZ>A-
EU*&#U\$|2UM=&/2T%YAQZY!;VT_XI7+01A%?BHB_-8_M/8&GD^#8AO/7DW?|!G?
WV!UNV0QYUFMV|XACQ61.)|X)K9P5X(W*='X#(A"M
DM1%,Z<<<.;2|8X2H|R|WH|#F;8=Tu^|VTR.|ZLZR-(5%""0XI0M05|E=P
M4\$|.;5UQHCD0|HO"ZM_'7\$=1ZEUCW'L32S=EOTG_1|.3=^6>H>\$3;I-2(D7@0FHZ_MX|
|6?CL)6206-"M)W4:0V_L-OWOQB3'\$M'|HC5\$5?=:R:V5D?O*IR_E%+ MF4!6E%55M
5?!RSHMX%%5-|ZT>&7NG#Z8@|!\$S*H>|Z1;+R|XO?;'+'X&'^8_ME7??
Z%:H78=FIGOH^L"|WX_99WFVC93=9@AMS;.&V_2>XA^7..PAF4;_MZ
(U(A:@BS62IY9)MIHHO_P.27I_M7H(GYFRUDU@>
<[DL]|B|Y\$8\$44K1F&U!SU9Q_MXX=IK?1U&WFA;.;QE<_MP6FH('51=0S?
9N(L60HL!>?@HPB&6ZOD_-3E8|?_:>T+|'|%AH;MS\$:AI#Q
M_!|JMA+^!D287237\$|'"1L|TW3(I5(|2+@8\$X)(3#&AC8QZ4"?QH14X"-&G_MA?
ZV\$5A71!_N6.N.&"Y+I?"PB\$DRT"(XIU@AOR&01'|T'TV4;L&Q%|MI%9_M5T0?FV0R.BA
B|2.K?G6P@114X)C0?!H6AR|8T'TV55Y.|NL@RM|/67YH=9|_MWI4_%_D-/?.+\$QXP.!LTV%
(ABTJ6X")S=,^H&%_*+7SK\$O,#Y(SOT/;H|62_M>P?@|N;|HJX"|_|QQ^S:3R;S_-T>:)|-
_E6%"HZ_Z!"=F2|WH-UT0I74A'#_MSOD6AO\$H4<_+/-
KJH#5_YKS3WG^|5UY.YLNYQB7)UYF|HPMD%/VH'340+Z_
M|X^:K(2E;D="6VHS=_WZ<|#NVV\$UV%2?4W3|J_|Z'#|N18E_S+C%8/A*2K
MB1XJ|CQ7Z2.FDG2)?T|7NW1M*V_P.D:X.V3BNW:Q*_';V|>MDN2(|ZF:-Q&?
MIW&2%V|26GTTGOXV76V66.6'5J7072K".W|3GM7?%OPUJO2NF@FNT7-E=S)P
MCHDKX)DI4*X^#<8\$2"F))FU4;3>B;N1F+V=D5L?O,XX16|R,NA!6D77)6H#
M04IRGT.(S|J)WK:NZ|Y+R%@5W3:ZON-D|"W;HZGBGBU((HO%F_BOL|EBIS_M|Y!5?
SG/E|OI!Q#8JX;|&'\$*N6V4.4_|A?#P.WB_FB|VK>0QDVW\$WSK"_4>>?|S-Y^)^FGIMGN?
JG\$LL!L\$@_MEYIH371CNB@2U%"|)%%:|7-EC?NOFCS|Q;:M#F9-
!=@PL|6BZ|9>@S#9+KR_MSG|A9V3^;3Y9Y'7++8^NZ\$Q6K'.D@,WI_IB<@J!\$9L|P(-
\$.TN_CWS6^LMOZ_MD#U\$.H+&WY_XQ<*I=_/S&_S^O9S!/D.N28.|3EON0\$"4/A_<.
(\$/5B1_MKC:65|/AEH.30#YMPM3>E=K1T#JS-82PIVXJ_-30,_^ZR9YKEO;AE|F"IO(
MKRE&(I0@Z?D**,"QB."<8O2R6;:RWO6>N/E53UWK'03:/WGY<9V,N);^^Z;.
M47|/T|_TW3^Q|^\$R3+|HG+;YESZ3EOGPU2EB>?|'^_&TVK|?_.05U*4:_M)_2O/E=

IN[(!YE\$J+@+X0B:GO-* .F4(VH00K6L:0C MA) -"(E<:9EB:@Y
+!"/A\JPCF\$0F18A\ZV8'BL!UK1<+!":0\$RGL.L-0@Z
M""E_1=TV@;VEW%WUDD4749\$'OT+?SZ;B.F8%AJ52;8BQ^:(AOU5/G3[<6>-M;R/?
LKQRW1V.OM\9EA4!.#O"Z6]B*4SR'R!-D M(:7#5#3]A4%QTF/?=
L@MVU..LEPN9YL\F*EGA!BS/+15'&AG2\ZR9.V'G<2'O^?):K6A^!JN M-
EF1H9^.HEX^O'LV!/?3'^<87Q<72#(A:BF)L)3)Y.K*(L2206+A.J4LW>T|
MUAOT^M"W/%FM-A=P^T9*!+6Z&OG^;:/9V'U^W?E=CKB8D:N>!\$J^BR7=<|
M)/ZIXA9L|L(%6SM"AU47M_K;)ZOU?L)MN,0AY?;|/^BCUR\$/->(JTKGG"U|MXF-
?,3=|IBLL:RHNUO<.H&-AN-QM5__UG'3&7N+?|90=@T=Z#OTQ&!\$HX# M*Z'V1=::?
2|=Z8&Q' HY?^FAE,4QZ'!#?J*;"K<16>08Y|U?A3(GPFT)ADI M&/@*I:V"JQ!_%
(2Y0@X|1=\$JW>YZW^0;7_04|5|/_00|:R&5UGF\$C_>3--L M>DY)84XXECCDS.C>=_0?
+!4*!H5TD=/U|X;IY;/'D4%|2Z7#CG;|U=|<=<\$ M,R8* X;3DZQ,+8H8>NKP#6/*NOFO?
(7WWTP'W6DBN\$. \$FY^%F|Q?T9X!>< M3^DG/V7Z2?ZM|N EQ?(3_05S_C:O>DRB4
MEPP<*QZ8S%PZQ|)8MAA;DK7|S2D0RNP>?U@,RLKZB_?"7*7TXG%RU#)YH7 M%K%
(T+&")11'41Y+1+_1EOGB92@#"PN|DC">A1U M"7O|!>>?X+D|3>2>6TU?#?|B*?
Y75E!+BQ.A\A.F= T\$SD,CF"3XI!DLA| M^+;&J!H+%S-
(RRYVE\$';73.J^_6H%P%I=G<^*|UG-K'^UY>*| M?
S8%KAU=NEECI2DD<"YD\$,IQ&9@,03H'?|RFY/*=S>MQ\$UU\$;#3<>K"Y2HNGQ-W|F)
SZ5=T6 MM?@C+T^2Y3YR'H\$'+D EY0+^>N84T#--9.
<#WJC'OR:YZG|QN)MN&OWL=#M MSRE>T'SI2C'C POT@!9%UQFWLB()&;!|)Z<\$1L?
|OA'VW:|JQH;13_P=-M2N M8K(|P=M)+LK3/14@&V5
25VQ"+4%Q|7AEI\$!F^:PYO=2\CSMI*T.RR*?3"?
MI(U010C0KM;R0TWN)".@.,FX*)C;FT8+R|VUH//7:~KMV<3_C7^3WV4YZ2
M|)\XGY;G;AD---!C3>>:H!L, MUX:Q-3+ &;%^&6LOZ&^T15_;MOR2H': MF|6P
#;J*7|=/@08EXJ,;|6BGIP3'P7*7=706.8N-0"1#&U#\$ (6|HF7P%*V M9/F%1=^Z*7LP #M-
+Z-<\$<'!O!6ER"%)I)*J1,'Y)|7QX|CBCDXF|D=U@IQ M|_6VEA*V";438&OA
4XCGG!>0704ID'4;C4H4\$+K@BI\$)LOPVMGIDP | M:V|? 8T(#*=)H>H(6(D%|+
\$3_PAJTMZF;(!*>'C9\$?+S# SBIL)+:1@0&\$ MX,4E\$X\$|D^GJ"
E"KE/02:2<14&EAYW\$XP8&V%FK#<4W*C" 45XG7F&"E#>@ M|_
W|3C@%VG#MN8I,Y#1(K|<.,#+ "S5IN)KC4PP&4"
GIZO7=N)KV)W%Y4@K&8O)C7|?)Y7F:|S MYOF*Z\$OH\$9.BDPE82&2-
L>;)L3X@THEHT#BIAQWD'0EXLK8PAL;|MK=Z.6H M@&|6I#HC*IVT=
G1P^*#H_XJ\$LFGSV8YG,#1S)X5@""\$O-3BSU:*>K 4L(N4NZN^L#J:QOC\$&!PH M3*D&
A:2%1B%.(XU;|Z|N)/.XUO(|S1BS^*V>BU\$> X(^)RW0*69 \$6M:>0
MK)3,!F*&"GO9RLM;%7|V4:\$08L_67#G8X5039J>JEB(*J-K!)=*+ #YA'CC6 M?
&3%GYVUMX^1BS^N"2D+#+:"YQ6&@Z)P0&;HMT4'BLIM4,H-TMOQ%G|V5F\$C
ML8U<_&%>)U&4KC#5%?Y 10B,&" (&=+%H)(8IM'C+O|LK-6&XANU^!-4L=ZB
M@JPTA;)VM1A-)! "1,>4P!CEPW=PQ%W|VUFHST74 @|@L8)R3@|'Y'&P=Z^2& MF,P" T-
F*%VC0>V^9;|Y<|A8)3U'-+:39_7+A>NZ3?GV:|YO(RPQ5""2?:%-A MKY*7X%+AP
73F2X=&NNCD/4"M|BMPG|K=5|5IHLS^:Y M|7S(Y_?O#8PE)&!Y" S\$NM"6REJ .5LQL3-
Y9YJ(-0&006:V*)!QQ:4A+CV%^L%) MYZ+(0JLG.1"RL_;V\$="(-8'&_16|YK-|J"
<<\$21J8OQBK"6)5O2L&-XO#6! MG5782&PCUP1,71|;O43A> 8E%?
F+6FF0=%58P9Q+=ECN^+AK CMKM:'X1JT) M%*=M|*J
5H|@KITU@OK@24L(0==44Z>?\$U@9ZTV\$|T8-0'T4D@GP,I00+&B
M*:P+JYRG8U(HX4H|/0>64U@%S6WD&:'FL|_|+'RW3_-WL1_G4WF^?U|BW/
MES_>G^)T6<=8Z*??ZE|YT;)6&Z,"BR:|0E,J:!(EC\$YB0|J&QWH=3=Z3U
M@7T2<)U4TH5OB"S5BYBG)_AZ1"*HR6'PRH#N=3M&0PC8\$@!.,|U<886|O9>
MBDV.VRY?_XRL920=;/3I.|:6UN,R.\$T7B|C6U9@VA:5-'|ZJC2(BS%+2C)K MKF+
(H'.%Y2UD:DYP#T6@%.A,7;CX|\$M*.V\$6Q<*#C|NS&#KZ|LC..8R))N| M,U'0T|PZ@?>4,?
VMHF.&;*.G05:7%?'F5(/U;GGV>X|C|*YP MBK:M+9;B;A| &Q8A:A5S#N@Y'^0ZT|=
<,S7ZW969/4C D|(3VTKML|;B;YC\$ M6A&UYO,Z21?;6
<0M4WYZ#';V\$3(N.6CAHJ:|9+R:": L?:1.0;H8ITISAHP M10|(27.&)?EC_NFI?D,9:6S-
;R/"K|QLO&DH^E>4FL8TU:>?CFK M;=-%@B8KY;1'\$+ %DLLC:XF<*!ZGJ|X|_
OM!#9&/'|KW_F4;-B7_%I7CNKR MO7?EGS/R|]Z'6T)6S*(|+U=86!79#*6N|H^YI1Y'
A,=/>SG|+:6HBK=:6H MDC;-DW,Y|1"2L)@A2!5!|:(A:&F!'@;G)3/'>1RLO!L?
_2QTM|NP&I:"*G|7 MSCR)!X@)"9-L'(%%>PXJ&P,!%0"B'DF?#8QJD%A|R-WZB-
D/&6=MY9RA|K1 MQL1CW>)A%
;MZ\$W7LBX|\$6#|R*#2U|E%%9VWJJPY"%ZCC0AO\$^JH9GX1Q@K MJ%7/53R

IS\AT1OSQR\Y7\^BKA94KM,&?RF;|_F\UJ.VST?O-|W\ILD;LAO MJ\SQ141V97P5K0X+6M
V4B@F15WYQEXKD)F9"<^-1\|N\$-%L^|N=4ZD)"6\$
M8QRT;96;@OX:#UP8H9BBA!M;YUXP8%HV5RJJ/GQG;L|<5XZ(SL!007#J)K0
M|6|7J;|2#H&H-O3>)E5"G>%%*#(BO!GB;OH6+D-:KFW36RBY6#=_7NH=|9!
MS!T:M^ ^CZR(W.("R3@W\FZDZ3#=_&^T-,(D|1#^N<90D(L-:T5F0#I022%%4
M=|1%Z:30873-)Z#'-HI'^OW'MHEM)-|!%BY6H<>US[7VP2ZS(8:QBJ 15'U" M\$|VN2*|J,
D(|9U:KXV|@%RQ@|:6FEEMP_-Y?47>, U|2=IZK|_T| ^|9%_G#
MY/:7Y:ORYR*O:#PI1?)0EP@F+FJUHF|L<|O-\$H+'6,,S3!'B3H &%L6S^S MG;C'B%K#
(O_KC'|VR_?:?+7/W/N&C|H|SAQ 8:L |N9W79D#1Y=CH0/L686S MUZC
%7HO*G1V3\$YSIUNW"V^B9>|@|N;GKIWEP(-%'D2|H#)=4,C!95|O/KJ< MN'
IF<|C1M8MM#SG?|R7|\$>39|Y/A*YZKU<3"Y=)8?%:.45/8PUHE+ ,4DD
M0;/H*+ZRT9C6T+;(2#E8B+FWBF|HD U\$W2.4N(>L=2-NOM@H,(# 7N'F8|0=
M*.ILHJR^U1 &8 _@ZYQ?,D9+G1"|YX_YFO=|M|@\$"R:92G|4168?X|?:S1_JL9;(5M|)%8|,
\$5E@YF2#()("IYQBR4REYK@R M|Y/R;|R"%J)NV,+R %D78X0#"L%'+.)J-!R+10W>/FL(?
<>T#);"10,|^3 M\$QJB(K)4L73MY>1!9?|_EW_T(L*4|7 ILTJ#(|1LDV5X#/H9;
MM;*|D!RD^?<=RH|SLAW))I- 01B&88BCF8_DO/C1!IP)P*O4%:EW!L1;%%#/O MBHXW)
("K15O+/3\$&6,(9S&|H0X0\$^G3C50%>0#4H|I#+7? M_
=H.8=WL|Z!2F#DC|V;U4|VM%UJ4
3+XV*M*"5DSD<@)*4=DJ5KYB5(N1;:SDK0AG4FK#K18J M\$ _7KIR672V?Q,!:| ^7-
6/MSMBZJ9?WZX|.& _"6 M_1/)RMP1_HP0*%W-.1%'RF#|31-
\$_@27#&E5J4GD+J|/%PZ28"IS\$SF MR%AD> +Y/<)6D27."U2"MHCRV-6CF-*\$|0)
_2|f\$2W+3'(O2Y.&3SR@9TI@H MV:*|)/STE^:TW5UJ-?
@/|OVV|94PH9@^\$Y\$PX|LH!":JN)|=826L8>+L;| M,9D8.8,\$FPABTALA0P!
|/INA#|_6ICEKVT5|NL"MTT41;ZPK.97*\$A1|1T)X
M3JRVDC@+5E(EN*:I&>1V"C,11*11=H;3?|O%OZN;IKSV4|3MWV'X**+&=R*
M&FT*HL\$;?-8CJ/<\$Q9 4NT*OK9:H%G>QA_A&TX)Y\$(H4JBP0GQ
/O/J"4'20=|70*8+4D<|L28"B|0& M>(T1<3Q?6|=L;|WRML7 ZVNDQVLBJ|IHEL^ ^#SQ.
|MQG&M62\$,\$QO2DY"BG M"B806:C* @07!7&J@#)5M(FC)8HK7D)%'-6_X|
(|Y|H|O3.MC|6A;/_F_NVN MZZV<.O\$Y*SPX_PB#YT|>U80|1LI4G==_F19.3!>--
/L)\VXUS|O6S'_TJ=3N MY|Q/VNJT%ZLC6QH|WA,_
|S>ZCZ)LXKYQ#QF!3L;|)#5/^81Y/VP&Z9M'X*1 MX/-).+;46,4H)4.E %3
MAY&4;W_ ^!RP7&;'O+ #F;0*&IZ>BOZOEL|L_|M4(%A1 0*MSK#XHW6A8L;G55:HX1BV
WNC|^VIT- 7V5S M%DP5@5*,9JH0|Q8J P:V*!(_Y(&&JL
PZHC+Q|I86L>H:\$P<\$&6_T;|3Y' M'5V+J^7" _?_=|=UM6C;C35&@"7"0I*3QFEQ.*9'
%:.*IAR@V?K&X--V"/I M59TA!GB"S6?|9.(X8Y1)FGZ@:K=Z9T?RM5V?
77Y94;O'VN2\$!BE MYM?FU4?%WJ|LU&L'P, ^ ^G,4@MJMM V?SV)>QKIMWRP\$'H4?@(
|8/0(A#CTN M,\$_P"HGB|55"|JM%.QJ7NFGOQ<,S40@E+ ^-
|DG: ^|38:0|&7L9C_G!MN39J1 MV!S;Q _BD=MBKD RU\Y6|O@TZJ8:2KO&N7XVDP|!W|"
<_RRO%CU948\$/S0| MU9 /5B,'?W>|O6'9+666 W2Y MOVGHQ::|NJZZBMI%J|+KQN
#U)BDF(\$% P CX!7@|!B"*.!M:N@- . MP.^E4P"9H)&M@3' Z=P!00,@ H.!@D#!P"0\$P,
^L_ 0/L %Y^;H," " M_-|T|_L'_&G|W?VR#_OO_ .5Z| (CO0,A %|!\$ &@B"!@B""O/2#TP.L
MF0\$Y_Z,=|!0,. 0D&"@;XM_R?UG#Q+J'00X& CH!^!|\$% P2*A_MD'!@&=
M6*\$^"+PC8&!&86%'9\$1"1D5C0X_1(R0!"@1R X> @\$2 @P"! =KJC1P10(@\$
M^8%1\$!E%09^(R9E 2)&X!I5|P/Z+@0.S4VU@8EU04'ULEM^4L)(A"-3.SLR* 8UW5^(62
0B(,\$9.MMV6(B@P"|T8*"08 MX"|. *!"!|D_O#%@.'|C02#0*7^A-[D9|H\$> |D 44\$0P12=?
P_+ _Q_||@ MXA=/8?
Y(Q!'=T+7IZ\OO.WHHB5%:0^|@ ^7|XY|3NRZNAC3+JJ.DJEW'C+H!?
M;YH_#Y5ZX388^ _^5PB0 @|!;+ _@<9P|YG%+;U!%|L9D7R|
MX>ZSOUF!1#|JMT*11.RVTSLRG#_ | ^", "3VMQ*XL6+6P-)OR^M=S@@)T0DCX M4-
K@#|?|4Q|2WD.<<+ #JP%5;)V-5FWL " BG>W|_O4HF5T65R5M/L,7(-L
M:7:ET<.D,32@Z2ZZNK:1_9LY:|H|%UI+Z6/Y 84U&#^U)' M=T27CPV)&;56L>\$?
7A*BULE)1ZIR?+N.^5!HP) NN*GH.2W6:|I<%+3'+?Y
M=A;_U>E4_0>3>E^/1K#2_L^5M+|Y0G#H.-&Z:MQ\FD)?@011G3|/(XP80!FW
MXC9A1+MB^VGA(|,%)S1FPM|&4;F#8WR;5K6|RZ;_I%UOBUBG!RM5GXVJ(D-J MX
O&)|YLX_F8#8|?Z4_.TYK E-ZOV_:^RTHD_)5H3P3F1|^IC6\$HK;|>LX&
M* @Y)=GR^D1>J+? *01@Y_Q|&+4#!ZPH,+;0F;NE3&Z>3@FWD:9WMA%<*=1B.|
MO&DBB^Y+< ^IOL=)6E^L<|;+FT&"7\$7MELD4J6 M+MIY_!;_8"|KVY4)>V0"YJ:?
RSA6B2Q5?;B%< P*jX M/_WJT?

@%W[/QW00<*8AS/KF="8^1:D&7R8)^N/3*G<2P_LDQBHT_9F'1W;R M2[QU^(YF-89-
:!'7]OX=C79^HLBIP@RF(L)_@?K<^NB.)81_+V2+:G5>G%_4 9 DPOXH_ OMJ
M%JL550U@!Y<+_,R'F,2H2<#U=UH\%?>9ZV-Z7>3>^YE3C/RFH>7MWX?6?*=W
M%I9I#X^G.V/^,Q*^O"^P@Z\XN4B.,= WW+^_.4%O8.JHHN&Q(O7E@HQM>JN-4
MS_7X#VSQJJS5XGHLUEG\J28%#D^R\I?/1ZTOWC 3F&FL\$EMJ7EGUDIO591J
MIC0=4/74'VRRZK!M2NRE\OMW!+G9E-6!'4/K^,?/2S:4AREA0\?3@?N"TI M9ZJL DL)-
J VU-OES/WS^J5'U6W@F;&03.*6,G#CYWZN63WG,*I?A2NVV0Z* M%!!2_C>1+8\6/V+OH
O7\$;&OS@AJ MK)LF\ (M4HYG"X%"6U>DF0\ "@ (3:B":.)%8UQ:->BCVV3;ES,-
P8HNZZR+)O'BT_C M@B:8+^MK!/ID
@773JB: +FWBY%O,N)\==*!:^=M\#:-7*GD#Q6Z<>,6W\$%#
MAZF.2_=XB.L0MWE\G=G5L M\I?MXZBIRG//R3.W9PW\UZ)@!SC#J'L,+?
>CS1;*PGLI_QXZ5W@=N*#F/(.D M6PXG?HZRP+H\$(-JG6B@Y713J#3/"YP<8-
J1D@EV#1\I5>U:LXL%_@0%L&.! MY4=)S+;BSP4V/UTR(! "KBSG\$SX!)\$ MFKT7A.-
H&>O.124\$(-17.U*E8PC)QS^LWP0D,9J*,I>9.:/@':W6CUD_T!!
MR'6D44ON.OO;F98M!0Y\(%J;\$0C7)G VM<|>H03NOR+{XG)Z-GU9VM()>#^ M!5AZ;<
:J)?WQ5WW!07-AX8(E=8NT9F'-F_XDM4\$6V(1&.ZZB% MZ,0,IST__=
KH+H\$R/'UITW#T<7_-DT\8|=Z,2,3,H:PU11=@8JYO??
@%T\EO6S>^.OB\1W0Q3K;C+U\$L.UX/??XXQ/N!S M\U\WMXTAA/YT#-
BMH/\$4+BRG=;E^47_V(>=U-WR2@Q*BE,Y2YQ/&&4JSF2,_ML?|3=\$(N\YB6-
@^Y0WV9JL:*VYK7D=FWWSW;V*VA\|<=JG(F MT\$-(&+IK12\U)>3_FTF? \HSYF@
JN:O\RM.H&-5%,?+W'\$G+.2OEWN40SS2JO"9*K86Q)3\$YD7Q\^O6\HW2/5&W'0QTE
M3U\NIDM D;6H1"E4FLY\7\PYX\POQBN;<=,I_<6BKZBI8SXMLB3G*-KJ7T
M*UX21M3)1+\$7P%@/5DYPX\Y#\$T?.,^+BV(F4-CC!C8JSKFMU:=0&8WMHWS
MYZFB0S!JH=5J!_90Y^|>;+Y">G>\$>W7CF/R;,Y\AYETCOEPBL\X,"FH5M0_"
M\I:0QNW@)\$W4!.N\7FWML4E3D)!&#D_)V9=KTS:("5JU='Q4CZP+&G+I0 M@-?
+HGM-*/G\^^\I\3\SL=7/.?RL1_VX*HO74<|_|+Q.=/
MK<<%X"+DC&XT:X\|C1|<>9U^/7C\|V! B%_JK", B\3&7_!E^L'YW7=K|^O M//Z)O?
+W_C|=OL GZCO@BQP\$ 0054%.OLYT=\$|I\VTAK)|"P^&X9*-.65G4(MZ7?
\$)\6K+/H50/\$BF*#\$72%OD\B34)LVG-'>+7U\J_U5EX|_/C-MZI23^8
M#O')Z7*24&PCP\V*._5\LO-6Q=V^+6;8KVE/'L:9HNR^8@|K_K=[WF?B.D5
MTD9F1IQ\T.T:L#0?B&"4<":X67TRJ'5222,#'RW<%&@KORYL#?1*=C?A?
%47ALGK0W3D|=V%KG)S1SOC>\$!P;|FG'W1D3'-0W;A|>K5A6U\$G!'_C M?
I!'/J%!=_YJ+*J-{6?OJ8O#FMEGWTF*K="6)>Q=KDJ_@I0Y')\ (4|>758H M3O@11M6D9?
USM'#V1>Z_R(C*)I>^G6!#JM5(#78V;)VU2,XX%\$3:D_-H0)+@ M;%I>>R\GBT\3
'F!8|A/UTZ4|&038M8L&6VV\|C(-!\$SN.,Z2,=G_|UID._'=U%7^D-G)Y1GL<@
MG\$7D9K/)ESH5U SX@V&*RN MT,3|"6CC'1_!+D\|5|&O.HF=A-@>74ZU6 MX:";=:N9?
MW3U!C*RT,YE,*OO:NT=5|+N7E",U9H\BL+6JJ675|,^'5,KL MYM^UK)0L<4_Y>_BK:
I;!VKLA,MR^D#U04S;^#;MFBX7_XE_J8U<+!'4T;9 M-B|_S-
_VP6:QNU7&MO3X!'LBN\5&7"J'/(^MZV8O5:U9UO6DT!@9:SB9+E^;M^J))YF!-
=O(&RW<-L2^ZJV5"8L1(CW\O42=ZW*!3;U MCH@V:21BFY.86V"L\ML%\$7EZL+|LF7-
V5C_I";L\$"(3^.-J63\5(3J8P, MJY?S+B+0<6Q_ (M:M6(^?&Q: ^@|%97U\KI\H
MJX<\$K*9;>99\3HQC;1)>|B8)F:EG J::8M9D>F,1:-\$T\$-V%K\$I3V(.#8-E M=,(KBP?
993O;KB5XAIT)&._2QR,WV<8.AG"(?OBP:Y\@J_Y(I^R77:_R7'&,%J9"
+6I\J\J_LEB0,D=@DDI"@Q1(&66! M\N,A0;\D1F7'S5:W*<>8MQI7VNZ@9-
*N6L:M3%:61D(IKRHBE876GWF&T-(
M=>8/%7;|Z8>E<5O7K\I/UI6+^|F&C<_J_T5VH\|BBH4%6385W->5@_.JML;A
MIRS#&=FY\&O9;\$C-2R;K"VL=CF+_V&1S1N3+LD)8MYK6J/83\ORIV.*<5=#! M4P!;S?
(RB\H^=3YEB-G\LA CV1=2OCQ=I&N)I?I2G\G;^_KS_NGYSW M;=VZA9M=OZ2
)DV!_2\$U8\$&B?ZA^,VVCL?KTA*A6J_YJL2SYH.YN.>U0%'FO
MFF^529^F#Q8TQU&@A\|S+B/R6J1,MZ9K?M?+A;;4L1:.*|F,
MM=W4#90;7K\$P^EBX;"|Q51A>O)O9JD7SBZVJM"1\ 1BR4=^>N".?Y8S-_KE M;VZ,J
5KOKZ?-VS'#ANDLKGZ1\$8\K1O=?L"_@IH;LD:.(TKOVR0B2A?B-1?
MHRUZZ,,L6'@MG6IVBN8\O\$49M0;HBUQS)4.3&(WZYDFJ0*C;90O M\|
;6V/3.Y139%D0^B*B6._%;3Q2G"P0-DCE/\$N9@|H#=#>Q)Y&L,AQ4\4H0\ M)%#TA!#0-
&A+HVUVB\$OIK0+B3O_6T6CR24KB\$2E7E:MFC*QP6BXO,*B4\|
MK,&AAAGPV.PN<0E<4OF&VA5BV&V>Z)BD_O)F>|R:9?JA5='!1+NIXH'/BJ58 MO7V,&
&LEIH75H6\$1P ?4*^!WHP/Z=Z-3E%O<)>P4J(Z\9TYE2\$I-G(?%A1\K
M%;"++";U54KK4^B*-.#VM5+Z4^B|><0A5S-6NWW*^5UX\$F+TJ+/8**\MZ'F2

M,9SO)B67\Q..^0Z"1P^G>JH@D?5(:J8LWZ2?@\$>XXM{3P5">JKP:WLAP*2
M)!W"13+1/P%K3\$7/F?YU)V/1Y:RM&"U>QI%!WAB"?R=&@M;-M!|JN@!'K+|:;=P|:'URP?
U?GPJ)<|/;>=2%6IPH-;@# M*#DBM8K %67P,K-"
#0YB&;183+4. G"1.O(>U45Y3\$9#">W<|,\$(R2OH/19/!,F-8Q0I1*=#\J%@Z#YX&|A0';E"9
MFKP8Z, &E6(T3=,P|*'-9" _POI!;?!7HPH/PQ;LF!19G%D\9Q|4AO%%GYT5
M=!'!"UQB^TO""|9AZX",V>B-E*O\5)%8XFSDXZ:HBOH*)MAGOX%BE2FD4'U, M\$*5-
RPN.KB%2|&!5|F\$(5!5#.Z,%UB"*FTB4L4G)B)|:62LY+*)YF>ZZ:4 M;<|H0'Y_#JD1\KB|
|K|M,,B9+B_K4O|N_|YXKT)D% M+<|HPD^)|Q_?N)(.S K*Y|TU->@%T#(B?
UG+H'3_4\$2FYBJ".RERY*3K'=DB M?4QLM3?GI^E@LDV0W-"_C0BG|6TZZ"?
9(B*QT>|/E@*ZR"XPR3_R0&VSE661 M3T7O4.7>:W\$S>M@ES(AJ38:+5^P1X|FC)X|Q?
^%%32J^G;5JAB@A.==%8Q<3
M_&KP^_COZU!#;XP'1@|&&"Y|GA)Y*25|B^=:K>'FAT"EKB*:V FUF0/Q'T#_M6!WW'G3|
<H+5P9*#T>,V^BZ*GT20F2"?|O+ &X/MMQ)Y\$M*!.3H8/SFZ@M.!3/U|
\$>QF|'B8OAT0'XV5?XKX KVH^\$^CX)52T1Q MIQ3)+HS55T;D-X3B^0X5%G9;
(\$MW=^,S|<= MJ@HG/,P5#\$\$.178"(O*9>V"C;Z<;U56|:22D*/ZQY1T:7844V.3\18_R'F'H<
MY|LL%J(T-O9D/3+/- \$N>-C.F1H(M|@TNWM5="K+AZ MIUZ6PE-I#|@1RT.
MEJ_O'L09^|UY.N<8TTQQT-UF*|U-1,*&"^!G4)V1"7FZ|8"=XYDID=P3H/*:.'\$;|:./%?
90OL|D)53!5'JMF-%L-:E=Q;52@|CF&W^D2N^R"*
M*H,DH8F05EP|G%H|Y/W\$B\$NV)LEWXB|J3LOD11=& 3P&:|L&<#.XR+XGF2XE?
ML^TPW4V.??X4A1^?("6)^U?8W%E,297<1'R&|5"9 5))|8O8KMDB\$K_"XB^!
M,OS^LJ>K77F;=S5/ZTF"XO;.Y55S,'DY|Y(LM|*0WR,1Z+C"-VU)W;%>9K|K(
MH1_VQ|VRC\$H5EA>#J?U3'M3\#/T|IT/1>(*|!DZ/Q5YTL,HGN':6EA@NEY
M@TR+4PA(#HYDR|><>K>B*|&0#K(+AK><^HBL!*\$JT=A(=0R7|X>8@0R@;TIX
M)Y|RN*N3Y.3+*|PZ;W:<)*MD:9X|&K65L;X62*XQP7#V,##^QH/_QVC)(46
M_(5=_XQW33F)(|>_H7=)+NNXHFEQ#=2D"QC M6|HIPC""1F|D|.PNY
Q|887R2T#AY+|3Y1BX+\$GU\$ K_|+S)G0;B| M8#HDLX"(N\$MJR%BYM6W64!
|::B(:D*R|YURF;"V(=CC#QQY*@J&VYAC7OYG M0?9Q.T(=PU U7+HF-<4._>QS|H"ZV=3-
J:&JTB>6TA^@L^-(Q|D-Z5QL:H
MBU(G;@>V!'|LWF9*!LW0G\$LF0!8E^=AYA78V^0FY05V\$^FY;9*R0L+;*U/BPAST M#?
D7"4E"C.S5LNO)AIAL"H\$)VN2J,0Q>\$R.78&YC?GMOX3HFCJK\$.+G)IVMY2V8 M:!,U141-
LWJ/3N7IAU Q'>|D(#|4=BM/Z)9D8|1O|YA4B6IG2MJ/U9WM=:8@
MWJ"P:;Y&JD,K239.|><9:F7!+|@K,ED7|SSOU<,9)8V&>?9O<MC8VMNA#@TQ(:;WT!
(5Y#7?2NC\$4+|A5P@"HNTL=1O@NY/(DD&CV\$D<=H0J|L MF@%=7\$Q&LE(\$4I
7@>9RT(U9.DCD)&ARS#&'+'-V:>EL4ZDM(RS#|'^;V8;/ M<.(?)
(I20J"!M=MCU^<8D:>7^/&=>J|LGDIFAF&.*>8#9+WK0,)M/V=WD^F9 M&|?
>9BS\$W|/J*;4G22D-BYR!(|6M|J.U;8?1-J/|F|FWH41CB7Q;ZA*6E3Y M3CGR+;Y*JB
(^1*V X;"08QM? ATEA0 M|_Q0|%|?44R3HWI^R)A+!&9,|7/=>Q<(0^FH.#Y-
!)CC&E2JG/2^S(BD9W(M5S,F>CR+238MAG;F|,|A@1:#&BY|,5X&C^4(8CD4ZH3_EH_
CI^XC9)499 M&XLG(\$Z9H|FZO=^M>E|A3
_F|EJBL%,2ACE;A|M@7Y8H*@UP!0"CTFC1TG M3)912=0'SA #(R*OW\$H%'OV"F7
HFAAFEY7FLM1R.#@T/77UZH 45N%:@P_W M(U8^#JFJA7=DA'+1)".
(X,A;|@EOBT+6FCGK%&%4T7WBH\$PFF20&'|8'F<%% M4>XQ I2@L|
T;W7>GV!0O(#R|BWU: XY1(>|H/L4XO|QW3;.FR4"\$U/>. MJ2|FP-
U/BHA6(YP|+@26!8L>J#8KUB|LNN12W"LF&(2M#=#EB+M=EIS")CY<
MA|D8T/R2M/FIN&LF+FTB>@#|B6I8YDCX'Y9NK8ZWD2%<2|*3HH^72G0YBA6
M40X|XW0I@>Y=|>?4';,T2!U*:LKTCSO:=7W^-*&-A44J5Y|T(8;(+57J;V>?
M+;+DC@C*=.9YG'VY&8'B#XN"3.SRK(MRBO2J635GQ"YC9/W^%;=38SNFMV/
MW%|X5O2NW+'(!Y'73;.1VVA#/M_J,N|E-?UNG)<023%3>)3R%^'ZM\$7I6X"
M*7L%I%2D|&%K5 @-6>2"1V0B002O"|.GYFPSSV2=J|KDQ0B%=S#VU3PES'
MCG%PFBVIB(100P+>_0Q/&4?Y+S*|&ORG|6@:'Z>*TT|64.D@R%TOS1#R|1@
M;'DN)R.7'D8%33|W9\$C'CAI7+2).B!'BW&KU0)HMK0P*G6#EZ+B=ZR)I\$|8Y M2?
T8Q@6|P;6KV(:VEG*6+'N8@+|DK|\$L0IS@5YB'YQN2L&>JIM&C')&.S8;
M/9.5VG).5YA88I?|52W.FM1O)"Z(\$>"X;
(M2(W(GBD(W6|'%@U+%92AATGGH+G,HVF2(&=N^,K*9\$-CB9E7?CL8-BR2 M?
%YW: ^AQ+%6N5M27QZA&^X|KQ1KJ.2:Q8>B|139P.7?2WBVLRXTH0YFH@5#:
M_ '\$CD87+M"8MM")QO_N2F-4/RW2/%BKJ|_\$+C_S6CDGB3'61 MX\$G+X;&N%XIW*
_V<|O=M8/:NO9W^1>|,L/9+|L2H/79\$|L20|QS;W4<14(@
MIQC'MH|)72D1%|^ (5V\$ _T<_+R\$-P_OGQ?6B9PF;#

(5YU2A8)E5GX@!)V%02IE?.Y&I\$AVO7RR..6M+2Q2DSZK[;00'M/NN.\$0BY<%K9L2JN)?
^QIS>RNR0%_SVI2\$JU9TMZ,%>[MV#X=*,).8_JOV/FNR^TK9+5UQ0R(GGBY:-
V^%!UF_J7PR>Q:F=W67#^\$-;
M!G'''G:QOB2^50C89POU)B^IE:>\$S0=%X^*EUMDMS@O/3^=G0F3X7,7HSJ:0
MMJ*D)C'*OOI<'9?DLNWIM<U4X6GYH7W3(%X=RONKFU|VH%HEMJV+=R6L67V
M:I0RND?"WGJ&_96_2DN?F@40A37%1(O5")#HIDL-X>Y-BGH/YYG72\$E^X M^'7,+ 'V9S
^N*)"!M@X+=W"VEE(IGJVHEO&%YBST7."^:J(^E0)!H.:! 'M-F113)8;-/U4IQ;-VTMU(V-
_,+)*M&QP*4KW)OCO6/2O3LD'\$DZ^\$1YS MY.D4E?-RIN9F2%PN6^E(Y*V-
V|.!6LK"UU"++0-UU!(3%J>AQ5'8[25GL-MMTUZ-M3Z>\$;5X/A7P*A&H<>CTT2_[?
%&S4G\$#.ISC7GJ1D*|2+NKGV2RA/I MJW7(1MG+ M6(*B'1*SK#?Q_
M//TTN: ^TX6^<@G,W01GZ?X3!:+>3OS;67?),T1::L2SBYI
META0:4!B|K>938N\$5JU\$=TU8W*(I2-%&/\$:W\$8_8(1+UQCQ:MOZ_OY5./3C M:"
(*U>@07GLZ"^/R\$P?-DR\$K@F?POUQG/#HS+|F\$'KU-"P-JHS"&PZUXT
M-.H*4Z>IW|OE>S'N|1VR|'-T>Y MM2B5W4O25>RP>%!4?) ZS>%&W=)9<;-G
M;|_ \$N&)P|_GR*X"J,TN&.CLW-@IEZ-&<:5.V%T%7-@7CY#D-S;LJ);BM.R.8
M=Q0TP).XM9SU%UIT,A>[:"EFA:Q|%0L&W2FJPN7B#ZO|#FSXW#Q7-^1W"S9+ MP
XH/(QR:2RE;# FB;"!6@;L_FPG(Y@2=^/ZMZ|0L>X.F=@E%G=(CI^\$, (M/(;"M69%!B&
<9|PYP)8"|8/T&38GT|063=(5GB98X2L *_|_6#FOY@!)@-K|0 M^/.R@00*]^ (I69!"
N|!%L%CV95L1((OLPN>W0&L5S.16:L3ZK:M^ ^7B*Z"J
MTQ">@F)UFB1+X.>T|^'=:>;E&86|+2JB7F:86 Y4.K=8@SX5<8L6JKN>*L+ M2|V<%86
L760>T|48:57=K@(1F:2HWC(3MJ\$42\$K4IPSEK26|!SEWE+ ^HOX+
MZ/B6?'#BP1Q|5/(\$%HR:)I=BRJ\$QJHAB=^A6N!CH):^BP'*|188T(K,F&@8S MW#?
9U<,WWXAU=-/!L'VE;)(S\$661<;:Q<;551K^&XZ:S+5)+
(@=KR>"K_WOK#!V%_9<6;K,E)AARW&>IYC5!,7X0-9/'7^ ^+E
M0)O#5P!!D9>#;&3@9T4#3PCVT& <8_>)*5/.5%0S|<<|Z--"2/.'I ^29*HN MU8A P
Z!:)#3T6YV|-6|JP|+OI9|:EK MB|.2(Z3M>.:1Z|Q4.(D-
'60"B*|5(+4+W!)/|+)|@+FLDVF@1L8.)K\$MR"O: M*.W1H"l)*
T&|9|KJ4!0"Z.>!*761_A+,F((!Z,7GYGFP|3L1PKVL8K-|JJ13BDK021Y
M;C::JLV3C)J90#T%|&\$7-4WDYJJC@F%-@WADY|EY/M3RMTN?BU/N#8%J82P0
M7|^YN-'XU8YWHXF|L>I|08_#,2NLU&-OOX=|LTH|:6(,@/9+.D)#',XC_Y
M)FEG=35%G:>%S1'IOA% |"8HE?(*H"P\$|<4V\DEE(Y0EGBZ\$V E|H|Q_A3JUI
MBT24.SR.JJ-J=I6F61'GIB5!0K4CP7.V8R#;6 =;3+XQ"NZ/5Y*I\$,UHP3Y8 M8 X>*.
(_JBQ&_O2L#0D)^0<)'ZT*7R9*?;8|F1,J&I;8|/%M*8I=R>^*4!!\$L<0-
N_Y^TGN;:K5PF:KVBFU5D(M M|B*:*G8J"*.IS^.'M19G/'1HU\$8M<4+0@05#G6
M&W(G.MSNE/J4E0XK4ACF|Y,^)|PJ?%Y_&%7!;@Y&67WR-498E|V,N-)|DC|
MU&\$KF>5S<5H04>"*BS:=J|V7TZZNM1S3J&D3:SQ'GI*"L1E
MO"Y0)G|0|V1.%*!^4::P&8I1?C<+^U-.0MW>E:(EL@-VB69|T0-6*KYG_CC
M9ZCO|QR<8-R@1_0S|C/&9Y"VDW"\$&V37F41CNRI/ICS3_|T+9)TOP&O)S:T
MEXZ_HFJG=0PMVV?-\$(#4;GWN.,IEG?-TUS|WQTD1NAUL=/_PDK" &9%'1< M!
'&|7DI*OE1J1C+^Q.I@>QS6E5=*W6ZG@9_A
+M#.1DQ"\$P/_O3>'.0ANO*\$\$(+ #X.M5VWUR^|(^DI#6163(<4F#ZTRL%>|
MATASP314C3-9N4'Y*4?Q<|90>7'80!_N;6)JP+QE8S'2_LB:@30%H@"IPJCO
M")'&EG&B\$6>._H1BBU@>B.^&BJA.@|_7YFM@I=;JH|)YQ&G8N.BK!MVB|J%QMZZ>49'8
(3A<^C MTSG6>0@V<|H)ID5H&|N:R<>EGALFCQ*F4XJ|+>;2.=0(9|&3)EILV**AH5
M%ODW&"; #>*E.C^N^,O@CZR)WW06|AD6&H?"S"*E@|BD(E9F"JHHE4#@@@3Z+
M%;M8662%#TU*N)^:'6JU>U'IJ"/M5\$^9% GG-13=B(1'I@.3YP1^;RX?
Y*GGMIZ)MAX\$|PC8=Z<-E-*M1GZUB#|7?LJ;.*-I!4L/=M M^&2E%'U4FI!>4LRK?L9'EB*
|=5FS"WKUE6P.VR/LYX.ICN!#|V>N.RM5X!-M|T(!_KPY98>;LDMT>O|Q>4I
M.*NC3N5N"+OG.^|+G:7I9'MN&>?EML-Z>CG&K"HX<|H0:S;NXKPR!="'S,*O*
M)DI4#3^XS/Y=XQ_|C|FL|E+B.RSHP_B(F_'T|TUY-'=FW9Q;MC2R)6IG16^ M21>O
PZRRN>|E=|272|=HV=7-%Q"(J>9^/?|*,<,)QP/&GYS7R=|YD
MO%|!|7!%THU(.#+AM8SNFA1KW/B^\$*|>XV?ALNR%MBWURGH9WB';L.>"Z59
MU:9AZ^\$)I%+77TXKZ\$|L7FZD1* MM/O|??&FQ| ^Y4H8:2"_PZSU#P1J|SO=CGNR?
H+Y|QA=DRB2&X%QH|M2AVO^'91L|H|SW|#&J86?GFS;71/ME@;?H_; M*|_8|!"K-
|WE!31FR"^,>NC#PK.L"60TJK/BE&E0A1;L|T*;'PCUQMNY9^O M#_)HHV?
V|)R&HA&|T:9YV%C//UUS)_*PO?DKJ\$??0W<*-0C(I%|Z0"6P'M
MZX)"7I0::X\$@=K'P=\$ _%#8NC+?D*/|/ZN|XAH1**D_OMH7WO(;X/F@_IGM,
M1;J?:1N.0:4369^ \$FY0_2KJ::,IHR-=M=FP6V6FQC|"-5L+%O(*.(&CZ@=-

MB0MD:LX@LM#%[_!8!.D]0I@A:;DY0K98:~0ND+'_#S-N)O>,:H@VD=G(E
M.BFM3Y_W|<%S7UWI-?0\$P="&V7GXDU!E-@HS!+YW?-/AWSA+QD'4,2FNF M>,&[-
NKDF39;:DL&OB!;+ 5MG: ^ U;NPVQ22 JX6)B4I\$8YT\!%<9!/*\$M M9U-) 6^62^?DC|1#Z
RMKA\$WZU*WI\$CAD.&PX^)^B:=QMY0&|:*=EJCT_ (3<
MXLT\$97=U(4>0XHN>V&30C*U9K00099)I;A**!7Q_6&.^/'LORS(DUBV#5BL>
MH(T6^>V=:I<,*?X8I++16 S99Q& Z%6-MU%>*S\$?&G91^?.CWXF75^QN|6>;
M.&>QX6\$^W"QYAI VL.EM0T4Y.RWB(PVU514.5582JSC9 MN^*@@F!M26AK#OAX_
5|4;:2|T)Y<&B*LD.H|"<;RE=H=6%|P7V9>NO)\$3N M)@=|T5PV&8LM0<,BTE:6;
C+|&1M4CH0"8U*7|,-TLW-+R+*SG^7@H/|:;
M+8\$ C>:1%;E(1&\$#1*\$D0#FY@A'0+LS<4 M:WJ;A|26_'C,D5UM\$;>.:++M0VZ?
X*\$|1%4IAP%#_ MNHBJ12|) #1%:18H.NC^L@|F|04|RU%8E@!|),90JTZ^<|ZUB6%(!B6-
GQ:%8 M\$SHKD-.ZM+\$>"|/8|**")GXJDM!_BX#F_A;-!=|0" HJ:YO8W,\$|1%C"U7282%1
MSU'4.THTJ"R2@JHJS7Q4Y|P!K KEX51&:AFW|1 MC5AAJDP6V9;
/9.ZN'CN^A3OL)"2&XR+*HBT=.7|1%*O(DG5M:BC8MGN15\$5H
MSR_(|MABGOI4|#B.A"00=,,IVP.LG&IT4VQH1^4+7B*2*D_\$|Z^_04?QB"
MV^AZIZ7!|8*H4G;T|6@4LV#|02=L?#>|X<+V;OY@Q(%0LE#JN2Z93S#.B71
M=8Y5YPL|O|JT>>_|U>:'*UO=YE*|O;|AQ<3L&P81Z64*M)88G|RM?|0?SC" MK-!;Z:<):?
=|<\$Z=0GV!;X'HVJ^:SR/6?1|?2W*CGK;W&ZQ6E>:T"\$ UVRU B8Z):Q0R-I(S^@3UGH?
27K-%CLB M2>3,T&^V<*HGUA|E#*D|WS0Z K'P\$RLVWAFM*4'WVE2?SM4-
;Z.%R.JGR.6Z MM'JJML;:2R/COO;=I'?
H@8ELL,22&WA%,1\$&V|3|Z|3JHOI0\$^+2D5U1&NXL%NV::?=KZC32S2?5-
CO;0R0J5^/U84>+N1*(M|>V96_AW3\$FQ9,4@|NIPC_"5=XCL5,SQ3_#B+-
\$>|4/&.G/!>_LC1Q:D|M*?D4=?|.??|@|HE<&-//JOFR;+RD6-'O&=AQ<*ZO:/
%_HJS%S4XF';L|H0? M/+IV2_9X_J|_?NX:/W@PRGQ(K5CZ#DFSC@|J)8C7IP0759_ \$+B?
N'3IARL9+ M54H=|O,%XD\$9Q:11%N15\$R|3KXFMPXRC^F\$355E%
|U((/PC?"_I3+M)S'*K^ M|D5)BE/|@V6A.6GG@|@|U553-E;=_080|?|PWZ82-.<9!/25YZ\$:-
R9CL;(B1 M,\$Y5QQCRG\$HLMAC"RIQ.V_;/M,3'_D>HG%2?QQZOQ%=CJ-NG>|.UL|=6/R
MH8_7|0@+8%>1:Q\$%C|5G>VGXT^QY%>2N<4.(H?VH-JMQ4QTAE2TW2CHIG*K' M|
<'95.=B5W(1>|9Q3@R-(SU800"V&M:TB\$GIC0!E,D&H!;X@#52_
*8N8D<%Q!3.S/;^GB=HL-3BWE*B?@\$;DJ M;=7NYN@.UI8'>W#|YJ|D2AWM^&F98JO|*
8Z3@^1N3\$|:"|WS=W6?93.'A8^A M#FG-Y3DJ<9AJLERWA-9XF-OS'AFCV_*"RZP>-
>|5M;|WXDFS|ME@+OWQ00*U(|5(+.#U4+>GRT8<|R|
(>;C|2Z=B)|WVSKHR6;M=K/7^J8/3 M+20>7PK2%B&DPX:6-
@EUBD#@CM;K&FE5S/>SCZ/0;/W?(%*:\$DE;:.\$PN2 M"EEG-8-|P?/JKZ-B(6?/ 8+%5AW|
@>F8_#R1|28^@=G<";T'>'!?'+(0NL.I9C MD?"MR\$96R|&ZMVAK9K(=EAUFFWL>*EA
D|3N9H*4?RF MS^|OSN);5\$ _Z5KP"3|Y9J*^*=JY5N5^Y.|C.#<8VE?%G(
M%FS"6M|N':G,N-.B.KB\$E#W'<#Y7=35|X;X|7|+2WA:E:/G@3Q^I@9?QO*)Z MP/W1
&37;\$GFY4)L4K.(A|U2/=+8K|<=R: X
M|YX)P4A2\$>B|'E+1<&\$#3@X6I(RRCM|/#%|F^5X#+|MYA)% M"?.,,!#?
GD|W|R'_M%5@KUPMM+52(?|/'++S/"D(XEXW^|E508MRUP=QG89
MTL|JF>MZR567FL U\$P?7R&B'UXW5YI^@Y(XDK,NDJK;JXV*"V=L^N3)MM0I05(
M3R=-,9\$;ER|Z?MR^NW.1|/0^G,^90|>&MA37#A@O (>+ZW<6
M|QDCH|.H;AGF"#,2L|DWQV50E'L_K#EDPA05H4)^ (MR;:4|>W9@WN+^IY4|
M6L9W|O-PG"6SK49E0*E;_C8**@EU1Y4J*\$P4TET-\$UJ+B:VF|60J|##+.Y?;
MF\$SW!+SXA-I<.*VY5BCA?@'_ (/8|XC M;YDHF^?9""11%R2|ZHGS|C7
F.K5A>D905K,03;0GOS4E5|18^62|/O.ABZD"E,R15;|C2|N>#:*S%TV@ZO#|/'
M:HQSM(2'3G4S@|S>IH8\$U9!85D)D#^+DD*|'|HMJL!@Y2%B(^AY'E|C>BQ%9 M.5?
IUU(Y|%-LYQ(NN6SR0M#=#5P!\$P8!1V;C'R=?MC-%06!H&O,*J-GD*C2!-
M8ILMQE\$LYKAC82%YZ:.'*|ADN5V/AEH')@XJO:IYOH7+T;M1G1_4B++8HE1E
MH\$>)&L5B.)<0 X8|*(>N4'N,=L."=(A|Z|L3&XGJG5?P-BKZ*W2A/MPM.^I6
M9^X2W:D)|8_L#SJC";-A_5UZ+2XPH\$ MZ|KV/2,D+6;I#,*|U.<+=8;
<0D:=K;BSBB48*;KH* ^?%P>&Z23U|CCMIR; MU^J>1#C/R=
(((*KEE&F184.V3+X@J9|E/4^NPR|)>#.@ M*.K%/'%LV/?
0Y/'F%)&H=D%JM'9L>-8PD(/11-&^|0R?@8RL9ZU|T6L6N(V
M.UKRW>@=;|JBR|>05_(3T+P_F6&M7.PP8XQZ'FE#\$;FY&63"-(!N.RL9I7|4
M6GKW*ZL@|@6|'(V+E2.+GN6J8P=LZ|F|8/99Z2<0/*R8HNB:MAWS^9!*K5^@ MBN
BE,7:HJMR=MV;!XHWJ;3B>3FHK?|(8*.RNBAJRC28| %UCW|@YFY|T" M!3,M|J/YV1,?
@J9-%W6:|Y|+J>LY2")HLV&Q,<%>!-X=-Y;|_X;|IE&HIY-

M>0E!DK"#X/WQD)&@|2+;L4'?7Z1!J
M,4_C%|9)LHSRA2J\$490*F0ATF#\U*=6TBK(YAC)"7_X@'YDJ7F*5J&&=IC,2_M?
IAW[CVR6R!;V0;;^78N_P41:8P=RM=+V1?G++1CP|+ZVZTE1EE7>LA+/7_M&_O%\$;G
DQDC"D2'B8_#5G?O,=QG3PZI2^VNT:GC4+ID#_NWJGX61WL_O9&2_M3P_9OG^E/I;6V
7A)YO)"(2FF:1/7C|)B#Y/>9+|EFF*G""ZVXQV!7_22D: MB/TUMG_RQR@UM6Q#?
O9%4QK_3G+BT+0)Y|5I/UM4|A?TPK@V,5+&Z;BIJ_K:
M,VHQ,;HJ8_*BEJ"!I=0LEZ(CDFB|M^UOMFVOGHS_'0*GVJ)B-' +3BB\$C%.^H MJ>P
GE||Y+Z|BT|@ (WS;N0NP/ZI9;J:4G?"-.W#^85ZL;3U4L5@7,B3W9;VD_M"AA\Y|BXF|,"7R-
&|EOW\$7!TL-E91T3N=Z0|CFP?N%0R>U;8LPMT>J,T|.2P
MNIX\AU3|H|QE(IV;O|#6\$,ZEBUFYVIYS_ ;CAAB3(4_VGRR/(>*C4_E_8;V8
M&V>R/M1|RN4KVU7IEP,+X:Z*&ZC|4_="ZRP4D(+@S.193;SOI(?S.>>?>
MG)SOFsYBVI8'F8%9=HJ2E10;N*%?B-48N|JER|7T,,ZL6JX-I>..Q/*Q:C|R4@6Z_2EVGB-
JA!\$ZA)W\$C+*SX^MC-L;3H\$;>UJAF0,,3QJ14>3_A2!E|(K>>O)|/)"TA&C&9?
DR\$*EF|1)X)XAH_M:[XO7#BX1') (S3+;,<>|RG.OHDH_LR2X1B@K\$U;DQ/ZJ7;FC=XYJ
MIT1'A-\$VKZ*DY/HUD=FZYB\|SF)@#_/7?="Z8CBG%.HBMI6*9Y=4?>6V&\$L"\$,DH/
MX'VE|31?LT07R,;K350|5;I@Y^V9|&0,+UP\$/Y:&:A2MINJK;#MT@"L/'M
M*2WU73:"P)G,7)(V+=|HEKJ?-J%|HT=!9L|H5KXS+\$I0LH4%_Q?W|J%5M'YL"WK@B
M8;3BZR+#32,GQ^*|T|UCR|&EW5X7C&^TP@,DVY7Q4<|KP->A;3KQ\$Z"B|S8;
M|&*6;H6QC;I//BQ64K&^#|JG%MH@L--XBU(B:@=|6=F|EJX3);%|8YP+TQO4_MI#A
23FL|YLWA,R>X9;V4#?Y"U'PU:6"Y9D_6V@YMNWC#\$K^/9,2A149V>+N
M;B@>"*1U10A17DVILF3W1#ELC.0401X*^X<3:50&#<9AP)BR@59-<:V_-R
M=_B10:ZD=WM82E.52\$&VIVJS>UIWWDKU3)K|C7&&,6MSQB9V_Q33L(65K|=A
MZ3LN^|ZULY4N/O5+|986-Y|607(7_L>4B>=_:P<_MKVV=OLP8|.Q2->@Q|N&
M(GY^Q%7)J%M4?|_Z1?6G+Y'^+2A:-32\$R-QBSM34B>2FS(0X=K7")|ESHJ|_M&T4
+8"N3U1A<\$Q+WVS5NV)>+ACG")PB;RQR.@L""SG"(*TV@)RN53.M>H8
M/^#1TXG>9.KQ.PS'U2B&GF2YD_O\$|+/|HZSZONNIXL.9A9XZ_YV=OKVJ?,C2
M1RL_*'H7MIE|O/1_%.9-)3(I5QK3CQ(45*A2D)NI3XV0J\$|ADJ"XQ?B>62>O63|!5(>?_M
(KE#XHE.+2;;D=LX@G#@W0-I@<,T@B:*>YX+O1H:63+OPO_T:'>_.3LQF%&_M1U?
|&_D+A|@2|F9/0@'4&O|D|. |MKNVE#OPM_5F5AIR11NU)T,A_T_B@HI/A_?
&/67/4\$,1U!.09A)^#*PR99#Z_M_""^FAA@J_K3CL@'""L)C1RRKAZY&E>F*-
CTI7KYN954B2J'W/5(T:;6I0
M*JM|VTPL#G575W45H,#ZF,,S<|/:#3=3'NZQIXP'/XSL;UH/W/F#OS_ZU|4
M'YG%KDL|H3B*4@2;6# #I>HH=+D8MNA,ARH2N*Q=FE\$SI^|K%H@?X%_7|H*%
MV=#\$,<(B9PJU_%2)*9#V>\$|_@L(_52,+F%WI&)R,CV%Z486|Y("466DQH%Y|
M&L|+Z%J?M>KN34\$1_8UE.LH+R&R((DG,><+5H_.NH5O\$M<<8>|B05+X1'B-
A26&.WPD\$CZ0+F9_M;T#4FD|K'=C^T|':Z3M48N?|V%L58K3+N_8|SX5'V^HS0Z|>0;)/0-
0;#N?_M5DS31K:|I7"ZZ78)&I_:HW1TNPI|!'B?4A^_H681RN;|X2L<9/8JNW\$P:F)*
M'1KJYF+"VK^26C-C1EL@JOH3IVN5Z3!BE5MN&>||/N2Q30D_M\$,|UJ\$*
(0GUH0'D9|MA"G2>"|6BN@H%>.9@UM_,?N<\$QF4X,;ZCN"|64MU^
MF^UF3SRH>_2B|7UC=V_.5'WAOO;)*B\$9M2=/(<1N_W9_.59GVZ'#Y5;J)G3KC+9))Z'6?
1B%|T/53?M,M,G|00.<,_)|CSHP)%W097^4D|O32++T|\$NQ=_6";3|M43+&RL((&%\$>=
+;6_MJP?*H=S'_M.\$AX)#*8=4HF7G>-R'I,5;W-8Q@V0T79\$;LF++1XI>4_-V|JR*GI&.2S?
&@Y5<=|3_+/60;VJOD1%JKS;H4RV3.Q&|GM66>#6Q6@_#"#Z*L
M4JEC38X8QO>T2G48J5H3&|+CK3&49A*F)'^"KA(@#<"O_@9!%1IVF5L|GW
MH7=08JG!_T09H-XCK+V!)!1J;"S+266<@10MD55_C&(R:
M(J\$K|BU*.#3/MG|5WB@67'FPJ*3V'#-7LJC6SK92K12?F33TP-4HBNLPBQ'Y-%:\$&+|?
R8F:@5@:A|_*S^40;2#G:ZG?&DMH(%G/'EB%
M(1VUVK.&M";X6*MKYI&A0K*MG4U\$9BG|K6P5|PSU60(8-T@(|80L-P@FP.M_N'V?
5%69|O6(&_D3&<-6V3-F5OB<=F&*>&?QBUF%|0V"5ZEEBHJ)7T,G;=6
M!DX7R)MLYVJ^1.)Q>)|@F_:Z|&/(WOV?G+ #;R^:M'EMMU,W*.(0=V7YGY(
M_|O%5T^>N'H/3|YC6\,Z=4/*M|PL7T&O=IOP#_T:=JX5;ARQR?
N9@WR443MQS2013##0YK0:N)Y_M01WY|_K|^&*ZG?
|SCMA?)4R.WSX,K9A^BJP^%%K97&|H_M_UQ2"M#/62JA;)_M-#B15|^55.5A!.40CQ%
(.65'+7&BYX"?YAVE26JZ%4"1L'O6U5VEP5ZIX<=,M0Y_1:A2>VJZ(EYJ'#ZS7-
QI^K;=QVV*|'2F?K%.G2G'FX|I*G12*#B_M_&E2/>9OLKTW)'_Z8KW(OW_MPL=;L5)Z
4M=YO|L\$0|CR/2>ZGVW->27ML8_ME*(@N)R)!%SG1N7N*3T!'P*Y|HL@\$6TYHQ8"8|/7)
I(Q54^77=Y_&A'1:^G->MTFCJLO>5.5+.YX=/0,8A|S+YA^W^JRHID15|/':LC|_LH6
5#:KA3I%OL>R5_M#(W:9<5CK>A,?

+EI+C"49#JK&^ZI:@6!FA(>^FONDZON1@O?/ZL[F59JJ:S M2U:S/54)E
A.=NJC\$V<3\$TX,\$S+W9?+P#0XCES_"&,:@Y>V(B>G@Z*A;0I^L
M<+9PWCE=JY=7&\$YZ:!/&/MODGCX,/?-E^G\$!Q=(MW)0VEW['LS,B>SW#CYWJH
M\$MORNS^;VG=""+.N!6Y!\$%A=J50%9K["FFOSGO2,JET9(H4-
MYI#/KFOY+AAF4ONG.SPGI=QBI:RV'80GP;5B9\O2F'4Z M0#N=|CWZGCAZH0XI#;
F+65'4 ;W|HD!LOT3WH%Q32*MF9W|RNU()@:T'@':
M%ND0R,&159BK)\$;MFCB;BHG"1_)U5_F-=3MX!&GYT9ZI/CP!52LM2ZMJF"K
M@R3H!*6="(F|IU,H/2AMJ&X.*!J.3S4;:\$.HXP>@X#1U_+(M6&%S&YA E!\$D*.T!?
^# '3TSO-=+*M-;;E< R/B) ==DV2 M/@N_ ^%KA|L13>;?
+.826_U,3J1ON4&D42J:=P1Y9C7309>"|%50*L&W#D\$>|
MN;2"6F#%/IYE8;%1\B7"G1R7N?;<(-8OZN1/!'-&K8/"BOJ:/%/*|^31)-8J6 M**WWZ?.%
/I#X3 NZ@FKS,4CN5BW0_M\45WGN>3SO44V&#+EL%5-73-\$R2S+
7;:ZP58JAW(G>XJ#"%"JUQI !|OYJN&U^)|YFY.IJ|P #.9*L5W;Y"=V@V61XJ67TW M1
(I:XR@Q8LH:7CA^1=)0HWD@#G373ZJ>X>58;=U>"7E?3CZ"SUBITZ3LS;
M6(VQVH'VW)U926)ZAO=#6/?J;5SZ6[9@">,043YCLF.GI:LLJA3E|OHL#
M)38L3OTO|T:0|/(N M)#.7X45%=-0G!QJW1BRY0>|%G-...*5|"G^V^:&HMB>*W)3H-[D
+|9ROV7E(-M2/OB++T>A1\$489|=#&)Z?U>9>SIC|XYR+*A;-I## (TY-I*)X*SGS,)1_Q/
ME=;#3SS@22C/94\$@|EC|\$6_#3FV ENQ!T32ZM |YAQ5TCR2Q"S"@+/%#S-GZRF
M#7E(HBNE|/G;/%=&|K;FHEHLWSD35N*S7IOP54,T"F\$|VY5_QY#MA+3I;#>W
MGO5&_B3%;9NOV*40S5O*WV|,G@BI=FI3_:Q;<8Y|7YE/(X*E1V7:B.MI@Y
M&:>3\$D_ ^@)-=*QQ9F=!#?;/*659\1JPC2Q?SDU!|E7".I"-@*.CC9\3FN|<MRM8E-
;K|'E:R73;HH|%\3KG;|96%&/K.Q%%;@6R!B\$NG|HJL45*>+A8[5D-L MJN<|L4'B.H7-
*9|Y=&>Z2XRQI|= &*PBXUOSIWGEID;Y1/QBU-'7XQ_03A MP|*%(=F==4.7|@LT?
_L17'8H%8@ (O^G5ZJ7S-I/^@08UA/D
M#Z|9I\$ _2W|6P"%A.VWT"|#0BKT;YL@SUMJXL1=?;7(LTSJ6D*"W+-*_:+^HV
MR|E15;^9P0U\$X|UT>=F=>=?LO?I=-=P?
MA:B|T@X|&4OCLJ)42\$3\$/S4JUP+5=OUM/ZA|Z_DV)JA#9&=|!_ =XOJ;E
MH,5P8,|D0OI")%|:-G9A95(5\$P|HC|KOYY/(DTB_&+48Y2T&R?)R5B=7E\$
M&.W+|^"R+XKXF1??\$0;\$5YB_'U447W.MR)NUN'2L1#VH_3TPDRG6;.8 Y>>L
MO_:8K|2"R_L%J5//6Q/Y;""T_-J*7P|R7>% T/V:AF\$;:3K5R+OT"53K/?
MB4K>#:W<&D>VO!M9S)RK9^7Q0|WD4J5':C?75G-DCY<&)|E/;5)M7"T"YQT;
M4K"0Z&?(B|_HY628_IM&S.TPGAD93|P.*T8EM"KDU/K&L*#43-//CORK65ZT|0AV
M:"|_2>4*=.W+M:(#"A0|S'!3.#LU44%|_-^8H&CY'%=6QZU<YA%,A4^S# M|Y*QPJ2)?
&WO#&1/J5% VG':Z8-Z7^/!: JND820_MVLMO?' Z0;OVI-9>0:66|*TJV\$14C/S!1
40P|NEFP!SB)6D<|"W17|*J\$>K M^I:|XUYSF9|ISF|;=)%Z\$^-D%SF>;,9
98/VXU\$9%;.R|/S0\$=V4YYV&2L@|ZR> 3I^/;+>K|8P;DS.*!P#6.U>C
MQP|"0#SYM@9&M'YD^4@C8 MUO|4 |H3|";#!+Q|>Y9M8&O?E:W|M"2S1K2';
M06J.8N|Z_|+2F @?"2?@+-3Q|S,N++8GN1 SU_2+54X17|J+F-)U5DJ^J5 MM;) (J\$!
|F|K0G&:K=EA3&WHC9@=BMW;!!|5,K|19KS|?BX5M3'..20SC!/?<MS,"LI,G*U
)2/QB'"7@ +!Q+(3A&K?
=J4=,2*X&*\$("I&%;|0C13#++@7G/H'@\$|HG(8X^1"8+P=M=DK5\$YXD MHZ|_ ;MOZW4%F
(PT'K.BJ7%72%8*L_D%O89F"F-SP6^U|T;,,81|'LR"2= M TTFS"412R8E|4!A|JUF#|%0Z--
SF@|ZEP*)F30|BJCHY(^#EU90I K93,4 MO5F!GS;,"P|0PA5UX?CFCKC=.*#\$K1|^M-
)"F9SJ@6Y^MZ MP_*BAGT|33'HSZ_#9TW@0IS|I<|0_DL.DT/TZM)3*ZET3>BTO|\$?
P2D&F4!\$ M*"TW2!& D%|\$UY"JZDW1OWW(!="|1(H>0BO.!(T00-<+!G"A+|<|<=107P"
ML\$U,(M7/2?3|ZG'"O|K:LY6RU_+CYL-4&Y|R.VT5TCA%T,GE|WRU#L.+&V/> M-
A^C8ZP&Z;XHQ(XC:P?YWHV+?;\$|H^.:1Y|05X_FJ.O^/C|C.HTQ*AE8
MS!W1QR@A',8%-6//4@=N?T0S_G-@\$>O,9%I7J@QH'NO76ZU8"5>;:H "4**
MQ+&B^&^|C>|9OX+R0<0+Q_/J&0OYI2<,Xl.9TZE.F+(!04&TP(8(Q0"QHx(00
M'+RBJ;ZMG&(B1#=#H00|;&";^<5_@
H(1)VH'5DJ0QQ',8J2'\$G48H;REMYQ_*A,% "K|T4RH MB*CDT.GE(X_\$/:-\$W?H&Q|J
Y|DJA|T4\$|L1JME?,L4Y'.|RQ8VM|Z+S#&?0Z4L8L
M&&#,JVQ#2"1VN'C9|W9(")A8PM6!*"27P<8L4\$#&GY?G+C,|^C|+I6G_Z.YOJ MF48-
O|B56_NI&BJ_!AW:%-_Z!4G5P|G0#P%8D%*=X2N!M5&B=.C?'YB&- =|CAN1.-
N&|&I.",VA/J3B%?0;MA M_OHV1Z'!-HS'29/?3QZ3"D\$'OI21\$Y*225'MBGZ?(ZH/1P9???)
/R^/R|X MO_6'2*2XX6|XP"|4<>;@)O^KZKL&XF%^7_1P&G#R|P|F)4.?E!>_.@SD(4:
ME5O,1M_N'R\$)6F9:JT&/O.W\$@%\$3*CQK<+UOK#;_2|+M*JL@A*6N.BDWX'P M./#R
'3|LAACP34(^T.A^Q8O)MTOJFJ-P%9MCD31=.2'^%CCU&8DXHA,#

MC+%9QFCVBHUM6H_8%[M!J6HWP<>N++@!-/AC BDFS1>30;0@^/3O-SE)V@# M
JL:Z7M%("T9P5\QIF<,.DE54M(MKEW\YCRX:A("ND<6;.SK_-V:Y,1E0A@=S
M'@05:)4M/V41ANPW\>7^HG93<.:!5&[=\$*;(7W_\C+UD#I_V/JC54LKJ^6M9
M'44CJM<6H!::\616?N&O'
M5\$B%KATU9#).S4?'5CA7"5G1K#DP(G4G^;I0\J\!D<_)!1IKJ!IZ\$MEG47-MZN-
)^*IHZ-[P.+CR+\$7P8-O+-\848U WE 6=^Q6W_7'(X8KKIN\$#2MP?
VDX?.QN91RT7M>^@2(CT;Z6W\7:2JK"[V"+KX) MS=R-<1-Z_?;M'?:
<)^5*%7/I+D9/7QE\6QV,71\UC01L=P-'%)IR!Y\$ _U-%04'6N(TEA%I
M:9/X!%I?!.CH3Y%O*,DRUC00@"I_I=XI:KQ.(MK*&N(#XJL6_B\O?T%KEBE
M01A^>DLL1J40"RD"W0A=B+G\H0S,MR>CB:I5@\$9%2,=1&\$%E-
C\>*4QFLJ\$'B9U\$ECLS!&[.J\5PS&"M7)HPP8>/F>%E7/TP'.3.^KF>'AHU\$E#&J4&\$
M\BKZTI6,Z^;J.%+\$F^@M^GD)%D/LV)5P72'3X^OA;,C6)X"PJM.[;D5\3R/\$
MF\+ICH*/J\$&5E73' B?NFUN D<@5E;VSOW*^N<(I,U4XHS:'C9X\$GO*Z7?S=
MOK;K\I!ALEJF6X!^,(#-VGJM>(H;7K"AD^7F_?/3,WR::3;0--9%V*DU#!Q M N@U"V-
(;BBQ/'DU\DV>WP*Q/2W/U/UE."U38<@!(Q_D6M\I/1@UGZ,,)I0!S
M6O*9@+,VZ.X*,D6NGKUX3IU4I:23@&*2L6/)WR5O,\$1U_N3:2B=W PS04#0(
MEEY7"#/4N)C#CA5%"U-C'\$/OB7Q.ID1>@5%5;.!\$94U/#^*BMXL\$N?%OB\SI
MJ'=B;"1Q\$A\R^/53?NZ6)" +=H62.%[8(HOI&>6W^LH""4\O(^N\$"ED*(M
M8:N+.FI:V,/HJ>L3YV6S44'Y 'HRY= \$PY\J%RI6*&"6!@/- MN4M'RP*\$ (5!5JMQE
9(HL4@LI=*.:->5L?H9X^!1S+;V6GT\$XR)\$AJ;VW\T M.N8I!"4\$7)FJ"VX%\$,-
!-4>>M6J"0<%48J_WQ), PJ>4 ##=5T_7ZQ)P&; M?N^M(PT'?
CUH;?)R295R5SA#,+@D;_X+K2MW MB_19J\3*IXBB@+1HU=[,A(WCP\6*L+8!8*?
W\I2+3 Q/_^H@;F""+9Z\K' M P>/2AJ\$XCY\H9Q0*Q8C;>;<)Z#C\O)T:Z\I-;5<;ITQU7"Q?
REXE?_HE: +U MA\N4=/O:D4?0<)>SKC(3,*B1%+N)) *3A\YAU@XPI
T2EW#/YU%&\$BB7I/'(P MN:Q\IP7(5@@/N;U4T4+RPM DYGOBO@QR
@CDFUCP&V%IW*.C#Z06\5*_0L.\$8S MC0)"EGU,OG -TDM+P9JUJTW99M/(N?L+8MOS
6%M>#<164_@G M -A*0(G;O)\I;ZR#^YO\ ^IG7B\NXDNR?
I")%7S8%_0D?!PIZJ\+YU\;4#YD MH6"JWHB?4L=5\@YBXB"QXXV6*.(JO\$92;0/O^>!"?
BC"L?V1H:'1^\$^JUN1 MG"93\D5D1&\V_ =2"K#0 I,HK!H&+_L3H @X_X4Q=*'-
MZN^!\NAX+HM4*066YPCKD1QI5) M#<(26L0C2;*V'7N(*I_WIZN+3+SA)02>@"/LD
S.Y8?)*Z^KI%?)5 .V\3IE M;3K;4#1\9)@IB)AJQ7/23-YH#S/#3K<&!, MX6&_="
:&5JX0303-I>J(V/@UZ\$,*SP NWXC M"CYM%H+OXH24:JH-
I5ZZ&I@620\CA>3*UE\A_MD*JYTVQ:3\Z7*454C+ F
M\JY\H4Z\OZ+)L^N\IS=JGICWY4U45I8+MRS =\3CM&3EX>YRM'HBASQRU
ME_"\3BV/Q--\$(\$NM;9=.#;2*3I&U7OY\IV^//PWK\NIC>VWG:Q)\=[G\$1\Q;W
PSED'6)_J,T?^HV2,VV&:(E.\$7/-\& M#S9>MF\$7YQL"IT\LE
S\IRE\3^:W*&=XSZFZN%V(7E.>9D6\L,YF\$YMZ?!^@ MDMSOOHEU\+HVI>IW\
(H!MW+/5%Y?8SS.BB\YC/?JUAH
MOD04^TR%9=&B>-1_JUJ7CV'KH\$R^04C2=^5@+S@W+HM6-PV;\$ERS_^'H_@=
MA%?/0WR M5I.RW\K(TCV^T!/+UV\>_L%;!GQG%AI(:Y<106LT2
M8=4M9YM\DFJ7Y\W-IU39:_L23:2;L^8F)_ (DQ_6\0\F>=.YGI.7&%@%D%B"M
MU5)2\$L2=Y"QZ.QALQ(8)VD9Q*B>L#CYAQJW2+=@UH(S>M1G^%K^=#7SVR>?
M\ZE51S)-3Y6M/R@EP\0 M2\IE(M#6B*YN&JE:1R.H&+'Z.""BPY/<@&PRL\Z;PDG8-
*V4;)"KFY4;43(M2\$F"0\&P!#NC?_WM8VU8.U*9\$)?IP<"%D5#ZRNI(CNCZ\DIH MJ-C-
+;&?-D0W8;JYC;7^3*X:C=LK9
M!;L>+8)XY\ICH3S\NYR>/W\99QR#SO7=6H_M7*K3T>I*J9I9Y+943/A.%VHV
M@5P_*4;L;%/H9R%!U=\$-@0YWJ)"@P6WP^5V_SRI#HK"DY\1H>Q_Y
M1*HZYQFG3_"J4%B_%\CI>/QW\J5_)CWZX%NQLU%J*Q-P\FMS\T10\!45\$_M M\B9"*
<.:>1-X.MBNZM^>DGC&K@::QN7T;V,B(UZDD<\$_IDY-2?5\$M'7X+Z?' MB
0^ROO,%\R05;/5>D\$;H\IS?0+REFB=^2_NGQNO.)R^2(P
Q@6+;MEX\#**92IFI4@=I M%>KN2:B M+E%SYENOW=\$HR"X-4H1_"
_V&K^LPC:.^>1K?4\KN\P6\$_M8JD@T08!V%^ M59W\V0>M :=*J0A(ZA<7UN.?
X7Y=_@?WJ6\1B)XE.UR 5?>&3%7"Q\!M?FK MKRT=M2?H,
/QW.EDFX#UU7>P;;ZT)_*L1+K!-;I\OY""JY3 M))&K-8?
VC"RO,X4U(DWR\$ZD7M77;@2MMIW^E.=@MR#88WGUH8/."I.V2T*/H
M&IVG'WY.'FMK^!\$>6Y6/Z:A ME;2 @1FUA/\$V4AC785BT?/59>T/>BKH.W P\>J?
9DVU&LZ;"-DO8GG3T M>GB03\!%-3ILOS\T6-X3NW9L1]=C0:EP\20?
H"7/;.#,S2:_BF)#W9V_'FU M%9#DU^M\!_YT+C>(_QO^OV-%%1H>7(!:JY-#I@A#\$S?

KJ==(J-J"4AK0H M_&DSZ*RM/JD;71\?G10=IWEQI.;B_LN\$ 7U\$| K
"&I>|JOYW;YQ+P^3'?% M(Z%*^A7\$3=[SH]1-@50##7KFT)_|
|,Q|HTIV="FT@>5'0MLQ|>E)YZ|&|YY< MLVR!;=U<""8|FK?-5TN>
|B>1)T|J0'P92B0)P3%I|M2=RN|^=MATYX2S"E|K MY*|>1&P(.2|5\$9P|XZR=A:ZMK
MK4AS#GQGCB1X8"2+_W#92_*4# 6A(3Z\$1R|8-^| O|V:*<4 >FHV^9|TO/G+
MFU9Z5 _|V&@(TS 646+.7@?DG(%GX-ELZ*@L_|!#6;%TZKBU+,SLXX)HAO=4C
MK>5F"K0X!=Y_=-@(YR_/W5X^3|A&6J|Z4CG!1,\$A|J90@GUAB0AB9<-|LG@
MT#\$\$C|02I<.*XT2"8|4REN7;CN;?V&(8C @8PUXQWM" |H|:T6559V|,X\$MR M;F9T2"
(|X%F4|P.4-U'?#EKNE|_|)0E0!69W"2-5^EB4Z;DI!R;MSSOO'@ MG8QB'\$1Z?
@=_|/*C@7/2GU|X06:0.3VH.0\$@;"2AO|6GTF+&-2LG/C M?V3Y@SO|?G4G7G^-
WNXU"V'P|T|L;(1NAA;X: OZG6|I*|4 FJS|! P>_6+I M&-C%BO1|KGCE#W?
\$84\$\$(|@2E5'E4O,HAMZ0P6A\$KY,H)"|8WU%A9/E-OV)<5-H|8R.NZ%F-
(|0LIGV!+.IXY5<^9Q_QNU&63<)Z0S=6B*>H-(^%OK&I&
M_#7)A"B;P4X2;73;Y1FG>Q"F2X!U2?GXY_OW?R-M^0@A=:+MM1HIF.,|,8NBK2
UE+'@WP9-N6A MH?2U"3J(MS\ D:RNOG.D3;67.W;8|!G>.K-UECC38#64P.8V?
PNRLC'1J44 MWA)>E)T)&Q|X<\$H_:L0WN_ '(WJH?EVX|9,Q>#=#ZHCD0#Y^!|+;|A9(N;'
M|FE.DY0YBH;P#OY;>V:H|65MYK=;3>D\$K*YD-BA)/7'|ZR(XN!F5E\$W3Z3_
MQB'>PXHF1L+14Y(P"NP; %*E1U6^;W3|BK#Z\$U"E:S84|5)T;|,0P'!B-
+&JV!FS1U)P*2;#A\$OQWI7^&#|
M4^@MSXL&>DJ\$|J;0Y.>PAH,6HZU2*-.6&F\$X|!#J,*0L6\$H6M(2&0^AX:7*N0*
MY%IOA:N4(V/=GIGOK)'S+66ZI,>G|9)9|&C=':XQUF?;M?_>%>-(5.F|PLT M\$8VG,S^K_?
DG0 49U.DJ^((G@EN"E)F2U\$QIPK,6V|AC9N D^X|OK\$*?=.)5 M|!#ZZ7.#
RNL8*4Z\$Z#O?M76_VSWB@7R|CW6^|E|!|7_97K& M L(G@M/
A>^|QM#LD90,%#|L@UV!>")!PG()Z M^;6^@D_,NL)3|DN'YP-
|R%P*P^VQJ%3J%/L3\$.Z6_4_)(R'\$1|?..|!"DU MJ'A<<*<
(^T(9^P":AQ^4@3ZZ"A*5CM!\$#@RCZ.|40Y|R11^LAP?.9H>'F!I%/ M!WF4|^S(T.Z
DA=WHB M\$AFG;|!)P7?^Q;,><@\$X#*4JR|<,M|I7Q4N/1JC6* M/G|D9-
U"Z:KFZ^|5AM<\$?3=<&YP9B|-A,?6_:%7BC3*=[4W; MAF%YO?!*?|
FG4A@\$"|KYBJO+OH2^"|QVW MGMZ)^1!*E_HC?,\$E*3=5GYKDYNW=UD-
,GYV,YQ<3L-\$LNE+SS+J*189A"/ M|D;,&PAMI3Q|)-0YL>6&R'JF8Q_87EB^-FP
MD=VC5VY*3M.:7!VML"Z@CK_|JC5H=<-2SMI3?@|L.T!>;Z|,^);05@_-+
MJQW%,|3@V&|=-)LCW<>UCTYYD82MGV>8#00|CVG2A1:;#S7%XHS6'1^
M**|5I,V=^KSSM_*^*RHFDWO|CE\$42|@2;6>,U|P|^6|O1+KDL;TZM.ZB,C
M#|#.|>B@7B4K6|HP_QUS%A!CEU^WG2-*;U E(M5>(|QR_S4H-O(.@;(8/#R@
M|B%FFIT^V5@4C>0A"ND+I8>_\$|O+|QFS|T3G1JL4F F!G8+MZ-+0KN%(->M-
L%P|_)9/E7DZ0SM+|(7HA?=#<./)!+UD4!;/?'=:(5=FU8\$,<AG3N
M&G(|,DK,T3R/#K%|J5'K<=A);WWVY_W=BO,J@JW2,D6;|!<=?9<5?@94ITQ MY-
,7AE'6ZL%CMTZY|@|;CG_|_XS@)R_9F;.%-)V4*||=|>|?GVG,H2;(5>U-
S)K.M,2&O%DT'=6H9Q0=2;+4^@R MJ_:\$|^7@S07R4'HGVZ?TB5Y.C5@N)">,IY O
MI:@|*?!8|),##2X1),9)&FH53^R9CCR?@-M<9P&>B|9XS42;T+8|F,A#*9(3
M:9<@OSY(HZZGNTBV G_OHGF_OTT#0^4V/S2CNCW=HJ_-JH;0?B.3!|6*6-#
M";0W/I@WBEJ=35#AS&BF=LMRGTH|M(%YDP^QD\$@"8RR2ZDGQW:^FI\$WC5|
MAX 9;RAZ|N7N75D4%J4Y6C@?C/SK^OI3Q^|LA0P&1RIU9_M72T0>J#DK:&ZJ
M!_7Y(I!104\$|>M+%;_B8CYNPO!|14 ?Q86/R@Z"1RA6RRO MDW7CX9037F<4+|SY-
%C,*^"!U\$P?LR B'V|5WOV=S@C7VXE"O11>@%"5'B M4X6:"F_&=H&M
J&ZE7|"YE;;GPC?/I6!/-9:1COB64%7%/|!-IQ\$GGO(N|50
M.0=X^L|_|@!87*0%.#HJZ\$QR_T|6#;|A1 M'|T+
>|IX4R>0|^<^'5'=:QFEKSO2R|9VX&B)6;Y;|4L7X_)%6A"5V:Q^9|YA|.(MS9K?J8M>A
9%#VO&?W%BD8H-04S:K|G"%|J:JM\$%M|BY!;Z1CA>+\$J9Q"K;
MLL3(6YY7ITO|U+^WX_|BJG^?2C@|*RL|&.;"!X6DSN2L|LLC@=-,;>(1^EEE;2;=-
#NJ8\$|8#S8^@Y6P|W+V;^U MRA|3-
FC8=VVV+63>W*MS\$R:&0UVTY|Q5Q!CJB39<_93@29?=_?H)|+W45!|3 MT;|_|.
D,DR4:I@^5X0|@ MA <# 8"B@\$\$,C_|VY4^?_E|3@U|_|IF
PC@_|UT7W7X|AW|1(|VQ^#;A-MR(|ZPQ#_->(HO^?
VZ#\$_U"@V@/_CJ#Q_XU00^SG>M_&5;B|WQ|Q?|%I_|W M_!;*(S_HIB15"5@RI6PH
>E17B@!5'7=JD K_^;PNFO%4)8#^_%R^|=2AM@ M,E\$Y8)H?
X&E_I'VK^6|,|OW"|"T|D/>W|H|\$_LW ".J+\$8ORSRS!_Y+RSP* M?
Z8#51<)70)#!JD\$"8/^6VX XE_|JX|@E|B|H,5.=*2'D_|E /\$ H#@_|J3 M@-'^Q4'!*|A.&&.YW

":*^8T\$.4<@/I?"OF7X%R=@\$CP6\$Y^0"1TYU_R@\$P_M_Z40D+(I(YR2!*XOA3
)%<K79_#J-S_000"7N*_>,"/PSS"&U.(A+MJ^0.X(@6W=OC?-
B2WEOB8"MRE8\8)E\$E,,_X@##0#3_J,7D#A7S\AY?ZM"K6@_M?
P3^_X_1P^H?IX\$0_IK33_D_0YTH#O",N@^\$"9W?=I40EM8,89_MK:H"T5?
+6@FP+Z0OF#CH^4KPE<7ADW+88Z\$.V-9I=D\Y'R9,2&M,53^I@2!MMB+
(M&D6^+_I2P:\$T\BN\RX6M4/A_%59)@2VAZ<^="OS\$[2T6P:#_E2\$<M,^B\$:%=_9?
K"CJ\$<1^Q>%YLAPFC&>,0L+9-(?A7L_M0@*)KLIU%#&#MY?W%?
3=H9L7=A;_?"P2():NOR3W\ (BOVI(^0IE?T?_KE*(S!0&N'H
MPA+\$**JL8AA%B\$[4A9V)@:P\$U?I#:&MZ\$K\!9S9B.25.(XNG>2HAZE_MTZJ-S*45I
I'X.)0;G%\$6D8;X@.UO:#E\A6J!9_)#S_M=FEJ>T_P8GX#\$UT3NDD^6\$,K<833M!V\$9(#-
IF#*U+N536T8'OZ;0K)D2E.M9)5^N_#;/K,45FF(7&'BMZ3!#LSFX
GS/H6QJ:HP9L\$;LW3S1\9-(Q#\$GJ8R_M*\$^:B"B)ND9LG8SL^3CP\$R
:H%*P"!T41@WIO:-X>#"\6&)L#[6^L%4ZJR%_MG?DS_OXUT07FJJ88E)\L<21.?AUGD(I)
PB@RL1P#2&L&\$S0E<*35Q.@9V_M>"**".*RQ!A?NUDS3>R!)3!X*"(@
@2_GKDRJF*)/*WIT&.!X_M-Q*<[0#99<^3J?5"!F=Y*W1C)F_S_9_FN4_"&=
<7TVNV?.52@&HF.^Y\$|_S_M,58.K;6'BJR9?Q=<"\$2_9M7=H8S45D-50;VA_
H='Z\$LL5U>XE56)T,PAS+_M&;2)'S2Z3_R";+L\$>|V1/Q33<+W|:"F0+;/WA\$@AOPP\$.
<)L<@42:BJ""!PP_M:K1V!|C=C_W@%"TBPIYI+E^@O*V%)2Z>")(+:?VCX3S/&
(A+947UFUIWGLS9_M3YN<#B)8D%2[P(:\$C#2%"";)8!O6W?R4.L!\$W.X)\$#9-
!YOH#T\544=.WK1I_M\$^1A\$FS0NS,D_@*3;#\$V%?@*./'4,@O
!3"JO)RVR.,^JH2KAYG4HU_M/W8Z;JISO_"\$PC2G5#O*)H49GK_XU8^<>.-
NU)'X6PQ_4\$!G2#D(R6Z,K%AE_M+K=0:#!Q'+Q
\$1,@I(5^V;I*AIE4RC%=R?:RD3/SNR<,U;+0?P&|\$_?;BL!*@\$9N,!B#NO_
J:.*O\$EESH#4A%R)HA4#4E|-M;-|-Q3^D_M'8KN=5W%Q.4H2'+:.*0Y#\$G6|C:%!
I'#\$IT7\$#HZCZ@DC|W=U|:=S&UE(:D)5@_M.WE:S+?I3,&)
Y9X^L%VFR55U=2R!^!H2\$@|X@RH<&&"5_K:45-RX:\$E3.L61/63RL_MLN#TV;<,-!;
<69NO&!&F:DIQZ)*0,HE.4'0(|YP"+Y_8(Q|++N5+F|C7-\$E37RR@P0P<=4^_|ZH
MAL@QV!(EM"ZR=\$5C>?I4H"QT@!8@_\$SXVI0Y-P?OG8|KK/4HE?HPJK_)8F
MF9BU=1\CAP1ZO(OG62KTM-"7?"&3E097P"Q,H#+Y..|!|QRHC^=G'=:IHT"
M57G|AQN%=+MCGN<4LX9NF+-XCVD7!"4(WJ_=R1Q>I"*447<=G_M;E3Q(*2?*2-
I@"K5_4>R0T/5'5[3.J>U&MW=-\$1.H_WR5?9XL4MD;8C>2*J_MWXF.JBP4&94QD_D;8_R-
<&*IL@EK;JM8U%A:\$I6_T,BUO71H&^\$;(\$J-O9\$-FK0
M&3G@JFG).%K94!RRJN1@:%%%'LEB&2='OGD;=DLCS9&/%^|(GMEUL=93&;I
M/2T32W\$P1V0:L(|CN--3L->G7HT.1!&A57J*|RQNVRL;G^|(G93/>K>|H;%8<
M_6(>DWV:R3*2J/JZ|YKI9N>W3BA)V#'\$8KTBW|Q96"-_DG>#9LN.ZL.+W,#?L9@+L#V
MS4VU"6QTWV#W=8*!^1,->QR+Z.|BK7O&D_RC;KX9B4J;6T.H>S"\$^(0AEG_M
K^:OE&*O#89VG2XJJW>S7B2>K23IR+25)L"=K5AN"\$IC&|7PCZ|J9,JL-9_M
\$X|W>^"AUPA7F&O|@T*E2&LP.DTI@OZ:18>E+'9A5(Y?3U2VNWD_M_TJ0!|BL&6G-
&=XNN&NMA/_*2_|+D'YN6|QJJ*\$P,9GH(Z"7F&G,%@.%_MM3D9|N/%R1_+6?
CT>_|B%/LP:|FL|7GJ|GHK:44T3V^OR::JSO|IRV"8KD0%_MOL?3I2XO;8)'Q.?XAB_W?
%>56#_4WH,FI|7?|7!Z=_OS<6G0P?VUA!CDORY_M.&Q9?
+M,1+)TAL1=+1>4PG,"K(>="@=93|+.1PO+6(I?
L=%AHSS29GC3+X|:H8S6MH0S^M*M?;O|^+H%'Z\$|9_-?4>#/T
MHJ9N'8.GV_|V8;AH6>K77=1#56!'M9QYVG8F1@!PSCZS).5.%>"8P\$D.X5U2
MW3Z!B!*Z^.6!Z>8GK0?_M|=F0SOC5TOXS82=/OZ4EZ0/2@YF3|C#+>CL4D74
M,QW,Z+)PO\$VUK5F2PF.;\$;AWC-IOI:CY5E0:MIY"6SMB*|1A14(J/8?;X^_.MAQ|5-UMGA,
(L!*J#!|WX"U4O_>3^VR+OE|W/.'VD=|2R:YFZ5DYD'Z,|>>5,_ML_++I'O.
A!H0^,COX&)H3+A_J1_(ZJJMOA>U/U\$_'A7W,^S%@OAYN?|C/_M6PSIP*:CMX)\$S?T_,X
@_1BTKPL<@NYGYD>9|M+^<6_FS_M8,!|B0SS\4|N9_3;..B%&H
(+J%PU"Q4"S/+!2|%#H.7)L8LYAQ>0(HJZJ>
M2JO%R". 'S8FSYH/AY+3%FON>^R9L%>A=H3|. =8+OD)/O'E_MVL*1.L?
IWXZX'(I<[4@7+|7D%ELW#FS,O<8@3^J_6M-|M>.&=FHN+LS._O
M^#W7Y=P\$D"V_8*)X6_10\$9AH4TK-1XNZ2DA.J0H&*.^DQJY#>:5X;F""_V:_MNN|C-
SA@8T'"8&G;JGFFTEWT;?.T*2?6+3A52WZ=ZR\$=PSXBBMBWD-R8?2G:_M^H_DAZS.4>I-
DF_'97>#_B&3R_0VCO7,C|\$1>LSU9@NZS|U_8QN#VG&W_#?3_M.ON!|*8^7ERSQ41'R?
KC(7.I7D/#_<(8(P+.D6|QODT/.<^HB.C_8|U#%I%.;SZM_6".S||0RU/R!@_A;"49_*\$FT^LC/;
M\$)#0C^DZV,B;-6((?%6G|I_<@SY_>),A*8|HXJ8'T=P7S&77D|AYM"X91P1
M|ETS\$4F4074YY12,[L3%K|;Y.K4?'SUZ,D#Z.-Q'N(-Q<8V8:HN|LDFS|G/_M4K61)7DK?

1SU;1L54U*:DN,K5OVH-1W_+I(M,RFA20AAS\$Q#/ZW0"Y"/=WE2H>F^>;
;7ML(0WP351R, IQ.&Q,CU,4@+2+7@
MD&_@X^C+U\$PBJO&V7*|9@T++YS&2.J3\$7ZX&J_HKQY|_|=I_XBS|2/S@3)|
MZ2TEYKZYOYPZ+8DA#X|ND?V1I9R?/%.7WOYWJHN6O2\$VM9|XQ).T|&^+^<.
MY:AJ?,:\$2>6|/%=0,DUJ\$U@1(&+2\$|&X=<B;#MU>#!?88_R4:QBX3I&KYS""V_<-
YY!,E3(1UAK'B,A:0, A M\$)13V%XRK5L^K2(R|CZ ?F3:Y\$KP,V|Y|N/.7^?>;Z<-
IB#?!A1=C8|\$YI#X MUA\$1!2|M0MO;:=D'!#^+)^75A^43(2: M7VFOLD^F?
YH65SI8Z|Z5_2#58@UOM2NUJ-?F#Y5'= >_S@4YBG(Q?I!:' M?
C2;GRX)S%)OA54.K=.1O4#&:4CBU+WR)Z: ^|ACON5#OM|.3.-K0?2^0_*P1'+J\$>
(DA|_MJGKQ M"4C=1,Y5#@P3+%%I 89*SWDY/T3M!5E'#
<5%R;@I90@|T.HHT9KA_YC1B(& M_-:-84D,A!&G|9DD7/4H^RNM@-:?!(=^K(U-
N>RZU9=KMR*)(^H.M&>*M M>YU|V?F9?^K2@%_Y\$=JN9X <+K6I|J&!S6S'J|_|+)|@4%
|W2-N U0>S43:W MC<: ^=[9+"OB|%8|1J.)1SA1R4X;2%O,*CVJ#H_JC?
*|.8W3_|R)&\$#VK MBR)F^;4)AS%:R_)3^60LPAP&?
6C,G26J5R%\$C^_\$.A.)Y.3%7>_MG=/4L'; M+QF(M|EZ9K=+"M)"V|AU/C
24OY,5/8:MZ|+)/(XQ|SV,DRG/LH3TSTPBT> MD8)?ZLV(0ZF/?)Z0OC?O9B?
J;.*5|C8BF+3E+%Z/5/'_OZ O|?-)#+-Y8-WBW M-
X,|DGU8@V2JUJISX|>4;Q_6)K%|B|GB|V7*87WC038,I!666T=0_|OJ MO432B|E*=J;Y6?
+UOJY"E@G@Z51:!/6|V8I6"Q|PLT9Y;O5=#!"X/?@L8_?: MI'S)(4-#NB!O@,EB!.PF/.|A>."<=
=?=#E49|= _B|?F)-S-=K2LV?Z|52@VO M<_8DZ@K??
96M4'-70M6L"C30K,"Y0Q>8W&>69^+*,J2LIER=+Q,MN."5:H_<=
MS6>L=3SQ@+Q38_XNN#!TC<-O+ MU'|E4TGAH\$|32K?8)*A6)H-
&126IUJQ|N8|>@07//6<7--7|#/B|M#VXAL M@S9+)|&|R*EGL)K(+O|K|3+|
|*NS/0W|O<(3ILJ|&.6-K/4RXU;3T8S2WNY2 MF|<)>ZZ4*TV|,4_#&I3M20IQXDT+<=
3M3:ZSA*?_,H=CD#P&3".=9P9OA7NF? M|B:R5HKP_1+K^KJ|'P|4 F|8N(|RU%ZE(-<=
#U#+\$\$.8HX1?PO;A,7(Y.>K6*Q M|E?A'EW\$8F+INMYO8P8BYK@|84=WD15X=<=
MK%+1N+^7#A|/#C.-3OW?JD^<*|DM\$3(. *N|Z;G&*)'S\$7W"6%/71?9J* M\$ TM"O|<=
<:9C0&WT!L&%)>|090|UP;"DI">|_U\$MGI&#/ZE|<(|K|XDD: GX-*M39+G>0W&<=
C(%\$%P@QI-M=8^LW5^Y|Z|1|SO4T5/LG(E_?#_.|4G+A|D^01!N/"C%&R504@<=
M4@M<#(B|_S5KPA-1W7G+|+?Y((=W&#;:-W:|G-%\$*=J05Q"GD)|=..&#"54 MR7C-
"1>|_Y7#-@L(KP.|NL, ^_0 OZ+/6(S%DM+BL^X;#X ML7:F|"K?V!|@4,&M!!JXF<=
P|>L6,Z)RNZL_|(|0GK5L5Y0*QF|J#U8*QS|RND?XGN!>_LVY277R;M,JN8-G(4N1&Z=<=
|GE4'8G%9KKPIK MR>0XHD.-&JM.N|87"|"I^* @0.N>9FK/69", (CQ|68J9|CUOP2<=
MXPC.P(7H-|P+|/Z1_E/7RFW&9D0B6'B8BV?)FA"F|Y"#,|'0QW1:FY5R3 M8%"P@EAK-
R3.ETWU?(U_YTPTXU93#=#KI|:P(VH#ECR#C'D?+A*M&N;*@_M&\$4<|A7-
NW0#U62CBP!!Q:6\$K|C.) |H%"0|E)1S@"8|Y0,&V|KL2K-<_KH MO7OVS">.:6>|?..?<=
OIL4|B'TW"1XLP5,R:/N>JKGU_&54|3Z0P7|P\$|MYZ|_M_X2DR8J|+ #Z,\$\$6>7F7(|<=
_>S?/LNE|3##MUS\$ "ZQY=)"P-K|8Z|")DXR|^8 M_K(25|JO-DSL@--7.S2^>+C,B|<=
M;'9|=|YS?S2UD|_R@%VM'B(3:<[*|5|!M=V|*R,D8=\$B&-PM&_*1|I9'T?" MF^0>@F|*|<=
|:L/QCV/&OUS;),?:PGA@P_%%&4_EY37/?@?2|VK_ \$?,6P1J<=
MWFL/BPU0'B'I0N"3+^_-2V8XSTUS=Z.%T"UT'W/Z|0@D0&30IC#|4_*%MOM@<=
MZZ0H:#V>8I*7K12P;2|V,MRF|55GQ_L%?|'I,HTZ+R2LG+|=7X"; AG@#M MBRDK|U_<=
G\$2Z\$;|C\$;|KZ|4FJ6XDRI7=#Z54@\$"NN6K.T/O;K|WAP6.:I44<=
MH%DOQ(S|SRJL6XLZ!;B',8Q|HZVV_LA*"|I"W|JF(? M/E2JUI.SUFS?<=
Y6FUJSJG=6AQ#)|%P36\$PP^*T\$RKPL>RTB:'I+T"(L|0+Q M&M5T|GV-<=
HX#,GW5^)|PA%2=7^A-%Y|DHCKJK|7M5Z,Z>;1L|U;S|_S%K*,V M-"|EM-
Y_43";LNU!S!;,"|_6+>.VPZ%%>U/L1|_|^,ME)7"F97KM.)NP!H4GA<=
M")O\$U;THDC\$F9I8H?YF_R@\$EG6HY?UM?;%*H, MP\$|_?#5P3S0?<=
HT|@_X1X,P|7|_W:2+9-+184>_AH!#7EG9)5K'G@:|'HRQ|I M\$.BDBD(%/"3)GMA(_%X\$-<=
V|*L64D9PH\$;N5(\$P0ZJCEP?:=*(SC*PPO"8V M63X'M%,@|&|L<*6?<=
*0N/X4Q^1H0IT"W7+1E++XVRIG5+|YK39BWL#_4+UCM1 M.ENEAH<,O!-&?<=
(WGR48\$;K!DAF*X7DU\$K;J^RAN\$SM*.|+0)>MY> B8/8*| MI4++S|1Z M2|S|J#OF>H(|<=
<4I3(YAFB6+M%K9^%A9I. M|HW>8S)4FH|1*70== \$4&1VLA-<=
^K=EF@ZBD%=0IF)C7*M|&"8"M,(VU\$_.|X M@0PN.Y"4N65@D@)!3%1|T0|HHYDC6-<=
5=FZIV2>CY|1R.; VUC"3|:C^H|<4U MK^K^79'=" _6X??HRP5S?N-<=
J_ETDU@>Q|DBUN|CR#U<#<=QOXAG>.: H_6; M<1:T(HC B?<=
C"2E3<9>&N|^N15_>7RT|^M M6|P:>|6-*E|2?^J3|O;|1Jv;.*KA-YEK;'C>_|<=
7S_YUWIOV|2QA|I#)GQCFLT M6(:*DT(<*S6U;UP-<=

./+L>6X\$%HT,KU7>HJSDKOEQD6S""L9-C&G\2<[?@H M]F- M0%)-
S%2(BEX8\3M^ZX,YJP)98@H#FS,E>LU#2AWO[?:"9(K!\$ZP9(+.#P8
MK;&J83L/#2\$HB>Q;/-".PH? 0\$2>#/Q2*1:LP#LOS(N/N2\(!SJ09&N
M(/)L8W#^%/>7%K)X3@;?VD*A20.*34_OAQ;#XK7_M3-
_,%J4,)?."14%TZ3WR8>9FH&RDF#-X 684^?P(8JG M1\$585M\$8F2)Y^K/P\$DH2N<
_D.GS+>3C]MS=S9X7<,F&@\CS[<]QI78\$,J5X MZOK!"GWV_L\N_L"/S)--#XT["J=HS>
_JB65IXLA+>B3Y/S,E9/9^(YGX0G?3B MID,X,O-3,I(AH9TH U G'3MT2G&
MT.6UOS8K=\$OPP;TZYLU!>*5U/X);PBUA5;^V?
TF)@8WB4*L7PU7:3U'CC;=*B0VCGH;W>'TJ^>.0'R-BZ!Z*YVQ MW3%"/-
K[Y;7FA7\$J4MGMJYMM!O-?^J;Y-MC/I-+5DR^<0_!F'GNVVS0_KA
MB%PZVY(P,2H DU1X9KWTk!9/44TYPBX4\$*_K%/I^W3N>X&5>K!+'+08/:XD^
M6%)1BRD.B=BQ<(Rj.CRK0QGP^!6G*THG_Q3)*0(\$P\CP\GQ>^@I1K^X"&J3
MYAB7LH4H71;DQ=3I(SDWEI=?G8T^G-)W\N;Z'X!I4SDAIZM.;K@(8KP,,F8I M_PU[6/6
MEQ'2G)"T-(=,KX+@H!92VWO@?GA:A M.?!R*>L1)'L=Q^2RY;S)0I(;JC<12
MLI(87=IZCX*L1,8KQ56/I^+R(SP;1DGYRNA*JM\$BC^V+6QTF,D ".D K\$U-+;6/*3
M!*X,0>.JJ9>VCH_R1W1.QVY\O'P@7P:OCN3>|CT6'E1Y-JN-52>M#X=%SX
M*KV,XI7FKO'V7Q!F/+DE5&IX'\$Z?'GXBINM\MTI^V3>'X 0\$EDJ!MDA|=HF M\$V?
HI(1,V7I_ (8N*AJ%#9\$#&L89EQ\VS'G')WN8=/2&\$SHMVO)'[Q#NOWW#"2%+17))#TLE
T?WL.WUO^9H(T;L+C=/%RA'?ZT.:++?LF.(^T*8ACA#B\KL M3S.!I-P. &<-
A>M52@.#*=Q46U"C73&_I>)>B/U6D;G6O?8'0+H%=2H_&/=2
MJ2=POPG_>^/F<^+MQ*TZ!"1M!*0RE<3)2NZ)>RM'FZ_W^2>>+@R\N'2A1ID
MN7T9[Z3 GK-^HEA_!\$15X>(?^PLA^)^4I&:'C"]="SHY9FP'/2(-.Y&F-+%9"
M??11KNB0YXNY>>0%^(OG)4EHH\|MWQ.Z\XD+_43^@C 7SZ,BMV9\V'VM
MVXLD#RSOCA;R0XESK';YX\Q\;B3>.09!YQ>(EWK:&*Q1*QM.#G>^/D4)@8
MD!T#@X?-B\X)ZHIEZ3P=>?"H>&S=*A6,"_%TSRJ&/1\$#0Q'V(DCP%OBO3N7I M\ID'^?
2KC1/;RR95_#VOB'VE@O5G(=C%NMAUEETL"7,?9I_8NIDNI*HS8I1<=
MI\$RY!I)=04TIZ;&*Y;4!3T6S!" R\$VE%,|*@!^!Z4,I1) 7L\$ CX1LG3<|Q> MC+K+>&*
(7\$UZJL6RNWXJ(>CF&>"YEH((>:NJ(^4<_R)O'5COYS?=
<|J\$0/XJ+""_&MNE^>OU9;B1:N.1 4+B_M-6#936-??&.*RA:05OD-IN&A3UTY*%@^O=?
\$F#0ORH'+\$86JNIVZJ;:1< M\YSL7ZL\$P:_KS[8*S6*0_I(HBUJ*"U?&OR
S(;^I/4\AGM='GJLO@|D,K'H\ M1QSD9A=KSG#PW\FZ^B(
FE@ (UEO7=38OU\YNX:"19,T4S@!W_\$G5+?*.?&>4 MSA|O-6V|>
<5&&^_0S^:P1,EW1JB!9\(!U7R\YT)6-DTFTC?#XHJRUE#A11_6 MGZ\MR2&2AB
1L_APFMPKWCAI5\#70[Z #@UT\ S#O,FTFAW,&LB\?ZWKT0W\ M-
OI34R%*G0,H#IK<_FH659NT-CIP.9YF: ^GD6KQV+W7Z;NJ;5F(0&R3=AE_MJW!"
+1I+>E@7@'M_N4^1OPN\!F5M'\$ W!*;1%'WZ\T3Q\J;XJE4PV11/H M883;3_ZK:B(#@
ZIUGX_YXQ3 M4!EZS9K"08<7:1*G%Q':DY188|Y':CXV|F
MJ*9D7J^1U>N|T<"RMX!MCR5IDSG7@@A.VS!AV.*'R@|'-#S9+,U+ ZA29;L,
M)CLF8WBLDJ06\$Y3>9'#C1^%I#:=3^*7-TPYK1U"V^-UM^OO;#:%?VW\$Q;17^
MGX+EB7&<72Q\;M K)V&NOH8K>%||J_ZCY2<|?A#X7@I7N#I9^NB,R#O47-MC!8?
D\K:N>"|B1O;6WBWT8KU@UCE M>4V"1:1PX!@0&O!P=R:\$%R"SU,F*|?
R2I,>NZHQ=4)API(_+AFQD_HE>C% MAFFLOAUJ!MKN
:OIZKN%*"W2HQ*X.4OX\|R(LV)E*(J8|L:LS2/-%W+<(ZSS MC\$9O\$M6AI9|B\$,@E
26|U*2,>S|J)E'LHU8O\$B/;T\O!,OW#HE+\$GJ/-2-W M51-2D2\SM?
B%))\$;+D|!8%_A:\LX|S0BM|P('JZ<%A!;I9*3N4(>/,KK5) MF&' V\$VN!9|+Q+9:C;?
UX,5L3EF-T_\$T,C7:Z-T_7RNMCRGM&,NL61P!ED1J MDQ-'NV9=DHJ|V-
9!4>^SL|/KVVO?=VFO+N;="C.;ET?,\;(M512ZH3NP%(S MV?&>Z|NWRIW
HOE#@|SCA\$F#;S5(:6O-@K'!P ?&|QN\XZVS\$'BI7/0H+P(-M)5.-
^G.,GMNZG8>;1AE!/'M3A=H&SQ0M|= @1K1(S""3JH5IC,?>85\N6-L/F M:4|(^)?SOS',-
B3I?!F6MEZI<&Y60L>&64"HD543JW?X 3BE@*(HA>7 A-#I M?
XQ/PART@AB)MXT3%3<"XWKQ_,V)U\(/*)">?)LH6.8TC,L<4EK(#7T;G M(%+?
^+=#UBRS&/&2W5IB|I>;MT1\$S1M_I9S;.,7I9='W/((^FSI ML.?&br/>U0|QI,H%0/#&.WO=HO!@+;ZMK_!=3H,IHW V9Y)0Q'#&)"S+3?W,S<@2
MP5|7OFU8;C:2WE7K1P@=!'TK\$EM8M\|P_-MY@2B J-WW?3W#|O:PY,6T)KZ M.I=J!
(89P|.3M"*>% .8RMTC^ (O"=(T0B<@/LQW=*BQ5\TKMM5SUK:C0*M81
M51O+@5U\H\$6\Y|I<2?J#Y"CO'#C(7^LV9GLX83E\$GQ:RN&W6;4* M=[5@1@2M?'V!)U?
LSU+R6R0_-MI2>;6N|?BTRGJZPF|*% ^=A\LAWK^XY8#XK@.9OGJ.+5YS*XY%-A'>,
|ZZRK>>OQ,(-9ZX M8RL^)^5#TY%?NGZG_!U!+ P04 " #UBB9996;R.T"" "CX@ %&-T

M;'0M,C R-# V,S!?'9S(N:G!G!+P'7!1;EC!>"(B"B"!(IE5 \$(26G&D5 0\$!
MR4@4R3309)K88@#) @)*5')NR1F4J))S3@V20Y,:+J JNWNS'MO=OX/^\U M^Y=?
07WU_=6G;JG|LGGWEN%'\7/I>4%904 "(B(N)X0 SYW!R,-MK0! M517@ 0#('@.\$!")
6< (=2H (!(<@6("4B0C !DG)W\!-@ XT|_* I 1SET@ MM&4)!6!9_1>H/PX 4"W-
G.-=575UMS&S-*><(+T#?\$0%*4E4"IG#RI M);+YS \$-
W, ""_ #?!@/2\$+B3F3G4TNWJ4TMK6T<9KJW:1JZKMA8R7'HBJK=5 MG>0L;6P?
>+M8;GFK:9M|0TE++@@LI3DTG!)N.(3@Z6;V56X@|VCJR1OU?T5N8_PFI
MD|N+ _2^X+O*4&3!R %DI*1G24G(SI*>/4=&=HZ0BX>7YVEH*#E86%@X?E/'_C/
/6Y,|\$R|1\$UX\$SU\$3\$U\$3X%@!\$< JD M1+|<_V8=B)3MWGIR"
%!'^"3A#1\$Q\AH28E)2\$X,>)_ C7 1)J4HK M
G?/7M8P(|ON3"L8\$/7Q'\NIXB|TFGUH#J&G+L_/DU^A9V!DXKS!Q7V31UA\$
M5\$Q<0E+NOKR"X@,E92UM'5T|_<<&YA:65M8VMG:N;NX>GG O|Q&1T:'
MQN=0|PL_%I>65U:W=W;W|@|,4?'A=%!! 3 _=OQ|XZ+FC"N,R0DQ"1DA=% M=,;S)P
U">DU@,;T=S7(S)PO7Q<,;\$=[+^IC|9?S|[\$*,:+JG+GWD5SB\$YSBW M?P|MEY'|;0-
|_G|ULC|_L_C&@J1T,);:46PFM0L+X.'QL\$L1GOE5'7_KR^%W1_2?S
MS@M|.G5D>.#ZQLAI8+GIJ;B1QAVR5WA@X>EVZFE@.AX8|\$MVB^W"F.(4P(QX M8-
0..!J-VQ %3)!Y0/7#OUQ,;0QPQU%GC-,WU%!,Z2*BY|;DX#9>O|V>QAGBB83J|+#C-
5C/NVO,EN2%C>|@/U/GN MQ^W.GX%3>'N|/(I5|'&?KQD>,_"GJPER) UUKSW! @ZG6-
C/5B;57*6O/G M&|;>A54J.7"IR;T?_G%1W_/+59;C)YZ+|,|'+(UT;KB|%!Y8SZ|7Z-
#HR!+_E#H=E(<8<>B|@R6)1.73;B&_M'-U=6^//7O|>5*=G;&'?
4=:^T12UY0/UNA\HAQ_0I!^ ^IX6K_D!AW*I M2'H>ME2I(ZOY#6"N=M:WZ%VY'!Q!_3
RQ8F>.&DV8C)DH6!?' M:0|9/+|>:SM"OZH=%#'F*1D93W)Q7MI?Q%RES|T-
O16|U3^MHC)EH"|(I.+Q M|>SB4YD2EH"9\$,UT546HPTC#?
+A2Y8S+7B.U56E5)5/1RX,WW2=WQ93|D3(/_M|22JZP%,-Z'3A' MWIUX<7-
N|FF_J|IH1(;GB0&;XEI\$Z!KB0 +W|<"1Z:_G.|YUYAQ/V\$;S8WD\$ MAJ=)A/N-
T1XZL%#"\$.:/&!KV+--+*|JW?;+F8L_G%XWXW)IZ8Q-@R.0:D'
M|3GJ;%,FD\;AS,V|IE|L3BS0P75:?\$,%O>TRB\LI#|X'GSV2T/2.4%37T!#7.G#L,,3"
MF8=E| ^3WKT|L@UYOU(EE|W5|)%RYY,"ME>Q>.,YGV"\$|+,OXZ8CZ2)EM678=
M'HCTM+T?LK!'!CS9C7RJ8 <&+5>.)O>^6GQ/GRJ.*O9^X6+114D?%;%J|'.V@
M+Q1H"|@<)<C@4AAZ5=G@DGI?0U/'SWR0ZW%|+EG0|WRA5NS'*)9%;5E>X--D^
M1+I8O7G:3Y=SVXZJ;8YM|:Q/'CE^74-'^L/ M6\$%YUT?Z)E1A|&)9_ ;A=1 ZJX5*9A5)-
M>I@=9^,!&LNB;QN=MI;UG F"Y_M-84";=QYW+*26YY|EE/OZ@8?'W^+1T|VN9FM=V.
(EB\;8?YM|ANR+EKW/J" MJH6EY|+KJN|:H:0RU
0E3N#^UN%AJ2S@72/'FAOBXO/U|U0J&|_6R*2|R&/,X3R'\$3"8H MM9,J=O#
<|&)|H%*3|/\$KM^&.<_N|+M.6-9A0|2YX,@!EJ602MC|:|+|'-Z690O<*M|ZGBZ%:/?
1ZK4TY6DLX'VGP7 MBEB7\$KM))NL,J=_:VJFT-, ^C1Y7)U9H05 M1K;9&-
>S*SNZVJ"8/Y>%^ (#@W@.U%MB8G#*PP%XP"@(|W+_10&E^2,T?V*& M_-R&DDFW_"
|K|^DW!6?H|B.|YR/;:AS|FW9@P<><@Z(QWV" T=Y0\$VY2O=>PI
MOLC)>Q0NEGW8.'O^NY8IA@I+TU8|#ZT71"TH?N@|&&X)3%ETAC6R|NE;MO?G
MPA/;|+*_B"84!1'+L|I=Y%AO=B-A>7)QX_!M+FA-
M9SU7OG6E!ELOO|&C|MY+L#L_7V'<,XACF^VY556X!@G3ZI.G"4),K(L MWHP|I*
*DON#;M!:#5O.A*W'3\$;:6B=39|6O'JYM&,75LN*0YG-Q+QX,LHO& M>+D4Q*TS.K\$?
O68E(R,YUNEY,: "05O,JHO#C1)=POQOQGOAJ)?,2P)M%5'QJA MB3,?FVC*3.
(,CZ2SMGOC.2-08,6XZDNS M30?ESJ_G.B.|T9"M|A,"YMC\$KV\$MH2*!|JX+V;-
TT.FPAV!FI A|"Q;2A#R M(;DR+8LAP9P&C&" _=.?9>B,,5\$K|;
<)>5JEBAX9&F|O5^YF"/.+&-CA@;XK9 ML+=@P|H&OL|11'A^?ND-|Y MG8.AY|,|NGD5=;>
|AA-%OAF?;8|;KXEfyJ|41=XHH+)>O9%_ M^M|+'2K-RU1?)O|92L=+IOB%T;Q-
34374U:5YI&1XX)-W|"FS'2=)0ZQ>WX" MO|HYR1*/RPHM|0 94DY,,JI&=1,/ %
(,:@NRBH"9TO?L4|A81/L_053YRN@MZ M|)(2^X,I+C97%7UXIR)4KAJU>\$R_2!
:5),U'5'K#+3;>;BP@-?E;S6 MS,E)U8_M%Q?BG.O.?
I^7"6C;>AB@"==JBC+M0K8C;=7R;^&!ZF@;Y4|D#>%_ ^PE!44|_|?WFP=X1 MR^
L:OY&(U)PP/=>5.'B()P;_#>.X|1PQ0GK?WS8:D|.WDI MM6N12V<@IA
MA;,>DK#.I3.AVH|VJM\$|LKBVZEK8115+ZF4IU5U#A8O?
K|J2#MQS"NOU|F;|=E9CXW.S77J..\$Y2AMD^D.PMPZ|KF+KG%*+W|%>=T6<^,Z4^SV|>
M*Z:@%Z9B-<\$SWC!|!/_8|8Z.Q@RG|W8OL9;O|8%-
@E123F;N9U24BDRPEM|7"%E_R*:@G(0K ME_M2X|!?'%
(FZ7UU2|6J1|A>M*,'WLKHK43TF0YKA=#?'!R1V%9&;3LOG|EU M:4AA,XKU"NN|*2:!:|?
2'97?."GX#,>Z("C7-PM|N19F#+L|5*"|!)V!&|/7PK> ACSMKPK|2N%V9#L|3M #

f1ACZYZA/VA./\$,XZ8f M\9G\!PI\$O#L56L1%KK4,'ZC\TJH@5S"5K5\$5+!QG\$91EAS5-
7B5&JV^4*:! M-
RB#*R\DNR@(GF/_R\$77\QAK,E10)S\$/QVJ89W\!8M1NZX\+))1K&Q5R_=5;J
MV539)34U'S> K5;>"\9LRH@9:*.AY0,3) U"1?9:!\G1K5%MZ?&!59^7M\SU
M/=N#B*SWL"!<"\44NBC+/N/+E\Y";T*/IH9^<39(A\D92QWX61VZ#M,*K (LB\K?F
M1_\$OE SX_:HL=2,%'OC:.\@YH53\$ UDGDBN_=1 (&-S5:;BN*G@>GJ7\$","-QL?
I+BL>/I9V:TB9Q5IUKSOSG@>S=G!:V" MR';_%HS3J9:.))4RT-"V(:#|C-FLM?<
GL)^%PL<_3C\A5I#\$\$J:'.&PG).>.JU#%IX/OA=|M?_
Z:K+ #LMA5H:E0\Q14NC)>"3.*/3>\$9 M

DK.Q7JF5@\#1FZMBNZQ%P1D&0Q M+YL5O=;LS7I0>#')VWE4#*,V3?
_6Z'&8J3M\PT7P=M>#.*\2*F"OAVZ(\S MS>-^>U92B7Z2)'&B#-O?SFJ?O&AUTR;838?
RBF(D/*8EI(%G2'C"#_(H8IC" M1\JR!G"=1Q4OIQ@/68#Y>S\W\&73H*L%&RF!>X+"V>
;JO@7)H"H"P\T@0EB MT7N(HCK9SB:\$ 'R@W\|FS\$G\|P?<' _0'W\|P?<' _0UP+6L5DC-
!&\>V M4-L1Q9YXX+(4 QO%NUMUU32&56E.'H;Y?B..=|E\$)O3\$YGN.Z\T0ZR*9B)6F
MZ1KE_ZJ0\B\G!_Z^#O\9"W\B\A(VM*+Q@*F_<6\9LSIZB_|X:.(610>K@D
MOK\RN7\$1\KO\$ "DZ%DY\ GE#:-1X\5:4H_H\|D7C_@I#/R+G3_FJ1^LJ_R<|M^&
<(BPR:_H>ENF?2 MM0J&-JM.\$N(K6GI?
9;DK*F"AGA4SU.64BO>&4A\5QTT8.+ ,K4C:0C3%=RF#| M.%3-0%Q-P@+X^0D/O,Q:;VX
(\$-I#6UH4WS&L\|KS\WOZ57\ KAX \$|SP&=T\ MY@Y(O\^\$T6QN#?P*Q(SES(#K\Y
&UIO=8@H05>N.46**>_SZJ=-8^T-\$&"4 M^,\(+0-1\Z-!UI4-5\$;
HJ=@S5CA_'>;QI0A=XN"IT\3C \XJNWO3Y09><4 M0\$C6+F->?/9F0WI%EIF,R@FW
\$0>=_1G?18K_ZOEKBZ^-941QK>_5LC^Q<"X M_\$2_.F01=Z"K?
T5CZ!)W1U1ORFWX83Z:.\%-RC*N\I(00>6\ZKU\2P+HL^_"-M,2FCI>:=:Y^_C?
M<6"P\B^5?^G'+F%_MW<,C*@GFKR*PG)
<>9SYZ(0\$82*O;>HB9G\|V0TPSHFP:OQ0)_J'9:#\#K+N=#P,V-\6,6,_Z RQYIO=;>&:N=,
(= ^YR M')JP72&A_LXN^-/\P1GN@()E=N#D?|955C>A&@T&_<+BH*DWKC'JY%13^
MS?Q,M%I?C_*+.BQP;BO#?I+647@F6]>M=_#^!%.WJ@;ZR#G(\$IY+JO4):
M#:.6_X*Y4;K=[!96>M25CZ@U&"7TBHC*M_Y7#^I9K MAW6YCS\$MT4("69"O:HQ.
(\$K1-KUXYHIZ"&92UIHH\7'QOL\U!R\$"80%!D\$!_?TC8X M+,\$'GF%6T\$;D1C)_ (CLP7-
:7P;=[5;B@485'%WP7Y)0%]=C=2I1 G>XUS MB@?
ND=BC"3PPDXD'R\$OE_ICZ/_KJW:L74H/Y#-CPY#)=)1@>|(\L3ERP:E
MC24F*TOI:Z6\H(ES74YGO%&ZY:O#MS&P@J.M9'K5O\W9P6+X91^&DFW*ZJ_C
MI:M?.H@KEK+S?K_4_=;WV.?ZG@8.7A@KPFKG-X68972MMJ7"D'6-WY3T/4P0
MP;H8VETR^L8N\U3+\$<7ALG)#ZGF\I&Y<5%9E".Z:C;=HTHY77"7(OBYE,GSX
M4\XG"1FBI_?F9S+|2%J)!A8ZQK#JHUP:Y#@/Y"K-,RU2,&LV?'3,4?X;W
MT84Q\G!\E8J!CQZ3:V<72:800^74R8SL5|M)60VENDXNN.
(A,5TS%O("9_I\GIY812KBZ\|S8G07(W!FS>-ZK;57CKNDE*0 MJ0?:=J#0*2\|R+=(!LG+U0
_7*\$&%N;L9-#6RB'4PA_1'8N\!@J:VB7&B_DOK MR^D3ZAV;I@MLW9
!ZVMXX)Q5EB3|M;^DFT(D1J\<>:.#%&2>I?:/FF/N@?^ M^M>X\!%NP0\!9"I=#*?
VI.Y\&ANFEH=7#Z"U)\JUR)Q0MS1G'C,=C3)!BWT>2 M8D\$|PWWYR+3X.709=>6%
XIA:S_M/CNESSXJENG)_7\Y_413X\$+;NG\2GB&@,CA(?8GV
MJYP3"^ (74:)J\A\|CZK!1YC2%F,'8TKD%W@_S\$I2;:9(NA5NB^BX=Y%6 M3IO?2TS?
_+9)"->M\?% 3W+CZ;\$I.OU\$LAWGNX\$'MOKQP*O':547FRI_HR:0 MT@+\$40<,
|A2,T4G@/O'Q7^ZB\^_:=)1L,&>HQP4P\#1UR IVAS;TCF:_
MC\QW.Y,KWV\$V5FK\&S8_&N*O@Z0U+|JE/JTD^V!AW+7W2!!!WGDB%NK>I#K4
M(DF:3\6OBXESD9GYSX'D# WI0A7K69)7ZW/SQJY.GI1RJ**?8?-XPJH8EQI")"D71J+, M-
N8%+=O;KY&,S(ASY%F0:Z)XWFBV3HH\$A\2+H!Q1;YAW"FZ4\QP3FI%,4'
M,0&KZ^D3(D,8^L\@N68\^EVQXNOV)(MG\;S6:0Z1FBJM&D#M\$N%WD&1D-7C
M\I^A5.S/4,HA2?3P"62UYOJ??F3M!!>FGO_X\+^F\CK\LS2!3DA@IWM_)71
M"!@2#':OGNYINE00DDUCIW5!#E34A\7>RP\|C\BAJ3\$Y.NQ\WOY4?Z.RDD\I
MBIN=.;/,\0\AO-1/'OI"<'Y.37\$9Z8D^*J>C"F>"CLVC^K&A<_YJ)8U:4H M-
@Z:GEK^:+_E\Q9Q\H"N\TL"U#73VE#"ZB;JJ(G*HS>/QPQM#W(=S,_<)?<:MO!N@U2?
_=,*|U\AY""?&W\3\0M^\$HW>Q\=(JD_9S2H.>Q>=JW5)MT^W8P\Q
MGG0N>K>:1D%G8U4:U%K"5\Q9L\7K^Q\LDQLW9_/D9T.+.=|MWTVWC5\!@|T
M*7Z\|J91Q+|1D)+3CNN48IKLWY2(I%W,:X&/F*UO1YBY7SFZGVSNA^Y27PM'*@Y^ M-
+S(O?*>@Z=K#_N;4BQO;K/%5QZ%@'-,ZYI7\QFR&R9W/" K8W!P:Z\$F%IX
M8K5L'1I"9%AF0N\$@=|^E8_9H7_2QM\$Z^>HZG:#&(AV@CH,,/7A38H5XVX-!R MY4J?

X7U((;KK_WNG:B)0B\PJGBFKVH\$,:8^G/@"
MO22Q487PN'8%BX##R>F.%ETGRGZ)C7:S3>C_4*JEFXS=!.S"LN&GZ,:23/N M?>
!:/B03:M/ 4MQ'ET)J6Y2Q",WM7N&07=@)I^(OHTYW,!9&76;DDU;M'I8
MJ6>A\K0,,/N=^8:= 3*7!M/(@
MB3!PX\FM06#_A_TU\B.8U76%"^;+'99=E8MYF5@V6A'V+8?0UL^Q&K'WQ:
MUJ!H;DNS0%U&\$F^=)E_DUV#%JUYAS^%%A?,IT_+1-VD%)9,"R3[F\D8&+*#5
MABIB;:9)%U*KWJ1B\MI(@ 2+(E_PAX32I)7<-XJT9>VG9U3_G3ZMK^>K_<[H/
MY8"8ST7^>*M036S?9;C^F"M420+6FG_?BTX?HASSL"F;URZ:@F M=D'T6UBDP"?
U7G?(JR<.VOXULAY!S0>%\$?2'(R1^_LLX=U%<'KL?I.@\SJY=DNP5V6VG.\$U)C-6W/X?
W&%- 7,4 M\7I+VR9(D64NB\$6%[\\$/BT5\THRA\$8@.=3WT"9R\|P2=(Q:56'C@.V6QY9KVV
MHN35CIY\T_V2&3AP9NZB)ST7/-GO#OKK=YT*;ZGNA/L.8K3BK/5^>\$2/0^R M.O-
TLY5,,J+W/426BV"XRX;/"=K F&UG\$.@M+-H"7G0.41C"JCIE3-C<'K_*MN OF#R(>S-
OAA>4-F5Y)*01W+A\ODZ'0P/=G4+%A5*3@.@.^0MDV<=X06\K M6L,RD-
CB0(IW6=&.;L=R.R\>DHP4#-<^O7(-9W*.:3(9'N&RHFVP%:\$YWA MV6,<=U\CNC,"+
(!TCH5_LPY6U\)(KK*I%OHDU-I*NH.(,5")M56%@,ZNL\\$4RDT;>
:+_I/-3=>PMM>MN\6(I\$.9J@<\$)_EZK^E_A)?DJ3_X M:.)ME(#*\$78&1\WN*8V5ZREU-
'8:OCW=6\JFR*SM61H.WLD#K8'0D @_HV#(Y M*I_P+RC;V@|V#DMKP;.*
*)@94C4&)WWCWK@HUJ;.:@0RR87.AA29S8%\3R0\9A M6.ML.+_J-80JB;AIB/-
N/@&^|7U\?/ &<5#5>=&=*.O#!ZX Z+! |U"\$S- M?./[T-"M))N<^#/5CK\$SZ?
W^+E<;GU,JYT3B\/%4Q\$)LI*55G@,NML5-E9B17=GE!PN7EI4XWT"#><
MOM(KA+I'(40C13#<&6,FF)*6ROI*Z*,5(@?OPX+K;4ARMY\ED\H(G7SV^?.I
MKN;/%W8CETNL^0@)8_)FP016)_#(PAGM.%Z@3TEB*5R/F1F8*^6E6?R;K9!
MJP,#0PLT\%1=:U_\$+I\$CF(8^=HC6_983JRO*7K23O MBAAOX*K%
Y&J9YAUU@|K^*!^?PNT-@T\^3A7;|7\GR;1T:|_WM&I"P\$"?7?
MK2.CR")7Q,6DU.\SQSH1T7E3=G%7)\$XL-^H8-CCR&CN'P=AKQ9.NN6M,F90>
MZ48.ZB<+.OFFYVRNP_5L/=85013?(>:7^SKN27UKE,?!JAL0^.;2>I-E^-7
M\X(CA#D0_!39M3\$G<>C2F&/S_2Q\$DWK.)\$%UA9K%=JS3C>F>^5<?|7(_#1"|
M2Z/0."4/^+|JELFD0S?AD-@"MH\+X)#,QF;0\B(V N89YGBLF+FR C*CKXHWL M"
(,L0QM-BYPHG0*J'3*PI^THX2,.6G\GJK,*?G&KWF-%\|@?MST_H93\|D\+
M#*)%0^MD)EUG'D B5CU3\$>I?V:|(6 MH>KG@|*VSG&31&-N/^-.3;PW/SH8)DNE\)"
Q\&:E9& M2*XRH?W. ^-R5=DS\IWM")\|\$\#%->_LOK\$*8-7Q'T;M,T54"/;K.WAIB1.BB6
M/3C#KR-I?M%\4A.S2\|^IB>4MJ;'3I5%T%^K\^@THQWSRA%:AY3\$0&M1L;YVLYUJ
M&W(2S?UUP@J8VCHG603?=-,R_/Y?T_\$!U#|W51D4,+S4*4NP5 MZ2F?
Z69HIQKC4IW0+O\QAN@S5Z%J@:|>6C8 =??#&MOUBO)!1V;.:,"RQJR M-S?
O\TN\ KPPJT?YT013.1<4@>6#;|?+R^OBFCE&^&,B(U;O3S MNALG(<\$%1'BI7_QR)1M-
C\K<.,C4Y>F<;US7;.(2>+X\G NF'WZF6Q,6G5D M8/QE8^PM=.:?
A+1.|_HT.@56\$AT11RK_GN&+1/H+H4P9>0LRDJV\$=NYU0A9 MMI/\$QE03*
R/=ARQ\$AYHZ25-X*G\5;00 --8\8P'G04CMH6)K\$(?|WV;P\O M&B%FA5.QJL#CM/Q?
-4&PT)-X\$(:2"P\ M'V^|N3DGUS1;OD_>6>G-'XUX=<|EROS2W?7\F55HYE\|=
M\|+!+4M8^OX#&.*F\|HFOZ605'OAL"\|\$\\$DR;|0_)#T\$SJN!L?TKKH##>V\$2\|S MA)@Z
P^@;'X-"/SU&Y_=ZM-I^',SLK+UM",2>S8&#P1_H\#6@?VJ75#OV98" M0G>ECM?
=S2E*/G\2Z,RR:'S*9U\$+Y3IL,Y3B\|S M)@YL_.3T;+I+G7P(\$.&6HZ86&R M@0KY>I4Q*|
<|0D5KJ5%.31Z;JJ=A M8M/(Q+?>CM4VN;|M%1E9?VO<#!Z\$|52'Q\J78;:0JYB-
R)8#=-.J2@&E\UK+ MGCE%0D(-:27">(!VN:9DLO\YWV\|D+?KY*V2\U^|PO\T4_PY=\$;39!-
+K:WCZ M\318>!^>9@F=|=XMM!6>R77=7MK#\$-7UOWV' 6?
9\$G1WZZPO^4FOLXVHD7 MDC=LV#9=0\6&L2Y#KG@>L5K2+;CB>B6Y&Z\|HBJ8Z5;-
J63,*G=3GF,1V"WT@_MS\|V71Y\|+*>S)35D#;8Q16-\$8?8BN)0YA
2>Q\Q#E>KBA4@\$*C2\CC#F^_1 MD/L&U\W*W?
UZM1\U4,89=|DVJ@'GQ2I6K>8&@1%/OL.0K5MSL"/+|&8.:3P0 M<\$L9#V#V+?2Q-
+T;R"/-ED)WE\FR^ 3\2OE(Y)8*@D?FI>X^?SQU>|F69E M=0)FTZ2H6N?
MQF8AM>%I^O*A.@VW\|+,RUUL7'OE-?1+8%" +X<0>L_C85\KFO M4;FZ52-
:OY48K#S*HTLT8'=>"5Z\CEI@/O44^ZW9N;E%:=SCH\$D\51TF&T/ M'@")'6_T(!-
VDG#*W=NNKLG;.:?V;!,T!YF'W_SC)0XPQH50BL9VQ*7\T#W\I
M\J(DW29BW#>*Z.8=D=QT,.5Z_Q QP<2 M.;HU<0VUE_OMALTH
^<.TD03#U<3VY,Z+.7/%'01I_JNYJ#QD((I\$O\$ Q,: MW5C%)>6.I0@J^&055XXZ>G<0U.
X68@JA1O\SK6ZU:'>506(L/I?Y05 M>QZH5_"E68P\3BP=|6Z?
7F+LEAKIFZ\$IF^A(!:97<&1\U.7,G7>4#;UNB"=N ME10_\$J\ZN/HZ9BP@.6!&5-
!|\$UW*G+A6\|D1O^KDW26T\7M%J\$|7<> M4#D\X@^ZP9-

EJ1X_)JIBI)"5*C:R)I48Q'0E=W9IR+JD=-"IVETA.&S\$B3,Z M1_J\$T?
!1%/YCISSS[A>AFJPU#E^1U4J2S\MZ*5&:IUMRT&_6S'RTH:Y+ # M;|+C3PUI/H1M?
(9L+M6[_JH:&'77:1T^:?!\$)%;,NOL99#0&ZZKW=^SH81^J M8Q1%?)!Y^\$IZ!=##NSZ
IBP@72T:/#/J'3Z*R1B|9>H-/57^IK^: MOZV=7 MJ0A3A5P[E:.L2^_"\7;L5K,6A6?ISZ|
I^Y5Q>#YX^"IAS" ZSZC2?-M\L*F M>QOU\ S*=T-
|Z@M|@LE/^VSW(:VZT.?:_P&5=4/^+6<>:;Z%5/WKYJ'6?J)5G M^BVS*F)?
+HUSA:PN_Y6YP7JP %T',<'0^4X+OH9;&|5|0AJD\PTFO*H93Y| MV\7P^+Y/A/-U:!)Q);#
I&>F4|DOPKI?/OHZC 300-+900>2\$1>(HY*KJLU2M
MR.ZJ#0"+&F\LDWK0<<5'S@6!TJ_QQ?>NN|G>C-*_R1=FS>K%N)*PY\U-W.TK
MA"XY:F|U,+FV'1FR*:WNDSCAEZA*95.OXIAQJ?..E\|EYZJD_6YXFT2RH%1N8E4T4&
MTG=2,7L\4A)USYN(:4=HU4EF|3T364LDRP5,NE|DEV.M_8\$R:QICP6.9+W/J
M)W4^>GISID\$I#.BG,1|6G.5=QG;!G)TQ7|4U+>Q3_Z2E0,NZ=J8|_I8H# M:6C9:
*+CG)R\$HY&ALQ.#|8CAQ@T(Y@,U';YK01OZ;QAL9J^?@GD M(4T^3&NG/I=%5)+
(1P5.29A;!=LO4+^G,0:1'.6HR*8?K.&!L^>J#8I
MSA.31)JVPJHT&|YE.W.%&^6RVGTNH6;/1@JR^>=53A77:D\$V;L*!>.H?0[P@""*[P\$>J-)!
M9(+0KX40A=M7J|;:MHB/I."EF7@ CGK|N,K-QZ/:|Q|_Q|T!1*4\$ J+:18= MWK'F.7
|^*&,>_I9!X31LC70"9*&H>JY0|Z<@|++BEBB(\$BR&QY OORK/)Y2 MU(D_/6E6Q%Y-
N(D'#"HU\4"C"QZ85^2D6D)X8B|=5&67BQ:B|L1!P8^>)9@CM M7E0R!'4V.>_J2?'JN&9|Y-
/MI-3">|A;F,P,Q%?U9C:6X7O|DE;(:H3DJ\$1 MY+,ZT6PNU4D_R|J7)
<6UW.L9+>PCOI@#+:+I0JOB" @6GB1R(!KT3NMPP-' MM\$XKVZU\G-10',4V:4Q*(93&N
TR^V"FOT9&#(5|Y2|"S_C2|H7*92%%V/> MMJ|90N<<2"5MKR#"KN(!R;
<8S_N|9CX5N&3 MRB|UX4;^ATB&C;|3(0W%>411T9#K=^%7".7)#'C%1B
;F58OICZMC1Z;6%MTHF39@T2=\$GA#/(.:WJ?' M\$4S_A% VH9-
OAJ>Z+XJ48+DY#FN&*0%H^V!OVY%>DX0*QU%(NOW:76NMA<|
<"MX"|72D@SK.#XE-Q#:O#J7L9QXJ\$B@N MT;-
!=04RU;M.|*S^6Y#O53W!#>!MDX"YV#+|LA/HE%E7;&Z(@NVE3U(9K TZ MWWJ*>(?
RO^%N&6 A5=LW\$L'A=:HY*_1H@|JQ|%(4*W54>*A\$|*##V,K2(& ME&?#+|?8A|+-
@TI;^??.#89/AIC|ZZ3<(6UDBP=(-S>F*9"OV:XF<#%8
M>%E>"ZK:@<|4">78UF0'VO/O20TW?K*YU^RR\$/<6W!'SYJ)+MK1|83|JX|U=
MS1"E0Z6DT8<-&3>YGI|Z8,,|DS\$Y.X\$8T">42LBB0+-<@|AW"M|..NY2K>=/
M/I0J5^WO@JGVZ&|4SR,IX\$ _\$#@X:S2S6AKF2&"\$DC.9'>H10C").Q00'&ORR M?
(O&>G.2L|BB G(PK)8:;|.25|1.3V:;.-):(_U1Y5)K#=@9|)'0K|13
M4\$D#6M/5:DEJ|1L5JYH"HNYOMF^9.090_VBQ=3?@>S+P08>D!Z<,4(NG90J M-
Y(6N"O0P&=:;K:)"R1L!T|10G2I3\$/2N8*+CL/!G3^#QG7BY^^K6Z 'XR
M%_J7;MGC@W*R7GA<4OIMU35XN=WCU&E RB3^OSP%%*,:JZDPHS'EO:8V45(
MG9C%I^GM3(47U*8T=|#/MAXB%XX*_WUR:.E53P Q|VH6*_J>+AH!T#9W/
MQID+AZ%>U1I#|1,V E| W59'AA,NW-#3WCR*3_>.Q0-,RV6-+V00-NJ|RU@M
M:6Y;%_WL7|)M| KH20OCEWDMCE2^*OCF|R6%)!MGB6WN\$K0-
_%ESAZ0FETHG.AQSX&O0UN/W|?Q@=EN/6#FLJS\GM,81\$ M)D#,-(L;U)H;"
|LB"46|W00< CR9N12@19 IWWP-52;US&Z'PWI:O3EP:C
MMPRJBNC6#4<'E3H."_R"E#443UQQ>@%V2989J5F9|:7\%XS3>ZYH>E=RG;4 MY4=-
|5Q:BB|L)G9|!1/7>8J\GF72=XLD"3%J|=>+VX22|7-ENKD4">&XF44 M|D1=R_V|
(7S^=,JK\$V;CC7A1DHB=ML768=+^BG8^K2Z&W8\$TLL7|I6E\BK)6 MOQW>R'U|_X/?
7#67#?9(70:&H5!H'\$#GVO\H|55IDR=|GJ&Z+NO3_0)XG MNWK1J5I&761\$C_-
Q;M|>|T#!-L|^L\$-.%HM09X(BF*Z9VVS<*74FWU0J:6&W-;)9J %&X"9;
<9.LU=9S^/Z99S+,CP;M MR_)O@D54JFYMI#-Z%7&<"Y'YAJHIF\$1H_!&?ICH|L4M:~*4|K
MMJVI?EZ+H+2N?(85@GDG!+7,T*BBIG0NZC)GG;:H+L=|^|SJO>"C9PDKG.ER
MC,,QHN=;|5_8NQ@3P6@B+5BB|@KG@W(YNZ#|6_*8D)BV1R^KO8L.^\$PGBUQY
MT3VFVQZ.LHUIH>EQ%&5OGC/_ =_2^16W=,TTXL@'YY#!=)OFJ|>^O M2?@V|_R(:+SQ
=O?3-M)6N!F:&A?C<.-BT MA&RU_3PZ;R&=*D1O#P^(X1Y&0H-SL>
(N13N(M\$94GPJ.9@5N589W0W M/#0|'\$"| HWAN
<)>L0@>T'KQ|#4>Z.#E/I25F:H!9;J5:6S,@^9:P<:F|JFS
M()TD00*NTAHX(%F.I0)F.USD>T(AHZS"0 MIP-
.:079NNZR8JYIL>3:..KFM|"|B9E;:QRR|0,U1|1ZWVC>T+D2|J,|44I+-
M(5|4"10HYBU|QB8M|7DWD|107K|'X,5>Z;|6VWCA#\$"|Q_|NQ|QT>B!478J
M|+Z+MIG(>_Q \$ND ^X)*02|D)X|4ALFJ|_?6)^NWVQ \$%|;E ^20TPH:O@ MK(-
X%6'|:EYDKI9D456@AE:\$'Y\$EX(&F^NVVQ.Z ;<5'/)+R>:..MGK6CU5|
M:KL@Q@E,V@3J)36F^U"|H88)LFGU*3C|+3\$|J >D-6EOG@&9Q=LARX\$5W:8/

MD;:;%L&]=Q\&/QW M7-XMCUQ!8?(-MF* M&J8\&\C;L?#Q M(JZS>
"P3:##\O8X6T5P1+.LP+'1^M M/1EGAK'JG)^F#+&VAP\C)%:%<6(
YR6PS\KXM:@B9XU)M:(R2\42WLB^4R"[M5)7+Z@<6H4\$W1T91=A,% "UG;7B"K-
EPZ7@:=AQ&)H,&\B@<|OLO, M? A!,'MZ6@@O\:/IB\B_?W\["S*LM#6H^4PGG6Q0\@-
W(M=!\^GH!5,[70^H))M8ZW"[S*./UP\$FH)XL-4M7(1H9K9!5!0L=1(U!E!TJ MZ6\,-%G6)
(B;FR#9234P"4M9V_5)_65,=(7#Q>+B\$*NPUX,GU;-^7IDOOC#Y M/.07"2X2\OG >D9?
T=A3>^;C:GSA=BN,H7\$EA;:1WV'&\$V+!SQ!D"(4Z?Z M(R^6D3%IPP)\$^X\!/?#
<&.WJUVTf/%RT9HV;2"43A8H31OX_*\PT/C3;!IE_G1 M\K'N*6WR8X,.^041-:EZOSO !^
V&7!Q4\$/>PN;/;XYH=\$F+H95TF1H(6B
MG@=@\$L0NV_*6*//&##9E'!;56T\$4<.79QS.FB?
5*\$9=5/ZG+SO5DM2XC\HJ726VQP"=H\U\$7>|.M3LFJ
=HGCNG+*IL;R>I\$YC!?'R3H/T'N2N^@,4\! GYWX*6
MEPS8EXT>Z\LT.J9CRX@A6M.ACP(W.@;D#^L1)/SVQJK1SW>'3K\W;%O'85SG
M5O6G\8#-&-OK2T1!*M%#@6WK1Y\G?/031\<53: 4A^#/8P0/)"*...JUA" MAD
M^JY5%VAF6F2!..Z@Y,8A?&I/7JPZIVYG_%A=;AA>3C9,U!&R:M\$?" +;Q*"/ M8#"J/-
WS.H7>"^\$JKZSE&5,K.:=&.H\!;KE H+32/^3\5H_9KO?J&9;)7<@: M/QZKZS",76,F6,U-
7L.0G&^M4^0:FKI6X""1X:\$G<->')\$R9\! ?YG_MR5DS\O MU:PB9\6?6R5? ?\ON &-
<%4*X"\+_X_FB7ZMV>^H_.S@>&(4J_13M^I^?Q/KM M>OE?45DB@LK6NO^<+=3#
VKTM!J_ ^_86(/W\T*WH+^_.\ R!0_9M*-C0:F'2 M#O\//HUK,+HE-
;U;0@=O7J9LUMQ_#;S_4X263UF?.D;V_)ON.%<*BB\!>'X_(W87'&*58R#C8
M\$J)*^MZH#JH"!JL:MO?I65.B;(5.P9F%A)<>AI M(F"D2=I\$-% MJ0Z\$(W^H,|9)
<'#PC="XW\^EY90"^FV#&D-;/%-%O1B:[5BZ;3)\. @J'!D MGOX-#I
JWIP;^%KNFMD)/F667_!\-Q^GOW\+./G\Z?+RSTUQ+6YB/F>9N_2
M8\;GU,1""9\RK+K8<21E^IGU@>G<4R!\WR\9OMX #PCX>8=B'\$_9N8Y9.9VG MKV-
B,S"PI@2N5UMT"7YZ4ED7SDQ8;\$0B3M;)(S.?
^"ILWVA,AX,T:P?!92D@>OO'P*C:94\$/E/Y5-05M'Z&HC\!/8D M)-DJU)N!
<3C^ED7%LLO34@.XSGKZ2@PJ_9&A/)QKYH:Y"\$\T^KJEPYKP5^2%DOI?0WG#0-??
&;BB+^J M=:8#_C_M00=05-VR-KP1%) D4?(@H(DD9R39)\$@.8I(EIR&K""9(0HH"\$@6
M)(@P9(><)2?), PYS1!'PO#C_ :KN?Y\WG-#??>>>H35DU7S:Y: ^<G>:Z_5
MJWOM\EZI3A_B9=-D>Z@QE%+C0QM!A\$>WPN M%, Y_#Q*Y+E\MD*L);NK6?LA)\/
@3.O<15OPBD?U/KOP1%I S MNPJFTH^_CI3"!@NFVQQO:UL8FE3-
(2ZGPFH8\["NA^415FJO61;3L\I+1.6Y+;-)29R_1B*Q KA-/B,AUB'CLDKL%P+9S\K
MH3IU;LI',#2<)CLN2QE/WH&3I6*/V%2&\;LZHNF_\$LMI>4A>\$5%2N9I(+T
M4G\IC1!::!/_UWK?) @TNO;YQ<I&N\1>C(L70)Q900U*%"DI/#13\H#3;5\Y1W2-
&J+W+R)/Q,NY%-UZ1" M1AJ%4;=E4,+A*Q-W4M0(P&6,4R,7C\1Q-?'IW-
Q/0OV'O7.RB.UH XNH\X: M)\$Y^_V:C)/KV;/&\;+<;?H?156\WJGGY^-.!+(>?
M0\$N/3\B\$IS&%'+M4JTS2J'5J#/1V-BC,/#02\$&IB>?)2YZ3PI'B\6O2&*@STH1G/IY
E\$8UI6YY-.I\$_.195^=@Z3 M(JOJ2EJ,(Z'W>"CW-6A=*VVR&CF?
8157@796J.G2N"JH\$J@U=J;*:1NP=UZB M7\!>%%4^1WE:!\,Y<'B:8J1*3RM7Y-P?_
"!3KZ-+L5NGO8\11NFBV:/UE ME2&"#7-ZG_.'^8\K)X,=1RTEFN03:M79&T;12KZQ4
MH;-Q"!*0^DT\T2E6!_C^O@.(^G/!\I(@NS)EW<^K23CD)I"B9WMHOF-IP=% M.9/-
\$M3W%3WN_=78+ S3,"OI*^S(!1%@"6A&N^CU'605@Z&L\EO!?,2-8A6 MDF(Q"
I@\$;MI&!'@R6-M5'.VC\+*1PNTI9-HLNZ@44\CR.XKL.0M\;VFM?D%
MS"5PA4VJ^)=,M,%I>TK")\GTQ%0FQ\["\$3Y54ECHF*#5@)'#X0W+I1_&^USV M@^>
<&E0F0=U*\,Q:3)-53=3"3^MOV \$GYV>_\$MJ.+P\$X^! *5&%)7_TXNFM!1
M+=4G8I;4'4;WN*NO/ZT*.>?>.B#SIK,XM,6W?/@X2N!Z5H>7FE/1H7\OL69J_|\FF=89=
EE_0&6;A7(\$YC@:=BPQI861\$ZY(M"Y12HYC\8<+V+E*_2Q@SYDS,"N!\#HUOR\
MVS^J\K'#*)W'IO\E_+!74&AQKZ)0S2K(QIGU80SI6K7LMNQ4"V7>O=0&\O?DT;ZE
M_ JUCD66>GRWBH5N\>@.9>X<-+J>%3+S4M9/?^ST'J9K(OG M\XRETC
/!):O"TY5';4BE)<8UGMZ*(C,R.?XQ+(W'_ (6B!A;*!(A%==80I M4ZJ*GGGZJ23K%CA.
WFH\$ M7V>LF)D-R""IN/EA_+,YKIU7PM>"4(M\B_ ("HP)OULJY"E*Y!1N:"L\!^P3\
MVR7^:P\I\$JJY\8SW=,8%N15P\IE5<&B8\$G1\9%M\1E6V^UJ#QQA?2%8.YT\8T M(PHZ
^G7LE6L7Z=Z;.(VQ;:EGA14\$9/6 MHJ7?2TI<.\JO+J&\XTM4O'HPT\!(5E\$?
\$>\$IDYDZ*+;5G';\F=G1WM5;)&'KHM
M\6NOB3\X\I#)#W2*\77U(H:6RU\4ER\PI;\4:6EX--E^|=5DRFP^M%_9;/'
M_7&'0A/K;VJ*N?^L7;+7_L;9D%PZ1 LA0OY*6_0D#!S,\\$?DG\$'3K'+4L\$
M;Q@VTSY8O)Z1:100@RAQ_+(U-R7%M:X5#I M)=HOHY:F= Y%E2
M;.F56&>R9FMCS62#_J5"_^0#FU7:QSV%H:5\KAB:<:A\!&E=<+|UF\|;:'

M3I\+7TLL8+GH2:6"4G()1"Z#!<=836U=V1VY%X!(Z)_%f(IAU"TB_N>Z9'M%*-
V<-AYX^V\RM*1(+UO*(-:KW.\$.)Q;"/5RP%'-
IZ5TZ5W2V;STI&.7M+N5)=IU26GX^1A(D\3MY(9-A-))LB)?TL7P?.D?2Z?
K@,Z5&B\$=X*TJG6U",X8*H<.T1UEOV\$_ZM%WEFJ)J*TNRI=WMX4U//
ML47O90FH;W+RRDS)P7V1'7:7.E\O*EV3K)=QT;1LEO<^#;?>J'"A1:"G?^
MSI>VR01FN?V';,\$E78#>W3V(A/3S&9!VE*\$8WLX!!JOH2K^.!8?_?42=HGBE M5|2JH-
+JL7+PL+|@P/)NPW,?^JD*TVJ EZ)O>1;^496G5 MT2E!E\$!3.7- CA|GABC3-0W 4S N-
Y/H-Y=A|=1OP)\JWL;D\O=O.\$-YL7 M|);L;?9NY>RMK. R/F,J,:KD
LMMVH!&0NE(2|HFJ2JCQ+D:=)"YBUGNAB4(
M0TY3+C)T2*1X(LF:@\$.:A28/"J7SM_GD&2"N";)>- @0%E|H(4?LKE89Q7 MYOUK-
"Z+7|/0E>P\$9^9BJH!/FS1;H/05O:;!%3HQ@OL42A%RIY>LH=T*X\$D==
M^#D>8J*4DJ=D&MI9U.+P*_7_8>L_SV|D_S)"2!C?0HZJ+Q-PD)\$Z,.XHWGA M+,%2=F
O8XN2.@70,N)6H*I(5 'B/"GVH?
MB0^V|9C=9.F/*\$M1FS0KZ.Z*M)F.;0V%59%F8FL5\5R^EP%8/'-TL8_K9X3D5! M^|+J;
M|;QSQEFRMF9"E6DBR3?*G%#BXAD2/1TMWU= JHW+.B ':^ MM.09ZT=^;;U=#+UG
PYD5|2 U?7V^WAX#N_ ZPZU_X|YDF MH3.&TU-**U,S\DY9CM1+ '4)E.|8K?
MV6=Q8O@0"D)GK?3G|L&H|)\$8RV-O M=#KF&|&=!'Z^,EQ=V|A?
6W9@JR_.*3#D6O5V50.1J-ULK|9U7^L^/?MG|JS=[9_RW" Q1AWPOC
M3/=AJH7<#=/E8'5CM_)DP;GE&RRN_T\$=>;0%;8Z_4U#<3Y\5^H;V3:23FSND
MKINO^;59LH+ |JUMCH|5&N*D,?'HN^(/+-+ %R|YF
"UYZ!MYMTG?'LQ;3Y5B1W8GTRFANY? M_X\$MC\$490^+->*.M|FULG0!P";R9%QL_
RVQ4_ET;A & SG6|_Y1*)1>H7F+ M=A J+ _1@@><)UC;^IWPT9+E?K;5^LAU"IU\5+3-
R1.),1+2=\$#J&-:Y6U;6J M+;^&/:0|U.\$)-V6!QT7!&(S|-
UIV=JL<|NJ;#\$K3!\$86U?.SN:MX1JL^88>+M\$H?
7=7N2+C6|D6)&:WDZ>&\$XT|7Y#*:X&Y(\Z51HR#BQ;JCU)'V6-P&IK)\$C M/*@CXZ#6E4?
TU.>:|NBL+#M\W7|<&NVN'D#76J_WGF/V6\$|SIN*(;7&?NG|
M/UMQ|=M2A0OAYC3\51AUGS|JKV_LC=_D)J2_+B#N>C"X/1<AV_//*^:O|C6
M.L8+:G*|,E>|J%T_B4S|'^N X)!>|!BX^SSG7_)3/L_|\$|0L_.P&AR=DN M_|Z?846?
^T3!|VD65T/'12*RJ*>*@>C;:0/(3 MS_B8C7)\Z!^VK%)ZJ@N-&HXX5?6K\HH-
|%.%@4|HYV,>*,KBN/B&/&V|:=Q" M_Z#LQ)F%A'X "X3^!)?L?
L;_YSOTW<=O_4T>Y_6U' V<1_K?3;Q?N|)#_
M5Y*|HY,B@IVH80^PEZCC=@;2H03ZYYK"H9|E%8V%9L1F>NF< 420C\|9&XLH
M33=SB3DZ27X\$2BUPH6\$XNKWGO(>8,3%E=5-+JG+4EA5EP698QW|R7Y#L|+^?
M_K=MYG&^16=_W,R|A|8LLSW%21^;\$I^W1&E80U_CD%8%*U&SL# E= #^!TA?
9R+C|6\LCT;76T Z8?|T'SZ@ MAQ>|N4F#4)ONU-X?0M6+77NDD_26KL".%/FF,&U-
JSFQZ7SWR,\$>^RVF|0S M7Z)?XNTDTX
KQTN^!CD9YK%#U5TL:^\$4SU*CAU7NUPGD55JIXF+7P"N;\$LC
MB?:W<"AS.#5+=SFMTN;23ZUHW2YH';J!%2'2S2+5";T\$EBS1+)AP7D)+8'&\$
M!/'_RXX4|8_91_82\$XJ.WX|\$DFSR5052K5'GV<
M|?!!A?|K(=@\$SGF|Y:>/Q*D8*NFKN|U^W4W\$='7WU3H1&G^|
(;1\$|M';03|@=TKDC^9(G_" M|JGVA^%_HWR&^6_&N5S&M*FY8)\$T=0%'-Z&
34)I_5WS*6>DJDAC*46>'@S M;LS52K/_5 0+CEP"K;5(I0M|&.@2:#\$!G:L#(&3%.>DE()!?:
@D@|7!_::;< MN|JR|f=|X48EKVQ/G4B93LW-4AV&WZC_\$^@\$S|3
M@2=;ZV&IE|YX%0E6\$.JT94!HS(+ER%%SHM\$U7AB7_9P^;-:#KPPT85>.#M
M5C%Q^TS6,>8OE7KXJRJ)AG\$*ND"*|,B-1?|=2+Y)6<:<%!GO?L"V/)I+ 9Q
MX46H;D+|Z<,OA))?17?,-%"E4(>%Z_62PV^J^)^VVG2?'BXR7FPL-> M8+N%="+IFWM|
|W:CKOM2O!>.BTS2J|!Q#E|EBCG<1FL9WRQ M3?ZQKHE8<_/G3Y!>&=FS|B?
ULRX_9N8EH|N'>E(RB&E(O7;|?3^Q% W>J&H4
MAN_@=DP+'Y>"XHXOVQ|6!6=S)O@4WXB7Z^R_|!L<.:U\$<2*.
|'4^2JWL.6GB9.*L(L|5AD5?7 ME#BV.C>BJ".RY(\$;(\$*W,Y?
FF%@1YM.RYOUFM#|Y|Q59#|F\$OUL)%%1 M2.=;LE09R)K%N?
DLVBY7XMP7EA|T(LCT0072|BT?TI#(,O> &N=1,K>MZ+P1\$|V>.4J!)5 MI2ZN9D?
<55P|T19<:L&D?|6|LP6RMM4+"T7>J(1TWM>^DED%U|YJK)JX/T9G8^E)M=/WP_-2?
L>|AR78 M#Z&).^ZASX&L7_5K"F6D2=N86G\$4NF587WT+T"@ 'W\$U-
_W9SK|=5C?/7YSG(?^7^8UO!W(O_2<'X3Q%N\$ MQ79:G?
9,D#414C0UD>:JXX<|D/RA3_2=M,\$)|X%T.\$9&6U8M9%KH5TUY9
MD"@#\$>:I=AN=NSA(LZEMAZ&M&AH@'A3&W\$P6S/TAFLU4*_1=+!%!'*>5OK
MX::GF*,K^6>A4BI*>GUSE,:Y)^D^>CI#U<;M|1'C5NO7&#<\$&.3ZNIP>34?

M@05BI4)^JLC@4)#M0@|<3NKH\WfV\9L37VD3K\l.9%+V^|VHE_!Y\JM/&(:
MO0ET@52!XSGC\c3%2&<+J7QP1<>G.04\VVX(6P97EJN^K:2+S!>@=0==,VB
M\TM&^5)?UDBZ'YQ96N%"FJJYNLHCIM^B_%7H/,,\$+@O""T<6N:9\$%1V9;>|;%WK=#7
NN#%F!7YG4T#Y\XJRZ6-M3-7;=2FFD4:-7\GB]=L5\U./I50L!^%X\$D4,+4-4<@'?|G8::N<"-
MC;Q#/%MD:UUA_F.>/(H\U2OT05@IWL\HSXH^'T-RKD]'4^_KRJDG4Q
ZW5KB@TN*+@4-M\%WYLU-BU|. %CCALM'<|B_R\$O\RSXR>R|-P?
VQ4I(EAS.L6^&>W/W%Q\$RUIA-M2LCO|=3EU)C)+0<_0I@6I@XK4598*0Q"ZFQ2'<
ML?K|B*IRDBGCNJ4CXH.POFZ1-MZ*,T8AJE%TM%>1LUBKHL<.*^/NP=&B@U*&20M-
!%JHQ\@QY\A\$)1PA-5.E* MN4GG=BE(O\#W.6D+@#9>D.MJ.;9+<|DNK\"\$<=_@TO_-
=^13/31C*-U(V\I2ZQGVZH("=?=1%*O.64-^SP-MPEMG(K=Z|.CNG/4>1?
J.B0TGM2F:AD85#6K-M^?5:20R)HA\6VY,6;*.0H1"3SJ8",%NSD5-"/(C\|C9+
MG(N>&W\K|!@"*Z'-7Q2I5\0<=Q/=9#BV4H=<*83PYM9&<2K.,%7K6\|M);Q77
MF21T_ZR.EV%B.;JYTH\HQM RB'^N^,=ZIM#K1E(L0XY=.\JJ\K8X3GI#T^/*|V
MZ)#"L1/R)8F58MDP>F'-*2ZI2&TAUO%5-/X58M\A^L|+;6:A;&(-!1?|#-A0-M3THI@V?
Y#-Y^5MY5TB;%>HY+(|)\|;CZ-D'DMM-79NJD\? 17EG5A!S&\|5U-M\|#+9%>5=!/S|:'-Z-
96\$%3F"Q)3RIC@>B,&QWMDAB#)*L0;;88|(B
IKC_F.18|^%3|^,U,KYDN#F3>P'0)O"D#RG":!F<|@B%/T6&3-M.M-D9=N8A9<'-\$3'LT?:
(-8_-2U9W+05\Z7>#5K*T)/0\6VZCGJG).+W-CY% M:ARA+-0DR=I*_D.58YK*Q(29\|PY+D|
M?7,N2W_\$.|))#:\UWOB\NKLZ+P58BT_M#*FPWN-@=JGK7"PK5A|_8F%Z8?/I
M(85*=GU!-FMQ=SP?#;8KP-<\"LA49G#H;S1+.>7=N8|<5:-4-M9CF\WE_YE1#
|FF(|+ZCUH?)A\$8P1;*. \"\$F_|J^%7/#0RH#|Y; MNI;HKD5\|T4!D7-U^|E5|"
|_N\COY)\$QK^M-*&EI94QP5^|I.7.|9R:86=YGU)G%-^ELUI3/N:4Q\$
MKI;E/X+KZRL,=T?Y'?499#6EL\$N8L72V^JX!;RBT\|BX)\W'!-8C2'VW"BU-M+!YMRNK
L.8KA=G"\$MX-ZU)Y.>!*5,IBVE!1F4T-:/(@\J9'NM5!"7)XDD@%YTFK\$VP|"LS_MBBR!
M'!74P?&/1%CL3&^T6U(83BLN-D\|LH-/K@/>|^2HDS)=\)|L+%>U"6PO4VE
M@X>JMAEF7Q221,7F2M#F+% ">\$|-X+H\$W5HT*+P6=Q;OWJV&#_"#W_IF*|Y=. M
WNIY91K,-I4K6&8)#J_T2B>A'13\|\$%FRR'<:++|B5!|L|Y9V/FE0&
(LDNAQ63DS)ELCPD*)I<^M(ZUT)BU;8WTE\XH\$19H9\$T;>M|&
MK2E0AAA\DJR,65S.+DOL/9\4^AIVH%\$;M3KM04(O5/O"4Q*)9AS|-P"
M>0JN(C*Z\J:K)WCACDI/:#WG=G.Y"K|7D^ (BTXL7GN^ (J_IU|=*73RN!\$M
MF@VAX2&C_T_3D"T&MVJV\W0O\KT?U9Z8+D4PPV\FVNM06^IS)IWN
M*.J'J792'@MDS9'M_%"1.B2FM>BAE-7L|<@HD85;|0OE2WY)HTO"Z|;/&H'
MM94OF8NC_+6ZNK)H<-!)3P,XGR+'T@KCZUE/7SH-D>V35'&5\$/B\UY>PI#&; M-K
W_Z!6W9IUM".^\$.;|/CDA'NM\Q"EAP0;VFF6P_|OY%("O:|JDA-)%
M:#XX=F)9<|Z|(M0E\8%(H(.RYDCFV2E@;=0! ?CS<7!M=>T-6Y\|Q2O*
M:1L1+\$S!+_L)YBTDQ#"G&Q\|1YT,B\K7&Y3;2@L*S)^!M>_9*N@ "A-M^6G*>)N7CQ-
2L\|D)1V52R)-OCJ;DIP+)ZO"(*HQ%ZR7@)=):SJ|R1|H\$! MOZ:H0#:P=(N^T/'\O8GY-
_|LC(O4-MIVS\|5'=FW5*+|M: ^DR62D-@K|B_PET9)YX/MG6M5#1WN4)H\W!&=;64=V
MW@6BWD=B&=LVFX341=! '2>).\@V.93.|!LST!C54=54_|=AY=G|(H-/#8Q
M"6?"GK'NXD*E?|U45C%X4"4D\|'2Y#_6.!@/-/VUM?(&U+|R|?'11"^DXU# M?QUG|-
+0S_0OD0A\|23AP^!Y2;'5&>UTIOF/|^<7TEIA?'F6|R*BE""R-3*^|!;P|-W&1|^ME
COZBF*# MT650"*AMI'%:*OUNCA)":E&SATDTR4F\$FOYU#&'1MC_N\$NEBULVN/.C:S-I!
M?FWF5N|^XP:K6-M.3Q<.<6&^QUM-7"88|@S*|SU(O>D:N%+0'3WQ@%V4^">
M4WH0;3,*M\|74Q@PVMA/7SF#&2|PYBL|S6,1L^ (%GIX/Y?0|?F2^|B65(@EF&-M
B\K:>58L'\$|(<3')51=P?6@_1L\5-L|0KKZ?#?1N=09L");G:USS-^&_4
MX;7S(XW2+"3\$6I?=EFUAA%?9?B3A14ZV\|%25^BG"4"119=M9Q(6I5S#'OOX
M:\$WPSW=D+YIOXFK4BQ/JY:>V9@AC;A'9M)\.C2|<@_H)'LUIYXLPZ-VE?QAL-M?-
VKC/_##L(R:H_|(PD?%T=V"3Q36-EX()@VDU_73)=. MV#% Z:(RH/,BS3D"1FQB;|0+|?
P(-KHE/WK^B,*!"M\VB2-V.TK\EB47_@-6-M(G-6_|/5,'\$.PS
8HATZ!DL,9YW").+1W1OXT='?R)?1Q9O46/GLD\$%\L3;
M(DVJA"+71J6D+A\6C>WEN97?"V=H"19:9'|/*M(*O ?H"3U8|2NT9!C=2_P?
MC\|9#1UI+7.4GAOG<25<-HY=A5W5<&'N9 ?_G45ZX@-57-EG,\$'S,>;&L!-W
MXKZIW/'IRN|>7KYFJ2M_P.JTB-:ZZ&G:YM^)Z6A.TD53..UY^CFR=:36ZX<+
M\H76C55%E":<=Q'5_G1+>M>R#"DL%*7&GEC_2/Q4-WFW.F-Y\440#.,@|YW;E
M&1H\$?.&&Z\|E=,2J+|08Q>5|02\VK|^Y@'A\|Q=S4@VMHL9\|S)S^\$GCU?-
M0ZSHWW\@E-D,|\$*W#C5Q">|!-80^V<&4;D-%;&%&'B2%286F;)A4W7\$D6,4;&!A(/:
M1M<_DCQ\$YR(3#^"*=05FY9'ZZC6C3T_T\$NU:5VC5IWA:/G#@7*=336C9^J"O
ML41\$T\$'+:1K4^A1^":.5)V2"YQ13*0L38M9VR1M\$&7PMY^OMV;'CD4&O+H\$E

M"I1&E&?6#@AZ";3*>J5(:214;J-
YJW=GO0,PM0RW*(>I(3WJ4UPUA)IM"B4/Z%];I%DAW62C:PF>Q|WV94Y)FD-
3^Q0RYFFNR ME.U6#"4U/?*!>Z+&QV\$91GU+I+>VW:[SN=*RZ%&IKL=
I@5*AC6VJNQ5*>MIG ME\$U@M&4/2] \$ N+/(S&W)\$76.)LORUP#>[JN|L8#H?
IP|8P4,FNK"A+4C|BX-- M4D?|< GZ V,&MW62N4U|1G7+C*0|!3|V3H3%/Q
Y6D8#YVK>,1S|Z38Q@GA M4 PN^-+J1>&'TU8G3@/.XM,;T/VL1,;
(:Q>>HH,/ %0IM\MY17.S7I:VGRV= M^1/AF6OM)Y^U>NV[X3 QWL;5+!
<>#J18,#2WKY_X|J^#EL:V0T6&F^2&9:H.)":.\$#XJ/:CEP^8R
M6*WR<#,+3V!'8RDP;HFWIMJ1*J:BQZ9()MV0AX*^IU*2@\$QUK
M|4T@G48.NFRK0XH=A3//.KGZQEC)X|CH9;P3Y5DU\$1%B:0/-DG|?KH46"NG@ZW|&V
2+ #MHM7@+X=C |Y+>RT)R2+.L:G+WDK_MHM:6FOI+
M/_16_CQ|A|*_2C@ER6A.|6N+F(;BX<5"P|HD^_*;5#S:P?!L_P_>./,WDV| MU,
|3OD>)4|BI/"IT!;A<==;+V'N,[UE/5RBPNCES4V,/'\$ \$ M;TA|_)A(?
SI0>=,04OVLW1K29RDX)TAA*=BH7XO>\$PPBV+BMN-FFE#C,PCX3
M*\$,EM*3#H&KI&A7S|4;+RI-|;|_+K&;S&C(TL<;-V| M6O^-OSG2O1 "E)@M?A+HW4+
MP01&DX+LC!.KIJH;*S4Q:N&)CA@3UY^O M\$W1PN+|K1G9C.QMEZ\$3WJBTQ0Y
M,6LX-HE8X|,FXW\$O\$|L&T:IC MSZ*K"ZFD3X"%T+UIEJ@7"H|8H+M9,9??D|
MXU'(DD9*\$CGZGJEY>|5PI/AFTM1T>R2I0ZHP<4(;M1++?0H.'AW_O%V6U8|D M|CF-
_YT+I#PEY^1PYR|&-"|923"/;VKLB Y99ABOMSQR516GF0,'E"|G@EU0U!
M<|HVB Y)9.R.ON&*U|07 -WET4268ROG6NH>YFO?L>|HNS_SV(@G3HE"T,&?
M)\$ME%T|9IAB%087RSGSO*+RUQ6ZGYNA)'KI#@Q"2E#K&ZD7QMAO'H>4|+HS;
MA(0A7-/?;0.^|R1P56_S4-X-#:G57+N.A1/S 4'R#O"|2|&=D1?*L&S|_BTY
M74(=278+"|N/!). "TC)|H04J?_%<6=<;C6|?&M/_7ASSZY;3WJ0)D*|L/1D&
M3|JVJ7.=45X|M*#@|%%\$5:03IO/T;<6C.V'FPKU8KY("1:==#D/ &6FU|Y: MZ/#"C8--
PGJG0N_"#6V|(X8GT^S?J2"=R.9:|Q|XW|5TV+.W +%I#M()Y?'E M9^O-
E%:B.+Y11G|RG&NEHV""X_|X2P%2|S(UE9G|9T^C.A36W6GW|\$70*\$LW
MBY_DNHCWEX;T MQ|!)>&A9V9Z@5|HJ*CDKZI"7-
6|W1&9T9O;:S1T'#YW|A|^\$S6',L4KERFU MP<0FH>41(W8/L,E-S(SL)V_9^QK-
*|VKB;:2LB1;\$|1V*S|AR%2#%/-N&7#
M)DJ1Y9Y^<9%&Q*|+M|Q|=/?G0L?;^ ^TH"">'JRQ\4H0!_|6/N?+CG@Z@J-N9 ME
WCUA/;DZIJEP#4I(.LS_%.DLW;3E:%-I)W5NXMB!A-7&<%%RE1%='=:DR5
MY,U)G; &J|3+N,J?=:409R8KFCF=UWP>+E)9L^Y@&*&\$F2R9^R B6PP=2K)C
MRR&5WR>M\$=EV', \$<2M =S\$>6TY-1%|!F920^8HQ4L\$'N@:!:MSLJ.|L2F%MVK/"C-
EY*W)_N*.RYP;ULQ5M|9"^Y44Q|H04J6|(@IR MRY3L/(0X?1*H\$<|;0V)UW!Z
M|1,_1|_#7:TE<|Q\$':OY:|R@GPG55AIOH;+ M>Z|,_,G|P&1-|T3'R@UK6LND?
S#VY:2FD.^3|;\$|;SI3U)K.P+J',XK+|,9^ M1<_|\$DFQA7"?*+J<W-"90PJ M*0'BNF8FQE
%UX-SE5&NPZWH;_)QD|)(+>TV|?=C%>2(C^M\$HEEHT()D;P MMAR+3
H:UG|B31TH*/F08>/:&-J;7F|U1<4Q|=^J*N+\$(@'M67PG9_IF* M+KD(JY\$+H270S-
4CHV FY\$;5_>)Q977+"X0|GD'V*6+Y>9UT M?0ILI\$D'=VC6KBN?
RQX6VCA\$;1Z+J|+GQ+=&P0-9P)E|Q-71Y NPZ +S.6IG MS|>O5%|VT|@(N#W&
<7J>@?;!";, M5W/
H(B^|;UIUTJ'AV_ ^0&61O|DE| "9PM/UVO6ZPK8.OW@"=E_7;@9Y\$JTCT M3.P-
_4U<3P770/()00WTD T:EI88=A:-HQX?B=CG?4D0F#*9UQ;:3^G3E%(?: M;A+3?4 Z2'? V#-
Y(|ZL:VV)5;^WN?'6F8G3QIR.=#D=|) |+"Z.X^W%|J7K'VM4L MOY>H_-E|.KF,U M X?
UG+&C>U!U@JYJ&..XH-U1NJ-J|_%GGUV+R+MARN^QL_<3*(K(KDF9!).P
ML9""NSH6D#'HO5:ODVEH=7J>.:??>#.W&H0ZS|:RKVGNY|M#%M\$KI0FE7*L)
MNE6RAV%#ZZLB)R..MW:D-NG6QBPK,SF:IV@%%-Z|*!0_BUD\ZK""E<>=0|L
M<+W(*&K)V|Q|;7I0/XV5ZJ#N|E--&>--1&X6G"('L30P!EGWVF6'#GP=/@
M+L5Q0=>|3PX_7^HQI*Q97S0U)A!4?Q>Z):PI|D%?L,1?9HQYW//LVTW%IM%G MR
|BT#_>IDY|H=SL4|F@6*1;?.7K2;FRUI6&\$!M|V7QXH>B|\$_0 M;@P18|_Y/DGV,=IA=Z'B-
N'>R=BS1<@/HUU_4;BX.=F4B;KC|8Z2B51M(U.C
M.79#IF2^9,>|HL7/U_*"J6_98IM%P0<*/X,+.WUAQ|+A\$|29 M?
I%SPCLW=#UT=*T&>U4D|8|53)9W,=I=8\(&E9)|O?-189(@K\$"3ZZO;:7>?
M3R%.1Z)7@QF0T01|Y5&ESVVS7&LSSL4%)2+7&S%^&J7"|;)1677VI?I*D#?+ M6|?
W+T7,L';Y= 4N@2A:TZO!J1&)&!4TEKR3HU|3F|G>9U(IU*\$K&#M@|C|/|
M|"/COX1^P.NMWHT\$>+|H\$RY0 M>G1 83!UP1Q:L|M^3C7\$3'BK&8VDHEZ;JS%3W?"
|W63!?:9:P--R|7;DX8U M(QYSJA>'GY0;OE5%"44-R*6_#D4&KV_J M&5T";5NV4E,XW,
|NEJ|B6*XTHG2FD6W8F86@B;C7&-(ML=3(Y1WTD^_*

MJ:#4.QS\$M362W)^WJY9ZO(E'LB;^C)'D>D1H/8?8.&UETEG+TV!O%7K=W:3/MX"
XT61DE:GHD8.DT01G@-P OF4L&!'MG7K?)^937[C]7D/EQ9C]^V'?<-L9
M@N11USL_E.:D5L=R\ZL)DW*W?>VIU|=+6*8\$XHK'Z,-[>V,5.%U*LJYFY"QHVAVVNL5,
I)2G:::D%X3AQ#R\WI::%: F44!R "; MI4ZH1R:'U2SR:P5-Z=6G!*>D?.GQ(=
0V'+IEN9U0/=0".Y]^V5QF0'HK:=1 MS9ORPTN ?JN^T?<)>M-1HBX!BF(C%Q(IJ
X% @9YJ_.*Q=,I02K_3XJ,J1 M7L60()4+>W1V)Z0&QJWV3@NG44;IDUX)PK4)NY8_R
L&Q&FBUUNZ7H92NDD MP5+.&P+%LQQ-
_IY'^=FCC%F'P)FS2)EM0W8[XIB19W2TOI=9I=^.&EL#&'&L MJOE:5Y/Q+(->R_M(PA72
M4K_OCO_7UF!T?6\ (USD'N6-1T8Z.TT@RE?I72?*:?.MW&\$9^%#_)X,>XIV MV,8\$?:
9*!&_41CIF"Y/41H?R? 5B5*2,JE:NM_FZN),5#61N,2L
MOQSR+\$I1@E)WWH0T9H06%1BO/(@AZWB7&-) 7.GD?2O>207.,9JE0NFGX8Z M;Q,1E2-
QGZJF_T@B= F\$^:,M+P&Y08S&I'6_ZD7 F/VOCY1471G-2W%AV/83
MTS%/U6C&Z'WBV9_W\$HY0@H0&@U:,=A0(9*3T)V#TY^J3'I%5\$TAE*/G;&I;C
MI>_N4=/'T'E^UX"Y_OK::I3JJ#I P+5+(%8_ UA?M-=IG\YQUV=,&H#1&@_2
M#Z&=7R9\91VKA-A0@3UJ6Y*:%P"^(32SV#((>.LKP-&I'T^L'PG'OV6Q;R!)
M'H_ZLB+;B0I,I%I>D^AHI\$LO=>K6RHA44AC!JG=>?AZ%8&K'I>BX_/JW5ZY
M!PMUZ:XOGWF7&>NCW>'<3U02A,)SP"ILQ_/^9%*\$#^203SH>8-JLI/
MZI!#U\1W\$Z'S#H0#;I7&: MO: ^)?=:,MU%R9P+%1KT(SW.#---:\$"'EF"'6)4-
8'1\$-9NCF0)*8/6L3*HZK*MJ>
<6FNO5=YOH;TT9S8IU.TLW+OWMM/0;83J.47U;6=6!!&=@ZEW.X9W2%#=
M4CY5+D0^UC# #IC9,KI8VA9_JQWF-
+UQQJGBZ'609I3+Q*';L>-1\$^*RK_G/I N""%C+3.IW9WSNXX4?AL:\$2EYO?.TD'M MG>,
(V5?G9S4C3OF-UO-I G^X>73*CMU+\$B8A5V\&\$W#\$VBZ34% @QP!>45"FWKJH1
MW#PPH6%+,::;>>&Z5O\I B8N8>7C:C>S%&;JXFWU.(^O'Q,9J8P2*A!6B7)8)
M^KC?I;A3IK&OD9A,6OWM?K+-YC151ID2K7T*QK==1?9;*LXE4*]@'=3:A!R\ MP);>?
VZ.N5\OQFGIG%/6K=.15\JMK&6IN"IS7Z1F+F^0\$QV)C%4/I-((:<4Q
MG/HIS.R0I=.'#;:B=O:Q,N\ \$R:/L@!7&!*" ^\TMB1JI) ^4H)P
M@W33AW2909FLTM(I*KX\$!C 7@1?>IV&W,0'E:G8G+IVSD.7G5TN@S.#_6;6*
M2B4HE\IHNLM*7TK4Y3SKGO<(OUTWIF00(*\$T_2S:I WR\ \$&"MTYN\$+))7_02
M(&V*V#XBDM8+: MS2E9)OSEE\4^GG/KC/TPF)IVO49_?A,"R5" I<&\$?I-^"L#340&
(I*/LWN0 MPNF-XYEH'Z%X+I6DL1W-&PYLNN,2* @4.I M
GMS#*4HS@,F!.WZIRNM.^Q_NPRMNJ4PF5-A^@0E-5L/"(&Q4V?
5&2I\$0;)3@W@K\4V\@F/D)FT'K,+1BNMCB;G_-AM7I3+%58-8 MY>IK9Z^3-
MYJXM(5_MB\$'Q(UL'D'R\I=K3IK())B*9XSWOHXFHDW5OBFEBI&?2!2B21<9VOKV?'
M#D>EAAX1!75ETM170T)#H9GYSMYN91^::2))\;3=W&37B?D&.)-'&J\7%T3G_M@@-
/9)KL7MYIS<.I>R\KRO-A6\$Z63.'I(UY+PX=ON(B29>/H.=7RB&WW8QB
MPM/1P5S=IFU2BODV6>KPBW0MK<)>ICI ^1JL&92FKNS,ND8/I>XC9:&+TJ0*
M^7,SI@8\$-EG-2-M-,W#W;=6IA\$.C#=6Q.O=S=H4_)5U!R'I^#T% EK(0(+D M6S&I9\$]
I<&4_OBV"IV;YK%>W8XPL3?-6;'+-8C_CF0H,I3CM#;A)BTBU:O+
MM^8I:1@E48O("O6S1=1(-96*B1 S*U\RI<_G4C*IR09F%Z/W.4N+8ADJ\X4 MF*K%-
Z1,>,L3^#)8I!;8<;PIHBB+!)WFD2#@D-I G3ASH-4D#I K\I\$6B#@X^
M?;R,GI4,+BMBTET!&I SWAQ C1:6&'?F!<\$TW5B=IS)_"QH\8=IM6;*VJ60T
M+ZPARMC7P_!QV)IJ+R.IH*Y(WK93B@0?VL\XB4G%R1U%7KZE)-?H@9C\$-I'8
M18N+,"_RISFO1\$B(P\$Z+Z!&&Y^H\$FJ...USSK\$E&\$U:P.CM6%I<8@DA+960N
MZWG\ANN8#!)R6I_8;I2HQ2@_H^F\37Z?
IV3BGM8*/GP%7X7LA7O/LA7L/I9X140\$ZKBT)73RH M-DQG\$&)2\ICJHF5_? MY+
<I.8DK6"?=,K+*M@,&X+S=#,)I)6?I5K?NV%N>6HC)%\$IC?M&)RZ.M
.6#Q\00.F%^>X4BVE>+_P_J:47C<-BPL;&X/NOU?MX;I"N. ?G?X! MA5I^6>G?
JR(923.2VG'R#3D)% JK 2K&MO3WA6N&I;D\#G2'A7M;0A\DM2 MQAR1X9DWWY!)8-
_N5M4-2>/4RO#9^N:X\I*70+;?K\PI?,O=I_WZQ9IV;MDI#R?
Z5_2O/LQ/&I&9\$#AG:6,)L+"R %>9?P#C M%W#(\$;8=1_!V.%L8B<_9@9?
DI_EY9_PYVMK_7^SL:P3@Y/DO#T8W(C%LL/Z ME(WE",JR,
(FR,+H!R!,^0_10ST6X+V%F8V\@,)D/- LPU6=C8RH M@*DO\ VX<IS\+GA 2%
I;G\$/8X1KGD5LB.O>S7W IG*IO\$76<("KJ7K\=S\TC M)BYQ6%+IJ+**JH>OH'AB9-
&9IY:6%I9VYQSN39V>6*JYOW#1I?/_ ^P/"(M.Y%1T3%W'SQ,2\$Q*3DG->?PD-
R_Z:."EZ5EY:J*JNJ&QJ:FEM:W\UOZ^WK M'OQ@<^C#I<7)J>F9V;GX!@I.3OJVLKGU?
_T':_KWSA\ P+INW_M8L%8&Y'^_MM\$N0:1?KWSW@_&L7"VO4WP<\$V0_(:W,
(F3MP7KLE?\$3G/I?(Z>P7I3W<"KJ. M1-KMR=XQ:3U<\$JDOZ;IPI+_G&'Q_YL^W\^Q>L

?&PMS\I@\$ 2@P1LME M #Y(3\V=1XMRF>H*QA\$Y,99\$W4&P-52'Q,Y5OE3?-
*2U+E37WUD2&XQ/4X; M9HWL/P5M':(I>C, 97T8W=B**C7%?\$NB6"(7PVA&(I"Z&?
*S3W>RN@E%DIHJ MY9"&XG73RKV.UF.J^+=D^6+
I3HJ\$=0\$K_)HD!V\$@P@.\$Q%P:0.<\$!;H
M6.A.=A;U^0P2W\$2@';Q<JL<*D7I((O.L;"PMI=X&-RJT_V^15//3%'@R\$E+ MZ';X909
:/JW2LJIAWHC;I8,0B5_H,O_NT#@#8\$6N(LP8P+_3_WI>JWF? M9@'Y:1!"96K4I4TW_Z?
8?XKJHA_BOVGV'^*_:?8?XKJ/TL\A26Z&@_KTON M90#QH:IRGY S22J&;K?
0BGJY'U0&D(+1%J)%'&(B M.ZN9;^A?O+.P0AZ5EQULL\SKO7I\36UI+=#E*C+D;=V
IU8W1*2+X\L/R8;IR={B:\540J/GLFW/'ISQ;:05?S#WLH<@\$MMY8!A\$'CL=):
MN";YMB..Q\$.(*GU&(>C';=BLIQW-S_2H);I%.NHO8/780; CJ=5AZ+I^><1 M_/-^ U\$-R-
I+G&D;<+G9.3847^+.EM+ !IG?3VM"[G;HZM8A^16LNVH+IOT M\TM1G<" 5W!STE"?
^YD;KR,B&J5!X#-XZ8I7QI8JJKZ%>C*.ZC=+TAYJN&UT> MH<."/I";I7V581*@\4-
.5.LR8P>?P:06A U)-8&NBYG&"!!EV*3;BRM[K] MG:"|=Q2C1:6FJ%MO;41=&I\AL6/:Z?*
IRMRN0M))622)=@FENS7&.O'KMJ NN
MTV/2AT93U)4O.I^XR;W)\#CB1#N,BP'T"%#%2=B!+H \$V7J-(OY((14RUJTL*ADN:55:6?
(MDFT8NUV";L /V"U9D6!)>N0A0B.3D?<9PLX;_PK\NB" \, #: \B MPI(C49)=T*!J?
52WIS@N?.G'W9UL#&^1XR^NS_J4,O\&R\I-PR8._>Q>9Y/+
MSU;X;Z/2H40'&"8,#JOH8@!-XCTAD4B.'UVZI."IAMU;K.MW\5^55OTD6=P6 M^K%-
"CU2J;9Y_*5R^S\KJML#*OD(" ^G7?J@376;2(HW?93Y^:V-M>6P9*^C
MQ.WO\$\$\$&OP;&:_4C4B\H(I%AS)WY02V%5/V]=T4DB_=X\XR1E=!:Y&3A.S"*W
M@H1*>"PHSF6HX-W>>I&\Q3!56JH?)B2 >P/79T."MO%'OW8#OI/0'^
MJN\UG\+2T:V\FPI(G.08XMP@?SR&\$.T^P "\$.MSR4-R(P_H%L408N+!*G\U
M>F&;IOV%) "H.BN=D5YUV\1/S>DRFT)H80_VG@\$T0WO&%\9QV/Z?GCL;WF1
M+K)Z39-4X\ HO< Y5D.*50\$;S\+M7Z(*@_C+P,E @#*; "L*6L9LIE!O16W2>
MJ4KZJ*S*K\X\9&!&PYKWCJX+J.J.MGG-J1H_F8!/NQGXI>:L6"=G'I3^%I0 M&70::V@ #
(+LN1J*OH%BHYY/HHLR@(2(OBKPU>1!GND/+AO)>#9C!5/V7;&/ MKN=:8Q2-)R\I
MI#+?I+?,Z=P95+S05VR(%Z>*C#.I(=8E"G7A_,^\$@/J1;Q*M)3RBNWQ\5V.2-
E4IGE2S:080 M!.5!=#. 1@NJF)?*3 E\BM2:IM1LFXWKU+ST
5Y9QF'P/MML<57IR%Z\JC_OH MOWMOYA9P5XH08AK=5#>\$7AS'5_3*>.,UW.KZF
GU8ZIX\Y>YE>TG\&(*)&X4 M7'EI_JH&Y<##:P)-9@E ME<(Q1C98X8.RDI#-
O\$/R>A:@X\+ ^GBQ(.M+P\= M/_KB14I8!69 M#^)XO;#VNE3MD+B0F\O#K_ ^+^%?
E0\$* \$VZ;H9,UPI+H@.S M'1%ML\$7+C%?V=\GH@"OP@13>MTL,0(U8\7@ GL"L9)IH;:;0
I9GMD/KE%\ MP;:E.-V^_"^A Z, O# ,B/ MP33F I)JN>!(ATW<,==(KD:Q#9
^&OV:'X9NP\2W\HC30-Q@JB\GXCJL MK'M+C+G@ 'I^J\K\HL\$:^3MH54GU:04=H
EZI_3W(C;5C&NO>-K36;SD)#0.ZT3?(!JN<7; \TN?0BA&D-R&"T,++'O:EN(?S2=(2Q%I=%
MB6UE=%IOGH'VV-%GO*XFG\27I9CONFZAVX_/TY.XX-K!(-5R\I
M%^=ZJ:E.*!KIV3FMMRGNUMR.LFD7:WMN\%N\N695\XF%'.06\;U"7\$71FXH7
MHGOH*(HOXBO&CRJT.\BL1KM971JV)4OC^)4DW.KKZNAS\$ _JGG&R>Y2BR*%QY
MD9RS>61\15D\<#00@J*T\K;5CTW6^>F".F)9+SH&8 I MIGFT W9R="K?
IWWN3*G&>'QI)'">FG:-Q&4(0KPTCADG^&V0"-B':XZ+JPN
MR>SOX/Z7B:!/14MGI;WITMT/90+WK!;!9\0-*IDG6E IQ6\ M_2ZNRFE5_8D.F^
MIRKEC9"ELTO,@IYWOT4OB@QO,3LVYC;I*C6\ P1@'7>SQDT;S\G_#I
H4*H02376G%78)4\$/ M 8K03X.IJT4X^Y3=NYQ\WR8VC\2\$7)XS#L:KE=Y^@2N\^:G8
_=L-/I-T "D M&;HY4T;-!&6(E!XO_699;5+19!!*L\$MFW4VT!A.6"#?9Y+5L=1H6IA@R?#(9
MBM0W--H\>IAN&0*?@+&#S"S"TBH@=)X^Y8T71/3@HQ_%XA!/!%F;22\$!:9=R
MME=J'J8\$[MI+9TG;*GYN:GAS6;'F@L2;J??,O\NCO8\$&HC%6Y)?@S\6VI+V
MA'X=#ZA&O;+>|+W R-W=)Q<5>K 1AC+;2^\$;4V,IU6\<E52-_D+(I0PH\OTG)\+HS-
'/-:)CZ,A"OGW\Y^J"/PUNV+ =NJ"J% MDMIQ4%E\MDFIU\16H:SF\YLFCS\$O\$M:
<,YDA33D..R^AQE MH#+DZ'6\$|^@IT\&7Z)-T;63/&080&)8":51"#17%
IWI;\$I@SB<)_WT%(_EW MBB2G*;7U^I4 V/N7OL^I-<><7+
LFS.L):#=GBIE0;9K;7#4X\&O6<\$7.9I%MQ.&-L-(O.1'M\$;X%46'>H!42:QI
M@)"XC^V97S3 MG7*&-A\$MC0R\$ID!%
(CJ%SQ'7BHL/O<_J_3PL>J_Y_IM0V,B7C)N#A@D"QH^D M<\I\$80!*#JP&MTN2BC;7?
^U479ZS9%!/ _60T;^6C1KG10XV:%UGL56PO7C<3 M\;F"G+TPB\$DLSEZ\$CL\$>
ICKF\$20,M^K*60I2W\26#,KVI7L8LJY%_2)8!KW+ M^RIX\;YLLJ^ OD7K5\$/-C^".U67\H)
(FNMPPF0:Z:\$XHD.4YN_PKAN%*N1F MZ/ *3NN! I-H6!^MS=TZZ
M3!K++>_8Q0Q0Q'F_Q56K7DU=.'OI_5'#2)XD-<5N8!^?"NJ2H4PRD0'W!4?^
MM@&PB'*6:CN\4=-A3V0_FV2REWS6N72K2AN9&J>>+I9DZF";\Q'Q0.I';:Y M'

BHRKJ)8+(6IO\$VVJM?"(4 WEH8^;1',J+XU@X?VZ;RWMJ(V127CKS-=^N
MCMWQFZ(SXK&AVV90I|JZ%&@P;-&*7\$TK0B|70_135S7/V=)1F?*2&J)!7&_MLB2<\$Q?
+T'N>_%.+|'N(:#6RK!).?+:6.J.97NSA@/Z5^;FN0SOL,0"Q0*? H>+)
M>"*|8*9RQKN)QIL*!|UCC.LG_&J|W/FCM#ID(&2>0#8_O?\$(7CAM9^M(!=B%|=
M80;/S&R.W.;<'VTI1<#%#I9=-T>YK="U\$1A4J|L#:"!D86O9):G#LZS&
M5\$):\$.WZU%BF5;H|Q*]&\$7*_1_K\$BY26E (US5C|N0|C M-
XNN^Q%)=C8PV#JUL0)E1/KBV537KPO)/"6L-B: FJWZB*?E)\W3@W?RN/&N
MAKF'SI3R09|*UM|CDK|#=C.FIO!HVOLN642W*0^X'&)B2+.^7/0V|QQ0MRG
MANO7HT+2E^C#1;MM7+.^|_.(2O3W1 *N:"NM M^=WFEX
VI=P_M:U%!H.J7;95+|JFW;S8+|0MG1#X_7L)OR\$M&VZ('^->@C|)\$% MB159'8?C7@3-
2IK8U&\$"Q9T;3=H>J.16|2|.*@8K%JW+HN5P7|CKIKAXNV7D|@H
M"P|Q&VY!RT7|0Y*=@Q\$|,0 (QB5"@/>(<#&.-'K%Q#U+)P_<,E\$K47K:UB,;)
M\$@Q6M=MY'.UZ&KADT.|XV)|P|YD,AO|(|AX4|'|T1,|SUB12H'>11"%?9
MT2=;B+#+@F"OOZOY_.T?-HVB&1'|)YA#8HB1Z(6|F1O=^?SAMWA&YS7EG>Z
M>_BC81AX%%9|C<4|4(=&S4*C")6|\$\$.'6, US25<0P@>2?\$Z!2T'R;PYWW-
ME: ^|Z3;^DU|*"U,|D0D+1YRO+R|Z6U(L4X\$|*3H/C"(%OTJK16A0^=M!|W< M>-
"X/ZHMKZ|NAWJ7C)'<|&WY|0?JYT<_55AQ7RS//\$T.LEV/JP+-CB)ZE MHZ
RD7MUIL.^*D@,|^GUL?(H20|P<^6HU;/RW)9!17F!E|3ZDL03GX^H'=CO
M^H<|AH.E6\$J!_8Q?6)#.1@_X6OVE#|;P5W)|AYV1|-OV1|XZPW7V3%>+|
M.;^(T93#M|M'&KV|X>JT1UTGHZ?H/#,\$Z*(48:@OHH'X*JU,"I+X>|S:S2/F M395,VX7Z
?6.JT/D9H|J@|>|,%^-:|< H;_^.4)!<=B\$V\$*,'|;/0\$+KL M?
(#RH)=|@6V(8XBS5%6H)M^<\$%<((6\$|_|!?:|BVP.G%:J|AZQ-[5H*,_ ^?
O6I9|9&\$N&Q%.M#TS,"7'&+HF|^/T_ M2NTYJ|'R(:&;W^K=HX_TR E-
ZH;?,C3Y</'K7J|@6#LR>%\$5K@*"8LJC#W?
M2LHKK/&T|2'I>DQ';#6Z|ZE"=&T.YZS:O9.SXCASKZ0H1@-Z5J6\$JT:A,W50
MHEFJK|AWW<%DPF*E)|_SM,|GW5|/3G_D^O2=8@Z#K^7%#Q/:6='B.R+DC|'I*"WV(
M<@L;6A3|Q,3DZ7SW3.@1;'#C|H.S;5"-;# MAS,((?
H?:B&UDWWY2Q017D0AG\$GN/1|A=HUD"SK3"0MFTU?'^Q_O%X,3W^T M."'
L=M'96'C5MC6PV^6:|RC"FZ),_XAM0F|T4"Y0'6%ID+=/(**;.5'>|0R48 M-
"B\$74_DC7+|=4.XT5|/|>))PXC7Q,2=95E,+Q%.F6%XF-G"#^H4Q*(FD-
"8='S+P\$NW(%&FZV"YGC?EA31VP7BDRF9T_G.M1=BV^#@/A MW_RS;_ ^Q3NY2G
B.6*Q<7J050OK@)76BQ|2#)0NK*MNO_?!JM 8\$.9\$6\$@5 M@^@%""%I"
VJ0^|13T2CN|T18O!3Q/WFS,K|BKW3HNS4?DA)|=%QX1L|44
M20M|)U<();HA%UP(%9N>%%U_NA3(7X8,^B\$)22V=KM/3;|N_B48IN?^Z,|'
MFN|W/DV;RQ<>EF,CBXJP_%;|2#4|.E8Q'_>8K#Z!X)N/\$6Q-<<-M+/UT>N:|
MV,!5,_|UZW_Q|L&UR.1"Q,YO-\$;+# 'G2*5TGJ3E<8Q|CZD"C"|ZO!?!+|SAU MD22I9A.N-
)KSP|%\$;*+|_.F9FU*C-QUT*=@Y9H&964VLHXL.D27_6I(W&0|& MXB++MV"/V9-#|S=*_
|J38NNWKUE_6!WX-6MM1-7*2;V6-|VE|L)7?K%FZ' M)>=#,3Z4&0#(!Q-
ADZF|17C2H78P'PE+A:%AE|+ZJ%;!;Z_I4*Q*F%+73AF MY5*E<-
_H)K%^Y""X0A:#4*'>KQU\$G\$4Q+M/+<=*=7I|^M;:\$S-5'?/(JHAE
MAG9+%IYZY=;F2W(Y5OT0|VF" T4=|='KQ_0U@\$C0.TM"-!Y|@7RU^#7P|9>O
M6)C4'5LGQ6QC"|YSP|T:&V/&C3'7S)#O*DOX/VK%HH"-N=P4/ H:H_01S+ MR0:
|XP+|/2:4HU|6G.TZ/DB=\$GR0N| F<;156\$|>Q4W7:~?KE1.'^-EH@:
MR+"EOX^MWZ**1.&L>O@O4%Q(7:| \$KIU4 MUFA=K"SY#1(R%_..3ZQ2(J-
!8U,^S|)1H".P_-M72)#X1B|%&|2GE|-BO#.W52 MM#6OBZO(0!RB?UPZ!%XCP
ZV% H67_38@A*UY;|^2 MTV>2&DO0\$O/\$? 5;R/0O_088#S+1;/>UD;&-W':.A?
4\$7^HVA|H|_7US9N0) M4YR1:~?HQ^%,>|KOMPYYN|L1M%QEXA17^7/V-SCB^-BAJ=
|P7-D7NYM8_V>< M8R:1/RK+4XZS& Y1+H6|XA?@FX+ V%|F\$
"P1/^,)|7WX(/&6)CRER_%"9/U|_.O8C'Y MR|I4806"7R|_TMT#FX/O"74"MEH)<
734C9/MW4A.W8A;E?81|KYO#3Y"!>% MA,.-VW/?
QYAM>HAD3U:F5=|!@0JOTBBZT5HX>W)D9YEGP*Z+EZBG)6 M0|0|?
M#_5I)+5\$HWHX#KVK7DINCMS;S9@E.2J|*)IC"l;|MT#Q|_|VBP
M9HV1|/M&W@DJ.&SMFGUFFHZO0|P|!-.\$AIP5:PZS5D|\$Z;.(GU|H|7R=|3
M*E;%L;|Z,DG#C(6.?WG/5_0,IYQ_3&.)(\$2&/H4X#EI"^B8#LM>7A\$DRJZ6<
M|YLA+9C!28T@Y>>34M&_1.0NLC|66G%YO.OY'Y.8_^. (S|/JJ@|@0|<7U?M0
M|;">)M+,IX?|V&3|(G,|!=X6|6@JS1.SMA<08|%V\$ MB|Y/9S-J%R,SK*=|2M&ICD-
A%T+*_L^L>&H6:LPKR51Y=U@66"W@=*Y-W^1 MO_Q|73*=%3&+;O(8
"@&JP_+%Z=Y#C3)4K5:VC+=TCV;ZF/:P>X'^LL<*7 MMO+IM|#EN2.+JS_,F6\$1'T*?

1TLC0R#)4 EJU!LPL1>25""H+0++4F-TP-IT M?FY_@W,QUZYZJP|NK)/15C(J)IN40%,I-
LQ+^DSZ YNN2"8(V1Z/((S 9" MQ7I'O;!6K7=,;^RHLIHL:*Z!
!;D1:~2<;K720I"O@7,G*QW2HK5Y"X<%50:S M*%KPDR1\$X6OW>5!2BN;7=W-
=X,C23V&S=9EV#YVFI,44Q99WV5-!-4<=<=5L? M;?
IUZ6\$04.R,'5D(IJSB, (8"C .ET9G",.\$27U=A_%35<+- MLE7JK-
HO+NA/'5N>%HE&S:Q\$K"R:R<6\$D#V6>O;W|OD'GII|UK M:ZQ@AA-!ZV-V4>=:D(>
<0TK,4PO=9WPD3_C4>AIJ.FFI2S|960TKPK, *7 MA8!/U<_%?95LM01A|TO@#{MD-
ZZ34&*)WT.VL@-MN)O+BH.*HM M;@*7E7(P)*#N>T%D,MM0K'PFY@;E;
(ZQ4&OON^'K"4X#08H/+Y0L-RE6=2;&&-@H9C#X=<= M|1K);3
3!JH;7I6(X:P|>1.DD)O*Z|X\$7R;.:! MNFN.MAJ-37(?
2;RFC#4ND+IML^%>-7:#JD5|@PR@B=.Y!>L0&(@\$7<6|>U-
MSD\XIJ1S(%J"W9+7(BF9L?3"=\$!&Y?(U2_SJ"H 8-DI);IWC<1)YSE%B8DV
MIG.WXK(P|@C%|>-!B",D77=HE)/>"B8R<+CUVL"\$B\3#TZ.'WFO<^XZ
M1"_8:CVL5XH!2_6BN:E:553;^!,=5N&X156XN8CVOME.?X%/HLB'W+O7(TL.
ML:."X72>,8HO%4XKZE*#:X)6%%/JI=;/8?!,=Q2-6K;X%Y=& OA1?Y?5'(A
M2NDYP"TI4YLA9&H\LN|M?.3|2RFYX&NH MUFFE={NR5^O7^*:Ezp@=
<3=Z.LNP+>HF'4/P#72"M"4.;C@A6\Y(+5\$7YN0 M,|01?%|IF\$%,|;VDDOA*K+V@_%2-
'J<*M1.IJ150(X9>\$!;6 GH>@(^@S ME9K!-
Q('R/FE0V%AH2N_SDA<,!R&Y\$O;4U8CI?)7O|W P*.PS7+2&OE> SA&
M8@"\$BO|O6W29Z&.KUB9&|HW0RX-|(S=,MGX<^'\$|U9H9+XZ96H(^,O9166N
M'G|_"0ZCM79A|#{M81Q7!D/?Q=8"}@I1CPMK^R2NCL&=VF#|=O.+Y# M')I41?I
0)6#V\$U|BC7U-,C|"BZ,LFH",VXO!IG*Y_=SWVSPJITR>ZMX:R"C
M=N5"#W5|SR>CXB1\$A|E@U\$Q<;BWS+Y22XYE"GU'/M3A511>Z3-^1>#AD&NBN
MV"HEL&|3?O/Z4,VY\$|TU6_,ZN|QBW%!!%3J#=#|FL90#<;NM+&B3?|JB:A1^M
M>38GW_FOB.75MT'9;2*FI/?MLLT@W00!=\$MB.<4+%OUKY")X\$ |ASSH/@S(
M|GHWD%C">B&K|V"DPC+&V->U7YT^*|W7-@(2Z?*B(AA&4F.U58V(KVEMGA
ML0*&*29.^+24,N*O|(-%G=EM.L-R32T.?(&O;(F"167R3Q4,E^00;<.:38; M*=
<1PVAV^B'\$9UD|4GGG>#*S"=1TR8,A8BF!!7!GH;-*%#T-;|, @O<)^7!C M-
H76CRZ|9I"2;9<^"-)?M&*L-N|A:G V6_0B%KX|+NGP0\X-[C%KB?L8N5
MF@6;UUT>GLL)B^*|R7|-1E,R83C0K|I^48H|3,JBBG8@1KKD9O34D9SK=)G|
MBR3QA)UVE=403#Q-IZ'Z.4<)?|OK7'"8Y&<&*BRC
MP2N(8RF)66%5KHN|3((EZJ>,LERLZ|-X4," V@K+"OZ!Y7SI'|%"IE8,-NI M!BE_(X3\$B:?
M|LF82JD\$TZ6;B|.|>|F_AZ23E,;S;|I#1OC@S=EO'1F&_FZ
M*JK\AH:FGB\$)=R.)UN.B=A2SGV*|Q5KMQ**BO/<:@F=3E&ACH|H-EO7_4E-
F.E\$1^@O!TP?(QBG)4CD2/|5JP>^JZKY*R2K?PM^ZF.CG>AG'_W)7OV/'T=^|J&RV)-&
M_OM?GN^Q,0".08P3\$5,H,B+#!"P|S/W M(0;P 0/#9=%SLBj&D5_\$:|&
M(@X6T9PUS"OPGYUP|Z:O|+RH?|8=,QN+S0#VXA^4\$JRF^N#"HX@8W&1'9GB
M|P|JEE7^7-5)!#|/KG('6W.O<|25(GC@5B_#()DJD<3|((?6B4RTZGZF|=QL MPQ>T,
|*:LWUOZAP|J2T6Q\$K5U3ADC@+'Z;<+%-Z'2KSKE)#8&\$I(T>;\UW M<44I844.B TFF
UG)O\5Q,=B>5HVU'M3&#>7U20R176)BPJO!(N_AGH7CKS+
M<10Z1=)5.)!P'9;.:&Z4<\$RU!NU "\$D%CS=Q_!4:SIGY=8Z1^S7-
HH_/_|3TMIZWG2V_U=)W_*L50_5*;SI% T\$)^7C&EU="Z
M%/((@G8<_Q4N<^,3!_ \$VTQ;%E*Z5CQ2Y*1Z|*6&=6<_&QG3;D\$T2|-.&|0YHZ M!VKA-
>UQNQM|H2#G1K%,>Q@'W+3E?8-XE%MV^M-BW_NSGV9X\$SP+GQ<-/)L*
M|=N)\$5776!OT^5?LBCF|JS
M/7^65O2F'(:\A"P5F9|^1EY%851VZ)S;54AAH;Z|KT>X!2T9&5QWB,I%C-I@5O|Q MA3-
T@06X4D7?JT!9E;GFQ1A-W|:DE8,'FMN;&D8_/*IEA)YOZ5D7;?00W^ MAPAY,(T|1,NM
&UQEK/4,YRI=5L:..SC5# \WC_6H V6/V%8&171UES"WP;/00AUQ8ZD MZ^9FZIL=(N
,^QJ)A-Y7?0|3@Z4U@89AE=%I+MH;AKO;A-"4)M++XGH1' M4E4^"PFXC""
|MB'42@1)I>#)XS@T2L7U9JU?*CEEM^IX1C)J?MWT1_1#B+?
7LIMP:L(HV8U;D^|)#K6PO* MY Y:(0-8?
H86|!+5ZK,|J#ZX_RN_VK8|0#OP\UA,>*R)EW5NN=7V|46>LPI9 MX? ?
HZ.&!Z2W^K06M, @#H|^S_H237#8H..2#,:DO+8<|AWM*K.Y.;1_E|= MW>-(5(27T?
PH)-I7!*O&I>ME/;/EIP2MFGPSIUVA CJ MEMXMLN|CWC|QBJ_3*|3^(EGP43* \$(#\$(\$-\$-
J-WML#@80/XH^|J%+3_ (MJ+M3;|;V<==L'TDC&/G87!XYT!;?
*HTX6>U"AL>R_:/@VXY)O;R-+&E>%%O M@:%Y""|B:J)&E_17C|"!?
%GXA^S>AN32W&+MI/G,:GE;A;+@H,N&^(4+<0L ME |:O)6!;JH89 ")>)/S=T(I
4_3"6|Y!579^&I|-;BVY MJQV6N|XE))?MRJOZ+=39(I-

./OQNRF7^02>LHP;DC:"S\KL,3<'%XBQS=0\$C|T+
M=RW8K04%8@|'''H,H+YWEP'86(CNC_,@/^3(-E 7B*Y;U/3R|VB%K/_@=
4MAUQ>0NU!LS"Z M|\$7D^JP;#5&7@(?M2=E2M1G I,/.GA8EG@EF>E-5ZH_!?!;C
1*D6>8.8%
M<@T(8LI4B58\$03U%XICLX&'4!D)T@ODZMX'RIU@|\$8?|Z!HX.M85.=X5WFKB
MQS8"Q205|3>,4S|P-JONMM9!|P3\$6@47N5; M:&+3VF7UPT>4:+AQF9D0?
0T^T,X#&*EA#"=RI@ MJ\$#|C*IS!;?O)TPJ'OF0;D;Z*M>*@^|
<4GM=\$4OT_,U(^EDZ|_O(1)J0?7 MZ_;DD#P,8.-FY|^=MH 0(^:HCZ
)2/(+P:PKO(2|8JSWQ,Z,PLK-.4)Q0"R MGW2*?V-ZE!AF3T4;-1YF "'HG9^;"+3+-
Y#W'");8,0"\$ F0C=/V>*4F(M-
|T;J/;.%J+|+LF_=R\$.,CGX@6H&+.09E;G(.T/ZLYJ@E8+|0CHO<|=5=<%|MYFIA--TK.(@|"?
^DR M@%!=|VC;==U8|\$@=M6P<5T\$;1.Z,Q<'>,0 9A(8_DM64#RPE;*4<#Z;J00#X
MH3/4SN\$MXL.G39|Z>TEV0_TWW8!I?@VT&|U3!?'I16|KY8/8%6\$<=E&=@!RR
M83;X+5'\$-(RGXT|MF678PI#|YXAO 7_)D(WX.5A0BNV/'H*CZ))\$16OZ+|J0-MR5C?
K@EPCF(#5P&YB;ZP3/J)V6^/S07-9B\$+CPZO37O=?LD50I>44S(HU;
MSS%CS|J&^B+GW)&12F*G(0)QVH7,6'&^; MU&D9P&.4ONGX\$##|1%71/5@5,JT%T>
|%.P2^78(.DT10-%+./8@&#B(>GZ M;G+GF8^YFJ6.IQAWR5IVSVKCH
"8QNA\$F6)R4CO?G3W&2K EYT MU9:MYQ=8E!9YB>3H^;_,/<9G<|_
DOINO)J/UQ"=M#TZJL!-Y'NRCE,&E,IG0 MT;Z7
4AX?4_Z/6#;.12^|BRV|_/1/.9(>367HM.;8G0Z_3OK|>M7:(2?,'8&-M\$
IC,OE'I&XBI#M+=AB?|F02YM#9;.4WDM4PWW|8U#&F2-0|=X1:CRKDZK^? M"8?
0N9U(+KAU&JH9,HJA /W#?B2?TS/PU*|9IEXP>#HT&OS&XCC<- M'SXA4_HY4K92H-
XY"%313"RI:%G-|:AJ056|? S.)H=|Z^MR5:@FI1/X7+"|*Y-AE2@!GS*5;|WJQ3|:D(IQ-NE?
|B+_4E(4^VR5+
M>Q%FXDW<9@"XN>2.PP1^#BL>,*UW23E>J5CD74KQX=+H&|&K*;TMA^U#S0|8
MX*'+F=CM#0BY+|R6P"ZM7;J'G^R|0N-.46/'"6RDN"#B#T)T+A|U|*& X@
MCEWTF|YVP_%EGT@4U&"9F9 ^*N5|J6V/:2T3,T6Q(WL,3258H2N#?X_V+KA<
M8MD9\$'P.'|EMQ:\$*X*CZ MHGK_ST5U%(2,0+YH\$=Z\$9V4*S0TQ*|Q%&*8=;W5?WSZ-
KDJLZ!U/D'PH*1D@_MRS>#O?!^|L_MA%|>JW@HZF-R1KR<&53A9I3?
7!>\$:DC\$;N@NHP|'_Q|-\$B'3 MFI&L;ED'.*X3BO|
|BA,E(U(D?./|XT2F,#=OC\$0#8WO.A|M3><> MH%RE>GQ&!NAW3ICPDNS|4_
HSNCE|2F|JZ\$KIX_5K\$;G=E2Q\$?P5)R46?*.
MH"W(0>A!)A8R9P#7ZM)DN6@Y39M1_0Q@?K;-!Q-XRS^|S|OF:9TC/LC6*OOR
MFQO6FT|;7F;G)L..\$\$U^O|UDMM|E5W3QR9(N_)BAP(YB^C6;.SMWGCE(>Z
MY"!*6!6\$0P\$2-*|S^BA:/ M3ALPFDMS-N_(&/9)7O?H*D%,7J/H^%K,+VOD-;_
SYZ8S_1D0J51_.@8=;/N M9BE%;@DOAF|T?:V<0HTE|5VY\$E#,US+E*VYT(_X'MU+LVXN|_
^Y9+A9E?KXD M<(|:IQDWZ3.;17'XC*S3QZYA=WP)BS*EWCN|D|F.7%-LX>|C@O5-
2R|/-5N(N MX>@S0@3)|. &=+=?:J(.Y-TCH)+A+<,JMBM.?F|90|W_J6@G;:RN.LQSX?BE
MYK#|D);(UZ0UA|D!R%D-S"M"3OC|SM&1TV*)E;BUK0DK|2<"E&R#@O;|'G
M,FW1NN2DSV&IA!A40AU5Z26RYS0TH-9|J"#VRW=F2>:E0DW?A|@|_G)XTWGR
MV|>N2U>;R@8E@B^ZM@'A'IP;(R3W'N0A: V'"*K2+W.A/2DOL(C
=|3)A!|QMES>WRQPO.+NP>(25Y!:=9O=RM,9)=;?Y2|:N@4J_ZC|U. M?PW9"!N\$)3+
|W=_O3I&RIOQP1|*1|UWRI-8,O5@TU_INY+;?2Z(M<+|SWOJJ MA,#0"
<=#=Z6CL#RY"S"SD.QKD-MDS(Y;127X|KEZ&-<'*9|4=X|IR(70.\$E(=#=7B-
!EESXL"|QE+M|YF@HEB?W@ M;N+|*M3|;:/1|=2HYLH-ZT&SZM34|C3K4E&7Y;G-
+1=4.W 4P0(2EI&9H#H M@BV+QRZ?->#>WNS>SHV6F-
6CB;XBY|Z/G.T7E0%/|W'"|=+'H6^O^GPR<<+U M,1%=I6T!F1^C;R>13"ZU#?
XDV9(K_F|1 M(HPE1|N=8|N/-|XL?F*Z?&DA_)YTWKQ-,)3|4/830;#R5Y/*?1)!?
2MSVDNX,IX? M8P^C/:V-+"01_%'^TZYMW5E*U#T'GVQGB6/XB.5G^M;+-?LIX|A-
E|6;KDO/QW)T?";L&7(6J*4SO&N4(ZB^-R3|9N5Z;#.WO.DEAO
MIVL=H"C#KQ'10TA0%=N/3C%E;YQ&OPVEBP5H?|_/>U\$Q'-SV7#5*+:|ZP";.
M?|>^ZO=L47G6R_%WT:'''GB"3;:| (PHKJF4H+;5,"KS30+;:\$6=I7=;-|/P \$
MP\$6849<-0LF)I.*AUU'"|/_@>K%HZVF^7C/NZ?4Y+U+SC|>%N)>^7US(\$|; M5?
#7@G2E^_,F.SP*5,E|\$\$% %FSALC:V2)Q#" FBW0X9H4Y*2@RNM2OJ(())M4>35|_M)?
\$>NZ+*)BU6@P05SPOV4927VDY73|(M2%+6IY?KZ9^?W-A_#D!9 M8,<0HWD0|BYVD-
_3Y*0X(HY@11 BT8U|Q4>F|=,=NF%U0S|>R#=#-ARK&AZ M/V64|(<|)<|T@PN
NADDD'KU|UC,Q)JC/V_P M_3J?-VDO>^W#HT81P>09VZVK97R2?CW(Q?S3(I401?
AST1P@5C<6DJ8GM|, M\$R_T)4>B9G@B?AVR|CG2=|Z)&">%/R4&L!+-'FNVX0Y*|%

(C*05H+6+QR?W2'Z-U@JG<.: 'B^-6?1 M_CUO?
DOZF%Y(N!&KX8"\$4GCZ6NJ&Z6'Z;#,\$+6\$0:<0(YO7&T,+N9C0/YBNB"
M03NOB:MV5A?:V7:SY<.TSU_H516S<*S+_J0+TT5\p#;,:JVC-1JJGH@!D8):H M#0XF0
AWG-5_+= (Y%:H8)G!ER;HN[\$(RN!2S\$V#38\6,XE/9M^180Q MK7I
MJS=.F2I'Z/,2G:8/EYS%N*1'5&VFBSOZMSV7>NGZ>30CP'C^MNS9',+SBYP3
M,&ZT_S@7LYZ@2&RXBH<1(9TS:7:D%>!!:/K\$DWM'3D0 ^NK\B-B22NNAFJX
MHX*!3N2Q"SPZ&YO2!0N;,:%BQ^(\$X\PRX2@M"PQL,W/L^[HBTH1BIZ8UC*
MXO!N9N?2_P44CFBX^9J9DR;_G9G;4BR8B,4>^=^8^3P#P-LS "Z7?U!S%4WD
M+*WE+S5G2O"/#EHGX?LUT/_N8O)A&%\2V M/(M1=
(&ZAKC233\$G)F.HI007&NPMTG&?OMQZGM5ESIOTGOJ%[> MER_UVQ;8N-
JHFMFO?;^8T(-I>^FKD79#**6UIA,M_I%:O/5%G=LWC28G//QL M9&J+RM-
JU=6OX)QOC[;+7;RR;2\57JNVZ*ZX&9'W7>DFVP>!T*M&K'<+XD18
M)%#NFGU+FC777474/PJ\$^LBPg+)>32MT=U^,,:JHR;SR !HAETV=_V:TOI((
MD%I=RE,"" =DJLR_JWPLGWG^Y8R%SUX"-*8+C3J^U\7VU2?_?
PN8R3\4VWH/_3396J*N=R\W"= M%Q=\$Z"
(&_O+ODWMN\7S(V,V>%D"RG4O.EL04XZD^7ET*)\JS4I?Y\+*^(1Y0
M6ZF!M_\$9*CQBR69J=../_C&.*_LI505@(D;L=..Y,-G+,4_)NG9TRW2LX-MT9L?
YI19\66ZZ2*;) &9AS;:B\8P;J\#I\O\G\OUL_M4L*+WO\,)U>IE+!C.N"EF<\CRO^N:3QA
6AQUI85'2MKMDB8*8H9!11RF9<_V&+&,M229M7B/N6H%VT
R%23B4&=N^J,KHMHF;J+7Z^3)F-KK7'<\$M*IE3X\$!W\/
MFJTL8;JZ6+RWXV59K'JO^*|_ ^ ^7_8=[&B*|FSH\$Z":HQ6\$1\$|RY)OKNO
M:7(9GU\,WN%K;'WR! ?6Q\I78E/_N.UET7GD2>[=4#;J*S\$)CQZ0B:5HF4V8
M^"GN,PO@@@|J,+W_==&CU:WNZ|=*@Y\3U=D'YY<4*I_<9'AX<>9109.RNB
MV^-4T]=T\F<,P(H9 GFAC4Q-(Y\|/I#+SU [M\%|OC^AU"1/I,+).AK;,:
MAO>D49B32"H\B=AF!\$O?KP*.-.DZ MNFL;4XS\!!/&5C-
!BB\RXB,#6"FL80#;,:I!_I04G.1/&*O&,!K=^FKUYV M,<4FS2!|=*'25Y#;8I/(O4-
98)P+55B7GLE,=HVO?@S@T7?Z\CRNRP29\$=_M@#;=9@|I-'XJ_-+9'_W_G!^LR!>"&
(#9;P;0K?3_L/?F\5"W?=_X5Y*R,-E. M&:&
(2MFW3!*2))0UYHSL22K9QDS(ODP(14Q94HG)7K;)KJ3)GI%E!LF6&3*&-MV7\?SFL\K
[NYSZ?WWW=JW-=SW/\I?4R\YIC^1S'9WF_C^_G.Z6_3,_DPW@ MOZ FS!CXI\|R8I%?%?
3?,LNE6FU,.[37Y\$H?>C?HU0_4%+I) S>151L=%>#F
M13^YE'\$R%HQGMW7MO6'6'O\O< \3'F5R-OGK;073/;'IS:>+P<'IP\4EU01
MOQ_F=5JE\5\$,8P\!OQFRL?+T_[G! ?X+-0/TH\T^ULOPZ?(:,P^)\07H8L\I*Q
M4(9L8!A'4\IE^=0Y_=C(R*Z44T;:J,Z)Y517OS)0RI:4'+,/?'\$ M,'>"3N_O!V\AP1_K?(8-
W#)C1-)-E-D Y@,H7(X%<DXN8L3MF5?NOG"!;*SK7/'\A\^
MY(KF#%*VE\$I<"Y2Y%VJ1R@9>*MLC+X,"D"%VX%_@QT<)"'"6=E&P%CB9#3"C
M02!T/!IW*=?-_5L8Q?HB@M;:"4B0B(4&4VQB_K^11 M*,TDRCL0;MVU\|<;U%K>5
MHIM"\R&KFR?|)\$XOVBA577S\G6\ (BH,HUDW"NT&2'HF:HX.[CK/;-+A;Z;
MKFJ;C7(QU\ @SHSM3WK%WMA>3-=+3N\&|&=FPSR5D\|/"J"5DGXF;.: (US^,7
M9O0D7J.LZ3W75_0208U)6XZO=GB_%7N@|T7QK5E*<5'Y4'_O.:7C%06D\8P,
MK2P%Z<@ (I\HG:PWT,J ECC IN !B-XV?A!'PZM\$VZ;_1+6%_<"WYR=[V]HNC M!G(A-
NF*28527F_VCM8)\EQ>LANWWC*S V;|@;R6D>C"*4_Q\|PFRBQ:6D\|
M/%KRO';W9XQ2=|AMP\2.L\$&,BY6@Q%%ZJ+R4# MG6<@%HSBFYP7\;&NJ?P\|><|G>*
(;|?FK16_R9_*Y5Y5#_C;?O+ /MS&M\$EEL MS-I)=3*Z>-C"2(L:'B2&|FC&1ZST1&G\AY7*
(%,*'KCKY"\$7\$D_=M*RW70R M9=[>689,?
454W@\$ /LFI=,&^++GKL;,:UY*-3JY6CU^2U5..Y8!L;JP(I@RW8 MW.V(FJ\$;JV"WKfy?
G@#F:=ME/+R_#0'9C7H'8^)\3<9<;(8OTUFC;&\$!U8 M/+|+Y.OBOBN8&U+S*OJU\^
#@!\$76U#W7F&! E+BLL:ZZ7\$JR)4ISYD@X3K M/+NY_ \X'&D'>IH^ ^/*QH\|
(S&4#13DQ<-^MV*"K&C&+,O%@->(0+^1G9_MB'+G).@2?^1(G=#?&QTQ*)-E#&
(! /M!4P_3-6!;-;NLO\N*57A_)D0_DQ#\^ M6-!TK3@+;4.#5423\FCP3S9U\^4\&L2Q#90
>\$N7^7/9J1, (^* @*?!Q+_D MQ3-?Q\^S'3_*X_2-U76U@&**_\$2?!-2D=5-
Q>VZC!1CG*8DIFA&ZUT,L=((M:G7\$EK\QF3CH,K:VV!48YC_IZ):YS &2;.^4;&:RV.-CKG
PH#7H\XQO M1;Z'5AX"??WF'H7@,|A"29L *G93YW?+SH\BM:0 /K\1=C#^.^UJ^?SU?
M?5E^12;X-I,R3G\$S6;H<-|5.6A*@MQ0W)VZX?YA\$FHA-U+LS=\$QZAXKMB\ M=|H8:=)?
L@5DC>0WHX\S8U_3KW;,:8R35=;\$C\A9DTH-6T6KGD,VHPN%;SQ*2M=#
MZ[X=;_07@>._YW1^X.7F8?\$&U+#)C\^C+K&!|<@>7*4&GDD M*(TT\$X,P>NQD
EL(S(NX4N/\$3)ZOR!|!5XZ>%Y\VRSW:'89E=C?D^K\X/RK"Z\|=)=7'#_='*@>
MI'X)K:1HN=GDGQ<|S\N+!L*|97)=\5-VIQ|=,:TC70*7(\$U@EL_M@8KB%IZ_R&?#/IEL

MS&T|^+G*4P1>Z=@B#9V_L#BG 9AH8T&CB(@WT"OXP"666\$HL\$"-6"HAG0Y+4
MF8[V%/X&?^1HY6JO6^L^V0Y38%IZ:G>TEMN1JV\$BNX^+,TV-'Z3>M?++ML+EF7E-
24O5\Z4HL>5\;0C[B;I^W^(S/QCWL="IN:3Q9
M:YYUD0TL@E"CDAIDQH*C1G#TJY9&PNOK5(_[SGXF-G#!=IT'R/KG6"!*#HQE HXC_--
+.D&!%RLP/VECXJ M&J-5IVJ7%!DK4DXF\;,<".>RD(I@#T*TWK(.1WZLE("9+_6\$L%S
Y)&-8,[MFUNLDNWA%@\X^0G/4AU\$^>HN(JNK71B;N+;\$QY6R@&2?%^B_%I0V3<>
<& M5^UQGDO"%QQ^I\$;M8.6\^I>/8H2S)8^.2EZ\I6S\MU_%HI3U2>(2C%L=
M'8TB6RY%A1SXX!@D+MV^I^HJ3DE3%_R6_H/MLDGPEA\$J')S'5IB-
HYDTRMY3D+0^6\$M?4=:EZ: ^<^#6-48=)9%R(3,*=QDU M;-C:G9P-^X63VY?/V,XIMBI-
I+ "\$_ ^6=.NWA=C'^D>E6)YLF(YV/TKD0 M6JCD#"D8LY)UV)-_+
H\O0/(B3\ENY\$>1*U(0P\-'\$E357_\$_=8TN!+"IK^
MHB94).8C;BO.'78+RE>Y6YZTO622OHTADRO5FU>#. ?FB>N\7K-F)1_E10OLO
M.TDJ/M?4VOU\ M M.815.WA*|UY>SGF\IFYQ:8U!:[0Q]R,LE%G#|"#YQ>ID1-*W(-8-
3%=2H*VQ M4RA\|XR8M2Q(M.P>ORLK#.5#1I7V\$_4E\$3R?7X(1?JIR)\$.33/5#YW*2KZ0)
M1Z?E,8(&+M_H4C#IVBS@Z%#@>33BB1#':M5W:H!\$@1&L&617/BPHZ)\^4%_
M#GWA0H DE:N19D\AG,P\$57LKXB#-|2*'VX?PN;V\3)R0\$C*+U/B-!00>Q_I
M,EGSBIV^F+@WKHBFW1AG"'&S8D593@X@=MKNX#|E5JBOU-+!F\.#K^ ^IOP*
MQ%TKA<+?X P=/Q8/: PG>-G H1*0@:4^ 1VO^?>W?J@OX:CI@4+4GGHWRK0
M+P31\$^8:;,.U;^0^U; IFN@3|S8|3|N_E_-__OYO_=_/_!YKV"S-J=E?
4XG7JYT\@0>'OJ#D3Z3LA0_1HR"J(47OJ M_?/OJVZN=GK>@>>FUU1G3BE|P?
VN1R#.S?|.B=A SR8VT%5|B@U,/4/134BX M53L*_RH,ST +H>)Q.Z\$/(2\$OGJ_292UC3H5?
M8(:)_K1&&+\$/13X+W9"&KP=XP1GH\08U;KG(JA 3>;Z7?*|6;|St.OZ-(:
M\$WXRNXN19\$T!PMRAS*BMQ+).%?UV\$-|L9*BRPKJ^HJ80LT9_L&V3/RTHYO^Z MH
AYZ@J;^=0XPS)YGI\X;O"!L#OFZ1@\$_D;,. ^X6N&SQV1@J/*ZZ;K^.
M;KAYE!|U3)C|P"N^Q64WUREOF|-63=Q|I&N|R|=(X7W 1&\$%|7EQ|-
"V=B%OH(8VCD3(4: P;Z-N3O>C@-C3, MB&,-Q8K;K.O0WT2K^7'+|
(N^P&T"E+1PB,*E(B|H0U;Q^R%K\$JN5NQ"W^R MGA|G.RIKOJR2-
QTK\|@+@Y6P+>HY)^9#3#&EY&SJ43(^N@0ADLDZ3;W."IY M.G0V;EN6M!?
Z%>7Q6NM/2D3?U.I^E0F#>H+V^6 MGCQ)767IX4AU M,I^
M1#ASP\$G2>M^2|CN!;H*D MZZ)\;,>/_E)6;Y'A2X|\$;WPJ+G,_V|%%AT0?
C#T;#B=JDI9;TWZL1.UQ R MBF\><1QIUZGKG%)46)7C
O&O#G3>^FP\$7\$KOY,R|VR\O1W#8HVVDJQ\$2(#P#WXGSP0\|3HS'0YM@(BC/M|?
&V|=FD,\$=<.NSTN5J|DG|PHR#=#| M4&^6UZ;,.N*S+H|LJJ=LF=H3V7
R|LB9B%;NCKM:PT&M;.L+>PXW>M8,_|B3P8(->IA!;
MY)39Q_L+GBN|5;_%|LR,+SF0Y0*C=K!CU+"2TPD;D4 M&\$8->C-1)EPQ2
MUIBB&!8/Z&E>=?|ENX+O>Z)<9QGH\$2|P7^C#34&YF?|P*47,O|;@V:<#VS|M
&PK:D&S&Q.J?>: QE+P+/,C.U0.O|<&|CPR:K,9|AMY"FB^#=\$///BUR *M_ ^C%S"9:45Y0?
NLX|^*B..*WHXV<-6F1T'8PSPG;-U:L)'FN7R^#KGU/>=^1 M0|T?9Z|XK\$ G,Y-
0\$X4PLG4=3!35I%MO35=#:)%9V(E%:Y.T#M8!UMC*+[WO
M6A8U>AU+U4=3ACC,S^_./YEQ\$QB565=W|ZHSL1X=&\$(DTL/U#H2=|W8S-|'
MS:=HFB;U?;,%USY:V3.&8V\|^A+)YF9>D:/"G"QQ;PP;_N^SRNNO0B9A/NE
M"9PK!WJ*91Z03IB*:@?@|X%|BE|?&N1#5%YTHE| ""[5;04!/ETB\$@X9PJ5 MBUZJJ:D?
=\$D4@04M&J1|&GLZV-M3:=K,\$RD! 80UA1KTM|D,J(%X(44<@2| MT?
R'X8,##7=EU%/2'Z;O2N@=#,)"U+9V\$^3A\$?4Y|13="^+ZD MB,0047S>FLID-
G"^D>)40)YWL Y|:1|X1&YO3H|TX9+|3)2)KJFFP^V/Y:<
MLRX2O|85|LR5),QI66|T>^AL\$|QV&=T-4H,%YS,F0H:POKI##-26Q+W;A(
MD*/%|"190/T/|<8=<)H@K7"|>3#^9=25)*3/*7VIB%|B|T?B;)8C@&C+0;
MX9J)_O\$*;-.71F"6)?;JF6_+|,|O^WA)Y^*#NT;-?&|.|^49 ZYM)4N%/C
MVGf#C1GJ4>8+U\$0!M+)C0?XYLH0#N\L MQW|9'&&AO=/XZJO8J5U\Z|!VZ'
VBP<\$IUR:S,=(5H1-9QY|P8ZUS\$108=K!A<;JW\H.9C/%%EP6+X7Z3Y6=| EUFM(JBT.?
B%:F#O.DX9'U M\$H;B!;1<1XU/FN^0!UW9O+A1F)>\$VRC4!-/D:JT8\$I<..T\$V0/7#R
M.6PT2@1A0\$1%0%_4Q#""B5X.>XB0G8:D+|Z| PVD*(%|5OVNJMUI15ZT+3^==.V\$'\$
Z&KO\$B^|:3^ (UM??VV,O&YP^C|*<8/T.L#|<|^/-/9)3|EU0 M"/4|N,KTBO-F4))T|
|L,8RMOH&3P&|T|0 6T9!*SV^|UOO>UZUP83?@?T^ M>|B9HLOQ(*F2)?0|&XA,9E-
(U|I%(R';6R%-/SLVSEF8;L|&WERD&.*!BPT@
MQC>_EL|=!LYF%Q,R9R8.L'HHZ&M(O8P9^7ZIDY(#;MS'MT23*HLZ" T6H>M>6#?
B4Y!72PPKJ? 8L(F_Q0FMJ/NQ|&7)B|Z;Y7& 2G//M|&_<8 |C
MP6@)TI*_+UM=R.A:@GA85QQ1*,'1;)U5V,!#&.NT"1MHL_RQ|-\$JY<_PH%="=

MG/MQ1KYLH+F6DLGD8 /++C 62 ; ONSB4Y0*066X?^'= *24 EO!0(NX+! S*
M('Z@G!>>":^W+B(T+(YEEBL,'1H+V05YZ/VWRM.,?SW(I+;EJO*. C=[VMJ
M[#HWP\OLOZDWYU!_7I+7;#US3.IJD;N+I2.*7% H/8OUC*,8I-!N(S_ ^A9*@W
M_%TCF1J@JHHS?N2'.8/^4'3\$BN6V%E/Q=/C>W?JLNO\TVT=_G>RJRPA!4M@I
MP.;9IQN\$WPK.2\$ M\$N@Z- Z/J?Q?3Y-L.IKTY?L?J0YI9?=<>*1_;;M!TZXJ M_ IQS;!03YG
;E".0_H63!,,CM=UK_:\$;=:>*Y1F=[HJ= M-Q.LW,7',X_[ST8YDP!V=S!;4*(GGNJF9\$;6*U-
XF/0X?6^>09/OVPT/C(MRL7OYI_(!>]=BRI^PNNC)MLV-PN2A\KU
MBO/CW)XV6S@X!)9^!@ *#+_D^\$Z.V_E1P+JIBP M@'L):J5ZG;#F/T2+-
%A_%U.4R2,M6>_#J>.+ MH3#Y\|L,W)B2AV3%FNFJ<+JM>ISW^6SX8,PC W73?
6:H^<7I_ JH8PTN_ (I8 M51I8A>LGW(9,PUR!*/45&T@EDE59':J0WXR T(\$ _DZF_>_XZ
CZG*OZZ&*3&_M\1NYGS\;K088P(D%!\AAW'? M%#_ ^PXJ\$*J_07D+-
OU7^!_-2MH";"@3I(E8!=[_DY^RHFX)F)(CB5E\=/^U M_TI_.M_ '!/HMQ\T?
K_/(19A0X:19@,BB#TT+,7\$F=7U0D1QYI+B^T\OQ,I+9VUZ"ZZ2YMJ\$BA79+8C5K2KE5?
R@+=&C"5WA#D\I)L(=5Y0IM@H!&LFRRE/D' M4BOAX966K(I.!I6"&/\$_F?
B6X(6+!+*VE;|Q-/6Q@93F;Q^*?8VG&98E9*V MJA%
T_R/9&D8A),=_&C[\$#;^10*+^Z/MJA|^~E^ (IP-. ?(_\N/R|^46G"#
MM+,"3C9/TCR3RCM., '2M>I?,S=BS T311;4!Z7XG\,9WV-0%T%U;7L#.8<2CK
M!&SP>)A_0^*UV?6P#B1 EDM/LRR"P.[G0I#_-C2 M3_<.,/CST*ORBQ@)@7!;CT?@?
+@%X'_T6/_R31^<|PG%ZYC--W^)R40C4 M^@XVX% !F8[Y!\$9>V;6N/Y)C_ =|F?
9#>|Y6%+'#>+G05WKCCS.J5W%UZZ2J, M"!F\$<)5#1 (*_ZW5_V/B_-G|92Y,2-DEIFS
B\|P;|D,#+2*#CG!%'39Y_ ^2 M63184+V852AWOQ%NN@I+O(\$9\ C!R1G7T'UD;G>I:
MNY4/RD+ZQY /D8U5>)6"! ?01CTJ3 X>(AW>OVFH|7 &;MK237>A#>'4ISP
MADIXRKU/-Q3Z\$ZT'AW6_9'^E0Y_>M31'B*|2?X.E_A73K7ZW/6_1^ZHI-R|8 M#9:&8K6
@.21(?SA3|IV_GZFE.P%&(W(!@IE\$|Z_ ^00S(YLM>TP>;*\$OX3> M_1UD_ "\I-
C,MNSU:|?'1THA+.VA)UD?>IZK=YDE.;1X^E6.R'7VMD4V?0K/ MY!Z\FVWJY0D1S
I_5JA@!\$(U-WT^KH#ZJ)&?&|4\$;O"QS@AQ'-|NJ=&&;
M=\$F.JW:YKIUL.O;^V=PQ;;7\$H8AAK|6-=(.MM :Y>0R =C9U,YUR@C
MRSN4\N/D<98@C)4^ ^1&0GY#-E7Z6K=,BRH MHKEUV^F/T?W|=ZF=>?
ONR%V/I++;WNN?1/RM'DL4>E?|JGLJK>S|=M:KL&|^
MAX;L2)O;7;)SCDZ@F>;;QL&#%|+,O\U.U59\QB3_*_ =|%LE1=AV|&U|&3*6
M6GZ2X\$&EIAU\42NPN*(A:OFR|-LG;MF0&7'A;EI@2^X>"K+&EXC9|D6S|G%A
MJ\$(WJ*OO#EXYG|E1K7/3I@C@2Q0Y./7BA).1Y3/K|PE*+;MK;M4 E)>00<M_ ^1!6;N
_RG47,9^J^6*Z|AA\$8IFB@%-+R%<|Y: M%WP* |N^S@|VRV|DPX1@KGA"_D115%H|B&-
A'N,B02@3I_ ,ZN45Y7;N.5/RB M6)<2^T8>T-BF%_ <M2&#_ 'M?+|I
MY^\$>43VW6'\$2SIPEAOP \$|^!H|1(9Y;.'R@KRSF_95W-\$Z\$ L7P5CO;9&,JU=E
MLYJJ;X2NTIB\BS!8BE3?=OM-W->U90|57W=@&;Q)FYC3J|(@Y3%HN:E6-36 M>J."
(/39\$V\$PH_I>-|?LJIN*23M|WSTL+X|X|<9*)T+)CV2RX\$.W0T#)*(8\ M&Q"">?B)?G%03-
|Y%Y(95^EG&\$6<<&+L\$) MV41L8KT;_4P+*3EX|?|_)CDJ7 M;*'68#YIW QJA Y+8XX-
5"JW1|-6KY,.RLP-F9;3&RL.U8G M=-E"#^Y:!?&QD)\$Q;W|H|:
|P|\$GHNH@R:CZ\."N0\$3D!^F8E1I3U3_C= MK7U_WG_N=SQX|T,5\$QOBYNUH,T@?
L_R*/_8RX M\;BEC4R:.[?#^.;78:O<Q%;U_9KMI\$FSQ2Y;8I!)
M\$VYGI;GU.5^1<3LS7OY3VFYA^E?Y-+V?F7I>4%GT7\|PLO|#WK:1X2;|PW.+
I_7@3|+CRTOMJFW7G\$6896S_#2+) M. ;E84#IQD&JUA3>3M<\$TS(*?WUYE_2\!)?+
|O;MYTUEN9/Y@1!SX3<(|H: MV7KB4/KV&DH^J3J<&.J3H>2I,?9T|ZN7%Q-
C!SI5!%+N/"1A\$>JTI^2A2?DH M%TI',UK*2U^V=|^UE#D=|8T+106NUT2.'|N8DJXEJQ*
(G\$3.2BR>3;.!SD^)|L,1^|Q(=@F5(XZP#;1I+X@SQ'NQ3)S2;K1'^.; M-
0;Z|D_09I<%O&_3@?1 |D>39 GSF*,<XGH:|AD20TC%#1033&THZ\$_.R@E MISN6)#"-
NGSK.UBJ>R|#&!87)W M\ XD2ACP73|5*G|+G6?+R3?=[D-HL|T//Q7&(PZ,%*@K);L|+*
M@Y;_RLD_-2I?-O*8L2T^OZQPG3=Y8"&^U>UM'O_K'8ZRD_ (+/_>_)>"FLAG M"="L*?
+M&Q4TP1/D_D"69H*5BC?@_3*=6)7N>U&YK/_8U_B"BZ_EMFC1 INE
M#E&4;R&LBV@C3;7I&S=+"IT*!W-0ET9G_EJEF-XMN'>&_76|VVY)N|3|U)-|Z4?R-
4*4E1SGSS3UY!; MTE6RZ!|?@6|38^=A|WG2@F&O_F\$;C&Y/'P-?D6CD*\$80%#
<+6IT9F|TNM??| M9;H^U.K:0_?(H,75>K3D&.OR\AD?CI\HW_3^;5U_|3^|K,GN|B;
<&AH6;8_ ;QA|_*|+J@HKD=0='90I))_5G^~U|L;DTKZ"AD7K
M:M;JM^J.*G0MS,>/D\$#=\$S2Q\$|F=(.-*ZWU)V1:1,%|F\$?OUXA)|'D4"HOZZ#
M\$9|UK)3*XLZJDNJ%|MTU9E'0_?IHNC;K|TH^@Z?MDV^!2/G|>@6)-
S^/M=7X;E;TT&9|R(N;NBL?DPPEF V7 M3_9X^73?7 RM:FPA-#,2!3I|#-CC;&!7ON-^T9"
MMI,SLQ?_Q>\$V,@#Y9AP*O_"02A03|Y>Z>;6J(RO|

ZP09J:P[7N2+05>W:EFTW,=6:MQ#V%&OJ61J: M//0ZQ'9DM2&T*20I.=UMH
YK+7Z:Kc=7'+:ZU\98!'J@)G: ^X7: R\$TMO2
M\7UO8CL_1\ \$K6I_2B&>6V_*=RPSY'9Z7%RD, 6ON'B.WZ#VU0J\ M "JA&4R9?
MIXL211HB[+9U""^&!05'YI#RJ/@0/@%I MNV+WW?IO!569N:/ YJ2VG.CAHE F";JM
^&&RGBI 471P30->=9NH,RIEKS MO!@>FG!5W""#AY0DX2*!*UZ M1!+I#Y2-
TOQ=D_HT;X\ -5G7I./YGBR3Q2;""^%BC:K(_O'MJZ,J:Z^AY6JY MFA_+;MA-
HN>HD3EE.8_AG\-(U?:POJ M_OW89=M6*/D")\$I?GT8DHYO@//JBGC!"%JN&I:EY^@7JW-
G@7LC^LD;W<|Y" M#RHXVL)POWLQ4-TRE"LIP-,S=E JK#3G77%O4HA*X<&"+/H NA-
%NX9E".%9 M2<5L0/F@)!M(VE|C"
(8\$4ZS@2\ \$W)R#VY=!8=X@GW&!IPJX%,QHJLD^M+ MJL;*+"_F/
BE8)PHXEL#W^1SN1SIS9C4J%WL"M2I.!\I?8 MP&?,&&Y=D*SYLO9A/W0+.ZZH!\L98
_7<.M%:UC6"0; 3UI#_ZY/2FM0XV%# MEX?6JZR!02\$5\K|:@B=8V\$0BC&Q5HC^P=(4-
N""^F&+^ZR09N=QAK00V"X8VK M?X6W_Y%((3":#)XAU&PW: >6KR|64\$01C_2\XF:-
I_^Q,>S8W| #PXW^9(2J7 MTQ+N|W MSD/>0&KAC#NH9Z|0*O9+<\$;<|Z/?U<0
M2IZ&T_9CF)*V+&<'33:PSW8I70A5.HQ=-OR:"<8\Z%PIG-%"V(#,L@M;* E M'37Q&/7-%
IX>| #G.N& "T+9E|7BP >,!-I"9D00Z@W3ZM!%TOMJ'<8=>""|D
MWB@&JU%CK8(A#0..^| \$URY_)LFYILK\$(TBL_Y5G4L@'KV30(-&-J&7Y";_?
MMW<7|4.?X(WG_GO\$Y_P(SH@X;J)@X^Z^4.5A7(C277F6(/ ^N:JNW?EY^_#,%
MN5D/80/2<:AY*L@XJO^M|_JM)L_1Q|H*RL/U:SH ,WOE>SX .#706R&|F|7"
MFC_3TBH08,DV+ #&#C1C= _OOV\$K;R_2A&9CS._.1SA)! ,=3@+18T\$011AM7& M
O%-7'?Z.\$ \$?3V4#FJRC|FGNXSK*#8E?)|6TZ)_C)SLHOA?O\$??&!/5|G9\$
M/DPB(!)JMYU>)'=\$:WN5MFE5&*ZV6CF|TT4G_%7_Z|HV?QCRD#H0)#R(HCI M|
|9,>##1H"Y|B0?6GOWLP)*_BC^8_M>\$ LI-OQ7;^IS.WY9NS'^Z."S&XF8#
M=TI@5NF:K"A'8?0\$:GTSJ\$;P"M27|V7_J!)4^+(N2\$:&|L+?#;:Y#J,ZET+9
M@+,E2M7QYP<2 _FLN/?WX_&X>UYZ1X809EEG,:SQ="O3>/4(<2^=^|B;AK_*7
M*YUDCIP_09C/+GO-X*6|=/C;(XP?NMCE:"OV<#RUDP6SIT-"AV^8<5^;N;
MD(YR<'3'UECU>2SWZM^?3O)|FC1_RC&+?C;?@/D_Z_V_ARB\+Y"5P5GI\$) M"
<=0CX+^_D^!<^S)SQ\ _B:JP_F_SO%#WM\(:7YV|J|7/AG.W9<,:|%-#8P M4*I 64FLIL-
/+)I^X<5^:V1"J_-&Q1^>D?SO^**PN_,|EW0\$A\$:R9*AI;4X
M*U+D;/D#B>;FV&|H?'2AT|9>8T=6^&Z6YOY\+5-1DBZFKJ1|X%#XD;=U%_8W MM9D;
1H*@V(9000G#_DV>)^?K4U5YBN>5700Y_08TT.QM=?SJ1>|V|+|_R MZ-
N(796X^@G^SUUB)MJ3G\$7"+C|Y*PA\OW8.5,A'SXSGK#^LUO"N'3^)MP_
M7>K=%@LT(H (BY;:-M H0UNR,X<9??BV|E?E."OKL<-@9V:@XJV*BP9:9TV_
M<*BCS/H7JDI4QNWZY%=\2R=,2Z8(QM_<^(HV;U+9.M^,*,^30*T^KH =|P
MN^,>=>B#S^IW0XF8^3'8O MS/,@"E3MB\$!01!C"?U)Y\$|. &HIOXZ-
O'.S0S2TKRPZRH|FRG-WX^FUV<(M_ 'MRZ=U.|&3|:U.;KJEGY07"&\$^07G@8^\$O<
M#HHN1\$U""/ \$FJ;')\BY-73>,1
MUB@EK&TT)LXEX|/8E<6|H1\$4^B2V;X/(J).S|>7#MS_XFC-|&WL=B|H=&K M|+VQ*0-
VFV"&QP3_>D64\$0+D&%PZM#(2)J8VLQG#ZXT16AT'&%H4D_BO!U@R
M09,MU\4./9>UXW0X=NB\W8A<;P:_=-,FE6M;#(-&!'?BN=\$.)**B6AC#U MHVKP4?
NP4BTG(:RO;L*,%>PF*%Y(3RR1CHETG&.%XVOM!+IHP3R2P@=<0 MM+,"13E2/=1&
(T3C\$:E@H++3(S@1&^ CO3F_3BV*WTH\$S|<|TK;-D7YP7C M9(%E-B/L)_ \$I;O^NK-
*1K+S1U-N;N-RWI+U/HCC,|SK8M'1*_F1F|_8.9
MHL(% "8#N\$J|T=3/8!!W|3*20#)IPHLQ3E'.H.G?#|?)+'|X'\$-T'O'5L// MX<)+'+4+C?
G%+&90|&W'T|9:6|24O.>??*JU0EZC/:%5T(<1AYA.DP)P^;\$/ MACHYDBXS2?
S\BN2#KAH|V%@>6TTQEUW1JLDPFEZ7E?UZ:PMZ496NRS!EQK\$! M|W,%PA^NA""<
I&Z1CKFM)\1I"/D'%-'BY'(52A<+JvX>D8,WN(2? \$|H* M: +<D'I/+)IA<:B\$?
@,YHK/V>M2\$9!+WS2(&MKU>N-!;<|B:O7IC>&J)#,K M0SUC4M#6.|UW.&*;H+#NW
&PG_-CVC1+NA7#GAE?;T&!.%*,HXBA3LI.9/U|
MDAFUKK&FO"YQ?;#| #,@GXW8|.BxB%X77NP7H/_Z3E2| #1|9)D#9|%+QL!LW:
M@|A6F0H7|@H1SSSMZ7L;#ZP(N.>DP@L9AD:511> M6YIUX?RL9JR:\$J_9J,.9.
|C&APOW3VRW*VVI;Y\$'4C6FPE-RYFAL@*K"S,5Y M^WV#H\$M:I,YJ<.T2%
(,NAY(26LNR/9(:G*=Q,\$#25.A>|WKJYM.R1B|7 MUU;AR;BRFVET |K|E3;X#B2;
<,*L3|HEEPX|J%,RNO=J*2>URTHLG6+5|+. MP%-V"A.%#&@)7| #W8!.I4\$&6 L**F7|(#
|F/1EAKG<^G|9WK1>B2DHRZ|,5> M&5|3A%LZ@^| ^5=FW;+H'D+MC;DX/"KJ:#Q\$PY-
15#6R*+H*SMM"43W7_|7> M&NLIH_W2V6#SD>+O?6JVR|ZW8|(3N@<^7)2&GJZ!
|Y|ME%R\$'<1/U)#1#=#C M-B/,*
<| %H*:1/J<_ =W#VU%>B|&UDS6:EW^:JEGG85%>UX|/293=N|M200V.! M5\$_-?</p></div>

A*0;7BPA![NUCCQU]_Z-MB9S+;/0<1*?P[BA+I*A3#+J06"4,2.M-JB8=RX7K?
#Z\$TIG&?),./4_VF';|CNEQF\$Y=%2\2S-P+.X)7<34Q(.WQIY4%!4LRB/F/U/A2%+J(D9
M12A\$+VMDW4>BI+N7ZY+-Y;*3PYJJK@|WW3KJ'D;H7(V|G_S(ZR0BEJ4(^&B
M>@:3J\$@'XQ27C2M%S^=30:NI\$GT[W^LJZ^_49(7S5CRKX)IN/*&"J\$I>(!1
M21#Y#E6VE,A2#MHE3UTM+!#)DCP9?CLPT%9@Q&3?(+%;'/%.:ON[7=|>0KSR
M&G/A+GWL#;:MS-ZN/>%^S7=?338#6LHIPKDE|&NL3\Z:-
%DLPHRBCR:O\$"VB*SU>|M0KE9H_M;BQ|.G>UZJV90QK7)
<|>X=>).SCYQQ|>"@LU00"@O/#OL#+N*#;:@A8\DH\$&U_M%990+E\$R&VB4G!M3J-
7,|#=Z9KQ3-W@:E74I@CC)6R=72KQS>#.N\$K(P33&D
MGF6FQ"RB)\8))B2I1Q23YNH,B:&X0^H8D0L7O ACZRYTIX+JRV.G1J)2J(I/M%
6.KW<"|,%X/!D36Z(')_JMF6%"\$>>ZR/6A=LM|SRQG8,A9A/U*U!R81C3_M\$B;PMW.Y!H!
|&2>&K\$|_ ^&:F63N@/)7TR8!GU?>)>/:7AVD?;1JJ6C5O4D8= M&
H'_OR458Z,3(2SHOLWU:7\$L3T4C?0B MM;4N\$D1R|DW =5^O2FW30S>Q|R6
5MVI*+VT>.#K%RS>@@=A1YNEP*DLVFZZ MD3=2E|(!?0(5XNA|7;.Y&"J"!??
C1Z|(|O|M#;)IZ^"UVRGQ"O%PVV;WO= M|>7H0+ ^ (3;GSZ,F="J*LACB616+Z6;
|+4\$1NG\$<#(_OUZ32.(+I<(8A|R%R MCV>N(B7|:Q\$|_!?R4D+IY0/URK|VZJI*1U^O)OO?
-|=JOIQ0?/LL&L,\$4/H MF_18=*/#D-UPKDE: ^_,@OU:4Z&J8;
|Y#7^Y#@)G6\$O#&70G\RT3OA^ MT;=Z|S3)W((9>&*3440AT!WYC00236ZQH
P+RI7B">6\$'7.U-F5\$-B <%!|F M?EF=US\$@E|\"B%<2@D :6V72R@;0J!TW_M@E?'=|
|=O&U?8,B3ND)T1EHR1"JJZG?*2Y_7I&9='|TI2Z9VP&@1|>3+6C|_M;!U0*48(,
|42+L"PZ>>:B5<+.TXW"%J***<6)^C&W#YUE?M=3^QPLK9+1R*I MX>N?R%(3|3I%|?
6X"\$,# 2N3-&%EU>2IV 2C_N\$#^;C4@|V:DF=/F0;9=G/\$0|/VSAT7R0AW'S
M@|_G.QD9/<(G(Y=D)WXI(\$Y(&GV5XT5+|965;!RA MF#2T8\$ENH3ZBF3P!
(^PYBA&^&:*0@(|)FHDKU1|*JMYX*S/2IH9^1QJS%\V< M2D37 @#TX3G;IO%*_
(219XJS|PG2&TB:RX*4R#G:4D3LVJ+)FU%3I2 MD\$;
M22XU**^N.F/|8VL*Z^Q9:6"&3QIPX?GJ>_*V+M@Y4W2QTB^W:WY9 SA.Z8>:@T?
UFHH^XL M='(2@|1EK5|O ;6HJ!4?#R>?62*(OH9OKEDI4IQT9|!%?W\$;
<@|E*FTYJ;*U66R*SYJ;=JPM%?@ ME1C6H=1G4KD9!T'XTZQ)T,BQ@_4--
;T,LX+N(F|!K|X#UY^K/+7|^XY1Y/L MWI/4AY DG M3EJA?3\$?-;
<.8X6H'32QHN@\$3P=Q)1=5|7WW5E\$8|W^N%>PC- M/7Q;-ND?=USQ*Z?D^SE83>9B
WW_)^0 9K/O'E|?824&HBV|S5|YFGC2.?+ MN;:8^+0')WD8KZ9LQ|+TTST>S6K4|LL1-
PO5013!)9|G\$V6YSF&CP-FE!Z=? M8G"1T:"N(^S8P.W<,(MC(((//4MIA:1JM5AF\$66
MA";P.)C1J(E'XV(!?@0E1WU),K:M1-=P@+&7Y#/BQ7|W4|,&ZQ?@V9MWIWRZ
M)DIK_1AK>6;6(A95L135J,!P)GNT^8E|:H:TH1+2V|L1N@E=D@>|<_J@/(0HJ=N2/5OV@I
|E'&Z*.TW3I MHP/:(
/<>2)^6/\$"0E^7\$00Y_+4_579OGQ&)%^A2'/K&\$#E^2863"/\$F=?'Y)'*W9A4<-B6UO1F4-
J)O03*LZF03PVKA530.KPFH:C>|(>63%/9!YV9(5)T#G-
"A=^8PQ5S,S>^GD3(L|S;1@#'+6"" M!W#X'G"F|=41%\DUK_UB C%">CY%-
PERP(G).9+3A)5)/:MXYL4K^S7GFVXQ!"E#C?
MH#_(+^ ^O6?),U6C7@:BK6Z|>JOKU+7P ^668M8U0MLHGLBF&KBX(%S3K!+
M&N(TY1VU3VV0@'A2JD873MI5U4IY.;I?4M98K^(2I|3)BQ_E9H&|_#C1#)MJ
M1/L,PK!S\$FW|A,0N.>SUX.M|WQ6DGY>\$D!2 T^&@ \$V2Y00%C=EH5: MZ"
|V@5=8))0H(|C)6(|. MGN/+ \$-(I-ZFR1>P>F
|2XV0H,Q6G6A,@8_@L=HAJNOMC*|> ^WW5HT9**0^ M6|HB^ _GC.P|Q|H
L9W2A9Y918WC^| N'C|,C>QM*"@2XDL52CC_WSK_UZ!BP
M'1#BH"QVM"YM0HZ.D|\"HJ1DF)A55Y+R%H9,GWJ#69N^0F7-'7O)KOE+U=7E
MID|@HWU>D5AAX(|M:9@+A8CO!,U"X)T=3CK#;XR%^?_B#9\$?%Q5|!#,0_KJ MN%
|'&AR<&M(H'XXZOL|^<>1#9RE*"?IF;OZ2I=7I)3\$1PB^O"
M,H>8K/2JL'!.4@8&,KQP@!1QM*W^I2O/*WfYB9 L(.,|\"|L?H%55G3K5)I=| MP:WZ1-
W|!%ZJW=#\$&%GFW|_F"Y07C+8/LNA(|K(K'ZQ713U!6\$N<+J/YF%:1
M|1_YDHJ=3N\1H2@=X&BROWGUO(YNNXKF;|!W6(BCW\$;MXV>V(A;S:4FUW:8Y._*#5!
MZ1VL|^, 0Y*NSCA80;LX.?SU2H;VY|H!=5^#2"?OS#[MU-!7'SEJ37>E6AP#
M+&|_|,O=":|674PGAU+7F!F+.#?TV|AU/!=ZE=N|XF;R%='(B,CF2FL)\U2C\$&H*5
MJ;"ZX9M6)9,|2#6M_#HM)_2WH<_D7*DL3CMPG%*Z?,M@EV+JUSLY|9NV?TI9
MZWWV+.K|=|Z:|EQT96_/_/#<&O:6R##+9|JLZFD =GN:|<-& (EB!=4W+8
M|_:3E3DJ0%I3LI(9"@,DUT^%0=RO6QL4T=>.T9.%PME'O15?Z\$245!^_Z<3>#H:F:H"
M<3H&S856RD?BKC"YJ6W,|!O|'AVP;:*VT3.M=V@*7UA"N.CF-FLS Y5)ZZ8
MZ01+'W#1,"^X-.4/=Y|#[?|_VCNSH*:/(|_!2RWH0&C\$26(8N1&! 1*0)! M13 "51"(

<)PB,"@J*B1!+10((#(\$;E58D%"#&&X+\$@4)6BHAH:C(&>('&K
M!&U,34@:,.WWCI9UVICSP\OZS>Y|=G;WMJ]?LYNRK8Q:5*>R'-P,7ZTNY24 M.OD4;
IQ\$24TE+R@["LI:":F-M0X;^@@@?OX:N'IP#:.?-2BF%W0D18)AYFW%7 MV@;BFU'@Y=QU-
+%CY:V"RX3U003P027@ZWOB\K;U'(1ZK/\$/0H16C!BPR6
M"V:628AHZDG>07&.@"/Q|^<)R*5)L^_0DQ><17F1&15*=H'KS)1S\VTU45DR
MV"QVY#&&25-S_K)5R@8%:Z?!)TKDKGD'!'+'_RA&VTW6\XE&VTINDCZ'%O_M)??
\$@50,N7\$XD'UV&W\HT;EOCE54_24T7LHJ)#RB /NW*B8R-!8#<5:67\$@9
MEP.JI04=B8Z5@16YM0DZ&"W,R#*GDB%'OT*"S2'G,\UJ VZVH NCU NDYJH6
MDHVRH2]_(R/2.HV6"QDQ#""*R]!+5N[>TM!O6Y;C%%F&IE?.'LZ.X7?=UE7W M_OX\Y?
+4047Y=KP!OH#RK-*&4.Y&(E;QOG MT*8(81&\ANL*0^?6\ITQ7-J_|?(S\7X+_GZO;4CF
U89S7>Y)*Z'.JM:E/'@L_FM5.8'YHYU<1&1K2;X4\7-0/*.#D
MEB71Y&&A98%]1:U/C3?I90/K+@9KTZ"J0BS;.:HUZ8HIVYT3E^3C9%,L.O|<
M10/E@=2H7E(BN.Q\1BG P3!MQCOK514?J+P?2\9;S.C7%6-&M\H%T\J4EFVN< MJZ;H_-
I8QX3WF"=2T9,WZI?*^+KJ/GM8>%6&VZ9W\FTWKY\$2N^@_C8=A\VM#>-+N
E9B\$T=4&\$P,RAG<"!E?2RE N06RHB0\94<@XCV\$SOHGMNP#U5Y9
M;KW%\$W\I&65);Y6Y^*H@BLEHD0.)U^Q11EB+#?''+6\OM&%?G\$R_QZXPWZ=^M-
#K<9&=;^KYU)?#H9\I&X#-[2I=A'?3&4\I5E\$B"FIX@M8\@ MM,X5H+
(ZUK>=^%\'2(WU\$BUZ-+@I%#G+IR7\&5_A*|*&F:YX%O\OU\$;J, MI-
X2HA>G0;U#;47I=;,&A_G3H@QM+^@XW8ES!+ #J!G5ORK8_%>\$7E MI?
@ADHC.UB4Z^WM"@|^"OB*X^"IGO@_@R8&%5"%>I(N@N:A/<(16\T:15!RA MG#LER
G_)K 7C?9L!))@PA\HGC;C0RJ-JEX3,I(T39 %?#K6W5'Y*O\$504/
MMO^GK;Y\4*O\$5MEVU&JQ?_I\+1(W,RCZ2?KBZX)%R;3<-BZ^27V\|@A.,EK
MP+@U1@_IS!6KK^1Y>0M+L3O=\$_N\Y\I/F#"OWSA>R-I.U/A=*8&PADQB)@S
MMB\X"Q/T5<\$0\WV)3^2_1C!-YGA :@0087^V-+"6 UW%\^1 KB\2TWA72EF\$
M5UX9QC\QP^'DP!TN#R0UB6>(9U:41^I=-L6P.J?FJL\K;H-6*0E6IOCW'C&
M2J<80#\B;+AXJ>PE;-I\YW\|?? M7#T?5=55=6+5.;J700T>@FXAE;(22C^U3-%!7!W@
M "\$<+&D 6Q,B0P L.Y%V@*XF#(6YK_!F\<_@), (INLT \$&#;+F/JLA@ M&+;_V.O?
#P"H>?J9.=UD4;>UL#&S \$W 18 '7 %K;#!U*^""4M#+N-=M/#Q5?
>F\J(-9?;/V\N;W%N%W=K,6\$+IUZY: H+" L# ? MI@>?NZ^3AYD/GY,
fVR\3W+%RMW"S=?&P=79B^5\$W,W?V\ "Q>GK:6DH\7LJ M9FYI* <9G;B9BR2;P
M!JR6%(@)6#E.:5DX>[AAI" FP"OS7XL2(Z,I(Z;X,3QB^DC==K,R\I"Z@P'9
M'TKF\$Y3D\$Q33_L2^<7\$)&0\$_JJ?C;I?;\$?H_ ("U9&4L+*8L?-#F\1\I(R07 M_YRV'6QE?
[NQ_)%/3/,?"Q@\$&.N\=.F2C,"O'E^3Q)0\$A(M=(F(DIB8DH>!AH'GGW\0'X"KA-
@WL&=QL%@!|*M8.%>QT-T,\8IX&'X?G3 M\HB%C8.+AT\>(F(&-.A\@J
C86#@XV+@X>'B_'C6(&8WP'FIM8VOG\N'IY>WCZQ?V+#PB,BHZ)B7U>5KZ
MBY>O,G)R\(+ "HN*2ZJJ:VKKZAL:FSJ\NGMZH1_]^D?'QB'9^<(KZ?_>+"#\!^M/S-
FZBN\$+&Q<7!Y?@!U\8V-X.ES%
MQ;LNA\$^NH\$E@YDK!*AQ"2*F8_*ZRXQ*;B!;RMQMA.@:N^@R!_P':W_@I/"13\$4
M@P:.)R1.)3@3E^X*2J\$! T\$F\>NQPS,0K\?#>I# R)_ID;X-J\6L#)!;%7@
M3T/X:.#9X4K\!38\&@!ZF&&9 7IH(LV>(D&XIN3Z,R\IO MZU"DH_T7TB)^
MD*."Y,RB0@:5Q81^+P+-KD8E%?.9&?8,X(#5E>-#\O1UV61,-7-KH_9_A
M2J"P8DXSN\$[@J#M,_Z;KWW3\FZY_T_5ONOXOT/7\I"\$B"Y\KYYB6Y?;_JKT
M\0\$[8"C?/S)BOV!"ACMO:I@> M,DJ6&0VMZI'Q1AX,EBH_+;<1FK%^SYDKY" YPBGFC
>VEV+K>0G\?#:2^
M:D(#%:/@ZR:,'^ELGIN47D'OE"CUA!HTE2B!OPWXP42VR5@=GLR/3(Q7!&BW M,JG@?
CZ/.D5>6RYHK1S+GC+I\$IQG?B4V_=B'6KZVYJK1-!3,S0P:7#JTM-AI M; &2.X,+)P65Z1F?
P591\$?*I#U^IY10ABFJ/8K(R6QG7'RB4\HROY7A,!"ILO ML11HT8=!=<%8UR=Q_W
9S,K((1RNfV+_DB^ULT*Q+,O5YB>_3,ZS!:W3E"<76 M)^6RV\1M_"&84\6_+7-
LN<\$6HU3!HGSZ6\O_LWSAA*IKJ&Z4)J\R74,I\< MG4:YG^)"F3E>DB(8AO':>
JR2J:W*YNW3KFE>F>-"F%9\I)W+RK>.C@)%-Z\ M;E*Q
3S\$B^&E;3'+DB[R#O+;_KR0B@ZUD7?\$V>RH!7.E%BH,YAQDHO+I:&2 M\KA\TKJ
""^=!C&6U"B\?S;W*WK";WUR_L\I\<*=0+4\4V+-+69: ^L,XR'KCN
MXP_Q!ZG>>D.VO*B'ORR8\%!\JVBMFN!_TE'T)D*TY-[97\O8EE;MO)7GI74
M10.Z@908Q\=7*L=Z9HCKJ+6#XU\$FW\XVMTI8,)=+&\$QX1+?(N7!Y-35-!8O
M4U_BG&=_LI2P*HI50\C&\$@HJMD^\$/:/3>R9#32Q;4R^N59DB72RKPW+FK_LI MDW?
XW6C.>/X\$W^CGHP,GZ9)%3J@*UPX)C&66GFPO\$I\G\6'_5WO")LTAO+ M#7S
R@WCM?BSEWE3"1!S_U3Y:D\N' 9EL(2:GL07MN!:@\PRZ"PY\!%!\JVL MO;3Y=,"[I"
<5+Y";GU>/RE*|+T1-%#G&0L*V+Y6+Y+*5OG=G"U3P_V0-.@Y

MUMS(8T%\$X>V&RH:6R\$?UJO86=8^] TH"1?0\+I3'="H3#A^|Y>=:HU6JLD8'
M5"LI>/LZ6SA-4:>4"4(60"6QJR-C/2CR^XDM!:_N?9IK9EM,YYWW?/-)HFX
MW?/4&/%"N;*ROJ5YO'REOA&:RB9!;EW PTPQ;UN:/6>X;?!R;+4I*ON-.. " M;1+
80_7\FJB@7J_WQ4PW6'Q;AF2\$;TZY-Q^H?APS44EA5J2?B+|E(HSZQ<
MQ4PF!+5OH&_#D#^|:D,E22-*>P."NOX,TA<\$4KNQ&!=%B9DFVF9ZA"?-%#I
M/+Q1'7AR;2+LX|3E:0<)(H7CV9A-)%;NS&8010(O2+V6WM>X0'6(*R7THLA MR#>;-
">FGXES)&-VJRH:[V_YXKE|K07P3ODMK&&|9BHCNZ\$LWDMR?!'UPQ@
M.*=J3T8|UP!48K0M>&"2RY"1H\$3'*JOQW/'SR,|V#F&=*NT<; MDRHR^|5,|=!Q?,-3-
MC6/5"QP7K;%5"Y(=F'Y,+1C2DLL)N4&GS9/+J7VQ1<
M:2HLDIP|KL.GUYTA%C/7X>O+_ (K2*B^*_ "I-YMU-&YPCPJG!"K*|Z2U#2X-Q MB05V=!:?
5SG64;7V)&Q>X%|S.%^H)Y/XNG|H/%BRKO"GW>#N;-->)F8KVV*
M/+^Z|1*PI/SFO0BF_PK*0=49.P|058\$C440I%+>5HJPJ:D2!;:64R=OW&%Y
M;/"H7HBOR!CE:E;/U%B2WL8Q*L!_/73F3"+=|64J+C7-9V4EP\$|SL3<3Q|BN
M4WY=)HHCX|KE\$F\$OZ_&0'I.:YM"S4=Y2U6OZ'_|6(,=N0I?K|%-@&PUN68
MP&N*L:BVE&8Y//#'L&4T<(YO"-|,KQ:9'4)&:8*G1O6LER#?KP3(H8\$G|X7 ME+4C
DN01U1(Y5_M|7F8O7ZCUD?AKQIDE'>&M?_19J_MC34SJ-R! M(16W,Z69Q?
<'00ORM,P4>YQC*(;9Z6V*UZ|G^S2-7ZEPECKB')6>@<-J9DGX MN|K|
<8|=F*;OYC')Q&46&1NL|E M95>\$|DU*S|XJ=|+?+%"AQ:QX0?
+#"Q/C&V|H9A(3!DURO==E|H/X&N_M),@)NS!;956VU_"5_|J+X^FC^F_|M
MJ&LJ6@ILR=W|8IP%U|"JJZ?|--@S0J2CL0SKLH6|1R5A'5-9TWH9HAF-&9_A7UIV
M\$=JG(783"/(E?C_B#|NMS=E,93K HF;1!'ZVQU ME251XF@SGXAZ_:AH",TT|UJTE7>J8
KJF&^J?6|_V<2L<5 M7/G;;S92\$43_0?LU6|Y"A\$B7GTA/LV:S8Q^-W/S(I-2ZK5SK!D(HE
I8:=7 ME@ZVC+5'=66^@7--2Z4?1,EE=V2LTG'%+E,|DxRN!;YS>Z:M'J8-6W'D\$FA
M7/AM=|C9Y'|O|@HWI\$*XK|*|%SLYE'#(Z(K?0WR"1(&O4RVN>0A96EJ^Q^F&
MAX5XD0|+9VF0V^%K7@LW\$,L6UC8QCJ(VV V:|A7,H'\$14C>XLDV)FBI3S|C M\$-
^|E<|*.H^O,1\$0643L0BDSY+I>BF91&FV/@'E|JU,|^/C\$^(>LUR1XP'6 M Y2:C1%?
K,WL.VK")48WK&D.YR%A(+@!B8|,|DZSI#CY|.&ZMFCQ2SFQ^L ML+YB2>YL:HB-
V"P01V(|>?X*?DO*^@KRBLXP%@T|D|_15>RJS52O5#N255RX MS|G;
|MJVZO2*H/1E3PM,T|Z|FBV|= '\$.H)P#Q+^S8^*ZAZCAC)J%|90J|@&I MZB
=BQ7',B|F>A@:|"|RC!'YZ1A2%_#73#|1C|T-?V%VASI%ZXG#61)#NI"A4WF=UD_?ZA
P;C)TWG,)(83@!PCTDNZRQ92P0 MWT+3)EQ3'0XQ&?M6|3VX)(*D5|!.X
J"B/F*C5>&T4P<7 DW|+\$^EX6(|<-& M(4,@%|Y@_ACU'01/|:90B-A:
|K=*"5@ZRPO90KLW?D%BVR; Z(/X14#QB8|' MEX,<8C<' ^YC+%58@V(: (7+7WE?
Y|CA95+)|#T|W XEU%0F^_-/&=4-9/U"El M;I_14P+5_3=3JF.QL18LKV?
8IPXL|LI^AUECQQ).G+&94N/M+^E9Q;U ?| M,=>1Q(LXY|>WSH"*9*\$>T=KHC6;
|)C@7PMNFZ^F08LK+>A1A?<&4,AY<<0 M"MN,FE,W=C\74YYA%JZ|MS|G3"G
;Z0V|JC>1^|+AFQG9*;<86R|XX(01&J M0P&8(+%G2W?CG*RK+HIV|P9)/4,XP^6@VC&
|++++=6E,ZE15:R-|5=,&(>0 (M%CIMBEM_78|
\$TNDGMZ)+1P<+S"%4W)|&KSAU:M5Y+0P&W8_C.';%F/HC+J M(IU.G+-*)/TY6U0
MPJ@|I9GX>|^./|T@UU'4W(Z|3N7+43,8@5)615(BAT|6?V |91-U_NMLCE
M(.SZL\$3NQA0G*\$)PF,_%NGEGWPH|&&ZASKL|C;*_DB5MH+L"7PKGE0VLC.
M(MG*9,#M_&V7Q3X;T37"9)Z|088XBD<|:01A.N.BK8JCR^451V/G=68M=T7> MB ?
VW3K-)A58|2SI(C#N9TW:_FD(K73A+8>5ABY/%;^ ^919='3UPB*\$S'F239RQ M7I#!'^Y;--
_VVV\$,W?"G,G;7^.; M;-(K0CA?%^W0|Z|>='-1'B|=>R* M&O2KJ,_KJ;#Q-
K#J\$E9Q9^HLU10_?9%\H|J5+1HG+R|7P4*F M!:(
<|^5IVKAB5Z6"YVB>UZ28QB5N7I9|KMS@|Q-/:*| (V|6.N#L-" M.:OP1-(IH+|3=DQ?
007,SZ3-2"/?2,CMO,F#\$GJDQT>O+\$0Q@C0;&G9HW#K MIF38K+
(#*PQM'\$XG"*K,>U|70_*#
M%ML0YL@VDA|P76|(!;7FQ70FU|NL5|04&U*M8IH2D!#.WWW|JKZ!' ^54L
M5^_=,U?|TW8BUI91CQWE2?|H20|\$H=|JD*"L|UPWF>3YG;2Z9UP/A.=)6|V
MD:3|*#0RFWZA6F&Q@GKK7X3PZY=6Y@.:F *XIGVQEIYXFM|:LCS=-9YX6_)E
M)H_PT|F;6N. \$"=|E|LO1!K.^'SQ2HL"1UN8UPG%)EEM87*4KA=JDP%>7PYH
MPI63O5=:W15&/0)E;8YV0=J#;B>|#/9CV4|\$@LD_K8#;==DG)?+L3L70.^7 M)T4?
8J>X\$-3CB#EW-M7'>H"9;B|!R!^(\$19&YU%8NS|S\$NEZ-L""8;\$J#&1C,I\$WORV
5A/6T|E^_1V>2WP#%N-"3S. MU;N>)?R4;&'I|V)?
MUCZ|5PC'JRNU***W<,:*_ (2YV;AE#G3H9&AH'RX(OQ;8'AA<>'9R8(M-,UU MLI%YA/4A-
G8Q\$GR%?V4|UPWON*>VD?EV_B<625|'4P1K?X;-.%=&J&38ZPT M23>?
G.F!O)>^B|D:BP|9M)|;5|SEZ<^|0_651Q""J2O3%2,T>FU D\$!!GEB) MAB'6WP&"ETA?-

),.)!V=N;D@H-L))%HH%OM(YH(">|82A1|N"Z\$AHP537. M"FU?
4"X_XLP008CK:D|H:&M|U_:=>DK)%O!J' M*
HNU",X:JP<,F)X0+^%2C;N2!X,%Z1V|14QVP;9<:/9H"=72Y02Q7"; V MM-
&|5A^Z:V|KI+C|>(_=UE@E^RE|R%\$Y'5|J93_!8@.=360 "9*LX7DV.7=LZ=W3 MC*
I)%D|FY<0_7+|!70|5KB;'WNRIWOEWS6:1F00*T=/^:2Q9Q;56 MQA-TC"
|HSX05#KTLOJ KYMGLC|2/=3NGGH!N;9Y"H8T>*^U65F89X+SXU05+Y
MB,7B%A@L|Q9PE|J|0:H5(@CN9H)T|V1N|=EJG/7YL"?YX3*0!9SK0HB1T5C1
MGI*1MC#S/_%N(0S(-TP<6VP#HJS62%#9|4PWGOU-)YY"J.Y9HN4EU|@7|2
M@|_DP@OF;#*^+O:Z%XN_W+5VIC'T?;/"T;DDT5Z!!S@C9GNH:QV(+>|3H:
M:CVY&04Q7&3 HG%I=4N?>B:|WADNH KKS2J=4P-T,K95KK|*Y @!15""H"9\$
ML8|!|!#QJB6&MEJ+AJ)V|HM8/S5B00R3UA%N.U|VB^=50T>Z*7CT)*&5J_"2
MS&MP@K#C0;_>F?|S?7M(7>|HL'2GZ(30KP9<*,7J4FDF-BQAHK)E\$#^4/>
MA3..+@|!#RF9#6#+G"9;EJ67|R^R"J!"@PI>UW-3;LD;JW!W";P+6T(#41HO&
MBAS%UL*5X8S91SX%S1_TV(3G)'!3_+EN4OH='Y4G,MCX0;-;S+*G|RQXMI| M^A>/N-
8!SFX;ZG#TZ-+M'D'H|<|V7.C_8Z;S %G-(I=N-\$V#0;1?>QW MX!L<\$J%Y|0D-
^#. @:CL#=#9J^5CYA!=OMZ80-S?>HTRDY=WY/I5=@ ;X CXY M0P?K"P)+^SQ+:R;;)
WRHMG3,Q1#>T7G:R-E\$M7G'N*T/'!9'6V<<"0ZN5B MBS/8|'7+@.XM(O>+;|=#5&;
|;7R9&E0=R_%XR?PO?5^|>|!<-Q*2"JV0NQE3 M3A"YAJ1878-?*W?
N'J>*VQ2H_4"R;6L3'CH(RPC^L@9IQ&-|SQ ?|
M&%X8|4&B7N._GKZG"08Z>*)):9%MTA\$|-\$8U9^|F=^!#IF4(XNH1':8I=UBF
M3<;Y;'FR_8K#^&|CS>KX\$E|VUM(^/A.+D/P:8@%W;X1M2QQJXQ;Z1K' 'A1?|@);9OC<
M#<5W^-C5X-0%\$|)G&(3&5|26\$^M.ZJZK2|P/\$|1G5Z\$P&IC>V)F)US."DX;!
M0F?.=5I2&\$U4L8NMZ#^R)|\$08N<@@|JWFNZ("R.4G7?U&8.;EA*L-C7&M<" M>1:
f'>D?PYD@V5O)CU7%;@13#GRF3I^D8#&<7CSDX*T\$4U.5@A5J=! "4MRINK(Z)4@
M4A7'1/59)|8=#?7!"|6|TWV|P;%(-KY\$OQ^>3+IT|L9YY-UZS>&5;CNKH00%0-
5W_7904RZT8MH@98G_R2Z>46.6K8')| M*.=W|Q#N=U_T-X|
|Y;UP\$NYB%V"._FR74%FV0^?=[4|&LMG4TY4'SYD#=49G
MB,ML,%C\$!7DR=PM<475<*<5K&@U:M+#+,L> H|4JS/"M?|*TVNH0(#>.Y"VW
MH_.;4"JKM.MV>ELQG_>"8&0Z-3\$?T)|HT?,4B&&!U<4+\$T>M'HH1;S#(!ULN
M^;U)+%#2@?&_*|W.Y)ETNK:WOM.U&="LUW|K;BE!>S7YM/W>QDV/TD&*%7&(
M;://R;+S!#'RZBU61G:.%+VP7NFQ2G |;3W|=44|>YW-0/KZ6(R=5N X?W1J^+=&GY*E2-
0Y1E58!54"|O<4|P+=XLPKKJE69&9YV(F>G|MM3SQ|NHT'?>'S|2+%G
*^K^&.!@|T:|SS#1#AQF'%P6^#F#!-^%'Z\$%^!BDSF8^_JS, MVZLN=\$RKKN%M
9EH!+>"T|N\$R?DS|04FF)^MR?7V*7Z9M.;6SBC*0<72/8Q M9^/JEO'?/V'^/? OGT)S_-Y3Z
QIN88".+G#?/OF5|4**G?-?MY M@O 4\$TL_ E_0RY*L"+@/!#X|B_V> 2,ZPUF50*9.H0%(4?
LK2-;.=>8;-WW M)22.1PV,.(M\$-0D<4C&J.J.!YH=H8\$H)9=[,!!6>.|N.X8*!|G5Q|M!|)81
M|RV"6<;(S7-O?O;1_+Y2U4("V3;(DYB4O:X_IO/^M65); T5&|_TA1Q1'R*D M6'2!=
<0CRF'/>91;.:7>BM!'?F6Q(Q56RG9EZ?G M1OXX->T>&UL|@|I^?KEMAHS=6?EQ:
|9|^&\$>1LPYAHGCO;-HSI2>)Q\$3EK2\$<7F5.#O(341T MKFV=*DG1U55!\$L%.|:5@#
(CR|1|P#9?@%*>|5:5Z>UB_U+"VW>X^=EE@G/ M-F+J7<&V|N;.:3DZL,>-<%B(-
Q&'#&_"1|VZNI|@RV)"ULX,/'?+60/RPCYK MXTQB5F@.@7\$1|<8?LU-O5=%+;S7#3R?
%9W#M*)W,H<%2NJ81 MX>-R5)">R2S2-X?Z;#*"VD-"2)66P%"U+4'FK10**ZI9?19(5K
T080OF M3NOI&5EW)2*.;J;+8100R%8;2<9F+ _J:' M,2
+8=2KT|4SLAT#JK<%@5NRH37VE_.;L&2/Z6'OH99|Q% U03.N1%&XO<,-#
M!XIL' LW8^NF>J#UMB.IC1TC.)W0V0:YT|0U%U'(Y=@CWV;-F,^4_X*5?KOU\$ M+4=V-
%2=%- "K,>IQ@G+ZLW+U5-ZH9NH_@)%KFF7VG.=R8,D:NT^3GM6|JR3
M,TWKE7BRARWG'.GEUJ!>%S;5|=2CC:S.1C00/29Q@A=>E%1&G?'FVBF'AGX?
M>|COAR)9-IL9J|C@@L;JNHA)?PKZF0'R<\$O'IJQ1;HVVW|4%D%
WS%YVHKWO|!|?N2=W^YRN-.|'V MB7@;)49V,=<-
ZJ|79ZF|K;FL.\$1#Z:4*E|##=NC=^(D^\$6#.4F7|/%HC"%| MZP4C*P>|R'>;M*7<3
>+9O+SLMR|7BE*#&|D&(L8C'F^_)4NLD_04K?ER2^
M",DW0Z3OW!^K| "C%';\$8A^0|/:=ZKX,M*_NT;UG)W"9T3R"V<-?/0N
M8|70QZ=8|*!@IS=3UY?>4FNT3,FH>?O.;QP2G|3?#_..V-(IH(W4F<90&*
MK7WRUO+|BWX%BKAG.,DQP+8,|J (6MUZ&*6).)*O,KOCQW IM&*.A"VKN4 MB6-
J'389)H004J|Q\$TCF7E?AQ%)9?&J;|X";WQG3XXY@-H"F IM
MH|C,EO6M_LX'E|.)J=W%J1X0S)|#; S:NE+.ROBB(1#"67,&W:?)"(,I2X-
MD5B+DT%\$L29KCTM,.5|/*=<+S_7+Y7\$|W8JZLC^^O7F";|K!VL'60'|
MXNVG&NVU|C/1S+ &#QDQ>^NTLG6S.U_>|C#.EWV@8Z(A_%|8E-C|BU_=4%'

7^NV'&+EQ/6XX6' M5ZLW[6,=F:'/\$%#OD\UK'O65T2D2M\$9'?8SPF6RXL%%6-
)UN%F8W.4V:F:Z! M&?2O2':E=YA-
)P&K"'\2K1+Z8[51/L;)0UCR(\$/!+;GD+OA6YTSW"'\,;&
M++4F\XVX6=,O^1%Q22GL95>>8H@(56_:8S/8"KSJ;BVJ4P7VA)"L&[DDSL
MX:/9/K'STH&[&Z]J:7/F6?:5L6*.;H'EC!G29M!6OM\$93H7C (-[P0MOD"0'S M*^3.L,
<^JG+\$31P6&=^L).?&V<5X6 MEHJ+,33<,5R4^/;BJL;:1_,7 RZS#)Z/\$I\YZ64I%7.&
(!56f%7;#&W?2<7G M9\$H(.0L+K!H+A(@6C@9!%GM+)P2]PH%ED\;CJ"23 AQB 98
M*4V/C]^*(A1=YC)T,"T\^P:4.)SS?J9#X\&X F|\$E@1^>@Q\W6;\C9+N0E>.BE"AGL+>?
+J7(S.=(6BM#B M;[P=;*J5N,?P&+)(+Q,8%6,0;:N=\$>N?
W)@[JAQ;QSWT7.>;700+;C!@I'
M#J&=9&L0U13U5@I&)@3^_G\1E'8<2%4_E77PZD+3&Q."MQS6\7 CFLA4?N>
ME3='C8U[*P7=B'(@\KF4/T%==6WLE3\$S!*^Q?:^>)MR]>[FL\$-11;L>%\V8" M2>|
<;%=:8K"X8%N/,DUC/TF@|&^+(V1!Z0@C[G4C]#:4&C/6M^G+>Q\700"(
M@R*J=|YT=RFQP@L1NKS&US;4VMM;)O@JF"V(ZW^%++.B5@3)OA)6%:1%KX@M#
M[>9:I5EGANHXA4WYWDM0G%L?Q&9&Y!E0D&5Z1RVU2RO-394M\|63C W?DU+&
M77\$C9%D=3;T+|RQ(+9KO<)QWKBU!2W_)ZCU\$'V(;Q*=;/LI
MM,!1EO)1@#^O"2P8%N&>@@^LU/[ZG+"O15DB0;&2P8-IHEQ)|%OWQ">^Q(M> M9-
\$T&IAS[J^W*3UY=D!|9IGI4NT5H@(?^IV:>|H7D-K M9+#+.8.7.
[1W=VZ79>F"MSPGZ7.@#^4>&N@\$N>9^YFR,^(K\DI^I-5KS\$B=H
M#OHR6MRU1.\NUGY2 "FV2S_YQ.1K7ZP0=W4X"9A/I-OARK|<_!9[9J,[W6^V
MCZNA.GKE#J|J#|:.-N UX3B#^S&IWW!#TO(Z?O2YS(K3&\K(W
M0&LG4U"ECGM&+|S18|_#_W H"<1:(M(R'N\J.JM'B
^NDNRK|T/I&>\$=|W=8V<+O9#_P*!;2XDUA'#OU\$38ON(3X|TJOTZ+F?3% M2KCRP.?
#T+J|^5GOHE9E^NK.QXMZL/2&M'=:49YA| MO>3/*&\$4J7|N_'40;:-
Y:'279J"9T6>59NDRJ;J-K2QSW.'A M5U)EJLHX?@*-"GO=&&
@5J\$NLGMLQYZ|8,7GVC5%Y0_4|9(824>:P'H*6DX. M^|1Z|K|6WR
NU9MEM2XZ8CFCF\D)%O)()%,K,*X=_%Q=M"U,.7UM7:\$RL+,(M1_98'&.*J|>=55J+\$T-
I&'A))/94*"')&0#G0:>!:;\$@,:4M:G'F;J
MKC^_DFGLPP%DBZR>&KYN=D/P9_3S\$/FGUZ9T?[,S#9?P/2*4U!L,I%=_|:|S?WCY.9/-
M/\$%:IYA|=HD9309E!5#(9(A D=|+'0V(HP\$ZN64?>^8CDFKD M+-(>7*+SS>
(XPH!TP1#,7&7_@|F|6^N*J"%""Q0(74@5^#XYFU2Z=-'Q?X MAU-AC
'6(I9XAO|%Y8@2!7?")N4VZ;V_UR-&CN^U1OZ>>62K|Y|2|6)6VE^(
ML,%X_>4R|+ #XT*\$S/'<[S9]@TC9S6T.'#^_?BKH/E'\&PHQ79^<#8K,<4'(?
H,\$11U1B0;D9^4&VWL3,2*0 M*QL#=?X|0=F>|1_F6|V*/4B?T/#;V4VP7|"/MDP-/''
M##^4FVPO_37E+|/H03R|S0J^O(5F&OR0!#;/&._^UCC%)I@1#1XY<)MO?|@
ME)"1=+ #4*A|F:ZAP_ ^O+;^S6Q7F-TQ|HDE.P MHPBE?
E/:V%Y\$Q%H0&Y)Z9";A6)!AIU_SP%SJ>@GWL7(VMHUO*(?FEZUE1BP>R=J;'XU,F9(A"
<4Z\$M0|F>(WOWSD= M_!U 5;N<2&SJ |\$6|_.|V\G_6GJ7F|;08&6HX5^VR5D
U\$&>X=7N,)6Z.P MD4I_??.-FT-
|PK.YY|@^4Q\$V2#%!\^S3KJWRG8P6.J6XP;IKS|U0\$54ZRP.? M!AFYN?
57N2JRNE&7FF"3^5841E!W^R!MPWF6Y2H5YVZZS8HVMDO1K|4F3R5
M\$0^QN.!)X+>D+>0/SJ.U7GO)S,1LBIH2%T!%V9ER^WM[2V)5;T%YJT^2U)5 MER-
O73.A=?17FEB>N)FIKA@;=WDI*;"5NVE8ZWW: +3'W",@|!&:!LX5C-G8? MY@N:M/7;+5,
<-+ #FTHY1%Z:02UY(@>2FNHV(.KW'7;:%%3IV<=E593>@#52)9 MG"AQ:(<|:3'.?4,;\$Q>-
*1H(X3%RL(2'_G6S/I?E*7?H98M2:8""1\$3_>03 MWYJ!M(9X>@OA4\$'7-^|'V9CDEC-
#VMZ7\VVH"MT++U P|8WW*HD!@GYVF%UI MD0|B34\|MAQ1?VZ:-
KXPIE8M9MBOT(RVJ|JR\$SYM)UX1G|.W-9A'JO>Y;+M-
9N2.JFT@KPJL;A.J^A^:2|)RU)QITB>"4"O^;P8A2BE,MG?*SQ?*?NI7O%<=
MT0#SQD5_I0X4"GYL_?Q3?R9Y<;J/*+P4\$/PCO>!KV;>_O'9Z_POG|WN
MFI#|H|QM>GH1L+0,;:/KDO\|6'|X4K\$LC\$C!<7GF)'M0%C<'J4RJ;JBEC M!Y-
%4JYWHX'+7S=S8DX2;_|#D_R_P;+5@KB_#.TL^G|T5/O%VCUK7|WBQ
M316O+C3>VPJ@|L_M"CJA.TF|>\$=U""*43=!#E2Q&6VX>,5I6DAC4UYDL7VWC2
MM8>T@" V\$ACO'NH?2?%2M-K@GC_U#COITBIGF^V6_(0-5)ZU"/^MJ\$QZXX:
MP"S,NOR^V3TD;LU_+\$.|)5"@4_>L/KR%MZ"&C/N@HN)M=0/5|E.+ \$&-EQH<1 M
209TPM@RJ/TNX#9^2YQ19_O:G&%\$JWD_.) X_!7*EY>W|?6W=>J*F%ZS|H&
M7:8>*K#2%'#7?(RA3I(-?I3_^D,|>=6YE5O/>S5|M?_NCY|-\$_=,
|8ER|;XYK%A,Z^Z0Z|OZE=)&<|> M/XZ)_+?
03MYF4V#NTNZ5RN9SY8!)QKN;^_!|EPQPM*C_KK-6"SSAY6F|D^,V MI

H=1>87MIC95C@J,M_8\$,)I02UJQ_!J0B!(O#6>HFVN/SMWQ5-!/,4E
M)8!MZKARA64.?*F^IM=^@R;K)D%YL':\OA"EIM:E^!K915C?
G%VG==#J#D"%A=_\$ZW[WEKCZ^F.;HL M6V2.E8+AB5MORW[7;LE61GQO<8F/M5;;>
(%^1QPQ0_P/SG3"SM)M+#T'MOR M.A47Y'I'9 1JLE*+6ZZ,F^*#05#R\$NW')^CJO(+%?
V6^E&^O>LC3GM6#33^
M/O"VFPG'GQ"XVQG"=6]HWRVPSCVPE+@,W.T=OH4L>='==\ZU_ ^4VMRX0*JC M.:!^
").YUF0D915?8VK?(A)#+M3 [XLTSUY56Q7;_#UN:/D]8G]7?"XQM ^ M+!4_?
8)%M:L9UN2H^UI?BL;VDPM)+Y+>'Q?T%
VU2<()LIF)M*F!!FC[7HMOIX!BD_/&':9NMx7 M!LZB(!=!(56ZX@\$"19O>4GXS-
M3\$[%ZK>%YISL6X.\$/E3GK7EV<-SXPE M##PR'\$RM]:JQNS9^W(?:
!6RUK>7!E2=,^EF61;2*DALZ3S,O_9-'I^*V94|
M/?'B|^Kuw,H\$%?/7DC)C%VVKF_>L0BYK|*B0UMKML^\$H"|&<<\$7D:D7]J@6
M*S0PK&[F8]B]0"O%G_BTO^";X6U:.00GMBLXAX|'^*_\9FE5D5&1AW6;BD# M-
BBCS<*7L|.C) 8=M;=JX)ZTS:%"-RNMGI>SKJW&J F"-.+8X5+/KIX"|Y: MWZ|!#R(
!4C^ ^2ENZ0#AB8LQTJ#V90^9=7IEN:79J(><):MB5IQ/R6>UR7RQ_M8]!::?7^P5AE%
<:/?H25E*4M=-_JM+-MP]O4S:-YW4?@\$;LD)G?6> M%[JK"K#!VMKV_5K|-
#5#G<_>| 3PVL)2U_';F9TSX|URV5>V@9>GTE>%.^/3 M\RA/'-G)<#Z4 \$*V%?
E+T;1B;6DXY3%%?=F8LA=_JXYPW):&,#?_Q>#)YZ
M9TO*L+G18<4)+K%M'3>MMRA\$NIF[BRE6"A)\%ZV=B(!)5ZM.NOJM65+WW*J
M.7!G/HP9>32&!O;/P7#1WU;%=OOMO&7VK66A9\$K>S+#B!4T!+%)+.H1:3Z
M7]>99AB|O@Q5=HT80Y\$|IE?1P)"Z' H-U*,!"I7_T% 7Z7+B_LWE2_C)HE>M=
(./QS300/LN&N@>^0|N^_F0&_.&4#_@%A1#*UD_R;U_S"i?%Z8|.1WT==
M5)/VC_BR"_Q#3ZW_/X1ED@:30ZD0HX\$SF-R9\$*|\$BDH@"@UL%&2A 3 FGHNN
MF%V.#!\$#7|9_H7>6:E C/\$NC??NZ1;-;IH)F+U9%(@)*^E/H-1^4W:7=F0+=% M-95|
@K^^@SC_ZTX5!HCSME@C_YI"YZ/4/M%A5;O)H(>2&-3Z^0%={(.:
M!Q5E,AKYHEA1|=+J21A+ E2L7 EP_Y_-VO-XOGC06UY(2*B4B>9U,R|P.J" M.-(
+H|X/V*R|+CV=BG,)X)CH)'X5/YX5||FFXQG1*RQMY*_ =46#=#&>*[O57
ME@00Z)-7Y8G.D/OIL*I.CI%,5,|:Z]5'LU!U62V2N8DOSJ)-
:BKOCVY2%\$CKV5P|H|Q>|Z^M>
(:M9V^D&X|&KAN#49WJF.R<0UOBAB'=N*:2D^7/SI|^'SQNVFNT?6=;-6>L M022I:)Z@
GVY\$|J2H:VK\$7&|&7 |HN7(>E|CT(&5Y;W\$SF8|0M9 =A%_E9M
MPX1CBI6D%;_LHSU;8ZQJ)5:ICS'PIU9F:59K5W<>#ZSP73IV_M8|SB+1.+L6
M25|=M|H3||06@RPRJB:09\UPVR"^M2;_MD/:|GC8HIY>_5)W\$BUUHB=@7/4
MHPWGR6#^R8*W:('I'<;VV+.T\$ R%(G'-*KL=(4UUE3|G48WF SZ
M|ZN/!LUM'ND!5280%1)NS0B7SL MT%%6HP@F*|^FAEMW^2T1@,AQ"A1+*^8L-
W)+*MSC9EW!W(;D)?BJ\$">NP4) M/L^2|E8IS|/27 %?E2?
+R8U9H1V(NI&@&&G_[(E7UNV\$-(| QU;?P 22CJ M-V:D?8T7@IE;M?
T(MV*RH9P>I8@)FBZ>O48#|O>*G.[7B17EQ,O|_,|D;:P#
M2&N*K3:Y2+V)HXUQ#P@73Q%|FN2:Q4|J4+E?N!O3=7C|YY"B0?QW|U1=GWPk
MQ=V|?>D2SE<6^)|LUP)#DDMY-OGZ@H_JOWXF/6X MTO%-A:=^H#YI@B0U#=
*MZ;DOQ5,_#.NF*VB7?3/C0=\$|0))U
M>YSI;=L^V*"|9\$=%HZA9A3)Z'ZMT.7RT|>.BF6^2W7|VZY:FC="5O1&92FI
MA&X8MNX|VD66"EDD#LCU5SF(2@RW74?XT:=;-S?;\$#;E B|W(C;1P+)Q8&Y7 MAE+J-
ID|&*+E?|B_SY.(F^"
M6C>KF<(7;>CMP=%7Y^TRC'LNDFJP4KC4+B^M'E>|Z,A(C!3(;6!BK+N6PLT4 MTHO?
=OE7#@=L M_Y|?O*K"MVMB]6|'2|U"K0*1+OW%V=N<,&7B%;M)-SC+KR-N9EM&%
(356LL MC#N.A KOKRNYO9ME|DFH'43R #;4+VDP6Z'<&=\$D*G?%D)Z1B?A+REJ/AYP7
M.?8G89&/NT8ONAP-Z&DLQ_BO-QK&O@|=#\$B?C<|MWAV>\$(@QG=*4"V>*%M6<
M4X1|"EE-OM>4^8R)\$"('GTS.WISA@5KDS7+LCD6M|+R!%%>4WH>3G:0W!A8&
M1MC(H\$|/M.HM'&O 0-'/@S^!0+|%M3.'R\$A_SJ_?DW;|
MC*1NI"W/!BK?".29CVY|F/_ "E7;-)=|(!-+V7@?G/E2\$C;2"|;^;T?|U3?
OTPG<%T+:Y|LSG!N2/YEJ|'Q:V_*VH^I M_.DK@_JKMYR'6'_ER+QJ>VR"VR K>)KI=+'D!;
D=N|:A:ZAM?OHAJ|H=_1@%N9SI|_|1#7 C&2\$& MS|0*^_.S<|*MQH!L3)IU(+NU&-|/|
|9||*KH;7-\$1-Y,1AQJ M':QY?"J4UH^;K+\$|?WSP:CR+W3D+%;
(I.=@)C6Z"OF+PJHCD(L|6|_JVF'R<-5/>OM%B>CJ=NZN|>+@@@'G.;BSBD#_XSNN|BN'O/
M?Z9G5P0_-<:5_WO-*Z*Q5^T'> &Y0^HUI.I&'NCUR?WE^E-!F""JEW)SXE M?
%;JMW"G2\$RI+ WW6!YTO^>3X.LV?2S%E=/P.?O?M|/_B5>=CO*G|^V/I, M+\$Q/@YR-
F,/O.=Z +#^<_E!O\$%|:DO@U;|3, 0W,XX9D=;;&=M=C1\$"6&_M@ M3(8;

!W::R&U2)/386OT/F(*9%!!HBQ=;>?Q/=79HJ>8UZ|WHRL5D;-^J%.7 M2<*
!D2ZM_T#UUO=';/6M7LR4WXX^MMQ:/B_GU8CH<|KZVL\$&JT.'A5QJS--1 MC-
Z)|BG_YS)0DG [SA>65U@N3<-K(I2|LQ5|;:_9@T5\$U"X!)=Z5X9Z6F!|PRBS"=6+J?
#XTB0'HS5+7KVV0AWQ3%1 M^|= \$*[TS^X]">Rj)ULBNIFOOD8<_AQ!M?.\$2TUU
M&0S%U-I+|@=U-3HN/;=2Q:D%K? I/2TN0'PNQY_4,Z4Y%FX;.#RC<'A|.R0L MT35B?
^Z1YRZOX8,5;4.|OJ^UN|S8X+6K9>"I?O
FUE'&.*I%69E:/D^&#N0D;L:QN:YA|,&75WF:F<@0\$^|MZ:VB MLEU_5CMX9SQCP<6/J?
O+=Z^<1/TT|V4&H<\$;-H|4K40%|RK5W%:27|1Z'CB MGF@ROK0OE@KV?KE?
E%.)5*L@(5,3|LU1*|97<;Z*D@#Q&+X?Y(V:45(/DWRB MKFZ4&!Z@6;0|Z?
<|X_G#F^D^G=UY7B WC7Q+6|^3^I-RWH>-XRGK) |L:*OU M>UD9CD!VY>6M,
M_ GYHZL|3_Y&|(&-6=J)AZBO^B6_W\$O|+_IP_U>WYF<&;8(3-|SMIZ/!HS5-M/9?
00(R|.3C"#1.2^JND_?.)4 =5M|ON-OU)WFFS7|'-I>Q|G\$&S;3|70
M@U>;U!&\$|O<7|B=|HV3JB*CVZP "?"^E-:S@+.|C#L%4" WU%=E*.?6WW
IS1(@:|PJ0&UB M7&AW%I'LYRPZT.A8<2|^-WWJ/^OO><.:G)?-H"=\$1J-%&*(
@HQ4(O4B(" M2H?0!*4DAAYZ#(* ()T*#.)|TCOO4OO0NA%.@("AIH7|SWWW'-|UW??
S'LS MQSMS_OC|D6^_V>SL;O:W/9+NHVEUXCL/MFLTH>6V+(:P^% ^YTQ#H@3B55HS
MWX|HC|ID:PA20B)=G56=O3U7=Z3.8NS6XY56A|=2/>|VM:H|/|5%\$LB|BZ
M9GK>,SF^|F7:\$*8;1"JA\$9T"&(L%&+P6J"4)U!PL(+8P87-10%^"!26&GTA|PUG!..?6/
M:@=U,16U>;#G&2:0@|07TKOG1Z77EZ3W2'<@|Z&_ ^YAGLJWWN/Y5J XG #1+
MF5&#;3HCET2&O:S20Z;N#<|980|W_YLS,T>?W*BZYRO|P=?QNO&0)"|X2|(
MA+7XB5CR*/E_ "ZORA-?UWCXQWUWZTJ&(-.*P1,^ZS2K@S&:AN|"#Z9RF^_A MJY-
CPHB|=K973K?+!_;)7#>TM4TC^(M_/B<|.X6FM*:OKEK8B7|@+KV0B M-
OMJY1%SOZKR^B7#R|8O#Q+7FFZ0NO5QT)E SLR.;^&L|C//J%@M;^N8: ^3Y
M='UE"?|'X&1L.SLUJ8.B9-5@+C2D;)M>8^IC9&-^^^A7
M_/>DSU/I"E10I_+IH;=|'"O/ORPD+;PP4@O%444)SBQV>S,E=2C11DR<\$;./ *DT'<^;#00SI
85MFG&
M3U6<"B&B|_ "T%0&LOF0P%P8C0IRO8_Q)8W'RF0MK#E9UP&\$XC|D^9TFYFS9;
M*K6PCQY0+7U!5;'WPH|\$RCK,(?S#<|O)"UY2M790E7;DKOI^WJ%.#!8@*QHZ
M!T;2(O!;0CNS;P_C;A.;VW3T@)|HJLY^AQPJ)6#VRVTV!2TM|H50FSA#7L6PE<|MS>B;.!
MRNBX,BS2SEMPNABYR/'E|C2' S(3|P<'7TCOD7@D(T-@8ZV|?6Z&P|NF;ZQ
MO1+|F2B+SWQ'L58L2Q|T) "TGN!7!5;|UHY4+XULCGX_"7(@L*U 9--
=6XU5Z17W;6NUF26+3R%60NY*NW MY%K3|^6.#D_@(4@8|!%3*0V-
J)23G53S,;=+1K_25TY|7/2FNK|!/?/^+!V<= M+DAOR37!@)94-18T@U-
*ZV27#B_#3023^O*A@W^_ ^IBG_16QU?1?;|U/Q-
RF|WDC#>T0+Z8*J>K|HLOW1|R.O!&.X\$""T@2P@)F M|I6?;+,9^UNP:<J+ MXRE(Q0*^
R*;|K9M3_%P*H;/A07,9QWMB=|XRJM.O/(1\$|N|YQM=@FJ.8|
M|>DWDG&WLJ_ ^|P1@>#9.16<2_4(QXC'^_HN4G8I=:'?P| TN+&^CTBDY/S
M..2|J>O|&|UK15N>MZ-1UJ#OAP90!-PJ3%"1A M IO5?
L(A^U=CS\$1Z+O4V/A\$BTZ.A7C1W'B&XLSF(&I!A./I9VB9OE0QF#" + M)|E,%-6T9|:
|_2#T?K6+->?1@U\$|0|&4))@|D>13&T\$>&MB(U4!#Y#4FQ0 M,=\$<: <9AKYSX-?
4U|.BS8O<*7P MYCIX^"\$Q?P9&S&H? X_WT(G4KBF7*YMMX5|V;+R,|P#-
_FU|UQ_RT_#|WT^< M;.&-S0?A7'O&5-R;1#RMN! |";NVC?
|I2'=5OU2XA_2UC|^E^A;'==|Z%0% M60/QU*)'KJD?
MV4F\$="X>39RHB#W53\$"8_|\$>XR_6AKL^9%/?12&_!8EG
MWWX2V3_1?'|^51;>7|,E/YR%^FDZ!_ |WTSY7YM@. @37J.)+,#Q|2F_PP?_|K
MZW^M(/PP/7+N5Y9G7<<"AA_!JO_ZXCQ&|,M?|?T'Y8#_K,|%|Z=10D.7#BL M&X
%K&|@>=?7P|9#3X*-N7\$%\$%9YD\$13|R/#4SBAC 3-T9KE3>Z'_HX4BD|HG
M/EW0'/Z'KO|+K3BE:&WU|W@^"&#PNKF7_F|8?ODAR64'
MJW|@1_4&7_5;0TZBF&+'TT=_B|UJIKJ;- ^XOI)%#RI'T|!&R8W N<:ZF|>
MA%WX1<\$GHK(- (3:2|R|Z;%(K\$OXVC|*D (QVE01*(N')0N6SUY0%?AH_Z4B7 M66E
S+H1_8"=@;PE+@=%\$)J/:0V33;|YGVVB=#@)CK|I;|V@F6|%T:G13=9H#U0?>IZ9K3&|G
MG@_!|H&IT!A=SHVM:G"1*?'DBCA0Q5AW+'*6_/?|C?ZJ0.G9T,NU3774?
M#E|/_<)=_K(\$HJB(0%+6^T*'|&8K1X GOF1IK&|O|IQRVW?8^B1KV,BRW@N<|
M:M68U:G1F*(U|*H94Y2V@5#M P^\$L_|)(P0RRS57;;LMQO5 RI,"#K=GF+G@
MXT5|P#G*_ =D)4KAIXEG55|H2HL&M@9&7U*IO|DFD72S5\$#F+Y?S\$K3!*+.#A
M(YORB;NOAU>KRZG2R))@F(!)CE!X.+P_FV>U/ZG%H,|I7)X40.SA/6|FO M=I@SDG?
XF@ZE;CQ7TEU#E_*|YDPC U*;ZKG;.=70LLH14)I&4 M4-
!EA|.*H9I@#|VX'_L|GA=8,A)#7=(8%O4)2?H+E<;.\$2|?M#)_5Y<:%</p></div>

MRKY)DL^#>1B!H_GV%K%/04=QL2%O,W,D7(2E%NB5>, #U;-&|@00835DQ|4_U M4
!AK!<(X6;54)7!(2D=#@=AP(!U?/2U!#KI!7GLB<&D%AT.VN!|\$4F5|
M5@ZP!|CZ(K^D1Y'58O=LT".MM-IOM9QH9J |@T)C!|"^KIH*W|5'^Q\$C.&E, M,
BO4H8B9!P5&B"4/IV89EW66V0X!7GXB|)=+JV(GCU:@&\$G8KX/!:+Z\$!*,
M'F@!Q4SEX|&|+3XD?K>!(;1|GV4WE-(11\$?
(-UO6Y|JL7|WOR0%'9+Y8SA_1Y6"7B+/AF"@JL24Q1'4#EQ(#;?(M*|2\$ M.OJ-!*B=3\$R%
f(TLDKDB#!CW;|T\$=WNF7&T;Z|-Q_52SWE*EG>AJUI/CJGBF
M|6AFM#BIOM6/RKLHQ'|\$ZS8S/#(X74ZSSYOAJ;W#OA|(B+O7/'")AGZE:
MH))O_#%MM^*|JWWA9FE6>ULU|SA (8PTTNZ!YG&D<#LYGW|S 8F1 X-
Y%8HP|;8NYC|G M8=5U"M'@!9:'BOY7Y;K%J-+A90^9H>R0%Z>\$O'@N_|^MN>|
<4L7.S*M2U.U'HU<+RX>VSMGK-7H94M|SETAPHRO--UZ3HL @\$7"N+Q!|=
M.W)YB0Z|PS<|4R\$5/:|C\$NS|=6H_*7H.Y^O<\$F-P6|'<#|+9 ES:Q.?U7W) M5
.:0YB#=#@|AY|KH1;:2W>\$4IJ9+)99'&4H=L/YM/';A^R+DK93N\$FR/| M57E#
|<(63+K>7>7O6TW&X+D|4)T!)_Y+:RIX6>AWG5L7/'^?)%R6TBP8L4!<MLS5IH-
EHUERFK:@-|SIR/-NX|5R93"5/>??"*,CF=?V>CS9>\$0,5T5QL#'- M(KMV@ 6.&JH5@
>UB(9FN1|53(?%0
MNI'1|Q.WIEK=BR|MBY|W|.)BU19U4OV)|O\$J;ER5;Z|U1;^3.7>J3MOG%ZED
M:9FWZD)9.#FQIBF>RD+-L@@\$5,"=,Z6CS5!(AO'JJ-
13J8,YTR|X|+O,E+X|^ (L7R)!|H|1Q=<&5AL59|)-178#J| M/OVQJ| #V,+^H^@5K8/Q&
| \$N@K\$|@)_4Z+>_|D9N!8SNZ@=*%HP4HO3+>K6' ML"1^K_K-PHV4E \$)2?
KP.8|U|0IPC|SN7:ZJ..H'145QB9F/91BK!.)S,7W* MD<:)QC5%'AF.YG3%L!#.
<|Z<+MPLP|<68!JV_F%BM,#NKXGCN5=8W-X5UK.I M077G|I-
AQ,WO|BR_Y8!|2.@RAT@4Y8'Z9J\$!@;=|&L4LRH6\$P-ROI#ZVA(1' M-|@F)U'&&!>->-
)9PE &ZS'E9X8K,6&3|Z_Q%C::BIO54M|6Y|!5T_:Z?*S+
ML".TQ>1YN2Q.N:C'PY|6+H4EI@M.|W&BQ;3\$|V)GB*C&| M'H#CD>|+
|L%|KN&|\$P6X0SDY9Z6^7-'D3M!R.>M-E06? BS PD@JRN52HB5A
M831H|&U|Y:&6\$|&+OEK'H_274B1C3O|;Z250|BJ3N"?!P_NFE/;|^>UM
M0NP8:2T=.#DL\$9#@_O!< DU%|.%4=VO%SFR0*7W1000ML:|J39V/^8
M|DX|W4WF*PYIEPG6K=@?E-#YPGHR>MNQDY E-3(|0!;VWU!^H^NY@|J(EJ?
ME\$.K*^>/_S_3\$Y;(W(^-&V4(D))- =711>: _9?#\$E5NS8 Fyb0_|J|3S5(? "KA
M>IM7)VCMXA|"?NP8XD0?=BO5O|:(P0-|(WZ2' M!GR(.X26\$TAKJF(>2S@GL-
4."7#J;5VWS="/'CG?=3\$6T+|M@/+PL,ZR/B|J9 M1GR*<1|MN&MA3^YV
M|J,@<%+@#"R93'4,1UJ&L8B|DVAA&D"8^5&(OX4DBCv=H%E/S>@H3Z%?@K%_G
MLK1T/IALB?/0?*WN*PT3 T|HS.?)NL!H2|L")N8W|X6*@G'^W!2Z_%<>=21
M#.UU\$=7;#X8FV|H^./+^4>_D;|!_.+H_MY,\$O|+FG;^X,MHW FCA\$ _&X@G+?; M5XTD:?
%TOCXH&G8Z**PM#8'J&&5<-8EA+5S%Z%A\$SDZ1W:LYUDDTH|>KU@%Q
M6L,*IFQOL_G:#,@P ?M|2Q#/E9=&KK=\$*C3=#^GXUO.I0:\$ _Z&0D+5|+!_%
MB1ZPM">+T#N*<.->U|WZ8S(F-OKMT|R/M1GL-9N|LX0V?"\$MLH^4E5|-38ZZ?
&="+:|FL^C:L&L%I=[E89/QC8'60U&+"^4K:"Y|*FR M3&5I8Z7|G5"\$3X#:*4V#
<9U7S+:P !TS5>L!&9:#Y%D3RC6706.CU8:>:|WI M7\$XTR!|: +ZCI:IF2ZEG?K4)\$J&7;
(HS9^<@L|HOK|;V5:-Z U/CJXT6KSZQ M|XJ_P@*FR)7I^@?^&#?
85|4W|PAJ|HBB<&H&&YWY&NR:TYUA<0?=L)#ON/_9 MB-DJ%FJUF4YV)
|HUQOH%T4C|W,G:&4Z^K+<;#8BBW,N=H^|6A&Z!1 JNR9|U MSMOK|B,NJHWEg?
7D&J1WRVSA!1"J9W&\$ZZ|@%(*Y&:CHM0O*,#B_%,?_17 _MT=W&3\$TRAP+
<&\$M9ZF|S>4/>D&YB4(E#T="=-A8#5|&NMA^U';1"|T>B|HK;X'P"1D6^#)1%512J\$O|
M;/W.K0\$T&J'EQ#AQ%PN0A(SR)%JG8ANOS5MO|_EU2-><>!BZ#31VINP/E5
M%\$J|J|/800NHE49,J(J^!;"46(M2@62E>-TIM"3%(P_ICF^S,@ "WGEU|DQC1? MH)
<>JP^<7\$E>85!U3!M').@:Y4T|EBD-O!D=H<7KG<90-;O|H6XB\$'/A5/ M)^%
(Z4!./)21CGJFDC'>D_&.!&8&E4O0|J?M*A^B@P0"&@9/+LR=LA|*;#AM M%RO>O
CBZ%P*/9" _&#CSC|\$1.:V!9Z)HHM)A%'N5!|?V#K';YN\$=*%(>@IAM M?^|G\$G?->
;3G+WDME90?8R J #OC|\$3=UIT-)K*I.F_IRQ|!%T\$F|UR6+>=< M(&UP0<7R\$.
/-0.1 _OP"2|NMWJW.VU!QBY/N3&RDVI\$%\$:RQK);EZB! JDT
M1FG=3ZN(MVJ'')2W|JX:|>.<;SU7AN8J^)H1>G4N,_04K,K76;S"&.:GI-=?
M,O5|!+8/5:BX!^N,D+^R?XY:P>J1#)!/;;^2>(N,.;D0!|R5+FI=W/?@G-A M(F?
#)Q/IA4+Y|*H|9Y=F8-\$492 M7O>?8?
G3SW=^@G|EG_#|^6V"/^YB;9>_TSG_U0L&6HQ(3G11RSD;B+E1T2.
MU:4T=H15V3N2CN:%I TL3_@2_Y%|MR:0LUKU)Y! OFS0;BHQG1T6X.NXHW|F
MAU8_(8W! H*_%277YQ-/ *M)S1IZ:6\$!RV1#.3TG'

A:TD\$U5F\$PL0!Z6>4:H@@6T9:6\JOT+ MSUJX_L+S%YZ_VRGX\$G\#D\VU@D7)B
738;0;'%'#%I/Q?I24-X_2RG-K1Y MPK-*W4^D5FPI/*XV(1\$*0_^AZI<@+@BU\$ /M9 4
8W1L="TR,#(T,#8S,%JG-2YJ<&?L MN@54E\$;/WPC(@@H@H T2 B2T@T"4M+=
("7=G:NDK#02DDIWP|+=*=T-TK'D M4KO?^O3I/.HSE?GBW/^LWL=9H;9F?
NJN7I7W(.81:P"S\Y+R4H!*"@HP ?D M\T"L/8!)>EIH! %!8 1_X"&*(/ 6<.!)3WH5; 0V0=!?
G534W\|Q>@ M ('XWMD #JR#QO9%D\$20+;WUU' JP" G)NWL3TSE8*5J:6QN2VR
RT:I2\2 MQ4=*+C_ZX3_J3;\$Q?ZFC#@ MHF+G\$WC#(<#.J=_V(?4 N'>@#%#@S #5("8
68-L(MCGP1RF(M8-MK?145F;"I%K<"F\4""7,+;UDO)W-
U;P5U4V\;4SYS>A%19Y@"GD*>-HYVIF\ M&E-YVMG:NPAX"E/_978!9/U/-
QNUB)"SV4\|+8N\#;8)WYBZFESE:KE8.IE1_MVL8F#FZNP1N;E9FA^-
/W*;F)EOLY@828'Y\|NKV;N\|I-VI96(O\U8_DKG\|CNOU:0"R"MI_'CQT)L M_|KV?PJ#
I6_&AZS\PU21OZ3Z?Z#\?WF1?|JN3W2QSV0SHQ8 "0=#2T1V@/ MT1^A/<)1?<
Q,5"RAB3 .<9-BX1 0DQ\$0'1"U(*^I>DY'3D+XBH6:GI&%XS M,3.14+%QLC%RT#,R,?Z9!
4= P/S,28^%A8^(QD1&>/ X8)H W Q4(0>/5% MH08>X**@XJ(@N@!*9%! 0_E+^?ONB/(
I2':(W2,QYA8R \$USX_*BH#QZB
MHJ\$I1,9Q%#_D_X&'N&AX+|G%'CU7,4:G=L+G^!SS\$X-&O**=0'7LA);3Q#G@
M,2;A'R)B\$KI7\RO&;FX>7CY^ 4DWDE*2E\#AP\1'Z+_X00E@<?>?;@/T5ZRA
(34T\$W=GI.S?;\$9 U\|YF=%^V,: M3M43 A/G,4Q"6JXU.N@?UO\|V?|^Q@+^3W'V#;|^R=
<|@/(V*@E0>*BX@"MQ(M@1E^//@/8@J)G8M";8G'X9\$B4256,I<0;E^M6?/%Q_6*
D1HD^>X+S7VD&W MD'1JH.\ZLDR?#|I-DS1J5GOOSVDI:NK"\JE#80)-.U"?ET*MQ-
_Z^C?5_9@ M9;RR 0EPQPDV\?132+F7'TB+OP;O)(.W6JA@\$_!G2D\ZB_P"#^'FBYK+6FE;
MIEX\|X?VZ4FEN1%3"*!L7^4"D P?1*E0!+8_@&&#+_)ZH_)H6-=I;YD\|GI^S*6#^**<5Z?
LDZ61HC6@D; M>;W\|:4H2T""HL;WA8_.E4:5?"RY;S&^O="<
:4_='WMZ8H)EMN+QHV>#=#M&\$027QGE0Y S GC69(\$,"B#%O1NT13 MS6Y"?<
@KHS2\TF2=K\;DK<\C>,>PZ\|L,\$\19BA*Y.CS;FTZH\6;I8E+5\$C=0 M,V7/-9\|@<
N'#>N4R@D&,>E(*3TLJ#0 S9+_);#,_Z#Z?0?BW1FC9VQ"E&2\ M\$LI557KJ|=&9&#%G/
'1WE\|G*Q&B;Z'\H5\NFEWD*D)^|Y|+!D\JK>+%&Y_)<
M,\$C@29.W_;/2!7)2TOEFX.6W==%"1Q =4\ T3H=0C>U<I6(5Z((LYF.Z'N"6O M\$"-
VG@2V"BT:HAU>M28=*Y,YS+NN*)\$GBX"L_-UAFB>M/EVXO3S,MX5"/.W<
MHYYD^7@M0!>_G\|*U\|G@%&1DR/V'^3W12\|C56 :>7\;\$P)*RDB85JHI2\4+^; M+<
QG>;4XZ/6HHI+WE>|@5!;/|C_U3Z5>-F58-*5V8/3,).4/%*#\|(T?%+CND7<
MH+OI<=*\$=R.7T"H7\|YX"6J^P\|7'YVL)/QU%"MT+61\U-XE MKKV78HLG.&MQ-<
I8*0J(17OLFVK+\$<(Z\$8>#)\49;KRWFQZ*U\$BR#A-?K=S#'=|,)"0?M%\N?3O4-<
:#:4_02?;:YL4\|K< M/L39+1X5D\|SLQN2;*M'4;(Y#<
%/&M^>O(C7^>^QT)_F2P\|ZPEPS\$9:M G3>,L M3L-,LK\I^MG^/\$F/U)C9H3W9^<
O\|YB0/K.B/Y<7-.9W5\|FTZT5C_QL@7" M.(L<
\$CAI?I:1W>*|SV@7Q70%85J^T'7_N6GS\7+'4.GR*T,L+@/1(|ZW\Y< MN_4-(7XS(^<
*IT;C^%/C_&1,352+OM^_%TKJ_EZH7\VC-2\ M""(SO(5>ZA"4R3=/WTA).^TK98(?<
ZU(A09+H+W\|T+Z05#Q^CL+ACPFB*:'&X<
MS"D=OEYH=.IQFF\6+=PC,0@ILV6YT".UV4\$-Q=7OJ&0P'BMO"X_2U9SRSKL2<
M#)5JREB/8J@_80LSW.\2X8\$>7B: ^RJ((=#*WL3\|>1 MDW8F^).>K'24\$5@Y+<
I-6%%C77D(XFR?*/;N\|S\|.28=(CQ?.T0?UY'-XVB;6%6AJXJH*"@VXG7T"QA\$%K9?ZI^(<
M#-I21?YCPR*/-9PG1LOZ!BN>'N_KZQN4JX:YP^U//X<_JDW/HUL"1POD\|9<
M/=ESMF;77J\|K_B2W:"M_GY'X+6OV>?>9)I\|"%<|X",_W.S@T!<"& 54HN<
MFV7B\BG7E:\D4_L&PLLQ15RU*/8&I@'RX7W/GF'A?HY+!W8-"&.RV\?<
I7Z_MA22R1UE+6+H7XX0W6.H<I9SVXWKMT7Q?SW";Q M%-1N-9L178_6#\NX&C<
OZ>BG\0R-?@@1E/4-7K+-_E!L0?<
Q6FHAH/9DG)D66T2L>6K3L2:*C^VHZQ4DU")G_0I/Y6S,Z/1^?|JZ"7Z:<
M;>9\|6;HF1+F6=#2_)_ITE\EQHJ13OI8JE*. 5D9Q\>AA+&G9JH(I ?0"1-+<
MIYKXFHNB:\$.LI(1WMF3A10\PN!5', \$5_6WFK&O=7;/MEUQE,EI5R-B>MZZ4Q<
M!\$M\|TSPF8S^BWM?%VG\|I=*GK&L?K(L^B39V,OI#SG-&%Y\|H M?!.W:"!4XKG_Z,*B?-<
(N)R/3*IJ+^B.GZ"DN\|C\44+"E4S,HGBM2M!WM2,F M,:<
2_0\Z\|HYGJ0K=P^E/%WN;O"WZJ2VG,/)\&<1X?DTX=A.TGK7=##NFY5-<
M)3EO>,8F_&Q3L.MD:K3#?-JA)LRH5VN^30\|& 6V: |I=E1\$ZE3-@ST4U\|_AH<
M_5HA8V:K80MHV"31%8IC5NGK2\|ECM%! -! ?2FL&^BUX)YMG2PJH>?U=\$U4<
MBWV7*@FI 40.-?E;X6N'M3LRKI()#H,FL,E%*X\$4#) A_.UMW\|S\|?1H&IM<
MKA('I5O\|2ZC>@M4@ R=SXQL:|JBD#^%FGX3WVX;2*>IA6FQ@>^Z44%C&_<|@<
M47LGUUBO68P*^J M&SCMA1<|YEISJDI S0ZGOE/4V2I\|_M_.>&)&WFU?RLAH%B) M3<

.5P2C8/-:P*\$GN/D+ML:H@[U/OUH)+D@ZCM\$H;(5SHM\$XJ2IRJM*7N#Q! M
2B14C_2W,P'%|<*%GHSIE/#JML,-#GYQ="Y+<^@+!._@R\$JSQJ71^JG MA(VV;LG6
_9VW;/A6'5R@A3B#|)/5!/:X209YH6N\$344BB5EZABOBH_GZUT4. MLVRI;P>PGV5?
&GJ3Y!5:)^B.AL*YC7:UV)=TY83S\$H6D&6%|M!0;5&>_+LLR M2\^?4""
JPH6<\$K+SO6,H/XGEPI MM\,GI=R^>YSVD^1:~L>D[C+T9-A/T4P,K'5KXT^4-
_?;!^>=>3I3XFKY*&%= @ M3C&N)@OR4*LW'4I-
9'VOG&XI92_=:LYOG3+FR\Q?;PNLGV'9,"L\B4L:43 M;*/;-
8M9ZJ81..;^U4L5^*;G(:':00'G/E\$)DIPE:-@@C R'K_Y)=* [RU
MT6%4#8E3=_\$LO:/"J,IGFIA8,YQ^+,JR)JXMB?_>1Y6STM7
M5G&"N1HQ0AN,OJSK;\$ZYD2JQ^H25DI^1U&-^EITG\$/_TAO/8,#3/TT9\I-"B M=IS+0*
#ZW/8>DVU30)*N&_I6_0:6[HGHY1^|O|6WIHG;^*C4EA=62IDP!"#5.GXGL88&
MWGOLVAU^4'ZND@J^:94|Z?G\ZS ZC /&3U0M+L2G_,VO>1L"BI(H)POMH^L! '/7-
O6|+;W \$6\$<@HS"74/2KY=N M)XN&+|*Y?
(8UVVM>5#=#R""DH4)"EOFW5;42R|Q|Z^T*N&7/N.CN7L;+>2^4 MIO-
IZ*YN\$#NC#SGZ_"Z01\$;#=#M-+!B'A'\$FKI:J153G?3\$2Y7,,L|>TIE_=5 M",P28:13H|/I9\L0!
!H3Q%)Q#=#Z0_YV!,EZ&33:(_2+|4+Y2@.7P,T0M- MH(4|JKUD5J*UR' Q|->02LR+T-
X+Z)FU?L1&M73-|#O|+"T%FE: _3=RM6WCI
MVAT!|)#KP6N1X#P:#5_E|;2\$04S=#34|XF5@|MZVCOM;N???"G|L0I#CV0Z
M7@LS,?:N'W^~8!+4:Q1V\6M>VBD/T:S^3I!'|2RH\$MM1FAYU!;SICW0'2Y"|
M)^KMBX.5>9:E@&91J76G8I1F MK5R*)5U\$NEUD_<-LXR_GH_)7I4RK(9'+K"?
+9>O'+|XWQ%|VA2I^>_96SW)F
MD(%|PNEAJH^6!!159^R.8.V+ZQ,LN<@S_4G;ULKSS@\$Z')K>ZOQ%1:6\$>MHC
M/J;Z&W/TF.E&:5!*,!\$N2|=16. |*|VW?F""519/6BPD!;,7BC+J)%%1U| M-P"#ZKR7^_N:
SG,H:?\$4XBMH 0!S.K3;IG\$/ (A+_5#YJ>U0*!Q\&F'4Z7W< M.1I (AUX?
OM\$32U.K8ZI>#AK@;LK^AT2\A01H1+3;#Y<=1/>|4??NRR",O60
MN&>L'1K)UR0M))DV5)|V)_=2C)\$UI96*|9%M/YR:XY=ES3@1'0J9!_N->F0V
M)?;T,#3!_*#^\$^J3W%(@))_"2|)&099VDSB==3\$TPG)|L4LQT-*@2|BS?IG/X5G0A-
Z^/N"CLKN|1' P%:- MA<.^PIG\$Y UAI: <>@1E^PV3|3)-\$Z'|^WWBQ\$&/ZY0?'0|
H=;R&\$0F983 MPJ|"+2|C=Y8:%Q8&BS@D7
2+8K9B,M+:VF@M^\$;JD\$3R4Y6K+M^AY@")3Z|^9(S MZ2Q C'A'<\$:B-8H,<|
PJ34TO+8HYA=CTB5-WKXTV-1!CXBFKC/Q|KS'R/6 M,Y|!'#3'15Z|^DS7?" B+R%UUK*+
|N3-6RIMW_L>7EUCP@_A1J(PF_MEBQ^=4)<.FG8>
M_|>3QPOO)X|-8OE4#SDYOSE!\$4Y"85#4Q|P@JGV2TL\$S^C2#)
(E\$IKJ1Z+-7;H+4HFEX M*F2H-Z-S5DOP9*7|A?|3F%WA:~GK|Z<5)8H.(H.@J.J%
(=|DSXKT0J|+W.<^ M?,,CS=U|O:\$|FS)>F UR|W.G(!|7\A-52P6DNS9EI(TO+L,
(E|M3!|)1#0 MN6A!3#"E%;A3M7?C<,AD XO^RW?
@5)|WA/0QERS.W/L;H@QV,J_O+_5BG0XC
MTZ%*!WGW|F,"9T@87O+@/TXL_HU*G|)%M.)8S#R7^=J%4I:~JELL/N)OQ@*Q M/TS:
|W&)|CYF:H-C@#H<-O ZR>5O7X|/- M):VSD-JWJJ<\$--
Z486:;#/,0FYKS4HR4|QRP@HDHS*Q,L?9GNFU0FO\K+&PB"TLM|=3M.3F3\$Z-
_GBC.G|B99N|JAL|6C%-^BU,-0^BTQ/AKOZ#@*C|A,-W^#&75.>TBHQG8L|T(F M%%/-
HN^~6C|=(%9U|RHVSU\+|#!_<9WW,/:=|A|3WF*+"=|DGG.-EGGF|+<0G:KIL81?
O*FRF MF1YX*='P\$XUB9'_NVX0.>[4D6K?BPSFLX\$SC)?#1-1 VC=|LNW"Y?5G44?3
M>|VXF87%C6\$X|=|533(L4 O*&RPD:9<_I(=6\$MPU|.24Y/J'0)!XMW-\$_.9H#NR!!E7 D\$-
_>,1C-R?E?">^ 3!V"/@FI&_LSP M9>E9B@=OC,&N+AB0.17?Z*=AD-8_OW8!7|Z+JD|
<6!K:L=|,7S)LLC) MZ_=8.E,U+)R*K7B&5CX*FRRD/2;8"F_@6?2_,0\$&|L\$?
XXPX(3'76PP<=\$U
MRM/6ZJQ;H\O6C,8L4XO\$PT;^RR)1|O.4>WJ=|2;)M<:|N;IWCN:JU|TJS"V
M)7O:4AQA_^,<<8<\$MB*CK|K^_OB'PW0+IWIP|!^SOJHGT V4%.PG)0C,O!DL4 MG)
|4##ERO"-YB'W-5AT3^\$G|F:(52PNK)|YQU^#:K0.>;G|^=?W,FV1,|
M/K>VO6\$|.U)3;7LVC&F@=?5S3<&0K8WSR2;M(GH(YUZ^0\XO5WRRW8|;EO|
MTKSTFUK)7>|:~;UQPEI>P|C:;S)W6ZAG3*J;S+&-<669&(1Y;=4@T&XW0H^\$ M^>!OO
FWKWXEL)6|4!:2 V3*3E|R;WCCOR-B@=\$0KJAGAE80W>.^5?C1VC#
M*5ZE+>J|L)LU(F??26;RCL:(1+8N'*2Y,SD|N:>+IVZ2D'59N--HE:7<@Q+
M:29G%/*\$_/3,LOO'VG FF!\$2^9'N.5E3,(R++++EAB^/'7)*!SU,-29|6FQ3
MDAE:NE81N|;T:\$<\$8WQSHHG=|)4YR.GD+|KK'D?D-KX?\$R:8LI4X60Y+FOO
M)KT@3|>+|FH.#'V.G+9AJ\$C%>_MZN6#&H8|#Y_@!B)#IA.MT#N'O\$|S|0@^
M(IUVMA22|X8<)0&O;CRQT>0MI.6E'U,|&;+"S FUF M'YS:-

OA6M10DJ>J,T);"&YYOMIS6>*18SJ(*D80?Q-|Y=((W/72T+L|>^UK MW4FOI=%T-
VA/^ (I973:*,0|1G|F(N.TX9U-.UUCF>=S-0.#%T?AZ'P"K#@=;!|
MB'(7K|O*G=>OAWAD;&8\WTKTL1;.H5N0DJ>)2Y+>GX^Q'&0J^JQN%G9BFD
M%AY&^@O+7-)4DO!JF\GD\$Y*=\$|6Z-\$=|T|)*^<-J|1L+_VGJUSAW6+'X1|;
M&AA^B/W'H?J_D8X(Q4E/S)H>_Z\$KJ5*EA)/C%4=9|G,_003PH1SXR51H
ME+@"3U/H8MA3NU).Z'|>|JTXM|G|KZ9G4_.J'C>'CTQG&1FJ3'@V%9JC1JN
M:0C|F2S<|4'S@,CL0WB MP:8H3:!?G("YYVPKDV'5>HNR<"04M*I)-L#2| M=>NT=:J;
|. #\$.!_U#"*Q;OH9JOKL/^,X?N'R6C>W|+^ XXYS&*K=Y.Y^?
M=0\$?/F@)_3\$ZA0AF>)FD7XW'CN|KVXR\$_.5;|H|711V%T._\$(#FRJ7Z-('_M">J:4H
O6VF:A?@OJH6P=K!WX('2S,F5<|2\424^?AV|43(3VHCU@2)#X6\$ M36J5|15G.#
(;>79)B6TKZ,LW?G3;_ '\$)K1"NB.>:DQSHQ< M?HL>,_^S5?H!)^8*'|@UL,7%66CCR1@_K^?
>#+J"/W9-(Z\$X'0ZHL"(MDMS& M'Q(N/M5,I7|N(X"IAAMO !VZ@F|@4)\$<.YWTR<):78\$)
<58E0S&|A\$ _D)I M*)|7&6_#5Y\$\$_G|!ZIP&TNC+_
Y'D37B>M=F:R*2E_074PRUOP/) #Y^BUW57,|1"U/2@:LJ:QXM1UHF&,H#A%P#E=&6Q+|
=N/PC1-%(:@51VFFQGP/@6^ M LEKB_KF6+ZFZE/3Y|6S8R:@AR?
*.:Y&AG9SE0/DJ<6KW<1- H;^&M,J0+>B M-,PJ_D+!@UW,0:PHAE|S.A*ZWFS3&1LR|K
5S!GW6##+H3!=E*)F;YD8-F;J MK;K2A40-QDFK?IG,U>|N(XMN|FTB<_\$/>|V>:|@QZCP
M/#P|HMS<> |C7ZF4,_M_?EOX-K_V|.#YE&BKM8%)Q&;7?\$VQ^YQR0SUSCE66
MQ%F)S&B?#;?^0N."EG+O%Z1^O:KAXFJG@_ZJXJE|MSWF?S1"9X0:+Y;BN+H
M|V|T=|LR>G\$A>_M&I%.2=MC=D";_\"4ZU,L"C58CD@O%4-(+RE%|F=0)B-X_
MV<|ZFE@CQ9VRR:_M:| NZ/Z(Q4.5Z,_^
:HO57,XH|OAA>X'@GW8|6L2=^G|=UW&C)A5LSA9DTEH5
M8C,X^G*K_K0&0WJNXK6R/*E|L/LA|38EC|>6;3S/P5A?_71|6OIWZ,CNFX:>
M&/RLIH1Q?-&K0001I-(9*5C.FHQ_J?G-"=%F&"BW69
MV)ZRYTQ9V"%JT9("+=IC0BK%/,S5O# M|."|KS<.WP2,93@+E.WKQ|^)"ZF8W
UYA3>VXOU/0%_S|")A;%%7@>RDCY?V MK^HML_G?_1_?)?Z%ORWT'-EC1=E3|0UF6WK
2DE/)3.Y|4M^QU>1@'!H.>,U,ET3E\$| M*|3* @WE|2H/BL?NGE!14BOI7-
5DJ4CES!*_.?U4*14|T>%S>V'7'=VG.8%R*
MCQ#:.N|^SD5HF?,+*+6+JSH_5DYS;YG1;)APG40ZT0"128OCI-|Y::4+,K;
M"/=3|J09%_K/=P3.O0/U4P>C1?ANE+G600@_28L8?PCG.AHP_+QY2C_ M75&-
>LZ.|T"\$F>D<|&|N84E/^H-D%GVBG6W1&J7Y-;2H=&@G1U?|?;?/2=+KN/;X+!H6
MH:8P34PU|73P2M;=>/-"MG:\$.9N|.M2W|FDF@B:G?JE(\$J#|)QI4>_7H<*(M?^#T)
|*A_)RD3^@N.C,O#JZU_34NCJRQOH;6V4(P!=AR)/2D"!>'!N1DY@A M?
Q1//((K1VG|DEF,18_,%0<\$W69G#A0:|3LJ'<_E3,\$WC*W_C>/G>A*"@/ M8MP2N%)R
MHN+:!K^49:GNS*;\$ (8YW3I_ \$C^=B)LV5N&KGH943OR&5\$P>KR9Y/FB_VO|E*
M0TE#B >P-X@Q^7;|Q|0G.(%'G)=^:NI5HN?+7-&@CVC
M7KXW_)>|W\$N'5L((0"Wf5PE%***?Q^F#CXP^O;6QHGI|TMSVD,Q0V7J72XUB;O
M'M-./9L@_K|JPC8;&A+6W5>82PT6_/.P?B'-D8K5,EQ+L125|3R9Q.*Q*|V M_7IG|
UM|B8OPXHWB1SC2\$ "F\$>W@:;,CT!ML|&;2-|/SZ\$G>R:%_ %1F;|+)
MKD#HGE=R4+=RF20|;SZV+&%#. <|6.@U|YF&G(.3=TZ7|V%ESZ?40JS,:(C:
M'D:|H:SGE-96|PN%<7L(UE5DET^<1\$O;Y62MN_)BVVJ|A8
MS|D??/MU8F6Y:HLHH8SKNXO.A?A2|=<((D%QR5(37Z;D8.WA->B M3S,8|,383B.06T#
|< MW#RUS_2;8K9|\$^<^|5KWIT13.-^8?E=W/LTSD2=EYY707M:+A8\$KO"7)4.H
M#@)?^D/>TB\$ _S?<9&;O|JB +P|F. NGWX|E-7=C-Q:;E_6_GV*G4)S>:MUZZ;+
MUO>F|MRAE|M|Y9Y^LVBV"O2+8TO|_.LT|HB?I@|>|LO+|>Q8B^AH80HAVA8
M5V:S2?)D6W6;T ?BV8MUSG8\$QB*, M;P7Y7BYD|9ZS>|>^>RRU4?KI|34ADEQ'N:
HJA%F1?, HKA"5YR+3%| MRRVCM>G2.X_O@0 |N|=JZ9|0X3:@^_0\$T=648ELM4
>C:|+2SIVO#Y10CQO&7SPR+*|H^|C|Y3^9'(IWL;>Q:U MJ?&<|=6-%Z5Y0PP^"(7?J
^JO++;0@RE.#Z,X-(VX+UKT7|2=%/I*EIPH|E2 MA#F<|7(ZOW",?/SP?E*|HV/
1.5|J^<.C:6RZUZ#33#OXMS:L;R(>&HK|"4 MJS);97^<^H2TJ%4M,8/H@F'1S>=|_0@?
R<@LM|S1WW,#R@C@V4'GK|@+;T3-M^|3U29|(7)H)
|E1"&|MUTK@5|Z1|W"30!KM79RQ|791'V*#V6Q8<:(RL|'5 M-
>OIK^:A|UJREKZ;0QF|03RSXD"Q#4JO?E@(&YD|+&W.J=J7J_CZ*0D^R M*A" I7^K|LF
K|,01W;.(V7|OAOJP7D&-SQUBI%D)SOW?"|SAK|L&>:E^#ZG7VI=Z_WT'J-S;@7^_,%5B_
M(-7JE^B_77D/H?F296\$/9L*3YI_969(=UD<"YSA227S-'F/-E|B7A-0HAW1
M)JO:DS#M*BC):4^*\$WNR_.<@0P(-#D_K'"'_#C%B1:|3WP:Y\$#^3F8, A I
MH%7'940;^U3LRF!8:>A\$XN/Y!5MWYW53LIUE^,>;:;\$ SAO&;V"78AT%9>H
M';L,*NY4LE:6|Y|)V=B.9RX4XF4|B@GYU|RI*);+;)ZR=^87Y0/=V=#HS3# M-

!X*:PX(Q&|E)B|01"UK%,:ANE3S*TDE&OX|I::#^:4I:B?FPY75#3|W.>AW
M531/17^66GTK(O@@AOX0=OP2 JV6|0HO7KOHd:H8.E7DY#<-|(KB74*XP,1=
M6%,.=6|^+>Y(=Z/9G!,"|J4:&)G MAZ!3!8ZGK#
<-|C7!%/EI0Q+AWB'4A^_B|>PXZA@'#G&*>*U^:3 JT+?:M7:=M*.0A! 8SE)X-|OJ^7-
>Y8UKGX|:0X|*91FA*E(MEE#|U5MHP|DY#=#5,W|0A)9J00#WSD9"HORM#G!7=
(|S\$V|&L'470|UU#?X|X MC9\$&|B3K!-_P"VN&S*:LL7_Q-%)5OY3Y5L(3*-
_ZUG'B,|3X6&3*D(3|S<&BN5I*PV|[*=EW|.CT MD4RUF:D?)^KT3V5+|B|Z<34(I%!(
%PL^&G 0E:,:^)^3+,0:X9W: ^R:QNV M=JT\$TOOHV/_%AH'|UPHH1O,A<3VW1>^'
\$ZHSL;U_1W'^^AM).+E6S0L8", MNW(T&=N_18OU49UG9R8-"O3\$V6P4\$4
:7S^JP5R?/(A_W+J:@@ D\$, ">B)B? MJ4ONBH*%Y:\$Y9=+ |9H&'I8TTT18Q-
W/G\$;A(B.:F7&?>=UH5:W,V-DD4) MR&TG! \$8_5VY:W|3K0|?Y0YP^_*7Z<,
<#&LG#_J7GOONIM-*7'V|ES|G/H>G MY"|8SYLWWW|AM2|W5GNK;:@Z-*,*?\$E@ K2#
<')&^(VHXE+7.9"5U0NR.#H MTW5.W^JS1B#2AB1YS/5&:G-(YSW%D?
G7#.|G@5Q'ETANU9Y>F-!"J'T7|H#R_M*).OK|NO/\$=9YY-*K"(G4X-"L&V?
4Q4XN*OI6@Z|Q?,U!%V<3 OESWKDM=T M27'J|*|B?^SHHN%K-)
(:|4/Z1"0|JROGT76UKY-BC8,/A&UD@!|H1*@_|*LU
MH1:C,|&O_W'=2U,\$LK9@|OC|H#IAXC.V V#Y9H*2:YYC|=>+\$09T|Q*#J|!
MM!)|HB,_RV2A3|\$-S5%';2_8ST@I\$,!!AJFAX|Y87S|UO#G?!^|@^KMD0BU
MNOGT@2,|K+|2#WR>"S0KD^KXFH\H# 1B|J|*4R;3K|,|:86_)560+ID#Y|K(
M\$XKJ:|+OFPM+_MROYG0Z2|/,*#0'2.T0Q_M|7C.)00&37RDL_(\$Z:1TPJFJ)|@^K&L:?
=DM#V:2,NO"8>,:!+V5/?AU(4=V|V
MECV/2DSJ|/@=V,Z)+D4^&!Z|J89U\U1,H"Z"l_?,:3G@(77BB,*-O XYJ,.5|
M(5,GVW7YD|4R%U|4@P))O\$ VG-|E+0"N>^\$|&->HKI9BC%#L9SIQ2X*I4'% MX7J-
F,X%|IA9M*F8=CJ0^TDE1^&R@0Q=TLJ'I5T-CN!::,\$:|"/2"6S? V=DR M7X
'DZ'(7:/%Q2':|&M-,@^*7/3HE#|XUGOZ>1|H|GUR>W0"83)?CHI9\$JYGW#6OI&/C+
<*&GHL"3 MJHM"SLV&.WZPW1FH X G\$H9OZ^1/N+|*|0;7AW_DN4_9K=;J0)
<|GVK1:,: MT2M*YUW4I H6|12LW%@B%GUXMFUC:J5AZEQ()96%&5*&C-
||9%3J"7)U8E^ M^C+);^O.&^[6J56|,"==M@.!4|3UWJ@2LR#WE(=
|'#@;D7ZAS9|%,4T<3="M@HBLDNV/1HEG,H9LE,L90<+MM/CCY_=!OZZ=2^L
MUI*8D4@QW1=F4@G5&F=QPW*XT&)G+N2)10!2):XK8Z|D=^2
M)>5.@EIQ|K641C<3*/;/_MT<|M7?KSG^1F.=;>@,*J MOQ:D==F0|8XU&|=I2,
(9E@|)ZR'G\$%P^8L;9'2FO1TV" M'2T)S=@Q%X>?
AQ8,2;V!RQKXPE8*3IK'V,>.YW)R*I,JW922>?.#BG#.QS
MD^,_UM1#;YJD.I63)UF9Z4\$>QD)%
|@W3|Z<4Z0/,?'\$5)9._TUA8,.%94ZF>J^XKM(Q=|\$ALC-M3)-
NF)Z'W#%U_(A2FCRPKZD|QYJ|6S+I.5,:-QG/CF1@H68N_(GYF0G|R"XK M0_ZI\$>A2T
%#R.3E(|E3NM#|R>|9.|M/0Z|D5RGK&UMS|:|M#S= M)BT5*KL|P\$<:4-%N,A0:4R-
W)2S\$7(:%W\$'TI94U?&;FK&?W5EBT"P52?"OR
MZKE5IL(.+)|I9SW24|J6>O%185*,:Y(CEX0&@XS4ANDZKQ.?+N>!O|M;H4TB
M,4^VM0C#4&4AFR8WA_1C Z,9*"0QTV%|?7@*'BO>|.IHXMT(K(15*"
(0S|CN)=@JM#,7!O?L1@%_RH3|N(Z3+ MY^W(|A?>B7;&6BEUHT.0T:DJB^A^T,K-
\$^_XUE VB8#\$GF8EM;CUE<#UIN9: M/W&_RZ?|SATCJC'Q=B4)"Y\$XS:Z:
(E03;BSOX3T#V|,I2G.7J:|7B,T7'QT% M::0^_5Z*VFZ\$<_P,%FO@OZ\$J9R=^WZ"_K6
7S,DQ>='G,4@RN*6XV48'&O/NPVI" ZKP='CXI'|5J|/7\$LWE<^N:/PA,*\$RH;=,,A|W^
M*/5|=|BK^W?<.HA(LFRP "9PTZN>_DO,_'>3^#P#38R^>#:/G B'+-\$H.>==
M7D|J^7|+RPE?&KQ>N1U"4G!"G\$6 TU|H5WEIV^D+M5UD+ MM:>1XDESQA?
|&NV>|X#"6>,.55|A/FBHPI&>&P3C6>B2YIMO^LH>0-\$|C_&M M#9_4@)|LJLS-
Z^S^'B>G42,|BAGZT52H?K X2Q8WP7V4;&(@G,:;^|.45PXS MK.F'N\$,OWRC?
L\$9"9N.O&GVM"*XR1K-)8WWF4-L?|O:|T-+IPC U-FWRKJOG6 MNVIQ|H#D\$"^7(+6:T'-
-OJX'SL8W#LG;:/GKYVU_6-CX,7A#T M^BI/T%1 OR|ER|8*=(U144>7K62MV7T-
SD0#\$7C3S1Y5HS"H:??|:W^K; M4X8"&A.^-<^OR9+RS|1:D3E!)O@&?!/Z
|+|Q7M4:'C|A8\$7W^R|U94P,W,9(3)O*D4M_@.|M&\$-R05-
1!447:04(H\$0H1YWW1Z^929XL:_"C-/|V'#;J M>|F|RUAAXB&X|PG|E8\$-
|/+2#K!3ZH|C0OG,|.)18000S+0&NM|-!ZU \$4#7
M|S\$KP'4H63.K&IN3U4;)LUNG"2/2;|I<>H#0=7*|90/>Q7_U'VI^CS4JN?ST^
M%FHU##R8O|C|,|K^-,Y>L:^SD7|^L7".K|,G%8";-M|VN\$YP7#I146
F1<:EF!.Q*H1CHS?>_?E|/D|Q-"K2'KE.6I^S'9QS!JS4:RLP8'=BHH/>E/Z-9ER*SE8)|SK>)\$
\$Y8&KHU M-O#2500PP:EA3?'|URQ2"U@|MG'FF3ZGUMYF-,^HD' %Q.AG(J)4|7V!+V+

M5V5Q7\#5PT4J!7>QO&.;W5Z&^RU>!7LH).:MD=\$QLZZ!<,UC#3-
'DK1)\$+R2IR>S658G8J9HM4?/'@?Y'ZJ]7-A^A M3^91.D60>GA #*)-,")4&=MP8 SJ&
<,1>WJ7W@_!P!SZZ')%4I>MH; 7WZN M/PWBS*O Z;+EM0R/H39=#E!J';51->SP
YRHN*,1>U9W4BN+G W9M1^3I> M;X6<0;_='(XZSIF^MTNI(-ISWQ)LT2OBJGHX??
@LXI!F:K&QXW<2*L^'3GY M7K^7,_V.45;:#[12%DAI%A':U1Z*EC,00
MS(I;ETP8_PC2#E!%[-2P3#2%"=KU!3]IAM!#3)%;G&+T<5%AVL,922//J?F
MH[-,==*MZ;-9.25.W&D=*S,FS^=FWA'APL:K4(*^*E5@T=UIQ"-EA2&AYF
MJ;_K,6=.;O&3=Q,+VV2*4DV):K5>3XX9/ED#?1%YTWIB"Z=+US!4% @_ENOGD
MI>'T*56%4BO'G4%N?3A8I" TVBO_NSW73MY7:!'GH *M MA?X;-);S[-
+R&CFCL.FI+5L_VYL:LR0\T5XD]U#DLC4AIK(!D;PGF#D#KF
M(*>B.A%WFH>AIWUM_.WTIWY77X6LA;#R#5ZUYLV06";.\$'(HW&19!7(%Y" [UU^0?
Q'_N])=Y+@IAKDOBJQ-LB+-&B8:P_%D1 HB,
M@A:K0@KU[ZLTZNO0J66)RB:\$. -5FXF*)&DTRM63L[ZTD,!B%K*P7"DV^U4F
M1=B3='U9S.PIK10UC-PT1D#L"C:T36/O'M.VHX,FLMC:C6 MGP10P-=*,VMO+
<*X!FTM1AK!0G[ZF#>U34,NTPS";.SR.C\ZU=1S?TSB_C M1XGNT&0(*_Y-B?Z?
O6HG\$SS;5_7!4!_ /&HJD9,#Y(ZI#45K"F.B5WK5F
M99#JZVRW2:V@'=&3>%B**E2F=LI7;M\R5#;W./RVRTFE\I-.38 I++U @S
MSM^GH/UU=* =0K\$0KH>;K.Y>XF%#1PX.'7O3&!(2YK5MTK1^:;!4F+/_?#-Y;
M='DS&S).5AL1&%K/VS5G=LPD?B;A:K(2K_@\$)I4=5G@(UXO+KDX3&L-=SR!
I#+7_N2%;NG84
MY@\$JL1ZS=J_MD.NW36=CQ5G&%NZI'3UU"MZ@FJG3&6)E_O"=%J\XIB@;./-
MWZ:XT%S4FDU&0A_.3]"LHYDV^&CJ"JHQ&4J9YWTLLZ5CW^)OJLZ"H-Y7B5 MS:^
:I7"6<9-6NFU#+SW2X\2.?R9WS"FR18.7XJ&--P=IF9LZ>75LXSN6\$.J
MSZF+JDF%W,\$.9?(G#UKR3XKJM0*K+1% HS& /I,6K11Z5'CC'2M:G/O^*^N
MM2_OB,EH?PN/WS9-CY%V?^ZN@TQ^!@7_DOT466,U3&8<15L/_;#3J!=I
(A<;%C!NZZ>68 /FQ&S\$@\$T5VC"&2(GSKDYCJS0_M"S3_#NJB9PYI_)SIZB>&AL
#X,F0\$!SJGK=4)CIW,Y4RI_.XN+=TNBETM! M/_S8_%'3U<%_6RR,
I^9K1H%B3SN'R5A0!\$>N&W1M 2X1?R]9!T4,T[%=HH M>P_4E7E(?
MIK>B;V,|Y'O>WS|AFK:FL,)*N|=-R"D.K_17MZ+H,.\HILSO
MA*WAN"+D.O8TU;>4LT\$Q_;7**3QF/'*7@NLUEOG>R_>2/F1H&>V'A!/B<;)V
M%ETO".LC2H)NXIZ;05.+_C_QO+G;_H#Q_E"RRI5P*+!)8,MMJNQULO)7M:*+
M#C@57(W=)OY0YF4RCMV.8Y!(^L*\$|Z=;85<,NJ*=OS7JR*\$O\|CH:K'J MTN-D4/+G
H\32N)?QAG8!@MA3Y(>6\$F+O T&,I3=_.:S\$1Z^,R3CQH7GC8
M2E%HG\$3K(SF^BD'/3^T5 GO))@\$*!.E!_N9YSA2T2UW^WECQ<'P\$FRV
MS||\$M^A_B/6/GM|9#/H:E8 ZQ-:7)%15Y9T'OU3==UIKG0/3WS3VO,FT^^?) MFH>0H;-
QE':_Y<6L7^OZJU2,@;>Z|I:SV5%W/@3GP9|;;<-;M-Y10(G7VK' M,IP|>\$^-1IHCFS-
RC27HM2>D*JU.B)-)'P7,ZN@;)#T!H_Q0LP|Y5"/7"LY M?Z?KDAVY\$/"D M|2|76F:G*.Y(LR
C*7CJS4\$T!(%TVAFDZROG"3T2N;X@7L:EV|C#CPB-A MXFHL4+DD?YUV(-
_I;_Z;LLQ/_.@PC=7O=L4_\$CLO3R5-9#\;I-5N M'E%MWG4*K6YJZ1?F?U9&TR
"L('7EC)>%%HG%N59Q2WQ:L|LH3>ZHIX5N75Y MCFH^7V3-0#5_*9C3ZWY^)UJB3S/_I
(2I*I&V"J^7-C5.5D)@V9I>IVNK_*\$ M-2|/+;S!WO!PYCZ>5'H|&H0Y40/O::PK6;|K5,Y3-
X0H;>NV!/A3%B>JK++ MDZIUOPEY*+6J6FA#%5,M'ST;L:I MR(7&_Z|K+!H&P\$)\$ALM-
+E"Y.OEB"CTTU.B^D3/J4&8-P^:PFW+N!HI\$@AY M HTE\4>3 _|UI"9H?36\$F^6;T?
1=.Y/0IA\$9,%=\$2OD:P-;!5F^O3;RF^@ M>JKY*30")15; >TAU4I>#;:_I_K9CK?
F>#;=MI/4:IMEH5C%+FWHSW0^Z|L\M313KV:S/4JLYO79:P3VFW;H*#XF@
M<5&XBWT?N\SJ:3&#:VZT|MS>|W?4NQ/VTSC|9QT8:C/^084"JM?^(S-5)%1D M^|/#
<+>JQD;Y8S^C=><+HDB>^;T_A8%ED0)2.Q?(^JSL_SLNPYTR83"M*OG+F M|R1=
(,Z7|Y;Q)R"5>)|FE\$9=_P*#FHYL(-G>2+P<8WKE;6<;YXM< MRWLZL|/%@>M.
I8Z\$A30P201@RP(!F|L(L-TGJW#> :S)6CPR(%(F@78N)SFT
MZ);*H|K'PAXXKWS42;Z3NQNF83"WJHS8% MY#@2/'M!VMVACC|HF1Y|_-
M3'METDL6A^?JM\$MP965Q-QN8NCKVZ%XH7.#PUOL-,|9R;|#/V>DO;V8KV8! MP-
'AT7S@WDA\0EK*)A24%TO!N7W?
0Y!IESK)3K4"%7H76ZZY@9R6+M1=2WP\$FV@S(AN2>+U MK/K(USA|HBC=
(IF;V7JE94VATQ2&W7"F"P?AKKQCBXR& A,=?CG MGG'RW'JP+%8Y_/618H?_I37=-
NFG0?,938TR+#NU+"Z@OA!GK.+Y>L_X,5+AL0T8+T/XP,Q4
MK\$E.>;ROB,K@+MOO#N.2-RI%Q;D&;-XMOH|J';9B!*F M(+ (DR<5-
I9(I1|^1HWP|W=#-<>RAZMK9POMS;I8/#Z|7\$(@Y(Y)V^8>'#; M|8&GEBP??
OSJASKF6W|(55F>ZUS|8J|K U|%3@ MNY^H5*0HLFSETD)._/XG> 8EK!T9J7T)51C9?

B8;0C+[ALSD5<7KGRRCAQSC TKR\$*9L;5W1_6^L09WJD!?:
MZ"GE*HXT_M0W\$ 20INS^(!_0;E4I|V6'#M=7D[R+8NQ/%.^.|WE\GI(\$BU^
M1N/L624(M2)GZ:%VPW^*F0SXB(-DVD@>09!06 &N!M_#=28 ?&'!_U"+I
M_H(1@W=B:|_-;VN2|JGNF?)B80E(=2= MWG1T>4V#TQIN!1?N"<0Z-
8|=.SA0"Q\$E8NCUT:=|0J6?9+3H\$1L, 4?0S.
M^YSM,0P(LV,STUD%\$!LX@OL"@^)^FN@6T#*^VLIPSDX&7!)K\$MNR_)9JT9:'
M7=3'HX@:M1,MP>42MXU(N4H|&%AW_3X;|_Q:GXP|1NB_)^Y_OMJ:Y7D>?L6%R);T1T
M88CU;K|)\$9)Y0*S&/N*"CO<<)!M4:FS*|T)#QG%/P8Z|2G= BV\$5I2R9B|:-
L5<5;@F|1A>J5!<3@+!;HF>3&P M^P.7=^;GG@.B"!Y4!5-
TA>E&,&=6TEJ,3^JYHX;964S"P6->Q22/LJ+<1C;Z
MGF9*7K>ANW%"@(1PIAZLFWKR5BI)4X-EK"-B52CX<*MA:_P1R>LVR2
YW(^-^*4CST:9_XJ_,UTO?K1)!-!(JEZ.7*0CBG6&@7^X' MW&Z;AX01FU|503LECA|6@?|
MZ\$|HV|OF54=_5%9%*E W64B/>5VL\$T_TL<36VMJP9DK69S|K9<9*JT%_W.\$
M_FBBKG|X&A*&@&<;\$7TGK%YL^L9_/7<|DA|B"J&9/|O<;):E|GL)^_X2TDRD[%|
M.B!9G3<>TE+/ND)|9B33A.2^/0W5B M-\$86'@P(F/8&-8IO4/NS_|BBFSJ6?
W'ST_&G1=6'G6TL#0|M4WTLX9Z*ADZ M>|!R|&
Q24GPS=&.4TE6YXQ4|V#7#;+;BB/^:E!.D|Z,MVT14AE+2:GR_ ^FY
M_#NW,F020&^SK%RR9\$*V|@9D>ZQSQ\$1PJ4+|)_FYHP:DSQ%(1N38Y|1# 87|#;V@
\$MHR53.-3J +P|P|HWK)>4VV| ^ MXNZNB(TM:W2-Q&_GX\$#*(EQ3 D+R;XWNVUR&3,-
TU_*MNKT,MS@RV7"Z1>|&B*BW1E RP&<
:0BOVJ=B:&8L21:D@SPM(_QE""NW|E>S,|Y MR&V"E!=(E&G-7FT)V%D-)|Y?
4CE3""UUF>3!PG*,Y;VRPJ" FAZC|+_?!6F M/=*&(6|'6XXV7)9;XA8AW).0ECZUEH>L
M_*UU;O_GSJP4\$94'0->X<|2^)|@VXLVJF5K;FHU|B"?X:M6NY55U5D:\$HMK4Z9RHEU,?
JWL86 MDUS^RR3!SBI.T|,R8GL^ '1H0M;=HT+*K.+BB!BD_G>A@CNUP&1?|V(|:VN
M-U+/|S/8T4O.MFJ.)M)"&V-<*:5?R)V|AR57.|G%EDC/6F|>'M7UPF2=#+MIY.?
ATT(P8^&EJ-|XZ8R"EIDMZURCS"LG?5D0(&-%";1**+|JH8'6)?CZ93(UW:.#V&P?
K+1M_IQ|4C<^SQ8=UQ3Q WY?OHB MM?!4.JR'BPQXSP%1_@\$JUA\$|Y%L4:BG H!?:
3W4T\$SO1UZNHH'B_2MZEQMFP6 MD!@/!58J"?/0S(Q3@\$=53AL-WXYV^UHS3
HBZ|AB7(SF-@*/F4+|>_#I^C@Q(0NT+@/?@_1447@9?
S|O_!D36NY+!L;/'D:O:R;J|@P42|O02KD6'.&5;Q M@"TBI!:_6'0Q:2M+8 *M0|_0#(N
MX&54 &CEYCBABZW8LL^_HO3_5^D57|H&RE(GTQF;EVI>6;R5&?EJ>OF1 VH6,M.
M73"MJQP51=5Q&HWFNH#FYK_?41H:S)E"M5/^_7U:P=9+L-(-WH|_B+74.E MG2Z
OW|2|?|/<^@;B ^F |L=K!)S0,5G(L.?Y M6'@X;:/WC2YPG36T#7+-R.J|B>'I(M6|O)?^_2/
T3U|6NYAP-CYA"TTTC(:U9#I;S&TA\$|L+BLZ.*E\$SQ#-?RG<\$5\$
M_DO9MW%|8EUJP""Y'OK,W|H|_E=(IU#(1G"-H,+M!^=75=GC*:IR !P&:4B M6'M2;_)W|
(K063U48(2^I4G9OI?K*_,|421##BT(0,6'6N&6^X<6SXWYV5U MPZDV|S4|M3^/H=H&?
MA)6,(4#>H;67_.+T5Y+G%A&V=^NR'OH'H^RO(RI+T
MQQM(B)IO:T@+H|VO5|_!":+:ENU\$.#%88|^EFVJZ&00 ,RNO(,9/Q3W%,@9 MPH=P,
(WC'X L X\$1=|/20^:P6Q<4LJCRGT8(Q_X7OXX|PS_L68&8&LE?=|MYWSG|S|/7'!^L(B
?.6UA; &SL;_!M| =@_00\$35W|H|H!;@!XL+%F@7, M.|N?X|K^Y^#D^/*Q|_||ON/GV|_
MY<7_) 7LK.Q<'M9^'FV?_^.#|0\$0WL>VP_X7!|M!:@%V8C4.8C=4%0\$?MN?
|A'AOP:P<_:P+V.@^|P?H-!H?AD|@YP"G.)TW)1;
M|,H=GH,!8B>B,U|N4SY;W2Y^=82DHG/W00SO?@E)*6D9U4-JZAJ'3^KJZ1N< M.GW.S-
S"TLKZ_+7KMG;V-QQNNKBZN7MX>MT+# H."0T+?_CH<>R3N/B\$Q,RL
MHDYN7_EY;J*BYY75KVIKRFM@Y;W_"^L:FCLZN|H?OXZ?1L?&)R:DOTS,+
MBTO+W|_6%E=(V|M|_RB|%)_|V)BPW@8/N_CO|A7,)|@7.Q_QH#G3UQL|*%_
M3A#FY%(ZSBUB>H7G3H#HP1/1^|3.9KRL;N=5UKE*\$K_|8&2_A,K)!57RG|_#^
M\$=E_+K"8_U)D_RVP_Q|7#,#/P08.'H'):+8=_(S0PM2&0W"9U|W6Y-S|D-(6P#M183_6
M5;6V+V6!+V>ZT6+CG=O/_="|Q|",=A=<'3'-I 9>QC5B9\$5&%D,>Z/Y->
M2Y_GBY1EVG;|_#0W/L;|/+M^!C'XA?>K%,N9X&P^UF82C7&VAZA>%P3XX*Y"2
M|_1EOF\$#7+I'R?L?M4G:|!|D|N&@L@5("^^N|_%2U MJ12W8?L:S110&\$Q@A63R2I=
|X_?5PVR|G;_XZ/N0'W4?MP!\$RA(G6*I, # MK?.(@;H*N*XJ*+H Y<0|CZUL3?
HTS+J,|=4MI8ZWWW=Q^ER1G,%-FU)J:\$& MT|P1@G%+H>UE1|U.7-
0MGG%_QWEB9MZ"S5-5XSM;H?*\$U|S4?(W| ^U+H|_4 M=,TN7:2Y
|Z_Q9|PB^*AGZ96/CR*(@).U+9_1"|"GROX2Z4IYG>&_ '%>?)#7 M54,O_P
_OFJC,)XC9&E&S;|NY-MAZGZB|R3+;HE5?|U|JO>8WWZZT9\$|H7KJ^NS?
=4LB^4\$K'5UBG*B7|LL%TER,O>A@#M12!EUO:FGB/_M,2>8Q^>,2Q?
OPBG&LHWV_\$OG/|;#^_R%HUHG10>M>|!VD8XC+8)(K02Z8|D

MNF,WAI8V18^<<+SY(BVXY8'L)O[K3:PY4UHE_O=P*QT_10WJMT1>1!QCH'^^MSGC=
(DKCHV9=)3V5&1HWM1=GJ9YZXEPGW@J>#(9K;HPOBVP?MLNA/,KWC2_M-0?
<'7I9:F#{O#950#}>EJ24L6,_8F31YGW25^:\$M>@'O>IPP*GDD2!A6>@L
MXS\$+|&C5(81N.)# S!EL?75V^Z:GWFY^:V674A0NCSEUU'3M;JB!VNONU6BX M,-
T;0IH&(<89Q4EB!;77GC;3X5,S9Q9.'(,T-|+1/7|TYVNT M\$;>|BLS\$?!ZBGE*^.2RYP (Z
+6W^HKJ6K+OLY&QZSZ59_-C(@:.)#/.1JC/ M&0M0XUQ(,IYT.DN^ P'7.;R,\$*@=&
Q:78KU/+T3(J9| 7?|HEHB.?VTU4 MHDUX:3>9\$U!^E LZIBFW)RUA%_<>"|>|'8PG?
>783U/?WT|9-%'Y-*O|HK> M6-WYL&LWL|K:),<0EEJYT^C+|YYJZ0/,*\$|5|+X=
|PD/XP>'H_2\$XG*-T MJS'CXV&:'W"BOV)318E%6M|V-
5J4FK"HKJV,JGGKVK+;|TGV14UFK|1B-\$' M^H>
|'E<8HBEJIN^8GX8WZMX=IWA;+?:^GN#8N\55I/E|:+.3HGLT0X1I:1I
MO*F|I0YP^A5JWIN2UW&,%T|L?!7&WUOK|HY8'97?KB%XUM?K|+^AKPP;:UU|M33C
B1&=0P:CAV-N&Z!!|FM;U MQUF7QY*,0E_. 3WAJXE80GFO<^B4_ '&/^@BTQ1/C.*
<)>X8.;K/! OP%(J742@E ML "NM03!C+JUVN^8/'U?1-
W_H,@QVE09|4:.2W/*UE1|:%P=AN.>|T|3&"5ZM#L
MS|S7@O\$)!RZ7'Q1HCG"U:@ET%GV+Q*/DC/68@SAIE*|V1QB1+D!::|<^FDOZ
MV7WRK9<:66!%'>W9\$A\$_-ZH7?
LD_=R,+ #G/6^&5Z\4MVZP!D=,P<2JF\$|E%&GRY!)5:#YGQRRZY M:1U'7")
MP<0@//4|0N?6W#^ZO;F^R+|_+++"S2E5C&:*SQF=9\$)0500%RWBE!773CKJY
MVSM@T_-%@W:X0DJ|QM.)VFTVH6|B=XCD#9<,Y|M//R879/Q0T&*4(<9H@JOV4
MD3(YHB?D|)(3U""JNJ^O=AM!XMJQS>*1!YO'3W!<4L?
N=OT""P%H84NHCN6G|6C9.GFW-.%?+4CFHMU(W>/6\$R64_.AM6)I!DI?1| MV#A.
|/D\$|/#7T0\$A7-@^\$Z5,XAU%^?+CI(MOFW"Y)83|4OB_WOMLUU.=X26CF
M57'A^E)DE,G2G1<2L@HF=CPZ1+0-3;2^IW)_9=:U|ORWJ9AR7%X=%E<<9|.
|ZEQ1A7N'F|&T0R<#5ET348JD@-Q|4G_);**75-< MX@NG_9/A+^H^|(*.V|03|+GAI|3JT
M9JCS8@2,!<0&\$V!""UM#\$SR""U4'%GO*^|1.J5|=7%3_E(PJ2W^8OT37I-72-M;U)?
@AW)3BVB*8:-+9E/=9.5.5S)-|=W). MIBSR)Z),AY'12ZH)
(B|E&1PXX<_Z:3<^2%MBQ0ZI1NK!^)=Y-<76 MW+J!=_BDDK@HR99I=J=3DWV?C+5
?,C7:|KM%;72R_-'K|)-2PI7|G8>^NODHX)=@,_>7"TN MT5@:K):GC
|XS|@G&JO,>ZDWE29J|V1XEX:%6L;*,=*9)>'Z_(VO|5):O!F&KB<,)AG-8?IY9=@ MIZ
M9ZJ|C/ZTJ#...:PE))K&B?S2 &^ M#
<*AW;*?,+OA.LNA&@XE9JD.#I\$E'CR|68TEA52RFA?@NEZ=(%IY &I8|? M3E8:G?
+T^Z6IH0NOL1H6%'K:HV^?I6IRKDX._;K M+?%RZ:VWUT_G(|SJ"O+-H2(OO0FO5B
)|+T!G#!842\OX?A\$K|XV!' M^1"07:=UMBE.<|OG*" _X>N7NUB-
6#CHJKS4K^*A2X#4_DR@P9D#>%C3F3? M#+O=2|:4Q/BUXU,J5-
U(*%M|0#=#8JW|'28U6_X1NVR2KF/&FI3W4K7;OI.YCRL+YI,.7M0=[*@MP'QUS=
|5,^<^%:F M/TC>)X49%)I6V*:D,9Y"";GS&M2Q!=B3G/05B(BNI5/HHGA;":4_9C\$66F!D
MHY#??R_OYYJA,J,HS>#X+7;OGQBJ*NH#;#J-\$L;(>DG&?8#&9U*?G2>?+|CF
M0\$:^Y)F>67@E(*L4AZZM4'6%'DY/+O5>Y(MZRVJ;_*1H0O-NV%#J00YX/N&
MVG*K5|9Y.JQ5(,9B|FV(6|C,E|/E9V?_|OFZ3Y';8"B K\$P9I&8LI"7?G.K0 MCH/6,
(L6NTFOX_Q12Q"1|D6;""EJJYP;R3US)>|OY_HKKF@/E=OX/+&
LC,,\$/%&AXUFH)JFWEYVL MI>*MF+C2T7%#3IG|>@|
(#GVKO&K;:P|U'Z,,%'W;,.60TN^E0V65|I*07/4| M_JH* S?%F'V\$1W!^\$
Z;:V*>!*5|@5|8UG:)|2,W"KR;:P8_EWNY^G74-S@C M!3H((X#W3L3&|)+%ISVM&
(>&>>W-!H<9"?4IZG*(DJVE MZE_|'U\$0U;_)7DR,@CAUS/^%
<:YD8I!AY"5Y8|=H39,LQ>"K"|>/M|O'(KU
M1V|&X894M(9.03J&P^RBW7^*\$QROQC%,^<,>LIGO:Z_KW?=>P8XKPOT))5->MROE!
T2!#S8G\$W\$OH>|ZT(QC4HD5|CEJ/IFBR@NF,7A!MS,53|&'S+A GJX2|+(|H?I7A
(B%+EL+.2!| MJ\$=VF197=^
98"%H;X5NH2!U'HQZ%C!6@=UCP-.A)"8'=U+!"N0+VYG70N) ML^|@:|32IA2+&!5?
0^1RVA_V+|HQUS,/NIAN|G89;:2>:,S>KW|M+Z+/'@ MEE%
K6J+ZKE)GVV1VT?/:1//4;0(MNAUYA'IQT+ #QLLW81P=#7L5&HLX2-
BC|GRC!LI#|)8"19;+5;-<@IQF3P M^CLE4|:|ASA':YVB|A).C'G;_>'Q2ZZXCJ&00H6?
WC+C7SL47 MZ9\$O/DP^;^:A_)DWZW#J,>_-F^H6|>Y"J8RI/*XY+O4S0VEE_EJEL|@X-
R|V-OJ^A5L)H@+H/S0A9@CF* M|\$*|2|M((&79DL|=S2M=#64JYCJ,^;R22#_Q40=2YZ2-
BFBO|F:3GOCGNFE8HG-MMW7M)T@HU9=)26'^0A%>0FMVB7&TNP9E #=#EW#K-
;NP'/.35>|R*+FFCDF M=474Y>R9Q>/ORZBD'I.*0;3LLN/,5U|PPR2HZ*Z;/(^6R8+1I"7;J6
Y;FH= MG^Q;@RKI3YD'6K;+E9|K&-^1/B4M-_6C@2|ZC!+

(j(>ZHV9%T.)\$)H)L_@X@W3I/Q/*A+TN^4%R%6\$>O&4_JI_'ZXV>9U9BD?9JH:=HM1
M3VQU-!DOUD)\$,%[Z8YA0!/OX#H0H)+4,DDW]>V;U=S|QHVVY-W;FA)GOML)
MR:2_L_AD>^ZC,N38B|1YT.3@\$/6(VL8UFAERK%"#D)!\$.!;LMPYX376V6?V5
M>8W%4.S\$ZY-J;= /#88JY%V M%*0D)&X6OGU;TEJ8/.;X*|_H2;L>.%1^S0Z9*MFxJ-
9U@/WQAY\$&|X8|P M6A>>I4%BGO|708LOM_M2^>N7:M(?P7GUO.=|CA&?
7ECKQ;_6|FC(JAF>W M|""WS0&\$ &T_LN?/;H#0\$WB=4.|0_D|0=VU4(1,+MI9T-
)FT:HY3^004V27QH+T?70#9T;=<01|&|=)G)#H8Q?\$E+**|;JPMYT|.F'QBM\$+%P--
:T9=OTIV56KM/./|.;%7^;Q\$PXU=DNK;/ \$"DZOM MB'I1,WK: ^O&V5('R5?
A^NOZ^UK\$JH6"G\$YZ(X>OZCXC49+00+ (M4*B.5:< <;=M':NB\$3\,IKD|^USZ@_ MF%
<,>|KS6(PA@(\$R7K8)4?%+"M&OO.;9J7.583+;%F2MUV|5Y|,K/I;UAMZ= MM-^?;')F2>;
|118YZ&<"%#|V_4"F1,HDK, JB=68/ 1R::308 M+;4K'8L_B7&,B|!89Q)^ T-
S7|.3|/;C(75G6\$ 4L0XO>\$ _FRMA)(=FYM6-- MJ_5/9,,>3^8L!=HAN)-X??
^"BV5>P6Z4OKY6M-4*E6F_#DV|YC|L)IFLA)2*US M,SEK;0+7-E92^GU6C|AN|W-
)SW=MF1U529|ZHL2&E_"/G M|::4,=+:CC-G*6@>A%O3._PY|?T
M""M(*N%|VW+'3#.A)IXOA&*-J9"#\$*QV*HJ F8.W;60=G|3<^?
Y5|2|5XUN|(FU=5XDU1@<\$ORT;JR_ X>LD.S>IA|,268-7
MZ@"RSV5)/XI^IUBULI@WX#8+S+E| MJLM^)40GW-*ES>W?
_1@OH"JA\$S%%3\$ _&RN0/3;6_0|)%\$ZQ|M;.!#/*MM*@T'
M9LYY4PSZYSXOJV>&+:07)"FF6)DV|FXRS%Y%'5|QKJQ*|FQ3S9SX)>R#|O,6
M_U9G9KN\AK;(DC1G\$4|4E-X9H|LO)2/V|SJ\$<_|6I#9\$D/H_A\$|8_M+/-;
Q#R|@LO4FQPV|94C2&|;)0RBW*6WMJR&(\$5/+_19@\$*QGJH=A.\$?6DG_M_3_=3-
\$8IT.#WUS*V0X;ZYG7&'8(LOKZ..)I;MK|H|9^Y-Q=H:06E<2"D MU-
_E&15,*.P"40&FBY"8=+(G'="Z| 4W12U>\$:/L|&A(4G|!57:?!>^_R_L1-
>%|C|5=E+21FW5^VPA.10&D2>'|EBF;YP MO|OZ^?>6MTP^>9HA<@95CRQ=
'&8\$^51>76| RG7|KYU GN*;ETTRVA:(.OY M|C^8Y^DP4U%|?_4"5?'VU(JJ&-
L@-4B(AW|B'9:TVUEY26JG54V B)|J5LZ MXY*J*UOLFLRT. LJ\$.V Z"DC^O|_G|33C-
G%4!%*O-7&(ZR3OU!DZ4^V>NW M>|) Z+L5A|5V;LW=J(VO)+:T'RV26?"96+Q;<+==<
M070G|^:!"F|>-U-B+((YT\$^G':Z3#9#F<=4LI@:/G* MO-B|.:S T9_?YSUB;FB-'(E+F?
J7;V7SE6/MT24W;*)K;!KO<49040: M?ZR='E@Z(#\$<|
T1"4Y|^Q14_4_J2V6RT&M!UA>|DVF\$"QXIV M\$AQ4",E((40(|1D)TYF1%
|S>CTG0X6P;K^LG&|E(>YG=-COB|N\$YGG"H|W!/_MGIL7-
^>2) LZXQGJG0^_5(H75Q5\$?JAWS|1V(E^G|KH>_ ^H|HWA2A>OGRP@_M>%|!#>
(PTF_4,(::B40*O|!T"2F G\$-CT|JAL_C%WG86P\$L_.OJ.VD^5T:0Y M'9KVYXE_|0<1_EJK/?
NQ1F|>HPGTK"V5U|@>LTH;LOE*IKM>QD*A2N7V@J/'\$X%|3|1=GU+IN0AAD%GP_|
MDM'<"NU!D:ZES?9WX\$B7AH3H2/^\$+_O>|VKDBLG|H5P%2-VVG5:-;UU=E/ER M74
E+N_(EF;|E+5(0=_"&K&9@=7\$7 WS)A!|0PM&3NF#"8IJ;_9/D@EM MKX3W;
9B'%=++XRZ'Y?B?*LK9B|?5G4L;S*0C-'|5N#MOP(J'Y MPJH|T3+H>+^6!_V">47UE?
+97?D)D*7|;@ZL<O^'|%5\$N=O4*V?>5I5|00|U|S;N|_Q^+M1?FV&Z|X9|9*N,FJ|J^S>S=
<,(KOY;J>OX8L@DI <"N?@02 M,NY)J)M0/_L01 J7?
@@WLL'0K1H3Q|XWU)/,FXKI'_*|X^J^Y?0IKN ^#?#1
MY^!NTDY!U3|H(:.\$H#*=1PVM%9!|=9L)\$GE?BYAEK3'5|_A@M;C6ES\$/&9;K05
M%.ZYAM<+@.N A5@:G*)<"^'0I1|@Q>9HT8J>/|3"NW?ZZSPZD (S=4)OI("C M,(*6
|/F%5S26/X>"Y#P_=DF3M=.7)LWNR@RRJ:.*?W|05*6=+_<^/17.78E
MSAC>%T+U99@DI SS*TH4Y?.,GH039PI3V_S9Z9I4C^)|Y|R)JXMBE^D(6X#1^
ML"\$|X1VZVJW>\$M_>ZILHCP2=?WWW.C.D|J8^PW)1;T0DM6F*|.J36,BB*|< MXRS=^
P6=RW-QO+1U4:.'ZD|6U)\$^)^I95_"B5J YQ-@O/T*=|3X\$*K=\$N4/
MXP1IA@\$""%S=9+7S<;?(VO\$S,_ #3BL2E6=&,D|J#ZFL;|@I7#C6T>8ZJEF=
M^_^7ARM*XXJ4MB7G|*>6*CO#?6_M_|531ZFO2|KQ!SSDC|OVDD^_
I8/<_G0U(9|2W6?)@XE!*(.%R_-W0BWV.B4
MTSYU/CJ.K|;%.&=5LKGBK@%\$,2I*DB8!"!!3T^U0R28B00K5/7ZPA-DO9+0 M-
QNX":W"R) U U=OH#Z_AIQ?9U+ T>JQ#9-V+@* E%N_E|,*454 ?|EJ@?
M2YS#V\$|2)|@JSKVJM6L4S,F7GOF-'85Z_ZW83_4X4.Q1G?"V|3 NP2|5- MT>>|
<3WW|K=K?\$QPI\$CVE+|8Q5!W&^UH?*UIU""#6&+OHZ&5D07Q|VEE,Y9R6W%V^6H-
7HC?_\$G>!XX*UTQ="MR-'Z|E/\$7=(X(1_0MQ_#YJYNZ56.*+.O:9,R-F:=^-,/YB
M;Y(%PUN=!\$T,1L"-/DQ#P?H|E-#SD,E6.*=9>H)6*GE<>".40+C>R=|@!-
M1N'TP0<_|MLHRE/*B|72X?N-UU|)%&>|#J>--Y""Z7K|=;HC;W&Y0<2|HH*\$6#44Z7
MI!VFNU\$CR-|MU@L04;KE(|O87P5VS%-5?J_S^|H|""8#WWKE:K|V?>ZJE;;W
M:\$10Y_XLO|B435P8N K<.+I%S-B6DZ11&Q2,VJ#N:T

M=7NF9[ZTT] "&R(&9P_N:#>F M6B3>B[PT.IU]0.?D]I'1E^D?C3:W^@4WV)/%GC!V
3EA"PMDMD%D6M30=QB M%"(A!U4J\$*\$@<.:Z#Z-
*N!^JGV9L"K0T#%1IY/QT409@C4KZ3/1J M6\(";5KU[E, @)64!TPE:Q@<[H'N0VFGAQ)&
M+;J2*CY):-KY+[J:YJS3/JH &8^<|2@29('22G:??;).JE2;Q%8>U8'\$0;&J
M(HXK|SYOIGCM8W/)(.?D/3H?6&=@2KHP#_4Z 4G*GC4L;Z+V)%?
WHT_%KQP(8/S%MJ+N8&4>F+_ %G31%E&0!^ ^Q!TZ2,R%JF
M"@N8@703H-;:'E@6X/BM%Q>:A?O)[J=K\/%XXU&W*NVQ\5^WYUK2)JR'VEK
MCOTX9C"36B_15Q*9/_8!-W!Y148G,G_1&9 %;P+)8)ZIYM7E[8!-_PX2ONJ
M(PY>U[H8.ED&]@&H8M^\$L@_U*&W_W)VWUD[:?1^GB@N>&={3S"7]Z\$(3&>[R
MRC3)C|L-R&VB876LUICG3M6KVH)38R&91T63)Q;:8FEJ:FX9\$.|E.5(R,1X@
M73R|+Z,CUT>TSN/-!R.A\YG_?I/@84/O?ILAG8W<* W?K%QR^ ^/R@5?2WW
M\K3_RW33B@'9+WPK>2A!-0NF\$AC RE([JG-7+K\$6^:5/+ (VDX#?"Z_&?)AA
MG(M!+=M"R3C&(:4/?;T9&4FU^ \^S=U^YKZW+\$#|,16+!02@&49X>X(O|C>J
M71SU31HM /VI WK|,;U@EFE^F07(@/ZYRH\$A*_ .BHID!QU"\$HJ;:UB&B\$|T0
MH4..Z|5"?6 *D.4*PM1,SB;J.8U>IOBYMK,9
M#1%@"M"-2/Y)=%N2/B65K)UJUN38'1!0CCB?"T_19+44"M<.2E4*;%9)%@%V
M,"!%CGD>%D=(>PSUP4QG=4/JDA^> (IE7M)V060H=\$G2|EQ(@<^!|&77^_BV
MX\1/SX_ QU%M6(KBI(S0!A!7)/KE%C2:%IY|@Z|-4!VM=%@1X?7*U9%\9EIM+
M;AO8E2HN;6|.91H)/I6ZZ8'733-@O\$Z"#X|M'@\$*EW8.3BZHT0^ZTT9#X;4
MUUV>+CAA'W@LXVS*,YA3K^ (I9"GC70N*##\SOL;C>_. (H@|=E-M6IZ7PVIA
M8|JN3T|=M+&6B?!BU|H4QK_W\7F4^%N3\$D|NI8NT_=G*,%),-Z(F\$=#|UUB M>
EI8@/B,MPB,TI-|;4N06|T&,8K;AO-W^V4G.'6E^ .WKZ;:C;0=|X1RL("I
MK9"EI3E<4F7;44^O"D9C_U?E<)>T-Z|^6|^S.)"YGAFFJZ9N4#(/&+*40.84AQ M"WHOR?
@%%D!D(WM\#1X08X=%S1U M5-@S1-|1^C#5*P; M7SKN7MV)[H-7?J@)G3QR0.
IYZ=2+X86@*.0.OF&#02,_ ^ (A3.4 &;VPK"!Z&(7=5,D((EI9\$<-?>U3!T#/_*D/I4+UKF
M>F?#E(?|@N_DOTF.-N^&|Y#)2(9B;=|*K\$Q>.V3CFC9J\$, "6R"!S?(@N6(M@BUL\$7K-?
V&*GFJ'HHRQ '/LPY3PT\$|,;|D*,'|*F4GW5MM.TV|,,SD1TF3+ M'KC(|6FJQ|G&<;>T\$/X>|?
XC+HS2VV5GOMBC4YB'P='5J>6CZZA#&EN"' J M*I0H0XB925JP3|66(?
AH|NL|/?;6|3@NMJ;?7"<&:\$3>,+IWMKE3C\$(N^\$"< M@?E;3;,
.907*"EJ0<9FF);69C"I^LS42C\$ "LO\$>|?N7Y;R&,V@OFV%L_UU
MKOQRF6(BQA;:/I9PQW|6N9L%U)CM.=?2G#R;!'*[FS5;0|N9\BW4: ^ (I/XW
MSVPG-'%7X)5VLOJ;#;/7\ H#5BH.ANZ(%@#%4-'1.\$DO1L.*K" T+01D6-;:0>|M)N^?
K!DH6=7IBS%/?D"/_2HT\$(I9(57SL-ZGCD&P6I-|?BGLH#:TFCZ'1)?
M+U0(6|8|L;J779";M/-E1+N" _B;|H|B|OM56Z24A4?&@;G)^/3?
|5;)OW00&UYLJO!1ED&OSGPK M*C&|I6,,* =KA!R64@|!|6P"
<"/STXTI'_ ^ZS%,T&54(|C(4,KI7,K82(M^ MA>G"EY93;|:U7M_J/="ZY9.;,;FJM':-DA#
(AZX(3' ^H;#3;Z+>ZK6# M|JUV6|M&-6#/N0;E:HCYTDOQK644&Y|8PPD;6;J1QFS:2\$*I=
<=>5'P?*Y5Q M>W4H(4C9T^*7JP _>ET|3,X5"\$77AQ+ _; K|ANDB)!G)095>&N(->ZV6|UFO
MM.3&A2#I*^F,JMNC\7J-P0G,CBC\$H)4 VY^TO^L6Q8N997T9LQ_UB218J3|G|
<\$%Q+504"*V\$N408VMI>QQS<6AF M:I'G\$;AF-ZEJ1PL6M:;>?>=>TRU6_SGIM^>--
Y/UZ6*+@W%|V%B?6^_)S|O MW#|V)U|+VMV)W#5PY,WWP8;_ ^)4D|, >
|%,0)^U!OV@N8;HA403HL(=7"CV"U-EWP+ ^D M48JI-))J+K;IC?=C?2
"Y*Q;JW"2LTGSJB%FWK4G^ \!*|PCJIW|+>U9X \$V MI7=L\$^ ,/XB OT*
<)>4%Z,)"P>PIP2U,@:Q)=DXD8XC
C^7H5.8JKQ7>FB2AIEJ\$%X2\$UXQ5X&+. *VW'X)FOA%!54K\$!BR@.A! ?9:2A.5T
1++QUE@FZ7*_ O/T/K8UX MI(|;)GINA5B|_."V82K_-A|,VA?K8/V@J|'LF /&;HQ71:-";,
|!4#&47SVN M-.GM,5E8E)E*2D8G=[5H?3|TGQS34_8\$SH7@*J+F=D,Y49XL0(2Z^?G=
MEE_Q!%*U'|MNE:Q_NYDZKO&7X1TS05TW.GZ-!ZZJA%1JDBHY5Y<;A|B,+4SRS3)L)#
|H:AP\$:%!Q:VSN1U"& !G.NCQ@KT M6R3|6%W_Q!;>-Y-/3*J"BU6)
|9OG5+UBUU4':D=*HN!_8ZZ6T M4V)\$1=(Z ULV?I#++#.Z"NP;:8063_*1D|_-6L.6.3-
VC=AT90%R>|Z7|.&0 MY\$>W|.CB\$ (->E|;+WAJG7;G9AI>XN3< UKW#'+=VS_A=
(R#24,HN;BZVZ^& M*X6|K|TV|K4;3NU+GG1)?TX%N
_=)LP7@A0VYQ|B5W=MJ|%3#00Z78/9UP M2 VM>V=K8A%I#88+
(*HKZZ.GLIT9!T\$#JM0|&B MMB^AGT!DVE2_KM50|6"U|J2XWJF&48<3<\$V@'ZA5Q*
MY(BQ%G, (#VJC|DK-WM\$PNZGKU6E.Y):JMS(D,F/VAE_6_B_7U>5Y=>YYWIZ M:)|
+Q^3WJN#>278_3N,|570*I30SJ_!;ZS|KH51;@(6! ("1@VDB3)WAAG M*M+/U9-
B"U*S"90|U!!*>/&XQ,2!(ZEWA7ME^HQ#M3K>'T"5^K/SLQ#EVRJZ
MZ+_!XT'S"EOK,>2L)743=^ -|%E1M_7SR;_RPZG2-VCH|*|:|/I NYT%\$ K: M#!@OF&+

(X3W_.*A760S-^G=(0[HQ7';E^%I#C;5"WIN*49N U|-%6=^XL/EJ MKG)"ZH+'\$|C%9E#|-M4D".1OZ.'/\$Y|B;&!)OE+0+"6+BZ<0V_P M.;!(O%SA#39;%?A=W;|@U0/^UH%E /:8? Q4NTIG|@-1)V2L&VF6&||\$1L6 M=\$9|H>*F44^/P|T8LH3GS^+? _&K|SP*PUGVS)A#DR'6Z(69509/\$2\$LT@CYL MT)/)?FY09|^|Z_:\$3##U3& (Z2J;1A\$OLRG_8(#E04M 4/1T:BZ(8./_9&/8J_M|9^?4JL@E=(3E-:U|!M|C> TJL,;%.&:=!7X' W?2_&?80Y1(KX< MQ4V\$9VS.+6_0EF1K|X|A_^A_+|0:2)>VY5" |/:AKZIAK7_7NX<%J,;%K.5IX MS|8@IVL;X=06#\$\$=*6;E=|(S=7*7QQ5#H'_TO_HKA=) |!(0SR/^3_="E3B09'_M_F^ S2Q-0OUK7^!;6;SXE#TA|^G5;O^>%0 MZ&)|K>OZ|30&4TG>|/F)Y*:'PCEIY_><9|H(<|BP0U*,:(#GL,VW)J_2BQ MV=D(B7^4|C&=9KG4G2LF^SY5E#B8SJJ57K8#>W2#|?;=^#^+&AOK|NG'QEDT5)DG@ <\$GZ^!6.#FH/A|RI|_K MQ7UNK2L8>M.A4LM/)=4QR7-NP7=\$YX6JX/%TV+G\$S\$0 X'BQ/OEO\$A^("E5203 H+EK=@NJR@1_5*W;%F6W|?XAVJR%8|2YM M\$80Z XVP)4NV;YLKE!:000;6+U0ZR#-?E&VDP%0%;,FE_0A|!SY!R-:B)E| M'MB!L7E+MBF1CB9AUBZ|7J19U|_|K_Z>:U|5_!E#2,Z8U_ E|U|_# M_D9XC;C^? 9+8YR#!P:O'; S0(*B|+*#3G&X#2O=0IHAVW3|6AKOR*9M\$B,=6 M"Y|ZZ|G%9XB5-HI. <7W#ZQ%.X MK<34?;,-=E'1?K|LP_FK|S MHVS28,EP>6KFX\$AUVN^|CWR|_4(=BF(M 4X_M|<@47=3EXEAQS"XE_0LQ4|DL.ON0|_*TTL-J*|6ID?9T41UF*C@J1^8|6\$#Z M.FSC^10S^@<+B+*A@XE8|X_%_&8(T7E1>;|TQ;>&Z,9OF;R@++349 \$Y?J"4 M|_M"=: |A"GHG0>XW^|K4'J<)>42B-0FVRS@@RK3E%&4RP*&5E_\$&_K0FS), M#NJ? BMB0FQ!,069!11ELX|^?0<6L'P:6A,(W^-,|FTMX1_%&.BSK\$=OCW MR(OF"-D\$*C 8MQ1(Y|8P+=GH)+>DH>0|C#40QX,.0S3H6F(!2B-,++_!LV M8@\$D7E0ZRO,;6 |V(%014\$2OW=AAOY;W"LL(&X"U:X#7?F&VAJ81/T63/N_ M=<0CFJ4V"T /@R'E_D:~? |WI<;9H(VFUL/NS@YVI:YQ)U7|.BFB|\$_A034.L4 M?|_>^>LTAP|/_M+;|(O^Y|? @TN>FO5S_Y3XK0|JZF/1MLW==/<0\$1HW62\$F|_! M?/ZV^9H|N+XD6#NA*JA|YNY3^HCN>7"|\$J97C#7,N9WF2VOF.|U?Y|A@|C M517! L8SL,U^?N=M,@J/%_YQ#TP|I4@(\$P=CQGC?_=OCX!|AB7N1^F.-.*RB MM9A;UOV^_8?:C- =UB1ZT(9FLM*N'TY)1RS=/_OBKO+";PD|8K|';(FQZ?XO MRB,T/Z+|_G^?A"J@OAO@ 2M=F)L8548S;GF8'LX";H/)5"0298AYC-|Z3|=A M_7<9N\$P7AWSO%&\$(Z!1TCCWH6AG M=NKL(H/'7|Q5C;05S|?FN^KHY!_T_D\$?OT3|2;AM@V'WR>3+(1N+M'Y;!H(M!VHTS8C:3'DYZKNA15?<^_OIR0"B6:=?7!KPO%RD!M,DD9,X22-UHT#2 M&.4!.15;U)03=_7=L'N8!|>IK6=^JMI64;DR?<%VJ_63M/%R;AU1LJ VW|3B MXXM;O.V&?7=6GDL8|!L.A">9@DW9G*M8@1|H(=|&64O/'<*MY/W+4M|AEW M^7*#%|Z7|;2UOBPG\$J8HY;H33NYS) MO8|O-A'|#KE" _&7=3E(A2M&<\$5=DQDN- K3|JNS)A'BL;(B57A;|GUC3#=9LT MKYB+O|ECF(1!F*8@|QMX/?\$?>R@(|XN"VLSO _LX*5=-PJ*KOGG6B5%@6|9_MSH-7/(5_GNOVF4;U;8*|P?D*2L?OH=3_AV-V)W)I:~? NXGY|D|S6K?Y;#93Z M|POS>A08V_!2%F"J6WWCG_ PMTNDV!&_T&<=^YAOX% |&^"PKO_T7TG M^TSF"'+\$PG6@W=*8*%<.,8ZV|!"41|? 4K>9'T"E;*\$A,)Y<PW_'CX(L&FU+\$O?N5_M'1F-|U?HX|B'&QBSJ;+D_M" (H:-9QLV*UPAKR;LC-1/5X1+_=V\$/&Y^J9|;+>WYK|&F?(EWM0U3?ZXGV0 M7:A^0OB!Q5R6KD|>C\$>L|4IG,RUF%JZA/R<0GE|EE.|6#.VAO+V-|R/&4>_M :U7J;IPR;WOMV:-969DD#Y&QF02FL8+F(ESOW;*9N|6K7?K19|_MR1>#<'JM0? X,_DZEX3DPC0|WM).6O_&3T5#|0_>30 MP8+6N=|WUV\$D@1=_4:8(.3#8=3@7/6#*_ M"\$;P%P_;Y_66S(70#_-+H;(T0K,M\$0^N(PP=>AWR) (|2TN1=^H81_?;7U5D(^J|VEL_#_8>^XIK9U M73B(B_B(=) 2D2I5J4J+!#1!0\$%1 \$;+T(D3I)20(TDL\$!|24* A(C72EA8YT M*8* E 0I H\$) 12N"O4|;2==? >W_V^>|XZYSM_3/U%YQASS%'>|WG>|8QW M!MHDU'EVF'G%R5YD\$(H|12<#;EK!FG192)1B5_E M;T?W_/K'_RSOG_3? Q\$E07|S3C.R.OP<,L*/LH<*Z6;L8AGLS8<<^ P72%K M\$MBD<7C5%W%\$Z=&:8V/% <(|O32VI)4^4O5V MZ:1)9FIVB8M:MFF(SDI@HM5S\$6V|_T;0|F4D\$U*P9"D9>|? YIX8/Z=,;W5ICH#Z\$5A0IF@-PX3@S1<;CW^; MT&85JF82+&F'_M^ GB-H.>?- ;T!1AU*>;C5TA%3>R\$;3"->\$9NI,?>XG2OMK.HQ9M;Q@M/(LY MPWE09CLU05I&'_B;E'"^KN|&+4%G|'@LAT59_L?#_,=|&(:%Z3/4,KBC4J2M M*C@*? 3N@CZP-(%Y+|XM*"K:8RZ#3V=_K/7V31Q:L'3%AF_0"57"3"+X|+; MU#5A* <|W/!6WM%8J8Z<%0KN2OMKQ6@JO2?-N.E-XA#" +JTB|_U&+E%FR@F:F MJ- =,*X;M>'")5N^\$2Y\$+(0R)90V26Q@&D+#;O)RR+|G>R-B'NA?TNO'EP4G0J>R3LX? 05WX6JY"+!+OO#CSI\$U MH2\$=-<.ZK-|!^+&8M6+ND/D|1%&|:IG4@_KL%Y;J':L> T'Y!"\$BFIJF>X14 MILU"N\$";P,/"B|H?|>DS!8>=R)|:OAQK?8KQ>1C|0+TX<18/?D3C@ W/5#AW M@*-TC|X=K')ME#+&(^KUET,Q|WR_7XX@>TA8#JF,I59S)CK5,8JO?|1^V!|=

M0"8X?7[101TG-2?V7K(EZI)6'="8PHW0HQQPC>N>&5.^V4FGZ7^41"JOM
M4(Y7."4%=-9+J%7%G"R6N9MB&?OLR>)LD>:GCX4=%"QSH!T(!=ZFQ;60^K M-
6UK.+S8/N'XM'8\$JG8@7AV\KS?D?6#6D_L+@V(YQ30Q,Z4"!0^LTZ2
MXG@XA05,>0"&#IKGI8%V+[*VE\;GRB;--?I3NZV(M?IU%=[F4I*!24:Sf0\$^H^G=
ME,U5>^CWQX:I=#@|#:T02X<@=!?IKI92%7M3+,DI4M\GRTOG^G2TCDIH.H>67;;7-
AS)M[SNF'R0A'Z(QW6C\="N.HI27PFA749\|.TYU;/D4%GPJ42@RJOE:PH)J3\PMX-
W+IUSJ:N\SK2O?P\I*O=A)\I=ID@)VZ1\$7P\W79=.3SJ\6UBH'X_.E3@#3=.?
7AMV<78V\$DF4[%GB0U'')@G_X0>T1_MM\3&Q>X/RT/B\H3Z2"E<;107)/A&G<|.)>
MAP\N;.31;;PL_?OTUG?!"IC8Q"JHP0XW1&'ILC.S)A,9RAH\XR_&K!@"E#MW\3HR;
_67D%;9+?HVHY,H.?!Y-(*E"EC3;6W00(66V\SA\@^X.GM'!7Q5\ M?
CX'ON'H2BU)A7^"|.+3F>LSX/AX%&4'2=M'-U4\3K&[F33A(KH\H\!/*'+<|M0\$^//MT,=X-
^ZL,&5#.T'V.M,QWJ?MH#I'A31XO,9 M*PC-2Z"F)(?":=GR/Q!!Z-^H^T*H(H*CIU-
\$(6);G+)5;/PG?UT M2PJN@"="*+N='@'UP"1HF"2S3IG:5_4F,BE5=-*,N_8 M;6-86=J
_V.:CEQ;2VA5HZ;QJ<4#E^B.XKD#3A!%=|2CH=0#X V;\$UI4@AI
MRQWP%J\$AI('H!427P:EM_(<@I*>0C#L5E5!"ACK624J0F!+^Q!-,JXX=T9@,F/H?
U=Z,KL,A+&C M:=#"@3M*TGL;H.?GTM4@Z=2FW\$GMO6G>.D&DY6_&?W\1R\G0!
IXZ>B9444 MU\J=1M>J+Q6;_KYS!W\J9_ GH??#S8*&S1L_MJU_Y4<)4^K>7(X?0QB?
HM M8N#MND6;;4DY:V8AY@>Z;H7C?B*EN!.2GC_|\#^IH+_[&JH0:L"U)'|+=M;
.G3;0'ILKGSGL,W\|-'YW:985YI)P.J#Z #?8 *#HT>)GQN?CG?WA\ M\N?
FT8'\$.>CCW&&"U5UW>8F^GHQ7+G4/X<<(<="/;|RL"C#GQ(^NP1Y!\$5';
TAP8,#41\TKI%,SL^Q<|L5\1-|@..7@GHVG9N=T10*MZ=F41-?I)^\^
<"R4;^WZ2"/XE/:0N%T\$|@AP4@""VC\|T*9;4< C4^W6 MR:X_%&M7DW;"[ZAULO19\
XJ=B;<<^LA%W^OF\|F1F\|BV'T*|("0E\$B>&M\|?,="JO0X7#6\|
|=#0R#3KRF<1M11"l:k%IY^|BJ7;;V?WFK:6L/HM&_T M&?%E31G&>2\,TZ%;<;1!
I6#B9D\$J&9&&18(^RRLKY3@L">^|66E71T_HW M^Q2*E-09)"K6\5@7?
I'H'8(VW*5HU:H=@H3\&G1J*T
V=G\KLI2\SS#>^U\$;XM!9&,|XY<;>V<3\$|5!08#@1\$X=#X\5;-/0!. M"|_:#F*GL,TN
7W*1E_K/<7?%^1XIK@S&^A4)EV_D&8H)>!-U*"OF\G,X_.M1-+>BDJ2LK,(TUB'1?#*@<
-9E8'0/L\4V;%S?4>%+EK2H;@V\57@C6J^FV M?_Z<'8=_#O(#53"3=|2=3<'D?
D"J0NG+C*[K&GY(!1(!6#|*_VUUE\OTY MTN"!_A_.+7R/!/*-^>|%L\,OMS#&#>KS?
F1/_N:TM6TFR!^P+G\UD-Q\!E MWVXKAKS\R??|&B\|+3Z%"9D7/?TZQ/Q_E?
A&ND"7\JK.3=FDYZ//GDS@C*| MEE;+?1&.!L'EOZ&OMAPGVOE!\JH&\$D,"
MDVUI/UPD3V #<2HNUNM9 MWDK19KA5GE,OYJSP.OA6\W M2R>KD:FE%
(36J7B1TS4^P\FCB'%8R\PR\')M-',WC3/<="\$/I%J/X4/JI) M4\T!WT.V3^P/>0,F9G.
MWP3@=Y0^P\IM\$.8;OX;10\$|0W'0>|'S=!*|/,PV5#\ZYE/?VZ#?(X)?Y_A_M_@!XBIY-98-
M'"&4S"6T11_|MEOC:9M<"IS.9"&|SCBR57.U?%SJ6-B\WQ MO>N\J;47 K2;1ZI'?
\$H\|+@M-7EA%*B9,E_0\$6G?Y5I=V<.7(&Y3?%WN\G99I M\0C7&"Z; Y;SMZ
CX=4&%)XX8@8A"L<|ZZ'1'H>YXNC#SM=J6VG\5.&=5S1 MG2ZAL,)F^3&V^?
|CH6UC?)3N*^U\ '8UVG\8\$/@BLX.\$+.;K0*>HW5&6#V'
M.1*G/9\ WCIOZK\$>EWA!TK/BX\=UFFUBF"/K%\$NX#6(|18D GM;L;BG%T5D!
I.+K4_.1CQ%/ M910^W:H7\$?0:L4C.>_F^Q%D(3%\$?L|\$XF6MD5+@07A^X\Z+&%\$(
UR1M2B&P M'.MB^#?OF1VK/:5=^J_.ML\$I-T0GTC>5ZG5>F/2V M95?O_3 V3VTI#W
SBEZ_5Z#G\H21\|/#0C"KRWY.DKPU>X!#*QW@|QTPD?* M/:1"T\$|EJW,I/>L
*X,KDUO&1U5XC.0B=-RP> MO<1!'WG./0#A.KREEI.9=@#;-B!;+((#^.=|&G1_GPG.S-
K^_.|*N>GDL%N MX-Y&/-%72X4K=O*GG@+^5/1001SU_|23BZU7L>79GH7?3LA
MZWHKMST>XNU47CI^T3RI\N1**Y/X_=F%6A^|:=-/?Z9X">A!&ZO8
M@*XK\5"QU0_J0#Y(C\N\0*NTW)M55)<@'N\KR4X@^HI4RJ;"?H"-GB%#@Q^
M^GW@U<|8&_('X@=>TS\T-X",?UU\$/<"?%!&/UL:U&C -=K%QUOI"P-A_"O
MCDIZ.|+P7^'4#N;?B:*@2C\IX@08@Z E(_*[X%_XB\|J=|P3P%S\1Z">|_><
MP\|+D%|!U5F2L!;(C":.#NS)8SQ\@HJ0\|P!%BFX*+3%(O\J^OMYRW_\$/&G
M#_CB^@ML@8MPIH7\;MXS_;;N_JGE^*_)=+^/Y&EX=5CJ1>HAMWH+#+@4OL,I
M"QHM;MVYNPVB7;)N_"K=^L/RH)'G13N+VW1/G,2Q57229A4R0)<("CZGU&D
M4=BS\$502LK1 *H'^\P+5K1>4\J33*^(F5\;^ZN8#,WHDO-OK:<|AEL5/-1
M7^B64GR\YPI%<#^U"=4T(,;|/="|+2)G@+2+_|VM#_8TOZ@F3X-|SPGN.>J
M:EK6'P&/TNG%UI37^+#+QCX."\$/.:S=Z37=HY4.*'N.@YOYVGSIX'#_%4(/@A
M&J\WC%\$MH2X^F3,6,7#2V:"XB3:YT_7DP>|+DQ(K\-,|N&Q+4/&NM7)+ M=|GU%'-
W8Z)I4VOD"4B=- M+VYF=|9MX<4>X!@)M!;!Q
|R_V7/6A\|T:/5N'O@9X,8^W/XK/W*|O4#M M5ZD?L(GN0 ^FT\!.-=59/=[#>*OM^|X9\!*

f0(HJ^1R28;X."RP8P\@/[5 M)3ECV*_=('%(Z9UTO>53H\3FV%)97!9V7M'+:I9A):'AZ+L*
f->G@CW& ;P/ M)DOK(Z*%/[!\$*\$*)<)\4D:D=IW@!S5
JLN62^>N4\$@9[Z>7+!\$@9/;_O9%7X M5%ZXL\$7#;>H7=54Z6J-GX\$3,P>;A>2UY\4O:#
CHF4P4!HV 2J73J"/\$B@Q M TEWHEQPEV4^BP&!
(6W#!Z^,'0^41@L30/FPQ)!%LCD4O>W.>B\$KB+Z+FCP^ MV;1.D%HDWB7T!DGX=6"-=
f0U\K^ZRRAEGNM_KU.K+-[H;N;?MV!Z B9440O\3 MDOHD*G\$5Q-!RB'Y:B_5835-
f41!Z7T+W\Y4A)Q;%3 MJ((JP.QC>!4:YT_P;OO!/%R1\$^@Y\$?IZ9?51XO@
4=RRLH_L9S\K*(Q>6HY^ M=?&^ *M4T&+OV3"CL71KE8Z/W9B8|
ACA5N0:7\#KJ)%\$ETSWH&P4[-S Z!4Y,,?+E]*P-FE9 M7AT[Z=Y8K1+H^-;ML#
fS2M&M+MN)+;A"t:X#R9(I(V@A;4U:4HD SQC.^S8 M4-(XJ+)RBN_F,3JP?
8&4>MUAC*%XPWW-T;CB-(A5'7XIVJ290U+'4Q.-XYYPYP_XC[D1G8A^)^A=#3-L-
f.4'6IO6!;@8B8.S?-*4C M2XKK^?&;IH3;Q*-IN;)R3H;V-
;)KCV2SP^N!"f5C9TWC(F)>/YV<"1(5-MZ M%I&H4C^M6#[FR1'f0f5QY5-OO(-
fPB)36V;;P^C\4?L?/K=X9N*V*37YP-+2 MS'+!B.I93+/6.=CK-?_04&*Z&F(.HY 9;U<^P*?
C45OI(BD=MT[SVLM@7; ML9R%4#.@M.;. ^&:'&C7J1\$U(TO*4J<[HF)0\$ _H
?;:"WI#*9TT,W^\$OD#G M!O)^2PE/_/);:EJN9\]^_UK@OR1HENNKJR;;T;K! M;/4NZ;.-
QVB#;./;J M9C\D-; '\$L;T#.IHB:FB#G M9DA"UE&"SJOT\1A=-M2WMD"Y)-^J"L#
M^JCA(=\$W7?;PLX(5O)ZJ=>.W)&.G8\Z/P8"/S#F#-W6/\$J8?UHMA3D!#L ." MKK>
<(IAJ!f0KWKAQM KHDJ:N_3_U\!%I2^'/AV 7:\$=@PNJ*SDYS9 PQ#X5J
M8(,3=/OM)UTF*KV-#SDSC/L'31LNN+Q4 4^?=UAG\ES0&-^R@RU% 8)VFE
M;7"!MGC>*FG!\M'O=DKZW\T#*M;K/*J9AWC\$?(XG32A?BQ*M@06!@f
MFX(4IK&0(\$1G0 %NO! *(@5B/ESG8 OPQZP5\IL"5J^?3%@PJITXP+S:OB*N4
M.4U8;I3';HKJ156><;MRND8N7\1A.Z7^%MI=TC,JJ&_%%OHQ5MS0=U AN<)&D
MBHSTHG6 *!&K\$Q*/W\@NZB8F;XJE1)CG/?GD&E">P^AC7BQQP,\VH..I@W MG9V3
9PZ,NGOH(1C)5^'J8(K:E:OY,#:P.4<f>XST1KY':<"HMI\$3[X??%U>
ME7@HJV,RZ9QTfEF3"N8_EH0EIDF\U!;K W58f'2*K;LLJ>%@P(
M&HY[%4U.);P\ M1NUTGS/_W4WHF9K2V-09I8BP(W?)A_-O"55.J/Q+0A45 ML.5ZZH\C?
C\RJDC!_YY1)<fHf;J!"IN#f!QMI;#N 8R2MGZ O.,f\ 2:&=U> M-&KO_C96R"C:0S;
(GMG=B-O)^%S\6\3Z2S3NU.\3?RC,Q0J4#KL/_Z^3KVO MYFU"7R\0X%8_'\$A\^HX\7f
(W^50V2,\S,D&8W6@7'0\,"J/T"#>@S&0?* MU-
LP;4Q(:*J!A>1(LF\&X)"KLF&?:TQ#/O+9;E.Q>V\CW?KIJ@*=8Z\NU&G?
f1:SC>JZ\PA/PFCL-V\$Q06-;X;+Q\J87?G8/+PRXX23@L*70M\PTV 98;;N M K 1-
0_&1QN"5T8UST3!A>O5\%X/?0UE,YT;,X9QDW3(IK ^I"!F.36JO\IC_0,&*D,(3C MXJAR'?
NHJ;JGS%(:NBZ<(3\H0fW"FIU/0M9 LI+Q\IS2%#W"=@N\$[<38\Y7.
MAK0K4GOUGL;.'SD^O-&='IAA8?-(.\$^#_977F:K_V+W\4)T+1'>2!@0_26-!MSYH>H(f
614I-KX8T\ M!;8:8/*197\c994^IMI;L\^<8FS\$6<(C+Q\.'7L;
M/4Z8:870*0f^!O(P::P9S@'1Y;^" 3+,6-LL92D-@LHX;RJS6"%?H\8)4XJ M@H-
%QDWXW;Z&G'A#N4,ME21)VO-8+U(?^T>TOY4C:(&C)A")J_5S=_:'fX=M M*(PNF\$1?
V^fU8&KV\0-;@P?X1>(+*@KNCHA "S9*P?K\#4M>X!#SNC&FU40 MSENVR\?:^fJ;!
<+4*ITXS^?RE/GM/#R-.PL\$ _W7"%!'=,/X;FB3#03VB1*FM M1-&,+H54Z 7N =,JV8=
.+R*!%M*G MTf\H=%P516=US6?
A2P_A\Y\RX1LW@#f5B9HX2F>FMU0XYA\$ _P@'f]@'6>'B? M4@,\B41?^(AH+0,<1#<1A.
_..YU>&O>#R4#Z/M9\;R\$'T'%NWBDD-UZ06E@7Z\$
M,*I8#H&5&WP#_>OB3H9FL\NGIU)"68"EZ-\K=U"*V?7"0_6;f\Z76.NG5DZ;
M04K(61U@_3,>_9H!74K2^G&?CH&?Z(GJJ^-W83E&M?1&@W\1PO\#YD40O?
M"YW&TLT,1@K\X6,?*=NNE?^CBG7_5N^YK<(72GW6)1?N6":V1MY>37DM?/^
M\&;!9793^~1A\19_ZU=WT,Q'A?N%?N/PN\7>7Y>?TY_&.2Y
M3ODC)_N2Y>@fA1\$FD/E6#?%XA.GPL_5MZ
M_Q/J\$?f7P=\$;FJR.RLS7J\2+OY>R3!R:N(>#+:YTQD,ALS-164??\$f(1
M\99Y2f5ZR9"ZD2WKD9J;."_06P9B^H;.*5UJO91CU'RX,Q*Q;9D&9(IDX+;
MQHX&,3=4#ZFHEE=?<fLP'S?/."7FB;,@_Q%DHQ-&Z"-X*7FC6KPACX\! MY^"GV^_
_L:8L)\$T5?XUHXYVDB M;RBF)\$D*U'C'4F:D#V)F=+95GU6?PJ2\V6:X<
2X&0A%J8@HLEW?P%;;NAI M\&K/G;D;4f6HH1^fDZWJ-BJ,E'fE5H)C>?
8f"TI7)\9;_<#KCE-Q+18A-U7DD\^WCTV3I1\;1 +JYG9T#9Z JE)D@HJ"i_ MU1B?
B8W"&>.'+Q'4<_("N 1 554?C=OWGRUP"FD-\$V>SVNY:<fHM:QG5G'MF MTVOS=-/O=+fJ)
fN4!=D1)C.>I^8:4J6^E!3LY7W1%:9_0%U21NDN\CSEZ(_M<0FTBNR
M,T4=SUL35<^>8VO\\$_@H:OO?*:N5>J\$OS!O\p6K\H?1"/60M'O9D\;#=R-Q' M;
<&GU5=3UP<;//+M44RV><<1VD.WZJP+UX(0K:@=fGM_2\6fS99;fH%WI: MWP-

FE(%/M6 Y:Q)Y50.'Z 1CGI S : 'LMJ7LV%W&SC JS/F M4CF8>.=<4QT91"JF-
6AQ*v>X*.M)?6&I=IX 41|^\$E,:):E4W^=%052 :8+N MCV-RD71G8%"B?
8/,2\$HG^I'@KJP:N4*9J0RU2<\$, M/89%:=* 6:NZMP\$?, \$J*%^?KK9?65R9V_DDV:
M9/3.HU-Z^QG%Y#9>O/^BDTGL(\$D2>HG|^*8!=&N/^#S0K+)2^SQ#+3V2|HAK
M<26B|*IZU|NJYA*N/4N12HS2&LPE45(A)S1DWYJFB^C;,>!E>2N5D'R7|0
M+.RAZ*K^M21\$,3TU%T\$DVI3|6E|48'L63/S'P6WRYL, 3UGM M(
SJPC^(J|HIM_PLN9GYH|UA6>3 |L.H #VN|KM<&3^M^E|NU|N;.:5'GFE M,NZ:.7C|E:
|7X7/-PE6 J%/6H+^KM6*E*EAI9<\$|Q +I%^C Y|*9H 2>\$#^4
M(Q7:NEQ)KNA!_ZDXJ6C\$)>?O=0-OY\$|EV?P#&8QMCA|0IF@<#CZY6Z*[NK'^
M#P1*6T=E=G&V/;L|49|_L4ZZ=\$)4=:N ?;G1'=.LMR6N/=K5LAX,S?RHANK&L^A_4
M24K-0;YK*9A.#1#5J)X,'?+P=,J9<+AB8|L6/5ZOARYZL7D.7B6UT='M*=U M0B'K8?
X|/J)ZV6232/GYXQ&WLQ8!-PI_Q22'=OTRW7//CA(?AE7&+SX8D/CZ
MZ0^0RS|Y%^%;=9F;LENT4% :R43O#F83V?9?F1U3P/=)JRI!M8OL"ST"!F?F M&/-Y|?
I@*Q|-"YGN(=K|W)\$*E*DMP_Z3UG| 3X10Y>%FUGMJ.NB1P^;K.#U|NQZ\$?
%-9U)U2H'QIP/&&'MHA) 31X-TGJ3K3G#TZK+<4X(GG3L!SHWM#_\$:
TKW_XY,G>4XDRC,LR M3I%8GGFR)"8^;-@Z*O|FW| #AS4!'2(K#Q (2:-8T#E3I'PT3"A E
MMV;)95ZO_PAU5HQ.'N#_3.M'3_)M8&.+?(#|C.R+2\$GT Y#0P'MR)%J&Q
M4:|CC=)+\$TY1P<7JKTH#=#JJ^;BHH.*1|B+7I=X/\$KTZ M3K!00|X-IWW1F*E<;
|M.000.^A\$;2G/^!84R'EE| M0QW=6U,C,+6
12*.E((WF!5!)6ZA6)9L94CGT4<;Q9""W#@<_8.*S:>U9-:. MK,=RWG>8J9P?8Q0'?
&2>+/UV5%#B3F&.-LLPXWO'N|Z!+|T ^|QU%L3M.Z% MD|2Q-. B,B/TM*7Y!8|H|O-
*87PT&6HJ?/:E%ZW+ #|A9;X B,7> #|^TV8J4 M\$TPJ%_%DKRO_K*CJC;\$=QJ.LU>UDA^
LT#EH(=03K+|/)% 8 M|A%9S?PC0>I'7.ERV0 F0:X#-.Y-TC?5O/3(0EW^W48OJX#?
(E<3:.8V&:L;Z|EIT#XT|/#Q,A1U3:"= =8V 4F M.EP|?
49;99;J6 _D.DFMW2F*C97|YT|5|'0(RVK-C"?|F5>T+!%8C4@1A9E;Q M%4'#FA 53A,)Z&?
7;JY=C(8D3'UQS\$XMO3?AMV JEB;9;=<9>I'"8>L3|TX%
M&>""KG#N1(9/'QOIE(\$WZ|&.H=I*;K NVPH"A9W#+-
_Q<^V|ARP^20ET8ERU|\$MB23|XP2|.|#RC<5;_*"8@S#K^-IY5XP!V|
M!8+=>|Z,6N6"U^4*Q*+>J6VD-/|>6#=:S5,W""H|H:?\$Q"N.<4A0\$JW1X
M/'#_9OI5I/Z(PAKTV7WWI1#6?7 ME3"5CO*H:|"-*D!->KQD'+R9U_Q=?"A4-^M?
|6ZQ\$"@FZP":E!2"CQT &VH; MY'WCVITE9HB%?)RX(I'4+A92I^L<=:Y2?3U=
G!&X(KFD/\$HMGACARBLW9 MA/ OI"(C-?-;ZR|Y_-
W3_PS4+YH%^"Q@>>,:S!W7DFN!VR%!XQ79|H+86
M^2I4D%K3*!;0WL'NGC|P)Q0#|5+,-+N^,|U"Z|:3O2Z6=>,2/E)GY|*7T) 7 M>M XK
WW|1_A14|\$-)R1<_|Q!=G2_99JPR-YRZ=A!W7@)"|/|58UG-<.J*!6A@0 ^KP#'|@ (U5M
MPSY7N+K6MHQWQ/V/G ^7G|S*!|D.,|UKK89'X;0*25IS_KA)+&@<3"=P!%0 M\$#-
_M! "9ERRN+5-U(N*=4P'N;O'A0%>))\5M|KYUN^KHO=CCO+8S"N|*(6Q3M0?(I*:.B=B;
MQ6Y;#+|, @70)XT0E)ACO^;/UU'OYQ>|S\$0%;D\$=@;7N *NN*OC M?
KCT(;E!V@G*17S^JND>8#^.@.R / 3S5X%%FIWMMFV!!EHJ(7OT+:E7T=(DP^3CUO^
M|=;,\$2HQ2K!|XY|MC%F(4<8Z5?J|1Z_R*:[@%]|X|XJ%<%@%)@R M?QB1SWX?
|F^3?:P!LBD64/>W(>3=0%)X-K&=L321-70%J_|>@,=WA@&J10#% MY9:38N;@|
UW:HOL&(<,:|=:/U58_WFY%7J(*|B'I" M8Y1>723\$M<-.AQ,?_3@:1U|LU54"|6J?L|"?
("HN46^R7-7\$K|)LPAQ6, _M?T/D+. 0@|J:W6A#K:1)'D"9R#U"^N#J'129<(9M|^R-
^CO& T?&M M3^(RG00>KWHDH_54T,:+68M1=(1AFXD7'X4#O22MS/*O6L.U*JD*;
(!":67 MM8@U27\$D #M.DEJ"C0>D@K5VUG*2MV%SPI|G"^STQ2XD'M!\$Y5(>0SKK6)
M!7.H4%!59ZRNE(%D|H1M:Q%- "1H>D!16..)5;2#UGV!4+^OAU E>"#94&>P M7|Y?
C+;R1^Z/A<:B'*GC|H|U(GZ%:-
W,YBT0X|@0G>@R*7MH^QY&'4'J#9C"9'N4S2(;M,!J1@%F|^=?;U MKW<=<=8R*K\$?
+G@RL"1*-D8|71(GM6+N725IPN#,:2>M\$5T@WP0^L|'P M|2
G^\$1^AZWLX%941@AL: +%3KMAUM_U+F6QF0>L)QUH&9Y(BQ:FNP|&Y' M!|)
%|ZR(?4U184/07"%NY10!F8%G88+JM//4UW3>|8";*AF,5T9@!9I<| (M-&+H*SNT|)?
@.E>(PQAGTO&+AQWNO/9DWO_UA'!ZE*YD0";Q(#47)@T|5\$M8 MC-
8VFW4'AOF#..OE7+\$O;*U7\$|2-#25BL>V*DE+Z"=WA|HP39V2<8"0,CTH M:QZM#|U+
<22S@'#-!;!A)*<|J0\$^FTZH2LQQQA9@ATLV/2%WAX>.:@,>L GU9W
M7"WHL@N"5E7!">A.>(TS00< =|58:\$"HV?CCP\$PNB28FD|Z&"YND|I"G/E
MB3X|V"B<%T6VYQ4|4!:(?%|HC/5M7\$@APY2#+J\$|J|Z)I\$F/U#'.0J'+W M7::H6-
+|7Y;O'OH3AAT"V8DV",)?1DVT8OPJ>)%12ENF
M<9U&2=KB^=J@AT84ZLT|BF0Y/00='M|>G^YYX0P",*?MG\$QQM\$@^S

MPI20VF0;^4QI-OZ:P|>R/C1AD=4JR+VOY|V9>UHJ@ZAT^:LMH6,TF4E&;<"M!;5-
"=T=V-TK|NU!MB_REUFTNS|>8\$/LN.4N7H|Y?Y|>5|ROT!SOS0.3:-T M@HV #ZPU"O1@
U5%|+7(5XQ;:>K|LS88D>|T4D^HG*-'MN\$M_BRK^50C>OU-=E)F:5V^8XQKT;,)RTJ>
HO>J2|*N94/5L^R+0;,)G6A/MQ/U|/*>;#S3>)0GBTR|17VO;D,U(*41;?-W2#"OL
(G=1XFMM|;;RLI=<|+M|8R2QRO?J^*6(27'K@H^SS)YL#TX/-

3>&U 7!;|*6-&PAUN MP|VJBZN1=|!3|C/6>*X!5^WI5O'2GL<"#P>?0\$!|?B74!JZ1QETC
M*IKHORY1D5U;R94#-SK_)O*N')B% ME.D4;>5=!)8C5A?>Z7Y&+J5I.*"D_ERQ6|
+L08+X>QR)#|H|A5ZGW'3^11S MR'.>LW69K\$*(#5VCY|4%!5O!GG(GJ-
J5+O;XI;2A5/R,+DI\$^M4ST # H;1U>:4KCEB&|)-
L7MSI@>ZC4L8>BUZ<%ON^"P*E8(C|5;|R-K_9O'
M+!DD)Q_WVS>='A#|UBCGBN35YL1R?\$/O! \$|7Z>#A|765Y5XOMPV\$D%7;K\$K
MW#TG?OCH><);A2RK4X)|V,PG:(V%H.<"E25QK=;&C4J M.A8R@-
&%5*G976RL2F|:|TSB8;QHQ6FNC=&99YPUGMZ 1CHT/@N.&\$A!;R M2)=MAB)+387)
KE;9W""OR!MP|WY4X9PZ**"SFH=UB++5<#G-K*V|2/Y;|Z MD5=:6>YJET3+2 &N|7?M6?
J37|H|V**\$7.FK#ZCKJ;#ENK.JTBL5!A6TN=|I,'M,)V# MJ@P;P&:T(E,;*7|Y<=
|@%8#"C#+QA2SW3H3.;1TDI3K|3IQTGQ4L;2^ZWB-
ML|E""|7W\$|_1C|OAS3F@!R|YK1*.|32?RL8Z(OGP;\$|HU0L)<:4I#T^_IX&VE MO M&
|W?'1LRL|5Q=%%1)V1%FZBUQHHPZNF:).I%R_2!'X'C_&-&>9"G|.(|@ M'1|N-
;+5@X.T38LG|ZSV%2YK>*N6|H|=)I^6>>BOSJ?V-KL2W|>,JNEGKW>N!
(O&Y|D&WD^H|Q)|?\$/L3MS^ST@|.)3 M;O&# M!|QQSNP+|P-3Y-R'U..E!K;S7 6*.*?
05HE6>"X>@*V1^:>H)W\$+M#(7"KL8 W+Q<"|YM|YOWNPFN,| M8|8|OJKKKYM6!
|O'Z:~R1#Q94P9|WCE+VUA|30VWA22 *SL|9B9-|8<|,?BH M^+7*\$H:BM'+R.DPD-
*Q|Z*M+0ZH|=@?-OE|E#3,=G=^<|8#@CF=) MD0?
|!!Q|#PO.'MKW|L#0|MCA|UT""@?"T6W3_JT?F>(*Y&U@ #+"H&*H)%|P&
ML|1S8L5+7(|,7B|B20<|97P)?%D@_TK:"R#K#_".#V/8<%Y5(1P=(%ZB+QE% MBB?|
(AW;_)J=3L#V9*Y'U)K404ZACQI^CG|;"5KG\$G1RX&0YN-S N>?4'-P! M,NE./\$M8|_F6|_
&0)6>T3-|##,SHB@W5&?E3"=;2\$7.LX\$2R2P|66AK3GS|B2PG|/C;|=
MY.XU8T.ORG_;"L;?W_R(6"L*XN7^ES;AM!)Y*6^*=%EIH!&?%;!>OM|L50
M:7QO;?"DT|L/R4BL84G)4T9A?_9|Q:X1Y)<.^NJ?|=>|@1|\$T|C;3FG\$U|
M|JH&_:"C::&Z|ZAOX)Y*\$:|JYU47=(5IDX)YB#LVO=GX"|F4OS|+% M++++RB(7C#_?
PQKF HR5.QA/BR@'9:3|2YH"R\$0<,8OZHA%PRY4F0LW%O |O MG9:L>6>HQHIF-
X7G(|1Z>OD5A+WV*Z%E1?S>ZG^U:W!ZCXX'L5) A|J.933L
M2\$#I'G'&F*".T,U|N6G"6UB1^XT:M;*&3=Y7?(3X>FOLGJZ,|;VA(GLGA>O1|2|'-\$0F
M0)7KN!CZ3.LBU='9X#1'1?4@U!";X&U<7SVL++TE&'7P5A>@Z|,1O+R>HO\$Z/(H
M')/Z,TH9&I*WINXE1RB4CO-BT.7YC^_2A.6<|F).6JH%JKRMAXIZ8&PDK=B M\$J3
2K+>O/>(RKV:"<|/SH!7>(Z|7N=O ^V!2R9J!%P9D8,&H:31")X_=
M'-6^B8W3NXF|5AK|A9+N=:;K_9AWO\$?0H|FXX^2'F #R:>QM,R
M"2IZZ9<)!^I"X*7+M0|=-W"B&PN&R5+,J0^X#>Y?8K(^MB\$WBU=6|BY+JRCN
M|.LTKLO*VG5&W3-)K7@TW?P+P7@#HC#,L>M* M'M_1W"Z;WVH?3?@4":^P?3
CJL@!|@V_%M#Y)|@&YZO&:(O'IAY#5\$OGCXY6| M?#GYE&/O|1>+YM|C5%^F#U-
ZG|U8@.F|IMIS-5SRP|T|UF<,?+WC5C4|_ZH0|_ZXAVMM9* M(|.^?
^B>M)KHA'B^_OI(HU#.QKX2 (/ \$8=-;@\$W@A"4QE)H!S.#A|I8VK%F5 M\$)E9-
-5%SOPL6AJZ|=|Y@M15"JAB%|.;+LN?Z4<<2R#{Q?C>,16@0TFZ_I MW|'^N>Y!)0_.^#
1B=6.K;RBF3Q|S|;C9LJ\$+?#;=8OCR.2GC-NO&1JO"JW MDC@;ML!7|SY"
(J%#1.0\$|UZT5P|+<=U49'V0Y3S|H MOG\$_*-2\$X4#)#(TE&
(_H!#*C|1\$%IN")&UAZQS*)@DWZJ|:YR_:^_0C3M1YRIXAX-9
MC=#9NDD^#36@HFG"TSMT|^FX5#\$Y+@=&QA|%1?JX9|+OL|N)3_,T@0?
E;-0U/!WJAV2#KCTM#R%"90|)YFI/GK@N;FQ=AFD@H^IV4/
ML(-&0PJ>70R|-5^)|9'<|^8W(\$7R|?D#8C4>EO#"L4U "H&RZ+U17D_Y,-&P4
M7%&2'_9|_:\$ED=GB^#YD"#=.K;,\$6D.5A|=ES2 M!XN@G==981|' R|ZA+4(Y;SMP?
7R=ZRASVBGA MW>!8T MJ |I'#,S;DT|= &S!YBHP+ZN.0H'1"!2NOROR/(5WNI-3XK: |2
MQ/(S77^:=@D?|XXCT|_1|HS|BT,SM\$/29\$.*->D|WLY029N;N8EU/0HF2B^T
MSEY=5#1M*#^DS7X|C-#^3K|OWO-8V+GIU/\$'\$*81!0_??89"|=I>,K*M'|_
MTPZ*54=XX%Y9S>D=BHX%7-4":%YE7ER,^,%_CH(HW&'|<3Y+4Y"&@%<%
MLX/*%0|7|A;>RCS8F5KQY/1-X|_SGX(|^"1Z_ I""Y 8",%S|H.&6_S0^Z-: MU_E)L:S^&9,&
(^9Z=?K/-:6=|,TJK30O&8U;Z>2YA MW|^64Y_D|4B.ZP'&VFH2;
MAV@74|\$IDG2'9BE"GJ8PDASH4W+>VB|)|ANC Z?>2CB7%:-(+J8(Y/?;VG3N

M%:\$PM@<0SH/=C&<+ O 0R%IP<3KFJONJST .PMADQ87%0 "YI;N >:>P%O/ M0Z%
I@&S,' ?EA">:.,IS@RP+IF!\$!BY.15%4I3L'=A5%Z02V)6UE#Y!HJFL%
M9@;EN92BM<.!VW?_F=K-5@O@LN3PK/^UVAL8G_EC^ M*/Q(OLSMHYFA^5?
5QT)L*Q0NEH:N4[,3)EEQ<0.=MFC(H%ABQ:MF3 [I^H
M_S&ULY+U|<|PXEB_X_T4V+YQ|HHE\$E5\|*->F;DAVW*/-UR6PU)U
MWXF*C0P\94ZGDFJ2J;+FTR_1SZ4F4P!"GW;G2TRY9(G_Y@3@ #@I.^9?_MJ?
UA:9YX6>7% ^E_Y/ L_0GP-2U8OKI_US_]=OE1S7G(\$_!OH;J+|Q|+>B_'O^A,&7%:Y%43Y
^&_-.^ ^*MQ^| T24.(1)) ^1:#&:<">|&O_PN:1E?Y^N|_5G\07'\$@U5M7S3_14_?
MZOKQS|_||LCYA+ F:3_+LE^:WVX?
MK?)3#|IF_5_ ^|Z^?;NDW_H!AOJYJO*9*0)7_N6I^ ^*F@N&Y8OX@+G'U"_00V
MCT'U(R@I'OV?OU?L3_VWP!HZ2B+%?_*!5#_>WKQ|BLU_4\$|^L^;WJVR^|MS
MV6^._R_H0)7TGT36OU|R/_US|5^M*!09@JE'RN4 M_V\$MS|&Z@:|L!
f8D9#;C^HZS6;Z|O= MBAH-?7K\$KCZ+HL:K&3Z+G9@|R"OU@T_R;YT8U="
6WD=*9|#RK_7O,UXZVU M/&@:Y.Q?_R3_MJ3UJE|>E5A-BK><;LJ|SGEU57->?E7O-
KP9#|.(MJ,F)(8@32B!'F4?MQ+OH:_W?8X&F&;DOYDH&M|9LR6O"HV)6UG M.RE=S?
0MH'_K1(.=;(!KH*2#1OR_+)#/(;OU7PLK'Y(EBWC&I6 /_0<2!2 MFY!'!_1_G-
'_ \$ZQJRO.14K?FJNJ!_!WC- "GD'P^;>H-70&S6K#I+4\$\$/1*|4 MZJG%H=
<8C/"%B;)X,-2C+@Q|NV50PO@3*\$K&2|EN/Z'2|FO<5/ >X|?EEY(_XIS=X>^|
M6H8L2)F7\$)|@\$\$8&(TPBF&?>#I6*Q3C4|LI#I1H)&E-R!/_4C!L MA,8J9F9W|'32'D-
#X'>S<271-|@%KD@#OWOO%S6>?N&KNNI_THRP9G2=;'J6 M_36D5#^&!^Q&S;ON?
='L0P#0=,XD_NQ6& YP_272P(OA1\$.%9B!@1;9|K^KJUXE59RB^3*SEOGW>/=**O_I
ENWE4 M#U9_Y94\$>+5F/=:|00WH9E,KIY=:U_R-*T^@?;)E_A>|C@?<+Z6/W|7K.L2
M4|6.O./E@|_T?)SXS!_0)B*#*\$@#F&&Y-PP)Y2%*F?QQ;&(^?QS5)C;)C1:P M40/LJPKV=
7D&>P_U^D+&H47H%-Y_5JEFX7^UO+41?-C98MX2?,*DQ5?@%YY MT&D/MNJ#/?V!
(L#,ZAX_:8YD?PX@*>;G-IOYZWF_-;6_AO;T|K--V8|_?UX MW>EH2OV!%)MUFOZ!|X\$S|?^
_.V6\$U?L/S=5W:Q/HJO7'500N*?>?UQ38L'_M_JFHY_-?
X>K;E|)XRIE<|3S_)E7ZN+YYE+AJ">B*UOE3ZP8A50-M23\$BG(4Q
M#+V8RWT5BB%|&8*<\$A|\$/HHQ-EH83_%RXBE^#|(RE64/&LA%H.K&"JC/'LB?
M2G@;:3"+%|JK|-M3S:UX#*A5JG|K|H|IE_,DO:LWQ|YVGYG-EB^Z:XL72,"@
M10S>*,P_J5|KV*#K2;1-PHZR-<_@2UZL(,/?N\5^'_<37I3|NMH^IH\$XJP3
MT90DOYQ2)H5EZ5;+93,YV32FYU?,^%WQ*W|@O+PI/^4/N3I5Q66|YN7;Y_U'
M|Z2TJ^|YM8QBCK(D2J"(U0;1XRG\$C\$20T1@1DOG\$2ZF1?VTG|,3*YIBMM/B8-?
6JF))H|R|RH|LIK-A+-O.XS-J0=^=\$<-6MFY)JC
MO+>KXH/^6IUR_'J|;_*U|RJ_E84K#D|;4\$L!?(2/_0(3_6+(8J|!*;4B^1J M-
LBD#;:IX5I63%?@Q&9*(8_*E080_1'|MU|&_8'Z#K|:002.&:%S.1<)|@3|
MWF+0-.7:S!A\$&#AFR"i08,2G8Q9:8*#M8(2!3COS!1H8:'40;V#RGMU"IRM_M|
XI;L2G8GVO/ 00.9\$|^1_%*%2A4EF&(?Y@X0%'J0)H5|_O"#B;'D4&'AQ M^7%.GM8GK!?
U./_9|Z2#0@_E'TH|^@_4_K/%VEG>|%9AHVBPLG4G5+^|J+KQ M\$NN27H|63F?
%S+HHNJ3LR|7.Q>?MAO!^4U=K|@X_YBH@D^.*WY!5?M_ZC^1> M'4K M5|\$_;^;4|
|HZ7"XLE|7":\LB#\$|;_H4W_CY6=>+WG(.4DH@B+@H5R.IC'\$#\$>0 MHT
P'A!|D=G9@9;8R6-QB3L|!%\$TBZ5&/GC3(_EI_1HP"W7T:|TJ|6LY@F! M<|X,#P)
<464136NBN;/H62VA,T?+FA!Q'!UK|+;EKI=7%>?;\$|!FJ?DIQT1: MN/JY#
|Q|O^%70HY6%8#|0A#Q@\$_B/_Q9EG@9)5X37?
X_AQ=7&UPK#O+O=,30=;7%'-69GY%30A_K_|3|V M^1->*0E?
N3H'58&#ZA=RKWWX@|TGVWOO+|WO=@|_9U^4S&+:F'7;D"61/@9
MAA&!@=SI0I1D#!+B\$QBF*8LX#T1_66|O>Y|6V+\$0KDER* (\$@X1S7R88BI@R&B: MT(
38G88-@|_Q%N% W"=J6K@_850|T9K"U&='&|!@AU*TZ/S41VD>| ^% ^VF
MQ_#3,FYQ8N^""&?G^J/ S'SZ|X*XXQ@!)ZV,/:|VM3?BE+N:|X7ZO+1,@F\$
MYV/DP8AE'D1A|(\$&211ZD)!4AE283<6QU(O9"T,3F;N^D9"L8_-Z*_-@S6/DN5 MX<'4"
+,#.^>|O^W_+@J)N=J=:1T47W|XZ(SNKD^ ^7DIYG4.<_8YMS\$
M9B.7|7R;E.CY@12KI>=3|J5!"_4-@D|!<1!&L(D|D,_%?(W2,O#>=3RU%\$Y M?
6ZO1HC>8#S6?GCTC=+);+A|J|JN,Y"/S&:*DY_OB^>?I'OM-) F4W?HY; MFF7
G%6@'R'G'|#TG14/CR7_QM=5_L3;8?>9US="CKWMYN-+43:W=^OV:H'*
MEG!7?);*J*NVQ4JV?O|Q+3|F.2DO\$X322(XN2((40>2G&&98W71-D2||+AA! MQ,@YYA;?
U-ZO?;0@;^#^|F:E|D4;>J4<=XNFV^GUR#;T*QWP?#_M#GL5!L" M"7K?-=3A!OO
U3'\$ (7308W?H-9J&5%=N(IN>.(!<|!%)KFHA#A\$D\$TXAQ2,-\$LHR|E
1&H7F71F*GCNHXN*S4> X_Y&M5MN H\$M|P M|:HFJYH1&|ZY,@S1N'Q18>ZK"*
|C+O2\$ _H#7"LY&5IB|;68|.&5+N5KYS(NJ MNWKN,?*/7HX<\$M9V/UC>;

/59I>&R.TL9L^/6*7+XWK3W8SJ(?\'S(=[JA M1-EN!!VW-,L@.:M /Pl./V"1UZ"MQG
N.*G)1"J)XTN*XY!ADL(84PQ1F,8P MXW*F#+*(IW% T\ 3^D41)(1.
[4)4*#ISO\6Q#75L(AW;#+P*BTfM \$U*AT?A M5\$09^B5?F2.3T@KNN;)+?
N"&,\ 2"V;*#U=;T&OKQL(+9MH=UF P?-?"AAZG M={YJTBXV?
ZLJ7E=7JU57(*Rl;+5,0Q3\$888@PBF%B#!I3H7OP\3S\$>\$A8C\3
M"ANQE#^Q96W%@T8VV,DVL \6E&J8TVF),G56G,H)WS&G_M'25^WQ=_&JGA,>
M#4SNM'S:6=H>#6SQ?:L#)IEBV;GLI#V.A\8ZQ'-S%"&C,:\$)3&C
MY'HX\R%AV(>10#@4,?8P,LI<:PMDGF07LX+?F>I
M#7*IGR5ZB#S+4==D>6B0LB(96LO5EG3/Y13^\$-1OB\VI!,:U16ERK!67SGE
M^9,ZO^O2;RQ)G*4,\$P&S"
N5I36"J8KM2P4/\$\9\+T)&LC6LVF3D6AFR%SS9Y\FVH8'5_FKC63/MFYC:Al:CC-
-6C5CLI*^_=U\$ \$34V\$ZB\E7M:SF(H899'VAMH:QL1&:HL+5 TP<-B M
E:.%0C886O&&JZALIE+:M\7&COQ61@VLV#)0.:,JG(=ENEVY-MJ,]^FAJ M!K?JJJW/MV,?
S<#I\QGU:Q:SQ: ^;59WSA\=5\YS%J:9IBOA+^IBV>\$ 3\3
ME.NL+2308FIO%,^C,K!;YH1K3 63TF@V!;?R(#!K8^TF9M+/SKADUL_+6A Q:
M=-6Y\JUAH?6"/\5J:(Y.TO%2*/A0S&.*\$0N1C'Z8B2*0!9RB(DYA'_H@\
M;Z>%3NY=U0A8M;IOJ,6HKM/4+4^F#E(''%#F.ZIWD?J*6R\HLG?XWJ+1NS;E
M6/)B5=SGM(JHBSQ*"4\I'%ZH%G:),@XBA;% 08HR%#*BO_U_T?C\$1F KS:IX MR L>--9;
(\0S&\I.%3.I@&*OH&6U\$WU%#:N;G-9DN)+)BW=FK%IR&NUAA9(S MSUB8@"9%3-
-937W33P7N722(I1\+\$(81D78-Q9S!-\$M\&-1)0&@D?R7T8Q7/ MBIG8+.S);:H@ R798
"=IT?#1CA1VLQ:G-37QG*<5\S AC@AP,Z:6!)A9EDN
MZC=H8\Z_/9^UN:C!@=VY_+1U"I07>.J.ST6644Q#GV \$\$8\BB*(40YS&0JY5 MHBCRB2\
(RRQJ(^G(UOI<1\=)>M-#^>D7UH%1CMRZQ(RKBL8=&.,+1EKDXP:-R!
[9V\+8H%V.\$PLQ8Z9.H9"\<4F=D*;7; [U^*54Z?Y1KA>PW> MRL_^[PX=(8<.,+(>.)A)G-
1X&%+RT'2:OVIF.:URN\ 6\RI;9G+BUWX+Z%)HO M88D\DB1^*!"*
KGDR\$0*4\X"2\$7H\Y"DF<|\\$|Q0=[4<0^==.7P XU\,JMP MB2T\N^"0 S.;<*R^M
[MX)_4"&@JL.@ 7)(VZ^#75/WEP-=\S7:S\20M1U\$^
MO_Q^\$R\FO<(HJ%5\$.DHY@5AX/LP\@BB/Y8:#:QUK7Q(TN
M523W"M\;9\,XT\+\$8U#=#R%>2@1(-?2"%JW3;S8JS0V&4=><#\,CTQT%9N-2
M0WOPNX+@+E'!!1UMLQ:<:W;.% 875'N1S^#2T_8E46Z;P&3YSE_Q:L-OQ*=<
MR.U\ M2E52/.2"B\1B8\ACCP.D2\RA^W+O38F-!1\D/D^UCHZU)8X\0AN@FFV M
\$"#H*GA+3&+0CSVB##+.K-M\$ZY,10:(VFOJH&Al:K#LA:#\F:01*&E_JGB
M\$7HOCDE:KBZA?)"@51!3OM\(-7M7J6F_[+!)7E%/R#5V\%&8(<0@0B*!.!\$"
M@7JLU#AW!UV4&S\VV1/=JYGVF<'K\JP3QJ<- MNR2P;1?L0(=ZAIN/^RT1#M-
(^|39C<+?,!Y.\F\|SRLJ MC=5&MKGG/44QC>-4Y>
[.U\$57N2XD<4A@%@@1)F'E1D#"CR_V#TB:VR4IVM\K9 MDVYF?X?
9TC.CSC@PLX:GU0>_3^GT=+1D2\$:EC6K/=%2^Z59T'O)^F"5KNR/2"O+D/
M3/74/W%)7_%V?_7JS4^N,O.%^KA_?H1 M.L7,[V\^|AHUGO@"S
U1/.5V\)#451PENL\$G3L="=\$D\IL:T@0KA\EH,K
MH^;M@/I(N42OSN\37#CLSM9#!GM=)3D_W2N\$\NS_QX\NH/7+*[AWN\U\OR4
MK_G'FC\<2EA_IKWIAG\$C#MRI8HWWAYL7)1PTTAV=0PUJ9G4\$=;K%V4Z?!A7:
M/W@:~?M#V.FN9/^%:~?NJ\;WKW,_D\+U/N\$=|#"?1Y)!<.B4\@)@B& F7R5SXA M
6.6\$>\$7!6M\K*/#P7M +55;&C"0P MBSB\2>AY)\$K#E
9&VSHWA(ZY(/Q:3.JMC9SR8V8='5!C<2U84UUG=X(OR9OY M0K"F^L>W@75?
M/3W\^|CK5\A'>INP3&8^0E?LI@%*MJ/PD+(;9I @FB64CC ME(74*(FA@>RI?
4#=#P0VNP9\7\U>.%8(V9-SH-IT-NYHNH6DX,W0.C:~+W\$-D
MKK@K7Y&!\Y'F\1N:4\F/+))JP,S1O-W(IPJM*[F>(*J\$N\;8'6O?R>SG(==5D
MJU\&0G1@#TX"! #! X0 M+=K\$ZV:VQY1P/?LS(8UF-L@M@;FR)
(1R;)/5/JL9LF2FI>FR;89BWP(' ^1' MJJ7(U_4M?^+K#W)A\87+KT\|>YT7Y?6F+-[S=?
&@8'#VN:AYGUM#1%APPA_, M?;D00K&Z8YA\$#*2\$NP3'!D:>+=L(8Q\3FX_
5H@(\$&&5#00(<-M." 0@?V MX(\$>T6-OO> A\W%L>,[^ST*001*
(66BV2Q(Q*=UFJ21&LS28:L*^|)?E2 M48QFX"!5Q?
C6+*OEJEON[XJJOB)576*JNY@Z>F\Z\(.4NNC2FL>G\$.MV=G
M57%5B_6H_7G+KIY3\ZC"ZMD';6.NVZ"JN1'5;985XV7T6-A(+40\^G(42!
MAV&PA\B3\0T(!\$E*.C\X'H\I.B.+#S?9NN+7C#@K15&8F?Q1 MWXQ%"/JP?
LZ"R,^(F3D,?%C9XT#N""\|"-;*\$WZU9K_B6@4/-^(7W'Y=JX\$ M@N^" I:4HTDL:
P%D7,%0L*#*#=(DPX0HBJ;<,Z>%,'P;S!G!)1DP:FQZ3N
M;:Q0\<7XC(COU.)=T\|D_)9N&+G\71(X+"34A8XH042WYKQB+=-37;_RSM>T\&.2QF',81)

X\86&*LQ@;WHNS M@S&QV3L U:P7.EB-WVD!6F1JL;#%!G;@S-
9@EOV@MQ";GETS4SH1L<9KLG&+M.%J868*8=74VCJB72|21K5FLTV|I-
+XV*WXC;OE|6X?B486*J%O\$HB@?VN-8
M_)C7>-5L9UFN:NU6;Y^|Y^>:&|C;BZX^C5,4,P+5"@^B,*\$PC8@/4QS%7LHC
M%L=\$>V7G&-S\$1K\$# O:1/(-.BP&:R#7G:*Q='Q%JLTL9
|4V2F|R.#E>TK|I7=6OAU^LQL&3T1J8,+;|)^ M*AEVVX&7&-
LB"^3:88L"L(@1A!A|LL_5/%,%E&8B33RL>=1GAB=0FE)G7A> M.OJQ?
4).LW6|H%ZRW;GM!C.O><8F39%J9'6CM;@>C)G77(T?!RA6WVLJWG MX(FO-|O/Y:."
Z6U|>;JZ>."E8>R(9FM3|DD; +LT64H<^\$-B #V(22)- M#!5WMNG4DSKS+M.(BN-
MI=GKEH>4JOYC!|X5SDS(P+Q)*"0497M#L(X@_1 M2(.8")*1T.>IT0GD0?-3'R_*?
P\$ES;*VZ LN-\$|%K34T//+35|/|.^D#JY. MZ@X;G_<8|J1B1V=LIY^R3,"6KU4RSR;2|%.2;
|*Z^=;N?=JKE|=B;/W.5|U
M/J'K|I5*R!7O9_RJE|ZG!*/4@3|2*B"GS&&&\$49|,*4|R1E6188I5X9B6?B M(=NA UT Y!;@
FPAJOWG%N36@PI^W^\$"\$JCA6!_37K&84;RS;R)&|ZOUYN'
M|I:'RV1S;DASE8YN))IY\$|:YH>XHI9VC9@U=W:HH6?F|.UVB5@2)R+)H,B0 MW*;
|H=R<,9W\$:AGK+DEV3\$|NUW|:Y.O|L.#*^|I+3^X(V\$H;T/Q MV^>|=|?
OP>W=U=WUK0.OW1'D@20LWTW-XT(|@KYU?!W_QBKX
MAL@=KFB'TOI>'1|55|_S:DF22|6|26";,"%7!\$\$(TY+*!:"(9HF!!N\$'=S
M6LKD(3=\$>5ZVV2>'/\$L'_Z.|4_G9|?*/08(CJ)*=AHQRS M8F:N+A-BA2% M\$,5!)%=KOL
X1J\$7\$8|EJ=\$1HB6.J5=Q"H"ZC|V??O5:"\$YKE9|L+:YR"DX5
M|J=R^^*Y82XWJ?,S|ML^TG/9S,"F57N 8\$.T5XX88L'|'JJ.9LL9?;UIUK
M9B0YCEPRMBAF=<6,IJE"V9L?VEE(NH6UX^Y;1)B/"NY"RO#|)2_P?'Y=LF3|K**>_|
M'L=A2**?\$CGH558EHK(JL2#R8I9P|@6QP<7S5U5&:Y2-OM7>H)5"PM0E=OC
M#6V0_018>U=:@:>)3*#|=2K?0:N|?B%)V6|_@J\$+!#_2Y&&SI_QD^
M&SL_P3_9YV/FFWCM;AMT>+P:N/F|**_-X%KYM7!C,@-5MDD!JMFR@I639<0
M|I\$@%E|G JE=,|7:DV,D|8,=|V7U#=_SAL2AQ^7S|CXV*BVAVXQ^K:L/94L0H
MC%69S2SC2&Z5Y:8Y\$RF#)"91(#R"8R|QV2H/R)IXP|R5#%K1B|H|U\$HWVS8U_R1G,?
91KOG6 M|IAW6|C_U+*&6V)&L|H0PS!"%* TCF'HDAB1)8XQP%|#/-XS2!0X|>|N
M9(|WN"R?U:*QR3|O'\$|YS)C>L;)|@|G8;B7#1C38R=YZS!KQ3H,J|9S?
JFY:NJ#0F;12C7(M2?B/V?J)N+%5J"***4H'2P(<4 M1Q%\$'%. (14:@|Z,L0BQ%?
F)4_T!?!26H \$"|N0N0(-%'3<= +3'8V8F#"C6 M,QC3\$&=F.MQQ9FQ&S-5W9%
_L|J6LP)>6ED+%JP|..J)IP5|HM<,"K|H= M-5|R9M=|C)(_O3%L02"@|C|I@&1|B?@B|_
"HX3D)U|S%#ZQR3E=*^2+ M?/J;W*4=5@HQ|R;JSAWYZ0-S.+@_+|MP!|V@FL|I
USLAA78N6J=4 MFCE0+;D8|'N:MCF?N|)2VP,OHVT;ENO!=9VS+G)I%ZRT=T,4,X|
|21S|F(<9 M1"%/89H)! E-LB!,LX!QHUV@)8%3K_WVQ!^\$>(VX4WN10|UEGD-
F#!=WXT@Q M7|I:LNIJ'7=)W+RK-TWEC|9LNN_9)%LK1'W/5W>-!WV.BHA\$G?
BI6*B6|2NJL@JZ)LE+A(G| M&M3ZF>YMJ-7;W4Q\$F)GE:N_Q|\$6H*<*^XIJ#0U2++OQ.
=M|5&V)KA|437B7 M58N,>7%6R\$A?|LRUC8PI.2YW9-Z\$Y?61OI!5E|"O7R(30A@F 8.>|""*
(4*@" M8@*YCR)!\$M,@|1-BE./HC)R)CX|D6-6CFR07A|7P%+9^?>|S)^PF@':
(_6K^@/|.RR869\$G|B&9Q MDD*.>7|/PX.\$J2U((*>>4\$<^T8C5E/NQ"-
X6X.OF>9V.+9!'|@&"HM-0(PN ML|HK!=|F8U^1U19%R|45-QQ'<-
+4E^EK*\$F%>>J'.J^;F=0/O/Z:Z^?2F+ MIYQQ|O;YMTH%ZVRMUY5:8K95| ^+
(CP(6!!!3(K<=7BJW'22)(8^BA/H,"Y^\$ MR|JH|4K/INB+-C(K6P#:8T5=T5!(0 |%Y<)_HJ"
?AW3KKPGV"%:@#LEQ|S\$ M&"M9V6F8=#,T%B0Y|:F!/@R. 8")
|5YI@3|M+L6+1@X3+|^HWG>|X3OJES MVJ^G@|B+<(A"R%#H011C'V:
<^I")C*KL@2P56K%ZEP1-O%C92@;|H@T|BT,< M:2A1'6EN9@U.*VUS8#.DO8%
|U1\$+=EY6PT_S,NJH=F@LW7H_?E|KA|:'A> M=9Z?>B6TO7|FB9B&?H!|@%(D0HC03\$
LI%D&&M_RF)6_R M1=\$DUP;M.9E|G?0ZUP_M;)-?SFZQKBKW'1%Y>2T:8H8#EWK?
5\$+C2).><@P M|I#&5QBLB".
(TSF#J)21!'N)>|D4=TA&>B2W9'J;N1(D>W/+G71:T7|ZLU#U_MPZI+
(|M"S|_-2+"9M=NO/+?A\5L"L,4FG,-EZL23R/1S%O|R0UU1V6A'#5K M9R^/REA+4RV-
<_VL4AG45VNF;J4^_O'QE/\$@2*,4\$I(RB\$B,(0G3!'HXYB"Z M,<:YT;I.7_3D03VM7%BV-6_-
S)P!@WH6;1H>S(S7R1+R/8Y%D|6E;N(0MEC<
MF2AS_1U9(P!|LOH>VAB+%BR77|4T22I618|'"|CY|8\F6'J-8Q|F#'DMB MB%1M+J)VAZ'
7BR".&0L-%I6G98SL:'8E_H_M|D3&LF&2Z,S-&DN><8K;|B4 ML=#;?&4RK)6K%
<<9*?.N)(95/5HA7'CR1|QSIKRM15_UV7|C*#@?DX#| M,& 15VYF!-,DC:!
(PCB*&8E1:G0E_*24R>?S1B;HA"|"Y.NLJ*?YT1NAH|4V
M&Y_&"IO7UAM2R%6)O9,RYJVT-Z3F4<&|P8?M!N6|JX\$'-X>;>X+M7-|8_19

M,I '*G.+%U*Y*O@)I&&RFH]- M6= M\OI;P7:...PUK, #ZU"Y)17-@>.E#4;\"?T!+|f=2EJ
MJ#50%D^~W8U;.6UMA^M0FL,2 VE^B&G\ZBU4TX.8K.75%3E%.5E7K"<=C]5
M:467F#, _ID(.F;KI@E)/P(SA#"9R;^UC&J4\3\$V"SW0%SQ!ZJMA)!:3+ '*Q2
MCQM/YO1HU/;+.2?"V"NG\$(#]9,I=+N6>K?Y7!^F4G?KFC#APYYG3\$SNW7\Z(MC!-
>.:/WS:=H.=TWI53*\NWSQS5KC@YTY^=3/TX\,7:5*(.U9GXGM MKE NO\,2YI7"N"+=>
(8=\$00?I\ZNV/.S7JJI_K= 2-DG)#W*JY *VB|>E7IRJHB^;' M*CGB5MT%."IZUJO<9E8T/#-
XW<|+VCBG^8C,CP!::Z+MYK?SJM7_G\,SUY^ MB&YS=<3SNLK,>Y+T0W32
=W\G&CPNZZL.G- M'@ZL,#/OYBP8FUA-W1S9P\$O29C52FJJ_M"*ZKUE>;)#8-*&EE^W#!
|I?;*T=! MX+->"%4!9\|@BBB%F<@R&% -&EL|\$^,3KH\$8.V;/2I-"V@;#| QH7
MDL83K;M++H@TS\$|1XOKQ>UWG|M+'>.)#\6Z"7,\J@*_#
.41CY/(.&|W&|EG,"4!2%,21S%41.P.-3R<^)DF|C, MM! BP T\$+;EU_90@#=#5|S/-&U>;3
Y;,%??\F-D136K&VPXS10?.1&1#K.&0 M?JG9:\WF9|\$(9JKV-
L#P+>OB=%AB;VI800#F?.4JV|D4T?SRCH3\$GJN79M&(>*O&QC9+L#HJ_
M%*N57="5\EU/O_K|D|O=|FUIO_|?+B&#J6=VE4SRJ??@/ MRR&F_=?R?)77-:;T<6
MZ47CLYJ+TXJJ',MGGK*L"KFA:H3_BLN_|I+V3EV=U7G6I/+^5?=#L??"4 MA7X
8X)\B+/"84H3#" /ATY#[#*"0K%*D!8B)!VT";28P!;40=' \$!A=H@>EM
MIMSU@9XAF)I9,W,Q\$:GF52E'L.*J4J4-A'FK5XX@Z;BBY9BV+!(H_ ;S|<|?
MN+KKNJ9J|8KU\$H1+#+(6Q= CE\$ D4 2SB&"(TIBD:8*C1&CE|J,3_4*0\H'
M'8#=#>>LV99-AL5M-!H<-D'M>#%9EI|38Y5^~0)&C1,S:B@ZF8|I< MRCQ)F;4U.DC-
K/^6Q05\|HWA0JQOGJHM6_=|TS|5J*_>>FJLI|\$'5Q<&WB M8I&U854ON^%MM31Y
M*'+R4=8# \$T2J'P-:(O!<#=#RF3O-O8=31DQ'Y);,+QT9G?C%062)PSV%MK:N
M=A"7!>/EL.%.>;V'B\$6TRD9CH?7G:=*.R
MV9#=#WOKA4XWEU|6T&IF'6AVMGGVLFK|LZ|&TQ8;|+^4',LO_NX;7M^LN:K#
MVE8AZ404I"@,\$Y587|! [KFC))4^#;!DG!.6Q#B-M/SY&K(F'J.=<*"D RF^
M+23;AH36,5;V^(ZL/17GU MN"*K _B_2|U=MVG#4V|: ^D-<|.Z;NI2M%LI?Y/J*[N|
<'8JY\$4);A:R=5U M>XS<1#=#4,#E&:XY13>Y%LOV.T;|X.&2V#*+C#&+1\$ /A#K1FSOW-
P^X-6JSQ:ZY%\$:\$X00| #R?0D0X@RD. ^A3 M'(5)&@2I,+QD<| #^Q_:LNSK2B
2|3-.K,X>\$#-L3|VJ:60PS#2VNPIS48|3= ME\|V9K|L _|N'70D+2P|, M*UEA/RI&2:&0?
7/+JH(Z/'Q71U9")|(M?^TZ,GKT:-21T6S(XM10M;BNVYO>.5Y=4;JV9OGZ_E:=4.*2Z5;|
VQMNG'2 M8@!;\$&" FQA&.>2,B7+X-!L&M+L#M"TR'-TDF:N|^"IFD%S|YVPF>MX<-IF
M;|E2IC^0N"|>.FKC|Q)|X*N_.=(|8D)#2 &?-#B((L@A@%,>1I2A,2!8'G M&V6|'Y
U|5*D\$05"PS-R'8|T5A.-.#>SA|T|^\$;J K1R%T";"/.4+)=5=)5_
M94#2O,E6+JM|E%E%XY69*V+VEYS2Z.(A)Z(8,!9"A'R,IC2-)3#/PN(+TCJ
MAT:|)L=#FM@LC*Y0,>(BHH/^TK,J|_:"F8D:7>)AHDN+|CAH?H*GU|G0J,| M
IW5.3ANV57"GR8M<%M%X3>% "Z^HBB&1J|73M<7Z"@N?BO6|RJ#UE=>;
IPXTZ.NUK*1T*!MX M *4*XRDS*!L??Z3N,;|>H|W|*\$'OS6&?8? -?W\$ MQ:XNCU(#*CW
UZZ?6X5 %WPU0V*?:7I@LCP^CN&^:K|M0,WIMW7^CPVOVH*,
MF9|P1),0.6>LO5D..TD>Q_'A.RY=I), ?5UO"P3DG|633.E
M3(M#FR|EP3:T_JI2|N|E)Z(,QP'#!.(@|2#R<*)|_O04X7)2>KY<:15'FU
MQL1F^..ZEO_,U?F6A4|EB|N-PZOQ&IN9LTX>: 4ZUM?@_&F|WG9G33;ZFYTP
M#6LV>)|TYM7Y3HZ&L1^<\$EUXU#*?P|K.6;|:U/D3WV6-NOY.500&V0<)>5CE> M-FV?
WXAK7*ITX)5<(#=#^ES;\$=TD8SSC'#-)(I!"%00*Q|FE\$?=)1D@4149)
MBIV@FMB(|6/<2L,&>I1 |338P|GD<^R0JFUQZ^8YLU^X9+&HP093ANW,|&|1T"%
CHZFXL), M|H)2K0Q|4P&<^OB_4!5FE4>Q"7-7&|8.=9 |TV&%MTHKW:-5%S^92>0/8
MS#8|T|, _V:O61FL7BU)\$Q=PYO5KL^%;DO3?QD MK=#, ^_K5E>-4%?
G+7YX+L56A9G,4H#=#E!'*(.9S#+0@P9IWX0QCS#
MH5\$I=" /I4SMC#XM*;,>\$LP#Z@ONB#S2K9C&M-G^I4#!HZ25V2-ZHBES8)\$Q3D
MNBS|U>IQ:=,R5(Y+OQ\$+|^+-=R&?|2|(*2>4\$ \$9@&H3*T\$0"9HF70N|)/SDG M&0L|;:?
B?LL3&Y%6E(\$C|4|K#7>AK2YFP|F58I/5Z4 ? W>@K5YV3L +W63F M|SL?=?=#+=_#"?
+Z|4S@//HG'|".4^HS'^|=7ORE*-@?^6HEUST|GWL7KR)P MQ|E#,8RRS(K-
HQSF|S|PV9-VSRU=T6::RM?W|_,2%QK^OR9US="PFN# MA#CM46B<4,8A2GTIB),
NE*7H&|S6I-K.'^R5OY:3?857IZ;=H00|WT81 %D*9T447"@EZ MU.!-
C_M|**NQV9R*4D=6U3F|68WN5.2^M,F3R;\$SV>_DD)#7'S|MMJ)=1180
MOD\$213&,TQ!#Q'D&4YRE,,9,Q&GBAUED=,AP2LC\$IK,5"7J9AI5K!MG1LW|C
M=3:S8<,J&AN?(7T<&9"3(F8U D-*OAS(@|:N&S>%JNZ6+^|L;|44:|B*<"
M1B&36S@_#F"61 R&\$6,A39B':.#MM#EL>^*AUPH#[VYM7!X06-!PXMCK9C;\$
M7*IEX,NQ5|_F|-5TY%#YS3^09?.BU?F<^JVT_W'
MM2C*AZ:SY(S_E3_Q|8;+/=HUR6N&7^2^RC#CD0KY3U//@RA&&*9\$SM#;|T,6

M!2@,L7XI@#%()K8E:HG= 6B<\$AU4[GE/= C?S%FNZ^MUIS0"
M\$(/%C"E'J,9AF(H/\$\$13WN)CK=7PK17U;Q^WRMX@L!P2MU!FO)!?
\$E!WZ40M!3)SMA!#D/((9 M1W+#+@#"50^RHN%ZSJ8GH16C3<-
U6JAK'@=X&W\$8KLJGUXE=MO,E^B=G1QGK; MJ*R;Z9?*O-Q
'W>|L;#:E7|H;ZF#T7YOMB06FSZ+%O5+MG>DJ0>3A/.8\$)% M"!\$)(HA9(B AF-
HR>1^.C2W(7K" QDLC":-"0E%\$/L,"I\$E|W%-B9MIZ67LY21=@ "ZJH-.Y'#\5
M+D|H;GMZN*\$GM!Y;T88\$7%T|<'L;30#>Z,B+=05BI) 4Q65GOC'-2T>^'\$^
M!H5U00!(A:73WF7"+W|?*[?7(VX|OMUV;8|X.B/.Y8^S1(8 1&O*VJ\$T*<
MA=+49\$*DA*,HT+L+.Q/>J8/AFKB6 _C@3:O 3|T@5"F#3V5Q:30!G2I-AA;P MIE7FIP7
HJFUA|^;V;JINU|/2/Y '6IF75^K+XW-|4P..|+C4Z.==0*8B?J7 M,|= <8L?
5M _G*FI^=X5L|F|Y _>U;L5+|2CG;G4XJMXP1#S&2*U8;I00B/Y#; M9A1E, H%S2*/Q-
Q'(XK?F.*9)RYYR6Q6F@Z?B6%3,WQ|'9B5W+GFF7>D(EIXO3*4=W62;=%T>R)
<5QY21C&*|25LF6K',UEZS;<|L)4JNXX<"M;9T! MGR5^IM*"4IX)B%(D(&&Q!R.<>
0G+,MBK4@/=Y FMH3|M7E/+85;N."- OS3 M?IBE<L908OK,K)T6F-H#
/T.SR\9KV1%Z1FUZ
M>LWLV E3,&INW<<0XLG"6(&8UFGG1K9F9^JN'OY7Q3/GM|4TFS=-906^
MLE@:I"\$2(4PI4907E,(T2!";,SBH2C\$B21MJ%RE++)<(6182Z.'&3X,%S%B*
(\$L|+|4XCGQ\$S>I@|1J?W)SL M1 '^71T;&,8%'C"AMP"PU< 4?NRDN,SMJEC-(V?!ON
MX%MWX+IDT70XIV(68+|@L!3J")BP,(0H)C'\$B1 _MS!
<^RFB61F9E*FV!3&QA6EAJ*|L!.Y%@M4>W!)?FW?Z9FV:(JRV'_1LS!SL MFED>'6+K A
NZ;(-15'^U 79;\$&!'2K#H\$)#R04,VH1\$FMDQUOR:
M!Q#.;>J;M!0^KSA@G;4'\$4)6C9C9Z)NZ3?.-BNYSAM9BZ8|L(RXYV>8!3!- M40 15|
I9#'\$8<1Q2/V08,V%BP=S"F|C |6#51M!162B|TV;'G;IG(U^O|Q;
MZ*F>>5|L.N;ZR^VNBKC;O|L^E9Z&*\$<6UC&X60WP-,2^M,|32;'+\$!IN>&L
M#82|P|YU.;DK)=(\$8)K1*)2+QXA""0AS#@)89 @'ON883 _C1C41STF:V*AV MA@'7IO=
SS.D9|:Z^J7 MU#VZH7|Q!;\$F\$<
M>UFL50Q%5^#D@79UWA51|2:.'@)K,Z>YFW/(A^'VK97<7)6>(%!%5S%7N|%+
MXN;=?FDJ?|3?TGUO?,&UOW%5/)FSJR=>XGO^OJNH!777"X*J)J4A,")W"MQ
M2&*J|HB%5/X-I?)O,?'#T LY,;H929^8DOPHF18CP=T@\$"/""A(3<)Z.C3C
MN>|;SV),QZ*9 _7!;X*C":_H3%|Y34/XJY5>TR=FJ;.:02L6T7578>1YMWR=
M%^5OM^ _YNGB0HJ6TST7-^ ^BJV/-|2GT.!2?2
%\$OA%@\$*:2|P+%)SLF9^;:0!76/+P1=>L%F";,N45|1?VSR M-M!.W3JZ7^?
_Q=E')D7E(L?;HG'-8U+BU9KM59F3OY.3 ?ORY7J)B, _2B H(
M\$D@PFD&,Q)GT*|\$QW&;18G(|-5E7DOD<+|N%V%19!#[A) M"!|'&728Y;|CR|7)>L%E-
^HLN5ZI3!|=|K|8 _=RG#N?C)<3D| MY?"ZTZ7 &1>H\$ _!TN)*=0L!X?
Z1FZ&V(DY"&4'C<@R@,\$20^)Q!'49;B\$.&0 M&YU&F *8UR?I.-#6F&US?^3K!M:>IV _;
<%I;|B;P1?YXX;VY SY(V<(E|WZ M Y?L3KY|J3VOEE|H):I4&(RQAR%"
(H(XE\$MR(1*"TSBEC!K=R#MH?>IEM9(%
ME##PNQ)G>,YY2(2>2;!6SW!AJJV9>3S""0UN/0&1JFXW(\$%>9U=G54=%5P=U#6O)5W-
M|9+M'5S!RU*ES _F^MU-8)C2,<1HPF*F*KL?0E6+\$R)*>)+%'N'\$|'K|*3\$3
M#^U>:)/H%I=DA|1R=C'VI)"9+|..*7| 7;P
M:0LO|1TO'SX5>'WW1|&KPIU:X7+O/*N;7Q(4"(HIAU&:!!!E2\$#LI1|,@H2\$ M?N#%
<:QUQ|50|L0#60\$!'@F04';5WULP|P>I%H?-!NQJN(:GXASZ# _E.#YN;SCHKK>.#
|M'C=*EU8;|FWT=JG+ _NJB3^, MO3CR/'#*")=+H'05U47*>
(HRH07:|7M,I0|UX)I=VM@X+J|HKU:4W(US.PT
ME%DNLUZ7+;,\$9E.P9IO3S!5|HAG/3#FXD 1-N|DY|Z*9ZO@B59KQZW;:S|XT
M|H>BY/G|NKT:0Y _O2KRNVIN3?|Y6N7F7P9IEA*Y)X51PN2&E\$B#F|)8|DK|
M+/*3#*NB(C85P2^+GOKLJ 4:(<U#L(+/_W%1UXRJW*R*MP:S>'G8:OLP, M;H|A
7K2>AA@#P=00+I2'^Y+5NOK|BHM8;@5RE|K4 _ (N<+8!BV8F9FJK)?O
MVA(|^1. _%H+3NBWN<2.N6-\$DE;W:CK ^8CW,\$HYI2K.Z\$JSZM9 M)'R<<5|K:--
&^-2N|BTX/K?@>-C|3LVCH('=/ MH+8A&L|\$D"F2|>Z9(?
FOG0FR\$CF+\$1I#1F^&1K7A8G?Y55W.N1& _57S)XL#'_ M?L0ABU.YN@FC
&*6^H!1+\$0D5SLATBJ6<4G0: ^P?&^FP\$%#*;P/8QNR#|DBS MV2;:4>%@7|C/@B|QVSI
|APN-/3XF/DSNY82;MW-|HK|AW.|9B>+VXGF|
MW=G'J9/LZZ)| _DNH|@EA\$&1IED60A6IAY,41S%A&8\$2HH|. (R9V8MZR+&J _T
M=F""S1M9|T0?9^N>@7DO<@%N%="S?94+ _C0VS?9:VEF=#|N5/O+H&K&.Y 3
M&CC:W;QH?-8=S&G%7NY2SCQE-Z3^5N8UOQ%"9<1MA^W+M/1+SP|1D*(@%,\$)
M1!S', \$M|##WJ1POC\$>\$L-'%T7!8Y|.*@ 2 MO5"+Y.U<8%V _PH!*O1JEB#+ MI<(Q'000

).\N10*^JHZ&MX: F<=|OH\$O#0#!F|:YWE|Y&7|K*(U%=K=OV/ M3?
ZH%ELJ+3MB(N!12""U4T|:!:>%!'\$0QY&D24.9Y<19FRR=>DL(@K>M9<2;?
M^[Y0|<^%IX CTK\HKG'PGL\$"| V#<|9)\$|D/& !2J% M5/I\$NM|+|YA-*XSGRX|4E%
<;ELM>NJK7K7|I|@|K?+|D+\$EBBBGTLB"5\$PIA MD* DAF\$8|3
2/O7TXCN'Q4QL#3^_^_5=)+!GFB@9.N-YPLT#8|D=|H;|O6L M|-8>OGHJG1BX%:
<_WQ=/O|@&VC\$K_|C|JA>:G660ZJG6#T_-IZT#K_?2Q*F1
M_W93J;P&U;OB@:B0)BFGDL9@|HGU3UJ0U;Y?5=SS LHZ,44AZIJQA>"K'G
M4<@)|A")1>;|1F66W<":>. W>@YHY0=TCDB8AVEZU;EGW:"WF+*(D\$31FD 5;5
MF%\$D=W1Q|B;.\$9'B4'A19K(SL8VPM/5#KTQC D^1H&>*9HF\$=!JE-X#<5?VB
MU|H(HG%|Q-&5D>M5_M-S\$*4;>UT7-=E3C:U2A-1%P^;59T_KGC3\$6K+F.D
MHEL B!B.2J|HJ0^X?836-M|!?
P8|JQO:+_1%"L;^N" OT++F_*IH8L:PIN|M5!EK&7HM#+L%PCI8G*NQ-)
MDZXNZF,N,B_-0A9I75.QD#FQ%6|1@|I!6(!'7((G)1VAV50,/(25
K\$^7R(K^VOLZN|U^6./E?FT* MCJ_VZ|ZMCA;TH;7'&F2@KQ==68H:NRE-
|04UJC>ON|>Z9+T=,F%6E*>/E> M2 *<\$LA1X\$,4D0!FC A(?
#|.0VE60MNZ;".136QR|DNR-2@@43# /E:P#Q:0 MYX;|.!"@S7LSLAK;V%
|4LV.OTC=FUNZX6|H|=LM;BVX94:+- \$87.J|. -Q?5* MA=DA|FH|Q15V'WRHN-JM/N>|+
M0D5(\$)=&F:IL+2PA*N&9#P6A7B92%(C4+.'9"# 3F^5M\$M06&UPI<&"KDN6
M>J+|20L1*(RF=>|&=(V>X9V+<#-;^Y+K3TZYMJ@Z-YXD9X7I1D"9N7;=>-* MR|LY:-
_R!^V)6X.8|B<1>Y<(JR-%*I>%XF\$^B'D E.(!\$60-M\$.|#+|/%"+*UEA *M'#FCD4QL(/?
OQ*HPGSU@:LWTX@ZM|5F\$?0?H6<)>9: #4S
M@Z>O'7>@=AQWL\$"+_S>_5K+9CZ3I*;SNZ0=NJ M,T_%ZBE?W|=%,/JL-
VE6DH9BGRY^ MI%,NM>A#_%"4)O'Z|*)C>;U|?|H(Q'>|QK95RX-R|4Q^L;H4!)4UO6)
|5/L|:/<=,A|B;K)5ZDL1E=R?GYJ*V*0JB|E=+V,F(>% MB!|H4?D'0DSYMK-
8SI<|T.5ZQHSDPG3'+4YV97M_|/GRZ^=LM^/#UYE?P M|?-?KV_O/G|^"|AZ=_?
QKQ_O/E|? MEL1K6@66^:G98|L^\$OL0_%!O1HE! ?Y MC0(\$|O5/8(L)
|!\$"!WWM8#N=E>TX<3=86 &:=P>T)>CFMCVC)SEXUXM0RAD:0_V"(-P&A.=7074;F<-
Z3& MA(:CH|JCERWG|).I49|;V"|#&CJ9ZKGKY GN94|XP2PUE_!|OF*P
M)5TM!H:%S;LNT%+|M:
(F@|Y:%2T|=VVEB/KX5*_G*UW|H|5!K.^5.OCWU|5|SU6A/*OC*ZTVY!EJ&U3IP%DW_.2X\$I
M%|1GB;H=M"JA|F8>#|F"H9>EWJM4M;JH_KD"5Y=?=)49X8K2-
E\$O9XT30(5E2A/\$UU7^Q-O\$EU)L<|C> M7#YNG02|J|?5E9"#|
Y_7T89XS'S(D@%"1|I5.7*(!60^7X4I"G.0FKDYA0
MZQS100T""*9QTOWT2|!\$%,3:W@KL.T|99/T(WF%F|/8B@=24>@.S3Y;:5#!;@ M=-
*&O6YL5 !O=CK(E|!#20F7|_-RZ#P_3F J8R5D*HLO+(4DR!\$/AI1ZG'N:9T5)O4-K\$)GI7
M|Z0U#|UX|*8'8'C/<9@Z/5/KC! S8SF&"^MB+X,Z,H|O|JE!&:"A '* M7TO"AIZG.83C1H98-
>N\$UESD"A@>W4QH,3UGF8L @/X0K)NP20=@S M8L;P04?
+P"^SA(D4^,#HML0\$OLY|:0P Y3 MFZB@|=6??
R4852W%=|Z"YVI630SD_H\$=C>9|HEN,H845X%H-A#F#44;0=)1 M,-
J8MISYWKSD^KN&Z|_)I=Z;|G|05GG_|79|ZF|QL90N3 ^KC|+@!_R2EK>
M_ "^XW\$9V^1'RI0\$45W5^4/C M(^JT4\$F@="=;%8#Z (&F,RE?
R|=53&M;Z2RG6W>2^|_O|(:? UG M@>%JHNM'U_|@NA%?
I*DLNVV",I/M=:| #2,LH3KR8)@%,.,HH@BK(8H1B"CR
M0X|)% "5&5RY=@IMXBFH@*K%T!Q=___*&-C,_9-..|1VNIB'YLGFG6UO^V0
M#FTSLX,W+>"?CJ>*>>|5Q.90Q'0'MERSZ>U,MFVX\$,|R"|ZW_4SU=_E*RZ
M8Q_Y8;W;KVM&V9UY?>KU^3|V:M/=I^JIDH_5ZI*?5&O"Y;L><8&+9ECI0W
M,TD:>H/?G?H@--2T"K|U^9L|7<7E-H/P+OTZ+@(|O#O|O3NUW<;1RM77.UR6
MSZ(HFY>^DD8AHAAN5L/8U4&-H%9'&20T31**:(D(H%-+)Z&|(E'LI+7)'&I M|7?0KE|
W9=O%X^G0ZKV6F4*JHR7(FWLHD2Q3?NU%Q.O2'RGQ9IUP)Z!_HY#
MIW0DOTH0GP\$EY|+Y3)JP.,|D)\$?6VTV^4LD45&J"Q@6E6,+DJ;VH1(T0M
>N%MG<%|3H|!8>8@81K' MN:YH,#,/2BK8B@52+O@X@?X&A|FN>+ |S'WQ11Q|!\$#|
|.LS5T7+P,'>P@?D. MY)_,I82R3-.U_D-JGD=5XVB-36JOK,ZQNA8EO# ME
A/FCWH^1F75H^D,(W#3!5A9%XBP|'9!2-/C'?J@.3F|@|>.|G". MD;?G&+@&H>
R|!4B.:OST.NC%?I7KU%W0_4:6:6_M*)TYL6_\$_-DO!<^/(\$ M|HL?^RT:&=.,3L+|<=9;.
<1:U.'B_"28/JMD_9%4I9755\$^?RYJ?E-^
M*O"Z"TI+@HC/'\$4P|B)5I3R+8(IYL|WVPY0)CK!^1*.VV*F=8QT.T\$!.R1 M05\$%2A08FV
_?6HU%LN3\$&;H4/LAN#*IHC4%9Y:ULYQO9U@SRY2"X4I9VJW-
M6!_+5,/ #JEC&;JNMU%5NKK7LI^>O^(|?Y3Q0YGBE-@--A*1>

M*""*,P^F#DPYHD71W&0>3XQ66I?SCBQ7952P4,OMME35IU@LR7P1=[TUK N MV3
SFE0)"Z X^?6 DU\| OREE/. NR6FKKZ.UH@7QU0>Z=+S=L-
6+@D>>5D_JQU7+:V!.E9^5 O QF00:<)>#J\$,8L)"B)*\$
M0\PR!CV>^&%,/(+4/2_12M_#XHR&L'GO\UYX,SGQ70)".:.H+TAK(I
M.LP&="IWT;B!ZH:0ZOTACJ=K/2T=C>X+PF8=XWJ*OQSIF_9C?>WFTL:CJHZ
M5SR0KE\N5TZ+^4*"?W(D)1;%/NL\$|"K=|G(^>QT0EKM8=;=/94#C\VF MS-?
W\3VMJK9?|N;QR:9R05W7M*\XFR9>EGF4R%@DGDJH562PBR-\$!1Q%H;.
MIY\$?:U6/L8+-'?%NBYSLFE,X-O&U?4%EW5.|T>LRC<\$6183@6#*,^4W2N22
M+4BDL4HFG">)>B-3\$FA"V7BM?7I4:C^W-[M,"GEA'-; <@CC5JVKUB: ^"F MX-J%L7-
\$LP,C9\K09 9/&|@K&S\3PBX;0N,6;8TBJ3^NJJLHJQV1|^,=&W0:.U- M#8R%XA:&8U
M9U:AM)29A_R@JL?C>?AQ%X\UM_5&;M/>%F59_*&*3N-'3//Z MNC3,
(8VD8:"BT")C\$>PY)?T:|H43)L9/2;,, "1D_<;| MG5.Y 'GB-T+D5(Y9BWP<%QN:V&XT|L\$6
.@1V"3FN\$S*L&5PSH>9+;A,Q02Y M.K3UMHK9QO:| "R^FJS M4M?
152*V3_BQDB"N5"@N56>AMS6N-|7|T:?(6|O8S11|(A1BF&HSA|0YJH
M94(@YA'E<8R\$2'P+I^T\$4.?Q|X#;_)A|!5!\$4"FS!MXDZ&_CJTNI. =|I
MH'ZZIX/9*F:* M9;|:Q6|UE9PE?J,N,5U(2D.EH38%PUA79A|2_7+E-*&
MJ+9&!S=%|=^RL'=75IS=|R|<=K?| %NZE(6VS%WY<2VO"JWJ9!90B'@:0(E6N
M'84>))A1* +DIMKF|)&UB:|>!*SOY.7,WREIR|0^\$J/Y6NMH-F|F(C\UDY77T.C)SV
M2W9;_G>X^M:E<8@PYR'S!|?1PJ*O)!\$D"0IA\$@749RH;>6A44FC7|,362PDR
MS'!O0GV|C:N=4F8&2\$!X^WA,71N|JHAF?>C!TK|'(/=>()RRMHN,HKN;VB
M5'G*56AD(?>9S^V?.X^,+H|IB5V MZJV0 M&FB.=5/V\$87L;2HT|O"+HGQ7 KU/.Q0|
K73P>_??20HF2GNZJ:1 MGM!YKP@9\$7%TM|L;3N#|3>>WW|3R"?>
>"EG|<|:981N0/M|M5'EN)J0ZIM- M7=5XK;|)0+D,A&"\$IAU%\$"40TIC
5*8%88)+Q*\$;|5M.-V5|H7%;LV&;LC1+\$"-)IE+ZRS|0*@1, MD|17&?
YQAKS4|P*CY/ZN@\$ULT@8*YKU14'|: @!VZ!|= @BAZ(H826Q+_8*8.@D M-
9VV%_6LX60TC9F90'GW<='<\$Q|@_19A_R|X7V^|J5_!|2YI>XTQ:QKZAP9
M5F>P9K6XKLE|:8J=MV|GHYOZK1M:-Y?QKM;L*V2UJHR2GVQ)?5W?QF+C'H> MCV'
A/)%)QBFJ?"A%|(PC\$B HM@H9XFNX(EM| &,9DAV0)KZ9'O%S;P+D6I3
MJV<8IR#,S/"YXY!EOLX|?)8I/:O@0G|S
M*V"ENDVZ_\$&|W.6Y/RUF|@3U@|J>R"P_+RK0?L|Y^5?|6K#W^<57175IN1+
MC#%'.&+0|XF*MHQ3F/J<0XR13Y-\$<|S|T;&0!;3C_M?/W_YN/?E@@@9!D|7A(&%-
PY;^K8PA2H;'ND,V MS\$.W"1'@=X7%T6T,#6VM|F\$,M3O;#0P-
Y?;O7N@|V/B)_V|=B)=^HVMB.99)% ME'N9!_TPRB#R/75?
@B8P3*F?",3#Q#=#87PLPFCLFJWV2AMVU^J|JB=^\$->%2L?@--W,>9U<)>KPZ
M%#!_0JN3"Y,6'7Z2;NA>%?B=;5JS.G.F2<'^V=>JU(\$|;_705D|1Z^D56
MGVVHSS6TC*D7HIZ'(8V0JGA,,R2D,(R|%+4QZE-#19A|L"-O&4+86#?(L' M?%.
S(:ZLQ|0,Q"OP:N967DOY3UA==^O LU=|P-%,T|>*#!MVA^6@AU:K'H MLO"!N;_2|V|
S>.(FB7X41-;|<|@ACE@^0!:_YR_7|8GJ+JX*TL>2JXN|Z>_ \$B|D0H)@91G(Z;799/(S|^1
+YBGY9,?IK.\$44&KM MZBL86Z,J0=|@|J0*X, 'ZAK?=AX@C* @*L&K|I8AUW.^|L20#
20LDB24L4<|813KE"U/2D44P5>84SP:H,8A,& MP,C7+A0KI+K.K\$|-&+4|!\$*3?5?
+C|4D8,_C|N|W0_1K>(\$D>OVL_ M3G'F M:8_LH'=R^O2|_DW.Y++FBZ^WG5M
92IC%>6HR\$U/>E+&B)(\$Y9FF4H37N'4 MJ65<#XW!E9@A&JVH1E|O
:DN)U#I7X^!9(4NQGTQ?5IDGI 7D-!SN=Q^:3R M:8;E|/0+U)NI<^+5|?)S^GG?
RHZ36I@_:(BW%9)8*M*1#>11A+:8EKPA!<8E2K.\$%9IA:JTTO_A2%WY%-KA!
|R!>J"2^'DKC9O6=%_D@S<_A M%0|C_XM|VLIX,|H!_YO7|27*3-P^SIME_3_VGR8|:
|:0^K=OZ5.MS|CV%Z)> M/C?
R;F;XFT|K88*Y/M0SK6EJ.C4%6MHBYSM^,JV"3!9RM;JKA3.5 MLQ?
RH;'Q(CVRA8CV.D1@W;J-R|(8C+YG/6-'^7;LI@R!!-A-Z0>"
MCY_RG'CA_)0G*8WMISPG|A\$ _Y=E7_!;U)_G75CW#9C|3/_+VFN^>?M=?Q3R
M;K;|1#WC|=46AMR4L98I2EAIG8Y03@1&)&|2E&2E1G/&<-"4LBROXB;@16#
MYFVK<&>TRUUDN1)7J1%4605_14U/\$=P8+W7D3=7""T#N_5"?9J@GH7037&%! :F
MFR|#!*QZ7 4-I%W.DAM5@;@*OZ|CG-_SO&F14_W7!Q)W="I<: ^*QWI6+ZR1 M|D-
V#M8)X:00*HE1EE-3GCDQ<9LT07DF5(5)3A(!BMMT(SOT'4O+Q\$WTT+)|Q MTT9.
|7"RBIV"WK2XP>IXS1(<+. =RPJGC@,+TRX|JSB2@-ATH#FP^F@K(+>\$HT_S6?
3VN>DM=>&-'=0U\$P01?Q?-#C#CN&G.2AS<77.: MXI7<-
FE,4LDF1NNCR:._9|/ZH0W2^)^TNNP+"7^03 M?6F//ZHH-
#IW>P_)6T^:&4UH7%6Y'E%4,4SC#A*:HHE2AA"152I8SG("LD M,'|#GV TM|:C8EO?
FVY%;%J6HRV>HPVK;>>:CEESSV#8C0R_P--.X,ET/!Q= M;XJ_9RG-*'

MF4+PZRK*,6<%2W,D,-=:LV9.2M*5.*\$,I\$*P1DPQV^/PN"NLX4-L;\$4??OJ M':#BZB:
I0%:H9_DKQ3O;/WTMG[1]_F7->5B4A\$2%ZS*D6(Q1:A4&:HP)|@T
MY9,BD7I,IW"X"_D8W+VUC-9)YK9>V'+>[K!V7[Z]+'1RV#4K-MKI@^/\$RIBI' M8"?
K*=.X0)G MZ QL/G:\$HV::LDJIM!ZD'+1H&/EA*G,E^IU|=36>=EV-%/#H_#E)&0|>1=-[4?
M(:CTI8F^J! MY@4>9K'A4I059H+ M*\$89HD2?='&6BA(7E(C?AWZ_09?
2/VRNH_I'65).@FV6I!N#|-;|=Q.I^-|_2OYLH@K>
MTJ5|F#>;=G&.07;ZQAAXO6G2T9IVM""NWEBG%X#^Y192=MB*.R5VP/M@5^&
M.NGT#CQ:*QT7|:9|Z3@HUF'A\$Y-(<>OWZ5*UVA"-+.5J1|DQMZ@',S643!@;8LET7
ML3\$.G\$U)IL_S16VA6/%Q\$ZVP"I_R=%
IN4&5)3A,:MRC)68\$/2I*62PQ:TA|#@!=LO4Z#%>H+(J NU7|/#|17KF,:|%>LNUA?
ULNU=_MDLL_9HVDI_I-I-CTFOE-.X&A|7JL|RP+-.*5(B65"-=.,:H,I\$3G&1YP>.4
M5|/%3YP1?!H8VK^?WMU\$6TQ%AGSTBV'@UYLV9&HS!K)'|2>FE!\$1.8-6M"I
MO#G72"|./+BIAR'1!1KP%P'|=0088?ID>|\$4KELNC/S8C7.JP#G20|=O'#_-MUOH:/AI?
PIW:U|&#A^IS&B"S+|I-9_\$DC">QJ4).<&FP15%!"<8Y43%I!!E MD7&0>O/B8F
=U_*\$+%/1AJMUKZ-C=5=OVA!S1Q,K_G-@IMR&QQ;F(:KA?7& M LF-WMOFS0%6L#*
I')9 &LV/AU'5VD4P|>NVRP:#7V*V.=?BLY3-;|W|^>G# M:).\$XWB'V3/\$P/JGHQP9TI&E?
1-IE,^7L_D2T!^|X+SMBYB:I(=IB#|!W2J8 M@RXS'63TNLOL&W>TJTP'X;9O,ET>|PI-
+VS&5U(L=WD_9I#\$\$CU;QYV3SR MN0UPO_V+-N+>5I=
<;"5*_X>L'HK+>+VAVSH@_PBS0V,_OW;^;HH-\$VBNRZ|1E|
MU@O|NV;P3N==NZ*5677U3'K&_WY3H@'FN)MV5NLC\$-
V+7#4"V&+VQK,Z<|A97@MKV|;2#_6
M+8!I+KUA*W@)HT'@"MR^(0QO5^GW\$!364PTBPA+Q|^U=QCK# \$N:2%PBIC2
MQPU<8(%HF2E4E(*G65%*(4!U9W>"|JW|_7K^V|?@7Z97?D=O2|>4@%|*EWE
MD@&ZN1P7(92_8W?P<;T91P4|!%4/^RNTPR!\$CM|1;-
M+YOGW&3!TG>.,M^;L:/QGA).DS1?U#WLWX M_%&:P(-/X6I!WR44M_'?WU
MJ<7H6P|&8).)(G0@|F)Y*BF%
2\$?;.*|*Y_6J2QUR9\$Y&D6\F^EO42Z67^A2OE=*|TJO%6">XJ%"I,XSIF0E0>Y_\$/6AEY0)!-
XP=0_V@F5_,8; MQ./BPQ"ATZF|36D|P&K>;'DB5B&Z65PIDN>F.#I.\$)8D043Q&\$E>
<9FI3*;) MDS4/(3JPZMG8AWRH?G8=>7!PJ!D#IN\$P0QV M^P,400=>R'6L|6Z,@-
+MW"5!W_70H0JR_M#0I^|UI|UU:F<4**M-28509@5 M"M\$J2Q
3@A4T+0KLUO|WQ|/@#;|9M@CXWL\$< <5!VEXD)TVL#2 A059=)ZJ>5
MMFD&4CJGQ>C5+T=>&T^5G.9Y1VOT/9|XE/U3(HW^7;>>07GP&FY5.UR.>##>>G8
M5Z+G#?6(FZ;K@-T:|FN6D9BGJ41YGIB"|F&&(X)2E2**8FK@B7\$V78+CZ>_M-AX;2
>;S!X8-JY8R-|Q%M,1)M<7*VG^"EF &LR.&P|S,PPV\$(LT*|8.@U M4&\$CCF>
I>DFZ8|ZC7!!X\$7K0KR=K<:\$AM;V#S*Ts|MS6YN>6202@T3?NDD9
MTFM|FMCX_NJS@A_U5)|_RS._=|U|_-#66|Q;5RUO&Q).4BPJJ52|TBI5H>4 M1#26I?
XI2UG.RT3DH/HA(.H#FPO;K3./"5|6T19#73|-8/PO#&PWE3\$8A)GA9=/8=)XV\$<'Z^V9V6Z
MU6_U<0_K PEAB">E,ND#;!%5QG")%XJ+*2E\$*5CJ?2|OH#N|YFPV7&KAQCMQP&3;
M.6H_7|W,6)NKGHI,'YZ7ILW,85VFO6|F19QKBZU,4(Y9AK"2L>D/JA_GJN*4
MY%+QS,>6"!)H)3@_@R|(A,#LO;%A!MXP;1G3YPKR|8P,D_8!H&.^:&(<5?%8<\$-
O|R|>H_2Q\$&@_M"J5<+^)^E7&T: K8#|1ED4\$|JN=6*78D,2|D2A*D0^C^,Z@,^+Q%-
BY3HO|0D M=FI5>&3LH779|2WIX\$:SU^MY;Q#L_G+VRO1WIF"_G/9SE;
MOO|ADG'LS3!G,B&|S!&70NF54Y2(8)HC+))""^3*/U=6J.\$1EZ":U)1I:F
MYX7Z,70<5|6%,@.7%U1<^\$+KD2?4BCM&8MREUR/DP1KL>_BHL D/-
"/,E|WWK3+VVM-?VOS3H|'&^4Y712C-6J M.?V W|YN>D\)%^7<_I?
_Z#39|E5<'<2TP(GA<@1D<:03:E\$55)52&4%UJ?! M.&?4J0:5&
|F|E|&:>&2IWT26_DY%:=AN>08|MYTR""2P-7@)&N#|T4W(0'OC
M&6*C|HMN@N_OB8YOP5NXM.W|S(!M%>|XOG1EME^5RM-46J9/+JZP\$8=>)5W
MS2+7W\$0;=J(-/S|-7X#&|2_87&#J0(H9.TC?&#PJN3#)#4;UE_"#8|C?C M.8*?Y;J
WWW^\$1KK;JV.NVUOS)Q,S8Q3I^T8VL|HK%,<))S!\$U3;93*?(T M)465*U!(@S/E@37-
IL#ZBI/=7L;9J*/X(Q#>WC=S(Q!0(.IF5!X@:T/L.R! M#!%WNJ/)& X|LT3^!^*J;-KO|&?
WZ11K1Z6EN|HIG|A.GYH2TAKM%HN)E3D M.&6<(R%HB3!G|6+
<^_J%I8JDR@BI0*6I'.D.K%Y,LU(^?YB9=J6FDF/TU#6P M!VH25Q3=|,@_V"-
E74YJ2XQQH126O_X+D|&(12*NX4AU5_MIP"AV-
&SVZB3"C8VSGH&W_DTV3D^P.W/>C\$!6G6/D\$|8WJG+PJ&*A)G**&|J&0N
M5)D|I%48;@=>AXPBV"\$<;RM&?AC8T>&#&7-31JD'F#;S',*X#*\$PX,3*KAA
M0\$|'C8H8'O*#<(H12'HJ=,|-|7OQF;Z8H*^WSTTC9|L)\$9A4%G+R/X!F!!Q\$BTW)1-\$
|C"|Q0?GB|Q3K1061(GZ8R;*G%. MW(-|B;_O7+" W|""%.8|(&>+-F2D:?

1'8:7\$XLW+YIFN:/WM7[01]S:D1!IMGNK&OK2XFVFFZKGX#VG2\$Z6X_2\$;^B#?_Y0-
K[O^X1-!,%\$QCE""HVV!HFV)(O82;3^X:NO@Q;J).L%NHBW1
M(KU_M+=1"OQHDZ^:"5@N[P]=-J8'Q! 5;[2S])# Z,WKE_\$FS&_"#\U?X5I
M";E[C,G^^(^)^O2%2;GZ%YW#3Y\BJ10U>5C78IKDO,T2\L4Y25)\$6:*(I9KTS?. M,I:CHN
J*=OK=A\2&'H+6E4'NC>E-ADP^?M9 M&1LJ-K IFF9^LM<'WEOQ&+6HG>+5G=|YR?_?
U1:AWV=KY83E)M_>(R+5"E MC\BFXEN.JHI@Q.,Q85(!D:=
&^GE@=6'IW\$2&\$LQRW(CN9M)Y"033"2ZR M@&V> [X#&2.;<4>U\$@I\$V=^^#Q^
)^Q^,5N||?@R0C).DAQ)6DEI7I257B"8 M(IXF6242K)A(7)-UUZ.,O"0L'9#O?%?
F_O7@+0EP?S0;RV)IFY+|KJ?TN;&V M5S!_J%\$Q+DC3W8PU6HKN ?O;Z;F'?
X3GZ7V:S[|H[2;)]69YH^_=;|SA;B@|3 M^N":DG=R@(%7@*:.+#+.(4\$;)IEDU^B::QWIFKJ3=
<^Y. |&_5HA %LL;N)' M?QHN
F7.G972*TGNJ*BCY<.=6P[|>W\PY>DH!AO2ALZ88+1G^O9P_V3| Z: M;Z2:-
W(=P&YB+98-U33T7#9'%*F6 "89DP MA#'. \$T91:FJ.,L+1?
+2J90Q"+P.K#6Z3(YM/^.&_6C#?|2L_%N9'Z:NRR|+
MZ_/_C/EDRPTRTFYG[2J8/IO#&G3G/#)U!,0V:U3,,IU?(!!H4N/90\2|++A M/LOY)SF__?
%@F|Z92\W;QR7 A#OZ_@@6W.?W|H\$G_ ;^55Z#MV;?KA.C/I7-'
MP|F.NQ@(N!EW.090,ZY72%|K|OB@8QIQO6+MV7#|SWHW/5|U@-@J,?:YF6OM ML'PQ?
726IH'7/Y_K)QN7E>=,Q'E&426DN<7/4|3B@J)8E7', \$QF34JT;FH+Z
M(\$/87E;B8^T4>G1*/^ M\$8:V"#0)|XV^1|#S6WT8&6'+?(MFM")JVC6)^DWRL_.);_+Y|7-
M|S M|&@;_7G1MK=ZAZ?|-OLO&OG0Y7%|T81FS_)C M/9/V-#M)8Y(4%:6(ED(B7+
(<42XXRE+,2<&K7&:@BM?G" Z!^V2_VK.@:B M/PT+D>4!F*|Z%D-'>S4@,D
#|3)0X/:HHZ2A#-!SY,:U.!V%/S Q7=^|N%-T
MO7B: +^CTMV;^_+2XFYF,3|V_FAZQ|8V8%)L+L?8JS+AZK7/J#=4?%I=?OTMI M#-Y;
(>JV1>)VA|EU94M&|T3@.\$-"J!SA0F6(Y"1'1)5\$Q3'ADA//?M-CR3"|
MNK)R1*T@QISL1(FV9=FZ(/=N63W:K+MIPU<^EV %"YS&45HC7@';|VZ1Y|/@
M6CV_QYZBGL|AH|/BM?|@S:U63V;
\$&1!|8\$40\|@Z6/,3\$30|?) "E,2X\$*!"N|DX(\$4DF'XX^J,\$Z*M|^<
M3S|XJ>%X8P+C6UPJRX8@U_6VV^>WS|ON\,76GM4IGA1*90DF1EUJE MDP(12AB*ES?
K>.*K3F"-.'8-#3)BR(FN4_)+U.\$*2:(5!PCS&2<9)0(50F/ M"*\$+D+HX\$&A8P-
S4X.5?"DS|P66^L/(*&U&7D-/ \$5@#D4#=#0MX|+^J97"RT
MW<1,GHVVF|ZL&VC<"4VD508\$W74-GM0&H)TEA2MW':98F,5.H M+
JB5|M6B|7/.)H3*14CT=(!-H(#X'UJ@KKJ,MMF^B#>/1-N==H?UHQ?M-
MM%EK>VUYHTZ" J+|HTZXF|9Z!=(,4W?7G4&PZAP8WT"Z=R@N1U7> T.JK_V'
M)N=1S>6+%%(^&|H|K3?77OI)7%98515&M"H+\$Q5>H2I/2KT+5(G05G*6NU5
M=2,WL#+?T(_VVL|ZA-X MBO5)=FK-
N+_EH>C:O!JJ_Z_@#8GLYY9#?)@/HFF#4Z2T_JQT\Q= M,QB"XRPak\$(Q-XW &9.
(21RC(DEIEN1QH913|YQ+F|CZHXJ5VB:NN"0%\$UARIZ)E0+H#;P\$|C\$3_BSX^>|HPT_4
M,12U'/EH* _#"#KI^&-Q@ZOTU00;0X|-YZ>Z T,(4|AP('IU-&"X|=0R7,8=
M3>SONG>FNK;QQ1LYTS\L3?9I=|OQ=TFGR^|O:6,#O|XU M1'09+;_+J
MSVPA_EL\$I#U@7'Y38_R;OY(Z|FDR'->XDRABL"(QFG%4U(23D#-
<\$|26G@%;BA&UG"D:\$<_G2!J8\$GT;+;5,/@@%L57J*
M#X|"/B=:J&#BDW3&C0D^)^Y!:_9%T(="MXOE06CB?/Z|&S::;|_?)K.7V1C MZMXU-
7NV65QK8S1E,4E)S)"2O\$"X3#EB*JX0S_3ZIE+#ST#MV"YC9V!58&HL M<%-
@MV4EVN'A4O,?!+OO&6 H,\$X M|R<#KU'!%._+;Y|5R_B@;VH2C/N|?EIT-
X"2Y*S"QD/)4Z)MFHR8: ^D\$22D2 M*7B*2Y5!M%T/K8%5V8IRU&R3!EZ@ND#FIJD"
0%30VL,OL P *L7!^D"Z8X^ M2J,J!@>|1U>|IRRO!+CX?Y|VR_IN^ ^ES4|^;K|+Y47-
|Y?|6'Y#JY:0@5%4Q M25!;EAQA00MMVY02)3Q.2E60,L6@.B1^;RL""S1:-
%2C3@X@=P36^|+S,(" (M!;G!W.+)Y&^VD'9LM7>9O|2<_3KH|24 FN&N+EV8N/:|)0
HATM+R&A^ ^FL_M_..=2>R48I+@C"L5YZBB/\$58FM9>6F,A1E56"9(750\$R1T|0&?
I4=9#N?|-U ME&&JZ|1;KHF@/ P9>(C-UA-G)\$JD|XX1674A7Y&U/V5?.|Q@:Y35GHNXMN
M3O285313-\$,2Y|@<+?1:SH4)@TP*DC');G0V'!C9.0KE/5.VK\$1^!;E%-J! M|D\ "8#C\$SJ-
>Y,CF#S5B7):?8>%W7)&? E^OG!LO3#4'\$S9^MU@|2_'
M|J^T+9'_0: ?A|AR_YE,2EY*G@1*|1H15;GG#;\$LX0H9Q62E8BR4%5>WR8
M&%BI':ES8%,|6K:BEJU4W3+FLFF^ZM| *CSO";!3=|_#2U,UPV%ZL65)2"P
M#%1NPHF%J|:@@(!TKC %:"R/P&1C6PB\AT*_7/EES:%*H212KC.*|,|OJ*
M<"93Q|2K|!%POFA&I\$DJ=/%W.%(>^ =ZPL)UN"PB==8*M7_., @;P%O@X#I"2 M6|Y?
E'L|<6B(_")#R&)U+SSSYU\$, %0D,02"WAABIX'&BQZ&R+43-POZT;?= MA+ ^!E8
7UQ|^ ^_BV:>U;|OP1B-|TT\$G P-759?^ \$5?U=M M*+P/TO4:|J|Y>>T-@?

75R2NXCRe%)2(=8;>P!K+4F_K/1GZT38#GJ%(YP!T
MTU4!88!H!L0@0==N!D9*O3Z#+5Q!#=1#!(PW9!S6_Y?V!D8_W!N/@BN:Q_
MF)/M\$!PGF&X(!%808!\$#J0FW&B.JBQ,,RK M#-C+EW;;^#2?_="6B!2?9:-
ME\$>3I/R&+J3X8U::8G?+^D>?F!B8R+)"&F MLT9A*K!CP2BJ2(I14J:\$4JH27(%JD%
!&SM!6OU9_AC5!T!9_B!D&(MAM&+1 M^SXXT!0Y&BZC
0^T:AYB_N9"S"!H>W\$)5,%;7'@QZK>3%6Q:@>1Z!+F!J'#"_U!+=VM*YQUI^M?.N(!P!/=I
R6 M]=%+;3\$#Q?!#W,_G-Z"%WSXHC5)UVKPW5PN/LV77Z2MH!OJ"!_981VK0+B/
M.+A#;LU()#0GT6QN:O!97J(5,^Y5(@!(I2_TX4""NJ V^!@FM.&QC+!LX:--
MC)#&A9_L7E4G &1&*T4!%WV!H7'VW!;_?WRNVRTF=&8QE@FH*C5.YW2F518
MZO.0-&[L.\$%8L@)1FI2H3,M8)BS-, "8>_5?ZJ3JM@XO!L%>HKKS>LB6!*\W
MT0S:'.\$.A&ZF0!\$O#1#B!(VX>B7EO2O*YL@G"7@)F0@2^,L5\$M 3?!HRT! MO!?!%OI?
I7B0'YYG8I6=C NO\$ \$U4BG@A5*%H4T)L?;7BR:QIM: MEUE\FW3Z&EM.Z&_:!H!C9LP:
H)^MQ_H>| \$KF=B56RS!>Y^=7!GZ9:Z,) < MAOR'K!^ ^FV?
THJ\$/VF@RU8%L2=%UG*"V&:Z324E-WW,AD* B0S@K,D0SDB)<
MT3RMB!)EXM1KY/6)-O3-
L9&BNQW>%C7:DC5B+!VKO!A@>|*;%R1DGJ"RK@N&LS"JW*C4'(P^!F:YI17!::HX6
M^J!_5O'15(!;O59!H-3^J4M':7_M=%/A^.-HAY.BK%:G:DW;P/1)EDA6<*<
(055F,L/X154D1HPK3,DLKS-(< M5&WA+,6!%!.&*M=9!R9J64"6!V@L^#GXW,RUH*#
UN(9/&ZB+O5DT!049_F# MA6R?HS=R8+:C^(?AUZXO>N3ZOE=*FA "XV4T?
H49KZ>UM0)^: ^: +1>=Q-"?
M7_ ^J%PO!E(E"F%!:&4Y&3#"6Y222A58%H123*>)85B0F!QKES_J!O%P.KD35;
MUCV^R!A-M"HK8M,D+%_ =8X8S0'*L!Q3TJYW1@(6IHGY,+5?71Q:0BCP&PG!H
MR<,A#+!/_/?%XLF^>N*=-7N5Q.!/?%0G_SN M'IJHW9A_?&
!F/^J%.19,JCD5!0E2A)5:'LRQHB46"&29MK4S/7)3(*:'<#(MCQ!HLF;F)MJP8V^6-
@Q%&XZ@F= @L-VLS^\$@A.G_D.AY9\$!f@! L"QI\$?0L
M:;!@#K.@O4;Q#%+=OK&:B2!R63=ML,PZBP!8WPXPXI#K8T5UM3D/4^/?0!A0 MX9D
RN/&:L(A.0C<!C"N!F;5:N=_BMN>54J\$DY27").:OEFLLMM^\$TS0AE"2>@';B?W;
!H!KX*E)KJ4W4Z8:+_P!<);./3== \$0X/F'I80V', MJ"W**X-^H-
J6#K*&JV#91VSL!4.@A^!INGREM^R_V:4S_,V@!Q_O*MH5K; MV(S;WV@!^VB/
"877Q.?(F0/\$!*;797%<)9FB)2<8Z89\$KE)2X%%1Z!FP_6
MQHGB!B*5AQ%6RQ%AJ>NH,7-JFR%Y@RF,B"HN^F/T"!Z*9,=;/I0=\$(.K%<+M;
BD9""41!4X!#LJO^?C;S3UM-9RM26D?QHJU+.2FD4\$1AB;J*<(TRQ_S M#4/2!"N>HPG
E3Z!#2I@4V/->&VVNI-&VBRZ*JN@I/O3^'EIC3"H #3\$9X M^*36GY\$M7#[I*4C)]&?\$\$?
A(YORY-SP7,FV6-: ^?]+'%G-NY/K!;DT6?6=IV M8C;\$XX^9V/Q!U2W
JA.ZJ+DI=J@J50B4X%0AS"IM9Z12HISCC*>T+.(8>Q@; M_5@;QPC9833:<&J:6*QYLW=
<.!Q&OZSX_34R'!\$EF>@8@DP?XX::*3A%-5
MGE.P!CRR,H7ZIP"NVL*!%DH"!N!H7&49#L(#K1IPZ NJG)E+HGOUH9!1&:_I MJ/-
!4=M+)BUA,M0_P;KKA-,YRI:TX!6# QR.0&1.&3AKG,DOZ_>Y0C"T1)> MKN_Z?>?
Y_H,8JJ\$2;J06X5_]756!HT+WHYW3!.GV?+B5*X4'E!49K'&<)8
M4D1)Q5"!R&\$XAE7%)R ->^"AA.6F+V5E>=@I7679@NSX\$53?M,1!6,"5R M
4Q@Y>\$A<="=J\$|JBK0@&1?H_@,X9M%-F^6)G!G63+NYE>E'Q_*+UV=V,M-
X;Z1*54L"KE**ERJ=4)*4V+XAP5B<2"Y465*Y?Y"S% @96(I8\, Y'AX"9: M!1
9)J(5%!#;IW,P.EH?(<\$!FAX7XN*1K>;H:| DFG/T1LYM<13_,.7\$!45/
ME2"GZFZV>&Y,G:POTG3RE?N!YA,>)56,8HI9@CG7"%:*JT>JC*M*H%I3\$%I
M!@XTAU8+FH-HS0)P!3L@YKC^P^ (U!\$ \$0=^6%#V@\$"AU(##A3'503N\$!RH M
L"KEW1*. B5U+!H&Q\$O#%4!ZO=)(C(5ZW:':<:7(!RK E6!4HCP,B9%(9,T
M2SVN+YT9&.>2@6163LBNX5E!;BG5^!L6!H80O'Z;SOVRY')NO=[M?)*3*]/FB M0_7-
!:+F,4-4Q JE@N(X)IQ+@8%YMFZ4!SY^!ZV#2>1825JZS)99B*ZW*K. M#|! =038U808
#:8<@B'F\$!>+DSZD(<5%HG14G M.:IB)A'/BZQ0,N%Y FI8?
ATQ!K^6O;@45BM>M"5?:R=\$2RWA01&C>K9N!>VK
M5:_T;/E>);_VKP1Z/WUQ':LA/Q"_8E57FY^0A:G&%V+!(E17FZBC!:>NOXUO MG/-C?
5!2<33)T:<7::E1J"Y!^"Q/Y!WG>M*IUV49LV:8YR!FI<,U-
MV;'Y=&H>6!EM(6.8!R4!%K.!GCD&.5!@0YCD@^>| %YD7\$!A6XQ^L:QC?L-
MDVR6+Y_US)L<8J,"GLS:GZ0LR2CE"E4Y8P@796;NZ3-S519CF>O#M_15;_70
M'GB9KCAI"W(L_-LBZJGCQD;%R!4KX&7LC*_S.A! "-9@BV_7L:P?8BI&;R+)R MT!;/NP-
>+HE>9;U!^>G3W;I=VV M-
Y9BW=UXE39U/UL/I&RE%)QAI(RSQ"FLD2\$%:DI0D!VOKFX
M7U&++'3(LEE+%&1E1AAF_4N!Q25_M598(PB1/"U \$Z9"SB!&1!N(?</p></div>

G,G1">7\N1C7,W09 M5 =>HPN\JN7WCPOZIE<+/0AF=4S2\XHAJF)?
_H,ZI0&U^M:KJN"G+;5\H MDZBR77%@L=!'97TD_J&?GSTP M"U:JQ:J5>>?#
JON4L<ZKSP00(&_YC58E:PW'-J%FHC37:,,VLGR0
MASI,U'W=FK1U^(7A/MJP'S0H:T!XP\5S#<'DV*%(@ P)))(IL2&J^T%3_Z F
M('G+068.*W)1\AS,?<_MPD2DV/:1ZP=6IY9/VG:G9KBGV"JHJ?+9<M%?R(4QSDP8I_-F?
G M;;;*?-'^JOVT?NQ:EV3U%PF!:W2!,6F!#DFLD14Y@IE64\$*07-<\$?:KEDN8 M&%B-
KKF*5FQ%:[ZB;<:B+J7D&,'M.)7E@"&_I>!'J@*<8(X/KU MQ C|P<+Z8%P(2F);#-
^OO^N"<:'T.TTP+AWKPF32KOEZ=P:80%+&*2|BE.82 M:JM94E2EF*.*9)+0(B|3_6P1?
H(29'EX=0J_VY37EBUESU3//80PQB(C/\$-% M%2<(9Z8D<48PDDE2\DK&+(V+B;U9&0V?
#35G=&Q,H8G%:2L7A(%&VP&%Y+1" MK"("X4*:30-,H2K&-
L0="T<*:,"7%O@_Y&;D=>P)|'+"^U#<
MZ)>.Z*|#Y/@>%RMT1N|>E>ODIQX7|62V|HG'0|VN;U_=...^2@N92U2DILVI
M(@FBI8Q1P4JJDCBC>N%>=DN^36Y@,_XNY!7V#DQEFB=YJF)\$TS)&6)8,D8*: M/4
(666I5G_*MC>&_ISBQP**M|;>U_Q0IR^|URC#WEW?DS(P>|=XA=^2H
MF.#G|Z2/ON73';3_NK UIN|F'VOY?*|,BN/;^6Q1BR|Z99+RE*DX\$RA+:8IP
MR0I4Y5F"8HSS(LEB&9,\$8,,X4Q|'G.GRKFK+B|FKFFINC,>)FZQ=OLT0I#>E
M\$|0.%QGAD/*KA7)%="!M.D.CY-F3,P!:P.Z;\$,'|6VTZC31B7TV(9+M--\$%O M>NC-
6ZX_CN>I43BKLA/;^6|=A9I*TIA+3E#*B.G/HP0B5*M1Q9*8Q9)Q4A;.. M%|1.)
>V(|=X."AIX'%1Z8:B@XH,C@U,16|'#LBX*LY,\$/!@X T9'"0_#1D
M+)B"!G=JR#=#1AI/08(DVU&0L#=#';_R66;O5OS|K?&?EU7P(49X41DOL+;
M|7X2Q\$10\$1Y)A)!&4D)!2J> V5@|)"\$8RJ9E MPNS!#+MX-
W^D|6S"F\$DS4R4JJ2DZKHSG/R\$9RI(XYKS,22J=--49.H,K)+; MMBC;1;*(FR)0VR5'J@A
M++++SP0::83VOCV=|G9=AQ^!R>/R"HF"?YU/|QJ(|M|.Q\$&)E<6FTG>1|*Q*
M1(5\$4@B\$!2L0K2J.**M2461H6-|O7-
/9(92*Z7^1R*T_SICM66MB2S"8KAWYDW'3U*_W0_#0|_LU
M"#BZTS,_D9V)2XN;@/:AC3I3=?PH;=B MS8K-
?;"|>X(ZC+J@%IENSGH#@>K2GX#MP>%B!^^4Z@3|6LU#85 T|_#%#1,
M**J|VTQEL96./|.U0?N6CLH5X528"J4(LQHKDU F2,IJXRH*I6B E5""<+5 M5?
P+'9_;A33J65=7^.@B|C7-LFP)E\$F5 M<1%+7B*ARDH?
OI,4T9A2%, =4JJP0&>8D)!7\$G31(O<*S0XQ;T09Q_*|L&OV M5_V_CHF(KKF:4L
L&XJ<1BX8'K/(&6C@U9?40^|/|^^(Q?.YGBM1=QQOG;_ \$ =_ S6:A+A#JP3" (#D
MA7G>W8C+%Q/<:,!&|4(Q4&=+F:HEPEA8FB5F@F&1YDI1)FI<@M|%Q,@,K|ZU<
MU379<|;\$)\$#<-.GEHL.4X);4_ ^>YJ1>BYFTD<:"H%3>Y0J?H|A*Y3H;N44%/ M)N@>?
_JR\$LFVU;:".H*/^A=W2_FXF.0%QI3"%9(BRQ\$6!4,TTS^5I"H%|[+* M*U#/NCYB
Z_8==W;+=K1GX9Z9,D#UVTO;&ZK-Q08L#7LCX-W=|^0/7X3U*
MZBKE=/N\$/E45M_<=O^5M;ZS6=5XV1\A5@|VUUV\$BLD06M"H0Y46B3VX91A5-M",I-
Q9%"|T!TW-YTP"&@P!1\$ M+|'Z_,L>2'>XTQU5D8#AV-'
M^8|_UR|V2Y.+S8H|=PHRZY?E-7:.O/497&;7Z3-%-RJ=/_VN6G,YJ&2(DW2-MA*-
*FJ(O99DC2E.&,I8317),,0\$%DY^E./1:Y+PQB?NRXP,U+2.K|ZRD@4/T3M.|2E3=6?%!/!
<*=?|'7-3-O MEM|D|V@26;|L58I3IR6F#*!B& \$81F7B I<(E&)JB0%5W'B5.+@#)W!72*:
M*C)D;?I3360H Y/!SB'EZH.X6'ZH_|!+=(|+_U|!@EW8'Z"6MQ?WV2O*;3|B8HPY7(A*
(H+HH4X:(H|OI.%4JI M+(J893PAD
:7;E2=ON*+RSGML&'3E^;VY+AH.8EJPPH@P?;AF/U+.R V7BM\ M%P|_-
NPLVZZBWMVM!0#DO0;%Q2_|U>E|'^5N@U%=G>7LS8,^/,EXBK+-\$_FP
M|F|YVBO\NQ3\K6P'?G3?#9?73BTWHJNEN@WT|-KDI%)JS2K9)DBQDJ,,|P M(I125
I18*ZJM\$Q ;5+|V|C:VNF8LDV5|*>^S=-YJ?=MLHWG8K|-4'C'S?^
M4IS\$69E05'&3#U')"A%.4I3E*;<%3SC,,XA>@S(P_+7-NJ:80R3|1U_G*AAW M-[4V))K
&|KP0((5F2|:@508F/RHRL7G'VUY3V.G|+2PS_6|:V_S1XS#;8?
MY(S7O8MF5:66N4E6* @B.\$2851ZPJ")|V./ MK\$8LM:@E!XKO/ 9#OQ*X4#C8\$H?
(Y;R\$>R3H<07KMJJUJ7_8+EC8XVRX'J\$ M6"VGOD<|KU':3EM?Y-.,6MRLOKOU>_TO^;_
V^?%4ML*S6+"8XS3),0+_1^ MC5!%V=.),>^KJD:QBWYN1F>ZO1)W_+3;1F!WA?XHZZP
MXQW)(+@!|T5"00:;!0%+'^KFPYWP N+<=8\$_.;CC@(WBXK+|^5<_\$NJQY%3-
MJ62(V*YI:2|+,A/LYG#ROW MMK'NZ5-MDNE7H/WJO/3:U/ 4|T>C?|3TE; M;W_-
)RPO>\$D(QZ"QXBM# VG;M 5G?.OI>RIY\$RDT'AI ?ILV1|?+K.F1 M*V0BS3\$RX^?-|A|_
\$VF|WG8HETTVJSCO|'S 8WJ5J*+CJ5,YIF29*@ M'.<*X3AAB&
(L|8KE1<8S5F4IXBE\$A"W.?JL|YC\$B.A%!Y(E0L"0.5H^BA-
8++#DJSX@7T"UYBM+H3L@S(A|S.9Y| MQ6|1_ 'UM_DAV|G|C39|1+=K|HPY%6|8
=XK@L%U4P5#0 ;3"Z'0 JL) MJ.B!=(8SV5\$5"!2,?6T"?</p></div>

M_*G5YF%K&9,H\$H1(5/-F0FYJ&|J<(\$Q=MKQSQ\$:>*EVX3D=
!9NVYHI&*&K1=PI%ZH6K?|&&!&V9/WE!X4LN0CG M%:_4._!HP4PNXFU'-CD|H0%Y|,?
7=/_IE#;OY&S^6,|,2'0>QU_EK)XWG^;+
MM47)%=%'<9FA4I0%PCR.494*B=*J4E(EG\$GEE\$,!(3JTJ?ZWKU'+!Q(:1J+|
M;W^|U'+3&2Y|8D"<,6U?Y4/A1;02G|-0\$"*08 S"_\$PAFX0\$\$80,%|PS-<MQOHO<
_HW4Y(!_1=W_8|3?U#?R(FB<1D^*YBNO|NQ<_.L2_O7(0+*RG'S9,M15MF(K;>|G8,A-
EICA#.3,MLTI5HDHH@:00N"*Y\$4&M2A:|D)_!08;:'.X5?|&&P?;&/K(L1H;'J&/2-
RW>;T|<=..(2\$-|E'X@CY0Q-M?Q%:P5/G_-BY4@|H1="=3J;-;%AXO=#WC4V!O9W1Z'QT;
|K5#3|K?KWA"B0Z|?^F7.G|G>A<902J*GAQTM+JBY|3:
MKBYZ|ED_8|4VM%LL3(NH7R8-|8@ZDH+9B*I,L91*4S'I@I7B+"L1)R4@LJ"
M)@*#S)"3E_9>H|?;0)K_1H8=6H:|XC:&;V1\$&>B!^*2_HX)W_K,"!
M|O33=\$;=K<^*N|/GW_!XY|UOJ'3=|WSPSLYU8>BYF5UK4IS4BE|QLA2HI>Y M-
*UZE8I15C">9@F1:>Q^K7J7_9+UWE6>>'6|AE^WG=N(L|ZJ%:OLU721"K
MPL0Q;MG:9(=|F=RDN45\$X7(4*EXCG"<Y>GKHME0*+ZY@?ZXKEQ7Z&-67!"|C1/\$<:F
M)BHA&:
(I+3A50N95"CE|.5&|PDELOQGST;H?"P^;N"6EXBPTQDN(DL.Y'E9R37#PR.X+X>1_)7|G;
<=R#YHT6_OW|Y|_H_K/W1EZ#|K'ANY MK)NV3?5&G2X^S)M/?-5|G|J+|F5YVTC1:V?
4_/&-;&=%#3.DXP5^F|9 MR3_7YMP096I9J|Z)<'6L|^_7>|9RVB1O+YPI|ST
M^XY\$VYM!RQ"J:|08+?^VO!<_VOS>Z %XE""DO_T@KY:V3\$O(E.N<,QU"
MH3N^JKX|JOM_Z'7-AB@JV?LI2YD"432.2IWC)%&2-6%ASLP(N M28|S'(-
Z|.^/O"^U='R|-WNXN"V17A+!|/3SH*!%>91 0)HK=VQ1U4=1|7: M7|_"_+MRJA-
ZC=T(<5V(C_QMT^AI;%?UR^:1|B+QUL1-O?_G<|U|V0L M1KA
MVWBS5N|JGEC3J|;Z*UR#?12NBHDSJR8D=&|L@(WA:E@#:|O/Y<-M.7?6O#ZK
|ZJV"_EC>,7|>95?%\$>/41?SQ0&:UCZ"D0:N3OJ*Y#XU(W5: ^+- MLT3\$IO.S-
O1MT/3W^52_OVAY7&=;)2G|6'*&E-Z^37AEBBJ.*R2S@BJ2B\$K\$ MH-
;MKH0'WEH_WMV^N?MX|^WN_=?HJM.|Z.O?;|^_|O|QW?OOWS|7_|/29/R M?T?O_<|^?
=|_<\$UA3PA57M|UH"+1@.186!S9/K5/_OR2D084-58W"E>RX|2F M8!Q4K(" ^?ZFC|Y-
<70Z86X!|H0-6A\$A>*1X0A N>(E8EJ0HJ525<|6K._/U MZG*D.|
66=T|SMT:4<:H^6&TM/%>/1G/_.+71RI&:-_9Z6G07EZP;8'!/ M8@=XVKESL2/XN@?
|HP7J%0P&MK|ST-S_KW"W3(SD_702/;CCKY_JE?Q|3E"<M=O.YO>
|9|G2JE_&LRZP:+%F)*I9E*%=QK&2)>9R! M7&U'J0P=0K"A&6V(AN3'D7'30E<+ #
LR0/%A;A_T6Y'X'IR_2=A,U*_|NOI^;|OUYDJJDS+*,HBJ0\$FT@%#EJRIH*K"11 MVE:
U8)WI#OPHMWAPF|M'1|VZ|J)5JS8?+6LBNP;JM|+A@ZST,4F U)0|
MD&)|PI3JJ|@!"L:|H*|Y&|;N03K477*GWEH&P3 ?<,6R:5Z2"1(R72'&\$L
M"6)EHG|*JBQ+&5>T4,Y)'YT!U8G'2-V>;27KBT3@,0\$ (-|FF-9&":8P5*
MQT1TNP=.U|X/G+*|+|(+D,TQ#&Y^*1TK_&2'G_FXYA: |M#ZMT")""9>|,Y M,.-E|
(!EW\$GK|/C=7@-"Z.HM68V^|H|:8J:FBI?^H,QU|NN=2SZQAC!H|H
M1SNTK4)O91%+PS|JB|D G KR4-X4!\$+%|F"EGT#CO:;0L7|;8+6C@|W)<
M1NIXAS%6%6%*D*\$Z9C_L64Q\$7D(T+0GS@S6?% MBO%I;:*@HME-
2Q81>/7^P8\$|L)N^'PHVF,X.@1A8Q?J(CDA-@DB/JNH0-E7 M5UYCP\$^|GW||V9.SZ|EV|?
S0-WGT)?JOB#|+1LV;1Z|HWTJ>=S_\$KJ4|?V#U
M\$0QX\$=E#U1H<5|8K_/H>I#1SH|;&^?,P_ ^YIG>^B0;:C('F0+R:* M|%
|H|9#V\$FE28)YDI:@026*|G|(L1942'-%*%&4J2EPH-?DA&S9WSCKMHP?Y
MUK;I.G|JR:^IM29J;R#* Y@K|86Z"#0_+!>^&2L1"|R&&\$F\$ _V?.\$=5)4ND M|@PG+.&%
(* HIF#@^54YD=:AUN:%F53'H>%S,S:"@0+37I=|2O!44!<90^5G M|JM(-
VG21>R#3\$;GE|QK.7^1W/3D>P%9""?J|L*IF/'U|;R#V;RY6S("K M.>|B<-Z2N%1XH-
70*G=8"Z-/R\$O*..|..8)YZ/B""G??PYGY*+LGG|.*>S M#WIZ/U|N2Y4=-)A9-
;I5LDH5XTB*5)C#?H&HWE@1X|PLXY*23#I%Z4\$)#|QP M;=-&PTID>(E6S\$3"59G
MO/Q3_Q9GA\$O?7Z(1_-Z(A1KA4NZ6:_1X_SH>Q4.'4"XE+U)&4<%BHY3S#1%!
M,E2E3"19S(HTR|=T?XK^PBO|@:|EK_07|2Q|ZH=Z_=2?T6RK|F M=QK3HKL-
F_G,YO=UX:K7YKJFR6*68,94H4"!-) \$6-EB2BEA'-9E\$GN7M|H MG|;:GE%-/JK-I4AGQ?
+^:-L;B!W5BZ_.9C.X6"*3K;\$-|\$(T5|A4679&C^ M\$AGBX7
&.3A|V"S@2_!|6;|NDG;:^^>&6(|\$|=-EAVKUO\$57T-VWBS-..|D M6W|38|S^K!
<31047DE0HCG&.L,.,9G&J*LT#|06B:P+.)C5_8W*#5-9\$|J MANI-9.A&?QK*0\$?
<8Q<+;H+)8=:91Y">YA4/4(%XN.T1C9M.D1||Z7O8 M;W&^>5|4,|E8:
(.'==&P7|956.^\$5MFUJLW-8;L2;OD_G^O&AA9M5R5H2V)_
MFK?)0;/EUM|LV/LDKT29:WL%"9Y4"*><(JIR@5*1*4JJK! X@:SV<=@>6'VI
MA(BVI+!535=%<+<%667 K\$2Q,8K;%3TZ:6RYIDZ>|,?M(DT,+4TTM?AIN=>

MWYS#%>KFFZP0AX7_4:~B2F1|TRQIV(3UH9.H^30??WIG|:O48|?=UM=M MV;M>
I/(W6L|L|5REM?F:J|^LRG:K=*4T50?JK_-I@@7288J_7^H*(R444N M2K?(D"#
<#+P%2O,W0:1W%CK+MHP;GZQ8MUJ(AO)3638CWXQ OQZ\$US\$CPW8= M;O-@7^7M
>;X: _YJS -@E;L?Q?%7E(2|<19|S^>-H,P%L&1D(N?|FDI<2 M&;\$-92
|=AM64AHT5,,VVY|7CR|LKYY)5|29U;.' MQ6?96&?
4IFA%R:@BHBBUN6I:*I050RS'%5ESGF6L((P|LJP.D5IZ/#(CJY) M/VB=N|LJ9,(N6F"
(+#+5,"AR&Y%3N Y4.=D"Y7P=)+.N-E-Y|0|2&4Z^X*G M\$^29+>0_G_7Z?_|#_Z<+3J-E6?
\$B(8BGA=|&99HA@@N)|"ZN=.,QX0(D!/D
M&)6AG2!KFI\$EZIGJ>!P@1P_(I6(#/2!@B>'NCSZ)0KD_CM(8U_W1)^:|^Z/W
MX4MK'I^H|O|X-)V_2&F++G_6W|_W_839SDUN8QL=8NZRVO"/O1I2>5FPA\$N"
MLM+T4Q:L0E4:8Y10EF>,J23./?N@|N?U|0?>;24);TEAC|:R^7WN9A/YPl.MMO'AV>
MTRM5G!X|M-5JHG IWMD:F|K:K.? "JC?|MRZ>V/U/V?!.LSTI M,E8F0C!4F
=SFFJU20ID0>)UG?-%K5<1(-G?0URXA/\$IL;G |.S. @P?3-=?\$!N!R#X^3G
M5W3!*Y"K\$"1OKS_0:3OG'X@R78|>|W/=UW|8|:R)E8?&ZZRAQ6&4^RHL|I M@1-
4%\$(@7%0Q(I5*4)HH63)>5KPR4P^&&Z^ 9QWQ|DY?>U|Z:|R M_60D40|UG>,U8_9ET"?
^?*&V2JR >7; (W|3&OQ6R,U)< XE/W2\$^7XMOC5+-Z:R.I.180/9"
%0A4I:S&"4).RWLRA*1L P1 M+:7@E.*3ZM^|GA-U?SF>?|VB7(67S6S_-?K(!
LWBPVSS3;IV MT#@|Q,#KT%".+.FHHWT3?
9C/E|,YI#%D'P3|RS*@|+!5V2=XX)P01QG|&G+T MC#M>CX|SPNV|7!XW.-"Z.WW-
|PLZ).G;J9Z=AA)_Y>_3%KUI7KOM&?7;V.O?N??/IL M2KC?/LZ?|8|^639+O?
GH7WR;O_|)'TUM#_WX%|E|;F:++_/IL;4\$(DS1+ M*.T4J\$Z\$ _# M5M3Q!;0*!Y|7-T/S-
&.,BB.XV5DIT;|&H13N"|!C-@@(OJ:L%QA0*_:L MA&=LV-
/OCVG!GI5BSWX| |R/)V_>W1H|^~WFHW@!|K^_ASCCYDZ7_-X"P%2"
MYCU@X::C3'MZSN9C7FX?97S7*|;_1X_|M0067MS.Q"WGS3.=+K|N^+@GYOY MD|
|C7TSI#5,^U01S/YFG)WDIT|PD! E6Z@.5)"5B+,6(J3(K6"|CBA7..Z|7
M"T.OGXXG6|=H094).^WXBE;W=A.:27*1Y#O&RF4C>5>VMOFZ^@1G.T1TOKPR
MITKR7*",RP3ALLP1R9E\$E2Q+DJ:R(C@#UK,^0F9@;;XB:N|0+%E//^<)D-SN
MH2X7:9Q?:3V*43=(U2X|M/"B(Q==+|T".EION>A|TOC7BMFGN9N(3?7I|
M'WKPTM"W&)|J\$^Y% C5YSSOPYO26!+YEM#S077=LJPJ>TN3%4#K86C7B%!1Y*C-M
GD=2W9'&NUH|)\0="M5WX|#P3IK@\$73XO|I7YS80R0;- "<,3UYH1P
MR@BB^I2"1**RI(B+|!'EY,GFF;Z?">?MZBQAR.>X2|HYNVR)1@M+U2222&VY
MS57T(BFP<9P3DER4:F=|/|H32?
K=K4_C+=9&3|.@">2%EB2N&4F+,)L%RQ))H3(I6+(+B"GI1^L M\$|@1DE?
N!G(:A/,=07K>|;E=FR^6C5SJ8YLM DM YTMZ|W)K:|O/GI^|H%4;
MQC&1*#.YISC""%&5"J0JHG)59AF/G;0%@.;0IV<|3*S|UC>F,NMK8|B|BA@ MAS
(HB|W8|%Q_EZ(71DBR(57<*C|;KA68+2ME=SP"|3^V@.' LLLMZ%&O+T" MR;9|705|U>|
(8 O'O)T_/M:VF|M^+?B8ZDLC8W*,HJPP@Q17&\$"UG\$|8Q3
MQ4%|K/O)#P|UT_5|0OSL<_@YZ;L14.\$YBFO @.L%'E)F4@<^H.L5\$-*3?! M|TTHQ|?
|%OTMU|O\$|I06@97+56/'#YKU=W)1|CJL/?_WVFTUJ|U+.'MW3Q M_<-T_I?M
|FJ1!Q+\$F.5;I3EFJ#*,TQ(ES%B\$O"E"AE24M0.20'FD,?1'=|WKLN M|YO(<"NC.-
HO2"XP13*=|G,|>T,?ZA_42SAYJHZ@Z5V&@@Y.'F(\$TD O% M414,(|_0%Y%:8>A*PG|V?
+6H_|S*8UUUJ'+B?\$M*NM"H&2 INB0;) \$-\$D% MRHM2%3'.
<7<11\$<'7W@)=_2BUJ'D:7HMK:/0|&_BB|6\$+9>(:Y+|%>&7I MDOJ|=AWJ'S;+
|_AHHRRT7D%62ZK_(:^|H4|I4XK;V,R
MQ|5/S_:S9;@T=P42Y6F6(HSU3|QX9M(\$RRHF90\$,?QN+|8%U0X!V#NMJ^JU(
MK6'>"67.RN;7-|&68#=1*H(C1J|@7XJ;@GN-|P|3FP'+(2?^O\$.*'C.P|7| M(T#9_M=H?^
Y&<&Z&_C2#O4\$U_UXK|W8A|:FZ195<5% C))<*81)+E E%\$8R MYZ605,A*T2X&|NN2-
MX17 >4X4%P&_K.NF<59S-?DS5Q2\$P^U#.3AAPJ&ND0 M5L8DB1-I.C_\$!
<),*\$2)S/0"C6F<)*RHM!EP<6AA %#!D87'(0T8VG4(IMM. M&1@>V"9W/+!K|+
!T.&4EY|=6G_=CY; MUOHX,WOH.AWH7>"-5/-
&KLL%R|7O|6S>V.XW::ZQWB|V1VF;X_PNE|_G8LL| M-TE4G":%D"A-LU@?.FB|J-
;G2*@JRX5@1.5XLIPOZ=1-TXS(.^CD;EW5+Y@G.,US%-\$.)B!7"HH@1
M(9RBJA*YMBJER14"17>C>\$!ZW<5DX6_\$:Y3FC=.X+|)1 M?(&*_#-
^|J\$W6M|I#*|I_EIX+?9)_^LWZY_EJD;^5Q5K:"/5OJL|+_GNU M+NZE%
<*KCZ7|RW/) _UG":E/9H39Y/%>^*ILVCY+?#D.UN0|:(T.|%=;=8P57 MF^%U8)Z;ZX?
FEYLRWJ#%&*-KI^>ECFK-T;ENE7G""5=WIO(F|*YB?/0M53
M^*>V6|SB)%XV/^:~/Z#&>B-39|FXF%W8C4PC2RS,9CW9A:QO8%D>V2#E|V(+
MZYOLN_Q.RUQ=%/U82XOOMR)?+P*|BB("?:#C\$O;+/5P\$A*.4R_.DM@/F8CU

MVPZ9\3"QYNZ80BU7S2)'BJ\#7;#C#=#7,(<4=('2<J&->Q,P,)4ZIO'%)!D
M.CVV9DFG6XQ)B_%\C3%7&&<*X^<.XW*'\<55CO)\$,VFH^,Z>P5Q4PZ'GRIT=
M)_M>KNK(H0S#U\;H9-"?OWG:1.\$:8^PRX51/7#-O\I?RI5NNW3\>-:VW&
MH\4/OK\^|+NBX4DR54A5IOJ(\$ZP\AX\,WORZSAAC<6% ^AQ'RDIS+M^4B@S
M1_K^4/YSS^*L.<>/_V\$V:9;\^;7G+=-*;K*IPN?QHE@28B9\$Q\$#"|(
M96GW.T=EUNWN@JB'^\NEQPW<)\0P;U0<&U/R-'P\$R_+^F;_J-
4_6:*F<(E!8^)C5#2<\$Z-DA2U#14J= M>&MB=@0\$>I&"6KF!
*##0:GY5G|-1^-9!|_*S'.^=M<|_9=2L7;)5K)O0_MFN\Y\>|FIGZ5?
=A(*H\JRJ2\Q*IDCP&D..C28-2'N.4"U.\|(H0::L8N,#"|\RJ8@!K"V\3&M#W\.(R@_M7>-U);
I00_[B,'-VE->5Z:'_O/9K\!(-7^4T+&|?Y#&SS3=D5_A&X8\]+PAP_M0"
(\D\SQL9MD8>0PA\B.5IWX4X-/K-EJ\46V&H\%F*\|UP3HO^98:SSQCFS.45:==TT=60+
|^)9%/(,ORNY3MEZX6:!\MDFS"U3;Z\|:OKHCXX#;,,3_M"_CIN0DLH@);D*,
@>=PZ8EI*W_KK5Y<|?T1#_*V\)\S4Y+HTKY+YK1DBV\$\|W(B3P=8N!E1%<|<3#W?
Q83SC:1ZQ.G&=/?Z_3-J97_4=L?E6G?M<8&V;(SK?0*2Y\Y-V3%'\,WB'
@X@2GF1=@3RE2RJCO TGA1U"YS?C<_I-OV
M\$0<,@)R\;8KL="|J:E2\GOE0JX\|PD9WF1H0=Z*64Z7DC\$D.4,\UHSN,L\|C-:P!IH_)MOP-
M\$\$_V\$\|W_F_P\|K\|/('7N#R\|*Z9*\|7+|HJ2_(IRP1;WV0WA;@5I7**D'MQ
MN\|+|9>"E2HZXJ;H5<0\|V3^@5S""")T\$|*P"#R&_ZZ*<"5>AFD8)(\$8^(0
MK6*4S#2!#;03Y4-V\R;YQSL!<"T!^M*?R5Z\=-\|3F8J0C(-X\I-5,+',|BN7
M\YD&_,NU4R;B:^D0WS6<>"K%@\VKJHUQGSR^2S&B(D0_@=ID.
(T#AS,LMAS_(AFL4NU(P9TJ4ZL,K9L_MU"L_|3%2-S-N64&*%|!-
N3:HPXID,JA@:N3540)\$%4R!EEEL@1W48!\$&4.D'MXPRT!YLOV@_JWU\,?
AEX^IWM=WW431_?BFVA#^0IWQ-EML;P9\G4>9PADG,M\$QS\$08!)\JNY6,|:I"(+8B;7"-
^&DIX\|^E#E8%5^*FJ\| "MINTBIGH=0^K_M\|>9TP=6ST::!#*9?MZ?
9=QT7ORCH=@JDY622BU@X\;JK>D2GKM<&A"0\$|7.
MH",8YDH*MI'6X?'ZNLJX<1^H2Y+|0P2^K*!'_MU)4:QW'C(N%\|8,I&9*.5.=E(1!
<90I"7P=?BUY*U9WJL_L,%?RX+6)E_OM MIQM4DQN7(GDHZ^4;Q!%BPA:KF82@F\|
SLAA=^AV.-=O\WADA^E=YYQXQVV?_MMEKQ/_/ELLY1SNHX\YAG7J)R(F,F=U2?
1Y@&5.T9%'?#^*7:T2-&0Z*W(XX2%+;<(#*"M\|>SX>9T_D'+G5=5_MZ\;/JT>2%PM?
^|D/H@#')/#E"LP(3L8X<0A6,JM7,LHP=;R0_52\|8Z\YZ+.C4W5=|%-
I&|H5C"+2\|KYXU=3!_MUE0\$OR40*J\ZPZ94G<(77AB'3B_BS)1J"*BZGTA8BJGC.@&-
E,||^9,.T5F_M8D70\$44MU204TH6ZR4Y"IL2&RLXU/T%E=G
R34DDC6'UDDB,SNOA@0|=E0-_M/CVF^|N/M3RV@030N\25?I5UC48ZRE?H?1M:9\|I
MNH:H5EN"G*;T"BT\|D4^W7)C^)4WU5#V9K.NUM+PS8O\|@|*#;7-<5OF3,4A_M9&
I*'8)#03(_GK;2V\4\;VYXJRO,_Q=:X(G;J;F
MN%"NK+7,K0_QM9OE@S0C|E=E+JK;)N4B)-0G,78C%N'<5V<.J&#>>IZDEO/1-
C\|@F+L-EH!WL)@.G;MPIZE_-KM82\|HM\$F\N(0IHJ'KG=-
UZ#E,DZ^|.6'3M>|)%G'3U,88E,G;MWN2_MR,R?Z9"@QU_DX--F'Y_3V\$|QDL19
MXL9\$'CU!-6^/*\$P=>UG3;SM7P,I-G@=%;S&.\$A6V#F%2@I?@64DLK;\C\6==M>&?
%.UQSYQ\TZ-FN5T5XKM@JL'4R\|>-N%LI0\|>HQ\$WVJ-IN\|P'A\;BNAG\|E_AJE'/1K\$*<@Y
M"F5@ZB0%EAUEGVVU2Y^C*W4AU/L\|+H/"K?F!=V\$(*OU*#XH3\|CFSFYAB"
M8>NB"DI^WJLE0W".+H-,QS%I^"\$J\ZD-OTD)Y=|^YL^JN?->J_S."AZF=89*5
MVHHIV4\JOKH395WJO\;ZIB#\|8PFX%AY343KD#/VQN'%-*"8G)H#=#M23,Q
ML%0%*"&.UB8#3UC5XM1LN\WNA@WE&EB^+WZZKZ+IU6ITLZ!EVKG7I_0*&HH
MHBW)22\6+LEE+0GY#)F9LXZ'A3U.,|HP/+P1RR=Y<%N_?*@;O2Q5D96?_Z\X_M6?H<-
PD\$)AE+,1!'#LX251!>3=P*0FSD,J5*#U+86*;HJ&)6J)U)9^?2)+5_M;|QR&I?
AM6E%6MBB!_L*.M0R*(Q1MY;3\|6LF50H\|?EN\$'8+;9#W_M#R8*4N;K.GJ\|<2C;H@-
_#5,A,9)MOG.\$P\|1CS"\$^UZK6=I3"YGZ\$A!0JS_M.@_|\JR(B34#Z
GG-:BNBC#T\8F7^YM;?)?NZ5U?MQ9EM9%L;JE=?E!&ZT4_M\TK"Q:Z?:R5MN\;E*!^M-
|S;|:|@K!KN0JY!PE\|D#MAM\JK97AFG"?|PE<19\$M44+|Q#-
OM0CF9_+PD\6>FBM6\$3ECL?Z;/_:*P36LMD4"+M".T\|M":\$3Y/_M47Q6\|
(^|O^IN(H&3DI_K9:2MJ?AY%M)XU1@|6EA)-YQ;:5QI@,M\|4T'\|9@
MK\|H5%8%7383N(G\$2WT^XJSH_J+-52G'*PP""7L8#D9*815K\|#41H!G0=/_@&VT!\|H\B9Z
M=D96NU&9"F_JYOD"V5>Z<=8#X_Q-L^;\|9EJHU\;DKO:U;+;(^+VU5KM'6VJ_M/'=,VC\$
=,\$DD=%*%<"!I@3H(P3L+(IQZHV*P>V8DU4+_)4\|+M&/#-.5"M\$U0\|E6(?
*IA"Z:/T>56*_+YHM0E\Z4-UO5Z7.=VL_ VR7J%;4FHA"%8S,\$_L_M*1E-
HK,J&!@0APH&^#8\->3;JK@5JV\B=?U\7Y?L9.L-62Y?;DG.>D@%X:9_M6\$=
(ZEB5FC(;)7=<M&GNVA_Y-(?M)' +JOF*?T?BFJ=5D?*G\K-I7@|U=EN?

[illegible]

#7TI558@%ZS5T \$H!BM(F.F\$<B+& 4T93B-".'B*:\T"&^5JU*.&)-:&BB[IO"3=W:
UKJ.8" M=G.@#.:?>'<(4('T8H>%PJ5I5[G/1-/2/ 6W%;0Q4\5QX_NEF++D6VRX%?
Q\$X0^B%EV\$!%Q4'J99A0[N\$PC&CD980\$ M8;HHQ#VI[TM-ESQLRL""7>5'D
MIQ%VB*.JG,8\$TS!C. F",,DB-\PBK8IVETE-?CNP)=P\$96_K0_)3A3EA.F@ M0#U=8P<6Z
W!M@+F!\$;+9=DL:8@!0K-J@LL""ZYXC3?&%B'Z(>Z57?-/*U* MY4#Z4F2K\K\$^
+!_:7I9U^A8^)S2. X\$SF(5XNVJXC,); 0J1JF<>(*!@5
M'M+F86KG3Z_*34L6;9E"/:ZN\$'W9/M\$4N(\$&4AE,@)[*F!A6H/-H\$D1'U D" M8V*]-I
^!Z!4#P@,T?D:0/'AS-39MKZ0:J=,*"=03>-#7 M'D46?ACOR/5C' 4DP('8A77X&/&.
(^8[XN,\$8@B U&?6(4U1%>J)HJ)0\$ M87H)AJ2>1HH,'Y@N^IIE@K4I/%W-
J1(HGV^KM.Q):W!:-7Z/I1V8^V5),1 M.):4\$HSVK.K(")9#160VB\$G""8?)7MVM4Q2 N"
90TIL LR0Y3&N?\$ M-KGW&I(?TF#!:#@Z&[!.@GP&P(<)EV8;,:0R\|V.S@|M2|+0"O5[NL/
MJ|>G4CPHG_9S6X=1Q0CLLNZN"ZXR\<3?2%ZHWUR7>;72|C:E_.JM75.N">(H
MJ>0B=A(O(:F#_5#%R3,GQ,3+\$OG/6,Y%DH0TT:I+,A%_\$^M%?'2RP3NLG\%
M>GKI!BNWT\$M:RCAG?4,'_5U;65+_NE%VA->=.K.-Y)6G\$+8M30?P MX&XV=GY-LT,-
O,:R"[RA_JM;YHSQ>W&3'O^MN<5X63N"\$ MKD@OGY\$<\$!Y)
|)GMQA4|GANFDB#POZAP1#)B;>/#0*065|A3K&E'_PQ /; M*TW-N|H1QB,X!KME5-
!#)L"QJ)SN^8SKV?)O)2.GW M=HRQ8QG>N&UH)?ZSD1_?IV?E!9:C7/_JX6?
^@F/J,"NDT92|T=*|PP|U+ .K17=. %QTT#7^1@&_%=/\$HL;\$0ZXLK*<\$-7>;W|?XA?|C4
M7G(O%IZ?Q"RC*8X)"W# P@0G-*8X%; "0IX2J7%AT3 @^I.'R-3PU"OX/IJ61|XE#ND4-
\$D5?X3/0+;IYM.C9|>F!|PF#XQ-MPMIF3(X1#M8"=6#49X|>,8+F.*3;|@S1=8% LH!?
SR0\$EJY|SK\$QYH6HKJ MZT8US4F*|UP2S-('9;K%_N)6\$//|&+SQM^BW55'^@7N/?2A-
I=4PUJDF_M MI BVOK#|P>?|KDX*=00UG7|*U#!;2|4I>|>)7C-YH-|L58+!1Y'E+%|O'.)Z
MAD05XD UW X\$"\$S%E'E\$%W7R791'C(H+98I=(3G|SOB6(>\$,1:C)=!\$W72K())
M!=0P:FAO4QC0NSXP+?U?;)I"NL):LWXN\$IS9X-\$%X-C&T7|33 TT_5G%5T\$J M|3V_?UC?
9+|5HBZ8_6,MR2@?7Z^+Z^VJRI59|>GG6ET1T*7XFE?KA>_ 'B2.D MDA"1B'
0!03ZF684191X?B>\$X TA16N)E8F+8^H9E*,>A2;>)5AR6A3NOX* M;7E5KLU=*^..7?
3'CF'TJ=@|M@U5@7X>.U.HH|=FGQB8:GN-.0&K0ZL86M*8 M=GB:5:E:A?
%0|HH=W#BM5:G^MKV?2I?|J\$|HK_.U*KVL_MWT-5BX) D%'C |%K+ 6I9
MJ|/BK^K_ ;KND|%BRFI(*DMQ>(JH>V;G33T%@G\$@ZA;UOIC8^+\$E5W61UD-
R)0YP*SG# @@@333.5J1\$D6N"QPJ0_*-SLF,;JJ-G6F4|UV=0_M&J).^D\$,'KK?
YRXL)4.E12|L|+8VGQGB PZS(I+^#A@AQXTCAJJE06PT?1
M_/FE^%*HN|15J9ITO7\$4^"EAV\$W#!=1\$N""\$5=NTP%Q52W8Q&\$&-2<&B6H|
MJ*/+2[SK>/CEK|SE0J7Y#L^P*E3-SCJ+=KQL!@VSFCE?|<1_D5!|44#"L.\$
M|LBVDMP&J U=T+39;%/)#!IO&12\$W^U)LOZG+"-;|DE+W4!UH;|4|!RL|JR
MEUIX810|'G7D:H|I#I+0P6D2<|O")-Y%+A9G.F7Q=>B.?&>7#/1G+1W(5JH MXP-
)H#B!"E6("7@|? <5@ (3H013!;|+\$*1,OG6@#"OEVp_6"L?)/IPN7R| MH6:LF
^2;;|H/NQ50_1& IQS4?#JMFS+|=266/V?142|E/'(P500!P??FWAT/6?1%)%DNRFNM
U1\$O>RXMOI*BP17=62HM%KB|(9;2H3HTWVVC- M\$*:_B(8>,_SCA'_OMZTS)QEE?
9U3\$42B/IZ' OA^E.""482+2\$?,#2E/N!>F M6N\$/>N2F-E=|WC4U2<8-\$Z:L%\$T(-
<|S5H\$|FJZO@@G@"&|5&|/3^V6,+)W9 MM64=/*Y?'F6^D|JV1'N'=|VWS,|GNTXH>XZ
A9<2'@:NBQGQ7|R(),4D=CE. M(I;&GL|9H: ""M6?H3*SF>OUVFF A8"
|O)93T3N(69(=I,@.QP: ?O" T)9.GB? MHS+KF?
N"J(?|4N/PTW|VH#|K>#E|N6^=VS0/V>?'6#B|2=)"DE3?8D|LOHF
M_GFY+QOZ5D2&+;N;)#HIL|6S|\$71C(S^|Z/:9OI?%*Q_+C|L*V(O.IT;XO^
M\$Q_SBBU7E8KQ:8H/AW\$F|T^?XM!ED3PC) (3|F?8(X|@@G@Q\4"!TE:X>H5#
M176^XS4I\$VYDW3=_ZW+,Q_B0SR418B#4<=QD@8@F/+URE.((&"^' M.(X9W+2;V#;-
M|ZH!Q|7I1F7NB%6 @JU6H4I3AU>(J=Q*4T"^(L|D#EA|0 MF5A1|E/4&|+^JB78-
+38A:\$A^DE\$|D-FGL-2F6ME|=I*C.W|AH4|;A3U_#C
MXQISM9GZ'^KN4^M%EJ2)B'B"L|HP6YQEF\$9)A|V'DR"-7">*02OU-)GI+9KF M!KMLJ-
9|:"8,4A5.0:1M:XP4'&P|-#)O:VNT).TWP3HMDN5&5P=\$7J69U6E! MSS6L.O/T^
S/P5BRA&9^YOH1#@5C> D? M9 MN.;G:QIQ=F43I@>'56^Q3@_9;_N?Q:BH4W9*
<7|D,T3,5?8*DR->/Z3,% M8RBU<)5-N'I_4%5/U6R7XE^(#63*5VIX7|L_\$ MNBDEFI-V@
_R>+ \$M>\$)|V\$D^DBZ4|X;H9)L3QU9K|*.20CU(TI.JM=UQN#_6*3R3-OEX.|#^UZZO/;
<^F'I=7 MF;WQ?I@KU#&.6LZ/9S404(|@7F=HO|. # \$A/YKBOQ^DKNW.L0W|9R6.?)&Q/
MX2)?7.O|B:L|ZO.2W,L=(R#D+DX|D(7|Y%(0U)B%D8^23A'@U|KK,#'(T| ML;
|>TD**F)ZF/99^6"^ .D@EXK:4GCK:B.RW(B=|H5U_X7"3R/A!SC;:(@#
M2AU,'9|@X3'FRY^E00*Z? +2GWAY=5R@FCCZ5=JXF_8FP|R+"H57SV*9\$#38
M^AV#%SSSW\$QJ6VGI0.KSYJR;07.4T&XXC*T370077?75#ZNBZ:>N;(7W+^J9

M6U*NN]=+C=.PA#3I5ID>Q"2? QH'++O86#E2&>\$UV;(+R\|J' M(T/X+A^!3-5*.
(O)G|6:U2/PHB8(HPJZG^F5XKM2^@8@PX4DH M2)@&<91"M.|<3\$^LH#L14\$^&*I23
O7%Z"+.TJ&|>*B597M+MJW5U1,(MIL=G^2IT5/U;FVW8;O"&)AJ:|'|)=X6F%%N?
@::R;(7>21ZJ|Y6R#:'14!6 M48%ISTN 3. |T);65@>GB_3F|>6D*_Y15R?
M%|T6^J^\$|4AE5+Y(|.)RFI^4 M|VCK;R11%'D9#CV/XR!-'9S\$|./-^|+R2./A>F"
UL0:8\$NYWOJWM V= MBD.8Z:UJ2TC 5KTQ".#%KB&>I64^1&G6!:XA|N'2UGG%>E.
Z|>5/.3^=Y.2 MG\$:4|IRFF%,GQ\$'HISCA:8A9|\$.4.BU/B9J|F;9ITYPT+.U5\$OL^-M6+|>|#J
MZ8\$) -(I!%M8V2RB?TKRZO\$LEP2|D)'TN/G#>L:J'2EIK5|E|STZ>>3**K>!=F=
M^+E^OU05|3S.(N;|,8XCEK;) "C%S,4EC*O|!PS -5<49|XIVM2_AIF>CF
M+3^|=#|@2000P'H*8#+88%I!&S'TA^(&U>Q8U!=&,-@JN "B/6|9!A-8CHHS M&
TR0@=|6#W* <_F#ZACS+!K"7U=5|5YDJU)|%TR5A^SG-7|_5-R)WYCOO<
M)|@G|O0=,W6&|+|+M;:LK@I>FV<& T=CR<1SE*12!LM2'"2\$@'^ (LD2WPT| MD4
32C5)3QTN7)-%94T7K0KTI\$)1R' UM;:HZBFQ:3""Z2R-MEBG^G&HE)<6 MV8;:5L--
&==S"9S) GC.\$G|E2)U+@%P.R;DX@D&MSYM" +HJU@^M-YX&J><34SJ#K
M4WX)RIGKQ:KY1.P%RJA052J"&*>\$4|%= \$GHAL\$S723H3ZX&OJ^(>WXGRL1?B
MVJ_W|.A5:Z;:|ZORG+UI^HR#34M3@.H:T>,A@5J--#U| (Z:"V)9V^Y/4Y EY
M;O|4|7@C'WY|7*D9>>YHK(#?"FGM+55\$5!|BO%Z4C2?D82\$AL1=3'Q/74;W*
MXPA3DL4X#CB+Y#DBC'U0,0MMRE-?6|JS6'Y?(-82-.M#.!?53 IX.F
M6HWD87L>V+&!.CY0PXC|&C;:LELN:W.9|JM4NM&&XUSQ& T|#,.,>ND2I7AY< MM?
WAWW-1RB\$?7MK>L4% IZY|\$=4I2"|&<4I"PD6+!\$^B1PGHJ"+(1#UJ76) M)-OD!%
{UDP+E^MG|!FU9,NS""X;:3^U;|B),J9Q\$21E=WZY_GZ"GKY'4MD(B
M0+3G#8PP@>4H/.)H\$ /7PXFH|J|KU2.|8BJ+_X4W7?@|0E47LJS*%|NLD|E?8VT._E|
ME22_K,7CI1.%|C#3+=*.NKKBE/17A5AMJF7;O\$L=)"1#HJB:1(B^9T'QAFKF
M+'7S@N!|@5.E?B|L1?AXO;K_X/>,SLKW GV4*R6J_N7|Z2N@;267TR^S;GJ
M:E*3AA&),24I0P'&0|Q&C(/1SRF41!F+F.,MJR|8***9QTZ1|ES\$|ZA;CH3IF|S*QZG#-
W<34#*-W.Y9_M44&=|>H87NX+K"%| "@K@\$X60S6.NU<.M+("'
|>5H+ #MD#|RFIORT_|C7#|5 M*UJ)LBYG|:5XVM3E+22(^;*KF+\$IR|RXEQ9?
7C5VWM_%DI-U4SU/_N:C5'@+
M(H0;"\$*DZ@Y|'A&IX0X5'4LH4DD' (=RK>OB&7B=V,C|+M|BT^M5&X**JG6^M7*
(R0HB:|1^\$*CL&\$*2.TW#;XYIU' "OYW),:YLZA?P5*RC/N^H81|M<5_7 M*&KX1|4
5|U)|>_MK&ZE0!_?U(P"G-E09V;-.?%08X9A705Y,|!TRD_,PGP^
M_7FPW+L2F(FD28CVMH?RJJKJBK?9JE2>^_K'A0Y+VB|WJZ_Y8|XLL>J' (|MTT^|12
8YPYQL1,*7_4M=S!)PA!|L>M&2:PB-K2JS8|B8N(|NM?>>Z7NSOJ, M7:&6-
:6!|YB|0BU|2/('B;LVG0B-O7@,>&&|HA(9"&Q|3,@;|!@%/QG2P*#Y MD0@-A|>;#CYC(/Y(^?
=#|L<.9MH>H7JX+KCZ0Y5(>B;+NI#\$NJN47F|Q"X>|MF:#4Q2+
((KDS1\$2>|7R.>1Q|@>NR+*6@D& MJA/O!(IX'7+&U%_\$C@UH P0= M
\$DB8B>D"8YB"9N\$+,34CPD./.+&<9HR+V.+|HOS(|U*=>O!.,A!_I@7O_X M.
|K^|A%|^M^??G|^NNG;W<_T/4=>O_L;U^&??OR|6_HYC.Z_?3|R|W"*>!--MO33U'4?
@3*@Z^6'BJ_(CTGQA<1KS-'1|ZK3P?BKXJX+;T1|-|2?YHTE!U?|
M6H<)9G5L5W'|EQX'5^K@UC'1G UM=NH "&VM/X<_S9F|<@!|@..|%-7G9L* @6
M>Q|LQ0W6=|H^J5-2|>DV73SEF(==UW09?:%F1HY#&!PTCEMT4^Q2F7VY|7
M!K'K^)|0D#-1WPY"/R?V5S<\$TWUYX*=E(=:(U%RBY7J'3N2%,-*Q&
|@XX)F#DR22>H^E MW/-*#@(?U.)B@-;4CITZ6W='VBC4;@@J/7!0IP-U?I:2BDJ^
MH*0('U(LQ%?+4EI\$|L9&Z0T2#1.K4=C#NQ=FLI(44*T.^X M)_>P.ADA#4Q!:
D"ZW1|S+99G^/>./-U.3YF?J_'\8E?
&SHY'J0FKU7E<7U=MK|\$5*U!T.RW"G*K#9O^Y5M9FB|WJ-
MR>O&WEHK64&+4B7Z&>T%>H\$QNU
MVN#,\$S_Y&|J)JR@#=%)|^JE"#35X|*+9N,E5S;:%SYCC4 MCW\$2NRD.W"C-&
(\$"YXXP@NY|S"0,_BQ8DW5T6_K5RK2@/OU(1#@+XXBG6!ZN\$ZDG:"3/V:G
|M3MN|JR/HCB\$ M10,9LS)UB%#K3F+_ *LR>5TCDWA3C,DV_.B&;Q" |K*(YI
M@8;'=XS&R%;0ASDC|T:"C ;L*#QD_(CP*Y9_EI*WCHP#QV6'YY+_L_RT*T)
MNV\$Q'7^."Q91<%U7_@=U#2#_6E|\$K.W=J!C#?_E"90|D#>Y3)@/!=|@7*6/B;
MID^,BBQ1C2B|Q|K5;YRNZP201Q!7(IYH%RZL9|A0OT04|X2 M|C'?AQU0A?N&
|N>L+H+BEE_ZB',-V/=I P=PING7T|?^!\$3>F' MQ;39COX,I?D;T0^+?+(%_857#/(
FPZU3.XG38&!7K_9E|. =9SG9%G"J'Y.| MB|0M7^6AZ5|0ZCTQ.VCX+M(EM|O5-
|S\$U16A=GH\$D1<+QR'8(X\$|S:HF4PDG M"PU8E3;^4|IE\$KT54_R*OW
M>U7WL|C':|6E0M^I-?=7,JP:W_#<^!_ ^T|TT|(.?R;4Z_69;F&_P,8.F=
M|T_&8\$+HC.S,ET(ZA9|2:>O0-|LE');KIY\$N7Y1EM%:@%.,D2V+YUYB|W-(-

"@7@2DQP*T?N1Y^#AG- 02"+L.%1(TU2\$19 +|2LMFA'\$>A+"^8.-P
M,|>K,P&FIT(MP0!3G7VB5!)H?%J*+1A|FJ3\ZE<|0T;Q,:@PN5%J:U5J|SQ/
M:>:*DQ=%/JXB>?F5D:V|=I7_5=7_-B^Q;2DE2)1Y3#B8,T>N>-_+,U"@2D+
M:9"DB8BY60>O :(3+_TSE>)&-N@: E%/|B&!J8.3%\$Q;|2E(;;M_EM#)%^G M|98&"&>
f; >F|:Z8:NH|P73_X+|4UJ|O<5+?D19T"%PY/A"|XA(FTGW"0^BZF
M0D181((PGWH)Y3Y\$+URD.+%2Z.C_1|UO.?A%W;B2E@GTU'!4PZ78=33#%;!
M@:F%CC1Z|H&/2TM&6UI!LNTYM5,6B+?Z@5|9%\TN\$>JKZ>:;>.4V
M'\$%%WZA(FPU9*O^.*I??"\$(Y)EZB"DQ"HHP%OCV?\$ 7!A8Q<7,S|_@LVKPN6_Q83U|
ME%_ ^+Y9||MKR#KK2+X|RGP=<6Z(JQ|7^6_ @P&O^K|O5K5BI&_G/Q:{TD&;
MWYG7I|YKYQ_:5.O::K|;H=M/-WO!+BI-:|4N5KKER8=@&-96EA WKAJ"H_ ^ML%I024-
6H|BWTW-_|^T(0#+|CG)MOQ5)|-(G 0 M>\$)E(*38"WT19J|:1B9=0|:(CN/-
_?;JL#=#)2|OZ;:U^=FTE "W QK\$4==# M.1X6TW8|C?@J(: AK9R5|0|ZE;;
fNB(;;^)^SB"UN9OBZ(A^HLF-UFLFAXYM
MJ31U>_QUVPJ7"i<'ONMA\$:4D)4Z./49O4X6QR()\$AK'F?Y1XS21J0|872W MFR;73J|-
KCY\$.L>)|8(##Q\$3RPPY,HR7W?"@8(0!|'PP+-SPJ>#,NS.>:8:Y
MWS|!7'C6|%\HD+U01QJ_*B7);Y@7+G|BRC9667QGW>\$9CKC*B/1Q0\$N(DY#%.
MDMCGQ\$ _36(B3 :I37T1TM!&-?\$KM"7?188#*R<_.Z=Y!V(+ #N#EAS\$2|_L/
M'0EMW7L,TIKWPD-'|*.;#JV7#\$R+7|G/_ "S>"ODYR!U^+U4(:^O5'YU|518
MB,3)N*HES|)06A@.|S%EL29E=+|AK2#
M996AYP:62O%@RY>I)^F@R7)AB/DL%SU9|@P8S5?;|)AOHLV<5A4DKH|)OJPK
M2BLWS>_JJ"D\K)9RO\$KU(6,+FB9A|'@^3KTP5@7O TSC+)4VCI^%A 81\$ _YB
MO5J3I9YE Z0/4H1;+O1=*F);6J M?+)E2;5):IA"?:ZNZDZ #&8#04\$/B<|8 MFK@XB8)
GF5C'Q,>"QP)CR21)TB2@LS)*4\$W|&_.|3=#U3-\$)H83M4091!!NM
MAEA8,F.AU&GRZKB_)EB^W).>_Q7)VJ O%\V7YG 3 M:YK|H_.6|:;\$.5B@3H013(A"
)K@C |IO5FM;D|9| ME;5A0N_5T0: ^:GS'=M"A_O.J%/E|T53>82^??K*ZOOMWLA9-M?>J?
7C7I7|! M?;F?.QDS*!@|1756HC%|-\$^)|G@JY.5?WRW5 MW@R^G+,P
7KVS.RPPA14RQYJ2=;Y7%?;?^TXJ,O-*K91QS>Z*TE1;-V54: ^T
MH=5K07O0V;L|M,#3W%>_|F|<1%I<7#C%4F!*|^2|\$_YJH*4UW7|2;|4D@=
M(_YI>AW3_O1>=MR42T|)L|422PF|\$,!R0,,5&="T06IC2,Y1^\$&,0SC&H
MGEB'CL'&#|EC4?F<_.B;XE>|OG-|L&)K|9SI*=HIX;<-%%V*IA-\$FC' F0O
ML=:8D|D3;L="=B(1=_20|_/G|H6ZN/^X/EGD|+J0=NZNUAFLKB)XX(DMQ+|5
MH,7|8>'|_7|5-|E|TWA0H-2?_H'5CBZEX^NDP(+4V(6,,5<-'\$8)*.3+IS:
M;&=>8R#ZIU_S0Y#&8_G2KT?PMU(>)(A8)"Z(HCCV<1?)(&S"68:HN M2:
(XRB)&.8M""CG%*(C#3.>|H#2LXWLB_3&ON2|ZJ#U'3M MF3679;-
DM0P0FM4HN2SPH^ ^B^/7|O3=S3DMDSG|9A'BE;V# #UL;W.@U1)UBX(T#HP9A'G7'F"V
(M(JGUI+V>^F&\$_9 R)W:Y0V@ B6QLAITX8/%.O=(D?)O.%JH!?-C/XL=S.09
M:0<9=7\$:.0P3D6:)|WI:F'F0LXF|U'"-/E|J/5L=+@M, 5V/"P V8O?YM614
MMH;.:N3M"W)H=|W|UK"KW:I:WV1_6ZUX=5WP'Z)|SJ4E|F.UY L:>|(/4Y4J
MFC(<)*F/J1>DF*1!D)!:(ZLZ0F#W>KZCZ-%5E"|S|'X-%;:W:\$AJVG
M3MZ::NW&Z^@B1=ABU|>+PMGJZG:>T+Q=VRX*?-25|?;(L(7+1;ZXWO!1?*0XD4Q#N*
(X|1U"691ZONIGSF":IU43@T^|>)|LR1GD-Y|8GA5 MCI4/N*|!1-->?\$,R#-
R/R=>:E2;_LEM@)P>;94D-B=\$MHL%G#(._VGS(NU5; MGO|LA6VYJ'PO|AG'-
_PH#GRFFGFY'G;D^2+P*<|IWT KU5 MXW1E?BNS%)>A6(<48=|GI
G>*8R!%TFC_\$)8=A).|L8SP",_M M#M^6\$R19:.*W%3/HID"*96/?
>\$P/OI='4_N))@!';IO!"Z(@W<2V SJO*=7 MASNUG' YJUK.QZO95HH|' (=AUZ_ ^<#-
Z@,\$R|CN"X: ^;FEG@0Q-5XPW#JYRF^|ROI/RW6-^6 M:9!'T*.7A.J.Z1_"!6=?MI/I??
4H|JB^#.7+5_+G|>-.|\$_N|\$"JAE|W7|(+ZIRY%L65*FM&(*M5PA MR=85:KK4Z&>T@-
\$9(.)#\$ _J=/XM/62;8^E::CBM^DUWSI@N0.FLM4C|FB6 >CEW*<\$#C"*=4,.QG
M@>^%JN.P7AE978)37|)N64 -#RH;1'&AK)2.#| Q4QO)804|!3XPQ6H%&FUM M
)5WZ*0HO^J=\$N6_=A;:-IE9E-4Z\$XI@-|SC3H?;SK_D/*>ZT"FO/B7A1,
ME0V)G"2F:N&G*9=ZP"5 M\$/7.A|P 6 =K"#TJEY(E3(#+?
D>TOF./K,V@Q(NR68M*|\$HYK#\$BR(?QR5> M?L5L;?|X(*5X3RK586Y71;%I/2=)?
2E4|6:17-K4L-O5,F|HJMP9: ^";AZ*F%BR&"J MHF:F|:N-XT'79;G*D#5|MAL&D-
7*FQ:0L*183#B85>&,@.A0\$8T9RE!!;10A M-/-'+PD)GQ'?
JHR=|HE)17A,J|YJ1W|1E:;@\$ ^1AF)E99^Z25;;Y^\$.BI7#WG*K7WK^: @6_(%HO5/F,>B-3
MF-G25'TSS0%0!W;=KU2HHZOKK2Y MZN^G6\$,|D|3ARGCB---^1G+*88S_P|)
(*UPU5(PQ-?_DI"A-KN8;D5=V46RVU MCBS DWL2%PTO|UAI8?ID*D\$!ONFQ
I|YH<&"PQS-0T(->I1/OCB?ZWB(|ST? M|>"#|!O_NY)+4UX-I|S-(FC7TYK-

^/4N/D9!+>T1-JE4UNVW^!RZX. M@:9G#MB# J8CMB@H!V-7>K2FC?
/HJ%MT*>J)::LZ!"QN!M4^E+[\$*I_7K&#01:\$1 MK0ZH@UQ@)X/S
TSWP;4T48_H),>!R()9^@ '" ,WZ(5X6^/"#U'C#/,/<:ZF^ M\PO3,(HQ90\$9TLZY-L_4*?2!R/
GIWUPJ,:X!&!:Y(*G#:&J.G\BZX/\$+HE@W5 -/#14V3&4L-TUVB!P5KLI&"6%-?^ MV+/JJI-
B'-JGTP^9!_G45!+795G;8-K1 ?VWIKX8.+XUU_04GA!P>,F.DPUX M2W B&,"6@7E>#L.
/_/VA9KST/R7" _FW_R2=L=60H/.HHC>:-JMW: :. _M M/N?/XG->,:)4UW?5W8,H!M_E?-
_92=T,:A.%EO,T.V7KE;V3@P+_HYD7?CCD6 M^/(!,TIBF*8Y(>P4;OI!J8OLF^/19C-
OS@K2MW#./V00)/1MHX(55MG'526J_MA4BR3\$0IO9P&TDP)8ADG3\$(!_MY:%
(.2Y%_JPT1W6]7*[^5"KY\ZK\N-K0=;997C.FBGY5!WM*R&-/>'&&W2P-_MY/"%23"-
(HIC7P1,4!YZ@*)#;ASB:3\|C"&AHS'8#R\$=/YS!#M'%2*RRVH_+*JZ0LG?!:|7>=%K(5T7
MSE;U_DKOH!I=PFPRNM,"OY#?KFUYW*5?"#/&LC77*9U8J)9+-03NH50"LSOR79P
M!5/W).PD5,-N930\JKV5CTECLWSSGPALG_V_7X?^UP'8Z=_15V)F)/O/^%I@
MUL>K3M2@X?(ZG,UG\|P\GOFTNMR G=6?_K/^N7ZSY)7U_Q?U:>?;'G_.UE^ M?
RK7_\$008_/X6+XH'JMU<4>7;>J7IC<;/O+\$QDM3> U= TDD4TARM6GFIE(7
M3FRYJ2^|)8|U>_O3JES7*4!|)=J@/G\$#="|S:<%%K;E&V*JJD,=XVJQ\X MG(S\|
;D9G/DFT/1|_2/& 7>V?I3L99?UN=|*1JWXX(%F3Q^4::|?2D.5'QZ MPF.*?2I_RF.1!
(%65/JIP:~6/#4YI.BAAJ!^7^LC'(85Q%CI@,M?7S!05^MS M\$AAUM3X;+:NUN?
\$Z'>U/OO,B%9|WU;%JDOI5]??12460<0#5|_8BSA,<"!H MBJD3">S|F?>
XG)/8!Q56/4=HXJ74G +Z=%%+V*!~WRF73>EA2|U <+-& M?0-
2V6S3=XK,_ \$WZ!H0|V.)OZ'FS!=M8_5MS'Y@#91P'OE#|CZ3!_MF|:,X#@,F> TC/R
PPRN\$U3FL;Q;BE?=7Y"BC6X*S4UC&"==@VRD|\$;6&5QP M SMM0+ 1!MNI46>VW
8\$.S;AAAXV|(W1=(#|W)110B,_ VQVGC6%%.T^2;|H),I MJ!0;5;+YIOA J@?
U/^5;>ZY3%*000N|SN8IB5K^X+OC^#WI/+E*?N!EU(^RF MH< !1/P./6>7W-
<%TMO>6X*I*!|BYJO^+>OQ< MH1VK|2/J*NG@A _MO-'U2-NH8UE;/6Q7
EO%3S+Z>OGOE.05;.,F|O.L&*=T+ M+2GK*3B<5<%/"/AIC EJ=%|L|4 _!MYU"ZC??
KMB36T(F'<;Z1I-RCSE-,3|V+9;#=#?E::0/1!IH%GWXI*3?*_^ M|3|\$?
O|@E^BU)\$#DZA:/)"^Z7ZJZW>XBH,3W?3?#H9=P:61E\$28QI9A%B1' ML9_0%%0_&|K
U\$|VPXK/'4>H90EM>6J>J(O\$ QWP4,PU'?,3(@ETV-L%\$>|, M-T3"EL?2GY>Y|A.\$>7
J;CF"FJ.LY"100XN%)#~+R(G"TG\$(NOEU,&!*S*< M4H=@X:<2%#|33@;*XS|8?
V(U4U.K>TJ@/OJ"P!HMAW#HJ8@10L(T \$0^V/(^ M(X6EU7LX^JR+|XQHAVOOW&-
F2^O7S7*=B|>GY>I%E"IO_ %9%Y;V*'_ E|D6H81:V^FW,F)|&F'D>8%IF MIBD
*RB+H%E2:C8XFE416H3P4'G;-'H@O^M<|/.|ATD|O?D|I7|=&|NKD? M-
Z6TKU3MC@5E*2\$A95B:/2X.N/!QZL,1Y&@KA/*?R=\$.WG+/G|3.[T|WZCJ MJXKN)2-
-?;>LLR+*72EK7G-31|^^(2)8_23(3S->PZGT#LP \|HU/3SE5Y.C MF:UX1HKI?N7QANVZG-
'K3A4@6>EUPL\$ZF9.K8W=6WO#|Y.7=O@&#VH1-'
M:PVH=9;:::RF:=#'X%^*|V2ITHA^/ BQ/LA,C%S7)7X:8M>)??76((3CQHQ!'H1L'7I2\$ M|H
#3H(>S|?.\$^V<_&W'GN5/AWEMF&R|=A;:LJDR6EF%49 M!M@&:F4&
|*0"6Y@4@_S>>2=G?-*N_65BEFYK#S>M'%H+Y.9/C+6'T):2W M%F ?9+;ZV|+6HJKU1J1;
<(ES'4V)>>1VPD!(;I M!YWL6Z*HHVHS]^"29-;2#|X2FCD#X9+ QTD(%|PSH4IE.2&4=
(MZ#M|9|L6<8,%?F=0 MF+5?*&_?
7=^W!|Y>F;M9Q9TK=4HPPB'65@"W\$3%.1:K+H70FZ0MM+U-)@^;<>4OZ,)S(8@*|
^)|V|&|Q|O?RV>|@|%Q4O^ M>4GN=4/B3K|RUWX7?ZH+.A?O|U^4;H'RUUXTC
K25T\$;\$;^1|Y^~""M3|E>R|H MX3>Q7C@L3*(T|"
<46ELIWZB.KM3^4_7|1EQ4A*!L@^&B\$V|(CO2Z\$)|&W7\$ MKYHFFH%T+@NN|NI8?Y-
>;KVL_/C"-:0A3O1HP1)1P>2;(\$JT\$ MY=<28&J7MN(54|7L?K&E?D,G^H+ZS|52-
06=KE!;WJDG65N&;RUE0ZUP*MQ\$ MB8=,&.3 !M5S?T%ZJO4M?Q=
'WLJU>|U/XGW|WX2|%;8KS00MGIES|W^O.VT M7VERCKIMOQ8?9IOH;4NBD
>@|MKY*H;7:64JM+YCGV":<8H#CWJ8\$;?E(K,Y:|CNTRKCK5-IB;>|+X+OF\$UH=K(
M7).?Z*DCK2ZKGA17==03T#2W,B%Z^|S<,,/VCCYW=;&"CK|KU'&(MAPBI1:0
MS6.W%:A7MFS:VP1L@F9)L5MA:59E;1/\$0P5L=6S34-;NLSOFZSNMLYJX_9A
M%@H'IR+-5.H,PRF-(^SS("4A,+5JX873VJE^NG;J.SK+ LR0S3
M/U.*"PUP""7VF"!%D/@&L89G!;L<+WC|ZLPQ?V=Y/X|:._^H@8*16FH=A>V7
MY%,O8<1WL\$A)*_4*23#QB8/#A&=^PGT>IZFV6NF//+\$R4:10%)JLJ3WY-12'
MJ50P=6%+(|J;|7,3""H"PA3_Z>\$&%S|>R_,M^1A;FWT\$|^+|+O-FLJS4I MZB;>|_?
K3V4=|O|N-|3CP|P-3FP8XNDH3+.AH!2?*K0JPVU8' !Y!_XS* MY;M&*X
;0>+6("N'_R_*;G0#>7|4V2XA+PK6OX>|/"8VKGRH*#"Z0N6+_-Z
M!N4/FDNFZO.J%/E|L8C|*&.!3>6&|,U
MXDTAHEZFD3ICU_E\$^WQ=U;|H6+M"+6|F2;?:D.NY/*8 \$J8:IL70L/2Q/B!6

M:R%KD'V%XLCZ8)RNE@QXWZ#9NUA=L_6&+)&'GS0LST'?XNU M2AGX(=BFS->YJ';9-
A/W*0D2AGWJ"AOD-,+\$!6+L983|H<|<&H+"C@:I3;P|M=|31CKAQ7L,>?GJ;M3548.MV-
"#PTA4Z@MHJ2C%(:JYR\$SIB'Q62T'K)((:7 M_ ^MN5>N.GWFE';K;?
VGB=;IK=H;6J|VMY+|;M|4E|>,XT%A"VY|/*A/Q1E M6\&YIZ0QB\G=&VF^4-Q3
NQ%X)Y|P&P+-MJQ?_,E|M_R\$6V%L5-EGT7=2O) MN|4/HG+PWF^JO!!5|5N1KQ?=\$=?
PP) 0G3*AV:8&#\$R=+<5QV"!+ M!L2\$U@MNI?2B-UKIE M^,";K1\$,EC9?&.U9-V,C6
XW9|!S-331T'E1\74F|2Y/|=|Q9?UN*Q:BM+ M71=-
SUOEER_%.B_KZ*N6GP\I+P7U8)%C 0BC7#&4R(->>+BQ/4(IDG,?,I(M2O6*,-
ED:F(|HF\$1|?:(B:WA=SJ#/OF!GB?T^TZ;7F%:34K4Z:G|.:>")@. MG<.<.P*K1)FB6-
*85EF95I#9!/-2O5LDTSJB|W2F\#G75 MZR@('F_"U=A21|N_2#Y0V|&LQXE.|&1F
%N_Z?"SBPZX|A#8HPA+(# !(?! M_/O@/,%(C(N1>@8#2 @9+X54@U4U|?
EZ+6/FU<2Y0Y|. NQ8&?J>0IYN-\$ M)"YV8^*(F&7<<9EVH-))\$E/|26N::: \$O4)-+G-
#0:BG*TP\$ 7Z&2R A3<:)G- M--FA|);4U* T@_KH|)OS*9Y!SO%,D7L-\$!\$'2LJF\$4
+=S=91A+=3.,/'5KL%(5YVS&807/4KL%P
M&#,U|5VP):FJN|1YDX/E1E'L|3S&F2H&%U#F8I)0!>I&P3R1UG,,X@B.J(P
ML:HYH@=3(<> Z"F)46+"U_ 1*?3')->|9T6RM)J/QY|UO9X5|W!%GG_0(ZJ
MJ(IK_J_JQS/44'7&I6X4U(EWIXZ!:GUZNXO."OT0Y7/.A-Q|*DCXTRG!AY>6
M#9EA*^N2N!::3""X)9Q;|= &K ^4*?:L39"WP:>L|\$NR?H>I= _K\WD)1?^O+E
M^G%5KEMGHPI470C/8=+\$%IBRQ,%!\$@4X34B_,S>B@1,&
(G;U4QDUB|.,.^V<9'XL9;68UNR@Q3| ^X_?NJS?B,=N0#.*G4PP'(29
MU*"^2W#B'F4^):@MT9|ZTW_+S/MQT(CVVT:->9/5 MA8ZJ7C;>>U+E;!\$D+/6=*,)\$|
P'3AICFH09%B('<:|Q'=:Y8) U"=6BT=- MEQMNE/^PX0?
U&+I"-4LPQPH.:SVGRV0(PA2H5?# ;AHC\$ "RY<&"T9W7O&,%R MZ/HQ&|34%5L|?
6^EC?=R5Q*IZ9I"7>|?^K^I ^"S1(C IP(|L2=P\$ L7)|3W
M<\$1#%E,F'/D_F(|6E_3DSMOF=J.F=RF&?BR*NH|=*,!>GP;6)2|6U5E#V4 MZAP?
2|D&YB):PAK\$Y|950P%Y-B'#|X|IES^L?|W;Q M?ECQ70Z;IK-
99ZR)E4%C:| ^6RONZ*M'=C^|HQPIJ>-%W0&N!<|DA;1L7F"+0
M@<3R;1!4:"/'M1:|V1S9\$"|CFW0>Z;9 T=M, ^O"##?932%NA?QJY-'V7MRN
M|F+|H6ZG^:6XKBIYY.5_%V2Y?O@@+1=UE7%7"GF0DIJGV@9Q9H2Z29)ZF,=A
M@@/7"U1AU%@>=XB719DO2\$)A2063|3JUDZCF4|GO|O|"#6NJ94|/#9-<:;=! M-5|
U_ \$%@MY1M55ZR;+3?JV'JKKA%6_X>| M-WUN(T?V1?^5^G3#\$R',J06UX-YAM:C>-
V6GZWNB0E_8&"5>88B-5S<|?O7 M/Z 6LBB2120(%'7>G-
/=LL5"9OZ*2"1RG=^NU\LIV|35Z0|+?<'@9OK%8J87
M?;R:: TI5^M)FF<5RTF"6(DQPC3+\$!%8GPZ,)TSD*2\$QFSS7+6F_KK4Q:W=&
M^&\$_.HG->LFBM?MI*Q^E|EJCM>,Y@4.,/+V&,BY96:1(|3KUX I(OK5()P+ M*66FN,"B?
0T?YI:|.J_U\$CH&|<_EIC7=-?&W.U_'1Q08|JEYNHFV7\$4M6U&?
M+U/5O,|9U+^F<3J%5ZAI\$9SPP|2XDR2| GDP|^+OZFY'65>&_6|QQ*;S=J|J
MUS3|3N@C=JFAGX|JFEURS6C2RENM9|1?SV=U5U7VE/WW*AM=#ZISFJZYHB
M_=EG\$QF<\$ \$J8D(|.<,%PDRKV*JB_B552E@BTXPIJY*?4;D.?"/:-C7H"7\$3
M|<2(^G(T8|U642=)|:?.LR=*9XC=1)|Y;.*XAR#2L7A';YX; M#H
C|QRA=06F^0:0AZ/_+O5U:9);P/OEJJZ%%W+64C?%P298&XM*R:N|+&" M
'7>&05:S2&+|*M|;%IV/)O+@# 'XM|7Y'^C2>\$W>2OTWLKL(/- "_WLOGI>1-
MJV&M5/LYK1-&L1*RRA&5)L&|Q155!;HC"N9Y;%6@*55?Z, O(4.>C:,1A_>
MWCVAOP6D7'I^ X*7& M|?TC-?K=#9SC9W.-|;|8

NXTK(:;QN M/4JU?_D^NW77FS|{#5|PT|DG-
UWM';AG0W;M::M_5M/>N9/NN6/.NIMV|O,E M1?|=F1L?
|3'^=T|9TV@'\$RO|DORO%SL,%CM)6X'(N'0'MF,J%V|F^D3X&'Q
MV_QY^GZZXG=S|8D^665(GELCL#5@2 "Z) |>SZUR9>?
OOT^2XR':A?;/3S)E@AIC^F8D-GT2 NL-|*%D*|M5H>6GB|SLL6XNTU
M8K;YO"IOO|_TL7\$B^/U%4OY=KGZ?U6E4(9'I&E,54 M2)4IP4&IGY5K04\$W7VS|
MY:OK6W'M|:/&,P*Z^T@<#<#AN+F\$XB |2 M"P.2"E|C|5YR??E>R?MYVR?
N=BXZIZ:Q^HU,B|E|)=,!&6T2AA'-\$DPPD62 MFKQ"@G),>##T&W5U?HSW@L8KM'K?
>WE?>Z|M&|>K02<|_J|38.6 |Q6*JR!H M+RFJLS/.X0(HHB7
L"&)2G%@_L#^DH1C5)*..HUZ/07(L%KT("9,G<\$DM%8_9^08"!KI M)QN-
H7_8*8I3ZXVRP<|(TVW, ^N\$8T-SY"8X !@. ^H 'G9(0/U_ M?B|6B|:W9%S0., ^R
M%2Q0@G68D(BT(XX/99OW/CY\$/C4\$ M>_9M|U|_|>GOWY-
/_^Y6/|I:OYYN>!RM9KD*B55)A(D1%'HBW.J\$.. "F6V= M8DZ*7!"017^<3.-;6BAZ1P|

J1@^<\$,'8HJW)Q87MV2^|F,A3KT\$Y#LPW?
M^|NTPZ)YVJXGB(RZ48<?;E%SWP:MCE7R_7DBPFRM%87PV41Z|LTBDMAQIWR
M%'55J-"Q9E265%6N=4A^V+=T#?HNKW7M_<+<|&P-#A?2CZW2Z0!|:_OAS
M=+6>|O4Z(.K2?|".|O:3_M-M'+U<;9>.<\$*;*:=^M|79N=>DG_YRNO|_K:+)|FLJR@_R?
6|S7)I&D(H<|M,DQ(I)?05L|(9H@PS_ME,_"*Y)|_L.ZA5C0#+RE.@ZB/Z+/VO6B|_1
M.VTO3->1&4QX\$|5,V;Z#@E|&E."M#+1_XI%4J;ZH);4:EC9_M&3J|54E-|08P*O
<+^8JP(.PL&W?DS/Z5A.-@HSD/"_8IQUAB|JHN_.;J"|W_MZKF/|B4/VLTI=
|CHNY|=K=;8S._H/._E)O?Q./RA*59\$C?4W.\$RY*|JC3Q_MJ"RM5"(R64AA|64>IA5XEVZ)-
^.;J*.?E0S4\$^2|KARS^!FX:KVAP9L&X|+M!;#-|0|0-|W1<#'_-
VH@|ZRL|L_9|W\$Z6/8^ZY2,N+5K^+6=R36?OY&SV_M|TNZ?//KYM64Z#|I;9S
5":Q)E,4|+|"N\$TKQ|5W'3|94FI<%\$J8>4"L*07_M6*UU#\$2&@ZAE(6IYB+Z"FJN-4FE%,A-
;2H2,L\$85Y0DS:0FY9'@B2,E9FP-^/.TPNM|PQQ@*L_TGU|XW#3?
69@|J3Y|60=5G|4RXZD^>YGV_M5!_@,=="%K;^*OEF63,E\$C\$B,E1EI(R36|9"%K &
M&H=\$_BNY>D+YCB;0=|E\$Q|Z_*=G,_,T&%M>A@N*T|/|*'XZ0&+EVX;20AX4'_M
Y|UVXSW:VW=|'H+=T\$-4L2T*FB*XE(*,U4X1H4L"L32/\$|P7"F56U4/G*\$3
M>\$O65"/^*7*C#XU9K_NWJ0&2?YG"/@E,CCB%F-T>|8_#;)LV\$/0H!HCFG!|"*
MTUX|1674|7I&U)<|HMS"?L%G.YC|^MT+N_6FDUP27|LB|D+(PC..48T8*7_M**>*<
<8XS+|@,V<\$V1\$-?(P8|RW4^>K)VW|S_DTL3|UX:|IG1|DA:)|8*2D
MB%9<*XZ898C0A*%4|JS(8RI39=6DTH5X<#^&\$53;L+.?V7O3A0P,4XAV7+7=
M(R#>1R#;._@|<0'>O&Q|_#OE_@FB,Z@MVDW?<*M.Z|AT"!X-GM84C/&K-
=RI/,&V#8('E@CL)Z|-6&*AG:_4X_E3>LL_,,ZTZ?L_M,/UX2FR/OA%;X=R: P|M/%YS8
OQ|HH#VWP>O@5-9X;:NL?;|. =G.A5_K#|)M|=V<+YYZB5^66|FK+&1^AK4N5
MZ;+4|64LU;:MWDU4|U;|5%ON(-FF7M^T9,F|K_BU5(@.\$>G7D<>1B_M7+_/95
=N((N7,Y1^0U<:|XMYOIBL|*X|UJ?EY/->E=%\$JKXGMU*_Y|LZIO
M/JM)@57|JY(@SD1AYD!2Q"3#B!TSW8JD.
M(^2|O3Y+|7JME^+=867S/N|S8O/K'M.>1W|QM+GQ'E00(T->-XWK\$?GSWLG_M
K^L?M&'1A*S/_%7X%NQ>-9'Q,<9?;2|GYX/+ "V-%0C0Q8E>_V<6P|L+Z*G
MI#|_|_0@._\$PCG9\$Y^F;(>|H>GA'.Z49Y:LW1+I%GA.K?&|HU"&6=0ON_NZ6
M|W39F9;_"|TW-3(?L;7?Y;KNG>|NY2S4M%,D%*5,6F/V_F!;*L5_B7.4MR_MQF)|-
QG*C7QH/Z_FQ_3*V7(4&9:B-X:IO|U\$.|H_QHTCVA;1M*8_OW%#O"Y_M5\$0X?
&OMPVI|70+K'G|6L*":LYH#(:5X*N.%UASEG@OM.:^BJ?IF_6-^J+9
MF_4*H16NY5C*"Z=S-F|8A-F|X|4FI80M"XR7S&WLY+Z&|?9+^O=89Q|HIT=
MQ;G_:=>R@.7TA|;S/^2OVYR|G*950@J*JL2,+B*X4=NV(X|+K++%6)
=L!=P0|&;I<"X.N'F?WG_M!1NT|P<>|^0/R_#GL5N|7'7MJQU9)_^5-
H5D;2A&SYKD332W;=HR@ (N=\$7"9M#"-TPI: M\$ZNS:#PU83DOB|?VJP<\$1FZ|>DK
PI:K)S_I4B4@Y|/%O?YRMRSZZ%I3|N_MZ/PCY:9TZ6>KZU4F.
<|4@N)*5@A73.D|6.1(IH+D11KG2MC/;+B&3IB6_,0
M;9F(#!>182/J^'#J06*%IH75X!TCV':^*CR0W|I?;#EF|N_"YC%#Y%|_.'??
M:J41_8ADNWGZ8.>O*!P^MWBZ6G:|&|J3@MDC\$5K#8955NNC2O?|!TU_MC\$<-
Y|#VO%Y?J9UFNMJ+@FFS^AT|^T'27KN_*@-0=ZD4MI?67N|W6LGY-|.MM7S\$)=?DA4?
V;LZ;J7)T|GXQFI&E^<#;M(T#9'F2EY7,\$6\$IU39YS%_EXABE_M&19YQ7E&N=5
3CCIT|DIA|&!'CM1PT|30WB+4J>T#1#0%O&H8/#!=,1K0PZ2_M_Q,*0<>T&!"2OM)E7#
8SJ!K3AB4HV+I/MY-DXKN#E/OL@??(^?#7L^2F!GWZI#|RK|Z:_.:"G+;>&9N5#=.
M&&!?NG4"4;FTU*(H*|D8\$6E2""2(&:N5Y_EB)"U0SLNT8K@@@5(%:=KQ8/H"B
M|9<=G"GYL4+|3KU=("-/P'\$NZ"@XEPITV7%%"-6-)T1|701Q24U3+6A|D\$I_MO7OKE?
|Z(@V;VEZK|W5OC(KI#%_'W7;:|D?^-M<_IZM5_9A1"A-"9*Y*FB&I_MB-
)V4|P1R9(*5;F(%>=%4F+|_#LS>V_J|C;=|UL-|HCF|B=Y|-ZT23-|Z;P;0_MEN_^|&K-
>52SWJYDF?<_R|I|XO|H%7>#DP!#;^8_T&O_W!)O|IK<;O_C_IZ_M8=|R@.N@#|41O//>
=H3W7@?_5+ZSH,8/KM64KY_QG8VOQA*24YP)E)M, "
M"Y\$A*A."ZJOKA\$E>"LOR5&FI%>&,EX@498DJ5N093DN2QU8E0QYX"7X1;3C|MW|
#HSNXMG?542"#WFM;RZ2G/%J^HCCY.WB_M|D|R)?LBR\$|O)!?OJ2KE:+WO%RMO|U?
\$=7WS|J<^@?4CS*;G|;S|OU1SI= MULT=)U7%,U%D%O7WHA@CKYYO?Y=#L:)|
<7)T8KA3*2Y@K;5G1."/((S&U3_M^F),BM3>0WB&6/XJ=;>TSJLUB1'UZ2C-
U^_^K|ZFTOFQCGL++QR'A\$!!B,U_MX;WP8TVZA20
%@"7F\$=,W|Q=EV\$#|UQ9"COHCSJWQGA>)DMHGQ'ML^X)IKH
M3;_AZSK#_78NOLBZ|>.M|5;5B>S&X|U>B'S""HLU_5V+1/1CHL@|Q:P|-Z" M_K9T1X|G
^\$X#-5#%W#VBBY-B=Q|V?SW;EZ7.K?WFOEC6T9G^OO((O|,<(D*MQC*\$;
<90568%PJ72UY!%TNZ_/GA_M/QN3"53A@B%3!^!((+?32*&A.FD;!B"U9\$+

M&)X4\$HCTJ"K)!9272LEI#7BI7ZWIS(WD-[W09BD!Y7U"@VL-YH#MWJ9;4G?
M@"OYCLDJO/TIB S;X>[2@@KU!F1R*LXIMMYH!7D#PO2+|(8^YAS+G6+[Z?
27%.SKC9@J#5M#:D&AVI1OXR^-H/4G^|\&YW8;79L" MO) RXRA->8ZP5-
H4H/K>@J6@:.)X6B:@1JTAFOWMUS3>_X6*>' | +2EO8K> M:)N-
ZTL+T\$H(^O: LH\FOXIV PIV&ZZAE(S)\WT0\SB/#>M3CO1\ZUW&_?<[P-M?Q-
U+W=O>G0GA->0="H_<6LP[\$Z=E [..A'HM[A.:J=%Q^G\^E:_CKJ86+R M:
IVE3,>1QH&@#_?E>OI_MJ4K\Y7\EZ3+!_V5DA,ITCAG(D62ZU, "WT_I%7%
M4%%6/,>9D'D!ROMOY".PEF^X0C5;T8ZOUL-2VSI;UKKTEIO(CYTZ' UUF%
(,#CB\@YP/H'PUD+N(MEW'IQ_F [.:!G)=%+VN)_KR4W\4RUBJH2>(T@QQO?I#IS!#
IN%A^I?V6=;L! MV&I-K8E)^9S0+)&290D224JF
I498A4I\$;EPEN!"5*H"S7WSQMDH;L;1KOT MZ&YX;7J_99UI-E#*IW\36I\$ _4W\$;K9-
9K5;M_ ;+7Z2=IKW*ZP&Z;- =W32M MDT^_@*_U"!@;-4N5_A9
WXES"WE0^'EN.7Y7U=I4>|-SE,MJ?T1<%/8ORP6 MXL_I;/:KML%G3)3B,4T19GF&
<(Y+1!.FD"QS+"1CL5 @R_6 0F %VM&I8%3%
M(2AV2NPB46'"8E6)V\I9K_255DSGCQ.597E)9(%22;3)\$^<58@(72"LXHPD996>F4-
\$0N!"1O2 MS3UDUJ6Z1Q^V(0=A, ^6#0LD\$J40PA/7%&E%A9N_ (4BNLG#-:Q)/GIH6RZ: S
M+G@O"5M#^%8^3N=U+ZJW=%9'5%'4A\6/9O1F5?;(C"0-PIJO..-
F\$OOD@7K^1PF=#1)\$ZJJ0G&4&R07>CN='3\$&37@:QLJNG_A"
I=DM&"I\!)DF8B.:MT2/06(CIVK8
M"Z8;&'UE\$/9IDYK+%;K.LM9+99_TJ5H_O"O^4.303')\$B98E:5()DFJHU2
MB*1I@3A/9OI2:K2?I8RA)XA\F)=ICILW\CEI^VO0J0\$K".%AQ1 4-^=S M_.K9
M\3;>&>[WJMBYS_IP&6Q\G7S2S#>5MY-2\$E:D>8&R/\1+B1%C&<%8E@05914
MX\0V\ P+V\F?'I<;KB=&82-">8%D1*+;(B.46X MRDM\$5"ZTMF
DE2K/\$@IM"7D!X%5B:DB>?.H*?_MOV.:JH7E/B"@;3TC8\\$('
MJ9P<*IDYFO5MDB'W\$F_J,>4-DW5">,B:!'>T@E7=@)BY<506E M!JL?
=_ZD\B\6G^E43*L,2,EIC)*T4@BSBB.:X K1'),XKU*)>X8>E!O5D@\$TV?#U*^LP*R@.:^Q
M\I)9Q+-_KVE&V-3-ST>OXTQ:5B_OY%Y-FV#:\TF;BLOOC6JJ:KK8C AXD_SZ?
M_FAN_KQI.R\MI G#LN+L@7S'X"[:3H*_IM<%4;L@W!B\T' E&7Q6)H=D= MMW1Q)/
/:AS'HNO@3?JY\/%LLY"E^*=_F>Z;B?1:M\J1/:VE6RB:\$ZJH\$0R M4RG"HL"
(\$2E07I8E97F2*V\$_I=N6:F!EWK 1M7Q\$#2/I CI/H?I&GY_3MM=S M.;JK#:Y%I"
(\$9#!%^FK0 H0\0J#F%#@?QBQXL0)%83!B8KW8>"\$4J'Q\,17P
MPY?;CMR.03#1//9G=OTR6S_ZVQ7!_IKX4W^N>6"BWP%EM!ZP7<8(<^9B"N%M5)
OE;(J*ZE5XR4OW 36RKN)=I\W1,75'GI?3\QHFH^FN=809Q+#6'Y_63JJ_ M(71\0Q8J?
\$S<8;K\?R;D+@,?1X#>[7S0BJ:%,))T:7Q\$[\&=DZ@"GC_.(*E5S MJ8^)A8I^_UIW':-
S:J9(^*427_18_MFTL/7SS_7\$X?OZ\ARP"+'=\$A7(E>8_7@A'L='EZZJ)NWZ?-R(3;<=
M9%=_E(*55A?&6(AA4P4Q%,T1"SP\$=22 MKC=*2QQFT%H!9N=Y\04#I\$0X@L"-
=_^,4(J(GC\8@J5&I\$39"O_0D6#WC8)_V MYL4>|U&\Z*^3TBPF18R1(E6NC5&JJ
IAB"G%%2Y+D1*126!NC(-+A(US-S\$)C MS\!=\$_W>C_*?0,#U<)^# 85.
(:UFSG=CAJXW1US#7MB+Z!&T Y>P H,! MZ&;R67S=_N\):.2?-
2@ZTXGMGE).F>C>6V@G/W35.N_&LSI:&9/M?VNINP MO,QYDB6HX
0CG)@TJPHQ+@H)98DRS_HFV" 5NB@64.YRRK<3E!LJ8.:9)Z\$
MS#*6Y0<(8:C*\$0.77I;GI//7K_(DI:%\4IX3^4C?R:./!A2OI&O#Z;YCYS-
MNKA)\$HM85\$Q?B%B%<)X)5.5EC(I"Q:4J94Y+^IC)P?*-VZ/GHM'_Q-"ROG M(AEA>I*
I>-;Y"(QW>R-'DE/9L5)(09-A.GQC;/3G*19P*<_I1K;Z#Y#I<
M&V_YV5K7O2Z/I0S5<3OSXMY\&5^?8D51S3)",H3N,2X9AGB"2J0H3DA<"B
MRDA1P3H&@7D(K%UZ'\$5;EO8;E40-6I%&\Q7M&(.V;H&C;V=)!;84ILT"P.G0 M
<89\$&^-8> 4Q0PF2,, \$M2K=Y3 MBAB35(@BI23/)OJEL<7H:/6I
O(;PN!DIXB\ROYYA1U)Y^Z@|-N\QTK\$8'G: M?5I7SLH^(O;Y'.QC#\%4H)#3R8?
YNNZJ_=>=T;W5\$UY;8%_VM36O^FMJAA/ M45FFS&I0YEE*H1,P:MJU>W>?
>M20MJO>Y_\$:WMI> M48!M;V<K#>UM7 #D^_T&LU>UC_LMO#YE4?
9OM8"=EO7_H%+1WX,C!RI?;L3 ME,V\5V?MLC:.\$KS1(PQ:0TU,SK%>X5,F8)F1W
M\J5Z6?
OI5KMP94&34N0I1T0JTP@ZTS^1HD))0@N)*TJR&)0EDUGH9"CUN/(X\$.@DM5?*X
RF2PZP>K@4JPO4RSGOO:N5DP2OI\$[. 7!/: MC9Q\TDU\ _&Z?*A:A^G_K://79EH-
^EQU;3\I8)S7.9EBC6^@3A*BX0(R1#*=4:1E05JV@QFS;13\E70*:=7AY.W8Z:C2PG;18G\I
MDM3Q=I.=D1MM.6P2E&L>V\9\J2;-OUI-I^@>=)J7E@:53OZ!/&E_02ZMDNM
MXU9_T;7I=2=>[770^DPO8QR'M.H-I JRPQU(BFM\$2)6F1B0*G*2L2^I' M:PY&--IV3-
4&2KV1?W7*?72">E@WC@*@NSEW!CMG^]<=3DB99&!8'4LF/7PU M@862%^</p></div>

P7#3ILO"(!907R+U?3'G)0FY&\Q>YGC8J'8R?
T\$O!)\$.5:F2B!>"%YB5LF2@6.1Q.H&5\XYH'5J*#-GHR\$.O#V?.,G.
M&KU<=)A:=9\$;."T."^7)_CM!9%2+;EC0ES;F4I9PW4N0D?FW+&;>U:FW#9
M&H(34SE2)%RAN*(89G&B.G_(:U+2RF%B\$EL5>0,(OMX"WI:Z/_^>OI1/Y+
M\$+/_O_YQ@.WG;9U#RT" _R+CE(7K3&HHWS31).EX#3,%E4&W""R.JV MC7'#
79Q.2O>X.WD]/C74'.2K!WSSC_5_YC;/_UM,GN!;_D'2F:=%EG4/T
ML)1S84KODPE.4LYB;8DLR!#M^HH8A,1.F
M21F.;I|HBLALP=M0B64GB6@2OG&=H"=#|YT'HEQZP#.=._??Q%\$US2V>U<
MW(JGZ7QJ9H.85B&MH;9J.Y3BM."Q:4V-A93FEL40RV6)"A)+FE*|,185FJ/Z;
M+CPXJ6C"E<(E(E5>(4P%T3_I/R:2DR).LRQE5I&XP'R&=@D;DV&AZ@Y@'6G3 M.*P)H?
JSP_R\,U=C;?0WX<.BZS\$=&ZC'MO;C_9I_'?OLL_|H4BI.WG%=Y@_M|J(?
+JL17J% ^KRIZ9>8(!IPL,(!#_0 MK43TI(V&8VJ4ZS\$?JD9|!YRG!=IFLZ9&ZRV(UO+
<3N1;J*R@E!9*12*--?; MNY2("*&0<=;+F)&*P>:%#!\$+O+N;=H>U2|;Z. WPBI(6
OH9!#I\$:=PZDA='(R!MGG%L|J|?_B?ZU*.18)O4"K;+#+="T6O WK M\$?
Y|J5WM+SUNF|4C0AVT53WVF:OT-JF,)OPX_2\$G
M4B1Q5C*."JZ,0U85B."L0)7,TR1EG%\$&LH5!U-00Q<-|WJCA#N&;B+-4D0-
M3_40S\APY=X,|#S<=MLX&(BP?7X:O_4B8K*>"WACC=Y%;02M40C06/_|:NU
M&K2&9:CYH/TB%U4?)%"RB=ZT"FHJ<9F1:D/^90B667"U(P15*62("X2SF(B
M15K9=W2V)!HZ%-1+'M_O|:(Q%JS.'83IL+()A10PXG-MD)QJ%+R!=7E9PFG0 MO%=>8-
M!9@R!;,CW#;".8KHCU(:JP(MHW8!O%KJX?"7-(FA N:J)0A)>NFS4F"J"PP
MBI.D9#1.>%+&N|EU|Z*U3MZ|ZOQKM.C7R#>EV7)M={DH|X1MA|
MY|U&6PWS|20M6)(091PRE")L^OA1RAF2&<-YQF5*."C'Y)#\$*#\$+WM!JAXHX
MA"GV40\$\$)YQE=0E)-,1NHL:X|OGD>,YJ*
M'%6)ML!Q@5/\$BI@2>_LC\$FJ+P42LFO|LOAXUQN&HUTO*1.E.YEN2^5|;\$<|M;LT-
=LMO='N)(S;-6|73.M=|5S"M|;+EU^!KNNFU/+@Y^D)@P9@_M<%0-'|@EQH("5O"<*<
<;YY,GIH4;6#|Z7DIO|OY:COJ|)-HVQU)<*'JK@P|I|@#FZ&#WG6C+9I-MZ|V|&SM=?
GW\$8?J|QUW4)-!S^+?IUL3+1SJ-9P|T;Z_>,C|XT ORM M"^H(8)F WL\$.5PRL |FKYT+
|!%HBU1@G|1<>_.L|)!O^MCY|W|(6>+Y|JC MU^0K?5|,IOSGL,2*93FF22FK#
(.;XEK0#*R#.PYJ M_Z_'0|VY@;=O&P3ME*MG7&";|B0DVV3"AH/H6_O?+(UO_1!X:P!TGN+
(W8"L M(3AL#63_J&.PS8PM8M34+?2J\$HAIK>;|??%TK2._'VN5ZP#?/=UH8/1=:L/M?
|DEGVH^EEJ/?=%?/7F_6;_6^NLVG3|VGUO|4TX?OVMM>/M#+NFCW'ODK7R<
MSN>F3(+.C.|OF10)HR7)8J02,WZ5QUHOB3A%*?EY_M|,^J5_
M12PPA/F*7H1MO/05L1PP6Z7^6KVMOU9M%""Z72X-STT0JV'7XIOC_HV!QWQ?
MX:OQ%6)^3:.*&|%^39*?"J"_1A|=|(*Wfy6^VZQ6M_P_FVG;"/KS;CZC%B M7
>+J&8ETKOT7?7>&';Y=V-N=1T%@@@QT6_A #JWRP|)TL3W=494E&(Z7
MF@R^@\$J|!Y8S'|H756XP#Y2'F=;?#PYZ(MP|T2A>.LQ(C(A"%<)CDB)ELZ
M8817/&:)Y%;N92MJP3T4+?FHH1|U#\$0HTCRX#\$_.B|^PYO".M0_3X@@-QG
MG|"X)3V?|L@*EC2LZX@|G.9Q<9+|W95IZ|_&;KAQQS(.ET^0>=;>1ODJXV
M34TLES/=#CZYHNUW8&F&|V(3OE);/VMD=G
M_T:L,8"!J96^7XU0.2V(HB@ME;S51+FDJ.6%Q4"1:)\$F75OIH/<_\$_Y<5T MK-
HG>#=>H|?Q3NP,Z6NB##M!#;=13>,FZC';-+WMLQLU_\$;|#)L4EY;EJ.;Y
M|8;+;DQ#S<0H+|R=GVS-VZ>;R|P#_*"0|%QN#?4C5::YBIT5L=9NSZ;7"B5
MFFD&)4E.#4&2,JUYBT*G,127R"H5?Q@D\$K@>|(>V2;%_6!GX3&XBK@0V"8 M
CLBJXO9?U)H@+GO0W@W,|)|)AQ?TZX0:/^Y;/C&?/G^|SXL|^V)M#M/YQ
M*>7|Q1.=SB=,Q'&2E@+E6:ZU3U;EB"19BW/W4?:E(C;/^E2M\$;7MA66R+ZYK.;|L;|@'%9
MB""9:_L@2Q!A>84JDH4<,\$K_E(OP3B|4JI2/|SD8C^C_N>VN2>&_YM=%M)>
M@LE6BC,>C)?NYU:>Q5O\$Z84^|E|YU_D6_|OTBTS*"3(M-|@O_Y?LY.2+B/M)N
\$)>AVJ+RCJ~\?9XL_/VG<|(|W|Q|R9=J&WLY%4W!O?N;KZ8^Z&NS|=,5G M"^_
ENV6K>N;6!(LDJ;#@2(K8#&*@!;*55(AG.4MYS-B)0=TQ+F4HJ!"Q^>?/
MOW|X|<.GA|LO_XK>WWU|H^O|U|^?_(CN/T:?)C^A=|=?_Q'=??KCP|>'NT^_M1+?
O'N|^N'OXU_&J?R+WXJ=9A|3:Y@-"YQ%AK6;J&4NVG)7EPUL^8MV#\$8|_M#J-O'8|>;
|N^X/*DBB|F9U2-ZPN|EXK5V|J.-VTS-F?*D9)FP)K:N(QJO*
M|0.HHE@BG|J+FA.%M\$ZD24F3M,A!30B.DPE|O^X1;>=N.WG63F!D>:F^6'+@_M?1HN-
/PF/2B3KTOT<2+CWT!|3VX.@|_VB\$>|UF;5\$_TG;?D|RV4SQVBZ1.8&)?\$YOP@X!:=
|UZ6%3NO%B#<;F!Q|>+S)V782|V9_%QF/Y9 M+=>|MH6_R,7CDCY_GW(ZJWM?
\$DZI(H(@K)29\$VQFF>/4_0SG_E:RL*J-&&0
M2F#=#TR<':@|Z#,VPXOF,\$SM0&2UWFM6L@Q9_WJ!GB6@_|2S_H;7'F4;6HG7_M;4*
|#SLZSGO-@;6%L>&FN4U|0_@BZXX(=2F^*3*O:|PG3%(2)VF&\$JW9M&G MZF)?

@K*"DXQ559(G(,=2#^T!V.O8W6/G_I>O100 PR?04&V|#V'@PZF Z1 M:AEHL&JHH?I5.
(@B^/+Y#ZN'Y<-V@.O+..RS@V/92KE=O-: #K9T73;_ \$ZD M(E-5EJ)<86TRI&F.6\$XXB2-
EZCIO",H&F)EXUFRW^ M-/42+[,W38C-?3SCEN2Q5@C Q+=.U|C*I!>:/*BYEA4% 2DL
M*.!%=:6G6C+3|W0|44BSLUV?/TYKUL?OK;3=2P"--QT4;J)M##>JV;Z)#.:/WS;-+%^R?
Z-M\$R/8)?+45ZOG0*] MXDN#Z==KOB_7P;^ ^4?4|*|@;=|
<8+^P;VA,3B;V3<5/|=2+5>WV/KQW,O,)9
MKHAI'"*V85MQ8(&9FE,>%D(E(5:\$J#E'<=>ZL'5KLUK<@0?0G4JSNYE|W3T_+
M>@;7:CU_8+./B^7M|XS_ M45-UKL'>"2H7?5X^-2/HOWB|+.E|WW|)=#;0Q ME+?
SX)IO:6./UL,S%D0C |;G|!&+!+G_NIQO73F&|+0H%>7CS!L07N*V#0NNQ M'-41L2-
J9"7YWQ|7/_Y+K|AJ\$ "YVB@-*9Q25XBA|IVQ<'|^LWE438-.FG/;= M8F|8"*^_
A"|J:C|8HOYUB76S:XJF1 OIPO1FL4(%QE!M% 22:X/?4;BHA*Y M2R\$LG)7
&FU;"=KC3%OX6|ZB/>;V_/_GYF?Y?B=V5L@X2,-T6T"0G2MQW?'Q M7*+KP,A5:G?=
3M5U'O|BI?\$\$^L@P'NYXLOIU\$B/HRM(7Y72L.42<0|>2(6D%NVORKG2SMDQ=;
M8YZ_#L0_::O37Z|..#-Y.'/1,|_7MBK#P&|A? 8B|!A|W<\$ M3>).%2+E!9(QUX>*_
&U(>4*1Q#EAJA*J3\$&9MD>IA(Z\$OLRU:LD"PY=|;\$. M0EXJ-
3"4"!48'O|;\$LA7%.|HC7%C<4-B'D34!C_LMBF|3+&/B^5>WNND9)21 MHLI1G"
<*X;A4B+&X0AF5(B,\$TPIF|)TB%'AK=F0CM5CNY|K#-N=)G.SVIP_I
M85O407#P)CTGE;=|>I+J%OUG+ O=^O9S|MWZS#_F)#)#SHS%.KEI|SDJ.M?
MU!GK_ ;_H?7*2QWF6<8)1'&-|VJK4-/U6)>)"<444S@LLH*TZG+D)O/4-M3:E MI4?
T)MKQ\$S4?:4HY|OZR_P2|X?|_|^|3)J.A#E,YP0%W:M=Q,5->>W6X|S)Z
MHXZ+8306I>/R1=V4YH>GY|GBIY3M7./CG9CT=<8^ ^BG7/6|+3
N'>^%V&OI5O\$:8|CX|3?/% M>|LY|;:AY^('1|.3B@_'YZCJ/SC<+X^&| 3|UPM|_
G^QF.M#J_|49TU|*=?3 M9OC\$6SF7;KJNAV=^DNO?
Y_1L5P;CK;)KLOI2E|&WM=7@L_U_)I>74\$NBXPG M\$DE6480)K5#%2H*\$(E6",)2@I>
(BPX0917#-\$|JRB-<2DR,9G7:73BX?|? M;YXT; Y*- 7P+S_WICWO_? F=_ 2S|O*_X?
88J2GFO&9|KJZ,5H1X'OU>9 M\$K6L1PW04I70DKQ:NI<1GA5D'J8,=AO=#K'IXUR0
MUX8=6J8FL1)5RG*%, "|%PC&)\$2T3A@0ELN!<\$,%! |;/T MM4BST?_ ^|>|
ME|9C"R=>OXD!|KMVCR\$EG)=:=W2CMZTU#U.PI:4TY?7|0RU,XL M'W/HCOG.*
G)O|7L|7CS|=RK3<-;0V3|&|F_JXU"Y|,H?;\$!S3*| 2# M6Z=,Z)< UBS30K3|;IE#SX_7+M-
"BKU^F3:?=RS6K=-.6K6W;6C/2DX8PPGB M@A<(%RQ#5:Y-#L=I!);&;5G+:UI T<""(?
%SKJX6%B8^NFF M4'7RANC%/RB2K|K>HS3&K?=\$=\$O.@UG?PPPX&PH-
SA=)M%0BO8T4&F.4Z7T#LW,7/&*2D2+I\$|YIC>GJC@3A57/)S#EP+O6 ML!
(97J*:F;CC)FK8B7K|N!RP((PM#(Y0R,%4P&L"#6"FA +/S6|Q"B+,J'\$! M8M#*
2TXGMGC(N>>'>2T@)MA5(|EJMUW8OTKL G.%A,B4|I280PCIF|KN1"(
M)\$6",EFF*DUXS)G516V02F 5V|%L>^EV5&\$&TG%X| RDBX6&:4>HO&#K:%>
M3|;1<1JC6D>#8KZTCH8_#&_N;RIZ%|.IJ'5Z7<-7-|61!'.E>(JJ)|19A0C M?
7=1B!4J)=H*JK+\$.A|::1+!728|HDWA*+B|_ PELAC>C'XFAGA*PL*#V_L/R M7-
#;_|3"HS7V'Q:LW|7_S"?=SL+?Y|MMGL<#_;MUAJZZ/7X_+|(K|=C=6|Z7
M&WT4B(04DB<92@1/\$"XKI2|HE"*I5%&6@K(!35L=. A|;MZL&E MS9%CON9-
B+5F+&HY@YVU+O#;G<2!085IAQ|X@L_R"Q#Q=-*|<#"J'7 !1"^M
MA\$N6U5GS71%ZAU'6FWU&|&U_=1L!HAX A3@ MEPD-K)M_ONU|>C|_::BN02305>-
T|+CN6PND7O/=7/100 .FA^UM(NY-/G) M/^3RYWN|.|+|=/6?#9UM&|
|>J|Z9<_NTMFVEZ;)V8"7>LA1U/\$5"*YGU(GK) MEMD|^Z859#Z",
|/#VGP,3&*!|B|H+3,O@:/?._.B=1OG MXIDR"_:RS*)7|O/VY^XC;45077MQ7_>M6GW:&
(_VO:H_M&K2#KO1'-U@CDF; M>25JMW1LIEP2E:"JR!*4D)F^B#-
!|QCDFQZ#Z="V|8G*N'ZU5<1^|E70;0NR MFLJK5IB;J!"|/A&H)LV^?
G8C!3@,|+|00AUUV#H'7|LZ!-GBOKN|ZWX;_G7#
MAP^.B+^OB85CL#SNF,,17|+!;0Q:/VPS/D|_|@S|Y=T9A9|EQQ*9^N? M|^5L:BS:-
A.'J03'65H S I\$4ZE0I7*)"KB.->%J)*LL&KW9D\$K|+XTQ)LO
M:D<^>K_|X|RTOC2!FM\$F=W/3 :SN!U97^#U|_|/6 M./JC;FIP-V_ ,HG_*Z>-WT^1
(*2PEC:D0&(-OU*|!LM=_|6|'U/1\$;KOYKK70NUM:(|Q=Q^7>5R)WL42O|M|4DX#A?
TU_#>(+?XU#OJ|HJ7^LKYN84>\$VOTZ?GX%7(-;Y|X56(/>2#>%4,
MNAD2ORP6XL_|/9E,3-3L0R'\$UKI*Q%,,I(Q1"6E"- "N\$!)D65<%9G""0D
M/T(C|_':48R^&9I12Q0X@>48-'9GRX4"P|0|5%:P:AV0QI.2.T9A5'4S(+ +
MC3_T4;7&+&DT4J6_2)&NT<892CE+\$8Z%0#1+A?YCE:5F)GL1PV9-#-,+K!KJ4K|3?
0&N|IQ0 M:_ME;^G0N|NAU69Z_|D?DM+!%GJ8 |TH|)O"63 W\$|)20)BY<%2&0>M@
M_XGQC(&CG.Z=_<<_ =OB0DXG7R7?++7A|. \$O_MUXY3|1)SG)|E2D62)1GF3U
MY&&|T5D|_#4F#< B:D M|4XY)|E /KA^M#ES|0^|H_ ;D@J-LIW/B=)OJ|.?</p></div>

M2BKNYW_093W9\0M=RV1"L2JSN&!(Q0+K+5<01\$WC1L%B4L6R8)4\$#7FR)1QX
M*QHV>H&QFZCF)&I8,46X'3.1X09F55MC:V=>AT,MJ4I@04VN:&2>[*]K|FKW+ZT6_?
F16Z3@XQ M^8.CC#'#PAF_@0067\DJ1A%X@|MVV(_@A>&7MLR:/M_N=T_?
WW^8*MY/*' MV2EW\^>-F0UHL)W.IMT@||W2L%,?@05-|;/>A|_I2JL,IEH9YRK5|V+U5:|7
MLWK=U80G>9FQM\$"BRAG"69XAE<297&2T%A60G+0;/%1N0_MQ^H8N(E6A@7I
MGQWMFTBSOUY.V::.D*GU#VL+3Z-G.@7V"AKWK=N=,*_V7<).G5U*P\$W4DR3Z
M4XL2|66)&F&B?6G,<-96GN:&<- /T"+F)>M^-|/5<^F#:BF;^;B>=QU+#J|P5
MWWD,H_!^G<2(,5_+R4R+49D(5"ZP.I6NV"8E?OA++OE4?E5)|A MK,JJDHH2E5F:
(BS2!%5,*52669DI6=*46V6#7(?)T"Y*CMVHH8?@\$4!_|?"^@H&&4RA-
!R::T\$@PU@C06#S|TD|_&E@|EC M3@_,&F6P%<>SS)PDW3/W%:X(/^M|?
X^77\$YT|A3N=BL/BV:\$6%\$S::!QEA=5
MFJ."*8(PIS&JDC0UFI@G/,ESEH%F#Y|G.4I&6C>F=X^'FVC'A4/6V#"0=B::
M7WA@ZO529-QRL:R\$|9E4-4QP_.PH*P".ICG9/7GQM 9MJ>G5VT;L=T_/QMLV
MY6VM|&ZDB=NX!KO% ^N\$EP,&3(1KRY9I.OV2,>\$!DN*UOK1-D8\$8#
<"\$WV^2+7\$G|T'=M^|R7/^1L\6PLW?8& M.F&R*A*<"T24Q BGC"*J|-
U0LK+,*6\$Q!G\$+!FD%EC|=+1K\$|Q'07.2P\$R1
M8=SLK!!O:,"4B#,08,O#2D!/:1LT=7WSW0JM'9I MYO28R<2SC3
MZ7J9;O=JKSO'U+IEE1|B ?VCFK7(|&8ZJ;6CBNJ|V#5|9D1= M/Z_U7KUH!C.U:X 5 G>
|V-4_-W|(9>_!T|N\$F|8#;|I.+JZ>K>ET;HAW=-.:L8_3N?
(HJD8HTX1FG&2C=U9F3T":1X0LM%-*<-1Z)J./-|!QNJ_5-)+GE|V6K M+*#5Y/Q*+"VJ,8
&6EL!,88;9)?BX|M8<^9C7\$/N4K@.C+R+%|QZ65Q=T3#! MK,HSF2M4BK1"F!"%2*
(RQ&B&4Q7G*2?IE2K?:@:#WR5GFOS|T8S';\$?RKA8S M\$8DFR+/^+J/G,J?
U:G5LS6NRTYK7!!_H_PI5C5;S_2K+S/80?7V59_U|_U.+MQ?; #5@/MD_GLL;N=91RK7?
%5--08A.|UL#_-M.@-<-MZVW\R8ZWC'2C9/? ML1*D%:,43")X;I=O1ODH+=1
LIYJKPQ9Q3(59P@QF.%XEQDHDB(D!ADJYR@\$|CD:*A&JZ:KZ:KI:CIM6KZ^:?X(G,|I
M"B|U>\$!|: ?KP%@KZWK3=OTUF-:X|!80A(93U 9-W5Q6-2#9,4S'|U-Z;)
M^JSL,"Q8DA6)E=9\15A)4HR1*9)U4I:6K5T/\$DA1\$S7X#Y<:=!L=N3%XD*
MVXTP*2_*63F2KN8U167\$Y+6SX@TEH%R2BF9:1GZ8KZ?KG^UXWJ+(|/_+3)^"
M58YP*KB^NR<:,6'B1%*.)|PJU_?EPH\$W5T|/_S>8>&'=|,E(L\$VD:TTH(:H
MQUAW:H2ZM|H#5"/L=|O?'KT|VYGS|W3\$|7?P2F=?5@N%|MWB^52\CK6EA!5
M54K;B(0(BK L,6))5B&5R32E,:E*!@H G*04>+OLZ\$8UX6A'&78BG8;*[F3R M
@!L<|G(#CZGSLKEZ,PZ36?4<^NLN"/_K_/N&W=YDB|5_H2^;Q8T=DOR|7F
MN0DOFLYR^FJYT|BKNW3^V>Y;+H&!>4Y 5%^MK'|:86%6*2EZ9=.\$TX2RJ: MQ)!-
|<1+5K-Q\$6V:B/C?1EIW6_6G9EA2|.VT1&|!\$8?K#.YA@Y7(! M')
|4C@L'HRJD'R|ZJ:HN6Y@1H?6"|U M6J|:|38|_#|J.J=B.34U>C_Z.6.3A!=
<9I4V[*]X0EA5)2)) +%%:BH107)29
M2&|:#*8Y0'6V_:6FZ)E@=Q|:.^KI88J|!|1'684|@\$@##>AD(Q"H=TD#?WH M84EK
|_CHHY'&U:DJ_\$2?3/L>"HSLQ;J:3L M_JCE8|9"|HO%:_R-
&_PK4AMIE1O=H^;R4O\$EMT3_/9-T;BYNGQ;+|?3-
MUG^OB>L|D3|L|=GK7_WX3^;:5V_,B&YOKZD^APF.%(BU@A5BB"LICBE"A9 M54I-
Y0+14+)TNWABS6K;D&;|FTWCT|1B/1X03H;?'U)BQ=,&.BZ|86LP=K
MGT4S'*5ELM9/?39OHY1_9-A|::^R)9;CSX;S_CY(IU2_<4%P7(+N.+:\$ YM?
6S:B+1^F17;'2=W)K*F<^&:X 2936*-KIR!# M8_93@-|@
BLWJ.R>E)-6|NCUJ^""|:"J:75&BL?TSU.L#^U*_4001^H_
M|7;CP7*CI+!30G2|YN3O/94|W&|6WQ=+,X-QDG)|BBN2ZWTAE3|')4.DP#'*
M\$J:_OBJPD*!S?(!6X/UR+/L_VE&_L/*A|YG=N>L)"-AV<|7@|B*(0^E"%4+T
M*%VW&.)0Y+,%\$4<><8UP*E,6WC:-NZ&SV;(ZF)N?ER9&L2>YZ+|U#V;31_K
M|W=5EY/+U>I>F<|WA_&V;):D)*M4E2,:OZ;) VL4D|,DC&-&
PO35'Q|=O|MDV#9M)8M/6O7-+F0KY4VP#QJWA5T#!QS734 M|E/C?|-
_03UW9'=,GWUV02M(1/86N@|'Z<@|A."0'X;1PY.\$7XIV%RQ- MY,-L^C1M6D=V%62R4*
(JM>VG1"X1+J5\$%"N)XKA(62YC*C*K\$2_6M(*;@CWJ M-
U&?/K#>S@:WW;E=8_6F^L/LGUO3)MUMK?B\$F58)(D\$B/&)4<8IRFJ2!DC+#+%
M*"|3BHLNWY@;^1!>""(JS_E4!_R|7=355:W41SN39G/3?M|FG+\$|Q2_R%>
M9)00BDN\$)=%7|(REB\$|3-)8H81*C7"F6XA9+7*RX8_G|W5GO28U|'P:;MJA1^|6
M*_W|!%U6E"LI->*!,M_)1)6)YF2%,YJR).=\$@_9\$'I('L|O\$8QJBN"&_B|!
ML5,*EXD*V_H0*5VZ|9|0Q%^+_I<\$ON|+?T+ (WX3WW2ET?_JURO9W5/P=7.
M#S0AF4APJN|0::X*?:70|PK&B"EE*@JB%*&%! W',.^""|ZM_G|NQ
M>*F'_3C(E2)"I#Q%2LC<*#N&6)9F2%_D|.V9"L(Y<|@D^|3ZXOMQCW08\$%U#

M#A= [R%#QR >AZB H,8!//P'Z=Z96 _!(3G/> _#C/OIZE\7\T>MY)\>2\9^
MT\$O4R<&XX+*BF**R*F(S"4EHG:RU+)|8ZUTW.X>/<)%O<,"W\IVI*M_>CS@5C9FKWQI
M,YV*=LR2_GROX=ZDE%F<%4QO\DKJJU"9\$=,X-D.QWN^9-,8#K O85:0(K%0Z
MF:*>4'6;15:LJ"17%WOO)&NFU?<&+;7"W43=4/OM&=U(N!UH;Q\LMZ"\$*:#K
M?)WL-,2K_Y+ 5/!K_WZ_U?U5WX^G\^0Z,HQZ8%WU-,T\\$. +C-N1^Y5_EV(S MDTU0X^
L\>?7S?-S8VO3V:YY^ZK.YM_-U,U33GDL*U3)2A^:@B:(E8H@A1DN M*\$OU_X\\$&(Y\!#
IV.JZV03S#V\$W49ZTWM@!X/+E";W? C H\(@ 8MG6"T5> M!QM\ L>3?G;E8E0-
>R%4+W7DIDLT:JA".V6_A&58MW@1%J8U MH'(Z\ -^(6\O65\A N\6YJ57E-SRYYP-
Z6_2>JA8F?35>:F7%BMS?'H>K29RR MO)(A0S1+\$X1QG*"JR#*4DX(KP65!*Y!
f\$D(A\6J(1RM=Y0CUI*^.)QY&E"*MA08.2Q.)Y@AS*A%3DB)6T30K8B6YX),?
J:SGY%L:+V<MLDU3,;!>1&HS%V-C\AQ'H*CCV#R8=69OKRV4!L_Y#L#,^7KC?
YSCJWN,;_)M>6"4PH6;3Y.^=LSY+"@6@>?S:_@Z OHMR.
f5+W0Z7_VZ,"G'\$YKG^K*:,T03 ME2.(E%E2A',85E\ -I7R1CJ2"F@?57<'3W-
XUZOLAGL _\L8XA;/OZS!_O MUO+I5\V+ ^>IJ0G"1,HDS1 HBDG3'%%
<"E1*4;\$B\$32G:VO9LVU1M MF6D'NT0\?B+#2/3-L%3_",V@@:;%MZ=G"
(5.G&G(1C7=J"/LE(IW\$BH\Q>\$# *".6--U'=@QYLA';3-/
MZ\O2YT53O+M%0\^M6I1\)^V=D\IE7HL4LN\F0IP1\B!=X=SG'<(-7\=H>IF
M8O3\NJKBLUQ.%Z)IG'3_ORY-%\2U^4\6;W-A38O4\$R;9 EXCAN\$"T M\$B5).8E+0JTC
E#JH4T,PTX\NCOJ&(H:CG:#S0U7B'9L10U? &M??324H(36->
(,PO0Y@04\T6ZW_1@J=,7OEQHB;K.HYBZU09H@?2
MTENJP+";:'EP*SX_A92U4\F7_&'4E-BWE"N*V\U-HW+76_SB,;3W7D9^B
M=I72\3.BGZH6/_>8-Q^T23ZM5\=F9/B,>HP>#<|M7X_A-J@3_#(P\G('FZM@/I,C@M
MW.L7\$G"X&=#QP.RS4A-1K\FYJ#FXB M5O-@;!3_Y>XBU"VNRF-A"5.?34G4'EN=B=
<\$!,T0M=>\$-./!;B;M?K\,C# MKML^T\J\>E\|\$8+QKN\<|JHD7A9T.\$:Z=E%W\^?->
>O6Y,3CIHS35V"9+Y8O\ M(><;^?
Z>VT4IK\$J\U(21"BA"!>O0D2R&,5E6L0)B16G5OF#;N0#QC; M?
F@-0\&.HYO(\%1G8D4M5U'#UK_UZ -RBX,C*)"PT^)U8@X\$H)BZ78.\&,Z M#.-
#W%/:M\9D4%=#UJU/ 7O+/&>5G=?Q7'^: 4:D)\$1AF3.>|0T@K(MAM7VN;BU5<=
M./@IC<*T\IQ>K>48FIVUVIU\$|7L+90"SET&O@\$|%TL(0%VG
M*/L%\$3XIV0T*7P.1@=3'G7OL!LW!>&/'99S"^V8S\ 3B_[NA2VVUS7\NYRM^
M7D\G?/L,9Q->Y15C*.,-WI95F97,(.%1E7\2_R7%&K-@%.U(.')^MI-'US M:AGL/
MN&V7;0#*X..F' ^R:WY6H@BPY6H M\$&>R-/D@&.*JH"CG+(DI\$JL%Q 5-\$0LL,)Y6%
(AH^66<#/:#^C\$'<+*TF/K M"0\$/EFJUJ:A\6DGK?>
f@HWPOARR0Z3&J;Y:"W@:K5YQK\$RVR3SOZ4F&VWQ
M9))FWJLY5)_7^HBNK<=_OH.O+=_DF7HDGY7_VB\A>W5OI_>9&
ZK?HQC:1VO808S6V:(GJ,>TQ'I M&?4_UPT*J3F_:BAT/65\5Z \K6L\!_%:|7M
4HZFH*F_OWMZIM.E(?9.4W^4JPDO M.,URE:-*QL8(9*:%;<(0UP95D65:T9=6L;/#9
(KZ*9IQ'1+%:A.3T\C:?= M+##0VJMEW1&,6HH>#;E!B7R9<,>)C&N\#0IZ8+8-?HQ5\
f74S&=:4R>YU?) M-\NZ??^'O_AL(Z0P=T2C/S;K-
HSS@2\GT_FC22JJUE8\8!>@;S0.7Z7A^FI"47D\ _SU?Q6_M_/?J\W+Y\0=_MUK_)I^87-
JHTH"0_O?33&!N>>(_JZLUDWGY_:D#0S*Y<_MIES6XX#M\ -P0",JRYA0-
^YE>C1MX8/#XK%0LJ!(0#ZZ58\<+ '3"D-KCK+! M+83JJK-1WU5EG_4MM!
M'X3E7(3%EL45+^KYW3)/3\$8^092F&<)5GA4D5\&B%_:FO1A7AU/H)*9A0+2S MGP-
SN@+(9.WS29^\$#(5@.#,@=K)"J^VC5>|OJL?_EH;GMA,?WRUGDA2B%(0A41EP@@Q
M31"5<8:*2N:*5_6/F=5,+F\D-OIH-<+U7C#?T M.0>=
<604_#\7RW\K#?:/D_7=-9S;J*6FZAEI^_N!^Q.\$, 6JBD4;#="_J6H0_RBZ4,BY
M:4!_",*THPL*@VH3M.:X^M1%SCU%Z\2_6_#W\5RM5WJYC_/M'E\/?(XR-Y
MS+H9@_WOZ4WT<;%8SQ>V,;:>&0!C6AY\DAVD^.\&C;X:5J,;%8P!X0%+G /"Q M-4<-|
(I3(//11!\^G\W*A\VOKGW0N/OQG,WVN,V39JIZ.:G,6#ST?!\O8_M4JV\ M@)H=;?
1.HWJ^V*F'_FRGO^Q^BSE\I?E8O,/@LMPEM\ -C9C.GIL1%_D>K.<
M1W^8S\$/QYH;^|/1%J3S9V4 ?&":RPZ: &^M_:9C\6UOC M?#S7IBF-
_B+YC*Y64S5MIVGN\@HW?GJGAX+25UC(%UOC1H<\@WD0)/*/\DS\ M"CF=O&_M\ -OY?
\$-GS0#="2V-\$Q=35&*JU6@J:.)I5J",Y%7"6,X)M1J.=(I M8.,K(QDU--
N)SW8:"0FPYK,AZ0PC004TEJ1G)-DP"32CS:Z0/^P4P\$G%QQE
M*Y13HN29S_G9MGT@S3;
(!;@KMZOY'_DG3YH"&5DXI@ID3&42)CAE\=&YD9/B):H9@IHHHPG:V2!#<8%OI M-
&3K1<2D\FXJ;FP UL/8.\$\F0?V=\$<|_ \%PO#S@X0N,W(K%."6/^_FVKBH M5=^J-C8>OM-
YVQO@#|E:FVF.36^29\+3,0L,J.N&4M%/ M/X OI#-(.G%

P*FZ=|JZE5('\$>>EN=XOTQ"EF"6ZX"E%14HSE(ND M+/*<\$BY RJ2T.-'V:'VYA|!C)*X|!#J
GX#.C+G= 0(1|5IC8=W|>|H\$QZV_ M3PB|2N?O:<-/?X^|Y3%Y7P|PBU3_-
+%27|2;VPJOY;D0E71%/)2IE;9XKU.X5)R3%48QDF\$F\$0R%02;,\$\$5R4BA|"*&%&303"
(R_ A=Y&8" MD*N|%+OHD1E?#BSW-
VOZF\$1\$|H#1'.CTD"\$=YBF@>\$91&C.1*IS1A|2S^'5.-?W|' M3EN9HC4E&-
FBj\$59\$VAS@L\$>0(O:.;X1GCTY/M|S|'X<5Z|X/M<-%/9K^VR, M|?WW<-9 X7?
FI0\$+=E5-ZX/8=(Z?BO4_U:71NB8!@V#|DU&"!;<+<7|L0.)E M00#!|28L0G&.;K5J28Z*
(I02"0C/"28AMEE)8U|JN_??70D+DD9%-P6;7_5 M5JO|L;JUYL=:>F?OTAV|!M.K5|&1?
4_!R>^_PQ?(V/7UT_ZY0"|TOX-OA<_ MZD_-|7JE;'RJ0R5JV'-
+6+.%|6:100+@MU|;565,FK^5MN3YB("/4|)\$3E&N
M3FT(%_K8QH5\$<4QEF|9!\$N:;@6ES3XGR|*<<-?P6DIH\$A6F;L|@X#H&/P1;-C
MG63G%QMF)KJJ-3TM;-X*TD:&'|2%-GO*;H;KWI Z=^H?U>;KZZ=FHQBDW@8*
M+4@296%)4Q3SN\$0XQADBLA1(1BS#/,.%%J Z^Y/2/_007;PIQ(>#-)'T6VP MR3X-G-
E<=P8';*K;(P&>ZD86.IKIT)FG>A&9K^<'|+@D;64&@U"GF;3FMKGMV'=,T#7Z^\$T8?
**+W|03%A?K|Y|>OWU^ M>NS|0WV9?9QS7F85%Z|,Y M|CRG|_
Z|OIS|H&5>R^!_'DV0YJE+2FNIZ;G|-'F9Q5&0T1ECDA?JC8.J0
MFDB41*\$ (8|4Q22VFDCWSS.C.9Z3)3;=4 C>SYFB;|1:|8_1CJ6EX@C_Z M_S|+|+;8H'
<9+& !| CE2.%MMY4#5NNM=#=%' [%4%R'*\$| MQ(|1F,P1B62,,30R#-R,0|/# F.8.,
MXR(A=E8|(|A|#H;R|PR(E|0!?!J>O|ZW,G^G|B5+G4|W=L7?Z+@5D1913%F.
M.,UT>Z8HUON.&/&8EPDK2|9*.IK#?DJ(;Y=9)S;HY'8)GTIR|,8X3&@2H>GI
M|INH&_QF10;OLYFZSRVT|..EN.^SFSQGGN9S|KMWR_5_-(L+# L5JC9=1'\$8E ?
6\$MM+"MT^B MU4DW>#_ =2F"L6M#I=JXWD|.W8+85|
(XMT|/B|U;P7N\$B6|QM'>QTF'4G<1%_ M+S<6EPUF49U7K#^01V%^?CV/M|B
/5U>S.FY|NE!;#9>U9Y6%'< M?77MBN#V8\Q7|'9?Z;TBMR| ^9>'>_ROJ?
5'PL>XS|SYOU%;|C?KA=Z|)'|JN M2PN6Q6442U2FNFI>*3DB!&=
(G;&C,L4X8P4W=OE;204|_3HU@MM@JTC0:A+P MK2K0-F|P4 WN#7Q_!9N#5T<)<.?@
RV|>P@WJ,\$N*:#63UY<&|VWV4&U+Z| M"P|PPS99R"ORL*KZJ|*(1"S+
(XQ\$G.8)U0Q9IXGB<' (WMF MQ4Z4S8WAGOD&W&9K%(R_-'D#26>UM,LR(|65YBJ+|
(C|TXF@XP=FS.4|HN=^ M.N:Q#|CY+#[6U;KNPG|?
UFC=E6A=B(AADA82L4BW>L>\$HU((K-M13RX%".Q' !GLR&|@)G-6/P\$(- MAI=^
=C#=#J2A*QE5JX?;'U6S\$|F)\$|4;0&KAIPB3A*\$BSM0?.,U%0F(9ID9G MIR-C>R:
7E+PAY8%3,P:(V VF2WM@DU90Y/ \$_. (HZFWWCD62?9\$9->3J5C M'_%4MZ
YE:._O%%2;U=|399ASR*^M'4JT6,2^S(HLCE*4L1%C(M\$B"U%\$ MA92D9*),0-
DO/I3T/(7|TH&M_."/3B1P)GMY-6:4<&W @4>-%F0M| #S2|O/X M+X|BKM1|&Q5_KFS|"T
&)^A?(LLR)|HJO|T;LFP|M|RMV/*)*W;7T1AK'5G^M)'A_FZ+T|,+
FP_KC6AT(9LU635J.R6J|HK0S0>Q6= DP@GA&H^L'25BNY4MWDSS7W>I!|(H6(|
ML|!9ZQ)EKTGS|;K|O>=+/5*M0@35G*2\$U3F489PDG%4)CJ./V5ED:4Y2R6H MFJY?
=3V3_ %VS1?6";P)M!W;KI6|)1<'_K|\$IBM#C_/JX4M%S_#6W41H^P! M;'^QS2Z5079,M
?@#6*I?4B|K"#|%_C\$Z_ ^,OSL;5?-8^|DM|I*L#3'CTJZ MXLHBHI3+H@A1\$9'*<-
/#\$,LA|*R9_BV-V.P_46O||U^F4A-|X/>-|):D:>??%Z7U Z|BD MO5,5KU((WP?
(|KG>Y%ES>|RL5XS(7CS3J'RIOJNKP(V3|6XE|J)|!U;M'+
MR/#)18HC\$F6<(R82AG:68%U=7Z(BRR5)"QYS0!@A7+[W^_).3* U"D8J|?)
M=;)1P&;KK\$Q%5@IQ.=Y@W|= GC06"H MT| %AG-G4F|4GM:_K"TBW89, "5XFN\$
T(1AADF%\$2J\$.SQ&-HR0)6<&ER0;L MR-B>|U@C:;#@T6,H3'/.A;.!F..3^%XU??
7EO=AO5|&D\$|9,S7GUV&B^JW_M MYOJQ\$6>9L1.F#/-
NZB.773%TA=:WCC(=NH)%3K(L3A!)"H%PG@M4\$ \$Q01!F. M,-
%=R8TFTWE1OD.+|E|SWR|A|(N&AP>=|@SFP+|,|DLW/! !:Q?Z:>,<.|*/
M"+J*_NTP:>UBW2??&3H97CSF>1XJ::@M4/#VWMPW|_*R M|?<
_"XR"S:J1/>>S)4\$G|A,F6!W*7XXUV|G|A!'CH_6ICUC63ZU6U4|K|H K
MR;774>#W1LBGY?M*B@7/J6_%EH@1DB,<1Q*5A&.4YQG.>)%\$+ M!|5,-A'J> M5YT*J-
7AH,?%3=#I\$6A%@!543? T6_15|AYXH8Z.:9'E(2)9 M''
<9@0582R0(&4BBPA3#N,,0|F>:6.K1="I<1,H1723L4Z5OM"P4J;+OX!Q MARFT9O3A_3
8@|C""DPC0,L=,8FIU%G)! C%2SZ!/FX5WS&NE7+7-\$|)\$6=8. MOY
ESH3(2Q335)VFDYCH6Z"07@W!4#Q M!;*?FF8%EQ#:&
>ZT%A\$TY0L(V/L\$,#&@1QUL0ST0ZGGY|SK.&L%2_B%|Y_ MWK)M\$N>5?
LUDJ2|S|U:OR;=J0Y;|9ID+(UHFB_6ZA3\$A!6H("5#\$DM"BI24
M80|:ZDQ*||Q5.JGMM3NJ5D\$O'ECLC;
(:)98|^.ZSA0("N+,I4ZP3B+U+FFE(B&NO4ICG(N0RE# M

4H%."//OQND77P.ZQ4;7\$!;X6?
L^W""MCM80^(C,DD%6\$J2@C93,CR3"Z#9!AA3&%C1A".+(81PB#4?YLH_,<3?8I2;-
M;@.37TYFDT<|1"\$/&7+'OKVY.C'D.(E04J9;;2.B I&4<-7K>2P1Y@2CHB
1*O,B)2*4+"81\.;)1*[G!;H5!|Y&,@+,^K)-0RP%>*M ME.H+HOVC5+./I&-
"/8UN@E.G4:M?YH;Y|V\$@6BXNTDRDCKW+1(\$BB,W2*#' M|K|1?65?A_^-
Z6;'G|L^=)S06(8UIHLOEA|HUH-H#\$\PH M*DN*RPQ+&88IA\$6@"GC?
|S+M+.WB!2JR#';*Z0#T%2>U:2D0;XC->.?O).((8T80\$25&DN=\$R+1(B%GU"0-
9G@GG5#->8!ND":S,Z,01 C#F M.-F)V'V@K(%|KCH-34B;MV'0>9./^OX8/&
(WF_M@VS8";W)DF3&TA M4(O4V>3/\$Y>>B|;"FF+)96TR"00
M2\3#,\$:X"!-49CI#+|P*7\$@L&:P/RTE)OB>X%J?++/5KE44#TM,@&:|6+DP' MSF60U?
#U^9Q%KE;GDW+F79O/F7NP,I|P&ZZMOX\$77>S%E|U%,EWT3D>V|_|
M\$)M|^87\6,14L)@1B=(BIVK"BA3IN S\$4|P(BOB\$F>0J6LD=0|/8;"G1.!!
MZSUE7;5|H8U7NL"FMQFH9E/= .52P:>|&)3 =@*QV1 UF,F>E"1 ,+RD#|K#K M0D#-J^??
R'^NZY:OVJ6MD%3FG\$O\$<:RV|H1S1'J4(8C2I.HI"D!O:P"9'NF MDLFJ-TU GX-
6G:!:0VTV#!"^>HNH5%:D:K|BLC!%,|TV=H"HRB.4D83 M5H1Q?"V|1'! FGG1-;IH,M-
H+0)M#J!UL=|3NXQ>(T)QSEH8+8Y@==F'5#1 MINO?&*#E)F%WPG2?
E:O'Q%X_A7<"#*-|L;AE|>GQ:ZH)&MX_K>E/I M=Q?@5"11GL,H1R+.U:GS%-
\$*2,HCN(XSF01L50,W0 NWN*<4,)H|NQ7_8>1
MSDAN,;L;#|S"MV+MS67(.9A=|V|(9!Z7*Z;H7P@C|*T
/H\$<-\$BW"O.KPV)3I*7Z!%;|Y_0'FC0\$5&7XB-I6 M%8;'X|Q67?B(|N/*PL=^#?M&
VIF',6K.E) MY!("V*RRM=YXHIF:-C'SU!#=-S%-_VKEJN M=FSO20:F4YQ'RVQ;ZP0#V'RU-
!|>==><::XJ|9Z4,V|MW7/F'E33/?N 14K< MW\0WM0=EK\5R^>6K(H=OSY^?
OGU3>|/MWU@ "29IGH291*E("X1SGJ%"T!*E
MH118,E&6L7D|Y+/B/\$_E7GZ@%0AZ#8)>A>#S+2 UZCQPTQ:/1RP67T&"6",
MDB\$D@#PPI|#897C9?EE@:5O&ADXF9)T?9;Y4*V.+|I*HS)|RGN%P7|_ ^JEZ| MN%N-
/U&M6/5MJ4|R*W&W\$8_-(@Z+%="=%C'+,"<(D)JB4D4!)FK,PH2(JI%\$|
M<6<: ^3Z_3\7SZTK|G8ZZ1MW>QWHU@S^THD&K*7"7=/F|,MM-S?H&8/P|"_@N
M|RM@/@/E/N#4YV?)P(#!!TC) YL&>S)O@K^M%3|TW>DJMN:Z;W+Z*H0Z?
2I57I&F:K|HDA" |Q"? ,AKEA*-\$)!QAR1DBG G\$HS@MHJBD26'D M|O2BG6?
2'735)RZM;5?8_V:(A'A9UF70.5BO@JW60:LV,!+5Z1LTH|^KO1<8 M%;M|)<\$?
KK|NFE^7|6"+'5)GP6+PT@P6B(1E- M0(54OW<;/VR#AZLK;XCH>2^|+4 YN.:V&
<.R87;5D(>'6G392=H%VI9::4EO MD8?J?U@D"-
_|U2E\$'!4X+U%9%CD/&8D8K'O.E##/A+,ONG.YM|+|;0/P\$#T) MFQF;N
(#QA|V,":9QL8Z*I|H2H>1MH&QA|T\$+;Y!G+LZ/N 4A)(|C.41"* M1K2(V|K6H;V<.WS|B-
|?_MGZ3F|_|::4/Z|5WT6P\$ _X8)94E(D2A(B7#*,: "D(RM66-TPC
MP;,,5._&1@G/2|%^F(EVK@V|H|T&Z-.T@MB, _T#|Z/Q0\QZ?8*=00Z;R%R" MB2-
>M5)A5H:|!*277'?16!=LUE^|H-<%*|.XC%F.(IGIFJ)1B@I=W*-(99*F M12:8!-4%."
|&=UANVZ4|8").)%E040W V|F+3+;?^FVW=+MELNM829JO@2Y<
MNVI<|H.6NIRAW4H9/|=T\$E#C^Y<3G_:(KC08|W^7NF&,_6|2O"WPC:7BC<
MJ1W.2KVBYX407)(TQ8A+|;VG*45%KOY6|HWE-D1A M%X| -FUUGE:C|G?
FTH8OH9WE=Y0@W&E&6"!4J?S@WDH6F@'A:N+2ICP>:|J MK8
YN*RT&|7RNG+7MZB+X5"B%CR/XY"*#)\$L)0A'6*A-5HY1\$9>)R"3.<2@7
MF|4NQFAV,W=\$"(A7MJ+,K^7&C<.&U/6^YI=&L7<<+Y?K/W5=!N!EY3'0#"|I
M+X0">#GI" 7X5>6\$F:ZN*(^)F=|J;NJ)/FS8Z=+.,/I+: "%8PB|BAXXA?@,)G
M91X|8%YRDN4H%KZ=SV*S6;::>NOO5.V7-9Z*C1S|_T;B%='5VQ>
(BSQ,\$RK,JIT9RO,=HK!50=6ZQ<8-*0+RFY&6@!|&@80 M&OAXW (#|. %> Q.
H=/
<8#.#.?P|?P8SQ-#V9^4)>EZCFV"G MQ\$TPJ-&VQKL)>@!WJK@|L4'-
=W::,Q8||^D."LCAF0||@L7>ZM53M>3=E?K= MX|Z=;W+I|R>2Q67*(Z,TV/B/'|(+N|
M%:|)MRG^,(V9P3|*&1(P?I@1!;#&R1D8=GNF"T"!;9>,|)S<*4V/,-|FR>AD_KY5*N:QW|N)
|3G\$|M*<)%J?^@.H*|,U0RIOX;1Y0)4'\$+L :>R>Y+3;@ (Z|JWD)B"#ANTE,|U#\$BO-M)-
"5!0;9;%(=E'!O*|7V.^_WCQ_=O?WO|X_-&|%JW2=,5?SM-0E<%J/U-9#U?
RCVGQ5G|?;L:.-UW7=AD|ON-H&Q5&1 M(G%"Q\$QK.(Y 6B49HCG.<<\$=WXF98%
M5VQ+TR@\$%?HZ*>?"<9:XJ"IZ4,V^EP'/F'E0 //N;9HJTUW:*EFQK03#T^9>
MCL(<3C67|*N:EW&4\$JK.:&%>QFH'E92(*E< ML'YJXP+'H4"G^ZA:5I2_|69|H@
M|A*D&>ZV|ZDMW*#D6_8@YW\$R8R;7%@/8QT+P|%)3U?Q+'9O8UT=2_ZM?
+%D89I2R&%&:8H35-\$6ER"4J MLB3*;!KB3&#(Q#TGT/,\$WA,?;/G!5@'+W|J?
\$OH_Q,R%XHUTC;RI=#:C:/-7B7KYZ;J|5:|K1H:YV M'-3|E_+H:\$=^:|?>*5^G:|J^K'.
|XHI6"8BQ")D*8(9W&(B"@R)+*(MBXPG-"9&|4('WNFK5Y6H(4%=V_,>VWNFS|-*!

<9!;.'4WM W3./ZF[5+G- MI-GZ8QXU8-
P0|_@/1/8+PZQ/O7ZDU:K;E&P07^ZXVJE4LB*C+M#_153I'/21 MTOH=T^/;=:8?
E+K(@S+G&5EB4C)2^U!56<.JO!@:B=IXSPJU-'#X@L:JH+S
MW\$D/)/0C&X*=\$<'8BJ%9QV#-'0=>.WA1H3I*!YI K99\?N=-.O.7A56T9D
M>W^MW5/NMD6S(.UHX^17UUFW5K/_G+S-810NY7H?O\&4.?A+EB9"RI%J_7
M\$[51*PFB41&A-(I+C.,IQ&&5!XY(@.T98,7'ME*# 2I5^J_0"X^AHH9@UYH
M*XSWI/@INT=NN*>Y8:L(:1)QR3,*LC#!AXLMY//51FUJ+ZV93BXV:ZfV1Z3I>
MYM7SK2X=07I/Z=ONC:A9)GD:)3'4.JFYL1I(8E3C%B\$I<\$E%&G(=&95*-)?KVM>VL(I?
H\^!4B-HJO^T)I TJB,L)R>P5X0 CINK@@.IJC8Y L*S*Z M8
MEQ%@^1M1I.!9JS/'+'!KOT8CY\$'+O+1M!91WZ_KJ>O6@CGV/K:-*5UTFJW\$?
M*5W/Z5ZJK=&B3&(913Q&8<(5;.)4(BKB!&64TI"D+(^C\$I2;9J.%9RK5:@3J
MN<"%Y0F\$2M"Q6EPMYY#%>=QXNG2B;|| M*.F_L=2B0=7C73V0LSX;VY|+RXI-
Q|. '3E/%:=|F_<:'TO2 I+LRF,XT MF|MZIFM(CQ3=="
I"CHS_3NK6S:++OPSA67FNMH0D1'&2TIXR2Y"B.1)&.5I MDL09*/CB4(3G3> @L*U-
9!F!=007,VJIS%H80P\$-!9/+;5L<<<01;-J=,& MOIRQ\$Y^T#6O61M18%%G(B<19CJ
MD(%\$'>C4;"4X3U\$F0JD>9X(+4+N@RU7R/+UI=/W;75H8E0N70=RN@'06fGVQ
M0C,'AKL"|#" \$W-G(=C0ZO@U<|<^;-?O7U_52/=IT?<@61-*<)1BC4DBLFY1P
M7>,D1XF,6,)IDC\$60R[NS@GT?(OW13|2+'=*W 0*7R\$>VWV VC+V<|31BMVT M%_F-
ILG0Z_A_AJ%'.7 =R!:76'\$>19J.UIT"2",L81#1J8M|,@@ 'G*U#)' M+'16W*P<8VK\2P8Q?
LZ.'I22>OG|27SK6O/=R|B5:UK70!S03')TH(4*,4X MULU\$RV6QELDD_@93:|W: MW,W8
0">X.=M(1&&J5GC)(IT,2AFH#=#E)29ZG\4YNT DV:S,1,ML%CO! #:.)
M+. +3T|+\$84TC6|K^DO|N-KP M=T0R8#(I3S_M>39JH8&6BJ)Q0H|
7Y#I@\$73I.P)|Z>GHA0+87/PO-'!UH# M!|/QO'D3F1+JX7X*,KZ; >1-
#SC+ESILTS#6#3U|8P?/5|_O?ZM\$K0;Z^OQ> M?%=VZ|
F1HDL1U+T+%OQ&EDK.L&G--"K|XTPB(DPTWS9ZVB+=M
M0SVZ|NR?.FMZ^>|>|\$7A"&!K#. \$T3/L"!\$<2U<-\$ \$V3K&QR|&IAQ.CN)J-.9.AM6:C#-?
5"W MJKV@6LASME%I=?6=-;IHBZ\$SCO9(DWP!UW'4|~6M5|*-U7#EFO=_WAWJ,ZS
M*" R@JBM5\$01CG4G|")/\$!,R%TPF+\$Q;1N4<8S?>Y4&_6#ZOSIO7;!3CUH M'-
H%K|!L%S87L#=#J!6\$;!%3SY"!%O_9*S(+(+5)DY:NORT |#Q!R:7F05,=| M9?=
|7>9XN*)Y_MAY=9LW3^*?@M1?_EPOXC)AF\$<\$18SG"!-.4)&*)6\$1.,
I0PZ0P^BR|:VW@2MM3=| M9^_-N\$>#I=?N"E|SH"OPY |RV/H7?_I0C:T_ WIOS+63|
J67,?S>KU7=M*= M>T65K\$|#U49M#;X+70I/3?MJ6YGE_-*?
Z_JU+@_@6S+X9.4I'&B#@1%B 7" M*2D0I5F)PC*,BS0A,F.P^R68?/^G Z4-
:M4)=OKT,=\$W0:M2T.H4:*4L4U"@ MH!L?
%WQ!"3XV.\$;1Y@1A@X6|DP1(^MPG"AMHCIPLK(:QN,IZ(YKJH8U1^*P#
MGH=VT1\$:.4QB'1B6%.J/B**2ZBC/&\$=E2@E3OS>^O3HNP|O'=1#:A7);|=0^
M@8|!I=3E-D.=H?|!:=PU76ZVW?72@?F.|I.F|9F|0CKQZ'RW1M.Z|UT4G?FH
M!|^T&1F(J/=KLEJP+&-YDH0HXK':ZA3J#XI9B:) M#@5@M-
00^J2YNU|E,HG#DL8H4Z6WQ(.5R'^4/'S10Y;@G.0\$&
|CF6KS.KAZ^9>_MYTY1|NB&Z5LK=ZNT/
MUJ85OUO7VZJC^U=6BSABL9!8HDP4D8|B#B1 M0X)X)!AC:9ED"8BE+M#%,V&U
MFJ&U1\$JWWL\$^:*=S|0?|VGINNY*XK8J|&UI@B|P+7HP9N|T\$-XSH_(-;XUY
M.4:N^F)>H.F|33\$OA^R@(:#(>=%I5+^O>+U|?OBL;P;T7<&-
A_KBHG77UA3/O*6\$"R5=3Y%!.;5J|^E9E6K15|OQ#RWZ@PFT|3C%@X8KQ@B M<1-
!%+7NT^8FYY7 M;?VWKB6)VK<(7*08E3Q.\$2ZI^EN994AM;\$HNPHS&PBC7PD:X=S?
VL?J(@SI! MIT|?*"E"!>C?GVLO/N\$710%YB.,0L3S*\$6:B1"4+.0IQ M0D-1,IEF
E0IWU2RYXEUKJ)QMW3|1U2\$;M"D?9;.GU@AUL!M_>O|X+;C>;
MNJ)/F|:9N5D"TFM*R.!A|JL*O2|9RYRUW#X7CH,0|> " +2^+/:|EY M4#BL^U-
EE|\$^|H:|+|&H=9+Y|8U-|HfZ.C1^RO#O6@36O2".XIE+%HUU!UUVYH.;5|^XS?1K1
M|9^DYO??VIO4=^M:BK;7=G.W^BCJ:LW_(1#5?#;|Z(F#^+M#U&SJA&M&V;!
MBC#F44A124+=N"B*48&Y0+',1\$)HPF4!VH|-;8!O.M:J(JHU#<8&C2LX;-H#
MV/B#O55!;|9-T!MV\$XQ,T|<;G7\$WP6!>T-L7# 9VODK@W?C<7R"SG>;/_+4
MKDCMBWYE^HUX->M@&E|ZH?@NN" M^XLP%&IQ"S&*DR13JQM-%\$67!8IR6?
(T+C'C'!9 NAU|EH#15EK;.P:;\$G# MP&!;V|9C#O=&04-
Z|0R|H(P3@,C+2(V#|PX'Z&Y>V3FB,P#70|C,|&_E3|'7;"9S;"HS*)(R-
&MVS:#HOMKIAW#|C87OU|NM_"GMG!708J M|?:I7E%VN2/UH^C|>T^O@!|=9?
J5:++>XO") +7<#E|UE81J;FFS MJ@U&5<^:X(|!"8?7+C"K'4U%0Z&S3BL8\$"^G"/|I
MV|YYNC+|NG|^(#8+@7F'#O@OZ= M*"EQ#T (AYF6N: ^=(=&'7:8._ (9"Z_+1U'+=?

VHR:F_140*M*!09R5&2%0QAP4I4\$!XC0EA:|C*6A93&CI>#X3U3QTB>S17C(1H&+IB+;
(1-M(^?F 9PQ%YEIYX|9B?R+(U_22LFW3&'3|WGD3FT9Y3Y02G8*30U&JL>LV?
MV.:^_BSJ|Q43;>1@2N(X2K,"B421 4YHCDBFMA<1CS.B&"--0V9""Z<\$^".&
M3F1|W=Y+!36_.(G+-&\$XL!9(\$7!#C6?0.6NF5E|U|&C55?_:K;@GAYUEDITS
M:IAF9S|GZ0!5G-@>DM|7*W&G_MHLBCS,I-JB(B&DVKG&@J,R*F)4THR1,A%)
MR6%)Y01M4!W',Q0N//LI"VNG%Z' N9U M5ITT,(#)=/J3=A/O5-2C#O:|_4ZJH0YI?;>N=>7
/@5*G<>^D!^+/"DI3C.*MDH1+A-
_T130K(B1YFI52TK#@H,Z*UIHXGL;'8J'|(.@N)/HFV*ES\$VQ516HG
M@AJE|(UN_P&;|O9OQ8P=9L\$:1B+WK^|NNIH0H|W*+Y5U*MMM 3J5YI<,O_
M|ZG9Z'DQ#3:8>BX&RA%#V>LQ*Y%=#-=+OKM|0 MOP-&.:OU1D:9%&F8E1E\$A
MJ:X8F*(BC"(4)T*\$.\$M3DI@'9\$P(|DOJO_E|U^UV>R.5%/6;@.G \$ X00 MYD;
X%UPA(2=G^\$T(HZ|#@;63?H?HZ?SQ-A8,6>3|+D|Y87>T^-V@4VC>)'
M6G7|KW3=YX=5J=^"WW"U!;AD1;8U56_9?SU5M>"W*S|4FU!9\$@=M@Y&Z-
!%.X6"L<9|Y M'0PZMXZ&D=9!K_:THW^6MVJV(|SBNX+Q|A5>\$ _RZV
^8KNZ5'6LW|P6T'V@/ M;JH|B7%5)627|=_L-&
E!99&9>\$L!A%'&.\$J4Q0@167)RQ*,A:RD*=TL1(/ M_5)D7RCDN'RC65|VL_Y "V,&.%
|H8E3/XF;X5=.VE|JT0,(@)K,UXU2ET#@N# M6,#EH!K(M.W>*H&<\$'OE*B#38)RO
'|+F>3NJ^5BOOXEZ|ZP'WR@Z>ZN(|9L^ M2^R*D6*99|Q(*C 'X"4Q)Z\$%P32KK=;
MMGDBR^6S9I> -VW>0Q0(^G6|5(-|VJQV7W'#@D&P43W/_OT|EZK=B4,OC=_
M";|LF)%J?2DM|^)#0 RG;<(<O?#"ZL\$3.<6-
B>T2LZB\$!1:K)JNDWNT8(D(0\H*E!*B=AQAE"(2XQQ1&I*<8*D. M-J &G1#A5_\$Z|6D3C-
2YV)5T&F1K/Y\$3Z%PX@>"HN?#LG#7?G|OFM.AK^V3. M@F+@<#D_AL7=W@>QV7?
9O-|&UL0R:O|A0(7"&=YBFB*&2IX3J,B9S+)(^_K MO=-R/!.*J_ZTNNI7UEP;X8!M:~0|
|@CL|_C"6. 8%!/3KG/& ZSTW(-C= M|AT|P|&UWGFK)F_U)AZ?|U+OO
U|=WH&'|?;%NFX|L5|NC"|6+'GM|VF>B0; M<2|_JE_H|HCZ PLJN8M+2(8
M*7\$3#&KHMCM&#(H'^&&P39:IV>|'.5 P0G.!\$7C+|+9T5|'3.:LFQP0#"|W M-|'|+=LPJZ-
U6Z/F=L7?53_::C5_K?5WN|Q8*4B2(YQ2|4>41JB@I8Y92EDJ
M12X9,TL:."O),T5LY;.:2=E+!O9-/HF2&0,XL1TVZ_?-'H3>!*U8A_V.SUGF MJK/Q23GS|C
^9^Y!M^*S#UC.VU'ZO^Y|_KC?;_%^|Y_&6XS&2ASBV8IFJV MAX6:|4F)LHCEI8AH4;4--
O=ZN>9(-:EZF61BH=JM=*5/3T\$2NN_TJ|3/2N
MH9_XKEY+\$A"+=A*N7YXA"5WOE0"i:UMEY68X? S*ZAX46W6#5M^;8*QQT*H<
MO'BA/B^A/|JBC<=:SV;37A8P(OK0_FE:N|@J&"\$9&P3*!CVJ_5I MH/OCS9;_>=2;
<>+G|0_8;7M^7Y"=;W1|70ZZ^>N:9|TBJP+'ZT:L4A(%I9A M&B(1IAG"E"2(TA MW
\$"FX'V6(#79^H@*GAC7-WUA(73L_!RXV"S|DM-VG//N\$"BF:V@.(S3)EG%6AP9
M;K9XBM.FC&F)CYE6_SY17/D/.9QR"*!TDS&".O@;DHP1YP669*\$0L2%T7'^ ME #/\$ZH+
K)J+7T2DNFIY<)0X.3R8".T/K2|K9<4B7;>R/J<0>?+15^CE_0Y MK0|+1SOI^MP.I_|-
|HDQ0U:6>V*+>X|3BG%\$F:W;7%WC8Z6@6M.C^|1APW8R@PWCQWQ%O_.;
MB+L=1_O"|_KC@;7_NE3'?>N\$(C;VUQ=68ECU4MU58FB_K6|XK_6TE2QU+ M?
+=Z3;Y50S3Q097L5L?WZ|6#805'I9|_K_PN=\$9#|TDHFIY|(-IB8UW|E3X9
MLYVD85B&D@B"XI)PA+.2H9)\$*M:J.U!&_<^ MW"
(OWP2WQ7(9/FKTRH%9TUV5Y_@M*BY*Q.<-?I(38+SSUAFR.@DMGO90?*
M6C8+QLN2AAE&65&J+5.<\$)T04R#>9846-(BI:"\$F"-"/\$|O+5)'HW8R;_I%
M%EB%Y"@X9M/Y4L-ATQAJ+3QK9<(<5TDJQT3.FY,R8>1!"LK49VU:YM25TG&S
M7KT6R^47M0D@WY|I:|^_1W&>,8)
(V!Y@HDP=8%+MGR02,N>T\$(E1TZTSM&0/C.G\$3*XU7%C-VQ6'C?9JL?::=LAS7:<8=0?
V^H|=|X: M-MV(Y_3C,W;D.6O#?FN>|Q^_L'7(D.#^63RT7J.V,0W+LB2-
HP+14AXQP|MLL^_,!1@_F=IMWV%DRA|7 MS4:.RKI.WY\$|LT^V(OE|R*+4V-.25P|WJG<|?
N%4;E;|WF|7#F|V|_%C7_ZS? M_M?F^?;/FC?JQ|K|^|WF_ZS|!
<6TZ)CE^)|XG|>NO^EXFJ%;CEM2D34S|NVAT MQG ;G|DF>->5.OG_4Y ZZ*_VV_|!3?
M!P?48K|?JT*O^Jc|\$J%!F" TT6|R% M.HQ\$ _N,*O\$!71VY526251\$M2YV\$#F7-
N7D0HW:HZM M@U;)H-?"KL39%)1F>QK',%(Z5)LK
N9&5CKN'49E,2KE"TS@.:4M3*31RU+
MOF^CL^YE>|O|ZN4M|RBHGWGUO/M,'_1KE2|N\$:&DP2+4I>"Y|J?L3H1%9(E
M2%%*22,I\$YJ#2@8YUL|S|8SB&M6R/HZ"VJA.E(YH_ 'PZ6TWI T|!E>KQG% M7?
&EP>CPV/MZ9?J^7EWWON!E|OV@ZJH:OF/MYBV:|P?:@|KZGL3_#|'M0&|_
MU\$P=/9AQFN3^4YZY|.T/4;.J\$4\$KS/R0^<*T|T='>ZM@9-,QA*%9H!/<<0NL
MSF40AIKMM'7%PMO%KO;#/&S78;BJ50N9AFB0H#?(45JL
M3FQQB5&94!Z'HF!YEL%"UX|*|7Z+|DRG5JQ%6M|YG,PHQX'U,\$JQ.MPB(FW2

M+&?!>ES!R'-FGJ80C:J,)NA4;:7:!'ZH2-71"PLB>4S+4/V?/?GJO'9ZIM_6
MJF#:OIEU<0:7)PI L/==-N/KPGGU=[C@?C_Sl>Y>L(V##\O%:XW\+|+_3UA&VD?OZ7
M/KF5^XG5GV\S^1.#<&PI^V^@KL6&^IT:>"/>5\|%OU/LLWK075A:7\^@YFU7
M#+6K"*YKMBT8%46)<[7]I057?X@4%;R(\$(_C@J1Y5I+4_)AOH8#G+6BG\$6I5
M"G8Z=3[PFQTI]CO7JN[P"%E\;X TV:9\AA.V>?EXD ?L+SXC:~+P^D(6MP!?
M,KDTVHP\WYIU@=5[B\DEXUBP_"UC8JD[B.Z/>R]?"&+6).1"*A+7CMM<\$WR!
M2B(P8B*5>4\$ESF.C/"&86,^,/M)C;T8\$J_)@|D!:@9K#:L#<7L "1H!<'2< M+W0!RXZ-W>
&XU^P^9.L:S!?:
%P+MG"/8>%/6P8H"UFM!'\E5NHO&UUIXYN%.%:9|\$4R7V=MH90+|CI!>#RNR#'[YILY
M:@(:^K\$#1P\$| YDR\;Z.@'N(+37S:BV34_>#(Y=4,3-_/<.8V=I8-(M; ^3-V87*9?
9\J.%8|U.SHGT>;DI247M#AY,ZL7\K0)AZU-#CYQ:5SOB5IQ_M+^)
(2UW/*8DSE&2YIG!.)**42Y2P@G)", \$U"4 U,H'S?E|VC<-.)BHNVC;MF
M\$)NM_1Z!@|WJ"9QF"L<%>|#-=,^I7";T'0G Z\A0UCX0_ZF_BFV(R-2M!| M?
OKV39V2/M_J>%N|7<.J% M!Y|O =Z+*;,-_#J.(("QQ#S6
|PUCE"P|_8H@'SR!B8..F#F7I^/J^+@15| M?
A:3SU06\$/^FW3=J!ZNY3YU3ZF>YKMNZ(PM,!2V3LD A34N\$" <6(1@5%/.)_ M,IGD<?
MS3-M@N:M>?L"Q3*YI&B'?52@<"MIW>FE&V(DM"B3,.TEB?;G!"\$ "69
M0#'A19(P618)J!C#E#/#|D3?1/TPKN.@_ I/(F5V21VA0:L&A\WWE.JCXF)
MKBK;3HF:M)*M@=\$'E6Y-GG'?WN.C_L%Z=;OJ.FY|7#>;6FRJNJN5M_, -KOB
MIZ^\$8ANA&T@0GE!9R!+ %F3J!8)R&J(B3"(5)&/.2Y"2D?+\$2#_I:IVL@:::V
M>=+7:\$J5W90ZT-K!,FOCLMW'1:_0<+=QS3?B
MK#'(+YW2O\;EYO@^\$4.D6H\T77ZEZ1I*EFQPT8AM%5_OGXA+A">H8G(16K^M-
)U%7(-:3?B1)IE9;A2H=&G0=WAH!XJ78<"%|3D)(BE#W)^!I
MP4DIBQQ4E.*H%,_ [NT%F5PWA:~?U7>LZF+ DR6F8S(CS8N-AK+=G|_IJJN&
M5ZSE+W>ID4:FN;H)/BICW@O>*3,/FTG/VPW2X4ZS M@4#?
B_C1_7FWL>|K'/W1*0*I>F "L,\$|D6-X@,O|U9 !W"\$Y1LCN+ND\4HZN
MDP#63EXKF8PSW_42P*J!R;(<_ @M=|V=9M1U|S++MQGYWJ/M&VK8=W).|+/)IM
HEI#G;' HRYC.QW|(HVL|4J#FYBV-EBXLZ;-HZ/ M_ BTW3%E|+D>BLX|+XJ4LE(JV)
(\).IH0DM="4XB4G*6Z("X*-=_1Z5XGG. M|MV3W&PK*AHV590&Q^ST<;'5L\$D*-
AA|Q)@TR-&QXKB,68|2DV:~/#Y,?JAZ M4IY(7&S&:39|JUD=._Y.?
2D6>2((\$QE'Z@@1(1SA%)6X3-34S8HX)D0F&0?.
M6@LU_\$_KTFYS,A&B;F)Z@*@CC#9):~9U)|?+N|6O/I>|2>R;&-
UHX|ZYEEYEA@)!~OC/Z8 MG>:")O|+ZQSW%YLRA:|S\$07!IRO4/V\$.7OEZJ<^=UD[K]?
K1ZJV'GI& MMK7PI^6H/I# U0LABK3\$D40\DB""6&H\$+1
89@QAF, "06EMH"D>YZ/VS96 M(V5NNHX*^H2ZU|QJ4,FNWy<9UF;KOC<\$8=/*7C6#
<% (#AN#68F^RI-PD"P
MG&H7!AO\$DHQ(4S6Z@Z%H!A_O|8I_KAY6;0C.:G/+F+Y3K58/|)?+BE7C8,LL
MCJ(\98J1BC)&F!4,T23G*"41I2S.RSPRRH%QH8QOJM*J=4T^=JU=0_/ST^
MDOJY|3RUTS38J1H,N@*IZY(W8\AD,^\$-)+;34\$ _CZRF2U@5*KICO\$E7F)4('
MH!WPHHLQ|6CR|Z2N=%IAF_JO&Y^'18A%5)9(1&IOAE.<(:+>%L)13B)!"\$NQ
M43^N4P(1TD@KJMS8=,7_@_1,JYQ\$X8C8!;!)"*3L<3?2#X6>=O*>, >SDA M3WX.-
LFXJ!9OU;3=|LI1&XLB*UA*4,AIB3"G A4D*1"5/"_.9)S1TF1V'8SL M>5H-
LOH4<|,I=6C_|%RZR"K8)#(VR@ "G51^PHF@GNDFC?
K+;JXR<<<%+B8I4'03;%M(D\$RG* M))%A(;*<9T,?61LS|PI", \$;KVP?7HR7F@1;/(-?
50*D7|/0+6@5O@D%X)=!R5|O M@E;/-EH+FKCHY(69;2_F?
@TP*ISC#8"W+"XA<|2W<:+2K)L@ER"^W"TY'=NV
M9"Y5LM0.K5T9WY&J_CM9/HD%+3DE42A0DD89PID,U;D8,Q0E<1%FC B:IK!; MN\$?
E>"=&JN?@(/8FT(*#5O+HO M;WL<,3,;\$WBUP4.(WS""6ESAZDI\$"%C D* M" T9"*F-
"IW8/HGI8O7ZJ:|f%BSZ,=QE|)M=(E M"19A*L.D% 7*0\K5TIXFJ
@Q17%:Y%&1T*P(091PF3J^G>4_V%>=>=>)6M@|> ME-
#_&4)+V1H(>2F>X.Y@ (1N(8ZEV>D_M'^407K!H%\P4C#0&IXK'^R@IKT- M6-
YJVH.4N7)->QO@SM>TMQKU@CW0Z=HJ^[KU'D>28EG&98)86NH6T21")"PQ_M*C
K*9.%^A\HY-%"AUEV2UHE|&FKTS")H3WE+X\$:L(WR|Z#-WFI?FOUT+?6Y MK|ER 0(N-
UY #>;?C=E!='2+9CF4'4T;->_ ^DR6HKF7?=\$BK=_N7O\ILZ\$ M6H_77TG|
()H%BS*>BR1\$8:1# 'R5EB.(H1'"&HS0/\$|9Y!.\$HJ_*>"6JT+PC4 M-D'KU
85=S4.= "Q>^|= @IU?0*P;C+##N9H3E\$TT86WD_\$DQ>MF@X8BZP^%EI MRQ:
|EY\V: >OK>JD>;M|^UU.U>0:&AOB-Y6^*,6W M(=0C!>ZOH%|!2| (R&A7|3F,9,|;E
,"PT\$K#M#MM%/^XF,'W3O5|9\TK4K M_KI>|S^KY7(A19&E-"E0DA"".(EB5!8T0C+)N:

!\$1@J):NOB=!9C@C55A%U MDEI!BI 986?&\$:X1@5'\$D2QQ?87[RU:%8-#!H1L#8K*S^#
(#D3,'FIF#WNF#_A_7J_EN;1162 MU>[RI_FK>E8G Q)!8I*KS7V69[K&-
A6(T)"A7.WU<<@4J5 "ZBGF357/3-1J MA:A6*QBKOEM 3?
#.CY2O2\%MOFJCNN==6I_ UTFRY XZ.H
MJS4PU/C=|%P'_53O&'@YJM!::\7^ZK8R\7:8\Z\8^|9QU TYK@<.?F'697
MVSU_BLZ\1_0.^,'&TK\|\$RYK 3X\|RS:8\&B D%KAVLB?CKY>1@8MLH3F49D2
M':K#\$(\$Y\$BDI",R1ICBEE41')?+\$Q\|=PD3:@5<.V&X/L+Y_896G__#1HN>R-
FO#X;SC#NWJFU=Z<(')")%)+(MM_YI+PAW&4HTFXHLN-!8UU\$<2+PUDV,/-E-!#
('#0(3A7_=T M63WT%4I^&;YJOP;#ETTO\$|%(3Y^A",?@|!9JL"?LRJ\$ \$QPP_'RIP!'D\3O@D
M\&::9YJ=?Y7_Q#U=_%9;#9+P77E\|O73YC5IOL:+5)1QJ\$|>B@VR\$F%\$%\$:B(
M&4\$YCF5:1)ADQ*B:~E"NYU/TGA9\K\9-T"O2\AA0F@1:%1AMF,)JQA|>P((1
MB0N*B>/'1746_-XZ ME-J38=,>2:~?|UN-A_6FW^*S2?!U@^KZK\%WXW4/=1ZJ;Y\)?
V\LED4>9SF
M0E\$2)Z4ZPB5%@DC,4H09S23&&:8Q*/GB:LX#N\|I0IZPX)37L36?|19USF4
MU%EPSQ&E# N>U3%F9JH=TLX^ UA='F\KXX9 ?|:?"L?8Q;W^'.EW/P#=#U
MZH9\G4XY_95H-D> "K>/NN2/NZ7@ZO@|6ERN9\>LR\757\|?+!|?#Z"ED4<=|K
M\|D=2\2_K;JV^6RG*5PKJPCZ?_R3?;A\JT<|518K#.\$Y9A&C2KGI1@2CE\$N4D
MBO*8E#0B1KVH86(j+U9:CT K\$FS6_4Y39P-WRG3UH\|0ZP58?
0#4%V#3OW_N8_#3'=OQ%"M*37F.,(JB5,0X0B\$K"U"@ (J2E42CQI!3/ M#-J+#0:Y-
X&2#)CY)\\$Q(\$47)L,X\|*BU-J5V3IH-X#<7YMO1&>REPRCKG%63 M#-'7RX?
D(Z9S^>_QS\|L-V7I+?5\|QJ-G5%G\|1.\|RVI5WKP>|GG?'U^HDW%*U)7 MHEF\$&
M.)\$>I(#KE2NARICE&B90YY6%!T@ (4\&0NVC,Q\|2D2#)KH.J\$A+W*L M#;R5
_#7\|.SO!S48MSD"#'SNAMONZ*, \$#SKR18.R,NCL,4(-F=-;8YNP-N> M0M?R=2UXM?E4-?
|B*_X;^<|U/?3D;0SS\$FR'\7CHV5-&3X9.G4#KTV;QM!IM
MFT0W)BD+;J"\$G(3\0FIY)O(!+?!X9(-+|\$)8MP9CTSV5N\?GBX8QUEP25M(
MXFZUK=QS+WOF+X3L\|W1/\$C#EH7C02^=7CJ*?
53/2\>SV%7E"/|0^@6\|@ZSVBY'R5\|L MC*DBUXZ3
0)F\$\$,#'=&.%C^*5=.UQ#B2/W^H5=,5_=@,+4_U,05SFDE!=W@_ZU:58\|CPLLXS1/,XJR/-
+)&31'A!>Z)F,4Y26"/0^-(GN@_M@CUO!=-@DZ58*?+33!HTUTH?H S\|L0>V._)Y
@|'7SX(7X%SO"3>|_P^ M?LUJ"TL:|'?Z@XY M7<\$YPH9?-PM2%G%4Q
*%0L>7A#1%940I8G\$6TI+RE,**XEKJX?NZ=.C=NM>E M=:1\$&^|&;1AI";G9CG,&
((&7L!=B:-WRUA(!O\UOH5IBI_W6TKTF?8_L;Z+N@KHA\0ZFJ!KL%GU@97F XV8\|P)T+
|H^!|HP\|8)@\$OMF/M(ZLWSF_4CJ=17EB21VM\|E MB%%1J\$-W*5')HP3E(4G"G!\$
M>I^MX^32-J=(?Y\|+8(_M\|Y\|JPAX"AL :CJ\|W<(\$G>:7(W19^NT9DWWWDWIX2
M>;W\$VS,@3&;=GG06XC34^NYO&:N?!^!YYMONOE_\$C\|TK90V\|=9G'><P(CAI-8
M!*T&P1\|:AZ!5 A+R9@8/X)SC":|0TX'%^GAD_171@09DY^1HQFRD^8XR
M(OVSC&P)RUX\|/UX\|?U:O.US\|(0A(CVZM1N1K"&9H^|)%9
MZ!:M(J.EKG;&\$:~Y0(64#"5<"IE\$A4AA=UJ7J^2977HOX C22X\$V.V#-"O^,
MR08|=,7&;:ES_??M+WH-7Q1)T6>T04M\|N\|HZ32NU!%F\|N)++U5H\|CA31P> MB3=U-;
(=0V\|#6E\|:T/_7B\|)T\|S^J)I%G!6%\$ \$6&B PCA,M8HB)D'-&8%;@0 M9O-
'KHL=F=T';0K0W/'U;ZUDA79MG48+N\$5LXP.7>IW:HL\|_LDB#\$,I
M0QXC02G5ESU,4T&.&*6"81ZE(36Z*O>LYU4NUW>*!V/-AWR10?=VH1\|7WKU
M;^#>*=|O&V-"P'49:RZM\$NWF"^E0TG"|QE_E)\E9L_2C4&60T M\|
>Q642>FU/2KN*6.6/Z*9_+N<=LJ91N^I?Q?&/5=NN
MXYT0NIFL_MV=XFZBS.LS)D)*LIR6B-."(2RC4IVJ)\$4\$ "RR*4D:X /6^!\$GW
M3+/\OU/JV8CH212H%@F^D O:\$@T%IR@J> (OR!-65D+LPO)TB@=:DW6NV'QB4
M<9T,806",P:~R)Z93RQ@.607FT\$NOM\|:NS'_L4\|QBXS%91+GB:(5J4\|SN3K7
MTSC+\$%/_QC1*PS0)+|A^G!;\$_SS9\$-S)D?0D /JS &[7T#N\$;S\|8W6\|8@J^M
M+H;J\|KNIO=W(W@55IX:7JR<3N\|W?+TU*O=8ED@D4\$S=%1H_/W))WZ\|)NSZ9= M47-
1@<74;/|H6KUY\$ +5/.GU+*8?|RK0D;Q(4*YX."44,|I|>G/2O3,M#OYNC)H\|J%-MMV?
3E\|N\|\$L!&Z&=|~L>.X4&QJ>7H0)O5FYJH:N&Y&?ES=MTW-3\|@|;BQ@~:
MT<&N1WGS97W+>5OPA2QUAYZ\|U6ORK=J0Y?'-9*M-WP_MD^B*Q0R=V+H^Y_U-
M>;M0IC&521@7*\$W2\$F'):~U\|V(L&D.S.LCJA\| M+JUG70\F?
A4OEY&YQ<,6HZ;>+%X_/3Y\|H)W\|59*P3;=V/?REJH;X7VQ%DO\$
M5L0RR(R:"IB+|+T\|W2H1=%JT\|3N5'GL;-F@" M+'8#P':G_V@!-RHN@'(F#SA-
D_OGAIMQ'GJ7SN^ PB:A:K@A@|L8_'D9=D2 M;W\|4F_9&/EI(=5HM(J%;PZL_U
DU027#)1)%&I<)*TI9@JH:'8KP'7=#6.?_M%TIB&TRR;NL9,/NJI"-XS/9?EQD-
F\|;P&XMS%?=T\$-#'=1CP1<)?|YT,|3 MH29FFH*Q%

M3WIZI@%/^0fO*K4S\$^BjXF4=+K*UYGJY*^-7#V.G*[Y02XJH\KN\;B++\$;1-
MPD26L9; MHD1Z#VF\F8S; MF.S.MA_\$YEY^(3\6E+\$\CD*&DD)
(=4K\$2J*A""2EG\$.E)W7DB M+KLJ67O:![HT^O\:: M.M1 B4BUGFKUTRK/ZEK ^"&9KQ-
190IL6?'U^K-" M\$)RI?426%6H?
(4)U.J\YBE@242EH22*:0'84UWSOEU:4^|_BA2>R%"\$K&.)2 M\$H1QCE\$9BA
E."YI'F9IP=+M?%}OR/+G?^|OYOM6:?,(:|\$)V+8}XF/7.23X MUJF]"
|. ^"5;J@VNI@Z|_CI=IMBG\|">8D;%-XW>D(W@IZQM?15M"7EK-N!3U#
M_7(KZ%O<9MMK9%6&6I(K?6200C@1'E*01*CGF42Y* M4232)K5Y6JQO0%V GW"
|CY0Q@9FSJ'@88.6XS6GH%QLFX00|!+[T6O}K/=S\$S
MVW&ZRQFA5\EV,0/B5+*+X=.N.IS?=. /JM+U1YZ)FU_MW(5@4EB07*,M)V^TL
M5AR2""5\$)%0F120)A19%N\$2?.3;_E|85AP%LS#1SP0:FH";KU\$C\9O@F%/_
M9S}Q*V2|-16':7/ESN)6T)UO+VXWK\$6&Q*W:6G'1I2"O=,,!O=7Z?YY(K;A@
M^7S\N*XWU7|W;CR=C94*FD1Y2A%F1/^!2HH*9 HRR(O0Y:7A=\$MJ(5LWR%R
MG3)IAOU6G6"K3S'6") L9P/S-.5Y!@|&9S\5;H"D"7_XV>5-N,01ECEAA\1D
M\@1PR/GR)^QLW4NAL!S",HN"-%|5|^O_O%74_YTL=6C=Q_6R8L^[5AD]5LHH
M##%B4:K=DAE1AU59H+)(^O5C(40.RZ0PD>H[7DT);Z\HV|^,U!F4!@!+:E M=
X+C&E/(J)VCZT.P1_|?TW:ML S*R#6N\JN,)(Y;X8%!(;#+ O0PW:4(+1B>F2+V?1 L,(T"
|'1&) MJ=19J00(Q4LR@3YNTQOI&ZF%;E'9++(P*O.\$2!053#<|R4)4L!@C*5(>"T:R
M)#4_>W&|4P'K:"VH2FDOJO(;(.3F)TQL,EZL1V0%DA6|EBV/VKM^J:%N6JB
M=JC^=-.CW<=G;'ATH.-^LZ/#7|OM!?'KDL*;Z=ROC)B4643T@2\$1 JM30\|)1 M0=71
:=)DN2%VAS\$H%/#E##/TWP004TQ-JV1"\$?-'5WA06,):QA*_B)O8Y
M6KHG1;:O4@5JP2C2|GL%PW3_6HWV9; MYJG,)4,.T%
MX"5!|:8ODEPPC".>.)3'H7@HFWK>W8*=,=T0>JP.MN0""U=!U MX TLH
|A"J=@IXI9ZU>+Z@PV,#@KU0_2/G/=!AM@#HLX6(UBV2*L/6*TL.7
MIX^Q\$|2_F|_5D6/_%*1^IQY8,\$E#13DI4CN0%&&BN4A7NN8\+8HLE7'\$08&S
M%^CB.^3F>"Y%=@>U><;JSG\$V6D5_ZTCL!O9!2_&C,UF@AM&;7Z1AC<^NOPC
M5VW1+M!DWJ9IET-VT%+-P9"NPHA>MT'2=ZO^1_=T63UT|T3KY?+=NM9E\$1=9
M&G+)2AUMB!.\$4)8V5V6?20B1J^=VO;::27|_#_,*..E.=,<<(\$EL\$G="W'6>/6\$XD>F7"/8
M7O|6W_|#/_=/-L9WD^SE,+/,FA/*#|/|@U*|MXMX8JY|\$O_|F;J)/2>|UF:QO MN\.(T)*GB4
|DNJ(4E*J4P\$X*D2<4A:)/J-"@_92?,=V|;)#|;R@U8!BR:3 M9M@97)JX1_0VX>8& Q*3YA
4RRBT2\!AIT9&CL=:9ND!E#RPSMV0\F,WWH
MPC;NW9&GYTY^KW/RG^L:"7Q%FJKY?;6FC:B_Z|S\MC*P3ME?Z7)!;?GU7|_M>-
N*NB_GE:8)+GA:((DQ1H@741=Q5H0L*E,L,D%_S3A*>J;6+6XH7,ZJ'2: M|S=DZ,GY"7
'TC<\$N8'O99#34W|T%91=_SM M%CA';U(J5FYV2V0+YG8\>@VD8TZ&F-
CJZ|_PP,T9|&MNT'PUJ M_M@%W3T_UA43"YJ+/(VH0%FF6P(3+!&)TOB5,B|?6T#
MI+4DBQZ6G?%F>S,|DX"L9&"-7:?'&/<5=-E3L\IZ_|^&>04?;\$^Y_PC*0NNY+
MCXQZX|P^;;ZN:|V%682EVb+D7*(T)SJV,BI0H38)".N4B9*'*&8T*4"CUI#C/
M4VDK_\$6WHT"P'#J:>S,9IT|1&_S|0(PX\$'51C:Z"JN>%C9O8+61X0>AU69/MN0K?
^2#Z(TC%^I_J(.|72GZU&8++/HG-4|W2!*,DTBMQ\$8GCFL:X9F=)W-)VZW7+_0?
S9_JI9I&J"ID21#\$M\$)8A0X1\$E*\$ MB4QD6\$84=G
U\$CN+S^|_=_^=FN3&D37|_D5?|F:*K-\$-R\@|"JN71;_1;^>E!;5
_=)&Q^%#_7|S_\$+_OX?;E8?ZUG24Z*).<(ME%JO0!J7@. B!XQ+4N2A'U)GWI;N'QKM
30L&.1#MNKFSO.4%WV71S&|9.>7)1 MS=XNUM7Z^:TZOSPHU?S::OEC_55;?
63Q/.,H204B\$!#*\$P A(0_7A(%8,H(%_MC)/\$K-CQ!3J|E5U+.=J0CEK:44?<3(-
=0FI8,Wf4WT|C.(INK%_,!1M(3U C MM#I",!3#9?&G63)&PJW6U.)J MVCXU?
J\$|ZDOC>7B'Z+.VS58_U^-Y8|B|>3HHR9_F*\$|S2D&1,*+.G0@#DL8Y
M\$#\$2,!,Y%,PH(JR6<&"%VW#2+NEMF)O+^VZ6\@>A+UH2+T1 M-
5M5W_1W=*_S/6:8HI01@D",I&X2SDN:5\$ F.*8%9"G66GE1QB@%5C!MI1O M-
E93CWKT9T?TBP=0LW,U/2\$A9W:'&#M0UH(* GNVZ(TJ2VFH'(A_:7R2M. M\$?
Tzt>>34)^!VAD>Q)L5^7'WM*|79,&5L3=CO(2,0\$DTN\+(D!PBD&NH\$O ME 3FG\$*+
(PI@_2-I#F(T#=[Q|H^SL?EXC>E,|M4U;ZZW!8@ M-2S+\$@N9WK1%_T>U_GK+U"0_->4-
MCJK_U>|7;WR== "ZD|L^H;236A8(>V9GU? MU?1KF5LW"S@+JMGNX
DJ.P4>#B6700^7Y/=7RALI:D+|5\2^40A_HNO^\$C- M_T16=ZOV/JXH?
9)K)HT@ADN6,J1Q"!A!_%(90H(YXDR:|59G#\$I&+?K=F9\$ M-
K"R.,L5WSH?,3N\K=A15\!MTDP8|+VS^)JIB3\HV6G+SP!-3*E_Y+<05+|
MSQ*|8HK_)2"&4_TOONVF2'1YO6S#L9=+L1BW=5154?A%-\$L QFB\$""UE
J:&EP@&7JQ;|E%+?UMRQMjG;8R@V1+VB8O=:AX%B?7"-I73 MTOJ_2&|2Y6XJ_.'*
W|/30DTE4\$;C\9<-SE<+KIR/^OUJJ):QT|=+|A05Q\ M5^M-G>|NY+|%,",(\$J4G!*"0)

!F.JQ/(@)XF@A.2XF2PLCGYHF?P"JDQUW4 MLKP|@>=)%X(E9E)5Z0FZ0TWJ:UC[8*-
-74RAW'Z_52S8|-8HXL#A?;- M;>E'BH%?OO -:ZVQL'FIT&8YA_>0="3OM,P1"@ \$
C8TF=XHPNCSY9F)&QH/TH M(-.7W.RCSX+I?
A25K%ASO:WKIO>NON_67\6I2DU|I=4_BO6=0"<_9WE*);.9 M 3)+((
I30\$I2P|4OT*ISEH9DNE|T:A|^-+VYS>231Z-E@|ME<|2I|1(ZY+CM M9-
!W*31,GRS_ =G/0!:"M.Z>VJA\$1:\$ADA/Z/N%.D#/Y|H<|)+AY')UR|09NTU)UAEQ|^-J+ \$%H
M)XC%"4",8:|VF1A@+DH@.2ND.OIR4A@EKMf1#7Z0W?*Q2=2,%="1CY6N^E'#
MC45|ICFPPOHS'%RV9|WK(V41WOH\$.,>H5U_ (V87#6@,P&"1K/MITH;/6\$NX% MU-
J_/_)#9I< H"GI"*BC)G#U?A>X_99Q31S#_8HL:G42KY7BGZ4H\$2G#"9"Y MS #,F5+'E&?
*D\$8IRJ @ G*G!IE^ ^0SMR|B0TB&39,'_KM;5|JFQLSZ(|VHZ M,L=NF9YGR|PJ?
@%S8+LWF|BJ M+?N-
V1R@_688A'UWW_3,Y76::X:|^FSOS4#D'&SKU|N5=EFMQ>V"OYU7C|6B
MC6_==.@J6"8X)2"G2GE#RC' &:4@PU 6B%.<<".WL@&MP%IX2URKX*A/WJ6Y
MV078#,QE?V#8J<.,=#K?A<;-PAOWAX68!|W|?HL?|WSQ9NV82#|JX%X:8SJXU
MDV7/F#5|Q;4TZY>O8C|?5F254.02"8#C5!>PT=\$P3/V4)CDLRKQ(8)G:563M
M#Q|Z4*VM1MI0="V_NH?&L#8:;+Z.=K(2SZ'\$ZBDI1E16W1MNXH*JIT0YKJ-Z
M|BG79:2O|-IUJM9F\$U|Z>OFT6*^>7R^YF\$G.T@3%\$*1"1Y"4NM5\$F1"04J+T M%(G5"
<|H#M20WC0+;8^%KHIFV|^F8232G-BNOV\$831>D-W"<5N@H7!P6KI&T
M(U;R|/@3+VTC88_7NMEK;K=)Z|/R/RWG%7MN_ |OY_\$E*!..; 4R%4%I *0!* MXA*4O!
LORDBR*H)A"GAT \$31CZSO|==L.RN;(RA;-N#"0&8|2GBE#>Q)1_|MV?
W7:WB%J^R>KCN,R4YZ?V\$+QN&%A/7|DW2=:2I,@D0(RQC/!4YM\$|7<^0CL-
X9T^|LQ>TN9H.->>?5T1|;8Z+(LSE)\$"@012"2#&"\$#JZA=9P&GJKD'4)BI\$G"M H>X!-
W MNCLEV%'NY-/^;(A#\$*1M*G>% ,V^)|S|O::U>\$::>906#+ "4)B'D1JY68QH"@ MA \$(N-
K\$1T"/@ ^+8>WH.V#X2<.O#XMW"PD)GG|!99 MO=*>TT6|G%>|N?
1HKTRJNJLZ(6%.DS0M09&) L!:V|P-AML^-,\$|NI6TETY3TK1^;/^DZ#-%K|JU:
MDWES!MH|=!/MFBS>LG7UO5I7PD/AYPM2>TL:WQ|HXB3PDZ(=)W6??LRQY%UW
M77>_;" +B5^+3:LF?|,2U%?7JF2PXQH*4 *.\$ UBHG1'+7 ">L|B7-,O2DCJD M<%XD;/1|C|
|+_"(>VKMJ?9FYX)6^R;R)-CFVNJ#"A^7B 7Q0:/&N-*|E|;N+ M
JLM=S|XN56V_2U4VATQ*,=|4NHV!>Z,Y745XV|B_2F+6|G*OY193OC%T?F
MM|3|U4W61=(S9(|(S%&&&2RS \$L4P0HQT@WHF 9IE*=8>V*YIZG%7@?;Y-)
M\$|X3%NO#LS,B#K%& M9F)ZBS&Z0&|BV"(SX8|CB@S?|JPJU"@,FX'5
MS7G_7|1&/=Y\$>_1AOFHOWV3.=/C|H)X%|X)=!F^FYZ|^BG7:|@1.*|BP
M^'I2RX&8G%29AP7Z<L(3,UMXVA/DEUQFEE20\$1*)@'G2M7#'#-,(%R3C M
A4E4: ^NFV|L1HB;W0K;-VE8;S*FR;Q\$>M*-Q&'JYU|+,QTH:.\$=B|TT2J
M(^1/UYS DWY.*V!|HTI5|4JS#|7GZH9%QC7?R:-F_OILO?|26|3I#0TP1Z*L7>9?
Q;U9N#.\$YR@5*(RAT P MF"JSGD- \$BY 4=(L+2')A3 J?GUR|.1*?4N2-7:7Z,Q?
J'2VAW;+|++Y7 MNPk/U7+5%2/T|!_*|\$ (9_CQF)-YP<^*TW=_GW_(H5)
(OWG5AXK0:EZMG^ ^7 MKX1VY_VV\$D0'E7TE35&JNX68)1@+284\$@C?).S(#-
\$;K+V6(|O(!#(V9Y0W|6K/4RHJ+SS7<<16O%4IM| MHY@*B*!%99* 2+J5*@F|J%TI\$T=
(!FN;V(XY7;\$31VGWJ|^XCN&:+\$'7NGC@ MZFF7=8,%244!+Q=MKPM=
(^G5|JO!;-|ELPZNSPCF2%+;.\$ R|<3ESY|(-CE?>VSMT?>W^4?RX94SG %:+AT^K
MY4+|R)K#8=VX_N.\$97%,&8B3F "8%2G G'*08HI(00H>(ZLFGU;4 VN7'B|
M76O%3;1C)HKQORFRP@YKPROW4 A:7LGO@/JB.|F1%: ^C/HQ)GO(<|B%D|B^
M;O&M:\$|HR^|"RY\$7P&D0-|7S.UG|2S1|NK|HXK5-+/TL@2F23*9 8*F.(#0K M
F!2;D/K%PVL D0|86|ZY5/ZIG3G|4V: M\$6|BZ7HR19U0-UWY#QU.YY*5-
>WG8:;|7NRDVZG40|.JDVA|9|^- HUG9B.6 M/Z5|E=GPM!-
_R_NDVAM5IN5PS|H.\$XZW5V;5;%I?35I*S%)=RJM(U=\$R0P1@ MC'*0B+) @LH8FY7"
<"\$>^N|*J\$)7%^#MYOVR@MKP|BH0@-975OZQL|_-<@#!
MUV66#>E|H|(<0#FZRG(9P|4GPC_ \$?/Y_+98_%E|J9<+I?F4 M3=;3"6DA88 M8
@%@@#PI)*D!"6&29'&A(O2*,+I(J7 "J:K|Z^)|@W|HZM&&?-32M^U^< ZP M8&.@\$.?
@PO2C>AP<&|DB7L;7!#PN*O!H1=&W'T=&BE=1CL1A2A2
M20#EN4|R*R6@+.8@A:3;.,)Y@F/KZZ_3M":Y 3LZ8SA6 1C"S.(F;#P2+I=A M#B"XW8@-
B^?S4NP,I>GOO89%/GDU=N\$5U|);>F^_)S_?5#6;+W47Q5WW# IY MEN29!!G525VXS-
4A@&6 H#)/\$P:S!%O6X3I/+/"R|@Q31=O6O32(D-D:|B6W
MW2+>B1SMZ"J;/ \$07\$1.)O57F&B U<9FNRT(?U^PR>.=M*7|02BV(;=&U_=#8 M34F@-
T|BVX(BR7F:OW\$"DD+7|Y(%!RAA5/|1E 7/99E;!:C8,A|XR;?L|,O0 MG| " *%&J3)&D!
(@4&##*("SC'.+" M2E=9T ZLICZ)U2-9Z%3\$2A=4=31.#""TM%7| F-Y?
R"E:\$L*|HR8SSH^|K"9 M_!Y?4O")*SQI#%\$/30? M0W?:?|=DC"M8(F6\$JN&1=7

M3M"U@NIRNJH=<(JA"WO7FO\0UQT@679X*R M.,MS#&(J"8 (QH BF
"8\P3EE.2\$YE8Q#98,A+;O#B S-QO%401AJ?FYNTF MZMBR#("P1=U,KX7\$TM)"I VC?
0B%(Q: ^XBHLR4);,.\$(SE\$ \$ANLXCLV85DLF M!* ?*8\$ ^BV^=Z^5.;M.C=,F4&4Q*PGB2
4JR\$D,"4!":2C*4IG2-(!QC8: MRHAJ8+6D\WC85_400G=37C9'#>J8A&B&HIG&\8Z-
G9K9D(T)QHILN.@6LI? M^VF+F@V/'9ALI/:5AU6DOE=>___)4-WW9?XWDAJ&
(7.Y&.!9D,YT2!CH[Q:)1:XHW?JJA M%OWRQP:U+2J!>CC: ^!)QU@0GE31V-RJ&T<1G"X
I_HFU>,7TMM6U"V109 M[@HBQTD:LT+?# "6Q.C"A3.D8E.<@ED5*U:&J+)!1IQ<#6H'-
D1WQ:-?J|U+ "> MLC5L!O?@ _L"P4Q.3XF!Q%>X/#I>|I#&XV%V&FTDZ>!M^88CIKL/-9-
F|S=|MQ;\$/WDKP:OV.L";2K:DHA@J:2\$D\$R),\5FZL++|ZU!T3F+8SW5D:CWK1G7_2 M-
1GTLWBH='N*Q?HC>12SI) B3:0ZG60);" &" H.(@%@VHYIFE&C=K'GB,0 M>-%UB8|
IFI\$F:100>8#)I)+S(.G=@K,4TB&E\10D(S(Y#P:<.('SM#C'>9MG
MGO/4SWT33"/JWU;+NI|AI\$0XR7* 9,(3! %%,D2E%E:|E1@1J%5SN8E@H&7
MWJG>Y#L.=/U^Q'7H\$QO+6>:%4;42'>RS>TXE<,(148S1O5&&TL 8YH 6L0%*'CQ?
MI!A8\$;3TFXK^#0>H\$?;O*Y+T)FM?Z^ V"F 2P"98(: " ^LM, ^L2O8E3L0S%
MAZI,GW13@|(QG6AXOOEQ^7BDUA^%\$M=V^7=8O<1&RSMBX.\$OH7;5EK6.YEB M
GOZ>Q=15/_7?(A%W::7?;=\$ROXS,V/+V"HKE;9P='IZ7NK'@ P:| M&J-
;W8SO%O7ED2=9S,8";A:Q^0NN 9O?5H*UV5JY|GH^OO>/BY7Z^K?|3UI MR5&1-
)=5F8|.I!#IZ,P8*.9R2?(24639R>0RT<#KOL|"DUW2IVT;9VD H=E^ M|AL8N[7?
IWX3;>F;P^,0*6DNK|>P2 .2\$|= FH-P'!/H|;Z;AFB."I|62UFM M9X2G,.<% B13RQ^2-
_X3'5?HS(O.\$QO&5OUXNZ-'=B%WU""LGJH);8-
W3NNN//.GR.B'2X2HZ|8C;8ODLV)S4=24KUJR| MNZ?UG30H@=@X0!)2""@\$
:S("8")@#KH3J=ZE1RS!"KIK;;9,IU%38|;PIP+<3E.\$Q=I:Q?@ R9-.&L7*I\$K,!VB'6L_+F*[U
M6?8+SITL\$4>02&E)0<(O5H<.GBJK@TE 40Y9)LHBQI9U62|2#'|FD-6B4H?F
M#PI+WG8%;7|TJ4%@@@J&9VO*,C)UV.BX%.4%).6-YO95:N4QOXA(KQA
OJ.\$LENDGN2QB+YSE!^,GMM|8;I8N5-|D7& MG7S .3%_/8-""GWM#H)*(LM'"
MP>W"-.)O'T*SE|BGETR/FUX!|,-SA@6P!G:*/YP)|#E.B8V%S>,=(S=C:#Q6
M=N:2E=B#=#I392-,96%;2|5E>=F|ZQ&W|("O^FXX?;.TS3M2K?Z#S)^,RDD. MO!
I8=M)THH901)K(HX:#2+-@\$9=Q1O)A'>9):#NEU1#L"1GM / 4:C\$LD5N0
MQ9DOIPNO&!9J+|BPI->BT^_6ZY\$|;#8_5:1?%-)92#I8H-D/L.9OM4@ E"(M.8"
I2IE*B^"+3IK6AP M^S4@7GIZ@W&A|_U^9RLDK4I8&&K6E_DXB54N#:%RK#:M?
%PCJF-3_5:#;QZ MK65>K%=M\$=6J_E=WVR<2\$A/\$"X!*J0OKQX72;*@ "8|A6J:
<#|9GF=:_ZXNNZE)1QO:.M;TN'9GR'JZ7RKE5R_G%6^O5#=A
M\$1DL:9'+!"0R(P#*D@*4%DH5Q4DN9,X9HE:=-5P9":R1|G68;-1;=6)^QIU
M+#5.EBWCBP== \$Z_/Y*8^DOJAN;UO,@FM(^|HB;'KP-YE&04)>Q&/D+M'-
C8^H@NU%@G0BP&S>>FUK|I6LQ"M2"JY/
MV;I=K73I2TWVU?/ND2Y'N+D)N_O67"O_AZC73:<+|9|CFK&E_J>|IW6|5DI#
M5_IZ>%@U;JKWRJZL%G7%VCM46F:"HTP"@7BBPY;5B2|N.&"24D)1C%AIE?=_M-
4E"!P%HI@'57.^GU?5\$T|7R^LIMBI8W\NF&B8V\$-U\$K8Z/-U)J#:/_63VU
MD_0FVLH;;86|<)G|PCXOLVWA+_1V.TK|7?PRO!|>76U|5Z>|KZ7'G:WZXG MQZ0;Y-
6GZW""O3Y#;EOTUM7T?O%-T?H@OHMYVEW|H2)E.&882)KH*KH)!HC2
M#.182LA(DN?<*OAM@%;@;:XA%:6.UZ-#&)GM|)XDM|/5.Q_M3=32O8F,@;!6 MH
8B>E)QOY0F54(&(A^J"9-77*|@N!"/^OSV;;6-=5,F?/>=9F6:\$HXDB+&^
M|I0=C5!.*9"%B%.!28JA4;5;.W*|E_..>+2E'C7D'5?X!?!;P%\06)|UG='
MP^\$8;R*DM|Z(+&)C^0F@A|?O(W>&N?V_"R:++G#)=)CNX|US@G('8Y"(3!V% MTY0#1
@&O*12I#DD6%@@%T&%(I?RAWH|R|XJ.P|E.==2K|:R|OM-+!|6Y-O7BI%Y5Y,|)044 M)>2
8XP)\$4."(E@#!E@L4RC8E1DML@E<"JH4_0;.T/8S*|UKU):K>V^|0|MUF
WDF9HU:H!>BM6_6VW6H?'GF1U&HFW68UF#SN&+%0UZ4|SS77A9W4,6#R)
MOONR|ST)0J#(2@EP*C*U&I,D%@9|S+!A*HC>5H(:!6F8\$(U.K-'U8>%_7
M3X*_>5I5BX>V(41SA?|1_&A^4|JP@7_"\$0,\$(0I@01E (D8 ETABDB>(EE:'
M>R.JH3U3S0&V92)JN>B:CMQL+K44*^T#EM\$ 9J: ^GA|0V7IC_&"DKVWQ\$9J M7YX-
(YK3>B%L8#CR&%B|;)|8|5G4FV@9G5/2%(R3*HZ|6KP&|TMO>B-4,|
M5HMOV0|0_.\$_SI*I34@^O9|V|I7#%+ "-*&B3(V*09T: M/'04GJ:A+&6-
%=%N6=E*9|6RY9P83NU:C@;:K%7+ M.3'Z;5K./N-X27T8|/_J^5Z-U"AF@O,L33D'A!:
(INS4D&T#;|;9#PZ6|UN\$-A?,5|6SM?%|@ "E::^3+XM| M=(EL|
(JKH|E>KY|8NK%9W|J9N;GVO|5W5&?KMX M>A0M@L|YIE('E2FJH3;*(T
2XI!@DLDXRD-B=F-|AF9S !-ZRK",V6J8C MS?7-+O)=|W!=-NWR7)W4'?M1CW|KGWB
>3;37|>>/7M|?LMM|/HK63WHOE-! M9|S!;Q|.4F_>_@ L3APC\$
IDX|B"@+0<8PF;!/W1=/G9-K!M0QWO%A|J0IN. MFK,"X2)/"@1PADH,2P!+8H"!%@I?

RR0E*55-K89V<#:NV,B:KBXZ?5)IH*? ME4FT9<4R^M,53/-ZA\K.UWI!2;
IV\$0KJ7V%*9H1G39BT0J(H^!%N[=H7-O M(J+?/2EE)IX^?HLOGYMD\06JHD!
/1\7/IKJH9F?^G(*N9.CI"A"4,YKE,K?I_8-&M59B3M M7!6S-,NS F8"H (E \$I2
L1S#!@I"IS\$5,8ZQE8H-PF7X2I^&A^B'8CK:<'VS MLV":4WS#"I=5A@+DVOG2I
I@Q:7U=>,-)<M+CW#>@>OONC0 CU-?M(:#^<05;4!BWHHL-
;7Y:EU!X&%1_!LA2^;Z'/#EJQ#K M6UHW3,T8)!P6'/'A52G^B('E#
"\$,LDS426QW8=MITY":ST.RZB'1MZI>J= MJNWJE7Q:UI6I%G>?!%I>VJW04 MD8
AAZ=*,_2J/P19:%ZP!?!?/(:9J0.%H2S%(&2\$E3 M-!F4
"=,G5U9F>K;04(PM&V,9(GHY4ZNB7'ELEF,JVP&6WXC',WD0-JT#S MNBW-UG)
I\$RE^+?I2C)VM844Y&?AN)2;_BH!;M B9\$'BWYB\$33(!==Q%/B WV M'1E+8(J.)
I0V.M5XFM,-ZOP7)??:#\NZ?J59\$H=I;KM_OB<_9WE1BJ1_#H MPXK+.
4H2R7@+".4HD0F953? PS@4_0 QV>?I'L_7H3T8:5Z(C%I6\4EW9G
MZE&38V:P3P6YW3X4&FUK6IX'3)XL^5&L3&K'^P#MT(KW,N:+*@SZIJ=8L:K6
M2OY+2\$'N?S!0G\$+>&MUP=P&#0<1@H\4UKJP#J?
FLM1:5>!X5VIE1J6B;/:D/B%RE^_1I0<_UF3[S M],@BO1009R7JWP71%_#I;O%9)VSJ+
"E0JKZC\62UF+5W'0T14;W:_^>MYZ M4%IKV\ZK!RQ:TKS:*9-GI1(LU,M.%&J19?-\$-1M?
@U MV0(4I9@*\$N/ACHDGY>G P*3:T!V@0_4V8J0P25V;7W21(CKKX5WU7Y MN3
^ZH9&V/HL' 9<[XE:%Z'9*#GK'!OL5_UO_\$QR M!4_)S_X369 I<+O@'M-
4'S\3.BGK&X+#F' "\$!\$<@ IS@ EJ 084I'1K,B(W:68)?W0'EY-MG&RZ2I3
MH=4&A:PU;ME;(NKV1(/B);=I G\KI= &I39N1M^J?I;@I7/6E?QI(&VXZSV0 M(PG;W
1_ZL(1(\$^JQ);ZI&K&\$9I#%>0ZC)MZ^K!;0==JI-?D6I4F M\Z;:QAV=5VV9I?
IWHDO^Z+/99_&M,UCNY*>56K\5-U.8\|VH;WE6% 3&!10@ M*;DZ/I60
LOI=;4R3A)&62RA50IR;NTEU="!H#W5X*#+CHBJVNT;/P3"3#;,>I4.="G.E.;206IF:&I"5F
M("H)V28G+;445M\$IV@:K?"#Y*,M9>/5WKP2I\ M(O* M<,9E?&Q&C^)-I-MJ67OLT6
BGN\W7LWAXD\>;<0 MG\1*E^@E#^+3LEJL-Y4>
IA:WC#T\|C6IE)^6I7HEUM6J#15KQ\GIK60FDQ3% MF\$"
J,X;X1@#DB0I*%';L<45F\&6ZYPEVOG:_PGSYO*#?SIP2 .PD (T(T9O^
M7.ZDB/;%V(ZY\$R3H=7X8R,-='OF\|HN@C#P&S@3 A%VWV/>DM6B6CS4BI5-
M8"%9DSPG(H4@U24!,"<4(!U# A,!,H1Y:),K1P\ZD\$/M)O:;H.5VTBP4W4
MT+73V:Q0006U-I>/.@LNZZ="-GSE!=Y"F+9G/MH#@C%".248U\FI\$:R;!D00#ZG6)2.
IWUD:FI_/.HG2&ZU2Z\$5,I8 M)" MH#(ODJ9K,9)*F64<2IF96+E;
IA(,7B40TL_T0,2;3C0QY&6AS82P#;: MX1**9C:(5VSL--M(6!PB(@Q%)I18?<8G>Q-\$2AN(?
QTZ8ONA8ZF2K803I9A,W M-9,X+W/\$.2@3J8X65"! :8)
*O."E)2C"%HE!YXF\$WCHW:FMDG%AJYEP9'3 M\$)DM!?
&"VZUK>YGMRWX,BN2KH,=I(M.6ZA@4I)*@ (Q_#3\FU_FISA^I>'WQ??
M*EVG;|N)W+3Y\|D! J^|AFYT7SWJS_#WCY_>I|LR@^;I?I^+|/SRO\$ENM_"& MA(I^U
Q\$#0>>^@%?E-"I* #Y42?K#7Q1L'Z'X,L/N^V*)\IQ\PK1.)-IYG-3OU-
F*0I;|0I;KOE>3<)S!6&2 I&6I;&S=+I- T" T7TYNHSX7?7^)!F!OQW+4"7,3=>+T?VEG M!
3^(E*,LPYQDC\J5OCLQ=N@C^8::9>6-4R@,Z\N1 MLEF>NLW%,E9" P(,0SU6DI;J+_M-
_6I\$2=9U@.B;:;@T";:KHWXKN8+I_I M(@7L?I>;,'QLE"!;RP8 TQ97
#F0@(\$\P3\$VCN71'>;IV%EJO"">=%?C<'G!L.=BZXB^(-NM_.OSV=Z^VB!'MN
MMAM/.W9M;:/4=9IR@E-/E^I;3^N%S_IUA_(A6?"9B5>9HQ@(HR59J) M88!
(GH\$DCWD1TS3GR*J@K2GAP+JDPW2YR/;:+1IW6D6(F>A4I9KRS3CHVQ M-
3M;A4#,3L%Y LN^*Z&EY+X:#9J2G;9WH"481^T;=JW\ T\/*P_+>K%+?IG
M_>4I>UVON_W+U#5PYOW0GH%ME=I/NDZY#OGE_WRJUVT66*=V(IUR,)/< X* M
S>!!Q0LO03&'C2VU<9>E\JN/;#R3'N./W<"1V\7RMY?-6-;5AV\ MVH=F9CS\%3X?
V\|F7^_+I9#\NVT!9SK\$L.+!A+K/=I4?(B M19PGL\5Y^:AC\$E;ZP;5:%.M")PK1)V
QDP9C!/8;MGO%8#JJ'FL7G=6\$E\% MZ(X)3%M#|JR
1V7@SC_IMO+NQ>.WY8JLGO7*7C^_)JO5LVZ=T!1Y05V05Q5I
M6FMKX7\YB31?'RUB*E,(00%Q"J#" \$N\AZ",|S)!%-*<6943MN8@|+|^67 A M'IM
W(. *V='=TH>JRU-%U6P6\7V,)LM\J#@V>F+2M1RXM2!!TW7T\PHC>.!+Q\$+?
J38D(TV=,TC MA"|"-.Q1?(MO>VXXDMQC#(":"/"BR^2F"S>V%38?
@"R\3N.D8":Z\6Z=>%I MKNI_M6X1_=-,QBS-<(P RE("H,X&5(LZ\U)PAFF1YZFT,BD&:
(6.I^M3;DH\ MMZ0C3;LY#?I_.JG\G4_U>OFHQK<,^1L TK>(H <=/'99H 0/) M?07V#5":-
I;OLLA'X7L&KSAV_ZT6U5IJ+|K\$K7*BGZH=LE\$=JH\$SA8BX_J M\$|C_(>;?Q>_+Q?
IK/4L11#S+.;?>TUK\$C==RZG\7#UIG#&8\B\&RL-(<
H@2!"C.%KS)*S'@/8(;+A!_#W+4SWST:Y#IH.*8YQ+5YA7/'=6UFL(-I=7;^T6\7CVU?
5I67\7J_BM9W'UK#I^_J2'6I?M%&Y\$X M\$|2,BSA.,*Z!S\$B&5 Z7_J!\$ M/3?7I:_GI*YWP5

0(HZAB-&%>BN+LQ1@07) F,00)CG.B&,,J"M+@3>I5JL< MW0-%7Y[H/W5[F?
5R\UK"-8#4>4(.IXQ)8;,<#3K>I.EA6W=K^!9.;P|=9;YF ML@MH#7-
W\0\Z[V&PS@Q=*6)V+(&G@VM'C_P2RW5NNLIH%M_%XDG,4D&X.B\4 M(,6P!+&(A%*I/
9Y7*893"E/X^S%5>||\$.) (C?R%BGG>1-MNC)V\$+ZFTX^\$7 MY'QA=>4/XH47?K3X"%Y8*
<@SD_&7J_OYR\NUK\O"3\NT=2//,3'BLHU>/B+1 MPR-2_W&=TIO,..|V| MWDV
6;2X)I\;MROL[9P[SB\|V40)\'Z3>KU\$;|KH7,^W4E|A\GGOY(>QZ6^6 MO
)Z\N|(+P4W#7V\9-4;L:J^JQ&_B_ |27VCL@DMKO^WX_B|4V?^^(ME\N% M3D-JPHN|_%?
&<@AY+!\$!9EE(IN1-,|J|+!9EC(LRD:55G8(QS_36PK=WK|HK
MBV_#7+3C+B)UU/"GUWS+8;1E|>92S+W_63'3L5-A;:=5Q|+L,8;9)U">|.DH M5B;5H#Y
.J297L9TJ.f\|4F/L)3;\$.)9GJ:"0\$0!S-)"UTXM \$)9#E"9YB5, M"DBA45S/Z>\$#:|*67A,I;1<3?
0;..874S7D0(|>);..HL*S;..D=*O;..M73WF ML\(.UF\$^?
FNZ^LMG.=ZKNWS^*5_%G9JC=>O'^T/;=V3.=/VI:A.5ZO2G:3T M>> S68M9D1\$94X9
G#"M66(("MC\$(N4T5P2E@FKB\$&_ |763!M2T4J7+/56
M#&K4A)@94|>#V4X\GBXCU>,U^J.Y9MAQ>|H H>;X)MK.EV8Z9(4I'V &*S|U
MBKDKUZ;R>SEPE5>J+BIY^X:LYY1F>,2,PJ2A*0Z:94"+-1Y-2=%EC,.BY@9 M->
(X'#BTL:96W\K%Q;05/..IS1E,@ "QD#B#-\$" %BT&!;4W5\|H800?_H97|
MHUU\XV\$PT^,NLVJG@3<4_*G+0YX|*;KML).JJ\$-A#I7+T>|=K;9ML|2FN_7V
M1NVSF.LO5"NA^BAVJQ=_DS")VTZO+UZ%3RW\O4,AR\3:ROW MTH4?J
LJ\A#6NG'KFH9F\7ZVK|?;OY2ON8U8|WJ_OEC\6,E;EDM(@37,*
M(\$\$00)2JXVE>IKA\$1!2 -M/M3;K2Y0/^O4P-"8DRQK Z\$V2|7DT8E3E+KPl;<_Q8I5
MM=A&D#>5|=XOUJMj45>LR:2:D2PM))\$I8'&A3)A<\$H 32\$ I\DAE.8I%Y.D M)UDP_?
(C+;8Y%*MQ=FDH-|%6FC9-FES|6YC.28B^9GFZ=*/ M'"' =NJ1#S|MLW\N%
M#D9_#51VZN(DS)C(""%\$.UIUL:H8*Z,S\$TE,,BAS:75AYXFOT\$=M\R9
M3=NV7|HJ0;_>|)O^1\$H(G:*T\$Z.-0=O),=:EXC:EKKZ4X!/EPXDRW1QY<*B, M0C28)\6-
JRN|4\$9!>=EW,FYXQYC MJF(X*>WFRZP=98FD'!;\$T 0SP%DB_!*<
M&0#Y45!FV;.>J0MP_?,.1YEL=O*8'(Q) MF%'=|D" 2GA;:-
Q@KE5^*0_^,8>HB|'10=!U&R\8^3UTO>RQ#9QS!;2>PK M6M&,Z+1QB59
'\$4@VKWM\$&NX2V|=UGA>|>D6C6F^9U\5RW(@E7:9M|6#VC2 MH-
L_MFZ0\$B.>9852QEPHZ|G(34;YG>P5
M0E:T/8GK7VV9W2LCTG|J\$2CH:YZ&%=:UT+=49Z;|MTGE#S<7%J&>5Y@3 MMP#1?
ID% MID;?="0>FZ^-W.C?B6WC.\$
|ZY+;XN>*AB^'0)QM%7+WX|XM'C^H@X_^;SWC!>>2POBD-\$Z5-M69P4@*KM"G!>>
(E95@B|J>6|)\$-O4RTWT9;=FTWZ>-3C*_*L1'JJIH?:|LF MA9:8&|HAT/2M/H=_\$8MJ
MN?KCRQNO6#|JQ'K!/R|7HFX3B+KP)P(AI*8 M&;56M";;6"5E?U-
|/>HY23ZXTO4XR5JF(E;|BR,,G-(#4S@(\$#9:1QCC"YG
M((X|R\)|Q*:FQ4Z_@.SLSBM11^T*=_MB.KAJS*X;I7^(+IT11N6|6E5,3%#.'H77^?
@/|07O^3,55\$KT?.7U9@K_ |L8|O#<""KS#? V('2?_0%|VT_ ^ZM
M.SJO'EH);:U>\$;:>\$8X(2G5(%&=2^WX0(% GK Y,20Y0FA116G0;"L!EXF|MY
MRH|J4TVNV M45U_TNSV|
;|P4=;R=%DJGVG7VGE>#JC/S?;^TSV#8INL.!@+TQ>.5;8)|"7
M0X>|4A07*J\$|0EU7S<@_ *WVUFQ.\$BP3DF2|FC\$0!'"&<9*#+)")>"I8RZ-,8|
MH!-83V|KS??(JB6K"%O>;9R#R4Q=>A#>3M^YR.U< O^,5)Z+U1|2N4I9^3.B MGBL ?
^YQ7P:=3EZYDY|6R^|55SKBRS>A;9*|E>|=J'7#\$YG?-Y9(HS&Z%W?Y
M"OVKTQE/(.9267,9S-2"C|\$.&\$84*'^^Q|L?:U JGV\$ESR#9E50_;
3>#OXI'ZWB:C1.J2K<|=HCKGB\$|R; M=GADVP/O8O4< M|5B,-(,3(61.0JNR#ME)TPP
VX189|M/W+_N0@CH3',0G"EZ6W|=O5TM'NI/ &|Q|K_6S|<_5KS^N;_J/^+.=L
MS=|O|M=S?=7^;KEZ_7W%_W,39VFPN7@B%?JP42EC0"QXK0M_M0\$);|EJH3;Z
M.OI\$*AZI3;?+=V|'"6T6*|;|W|HM|=G(>>"K=O;RJ9:R+|;3>IVK,OO0K?! M^T|!#\$. \$?
4W3\9TA1FR/\$Q./#D>NZ-XQG:@4IRBU!TG&-^=(GS1GT31>@9K
MHVE|/^MV<;1&\$|6#.GPJ5/&
<|(A/;"M225W?|=Y7:4@P3U<,)TE,>C,P).3A@7|P68=S>+,AO";J#V6>?WFBS=_OY&%>
M5?X1B7#"5F):WM20=>Q|V^V#\$3U4|4K)M_ M4F?MHSQ"E^P=.YP-3M#!T+/3!2\..(L#
<#_W0Z|5D|Z.N@Z03|XJ+4;<;H# MK).D>X=5MQ%<|DR_?9M73)|SWR^4)A-
UU_VD*65;_PR8 ::U|<.=HIS,@1LLD\$|(>&F M=T1L4S|)!R.-=S:()TSL-Y-
C/Z#1YP;X9P)MNMM|5-2-S?87P3OU+/2.9 MQ+1@*<@+J1TTN5#&(H& HP+CG#!86|;#. .
_C=#W8AW5J"7;7HTA,U; 9O# M9U@O>9+9|J;)7ERK1@ 7!')J|!NS,D: 5P0JM\X-
*CKC\$Y=+TKS?.1/(HW MRT=2+68)CGE1Y# '@K%2'-5)2H*P'
@HFBRO+)2ECHV8>=RUY MI6-N%<=-HYDQA BJ"@8B\$D* 62\$

20+9=MG*#>"\1QRJ|2&@_ \$#+|.WC|_F MRV"D+MCSYQ
MP:>3HAT7=#K|V(A\$^5O&5D^"?Z@ (K>9-^OWKIY7N^CYC15;DO\$ @144"8*+V
M2LOP_5+U9R|3HL3C3?D7=(G3V/69ES),LL5TJ*IP"F ML
1(QU\AD<2QR\$J!\$)TU%U>30|8E^L(@,U->_H"PTV4M!AWAJ\$?Y)NIH>RY\$
M<%%&GQ4)SA.;OC3!1<%/UBBX_)::GR_8,M'H1L%O%/LZNC/:O%4+1|NOBG|_MVR0
O1)RN1+M<_?DIZ@[W|_,0D+CG&AO+5:&2LXA(#\$AZJ^0)SDGI916M0?<
M60FL4C\NU7__IN5OT7++B9UF& &RF=:8!CH|C=+2VK0PT8LAVC\$6|3B+;:-:
MU#W?,'<3=>SY4SKC(?*DD\$8P,JFR&@_8H2+S,*)CV\$FUJ_-BB2=|OUBKCU27
M86HC"V\?M'WF3)"UCYX9!8RO^!HW)J_-P!D%U%&,SKC1W#TPK3OG|8+K6@ZS\$D)1
MY+I\$%-8ETHM"GVZ%LM5@R3D6,\$_STM;_LD=A*N|+YP145"V*5)S'Q=SSXBRM
MH|_%5%_GK|M)84;Y7/9'G-SCP9RIXPVFH,QQ_2!*4F4::V4E@CG99EEB5\$"
M|5A&@CNF6LJ|!7;3|SJE%N*)1|8WH<|VZLMY-LSTV!08VRFT8!/:*|:QV'C2
M<,YL3*KJQH)UJ/-&C^=|P:.=A1|\$J7=C;APOA)>Q+&@.2L8S_#%6"@|/%NAD+
MYT4J*4>9U3WU\$+'PES6-O|FA?,-:/9>=-:/P&5^Z>'#^FK%\$0>7RY.+OJ|
M(CE/:NJ+D(M"G|CNN/R.0R#|H35Z^4C|G.9|J+I+5YSLVT^J,&%_MZ'QDBX=|_=J5=:
|?:"V8E\$@()D&2Z;IY:2>C"9C_ML|:4+9@!H3UN!':E5RKH1\6VFDUPJX"5*Z_ TH677'YC|K?
4:W|O#TU&;F8_M09PD,064<00@3YDN|L
!XJ1(6"PSGMLU:)N*|!7YP9M2BYT*>FJO00|L;?1_M?
&LEU*Z!Q58N|>.3>8?.Z3|5PZO|E_@!6#H!#|J37&A/XGWN_3&=@XJV0X^;MSV|5%
|6V::;R2PN2:V56\$| (79-F';:P@:F_M//F-7(&K|4M.<|:=)O/95ROOA7VCBO7CTW@7N0
MYZ2NFW(;;L\$)92P#97V.ZGF.M#KW7+UA?2|?|_R?S|5_M3=OA-NWELV|Z-
52R8NW&M_U|_5&L|^0|^3G#K*0T3DH@U#D#0"AR0'A9_EFP_M,H&2J1FRND::C//
V|BV??9.D&@O>TFVK%_\$VU%_X|H4"OAU+|MF;|9I*0=
MRM5|1@U"Y%HO8O+3K2EY^(_%;_ =^D9^G4*|>_W^)FIJDR?Y"_) /J&U"ED_MAT5TL|JR?
^,MSZMQV?3)|\;=R#|_W5=K#3S8=YUK.3|>XP79T|=O||8H(?_N_M16S3(?9-
5:/YLGYZZW\$7?|_P.\$MS)(%_9_E@44J_DPR!J\$H3TN1T-*N#|T%_M|=>FAXK!
|URWR_45#RZ%+:QP=;PBBD08I9W1^?!ZC%BUAG'_C;(-0)?USPV_MI*>|OW\$
Y>ABQF4_-ZW3TV\WRUO.FY:59*Y#%707VF^58N'T/=&F\M27M>+B
MD_H^OO+=OERWC7G|+-KVTJAKKY73+270UT|LS:^2|.4%"@'_G*<80)FE@#)(-M@1
LRW-)RQ@;5:F|LARA;XL^O7|<_JZ?G>&O8G>?OGTZ4;;WRL=M|"U%M\$)_M3CM&|?
3EM;X*_|7|%YAKRQNRWC2_"C/-ULK|RB!|VB>N)<6D6\Z5I^IP|HVM.
|YZ+|>+|B@#7RW\$KJ&SODC=M6.2,8EX\$A<"8)'H_LE%|A!-8B!2C'D,98Z0_M5:ZQ;R>|_
Z;=W>B7IAG@KW|?;FF;7)L"K;9#C\$)A'8Z_G1SXKUJ+TL9|3!N
MW2;_|C|-6008DM|@049-N7CRCV\$+>&ZW!_8=D""Q)ZM+^AW93ZH,T0;|!/:
M/***S'NA0\$VF|S\$@M"PYR8\$160%@GG!_\$YH"(D6F_L=*P|Q;_ =I2#ZS,>JFR_M?
89THDM2WMA?FUM)OV\$-9X#^NVX"C;Z;7""!%"E%((-T2BKP#:I=BY_K(
M8,*1|: #3I1^YRKN7C.0|B"|;M;Y=|:."^Y,Z"*|S_NFIYZ#^Q7_5BYZMG4&9)_MG!*|K(\$D"
<28%QF0'),_U*D":56-S^F0NL_\$_98G73|HKU: ^|S>_#888T8_MLPB"\/|:AE/,TOCC>7
\$^3!AAZ/9#"S>@1K5|:TQX-ZV?CV0,-'\$YE^V:)|_ML5)KFFD/%5LV-&1DLYFS8@;|:7-
|8JM9|Z*/MR!YOQK81/-=:72>S4K_MZGP34WVI6!"F_Z"3G)>M|5|&|;"9*O
ML#=#3)4\$1M5,N=GGI-R90!LM1/X)CXF3U?T7F;5^!(|K^OKQ0-Z<)8P|/3XU_M+:BZ?
^U|2""-.%) +EL0G54MNP!R|<=1W-32IY7XIDSIKL'\$YDZH4"QJ?9TYBBG#%0
MXDSW/N0(*;LH2Q/08&2YI;E4ZTH!E8_74<;'K5|&YI-RUMG&JEFH|HFD|
M0V2G7L:C8ZU2+.3UI\$=,*\$ZJ/"P@_-08-J^ZMXS9!7A!%M^6J_6LH'%:J&,0_MH"2'VD9A@
AEJ*0HSA*8"DB1M.T;F>?==NI3Q01067_|52MA(XH%=5W_M|>VIM|
|H2B3)"FR&*@=6NW:I"0 (<0_HYP207-:I%;5)RSI!UZXITO9;AB*_M=ASU.PS8|>:V@)OM|
%AM_-?2
A&TWO\$=2>_.PN4NK/R_G|W7*E;_\$<|&4J&1NAJWW37'JYAN,0C+;\$HY:ZN1=E\$*S+GA1?
\$-@M))X!QVPC'B^RW<+;_6&9?*TSYXA,NGF_M.BSHX8YZX6F'(A?
EHL'G;RBK/L07|5RUS_K-) =;6C>!4B9%""Z-\$>Y3U)2!_M6K"/31Q-0|S|:Y-)|>>&_9LB
Q(6)51""_6>E;|*(74)D?6|5-3T|3AP+*(X1!P9ENM+SCLM-P8).SK_!F(
MZ*L8WQ"1:2OF&0A|5-;Y!U?Z51O*GUHKM:ZU.MQWD|9,(XA"#A@BLCFB-
MRY0#KOY>4E:F(BG'Y5,-T@|=1|BC/39|:AA',R40\$!T|O7#:\$7*<-'43|1@;
MF4%EA\$.P%*IAZE?H3*"YG(2E=DP#N>_MU(*ME:CWY.?^Z\$T\7FDE|!|+|
M|JZ>4:77H519:B),%_L#@&\$!88("83D\$F6Y53JFD%&F9PC>_A|";=AJHEO_MV6?
K)E*;1=-L>U=Q9G#P6,NK09>_J<49+SRV;B>_4!C;_M'0C'H3-
X3'0<>KK#XSC9|XZ4(X=RV_ZUJTZR/YC5:W%G91'YR:&6%E@R0\$3_M!_/M7-
59M06@ (B_S%/(%+;OB)F/DY_MU_I7_ZT>_*T1YU+%0=2P\$ "D>>D4J%4869W4KC"RT=

"LW-2R\|SLE+"E\(-:
MUW2LZ=2LI71H>M7VW1&MSNGEOKKT3%_=^AU7;^3S:/U+,9*LV:D!!")D-2
M"X"Y+JE20\$\$\$DP6F2^9J|KL5N+:M\|V>W=?CL<6X|=6YMS@-
AZI//N6\6IV|T'@CDDYW.0I'RV&_D::&N=^4HWPB^&M
CG524\WU|0_|J+++\$2H2Q\|D!,,,40)\$@@@'3\4%\$01F".DIB-|T4RELO-VX0^
MZSXHFG_9:X#R+UE\$H29,=<[Z(GGP4|=,T?U|_6+;9O##D3RAXG?#XIUR,8I
MHWF|=MTQ?S;-5SQ1LPU0JY>KRJF-I:FW|4?"YTY|^6/+A:,L:Q\$94H!PX0I MHS|F
'%\$@53_7F*80@BMBI8-4@NLD7>THX9XU%"/?E'TE7Z^&\$WF@)Z95O6& MB9UV'
F'0W"=@9C>8NR&:\$T<:F<@|G'\$GL7\3#8S_(MM?+N"DLO?U|
M4Y/L|:QZ|,H,S!*4"5:D!!1JX:N3?|X|P3@#259B1%F:<6X4,CN.C<JHB\$.
MZI:Z,MC:BGMB1|_B/M\$=:H-,V\$D-M#O<=ZCM0N9|3+4UY:/=,RVR;R=&UN+N
M=A*\$W6YSOVR_SPW250_HJA\$/_-|W3|>|HA:O?-U'G^X2>#0">|?"XT?S M7|_@G;
(QJX=%FYO\GILL2|*ZB^OF;_#_,W=F3(A/"49*P""7_*H\RLH\$Q# MLBQBR22FN; (=EVL R-
L=_%IM:5LN35>K/?Z%=TE6?,7L8|!+:WC*2*|5K4W MD9)N/7".G'0&S>S7%S
OWN\%,KZC#>-1C_/&.|OC/?A50&")TC)\|EBTFM MJP"U38J\#W)N&|*FM_L;T?|W_:
(YA7Q=SM48|=O_>M)5BW?%=6:,EK& B -9 M0*7>8RH %8D N(Q1(4H69YF54|"2?O
S0=?I_|I<-/|J&ROJL_0_HI:IZ,|^ M 2K+JP1;U,V4MH6
MR^^5KD3T|^B7KI3GK_HXIS:OYL2@#FO6\3HC@#?:|2>"T_*"L%?"<|>6_EMW M^
)QX)L!;^|VF |31E/9YR|U_&TY^1*A3R=(3M?R=-JR!'.SR>V;@(RU%_\$
MZKN898B(&)% "Z38J=7&0\$A J!2|YSA*9H:3,|&PA'G3AC7M+U^,,#
|=NHEHLNMD#* &*GUE0.,\$P9@DBL+K\$B5ED(R)FE""AP;168<#QW:H&H
M6091TSVUW M^HEKYFR\7WP2JVK)MXT@DAE**>>,\$<
85=J"H!P03!)0YGE29"S.\$433YVT< M,QI8|_C/W=!WF*T0|FUI@LVZX6'Q!QZ'Y31>*9?
C/,80*I_C!)M_MP9R.\V""R>L8H.?
LQE,:%U&LV'BP|*-7'^S?"358H9X!M7I+0G|HRWQ:\$,|^K.E;^^*&T#.V/'F|P|+U;C%
M8'>OMJ%|s|TB\Z9ZUT587%QKE\7UYT@;H#6UV^RRV"><9-8O>2I3?_N=5'-|
M9_9NN?I"YN*+8.I NJY\$K0NZS2 N2)K2%, R)0"R' &4I P4)1Y:VOP"YF?
X("3MX=8:PR|&(&XO MA&^&1*BR^!>H7|= (OADT%TOF&PYC|H5_O?PBYD(G-
OPN2\VT\$A_)H|\$UU=F7 M
VL0;=&1A3I*=)2CCG2D:9O|T_+/:P)O(ALM|;=I+7RX0|*Y.3#/SWB9#|
M08'Z/OSA:UV2>?2AXM7E<|>KPW/'|HAQ6|=/C^TA1'09-&|OJN\5%XO-|4Z
ME#2#S'+&*")/KJ60*1HER4F>)-TKJGHU*2Z5(L/B.CD;<3N MRB'JR743;22+-
J)M7E2_ ^Z3S:~20-IDSDWXQ!A?T+ _8|<+B0^O|_@>-/P";A
MZJ5^"FX.D_NO(M)%4Q^;_ARDR?-N*KEU'-71-YVFU7P0RK*F(OI&*JY_|((E MI
<.Z1,330OUM_JO|MLW3=?2+V'P3)P;|_5I^5S_K-Y<-%O|#6>YB|?BW|0=4 M1PU-|B_1)
(LMM=N|X8X*1IYJSC^/BH>_.<|H?'_H'|Z7_|M\|R_J#^UA^%_?|A!4\$L#!!0 (-/6*
M)EG"E7|;X8!_.)\$@ 5-8W1L="TR,#(T,#8S,%|P&ULW+U;YX6!2T+F-\$5J2,IESZ_?B45=
M*(F22"XL+:B|HB62HA<2F1\2F8E\$YK_|CQ|GLU^^PW(U7,O;Q?QX@SFZU_>+,&O(?WR
MYW3|H9?U_ CE/O;+OT^ _^U|^S?PZ+Y9GA/O;|_>+Y_+J>GW|;_<,KEU=>N
M_KK\9ZV3#%Y3PIAV1\$?:B.>9\$ZFTC\$9Z(W/^_T|_F461&66<6&,%D=D8@O|J
M\$0"ZHS_L>|A|ZF|_<_D1_ I^P>G-5|W;?_WUVW|_L^_?;GGW_ ^Y4=8 MSOZR6)
|^QBD5OUU|^|?+K_ ^X|_T_1?=MYIS|K?OK|5=7TUU?Q,>RW_|W|Q^_
MQ&|PYLETOEK|>2P#K*;_O.H^_+B(?MUQ_4FZ?GGP&^4=N?H:*1\19)%@?_FQ
M2K_ ^VS_|LN&""^-"LB62RO_N7, M!YAUGTI*Q"97HUW|?
K5CU%=AM5|ZN)YX1;7E+!,I=212>TM"RI(X1\$;,,H1D
MW5/,.WC4#4L4I"8QF8JB0%I>E5=' L5|Q?%Y3=^_ =+?!")WZ:S=/6O\W)Q|APB72|J<'8C-
IS.K|@5S(LEY ^M;J3VX.2|F;|1H4/WS1J|>#6?7_C99SA?+-
<3)71*V6L2R&\$OWR\$',W1I#R=>GGJVEAR>4<3*0&LG.X5T?%292G
#U(6T/O!1OUCP*;8WD^,G!>X0Q2-XN9/YT81V., M*1&M72#2Q\$B"0%;0Q
\$W74B&L5Y@N37<7@#1+Q<@O_.V\$6VRP?2|>7KKUS!A
M4267.">),;2|8E0DAS@)*&Y4-J|BS%4TR:UA|P*)>;D@Z<_KD<&R8H?
Q1|=MQ|HZX%T3LRX5(+PXW@8X/ M|A8HAG>|>,+R@;>+"|FZ^7/-
XL\$\$_|V""UIXRPH/P1":+8&?>|M F>)6(O#+F7CJ%Z#S@@/\$_E=@^,GB* MUGRU!-
_1G8\$ZRZPDS#)))&A'G!"9H\$.9T=/GH>9&^/MA|_7G H^&C6C@R)
MDFLS^_1M;|^+&\$075:9>\$^\$HTDXS\$.<-NH "IQ&3H2KULWOOCK@?-%YP\$+@7
MBT>&Q|>E+PEO7WZ>A<5L\$FB4TH5(7(P!32T0Q*,S1UB.7G"9D00|#@=N#;/HJBD1B;
)O7Z62|9B\$,1\$!6A;698 MJF!^W!YU/XR|^,AO#U8W 94WR)ZEGWV8)_CQO^#G)'N%
_,^|J* \$D4D"L:C\ M2,I1.,=# -M/D>P<=C^PO/@0;Q|FCVV@7BR7M|(PKDI#A(L;-)

!,%+8%H@ M1THVAN!;!CQ=3^KY*1|NO>|&AW"HL;T+)_
2,90|K00AS_@7|"JVM|&&U MND!S*WF(J&YY5U"HC,2\$#R"<|956=0/+I^CLZCP^|H!
M-CF#Q3I#85VL)IP)2Q4NA\$RS(3*6U)Y@\$S\$*=|HDK9?0+|GWL='WP|"+C^U6
M8'T3\$/KWQ>P"Y;/L#NR7JXGUD65A%!EH|N-|CCGBZ6/R?!&4E%<\$3K4(PUDTB@G!&1-
Y%,7 |4ZQV M#+H?4EY|/9X1C>|DW=GL#Q%K?C7Y>+|/;W+Z#9P|@U-^2N44|Q-*964
M@.TO93T)84|D.P0|B8K%J%&%LSVF/NAY 6'?7NRN0F0(.%G)7|P\$?_^Y1OR
M=75RL2X7N4L|>Y)1_^&HBLA@.9\$LE*!,D,O&>,2B=%J M8F@ "5!_F^#1DR00|O/5K?
^D.3J2"H)).N+5FY%,TN,EFAN9::<
M1*R|P*AQ63/;+W/J|HC|0>0%!X5|L7A\$>%RLR*GWYY-'-U8C%!7E/,32((FF
MEN(T/"8EZ\NTA2_16JJAM5&4-WUT!!80%K17K.RG.JK4#Q%Y)&B04DJN\$_|SJD>
M'GL_" +W@6'\$EMC=A)G^Z"+-I?#|;^/7\$215%,I:8G)%X+TP)0&6B<\$8"(L_<
MJPJV|=0^T'EQ0>+CV5R-83|RV_W&/P1/SBF%LL>IZEF5 MK
CRK269:9B8842FA0VPA\$&O1FTE:> J(%<7|F7EW1^Q5EF'S
MK,ZVSI(I:Q(CG"M64C&0<.:94*9=H#\$G2Z\$&X?MGU-5>WKWE=:OJPI&L&|L0
MQ^7|+ZL?3DSRP5+474J|A".S-VC0<\$:.84M1KG450_>
(>=P8&&Z|8;Q:SU6(V3:6;:'=9K5@|JT4^.:8?-S?W5,70X'D_M0:L?2GG/??|*/2QE M#
<|@>L!K(U!R*%E#&<4? JI_X=&X|VZ)J&=|0|L0#@.:|Z Z3TC4A|AN|P MOX#51"E?
@B:1:(A)"*<."L2B598A>0%1/.8%7/,E*|&'L6\$,3<='AMBZSLN.O40-
>/8%\$,BIA+G&|&#07Y>+U>K3Z9=,;:(- M R+ XZ>>|?:HO7\$,;+:&'|?^&!
(EQ_+V>%@L<">N HLO.)N5;">8XXX|0XR_M2F?3>7?|J|P/OOMOQ#0,53'2*&7B
%2;B#@07:7UA'I4A,?/3(Y!S'Z4 MC5.K=\$@P#2"1!M3/V^GJ?+'R,UPJ%^=+_+<
;X/B|FZRENQ^G:6ORKG|X_XE(Z MF5|J?1*XTMP'5|K#H)8%)DB0\$@U|SO"7XLP|6BOL&.<
=2>HXY4^'1.)SR.QP M;+H--.=P6KR.K|40>K+^!LNRWY,*JMC\$|UFC'-
'O'O&S#!NFPL6*TW,|@\$_Q^PG@C/
MLHV>\$B5|1"|5>_0U0B1*&DI|J/+_ZN&,W;2,4W)U2.!4X7K?W:L*?OY8S!>W
M5|&5C2@U>*U,(%DY0Z24F3B4.&\$A6\$@J:YEJ6^T/\$C-.P=4A\$52|PWL5S>J
M|STR|LW&Q,-)W41Q7T->+&'SO: _^!ZS>_4#^H="F<|_V<7RD10%.\$329AT_M-
JMK(AD\$Z70BR.2N7|B5FI*DLLQ>1GCXS?
S2#&S#R/_GE>AJGYYVU<)>DO/875VQ+7FX8+M 71|?W;/-V|?^>7<_SN MJLSVM5|<
X|0YY@,7@C@'F<@('R9|&F1XM%C?,9BJ0/9(Q6:'1.)S M"|.=(-FM-?
CJNY_B=V;P=;&5L/UM,4.17LY266M1?S-BN44M|I(B07)*+'7< M.I&A79(-?
@TB2,5LWTV15E92_VHTJNU|_F6W>6_S20,U5Q&IXC7"=|>8!%Y M!&6-FU)H@P9
O|TRTG82,E+MVR'QU)_A#1CW=R?Q=CHKBGG"(O#DRQ5|GR21
M;'OF>:DE+)>RG)?>U8Z1/\$#*2*5QGG,YQS"|>R4_(|_H/9A|_S/UT6|G0F
M*)/!RRPU|1P|D12=%+5_MC^EJ|I*A2XJ&GM*N1.*"*(F.G&0FM19,9("H(C;,\$&W|U
YL'!&T'-\$9)< MU&3KV+BXL|MO|4YQ&F>0GJ|./3^82Y4-
+0+\$E)XWX)UHL6X=&:NKUVH+O\$C)NH7D&MU&5W |C9IO|2^31H9(RVQ,221NA*
M)K6%3)0'%A.-E.K;)LM|*AK9@/J)|^ZEAGZ|;@ MUWOY|U|7F|)HYXMY|3HZ
MWN3(+)= "\$%2WEDB&/QR4|L.DA0;*|7^U*|8|2M"X%QZ&T#;|V=X AN|,X7(A
M!&9+85=(!)0;Y,(\$= &R(|\$+)|P6+6?#JGJ>_H.|&'MS?43H M=&5)7KTY^?
JOHNSBUF)>%SEO_NEW^'=5EB-P>"OT/7_2QXSZ-&/|)U|UW5
MB"1\$)0C3+!GA39;L#J;N1W6.&WI<%%60|>+9&-^1MJ:W%O(TSFDRV283S,<
M7|U*_WFO6I=*>3,|W**|D)U2:|@29\$F|T+=%6BK.6FL?:V|QA%(YK9==#WS/(
MIP'T7>O|C|?E&;S58'WT!-#;1-3)^5;:'/4W)>|UD|7NB|ZD8|X;?;\$-;3 M<0QN
"*7EW1VAO7_@/5)_NI_?(>E=)'P|R7X%;R%S>_KP&H\$:Y26_OT6SY&! MWL<
_R7:^(3K)&A*:^=2|J>Z\$6/L2-SLOFGU7\$)L +;:F|G=^:%#SK <@0@I M'9&XF-
%T#8;0X'@PU#*1'VM%>%0*W?7HX|+HN>5^_V?N."\$T)'&/=^L83I
MZ7Q3030^+_I\$0Z_4UD:1SE/W;K81|+5Q<,7J4FV;6:TD|4QX(L0-1FNT*"D1 MC*/E;|6M?
B-PD)E;:'^-.#L&P-'X\$OE4/NBFW'WKTP*Y#NOILMO2=AO0UVR@ MP"-
+L53YI:YDE@!'P45|HFZUR3Q3J&V #C25<6.#2^2YX)'SG4CW'C.EL7 M=
<<7OQW2V#%|QERR%%T0&P,JB=+EU|G,B-4Z92.X|NHY;>E#;:_7J6MX.0P&
M@+'#IB=O/KR%L-
ZZ+8\$,_MZ5M,&U_S|AG<)51-15QC%OIELV2YQL2\$+1RY=\$0K@,KX>F(+H;A|6Q^,%*DD*
MFLW(\$|A3#M56PT"9|;|L.@P10GP#6/?H;_|L*K9|H_063|O_OUTCH--0Q= MK.GMWAD(-
P|E*FIPNO3.X"7Y)Q"G+5=6&6Y|H:MS^|/5^SAUM4*VWBPVYH!%
M\$XDSR1(I'2,A9DDXQ& M|ZNJHY|=I|J"14X1:2+AW.GH|NQLP|3;47W9"O)Z\$
MADX\$BJJ0=UUE'"CB5"J"?D5VF8+PK';A:2E%#2 |\$YE2J&)|I @J"3&>^"HI5I!|1)6>Y
U|LE!?!135ED0#X-J5-MD3L)UE%&NXJJ-I>BX)+8DCFG?;:1,,N3J>UD|J)CW:|J??

CTYG4#>+D-JB2<MLDQYDDO;#*EP!H\$5'T/CQP\$M^:QJH>|?:YQ ^<#F#-
'<|>!H/>G92FQN_Y9 M,@ "ZTO!HX9!?
GH%.4D8/U%" +CFCIXA19N1JK4\$NFX+D% E9.N'<% ^C)YQPI%# M|\$R5>-
!\$>E1(:0G(P)V+8'VH705D!QDM^\$J5 M@CM|6=S 5G15=FB2D=QRF9^\$G(N?
%R3B.WAB>0P0O#?@:D>+K|9N(\$VXCQ ? M*.1T\$\$<;0,('Y/G|=
(J&U889J/3> _;@|5|N>4S'*N0N.0.;(&"/*53.<&-|
M>"\$#T|5K&NQ#5P,9N1415%T2#:#K|>6PU|6OKZ GRW.E/A2^,>L@< KTB.K+13UIQ8
M*1CA)J= F2QME8>S9VX(:2"|LR)J^O.Z!001/,@QC9@!_|<>K#+=,;)(YZG|1+0FV02-QD
&7P4 MN\$;|*F7);2J-3"40+H;;9CWL78+|7UI:Z1HTU#Y\$X.(J'-LS6ON|\$)P<\$%
MD0))H,HBRI3@PM1\$0\$DYRY*Q5'N_>IB:<=VN8:3_,3ZB*(!4)4T|*N0IC<,
MS;5BM7E>DLJAA+<2DLZC8H:%0GUU@SD<= /K|'+#D)=%|AO)Q|&T &5>G|Y_|
MSW(JHB;)|1>,|I89KB;")/Q#;,"4.=FUF(OM!|+J,^2-&X-O5 4*HH MA 8@M6,&
H"72O6\$>|4Y'Y18&|!ST-&KY+0RK09V=21T!O/0!X).3V:WX*8M MYJ=?
87E6|M\NI_%|6AY=+HVMS96G!&CQ?-%K M(5:|1#+C\$)!?2>K:J=(/4S-NSN*S(*N2*!H
56FR..UJ'JRZ'C.EG_8IS&/) MRZ0R>R=,(L#0@Y%"<&(9-
22)1!UJ9'!Y@"O7#Y\$S;J+CL"JEC :P-46OR9> ML6QD B+*E7')<\$.W 23)*G\$+Y<
Z|HKV_|WPX^8Y/G>@_"|F-^!|"?H6S||72 M+W|>UC^ ^O 7WZJP\$Z&Y7 OCD-
RG!D"E(K0BN!X:|=M2X?S-&3/+64HA,^-! M?@<3N1?F|(O&W+""T"#;4?
|H|!KEY=K+|MEM/_AC2A43#N-2742?1.@C#\$
MIHA3,>@PO|B4\$K5CJX^0LOQ?:W(M&6RUAM(6K|H|OR<5ZM?;SDAXXL4KY+#TC
MX*!S9))JN"2 MY+@NRMV*S- PB Q?26 Z2*ZTC/D|1?O!ZV2D,%672 ,)>I=0E\$/G9)S|-
M'^:7T>2M-33)5ED/7) (Q?U%#4R|)|\$DK7193IE#|>.BIZG:#VDO.|!638-
MH.TSK'T)&5|U9;_3SR1.T:0T@H%ER*%(T2D&9U!#HUT)R<5LFF)IZG: M#VTO.YI?638-
H&UK!GN58|1!.I8L)ZS4<98L4>*CP>DYZM >U338VD&-TG< M#X(F: ^N|'#"A>2=-
^R'K98?Y MJ|KE114WW40"O\%Z&OWL|@QZ5CJ|_>3ARIX^,H/GK(\$;7!*E)|M7B4B5;FY
MH4TFV8#PR@\$#7K08T7/40-WR5I#1)|MNS-2YS9|@V47^)|HBRBO'&LOYB_.W
MFCAA*"9-5\$4P#MM5C(>404Y(F>72-R|6H M^/^Y-
LDK8ZB6(%C'U8;6ZP&EHFR5/&8B2JESW M+TU/K 62F+91",IR|9+5#Y#22'/W9\2\$0)H
\$>WP|8/EP9N/&4&Z*M14Y% MZX A3)8\$-
K'<17&2R=OAK\H:;8(|%,H&\$|SH+NGBAT#;PWE):<\$?Z G3!P5 MLB0@19Y#HCS5/O-
^G*)Q|PR?&62|Q-\$HN+9/PH"ITF,UD9@,17_:I5*? E|E M':V*EM'JI>N?
(&GDLPTBY.:|P)J+B)35D@.WEV M'6;BC<%%J+T7GX. M:|W@60Z6A3@.KH X01
.8VK7U7\Z\$B=*,M52'4KPT)LZ4>,BF5%X&E;623M2O M4?P0-
2/G'XYB@ATAAP80|6HV6_Q9#DG>+Y90%Q=AG2JF|_N27#IU_PXB<.3\$Q,%Q-
YRT&H#B3CV|H=@HR-9+=&>0 M9V@:,Z("Z7: DO1)19!F?@0|_#|SU'J7H0?
LS,ZA^*/Y*486Q63 4@G)=(A1*Y%/CGQ 00P05/ M<_6F+7L1UC|-
|'0KT4Q3P(\$QFW0N#Q*: :8+:\$_ 1EAF3C(=':C:1MIM"iHY M|*Z\$A?NI7T?
SNX\$=|)KZRYMY"U2^| ^Y.|8_I:L)#T)F6_A>2.R(%5\2BM(D3
M6@;|LM*|JM'VHP0U@J4C)/T0:'JS00\$,W9G#V\69G\XGRDJMN'6\$)XZ^B,V:
M!:HX23PJF7PY8*V=|R3D\$8PTU_0B|H<;P Z6T?PO|-9@.4D(9V92DJXTKBT
MK)+\$YJA)%CQ\$D0*ZL|6/J>|1,2YD*@CVX42'(|C<\$P>N*|T.1D:@S'@2G^,M6
K@:T<|2X+('\$H&+1EU0N_/T;0N"E8|>%3C_L-0.GN9:3+603C.&IC0\$U< M=G072B|?
+XB-8\$,(E.E0^ ^AE-R7CYES5!T|?%C> FCVN#EU.S+O,>\$3-ZFGL M:M%Q?
%5JT6ECLJ,RLUR|-?K>Q(V;:36
8AI\$*B/";;5<3|YLIH0S>))QN\$Z8V#Z'+Q>>YXDNM2|H*0&2)B"U* WD/7\$V,D*E<,Y:
MK;W8ZQ2EK|:Z0U>|@#L&\$X=HLSX":L :NU;Z'|&R_ (O<752BP9#|L0KX7"# M5Y0\$-
"!*O3!*E9&1T?HWG>|2T,8W!\$T|L;EKKE;V'S^|A?OC_MV(V>|H8_NF7:
<+0U&1:L<0#B2QD3CFD8BX MU_=T./\$T@+|H|D\$);|JZ?EHL.YG=*GI82@(OYFND
HX^F&E.!,J/4DT))J% M(9%I7,*^9!ZZD(C6ED:6LTJ|_O%+#J@X'JR|./@DCX:W^>=&8
K>;D>M".6=%SXQ/G;BP\O4"=(YV5I1HD>MS0.|1\$)2M<.@3Q_RKB^Z;@X/%P6K2C:
M35KCVXME640=9KNL_S_@S^XOJPG:-<9'#B1"Z;W%J=4EL^ ^W%>#6E6L#(+X)D*Z^
M+AY(?^@VE8!<3^78\$>;K3NR? ;F^FJYQ\LOOTP@;+GV&N#B==T_I&#:Q-%!:. M%9!
<>DA)"PYWG90)|CQ9,S|=
MQ7I=?/4 _F.Z_E:8CXH"6=YQX_5=;DQ2HH&#QUTM0&D_PTK-DX"^JA8J9YXH
ML|63;HZE==R+T,^)|F>1YN&H=104SN&TH^KY5?V|"6^;:T|N|(F,5H&AOIP<
M(XM\$N1EG)2/"^TPM<-O-(W?;VKCWN5N40\$_(U8:T|O|H^G">9I=>>.'^8?IW"!;H9??
2O7#7&&R|WV(Y,4-\$M!># 6|R#.VCV&MR)..F5@5>;ELZ%\$6,A"O@0MTAW-
R|;O>C#'3D6^J-VD9C >E!@R%X^VG=V?G ML|5/V(1(UTLXS?|QJ?

EXG3ISYFF\$PJ0,U,JHJ2 1E66@/94\$(098X6/P %3B)X)ABD1)I2NM?5XZ\N A\$!^&%JH\$V
TLBSSM5; M+=PB8.0V0\H^,9WX!"VJOU%H"7,J('X47I<.E \$LM!H;>JC%0153#40@>5>
MKTO:A1Y7W4Q-0"/2LF:98\7@7DB(*1/B3B9'(D@^#,L-"K@W.YTS+_8XDFNS2*\$!':
;9A^)&ZDM\K'+O\1F%UP\4\5S58VR\IC*Z75 MQED)I+"X\ S3Q-LH258N4):-
BZKV,=AC\#1R=|L.S*HQO@\$0/12(Z#Z_CD1H M\$YQ6Z)DI 5W?(4VL<(:
X3,)N>=H):36STAK-H"&.N),O@9'Q\$>|0HSD6TT3#Q9#WN_8=KI%5= MA@,Q-
W:AQ^CEG7?J&:RHVVOCW/H2JH\QIXA.+O3\|_6>O\Q\2\5TP0FX A MRKU LTI(\$A5
9BP%D6JW>ABC'KS+B<:,-B-P\$M9&(E^#_>\$_.AFUU@ETJ)V/M^?+JP1^"A2?JP1_-
|P:LK1DQ<9-5+(82CP M-%\B!)^U0/_A"V-
X"AW84^-7/:2L6)JB:B6>@R\5P'8H%9(:DKV|U%I=.U|U(NK!
M'R38)^O!\+E!F"RPTEQVD:&T\|(+!Z\$ MB)X%+13P/H>S0 RYS*'"R0*
(IW834COK3(Y(&FQ+GW-2NC\8\|MW,3::# M@'!
(6/P0J:15@N^A\Z2;O!"N:92&,6)%*N7OT;/U*2+3K# !+4Z.&\5S'OH= MEM#3S
VA/M@;0%(-Z+DC"FX)HP \$-;BP=#\$URUR92H11%|0&|B74|H\X2,FT M9J\1#(:+_A)L':-
|G+D+C?9,T(0'P-ER&TEI94P<=;X4AT-KYFE*4M5,F&CF M.LU@V*TKV09P_*CU0GU.-
D=#A+0E\|G\$B0X(J4UZ.C)!-5|H/6V*9NYBS.8 M37F(5*JFCPIHKEE.|?
SJV_09XL\5M3/+6P|=YCSR8;KKGS5>#W1\K\2\$C\$E# M(*;+-(0@2WIV(@
J.Z.IPX^'.V*\1T^%^W_EF9^6BW*K;,W^>=5*1+Q 77M M:EUR+N-Z^KU3M=
<OYNEWOR|; <^3_+M? AVZS-|M\$R |D2*@TH^1RM*& M4)-@T.D'GU*4"?
55\4L%|Q,Y+AR'1LW=ZG.#BK %C%Z6U_NZ>|71\$%G"J^|^ M.BMS*I7U_/:4WD)83PQ-
/FE":@2\$")\$VN8*07!G%2)!:=K'YL>2.*X,9SG MQN> XFL\G7>6WTG&3|#
7AL%6G6N\J+|7Q^UMV;0.!\\$3RTQ*L"FRY1CCA)# M!8\B4J@?5#R O'\$C.-
KS5IB&SL\HPNLUL.-,32_F=N7B\'.|JE?%O7/%>!/ M*(N32"5|%'D7C/6\$;8&:@E*:6?64-
|+G6.,&5IX)4D/PO3"%|G;:L0RM"IS4 MU570#_-;#N/V5*GSUD>-
*\8Q|. *Y"L0IDT@4"AG(O!*|=JF<'N2.&WH94?-\$ M*=9VBN|<,T!>7ZRF|"
M6L.2AQAK7_HDJAQ&Q>,C<)>(FIA8|H(>1DNBA,@U>XMG!'"*5D8W'Q1!/1
M!:) \$FN9)3D\$B);'*\$SMBQU/\$C5N.X&Q,==+1.VHN_W9.\$G:"XKKAR03(RXJ
M'W\$|412*?,N=52)U|;@_M2-6\#_F<\$XD-".UX2+M9|-"@BE 7AMKY-
2P/|ZF2BD)U\$=D"F^M&_#_VC-.J(5-;9?KB=3)G&U5MXL5N@PB8P^\$LN1"/0'
6=;*EBA@% MR1MMLZY^6^D1|/?2IV=1.U-|")3Q9-2|\$Y MNO06|W|D)L^(Q,;53RJ>
(JK)XXGGM+)S%D8P6U!/11*MUJ MR\69D(B/+G+.,MHBM8N)'4ABDV<;SZ%/:XNO
>VZ/SN)V<=VUQ=S+2&*DU6\$F\$S!9M M:*)+RLN&2USYEX'5=OD/S*1DIA/I.16RUQ-:
@<6IYNNZ:PH%0QC(M".AR M|R!HB4O)HN\$7163<|W-JUCF-X 7&YU4"TM3E\$?S^!6
M<|&OBT-9R;@)0H\$D1D+7RC(0GQ*N58F3MU)\$J)Y2.,0\FCR3&PK"HP.A@<7P
M%G#D..U\$C*|GT,EZGEZ=E79Q_ |WQZJSG7KJ2+|.=T-OMP=NZGRZX.7|?M?!)9R
D6@Q MAX3V4\$E1\$S2XF' JD=.^FK*;DG'U97,0K""N\|D#W?K&\$Z>G\|S06./8_|OR|/M?
(6<0:'^U4_G94:O(>-W2M>/) \$K3#X|.FHR22 V:6)H82;B|@|@0T?5CMI(<#
MR\O7I6D.GD.)=OO(9G=|<501HH_C^5T#2PXX;IY\$,R@<3\$8-
J,RK|7,R+W=F5R=Y<|.A6!_E MQ|0B =><\$W0>BS'B*0G.
Q\$B2V'1>D^TMMX|E,9QLRZ:@>VS MB+@!'+"^=KLX7*S_|ZW)Q%CEQ
)D%&BWL0FNTV.TDR,!V,"%E4S^4|B;!O\T7:@_)@PFU! M,<-R^MV7:Y-
;B_'Z,^3Z);:4?/\$O?:* QA):3%|JA+8Z%PO\PA^UCSV?)&K< M?)\$&\$5I3B.VHU0?
R8!BW18|V(L(9M'U4B7AXY)P2.BL1+41;O=W<|6E+@R6" M- ?
#"N)J0"/>+ _3|H*0#5^_^A|H?UL:LW34\$% E>X%G2APX00Q(EORGTC%5 M&8-
|39R'DASF*POS?'5XU4?W._34HG|_6+YVG>&2#%(RIWS.?ZSGQ-)7;#;
M14+!*B*+\$6T|+D P(6JH4.>G.VDA#S<8?G2D_2#WCW|45%\L36K#;|:|>?3
MM9|=|R#|=JCI<6:YN|F+*F'9 F-2DO!+1.L=A._:EK|M+B4&?O PFM23B^
MBG%QT6531T"#MS2ILU)+YY%U5D&I_%(6KZ>4<.1G"CIZ|+7+V^Y#5VLJL>I@
MXDGH|130^-OMPU.|TNHESU28Z*.2F>18JJM9&XB+6A,;<"/)TC*E:SLECQ+4
M6A>L9T+;L2)I&697*^B3_|E9/A|72&:..-3Z20NB5/1\$9714E4Y2!N&;RMY
MAZC6FELJLW(|1C1;J?=08Z|S"L1)&UR-L%E=-M3,;)7AH24*\$E9EK|VR2HW
M_*;Z\$'6MM:=Z)O15\$58|FF|_*QDG&,8JDF*)9YIHB2>6>2CYCZB*2&<=971
MN#|UK36J&@2-PFK@2LX|W*&N#|D|W|\$;WY^"T1Y2?S,MGR_U+T_GO7%@HM
M6N3C-)9SH5)G=YYN?| #US8G*.C+A\$Z&,H<6+GAQQ@B,?P\$ TG"?@M;?L :8Q MKIH=
|!+/V)OP!#H-JF0M @Z(-^M8&CU9\$M"T((:I2G@4I&:JL&P^X, 4| M&(Z?
3X@O';&:G|H=|HXNRA7|+<5P48Y3)B44>@82?:1E3TL\$F|00M1"S M8::V>_^|,QPW?ZG-
-3\$L3!HP=2X9<&?:K|"R6RY_X@S_W<|N8,*U22 4N@^<
MJG(\$DHBETA%GO1"E"EX.M3-|B)LW#RE02%;5R@|V\#B3)?KY\2;I8\$*!|L

M*H7(@F3\$Z5*AVH:A0S&A2',B3IX&RSK:&R'2"4JFV'^Z&ML.F/Q3SBRYMR
MH/.THU)\$R5"=+5872|@J4>\$.S4+A&E/E/I_4Z+BF1)B5\$F+6*.O:E17ZTCQN
M2M* @&'TV439@W3|0A;Y;BD\|VH>|_VRE14RHS(A\$R !:&D93B4ZHY")<|IP
M*X*3LO8&7G4"XYZG)JOVI#ZV16FASS M8GFV(> *KI8|A|P("-=<,N:3(<%12F1BE@?
AE#:U+^GL2=K(*;Z#V7A#2*;! MY7O5-?23GZ:R +/ORLO:0FU&OSU)3_
%)2P;KH\$KI47MZN=W2!C7G:H\$S/>.MRH_G>1.0N4Y-OYY!25%GVN-.JH&+EKUK,MIQ?
G&|#.Y1G_NQ_G,\$|=X^(53JH4Y4BO+|:XK_X?Z)9%*5:\$.)'C"E)F!X=M@F T)I
IJ\$LP1AE5OF|HO;2,7BWP&G TBI0;0UQVE7,1UYZKB&UA^ATWC|U1*
M7"\NNJ01/J%,JW)-EK:"=PYTNE+\$\,<+ ">^;AY|>.T/4D;^3;+8-;5\$))IM
'#E@LUB^1GP^7Y^6?KE W)PI0GEJTT9F"Y+|M,"IP_KZ;)C|M5U|LMB&L:E
MDI%NB(K9EYK5I4E8*=ZFP\$D>T4L,0US(I TOW?E:|>5TLGUVF#>#X=BKG32#E
MBK/7S)XDKX60'(@,A(IT'?W91<2/BHJDD#Z:Z<^|DW66>AY%.-=C|
MRV_W^/T1/^C^U/VE_*O/D\IO_V^M1 M?IZ^7)R=^>7/1?XR/9U/AS3Z^?HR5%-"THO9-
):|UUS6DW/T(RZC<3|-TOI_MC??;S0S0SOURV%OP&G*V|&.-
EARD7WN63|XWS\$VR;E8JH+ G*/W(2-"TC<
MHKG05+'@\$X/X>N'J>FK|CK&G|QB/&KU1_G|%5G|>E::1DG(FH(2N))+9W?-
M#+ '@-4%#F:%'+P"J|R)/O2.7\$FW#J+N:L1G\$V"+2O(S?(?Y!93+YCC?KA+(M\$:IOQU-Z*
J2G**NDINX/2;&F:X8TG+N!68YQ*TJ4(NGJV|F/T|+;6|C_|MYH#|ME:<1>
4Q)TIJ34N\$5OUSL"+\$NEE8@^U.YWNA|EXZJ=:DBY9P/5%TN+
M"N>JHOPQ2N;ZW_96++NIJ*1,KA|>5>I9^_EIR:/E.#=D/NV?A'/(J@(
M+-6^R/@(.>,JEN%0\U#KA|X2:5&|O(4|16L0/DZ_(S&+^6GW8L/&8U3.H|_K
MK8;VH:G:NJJB;WOQIJ5(:;7"/=8.D^PH)*(DE!"54ERR%F1|BCZ-0S .2. M|4ZSHAW^+
5E,>6#I;-CO+,@G@0 M">4J\$LF-("Y)5A*
(C,F>6R,'S7#8D\ZQ(T)#X.O1U(XM9'I!.56<")2>TI< M#H@59RR@NN10/>2ZFY(:&66I-
@1I.(- @42O.9')1>+*)2+E)'. "@6%QV_DV_MLF=7D/^NA*^+&|1_|SSRWE9AY_*ZD3F'J-
A|CVCMPYYG*I*6N+N(-6<&:'=U,+GUVG_M/?3-8F.24Q\$C)4D'*#W/-
;\$@!/H(D0G&0XZIJGES M'WK'-IN>!Y,/JP8;6,(MJM/W?KKL2F7|#K|,K*B@FWD>I42?
>F1OU7D0S944 MYO686P/=G!X\$SF70M-1L,+A3.T8"6\$>,0@-
<9|QH5;J|S!^CIW<#^AW/OD&| M%1%2Y2@<956-5S<:Q9?30@MJIWM?FQ'
M)A|H=SZJ),':FD.JZ?OV/?8M&!TN6TT2\$N9/2<>.8%R0EM<158,JIV|^9'
MR*EV*W_73ID,R,09\$&>LQ!6A/?\$6;_G'S35Z)#)4+R|T&#VC|QJJ@HD';^?W ME4
#|S:/SL49YG7QACDM!9EIUX|0%"5K)(&0_4 '5Z>0%/P|BJP<5/P&I?
MW=Y|#7/(T_6GF3|NF_F))_8/FAU <27-NMU\$M3LWNAIYQZJRRD0M()#HBE|@ M\$*,
IW|7RZ+W?2SGL|1%|2.%,Z|Y|L> DR0236)%Q'
MW"?512T.EN.I77D&H<#8>VN|G|62;9H\$|;*NNN?Z,JIBO'BI*(I_KY,WKEW
M&%M:EAZE P|=H|J6|'6K2GJR*Y'Y;3'#%;+;\$%2JQ^W,Q |I9X|(Y=YK(M&!
M*87_+,DJ2.\$D^%2|HMW>Q/4^C.@>?A,R\$BPX(RGA%A*17@?
B+#C"KZP^/R8_=|=H5LV6-F4>L\$ _/BB|@H M1-2<")U2Z?
OMB=69\$UP47BACC32UHZAU%?)M%FZ=\$6A%I9>!9,I*S|1G^|/?I63C=-AN/63+SBCDA-
_;&4&Q*3 QV- M|!KE|J2?+(9|;/A||=%=^?3=0-1(|J=PRKTLUG4?FYUS(BIJ\$O/6>2-P+
MB"MA=)_!>1HE4%Z|/F|-(Z;=C|B=@<59HO|>N>I7%TD*)P^*M-UQU-Z|^9/
M459I(|!D5|)=(-F#0'\$ZQ1Q|N&8*#:\$BN9)M9&D0U:@UM|EFN6;'R0HBK5 M*J^?
WKV|&*7E|QIY"GC"@+#+\$-ZB=/X0_5 A>Y=!!I5,|7H)!Q\$X|B9;\$3L| MRU8.
(J86M=#'TISSN%L|FW_9_W;.#@HJ:9C-HZ|1P3-0JF4B(F3T+FF7DR>+
M)QC1(PJ|>HM\$F|3T%>#;)YVDC_":@6|@_4@%7.6\$L9+TJ,50'#7E8A^'M"3 MUEQ5-
I:?)&I<3=\$# WJZA3FQQ8Z?NQQ MO3>>O6FMEYIR=ZK.^/M2!B@.GBF2|SC08'(E,I05
2-,^!HYLE|0#)*?L3 MV+OERCZ#;6E6FT %R@@OIV02G;|+IS2DGMPZ.^EVE5"#Z-
PI%24@;|UKPG+ M<')K4:%|@=,RUZU6-L?HL1U/Z:V^GJ*L5J+(9IC/<+Y8=G7|KT D1
101A/(M\$D\$4529.*DZX\ZF?N=/049%\$:8BB*^SZ"EY)0DDVC
M1ELO@A,54^#>9JLD;02U<#&O4!@96\$TJ56VNF6|HK-B"7|Y|M!;S>SQV/YZ
MYU#::|4NWAKK,AZ|ZX*-5MD'|02AWALB5=#\$TIP)#=R:@ :TC;7=EOTHJ|F#
M=7O\$G9>!(N0N.&\$*8Y<|%:B'R%-=A)7!B7C*E|L^(0^D;N;5P?28^U9:TJ MK#:U65C!?
UW@9^^^PU4?XN/TUZX'5=!83|)7RUBZ,|)-%F&DGEKSF
M:'\$GPTA0)LMDN4ZN=ESN(5KZZZ';S|U*|*.:A;=:\$6D"|OI>&9(T CNY
M'"34KE+R(#%CM^NM@(/I,J4&XUM4(TZ2HW51ZN-?EIC|=5R7 A?CMR5DQ|=
M^NR(S6"(XI9*CKNDK9Z_.%Q?K;L>QZ;YR=T6*" SBRQS\$FF():://@?U"3?M MD+-
DUB2H'8':B|!F.V4=@I&GC,#^(FG@N.6R_=<=EMV;E6)!."8I 1LDD9I' M8J-
0!!RCVE)FDJYM*^Q'V;A', ,A:0"A- "UOZW@)+|;K:;?HD;-JPA.PS%PD MW)=.4<9&XH471.

<<<9EX*[V8<)M"L9M3CX0='HPN0&(?(8X\ZM59UIT-5\$G M-JM E6*':@NE-
/LDT6:1091R< 6K;|A8B^@R!<&E'ZL;@ K|Q=+0#/T
M32F0/\$>UN/3S%3*E:PHU3|W;V69F|H9H@0X(99Y\$KM UX<@[GX,F#G |Q,"H
M\$;6S^(XF=B_LJ1>&O><170,8+6VERXDD_BKYP| | + ^O>I*A)(?A2D|ME-!F#
M<<29<@U1>RYU=H:RVH|+7H3MA3W|PK!77R0-X R5.>!4P@SNS20|OTT 1|*V
MR*N4-/ \$ ^*#0#*%J,+.H4:E^J?IB:O1!E7ABB*C&_ 1B|6KO M;Y"&Z;J|FB3PW&ADCNI*>
LF2 @4W5P=L|?*:DBU/?IN)3RPX9SA8PG1F1-)2\39&CI8BX&JQ7@A>^|R|+|W|
M14WT"/T|DLTJR >1^6B|.8;G^6>K)KVEA?H'D4P#B+MI=+ #Z'=:;%NG64=AE
MNX.M+TV"3C0XRDBVOB2PF\$ LYY9XL-P'R|N|N)U8>"B-^R'PI9TA#"JH|LX
MMX/#C:UP+RYM-5,B!J)+;T6)"KUQ+W'|8>W%G"/(MI@'0_>Z7?
X=U'"2=^@7BQ|%JZW\$S&1V8\$HY%P;GSIT"UQ!5%%0!NEW9(4\$|@ #J"|SRASFND9+Q_1E
<5L!-JC M25.2F=/(<2YMC|6C)'F3M!ZZ7=EY06QX-0&Q'<= /NI@;)BFUCF10#9%,XKPD
MOF44J&>!H0|TP)7906C;#VPO|TQA ,DT@+BR;I' /&|_*7GC:6F^QF)BWJ8
E<&V!UG|X>REG304ED<# \$+O;G/3> MB0HD;14
^M&|W%|@WB00+DCA+0U1!"%O=%'N"iV285_:4)-.30 J^O^//>C MSC1ZC|ZPRA" (#
(H2KT4B+M(DYLG Y M9<^7#UT6 6|WVS% '17%Q5!J5R/S).6X06M|JY.2"EV6K*LKJR/(W
|W+^U, M8&AY-0#)/^#|/+>8M%W-|&;N8S&JWN>F3\$8I23CAC.#^>@7B1-HDF13^&1
M?S8Q%5-M9;@'6?OA|:6=\$=261XMWA3^CQS_ @,+34GRJ|.S/Z?K;FX05&@V.
M99_KP/L^ND*+E2/F4.E2|^78|I?&_H^ML6|JA+%LN"M)0 DLD1\$B|0X8H<*9
MQ"E8!K73&/8DK7|XX|!%A|AFLS#FJ\$B^1P5++ "\$U7FX4B@H\$, 1@%5CM<>QB%
MXUX '@)/|P,>@TFL817W&>+B=#XM3_K:9;SWT&GWGU5+B3U!9;VF+_|T= FG
M&W,^7PY^C2|O,A?<GS'XXD1 M5MMD(@DXRW(:.1&08D::
(5F:HE="U<|_>8R>T1NN5;/&CHXJ|=:0PHK6^6JZ+
M99@NXOID^066WZ<17OV8KB8J!!X-!Q*%0E.3<4-|E(GDI(17\$E_NETB! VPA M"-
_=H.>AL9M\$S!%2751D<1L0*;"= "+V>P>KLX|I/Y!/T1K4/V!%QIK)ZS)\$ \$*
M25)B4C#G3:1|50_8#R?W"1@'|+'5D>A|@/1G!<6
K\$,>K0R0S)"G#*V.JH8_0,SIV^HK|OHM?
A_LL|0)3HE4TA(O0!\$FK\$A@>\$QBKQO:3VB;|PD800-7 M_:VI#K/'1LRF)-3V%["7DP-
N(K*&6"M94+|I|= /G&C%"|?W.B\$F_ '&V3(&_!Q!QY8WAW48X|+K\$:C1.* M>4;JC;8!C6"?
W&4Q|W33"#"?#. >J5C:2^|_-, (X%|>V M==| -IF?3S2:JR,O-
#/QZO9R&B^X>W7IQ=C%;3|GT#VH*SB*-IN.07(2LD,- MGADE094<_|3S(|>20A!
IF4%#'-|DQM8/|BAW;4S|8A?W?I9\$+/W8-6+D36 M(#BAL?06M%ZB|
B,3EXD2|Y16M?.#N\$OEYK|BK0Y,++|DY|F,XV|U1O|RW) M2JNXT(2F;!!)Z#|:
<@|ZZV@M=<@>|O=:9/N,UD3:3WU@W%IAU;G>8KK/ZXL5
MZJ+5ZLWB+%RJD|7Q"3^//*U_IY(|*:W5|6W'<#?=N1@##|Z02*-"15JJQK)@ M2?
82X18|S|/%V4OMC|/2^9Q*_0;J8P4F^&N55_*^+Z;I:6JO7/|?>;5PR)YES
M04N2T\$)!J8&=,B+ _6*|=|Y)R'URN//|#:1RYRULM|_R|8C*D|K8|W?JCM2
M|CFANY2AV,3=K65!O%294 T)=/3(Q=J(>X"4D9M|/#2K_N^U)*@BC44R5ETN
MJZ0()9F(R"3&F"|9>IH\$CRLR6J>8!.&9?@YTW2*J#0762_1|P.EX.8SM""_R
M2W^ZF%^&J,\$(:5U\$Q|UG2-D-(3HN8Y4#^4=|*)G7!2- M;; <)Y8&(';#N,LXQW|/#^I#*!?
(A;0L.GNY'M.K>=H*4>#?+LX@W8E46%! M9L>(43R4|J^&A)@HH<&"S5'J&(?
SV;I;H;G=| \$AL/>C2/;^@F|+YV^GJ?+R ML|N%Q?GJP_S.+M(I:|H=|47Y;
|R!;23<|ATS5AM:GQ&:HH4AH16QV!KX=FFV8;Y;& (I\$W M!CF MO>K-
<'QH|X3>H=S'Z.H4@CWD884-T+>.B>P6F@94*8^\$2D-)Z|H<<;B-E0*
MSU7M.^<' \$5A/SUZS_J9R+BA)I60XXY)PF3PKUS8XT3;RTLLX@ZU|OO\(>|N
M||.AYF%%UD|B+2JSRUMV(ZE/*>RJKSAS?-(V9E MH.DUYGPW9+J/.95YTEW)3@:2R*@;
<2%2@CCTV1JF<\$/*^!PT+ #U|_ ^5;;05 M,N/N2GO|W?_GXOFF|*Y|F91,#0;
<'%YPJTMF:7&\$AM4)@I4R9|'_VCUXL6| MJ1Y'FPT,JX=5V;;(MR&W99\$?F>G|BW7A|_
EBN9|^=R?SRT*I=UVV++ .8EYJ MBKL(U|F8EY282&4,-.F@A@)V#?K'<31&@OBS"|S%
|?TS(\$1&#-<+1#\$PV0"0D%@H'%#\$1D6)
M|26D9IT2>3B/9"12QTZ!&P)5CX4F:TNM1;56S/VOL#PI"/D)F5W=:4FOGQ#
MG5|^|GJQ7"|^+'6JCU=U1XW36_WUGUVM@EH0UCM|:K!3I+ #4I|!)<=Z6-4A)RR@2B
M8-S)R&*H7:GD::I&O|_3'Q6/A(IK"* (AM^,D_ ^|7EPV+30+5RBZSO&-I2BM8
ME.")=PZ*I:F(TRD0|H1+TCC-;1H;:/O1./ (5GR%A-X"0&@ #A=4NVK;:2:189
MG6/*N)9H0N|="F=(*N)\$I39X%,TJG9W@|?HZ97L MH)_J9|MJY9.M+?
ERS4DF95#&|R@N^>*N^=\$ (EY#=-09"\$"?LAEJ\$C2NHJ|&
MGULY16/(JD4;|FX7E3=^%B|FOE|EUZ|4=':QOI=(\$@U#=U\$G
MXCPKN;X|\$*MQ4<;N#R,%8+6 MEDF2)/Z0#HW2H/

5\R;E+))L?;R'B(*>G\57(JR>3'EUH642QFDD_GG8M:7 ML^+BK=Y=,U3JR*WBIZ?ONJU?
J-)W?FF6,&FD5Q/U.Y&I(<12-2&6=AO"9K1XH/);6-M<7?
T9\#M@*)K<>^ ^\G/=9Y^ ^Y#>>_(3=%7:??Z\^V74M@TO+7%*%\$:=1*,J(
M/!..1\JH\^X+)O;J&G3 HGR\$G)J^11GD-:#!/#<#XJ_5NHL)O\?/IZ?SNS8J
ME08\E+A8,\$3FD\$E@/!'K6=!.L\#AK'\$RN#ML+60\YEL,+<>FMM02\$UC, MBP=W-
76<[F5F]\N80Y\>S8B@3\$@+Y1@XZ(#6@P(2'4B+@.*
I^FH\HN9XCKZ\#5_V7OW9K;2G+P: ^RL>^8R?LE8E\<=E6W8UUE MA^V:CO\3(R\
(FLTJ2\$I5WL^_2))4: +NAV0>GB\W1D>[9\$EEXO+)(L,_,1G MC?IK9?X\D4-Q-&/@+&W\B-
X498MTLELL:WMTZ9>"MKH\%/BI\|^=|>=TCAUB\|CU6'Q>S&;G,?X7EW>"T M?
TS0(I40>NQL<"BUG7\I7@HNSZR\,29H?OUV,5O\0/KM\72Y;3NSY?G#+)S2
M9\O3YY\^(O-@ZAME=FJX0:%%N.KL?K/^OW=|T=?;,@TZ"+,=J1*D"/59DF&B
MJ"1XZZ+) \AK9_G^P)WT;PI6\U\|,>101,,AG0*!404P*B MT+6H)4B&67A^MT-)RR>8AY
Z;:,F_/#L3X\#!QZ?+KH\^L?|TL\G;8^|.ZF MINW\|1L@\$XTHY @G;VJ5%X-
H19D'D0)P@O%3:??XXYC5ATW\$|(V\|RAE!\$;R MSF7Y8\|?C?X7<87+|Y77M_.+R_6=C-
0U^|+;:,OVIT*&@+?G:PM;YF9%VGC,Y
M"MJ3OM,, ^F.>CK1A8=CLS;F;ZH;Z'P'L;|Z4OV.8K;^^KC5;Y/)\)AWEFG&| MJU(N:
<^**^!\$|40+Z##Q2M>(3@JK1&(H> N\N-PR:&SN|-|*"Y48;A_W,Y M7?|(I|SQK?()@?
EQ*YT>JC?@L%'P?006\+&U\WK&Y,*#IH.>)2XH)&(28JK@
M,DD@D^1T\OX>)W0B\51+N57.|=;UF',Q2M-N\K4-3\|^:=,&;I4_\$Z\J9E ME;
MzM/8M^I&Y;-T8T\&A(C-OK(14\RYF,(7@?& M='9V2,(O;2;|2VOV\UCO/3>YTB-
GOW26YK *JB\|)EJFH)A@LHFI! <#\89 M9OI\|7<,QF(T+U7TI>E2P_O.)+?
SX>TATB43M&>BD'871UI")BT(9023 M*C/L,3\|U%,G#WJB-
MC\|JWH\$R\|T,IRV\|)VFX"|:T7,SA8\|BD.*N<-7M)> MMBY9X5G)&%AC-!|YK"/L@=\$<-
|J'0%J'_D-A)\|P).U?J&*|7-G=XV\N3_8E31V6B'_VLDY/0
MW:ALE'_>6^S5/%^M=P.QXHQ*+M !2QJF*%|*" \$%JD,5E'JU-&EL70SY-43OG
M^|H64F%&4)^=))4"H: ",D7T%*%RW@6V.-<^\$,H'3;K MVQ!-C\N*O2ENC";K'3D4IS2NN?
7O3Q^.|"@UCM(IZI,> 6K9-4 MO>?@\$B@*,Y#Y&/_SUXMNWZ7HWIN'U8EX\|20?
X13G_/D//=EC/Y#N M=KT)=JN^NK/J
V4Z&9DTRFX\|0\|*)@9.948H\>B\BL*IUKG"@PAL#J9/^*4N
M_7: ^N<(|H47DHY\|U,G2Z4=FJ(&:[V\$>|J%/AR0G?@2-Q&UC@-D)7@97\(|2<=EK=^=|L?
Z\|.WO.+<)\$WB=)W#>MI*)JPF-(MKLA6UVJVR\$RHM;_ ">,U=,K;J74"%<,&?\$T
W=5'+6)\$D%@G64E8AWT6">EH3?19)IE|R\|TQ\|Z M;+C8%)IG5=00?CR);\$|7M>T?_3U-
=Q6^K\Y5@?|OYJ\|7.=YZ9(>+*1U8FV_D M*;FA^: ^+XKKV3G7\W3N>J3HN=,B&C
U(ZWJ8)*@M *7M,J).XK\92>;: @S\ MPX;J\WQ" T#!T!ME\|V\|XT?7?
9'4Q\O7UN+. =6XQ*H02(##N0&FIR4B0ZJ0+
M)2J20KF;77\V%FY"V+!A<@^QH:Z&P\F;QRJ.N\|W?0\YNUQ\|LN/O^'BRS)<
M?)VF5TN\ZVF16^58G:\$9\$I?D:7D-3I9B\|A2AGVFURJA^!^80?|%: ^>+CTX028)GJ2F
|:D.F8.)83L M):"R1G!>)(;6H40WREL.'J%|1+_X_7E1'(V 4N6M3\|S5 T;\$|_! MAC56S
B@=N=5WX.|1PH9?(H63,FUYAH-1>?*%8=2.8\VN:MH#J0-6R0>M8#
MLXUJACXKMURDM+S\$)X8^&(JMC4X(3(0:3!\$SC@)J"-JZ0E^@D:|3,=EIN6\$C
MRKY/R/82'OI#GY\$O"%R(@03&&@I*C%&BZ)N\U\|^6\30,6Z35-JK.D)LOIC\$V\66+
MAF'OH\A7\657H\|TR_S:9FFZC1L!3"=?
_FPF\$WK1T8D)E0V.'USLYJV,#L(2'.G\$=1&4(B>OUG!#\|CD6LI2. MJ6\OUYY6X->%#
(R\+U9? O3^:1X)X/4
M\DR6O";Y#\$1\$#1Y#Y"+DD\$7KOGGWJ1@6.GWI^PE8'2'\\$<#G>H^1LX%OZ2\|G6@75,(
&/ B(41KQ= MK2C0?7-9.SY\|P.5TD;?%|'_ @7YL?K6IU111<;?J32(HNZA8RG(%FPAI47D3=
MO,%D)\I&B""!%2'+IT+'8NF\X9O6!GPSV8'<.%^K0R?\$ _+K\|7"/|*F\6*
MCE>RAPQ3\5"\SZ"PCET2S(-&.BPM=*F.Q'6(XFJ6Q\|!+GH^45ICT?/K MR\5Z\8T^:0D-
)H1M1'S-X"@H\45B&UEK\$;DG)>Q\|D)5%'_H^3FH_MVZW#Z\4T3\|;:OX5?
Z_CA=_9,^XO?PWXOEM9RV>?:C7F">F<)|HRA. ME6B+JXL#:+@9CQ-
<44X4*"4:4%K3X6:8@.AE"DP\|J4NWTL8C%F\|S6%1:%X<
M@E1U;K7S&KRCK>V=TL47:Z10\|Z/Y)JC;|4 <_EQB.A'X#;?DE85TB\|/M,_
MW21;HV2(FAP'H2KI7L9ZMD"0FHC938^|HP814^0,Y+,T!%:OA=|M1'Y&-%3 M&;G*K2-
S23&MP%OB0D7GZC0\|P8-?3LG+D/K%4X66<=.' IO(G,LQ1:SQU\|AJ210>I8U=^%
M5\$,|C %6\W?>+SA/7\F/_>=F^S%EC/;* @O;3J:-(B/#'G@)6HA"@5!S7#U#
MTTA2U\|V<=,<+?Y1@VG%SM?%2P9AXX> 3)W\|JQ!;?+GR>I7,)%*|)=@&B-I
M;_FQ@>840=X-UXX4\ACP<3\|&','*28<\$)9,XE'8>?#0:=*,_1>&,Y\U\4AWW
M_*/_J\3SZL3:3QT.OS>OGD@T^NTTSXK0%GG)E@6(3J4(++FN81B@NKV\|O_Y

MM482KQ^IRD5_%N_V5*NW1;PC50 M/0UD>@?-KK>5=HM<^T,4W3PK)P=.QT@!J\$
M6J5O!EPA.:2&>8H*56<9"W-2BU-JV(9B2P"L,5G!#|4OKJP.9 V+JN90Z-S=X#B|
M#!T8_')XMS.\$WG[[6*Y^+YM0'@5!8>,P>B00;O*CJ/8R6?)0,I" Q-%^+OO M+1\YHH|
<9J2(.5:CBUI\$.P*;!L@4L%.DX"4=Y(&BG\$!?!04 M8&-B7C ETS/4|-L'FLO@'52
L#XFFU7\$|^4DR|/> 5 MDT5)5B QY4#581Y1T%|+ME)Y88W1G5ZGT*?
NP8;^=@.96PN.ZE;N&\$?Z>/&- M0>=74'7*"1D2 Q|KMWLB\$X(NCNP?
T5M"=.;NU)SCM3ZDXW*"LNZJ^PC)#:.SP MWZ?SZ;?+;U>\$WV_O YQ>|O.HR5;Z;X
MH^4W!C?Q|=SU+S^V#W=G8;7:&\$2O2N+>U/F|O-|<)G*\$**J"(P(.@F6FF=%
M#B!O5!>BI^3<^E+)-N-%VP|@?X=O.118\,4R '|Q|6YA. |E/">J>"4LT' M !J(XK
9EMZ@TAV2)^MM!+#+|M"CKO|(F2-MJ^0: XVRQ"07KY-9=T*:2XC9;
M!1*1&!,^@B>"@!=\$ (8HPJ7VQ?5?B1@O%TR%RIUJK%WV- 8CW'U DCZI(8*\$X
M(HDY(%|!"@2KN+ (.F3!+>=XXQX;|5|???K9>J* 1P"1_<%(\$R)0LY(5E!+(!
MV42+\$\$.4D+@F>QZ*D;KUT|?|H4=RS7FD+A>-!#L"4)##19+^UO1=C1*: _B_F
MB8C".S0:DJR=2NAK<"QJD"EFVB|6AM+:@7J.EI&D|MJI8G
1P"M_WYPK+Y>S=M."DOF&) MTC-@|3L.H4'PGJ*%)5!8R3'W'H>>0>R1M?ZYA2
M5;#")#U>/R|QY.+1#5R M TI\$6+V#1.;92V!%>ATI<%&^=9>U+G2-KLW.*=AJKHB?
K73@(- T;XN8K_8.|MK.G5(*N!R@,ZT31H"
<#A4FLT7G&W!N*N%KY^)P2'|=DY|'6|.E/H/JFKJ_8>P/@A;ZU>MKI-EG "7I0&T(0EGM4RJ
M=8')\$^2,)'5VA);O94+:B'R|Z+FZL(A)64U;"%R4%.ED4;|2"K)\$;Y,KF&3| M5-H3!
V+H&9JHP:G(W0P-D!|PAG|Z,O?<(|+,*LYF_R-O-/5HJKU.U|9|>O" M>"V40)4AFUCO-
7*=BT &O"B7O!72FO8==|A<)2 .P88|H(=?6EI!"L">KW M9;_@K=*)" \$5^,!Y94!!%-
X#>A&#H<@'9?MV*7>(&/8NH#|HG2;M\$<#E@5@| M."|<9Y9L>)
(4*AL*E57(@\$SPPD3RO+U9&O>PDU/3|1GIWOW?.|^O+
MY7+SG&>^"6LW*;P/N*S_+GS!">TSGXA5|-DX\$J3-\$#@R\$+5)D|H|
M%\$/7DU)^ODQ^W72_3>E?I&F8W?S"IJ=)BSS4-U^NA,V<\$|_*/FUZ_-S_-+7
MZ5PI0|\$ZU>:O=:9>DF10%06@4G)O>2K26;-IH.N^YJE&|0_+T_:R|6XE|M9W
M&2<1/&#GH)Y@=-<>GT^?(_ (7N7_IM-EP|QOB^43K&^2G::8(&M|IH0JU"D&
MM3V3)#8=HM<2#<6'C<%Z\$('#!D!G!;|B7%H< 41K=X+WY55>7%1%7J6:9\$JR M6;F
<0H"%4,,9H UB;ODI&UO+\$Q\$A^B8UC |.CV16,=C '!#YP7?UYDVXUHF_ARD9%CP-
5'SO0N-D>0_=)@E7NRVU":UALF3\$-6@?"I&^>1Z0&(BB M2M#.;|?M1'NN5=+M98=-
H W#I5|N,!S=4F*DS488@60E"9A* =!;,%9!M1 M(M/6QTZ% =UA,^1I=++Z'H;:\$;(<&
B? \$L|/#^6!>??: M*FE;::#6-0V4A0(0-3\$D,B1%Y=C1-4IN_0,+IZC8Q0P.4|BYD/0)?Y5BK
M>W-#QW+A+HH\$5FE/H60=P%JL 90+T,ZK|1' ^ T% MUE<(R_O,-!'3D.T>O6S6L?(>5E
M9M;/:,2BO7;&"|+K*/E|N;Y: ^|!83:MN?ZV7OZM:4 ANNEI/7)8UYZ=:EU/
M#G);@@D"K)-.296,YZVO?TXF^F5FN7H%;D|:'^.#DX_X'>>7|4W7XLMAP^";
MZ2H|^+;\$+YO/792KWX@_*OF+\$M)Z^GVZF4ZSW#W(66T?Z)SPO*0/,DY^3-*I
M;)K5A&ZH^(TVU^X9WC^FZZ^|5U\$WLX,\$"|F* EG7MWB69W!)2,B9T|CI;:&> MH&?
HFM'V6+G7.ZN5-D;@\$UP?;|H<@%\$8PA@K56ABR%^F2YFBR_3=-.T5!G
M,8*)*='&T05BT99VC^-.9960Y>?&#-'Z^?12-A#:.WH#U_#|EN@4WAU M22?
OWS',UE^OV&!:: IK(B1&Q"LE'83(B!?'N7,#,M#='OD^OL; 52IMU-H
MA\$,CX?."0H_75_%^O+)8XG2^>R-E);:Z|+S*"JYP"4JO+-.!*<
M"L'SX\$"*6\$1BB9,'Y: +?)G6|Y>? MR8:X2*6^B@ZBSJC3\$(,1X*0S+#+=:;|T:*X;3NX3,-
R|H^DZO0^0\$P4|)|'R M>YA?UH3GY7(Z_)Z|8W|KTV:?.O(6LVG>*%&SL|@| D#V4#
<4!Q'63+N0B,<9D|=9A_YLOY>/5AXYM>O),&8AX=4*[V#|KL M7(WSDR*(|;-
>Q\$|28B\$X5.F|+^%&_O8^L,=.2UT^B1\$CA#P"!+M;_>B^%_O
MA>|LDNVKTX(T^6N@LE,0(IV9.0@403#08NLRMB<)&A-|CM'W0R-1F@A_!\$BZ M?
B:RNY|8I8_2^N*8A"1-K9"Q%/@'IJ!(7I AVR7#7^O+F\$5*&V=Z04|+@0_M
MWM|CX==_I=EEIF|O3?(49.F> \$F1\$MAI2 7/F<&5C@KH_*:YV|1TI\$\$. /T M-(?2V70P
OMT_5"i2JN^DL-E62R_A7G"JW\$VW3J0M3%<6F/^7)G|4OM2KJ>K MS9.EQ?
S3.BS7;|)ZF|APPF>RQ@C&JLW0(-,P|1!HHC"X62V'KD25L.ADTX M|_8,8D
U#VU,3V9|P|4W0E<+!A3CP_AV':F=T"11.(QR|OS A|MG=2-G&%G
M^#1'Z4!Z>O'(O#KC@A1.|H5.'\$&JO:2C;Q.:N-,1J=C*J';L=^(H\$';6)T= M1\$TQ?
(1&AT;QWY9(Q+R|X/T|H0&7/'*W1CP9&X)\$^1 E (N)HD*G2^U/XL#6
MBY3"B(_2,,HG,DVQUHNR7GBQW=|P|649+K|^.\$|1 MW;WESED|S2O9RZ2BUQJX:R!
(NJ@69DS>!(Y.:VP(KG,@F#& M>TA8GTM;-.""0Q
E;J92<<:TGD7|HOD#L'*045RAVACZ*8UNQ*>W2Z>IC#;:M!;
Z%6Z3T!M#U"!|89IGZ;WK=,/Z7+>:QP@8I9-VA'X7K84|-&*V
MMR|+R&;1EM2K(>A*O5.ZX(\$@N%.3P5AIZ"W"@Z73P\AYC"!CN#KZ18A>M

MI3PP5'Z]K*/A=QV92N;*)@&,"0I(T N(H389-#&S(EERJD57M/TU!P1\$&_4M M&LARZ-
SDYJIV>ST;9N_77Z]S8EISDX2RH'DIH_2S=/_RR_%Q)0RGB?4,@U8((?:/9)3^|_8]L
:EDX6)R)^: M^|W"|!J?%M_|^H3M!;@ZB|WMN!FO>%>1#2&P7\$2'\$!_
|HDLA&>JA\$+BX#)* M|L0=J_P4<-&A*-8RXUT;4W2R<.4-AWC?
O:BBJ&EKV7/XMR5>D9UNOE-%ZN MJZ0HW+N*,>AB!";O.JY/C58PI#IB)=
Q&I2"JF&CS6>F2RR7GUIF6@ZXM MADLE'P.?D|3|,G+\$NQ3499CM.M1+|919?
HVN9_IVC8S,W=*OWJ MAJ>)/67(.7(L@<9:.N\$|@UALA*Q"">BCDK*G/=J)OM/'P-
I/:MYT|712.9F+ M@<(#N9;U* J(7!NI\$(AR9+&'D?|/\$#2*7'!|W-R?%M]**2,X|9YDYK9(_Q?
S MI%BB?U.JE+FN|=XCD_VJP65K/+M'Z%O8P"H<|. <>:P=/_4-G90OIVG96T"
M^P:W_UML;R>:9W^YW)*Y+Z={J405Y|BU?^ZD27D'QV'*2KHPJRRQ_8R3NZ
M;.@'S&EV5NP>R|BPQ;|C@/_A90#"G=#IX<4D,1<"8PORK&4WC%L(H@@(FIER
MTC"C6X^0|/\$38L.4=9T-J>R6|N'CGU6J%Z|Y"G=N?WF^4|P0GC0*Q+"=PYEU0443?
O3GN/B#|.|(TL/UPNTU T-G?|_E9J)#
MR#JIS;:6!4HJ45_NDT>:SYW>D:\$M|CES|_02PP81;5#14(@C|(/N^GMOYX^S
MYC1Z9U,!&ZPC%X_"GFB,)|#7<1,<919/73H>US"B,WG#>N|M+4Y?6AG:JNSX M>HJ?
+%,.=M,J!A\$7N7*8_O*&XPG&;DC,2I>|ZIJ\$-9GKSHQO:HI:":&?7/;>
MI/ZUQ^3I/O)SG|S*/SZ(@W-/2)'!DGF W,=86LI7_LL9RBAB"(QTG|:S|;_MP^/OH\$3(IB
4&VCC>>W|LV(A9B|5:F5|:MT+Z>4_CX\$*P<|_CY\$&^/H%7N| M+ZKE(?A0"K"(M7 L.?
#2,LA:((I6,UA1"(56|1V?"GMA_2::=VPH(>&C?^/\$>
MIFAMD)\$|_"*J5QAK2UOND=Q)U-667'5K3'&:X@@AX;#_M_2V/56#,*Q7!NWH.&T%?
8>UU&3DQ')CBIEMOBL;=I<_M+J458TQGPJ6IOIOQ=)\$
JG\$SDA_>=N,Z@1S&X;YKWP;:Y+>R6,_5&W9HD8_M9IS04@#71=:VA+0=LG)0?
A&|R^S;QTV09C9;0>ACZ^XXLD24 M|Y,L,,X2*%\$-IK<:,,9@'3*G|C:.(?
7FSVP|2SU.SVPX1UM"*?F+P6,K9>5|X M")\$5J"0<."T*2&MS2HI9P|O=
(IV,V6U"J|^1"\$=P*CS|L|V3")A57Q;&I MKW^X6VOM&KB:D,OM
J2ID!1J>PA&#IAZ=A1A?0\$07.=CJ:C21A%:O|_2_. M+OOQ&)YG'A|Z*Z*2M4>
<5@64DP%1_T^2???|_3:/|HX<(N+|(-\$HF;YP"*>J;_M+4\$1F!?(R:\$G!SZG[*UI_W MK;^I?
#0QQ0S,F/HRA/B/PCM((C+E8@@I=IH;=4@:YT:ASTVFZ'G7J*G3U6- MX!!|@*M-
I|HKXR1_M8FL;FH2|\$==*DP=;NX07P^GLH59-/F'&--)Z_N?.FPD
MUJ/2CQ;=T#K_/7SZ_!67KW\$VVU'/173!\$;F22V*AIB9R%L Y,S8J\$ZQ1G11_
M|Z.'S3+WJ/W3A#@T!#|I\$V<4;?7NTF1SO,NG \$(|'4 MRS@#47D\$GEP@E|L\$J;L=<^O-
6P90H@:2SFH5'S=[P@K:2'N)D4M\$'8&,* M^GB1)P'!YPQ9:A&X\$K>?
3C_"%R>6&38>6D|XJ258(<&R/_|8|%>7\$ _XS4&: M\$"%H7|,"IH!C3(\$U7"D=D|9WDTJ/
&+00X<=T,C (X5W-*?Y5(Z&&+6;PD M"*>SM,5'IQR8;F,8)*L;P7)O/FL!6@R:CG\$X+!T|
3BW0"A'V!|@&@EV*\$! M|@9G%U^G?|,Y5AZN3STED66) BCL)J-6BH0H
LF%1)2B4#YAZ82-AS^_ \$RS< M"X1% W\$.C8A?<\$V?%/Z^F-
4IS*MW|U|ONE"3D;L^F'ENA\$RK|"T1%\$Y\$.C8N/7W\$ZO_& MD;OB@^;M'?&)3H("=4J*
5>_M1PLB2^4CY^AXM|3\$X\$XMT2TZO%PB/5I(=&B\$?EM-YP05BCYMZ&SDGCAB&?
%NH|'|,I4/?HW3+S(C.6ILAPC&*XP'8,/#"4Y1(&(M5|Y*|\$EF""G9D)%9?7>RZ
&0,.180,2L9B.Y#@V/_R*B2\$2W2IM>S?/;^7SQ M?;.GUR3FY6X8BG+!<|P6G-
S,UA44.R6ZSIHV6X@>HG)T?ZD M/S2N?IDM_OIM.IM|PC#;,"? ?BT5>K1?
IG|O'ZY856<@1YU*\$J120^1TQ'HM
M&1;RQU/J=B1U6*P;AEYB|K2UI(=&SN^X7M|X75XXHU*(4-*F+233X*N I%:%
M.Q):="T"X%L?VPT-+S%#>KST10!BXPW&|=OY:KV|K,|_@|V8BC*B9C|YSJD
M()U"T8Z*\$8% C8C&F=9/SNY3,7_5T3G?_IRH@M&|Z(_P;:>G6)"!;N!8OWZ
MEE@K"+VB224U8Y|P/ETL_ST M|N>+33D"YC|6ZUU;B.O2?I^"R@R*DQ)48%(0>0-
^QSE+.>>'TL=QXO&%L;T?'X&61 M%"8@9YG8TYRV6S#D;Z+)D16;0^MA/@>2.*PH
TJW2%YLMY&,M=@|"/-N6_M2'R=7MRT-G &A9(0M+2@M!'2J(#P'JE/
J11/,>Y8^3,UJXG0Z#N|W+&^ED M:#_N|6*)GS%|G=>.&=<)V<@TYD0QM*<_%
(8,\$5T&H1S)IT3&?.SDLCWTZ<,& MA^?
2!O!C@L95U?|5WP4EY,@AQ68(R|6V4W!;4|@2G1&!Q3<=)M4^L0BPH4 M
^D>#&(X)QZP/E|=UV93.&.EHEO?\$PRBH8'<\$:1@'A1+"BO;5N,_\$4/<,_^ M#1ZZ/.TXM8P
8A_"CTTGL,^+JP3PCCE<_8'K|^5U6'W=S=::&31H"N0E;|O MV;2\$&
(T!4R3%X4%*'3NU"SX_6&SK5,8A|(VNW*L-%GM3T8C@MR>TUXL5 M'0 |X_K?
#U=_|BP&-+NQR1/'A5'2Z=!U_R44:\$|"P8T1=1<(.L.|?4>Q" MZNC*R|J"LD_%C0"?
M2'U8OZIOOJ@D^#|K-&5J|7!76N% C|C#|CWFR'7;S->UJF MX3JSL-
M@K^;YOO_Q8;FXP.7ZQX=9F*_I-WZEW|TTXY|8&X.Q/D!)@OP254?! M.N;
J%"\$UY;%TKL;|D8&UU57F^'_L"@^,EVRMOY=_K|Q?+)(7 K.<&LE.|

MCF;3\$+ #D6I3@,9(I<:FU >Z%D=&5(XYO)QRG!;\$@_V^+1?YK.IOMN'NS>=5,
M)IYTD2<^Z*BC=R"2K1G@FE%V1M8:"BM929%V=V,/T7/Z.H?V^"PF0I&* >6
M>ZIF1RZ7535I\WNWF'YC,MOI9W3A/:48-%Z8-)13(ITWH3:1Q8Y>J195Z\Y
MJ).S,CBZTLIQ&=ZV(/G)=M#KK62VOUE;;B!77(%.>9/!>"38"!#Y\$+YS\$3S
ML2ZL3.^LM;Q:8WCM?^3;8.;* 351+&L8@D.&&91.YJ19Q:5A5"PL!@UCZ)U
MA4)/K(ROBG=16^!8S?JD&V#O.Y.(-FN>\$62QJ2Y?"8B"D3"05O+:ZXTU?S7:
M\$ROCJU8>WP8X5O,CV"W*QDV4RAPM?X8UKA-S5*E*K"OR!)6Q8I-D%28:!(M)"1H3)
-2\EP9HMMG6CI3MWXZJ:P+OG_8P>0\LP-TFHXY(T^JU\ZW>X"HM-MIQ?
UIQ,1K)961A!1U%IOI2#Z4D"JE"V=.XZ.G/Z-ZM-\$CJ^FNC=SV5!;(X#C MCILG'H7^Z=?
OM*>>_4=E\3A_EQAN9R\FQ:C8=OI2A-W_@^K:ITGCHS:?.W\O0FV\88;>I,#\FQ>(*>DX?
>'**J\$1S#AY03ABO2RB%!O"1)CI&^LBR-B2JX@!|C MW2\CHRL7'LJPG(-
P'ZP1I_ ^BLM';:+QB<)>CV/114-\$QLHFJ#LQ@Z*Q76>G6-MJTY/D#-
LQ<0Y3ZQ6.AD!O/9V25@|>O@:'Y).0D#&>F4F'8+G,0+66!>EE"RU MCMPZ\$39L:
<(Y(==>3R, WV,#C"6SBA/-X WQHCS)*JA(#,DO@3S19ZA7NL?9*VIR+\$^J2
U@5MA4'DS=M@O-!X@>I M_N!XH?H86B__?8L;![08HU%K;-DOIE%<*QH")J:B+&D?->
O^AD&B1^DK\<' MB1\BO*5?F<:-DJ5;
TLZU#;Q#E4:HF%F#'+DK/LUICP)0T2/UKI1XMN:)W? MGX\$==
G29UFK_0,H\$|BE)T+O"V"TU=%9-9)\2JND/C1VC|-B\$-#X)&!E#JA
MM#:R^E)P<^T7(>K":FCG,\$:31.QF|D^8|SG@T)NCP=! G\$,CXM%AE-PF7T+,
M(+0@>R99KD-*|47_KC!|.9|D9YCO.>#PFZ-1T42D0^/BJ2F4!.|B/&/C*OM-M8I
/4E||KI\$|R-D=W,Q:GS/0><'7XT.EH)=FB_!TO2!UI;^|@IN+B\5R-M?
6T&K7,K*,%'NH%EXH)G/::8O;(0B&_FG6;/G_B\$-!IXP?'X6V\$>O0Z#AL"J4H
MF\$1Q\$FPH9"HIMV0J"TF+*>:R\$D'G;KW2V||'7_F^=\$8ZD_X0\|HBA"1S)0
MM5:T8&TVXT@VWND"QDICE\$Z&E|X&.0XXC/SX7R-%S.YZICKE992'M'U2K_|T54V6(A
M_XS% (H.)01//IO-R.N#K|+*F+L4G-94LGF*ORD\$!^DG>0@>?K)-F?_V MY//7,-
_UC9ODS"(Z|4|JED@XHAXW"LR'WBR22<<=>'474|W5)OG
M60:'|!>RN9IBX_QS(AI*:.=1#Z'?UWUDO-2>V|"AFP+N<\$^DD'QT@(ZTIO5
MQGID(JXS|Q@:YN+MI>R1T_0_)|87C;=%\AFA,0FN-NS3|C\DWXZLL2<>-P
MYFBMSQ2|NR_X"9|S<+E6>.HB0LJN"-?MRO_A8>Y|>L#BKV+_2=S56Y:B(=B
M74B*MA=|8IK!1Z-H<80R-M02Z*S|Y#SE|7.6?UG9#-8%*RC,Q_3&
L.T>Q|CH:Y=7TIV^!\$|/S,^ ^#B_"M-/ZKPN*Q|L1\9#38:1D2#|E6(@D.#
H,V88_0LOX"X|7E&A|F.M?I&|HOE>?K)-M1?|/?#Q2@=|QP!=2UNB"+5=^B_!#|Z9BR:#
|=I'^NAKEY M?RG;I0\$2?K*|04J;D '@-C\$/Q65+X;PNY'I2.!XHG3(N+6M.T,U9F&@AP4O
M!?:'*GE\$&-^|@O|PN4Q?PPH_+&O*8+;Y#/KV|HJC'GMIO=G;;|!VL-E|HFXG^Y7L:U"!Y+,
5I-SE4_M:0S|8*|U:E*Z"&I*0%\$PQ7P9R.:PYUCH|N!_A0Q;IDI_N=A_V+T*JZ|7-0K?M-R,"*-
ZPDGDT"9)! "6|.?HE D^IT3J8=:I<6R!CAQUVPG_OK>OIT'@9|L0_M^|'WWNB|"<|T!,JL
#=A.*D(@JO/G9B266KK4=@Q;XM'^.JV.?YM|UJ;P&'H MZM@-|7M7%;=?
P5WGIO9^|FXQ_T(OPKL|9|F\$TR)!;|@PVKL)S/6#_I:VT("Q4R)Q,H7J37U#N\9_+:-XEX
D)I'TM_X8UCC)SGMG702I VVY7%^(AY(E-O^Y^='F)_5??<3R?|7_OGO|?7G
M\$VPVUS;_D1;?MA_|@!>R^K!<+98?@L?<75)!N8-KL-TMKK-Q6KZ|6+V|'#&M
SH/V^HO\O7U2*W0-*. \$S7&N>TL_0T^8T|Z_S*J|62SKH)D)Q5XPL\$(.I MHT#
(^7(N);"6D\0\$0"7'9>/+-"#M|4GLVT_(\$7.HY*H("=YL\DXL89_2G0_MCG!%&8%|768|0=:?
05;*+N#!W62(D;@+3W%\$EGIMW/:N?ANL5I-I-&&(3<@ MK(JUN|VKAMD
_J=+%00CWE=EH/\$#=#B*|IPX.UXI+^5@>T,^WXHBD)_\$CC3&*MS\1#:1S';+V3T7/7@/6J
MJG&>FIO:E"(SE&20H5!@0?\$GEQ"C0'#:F1"XT:|Y/.)3!L3V|JQ^|=|Q0.PA
MRA@HK;1\6X,0"R2:U06-*NBj7=^WHE,KJ51_7U@QH4SH.L64>,P8">I_N!ML8?
H8>@LTR^SQ5^_36>S3QAF_|^L5CDU7J1_GDU%\K7Q^<2"YU+D0GBPI
M)T^2N"Q2F!*9#<|Y6UT7&Q|>3M#MHD=!#PV<1X8C*D\$<1!9!1\KV%17)IEG
MP&1RDBX+;O=P9|P:W+L;-'PZ.:!
(=&Q*=_XHQ"F=D3X|R"8U9)2R<3S)#J>7VOL(VJ/1DIC,0^FD?':8J4E+=T/+NH:TE"
MX>_2L>,B)N8LTZ)T>UA\TH32>?6'G_4M!#IT+@X;&29BLH71R>G5X1S%9P' MGW7-
JE),*H+V,G9|H=M^7MR,VZ/1E!_PA|!|(+5-CWXB16V:|=|ZM>T"0Q_M;,>:-
W(\$VE15AB95@,EARPV20@F%LG1)Z@IOA09VS!NFME#)>?%WM268-\$X(-MR(KE|?
WUIH+"DWN?;-0VNM:/^YXD:-B JYG:N\T"!T,"*C5'-
>!O#OI(6B;@ND!;\$@V=VH0^#ASYY#SCTMQO0W%OTA M4O\14AS!F7-
MZ5|/PFKUOGRJ6:6-0\$K4B8NL0.K:0-6Y^N2-!!*25LDKZ>C| MK2^Y'B-FV(CKK/Y,&X6,
%G|H%_M#:L4TOXHH"W6J@V#1'S.P)(0)JE S+5N MF7*?BH\$OL-JH=|0%4UB-RP,
|Z|WUT\TDLCOC?NJ:GF&C|Z&00(|3RP@@|F&Y2(AY|1N)=.19S8T<<;5)56R?|Z|>SE^5

M,IU-;2JZBBJ061ECMB56GR#J3A0*-W@?F>#@ZP1R1W<7=B1F%L,H<18M?>
!S>Y%^UYKD;M%57YIMW-9=A=M4(D^TS4LR\$'B0D\$JT9-XML?
D,P\0[TSNZJ[DV;#V;"E\,7\+T^5_A=DE3J0L4G*O@;O\$ZGAS0X>3"^2<M),-CR1&%'
2AUR2,JA;PG*|3E'CO&'=6]/YE^IQDWLT);U=:7\$9Z+O5\$U| MK%^|+^|OUS7WMHP_O?
IEZ|3X;SVY):#WC0W,2'XT&3"*+PC'&?Y1GZVYW MP>AN*GM#|;G4/*0;PON/U-
YD)&T19>N6N4>0;IKT39P|5MA(|#DDPV# MT1D4EA=@.M1;\$Y;!>3I\$I&?(LY;)B-
:9Q)/-3X=9|#|>+<)|PVJ-W4IRAOM FRN@!)4| Q=9 HDQ|#J|2)5N+UF?
M66B82;&|0.BY;\$=@OX|MC,*5\$DOZ!5Q7-FM#9;H"HLZ,B%|1%|,|^O63N;
MYCV!SQ9A)*FX\$=JQ?RR6_R2GX76XF*|#[%7^|O5>A,|36RPOB#SU3;3'U9Y
M<)>F\$Z71)VC,ILNSV3O*050<;|O+N9,6A^:(/:X7|J#US7(0J|WYS(D&-PFO/=#\$T7Z-
:|J&*>)?2SW67?:Q*ID-U|I/?\$ M7JR-UZW+(N5)HE4')ZA)^A3) XTZG-,6>J#-35:(-XPM?
&-MY1M6I'R20E1 M64?1FHC, '\$K@7:8AFR9%5\$4GMT93O&GB1QHQN9
8&REK:%/WJO!1+4/+GVU M9_BWU^GORRU>MS>=F">LOM0U(0&/(M&.O/=MSZ TVQ
M|/<\$|H,J1F#|7J6TO+SEJ5|?F==|1YE;*#IEB|J<|!|Q4^V5=|,O|/O+Y8-)MRS
MS#6GH,6R",I&12ZF)2&\$HDW@#BT?|^T:T8&&G/YHK;"<5K_R:|>WQ<|=8+
MENITVR+HN\$Q|VW9!YJR5%9SIN|F44<'_B+F!_||7=,=K_^??%U>, MWKHV?
5|VR=TK\$4P*M',-!HY\$BUP4|WN#|VYN9ZZG1!
J??:>059A|QHB0TST5Y0DMFB\$TLVGD!|J\$
M8+NA(|MEM|TZO&3)"20|;6UMM1ISK800P)C.5B1DI?F=X2.D#-M%HC^T/#Y3-MY'A-
C.#LO.XLM#/+G_#+QE'8=!?B|B2,.0(S)!L*R#P\$;BU8&4Q!\$|_HKY07 M0P2-
98S("2I_K"7R?(? YBVM%_UDLJ!>ZU%AB XB86CA%"\$ANR+MZ*VZ2VM M^R_=(F
D+;M.5^Q=R!PMY:\$?7'U:E/47K,:Y_3+;/F/Z.E_,%E\HY+UJ|1QS MHCb7)0BUH;-2|(?#1/
<3=5H8&PTIQWM
M6@:U>6K#4#%0)@@RKR)!X&SZ'9<_KEC)Q5G28(*4\$OEDGBRC2|P
197\$H_#&H.ZD|Z?7&;C-M:YFZS.9Y:9>!NL6T0T4R,0^/AZFQ|X%#>DD46
@=9ZLUI5O6%N67_|_&M.5G(V|WB(QSI'/37J;.I&0;5P;Y:77^Y8-N4*D|8;|-(9.N|RIZ^0
MA"2#;|F(+++M?<\$C<_QA>[TT!|Q.%-W0VO_P-2R_A?KT_(:+O^.=,9|O9Y4
MID@RRH#3J8Y4E*|.G,H@2D;.I6'>=#L2'E|CV&8KC5#02(0C2"ZAP;A^U^M
MEY=5+ILHVAMGB|=\$LI6NNKT)?,X(0AGNK+1*-W|Z=9^*L4S-.9>3.E'2H|/*
M'^';D15D4\$D0R WNJC:(\$U 2#*"|4F03+0/JE_\$W-R; KB5!T_"9DC|3|F
MIA!%09AH"V6,RQ,: "XY%|:++& M1F9,IN/ T0Z+C0DAQZIT:-|A|>+9NQI?
JZXXL9H)J6LC<=G;1+#.G\$P9#G ME8/FK,ANR:S.2PY|*O6|G3YD/8*CZKK6)69%0!)D?
%5-+3MA(|@HLXJRE&1:5W8>1."P1V,?"D,A,W5-28L MOIU?
7*Y7&XF)ZZ'T*J.K4^BUM'4\$.8)GQ@-3Y P(8|5(K2O%GB!G)#AK#X+'
MX':B1L8\$KE|^(GME|":7EV|IXC>"0/!:(3_0F>=BJ\$|',WLK(6S^5>H:D MLU'O" F,6|?
WS|,7D:992#V5."Z M#O&+X\$Q,0"%T89\$)\$G+K6.% \$H>%86|0N3M?
L4>|C0"6K_X*R_R9?GFS=U.1 M/-<>VQHQZH0ZET%*O(^D+Q@\$PLYO(U!=XN L8Q7; '>
(B_?<\$8#CTU>2&UEV MS*|7WRYP0KHW6.>7'S>_9*B\$2|R->"B./#:
MU(U>>&\$Z&M7Q52*"PZ|T FO9+!5 M" 68"|+(P&5H7GQXCXB|7|CT<%J>)N<1>7C8C;
L;:&LFVB2=!*LSH30,M1" MW(RU2T@\$DTA,:.POG5SC?(&\$=)UY&*?00FQTIY1\$"9J-
H+0&4-\$IVJ=Z4(M/DH/+!>CA. Q!|L3.L8|B;.5^ @H#I+HT4BXV
Q7^|0.RW53/#PXPLWJY|0* M 9:QS43 "-\$D"S+;Q+4HT8;6VE#:6&|"A)^A<\$S'L|7)?
>#E.QB,"R;:9^|MY6B(Y_V|P M^|HJ|1EC=|H+AM6|H'V?D?@6LEDN-\$RM1X;21|P|ZK|
6>TV4_(B"18'#Z M9;|M@92VD|)%FM|8|3@1&9Z51Y./Y>HMN/=1;L@YJ1A=
<%JWSF9WIV|8K&-? M\$&NLE1'A|>VWBS!=UE3%A@M?7|P*.: 4|*"D+)|L#4HO<59ATCT
MQ#CKUWENBH9_+*?K-<|?E_(19_4%ZN?%IS#;FQ7VYWRZGIC:Z-ZG#,X&5P>3
M(\$2A"C%8D)?!HY3Z@DPG-L<1A|5-Z;37S.'0|UOHS?'+AH">"EK>SLG*X6K|
MD1;9|!G)%'.FJL\$O."G:F^BD-B%<)7J4&QI*<(HRH?(A>2V|9G6G;IQQ'-M M<-
>33D9P|MWF|/K!PL06)D)2&61(M'>4\$|5|-8-\$.2N*\$KCPK6|N'B%E'*= M'S@Z3MHC
,VS%X:/W1>^WW1Y7+V_7*_689ZG|R|_7&|?WEAAE'<4642#Y"|B
M!|HLFF+:E)AE6<74&F|F1A'@-@&J;-J>"P0C|+|(#XO@'|0@/VUO@G|CDLZ
M(3YBO1^OT|P7|TUOPLO:T&GY34RT|3SKD@')5R&%*0M>,0W><)43\$Z687C;!
M>=D<1_S;:<)N,&"4_P4;Z+W*T-NW4?_W7!;:-JU^_=;CD^,1AP%@HE"6-6U!&
M.?!19%#>FZ02IUBA=;W)>+@?1WIA'-MN(\$S|O+OQUW|1 #1=U9<|G26G,D-I
MBH+ ">*526@D,@W9H*FUNR|KU@|>QL-|HW8VZ"|)%|\$;^|,4T"|*KS/GFS*|
MFPO"K16HQ0,UN_|L?GM|MO\$%2&FQ(NC=8OZE&M2/^!WGE_BWY>*O|=?
*Y,0SPUAV"EBL MMSFI)
(B)6"QH"QH?"6//3K(X;NEN:|KYT|0S2'T\$3N;M.V\$ZME.Z_':YN:>Y

MT\$%DCCCG(LL5%\\TXEKA0@7MC%65N5C'\$"SOLL M=):O\\=WT.Q%#6VKSQ78NR-
5JMO#0CY=QO\\FMW.]>/6M%HO^\\V;UX^?T-%W_
MY&D^_4GCQ)D_&TQVX;VVK.48NX='6%#1[X_PD7'R*,R%KPK!E11 KS6!81)
M7\$9CBF#=#G."#EFTWQN>W&TW8?+XI)^FRAK!F?
P\$/\\|^#W\\V+Y>D8BW12**L=0>V5_\\B2J_M"\\O:F90@*6=%,<\$XVSHS+EH(=@<%Z?;E:+
\\HA MMJ/^N8BJ\\6-)K:8J\\LH!..?#IHK59N=LL;+;_)V'/W\\L(S5Z MB>9:R74\$EF=7J_Z\$G.[S
MI2);E\\B<0N^J:X68+G;6^YKN!/NE8='T:62=BV<@)!LA
ML&A+R3+DNTY5G\\F\$#4W#6,"^T-94 ^-&U-X=VOYER21;\$Q-S\$G+.EIP)^H/V M34U
NOBYL%F9UH\\8X50.X_H/\\+H66CJU.+!O)/Z!ZPF7KJ1:=^81R5(;CN"5
M9&!59O0S*40X8]*>*!HF A@_88=*WBKMEB'V?EOS5_E/*V?'69OYV6Q_-;C M!?
E32_5Z%\\Z9Q_-?>RO/)51ZP-Z7WMMT\\X)S\$0@3R!Q\$UAFK049^31%+^9Z^Q XW
L%VBEE M!*[9S<.E^\\SLR71"PN(>B\\NZ;HBEQC");#-7GD!2*VQ;E_UT)&U_U_\\H.M#
M34/GRLBIQ!G%RG>@JWM;YBI#\\J% :9XXH6KK&VWX<6=EQS0 ML^\\?5#U*_Z4\\9OSM
6C\\SKXWB^G#-GENN5_?L(%\\I/\\Z+Y;)43*=6N MCJ\$&%A)<9@D2>IE,0TBE^,BW<(G
\\)A#16Z@A#\\'J/"EXE3 MAY.++-69DV><-&UL32%94Y8"\\I+Z"/&\\NP-O::U!?
C=9X9JP>K\\46B\\;?% MY7+"=.%%4.R6&*>SPYA0*Q\\E1)*T"8REK/3@8*V4#IB9'C-
6#U;BRX0J->\\\$ MYB"EM@Z,U,2EK(/C0I*
D0DG?;/1M!ZG<1REP_04&S\\4#U7BBX/JJT(KW_:
MO%0!;TA/H^*D8'GY)N'J#GGK+XQ:JT9_1RA^GP-6K0'J_.H5.=C_.Y:|>R
MS^\\G>D4Y8;*V\\!41F*ZS=2R+\$(63P\$(LFGFNA>CV90"(O8?IXN@8A(DO(6(84>'W_'A-
XY048ZY)6W!8,K0^6SL0=;\\8R M3B>_SM>;S\\J^W>7!E*)J3Q9>APV&A!!E=)
2\\SGHXI\\Z@9PA>D_OBR^_R=\\M\\)9!^N*&KWO+#5O:U8_N=P;H--
D.>)95PM_AES#;4/\\C4PTIL\\M&BP3D+S(R
MBBF#3Y)#U\$(&LHI^"J?:IS\\BSL+#@.,\$U6V:". @56_I?J\\VH,\\I.FB)8W"Z
M#E#R60#\\I/\\3N.M*XVB4 &YB#T,6\\Y^LKKO_1C9#>VZ_K*8K1?SUY^NBG&R M#>A"-
B!<\\6SC6\\W QAB4,*KGE6KU\\DKO?VY^_JH02S:".E 16\\6JXG'VN# MR6U=>R)>4\\X4YY
OS9(%_.\$R*4R/JBHRX, >UF7\\I:<)B;F3:6 M_'C)C4'=5RB5Q1+>?021O:F^"X=@4
!/:SSCA/5NDT^Z*S'(7Z"LNZJ^PC) M#:SPJZ:<5X3_?\\Q\\67-
+;+F7YF8\\^S!OD3,B\\QU>)\\5\\K5,^,;#;O"V1 MOB3ELOO73^*0U\$\\ID,3A@:H>7)(E\$\\E_#
(3N5@7A4Q,(RNU=VBH*L KBP(- M07JCB=*RUUO8,RJ_L^C(2C\\\$9?;\\AM;\\M>FMMZ?
F5KTK?:?XVXN.<\\!74_S\\AFL@3MY-5.K:1F\\F>9VGK^7;=0<;53)1 MF\$R018K%B\$7S)#
(&3"HODG(AW<^&\\IY'VE,\$C?/N7<<2J'_Q"N"SIGUC%?/H ME2':B7>XXU)2XR#\$F
A:9\\#EE'73J"X0\\#(SBCOHKB7!L)+R>+\\I/2\\E F3%Q;VR\\9IL6/M;^=I,T&;63(M-169=2Z
2R)!\\ASKIFVOG9-\\3,DC9,Z5M?H\\@T=C.) M7;2,ZU_#JTJ*F@_2MO8Z\\N?
TU67^4DGUNJ0I%1@8T(0FDWZ\\I\$9ZX(IYY8 MG7-E\$#VD8MP.O8/#YTBO-P"
<.R+:R&;B;7 R*H&X)R5UO,1BMT908_1,8Z\\I\\ZU=HCHC^T8^,441M3\\6;@JA)6O)Y\\SD"
(*;A,0&1\\4%SH M,6=*96 H,<9::\$/=)FV<'L1-DX5T L? M&V@;:#K\\F)=R+?
6U!M+;Q\\9UXE#I\\1?FE^GCX07\\\$LG\\EF;+Z8^T_LNWI5IQ
M6:I\\WY*@L"ZL786C'%F&*1\$RXRY,JR:H=5,@J%"*2NEK-W:=0@^1IY>?UJ\$
MCZ'\\UO#?!0DF@2K/'=H\\P4;%44<-J#W1\\2,7(L^Y/B\\W\\ MY=X/1)&'E<_
M.&.:D7B+'0U*A\\,O:7'YT5\\L/*_EMC_^;?Y8E5^\\FJ^6,S_1(6\\L%?;_&C M.R0,)\\
(=*G13>)+\\Z\\I!W1_0^>ZTDN&03WG,"P2>S@BQIF6U31DO4?A=_G)*C
M\\B)OH^5#UAG4)! \$Z-E,V6I0%B?
T()5\$4A4)G.BC/\\Y.73M^O!Q'^O7K^LM_3/&878100S\\[@@70196>Q\\)2CSI79A1:J M&N_
_3QTH\\6!2TV9\\M6\\H?6B;_2.OD=K_WX\\J?JJ: E@OR57=MWZ0?20*)FU!:Y+9ZM_\\
\\!\\QY90<"-D%PNKJ:@F+\\V?? MKU;+3F)TD\\>>M756>@U"! =RY*1-P'/F1C"5I00%
:K^J/D%.(SBK#X)=<#M2 M(XV"BVVK>'E25M,\$*92L.RK1ZTG.Y?2;\\8M\\LS:
(84GR!EY1ORHX#I\$(RV! MZ\\6O6V)\\Y9;3=2%GM"DZI\\JT\\J638.\\F-
B4@.20NC57!5N\\.^C1)(W:N'\\P M.UKX+6'\\QA4JL9FSR_D5\\L3-OK,2,AZ=
)H,1Y^(^O4S!L\\J)&\\QOTIR?^5T/ M4\$ _OU;!C6&BIP1#C M('A5?:2\\OM%V,=GU?
8GKQ'<5\\YC2A.4\\!&7AL#BDPAK XRMW49XP MSK^EM/I0?KOHK5P>Q)G\$"8
+= '6UPFR7-72+::EO;1\\A%RXB37&K; M;E7\$W2AL-IO-"RJ23;KDM O<(F"\$XF!,HP)S;
(SH5R\\4H'9B%P"->Z'BM@\\7:@4T*H:R\\UO<;#C MO6?7"B_.VZEUG-238(LPV*!9E\\D)E+
)B84C,+M0AB#H'*F4HND!#T8"&,> M#Q6U\\QP>#A!E \\+=X>3\\K*1O=/FWZW\\X,VMD
VB7T83+B\\H,Q3\$+F60=) L.T M=AKJ0RI&G'U4VQ Y4L3-@>1W=YDV8%Y;"AZ6K+X)
<_Y\\O>\\2)(%W4\$6<::B"0B>)4\\&NA9)99B\\/>;X^P
MT',KC1N%J8^9JDM#":OYY>7TU7WT+@-&DFOO \\\$I\$=W33B&=\\JW"3@A,F;J
M.%?\\VC\\^M\\J*X'1H&A\\EQDAT;)F7>+MU>+ M^9LTFV\\]*>WZ?K\\J*62VYSYCHZ\$-\$3\$,QY,

\$-PQRI%1%-0?0I>N'G8!+&[=U0 M'UBGT<78B/OC;^=_6U_!#889\3<4SIK-
VWQ1RKU&SP)B*2<3HE32",^!B,R\ M-8K1W&J8S1Z+CM04H3ZJAI+WZ#@Z7W-
U:TO@M?R0)U\&.G'<\$=\$G#<)'#48S M"('Y(^!,\$V_>Z\G@N,V:A@ /P/(>6SLG#&^A?
+3IZI4U"A?NIP8EM KD!RL MC RH)(H23;/N6070:[EQFRW4QTU\&8^-FC4S?
+R6*5PMNNXT=US,;??G\$#PB MP('"&OE\$(R<8V@,VB@8"BLXW:~5?J EQFV/4!\U\67<0-
CPM?L^7;F+#+\DM MTZT*K^U(J^H992!DJ4->ATZCW_ ^R&T ZA\5%<0X M-
A+..&6;^Q5-M,=O5SP8@T 1@4V!EH 5 ^^\, *77=BN F0FY4,!*H"243D1MPI5N?-<(ZI2+S
MPO>"S8X%^B'D!063;PAR;#!4%AXH'\$/3:*SOAU6&G7=;NUTF(9R!TL1",32DX2<(FBO1:"
MXHG0*&F_EX?>2_#;T L*"@|C|+\$A=!TMF%\MGML:7EL>8K)E \$3 U8\$<"88 MR-
0C65P3R?NE?.ZQ:#!80:~8!% ";R%F>KZ/:=[FYGDRON'7<0=(E7YHR MM-
6HM*ALE1CG/AK7\YWRV:5:0L8AJGSX7E!+K@T<?*JTBVDY63^7!;)EVP0T
MOFQ.&0@A:'8Q'E T\$>436&E_KUTBJO)QCAU2,>Z88X_/@C+6;3
MK\H6H;U.86E\WG>^G;4\$>)#)&7V,=KE)%(P5'O0FI+H68D.U)\ U).T=N!T M" (>-
&VMKXX14;9SK>J=%SE/0*(I RE,\Y>@|RFC+>-G29(UX=3^| MZG\$,X:?
>P@| ^=X,=.PN.D_!0\2XZ7(M:'W\6F%HB,8:8%EH\$D'L)(*B"1F MFX+UUO=RAOOH?
&_36?3RZO+;;X6D\AKUN!CP\$.*!@>> ME
@.R31FF0V/O6;%/*/R.XN.K/1#5#:O(|&K(A;K9X^X'78^520+|QR73+, MF
+43SZ0K(3S;+G\$5?H^N22(292@7 ;KY_<80>-D+0W=;;U(P;>\$HBTKT_+
MT'4.BQ\GGXMI5)KE=QW\$_IC-?6F67R38-2S\$ \IGQ900%'E?!O3S+D4(A\ M8
7N~"%)!AI3+4 7W9G#SZ()SE6-NKWT5+(V!L S+S ?0W>G#ZS@7V MX7I2"4094YH=A\$
I"\$<5>*~8&>3%4C!4HA'<+R3\^ (CI976;XM30X- '\$:%
M^+-9W)\$M/?'<6LLD"B5W3=5U204HXB\$!MXMRQ/O:XWV>IJB9R0<':OR19A>5 MQ-
(F&ZR#:Y\8G,4>*!JHH7Q\$ (\$\#@GV!45\$+DF*FI/7%T!RG-|&>N!Y\G
M!=X(;EZ7.7RSU22H#W>S8AQAE>G\$!2\AEXN5H#48GXVGW\;BW?3_(>O@X M1+
-8&(I'NN9\$S)X8CW!6\MPKDKYA@+CB0:>=;0TQZ1(;CTHZR9\G\UD#2 M.AH V?L9?
E9:KKHT\ TLT(G@FB@B)!5"E1#J0NSF8/..=K@(|6Y=ISK44*: MZ0-7!T+\"|L!Q-R\|^N
JZH*QHY?EUWB+BX*0QN^WLT7'5_+;D\RM A"AK8RQ%3\$2@72EB!F-X
L=THL\$)'GKV.GQNI78BVL?!I+Y8V\-(OL;?R6W M^/+G?.)M(C:G (-D8@|Z#-
|D!\$2YR)T(G,1^Q84\|%ORL;<*I\$'\D%|\\$<\$H M_T1'K;J6G\|
(6\Y5Y@_SAD4F2\$ "8S&5SH5\|S<>\F1&B;")Z\!T2X%/*)R<\$;NC-<2DG"!&Q<9%;6?|Y^B
M9Z2>"X,AJ9KLO\|1/EVD^#7=1!\^YLT#T/E\OXUX2ZS1(6!S%C)=6ZH>0\|L/|<4Z-
D9^\$MIL,D00;8C\$ZWY-Q)Y>IQ\^VH\7UQ;IV.BX&_?^CRNWP ^^ M^7\BQ\|
GEE#M"41I IZ*A(A):9 C4Y>)IM\$OSDW/1?LAY?V0\#" ;D! M_?^FTE8E*24-
VG\ Z\KZ^H-8E&\$"=D L6\+ |T#,VMR\$&K8(1)I??
<*MT4\2VB07+21*E2IL34,*5AU\BP!D)@,58 M IN6"E_ |>707+?V0U'Y%F2Q>*8O\NIK;/
M\^6R\ C/A38IH?VF8V?2; Y6#!1<>311T%J\QKK1UD_7+4?NGL'X&W\0/-R(LQ'
MR\H!O%S?RVM\|R93:6OQ34J4B@4M(9ABX9%R?A+T0J4+G#GKE6"U+;-GB>J' MI)
<38:ZKA;# />3W\|U43_F3XOI+\$R_NXN)MS2*S")\$@|>K4-F 80HYC#\S M0\$6FK-
^PP'U7\|H>C%Q**E3LK6'JS<+|>2M\=T*H2RHA\9FXTH'+=EV^.% K M,DEERF;L6?
#\|\$\+|\$/-"0M,UA=K
7;8H;8K@/7K5X@J1^:V@|D#Z&!:H#ZO_ G@721VW\U/^I^40\5YY3_5_G_ M'Y_?
7W\^X@U=S-GJ;V%^N?|H;?G9>U MY?3R^|6S#V;'+OE_ ;OB\+X'-
RG<@-3#/Z>A.:E(8@RP%4D1'D6HNZ7S??<2J3@1%\0E2% MU&\$UMT-HN8\$\N1_S-Z?
&#C%LTX^HYP+-%1#)@(M\$H8F: ^ (2-(-!=|D-\$Z=M>%|.1NQ#|+UU_=?">I?
6G0BQ7+CR\[*=PJT?FOZ+ 7WZ(TV\$0?X%2>!3#.C\FFY** ?-N,8;S1NF:I?&5F9AQ\$XF
M+P;H^VKZKP+TLXP\$74L \RS.'5YB1AL+PHH(3B<+G'J1>#,LB8\|3MRJ5#WV\7\$TO
MRUOC\;?@OWS_ |%^>|DWD\ R<^ EF/\$T=^;JSW6W72\^9+L/%O/"PO-|&BGKE
M*/6@72Y)"R:745L<8FG,'KCPRM9.KWV*GJ.2&A\5U,=';5N<\X=UWB\2#R^
M)!XYI06'<<2"Y)1KY;2S/0MG\EVYD4\$"QP+B3O;#H-)OP%"X^QC?#0"AA@24 ME0
7!"O=QA(8=%:!:O:0AR3\$_0K.RAD00>?]\#//.ZS*GTR&V%O^S2'HUMAY M&U)P4D5
BCF(P'#)>' !HIV\$*5*WA\O41E'-|2,>S(=J^,G(7.@P,=.U2NQ
MWD_SZ6QUGGZD60D/;#+,UA.?WUXMYF_2;'Z)FP\MC_ GJ^O)*XJ%((D*H*,M
MHBM1A,ATE^3*\$\FZ\#O>CN4A);0=*CZYR?7Q=B(^^-OYW\|L|^X<*B?;V;\$
MWXR6:S9O\V6#Y<)H C'D4,J\6Y\IR KVPT-(M'V*U'?8\|Q'O'OV'0\50\AX=
M1^=KKFYM"4G(0YZ<512/= RXWS,#T< M;NK+>'34<,HV'.&FV'\$3LI'\$K43_?K;JEYRG'?
\$(:^A(63\A TB3(&A>8\T"Q19+D'J"-==#%49ST5B(\$R
M2"R75L\!O,3#U"G>0GDE\|6F5"\$B7)\-J+_8BL)\$WV8H(V07"ZNIH"8O=M/ME)S&V
MG4#O/4L"S4C&LB_36008K320)/2K+@5=BCD/22G\$9S5!\\$NN\VID9;-|>K7

M+;&|2*#!\$Y--RF:X^_4QDD:L%AOK8CU: M,RT!|28SIW21V.23;39ET/A?
C@%B| "5#IP38I!40C: #,F,1"\$\$.A|0FZ&CG7 M:@!A%|AJ::4!|TJ/8Q0-:MKYA|A#H?1L0*N!
MRQ+6B8!&,;)H(ZFJHR?/4D<%XN#065^_KTU,MMSC;:,+,+T6M%2,2+!*5)
MBO%BP7*GP%A) |;^L-UQS&/FXV1N)J M37?;<##1<@B,E2D%6FC>,^WO@-5'+-X_B>-
Q&K4T<K>C;|?X7 M6H8@BYS 1N/ 4RVI4SHGRRL?>#M(>1F)
|P<"X,E,YL.TT0BH=A>53I+5Q'#D M@9M |0Z0
2P:Q| " #53)9ZR,:8AK);HI>QOM\$/8A5TLW++|^|W6OS9%64CRUZ
MXF+'9_FN5)-8P'9CF5T7G|5@O*%, %<:,;,L|3B3-(.DTLG|X:|Q=U M
|=BV::K38'|%_PW7<12:L^| ";;4PY>N-U:7.88!!|'GOTW7@;04,?+ MD5)N#B>WTNZ\$-
U8QQB'2,GI9F!?'O_|: H|5:.96*>0;2R))5XW%M)>3"*RBB32/E^,|L= M|7X*B8|+
I<_IO_SB1^DL=KM(Y->7/^?;UR2B8S0R@!\$E)|E0-MA|OX!Y9012+G7/8|OA|?
SRY!F|WJS"4H4M*J+)Z'EJ4R?EO*: *SSVM9.%G| (Q;C.|W%?:?0(B|XBX ML=OFH0\H)2&B#
(G*2C\$0T>/5F;T&'8.+WD3K>+ _6!56|ZY-@XA U|N57|R/3
M!DZ139..CS_28C;|^FVU23F9?2W".I_G;6V|M(%0*?&DM1H%#@(#O|P#%61*
MBD1/7>UT|)ZDC1NYJ82M(=7Q\$E|V_9/WLYA^GO_I0I>?;)L,R/J7%=!X|
M>X(SK|&2\$!!H28U+BH,01;200M+C)8BUK:QGJ>J|S?
Q(9GWURO4^+=+7TF'8|%O:"V@&* &1%LRP6:IV|V
M=>WW),YL"\$E#BJ*K@2WQCC(Z4,J0?5;1DUYMQO%3;R\$)O|M|T9T%6XI'GX\$
M'2|/#%A2_N72-2S00QH|Z(TI?(XT|NPA4<*|HH+07N|:250_IG|WA++N|_L MR8VL+
^FL^GEU>7V74X'H;H>BHKA'UE',!PM!/E8X%HK*WRO_-%G5'YGT9&5-M?HC*YC7D-
|;BW<|;A\$O#/-+M@ "2|EH2/J1QRI=^|1L%XPW2_|B3/*?|VHN-X MW-44?| #|&C
D|XQGN|YXI6B""=0%*:H|H4P:)G|2GYI*A-+*?:#|F/\$M+2 MH|+Q;LCQLFX1,-<9S=8DE
(D7XQF@8*QF@EP&7_"9#3T?M?:^!|IP;^HH.3G M8'. Q|L SMWX=B<5K64.A.
(Y:W,\$0:P&YXT'9Z07(89@4^VB@X=4M-0.^?@S MYD@I-
X>3#=:CBK(4H0)/HM1+E!/TQJM:<'2A+1,QZMJGRV-TC'NT'*O;)Z%R M@*#'?
HY|POKRF9WL4WOV9IR/GEIO_\$J=8D2NXS6=|B0E8C))D^D|H>YN7.) MEI|PB.KFU>4X-
AK.OG^_F(9R@&|+D&^'|*P/*E,.*@4|4IG(X" T:Z=Y;JG.6
M41K1"Q!/K=)2H_3#;Y*ZPFP5%9L|DQ1-F6:\$=2YSJ#TZ|(8J#2P(PFCPD=-^
M|!73ZXS8;*2>)0O@XP"QCHV0C|TVWRV^K8Y|I*K3FA/P%);H@#: %VDHX%Z5-MYX
4E>.|\$ "W;A/|3>E^K0F>D2:@':55F1.*5RD-MA"-3T;#82^OW/WG\$'C|.#Z?
THX8VM^?/IS|ND^Q""(S&#M&6PIL(#T*A@ (05! MLU|TKZ3F>Y|H@-E(?
2^A&:"| "IO&L:0=C Y%9|UF6|KXEF|4XQ*|+
MB%O)K1+5QPKL(*6E>2FU,RX.DW=SL.GZ09\C+2Y^G-W.BJ(3I71@JE2P)8Y|
M.=Q@GEL*7)61|H|QY>W^R3F4<|::MI72+ X'P)+@J::41M#W10XUKR9)#.UTZ
M6|H.^@@F\$K3=A?>94969&R)1K+7^=D.CJY(&QC9TSBZ|3FMWI?0?5VZ!GW_Q
MZ^RR--?|=|=7V2L39UTT1"J0I-SG/!.TWI&UC!N&^Q@/H|,>#^S:VN%M W4
MV1UB^*_D%E_ ^G"/W24M#/22B\$MH?4H+3D0.+C\$A*43*LMF-1EX.6TB|/">|! M-
/P7PW<) \$TX8=SED,!J*D"XLM.-#9"DBU:SP'2H?+4YJ&E|*+V,+ZWE0|: M*"|WOUL,?!;>E-
Y773=L8;0'(UG GTAS&H;Q7PSB-MTQH\$AWJP5(.B0:VGFCBK,=
| #%W; %+)CBM9NY%F9A9;>W=N#^+XZ_JM_"PC M0=<28++DP-
@,*?,R1:J|@+@D2V*+SU:Z|*JG&M;GHJ4W@H: ?KBF6QPU|=8M
M9F68PJKR8!*S+G7MDH-1OIOSQ8CES"A5>|C" R*./3S_Y7:^13/?J2%^YI^
MORKOM1|S)|WEQZO5!K@|2)QW.>MDT"OBG8:-_j6^-:9B1|HY!6D\$0C'PY-8.
ZU@U2|: #EZY0)BGJ>K#_/EH_M<\$|??|58.%V?=\$\$89U@+*GF8+07(-)@4" I?
F=6EK?)Z@.ZCR={W--Y&!B>
M6)G|X|>N|3M+7TN_W" _58/Q|0L|2/814&#G|@19_2>+Y,B|=5^>S|Q5>@|_F
M%ZC2#9=EW*_CUN#U)!((Z4M=BK6@C)\$V*\$&LJ?UVO">)XR8V#-+/(974P%&Z
MGW6.+ "G#2A=048PQ%0)8800DX|C45F;N:GN*|?VFP;(3!L'?<H%7V|S|.S M^_
|7RZX9|41*K66.&6(QSX54\$5P2I0&^X=QQ8|!5/ 4.GR=UW(2"TR&RLM): MQ>83SJ-
*B69&4(:F%(6\$DB9I!44;1&N?3)2\$U'XT'<*U'^SA_Y2G8Q4E-8#!
M^S);'_**\$YEB&1=#O2DM,#PX:SV03"+SGAH7:H^CQ(R|B|/C@Z7N-HF:S
M&R:6,9*'D'::: \$ O/V5PO,S="|):XY+6A@R.FPTIX|Y=GP0YAPC|)3S,/1!> MC-
/R^>YB|VA5|6VN|UK5G^<,X|+2" |U.?/*41)16 I\$E<:>TQ_=42>"::VD-
MHO;^H(%FX|KGX5N*5Q?I8SZ;K::Q;);ICW03_GG|,UQY%5_O|U5JC
M'Q|H:E:ZK|AB)|I0TV0|_ "Y*P5ZKY*05%/G8SEF|?/Y'|MYB|4CC3KC
M7C|X|: #^|3Y2,#C'2.RUHG=/^=V5"@_N|2X3|N#P&4 &3=P IW|Z1;QNL;04?2E|C^0
MH(+)M6.-P|!Q|CWZ.&P>M!1>V0=-X#S1RZ#Z|\$5DBNCT\$X0&AGQY>7<*@_
M44|9\$CK(VLW_=Q(S=B_WL7%R/|1>16D-H.JS*CELH;Q,%E;^F\$U72|1#MJ.U

M+;JJ01*RU ZCS%PQ#F@A#F==%8AU#XNGR1HY)N]-1364UX#2\$2S)H7EVX6
MTOJ1?;.&L?B/N*6 "H(&\$1>L5=E;PSF5KM<_53<^&@IK?'G MJ).?
JOW'+Y,7=;1UC4LH8/++=*D8\$D30!%Y)";K2BW#@M:>V2K)W\$C(R| M=GR:.NH
'>WZ=_L1JMB3DOJ*.6QZ/4K"8Z6L%%4)CH|S8VH'4%^2,7(EEX= M|=Z?
L'&DP+VFH%5\$#XOQ&#C9E!OA7(BOB9'"U MD_"?(&?D@1Q':OK!C.PZ8F|
04>>W!^NVPS@?G,9A09,YC*+I-3U"V,AL6@= MGNM1T|H%H|5H'S<9OZ%;=!0PO/Q-
<'8YOYJM)M%\$3|ML'^\|6LT|&|PJ&| & MSX3HLA9\$M|4#UH2W^/PV-;J O| #2
^EMSI38U8IV_=K9:ER|N|)=F/W#% MCNV|H|VDE-Q2J1/(O,N
0X6FEU8,"#=:;)X\$GCN5|7XDR2V^')X8Z:=4>HM9 MPF_0=/OAB@IN>B655|9_I/BU5
\$%- \$ZG^0ZD?;|K MHE&_6R;2'9 Q76??H MJ.'ZW%?*)'Z4L+-'"LS78:+^?+J5NJG)-K+\$":
|J432W :K);%!0PX+I1" CH(LKBJM'BN3' P-%C07%GIN99\$#3' XBX5 MK8#I
*4^_09E;PDWAY%;|P,F.)Z)R1"#002G(\$B@F1N M" V^WSRW)Q9I"1&JG
^@#R;.%"VQ^N_,.YY5FS#);"TC8M!C!\$E,1>ER MPDM7^W7C\$3+&GI54|JHY3L9-
P.3).4^4BZ"|15O-\$P)"&0E&4PY,:>JH2D96 M;OI78=#6"6R6 Q6^WY"M?;3?);^+
QLN6Y?>|AX|U|T75+^I'6WQ=? (761 M\$63V35K__^^+>7DS^N)^3B3'/>>|
>5=B:F7(>X6#UPN4K1*&B-Y|:>T&G2W M7)-=D >AJU;G^?K|ZDY?1K9Q"<+3>.|JU?
^#O:&Z4)&\$IFHE&J27 - M.ML (E(*+@L!4G-+T>OEGM=WZHXD>NRI<|7/TU/JL_0?
EQ|2XL2REZD;VfV M|!@O?>G^F.%NO)C^_15_S"|*DYL MCQ|GM|KX%M,E_N@-?CO|NAZ-
C")8;|XR M+-0K\$R%D7SI4. (^D@A,*"HX9T2+VE@>BI>OI|/5A7@3&F|_9|6|Y|27):W
MG/?+Y55)@OR8/Z>8TF4Q|.^H<1,)'?&0\$Y=#|Q(2@%@_KR5I)<&NM,93SO
M1^'80^;JHG1 |;2 O>O!&QWY6P9?SY+3! M,Z)B|=2\$I^@9>
|;95S5DGP#*+J1S7/L5N|O*6B7=NNOBGN|C"|_?A#S|_ MG9|>3%>_)B&H&/(("DNUL
(N,0%A."8#H\$&PFK'!@^E=>PA9W4A>!*--8#, MARR@03HA*E.6.
%)&07A101+B08K5+*Y|84,?:H;(>^V7K M(?#?+E?32W3AG|X45F<9G?
M)JT#Z60Z;.I@VF4#9\$?QIO<1;|DB(8@H|XF90M#*;\$>H-:RV|BG'79"0T\$G
M0UED&F3T&DHL%TS)?..?"4*^%%\$K4KLFK8R@4*QW*.6, M??=|F;..F|9#_(-
!|9'%#.#=BVUW826HPW\$CM;+M|JVDKZ
M+;F2J1T_SCZ7AZ+%9F|0\H_9W" 3XD>)U| ^??:J:++?'G|UG ?|1NKWBU"-<
M,BW/W45:EE L?MF)KPO13@2G*"T+X41I(QV03?_9O0YE2;>Y,2LK#UG?\$1V
M^VV"%Q,8?2G :6""/>J5W'4@0R3.1|) "VM Q)*+*B(%JJQGGAG"S'.Y"ZJ
M^B'VQ<11*ZNA 6"|QCU5|X2:L)=?'\$ _W_XL78?2JS1+>;J:>&F|E%&#-QRE ME=&
|<8H(P"LI9F|C|)VJMPS)/6#U(L)H|940#MXZAJ|G,WB!_P'CS!E'(G. M!
8T"8X",PYLSAI84"JCWS1=I^G7VD!VB MA<|9>9!EKK3(O&M,ED&9S)4CE*,/-M")M8.D?
JAZ,0GE-170)YV);N5>'CQ MV=Y=S/_LTI"W0?*SC(NCM5EZ\$WS-
'2:?)7RO+1L^3GABEM9SNK,2|HP8@PX MRRQP8AW#/Y*^7Q,U6%;C@2STP^N+230?
4|\$MMDRX-ETWOE5I&'!33'W,&+6> MGWQTVX-#. *C4V.!ZZ5OK7=>?
1Q:SHVCV9|L8"*|JHE26O GT \$+DAI':QO)3 M|%0+
|'0N>2G"O_72_XACCK_P^WRVN..GEW_?;?="+M|FT_|!-WQ=\$|<|HT03-M
ED3"X+I4J;/26GTESU#!USIVM?TD/R,6S-6#94|0S1C0Z!0^%:%J|^77_Y
MCREZ;8OP|=>'|"-==7C@7+O>"007"P=+ D'JZV\$9\$DN%I%SU4>\$|Z.L\$8B.
MCJ1=\$*^GUL; NA%M%_5|R-|VQDVDF5!%@*C@05!11"W^%?
JFM_>U*5/8HB1(2,0\$RG#A(D#0W*&);CBF3C|JT|%(R. M1FS,)H
RKZRV|J!77A3.NQ"F73+=8TSE* +G>"%9W'0@ M NY#G|6#
| #7/N""%|K)ZNT8NP1HS>%M%:7|/\$-H/5VRO2=E|M. V>K:Q8G3'L?
MB\$!7P\$4)0@4'>%%\$-.*D902Y(|V0+,W<=>|V"FH:M<,H>.P*BR|+5YHEW6J1 M=
(L1D9C5E'N0""T;H9P\$'R@ZK9G1K(URV=X+(^PJOGEBE7\$;_S0)N;J:&1MB
MCTXP>ZRRE@MK)\$^A=\$@LE4E9@Z,V@|4DT>09_KQ?K5??
%)Y3X%J;D(S7MGHGUKT(' +<349/H'5|1+2;- MK5,&O|B?U2<)|?SDHY/F#N&@4M+
<|=*/S&R)(; H+07\$H2BJKRC>LIQ#HIEX MP7/4I/|FR?(J3"#;?W1K^>S%6|!-
N_UN'=I&0LLT3!H.9!""D S_4 05)O MO2;45X|^|B1FW!!D+30|_@JM@NR;N\$(WC)Q=K;|!
%^4D+?DEQG#ND.0>%CB M\$1K0\$@\$@NHY1XMB(P+>_W:*B'H#N4-*?
X|2|"SR'R|Q)Y&R>7&5Y")4*C4B& M'HP(E)5D)028RXHQ C3SRVA&|7;0T@IXC|/PL=
X0>@/(@0:K1G)N&UV7XZ>+7 MYE\$|*:6R|!0""%<7|"\$|3Q&HI9*A1|*=KSZ/|C%"6H/-
(3J^7TUAM, ;0,V= MXL+_=[68+N,T%+5LV#%"JDR(@|CM)Z\$3N"
91)IE\CDR+VJ?/;^0-.X;UR!(M|JF\$|C"U*2V|NR|0#C0EC|=Y5F6XH|G@M Y
DG,\$Y>-9|8'TC|SQHO3(.@Y M6MP-0.8ZS'%V<3'_L_3K?
O7KS8:4(J|N_6!|TV=C7500@BQSVZ@"JLIAH90A M.R^RK ZCOK0U+O/PV8;XMW-K%
(4,L6|)(BRWX%TJ;P;*&QJD M):G^>)|!*|G77!I&ZP^:L1RM@A: |*@1:(VWR7E?

BHHEB*=@=6\$<3!\$&H%8S MPM5?W^JNH>%>-
O<^XA|HJ6|S6Y>9.M_3PI6CNA2M;SE)U\$;#162%/JS@3N.I
M|1T\$AA|YY<9NQ)=-5@45FBC6+Cl;(D54Z7WU+<,\$5X#E\$P M!2J76K5<4H"8|<
D1|P;A/S|F9O|P>3!BF//@#L)8HZ3|C@Z1|T9F|,+1#
M8L)3EDM((I@D2MMU"E:4!B|B,@X(8+K7KCIL=C8,17J0J;V=,=&RQ|,_,|:
M%W;HFC<^RHY7VE-),C|ABJ&L?+KG01B34+Q4?L@|+-K.OBS:XT|V:PN5BK+
MM@6H;/K;|>)&>L.Y11Z,+F6!CH&))H.A-&F1|)8EM#=#2GEQJ|%%E|8%23|(-
M>\$./!2\$^7*>K;.|*;;T"FET"(9T!G|)!T'/EHX|*FGO):X.|H7_8JOIM^%C@ M, ^A1VN@
3C=LN|7B5YXO_G2+N)PD03S5G(/Q N_4!;*2,E|FDDGB96+9 MQMI8VDU-(X|;QZO|?
NNU.O(?^P+;S<;YE?_O%%9?YA^FE|UQ|;GJ7MZX89-M)&.EZZ^'" /*CIF 3*
(W0%T2"4|@3TWH=;|=2D%|(>7C@'4Z=;2+N?>SF)T M-EVE#|,.)M23S+-WD).V()
(U8,O4&4^5#4K*H\$0\F-W5VSOUAL44T>(NX\$; M|
(I9G"Y7BZF_6J7XUBUFR.+R8|X\$,'_' +=QZDHJ^H1JPS)C'C)QMI34U|<2O+H.RR
M/.Y,4%1\$)&|A.CR?!?4>' L&MX|F3I19.JEVONR^-(X;C1CN5!M45PU@|3XW
MRX<,3YADG%*+OHU&J8D4)3KAT8)4RE*!6|SJZHF3SY,U;D'3<(BKK9\$&0/9' MJ>2;?YU-
_IVQM6FOOYPXG;((B@*-5@,ZT0*,Y0:BHYGZ0)F|_1|P4Y|E)1Q MAZ0/:90=+_EV
;0MW/LXNUT2%L+B*L6)=(IRQAE882(((S48GP)H3US@P1DN M:R>>'\$#FN)/43PZ|:AIK
)0/#NKNH;OC:**=S#\$X"B0(5K+!'"B6!7HX*J:#WUEWI S|ICU\$|Z5!ZJ@133|?
8&>SX09BH.\$@A'5M!|++&WT,@>2.&' ML9PI'1I('27|/0"(_L5!#|VC.(!"S8P-
9_NW\$Z9EMB1;(#\$4|R(1<GO M8*|CM0=>,.)|,|MO2O+M(K_2;V=,;4W2ON
M(L%'3&4Z;L&::2>.Y?<\$|2BT\$)(J0B&AP5-&Y'CPC);F8LP:KTW@U=,"!F|' M48+!|W
7K|?K%>|839QX/ENNOYK=TM%6%1-'>+(B*7#\$>#RF*0 MB)S\$, TK#B*WD0R*
(Q'U>#+.|IKP)(_@-7.43%Q-'!'.7 ";T*H0V63TA?\$K M+F-F91JEU?
6;2!U*;2,9&>, #|1#MO4R<_C:=;:6ZVS#.V2S>_92W_W/5C;I? M?9OC3W|@KZR'U#-
+;&8^0TJH#)&216_*.+1|B M6<4E; /:A|/621S+^3C@)
M/@|?_G.TZ,;F|_HD80"M.96_SJ_(O?Y_C3V0D)PV6^;D4VL80F86S VRX&
M\$\$.CMK2W\$!2QPI?^|;1VZ!' =AK)=AE_ :PRB_|/PC*J>#XK&WSK)WVYGK%=
MQPWLLT)-OV|OCD|@Z#E.K;+.@S!::3"!*YG\$CM,=T#.GJ;F>SW
MA;MY0|LJUT+@F=/B8X.&.4&!'42K,|.(H^!)LFT4+4;|!Q;MNWCYX>C!:
MXC3::|!ZWG|Z\$P^R^J\$"">3HPRD8*\$TO|)@E2: KJS\$*X8\$%.XP8-Q%TKB(
M.O4R'@=D%36U@|H|7;(>,A4|E') (JA2EB)H4&C:> ^:6):R3=:?3Z2OA;VG M"1LW8C N
BNJK|T<;B(?#|GOE&HO<#|11%)Y?&=@>(Z |XC@01/OJDM>8:D
M<7WTD4^_&F|;W4|I#B1)D?KC\$ A(2.")0|VZ0S::T\$, (RGPV|HSTQ2-Z_R.
MB|D:2FH@TK-|RCU\$BH+QTN_4@A(^4W&E-V5RKP_@4Z|E+)|ZVOX1Y+8;SC_&
M(3F5_AHX';>L;FS=71L0F3+6.*2R-)?DP&W3_F"&UMH/E1COZMIK2\$|F|'.
(WFCTL@2VJ@T-*!5SQ#%(XD1DO95^V7|V=(:J;W5CH
MJZ&G!OR:76RHE(EC.8*D&D44"9|D,EL(*8A\$LB#"#C::IZ5#;BA_I(;G%|_94MF,??)_Y)IOO
OP<8)G7|CWFMIH0=0^B0*1<\$X
M3R#ZK\$U4S\$GWXO)Y'PAWQ_8XVS|@%&OT"C_YU|V_1_-T0KASW%,#VNI8@DIX
M^JL@7L|E@5G5M_ONEA/-C48:/!"!_4|3SK3|C!|NRZ""+19!\$> :D9_Y%1R|M&M3X3J0%1
9@<;9KH?J>W:B0/_LJK>OBY)?(MT MAS(B_
X|=QG^<^|78QDN=LRRJ4M)OE>@&@&3Z^<=@_*W^?%K+|!22!_&X-EXA5CG(D(WI9"
M#U;:VTO|0VF)WH(T;C!,BZ?)Z^1?G"G.1"/UD^|T+M3EES;)@HF5"310> H M.<%5_\$N9
6;#\$.2:V MM!^V8#2+11L0891Y|)|.#L |J&ZD8=QI0#J4-MO%;|F62,QT=5V/&4V@ (6LT
M.61*(+PWI3&|_15D)\$HF5;|_#6%_:&NDW=|H#|W#-M(NX3XOI?/%?R2UNQP>H M|T1YFX
J7GK12@G.\$ F;:A4235)4|_RU!WF-M)L|/#>Z.UD^|T-L>|V|G*+ON
M=.|BI\$Q)1Y1PP"GE(*SLQ@)|PH-%8Q75_8^1\$%N+C|+;2B.ZT=_12FH7@3>' M^F?
4(E+X;4*D(|D!=J6?D9<;G A&8C**9-D(IX.4^3?@|A6VM>=^L8|2#G|
MH\ZN43=+7UU!>N7XX/^NA9|FW>C4H%|_N=TN>Q^*|17EY/D@L|H^Z-\$K0(4
MJ"A|V|Y|7'U+B|/XWU?7+2L8"8;: M #I8AUX3H>!X&<83
AH5,CJEY6E.N_NDM=)4|S1GW5&*;0EO#W)JM2(F!#"V M9'S;3/# |@HX"M"\$R(QBM8?
8')68_V*>-VH*?L1,OF<.Y5N!GX|=>,"!|\$FPI?OA|6|:IQ*\$RU=J0_FR7*E
MN0M"@F<6=PT5:(MR*4|F+V7*CID|6*+@?6+ZX>OE/D@<)?Q&4?3ANCET=DGF MH"
(JW)89=HY"Z=R%|J9T)/,4!|LV"P!>3MN<_0.E|37#>1P.--TH|S|7 M)UE^Y|?
63)/O1_L)\$N2#)(Y4_J_+ "_M5P5XFS/\$|!2CFK)(!PM^UT^0?WPL MQ36S)@6;"(M
2FV;B#J_YU%"|BY2X4ED<;@JL@^HIE/LR0/UZ?EG^O|;R+&Z'D9U_M0YV|W0G=2-
6_5Q2DC645"+T/O|?|!_G%Y<=):MG5| MZQ|_2,C)QY@@.IY1A;:"BSX
%T2%D"VU9*C60WWH&|>>XY3PJZ6DL=^!'_10

MNC&'\$WID=X(0/HLR[P086B\$@G\$6VI\$4CQ;J4/>?"W8\P/3.'/DUQZW)& !/
M0\JQ;.LRP0KML(B?2NFP8\N0L_\$2J&4(OK0H*5H'0@&/@A>&CBD0-72=<=>
M"J*3M'&K,4\JQZOFF81A^9GUC\B1N'\$H=&9T1I GE!#N\[@=I2, M7%YQ-1JH%BB
!\$1)C8*Q"DP@#*S)3&>MI6%L<#MKT?<!\&JY(MXJ0FU=Z2;Z\I8Y\BWE@>;XQ##Y@H\
(5Y\.@+,.S07*KB" MB%,BZTB=C%\HLY.SW\J(CR5DI@{(3!*L1G3>-@J\X9J;M-14&%=(Q<
MXG!*.TK\;;J50^Q;5XI Q>6HKBL<7JKZ\;@;JUBAN\MO TF*RCJM8!^500&6\8YI-
EP!07:_% @A6.Y M4D
<%50R:50^S8U\;+C_%!;?:4!92UVMP_+6:^^F<23UQELI"&21"7I+:/9Z M92UD'D+PG&
<JY+/34Z0UDRUR&@@>IYKQ@??X^!GZ==OJX_YCV6:\$*OZ>1N+ M=>U!D&#
L;*M=*2>I9 R.? "1Z6:19O(V:F&FJE2;=2S6)>7D,Y&)Q75:E-"! MHRVJ(SKRFEG,J-4?
F3G(4\0_OGR+?XC3'S_XJ&/ (N<-1I?ZX_<J@W/\$HIO# M5\$P@+! "@+!-@6;;;.6^2'
I5C\33\I%4+ Z6@E'XVK@R-J\$ "J'+Q&;@T90 M,PU@ "+"
(5"/7\NT25KMWT\G%*FLFA.,T1M9?@&Z\!>4NRF/%^>45G7*3Q_[MQ)J5A\J2?
(*B4QVC#CF6A-.8\7I2#\$\$S(' +1SCD?*!0V#I9@=KNCT>HF;)X@@
MDXB2<(C"TM*U.);^<1;XD2ZHX%/JYN.JJ6FWV'0?/#Q\7QTF_69MZHE\$^J^ (M4
9!E#QM4F;.:VJ\X'\L48-)P.,VF")Y5*ZH8Z>'22U.S.HZAUVA\YJN_/#V,VEL"J.
MO\Y*:1W^Q;8XJ8X) J M_OJYG*O96G>(>RW\/%59S.OIY=SJFI<)M@=(OC^?-?
YF\ NLOI;-U& /*VN M%K/EY_G%Q;MU^? D\!EUPCWK+/6X9\ID#1\6'Z\TA9>
6\;7SLH;FJ6\$C?P\J MWC\@FT)" Q?W#OXG4E)"HN-@A.0@C-)@5>2
)HEP0%MI7.TLB1VDC(O#MO_R MKZ^ \@S'X/2VF\WB^LB^M6GC@;+I4_S
MY735%2,"Z64 AUTXM%Z\HF#XZ0T%4G<9DJ%K9XA6X?R<9WBEXCS('1\I M\ M.-?
=L)U">'8V2\6M!.*=!9%C&4CK\$FBN@Q9:!\^J\W;5H'M<3_ ^OLOEJP**=
M9IV=/M(^K\$>E@I54@\$R^7(ZBM%76>!0\$38P)TLCJ_7\JT#UNO.(E\HCA8-'N MY?
XS^=IM;I(W7B._YRNON'O%Q5=K;[-]-%&(HB7EFM0AG8%+AFLBQJRT5EG MQKFPM>.
I51D8-!OKK\YJ@*E^7OC\WIR->[^T+XX+XOT\=JOW\Q31T87F\$
MTM4*_^K#J'*ZAM5RPI/"4Z%8CV76L(@\@??X+3?22>,2;EV#I8\I!\@WI^TE
M;IR3@;:Y\3.1T1MG@P;B*'+#>08?7_8J9=22V9!%[1%XDPWDMY M1\:(W\B,,I
:R^_7\Q_)?SMU73175L;J DHIT?(LOLZVL=01#42U.*[TL(>\$/5(I%Z*7.
(W/('7EV>'#T8+048PBA'\$"I1O=WC M'N15>/(@N^_-:F:QRYU&WV*U>%1?-
V0LUU,Z'!\&6+QA(\;FQ*A8\JH8OPTXF#?2+.Q\P7\U\G.*#@)2099\FQ+
M7HIBM+C)%HA0I7=9\$JEZ//%Q2D8OW#XU)!X\9\ZMGR91\I9^B4;1)&>5F>(*
MLJ"EL:=D8+Q*0,K\$(N%T5B(/CK,U+6,_0\ZOYV>AF_=V9" MI4N?%H4?
Y1D+X*5\$(94VG=T\$/4<\DT10E%+M&:/T=0:F [1_'Q-30 JS?) MK\H\!" *H+J=AM2KWD*
9VE0\$"@QX7B\$27WQ&=NBFO&ZV??WZ=BI+80(HX M1^JE.63\BZWV\I9\$K-+2#W3%
(3Q&L_U@%Z^\$T&;C+3(^N/\$J=E;+OJ.!T_ M"9D#!3YVV^:W>(9Z%
JYMSUD4VG2YG")^_3Y?I8^+ #W,WVQRT4963FV= 1Z=\$
MYWW7#;T,E(A.:^T,O_ ^,LVMB;J\E6T++H>J=#R\K)HZ>^ \?WJZ\A3E?C\J-M MTM?
YHA1KEAT7-.6\$XRVMI!77ED2>-38D#5='8Z(@+=H "Z;\DC=Z(901KTJ32DP!\2
2\J;H>7A>72"\$\)(7>0/(>>V6WS:4!\\$URT& \$BF#H)*6Z7:=.9.VL" TJ=XS\6;U<1V_
M81!RH&P;0.6;;0/-\J+ _FXOIRWS-)J'Y:D_Q4\NL9JEQ:M?MW_U.G+GO#3!
M&P\$A:=P\$2F2PP7((G%BN@M",^=K6U7\$DC\YW;6R+ZX0;:PS@MT*\$\$(N"65IR#
MMZ6+>C_6O2NOP&N!'#C\2;J=[?X\$)2\;7Z<\$PQ- /% S8P2@I%9@H\>"Q^JHZQV
/0A%2,'V.LA MI9* @&X#*09= _=^_23\7K_"C_O4\/^#J*ETN)Y(E&M'7 *(L0?
76HYV=%J% @X60"2U)+0BF! M&!\-# P@O-)<)P3M3HVD4%7&D=C"O/W4O\U^"
0/I,ZQ'9H'&W/Y=KF:7A;: MBN7E+DJDZ_9FG-B4%'4^0LHAE#\$K%GR*E1HAR-
2#3E7M\W.DN_P*>SFD@ \ M@;Z;.:#;OB_D_4^D.C_S\2
O<7ETPMTS""YNJD)BL\$J6H3PHO<;LIAPQ*#4\$(M'U1VA.D\!)C\I1^0+C\$\$. "
(U\XOC2B&&+MY *4OT(D\#8ZKJWELP^ ABV=AA??+#+;W+&X,J-*<
MQL000";%48Y"@^6,@/:X94.(BG+3RS+8?^W1AULT8!H,K+\$F3\=;%?W;\$Z8
MA5+FS(\$FB9<&J\10<3P18N3*B<#+8X2-ECY(V^K2,5L_/XQ79)#XW7W\T%I.O
MZ\I M@_?+Q;KZXX7BBF?#*6P_X?P\B4@761 /!"VE3S)S'X>LG>Y\$Z^H2.50%;
M7\ \$M#OQXIHX\A*O+JXOBBSX0QW""%ZST6;I^?5^ ^1RACUT1Y3A'MUI23M!RG-M7G
'2A)K50XJ5A\;>\(R\O/P+<6KB_0Q/W)\$/'C%(9)FRZV;&T9"H:VN\6
MMV)P@@7#DPBURZ'V(O#EE*7O@ZK\9^AP.FO \$MA1\FK0HD9/CT&B/) ?S/X"A
M60'W@D@\$C66Q=JBJQ?+S_57?K\Q\STTB:9-=@5U!DV5\$(%J668<>@4F"8G;
M2\;IMOR%,SB>6DAKJZ'GOF7F^PB\]? \6\ _L@DPD1@7\$E_D_4AKP.I4L9NFX
M)Y9I4KTX Y666F>^E^7W+S/=10P.P>BYUYM%*>D\2(H%="#*Y,S4P!+*,9K-*1
M*4*IB;6\8AQ YMB=S < W\#*:@"/#RV)&T/BQNE/WAD>0@;D@5A) 5K)0=F M@R\-

#'UFM;MYJ2)L7,R=SAZKKZ4FH7=V.5^LIO->-%3\|V?Y8?Y;(("9JHTK6\$CK
(R^Y+66K78T.)Z%7OU-MOG")\|)2\$R*R M(9\$;4-\$Q\$-P0L!|Y-"\$0A|N;,#/S.
<|*&PMJ>P\$4*REKR;1^/J;FWU-|Q|&MRF|WBG6.9U+B2)ZC>7M8% M+!
<;BKII99&L5(5!@5B4I;|PB44-V)(;S|FFJ+>*|!\$=[^MF=|&RA
MIL,,C!./1<8(7D5+3+K.X\$ N/299HG7.&'^*=.5I"GNKOOXE?VFDP*Y1^CW'
M*5|01WR;SM:L77US.=%%"AN4!&&* L52|?M<0=&8',F3 #9|K|73|/5683T&
M0MLHK|M#^?I#|KFIG74P2/F)X@!'Y(&CW4_92@67#"\$9+ E21M5T,-C|UD2
M=X*G?|7P;?*"+A'ZT^62OK);1M^Y'DJ<(5))3"F MCNHEL0(ZR8!DP>A \$5'I\$|S(C\$=?
79*L^'K-)XE<3?D_B|H SI8AUU"=-V_NZ!0J;-E MU+*4";2R|0-9|4_3)9
MNP'T?|F|TEZZ;KH&?(C2N'P<|78E<4SUVZ30?Y7"2"AI6-%8|I'A;.04^&0=9
M5MSZHX7.F1TGKM5RN+5)>/N"/5EO'97;.84>?|NIR;?NP-8|KDJW'S'C= MTQ-
B'=ILP86\$Q%;4ABGHQO^-?XIZGHMJ#LQ,ILHKTm7>; TY7J^|<0&:|(
M"ZED8DPF.H2,5F URTX'EY(>OJ|X">)ZK;LL2A;J*Y+3-X*[X7"+*L4INPD M1)=KF:%%'
(7|6G48&4;D,IZHD&D';GL+.\$="|2*#|1+&C|^,4OI=RKH&;K. MI.\$,@I\$<2N\$V1(?
>XTEK4/8|ZT>HP3LQ0(|7VYE6GD1TQC!G@;.%2E|?P0BPR
M!HE1A).3C|+YW*GFE2LS3)8@BP#EZL;Q MD"FD4;J
X"P*R8Q1:O@|S|=IZ|5D|2P;*"X+@_Q'8H/MMCU^LG2M &K8@'0% MG(.09 *O73:99,#T|
'I7B3W6L|W8O@.I^8N47W+RYV*!*=,|BH&2,Y;4"5I
MLM;@@1A,WOKBDQW>S3Y.6Z^%?;-E3PX^|GQ^1NVCMVY?|
|=UO'>=3'N=#PG9|.F@9@|X473*)C;1S='1)1#0;8_*;5ZX;%! MH"Z>APPZ2G+F3"
\$KP)\$9QWY=2F+M8-#<4^B>|MY&AZG0VKU_/;9_(3T;R_M?
_GV0OU>^VGV0?/72)IJN9|8J| MPH4HX!C6%A&N 7-.P+ED+"E^:9UP?I9|2?92|^|H|B?
91^@=@.??%Q1BLMI 4 MRR!;I^J2*06NJ+%",Q%!V1%P\$F M!0;U6AR"
<0ZX+J5DJHFRK1||7L|^DF/-|2R.L#C;NF|CL9PHQ,DSCBH)#3%
M\$A@@4;1*LF4LNN\$W%Y_Y?D)CXK'V6NH2>IOUW|M/.39*43L00P>OZ?B.R 6|0-D^H|
(1%Q3|AR?<+1/8&ST' M|S)D&VJR ZA>!'*HZUH|!9A/K.M^JLCV97R+XRW+%C+Y1
\$Z,&\$#|1XU M)OI<@4V!+ #R88IN/-FQ">&^|D#U" 7B-|X/VW0I&!,G61POGG=*)
(V|+5&Y\$,C&BH9^L=D>IWQ/4<|< Z|2?9/2A5*EP
MKGG@(@'W=1|J3!&|BP'J#\$YOM)!>M9Y+/3!+W>72(|A-3ZC|E#9+IKYQW3U
M|;D5|LOWLU_ ^B'FYW&YWNu&35-FDD&N?>ZUF*-P!,JE
)NMS<CMTAD_ =QT""*S6*+U|6ZP/PXV+^7SD^|N|F062.I"K(GFE0460(V6I@IBC&
MK+\$N#3|^12<|G8%,!+03V" C5'WRFWSN7Y\$06|M.15I^MZ.F\$*(4;D"2+
MJA038Q|^%NXT0/9VY_#Z|;;9|EZYA3X^7R&&&0,&J(7E|49!"8R?0|C|SX M6B\$Y_
:A@9GL+?Q|_39Y/-Z-,9Z+|H>VS"-5U^M5Z.W|86*V(MU!K2MS|J, M&0C!>|#
(?/#.9)3#=#_1|GL;>KC&&S|0;Z|Q+3&|=T4^8*%'H'\$"RNKJ!\$1|>
M66*F|K8W;*77PSOS+8)Z2U9:8F&'N<:.*;;32;'09X3BO%Q+;)*S9)I9!*.R M
F62!+3!02DY6,Y2"F%XH&U3U%08?5*D':R.3J'VRQ_?UPGW(_L_A!<2G8T@ M;-;
P5IP*4HH4I4L@|#V!&LRGJ:OMTCSI#!LI+8N3|DWW^:+U?1?:U5^*/=J
M2;;S33*|F(H"EI6H8YPX(+<*"%.NCL0SP8O!;DCL;W%@B<%ZQ */0/D/E|6
M,?'>:5WW,CHLK\$YRI,R;V-,1P1FHS|/9R46>GK?
_(TZ8PJ(3=8PRA>&*3I"@HX)B',NA^+JP M;G"L'D1Z;V;.3XKCX97=)<8?
E_\$\$C4X>M0\$FDB/9Z@3!"@&:|V(P|Q)CZRE| MN|+6VQZ-DZ*T@;H.A^%|A1\$FL-F^Y*C-
7&M3_% V96C/CBA'(D>|H.C.H5Q<(XL-6>>K"JF.#X6F-MPV%ML/-;=_@AX.2.G
MOI'.W;N;>L@=)*.036*4;Q#TPWH#6@!OT='!5Y+5.?IR@DD;P_/96V@_KF6-
M@)VSLZ^'^=#|QV +MVA!6E\$1!3S>|J7E5X!AN5TB'R1 ;56!;O= #|/J@Z;@#|/CKK
M(+IX8B TK_-.? H@L>YT3?7UJ9::YUY+ H3+ZWCZ_,?P+Z7ZG<;P+Z/'KI\$
MT_50WFPXB<:"0V2@#&>U.\$1!RMQ)HMHUS7N7SVH ^UYZWGD ^QY"|P|+T|^
M3L9RX8L"(6K+LF)-'Z:>-O(\$*LX%J,RL,+K@' #M
MZ;@C5Q.T\$16P@%ZU3FA&8K4WLQD!
MOILO'@|HO>W!N96B,"*0(3DH2I#>@T<@OU0@IL*"T47)YN/+.Q-!;SU;/46!
MO2.R|S1MN|SD:-\$|H|B!OY<;53*DX!K\$Z1>5Y@6 *UDVW7"1/XL/6|VJ|H-Y;
MF6Y/)MPM!CNPW.;T5X6|U=%R*P3R6\$GEXB!;S4@(3H%""OI-X"J"P@3WK6M;
M!F&DMQ+=4UO5^_CHP\$2:A/>W?N=6#LD8&15WD\$RP53,*G*!'?K'.R"*LD_J\$
MQ|4QO/168|O3|7,RC!R=XC5KPMK|NF1\$W7Y2-Z|N3^|F>EM0E8!;X^))(% MBQJ"U
\$X%R8FDDEJ7KT^,\$N|73NV?K_J"1\$=G"E/>JS/7W'UC^G%Q4_Y\$?6#
MPCIOW6U(_GN2WA^K=Z0|O*A713>^K7@60|(;?KSFVJ|CT=2HB>_9HT+P=F3-M3)
9CL7>;B!|/I@#<6*Z-*CKAK(=9_+<%<-\$1"\$5CPQ,J@,F&.. B-HLG<5>
M&.-3.MU(L(-8Z/1IMP>X|CQT;'CL|,MOZL4'K\ N2<"Y8/-4F1PL20*6WV MD+T

H:PU6=/W3CA1;W_Z>XO&SM|VFJ/FC,ZIPRCRSG.@0NV@PJK==|M>0|.^!!YMD';X8?
Y|S-Q;R'6^5M%V1T:0?_R-,O7RNW/('OV0Z+B^?5V/M>/H6>|BWN)%K*JA/
H7|T>IC<*4\$XD%H4!YI!2.JTD^"PL6)>8K,L@"QN^M2KH%)(T|KPZ?
FIQ<_UU:P3VVGv.ZJJ0ZLU!.-<'"&/%70)O\$:C^KKWL@)3@4M&97WGIU@-
L.!Q/>6=9P>B2_G|2>Q;G;0V7X0|ENJ<3>Y%Q26*(@0UGXC!#)
M+=51D)R4H3W|4>M2'&?,#G|L-&&EMRSCO&VE\$62ZM)P|-'R,!4+!?)::!8ML)8G9
@R>3"*M!98ZE^M|FZ^BA2S1=S5J4S%@AZY9EIBBK2W6_
M'2H/R4@MO1\$QF|9YSEG-U=U+S|O.U=U'Z!VY!6!KCOZ:|F!|H37)?
GQ@MRU|OPXT|FZ>VE^W|FZ^ZBAU@=,JH5L_\$&382"B4X3&C_R2H
M&+1S*'AH_J3V>N;J'@.^H9751X?1A(7EUCYI7;W&50|P7T|Q<'PLDLL)T ML!"
(U/#1+%%3&RE3H(IM"9X1^JGB3OG&;L'A.;#.6Q#L#X"!M75FS)C'4@_M
RXJ(\$4DR8.+DB(2S\$GYPE/VO/5A^Q0QO5W6-5+_8.WB2XZ-4O_W,Y7?WY
M6X|U8HFXN/+3,>F2;/0D%RT"BjL|&X<9D\$83)I?4;X>.4CNG1FJ>-Y=YM|CY_?;
F/(BUD|H|H|R;-8A9/#Z@%?UF!A,@K(T1%?ADS,H>3M463W|17W^8(D|2@SPHJB?
\$UTK*L+1+0!9!37!H8P_MHV>EQ-;7K|2-&Y%PC#(J>!#N#T*>/%+|NZ?
_*_*J)1L3HL.*Y'>029*15R_M#\$0FPI--P39_&|U/P|@=6|.YB@YCSV9^?
V,TA*XS(A)=P"5W2J@I&4E_M*\$)|9(F#|G6W4,P*N"J>|T=/_+/_F_M";?E2M899;+6H\$VD*
(H|""9!2DYKVH|GLCLU\$6.3|#:VTW3T;#9M|ROA0HMQ_J=*K=|;-;ZML_S!
<_M|HDOBZOL>SF6D+5O_2B@***6D^%(K\$W*Q2L|M/&3W(;DWY_Z|JSU+&5LJ^?
PP78O|O|S/G&(I4HZ@V(Y4;C\$!:_)|G(J0H0<MN_FM5V0?1FEQ;4S|(?@0E9XI<
F)F6)S49@IM>,^4UHO(P*E|O1'IS0&BMJ5_M'7|V^FZT|M8MU"EX|U;K><+WW?
R2,DN#3",SP%\$+4,74|1%IS6:T0\$B4S=>M'TAJ;U.=^@3OWDH|4^Q.?
^1)SAB+C1(CBP64,PC.R@F)8PR">GM"5*V74CM
M;6Y&HC=5ZGGA|W*XFU;R_+SU|S(6(B26!R8Y%*S%_W3_@(^/P"D;TE=<-?
J+74VMAOE8|T^|?5)5|:.*DT8:."C|HUK^'0&M5."Y*5PPKS1O_51Z&*6|95G#N|+F^CO#
M9G*<+OZ.%Y=YN|H^Y|P=.OXLQR-T#&.7@IZF)9|2G8S#93B.<-Q9Y6;

J5=HSO@ZKC.L;W MT5E_>%61.
MGP_|CA%XU_"Y*N|JVAMNZG0RKLGP4D'PF!%L\$3&BYEYJ?3R_QFPL&D*Q.V/F_M
"EWD!O|):0K%96>VT5K'UL7A>;/9|J7FW'MM|9-X!ME2|_U|+C588_6UD>36FQ^"Y|
|>PQJCI9W!YAYT'#'_M-!>8*)HDH!|/TBIPZ^|,Y
0+42CCNVAL'*\$;|ABL'"7G#G#R2'L5BUXF6R@(_M%"0-0QC'3)DLY>HL8!|>-
H^N#VMD&Z\$%|ABD'"?I#J#R(,6,R1DM%*L+2NKH_M@#J57F0-
SBDG'1VE1|<>,OH1&F2/_7FP>FG/V|^Y=I_M7A!97_|:Z1+S8C%(-+6;
(\$QJA4M|5YH)IEP\$LG_I=US4WK/H?=#NGIL=C_M4O@!|-2|G|IAY6|9JZ_V16?;|^TKB?
^*.^+!|*XF4_M)E0B#OI(''#(&D;1,J(WK2>0|D?A>/>5XP_P?
9ZZP"5NQ7;E+!8!@<|WY6"UU";T;4_M0;HNR)|JC2|(4_M|"0B8D07F?|6@=.8>
(Q6NS+|E)-'2>OM-?IH4+P(N^,U='|9N@8|/#*^+L_M?N"R^&=X&.\$F7D;T|:
(\$&*L#;;DAR,3_P64,|(>@K:^A^JV)CX95HRG!*DN_M^;
(016<(OH|&>8N&!.2:C_%H37Q^Z#JN)KX?736P8&|=;&Y><&YP.6F6;DJ
M79),"@36ABJK/7AM;GBNBDU1Y-Q|^M*3Q)Q3P?Q>'CZ(>(|?0\$J^N'WDV;
M|&'VJ=;3+*.S+S_A2_ME^!)DJ!'">X<;(*,+D@G9;'WU|-;2=|>\$B-JOR=QFSOHXFOX;0NF-
D6VTWB_MF:A080P"V>_W9C^GDx:(8+7324^'|?_VSE'
M*^K\$_.W0@%+\$E2O.0B;SP>B\$1-8Z&VE8IM))ITFCZ+"5GGI"WTZW|E\$PXU/)M8%
(N9%J"7'BH4T0+"TD|3|')8\$|NKZ9,92^\$%'6FLH^Z>L+B(T^+D0<6O(H@
MHV:@2@QU01X#)SEG2F?&V&#Y|(&/O9V4J>P%@CT>>?12\$@>H!QDK|
MH+21PA|T@P\$5BD:-"L0')6,C7;5TE/F+))VF02^|@)4-OGZH.#!"N|S2F^E_M;CT+|329?
ZOL4B>C;9(11*P;/&-MFY;T.Z>=B|(C\$80'OF#^/'A,GMM=3!X?&0J;=?F;
|3;RM04#PI@O-0+@%1()3J|C#L;HFU1QO=|(JOYZ&WR|F=/_L#X749PL?+1?R*
MR|Q<"^+|323+5@5%&G+U(IL%;Y>/5N&ENM" M8M&MEQ,/Q\$IONX?.S68.AL7KLHY-
/A:5+T(*!BS5*@K)=1H'&!2|+E((Z49_MK##@E(GY";<5G9LH
^\$(Q/S7V9IC+X/8O;R6TY_R7BQ^AD)N9|)O^D3)6/+
MP9H!=OC, @3M\$|N5ZA+:1N|K4O(+F#&4F0:.\$P&C3Q(X<@8FO?Y=|LV4K0I
MPH;:4A|E*!L4H\$L(P81(^9'6|?Y#X+;1HY'U7%M(_OH;.R"U(|S\$|H1|'
MZ<|W7_)_.:7WS>S;EUD/M61VT514)14AL"X_Z(WZ|B|GJW;0J|?_HY|8?L
MI>GYD&+O'4=7A1|UBL9B!A\$>:=2#@'1BO559_#%.L|WJPW8|?-&'(|?7L|/MX.<
(*OZU^*#LZ2LTZBWH;GX,BF*#+66J-E4D45W,XXN?ZI';/A\$'W=MQ|_
!PNL@A|T|M:N3_4S_:_FF;PAI!7M0)S|:-T>0;4AA0"J-.MB"+K8>D/(X

M)>=4DG[(@=10#UVBZ1.L9)T_1,FZ(MTT+/+T+G*%W
)YUQ>&COGIC;GD!E=8#W6K8R*FJ8&T\$B+KH#3)P)M8=SF7'&R.
MT=G6J|R7MBE0[&3E!S,'97DM=0N_.S>%;TL%;LKW;V!.;BQ9MHU08Z>1(Z!O
M+H(OF&L_AJ5DYCGEUFU=!Q;/6Q'?TDR-8X2(DY.A=,!\$=D0C*&AZR9R?=[%@;[#X4]P;
<06#U(I@TW&7 MB/[H8C7]1NP]P36?V."3M()\$*A.#%:(%SZPF=V%+H"@^VN95U?
M3V5OEZ#C(M;:K++M%.;>X)[CYEI.!L>2V#FZ]/1)1)<./!"\$H_E1\$*@E>LDKT3T*=Z.\$&
M! !A/=6^3D.IH?6>)QJS*L5929 MN@PI4(*J- JHZY5!H"DAH4';?
%KB@.STYN:'CZS'0<*9&<7/65QD7.8/LS"SXB60%Q55=5:F?EL70*>K,RAOBLZ
MF^G0#8Q_*(BU%G.B8EHI1_SI-F=D]X.F7.VHJ.H.3/;^3GO[TOXA#.N16\$<
MB@L(JDK%4"FMH>V<[:DM;KJVHC^MDS1R>G>YHH3UJJ!_L1]A-
V7%3W+>Y?;D7/BG%N0"-OKCRXHDP.)!!WJ MUHL7&Y#=#VVES@DN"037;9=BU=BC?
UZS]OLSI+5[\$>BC6GJ/IYV"5_QRMEI? M#:H4I.!*EF>K)/T&(1B"Q212F(4;LH_ %*J
XGOS>V?Z%UY8"V?&;Q_S:N/ MZP:W::SZ^_6\NL-J#%P=!&\$KN-O=&2-
DM(K&BAG#5DZB-B_&4.>FL^A/H MC?5]!INT!FN;/%%OY)-
D)_IY_Q\$7_COFP!:1\$A%"^+*XG+E_BQ>>|^#:=;29(;_YAG<+P M93;15TX_7]Q"YO
89)R9CIR!(J(K/W&6MFI"UUT;]=0"A]=MN.W4=2Y^83;.UMMO>&* @K.\$F5".4&
(%FO30S;)1"IRZTZ1 MNQ0>4" M,T4')EIO7GB&G'\$]WQ%ZO^_B6HF]@/-
[BY6/N/BP^&U5+70]X@/[HJB?44 M9R>NP=IPM>_+*5M,_O31JY0-
:YVC]#\$6N(4.PZ"IB0HZ0-7'Z[HJW\$8TL]FK MJ"&RNLHC^!H>& \$LN*P%DT*:UM?
8SU,T]J+0RPUP%'RG,/IPN5JN*)Z@D'"2 M@XS1:/1U%9940=\$>^V N1PME]9HW7I
+@LDC?O(,3"0#A5]=TAZVLTR\$WF. MM8J+?*VRRH"O3XQ))AZ*5+J4UL'@;I2-
^Z8P&*Z:*(#>*V9J:.%[V:K&[Y M-?][S_ WE)\$19%_ZT-&2T7 5
8VRY(V1]Q.BKYU.+X;9>/.!VT(KP\$4T0.+ MUN1OV/JXF.8M.T&/6D@%IMCZ5!P8H-
<)6+VSD2::X&5K1#U%S\$X@LN< HB;B M]@\$WCUO#VM7>&D-
F7\$1G*BO>DS%0>.C1"9!<)F.U2^A.EH[O1-A.>' +G@*?F M:AA[,%UIUE_,8\YI_>#_>?XI?
<_?|YA]02OMVPRR92PD7RM#J\$&CAYL?5H(?TU/N^+'
M>!/!"E^A\$@)36Y0920W!.0^1&H<_:FAV7SN]YP;MAJ>>[L'%W4M]75^0=jX
M>KCZ=:ZZ':JMZGAM3ODK,_6VC0ERLY9^\$5GEQ"WS\$EM?;NZ*2,77I1+H=-3)*=!)
(4F@/H8RY@'I9Y0"4]"Q
M]07=OC2.7'G2#D'WHAY!E=6!;VI"T)N1G66XC(3Y)VR+064Y1Y"R@88SY3> M:R=Y:'VU
<6\$TK*[O ^M@P7> FG48]Q/6*N7M10F+1>WT6F\#^G/V]_S M\$?
^L7UMS?,OV+-6JEE_QV_7(3HS28UT,\$QT=C0J9!;>5!8PQ998E]W?LX;@
M8V0,'PZKQ^YOQM3QV%'NSWDY_3*KM^J;J/UJTJN17BF6'9A8;Z]B)A9,*!"
MB<)&4X*S.P6SC_1D4_2T94^;ZN!'IQE?9FI/ARO2B* 73>I#2MJL"+CSA-[V=O]?MT
MA1=7WC8Z+IRL@UEI?#B4 SZ?< MI=W]UJOZNO+\$XX.10Q6NKH1DD)53
XAZDB1V>T+N/=;_QUK^Z:PMM*P>;10,9;-JHQ
BZ%G45]@KCW"D10WPA]JS.6B"W0'J&7L MZ[*];%0&#=#>*%])3XV M>[Y%G)*.?
U,LOE!ZOJ1?UEN-DI*^_H'R1J"+S\$]1^6+954@>H^WGZ8YKR M+"WO92/UEPGG5F)VI>
[MS93G"@^A3K15AMM,3MYFVWIC]G/TC%MY?G*L-5-- M!S"LI,IN,A/HV_?
Y_-;@ULPK7RGO*8\$RH27 V@)S28>|A1\$R!=M|=IXMKQ %DC<9@HY'))TF=9<:IN]
M2ZU?\$(ZC>.1R^9-#^(3Z]0#-+|TBB%PPF>L#H8D,E\$0!3G &OEAA"]DFBM:O
ML"W&0/#7^NIPG(8Z-QS;2LO6Y=Q@CDM\$N2DB-FH(@0*G<'&P%5QE#SGUG+
MBN#=#P/IZ7BU.IJT.H/P.IXOK>ZW;*X8WRV5>W=PS_"UC'?^8/LP^53ZK2'["
MY73Y^VP>EGGQH09EO)H)WNN0OEGD?[1&AX?+Q?Q*RY)17AQ%3KK;!A0EG)
(Y*AJ>5J)2=&W?>OP=T1V=S.C]W_&Z4#4>R'K-4P! M??;O_8*+&0EV6?_B"0>%
[DW3R6>)'B>U8<:-.N:4SAA!!E:G/ 0\$IS% ;>;3
MA04TNO4TX];C1G>4_::2+S@;2QW4FY6HW/*ZRM10MA\$DMY\$1OZ[U>)HJZ.NA
M(/<@9#RH>AQ**1U\$, 'OR7.:R.2W3N%8-Y14?R@X,KROD!2M MU]>
<75/@7HK>J2EP'ZEW)TM@_N]P-GR8J.8]%^7R_6LH:O^- \$R< NTZ Q09
MUN(;,C6R,4@EQ!"_A]7_?XD7T_+G=/:E+2Z_OKN8_,O.7VYF0>:(TC^@&-
J;7Q/H"WF"&B M3MS52<>A^7RD!G3WL'IA((2>1H=C%XUN,?SSU<=O3[VXGE;A"RM"-
ZV,'0 E0#";@OE_?(GKP'#ET4E*4\$ RXC M T7Y\$SA?
#!0>1/(B>AL'O/S;@<(>EC4,Y,9:ZZ<'LWCI!:=Z=89OUFNW? O M?12+R]00LI5
/ZZU<,5KUB4E@P\$4&DKMZ^(*5Y0"HY.(DK+LD%L_11Y#;P_K M'IHB]U2Z&_U@??
OA_9897H<2FU=90%-)<,4=-UZ[F! 00065BJTCY0N0-+5.
MJ&W2;K=#=M^/F'I0]L#=#U#!J^#^L2HO16F8SH7SF]G_W(&I=^P_&V^%
M\$<(K(!)H+CDY-[KF"!%>19RU'S('8G&GO8&#%<'M%81WUA++FKS-OZ\$G)1
M7&=:I]JCF[A)03)ZCQG94BTQ'!J?NSN2>/(+?NGNAP>5'7G TTRRP_E_XQ

M*8EQHZ0#PYVH69'1H(52>*2#01;P1M01D)XKJ;) & WJ# {1AZS^*MK0UJ
M3Z;6SB%|8Y8Q|BQM%"BI6=!*%77REA(&>D_&%T2K>OHXY=?-
V+04AG-; &Z&\$|72. ".0G'OG; L M:R9*Z|>7@5@9>7Y0+P
_%1@ZMXEW=,.)O|S>7A)=L CG^LD5U|T!))E"V!O MI< IWRQU" {35B>*J.IE<(:/LE,
(M+JS@JO7THF\$X&7D 4B|6<2(H=&X0;W|@ MI*(FT"2.VDIR>Q/X"-|Q1)-
\$, #7J_ %D">#K*.JBK-2*69Y+,*\$)|\$/R.< M>@|8.KN'.9/I:PWK#)AN<2ZQL(1EY1QA#IR-
D!4(1MI&8^R|>R=(|@=>3Q4 M+V!NJ=0. |N?D5IBLX.L-P?8ZGJ-Z17O 5TTW&?
(!NNR0)XAY)0!K>*VZ(3F M_FC.YJ7QQ|_ |MRI4R)|-+7O#WF_@?PL?UG7*_;3 OJWZ6SZ|?
+;59)STV%|
MPH;/%R@X>7OG/A(9HDS^T#98=&01=+D?:VFZ\$'5'5\$^(1=:)|TZ6&S;S/EH
M#D!Q\$QG;|9OEND3CVOPVODA*6&1>'HW1
M@;M46C^GM**|AW+K@Q:UW\N.HLP.@HH|S/YU/OM"7OO;^QE|'F*|SC;SGMO
M(R>)W%+@;^HP33I&?&V3X)HX->BSIT@*9?.%H8<0VD.M=1-X#J^F#K#XN U>
MSN)F3|+G^.:?|?;Y8U1KRJT9%VP1HW6<-6\$&1R5F1M?;>AR% ^#)EXR|/%&>8 MC?
4U.EC?OO|YA|5MJ<4S)T+E_);3FC+6")O2/\D1=B2!5",CH*0DP%3BK31
MF1#O|U|'IQ'4C+R,HQF:#RE0CI(>9K4A:Y|JO!;O<+|UVT+Z;A#'*#K\$@. M3-
9.%.XX.,9)2R58%03*P3|SN ^|?P;1Y'LG#,>V:3\$H> MI;)42G
'2DL//K(ZRLD9Z9,U7)ZR8F3HWEU^#L^7/>BZ?S=^.Q3J+_.+NAOQ M.EK|,-
MJ5'ON&H')Y(*1"HRUA8(Y\#5*8Z1=.:8-4J8UC/0!V-F_3W_#;: ME|X|#|YW:PY.QMQN
MAM'S:VW?>'@UAK*^6);9>&-(W+|4B@MH-01=\$G&I>R-2J=,:_@|_SZ M.ZX^SQ;
(E5'CM/:Y&)!U(|3*01#+CD|/@-|H\Z2%JVN6U90J=8|<6W:KM>E.;_ %KSE=7N0/Y5-
M.7^KL/UXLZ^|;NG>3/L5F67RJAF".&M 9"^D7UBK<)>1F2E*4QX(:@8^21 MVH?
#ZOZFS|/%UW'.GS+_|T*BD6TM=A.6%^+|22#\$"G<7"_4#3FA"JUOR9^G M.:25H.;CYL%
(J&J&|OX_79'X%J"U|L|A\$NZH\$%(3%:SSJHFRP:"48Y|)RFF MV2U^>_SGCSL7|L|M=+
V"!ZRA| ^>C. S47)G6(C V4N_J@P6579Z)H3KPA M+T'OA*<7/VH<;
T>W@T@YPI.P;ML;/#_YG+U=;ZHCXZ3(DT)HI#|U#G7+5<: M0G\$.&*57VD=52O,Q1|I3-
&+NT%CW||\$4T1VL/N+BPV*|=CS|'2|N||>|6#,X
MR3RX3**!R\$U=VDPNVPEE("7OI4>>E6T|1|WRD;T8:>\$61/%=>WC?&|7RXO
MR7"|T\$9H5XOTZQ;|:5X=HD)J&P&\$?9T@DV(:.<699C>2|)#E# V&'4738J M
SB+>6T:\$T^)|\$Y.-UW !: #H\$YA.!S\$5FXDO1N?DS'S+. *@!|= %4JMTY
MF@T+%":.3.R#9H\$!'<.,7#JY:|E?Y!V@9ML? M?EQ,X^TYRT*QPK \$V49>1_C5,:F6
CP,+B6T.MK6#.,+AK' M)OVJB(Y#GE_S:B*YD4GR
"94V>@4:C|4&0R7UFCC."4#QT8||#GC3!<.:?#9 M5|;=>9|
|,7Z*41C#"MBBZ|CO0D>Q3U@;HTLLBF63ALWCGTZR#N!S<|V|_%#N
MJ*VV@2|GUO#DN-9@G:D;?T2I>RP2Z%P;OTNQGK6 M|^"X|")PCEP|Y%LO@G*@:2-@#
(4E3R6(EH'@?N*+|)"SFE G&Y!OVR M7\$V_X2I_* ^ _=|W8|(5"^O!;IB8!E4P@G:0?
31.B4Q%RP|G30'\$C#2E(RA MSZ!3J*,#\$_N?USK8Q*4
M=C9P!DD815;G.'BM3'4D'I.T+OG6;0|H\$SG29(H3N/=A|=5OW>W#1^^4HL% M \$>7Y.
|PLQM5Z^|+1:-"WI^GRW@Q7UXNR'=M?_JGO-|VM(X-UI%@V"H;6-Y4
MA1)0"NHZOU,\$.F<9|Q"L-(#*,2=MPL!;Y|?47STO=/-<_CA!1>;!W;7A':8 M#3A?|Z@ (YPI-
\$>|SB=Y:%P-O_0|"-DD+QU>/H('2/7/^G|OOQZ+\$ZZ!'U_60.V&\$:.B 4 Q|H5!3S#((K(YO
M4S%:4|+AK/7>F.W/'|F^M NG=; ^.L+256VM5H+4|OM0F\$*6P)FF"\$1|RO>D
MC)E;JWP:"\$T|H%XSWFJY_#%S^H#X>H<3Z<3#OP&VO7^3-E-FM3B4C< M%Z?
AF1!U=Y_5^LTBH@L<,^S,*T|W^|0. |NR#Y.H<,UTA.P'&33>D=R(BS|966%3| MR!G0H@
93)\$:D^7-|X?OW|\$|V#3=COS,01KI \$Z#-*1%3\$H6@:"9""52B"%I
M.DW2M)Q"R*1E:|TTO_ :VY|U@=8JYVWUTW'./^7E:C&-JZNWO-|GT|7RTV^_
M7|6;J\$*T*B707-8ED%(!^E3GVPA*.P2W6;<:UYXEZ!4V/>^%EP=-SZV4UP\$2 M?
_GV_6+^9|YK5CYLW|H5(40LHH"/BC(>= B4)'\$D.F8M\$O6M';:3Q+S"MND
MCT%&&Z5U@+Z/>5'FBV^UHNQ.SS=G(?A0UXJC*[7(,'IR"%:EEG(4=OFV|:?
M(&7DU+4WY+506->X6_=:5EF|K?-HKVH;UY&-83%@(G|M*|-Z)OV3Q(R|O;V/=*;-ICJ
W#;|5X98(F;|Z_@#66>"|Z(!>7"0A>68
M8|SDML98>TC%R,%=&_7>W|%^G*Q'1,MRL9|JF:UEH%PT47O(|@<#:AH*8ST
MPH\$A.RJ&1Z9WJY2BG|H%#OK3+3#N?. XK6=|.)S#)=| #7&Y>*93FJ#;(\$RTH
M58|V^CAP*0?CE67%|H0*;A? C)D;|J&L ^ ^H^0'(C*_QOT|GTV^6W*| (C3|J MYL%
|1WZR9IX^)|P^:B%;>>.GR3FG:"RJ_ |Z\$C*_T0E,?6X0+GK7) MR@ (ON&Y;|
(#>@B:&R.U0N&.*|H0|?)PYLI_F#Y=1 _CTO:|W5VN&10RLB
M4O*F99WE@>3U\$&O;HC':(S/"R=:2EL?/TX|<1|1PK':Z =(UW&QD<8D70=: ME00J!#
(C*P/(G*PHJLBL6|_ '<2,TJNZYN5J=\$X1T&G MKXXD&!Z|306M;MW|HI&3MN+0C>?

OE* WWS(R_P2_X/^@&K60[Z#J>+S5!!R3U#Q178R,BJI8D0
MG(Q@K\$P^)^A!&."2(.@EW(U>HGOEY,R(>C&00Q1SSZ|LW|VKF>|OW|,\$7.M:#F-
&YD\$JU..Q@!+M3TFR0PN1@%:L:10E5!BZZ+J4_UK|RK3SG.O|QJXK:1T+OYXNI+
M|> QB0ZL,*X,V%2|/UCMV#!8P\$HA4D"OM6IM5J?E<.2J@'-\$-K&,PC=V)^N(I M7-
>/_/B5KB6J.?I\$V0"R=DMY!&>3@N14U",3,/_HU#H/I:|
MO/_!\$MZ,U'H_(PE<;D9>UE7%G|_B|JL_/O:Q:|?|^+;M).C(F:!(DCE?
PTE#?"%W4(*603"%08N=#H 7/VHGK/I7AM4!M'#.;OW&BMXL MEY??KK.>
|HD>O.U>&XV6KF03|/E?|I;Y/R>SF1"U&KC0(HO&3.G M-#_16:QC
J<#)_D\$C=EF;WCSIK.AF1HCGM/UM,-9D;/_88XA'^>_IBF/+N9 MU7NS3O9P^
MAYS#JR^@^20J04>L*&!8(7)JB#-,PBN9#:NWB8TGQ|>C/K=|./?3^=-47#.
M^+|SL7:WE&P2N1*1"P:N3BU2*2CPJB1 'P36\#/+THLE/./;C:QJM^ ^OT3&
M&:TWV;#|)J|H5%S|V7|%R>,_?Z@U)SMPT|>J\$V,\$!NT\$2&DO,OU>=|(O9 5>=
M|'^^#J*4.Y|7>0L: ^7I% L:5/ 60BP&I!>H<|8AA.9K./>=^7|.BTKV@|<+++S&.UIE#;V
MX_KGZ;?KP6A6)!19&+ #&.X|8@*T;#WHF6*8Z-&DW5Z^;W|FYP,,3@698R0| M-
D"V9G9?41^8L,7% JBP%F#END2/O+UE\$GGVDHNPVX*X!S^Z|S\$)X7+<7(?
M&S5_P|5_Y|7U!E:CCAY!=@H@ZFXQU5K/<"3#;/_|7S7OB38N5@ M:8|
DU_ ^B!>7:3K|LGD_O6HV>#|I.Y|MIZ3!M53?S1=OXO|<3I?3|3.V>J6B M3%
TG:R*3EKP.AC0AC%EO8VR)TP=3)G7>.GQ2 I|%C|Y'ZTQ/G@X_<)VZA M)\$ ^,>(40>"Y
3CLEYSRSN: 5#^>PR>Z(BX|VFNH
=G<_JA|W4^+_JAWUDW<,L_|WZ"V,6YTCL2E%O|)S\$)C/
M(O)V/Q:3H0|QD)OAYK7|82UE/K'|81W(=G";,ZMY|\$PYC7BOH/|@SV%=S!%!RJ':Z =
(U_4040!4@_!R,%J?'80_#XR|0 0/UTNI|.7&|E>)MXC.P@* K N(P>ZF0 M0*RAV9198K:B&-
=Z3|D3I+R:U1-'>)P66NH4;/6WBWQ|EZ%LM#JC!OE%W65*
MHSGPD/T)R@WV: ^TS*K(V%WAZAQO503U>|I/U,/9UY\$=;JRDA'4OK
ME1|)IE|H8Z%>@8&W+ILHD/OX8L/#PQ_ ;'P: T->|B? Z|"<-FI%L*)Q|3<=U
M9@&4"!F"=!9D*DPPR8MV@|R@/XKJ5|/%Y)B;PM/JOA>T/^A|V|S=WVZ: ^'U&
MVM^J;JB/!3|>J, | ^2G_&4ZF|'?_0DO MZMLFGQ@NI4U>@T^ ^!LP) >N,,J\$R)X=3
I>GF=@|#O^=5|4TQOY.39AG ,1> MC/@@EWDEG?
4KW@X4|F(^K'0D9Q95<,"|4J" T=*3%DD%)SZ,KF72YTTK64QK9 M7A0V7M|5N9T-
!Z;78&KOYHN2IZO+Q8|R85HJIVVD#(%.? (4R4<*0%#!6=,"Z MSU<,,FOPA#QV7B'7N;D-
":C78"" _/%)NJGKVM\$A:89%4TJ>@D-067G (!&B MEE;@A MP4@/PLGU5FD+
(>4"M3PA(7-!E|:O<.-R?/9|9P8UOG| |GI|THF|7|Z66F% M.I="I@S<8%6T+A0Y.
<>668I%A;Q3\$QS1X|/?HE.AZ8Y!-A>@6EN>;S-J+Y) M|%R5K&U=2%3+@S4'M%F =
|RD XK5&T|V:AJ>8./LM.F:;T'&0> 4VF=>):0|+(%03-!ISF\$0PS#%5A)K=?;SO,>O2NE_
QAM;H_ ;OT&M|A M!3=;23IQ|(|<64X8YRX(&< 9\$K>J+5&.LSJ^VY)"0J9?
NMDL^#0;Y|I,9TS/ M?
BPN7H^%/'+'.*'@#C\$*#IHI|A6JKK*3,4!&5RM"BA6R^:C@|FR<_|*<,2WD
M6%R|' @MY^>;O*FF2WF?4CAP(-R0>'@IX+T@|NHBBM")E|G:PLK; ^2_3Z?"" MZC@\$|9!
<# 'YQ=R47IF0R2E. ^I30');D&GX4"A9BMH_F(QR3^X&KO={47UA%W|\$={ZH|5|?
W1S(|.C_-+E)@J? MD+MRQ: !N2Y:%
(6#4|GNVM/&&JM8%O<*S@_=PC@:C|O9YFNK4.A<*7L|I|Q4<
MG7N_)C|E0#ZQ)1J5901O5:F3W#A@|2IV(69I_ "QZ&Q,@K,)8"32?
YRN|N"|3+H.)F\$ \$61PXD"0DN.@Z1!>>D"3F| MWNXU=^%K-Q/Z=VW\$B9#S"JSIY7O>-
U^ ^+;:O&_<\$O9PJ&+F Q(P@3: (@30;R M/1A1F"AML6=2\HRL|OU%K_ :THVSP-CK-
<;M"/HI02GFI632@J|HHH|RG43 MI;ZH#(:DLN5G^_
IPE#'^NXQD3(QU8(S72XVO5AY_GG_&/_XQ77W|.K^H+N?= M?/&X*" =8A!-,2! ^&44
*H"7V8,M060N-?>E=2G)H;3N9@JOM5|D)!KN,EM M+F:N@|YW.%VL#9|G#-
VW7QI?:X|+DVAS#\$I\$#:JR#*\$;WM|/GN*E|TLX557 M>XR-D XLY6;;6U|F;|N%9^G<|^;
|!*H'E.@G<_O|: ^7+UZWSUGWGU* 8?_GUO:|W-U M|1EW;-J,C_S*|L2'47'N;"?
HMX,5|>+O*""S?!.6Z^?& M2>0E^&()-8%)4#%+
<"EF(%EF%;U07+1^|Z,XJ,SB6:C>KEE3,A0P.A\$HE/;
M@RM:0I&B<">9*>A;IPZMB:|W6.L).?L@31A%_1V\$.M<;\$C?|@B@6BR4YJ"%9
MW%3P.!.|?W|RJCXZP=#5IW_GB>9V|D3!S M4"\$5(.4\$!TWF4+^)+#US?M="L;%T^&:?
(2!XBU U"L|>)G|M^;|4%,\$C-9.,H8"V|I^W2/A'&|S!"*?
H6!TBV%V"LUSY70>A<\$A.B+GGF ML98YKR= U8=R%3(77!K9.@B_0| # (HZ#
|3,':0#.!TNN&?VCY>LLC46H61-M)J5(I*BL!8D^1.59P6%*R!OST8".PQ6S4:Z-M+QV
U2GZ??-KQ|RH1#3VO- MPWK>S.^SZ6IYO<"^KI6.+(*LFZ85Q@*.TFD0RBGT6DIY?
ZIQ\$YU*.WQ8Y|MB M!H?#?

\$#==.!3/^9%F2^^U6TT:SE>LX%)1J1KZ4&2AI(WA#R9\$6\$G/.4C%:
M6B>*CY/2^.:44P&PI<+&JG&?/O VZ3X?VS94XV(6I8#@1-#%E(-Z/-^,M+5-M*4%"
f;8%\84/ZGPYR\$EJ6TN==.#7'O/0GW[[_8J9Z&)BGIAQUL.33D)1'E40 MG.
1,0==6.N@fUF".E^;<6H?UTYY'2#Q-U+D6HIO+W"YI/2OLK2Y@-26Y. "
M.,G):ZLLP00ZA0<34DK9!fF)^\$I8D9&8!?)<1M=0"Y;?JOS#\$Y7GA-0Y#0
MJLYHR1",K=WF)LJ07#&EJ9W<0RI&SB7:J'?>5-8CHF6YH%. _FM5:!!L:58GQ0 M("E-
(5*9!DRH*!/(7HBVL:=G!fU"UPT)JN@7'G T=>7#.JPSE<fCW Y>H8
MINB2H(066(P%-F)ZF
MWRZ_71%N15;.&09.E01*LP#>\$@N,61<%STKZG2KP7U#YG0\=6>F'J&S>0GYC
M*QI_V")%J2_/:CG/OTTSQ!\NO M@_BQ-EC4/M?U9:fWD;N8
VQ3=1&P\$(0#C64R9SH%KWEVU],@;M;I(2PI5-M1C]NHJ+*3VGM-UDX-JOKP0H<=?
U31R58UP&'FWKC=YW"!@W_3A8C8_#X0"9-M=@"
(fF7_3ACDPK(:5ZKK7+*%@X,OI(*:PPI)(0>0\$1 M3'92V<"QI7/=R9CK_
6Z,6L&7CJ"L2X15&T"J'/C](M#(fB/M\VOO2GH7)I MVW0VL.RE9JF"#6BE,C^E?
NF#M>;' MNZF?1_BWK^/Z_R-JJ6(XAHLy8-OWV'CAQ*4> MM *
^J4/W)WM_*1f.KFS^fUfHK2C(0*>2ZD1H2)W)/&8*1-X"C_-@:4V"7 MO=7/9@#
>^7/JR/S?'#C#.,F4"Z <0P3,"L<-LA0SI^!K5BB+EE MS4OK+
fWYROF67_78#@G!7_KL/K;X#S-.,fI(A@)*RCBF"1P"01H/f9UXBFW MAVMFL&KIS5?.,?
RJ9W=(f/f29_?!"C#7.-&6V,)0P(+C<"?5\A1Q9'Q(FEC ML\5R.<&@8W;>Z=2V/&:DS5,
f&/@N^W\$VGHf7R^)\$J1ZLL2!HX+B\$HG26D)BD_Q_0D)KfJM4H#.:I=K>(@_f;5=KR8'Q\$
M5."KVR0G78f0_7=E1#5XN# M"E;.:?3>%W\<,6Z:BU=.'DRP>
f'>@P@ZTEEH,"#KVU&Z<\$fYNT!fJ8C2#E MQ"D%8X!GQ%*#F*&6"QL,Q:5-R_T4f57-
fJ7!6)H@PLH/Y;.:?& D:.*>6(OT MJA07,XR<(fPEfJ+3P3\$I2RO/7;34?
=50\$!%/-5<1YC=POX)/#';,f4-?'OJ M?WX&S;L WH" ?K/CZ?O98O'G=!!M9#5,21A!?-
(>,4UU?A?ED&4)_@-6M?7 M.YU*M_(YAKZZA?X#@FTP(34 P&
<'Z=%L4J6:V651U1CA;@U"fEDB'6*42V&5 MH*%:,X8^NNP1176+WL^fT4X71
_PVKT1D=^F: \$fRG6"W&<%G3NX:>JT98IB M04K?COW-)CQ/R"8RK"
1RfCFYYfV;f.;T:f1^3E;#Z?_04f>V6_60f^R-L8-M1X01'
PSR"@E\$6=PY60*-1+@U3L=C;6^=\$U65fKJ5BD/B+):A-,\$Z;CfR"@ Mf_V?
K^:WO_LCf@<*>5(\$LDBQ;"#>5+/E&)40)1JY DE:6K=P\25;>J=E"8 ME11'
_CZf_EX&:f2NDJO-P2L3M)B<9;:XN;X^HC8S!05\$:AC f=fCRJ"4-&
M1T^3U<;0TG;78:KJUGX.B+#" FD-8F_L?/+S8_RVCME=f4fQ.H-fZY&X!># M
f81&6D#XLIKI&542&CM)=->>%LQf>3FKJ%B0-"Jf&H!25KJ+K'4CZ-TW M/f))>3->?
%UO:f4A9fP1R3FDA,TS#)>CN/B?80?QCND*YfXQY@BZBS) MV2F)M)
(,f10==HQ128N/_3M(5>^@f0/6?fQ9Z*OTYR*NOCLRH,)5S",+0%3@ M7^<'D3(1%
55.)G\$fI'Q=VfR'G,H#FfKBXUE8MI-8&KACfPfvULU8J2@FP2.A
MfM05B<%fQH3DJ1C8^62\$H539_L(JAOH'QA5Y41Q,JZ^QfF;E4HP/3@DMPSf
M>50*_fH&W.CN8f(>f(T<12J6SQ M)-.1-;-9Q1fQ476_J:NO^UJDU4-O8<89Q0HGF8A;.-
+)62T0-MB0*%f4K M'5?;1T_=\$-H)TBB_9 M6;+8f7=Z?!(S6WWB(1DT\$%!'QODf
fBRBZfPP4U&-3&Y fKU@8&4D%f/HfI= M;.:N;.&@B\$<)J'@f=C1K;XG"G-
#&4>2Y'X"6D>D->Q+XVM523fXGfP/T5U-M664%#=#OKAM59/(H
MDNfF'6K8=2>*HP%Tf3@K#S:4B&4J7_RfF93fF0VT&B MZJ8?ZJBO\$T72+L;N9OE=f?
6A&MO)AfEBf;KM30ZA+f9N GfHL1Q9)C3V42%O Mf
f-2KDVVfB2<,1&THH;5SH%UfIOHRL_YZXfTfDV.*M>O^((f1K.3-1\$(fTfZMf!GE-
68A(6JfT@CO(PAUDF\$/*)! =2-'@)Vf4=K1'./+ #E9fU#X2f
MP450&UXf;/8fNTM!>AUP1"K\$;R@'EE)P4:W.G*fJf">* =0+8T9_N!K%+Rf>< M00P-
7,UK1KU?CYU8^/EXU;1@/7PP*L^QX-01D;+9+)8&9(#\$QU3-fHO36E/M?
@fYW5fVV>#^_B0_5f68X?(Q*:&83LB1&4,XN(FND1SC1 M)-2V+fJ32f02f:&D/0*?(>C8
XRL":#%?CCfFMD^KPf0= _?3.+C*(W-B*(\$, M)0093YTD2G&F.CW2AU4?:(
5^=X^21Q^L6U%<^F8ZG9U:%%WGE:.*#)#U04O9.DNBf^AO)<2fJA-5CM>Xf'G'5:
M.8%4fB3'AAC2'FO8#X=-,"JH*?V\$K=EGD47%?L2;R&-DT "<#E>9<>-E4%Jf"
M0Z4fXBYJ4,#&(*6fHCJ%5+X+3YG"OS-f,f6@558>M5--:TYfCO/KJ_1J-EW'
ML@V+f1\$N54_RYR8OP-H\$*-fA8_?=XfEP^=7MW9).VK=fB'=8/&648V8"JZ?SH M-YB
f>\$8.4QSB@-L/&.#1Y;+(#0fU"7GEf3f%7.8!GO(17/(-fHM_);C?5
MNW_)PT4*M2'925>A;B*KK^2/W*4630)U(:A"/,35N"R!7-2GFCO-G1&8<5':
M:'Q&Q(f&f8OKV7PY_G_K(6%*\$,V8TfT@Z9?-<"G!\$LU_*97("Tf=f?Z5'4FK
M;2SW0<41YO')TfC@_GJXK7=36#0"!fTA
MN8RR=#W#G)fJf=f#@:D/fUVN;P@_W<4N_Q8%8IPS2*^9(N\$4-,7>E\$H1<(9U

M(TTLX2V+US:\$2V"@",,:T!R/K:K:303!."@^CY@\$;XXIV(F3U""G+%>*R=%
MZ63Q5D)JVIOEM45_3C<EW_8^3B'/>|8,R*460W21,+A"(HN<>0(SY5_*4IY
M8\FZTHOQO%1MS-&69CTXW#\$+DGW%&'?:#@A,7<(2\$0B70-QX|30'Q(3K+B
M6N0X2-Q6-ED6\$J=QM+95|>DKV-,Y+'1'_F(DN+!@46.D?(X">#"KM:6PB=P# MGB2FC-
>=K(HMBI=M&%0JNC+N
9TP\$/#Z,F!OS^EZ/5|XVK6W|I%2G6,36\$:.!N"*Y28M@2./L;QAEC1BVYUS+SA<;X4A070TL
>|Y/..?AT M|^W;9/5XWDY>V<77MY/97^F:3:_7C_6*#?;H>.7BL|Q.&6'/.L*|(.X(:FO MON.
(89NG>B?IK3TDA3*DE+34/LS'4S_ ^9B>WU03@<&NJDV'(Z|P:3V"/+41
M,>>%SM6^5H0!#;-G!-5)PE8 S3Z;K9^8&K@AMV4,-WNYFMZ5M(PLSWYUSAQ) M#?
S2Q"\$=|Y/Z(#E/3F?M?H:4|7/*ZF1O&T-A(<\$U,?'ML3=H;*)\$Y|RBQ#-MX5-ID3?
\$XJ:Z!'U220.VT_S**57/0%'<-P*"*8!>#TIL+ER8-5,,P/?-!/? MQL<8.[6;C8C%W20E"N4B(-
!X1W7JR&&)8Q)P9&EVX1W.8T.U!U8+KXS@C*K2#QP_' "
IKC)WZYN'M>@@,EBZ+O,2X8P\F8B(@EV<"4 M#!G% @J:&J)XLIYTZLMP;\$G%
(%YWI_DNPEM-"4M("I'>Y.\$#\$L*26&BYTD2 M7KSUS2#CR(-49^&D-
ZCQXX13@,7^:'|Y6YVG_ ^:C8+SQ@9|P"JA&G'O\W-N
M(Y!T)O!HJ0FR|GK2%H#Y=/G@=HIHK@4A %DX@@,70;GA2%)#3!/X8BL5!H
MD@O<1)P2'_)!|%|B&BC0/B/*CA;'A>#L|>QF/A*:8 -,0I'!*Y6=\$@;3E"2
M*CJ'.?;%VWYUI:V!XN|SH>QH85P*R,;?XT@DAKEU'A&L(_@|>12:2QYY|. &G
MP\$>JAXQ7|Z.M@=+P,X+L6&%<,A>)/C6W>8(=E+
|W,*"GWUT<1V\$#9^7G@=KI8+@!S(OL29UIAY!+)=?::P!ER\$KF@=4C.2"/
M#;,&RMO/@ZRCF-|F/Z%T^ MUCS@:/2|J|3+0.XLTKH@5-|& ;GW"5,ED'4&#AVF 0%?+
<+@UD1+L3>^|#.= M(TEH53|O!@|13:7!KU5<- P3\ DT\$B'K/&E-
;G*T"&OI7,)!XE#Z23^T42V M4.1> 7Y'R^?" +B*&V*+ ^82#IC,(P2TC,@99Y'A@N%@@%
^JM--P+(V51_U5 M@M_1TKDT|.7@#C5;,*\$%TM;A/, BP:|X1\$(D(B.PU-
G275:/I;'RN+|:Z#M6 M.A>\$OL?Q18NMB+!11 A)N7ND0Q9.&S+&|0#>NB;5('A|^>XF8
5<'BZG"X(MC"/!D|?YZ2V/+AG<|*F1N|HSC"01.V|#/MHFU?AQL06_%R1TFC=93MC\$C*
M%)32S"-/R2"H5,LA@E'J,)(BECRS=/.H'0;OB|A,3\$|')J (R|BIB)5A9. MCT8V@.?.B?-(1
<1,%1AD9+P9-B.?)=%C|DEI"!|+IV%Z_/LZ6=|+5"| A? MITC@8A42%^ "22:0D0*CJ(1@X
&OP)|\$2':|N|TN6X(:3G!;!KVP=+ #A=2 MRWW"QJ-D=4!<*(RLE@;YD(*V993-P.Q)|@+
L@KN,>.=|R'W M124>6&8L0'V!;%F(+%J1'.W6N|K;|
|H!IN7(^U#,00"K\$)HS\$87*471&HPX3P)9 MFM^S*.HR5<|1|EHM)!D|= MD& K!
(_!8\$B*(FO|B0N|I5S+A>)UXA)|C_ ^(^ ^"TBHJ1 V':|U;ER=E)J0C M|%;X;5+IQ|S;L?Y\$|L-
C1|&ML6;/H=6UP5@0JP5**FC\$(X|(Z,@ |X\$8C3F#
M70QXG@LU(F4#*BR>DY"/;DUGN972'8IDLE3|/+7@)'.B M"7(AL=RZ*,(?1"R>CASN?
>B/(K"O#NSTL<_ ^I?PK_Z51TAS3Z1%3N>&R"2! MYR=\$0,E*^+DC^4%A#7;
<45BWV46P,W|7R:YP_W.(MR|"FM"8/ MVV(H^=F6B,#N@UYIYDQ+%GE:&F;0A@-
@NISGN-VSZ+@ M5<2.!^1<\$:|STGP:H|S|Z2PS1(9H2|MK^RFJ'| R4C|
I1XB:|50(V|D#/F- M U,<|[%XK) *'. ='G=/2RF!4|9D*VPAI"SY|)-T%1\$>Q00'LO+Q9C*K
S@%S_&BY&TWC)O+9(J=|D41((K@QWR."C,)&\$8ET;/#E(:Q,|Q0IZ5 MYWBBCP,F_G,?
X>I9=XU\$2,@7/'1*:>6"2SPT:HD&16".M#(Z:F2E M="B\$0
/#2GDZM*%|1TS=AI0E+ZDR7*^M36|/%FS\$C: + ^ |
MN8DCXG42\$12NB#X/Q1QV:|Y#H5\$K"5Q|.G|B1VJY?"WVC)D3I3H;#CV-HB6
M#S=S_ |6N)@KY/&|OTU?@|<@2YJ*/\$1%*&!PG*G,W#8Z8Q=8\$3PPA_E3,;/UB
M6HE&.3T9W4#E|7|6=|3;0SLYYO%B"V%U^_F6A=EP\$FE03>7LX^:7;R<_. VI-Q9
M)3F6IT5:BC3V>=P\$QV#|*|X|F=GS=9X9' MB<|.F?
T|;>|U4L&"!8\$14Y&BK@W\$1D,X,X#T'4P"9M0NNOH":G@@|I#|%+ _D M3S|
(R_+|EQ_C|SB|B2"LS1^<=>-EL*>7))SPE=Z|+NS00C;?.=C_#;KV;8 MW\$)-
>TT%)R(7RZQ&FVND3:ZK"H&'2 GF0A2&VBY:>D_GBGX&@)V,5VR^2ALN MOX5;9?/)Q>
<9('LOFXP#6 AA|40KP2(VDB\$|AB@W&OD I8H#R:#CXA 7.FZ
MB|,HK>M=%D'0LVE;PXNL_9_A\$TAI%9^|M3UN|H8*#0M'L+0.?&>9 N)!>.1<
ME(@R2|A@P0=?>O|'7H+JPNP4\$^Q0R)W.YMF_Y:9:67^(\$;+RKN9U|CO|K=#:9 M?
0\$S;Y,|D%8 0P@8F|KDGA2Y@|E 47*F+8A"?@+G5S+0U|JXCH|18*SH=A9
M&QLOORO:_2WM6A+E#)5(6)5GJJN'(\$#&T';>F=|2K;VX0G"|<-=A:2?|F
MU1;TAZ|6G)%|B|Y?;KY|F_S|%.?? MQ_|N1@O2><\$8;"1\$@+?,D5>;(F(V\$1%"9-
IT: &TIRMUIW450D0Q-M;P^H% MWJM-;O3C5O|_BH|#0EL=L:3H4XKB@@CP"/_#*
<*2BH=HI0@/MEG_ZK-U M!VX50LOPC*X(H1#'H_?QBYV|F2|RY|KYXM8|!@#E|N;?
\$<"PY#%P2)-HB(8 M6S"-|TVH643_'U|FW_|3EE|H|"+>U=TRP?
KFIQG#&KT979EG*RIWAPC|R2- MQA"\$D|OE388C;9@&06,

<70)3*NR+7AP&R<.OU7%'>XMK5H!WM: ^7JQ!) ^'MK M/3L9)*.8F2@HxDZ# '9VC-
#J!70U.- /: YVF9P/5JTGW-.%,BO!H=JB_?37 M>!HFTPWE"6NJWEQ/NZ3QJ)IY
M9YILKK: {&V_Z) ==KO+ ^KV\#&,DZH0R: !QR*NO=OXEYGK#W\ " SF7:5!-/ =A*OTH0%
(BX7 M(VIR6U@M\$85##JLB%IG ,0K,\$A.T8L)T\Q>Z?I.)Y-3P2G(@ (1R/+;/&UC1 ^
MR<9L\$8/OQ63U=V)8/3!Y:1_>H=8.?JJ)-KPVJPLR_M"
MZ',QU_7U>/%MMK"3W^:SFV\ _S):Y\$GJ5F7\3PZ9!Z6QZKJ9O__K(>)Y\$#AY3
MK?,:B^0,:!O37VDB@5+2>GG9R>2VD36|BRZ|ARR;"#:LCIZ? \RF8!W?
S.\$0>2&9&L2DXBUA9/B1(*3DD)!_D_Y"(XJ:6UROL:'UG9:NH'KHM,! M1<71P,6XIC\ '47+-
S+J1Q0UPZB|&LH"_,;D)*,/F:L@RN5R/G8WRU7?X!EX M.CDN
U2M^+OARHCA%**A!D7+ _,NL#U-[N?I"% ,6;%)0|:7|) RSDVZ0_B72 M"PU
H<7^0,|:DCPN:INE3=9|,0'6I1VL6| *MV,I0,< #5M*T!B" M\$0@|Z>'(Y-G?
>1H<* &JB>9*:F(\$>_1=OZ3+0"0Z*Q(QA812<%Y= /K)ZU <":L MAU_@1\$IGY/H&B|
|F:Q51:*68WP".=OJ(2NO(AD1\$D3M@<(LY MI VEA|7UQJQ4'7AY42'P_JB7,E)M
MA|' *3HLIGJULJH!9U8_DVN@|W'N9@T^U\$@LX40)G!_A<.|!D,U#0A\$UFLBD
MI>&F6|,;"@ \USE84_:AM-,34ZD-V?^6\$|H|Y)QERCH !X(E!)F"&8(>"2H-
MS&Z#!OH7J9RMR*D_H,KQM+:K=T0=OL\$:=A4E4M:#!ZN90*:19|G./G= !-
-0KI)BPA@K82^S6,*|,MTX;S52SU5TYEF=N.N_&,D>=*A^EZD|W8|5/A>)99Y9G_M !?K;
|-9^&L|F=P;\$*NA0L*BC9"(1RLUNM/5B:FB\$B@M/.VF2?CN'ICW|-TGDx='#+:Z219
ML)%U&W;0\ B0BWE.1Z A1IHL%|TTP.6,P#D9 M\$05961L5>V>W2&Y\$(E@(#
<2<0IWFZ:.(R&),(1|3&.W5/REC_Y&1' %V% @= M#|=E)H#O!YTW;|>B,'8T>(N(8V!)
<|61EKM5>..#9 9)P_&Z^,UY.\$D2C+\$)|YK^2#V/@+;&L0T?&!M,.\$U@,Q-
J9QPBH8|^(1HG(%4T#&: ?B/ M|2)% \/* =+-Y(MWMYXODR
>5\$NZUCT7%|OHQY<,J_ NXRKMH_K+ #=P;(9QZ| MNZ'SF|I\$2;T6R&KBLU.NP?V2"07N
M,Z\$<+PT%= #H?SF)_UAIMCW.8Q7*X=D#B8 MC.-8>2,D19I@V\$S4<)"2PA|8<#
|32GBCK.I+BBW>90\$C\IM'L/.VMAXFJZ+ ME&CC\QSZ(\$ "I^@2|D"*I)"Y9(*-'<=0-
)S:/%GR?9A56|!| \$G,Z4:,2|LB0 M|!X*7%)DL83?)N' 156.<|U)YI>1VSQ9_(586|L)!Q)RV(A
\$Q=(^Y@'ZW"/ M' 9&)4NP!07& ^V&ALO);9Z,B(*LK(V*O4DYQY,RRG(4N2"(*Y^KXFE
U&/,MM?6./7W3XL\$REX_BI/M);6&*.P MD:4G"#TAH:54YRD0*
<'9!H"OOT>_#VXK120GU""(X"=,HVL-?+6@Y| #2%1 M7SS
T8&NRH;HN>,AM#AUY.XK1|,Q)8|!|>ND/E%8# ,Z9 -(A2+ M"->RTK1T8+<+74TXP
71L*>M71'17\$;*ZI7|-H: M7I#&,;+& A(T535GO4' M2%%UW|/QP40KPE6 MB
D13&38QO_-C5UE&#WJH:.X7+MJ-/A=V(BD2!L0+ 7V(PSX;E@6PFC_TF M.DEPO'^YU-
11\$CSNV=T1|*R-C: ?9%B,,P"IOQ/R**Q*X8D) #JYS|6FD@E_|
ML|N3)= ^'6;4%O2>O\$C\$F3@F2\$RD&<4TU| \$""5M2)*H6#2J';|: ^,U-3)XB_\$
MPMI(:)!/D8++E,THJDE\$G'&PJ_07B(%*4Q1K'52W-,3EI*9.1D1!5M9&Q=Z<M2M)">
<,3\$ESG-E!4(D.503C8Y*(3>?C6+Y6:,AD1Q=C8@%_Q+(%B#:-,4Z28 M2XCC),#A<-Y1\$9\$
MSH6(8G_Z4J?!"|=! ?C73\$WUBG.4EE0#Z/M@?ZX\ ^L^S% _|?-^-Y_ ##/?0:7 M/S|,
|'29G|,"3|_EOS(2+)>&>(Z4E0%V)E.>84D0CC8ZK)DHW^*Q.W5-.,,%
MD3\$|BYAJVTFWV\H)- ^_G-W;298=>@3N@N\$0QY2%XV'ID77"(D C7B!)4Q6ZO
MU\$ _Z?!/=WFDG4D>EY\$>73|5M-.PF>N|*#D>=M?B_R1&.^UCZ*PH&&#|Y"O7
M"14:9|&(+1FU5XI!4I9HL6;(K:4D-0GXH17>3!>WC\F'FFL(PH*V"(H!6.U M=
|A%VI(>@QZBC0D/49<%>_/Q7QYGY_Y+ "VP|>I3<9Z6%4!M):|X\W,+& M,
|<^%X9JC*SV^<5_%,@&3Y E 1I&=SQG69B'D+2+@+J(*F@8&>EN5S3:)= M3)?
SGZ_,/XU4)-2YA)%F#,Z,\$Y=!=!>|QSI%&8W?AXM%|/_Q9?;|/S89XKIW-F*(,9S\XZ4
M5#2="E4/: (2'WZSCUG;6\V2GJ_3?L_DDW#TG=)%C924R;-4@,|=* MM4SD'E3&QQ")
|HA! \G:=9*< QSX_JQK0?*S-?EW\1H)KSUP#QP@HTZBE@> S>O,3Z,
MPX,%|*_Q%+C@XR*X| ^_I^/%UOCR<.,#%N^EW^+>S^3C"+_WD) L2/H_?X5S/MQW:R
|HG<_@G5|_C_&NTH4@W2CKJXYO!?'S(?|SO5|6,\$AG
MI(D4/&"A,BCQZ*!G7NNP=@)0@:JE2.EZPL.T517+0^ F*>*N:A0&KCS|_:3 M=<*<
|6YTP4E@Y|W./@L# (#?,(\$?ABO\$V=X341IGBO7VW4U+7K#PGH\$X70\$LP
M^FV>A_6"F>,3PQQ1HH\$A\$2=D*=C8BEH5\$H|BQ=(Z^3\$%=2O^SPF;XQE^.EQR
MX_VRAM^;*?6O;N;S57&RB"\$%ZE\$* M<#*YCP9I9_.T:14L|8ER4_K5RU9"+L*Q.P8;SR-
N?=G?@!G^:C9=<=>*_Q\N0
MKVX6R|GUYN""EK|=DB3!!>T\$8MP+Q!5A^7UXGLO',/ &&\$&M+WXP=R+H(/ZV/
MODJ+IF6T?;B9^ZIV\$4?"\$A><8OD N?@/|+< "TI"AR" MJT
UF=P*4O&%RE1="VKH_:4|29^(|PI(R<"B!"?&,&B61L<:"SRD5'#?AD><&6T,"
M3^+)|Z>S|R"X|H%_06 |DT@:T'OI(F@C2;C'1F&D)<^OGJE%3G.,O"51.4NP M:(6KHO?
1TPUOEQPO+R:-"ZU0O3U6JL&)&C@?N/.#YTD'=MOO>,;.!-B=BB,H| M#J5 '(,RLY0S)

#5A/#HO"!=QWS8;.!*G;^|)K^|@1,^GG().OW=|;?Y|/M* M/HM1Y(&R!* =4B93;%6F'7+
&4<:4%IY025VGBW3?5RXBW7>.!|=E|7XV|"M M^+L%9D|C_?
#JWU=%&.DL%))AXS(3^<4CL@\$3E'BS-&DG3>R|'BFW=1<1(+O
M%\$05%D0#D'H,Y^NAL*|R\$|#?JS&PZPW(J/4U(B\$|'0LO|YV2%N=&XPK"D8C
M8Z9X|G@G,1>1Q^L#J#)B:!/^\>7=;K>"(P-/@4SR\$K82 M6;89-=*>&.152";JG;
|+G(N(AW8!U.E1-\$ JG;ZM>O=1*>9#S0BEYA"/.7& M 9: ,V(38S)2)5AIAW
_11>11NR#K8("::!\$ _87W-JV I#Q%3L;&EOC002|%^\$G+/I"M(N0FBN7W/C!.P@N% QBH
M#%/|\$><3(*"1))F|'<,)+MZXN.|:|H9T\$TY|'N-#B^@I3|7<26"D8N!T "6;Q)@G_# P5-
/. "%%' , \$A<5#?I7M; M| "7H(J)OOV#E6(|@|R*B='V0-Y2H&G"(
M7V|^ ^VIVG8M=UA8K,'1|S8PP#|9).!QLR-E>I30R,G#D=7"&* SF:FG@|: ?H
M(@)X?:!64"#5:SZ _MOV^".B3.1\$6C@7WN?)RP%,75#7@F/O6%">R(ZE' J6
MO8C0VREHZ,> _O3*>!K#RSB%7RSO ?QV-L^ _V?P|V|^MGR3<,I2Y A3GVO(MN4):.
(EPE)T:5*Q>%;V:"(O(AS74 _L,*+8V<+GZ|-OQ-//RU6SQ<#?9=68A
M29PT&)*Y>P'W/B#C*\$-@3%*=(.O,E2Y_/\$C41<342MOZ9<32 ,Y>V<773ROJ
M03:KOPY7Z?TXQ7=38%K>XHA'Q8BV!#&;QPS&!M7+_VN|Q=| =8+-=%FLYX98-
<9WKS6|U0S)(<1|9=3P& M43HDLY60BW@IT =/_ =G? (->36\$MH/TC< .AUG(-
OF->S00A?+_ _! ?JDC)AR MRA*P/I/FP"@X&|BF()Q0EAD)76Z=&E01|(NXE5 'YP-(:
(&D/<@HOT|<"Q. M@)%Q=O/OO@O/UX)Y&5 4E@+7)&P&V|SH(&EKA<6>E%9EAZFZC);
(*1@%T SI"4^RU|ZY\$. 2/K79!>4IEPZ::#6PFYC-K 0H@ZD?| _@.AN M6M6Z&7P*G%*
_1+2J#Q0.X&F50:1.\$*"R|^K5/JM|V,*NL'FDF/O/3C> %X> M,NA|_MM9,JOA9@X(EIZ@P)-
#G+* K&0,X:|@8U|CY\$NW&MA%2^6N^#WD.QN MV8V"9C/S)+
<5(U'H7"&2LTOYC93P&D4G K?:>BU+)YUW4|-.QOET:7> T FL
M;P|\$J^OV_J+=F'*W4| \$DOA|<L<|'+@8H|ZA%WF&%@DPBQ=.AI#SGMP>@4
MB6^S=@JPOP\$DW6GH|W=32A3&SB:K\$)"MAE--ABPW&!G"7<2&PP\$L|90|HZ+R
MB/AR|U9!/C< D?VE.2DQXG(U1" T#W*U^6\$O2>28"HL1P!9FMXBSRPQJ#HJ1"
<=>C"Y.XV|;ZYT_ U@9_8SOLT7'C#| MMG^8\$Y: K>^0X/FPT121-M0A%C"AAM%
>6E/_B!1|7ABA3#SU%@J*Y8&#._; MO. ' ^S.|(7>M\$/_D4F(E4AX<\$0X|0@8GBPQW(D5"G-
&E!P!LI^0B2L/|(*J M !J T6WYU=H6|W\$K&*@N?^X43F!ZZY2Z'R M2JH<13%I4:
MX#WS=F(NHFB|#YC*B*\$|/*WLUBV7=, !12V(TAQ|)%&Z 3288B42PF' 2j2->
M_V,'*1=1\$-X'2R5\$T J2GGM M|OA/#D*VX%+6@OP?,'@LX0)))+4T%'2M;-QX
MA'(O11=1|-T;5V4\$4K'OQRJ(LMG%XT#L@SV-N-8N,D:0\$H8@+BE%1DN*HG.&
M>>\$T84|JC'.|I@Y|Z2+*MT|!37D^-Z"3/L9U5Z6;.6QF,T%S1\$)|@A.>IB,XZ
MQ!V+R&EG46 I<".%Y%*T1=\$V.BZB<+N/_NG-_ 8 M+VB+@+N=0P">4-%?@B?
M>XKHA%)&@NP|\$43QT?:G5S36KLG N?X7U87| #&+IU/,%-N!W6N?
|!VGL8,UTB&%!")GW|1GVNFJYY,9G, M_LI_ #|Y/MORW0S 3,@-UK89"46
R5MNGSY*F;HSEPW@1.3-9)3, P)|G6 MCN=1IT08Q\$+2TD;!K2MMKIPG@7/"H?/^7|?
.3C;#(!P?QEYV&\$L0/G).18 M76ZYY1E'CD>P(!11|G-GA"T>XCJ6R(M(!R#J>?
O|8846P/W=; <-C@(@)R@OB M450B@!4"NS(V,L0M-
HXH*H,MW4RA&V5U\$3@P/\$X"XU&R.AF!X#2/9^'3TLZ7 MI5I! ?
A_GVI\$M>QL%QS1/%B,J<@|DJP/2V\$BDF70,!T+T77_/1\OXU5*BQ&1W'\$=/')&\$CA(AL#V9
M4?N=)KW27LVID=|JQOF3+S|Z"*XV(:ER,J%16*,F1@NXAKPU%^ M5I 3<|:;
(+7JV!.K)R%U,Z+G@>79!=8:10=R|HWU-S" |KQ+|I3C^,GWSPW^U
MTR|Q)\$UR"N=QSM+EIRH2(^,20|E01H.-&#AR\$)/(:-NEK4&/@<7UL5<|Z.8 M&U=K&E
BB2.N1\$(F8M@D|/#)A%\$4K;DP6=&4&R|&V>)D?:N>KLR:;1@J+.D6
M|=|W|+,WWV/?..|V|0H\$#C006"@2^/1;=W\$;EZ+R6DIDO09AP|;A5RRB%(0S MQ#IN:>F
URY:>C|Q?+SN^DF?(|F7CJ/YF6;N*&W!:(TF/_|,2A"JOY"EBVBW MT5'YM5H)Z3|H|
B7W0W<7B|O%N-I7"Q6 W,7X|O7Y|HF*3@8AISGAZ <:Z0% M<2@:J|G RLOB|_VD-
(4<\$Z0|=G^048WBANUC.7X^;9N63.1|)\$4M1MXH%:
M)X45*W90\$YEHL%DHW!IXAY*)T\$VD%*Y58-I.^B\$@QO\$S>;@R2P(4%3@3P'
MAGE2<(9BCGA%XA(P*#)1NCO53F+;F-.\$05A^)S |_8 =*L|;9Y1 =#YT3.-X>;
|?|4\$A5D>_ :E>;LY(| ME|_IE!QB"7L?P+338F"/^ _U1S84&R|0-?6.=QO(&H'-K
|Z:7;OQ="6/W,ED M//T"N|SBL=A|3H@!|/6#P-^WKU| "P|L.BM14F 70=| \$I
MK"4SN/3P|9W\$U*U6&01-91C? ()^FAW"7^)))?0C.>K+IRS18|F"&R-I"+64 D186-
IYKQTH|G=DKJUI0,@IT"+&| _ _>Y.5Y.X|?:(T,IB1\$ MJ1'5G,)9B 19\$BC"8\$
:DH_ ^ (M>=KMY' MY4&(MS9A_C49><8,H|7V(OK_ ^#+|_I_1A_7R M+W)U^N?Q-
=RP|!_#Y=;/U(<#Q==ZPP?|E7%|B|<685|,O&EZK !|?&E762+ MX_I;G"XV.)
|GMQ|K+?/RY_W?^6!_YI^MR%O3F"L7IB%/T(T?KR/TN@70/Q|UW9_ TW(ZOU(U9G@\$,
M'=E<|>Q_/_SIXU/JCCWWA|:H&S |UYGOR,FZYWV;/OKXZ<|!3OW^;U7M&WK.

ML[^]Y750 ?[M:+VAZY5?>Q=-/ID'W[UB 1) GWX;YT4_@Z_!\$O[P7T7(?+YJ
ME6C205G=&([+Z)]=SJ^GX>W\$ M?BDBJ<+/%DEA*R]GO.BT8\$15^SO^H
M*ZL!=RQ=)8!RDN#V\Z:R_ N5/#AP]M#[KQH & MJJON@TK[#!U)#P\$?
K5W76>YTBO8RI;BPSMZ;?NNNGM:;!#1F>K_WV_G\MT\$^T+N_4I=>[(S!YX.L;@_.*]H>?
(//^_&^%1_7[XN%Y]>?/PT^P. M?Z_NB^@SPJ.SZVL;_MN#[C1]P[+>P.W^U=)4?
7W!Y[PI071_3D_+G/+Y^B MOYFOIGB^N%[VE]O65>O,C3M>;OM8TH+(WOR8^|7+|?
YRNE^JDW_:2*T[VWP+ M\$OD;_H#E:[N;_UXGM_%"1#-EC4[R:B\A-IN=E06UN.3_?/W?
RU74'KU=?KE M@^G]@XLW4ET=7-LW9C3ZB.&_5X'N@!PS/5R_R>.\$ T3T?
+F2A;L;G_+Q* MS[[U# PGX;[3:WHNF^U-DQ\GEX6/>QI;*2S555FV=X^0[H
M'6W>MEXU>>WE^ZP3\$ Y'YP\$&L4ZZ"N7O#,#?&8"C9//;/I'G)40RN.5ZF7,
MJO%Z=F#C#TK\$9;WC1OR_JUV_7S;.%J2NU4RZ+ FVJKO"!?EIM-18XV/5ZJ
M6B7CJ=+;SHK*|KDE:&HG/Q?C19DBG9V+5JMJJ&E[HV1/9>E]6O[KP]Q?S3\O
MYF\6R_&U7;>6RI5[=_IM9+'4Z5Z#-LJ2_CJ9@DZ'N[QZ9>"JG3WJM5J(\$^5
MY4\$&M7;_!C%;_C/>W=2Q5#UREP\4*XDL<%D>9%ME";^%16?3>+O3\$@G1'4M6
M*XT\58K\6=.6W%[?Q,^SW&ANNHBPSVF:S?W*M.ZK;(_Y3K5D=R\$)=V%B@V+_
MQW@V6;'Y*OW7\#J^RK-VYS_?V\^&D/W>C\5+G)=\$0!=^_@#@#V/&_^SDKGOW M5?
IL?|R.TYC&R]H%\$B=|L%ZJOB0V;!Z7\$H9 MV^VT+|:K#2@\$BN,XVXX'5M+\$V|-LO0*"
DY8F[;_>%@(+^|)%/E^TDQ*9B78=Y MU%:68!87X!=^C*N9M'?
9P")*^8C/=!)R4Z&OXWG8:A70A^| #50_17KE(|<|> M8@M4_GRP/_^Q>-#UJ'3A3Y?
U>YOK8\$|_6I^|1:HE7(^0PL_3^73WM1_-"/Z*_M68Z_OU>@)K\YC|EXYL7|&>F)|R>|9Q|
|4#R9/4_+&'3H%=BHBV;UPO>JK MO:*8'<>7RJ+|&&
<%Y'2_2LV:DL\GNW9>/TB'R#ICR+B>+I6O4>|1PIE!Q/^
MKE4|YTWS=WWBW_6)O\DF_-/_LY4_WO=X/%ZI6AG5OM.Q=;_U!3"9W)%5YF@+M7:
|>M;Z5W;_N>Z\ME"!EJM72|/%|!6#N^GF^OK==QJL9Q^=I.WL_F+;Q,W
M^>>|A.R_ E\2VV7Q&8%V-> V#/-L,7%I^_ ^U6)92+I;%ZUIV744XCYFU'9^ M2LOI9!D-
<|_<7_6C16-2.G#?%Y<4\$ _7K'>>3I#5#H;4CM+|>_GS05_SL,@D
M%A#5MO7JM0KNI;VL*5X0QLCASSG7IQO#UBVB;-B[%!FWLS0_^0(6U,=O
M\V5XOH72)|3;Y^HJTCQ2YD=SL++H_SE_PUO<[N+JW2WB= FTTXJ^_SL,JY
MSJ6'U13C/Z??%M0_G?|2-HW^C?=T/^4TJ?|_6/CG_2 M\ GI7VU#:9R,EM|LK@R7?)
&O|Q>;L4H/_^ ^|V!6|R_->J&85EX'\$R>|O1 M(B\65VFSC:NT00#=-
@JCX^2/5GOF65R'G,3LVF7,MX2OZ9V&Y_?F6O&|G835 MWE|-IF'Q>@Z_*
(6<0B14>UA;|D=E!5\$95:_^A|'XFE\MO\|? (6+#+^%J>K>;
M/Y;YYW\M/J:)S\OZO)QD!N4)%:4@5>+[U1ZWEL%301'4GNX2;:Z+ZYW*?+A.
MM4MG7R)SRT9K!WHWU):IE7Z^6KUJBW|EEZT|.WDU^Q0G,0^LW&"H\XN3|2O6
MR_ ^?)J^|?E=7@;DA+M:K*N4QA|6?3LM<|8.KUY/!9XFR\|JTS8YS_-I=M?'NW6-
P4E.B^=:090J?JT<,\JU10^;>=>&.T%)2W+=N-8OS5.UZF\$?5S^+L MAVQDR6>
|SU=JUJ7E)/W%9>U)?0"|^L9/)SP|V' H):MN2U?JAG"ZO/9RI M75.54^Y
XD=J<86Z<^5ZC4'ZZ-5#C*I>YW,S M7O\,HTW6K 3WYGHUPNWU. \$Q\$79;2KI'?JH>GY
3Q7T:*VN[C4_4S#|6JTM D M-?
SMZVP"7/ZX+.5)'O>I>BU&3H|=G<+*YN3_1UR^F_K9=:\$8>J#W62>%.QHQ/86%GR6|1A
CF1> M\5-MW|=JW829TOAK(, MJBW YYJE;R1DQY*=JA5:"F;M9TWUR/^MAB\OP\$-
K=Y)D2Z&LCLRJ*_-;^>1W MAOO[V6]?O=8I8^?
K|U)B*T\$|:R|JU\3R|GO\MB|825PM!: #VL:5VAJHL M4.4=%1+8MO4ZR:NE@-
\$>IK00XB\RU>SA0IT\$U%*49QL;JALAL|ZEDK=K=))'
M2S&8)YMOH\|R|MSB.K5>E+85)&BQ3G4U_+E0|CKN/#S\2H-4ZA.|?#RG838
M4@"D.\NJWTMAG.FR\$X|H_ O=E4H_'UJ|DV1;BH5T9ECM.VVZF+Z!+04%3G
G.H5!/>00\J5"FQ?LY/H6@J#'|&!.JL'WDT78V#FY|E=
M39ZD|7Y+^F2I;K+9R^VM4FGH=>F+R62+ M+BG3+G?
WP@W(:D_GW(,_,^;OS>JTS|<7|K^|L\7T5K.)Y_C_'IQE3|/_^"K
MC#6_9|EJ9^@X&^\$P8ZI;'IFJ\$|;'Z|4?W\L3; MP|HE\$<J'R5CS>32+3)%LU8?
9M&V6X=A?CU>#X4OI F?KECOY?HI MVG 'YJ0U9L?W\;SDJ)ZLF"|=_^FG2&H|-
YH0U.N;-6\$%1'2W5+U7YJ<(YRD'
MFA#+I^AOYN/E."Y>?/GRXKL=3WJ_-|BS;KUWXJ<(:|O+B,=_&\$V&7O8P(?Y MS
^8#G|TF0'2P;NW43P=_/!3SS!2(" ^|?U>29/-\N'ATJ5\A.K-Y(ZWBNW
MQYF6CORJG@S;1N_@WQ\$;?_ '\$^C|. + ^+_ U_+ M4\$|! A0#% @_18HF68+)|2LC# GU4 !L
(! M & -A=&%L96YT+3(P,C0V,S\X97@Q,#0Q+ FAT;5!+ 0(4 Q0 (-/6*)EEG M7#2D>#P
(_N 0: " 5P, !C871A;&5N="TR,#(T-C,P M>&5X,3DQ+ FAT;5!+ 0(4 Q0 (-/6*)EGJ6Q((M0@
+?, : M " 0Q) !C871A;&5N="TR,#(T-C,P>&5X,C\$Q+ FAT;5!+ 0(4 Q0 M (-/6*)EDJG|>O6_.

&@/: " ?E1 !C871A;&5N M="TR,#(T-C,P>&5X,C,Q+FAT;5!+ 0(4 Q0 (/6*)EDD *#CW(!8(M: " 8E5 !C871A;&5N="TR,#(T-C,P>&5X,C,R+FAT M;5!+ 0(4 Q0 (/6*)ED'R WV#@+0H: " 9U8 M !C871A;&5N="TR,#(T-C,P>&5X,S\$Q+FAT;5!+ 0(4 Q0 (/6*)EF-M78F.* @ "HJ: " >-@ !C871A;&5N="TR,#(T-C,P M>&5X,S\$R+FAT;5!+ 0(4 Q0 (/6*)ED, K6--P0 !80: M " 4-I !C871A;&5N="TR,#(T-C,P>&5X,S(Q+FAT;5!+ 0(4 Q0 M (/6*)EEZ*D1F-P0 (00: ";)M !C871A;&5N M="TR,#(T-C,P>&5X,S(R+FAT;5!+ 0(4 Q0 (/6*)EE'>V2ONT# #A1 M+@ 1 " 2%R !C=&QT+3(P,C0P-C,P+FAT;5!+ 0(4 Q0 M (/6*)EGY#L^UU24 ". 0 1 " 0Y@! !C=&QT+3(P M,C0P-C,P+GAS9%!+ 0(4 Q0 (/6*)ED-&+?W,BX #34 0 5 M " 1*&! !C=&QT+3(P,C0P-C,P7V-A;"YX;6Q02P\$"% ,4 " #U MBB99YI"FU:KU #K4 L %0 @ %WM 0 8W1L="TR,#(T,#8S M,%ID968N>&UL4\$L! A0#% @ !8HF6>J^C'?UI TI !0 M (!5*H% &-T;'0M,C R-# V,S!?'9S\$N:G!G4\$L! A0#% @ !8HF M665F\CM @ H^(!0 (!>T)& &-T;'0M,C R-# V,S!?' M9S(N:G!G4\$L! A0#% @ !8HF6:*)(T*GB@ C\L !0 M (!!= \$& &-T;'0M,C R-# V,S!?'9S,N:G!G4\$L! A0#% @ !8HF642-MG^'W6@ :)\$!0 (!QEP' &-T;'0M,C R-# V,S!?'9S0N M:G!G4\$L! A0#% @ !8HF6865XN"+40 ^UD !0 (! M H<' &-T;'0M,C R-# V,S!?'9S4N:G!G4\$L! A0#% @ !8HF60 T?>#) MA0 >KP !0 (!K D(&-T;'0M,C R-# V,S!?'9S8N:G!G M4\$L! A0#% @ !8HF69)1? LDG.@(K^86 !4 (!IX)(M &-T;'0M,C R-# V,S!?'&%B+GAM;%!+ 0(4 Q0 (/6*)EG"E7I- ;X8! M ,.)\$@ 5 " 0*"@ !C=&QT+3(P,C0P-C,P7W!R92YX;6Q0 52P4& !4 %0"?!0 HU , end XML 148 ctlt-20240630_htm.xml IDEA: XBRL DOCUMENT 0001596783 2023-07-012024-06-30 0001596783 2021-12-31 0001596783 2024-08-22 0001596783 2024-06-30 0001596783 2023-06-30 0001596783 2022-07-012023-06-30 0001596783 2021-07-012022-06-30 0001596783 2020-07-012021-06-30 0001596783 us-gaap:RetainedEarningsMember 2023-07-012024-06-30 0001596783 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-07-012024-06-30 0001596783 ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember 2023-07-012024-06-30 0001596783 ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember 2022-07-012023-06-30 0001596783 ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember 2021-07-012022-06-30 0001596783 us-gaap:CommonStockMember 2021-06-30 0001596783 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001596783 us-gaap:RetainedEarningsMember 2021-06-30 0001596783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001596783 2021-06-30 0001596783 us-gaap:CommonStockMember 2021-07-012022-06-30 0001596783 us-gaap:AdditionalPaidInCapitalMember 2021-07-012022-06-30 0001596783 us-gaap:RetainedEarningsMember 2021-07-012022-06-30 0001596783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-012022-06-30 0001596783 us-gaap:CommonStockMember 2022-06-30 0001596783 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001596783 us-gaap:RetainedEarningsMember 2022-06-30 0001596783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001596783 2022-06-30 0001596783 us-gaap:CommonStockMember 2022-07-012023-06-30 0001596783 us-gaap:AdditionalPaidInCapitalMember 2022-07-012023-06-30 0001596783 us-gaap:RetainedEarningsMember 2022-07-012023-06-30 0001596783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-012023-06-30 0001596783 us-gaap:CommonStockMember 2023-06-30 0001596783 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001596783 us-gaap:RetainedEarningsMember 2023-06-30 0001596783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001596783 us-gaap:CommonStockMember 2023-07-012024-06-30 0001596783 us-gaap:AdditionalPaidInCapitalMember 2023-07-012024-06-30 0001596783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012024-06-30 0001596783 us-gaap:CommonStockMember 2024-06-30 0001596783 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001596783 us-gaap:RetainedEarningsMember 2024-06-30 0001596783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001596783 ctlt:PharmaConsumerHealthMember 2022-07-012023-06-30 0001596783 srt:MinimumMemberctlt:BuildingAndImprovementsMember 2024-06-30 0001596783 srt:MaximumMemberctlt:BuildingAndImprovementsMember 2024-06-30 0001596783

~~srt:MinimumMemberus-gaap:MachineryAndEquipmentMember 2024-06-30
0001596783 srt:MaximumMemberus-gaap:MachineryAndEquipmentMember 2024-06-30 0001596783 srt:MinimumMemberus-gaap:FurnitureAndFixturesMember 2024-06-30 0001596783 srt:MaximumMemberus-gaap:FurnitureAndFixturesMember 2024-06-30 0001596783 srt:MinimumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-06-30 0001596783 srt:MaximumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-06-30 0001596783~~
~~ctlt:ManufacturingCommercialProductSupplyMemberctlt:BiologicsMember 2023-07-012024-06-30 0001596783~~
~~ctlt:ManufacturingCommercialProductSupplyMemberctlt:PharmaConsumerHealthMem 2023-07-012024-06-30 0001596783~~
~~ctlt:ManufacturingCommercialProductSupplyMemberctlt:TotalCatalentbeforeintersegm 2023-07-012024-06-30 0001596783~~
~~ctlt:DevelopmentServicesMemberctlt:BiologicsMember 2023-07-012024-06-30 0001596783 ctlt:DevelopmentServicesMemberctlt:PharmaConsumerHealthMember 2023-07-012024-06-30 0001596783~~
~~ctlt:DevelopmentServicesMemberctlt:TotalCatalentbeforeintersegmentrevenueeliminati 2023-07-012024-06-30 0001596783 us-gaap:OperatingSegmentsMemberctlt:BiologicsMember 2023-07-012024-06-30 0001596783 us-gaap:OperatingSegmentsMemberctlt:PharmaConsumerHealthMember 2023-07-012024-06-30 0001596783~~
~~ctlt:OperatingSegmentsExcludingIntersegmentEliminationMember 2023-07-012024-06-30 0001596783 us-gaap:IntersegmentEliminationMemberctlt:TotalCatalentSegmentMember 2023-07-012024-06-30 0001596783 us-gaap:OperatingSegmentsMember 2023-07-012024-06-30 0001596783~~
~~ctlt:ManufacturingCommercialProductSupplyMemberctlt:BiologicsMember 2022-07-012023-06-30 0001596783~~
~~ctlt:ManufacturingCommercialProductSupplyMemberctlt:PharmaConsumerHealthMem 2022-07-012023-06-30 0001596783~~
~~ctlt:ManufacturingCommercialProductSupplyMemberctlt:TotalCatalentbeforeintersegm 2022-07-012023-06-30 0001596783~~
~~ctlt:DevelopmentServicesMemberctlt:BiologicsMember 2022-07-012023-06-30 0001596783 ctlt:DevelopmentServicesMemberctlt:PharmaConsumerHealthMember 2022-07-012023-06-30 0001596783~~
~~ctlt:DevelopmentServicesMemberctlt:TotalCatalentbeforeintersegmentrevenueeliminati 2022-07-012023-06-30 0001596783 us-gaap:OperatingSegmentsMemberctlt:BiologicsMember 2022-07-012023-06-30 0001596783 us-gaap:OperatingSegmentsMemberctlt:PharmaConsumerHealthMember 2022-07-012023-06-30 0001596783~~
~~ctlt:OperatingSegmentsExcludingIntersegmentEliminationMember 2022-07-012023-06-30 0001596783 us-gaap:IntersegmentEliminationMemberctlt:TotalCatalentSegmentMember 2022-07-012023-06-30 0001596783 us-gaap:OperatingSegmentsMember 2022-07-012023-06-30 0001596783~~
~~ctlt:ManufacturingCommercialProductSupplyMemberctlt:BiologicsMember 2021-07-012022-06-30 0001596783~~
~~ctlt:ManufacturingCommercialProductSupplyMemberctlt:PharmaConsumerHealthMem 2021-07-012022-06-30 0001596783~~
~~ctlt:ManufacturingCommercialProductSupplyMemberctlt:TotalCatalentbeforeintersegm 2021-07-012022-06-30 0001596783~~
~~ctlt:DevelopmentServicesMemberctlt:BiologicsMember 2021-07-012022-06-30 0001596783 ctlt:DevelopmentServicesMemberctlt:PharmaConsumerHealthMember 2021-07-012022-06-30 0001596783~~
~~ctlt:DevelopmentServicesMemberctlt:TotalCatalentbeforeintersegmentrevenueeliminati 2021-07-012022-06-30 0001596783 us-gaap:OperatingSegmentsMemberctlt:BiologicsMember 2021-07-012022-06-30~~

0001596783 us-gaap:OperatingSegmentsMemberctlt:PharmaConsumerHealthMember
2021-07-012022-06-30 0001596783
ctlt:OperatingSegmentsExcludingIntersegmentEliminationMember 2021-07-012022-
06-30 0001596783 us-
gaap:IntersegmentEliminationMemberctlt:TotalCatalentSegmentMember 2021-07-
012022-06-30 0001596783 us-gaap:OperatingSegmentsMember 2021-07-012022-06-30
0001596783 ctlt:geographicalMember 2023-07-012024-06-30 0001596783 country:US
2023-07-012024-06-30 0001596783 country:US 2022-07-012023-06-30 0001596783
country:US 2021-07-012022-06-30 0001596783 srt:EuropeMember 2023-07-012024-
06-30 0001596783 srt:EuropeMember 2022-07-012023-06-30 0001596783
srt:EuropeMember 2021-07-012022-06-30 0001596783 ctlt:InternationalOtherMember
2023-07-012024-06-30 0001596783 ctlt:InternationalOtherMember 2022-07-012023-
06-30 0001596783 ctlt:InternationalOtherMember 2021-07-012022-06-30 0001596783
ctlt:GreaterThanOneYearMemberMember 2023-06-30 0001596783
ctlt:RheinCellTherapeuticsMember 2021-08-012021-08-01 0001596783
ctlt:RheinCellTherapeuticsMember 2021-08-01 0001596783
ctlt:BetteraHoldingsLLCMember 2021-10-012021-10-01 0001596783
ctlt:BetteraHoldingsLLCMemberus-gaap:OtherIntangibleAssetsMember 2021-10-01
0001596783 ctlt:BetteraHoldingsLLCMember 2021-10-01 0001596783
ctlt:BetteraHoldingsLLCMember 2022-10-01 0001596783
ctlt:BetteraHoldingsLLCMember 2021-10-012021-10-31 0001596783
ctlt:BetteraHoldingsLLCMemberctlt:CoreTechnologyBetteraMember 2021-10-01
0001596783 ctlt:BetteraHoldingsLLCMemberctlt:CoreTechnologyMember 2022-10-
012022-10-01 0001596783 ctlt:VaccineManufacturingAndInnovationCentreMember
2022-04-012022-04-30 0001596783
ctlt:VaccineManufacturingAndInnovationCentreMember 2022-04-30 0001596783
ctlt:PrincetonCellTherapyMember 2022-04-012022-04-30 0001596783
ctlt:PrincetonCellTherapyMember 2022-04-30 0001596783 ctlt:MetricsMember 2021-
02-232021-02-23 0001596783 ctlt:MetricsMember 2022-10-01 0001596783
ctlt:MetricsMember 2022-10-012022-10-01 0001596783 ctlt:MetricsMemberus-
gaap:CustomerRelationshipsMember 2022-10-01 0001596783 ctlt:MetricsMemberus-
gaap:CustomerRelationshipsMember 2022-10-012022-10-01 0001596783
ctlt:BlowFillSealBusinessWoodstockMember 2023-06-30 0001596783
ctlt:BlowFillSealBusinessWoodstockMember 2022-07-012023-06-30 0001596783
ctlt:BlowFillSealBusinessWoodstockMember 2024-06-30 0001596783
ctlt:BlowFillSealBusinessWoodstockMember 2023-07-012024-06-30 0001596783
ctlt:BlowFillSealBusinessWoodstockMember 2023-01-012023-03-31 0001596783
ctlt:BlowFillSealBusinessWoodstockMember 2021-07-012022-06-30 0001596783
ctlt:BlowFillSealBusinessWoodstockMember 2022-06-30 0001596783
ctlt:BiologicsMember 2022-06-30 0001596783
ctlt:SoftgelAndOralTechnologiesMember 2022-06-30 0001596783
ctlt:BiologicsMember 2022-07-012023-06-30 0001596783 ctlt:BiologicsMember 2023-
06-30 0001596783 ctlt:SoftgelAndOralTechnologiesMember 2023-06-30 0001596783
ctlt:BiologicsMember 2023-07-012024-06-30 0001596783
ctlt:PharmaConsumerHealthMember 2023-07-012024-06-30 0001596783
ctlt:BiologicsMember 2024-06-30 0001596783 ctlt:PharmaConsumerHealthMember
2024-06-30 0001596783 ctlt:CoreTechnologyMember 2023-07-012024-06-30
0001596783 ctlt:CoreTechnologyMember 2024-06-30 0001596783 us-
gaap:CustomerRelationshipsMember 2023-07-012024-06-30 0001596783 us-
gaap:CustomerRelationshipsMember 2024-06-30 0001596783
ctlt:ProductRelationshipsMember 2023-07-012024-06-30 0001596783
ctlt:ProductRelationshipsMember 2024-06-30 0001596783 us-
gaap:OtherIntangibleAssetsMember 2023-07-012024-06-30 0001596783 us-
gaap:OtherIntangibleAssetsMember 2024-06-30 0001596783
ctlt:CoreTechnologyMember 2022-07-012023-06-30 0001596783
ctlt:CoreTechnologyMember 2023-06-30 0001596783 us-
gaap:CustomerRelationshipsMember 2022-07-012023-06-30 0001596783 us-
gaap:CustomerRelationshipsMember 2023-06-30 0001596783

ctlt:ProductRelationshipsMember 2022-07-012023-06-30 0001596783
ctlt:ProductRelationshipsMember 2023-06-30 0001596783 us-
gaap:OtherIntangibleAssetsMember 2022-07-012023-06-30 0001596783 us-
gaap:OtherIntangibleAssetsMember 2023-06-30 0001596783 ctlt:BiologicsMember
2021-07-012022-06-30 0001596783 ctlt:PharmaConsumerHealthMember 2021-07-
012022-06-30 0001596783 ctlt:CorporateAndEliminationsMember 2023-07-012024-06-
30 0001596783 ctlt:CorporateAndEliminationsMember 2022-07-012023-06-30
0001596783 ctlt:CorporateAndEliminationsMember 2021-07-012022-06-30
0001596783 ctlt:TermLoanThreeFacilityDollarDenominatedMember 2024-06-30
0001596783 ctlt:TermLoanThreeFacilityDollarDenominatedMember 2023-06-30
0001596783 ctlt:TermLoanFourFacilityDollarDenominatedMember 2024-06-30
0001596783 ctlt:RevolvingCreditFacilityTwoMember 2024-06-30 0001596783
ctlt:RevolvingCreditFacilityTwoMember 2023-06-30 0001596783
ctlt:USDollarDenominated500SeniorNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0001596783
ctlt:USDollarDenominated500SeniorNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0001596783
ctlt:A2375SeniorEuroDenominatedNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0001596783
ctlt:A2375SeniorEuroDenominatedNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0001596783
ctlt:A3125SeniorUSDenominatedNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0001596783
ctlt:A3125SeniorUSDenominatedNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0001596783
ctlt:A3500SeniorUSDenominatedNotesMemberMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0001596783
ctlt:A3500SeniorUSDenominatedNotesMemberMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0001596783
us-gaap:CapitalLeaseObligationsMember 2024-06-30 0001596783 us-
gaap:CapitalLeaseObligationsMember 2023-06-30 0001596783
ctlt:OtherObligationsMember 2024-06-30 0001596783 ctlt:OtherObligationsMember
2023-06-30 0001596783 ctlt:DebtIssuanceCostsMemberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0001596783
ctlt:DebtIssuanceCostsMemberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0001596783
us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0001596783
us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0001596783
2024-04-012024-06-30 0001596783 ctlt:RevolvingCreditCommitmentsMember 2024-
06-30 0001596783 srt:MinimumMemberctlt:RevolvingCreditCommitmentsMember
2023-07-012024-06-30 0001596783
srt:MaximumMemberctlt:RevolvingCreditCommitmentsMember 2023-07-012024-06-30
0001596783 ctlt:RevolvingCreditCommitmentsMemberus-
gaap:SecuredOvernightFinancingRateSofrMember 2023-07-012024-06-30 0001596783
srt:MinimumMemberctlt:TermLoanThreeFacilityDollarDenominatedMember 2023-07-
012024-06-30 0001596783 ctlt:USDollarDenominated500SeniorNotesMember 2024-06-
30 0001596783 ctlt:OneMonthMemberctlt:IncrementalTermLoanMemberus-
gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-07-

012024-06-30 0001596783
ctlt:ThreeMonthMemberctlt:IncrementalTermLoanMemberus-
gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-07-
012024-06-30 0001596783 ctlt:SixMonthMemberctlt:IncrementalTermLoanMemberus-
gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-07-
012024-06-30 0001596783 ctlt:TermLoanFourFacilityDollarDenominatedMember
2023-12-19 0001596783 ctlt:TermLoanFourFacilityDollarDenominatedMemberus-
gaap:SecuredOvernightFinancingRateSofrMember 2024-06-30 0001596783
srt:MinimumMemberctlt:TermLoanFourFacilityDollarDenominatedMember 2023-07-
012024-06-30 0001596783 ctlt:A2375SeniorEuroDenominatedNotesMember 2024-06-
30 0001596783 ctlt:FourPointSevenFivePercentSeniorEuroDenominatedNotesMember
2024-06-30 0001596783 ctlt:A3125SeniorUSDenominatedNotesMember 2024-06-30
0001596783 ctlt:U.S.Dollardenominated4.875SeniorNotesMember 2017-10-18
0001596783 ctlt:A3500SeniorUSDenominatedNotesMemberMember 2024-06-30
0001596783 us-gaap:AccruedLiabilitiesMember 2017-10-012017-10-23 0001596783
2017-10-012017-10-23 0001596783 ctlt:SeniorSecuredCreditFacilityMember 2023-07-
012024-06-30 0001596783 ctlt:USDollarDenominated500SeniorNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:EstimateOffFairValueFairValueDisclosureMember 2024-06-30 0001596783
ctlt:USDollarDenominated500SeniorNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:EstimateOffFairValueFairValueDisclosureMember 2023-06-30 0001596783
ctlt:A2375SeniorEuroDenominatedNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:EstimateOffFairValueFairValueDisclosureMember 2024-06-30 0001596783
ctlt:A2375SeniorEuroDenominatedNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:EstimateOffFairValueFairValueDisclosureMember 2023-06-30 0001596783
ctlt:A3125SeniorUSDenominatedNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:EstimateOffFairValueFairValueDisclosureMember 2024-06-30 0001596783
ctlt:A3125SeniorUSDenominatedNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:EstimateOffFairValueFairValueDisclosureMember 2023-06-30 0001596783
ctlt:A3500SeniorUSDenominatedNotesMemberMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:EstimateOffFairValueFairValueDisclosureMember 2024-06-30 0001596783
ctlt:A3500SeniorUSDenominatedNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0001596783
ctlt:A3500SeniorUSDenominatedNotesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:EstimateOffFairValueFairValueDisclosureMember 2023-06-30 0001596783
ctlt:SeniorSecuredCreditFacilitiesOtherMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0001596783
ctlt:SeniorSecuredCreditFacilitiesOtherMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:EstimateOffFairValueFairValueDisclosureMember 2024-06-30 0001596783
ctlt:SeniorSecuredCreditFacilitiesOtherMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0001596783
ctlt:SeniorSecuredCreditFacilitiesOtherMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:EstimateOffFairValueFairValueDisclosureMember 2023-06-30 0001596783 us-
gaap:EstimateOffFairValueFairValueDisclosureMember 2024-06-30 0001596783 us-
gaap:EstimateOffFairValueFairValueDisclosureMember 2023-06-30 0001596783
ctlt:DebtIssuanceCostsMemberus-

gaap:EstimateOffFairValueFairValueDisclosureMember 2024-06-30 0001596783
ctlt:DebtIssuanceCostsMemberus-
gaap:EstimateOffFairValueFairValueDisclosureMember 2023-06-30 0001596783 2020-
11-232020-11-23 0001596783 2021-11-182021-11-18 0001596783 us-
gaap:SeriesAPreferredStockMember 2023-07-012024-06-30 0001596783 us-
gaap:SeriesAPreferredStockMember 2022-07-012023-06-30 0001596783 us-
gaap:SeriesAPreferredStockMember 2021-07-012022-06-30 0001596783
ctlt:USDenominatedTermLoanMember 2024-06-30 0001596783
ctlt:USDenominatedTermLoanMember 2022-06-30 0001596783 us-
gaap:FairValueInputsLevel1Member 2024-06-30 0001596783 us-
gaap:FairValueInputsLevel2Member 2024-06-30 0001596783 us-
gaap:FairValueInputsLevel3Member 2024-06-30 0001596783 us-
gaap:FairValueInputsLevel1Member 2023-06-30 0001596783 us-
gaap:FairValueInputsLevel2Member 2023-06-30 0001596783 us-
gaap:FairValueInputsLevel3Member 2023-06-30 0001596783 us-
gaap:DomesticCountryMember 2024-06-30 0001596783 us-
gaap:StateAndLocalJurisdictionMember 2024-06-30 0001596783 us-
gaap:StateAndLocalJurisdictionMember 2023-07-012024-06-30 0001596783 us-
gaap:ForeignCountryMember 2024-06-30 0001596783 us-gaap:ForeignCountryMember
2023-07-012024-06-30 0001596783 ctlt:U.S.FederalDeferredTaxAssetDomain 2024-06-
30 0001596783 ctlt:U.S.StateNetDeferredTaxAssetDomain 2024-06-30 0001596783
ctlt:InternationalDeferredTaxAssetDomain 2024-06-30 0001596783 us-
gaap:PensionPlansDefinedBenefitMember 2023-07-012024-06-30 0001596783 us-
gaap:PensionPlansDefinedBenefitMember 2022-07-012023-06-30 0001596783
ctlt:LumpSumPaymentMember 2023-07-012024-06-30 0001596783 us-
gaap:FixedAnnuityMember 2023-07-012024-06-30 0001596783 us-
gaap:PensionPlansDefinedBenefitMember 2024-06-30 0001596783 us-
gaap:PensionPlansDefinedBenefitMember 2023-06-30 0001596783 us-
gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0001596783
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30
0001596783 us-gaap:PensionPlansDefinedBenefitMember 2022-06-30 0001596783 us-
gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-07-012024-06-30
0001596783 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-
07-012023-06-30 0001596783 us-gaap:CashMemberus-
gaap:PensionPlansDefinedBenefitMember 2024-06-30 0001596783 us-
gaap:CashMemberus-gaap:PensionPlansDefinedBenefitMember 2023-06-30
0001596783 us-gaap:EquitySecuritiesMemberus-
gaap:PensionPlansDefinedBenefitMember 2024-06-30 0001596783 us-
gaap:EquitySecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember 2023-06-30
0001596783 us-gaap:EquitySecuritiesMemberus-
gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0001596783
us-gaap:EquitySecuritiesMemberus-
gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0001596783
us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:PensionPlansDefinedBenefitMember 2024-06-30 0001596783 us-
gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:PensionPlansDefinedBenefitMember 2023-06-30 0001596783 us-
gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0001596783
us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0001596783
us-gaap:CorporateDebtSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember
2024-06-30 0001596783 us-gaap:CorporateDebtSecuritiesMemberus-
gaap:PensionPlansDefinedBenefitMember 2023-06-30 0001596783 us-
gaap:CorporateDebtSecuritiesMemberus-
gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0001596783
us-gaap:CorporateDebtSecuritiesMemberus-
gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0001596783

us-gaap:RealEstateMemberus-gaap:PensionPlansDefinedBenefitMember 2024-06-30 0001596783
us-gaap:RealEstateMemberus-gaap:PensionPlansDefinedBenefitMember 2023-06-30 0001596783
us-gaap:RealEstateMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0001596783
us-gaap:RealEstateMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0001596783
ctlt:InsuranceContractsMemberus-gaap:PensionPlansDefinedBenefitMember 2024-06-30 0001596783
ctlt:InsuranceContractsMemberus-gaap:PensionPlansDefinedBenefitMember 2023-06-30 0001596783
ctlt:InsuranceContractsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0001596783
ctlt:InsuranceContractsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0001596783
us-gaap:OtherAssetsMemberus-gaap:PensionPlansDefinedBenefitMember 2024-06-30 0001596783
us-gaap:OtherAssetsMemberus-gaap:PensionPlansDefinedBenefitMember 2023-06-30 0001596783
us-gaap:OtherAssetsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0001596783
us-gaap:OtherAssetsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30 0001596783
us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member 2024-06-30 0001596783
us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member 2024-06-30 0001596783
us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member 2024-06-30 0001596783
us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member 2024-06-30 0001596783
us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2024-06-30 0001596783
us-gaap:EquitySecuritiesMember 2024-06-30 0001596783
us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member 2024-06-30 0001596783
us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2024-06-30 0001596783
us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member 2024-06-30 0001596783
us-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2024-06-30 0001596783
us-gaap:DebtSecuritiesMember 2024-06-30 0001596783
us-gaap:RealEstateMemberus-gaap:FairValueInputsLevel1Member 2024-06-30 0001596783
us-gaap:RealEstateMemberus-gaap:FairValueInputsLevel2Member 2024-06-30 0001596783
us-gaap:RealEstateMemberus-gaap:FairValueInputsLevel3Member 2024-06-30 0001596783
us-gaap:RealEstateMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2024-06-30 0001596783
us-gaap:RealEstateMember 2024-06-30 0001596783
us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel1Member 2024-06-30 0001596783
us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Member 2024-06-30 0001596783
us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel3Member 2024-06-30 0001596783
us-gaap:OtherAssetsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2024-06-30 0001596783
us-gaap:OtherAssetsMember 2024-06-30 0001596783
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2024-06-30 0001596783
us-gaap:HedgeFundsMemberus-gaap:FairValueInputsLevel2Member 2024-06-30 0001596783
us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member 2023-06-30 0001596783
us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member 2023-06-30 0001596783
us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member 2023-06-30 0001596783
us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2023-06-30 0001596783
us-gaap:EquitySecuritiesMember 2023-06-30 0001596783
us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member 2023-06-30 0001596783
us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2023-06-30 0001596783
us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member 2023-06-30 0001596783
us-gaap:DebtSecuritiesMember 2023-06-30 0001596783

gaap:DebtSecuritiesMemberus-
gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2023-06-30 0001596783
us-gaap:DebtSecuritiesMember 2023-06-30 0001596783 us-gaap:RealEstateMemberus-
gaap:FairValueInputsLevel1Member 2023-06-30 0001596783 us-
gaap:RealEstateMemberus-gaap:FairValueInputsLevel2Member 2023-06-30
0001596783 us-gaap:RealEstateMemberus-gaap:FairValueInputsLevel3Member 2023-
06-30 0001596783 us-gaap:RealEstateMemberus-
gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2023-06-30 0001596783
us-gaap:RealEstateMember 2023-06-30 0001596783 us-gaap:OtherAssetsMemberus-
gaap:FairValueInputsLevel1Member 2023-06-30 0001596783 us-
gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Member 2023-06-30
0001596783 us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel3Member 2023-
06-30 0001596783 us-gaap:OtherAssetsMemberus-
gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2023-06-30 0001596783
us-gaap:OtherAssetsMember 2023-06-30 0001596783 us-
gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2023-06-30 0001596783
us-gaap:HedgeFundsMemberus-gaap:FairValueInputsLevel2Member 2023-06-30
0001596783 cttl:EberbachPensionPromissoryNoteOrLoanMember 2024-06-30
0001596783 cttl:InsuranceContractsMemberus-gaap:FairValueInputsLevel3Member
2023-06-30 0001596783 cttl:OtherUnobservableAssetsMemberus-
gaap:FairValueInputsLevel3Member 2023-06-30 0001596783 us-
gaap:FairValueInputsLevel3Member 2023-07-012024-06-30 0001596783
cttl:InsuranceContractsMemberus-gaap:FairValueInputsLevel3Member 2023-07-
012024-06-30 0001596783 cttl:OtherUnobservableAssetsMemberus-
gaap:FairValueInputsLevel3Member 2023-07-012024-06-30 0001596783
cttl:InsuranceContractsMemberus-gaap:FairValueInputsLevel3Member 2024-06-30
0001596783 cttl:OtherUnobservableAssetsMemberus-
gaap:FairValueInputsLevel3Member 2024-06-30 0001596783 cttl:Post65Memberus-
gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-06-30 0001596783
cttl:Post65Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2023-06-30 0001596783 cttl:Post65Memberus-
gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-07-012024-06-30
0001596783 cttl:Post65Memberus-
gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-012023-06-30
0001596783 cttl:DesignatedSharesMember 2022-06-30 0001596783 2019-05-17
0001596783 2020-11-23 0001596783 2021-11-18 0001596783 us-
gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001596783 2023-07-
012024-03-31 0001596783 us-gaap:AccumulatedTranslationAdjustmentMember 2021-
06-30 0001596783 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-
06-30 0001596783 us-
gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2021-06-30
0001596783 cttl:ACOIAccumulatedGainLossMarketableSecuritiesMember 2021-06-30
0001596783 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-06-
30 0001596783 us-gaap:AccumulatedTranslationAdjustmentMember 2021-07-012022-
06-30 0001596783 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-
07-012022-06-30 0001596783 us-
gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2021-07-
012022-06-30 0001596783 us-
gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-07-012022-06-30
0001596783 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30
0001596783 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-06-30
0001596783 us-
gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2022-06-30
0001596783 cttl:ACOIAccumulatedGainLossMarketableSecuritiesMember 2022-06-30
0001596783 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-06-
30 0001596783 us-gaap:AccumulatedTranslationAdjustmentMember 2022-07-012023-
06-30 0001596783 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-
07-012023-06-30 0001596783 us-

gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2022-07-012023-06-30 0001596783 us-
gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-07-012023-06-30 0001596783 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0001596783 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-06-30 0001596783 us-
gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2023-06-30 0001596783 cttl:ACOIAccumulatedGainLossMarketableSecuritiesMember 2023-06-30 0001596783 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-06-30 0001596783 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-07-012024-06-30 0001596783 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0001596783 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-06-30 0001596783 us-
gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2024-06-30 0001596783 cttl:ACOIAccumulatedGainLossMarketableSecuritiesMember 2024-06-30 0001596783 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-06-30 0001596783 cttl:StockCompensationPlanOmnibusMember 2023-07-012024-06-30 0001596783 cttl:StockCompensationPlanOmnibusMember 2022-07-012023-06-30 0001596783 cttl:StockCompensationPlanOmnibusMember 2021-07-012022-06-30 0001596783 srt:MinimumMemberus-gaap:EmployeeStockOptionMember 2023-07-012024-06-30 0001596783 srt:MinimumMemberus-gaap:EmployeeStockOptionMember 2022-07-012023-06-30 0001596783 srt:MinimumMemberus-gaap:EmployeeStockOptionMember 2021-07-012022-06-30 0001596783 srt:MaximumMemberus-gaap:EmployeeStockOptionMember 2023-07-012024-06-30 0001596783 srt:MaximumMemberus-gaap:EmployeeStockOptionMember 2022-07-012023-06-30 0001596783 srt:MaximumMemberus-gaap:EmployeeStockOptionMember 2021-07-012022-06-30 0001596783 cttl:TimeMember 2023-06-30 0001596783 cttl:TimeMember 2022-07-012023-06-30 0001596783 cttl:TimeMember 2023-07-012024-06-30 0001596783 cttl:PerformanceMember 2024-06-30 0001596783 cttl:TimeMember 2024-06-30 0001596783 cttl:TimeBasedRestrictedStockUnitsMember 2023-06-30 0001596783 cttl:TimeBasedRestrictedStockUnitsMember 2023-07-012024-06-30 0001596783 cttl:TimeBasedRestrictedStockUnitsMember 2024-06-30 0001596783 us-gaap:PerformanceSharesMember 2023-06-30 0001596783 us-gaap:PerformanceSharesMember 2023-07-012024-06-30 0001596783 us-gaap:PerformanceSharesMember 2024-06-30 0001596783 srt:MinimumMemberus-gaap:PerformanceSharesMember 2023-07-012024-06-30 0001596783 srt:MaximumMemberus-gaap:PerformanceSharesMember 2023-07-012024-06-30 0001596783 srt:MinimumMemberus-gaap:PerformanceSharesMember 2022-07-012023-06-30 0001596783 srt:MaximumMemberus-gaap:PerformanceSharesMember 2022-07-012023-06-30 0001596783 cttl:RTSRPerformanceShareUnitsMember 2023-06-30 0001596783 cttl:RTSRPerformanceShareUnitsMember 2023-07-012024-06-30 0001596783 cttl:RTSRPerformanceShareUnitsMember 2024-06-30 0001596783 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001596783 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012024-06-30 0001596783 us-gaap:RestrictedStockUnitsRSUMember 2022-07-012023-06-30 0001596783 us-gaap:RestrictedStockUnitsRSUMember 2021-07-012022-06-30 0001596783 srt:MinimumMember 2023-07-012024-06-30 0001596783 srt:MaximumMember 2023-07-012024-06-30 0001596783 2024-02-05 0001596783 cttl:MergerAgreementMember 2024-02-05 0001596783 cttl:TotalCatalentSubTotalOfSegmentReportingMember 2023-07-012024-06-30 0001596783 cttl:TotalCatalentSubTotalOfSegmentReportingMember 2022-07-012023-06-30 0001596783 cttl:TotalCatalentSubTotalOfSegmentReportingMember 2021-07-012022-06-30 0001596783 cttl:BiologicsMembercttl:OxfordMember 2023-07-012024-06-30 0001596783 cttl:BiologicsMembercttl:SwindonMember 2023-07-012024-06-30 0001596783 cttl:PharmaConsumerHealthMember 2023-06-30 0001596783 cttl:CorporateAndEliminationsMember 2024-06-30 0001596783 cttl:CorporateAndEliminationsMember 2023-06-30 0001596783 us-

gaap:CorporateMember 2023-07-012024-06-30 0001596783 us-gaap:CorporateMember 2022-07-012023-06-30 0001596783 us-gaap:CorporateMember 2021-07-012022-06-30 0001596783 country:US 2024-06-30 0001596783 country:US 2023-06-30 0001596783 srt:EuropeMember 2024-06-30 0001596783 srt:EuropeMember 2023-06-30 0001596783 ctlt:RestofWorldMember 2024-06-30 0001596783 ctlt:RestofWorldMember 2023-06-30 0001596783 2024-10-012024-12-31 iso4217:USD shares iso4217:USD shares utr:Rate pure ctlt:employees iso4217:EURfalsefalsefalsefalsefalse2024FY181463702.0008873--06-300001596783false0.010.01100000000010000000001810000001800000000.010.011000
gaap/2024#SellingGeneralAndAdministrativeExpense<http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense>P20YP3Y<http://fasb.org/us-gaap/2024#DefinedBenefitPensionPlanLiabilitiesNoncurrent><http://fasb.org/us-gaap/2024#DefinedBenefitPensionPlanLiabilitiesNoncurrent><http://fasb.org/us-gaap/2024#DefinedBenefitPensionPlanLiabilitiesNoncurrent><http://fasb.org/us-gaap/2024#DefinedBenefitPensionPlanLiabilitiesNoncurrent><http://fasb.org/us-gaap/2024#DefinedBenefitPensionPlanLiabilitiesNoncurrent><http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet><http://fasb.org/us-gaap/2024#OtherLiabilities><http://fasb.org/us-gaap/2024#OtherLiabilities><http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet><http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent>SUBSEQUENT EVENTS10-Ktrue2024-06-302024false001-36587CATALENT, INC.DE20-873768814 Schoolhouse Road08873Somerset,NJ(732)537-6200Common Stock, \$0.01 par value per shareCTLTNYSENoNoYesYesLarge Accelerated Filerfalsefalse>true8100000000181463702248Grant Thornton LLPNew York, New York28900000028000000023000000460000009210000001002000000574000000777000781000000262000000-404000000-35400000036040000004611000000975300000010777000000438100000042630000004749000000-163000000730000000-254000000-186000000-12300000024000000700000028000000-1027000000-34200000057900000016000000-8600000080000000-1043000000-25600000049900000000016000000-1043000000-256000000483000000-5.76-1.422.74-5.76-1.422.73-1043000000-256000000499000000-3200000032000000-110000000-4000000400000014000000-900000004000000-3000000220000001800000027000000-5000000040000000-77000000-1093000000-2160000004220000001705490002000000420500000025000000-3170000003915000000359000000935000007818000362000000362000000-3590000005400000054000000100000001000000026000000260000001200000012000077000000-7700000017930200020000004649000000518000000-3940000004775000000097100003500000035000000-400000040000001300000013000000-256000000-256000000400000004000000018027300020000004701000000262000000-354000000461100000007250006800000068000000-9000000900000090000009000000-1043000000-1043000000-50000000-5000000018099800020000004787000000-781000000-4040000003604000000-1043000000-256000000499000000489000000422000000378000000687000000210000000-130000009000000-3000000014000000800000070000007000000180000000-29000000-98000000-3100000068000000350000005400000028000000127000000-90000008200000014300000017000000120000001000000-79000000-5300000073000000-109000000192000000128000000-84000000-21000000370000001660000001280000004230000002680000002540000004390000003327000000-955000000-1884000000120000000071500000011000000001116000000230000000780000001600030000003600000012000000740000005210000001031000000-600000011000000-3300000090000000-169000000-

44700000028000000044900000089600000028900000028000000044900000022600000

Business

Catalent, Inc.

“

Catalent

“

or the

“

Company

“

) directly and wholly owns PTS Intermediate Holdings LLC

“PTS

Intermediate

“

). PTS Intermediate directly and wholly owns Catalent Pharma Solutions, Inc. **“**

Operating Company

“

). The financial results of Catalent are primarily comprised of the financial results of Operating Company and its subsidiaries on a consolidated basis.

The Company's common stock, par value \$0.01 (the

“

Common Stock

“

) trades on the New York Stock Exchange under the

“

CTLT

“

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%>"".</div>**The Company provides differentiated development and manufacturing solutions for drugs, protein-based biologics, cell, and gene therapies, vaccines, and consumer health products at over fifty facilities across four continents under rigorous quality and operational standards. Its oral, injectable, and respiratory delivery technologies, along with its state-of-the-art protein, plasmid, viral, and cell and gene therapy manufacturing capacity address a wide and growing range of modalities and therapeutic and other categories across the biopharmaceutical, pharmaceutical, and consumer health industries.**0.01<div style="margin-top:9pt;text-align:justify">Reportable Segments</div><div style="text-align:justify;text-indent:24pt">
</div><div style="text-align:justify;text-indent:24pt">Effective July 1, 2022, in connection with the appointment of a new President and Chief Executive Officer, the Company changed its operating structure and reorganized its executive leadership team accordingly. The current organizational structure includes two operating and reportable segments—(i) Biologics and (ii) Pharma and Consumer Health—which are summarized below.</div><div style="text-align:justify">
</div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt">•The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA (“pDNA”); induced pluripotent stem cells (“iPSCs”), and oncolytic viruses; and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; analytical development and testing services for large molecules.</div><div style="text-align:justify">
</div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt">•The Pharma and Consumer Health segment comprises the Company’s market-leading capabilities for complex oral solids, softgel formulations, Zydis®fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.</div>Each segment reports through a separate management team and ultimately reports to the Company’s President and Chief Executive Officer, who is designated as the Chief Operating Decision Maker (“CODM”) for segment reporting purposes. The Company’s operating segments are the same as its reportable segments. All prior-period comparative segment information has been recast retrospectively to reflect the current reportable segments in accordance with Accounting Standards Codification (“ASC”) 280,Segment Reporting,Basis of Presentation</div><div>

These financial statements include all of the Company's subsidiaries, including those operating outside the United States

"

U.S.

"

), and are prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). All significant transactions among the Company's subsidiaries and reporting segments have been eliminated, other than as noted.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires the Company's management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, revenue recognition, including determining the transaction price and any associated constraint on variable consideration, allowance for credit losses, inventory and long-lived asset valuation, goodwill and other intangible asset valuation and impairment, equity-based compensation, income taxes, derivative valuation, and pension plan asset and liability valuation. Actual amounts may differ from these estimated amounts.

Reclassification

Certain prior-period amounts were reclassified to conform to the current period presentation. Specifically, certain line items in prior periods were combined within the operating activities section of the statement of cash flows to conform with current year presentation. These reclassifications did not have a material impact on the consolidated statements of cash flows.

Foreign Currency Translation

The financial statements of the Company's operations outside the U.S. are generally determined using the local currency as the functional currency. Adjustments to translate the assets and liabilities of the foreign operations into U.S. dollars are accumulated as a component of other comprehensive income utilizing period-end exchange rates. Since July 2018, the Company has accounted for its Argentine operations as highly inflationary, but this status has not had a material effect on the consolidated financial statements.

The currency fluctuation related to certain long-term inter-company loans where settlement is not planned or anticipated in the foreseeable future have been recorded within the cumulative translation adjustment, a component of other comprehensive income. In addition, the currency fluctuation associated with the portion of the Company's euro-denominated debt designated as a net investment hedge is included as a component of other comprehensive income. Foreign currency transaction gains and losses are calculated using weighted average exchange rates for the period and are included in the consolidated statements of operations in

"

other expense, net.

Such foreign currency transaction gains and losses include inter-company loans that are repayable in the foreseeable future.

Cash and Cash Equivalents

All liquid investments purchased with original maturities of three months or less are considered cash equivalents. The carrying value of these cash equivalents approximates fair value.

Allowance for Credit Losses

Trade receivables, contract assets, and other amounts owed to the Company are presented net of an allowance that includes an assessment of expected credit losses. The Company determines its allowance methodology by considering various factors, including the Company's previous loss history, aging of customer receivable balances, significant aspects of a geographic location's economic conditions, the current and anticipated future condition of the general economy and the industries in which the Company's primary customers operate. To the extent that the Company identifies that any individual customer's credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of that customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, trade receivables and contract assets are written off against the allowance when the related balances are no longer deemed collectible.

Concentrations of Credit Risk and Major Customers

Concentration of credit risk, with respect to accounts receivable, is limited due to the large number of customers and their dispersion across different geographic areas. The customers are primarily concentrated in the biopharmaceutical, pharmaceutical, and consumer products industries. The Company does not normally require collateral or any other security to support credit sales. The Company performs ongoing credit evaluations of its customers' financial conditions and maintains reserves for credit losses. Such losses historically have been within the Company's expectations.

For the fiscal years ended June 30, 2024, 2023, and 2022 the Company had one customer that accounted for 16%, 10% and 10%, respectively, of its net revenue, which was primarily recorded in the Biologics segment. As of June 30, 2024 and 2023, the Company had one customer that accounted for 34% and 20%, respectively, of its aggregate net trade receivables and contract asset values, primarily associated with the Biologics segment. After performing a risk assessment of this customer, the Company has determined that a reserve is not warranted as of June 30, 2024. 16% 10% 10% 0.34 0.20

Inventories

Inventory is stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company provides for cost adjustments for excess, obsolete, or slow-moving inventory based on changes in customer demand, technology developments or other economic factors. Inventory consists of costs associated with raw material, labor, and overhead.

Goodwill

The Company accounts for purchased goodwill and intangible assets with indefinite lives in accordance with ASC 350, **Intangibles - Goodwill and Other**. Under ASC 350, goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment at least annually. The Company performs an impairment evaluation of goodwill annually, on April 1, or when circumstances otherwise indicate an evaluation should be performed. The evaluation may begin with a qualitative assessment for each reporting unit to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than its carrying value. Factors considered in a qualitative assessment include, among other things, macroeconomic conditions, industry and market considerations, financial performance of the respective reporting unit, and other relevant entity and reporting-unit specific considerations. If the qualitative assessment does not generate a positive response, or if no qualitative assessment is performed, a quantitative assessment is performed and requires management to estimate future cash flows, growth rates, and macroeconomic, industry, and market conditions. For more information regarding goodwill activity during fiscal 2022, 2023, and 2024, see Note 4, **Goodwill**.

Property and equipment are stated at cost. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including leasehold improvements and finance lease right-of-use assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following range of useful lives for its property and equipment categories: buildings and improvements—5 to 50 years; machinery and equipment—3 to 10 years; and furniture and fixtures—3 to 7 years. Depreciation expense was \$354 million, \$286 million, and \$255 million for fiscal 2024, 2023, and 2022, respectively. Depreciation expense includes amortization of assets related to financing leases. The Company charges repairs and maintenance costs to expense as incurred. The amount of capitalized interest for fiscal 2024, 2023, and 2022 was \$10 million, \$24 million, and \$15 million, respectively.

Intangible assets with finite lives, including customer relationships, core technology, patents, and trademarks, are amortized over their useful lives. The Company also capitalizes certain computer software and development costs in other intangibles, net, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 5 years.

The Company evaluates the recoverability of its other long-lived assets, including amortizing intangible assets, if circumstances indicate impairment may have occurred pursuant to ASC 360, Property, Plant and Equipment. This analysis is performed by comparing the respective carrying values of the assets to the current and expected future cash flows, on an un-discounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, the carrying value of such assets is reduced to fair value through a charge to the consolidated statements of operations. Fair value is determined based on assumptions the Company believes marketplace participants would utilize and comparable marketplace information in similar arm's length transactions.

In conjunction with the goodwill impairment tests performed as of March 31, 2023 and September 30, 2023, the Company identified indicators of impairment related to its definite-lived intangibles. The results of the analysis did not result in an impairment charge. The Company recorded impairment charges related to definite-lived intangible assets and property, plant, and equipment of \$29 million, \$98 million, and \$31 million for the fiscal years ended June 30, 2024, 2023, and 2022, respectively.

Post-Retirement and Pension Plans

The Company sponsors various retirement and pension plans, including defined benefit and defined contribution retirement plans. The measurement of the related benefit obligations and the net periodic benefit costs recorded each year are based upon actuarial computations, which require management's judgment as to certain assumptions. These assumptions include the discount rates used in computing the present value of the benefit obligations and the net periodic benefit costs, the expected future rate of salary increases (for pay-related plans) and the expected long-term rate of return on plan assets (for funded plans). The Company uses the corridor approach to amortize actuarial gains and losses.

The Company has elected to utilize an approach to estimate the service and interest components of net periodic benefit cost for benefit plans that discounts the individual expected cash flows using the applicable spot rates derived from the yield curve over the projected cash flow period. The expected long-term rate of return on plan assets is based on the target asset allocation and the average expected rate of growth for the asset classes invested. The average expected rate of growth is derived from a combination of historic returns, current market indicators, and the expected risk premium for each asset class. The Company uses a measurement date of June 30 for all its retirement and postretirement benefit plans.

Derivative Instruments, Hedging Activities, and Fair Value

Derivative Instruments and Hedging Activities

The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and

operational risks through management of its core business activities. The Company manages economic risks, including interest-rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its debt funding and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments from time to time to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the values of which are determined by interest rates. The Company's derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company's known or expected cash receipts and its known or expected cash payments principally related to the Company's borrowings. The Company does not net any of its derivative positions under master netting arrangements.

Primarily, the Company is exposed to fluctuations in the euro-U.S. dollar exchange rate on its investments in foreign operations in Europe. While the Company does not actively hedge against changes in foreign currency, it has mitigated the exposure of investments in its European operations through a net-investment hedge by denominating a portion of its debt in euros. In addition, a portion of Operating Company's interest payment obligation on its U.S dollar-denominated term loans is exposed to interest rate variability. The Company has mitigated its exposure to this risk by entering into interest-rate swap agreements, which qualify for and are designated as cash-flow hedges.

Fair Value

The Company is required to measure certain assets and liabilities at fair value, either upon initial measurement or for subsequent accounting or reporting. The Company uses fair value extensively, including in the initial measurement of net assets acquired in a business combination and when accounting for and reporting on certain financial instruments. The Company estimates fair value using an exit price approach, which requires, among other things, that it determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of assets and, for liabilities, assuming the risk of non-performance will be the same before and after the transfer. A single estimate of fair value results from a complex series of judgments about future events and uncertainties and relies heavily on estimates and assumptions. When estimating fair value, depending on the nature and complexity of the assets or liability, the Company may use one or all of the following approaches:

• Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.

• Cost approach, which is based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence.

• Income approach, which is based on the present value of the future stream of net cash flows.

Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

Self-Insurance The Company is partially self-insured for certain employee health benefits and partially self-insured for property losses and casualty claims. The Company accrues for losses based upon experience and actuarial assumptions, including provisions for losses incurred but not reported.

Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss, which is reported in the accompanying consolidated statements of changes in shareholders' equity, consists of foreign currency translation, net change in marketable securities, and defined benefit pension plan changes.

Research and Development Costs The Company expenses research and development costs as incurred. Research and development costs amounted to \$17 million, \$18 million, and \$23 million for the fiscal years ended June 30, 2024, 2023, and 2022, respectively.

Earnings Per Share

The Company reports net earnings per share in accordance with ASC 260, **Earnings per Share**. Effective as of the first quarter of fiscal 2023, the Company computed earnings per share ("EPS") of the Company's common stock, par value \$0.01 (the "Common Stock") using the treasury stock method. Prior to fiscal 2023, the Company computed earnings (loss) per share of the Common Stock using the two-class method required due to the participating nature of the previously outstanding Series A Preferred Stock (as defined and discussed in Note 13, **Equity and Accumulated Other Comprehensive Loss**).

Diluted earnings per common share measures the performance of the Company over the reporting period while giving effect to all potential shares of Common Stock that were dilutive and outstanding during the period. The denominator includes the weighted average over the measurement period of the sum of the number of shares of Common Stock outstanding and the number of additional such shares that would have been outstanding if the shares of Common Stock that were both potentially issuable and dilutive had been issued.

0.01

Income Taxes

In accordance with ASC 740,

Income Taxes

the Company accounts for income taxes using the asset and liability method. The asset and liability method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities. The Company measures deferred tax assets and liabilities using enacted tax rates in the respective jurisdictions in which it operates. In assessing the ability to realize deferred tax assets, the Company considers whether it is more likely than not that the Company will be able to realize some or all of the deferred tax assets. The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax regulations in each of its tax jurisdictions. The number of years with open tax audits varies by tax jurisdiction. A number of years may lapse before a particular matter is audited and finally resolved. The Company applies ASC 740 to determine the accounting for uncertain tax positions. This standard prescribes a minimum recognition threshold a tax position is required to meet before the Company may recognize the position in its financial statements. The standard also provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, and disclosure. The Company previously elected not to reclassify the income tax effects stranded in accumulated other comprehensive income to retained earnings.

Stock-Based Compensation

The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. Under ASC 718, companies recognize compensation expense using a fair-value-based method for costs related to share-based payments, including stock options and restricted stock units. The expense is measured based on the grant date fair value of the awards, and the expense is recorded over the applicable requisite service period. Forfeitures are recognized as and when they occur. In the absence of an observable market price for a share-based award, the fair value is based upon a valuation methodology that takes into consideration various factors, including the exercise price of the award, the expected term of the award, the current price of the underlying shares, the expected volatility of the underlying share price, the expected dividends on the underlying shares and the risk-free interest rate.

The terms of the Company's stock-based compensation plans permit an employee holding vested stock options or restricted stock units to elect to have the Company use a portion of the shares otherwise issuable upon the employee's exercise of the option or grant, a so-called "net settlement transaction," as a means of paying the exercise price, meeting tax withholding requirements, or both.

New Accounting Standards Not Adopted as of June 30, 2024

In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, Improvements to Reportable Segment Disclosures

serif;font-size:10pt;font-weight:400;line-height:120%">>, which intends to improve disclosures regarding significant segment expenses. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.

*align:justify;text-indent:22.5pt">
</div><div style="text-align:justify;text-indent:22.5pt">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which focuses on income tax disclosures by requiring public business entities, on an annual basis, to disclose specific categories in the rate reconciliation, provide information for reconciling items that meet a quantitative threshold, and certain information about income taxes paid. The standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.</div>*

*REVENUE RECOGNITION<div style="text-align:justify;text-indent:24pt">The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. The Company generally earns its revenue by supplying goods or providing services under contracts with its customers in three primary revenue streams: manufacturing and commercial product supply, development services, and clinical supply services. The Company measures the revenue from customers based on the consideration specified in its contracts, excluding any sales incentive or amount collected on behalf of a third party, that the Company expects to be entitled to receive in exchange for transferring the promised goods to and/or performing services for the customer (the "Transaction Price"). To the extent the Transaction Price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the Transaction Price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the Transaction Price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment.</div><div style="text-align:justify;text-indent:24pt">
</div><div style="text-align:justify;text-indent:24pt">The Company's customer contracts generally include provisions entitling the Company to a termination penalty when the customer terminates prior to the contract's nominal end date. The termination penalties in customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated durations of the contracts. The Company accounts for a contract termination as a contract modification in the period in which the customer gives notice of termination. The determination of the contract termination penalty is based on the terms stated in the relevant customer agreement. As of the*

modification date, the Company updates its estimate of the Transaction Price using the expected value method, subject to constraints, and to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment

Where multiple performance obligations exist in a single contract, the Company allocates consideration to each performance obligation using the “relative standalone selling price” as defined under ASC 606. Generally, the Company utilizes observable standalone selling prices in its allocations of consideration. If observable standalone selling prices are not available, the Company estimates the applicable standalone selling price using a cost-plus-margin approach or an adjusted market assessment approach, in each case, representing the amount that the Company believes the market is willing to pay for the applicable service. Payment is typically due 30 to 45 days following the invoice date, based on the payment terms set forth in the applicable customer agreement.

The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material.

Customer contracts that include commitments by the Company to make facility space or equipment available may be deemed to include lease components, which are evaluated under ASC 842,

Leases

. For arrangements that contain both lease and non-lease components, consideration in the contract is allocated on a relative standalone selling-price basis. Determining the lease term and contract term of non-lease components, as well as the variable and fixed consideration in these arrangements, including when variability is resolved, often requires management judgment in order to determine the allocation to the lease and non-lease components.

Manufacturing & Commercial Product Supply Revenue

Manufacturing and commercial product supply revenue consists of revenue earned by manufacturing products supplied to customers under long-term commercial supply arrangements. In these arrangements, the customer typically owns and supplies the active pharmaceutical ingredient (“API”) or other proprietary materials used in the manufacturing process. The contract generally includes the terms of the manufacturing services and related product quality assurance procedures to comply with regulatory requirements. Due to the regulated nature of the Company’s business, these contract terms are highly interdependent and, therefore, are considered to be a single combined performance obligation. The transaction price is generally stated in the agreement as a fixed price per unit, with no contractual provision for a refund or price concession. In most circumstances, control

is transferred to the customer over time, creating a corresponding right to recognize the related revenue, because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date. The selection of the method for measuring progress towards the completion of the Company's performance obligation requires judgment and is based on the nature of the products to be manufactured. For the majority of the Company's arrangements, progress is measured based on the units of product that have successfully completed the contractually required product quality assurance process, because the conclusion of that process defines the time when the applicable contract and the related regulatory requirements permit the customer to exercise control over the product's

disposition. The customer is typically responsible for arranging the shipping and handling of product following completion of the quality assurance process. Payment is typically due 30 to 45 days after invoice date, based on the payment terms set forth in the applicable customer agreement.

Beginning in the third quarter of fiscal 2023, the Company began recognizing commercial revenue for certain contracts in its Biologics segment that have a notably long manufacturing cycle, and for which the customer exercises control over the product throughout the manufacturing process. For these contracts, revenue is recognized over time and progress is measured using an input method based on effort expended, which provides an appropriate depiction of the Company's progress toward fulfilling its performance obligation.

Development Services and Clinical Supply Revenue

Development services contracts generally take the form of short-term, fee-for-service arrangements. Performance obligations vary, but frequently include biologic cell-line development, performing formulation, analytical stability, or other services related to product development, and providing manufacturing services for products that are under development or otherwise not intended for commercial sale. They can also include a combination of the following services: the manufacturing, packaging, storage, distribution, destruction, and inventory management of customer clinical trial material, as well as the sourcing of comparator drug products on behalf of customers to be used in clinical trials to compare performance with the drug under clinical investigation. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service, and each service is generally considered to be a separate performance obligation. In most instances, the Company recognizes revenue over time because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date.

The Company measures progress toward the completion of its performance obligations satisfied over time based on the nature of the services to be performed. For certain types of arrangements, revenue is recognized over time and measured using an output method based on the completion of tasks and activities that are performed to satisfy a performance obligation. For certain types of arrangements, revenue is recognized over time and measured using an input method based on effort expended. Each of these methods provides an appropriate depiction of the Company's progress toward fulfilling its performance obligations for its respective arrangement. In certain arrangements that require a portion of the contract consideration to be received in advance at the

commencement of the contract, such advance payment is initially recorded as a contract liability. In certain clinical supply arrangements, revenue is recognized at the point in time when control transfers, which occurs upon either the delivery of the related output of the service to the customer or the completion of quality testing with respect to the product, and the Company has an enforceable right to payment based on the terms of the arrangement.

The Company records revenue for comparator sourcing arrangements on a net basis because it is acting as an agent that does not control the product or service before it is transferred to the customer. Payment for comparator sourcing activity is typically received in advance at the commencement of the contract and is initially recorded as a contract liability.

The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material.

The following tables reflect net revenue for the fiscal years ended June 30, 2024, 2023, and 2022 by type of activity and reporting segment (in millions):

	Fiscal Year Ended June 30, 2024	Fiscal Year Ended June 30, 2023	Fiscal Year Ended June 30, 2022
Biologics	\$1,151	\$1,151	\$1,151
Pharma and Consumer Health	\$1,151	\$1,151	\$1,151
Total	\$2,302	\$2,302	\$2,302
Manufacturing & commercial product supply	\$1,151	\$1,151	\$1,151

[illegible]

[illegible]

	\$	450					\$	1,452					\$	1,902					Development services & clinical supply					1,528					835					2,363					Total							1,978					

[illegible]

Pharma and Consumer Health			Total		
Manufacturing & commercial product supply			\$		
608			608		
\$			\$		
1,474			1,474		
\$			\$		
2,082			2,082		
Development services & clinical supply			1,926		
797			797		
2,723			2,723		
Total			Total		

\$

2,534	2,271	4,805	4,802

\$

Inter-segment revenue elimination

(3)

Combined net revenue

\$

4,802

\$

The following table reflects net revenue by the location where the goods were made or the service performed:

2,534	2,271	4,805	4,802

[illegible]

Europe			
1,359			
1,257			
1,506			
Other			
356			
355			
327			
Elimination of revenue attributable to multiple locations			
(157)			
(117)			
(115)			

[illegible]

within 12 months are accounted for within Prepaid expenses and other. Contract assets expected to transfer to trade receivables after 12 months are accounted for within Other long-term assets.

Performance Obligations

Remaining performance obligations represent firm orders for future development services as well as manufacturing and commercial product supply, including minimum volume commitments, for which there are incomplete performance obligations for work not yet completed under executed contracts. Remaining performance obligations as of June 30, 2024 and June 30, 2023 were \$618 million and \$335 million, respectively. The Company expects to recognize approximately 50% of the remaining performance obligations in existence as of June 30, 2024 after June 30, 2025.

The following tables reflect net revenue for the fiscal years ended June 30, 2024, 2023, and 2022 by type of activity and reporting segment (in millions):

	2024	2023	2022	
Manufacturing & commercial product supply	\$1,151	\$335	\$618	

[illegible]

4,383 </td><td style="background-color:#e6e6ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:right;vertical-align:bottom">Inter-segment revenue elimination</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td colspan="2" style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#e6e6ff;padding:2px 1pt;text-align:right;vertical-align:bottom">Combined net revenue —</td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6ff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="2" style="background-color:#e6e6ff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,381</td><td colspan="2" style="background-color:#e6e6ff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Fiscal Year Ended June 30, 2023</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Biologics</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Pharma and Consumer Health</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#e6e6ff;padding:2px 1pt;text-align:left;vertical-align:bottom">Manufacturing & commercial product supply</td><td colspan="2" style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="2" style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

450			
1,452			
1,902			
Development services & clinical supply			
1,528			
835			
2,363			
Total			
1,978			

2,287			\$	4,265				
Inter-segment revenue elimination						(2)		
Combined net revenue						\$	4,263	

115100000015770000002728000000801000000854000000165500000019520000200000043810000004500000001452000000190200000015280000008350000002363002000000426300000060800000014740000002082000000192600000079700000027230030000004802000000

The following table reflects net revenue by the location where the goods were made or the service performed:

(Dollars in millions)					
Fiscal Year Ended June 30, 2024			Fiscal Year Ended June 30, 2023		
United States			\$		
			2,823		
			\$		
			2,768		
			\$		
			3,084		
Europe					
					1,359
					1,257

[illegible]

Balance at June 30, 2024		
	\$	255

Revenue recognized in the period from amounts included in contracts liability at the beginning of the period:		
	\$	(145)

180000000255000000-1450000006020000004170000006180000003350.50

BUSINESS COMBINATIONS AND DIVESTITURES

RheinCell Therapeutics GmbH Acquisition

In August 2021, the Company acquired 100% of the equity interest in RheinCell Therapeutics GmbH ("RheinCell") for \$26 million, net of cash acquired. RheinCell was a developer and manufacturer of clinical- and cGMP-grade iPSCs based in Lagenfeld, Germany. The operations became part of the Company's Biologics segment and built on its existing custom cell therapy process development and manufacturing capabilities with proprietary cGMP cell lines for iPSC-based therapies.

The Company accounted for the RheinCell transaction using the acquisition method in accordance with ASC 805,

Business Combinations

The Company funded the entire purchase price with cash on hand and allocated the purchase price among the assets acquired, recognizing \$4 million of current liabilities, \$1 million of other liabilities, \$14 million of intangible assets, and goodwill of \$17 million. Results of this business were not material to the Company's statement of operations, financial position, or cash flows for the fiscal years ended June 30, 2023 and 2022.

Bettera Holdings, LLC Acquisition

In October 2021, the Company acquired 100% of the equity interest in Bettera Holdings, LLC ("Bettera Wellness") for \$1.00 billion cash. Bettera Wellness was a manufacturer of nutraceuticals and nutritional supplements in gummy, soft chew, and lozenge delivery formats and became part of the Company's Pharma and Consumer Health segment.

The Company accounted for the Bettera Wellness transaction using the acquisition method in accordance with ASC 805,

Business Combinations

. The Company estimated fair values at the date of acquisition for the allocation of consideration to the net tangible and intangible assets acquired and liabilities assumed and allocated the purchase price among the assets acquired, recognizing \$361 million of other intangibles, net, \$72 million of property, plant, and equipment, \$31 million of inventories, \$23 million of cash and cash equivalents, \$16 million of trade receivables, \$17 million of net other liabilities, and goodwill of \$531 million. Results of this business were not material to the Company's statement of operations, financial position, or cash flows for the fiscal years ended June 30, 2023 and 2022.

The carrying value of trade receivables, inventory, and trade payables, as well as certain other current and non-current assets and liabilities, generally represented the fair value at the date of acquisition.

Property, plant, and equipment assets were valued using the cost approach, which is based on current replacement and/or reproduction cost of the related asset as new, less depreciation attributable to physical, functional, and economic factors. The Company then determined the remaining useful life based on the anticipated life of the asset and Company policy for similar assets.

Core technology intangible assets of \$338 million were valued using the multi-period, excess-earnings method, a method that values the intangible asset using the present value of the after-tax cash flows attributable to the intangible asset only. The significant assumptions used in developing the valuation included the estimated annual net cash flows (including application of an appropriate margin to forecasted revenue, revenue obsolescence rate, selling and marketing costs, return on working capital, contributory asset charges, and other factors), the discount rate that appropriately reflects the risk inherent in each future cash flow stream, and an assessment of the asset's life cycle, as well as other factors. The assumptions used in the financial forecasts

were based on historical data, supplemented by current and anticipated growth rates, management plans, and market-comparable information. Fair-value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors. The core technology intangible asset has a weighted average useful life of 10 years.

Goodwill has been allocated to the Pharma and Consumer Health segment as shown in Note 4,

Goodwill. Goodwill is mainly comprised of growth from expected increases in capacity utilization and new customers. The goodwill resulting from the Bettera Wellness acquisition is deductible for tax purposes.

Vaccine Manufacturing and Innovation Centre UK Limited Asset Acquisition

In April 2022, the Company, through its wholly owned subsidiary, Catalent Oxford Limited, acquired a development and manufacturing facility near Oxford, United Kingdom (“U.K.”) and certain related assets and liabilities from The Vaccine Manufacturing and Innovation Centre UK Limited for \$134 million in cash, including \$9 million of closing costs. The facility and related assets and liabilities became part of the Company’s Biologics segment.

The Company accounted for this transaction as an acquisition of assets in accordance with ASC 805, **Business Combinations**. The Company funded this acquisition with cash on hand and allocated the purchase price among the net assets acquired, recognizing \$1 million of current assets, \$165 million of property, plant, and equipment, \$18 million of current liabilities, and \$14 million of other liabilities. Results of this business were not material to the Company’s statement of operations, financial position, or cash flows for the fiscal years ended June 30, 2023 and 2022.

Princeton Cell Therapy Development and Manufacturing Acquisition

In April 2022, the Company acquired a cell therapy commercial manufacturing facility and operations near Princeton, New Jersey (“Princeton”) from Erytech Pharma S.A. (“Erytech”) for \$45 million in cash, subject to customary adjustments. In connection with the purchase, Erytech and the Company entered into a long-term supply agreement, under which the Company agreed to continue to manufacture and package an Erytech product at the Princeton facility. The operations and facility acquired became part of the Company’s Biologics segment.

The Company accounted for this transaction using the acquisition method in accordance with ASC 805, **Business Combinations**. The Company funded this acquisition with cash on hand and allocated the purchase price among the assets acquired, recognizing \$22 million of property, plant, and equipment, \$10 million of other assets, \$1 million of current liabilities, \$10 million of other liabilities, and goodwill of \$24 million. Results of this business were not material to the Company’s statement of operations, financial position, or cash flows for the fiscal years ended June 30, 2023 and 2022.

Metrics Contract Services Acquisition

In October 2022, the Company acquired 100% of Metrics Contract Services (“Metrics”) from Mayne Pharma Group Limited for \$474 million in cash. Metrics, based in Greenville, North Carolina, was an oral solids development and manufacturing business specializing in the manufacture of drugs containing highly potent active pharmaceutical ingredients. The operations and facility acquired became part of the Company’s Pharma and Consumer Health segment.

The Company accounted for the Metrics transaction using the acquisition method in accordance with ASC 805, **Business Combinations**. The Company funded this acquisition with a portion of the proceeds of an October 2022 drawdown from its senior secured revolving credit facility. The Company estimated fair values at the date of acquisition for the allocation of consideration to the net tangible and intangible assets acquired and liabilities assumed.

The purchase price was allocated to assets acquired and liabilities assumed in the acquisition as follows:

(Dollars in millions)				
Purchase Price Allocation				
Trade receivables, net	15			
Inventories	5			

	Property, plant, and equipment	195
	Other intangibles, net	52
	Other, net	(12)
	Goodwill	219
	Total assets acquired and liabilities assumed	
	\$	474

The carrying value of trade receivables, inventory, and trade payables, as well as certain other current and non-current assets and liabilities generally represented the fair value at the date of acquisition.

Other intangibles, net consists of customer relationships of \$52 million, which were valued using the multi-period, excess-earnings method, a method that values the intangible asset using the present value of the after-tax cash flows attributable to the intangible asset only. The significant assumptions used in developing the valuation included the estimated annual net cash flows (including application of an appropriate margin to forecasted revenue, selling and marketing costs, return on working capital, contributory asset charges, and other factors), the discount rate that appropriately reflects the risk inherent in each future cash flow

stream, and an assessment of the asset's life cycle, as well as other factors. The assumptions used in the financial forecasts were based on historical data, supplemented by current and anticipated growth rates, management plans, and market-comparable information. Fair-value determinations require judgment and are sensitive to changes in underlying assumptions and factors. The customer relationship intangible asset has a weighted average useful life of 12 years.

Property, plant, and equipment was valued using the cost approach, which is based on current replacement and/or reproduction cost of the asset as new, less depreciation attributable to physical, functional, and economic factors. The Company then determined the remaining useful life based on the anticipated life of the asset and Company policy for similar assets.

Goodwill has been allocated to the Pharma and Consumer Health segment as shown in Note 4.

Goodwill

Goodwill is mainly comprised of the growth from an expected increase in capacity utilization and potential new customers. The goodwill resulting from the Metrics acquisition is not deductible for U.S. income tax purposes.

Results of the business acquired were not material to the Company's consolidated statement of operations, financial position, or cash flows for the fiscal year ended June 30, 2023.

Blow-Fill-Seal Divestitur

e

In March 2021, the Company sold 100% of the shares of Catalent USA Woodstock, Inc. and certain related assets (collectively, the "Blow-Fill-Seal Business") for \$331 million in total consideration (\$300 million in cash). The Blow-Fill-Seal Business was part of the Pharma and Consumer Health segment.

The carrying value of the net assets sold was \$149 million, which included goodwill of \$54 million. As a result of the sale, the Company realized a gain from divestiture of \$182 million, net of transaction costs, for the fiscal year ended June 30, 2021.

During the fiscal year ended June 30, 2022, the Company settled a post-closing purchase price adjustment, which resulted in a gain on sale of subsidiary of \$1 million.

All consideration received was measured at its divestiture date fair value. The Company valued the total consideration received from divestiture of the Blow-Fill-Seal Business as follows:

(Dollars in millions)			
Fair value of consideration received			
Cash, gross			
\$	300		
Note receivable			(1)
		47	
Contingent consideration			(2)
		—	
Other			(3)
		(16)	
Total			

\$331

(1) The note receivable, which provides for interest at a rate of 5.0% paid in kind, had an estimated fair value of \$47 million and \$51 million at June 30, 2021 and June 30, 2022, respectively. The fair value at divestiture date consisted of a \$50 million aggregate principal amount less a \$3 million discount determined using a discounted cash flow model.

(2) The Company determined that the estimated fair value of the contingent consideration from the sale of the Blow-Fill-Seal Business at June 30, 2022 was zero, and therefore no contingent consideration was recorded at divestiture. If any contingent consideration is subsequently received, it will be recorded in the period in which it is received. The Company has elected an accounting policy to recognize increases in the carrying amount of the contingent consideration asset using the gain contingency guidance in ASC 450.

Contingencies

(3) Other includes \$8 million of transaction expenses, a working capital adjustment of \$6 million, and a \$2 million assumption of liabilities, resulting in net cash proceeds of \$284 million.

2600000004000000100000014000000170000001000000000361723123161753133 million50000000030000000800000060000002000000284000000GOODWILL

The following table summarizes the changes from June 30, 2022 to June 30, 2024 in the carrying amount of goodwill in total and by reportable segment:

	width:1.0%	width:66.736%	width:0.1%	width:1.0%	width:9.133%	width:0.1%	width:0.1%	width:0.530%	width:0.1%
	width:1.0%	width:9.133%	width:0.1%	width:0.1%	width:0.530%	width:0.1%	width:1.0%	width:9.138%	width:0.1%
(Dollars in millions)									
Biologics									
Pharma and Consumer Health									

Total		
Balance at June 30, 2022		
	\$	1,566
	\$	1,440
	\$	3,006
Additions		—
		219
		219
Reallocation		

[illegible]

[illegible]

			Impairment (2)		
(392)					
(295)			(687)		
			Balance at June 30, 2024		
\$		1,163			
\$		1,170			
\$		2,333			

[illegible]

serif;font-size:10pt;font-weight:400;line-height:100%">1,566 </td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,440 </td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,006 </td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Additions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">219 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">219 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom"> Reallocation (1) </td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

[illegible]

[illegible]

			(295)
		(687)	

Balance at June 30, 2024			
\$	1,163		
\$	1,170		
\$	2,333		

(1) The addition to goodwill is a result of the Metrics acquisition. For further details, see Note 3,

Business Combinations and Divestitures.

(2) Accumulated goodwill impairment charges amount to \$897 million as of June 30, 2024.

As part of the business reorganization discussed in Note 1, Basis of Presentation and Summary of Significant Accounting Policies, the goodwill from the previous Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services segments was reallocated between the current Biologics and Pharma and Consumer Health segments.

Goodwill Impairment Charges

The Company performs an annual goodwill impairment test for each reporting unit on April 1, the measurement date and more frequently if indicators for potential impairment exist.

Fiscal Year 2024

During the three months ended September 30, 2023, as a result of the Consumer Health reporting unit's underperformance of recent operating results relative to expectations, the current macroeconomic conditions impacting the consumer health and biotechnology industries, and increased interest rates, the Company assessed the current and future economic outlook for its reporting units in its Pharma and Consumer Health and Biologics segments and identified indicators for impairment of the goodwill previously recorded for two of its reporting units. The evaluation began with a qualitative assessment of the Company's Consumer Health and Biomodalities reporting units to determine if it was more likely than not that the fair value of the reporting units was less than its carrying value. The qualitative assessment did not indicate that it was more likely than not that the fair value exceeded the carrying value in its Consumer Health and Biomodalities reporting units, which led to a quantitative assessment for the corresponding reporting units.

The Company estimated the fair value of its reporting units using a combination of the income and market approaches. In performing the goodwill impairment test, the Company used a terminal revenue growth rate of 3.5% and discount rates ranging from 9% to 10% in its estimation of fair value. The evaluation performed resulted in impairment charges of \$687 million with respect to the Consumer Health and Biomodalities reporting units. While the Company believes the assumptions it used were reasonable and commensurate with the views of a market participant, changes in key assumptions, including increasing the discount rate, lowering forecasts for revenue and operating margin or lowering the long-term growth rate could lead to further impairment.

Based on its quantitative assessment conducted as of April 1, 2024, the Company determined for each reporting unit with goodwill that its respective fair value exceeded its carrying value, and hence, there was no impairment.

Subsequent to the quantitative assessment performed as of April 1,

2024, the Company performed qualitative assessments as of June 30, 2024, which yielded no indicators of impairment. The Company assessed the current and future economic outlook for its reporting units, the Company's stock price as well as current macroeconomic conditions impacting the consumer health and biotech industries and current interest rates.

Fiscal Year 2023

The Company assessed the current and future economic outlook as of March 31, 2023 for its reporting units in its Pharma and Consumer Health and Biologics segments and identified an indicator for impairment of the goodwill previously recorded for one of the reporting units in its Pharma and Consumer Health segment. The evaluation began with a qualitative assessment of each reporting unit to determine if it was more likely than not that the fair value of the reporting unit was less than its carrying value. The qualitative assessment did not indicate that it was more likely than not that the fair value exceeded the carrying value in its Consumer Health reporting unit, which led to a quantitative assessment for each of the Company's reporting units.

The Company estimated the fair value of its reporting units using a combination of the income and market approaches. In performing the goodwill impairment test, the Company used a terminal revenue growth rate of 3.0% and discount rates ranging from 9% to 10.50% in its estimation of fair value. The evaluation performed resulted in an impairment charge of \$210 million with respect to the Consumer Health reporting unit.

Subsequent to the quantitative assessment performed as of March 31, 2023, the Company performed qualitative assessments as of April 1, 2023, which yielded no indicators of impairment.

1566000000144000000030060000000219000000219000000-150000001500000001200000012000000240000002100000002100000001563000000148000000-11000000-190000003920000002950000006870000001163000000117000000023330000008973.56

INTANGIBLES, NET

The details of other intangible assets subject to amortization as of June 30, 2024 and June 30, 2023 are as follows (in millions):

	June 30, 2024	June 30, 2023	Goodwill	Identifiable Intangible Assets	Other Intangible Assets	Total Intangible Assets	Net Book Value
Pharma	\$1,566.0	\$1,440.0	\$300.6	\$21.9	\$21.9	\$1,589.5	\$1,566.0
Consumer Health	\$1,500.0	\$1,500.0	\$120.0	\$120.0	\$24.0	\$1,644.0	\$1,500.0
Biologics	\$1,900.0	\$1,900.0	\$21.9	\$21.9	\$21.9	\$1,943.8	\$1,900.0
Total	\$4,966.0	\$4,840.0	\$622.5	\$453.8	\$67.8	\$5,348.1	\$4,966.0

Weighted Average Life		
Gross		
Carrying		
Value		
Accumulated		
Amortization		
Net		
Carrying		
Value		
Amortized intangibles:		
Core technology		
11 years		
\$		
480		
\$		
(205)		

	\$	
Customer relationships	13 years	
	1,076	
(531)		
	545	
Product relationships	8 years	
	242	
(223)		
	19	
Other	6 years	

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Core technology		
11 years		
\$		
480		
\$		
(205)		
\$		
275		
Customer relationships		
13 years		
1,076		
(531)		
545		

weight:400;line-height:100%">Product relationships					
8 years					
242					
(223)					
19					
Other					
6 years					
20					
(18)					
2					
\$					
1,818					

	(977)
	841

	June 30, 2023	Weighted Average Life
	Gross	Carrying
	Value	
	Accumulated	Amortization
		Net

[illegible]

[illegible]

1,828
 980
 amortization expense is estimated to be:

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Depreciation expense	13.812%	0.1%	1.0%	0.1%	0.530%	0.1%	10.449%	0.1%	0.1%	0.530%	0.1%
Amortization expense	10.449%	0.1%	0.1%	0.1%	1.0%	10.449%	0.1%	0.1%	0.384%	1.0%	10.460%

(Dollars in millions)

2025

2026			2027			2028			2029			Thereafter			Total		
Amortization						\$			133								
									125								
									109								
									102								

In connection with these restructuring plans, the Company reduced its headcount by approximately 700 employees and incurred cumulative employee-related charges of \$26 million, primarily associated with cash severance programs through June 30, 2024.

Restructuring costs for the fiscal years ended June 30, 2024, 2023, and 2022 were recorded in Other operating expense in the consolidated statement of operations.

The following tables summarize the restructuring costs by type of cost and reportable segment:

	Total	Operating Segment	Non-Operating Segment	Other Operating Expense
Fiscal Year Ended June 30,	(Dollars in millions)			
2024				
2023				
2022				
Restructuring costs:				

Employee-related reorganization		
26	38	26
Facility exit and other costs		
13	28	1
Total restructuring costs		

[illegible]

[illegible]

Non-segment (Corporate)		
9		
17		
4		
Total restructuring costs		
\$		
39		
\$		
66		
\$		
10		

The following tables illustrates the change in the employee separation-related liability associated with the plans.

The following tables summarize the restructuring costs by type of cost and reportable segment:

	2024	2023	2022
Restructuring costs:			
Employee-related reorganization			

[illegible]

66			

The following table summarizes the charges recorded within restructuring costs by segment. These amounts are excluded from Segment EBITDA as described in Note 18.

Segment Information	2024	2023	2022
Restructuring costs:			

[illegible]

The following tables illustrates the change in the employee separation-related liability associated with the plans.						

(Dollars in millions)		
Employee-related restructuring		
Balance, June 30, 2023	\$	19
Charges	26	
Payments	(35)	
Balance, June 30, 2024	\$	10

380000009000000130000002800000010000003900000066000000100000001100
of long-term obligations, including finance leases of \$332 million, and other short-term borrowings for future fiscal years are:

<table style="border-collapse: collapse; display: inline-table; margin-bottom: 5pt; vertical-align: text-bottom; width: 99.415%"><tr><td style="width: 1.0%"></td><td style="width: 35.223%"></td><td style="width: 0.1%"></td><td colspan="3" style="display: none"></td><td colspan="3" style="display: none"></td><td colspan="3" style="display: none"></td></tr></table>

[illegible]

[illegible]

[illegible]

[illegible]

627	650	566
Senior secured credit facilities & other	Level 2	2,366
2,107	2,284	2,141
Subtotal		4,949

[illegible]

[illegible]

2024		
2023		
2022		
Net (loss) earnings		
\$	(1,043)	
\$	(256)	
\$	499	
Less: Net earnings attributable to preferred shareholders		
		—
—		
(16)		

Net (loss) earnings attributable to common shareholders			\$	(1,043)				\$	(256)				\$	483			
Weighted average shares outstanding – basic																	
</																	

[illegible]

[illegible]

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

Risk Management Objective of Using Derivatives

The Company is exposed to fluctuations in the currency exchange rates applicable to its investments in foreign operations. While the Company does not actively hedge against changes in foreign currency, the Company has mitigated the exposure arising from its investments in its European operations by denominating a portion of its Senior Notes in euros, the functional currency of such European operations. At June 30, 2024, the Company had euro-denominated debt outstanding of \$883 million (U.S. dollar equivalent), which qualifies as a hedge of a net investment in foreign operations. For non-derivatives designated and qualifying as net investment hedges, the effective portion of the translation gains or losses are reported in accumulated other comprehensive income (loss) as part of the cumulative translation adjustment. The unhedged portions of the translation gains or losses are reported in the consolidated statements of operations. The following table includes net investment hedge activity during the fiscal years ended June 30, 2024 and 2023, respectively:

	June 30, 2024	June 30, 2023
(Dollars in millions)		
June 30, 2024		
June 30, 2023		

Unrealized foreign exchange gain (loss) within other comprehensive income	\$	21			
	\$	(30)			

The net accumulated gain of this net investment hedge within accumulated other comprehensive loss was \$119 million as of June 30, 2024. Amounts are reclassified out of accumulated other comprehensive loss into earnings when the entity in which the gains and losses reside is either sold or substantially liquidated.

Interest-Rate Swap

In February 2021, the Company entered into a new interest-rate swap agreement with Bank of America N.A. (the “2021 Rate Swap”) that acted as a hedge against the economic effect of a portion of the variable-interest obligation associated with the Company’s U.S. dollar-denominated term loans under its senior secured credit facilities. The 2021 Rate Swap effectively fixed the rate of interest payable on that portion of the term loans, thereby reducing the impact of future interest rate changes on future interest expense. As a result of the 2021 Rate Swap, the variable portion of the applicable interest rate on \$500 million of the U.S. dollar-denominated term loans was effectively fixed at 0.9985%.

To conform with the adoption of Topic 848, **Reference Rate Reform** and the **Eighth Amendment**, the Company amended the 2021 Rate Swap in June 2023 (the “2023 Rate Swap”). The 2023 Rate Swap continues to effectively fix the rate of interest payable on the same portion of our U.S. dollar-denominated term loans under our senior secured credit facilities. As a result of the 2023 Rate Swap, the variable portion of the applicable interest rate on \$500 million of the U.S. dollar-denominated

term loans is now effectively fixed at 0.9431%. The net amount of deferred losses on cash flow hedges that is expected to be reclassified from accumulated other comprehensive loss into interest expense, net within the next twelve months is not material.

The 2023 Rate Swap continues to qualify for a cash-flow hedge. The Company evaluates hedge effectiveness at the inception of the hedge and on an ongoing basis. The cash flows associated with the 2023 Rate Swap amendment is reported in cash provided by operating activities in the consolidated statements of cash flows. The unrealized loss recorded in stockholder's equity from marking the 2023 Rate Swap to market during the fiscal year ended June 30, 2024 was \$26 million.

A summary of the estimated fair value of the interest-rate swap reported in the consolidated balance sheets is stated in the table below:

	June 30, 2024	June 30, 2023	(in millions)	Balance Sheet Classification
Estimated Fair Value	\$26	\$26		Balance Sheet Classification

Estimated Fair Value

Balance Sheet Classification

[illegible]

21000000

A summary of the estimated fair value of the interest-rate swap reported in the consolidated balance sheets is stated in the table below:

	June 30, 2024	June 30, 2023
(in millions)		
Balance Sheet Classification	Estimated Fair Value	Balance Sheet Classification

Estimated Fair Value

			(in millions)																	

A summary of the estimated fair value of the interest-rate swap reported in the consolidated balance sheets is stated in the table below:

June 30, 2024	June 30, 2023
Interest-rate swap	Other long-term assets
\$	\$
36	62

[illegible]

[illegible]

62

ASC 820,
Fair Value Measurement
 defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which Level 1 and Level 2 are considered observable and Level 3 is considered unobservable:

Level 1
 – Quoted prices in active markets for identical assets or liabilities.

Level 2
 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.

Level 3
 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses of the Company approximate fair value based on the short maturities of these instruments.

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification as of the end of each reporting period. The following table sets forth the Company's financial assets and liabilities that were measured at fair value on a recurring basis and the fair value measurement for

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Earnings (loss) before income taxes are as follows for fiscal 2024, 2023, and 2022:

Fiscal Year Ended			(Dollars in millions)											
			2024	2023	2022									
U.S. operations			\$	(1,158)										

Non-U.S. operations		
131		
68		
355		
Total		
\$	(1,027)	
\$	(342)	
\$	579	

-1158000000-41000000022400000013100000068000000355000000-1027000000-342000000579000000

The provision for income taxes consists of the following for fiscal 2024, 2023, and 2022:

		(8)	
State and local			
		(5)	
		(1)	
		14	
Non-U.S.			
		48	
		43	
		66	
Total current expense			
		43	

[illegible]

			(4)
			(5)
Non-U.S.			(1)
			(24)
			7
Total deferred (benefit) expense			\$
			(27)
			(127)
			\$
			\$

[illegible]

[illegible]

State and local income taxes		(44)		(13)	10
Foreign tax rate differential			(7)		
			(5)		
			(28)		
Global intangible low tax income				11	
					2
					6
Goodwill impairment					

[illegible]

	5		
	94		
Foreign tax credit	1		
		(30)	
		(43)	
Withholding tax and other foreign taxes			
3			
		1	
		1	
Change in tax rate			
1			

[illegible]

(1)

Total provision (benefit)	\$	16	\$	(86)	\$	(86)	\$	80

Deferred income taxes arise from temporary differences between the financial reporting and tax reporting bases of assets and liabilities, and operating loss and tax credit carryforwards for tax purposes. The components of the Company's deferred income tax assets and liabilities are as follows at June 30, 2024 and 2023:

216000000-72000000122000000-44000000-1300000010000000-7000000-5000000-28000000110000002000000600000080000000900000000-10000001000000160000000500000094000000100000030000000430000003000000100-1000000-100000016000000-860000000800000000687000000568000000

[illegible]

13			
Loss and tax credit carryforwards	293		
287			
Foreign currency	3		
3			
Pension	18		
19			
Interest-related	101		
50			

[illegible]

[illegible]

	Fiscal Year Ended	June 30,
(Dollars in millions)	2024	2023
Deferred income tax liabilities:		
Euro-denominated debt	\$	(4)
Property-related	(205)	(247)

	Goodwill and other intangibles	
	—	
		(71)
	Deferred revenue	(2)
		—
	Right-of-use assets	(16)
		(13)
	Other	(2)
	Total deferred income tax	

[illegible]

[illegible]

Settlements	(1)	
Lapse of the applicable statute of limitations	(1)	
Balance at June 30, 2022	\$	5
Additions for tax positions of prior years	2	
Reductions for tax positions of prior years	(1)	
Settlements	(1)	

Lapse of the applicable statute of limitations	
(1)	
Balance at June 30, 2023	
\$	4
Additions for tax positions of prior years	1
Reductions for tax positions of prior years	(1)
Balance at June 30, 2024	\$
	4

500000010000001000000100000010000005000000200000010000001000000100

RETIREMENT BENEFIT PLANS

The Company sponsors various retirement plans, including defined benefit pension plans and defined contribution

Retirement Benefits			Other Post-Retirement Benefits								
June 30,			June 30,								
(Dollars in millions)			(Dollars in millions)								
2024			2024								
2023			2023								
Accumulated Benefit Obligation			Accumulated Benefit Obligation								
\$			\$								
206			206								
\$			\$								
242			242								
\$			\$								

[illegible]

[illegible]

[illegible]

[illegible]

				7						—						—																												
Benefit obligation at end of year			\$			211						\$			246									\$			2									\$			2					

[illegible]

	Company contributions		
11	7		
	—		
	Employee contributions		
1	1		
	—		
	Settlements		

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

4.3		
%		
4.3		
%		
5.0		
%		
4.7		
%		
Rate of compensation increases (%)		
2.7		
%		
2.7		
%		
n/a		
Financial Assumptions Used to Determine Net Periodic Benefit Cost for Financial Year		

[illegible]

n/a		
Expected long-term rate of return (%)		
4.3		
%		
3.9		
%		
n/a		
Expected Future Contributions		
Fiscal year 2025		
\$		
4		
\$		
8		

[illegible]

[illegible]

2026	13	15	—	—
2027	12	16	—	—
2028	12	15		

[illegible]

[illegible]

[illegible]

	%	16.2	%
	—		%
	%		%
	—		%
Property			
	4.5		%
			3.3
	%		%
	—		%
	%		%
	—		%
Insurance contracts			

[illegible]

[illegible]

[illegible]

[illegible]

		—
Insurance contracts	28	
		30
		—
		—
Other	34	
		43
		—
		—
Total		

[illegible]

%		
4.5		
%		
—		
%		
%		
—		
%		
Equities		
	2.9	
%		
2.9		
%		
—		
%		
Government bonds		

[illegible]

Property		
4.5		
%		
3.3		
%		
—		
%		
—		
%		
Insurance contracts		
16.6		
%		
14.9		
%		
—		
%		
—		
%		
—		

[illegible]

The Company's Investment Committee employs a building-block approach in determining the long-term rate of return for plan assets, with proper consideration of diversification and rebalancing. Historical markets are studied and long-term historical relationships between equities and fixed income are preserved consistent with the widely accepted capital market principle that assets with higher volatility generate a greater return over the long run. Current market factors such as inflation and interest rates are evaluated before long-term capital market assumptions are determined. Peer data are reviewed to check for reasonability and appropriateness.

Plan assets are recognized and measured at fair value in accordance with the accounting standards regarding fair value measurements. The following are valuation techniques used to determine the fair value of each major category of assets:

- Short-term investments, equity securities, fixed-income securities, and real estate are valued using quoted market prices or other valuation methods, and thus are classified within Level 1 or Level 2.
- Insurance contracts and other types of investments include investments with some observable and unobservable prices that are adjusted by cash contributions and distributions, and thus are classified within Level 2 or Level 3.

The following tables provide a summary of plan assets that are measured at fair value as of June 30, 2024 and 2023, aggregated by the level in the fair value hierarchy within which those measurements fall:

	Level 1	Level 2	Level 3
2024	\$1.0%	\$30.186%	\$12.057%
2023	\$0.1%	\$0.530%	\$12.066%

[illegible]

[illegible]

2				
			—	
			5	
			(1)	
			—	
			42	
			25	
			—	
			67	
Total				
			\$	
			—	

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

#000000;padding:2px 0;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24pt">The Company's investment policy reflects the long-term nature of the plans' funding obligations. The assets are invested to provide the opportunity for both income and growth of principal. This objective is pursued as a long-term goal designed to provide required benefits for participants without undue risk. It is expected that this objective can be achieved through a well-diversified asset portfolio. All equity investments are made within the guidelines of quality, marketability, and diversification mandated by the Employee Retirement Income Security Act of 1974, as amended (for plans subject to the act) and other relevant legal requirements. Investment managers are directed to maintain equity portfolios at a risk level approximately equivalent to that of the specific benchmark established for that portfolio. Assets invested in fixed income securities and pooled fixed-income portfolios are managed actively to pursue opportunities presented by changes in interest rates, credit ratings, or maturity premiums. </div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:72.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other Post-Retirement Benefits</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Assumed Healthcare Cost Trend Rates at the Balance Sheet Date</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Healthcare cost trend rate - initial (%)</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom">Pre-65</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

n/a		
n/a		
Post-65		
5.0		
		%
4.8		
		%
Healthcare cost trend rate – ultimate (%)		
Pre-65		
n/a		
n/a		
Post-65		
4.1		
		%
4.1		
		%
Year in which ultimate rates are reached		

[illegible]

benefit obligation and fair value of plan assets for the defined benefit retirement and other retirement plans, excluding the multi-employer pension plan liability:											
Retirement Benefits			Other Post-Retirement Benefits								
June 30,			(Dollars in millions)								
2024			2023			2024					
Accumulated Benefit Obligation			\$								

[illegible]

268	2	2
Company service cost	3	3
Interest cost	11	9

[illegible]

[illegible]

[illegible]

[illegible]

			Actual return on plan assets			3	
			(38)			—	
			—			—	
Company contributions			11		7		
					—		
					—		
Employee contributions			1				

[illegible]

[illegible]

[illegible]

(1)

(2)		
(2)		
Net pension liability		
\$		
(43)		
\$		
(44)		
\$		
(1)		
\$		
(2)		

2060000002420000001000000200000024600000026800000020000002000000302800000000-40000007000000000211000000246000000200000020000002020000002400000000030038000000000110000007000000000100000010000000036000000400000000011000000100

200000060000000016800000020200000000-43000000-44000000-1000000-2000000-43000000-44000000-1000000-2000000

The following table provides a reconciliation of the net amount recognized in the consolidated balance sheets:

	2024	2023
Retirement Benefits		
Other Post-Retirement Benefits		
June 30,		
(Dollars in millions)		
2024		
2023		
Amounts Recognized in Statement of Financial Position		

[illegible]

[illegible]

[illegible]

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total accumulated other comprehensive loss (income) at the end of the fiscal year</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><tr style="height:12pt"><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Additional Information for Plan with ABO or PBO in Excess of Plan Assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table>		

Projected benefit obligation		
93		
129		
1		
2		
Accumulated benefit obligation		
89		
126		
1		
2		
Fair value of plan assets		
37		

68								—			

Service cost		3	3	3	—	—	—
Interest cost			11	9	—	—	—
Expected return on plan assets			(9)	(9)	(9)	(9)	(9)

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

	\$	
—		
Financial Assumptions Used to Determine Benefit Obligations at the Balance Sheet Date		
Discount rate (%)	4.3	%
	4.3	%
	5.0	%
	4.7	%
Rate of compensation increases (%)	2.7	

[illegible]

Rate of compensation increases (%)		
2.7	%	n/a
2.7	%	n/a
Expected long-term rate of return (%)		
4.3	%	n/a
3.9	%	n/a
Expected Future Contributions		

[illegible]

June 30,			June 30,								
(Dollars in millions)			2024								
2023			2024			2023			2024		
Expected Future Benefit Payments											
Financial year											
2025			\$			12					

[illegible]

[illegible]

	2030-2034	71	84	1	1	1	1	1	1	Actual Asset Allocation (%)						Cash	1.0	%	4.5	%

[illegible]

[illegible]

3.3		
%		
—		
%		
%		
%		
Insurance contracts		
16.6		
%		
14.9		
%		
%		
—		
%		
%		
—		
%		
Other		
20.5		

[illegible]

[illegible]

[illegible]

—	
Property	8
7	
—	
—	
Insurance contracts	
28	
30	
—	
—	
Other	
34	

[illegible]

[illegible]

2.9		
%	—	%
%	—	%
%	—	%
%	—	%
Government bonds		
37.7		
%		
36.8		
%		
Corporate bonds		
16.8		
%		

		16.2	%
		—	%
		—	%
		—	%
Property	4.5	%	
		3.3	%
		—	%
		—	%
		—	%
Insurance contracts	16.6		

	%	14.9	%	—	%	%	%
Other		20.5					
	%	%	%	%	%	%	%
Total							

#000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100.0 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div>
130000000180000000001000000100000000055000000061000000100000002000000-
43000000-44000000-1000000-2000000-1000000-1000000000-58000000-
6600000010000001000000057000000065000000-1000000-
10000000930000000129000000010000002000000089000000012600000010000002000000037
2000000-100000000012000000010000001900000005000000000600000001700000000-
1400000000008000000-
1700000000011000000022000000000200000020000000000.0430.0430.0500.0470.0270.027
style="margin-top:9pt;text-align:justify;text-indent:22.5pt">The following tables provide a summary of plan assets that are measured at fair value as of June 30, 2024 and 2023, aggregated by the level in the fair value hierarchy within which those measurements fall:</div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.066%">

As of June 30, 2024 (dollars in millions)		
Level 1	Level 2	Level 3
Investments Measured at Net Asset Value		
Total Assets		
Equity securities		
\$		
—		
\$		
5		
\$		
—		
\$		

[illegible]

2				
			—	
			5	
			(1)	
			—	
			42	
			25	
			—	
			67	
			Total	
			\$	
			—	

\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">141</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">27</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">168</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify">(1) Other, as of June 30, 2024, included \$12 million of investments in hedge funds related to the Company's U.K. pension plan, which were classified as Level 2.</div>050000000005000000009100000000091000000030000000200000000500000000420000

[illegible]

	\$	6	Debt securities	—	107	107	—	107	Real estate	—	

				2		
					—	
					7	
		<div>				
					—	
					57	
					25	
					82	
					\$	
					Total	
						

[illegible]

[illegible]

19		
Actual return on plan assets:		
Relating to assets still held at the reporting date		
1		
1		
—		
Purchases, sales, settlements, contributions and benefits paid		
(4)		
(2)		
(2)		
(2)		
3		

<td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ending Balance at June 30, 2024</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>2700000008000000019000000010000000100000000-40000000-20000000-200000003000000003000000027000000070000000200000000<div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:72.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-

[illegible]

[illegible]

[illegible]

0.0500.0480.0410.0412040204010000000001000000000.010.0110000000.016500

The components of the changes in the cumulative translation adjustment, derivatives and hedges, minimum pension liability, and marketable securities for the fiscal years ended June 30, 2024, 2023, and 2022 are presented below:

[illegible]

2022		
Foreign currency translation adjustments:		
Net investment hedge		
\$		
21		
\$		
(30)		
\$		
121		
Long-term inter-company loans		
1		
12		
(37)		

Translation adjustments			(50)	43	(169)
Total foreign currency translation adjustments, pretax			(28)	25	(85)
Tax expense (benefit)			4		(7)
				25	

Total foreign currency translation adjustments, net of tax	\$			(32)				
			\$			32		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		
			\$			(110)		

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

For the fiscal years ended June 30, 2024, 2023, and 2022, the changes in accumulated other comprehensive loss, net of tax by component are as follows:									
	2024	2023	2022	2021	2020	2019	2018	2017	2016
Foreign Currency Translation Adjustment	\$10.449%	\$10.457%	\$10.449%	\$10.449%	\$10.449%	\$10.449%	\$10.449%	\$10.449%	\$10.449%
Pension Liability Adjustments	\$11.034%	\$11.034%	\$11.034%	\$11.034%	\$11.034%	\$11.034%	\$11.034%	\$11.034%	\$11.034%
Derivatives and Hedges	\$12.204%	\$12.204%	\$12.204%	\$12.204%	\$12.204%	\$12.204%	\$12.204%	\$12.204%	\$12.204%
Marketable Securities	\$0.530%	\$0.530%	\$0.530%	\$0.530%	\$0.530%	\$0.530%	\$0.530%	\$0.530%	\$0.530%
Other	\$0.1%	\$0.1%	\$0.1%	\$0.1%	\$0.1%	\$0.1%	\$0.1%	\$0.1%	\$0.1%
Total	\$11.034%	\$11.034%	\$11.034%	\$11.034%	\$11.034%	\$11.034%	\$11.034%	\$11.034%	\$11.034%

[illegible]

[illegible]

	(78)	
	Amounts reclassified from other comprehensive loss	
	—	
	1	
	—	
	—	
	1	
	(378)	
	(38)	

				(4)	
			(1)		
			(394)		
Other comprehensive income (loss) before reclassifications					
32			(16)		
18			—		
—			34		

Amounts reclassified from other comprehensive loss	
—	2
	2
—	4
—	6
Balance at June 30, 2023	
(346)	
(52)	
45	
—	

			(1)						(354)								
Other comprehensive income (loss) before reclassifications			(32)					2				2					
					—					—					—		
					—					—					—		
					—					—					—		
Amounts reclassified from other comprehensive loss			—					2					2				

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Other comprehensive income (loss) before reclassifications	32	(16)	18	—	—	—	34	Amounts reclassified from other comprehensive loss	—	2	4

[illegible]

[illegible]

				2
				Balance at June 30, 2024
				\$
				(378)
				\$
				(48)
				\$
				23
				\$
				—
				\$
				(1)

Expected volatility	52%	37%	37%
Expected life (in years)	4.0	4.3	3.7
Risk-free interest rate	4.4%	3.2%	0.7%
Dividend yield	None	None	None

[illegible]

[illegible]

[illegible]

[illegible]

family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%;>5.7</td><td colspan="2" style="background-color: #ffffff; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">8,655,393</td><td style="background-color: #ffffff; border-right: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="display: none"></td><td colspan="3" style="display: none"></td><td colspan="3" style="display: none"></td><td colspan="3" style="display: none"></td><td colspan="3" style="display: none"></td><td colspan="3" style="display: none"></td></tr><tr><td colspan="3" style="background-color: #ceeeff; padding: 2px 1pt; text-align: left; vertical-align: bottom">Vested/expected to vest as of June 30, 2024</td><td colspan="2" style="background-color: #ceeeff; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">64.81</td><td style="background-color: #ceeeff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="2" style="background-color: #ceeeff; border-left: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">1,187,497</td><td style="background-color: #ceeeff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #ceeeff; padding: 2px 1pt; text-align: center; vertical-align: bottom">5.7</td><td colspan="2" style="background-color: #ceeeff; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">8,655,393</td><td style="background-color: #ceeeff; border-right: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="display: none"></td><td colspan="3" style="display: none"></td><td colspan="3" style="display: none"></td><td colspan="3" style="display: none"></td><td colspan="3" style="display: none"></td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: bottom">Vested and exercisable as of June 30, 2024</td><td style="background-color: #ffffff; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #ffffff; padding: 2px 0; text-align: right; vertical-align: bottom">65.78</td><td style="background-color: #ffffff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="2" style="background-color: #ffffff; border-bottom: 1pt solid #000; border-left: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">521,898</td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #ffffff; border-bottom: 1pt solid #000; padding: 2px 1pt; text-align: center; vertical-align: bottom">3.21</td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom"><span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-

[illegible]

83.07		
Granted	1,611,350	
47.77		
Vested	220,139	
87.79		
Cancelled/forfeited	263,348	
65.22		
Unvested as of June 30, 2024	2,154,592	
56.14		

#000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>
</div>102672983.07161135047.7722013987.7926334865.22215459256.14<div style="text-indent:24pt">Performance Share Units </div><div style="margin-top:9pt;text-indent:24pt">The following table summarizes activity in unvested performance share units for the fiscal year ended June 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Performance Share Units</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Grant-Date Fair Value</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6eefc;padding:2px 1pt;text-align:left;vertical-align:bottom">Target Number Unvested as of June 30, 2023</td><td colspan="2" style="background-color:#e6eefc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">273,985 </td><td style="background-color:#e6eefc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6eefc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#e6eefc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">99.58 </td><td style="background-color:#e6eefc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Target Number Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

46,899			
Target Number Vested	84,342	88.35	
Target Number Cancelled/forfeited	76,554		
Target Number Unvested as of June 30, 2024	159,988	103.17	

[illegible]

[illegible]

[illegible]

82.36	Target Number Granted	326,062	39.52	Target Number Vested	190	63.13	Target Number Cancelled/forfeited	81,389	63.42	Target Number Unvested as of June 30, 2024	587,029

weight:400;line-height:100%">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">51.98 </td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>34254682.3632606239.5219063.138138963.4258702951.9855000000P1Y9M18D: EXPENSE (INCOME), NET<div style="margin-top:9pt;text-indent:24pt">The components of other expense (income), net for the fiscal years ended June 30, 2024, 2023, and 2022 are as follows:</div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.057%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fiscal Year Ended
June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(Dollars in millions)</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2022</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income), net</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other expense (income), net</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div></div>

[illegible]

[illegible]

(7)		\$	28

(1) Debt financing costs for the fiscal year ended June 30, 2022 consists of \$4 million of financing charges related to a tranche of U.S. dollar-denominated term loans under its senior secured credit facilities.

(2) Foreign currency losses (gains) include both cash and non-cash transactions.

(3) Other, for the fiscal year ended June 30, 2022 includes, in part, total realized and unrealized gain of \$2 million, related to the fair value of the derivative liability associated with the formerly outstanding Series A Preferred Stock.

4000000-200000008000000-33000000-4000000-10000009000000024000000700000002800000040000002000000

LEASES

The Company leases certain manufacturing and office facilities, land, vehicles, and equipment. The terms of these leases vary widely, although most have terms between 3 and 10 years.

In accordance with ASC 842

, Leases

, the Company recognizes a “right-of-use” asset and related lease liability at the commencement date of each lease based on the present value of the fixed lease payments over the expected lease term inclusive of any rent escalation provisions or incentives received. The lease term for this purpose will include any renewal period where the Company determines that it is reasonably certain that it will exercise the option to renew. While certain leases also permit the Company to terminate the lease in advance of the nominal term upon payment of an associated penalty, the Company

generally does not take into account potential early termination dates in its determination of the lease term as it is reasonably certain not to exercise an early-termination option as of the lease commencement date.

The Company uses its incremental borrowing rate, which represents the interest rate the Company would expect to pay on a collateralized basis to borrow an amount equal to the lease

payments under similar terms, in order to calculate the present value of a lease, when the implicit discount rate for its leases is not readily determinable.

For operating leases, fixed lease payments are recognized as operating lease expense on straight-line basis over the lease term. For finance leases, the Company recognizes depreciation expense associated with the leased asset acquired and interest expense related to the financing portion. Variable payments are recognized in the period incurred. As permitted by ASC 842, the Company has elected not to separate those components of a lease agreement not related to the leasing of an asset from those components that are related.

The Company does not record leases with an initial lease term of 12 months or less on its consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term.

Supplemental information concerning the leases recorded in the Company's consolidated balance sheet as of June 30, 2024 is detailed in the following table:

	Right-of-use assets	Leases with variable payments	Leases with payments based on usage	Leases with payments based on performance	Leases with payments based on sales	Leases with payments based on other factors	Leases with payments based on other factors	Leases with payments based on other factors	Leases with payments based on other factors
Balance at June 30, 2024	\$1.0	\$22.438	\$0.1	\$0.1	\$48.461	\$0.1	\$1.0	\$12.057	\$0.1
Line item in the consolidated balance sheet									
Balance at June 30, 2024									
Balance at June 30, 2023									
Right-of-use assets									
Property, plant, and equipment, net									
Finance leases									

[illegible]

18		
Operating leases		
Other accrued liabilities		
13		
11		
Non-current lease liabilities:		
Finance leases		
Long-term obligations, less current portion		
312		
323		
Operating leases		
Other liabilities		
\$		

70

	\$	55

The components of the net lease costs for the fiscal years ended June 30, 2024 and 2023 reflected in the Company's consolidated statement of operations were as follows:

(Dollars in millions)	Fiscal Year Ended June 30, 2024	Fiscal Year Ended June 30, 2023
Financing lease costs:		
Amortization of right-of-use assets	\$	30

\$		
21		
Interest on lease liabilities		
21		
17		
Total		
51		
38		
Operating lease costs		
27		
35		
Variable lease costs		

	16	
Total lease costs		
\$		
94		
\$		
83		

The short-term lease cost amounted to \$9 million, \$10 million and \$8 million during the fiscal year ended June 30, 2024, 2023 and 2022, respectively.

The weighted average remaining lease term and weighted average discount rate related to the Company's right-of-use assets and lease liabilities as of June 30, 2024 are as follows:

Weighted average remaining lease term (years):			
Finance leases			
16.1			

Ended
June 30, 2022

Cash paid for amounts included in lease liabilities:																																						
Financing cash flows used for finance leases									\$			19									\$			19									\$			15		
Operating cash flows used for finance leases									16									15									11											

[illegible]

[illegible]

[illegible]

	51	
2028	34	13
47		
2029	34	
9		
43		
Thereafter	337	
36		
373		

Total minimum lease payments			518	104	622
Less: interest			186	21	207
Total lease liabilities			\$	332	\$

83

\$	415	

P3YP10Y

Supplemental information concerning the leases recorded in the Company's consolidated balance sheet as of June 30, 2024 is detailed in the following table:

(Dollars in millions)									
Line item in the consolidated balance sheet									
Balance at June 30, 2024									
Balance at June 30, 2023									
Right-of-use assets:									
Finance leases									
Property, plant, and equipment, net									
\$									

252		
Operating leases		
Other long-term assets		
77		
59		
Current lease liabilities:		
Finance leases		
Current portion of long-term obligations and other short-term borrowings		
20		
18		

[illegible]

serif;font-size:10pt;font-weight:400;line-height:100%">70 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;padding:2px 0;text-align:right;vertical-align:bottom">55 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>252000000770000005900000020000000180000001300000011000000312000000<div style="margin-top:9pt;text-align:justify;text-indent:24pt">The components of the net lease costs for the fiscal years ended June 30, 2024 and 2023 reflected in the Company's consolidated statement of operations were as follows:</div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(Dollars in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fiscal Year Ended
June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fiscal Year Ended
June 30, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Financing lease costs:</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Amortization of right-of-use assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td>

			21	
Interest on lease liabilities				21
			17	
Total			51	
			38	
Operating lease costs			27	
			35	
Variable lease costs				

16

10	10	10
Total lease costs		
\$	94	
\$	\$	\$
\$	83	

The short-term lease cost amounted to \$9 million, \$10 million and \$8 million during the fiscal year ended June 30, 2024, 2023 and 2022, respectively.

The weighted average remaining lease term and weighted average discount rate related to the Company's right-of-use assets and lease liabilities as of June 30, 2024 are as follows:

	90.274%	0.1%	1.0%
	7.526%	0.1%	
Weighted average remaining lease term (years):			
Finance leases	16.1		

Operating leases

	9	
Finance leases		
6.2		
%		
Operating leases		
4.6		
%		

Supplemental information concerning the cash-flow impact arising from the Company's leases for the fiscal year ended June 30, 2024 recorded in the Company's unaudited consolidated statement of cash flows is detailed in the following table (in millions):

	Fiscal Year Ended June 30, 2024	Fiscal Year Ended June 30, 2023	Fiscal Year Ended June 30, 2022
Cash paid for operating leases	\$300,000,000	\$210,000,000	\$210,000,000
Cash received from subleases	\$170,000,000	\$510,000,000	\$380,000,000
Net cash paid for operating leases	\$130,000,000	\$590,000,000	\$350,000,000

[illegible]

[illegible]

[illegible]

				51			
2028			34				
			13				
						47	
2029			34				
9							
			43				
Thereafter			337				
						36	
						36	
						36	

373		
Total minimum lease payments		
518		
104		
622		
Less: interest		
186		
21		
207		
Total lease liabilities		
\$		
332		
\$		

<td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">83 </td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">415 </td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

</div>370000000170000000540000003900000015000000054000000370000001400000051

AND CONTINGENCIES<div style="margin-top:9pt">Litigation</div><div style="margin-top:9pt;text-align:justify;text-indent:24pt">From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements. The Company records a liability in its consolidated financial statements for these matters when a loss is </div><div style="margin-top:9pt;text-align:justify">known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary for its consolidated financial statements not to be misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the Company's consolidated financial statements. Any legal or other expenses associated with the litigation are accrued for as the expenses are incurred. The Company intends to vigorously defend itself against any such litigation and does not currently believe that the outcome of any such litigation will have a material adverse effect on the Company's consolidated financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise.</div><div style="text-align:justify">
</div><div style="text-align:justify">City of Warwick Retirement System Class Action</div><div>
</div><div style="text-align:justify;text-indent:22.5pt">In February 2023, an alleged shareholder filed a complaint styled City of Warwick Retirement System v. Catalent, Inc., et al., No. 23-cv-01108, in New Jersey federal court against the Company and three of its then-officers

(collectively, “the Warwick Defendants”) purportedly on behalf of a putative “class” consisting of persons who purchased or otherwise acquired Company securities between August 30, 2021 and October 31, 2022, inclusive. On September 15, 2023, the Warwick complaint was amended (together with the original complaint, the “Warwick Complaint”), which amended complaint expanded the class period to between August 30, 2021 and May 7, 2023, inclusive (the “Class Period”). The Warwick Complaint purports to assert claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and the related regulations, alleging that, unbeknownst to investors, the Warwick Defendants purportedly engaged in accounting and channel stuffing schemes to pad the Company’s revenues and failed to disclose adverse facts that purportedly were known to or recklessly disregarded by the Warwick Defendants. Specifically, the Warwick Complaint alleges that the Warwick Defendants (i) overstated revenue and earnings by prematurely recognizing revenue in violation of U.S. GAAP; (ii) suffered material weaknesses in its internal control over financial reporting related to revenue recognition; (iii) falsely represented demand for its products while knowingly selling more product to its direct customers than could be sold to healthcare providers and end consumers; (iv) cut corners on safety and control procedures at key production facilities; (v) disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company’s financial results through premature revenue recognition in violation of U.S. GAAP or stuffing its direct customers with this excess inventory; and (vi) lacked a reasonable basis for their positive statements about the Company’s financial performance, outlook, and regulatory compliance during the Class Period. On November 15, 2023, the Warwick Defendants filed a motion to dismiss the Warwick Complaint. On June 28, 2024, the Court granted, in part, and denied, in part, the Company’s motion to dismiss. The Warwick Defendants’ answer to the Warwick Complaint was filed on August 12, 2024. The Company believes that the Warwick Defendants have defenses to the remaining allegations and intends to vigorously defend against these allegations.

Husty Derivative Claim

In August 2023, an alleged shareholder filed a derivative complaint styled Husty et al. v. Carroll, et al., No. 23-cv-00891, in Delaware federal court against certain current and former members of the Company’s board of directors, (the “Husty Defendants”), and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities described there led to, and will continue to expose the Company to, costs and damages. On February 20, 2024, the court entered a stipulation staying the case pending the outcome of motion to dismiss that was filed in the City of Warwick Retirement System action. On April 23, 2024, the plaintiff voluntarily dismissed the action without prejudice.

Brown Derivative Claim

In September 2023, an alleged shareholder filed a derivative complaint styled Brown, et al. v. Chiminski, et al., Case 3:23-cv-15722, in New Jersey federal court against certain current and former officers and members of the Company’s board of directors (the “Brown Defendants”) and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities described there led to, and will continue to expose the Company to, costs and damages. On January 8, 2024, the court entered a stipulation staying the case pending the outcome of motion to dismiss that was filed in the City of Warwick Retirement System action. On April 19,

2024, the plaintiff voluntarily dismissed the action without prejudice. On May 2, 2024, the Court dismissed the action without prejudice.

Merger Related Claims

In connection with the proposed Merger, as disclosed below, three purported Catalent stockholders filed lawsuits alleging that certain disclosures made in the Proxy Statement were materially false and misleading:

Garfield v. Barber, et al., C.A. No. SOM-C 012027-24 (N.J. Super. Ct.), which was filed in the Superior Court of New Jersey;

Moore v. Catalent, Inc., et al., No. 652403/2024 (N.Y. Sup. Ct.), which was filed in the Supreme Court of New York; and

Clark v. Catalent, Inc., et al., No. 652407/2024 (N.Y. Sup. Ct.), which was filed in the Supreme Court of New York. The aforementioned lawsuits are collectively referred to as the “Actions.” The Actions alleged, among other things, that certain disclosures in the Proxy Statement filed in connection with the Merger Agreement omitted certain purportedly material information. The

Garfield Action asserted violations of New Jersey Uniform Securities Law § 49:3-71 and negligent misrepresentation and concealment and negligence under New Jersey common law. The

Moore and

Clark Actions each asserted a single claim for breach of fiduciary duty. On May 17, 2024, the

Garfield Action was voluntarily dismissed with prejudice. On June 26, 2024, the

Moore and

Clark Actions were voluntarily dismissed with prejudice.

**Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subpoenas and Requests for Information</div><div>
</div><div style="text-align:justify;text-indent:22.5pt">From time to time, the Company receives subpoenas or requests for information from various governmental agencies or private parties, including from state attorneys general, the U.S. Department of Justice, and private parties. The Company generally responds to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred.</div><div style="text-align:justify;text-indent:22.5pt">
</div><div style="text-align:justify;text-indent:22.5pt">In June 2023, the Company received a demand from a company stockholder pursuant to 8 Del. C. § 220 to inspect books and records of the Company relating to, among other things, the allegations raised in the Warwick Complaint. The Company has responded to the demand and cannot determine at this time if the books and records demand will lead to litigation.</div><div style="text-align:justify;text-indent:22.5pt">
</div><div style="text-align:justify">Fire at Biologics Facility</div><div style="text-align:justify">
</div><div style="text-align:justify;text-indent:22.5pt">During the three months ended December 31, 2023, the Company had a small fire at a facility in its Biologics segment. The fire activated the sprinkler systems, which then caused minor flooding in certain parts of the facility. The Company accrued \$9 million for estimated damages, repairs, and lost inventory. The Company is insured for such incidents and has submitted claims for reimbursement. Proceeds from potential reimbursement are not included in the financial statements for the three and twelve months ended June 30, 2024.</div><div style="text-align:justify">
</div><div style="text-align:justify">Entry Into an Agreement and Plan of Merger</div><div style="text-align:justify">
</div><div style="text-align:justify;text-indent:22.5pt">On February 5, 2024, the Company entered into the Agreement and Plan of Merger (the “Merger Agreement”), with Creek Parent, Inc. (“Parent”), a Delaware corporation and a wholly owned subsidiary of Novo Holdings A/S (“Novo Holdings”), and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein and in accordance with the General Corporation Law of the State of Delaware (the “DGCL”), Merger Sub will be merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Parent will acquire all the issued and outstanding shares of Common Stock of the Company.</div><div style="text-align:justify">
</div><div style="text-align:justify;text-indent:22.5pt">At the effective time of the Merger (the “Effective Time”), each share of Common Stock, par value \$0.01 per share, of the Company (such shares, collectively, the “Company Common Stock,” and each, a “Share”) that is issued and outstanding immediately prior to the Effective Time (other than any Shares held by (i) the Company, Parent or Merger Sub or any other direct or indirect wholly owned subsidiary of the Company or Parent immediately prior to the**

Effective Time, or (ii) a holder who has not voted in favor of the adoption of the Merger Agreement and is entitled to demand and properly demands appraisal of such Shares under the DGCL), will be converted automatically into the right to receive an amount in cash equal to \$63.50 per Share, without interest (the "Merger Consideration"). The transaction values the Company at \$16.50 billion on an enterprise value basis.

Consummation of the Merger is subject to customary closing conditions, including (i) receipt of certain governmental waivers, consents, clearances, decisions, declarations, approvals, and expirations of applicable waiting periods, including the expiration or early termination of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, with respect to (A) the Merger and (B) the sale of three of the Company's fill-finish sites (which are located in Anagni, Italy, Bloomington, Indiana USA, and Brussels, Belgium) and related assets from Novo Holdings to Novo Nordisk A/S ("Novo Nordisk"), of which Novo Holdings is the controlling shareholder (the "Carve-Out"), and (ii) the absence of any order, injunction or law prohibiting the Merger or the Carve-Out, in each case, without a Burdensome Condition (as defined in the Merger Agreement). Parent's and Merger Sub's obligations to close the Merger are also conditioned upon the absence of a Material Adverse Effect (as defined in the Merger Agreement) on the Company.

90.0163.516500000000SEGMENT AND GEOGRAPHIC INFORMATION

The CODM evaluates the performance and allocates resources based upon a number of factors, the primary being its segment earnings before other (income) expense, impairments, restructuring costs, interest expense, income tax expense, and depreciation and amortization

Segment EBITDA

Segment EBITDA

Segment EBITDA is subject to important limitations. These consolidated financial statements include information concerning Segment EBITDA (a) because Segment EBITDA is an operational measure used by management in the assessment of the operating segments, the allocation of resources to the segments, and the setting of strategic goals and annual goals for the segments, and (b) in order to provide supplemental information that the Company considers relevant for the readers of the consolidated financial statements. The Company's presentation of Segment EBITDA may not be comparable to similarly titled measures used by other companies.

The following table includes Segment EBITDA for each of the Company's current reporting segments during the fiscal years ended June 30, 2024, 2023, and 2022:

	2024	2023	2022
Segment EBITDA	\$1,000.00	\$1,000.00	\$1,000.00

(Dollars in millions)			Fiscal Year Ended June 30,														
2024			2023			2022			Segment EBITDA reconciled to net (loss) earnings:								
Biologics			\$			272											

[illegible]

Unallocated costs	(1)	
\$	(1,153)	
\$		
(559)		
\$		
(286)		
Depreciation and amortization		
(489)		
(422)		
(378)		
Interest expense, net		
(254)		

	(86)	(123)	(186)
Income tax benefit (expense)	(16)	86	(80)
Net (loss) earnings	\$	(1,043)	(256)

[illegible]

[illegible]

[illegible]

[illegible]

	\$	(559)	(286)

(a) Impairment charges and gain/loss on sale of assets for the fiscal year ended June 30, 2024 includes right-of-use asset impairment charges associated with under utilized facilities in our Biologics segment, obsolete equipment that could not be sold or repurposed in our Biologics segment and under utilized suites from a canceled project in our Pharma and Consumer Health segment.

For the fiscal year ended June 30, 2023, impairment charges are primarily associated with an idle facility in the Biologics segment and obsolete equipment that could not be sold or repurposed in the Pharma and Consumer Health segment. Further detail is provided below.

For the fiscal year ended June 30, 2023, the Company identified an indicator of impairment related to one of its facilities in the Biologics segment given the plans to pause any additional spend on site development due to a lack of demand, leading to a partial impairment charge of \$54 million. The Company primarily utilized a market and income approach for real property and a cost approach for personal property to record the partial impairment on its idle facility. Impairment charges are recorded in Other operating expense in the consolidated statements of operations.

Also, in the fiscal year ended June 30, 2023, the Company identified an indicator of impairment related to obsolete equipment from a terminated project in the Pharma and Consumer Health segment, leading to a full impairment charge of \$18 million.

For the fiscal year ended June 30, 2022, impairment charges are primarily due to fixed asset impairment charges associated with dedicated equipment for a product the Company no longer manufactures in its Pharma and Consumer Health segment and obsolete equipment in its Biologics segment.

(b) — Restructuring and other special items during the fiscal year ended June 30, 2024 include restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization. For further details on restructuring charges, see Note 6, *Restructuring Costs* to the Consolidated Financial Statements.

Restructuring and other special items for the fiscal year ended June 30, 2023 includes (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition.

Restructuring and other special items for the fiscal year ended June 30, 2022 include (i) transaction and integration costs primarily associated with the Princeton, Bettera Wellness, Delphi, Hepatic, Acorda, and RheinCell transactions and (ii) unrealized losses on venture capital investments.

(c) — Goodwill impairment charges during the fiscal year ended June 30, 2024 were associated with the Company's Consumer Health and Biomodalities reporting units, which are part of the Company's Pharma and Consumer Health and Biologics segments, respectively. For further details, see Note 4, *Goodwill* to the Consolidated Financial Statements.

The goodwill impairment charges for the fiscal year ended June 30, 2023 was associated with the Company's Consumer Health reporting unit. For further details, see Note 4, *Goodwill*.

(d) — Refer to Note 15, *Other (income) expense, net* for details of financing charges and foreign currency translation adjustments recorded within other (income) expense, net.

The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated balance sheets.

Total Assets

	(Dollars in millions)	June 30, 2024	June 30, 2023	Biologics	\$	5,326		\$	5,746		Pharma and Consumer Health		4,643		4,867		Corporate and eliminations	(216)	

[illegible]

[illegible]

34				30	
Total capital expenditures (1)					
\$					
351					
\$					
594					
666					

(1) — Include both cash and non-cash capital expenditures

Long Lived Assets

The following table presents long-lived assets—consisting of property, plant, and equipment, net of accumulated depreciation—by geographic area:

[illegible]

[illegible]

The following table includes Segment EBITDA for each of the Company's current reporting segments during the fiscal years ended June 30, 2024, 2023, and 2022:

	2024	2023	2022
Segment EBITDA reconciled to net (loss) earnings:			
Biologics	\$	272	\$

[illegible]

[illegible]

(422)				
			(378)	
Interest expense, net			(254)	
(123)			(186)	
Income tax benefit (expense)			(16)	
86			(80)	
Net (loss) earnings			\$	

(1,043)	\$</td><td colspan="3" style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom;">(256)</td><td colspan="3" style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom;">\$</td><td colspan="3" style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom;">499</td><td colspan="3" style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom;"></td></tr></table><div style="margin-top: 9pt; padding-left: 48pt; text-align: justify; text-indent: -24pt">(1) — Unallocated costs include restructuring and special items, stock-based compensation, gain (loss) on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:</div><div style="margin-top: 9pt"><table style="border-collapse: collapse; display: inline-table; margin-bottom: 5pt; vertical-align: text-bottom; width: 100.000%"><tr><td style="width: 1.0%"></td><td style="width: 59.718%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 11.473%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.530%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 11.473%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.530%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 11.476%"></td><td style="width: 0.1%"></td></tr><tr style="height: 12pt"><td colspan="3" rowspan="2" style="padding: 2px 1pt; text-align: left; vertical-align: bottom">(Dollars in millions)</td><td colspan="15" style="padding: 2px 1pt; text-align: center; vertical-align: bottom">Fiscal Year Ended June 30,</td></tr><tr style="height: 12pt"><td colspan="3" style="border-top: 1pt solid #000000; padding: 2px 1pt; text-align: center; vertical-align: bottom">2024</td><td colspan="3" style="border-top: 1pt solid #000000; padding: 0 1pt"></td><td colspan="3" style="border-top: 1pt solid #000000; padding: 2px 1pt; text-align: center; vertical-align: bottom">2023</td><td colspan="3" style="border-top: 1pt solid #000000; padding: 0 1pt"></td><td colspan="3" style="border-top: 1pt solid #000000; padding: 2px 1pt; text-align: center; vertical-align: bottom">2022</td></tr><tr><td colspan="3" style="background-color: #cceeef; padding: 2px		

Impairment charges and gain/loss on sale of assets	(a)
\$	(29)
\$	(98)
\$	(31)
Stock-based compensation	
	(68)
Restructuring and other special items	

(b)

[illegible]

[illegible]

(119)	Total unallocated costs		
\$	(1,153)	\$	\$
\$	\$	\$	\$
\$	\$	\$	\$
\$	\$	\$	\$
\$	\$	\$	\$

(a) Impairment charges and gain/loss on sale of assets for the fiscal year ended June 30, 2024 includes right-of-use asset impairment charges associated with under utilized facilities in our Biologics segment, obsolete equipment that could not be sold or repurposed in our Biologics segment and under utilized suites from a canceled project in our Pharma and Consumer Health segment.

For the fiscal year ended June 30, 2023, impairment charges are primarily associated with an idle facility in the Biologics segment and obsolete equipment that could not be sold or repurposed in the Pharma and Consumer Health segment. Further detail is provided below.

For the fiscal year ended June 30, 2023, the Company identified an indicator of impairment related to one of its facilities in the Biologics segment given the plans to pause any additional spend on site development due to a lack of demand, leading to a partial impairment charge of \$54 million. The Company

primarily utilized a market and income approach for real property and a cost approach for personal property to record the partial impairment on its idle facility. Impairment charges are recorded in Other operating expense in the consolidated statements of operations.

Also, in the fiscal year ended June 30, 2023, the Company identified an indicator of impairment related to obsolete equipment from a terminated project in the Pharma and Consumer Health segment, leading to a full impairment charge of \$18 million.

For the fiscal year ended June 30, 2022, impairment charges are primarily due to fixed asset impairment charges associated with dedicated equipment for a product the Company no longer manufactures in its Pharma and Consumer Health segment and obsolete equipment in its Biologics segment.

(b) Restructuring and other special items during the fiscal year ended June 30, 2024 include restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization. For further details on restructuring charges, see Note 6, Restructuring Costs to the Consolidated Financial Statements.

Restructuring and other special items for the fiscal year ended June 30, 2023 includes (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition

Restructuring and other special items for the fiscal year ended June 30, 2022 include (i) transaction and integration costs primarily associated with the Princeton, Bettera Wellness, Delphi, Hepatic, Acorda, and RheinCell transactions and (ii) unrealized losses on venture capital investments.

(c) Goodwill impairment charges during the fiscal year ended June 30, 2024 were associated with the Company's Consumer Health and Biomodalities reporting units, which are part of the Company's Pharma and Consumer Health and Biologics segments, respectively. For further details, see Note 4, Goodwill to the Consolidated Financial Statements.

The goodwill impairment charges for the fiscal year ended June 30, 2023 was associated with the Company's Consumer Health reporting unit. For further details, see Note 4, Goodwill

.

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">>(d) — Refer to Note 15, Other (income) expense, net for details of financing charges and foreign currency translation adjustments recorded within other (income) expense, net.

</div>272000000277000000777000000597000000548000000589000000086900000008251153000000-5590000000-28600000004890000000422000000378000000-2540000000-1860000000-123000000016000000-86000000080000000-1043000000-2560000000499000000290000000980000000310000000680000000350000000540000000178001153000000-5590000000-28600000005418<div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:24pt">The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated balance sheets. </div><div style="margin-top:9pt">Total Assets <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%><tr><td style="width:1.0%></td><td style="width:73.022%></td><td style="width:0.1%></td><td style="width:1.0%></td><td style="width:11.473%></td><td style="width:0.1%></td><td style="width:0.1%></td><td style="width:0.530%></td><td style="width:0.1%></td><td style="width:1.0%></td><td style="width:11.475%></td><td style="width:0.1%></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(Dollars in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:top">Biologics</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,326 </td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,746 </td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated balance sheets. </div><div style="margin-top:9pt">Total Assets <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%><tr><td style="width:1.0%></td><td style="width:73.022%></td><td style="width:0.1%></td><td style="width:1.0%></td><td style="width:11.473%></td><td style="width:0.1%></td><td style="width:0.1%></td><td style="width:0.530%></td><td style="width:0.1%></td><td style="width:1.0%></td><td style="width:11.475%></td><td style="width:0.1%></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(Dollars in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:top">Biologics</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,326 </td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,746 </td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

[illegible]

[illegible]

		214
		183
Corporate	16	
	34	
		30
Total capital expenditures (1)		
	\$	
		351
	\$	
		594

[illegible]

[illegible]

646				\$	781						
Work-in-process			138						186		
Total inventories, gross			784						967		
Inventory cost adjustment			(210)					(190)			

[illegible]

	\$	53		Short-term contract assets	585		399		Spare parts supplies	29		24			Prepaid income tax	45				77				Non-U.S. value-added tax	60				38

[illegible]

	(Dollars in millions)	June 30, 2024	June 30, 2023	Land, buildings, and improvements	\$	1,987	\$	1,887	Machinery and equipment	2,538	2,287	Furniture and fixtures	62		61

Construction in progress			971		1,043	
Property, plant, and equipment, at cost			5,558		5,278	
Accumulated depreciation			(1,915)		(1,596)	
Property, plant, and equipment, net			\$		3,643	

3,682

Other long-term assets consist of the following:

	June 30, 2024	June 30, 2023
Operating lease right-of-use assets	\$ 77	\$ 59
Note receivable	56	

53		
Corporate-owned life insurance policies		
48		
41		
Venture capital investments		
47		
36		
Interest-rate swap		
36		
62		
Pension assets		
13		
18		

weight:400;line-height:100%">Long-term contract assets</td><td colspan="2" style="background-color:#e6e6ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17</td><td style="background-color:#e6e6ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18</td><td style="background-color:#e6e6ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e6ff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top">Total other long-term assets</td><td style="background-color:#e6e6ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#e6e6ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">332</td><td style="background-color:#e6e6ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td style="background-color:#e6e6ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#e6e6ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">329</td><td style="background-color:#e6e6ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt">Other accrued liabilities</div>Other accrued liabilities consist of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td

[illegible]

Operating lease liabilities		
13		
11		
Restructuring accrual		
10		
19		
Accrued interest		
37		
35		
Accrued income tax		
16		
44		
Total other accrued liabilities		
		\$

			(Dollars in millions)							
			June 30, 2024							
			June 30, 2023							
			Raw materials and supplies							
			646							
			781							

Work-in-process			138			186
Total inventories, gross			784			967
Inventory cost adjustment			(210)			
Total inventories			\$			574

\$	

Prepaid expenses and other current assets consist of the following:	<table> <tr> <td style="width: 1.0%;"></td><td style="width: 73.022%;"></td><td style="width: 0.1%;"></td><td style="width: 1.0%;"></td><td style="width: 11.473%;"></td><td style="width: 0.1%;"></td><td style="width: 0.1%;"></td><td style="width: 0.530%;"></td><td style="width: 0.1%;"></td><td style="width: 1.0%;"></td><td style="width: 11.475%;"></td><td style="width: 0.1%;"></td></tr> <tr> <td colspan="3" style="padding: 2px 1pt; text-align: left; vertical-align: bottom;">(Dollars in millions)</td><td colspan="9"></td></tr> <tr> <td colspan="3" style="padding: 2px 1pt; text-align: center; vertical-align: bottom;">June 30,</td><td colspan="9" style="text-align: center;">2024</td></tr> <tr> <td colspan="3" style="padding: 0 1pt;"></td><td colspan="9" style="padding: 2px 1pt; text-align: center; vertical-align: bottom;">June 30,</td></tr> <tr> <td colspan="3" style="padding: 0 1pt;"></td><td colspan="9" style="padding: 2px 1pt; text-align: center; vertical-align: bottom;">2023</td></tr> <tr> <td colspan="3" style="background-color: #ccccff; padding: 2px 1pt; text-align: left; vertical-align: top;">Prepaid expenses</td><td colspan="9" style="background-color: #ccccff; border-top: 1pt solid #000000; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom;">\$</td></tr> <tr> <td colspan="3" style="background-color: #ccccff; border-top: 1pt solid #000000; padding: 2px 0; text-align: right; vertical-align: bottom;">\$</td><td colspan="9" style="background-color: #ccccff; border-top: 1pt solid #000000; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom;">46</td></tr> <tr> <td colspan="3" style="background-color: #ccccff; border-top: 1pt solid #000000; padding: 2px 1pt; text-align: left; vertical-align: bottom;">\$</td><td colspan="9" style="background-color: #ccccff; border-top: 1pt solid #000000; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom;">\$</td></tr> <tr> <td colspan="3" style="background-color: #ccccff; border-top: 1pt solid #000000; padding: 2px 0; text-align: right; vertical-align: bottom;">\$</td><td colspan="9" style="background-color: #ccccff; border-top: 1pt solid #000000; padding: 2px 0; text-align: right; vertical-align: bottom;">53</td></tr> <tr> <td colspan="3" style="background-color: #ffffff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom;">Short-term contract assets</td><td colspan="9" style="background-color: #ffffff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom;">585</td></tr> </table>													(Dollars in millions)												June 30,			2024												June 30,												2023									Prepaid expenses			\$									\$			46									\$			\$									\$			53									Short-term contract assets			585								
(Dollars in millions)																																																																																																																									
June 30,			2024																																																																																																																						
			June 30,																																																																																																																						
			2023																																																																																																																						
Prepaid expenses			\$																																																																																																																						
\$			46																																																																																																																						
\$			\$																																																																																																																						
\$			53																																																																																																																						
Short-term contract assets			585																																																																																																																						

[illegible]

48						
			42			
			Total prepaid expenses and other			
			\$			
813						
			\$			
			633			

460000000530000000585000000399000000290000000240000004500000077000000

Property, plant, and equipment, net consist of the following:

[illegible]

Property, plant, and equipment, at cost		
5,558		
5,278		
Accumulated depreciation		
(1,915)		
(1,596)		
Property, plant, and equipment, net		
\$		
3,643		
\$		
3,682		

198700000018870000002538000000228700000062000000610000009710000001

Other long-term assets consist of the following:

			(Dollars in millions)	June 30,	2024	2023	Operating lease right-of-use assets	\$	77		\$	59	Note receivable	56	53	Corporate-owned life insurance policies	48

41		
Venture capital investments	47	
Interest-rate swap	36	
Pension assets	13	
Long-term contract assets	17	
Other		

38	42			
Total other long-term assets				
\$	332			
\$	329			

77000000059000000056000000053000000048000000041000000047000000036000000036

Other accrued liabilities consist of the following:

(Dollars in millions)								
June 30,								
2024								
June 30,								
2023								
Contract liability								

[illegible]

	10		
	19		
Accrued interest	37		
	35		
Accrued income tax	16		
	44		
Total other accrued liabilities	\$		
	622		
	\$		
	570		

[illegible]

M9GRP.PJ*5YQ<-(#NOHC!FF+ EYE#MWXPJ^A5I67CHW<_0IR87?EEDK6QX+5?X7U>Y9>H8'5-M0WVK/U3;JO+!PJYUUI>5CHG);(0^;Y?2X"=ECJ;8G=;4I*ELZ5>V!/<MXI7<X0@AI/E#&@NNAI0"B%<+>Z1+^BUATOR%A?ZL!L!#-5@.5#=-LAI!"

[illegible][illegible]

11/11/2019 11:11:11 AM

[illegible]

9Hh*11,KRGL@NLE=#7,IR,Q1!>.<2AX7A-MX:72+6:HL:SLY7LQ3/23-G6Q1YF+Q-V-IL20Q4)EBK^VXTX:5A4/MA072H1
BB90*80;<CJHEHJ0R<C*CPBBD45+L:3S*27_216Q62<+M;H1<3*Z M?7F+AI=M;RBD57012:5(S/2>+ZK1=>.(A/O17Q07W1A=C*3FWZ1(>+O3\$ M29,B)TX8-SYB-(346-
+1TZB:5#JL#4+26K+U:M7JR<5FU9D169D2Q&&-MIA:3\$-OW1VH;FIG90<9&F3#146R>.%7F1AWJ-R>TX6712\$7T0M:MG6TFB+27/G>.\$3@+1M1..+1Q1E?>
>N% WKM72+ MXCM.>+1+2E88R0.<+1HJZ+7KE/C:5.DH4V5018B8..3RAI+4A?Z>C3C09-P9UXCCG+7+S=E8*QA7IS MEO />+9&6/
GOYAA2WZ1Z/(<89A.3DYAPX+2MVIMV65E:6EY:#+(JGK5U-MY9@#>+>1Q)8D.>BYTF1FGK7UXS.0T.7Q)CHO")1%2D.N-BHKKP)R MC>@<FCK-%.FJH&@:;%MD?>
R/M?>.0.15\$XGLOP+D1=>+G24>+R/G+H+1#OH+M?0:1.OE5MOH@>+J2VYK.@CZ/SA32FB1LAAAF.D:~>H.KHGX&+IDE
M:5%Q5_R/W~7%1065VEUHFRL+CH/O.F1KESV9.O+>NJ.5:L.B?>M-V+BJH+;S/OFS9>.KD>+T.S0&G9.18TX.YD@<+ITL(<..M++1\$1Y.(RX"SZ">>+&@&+P
7=R3CQW@>E3T:J50WY@>ID86T9.F?P.HIQS..MK0'DJZL'6-G+>+OOIW@>015B7Q535CE66B.27\$BQ@<+D0\$1HCA5Y-TN:4?>
MMDBST+P32+W0A41J50V1D35+10W4H1B3P=>+>=J+X.W.29127T0)BK40&+>P5.TOL.Z+5L24Y.W:JH+7T1\$>P+<8C M8CM\$51Q.N=U+V8A/H3<41UOD)H&R7HPR^M^4
XGRZ+1^CQYF7E.N.MINZK5Z+NHJ^CWO18+0N3Y.OXWOV175T=IHR.21K4XPS+>GL&L+VWKB#-1.M:ASDM.WRBO.U:~1EFF+<LWZSD175;BB%>D05.4U
Q+19.P.M1A-IEH4S@>F&B.H&@<Q6.#0C@>058+K2RHH.3+3IMS+4E9<+P.B\$2/X.M4M.4K6E+APPH(<1>S@>4.OE.F1&XRK(IJ4/5D0<
LCI+Q53K6%U.FRIJH@>P+P4Q\$050G61/MC0T=-R0.7Q<>+<9.1)DB2.XS(*D<1Q3QKDTV@X&5#1+519%0DCRRZD2M%
MD<3/TP8B3P@<1C0D.+TKI+M0'46<1U1UMC9CD%=>C0TLHR=>+YTX.72WDB+1.Q@<+1/J2\$5C1M.KW18M%1YMB4Z.V.MWNXS_U)
U.FYV6D71Q@<I5H1NO.W701>+<K&C1>>CVE1.VOYU5LFEHE:KE2=C.H+76&KJ
M.X4+ECUQF1UO?FAZ<0\$T1V+1.06.0%\$>AW(8S0:12'FJHA..G+>48R3\$>A79H9G.HXVQSZ.14A1'V.MDC.L1J&+RS@<TM.K(W@<1R6B+>OL%125XE-WSJ^<60>=>1\$#<C
K9UJ30F&K)DZ&ORI+1(401'2)NQCENZ%LL.V=>6.9M.WW@2)FJ+1@IQ&+13+P\$).\$B.TI\$>35%A39H1T+1Q01+OWD.N%HB:
M/W112X@<TR6=1>+9&AP(N)SD3LXNXY14+116YGF8FFSAVBR1J(SA@<F7?4..99.F37L.M.K-6HJL'K6L1NAIZWN+<X+R1/MC/E1H.3IG4/EW1H0R+9C/1-(\$ MDX<>
(0YXVXC&GX+1/DL5LFC-#<S7RENQJ341.G=C.MT.&Y1.6/f.T.M'~<K0?E65H92V/W9>0\$4<P1.9000Z5%6STV.P3K1/03.E3(T.B1-
MGOGR10HW.K.L1PAQY.IVXMS<5>LB&L0>VZZW~>D'S.DIE77PWO1T3ZN~>M'>+<1TK75C)B%2'FF(70=>+1+>MGQPO'53W0.3@<B<S\$R.MY83'A,IN\$3N452.SKT7H0WS
>+>4KH(\$>1<Q14/<E.E.SR/LBS1005:5\$>K.B1B758NA+Y27G5.MWU'JSR(<6'G)M.L.OAEZ\$W64HM<2R0'+Y08'39PB+VILZ>SINW.OPK.ME-8EY+8B+1)S.<1V>+M.MW1-
6AH(C)TPQJRZLDZG805006C%0#>TSS@<SX<+MHL@<160.C.BA@>01^U2ZCH@<DQW8K5HJRL8N60.Q/Q.MSP@IS0.<@7XO.M#>1BZJ1H7X3L3\$<01<CDD50<G.1@44%AH32^
M@<R1A/OE155V.OK>1\$T:A9.U0#>M.OJRX<+>M=>S0+>Q.7@>+>31.M.O+>RT\$>.<006C%51-H+>71941A1H1#30<@<1V+>@<1@<1Q?P'>X.MD52Q<+>
1@<SR93D'1#<C>S<K>+>M9G#>+>F18(OR'AXZ/S03=15*U6H93&V\$<N1V1BHDD0\$>+>C=M.191X+>+M8\$4U0FF&D.LDZ2).59JAPWA3Q:FJWK6QVVDH1'"2 BBI' GTG'"@51%U.'Y
M.B<+>+<@<LY@<HN+<TN+1JRL20U<K-Q.K.J+>+<7WR3\$<KLN>QF.KV.L1.TFRWH0@<+2.MVGL.Q+<TX.9SH>+>0YH<+>M.H1+>N>SAG10@<RHJ0X.D.7%ICR<+>1HA.MS?>
-00-Q.Y=3\$01.RKX+4+37LV9L8P'02.MVZ&H.LZNGL+<7QW8B>R+4.M01\$D.L'E9U97E+>WH1L1.D1L3KPHD(HG@<DOSO>ON0H@<S90@<4E4+1>5.M+5M.S.E3C0G<N1ZP.6L
M'>1H1XFM%)>..UG<N220X%4H+>1+>D>9YTHD+>MXYBV>C1T-Q1K1+>H%<H930LX@<9%P1>7=>+>TT=<G'Z/L=>+>1@<IRUW'F.M#>1@<693\$V7P/3Z57H+R+>ODX>UM9V+2.P+>
+>1Q.8>+>2.L>2.F%P0H66\$X70G0\$1>+>D7.MANV7K-F58L(145%>MWOS<XIGI2+>BS+>20KT'565.M1Q@<(85AA8>+>CQK'ROE5:HP451+>1GIZ45134U+>7Q35-8@<PZ.W\$1Q<+>7%
M08%2141^<1Q>..S2J7R>+>3.DYR'V1)'D#>=A.S7'EU9..P1.\$&CQ1'"MAMK;WMY<U1>9.C(E%T2S%0)ZHMJYN7\$)G1-3'\$S-O=KXQM^YA8(T#08.MJ@<Q@<D1R#<@<U75+BF-
371VLWKU7\$T.#>91XVZ.MJH1J28+<1@>#5J1L.B6)34L6MK+ER1+>PME'K@<IDN9R'<K'PLG4Z.M#>8JFE+<K=NW3ZT+>E+>74-88L19.04UQDD4(1%HCY)8BH&K5>07X<+>
+>1V.MTBAAYQ+>DOE50RUP1J7+>B3<1\$>=>06KHJ@>O.L64Y.GDP&C%5%.62D1+>W.MH75U5965F5E97H+>#1+>B9.R'CUH1E+>0'SS/40154E2E&SKF+>4P1&P+>M+N29\$5%
M1+>9B18D1\$>BU'F1A'>5K9147%JU+>0<CUZ5%10@<SVXOMGT+>CQG<+>14Y.M3P+>+>00TCA.01@<H&CCGU+>GA2XR7H5DE+>L3P+>2TDBAAY8X5Y&T4M/#D
M<91QB10D11(OR10A'P#>1SYDQ2.C.B@<0R1J+>YGBK.M#>SMZL.C@<0.1UJ+>Z1=>M+>1B'>01Q/SOH4+>NVMW;KUX&+>+>U7551E.M\$A-
FT56@<TQ+>2UNT%>@<8&GSIW;MV.OZ<L1=>+>D>..2N::5.9#>4WJ=>1^LN7.M+>INV.7-Q<0D(<'CPX\$>#1+>R+>+<@<N&Y(<+>PPD.'3P.3\$<+>C3P&L'2/7QX12%BQ<+>1@<9VD1YMYL-B6BX+&br/>MBHJY=>06H4+>+>W.WKVEY.OCCG.Y@<0BP(N+>3LNR#1P&B.R1AP+>01C493.M45QZM213H2FM61=NENW.OGSZ+>JH+>C.OHB4115+E524M+1^2.H^<+>L6NP
M.S1.WW9+>D9.FWK&A1XOJH3'>SHE2

LSK(YV816/-%L3/S+7KU/LUJIFUFU M<@W>K0X9C<=>Q\$T45.@A<\$Z F56K9DY0JZ5SMX>J 7/G:HA?H?H?/%CFM3S#1L00G-8IBV-HJZM0\$FOWOHO.K3WCY
10X;KX08LK4L:M77XRIGEL4 M2\$>+20 KD6G20.5&20>=362749KRB.NNVY1T<J>1SL<Q>J2KZ-OZL1 M3W<=>8\$YA(8&/-6E:C67X&CQI09;
<@>N&5+1F8F.0J1UHBBZMJ-OW MZ&BWWGGT\$%LJN1A8I<C>C>FV<2- VK68Z2J\$F25/GS:G<DZ-GA0I<M-Q0\$9N72 M07+YIU>2P?>@L8.
(4SPD<C@20Y9GN>2DNT.9X0J.0JN<D7K M-FW=>@>@>LW:2EV<=>G/OIO<M-C1TF5F5YIB8N&3ZK5KUVW<.&2@O.A44+M&\$(I0%-3IV<@PIS-5.PIL(I@-B)O7\$A4I1PV<-
OF>2I=>C95MBP.MH68VU.IINK<M674EIOKV630&1T.VJM.WW0&0.3-FE2+5THIO%B@.(BQAXI-MY>C/L2?H67.7CIP.0B530/B&=NGO:F5\$3/GU/H.
\$E215OZ2N.DD M17H(SJBR-7M8V?>+L 7Y J7Z&RW7GX7%L1XW6@IR4P+5996)-VXMGKU@ M1-PL>CYLR>S/LN1:J94ID9>O7-0H<3/3Z+>#PD=FICXK6XREHE MR?
C-1BN<C>C<X9291<QM<PL\$&ACIN>=>HJUC<@/8J>WJ\$D0<R1.MCOYQ7J5648S<-(4C<AEV1-29<MCKJHNP0WV7=>2YVW17535<@>9K?T>><44BW>R<7.D-0?>2D1+DR
6G/RWN<FYQ065<M41\$5Q+>L1955=7?>2D9SUHL7G2BHD0<6AU@ON.HJN"NA<A8I0M<#>#TJ@<X-R-U-LU:GE6<G<3V13Q<2?>FL.P1Y(OH1+@<W17 MGB-
Y51752LC.NO2X81LWY1<4FE4T.DGG#4PM<=>5WJHMRK1?2I7ZJ1 MWKI@<G. OS-SL<YU7?H1V<@NIH1N.WMW91.VSGS<@YGHJ<A1VPH.MNH(A YEG<+U.GY?8F)V9E9?>
7UA:6E1.EI0FUD1V7EY26%4GJZ=E9J9.MD92>GEMD073\$Y>7E:PDDBRTN<#>5Y1Z?R8GIB0D1F9\$S.GCV>Z/SL1GQV T.J.F MBL3P%N.%?>
7PD6J> 9KU<K#AHL^2FW+^*XI4N2K+4M^2=GJH\$F0I^Z0T& M010YS(A-^T):5ER4G+HX>OI<^2TU.G-\$HBR(\$ZDH^Y.9C@>^4^THS\$1+2
M\$E(RT1.RTK<BTFAC<696GCLL<^EYB<EJH.DPR.G9R1G9I25EWF.(Q2HHY<@& MDA7E6.6DYIRI>>..G5N)2?Y10608HHQ8F63M3WUXI3J#P00A%95\$12F=&8
MD577D9V5EL2FC<..9D1CX<34B1H4<#>PPX2(09>..XROS<E@>H M J 3.L<=>UEZED17\$J1+L1D+N8<=>BBA#015X56%1Q/(M4/>4.Y151HD<@>Q5BR
(E9AC<0\$B1<#>MSPSAGP<DNY^B<C2-G10+I<@>(E629J?YJF<H%>H1<=>76<I2H9.0?>H1T<=>M<6>2+L45581E1(Q@>1.55 CBL1<+&=>8F8M3(CY(M52(QX0E<+T@>8
D8H1MDH11HB0DBS<+1+0.24P4E4H<8U<X>1?>@>90P>?>2?>55Y?>@>D?IC M1+1+D&L25GE7DAQ0+R.HB@>0PE3Q1AYK6<G&R-T&X5N1LZ@>AMDYHBT>8I MP
3IK&0?JGFIHB.A:))H\$R(A)(VH D<*)H8^L#>+JBH@>L7\$9I:@>DJ1<MHB)3V1\$)2&@>C@&E^52DTL1^C>P)HN1Z>-G L+PH^H%>XH<8W=9DI(5R5
M\$MYR152GGVY01M<L.ZCTK1^F52JVH8@&A@F002R2HQ@&H S^6&L<^YB^P^MDK<=>1GT@>K121H2V42&M0+2/P<@>(40C1)^0*0)10X<@>@HD<=2(BJ/L@>H
M55GEBLJ3J18DGA1AEQ^B<@>@>L1/AED.S1F^T>^1E67266R(1T^G)0&0<1+1#2&0.@2 M KU4U4<#1PGA011TT401C1^>T@>7Q.2 IRA9I0G6#B&C<+1+P5Y/
M/>#>H0UH<1+>+R(A:U)>@>TVKGIO<EF>Z\$>B@DPT#F.1\$1#>M<A#BYVP MS@>O:DZV1-N3V<C1U0.3R9&<O>M8&C&WIB@>B1J3CM1N<2LD6-BZ=>1LU+E
M6TLO1<0\$>2(C=>TJ316G1U?>TFL>Z3Y14+V1E1F7RZJF<L1#>+44&+M<C.MV.W:M^A18WJ&M81+7H2?EGC5?Q51SW2J2R02Z2 MLH9I&D<D0>R1XTE@>GKX<
&N2Z\$1DEZZI&C8.6+>DX^*8LHST4PN+9+>B0.6N^YK<D=9@N8+7?M<X9U0S1 M>I<3SO1BGKTO>7KZ<#1<^YVUF9FVIOA^A2AJ>U10^CG6<^>.%MSLX\$UK
&#0A1U<O+>C<5>5?>I2A2V1W5VYGRG9@N8+7#7L19U0UP^M^W1L1Z<35ND<@>U117E2@>M0?>7H<#AK30TKE1UZ5\$>#>X<Y<C6D0+ 0S.04K&B+A&2&95-
2.TZ=>M/QORU1E=N.6^FIE#K1=E=65A1ARORFPC@R(P0A J87V8+4V1@>ML^RPF M6/GZB1S1T6.7 (HQ3TM-VIMGIMP 600?>NYIMV.SADXXW030#^H2.SY2
M=10M\$>U2E/UOYVAY>S>L16;1JW1M=2?G1N3J1MBA(VJHBA&A1(V3 J58P6L1&3^0FFBU+1Q1Q1F2F01<MDDC5<9+13L2\$B>*>41/Q000)80 2&Z
H2Z1<#>K^F12U2NSNLS6E.O M.&S1Y<=>C#&FCG17Y&E<SJM.OY44&5?^A1D<#>10I5.&8&R0R16 R9333FNG M\$<#>K<BT^GRA<=>K&D.03N0)<#>NHA.ON1H<^>N2F?
MKCYLT6.%O@SV8? M.ZRI?R 1O.K+OW0>0 1BHUZ9T0695 / 3 F-2H0P-IOGO /AZ6+1OFF9P_PAK \$Z8ATCN@SJ^@ P442?ZRT01XDPH2)N#H/M^*(%>#>B:0\$?
DXZC@>H2HAK05=&JE@>1KVQ1Y1HYGZ9Q.NY9L(Z0=>7 M JH0WTS<=>@>IWXN<X<=>=>5LES<X^JM 3.LJ4W TAVM<@>CTR1K13Z1K
MO<ZMYH12 0340# 655515XDF2.PGE.E^3\$P162A1<#>#>FRGM<04JAK M^N>D(RZM<1WEDCVBQ9215&<@>@>HU9I>Y15\$>#>2/5=>6.RF49D1FLFA0 M1B3ZM1#?>
#LBRUB69M.8W15E1HR M+PINRU&1\$A537#<@>Q1T>0#6H1 M)>3&G\$>2>U0TS<K1(KK9.4A<3<K)>I.W&<VL>JH8.LU0.U J72<=>#>M-D3?2498939(P-
IAB41623UA1A1815\$.PN:7^M6<@>P2Q1Q1\$Q0SW<=>XNB<K4K3&AGHR ZGN6O<L1%>+L1&2V1D3B8.IA1UHT3J+1WE1\$<@>E15^4D1U1M.N
M+1+1+Y#M^M75171\$>D^MA=HGVC<F^>S^>L^>2J6G1\$ M1.8.HDW0>=>D61\$>L\$>7E+H1@>F^F1^AN &H^KZ\$54E\$>#>0CH>0^ M:A.AYVE-
C1>2>B2^>B2^>40(NP=>3VR7W1WIMZK1JE.F\$>H11\$>@>EV7)MS MZ=>I&@>04E9N8.37>W=>=>8&1X1>A035Y.7E?>WR+H2?>5VK.F@A2555)DCB. MT->8DERS77VGIZY<O
W>3649J10L#?PHY 25<@>(RPFBC1B.X556\$S M^GAB.R691L1E@>2KJ.RP087(51^OJIGJ 26GADA1>X>B?Z)>U&NQ<^IAO>@>01XG<@>#610D<L1J2M>U^PVLP7^M UK
#&M1.2P2HR.21+D=>4<1>@>4N<@>@>1\$>F&8&S<BBDFF<L1^454I@>MRPHQC Y<3\$3MJUTW1<3\$>5L<2JHJQ1\$>6XN#>@>S.Y.R0C<1&gt

[illegible]

!P15%T>=>N<1#HT#%\$9C%\$ M163%}[KROJ]#%E2.P1#=#D>1> MQ291554.RW+E9>7+EZ.LWCT.PPB#WF#RG6.1&4UITQ^^^7WCIOHUGSU^4EI># M0P..X0&2LLKICJ/>C<2%#A00Y.S%>2>GI&S%O/GTFZ=%144/SI.R!\$+<#QU.ZI<@JAE^H".S5NYW.YSI.=NU>N.FYNI>=>M2? TZOG0.#0HKY+JY6KG2ZGIGF.#G28K@.iX4%3NN< NWKUWIL#FAR.MMGMHHL#AT&S#J.DIDP#WO#RESKJATXN&39HLRH+%/PI/SIC8V+GSIOG.M@0%+<H#H?7GKRZ? 3/RY+C@.O16H1L=>SGTWI20X?<@2X^/AH5/G#SEIO# MB+LS1X5A(5B?9.POEI.A5YTIOWW#B?6K<=>.&72RY)DI=<^N720IM5K2Y<@PJFOW+TW.M8<=>.D/A^BVF. YHF39ER=>H5A1JTKL16P.OY.GN>3.G10<=>#610#1B?H.M1D(RD=<1#HWM3JH=02&RC9TPX45^JW>97.Z#JK MHR.OWG.HJCF#EJ.HMXN<1#<=>O7%G\$&7> MQ9JKFIJ/GSS=>1%W.M8WGMW+2QO.O7>2D%K+RGYJ>2O>9..#)SSI=<S9H1M.4.M#Z82&88=>YV76%\$<TN.F^INT^5%JM5J=3JO3)?>M>..7^Z^S^YZ>OWT MQ2#<K)XKKI>..71^94^JW+SXT^G%984.MTRP#40.A4/CK<1#1H.7O>J.FL<CK4.HD3@<8442E6KUL+>ERU<=>I547Q? MZ1=YN.G6N0<073EZLK5.T+^PALT=<1LY9FR<J?>HB^92?>DHTZ<8^NUY^3^M1QW>+W1Y^E4?3N?>??ZHJRC?8H1QW^6RHJC1XYG9@PT&KU.9M^DY1#? M1X13+1QIGU1P.X^6%?FGP7625H1U1R.#H&XH=2@A+M^V.M^M/GCA4H6M8.M<B.W02R.H1X1P2R>41#<=>.<KNX^F^U@C.42S^T11EL15=N7P1.26S84? M16.2Z1ZIBGVVUWNU(IUOJH1L.GL0HT>2P> WHEIS1.MRPS&JUEI6.M+J.R3P2RH7AC54JE4Z7.63(ZZGRBK^2TI1ISUXL&CQBH^V1AHQ6K5M5. M1+DKJN6+EL9^SBJ5.3.1.6TWOJ^SR20P3=<C%L\$@A551E2^63M6.NY1.MJ1.5E2+<EC^UJZAK\$<C0D087JBX.L.P+UZEI^55P1.^#H#1#<#?PC@<HP2Y^<66ZVEUHKD1+G M1+<INW+Z19>NV@<BZ.2&I@<UV<9%BI<K1KQ<6%01-WI-05M75.KQWH8.M75^S5N^2^VOGNCUNZX0.HJ1^RR60<1D9&J1J-B(BXMMMOOWW1 M^<#%145551MM890+4J1#6XPG6Y>NOQ57EY.KYV6J.B71671FL6B%\$S.MFF6>7^PT<F15H3U+1UF+O^KRO.D/SR+K.A1<#HBT M5.F1H^ND#SW.? 4HS1B01<K^PN/CP.T.#A@G5KH>D9P1H2FKBQR>YHB15.MU1@X7P1#AAIYZ17.MV1=<K.F7R1=<OW7.X7+<B&X&X1H\$S=NAWJ67LX^E1MMPUK2.K161<=>S^9^WKWL".S1(M.<#L770J<K^JX<19.AFC15H<C.M.0.B0<2@<C.V.NGGU1GWS@TP6<1/9A.F390G4JW+<K(OA5Y.<A.MXOJERA(AJ)CLTP2&IMMYZJZF16.MY2B2YEG6DD67Y9T^? Y101.3FKB5T.BYF.YE^O74P9.7GD1H.C1+3Y^V^1^9.M.67Z1=<F@R^X^X^?F3O1P1.#A#T1H4JF.B8.K3QW^2X7+<1^BTD81(AJSBTK+YWWUG.M1^Z1.WXG4>23&" \$<66>^V1#>..#1E1&W414V6.PCHSL<WVZR@Y1.Y?+M<C^V.BHK:OVK605<=>K.WRRR>=<F.72D70WRH\$1N^K^B2XG^KEAR#V4.R.%S4Y@M.480+1^F 6NVK^H+>=>Z&Z^9%<@..10JIN#<#<D>=>[< MW.WG500^251E1BX1.21H2Z?<H359A.C1.S.670T^22^AB1+86E9.0J2.M@G1TV\$S.KBHN+@4+Z^4(^<#>2=SHJ>=<6@>)<P Y.G1QTXV^DF.MUE.M56B2&6H^Q^OJIM=<1^01.OY12A^3%TM.R3Z9P1K9X.W^0?<Q.F0M19512.M<H.ME.4JN518H9^DEH.551^21P.UW1+1#T@<=>D7KH1<IK13\$>1^TK+RRN& M1.G1QTXV^PF.#@<E^96=F8Q9A4.PFMS3L^O1+E25M76&@<3PL81L?<C^X9.FRMB1M3.OF.FOWCY&L2<66XEF8ZVU.M.6LVK0QO1U.JU<(^/Z>#H.2TM&2^EY>7C. GSGSUZQ7#B..B42^6EY5..MEFNKL1..#10F51H21JUV9W^\$A<#EJSR&4Y150^P2^3%Z.R182<=>4^5^K7&M8#1.G63FE2<=<.<OM\$1X)PZ>=>#TJZ1S1.0FHZ.8^>BPIX(2%#<0 >41.M0E5X915JR(BH05^<3.V11^W&YQ3..JR@5&134^C1+YX13TO+H6+1^L.M7K2TML812A^D^6Y1P47157612M7&D>2^/S.7CLB1TBWRH".KHP.G.<^?1^M1 @.P^7^H19VYVP0-AA.Z0<=<=<U>0>10>#ZHD^D3?<G.B>#>=>MO7U41Z?<6&UW.#B>1V\$M1(PT^<#?OT.KO^W.610>B>..Z1J=>YWDZ! MR6)YGA\$<P1>0#MKM1F5^ANL^C&GAL/KH9..(A\$F#F&RN5>S1G4&L^E1^M918H.(A8L+@<C@11E2=TCF5&VW^SOV+^02.BD1735U.D10K@C/OX1H MNZBHSU5.<1>#7^?DGIG1P8F8H1&2@M1+J^Z.AIDX^M9NYX.N7^2P.MB\$%<0X8.V@<A@LWAD^P^<Y^G^M6<@<OOQJ7B6H^6D.0.C.B1^1^> \$F61+OQF>BDRP B^H.AG2L.MW&7Q@<0.N1&N^1^BV1P.4&S&R1TG31H1<^YH1QZS8^T.J@<B+1^H2KQ13.M69G99K.741Q10<8.OGGU0X<=<S)81Q.O.CA4X5L5+YX1^2Z.N@<B.3&R M^A1)2O1E.^0Y^95N)JG.G3WWRU1WGS(O24X(O.P36736ULHY.BY(MD(FB)WUROK6M^232(C1&D&S8.B.2X.0R01.W#<P4P.01A.M2/9M^3>629TH1>1^DINTI @>W304518).B6:NR1#1.B^MUBA)@AW.MA2(M^<O.K9L.MGAT+<C%(A95\$>^T.JHZUS?M1071TO^C)JZX?A/U>H.6)D.MLH@<8..#1T4E1\$X<=>^<FY17^08@<^ C9J6>6.TV34K#<=>Z79584QF>DT0^NT^<P^%1.LG1B^4K^1L62<=<#DR<6^C1.N3>.<161.EELM+PA5U^5^1.M24EA86H1J^<Y&P.D7R^NL1&E^/=<6EH.Y1Z1H^>..G:NM5=5(N >0#1#>N.M711T9AS5.221401PX^<N.M&K&F31000.S071W>2A8N70P1?<3..MPX#H1^A&R.E5UJC5.DUWCY^RU>N.BEUYM.MVBV1LIRA02)R0? >6\$#<0RBB/OB6I^R9635UO^<X.M.OQ0S.<6G.2A@BEU>=>WJU6M&GN86P.F61SBJ3.M^F@UKDAWNS1^U.ME.B.GGY=<6S#<3^<C&W&X P.H1DG.ZY8X<=<0^U.OG%3QB.2HUPVM6+M^D^2411510^XG<Z(C^03UF2A1H7X#P=A1-E.34V5.0E1PZ21TD.MD6^D4?1EFG3Y69<=>XNVIHU&K^9. 3H1>0716G)2<@UVI<.<7V)G5ZF^8.MF^2N167G=>^9<^CY.<O<^3Y@8T+213F1>7H100QW1Y15R9(14FB.A1)BV=3/Y@V..+<M>+<D+H.M%IX:TR.A%+<1P8P%AO=N. M7U91947105161U<@<OYW^E.IK.R)@<M.C.W^16107P+7227&X^<X#4.MYB0+BZ)DB3^<X13J10H=N0676^A1J1M^C935X^B9>O>JY^E0.71^=>F9.74NEP.2A&418 M12NX>90X&R>2.A^<130J1MRAX1<@PV4&4J1S1.(O1P1&C.GN.DN3Y^TO^1E.T01QNJH>?>1Q19.7RF.ZD@<0.P16.60L2<@01^M^XRT>..? W&3/3^<=>RDF&S1R2NUR41MU<0.38B.VY<147C^<=<=<NN.UH)@NW.M4/H4V1/B1@<XUB1=AT@<^\$42A^C@WGSMT1JBV41Y0^G^0L5.6.M^1Q.<1M.HH1J <1+1O1G.MN^T17^<17^2F1B&C@<0.6B^<C.GSD1Q1..

000Hw:2*22*253*25#ID<L.M6ZB14WZC/S:UICYG%AZS8@+GRI>_Wl.M@f.COXNE41%48N_HZ%JUZIG86%P-BHOJH5.AX0\$*6"1B<6NKJXM6K16YX.%Q3%>2GJOI(YDZ21/3H4?7H\$PF571#@+T+YQICQW QWUWLW4.EE M1+5Y.3F+LW6W1R/2TM+7J=74C/OH/Q1@1GWVY6<+>.<2<S?TIP:~>6f5f~M. M2f1@%6f+@OVMWKKXNHJVf==ZQ9S5C2*G293*04BIR-1-1-^YA27M^ M6>2+13K^=5ZK2COT1@~7471=O5=26PJ~9*AR YE 7YD.FEGRHHT@EATf66D*N^%E=&0! M^M^ (051 CZ-4DZL\$S7MG6M^#RP(KL)T.5E(GI)8/L2QOL^M9f1+>2C%R-8L7L-VPDWX3Y3K0PDA/C1O.0H(E4KE MZMKWTT2967f3f1B%)4-FS=-fA2D_SH\$- :COANPZ.B9fSf. @C\$KdJL?G7BSE@~*9HH\$R.R.ID^9Q6VZLJ.U#1A2H4S1+<(G<1B M8MCO\$TN^RTfDS+U#AE+YQ>V.08^180T^@>OJL)9ZL.Z.CP67 M0L1~RHM^SQRORNN/1@D7DfD5D:D:6EVA^AHTY<1>L.LW206_3EMf2V^9TADGP4R^Y&T.D55+:(G.C.SOYH\$S=H44K(A&(1(9?2BHDQ&^4A2\$~MfJfW39@>^Q^\$0(f2 XD3Q-72YAX1\$=6^?7LGIR>^OROHTY^XKJfL1>1=O M^\$S=NG5P^<~&^V^=7Yf.<80D^)>^P>=90N^JZKNFfM:P8<=V>6E(f1@-MFR@fIO.C4~@&f1-RfO-N7.6C^f1 D^MJE^ERN^E2PHT(HC@+V+CfSR<1^f1MPX ZR:(8S+7fW9M2^P>^1H(A67GCUAW^LNQ9?+f483 UB09^CTATON MRLNO7Kf1f1OH0:~\$BDAEfKUFH^H8^#DH (7)>1+10RS^P4Z= T-1.O^>Y0PDQ.SLKfY.1@>WNA2N4BfHfB\$7B?>fCf1 M0^@CfS:21@>85 R4fL^U@>P\$8f1f4N3fL>^>4>+>=8Gf1Q M11L^>^C70T&VY#f1 <^G\$D5.NC42.15@>0P4B7?QCRN65Z150R05^Y\$S4Kf1 MUZ3QfMfV1.K0f13<7+>fL@Z2f5fL^&U&00.f6(3.FTfP4fL.Gf1-83fB=B=3f MG<=3fX3^>D1\$Hf40Nf3fHfP5fH89f7f7Kf1\$^WQf1\$^Rf1(f4^X8f1^HJHf0.M^1JM8^fSX\$>V^f10fTf.6E^TfZBf1DUE9WfHfWH-3X5f5f10fK0XK^BU M^A^S@+H@GN.P^f) M6\$Hf5^>E6NGN.6?>^S.IP.21KD-2.W^fMDf@>9>fLWO1Z@9f1Hf5 M^fYf MWfJfZfUTfOWY^+C@>Df7f.3fFXf@fZf1fHfSAWNf35Vf1NKU9GURW5Z<^#AYfV M.X@>S@f1N8fHf1fCGNf1fFNGNf1fAMH\$Z.M.VfP^25BfRfOPf=C98f1fHfW.WADE\$Sf MOf(T4@>OW=V>K5^&EZO9fXG-8fTfP.O^f) 60A@>Sf1>W7f0.15X22f1 MR=^fHf8fA>@>? f1YX^f1H^fIANOPDK0f(E#M^>YXG^8f1L).LEWfSf9fM.72R.M3@>1 M56D^H2^&A^f1N/f1>H9A.MD0^#6f3f1f1\$3?>^f1E)06=6P.M^V98D2^2DYf(CfGCZNfHfHEfAFTf. FUf0fT.MX.M^100L03f10f)9Wf1>A M@>f1G\$259fLW^O^&f0V9SfU^14UW^f45f1MfWfM05^>U9CEfM.M^<KBPDP^5VfG?>@ M^Q>O7fU^f1\$QUCf1\$%27%<?>f1JTLN.158X^ (fKfU.VD^0.Y^3M_>^fT\$O.MfM^>?ERfN3fDfHfSfZfH70f1^=NS4fC>5H+>C.BDDW0.76K5fJX3^f1A.^+Q^C9WfP.Cf3YfH@>f1^Q^U^NfGfIRfHEfU.M=f1>^>f1^&f15fW3M3XfH@f1.DfLH- Q>7+1@>T.O.W#<=^>7.5fO)9fA^>6fRX+>(XO@>^>P3BfQfS^R7GfYfX^f1CfATf MJE0DfRf1A.E3f1MfL)fT^<fL.GfWfU^f1^fE^HfQ4Wf17=MM&4Sf1@f1PN&4HBPfTf)~ FW:4B24f1PE.80B^fOTZ<~\$2f13f1^02f1HfP>M^&fTFE\$B^Hf4fH@>~<#SER<1@>COP=VfGY^f1f1+3%>~140f1NfV.09fFIAT M^>1005f17f1&GfY=Y>U.SfP50GfP2MD>@>~1+2V>5fCf1XYfTWfL.GfV^fLlU@f1MfQ.MZ3QHX^<A-1>WPDf4fPFK MfHf1<~2K35Z^>^f1f194%Q.BP.f1XMT2f.CfDY> (6G5:42f+>Sf6SfNfN^9NfM^M^<3J>3R>CfY^>S^=LUAEf1GfV^fP\$8f1Z(GXVfLZSSP\$8f1BPL2f7fTfP.M^<1>QACBfHfN.XRfQ^>W^f142=1%K63NfTVf19M5S UQfKEQf6f1f0fE0X^f1B^Q^3&K^>fDfV^fMNUf/GHGf1^8PfUf+>f1L RRZfU>=>G25fHf1fXfE^>Sf.HG6fBfXfPf1M6fTf1f1HfU\$>f1AMfM<~<6.R62f1f.6f.TfHfBDA^>N^f1.Sf3Df^N^+AETf% M5HfJA^&X^>Z0QZCf1PfYfVf1B^Q^3&K^>Mf03QX^>MfMf8\$00B^fPH^>@>~#0Tf%>MfW.NO^<~>W+>Kf18<6KfHfX@f16K3fSfYDfO>7+2fO-S6Cf1QfY^>Q>?>SfYf M6^f694^Nf2f) f1@>+24FfH^f17f3^>XfP^O>8+<5NHVfTOLfK.EUf1f1M^<C3fL74-/3Vf73RfUfGf1^>^\$>f1V8^&GXR.N7f1L2f7fHfC9>7fTfX)f Mf1<^>0RZfO)fS9fTLG&30M^%VfSOW^>2<^&H4Q3f Mf1<WZRf1Nf10fKUE@>@>f04Df1.35WfM^>P.LPMRf12P2A2f10HAGV^1=9f12A^>2f1MOW4f2KAUfPTf1M^>6f.S9S0f136Uf1\$>^f1Q^>3R2f1^>f1Uz1fY>2Df1^>f1MNUfQ>3<SfX>f13f15f YfN8\$>9fL^94f7^>M72R5f3^>3f1HfWf1@>^>42@>Nf8fTf0K@>f1B2fHfO^>3f131365f\$Kf7fZG@>f1G.Mf160fTf15.N^>6fCfH294f1L@>f1WHfQZf3(25fE4f2fTfO7fVBR^fK>X>U M5fPBDf10f>52f1OYRLfHfHfM6@88fH^f754A1=C.G8f1Z^>N2fU^f1fHfTf2P2^1A.MOPWf1^8f3f10f1+>3Yf1f1306A5f.H7f8fBDfYNfHfO^Hf7f1QTTf.DfHf1=0 MfQ5Gf1 ~f1.WfMfTf.UWfS9fWf1Bf1fOHfMf.#Y^>^>Hf.F=QOXf9G26fYMHfY@>fH5BfJ@>M@>f1=1A)ADfHfO^>f1+YfGf1P^f1SG>^>FC27RfHf4f5fL0fE3f1fTCSfP2f1Nf8ZDf MX0BfAHfOHfH^fTfO.02<3fTfCRf1.7^>E1fE)Zf1f1f5F0fL8^>?>ENf1?>f1HR8fCB^>7f1MfM5Zf1QOPf1YfHfFfSf4P8BQDf0f.MU^>Z4f1=7D^R2fR M6f186QfN^3fTf1fVfKf1f63fTfA^>B^>7R5fFWfQU^>X^> f9fTDAE^>Cf830fWfOY^>6UWf1fM^>Q.M^>KfU^>R4^>K^>20<4ZP^>1?>^>Q4E5f2MH3+>f1P6f1E^>M6f1K^>BNCfGf1^>@>f1\$>^>O&A^>0D^>2f1FBUf1^>f1U5fYQZ^>B6Gf1Jf1fWfMfUc f59fTAE^>22Vf50Yf1U^>f1LVRfVf1V4K5fVf10>3DZfK9MfV^>SfBf1.23f1>?>f1PVf9fCDfY.M^>?>CPX0fP1fMfL^>SLfSLfP^>2f5Q\$08fXW\$>QXfHfU^>N\$8f1B^>HfYfBGfOYfUf0fBfM^>Hf3f1GRLfQ^> 1%>f1PBIEN8?>ZfLTf=P<~>^>68>~>f1GfTfNOWH^>@>SfM^>W6fU^>D^>Rf1fF3<~>^>M^&gt

[illegible]

x%6=>B2/GCQ3PLCRX014VHCN.5%ZL/0/>L4G 1C24A4H.5K%5B M3%COE+SDLA WGT(FH3*UJ0U+J)J3.4%124%K3VU4Y4A6E6FK.FSY89E<2>UJ+FPF49&7G.7%6A.C8
 M1ZP(XSd\$ 4O27)20DJG3NHN%PB#++M.L2Q&S9LM+*R*E^<^73IC.RB<B\$<B.Y<1^7M(P(Q%?HIDZ=>U?OQJHT.M.NMOX<3ZD2187P.25E<1)H(K@&\$F5L.C<1
 IL<SEM.IN70&+2PN.M.<%(#T.7YIO 9%>124F>M6K.1034)DU.LR10%>7^SRJ9G=4%#M<9519D/0/ (874C5+5RXL+ERN?Y>GJF<+G&F801&E13+*-.8DKK15NI
 M0XLD491.143%01.L1F/AY%KEZ?02)>+H.1.1E4(4F<^Q3NMW+PQIOT<# MBXN+844..>JSG7C1R7YULD5BR%GJ00P5 14Q/+X/G>..D>YJ95R27M24A
 M&(6P=>+E>..FV7QZ0.36\$&14R21.NW..<M.L1L5M6K5JH>N89(VLLP.M3%5AKRNI.U6@<+J.Q.C.BH0..M1J2PAHY#W+T>N6G.RX0&>D.4)># MPV<S4=JY2
 6>1>+W6UBDI.C6G3ZC66<B31A.P.4\$(N1).L4A=ZELAYHYK MWQK.R@<^A67&AA15E+ONB+@R(RP3P8PDIGZHEFA)<#S#N>..>G&H3D3669.M3K9D.6JLK&366MOT#
 IT9=84VEN>P+>L2.ER9(<1/P>MRX<05&LYG^H<=<8\$%J^U=>1%TSYK8T&90>N.U96HX>C71MZRAEIR.XB#(GR^Q/PJEL.L@K#<Q>87JE^U>INVIR^>HGOB.RA&67V&S&
 MJU=OFENW&6UVH^<^/1D1(OR1^A^H.D.1%QGILUF73Q08X>P.M/5<^M(GF9)PGOY<^W>.(THH/PDQJW7H&09?LOF67^NE&C.VG7U3/L4.M.HX015(W94+5T@1<1
 <6214<6&37.WK.L15O\$+12Q1Z98C1&A5F0<1T.MRY2Z>F0.<1\$NFTVWIMCM4VWSDX<^%=>+HXGD60ZJH7&07B9H45M#1K2K5YU.6N6GE67&134M^JHOC0D1.0+H5918H&88P
 N4.PE<^>H72JPO4C<1YD1H1ER63QDR.MAN<D22.NB5U<0.1.A#M#JEL.F^A184J3B.Y6<0> MW.R&X(L1ZQFJL)<3\$NTIN.#H1(T1F1C6.#95%W6%0=0KB(HV(CV+Q+O
 M9D1D<479.CGD1N9&1HEG212<1Z.L7L6X&39MMWVK3.YXNA@<4.B.M%CF@>4Y56(T&HE1&=>S7^N.Z^J^O01=>3\$N1^7Q/>+1SUZE.HV.KR<L.M.
 I2.K&PDR0S+BO<Q^S^O@SIT.XX3^>N+Z>1AIFQFO.LUV#<J8<=>=>D2ZE<018S.BV#G4<^P0H4Q^BHO5BS97>N014.%VA.GS^H1.M&DR^R^D+1^+2M3QQ.ZV?
 HZ>+M8XV>TO*#<#<F&9D9F300Q14RPGJ=>1.MF.<1#<8<=>.%?>M1D<14.L4.R^O5.Z14+150&J77OP51H>#D0.<4A@<M.RBK.W^W1NW1W+M+M^F+>8Z^<?L7?
 Z>=>V81V>1FAB.EC22)YXND\$W6.MFSEBLXQBNCIBHYEL1V3D<18Q>#D23T>U6HGK.L19BQWR0D(NAVSVK&?)>M1(TRK N0L(CZ73P>?<CMN&#K01<S&9>T?<5@<HPL1<:
 6#^AM0.EFTGCGUZML.2V3AP42.R5/W0U7U>5X^>..SYXKU.M.J1LL<2.VY-H MG622F13H1S1>=>+V.L.#B=IR86=2H0U1D>+JOS(L16LH1M.
 JE=>Y1(QOAHGU.<#D52125E.G@N.#KH0WY1^>JY1HXK.MQ0HMOEPQB.IGS<^<61P.LD^D%065Z201<#MDNMCKX7G>V>T/F41.X4+BLIX.HZ.R=>63C7H&+
 <#E90CLQ>OHR.L.C(MCY.R^B>GFXPT288423J>C)DSZ<69VCHZ1K9&8.P.G@8R<A^N<1@<M.L.1\$7LS.R4<3(K.RLG)S14N)191A&78<66IO&QFR?RM?M6:57^>.>G&F0H)
 MD(42S\$1<Q<#B01.<#YVZ1Z9=5M9F1Z^>*<06:LO1<#<G&S&OV%#M0+>1^MS&W.M:IVG0.<@<=<W&C^<91LR<290POXL>T#<M14+<#VCC&@<RG@<NW1Y+M+T+<
 \$1@<D.J.1^>Z=NO<T.Y^ATN^8T>..<Q6?QOQY.A.U23JHJ/C.NNB-M69.4Y(DEHSM&E.G1F9F64<T^E^<@QJZ.F1+U^E@N+<3^JL@<R@<LQPD7M^RH&+<
 <^>J^YHDO#923>QD1P>..R^<V>MOW.M600V16-C8Q7Y6<2G2D1.0TB.X+58RRD(CSOW1N1=<G08.8TOP1^CYRH
 M4+>?>2N1X&MKEY.K2<121^>N9S^R698H14OX/G^N^WJ^PFD1B+2AG.M^5<VLOMT0185(F10S2<4<#<#UV07H@<#1-REMI>+V.691&HLD9D9C>#WF.
 <7>Z.EU3%60L<57Z.D9DYV.S81^>#1.GD.8&3<3.WTP3H>>Q7^HONVH@<B=<M^P3.5MP2.L^>6HRH+Q2BWZYDRY7UJ^>ZZ>XX21D<182Q3AN=08>?>PD0<.<EO.YE6HY#US
 MUIRB8AY2>+W1>..LN81&C^A3M1ZP>0>TH3EG78>1A14FPP.#QDQC.S7.L&#M^N^D+K9L179(2O//>SITF%<^>YU>M6E4WL&E(RI8K5X>F9V81N29Y(D+M^3%6\$Q@<K1^>1
 (E2=D9.YW7>3.5.KY3YZW.A4MR5PPU>..(S=W&S&N1 MC>Y8)H&DLEL.C(3H1^>F5\$#BG30K1^>H%>14Z>1BE&2.2^>P3V>1.MTKF&B.DS91V>4?<
 <@<G>DS&^>Y+ELB<3H6&^>YOWJ5C^>.(X&E.2KN<^>J^>M=O6MVLW7GKUSBXHJ2>69(PF)E.NB8C(LW^>D.M.T+>^>PYJT2RX98L61S2HWZ1FTV32?
 CGXFL<^>#E1&02182<^>#AYHYJF.MK8.7KUS7&8Q9V9F+ERP(CGV1U.UMTH=3T9>NMM&^>M8D2(9DR&1^>#U^<^>
 M^CVA0=TF(X91^>Q0A1>X.M.S2^<4L61ZTUSBY>WG15O^L.Gm3V1=NWY09M.M.S2^<G^V>..<KBU.3T^W1<^><ZHS15M2164B#<^>V>FDZ2(CPB(B\$B1^>9R.M.(1Y1Y.PM7KH0
 <^>T^<#<S&Q&R&0<..0#D^>#EUA^>YGAULY1F=>J5.8M.M&ZY^<ZX<=<XO&F99G(B9#<^>S^>7E%1^>U60012^>QO&F1IPL1A+<^>+00T8.MC<+>M5L0&H19K1OSSU#<
 (Z.B1L15ODP&PDD69(3B3VZ+V1/TPZ7BZRW&?#2E<5.Y3\$01=>@.91F&Q82<(\$S<G&D^>Y14JH8.M=69W5^>J3G9F<.(3D^>J1F^>MY1=>MTN0U&C5G>9.G.UZ<
 <@<R1>Z1>EUN8PZ<=<@<D1Z1^>EK.S<5.FU<05^>H3V^>OK.L^>W=GIRKUN08.0Z7UWW<MYM5&K^>Q1^>DDE@<X1^>72K7F1^>7RB&K^>M3V1L^>T6^>D8^>G12^>2(0L^>SHF6E9U^>RS.F1DS
 <3^>7W1>..1D7C.9P^>F+>Y.MJGE(R<^>H^>JW.5<5M5U&GY^>CIR<O1M5V<6&K1D.2 OCV WUGW1^>P^>AHR.M9>TOKU.D^>62MH&73Q?2
 <4K1U^>BG<70HQT^>#P.#Z2&B^>3L^>4SR8RD&81M^>J.2S.M^>TW+AY0U^>Z39H&CQO.3=>3=NV2V8S(O1X&4U2^>BQ.FBQD\$<^>E4G<#<KY/N.T(8558R0G6HFQ2V.YY^>YQ3
 M5.71X<0^>3B6.MQ3<A21BU91^>^>01H

[illegible]

[illegible]

[illegible]

IRT(KIO#6N9&BQ(=8LX>5SU/-IZ-MZ1,*ZU.NJYMN#)WACNK^YHKNO4%+?J,HZ4BM,RM:BNOLWFWJFJFCIKFKM:
MN@:ZAPP.#NDE,\$\$P.K41,.\$>3NDP\$T\$T\$D101M%IG4#A1Q5<0#V-M*X8^1=,M<-8K1-&7A5\$)SAYB5:71\$D6:IR#Y^1@7^+NA,Z&EZ#&T&=-,O-MI_3@7^<\$/(-E//_K5,
^@QA\$6P#^WC.PI_@(-02H^89@#@YI_@^39M-29.MI@4V>U,IT/5^&I#JH8ATNI\$Y/8@.9V/ PX.N^2M6NJPB4^1+ZT/O>US04OKLV\$>GOI=A590W
M+CH\$A(-VO2^8YZG^5WYMM_KK^0%GLI_B7G>AY8NK^8I/ISGKN2MYYZM:IQ+9C-MB76?G/HVY0@&6:GJA-GMZL\$&.,331@MGH79HHQ-81U86G0HJL57IR/V:RS?9-
N@PL(1QZ?>8M1-M(0-1J2LOX:9=DGVEDSMY6^MKN6W.^%APN&7^E^T+ MCMR:7Z1SWE?W/4,K3UGWA0N?1B#1R233U/K@21Y:JT+LRXJJA8X3Y@QAI
M5S+>GTN^KB^A322QEY0-D19ATL413X:6:OM:YM2I(CV00@3^CGMI_YL/I1#I+M+4^,@>5U6-P-W0_4642TE8#61QI^13TPRC90TWP1%4HHBHE9^2)2#0M)*DW
M%KU^K<1^SEKX&X%*IHFV&NFW)*AD(K#EOH(Z#A7UYFE,0^U^LH^/U7-M:U0_0U00EQ0->B^1^XUD@EXY^DR_%91^~7.P\$2_&*^H+FTYKJOYU<9 MKP:435^8:
ISHOSGO3^9LO?WSSW&GJ1I%=Y9UG8AZL4\$#3DB73+J_BQ>#BI^*MT\$^4COI.(SL^VDXG4R<22>MJI#A(DOKR:068,40IS4C@J+^*8I^*JT-M^
@JLD8M:E:16+#+LZ:"X:RI6>8\$@*50\$(D&5HZ&.3DG^H7ISZPNG:~\$S&7I3:2EM:YK-M&EUIVUQI:EQI:12Y5#GZ%#GZ%+GX9L*RI-SX%6==,U^H-MOZZ-VMHPT#D_X2F&(?
D.L8=W=IJ#>L_#9>6SUER?\$(%CD\$) IQCMJM&>^*MO7>JLU^:T#>:/4-I4)ZIX-I_D"8^4,OIPOEM@YL2U^0,V%Y<6_1T0/Y4-MITSWU2D35Z=-,IDI=YILOQ52ICJF^ZNU?
2L_!\$6MB759(N.R:)>Y9=>B0: MKBW8\$N>WJ>RV_-%2A95<3^Z/O:17MZ:75584J>0_#76W?2NJDH-251)1#U?7-M:6KH<-.B3UF14IAFT^2,^B8(f>2:A^.-@7>^XTFWHR-WWC
1WIN2XR-M&@0_V0Z2)8G^RR^(-C%_0U96^QI>809J^%U^L)J23^H40SG^R3^1H: Q9J#I7UK8\$4SMM<OBSAL<4ICJNB-MOZ^1+1JQ+NA8?6A:J-
&K/MWEAR96I91F%_5VE=WOM@I6=NGO:7@MAPP^M-@F4I^*E+0HJDU5P\$-X8?#.C<@FS58U\$^HF>D:1JD#%HJQH,ELA\$B808
M5Q:6I@<@974_1J^Z34MBEHGE)\$C#F9\$TAGCW0IO=OF-MSPX0IB)^N/TJ#2.CYD3=-IW>M0U>EBJ=H=11.0A(FMHY&I@83AT@%R-MI0=8+V8G917,#=E>J)H^
5VZZHJL#C3^KJA^CDN%H#95:>166S<#9_V-M-M8H+,-L7?P:*CBMCI:M%X<1:0.5_AISE^O&8A?_4R8KF&11D-T_RP%_M3VE+&P(-1)1\$%4:
&CJH0%#C#P^/N^@725FY_2,.\$:CL1KNPEPN%L:N-M>^PH>L\$ _JEF^R%#DIEY_QN\$C5ZICHF^_KJH?O5E5YIP5J^+=OIG6_0H5C-MJ<=>#SSVY,>*)C5?
_R3BOPB-AJ<1%3PM3&AA4H:D<_7#IC2^7T31430HOM-MO-&K4H195E1YB0Y@_QCLGM^TZ("T4)8X-3QX\$YH7&V.^+LEI791>8-M/MHW:11WOAB?#0?3?O?##N?=>N^2-N?2
M-%KDL_Y9,B&#QD87^RVOLIE:~S_MVT^G=2YNZU(FAT:ZIT^, #ICLYA^/N^*A-"K\$X-C)X7\$NP3\$C:~+ZRM@U-MD>+1_HZ(31CXMJLB6O3)H0F300-
GOI^QLRMN3_Y9\$2#YE^>L,S3FOI^Y_-M8V_E6Y_="NWS3FR-M+VJH-CEGK>VG=IS=?M:RI9MT:WGR1^1WJ\$H2^++M6.VT^UXB9S:ALMZ6TM:>)AD(6ZWIHS:J?&TA^P-
T92#P9)F8^2I-\$^1^HK\$8=F,D1G+!BSIL:3#DDX&ED^11/OB-MK(T2%,@X:P+M(OR1_6_@GMV6YHUX&8)!-%518#-"F8YO&WTUB_0-J-MI9IQ+?ZK/SKB/!RK1W1D?_Z\$>_%)(L*8^
<N_@O16C(X#1H\$<+4^*&^J8-M^&413/Q&B73H3&E5G=0#^EYI^@)JQ+^NC#:.9?TUYWY3ZL&K4JXXW=#9JF-MZQ-I^%RGO+M
F+KISQ^9=>60BZ^+^F%G/MAS^UB56:W&9_5:>V8=#88^_M>4DG(KY\$1)B00(#!A:U8=&2(680820B7H8\$X^T^BSK"=(29_<+/?+&^L)Z0<0U7?
^XU:95Y=-7AIE/R?>4GJA&6JL1NO1_8N?UL6E:SMIN(MO02:=-RL7+4)5\$80#2/AUJRX^SIF\$>,D"9_7^5PKJ^6E^6_K&\$^/WH
MMF0U+8_@P\$J,EBF^QI>ID=N1<83T2JHXGU<~:RAXN!J_28#N0^N\$U930-M9-F^J^L^LRDFY+%J2:8T3/1+WP-M^YL><?)ED)WTC^X^H0Y^H:-
#C@U^N#8BR^W_VR6N:Z?7DV^8C<0A+<0(GIE^:.\$^1H2%#X-M^*^(B2&1H&QDI&N07^N07%.08YARVKP-MM1<#^UL:N#;+VN63_KS/K&S?>-
>^,K1>DCDQ_UA2W\$>^~^L05TZN\$DK^B-MFIC^YKC:30E5K3EU_SEW^G-J>)DOWCHHH^1_M7H:~^N8\$2)2\$@-^J9#&:*#T#ADE@Q>94UL\$VE!M.K/7^~G^+@3^TF-MJP%DO
GXUYFLB3WJFT=EH^!S_I0D#\$:~@BRF^2^+<A0XA<+DYFHPY\$21%_M:95)A89\$U9)=,4-SIU2Z^&6,69/XIS_**^D<7D:B\$9!_D@.9\$)5I)I/@:R^Q>1M^VQ2I^\$*!_M5,D//_6JH:~QN
AX:Z+Z28^Y_HBSO4\$^X09M^F,E<0%+~,%@f>=>P.P-2-MPX@:2.5K1T7#1F>NS01+^HIP-M6I9D_UFF+3798GO+NK9D^R^6H3:D?0(IVA898>XAK@9@9\$F%D5\$R(PQB_1Y
M&ID(1/LD#1:(LYNE#1)2I23^EG+0T(IY(AO4I:C^Q?2?6QA)RH=^M%9P-&J_MU5)K:OBP:0:H0V-0-MRI^JO_?TOI%K(61\$%T51+1PKI\$J>@!
MRD(#N618:14^:@PIA9%#1%:33CCMO9H7_-FHW?G:~PUY:TLM:59\$Y>7CE^9-MV:(Z?KOOL\$X-M39AWL.KIKZ:7G^A^I4#IS1VY:NN2?R3QG@EV^LE.OFF
M:GLGC^MUV7EUV:SUX:N/%R:6^DDK^E(5OGG2=%1.8S^?>_R:PFE==PIKPYK++C2-J=5=0?^JY-M:&IS^>=1-
PI&W/HB^N9GD17IKU8<2ZGDKWQ9&+B3Z0?UNRY3@%>7D\$^L%>2L&^OH^>7H%>7B&ST^C,I%Y^H\$ _YAI-M:Y:7V9C^W\$ _YS=GO+ _UZY4=>:~M^OS:QZ60?
?3TFH265LR7MJ:~Q^S\$^C_MU2%GZIV/E^PI57BD>S^Y62G3DSH_UGX0-7?PQT8Z42PM^DP4_#13POY^MHL^@=,NOPFHRU2-ID^20)6#TAPP4N-L_SJFM%HCK+%A\$IP!
(MH^PD@6^MHJ:HA:~0^+=E12AQ1JG^1@_1W1NLRD1MMXLK_IX^3N&S0SGUY:IN?^?E_M&7_R2/R+=_SHP-2IK_-6GNRI<^K:)_D^@CEL&Z<^1+W^AK_1@8G-XZ:UJ_MK43I0K
1@PEG+(3P-P04^J1^QESIGA3TZ^=P+Y_IW31^XW#_ID@UF-<0_M:8@H>NJS@%&^(\$^17PL\$E>_U_10)0U^SV%3SDP)9#1:??W2LS_HRR/(0-MOGV\$U)CEU
I=QXGW7HQW6E^RF/SLNR7%CFN++525C_EN&3_9W>^C\$J-JKQ5-M-S\$4CZ^=S@(>4D\$^J2@#@ZB^==>@&0P4GB^GLA:2^ACAL^H%\$E7>T:Q_MRG^9LJK:@(8=JD?
E@ZGI7JOR?^M59_DFIQX3N^FCIAE/O9#DQ^Y:6#%I616I04A)26?W>CHLKYK7V7+AAS#_MXO/U,SJ<Q)-6%UQBOK^IP/UQU^TIO?P>TMTU<(WZ-MOOJAIDZIL<^S:T
M15^3UM@PH^WKUJ3U:QH&M(V^NH91W=TH=TL_96U^:(SM^BX^AW7J#72ULCO-M#L-2K^7KM.(=5H1Q?7UFRIH#15=NO+INM)IVHY7Z.C<%QE_JE:EQZO^A1?
6_UR_Q/GICZIDB?G7<+^AB<6I_M\$X-3Q_MV1U3N07\$SMDTNY:ZD?PZ-M7L^1^UA>=S:S/K^BONFZH^8H5N0:\$5HXI^HQPQ^U6W5A1H:0PD^L_MP^TL
NY6YKID5DN0@_E(GD\$0\$3/8>1\$58\$1>84!_ZDK29IVT^?^G12_MRG\$Z=W8ZX@3)G8\$9>?L1&\$6\$F9_18T:P_4/8B6E.G08_-G^M03R=V7WA
MJ>NOID@9ZO.V:N4E.YI\$.^D/I7=C2R.GK4Q8D4P8-M:~<J_@-8+J(S@)\$_IB^S?^WJE@/16^UF50@^(2/TP^%10NXA-M#Y4=-O?<^J)=5^>,6YX09GC=F>=ZLE4>6?
A^OY_SUI+K6!_@X195A1_MM_CQ1:~Q+J2_.RK%NH72^LR^GHZ_ZH54(N>^~^H0UDF^*YTHPZ!>GU+00>A_MZSO^HEM24=1^E^THX\$^&H)ES4W!=SFTV1=1)54/QMP=B
M^*NB_01=K>B16CD87C9PQ=G^Y\$CUK:504?R?0YD>7Y>Z74XP^MDNN_L)3-M>2N/I<^_E_C^HLO^XQ:L5F:\$Q4P.CW^UC)K\$3_1+G>^?>=D_9ZWEK-G
MQEB_S+%^F0ZIV0ZIV79<0I^Z8I^?>B>~\$EP^4IS79DS=D#EU?<T!>G/M_~Z>M35GYH:46:&79J^~&O1Y9G!%Z8\$G)T18T^J5@YRLX<^B^
Z1YD+1K2>11/%X4+#+&D41\$(IR@&C(R^M:%2>@+0\$)S_R8=D\$@%C_Q+(V4Q_U4#-+C81_Z@\$O_D@.&=^Y2_PL_I(8PX-M-3IP^*O-2(C0.T^~MXYPB^413F1Z1
8X4MN^DBL(1#W1U:O!E!9f>1(D_Z\$T#2C2DQ91\$13A56(#+<@HMH(^_MZW@:(G7WM?+UOH&TZZV1^I?:#/TF(B64J68:&9!_N9X,X#JF20^A)DT&S^UH1>QKEEGU^ULV<_12!
=@+I^_903M21HBFE?FA20NN^_973-M_HM=U^2.6U/QU+BYI^>^G3S_W^O>5U=-5+3G0DU87D?>?>V=0?D^3S0(@-S@_M:~)H16:1A:4!8^E:7E:F-M^W2>O:RVY1ITL:\$2TYICFY-
1^C=^2V7:H5O1HQ4IP8NN1LRN^YU\$^6/Q_ML^+CXE+LNZORYHU^1D=7>EMW4N:JB.K6-MT^5WOBZX6Y=J7U_IEB_-MC+%^&6^1TY_T2AGMDS:6+WY73ZJ?
X9C<(&KNFL3WB1TWU:09609L:T5HN^*M1P3H59?HKDU1X_?YQ7+MOIKE<D)HW?GHI/J_VYZ+MSSDN^=:~71+EM8IZD56E3>1>HLSJW3THYGVW<^*KMBC(DHV\$(W\$17AIE
M(&H5_4GBD_@Z\$5CB0)Y5EA#_-BH86LL4#-IN5^I&DC\$O84!^9FCH^17B<>2-MB\$41A&28/D4DYGI6S)I:G=
(X3E#FX<7+HM<16>BET7_RY0Z+E+Y54\$^#A^>F6&E)6C5IZ\$2^99M&OOIQ@#6J^N5\$-M12I^IAXN^IOV8G>?.\$>+/(^0TM_9WRR#&6>W.MG^ZYJK
M3)&LD/37/RCR/AWK4)H^LT&L.Y>##\$)1MH^=*@>)&B!QI(4R^<~HV4@R-M\$6A2BIX^-51-@=5>(1%7^1^H4DDR^3%MV\$)7I42-M+E^F^@XC-M_-BY0-A+7ME+9\$T!/_30Y_5FE
(L#M#B/0CTJN0^DQZ:6D727F6^%7>?R:K_MI7Q>5Y29+K+<<~:0I^U^1Z(NYO_5H8<+^_YG+^LIRE^S(GH6_MS^KZ>?Y_MRP16+314LNQ0Z+#+97^G^T7:
1^ZGI=FG>^,##BRI361@H2:6&-MUHD(T=)=^IP^D.\$H^1(#BOPHBI^9N2